METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF PROSTATE CANCER

Abstract: Described herein are genes whose expression are up-regulated or down-regulated in prostate cancer. Also described are such genes whose expression is further up-regulated or down-regulated in drug-resistant prostate cancer cells. Related methods and compositions that can be used for diagnosis and treatment of prostate cancer are disclosed. Also described herein are methods that can be used to identify modulators of prostate cancer.

Description: METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF PROSTATE CANCER CROSS-REFERENCES TO RELATED APPLICATIONS This application claims priority from the following applications: USSN 09/687,576 filed October 13, 2000, USSN 60/276,791 filed March 16, 2001; USSN 60/288,589, filed May 4, 2001; USSN 09/733,742, filed December 8, 2000; USSN 09/733,288, filed December 8, 2000; USSN 09/847,046, filed April 30, 2001; USSN 60/276,888, filed March 16, 2001; USSN 60/286,214, filed April 24, 2001; USSN 60/281,922, filed April 6, 2001; USSN 60/263,957, filed January 24, 2001, which are incorporated herein by reference in their entirety. FIELD OF THE INVENTION The invention relates to the identification of nucleic acid and protein expression profiles and nucleic acids, products, and antibodies thereto that are involved in prostate cancer; and to the use of such expression profiles and compositions in the diagnosis, prognosis and therapy of prostate cancer. The invention further relates to methods for identifying and using agents and/or targets that inhibit prostate cancer. BACKGROUND OF THE INVENTION Prostate cancer is the most commonly diagnosed internal malignancy and second most common cause of cancer death in men in the U.S., resulting in approximately 40,000 deaths each year ( Landis et al., CA Cancer J. Clin. 48:6-29 (1998); Greenlee et al, CA Cancer J. Clin. 50(1):7-13 (2000)), and incidence of prostate cancer has been increasing rapidly over the past 20 years in many parts of the world (Nakata et al., Int. J. Urol. 7(7):254-257 (2000); Majeed et al., BJUInt. 85(9): 1058-1062 (2000)). It develops as the result of a pathologic transformation of normal prostate cells. In tumorigenesis, the cancer cell undergoes initiation, proliferation and loss of contact inhibition, culminating in invasion of surrounding tissue and, ultimately, metastasis. Deaths from prostate cancer are a result of metastasis of a prostate tumor. Therefore, early detection of the development of prostate cancer is critical in reducing mortality from this disease. Measuring levels of prostate-specific antigen (PSA) has become a very common method for early detection and screening, and may have contributed to the slight decrease in the mortality rate from prostate cancer in recent years (Nowroozi et al., Cancer Control 5(6):522-531 (1998)). However, many cases are not diagnosed until the disease has progressed to an advanced stage. Treatments such as surgery (prostatectomy) , radiation therapy, and cryotherapy are potentially curative when the cancer remains localized to the prostate. Therefore, early detection of prostate cancer is important for a positive prognosis for treatment. Systemic treatment for metastatic prostate cancer is limited to hormone therapy and chemotherapy. Chemical or surgical castration has been the primary treatment for symptomatic metastatic prostate cancer for over 50 years. This testicular androgen deprivation therapy usually results in stabilization or regression of the disease (in 80% of patients), but progression of metastatic prostate cancer eventually develops (Panvichian et al., Cancer Control 3(6):493-500 (1996)). Metastatic disease is currently considered incurable, and the primary goals of treatment are to prolong survival and improve quality of life (Rago, Cancer Control 5(6):513-521 (1998)). Thus, methods that can be used for diagnosis and prognosis of prostate cancer and effective treatment of prostate cancer, and including particularly metastatic prostate cancer, would be desirable. Accordingly, provided herein are methods that can be used in diagnosis and prognosis of prostate cancer. Further provided are methods that can be used to screen candidate bioactive agents for the ability to modulate, e.g., treat, prostate cancer. Additionally, provided herein are molecular targets and compositions for therapeutic intervention in prostate cancer and other cancers. SUMMARY OF THE INVENTION The present invention therefore provides nucleotide sequences of genes that are up- and down-regulated in prostate cancer cells. Such genes are useful for diagnostic purposes, and also as targets for screening for therapeutic compounds that modulate prostate cancer, such as hormones or antibodies. Other aspects of the invention will become apparent to the skilled artisan by the following description of the invention. In one aspect, the present invention provides a method of detecting a prostate cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-16. In one embodiment, the present invention provides a method of determining the level of a prostate cancer associated transcript in a cell from a patient. In one embodiment, the present invention provides a method of detecting a prostate cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-16. In one embodiment, the polynucleotide selectively hybridizes to a sequence at least 95% identical to a sequence as shown in Tables 1-16. In another embodiment, the polynucleotide comprises a sequence as shown in Tables 1-16. In one embodiment, the biological sample is a tissue sample. In another embodiment, the biological sample comprises isolated nucleic acids, e.g., mRNA. In one embodiment, the polynucleotide is labeled, e.g., with a fluorescent label. In one embodiment, the polynucleotide is immobilized on a solid surface. In one embodiment, the patient is undergoing a therapeutic regimen to treat prostate cancer. In another embodiment, the patient is suspected of having metastatic prostate cancer. In one embodiment, the patient is a human. In one embodiment, the patient is suspected of having a taxol-resistant cancer. In one embodiment, the prostate cancer associated transcript is mRNA. In one embodiment, the method further comprises the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide. In another aspect, the present invention provides a method of monitoring the efficacy of a therapeutic treatment of prostate cancer, the method comprising the steps of: (i) providing a biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of a prostate cancer-associated transcript in the biological sample by contacting the biological sample with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-16, thereby monitoring the efficacy of the therapy. In a further embodiment, the patient has metastatic prostate cancer. In a further embodiment, the patient has a drug resistant (e.g., taxol resistant) form of prostate cancer. In one embodiment, the method further comprises the step of: (iii) comparing the level of the prostate cancer-associated transcript to a level of the prostate cancer- associated transcript in a biological sample from the patient prior to, or earlier in, the therapeutic treatment. Additionally, provided herein is a method of evaluating the effect of a candidate prostate cancer drug comprising administering the drug to a patient and removing a cell sample from the patient. The expression profile of the cell is then determined. This method may further comprise comparing the expression profile to an expression profile of a healthy individual. In a preferred embodiment, said expression profile includes a gene of Tables 1-16. In one aspect, the present invention provides an isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1-16. In one embodiment, an expression vector or cell comprises the isolated nucleic acid. In one aspect, the present invention provides an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-16. In another aspect, the present invention provides an antibody that specifically binds to an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-16. In one embodiment, the antibody is conjugated to an effector component, e.g., a fluorescent label, a radioisotope or a cytotoxic chemical. In one embodiment, the antibody is an antibody fragment. In another embodiment, the antibody is humanized. In one aspect, the present invention provides a method of detecting a prostate cancer cell in a biological sample from a patient, the method comprising contacting the biological sample with an antibody as described herein. In another aspect, the present invention provides a method of detecting antibodies specific to prostate cancer in a patient, the method comprising contacting a biological sample from the patient with a polypeptide encoded by a nucleic acid comprising a sequence from Tables 1-16. In another aspect, the present invention provides a method for identifying a compound that modulates a prostate cancer-associated polypeptide, the method comprising the steps of: (i) contacting the compound with a prostate cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-16; and (ii) determining the functional effect of the compound upon the polypeptide. In one embodiment, the functional effect is a physical effect, an enzymatic effect, or a chemical effect. In one embodiment, the polypeptide is expressed in a eukaryotic host cell or cell membrane. In another embodiment, the polypeptide is recombinant. In one embodiment, the functional effect is determined by measuring ligand binding to the polypeptide. In another aspect, the present invention provides a method of inhibiting proliferation of a prostate cancer-associated cell to treat prostate cancer in a patient, the method comprising the step of administering to the subject a therapeutically effective amount of a compound identified as described herein. In one embodiment, the compound is an antibody. In another aspect, the present invention provides a drug screening assay comprising the steps of: (i) administering a test compound to a mammal having prostate cancer or to a cell sample isolated therefrom; (ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-16 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell sample or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of prostate cancer. In one embodiment, the control is a mammal with prostate cancer or a cell sample therefrom that has not been treated with the test compound. In another embodiment, the control is a normal cell or mammal. In one embodiment, the test compound is administered in varying amounts or concentrations. In another embodiment, the test compound is administered for varying time periods. In another embodiment, the comparison can occur after addition or removal of the drug candidate. In one embodiment, the levels of a plurality of polynucleotides that selectively hybridize to a sequence at least 80% identical to a sequence as shown in Tables 1-16 are individually compared to their respective levels in a control cell sample or mammal. In a preferred embodiment the plurality of polynucleotides is from three to ten. In another aspect, the present invention provides a method for treating a mammal having prostate cancer comprising administering a compound identified by the assay described herein. In another aspect, the present invention provides a pharmaceutical composition for treating a mammal having prostate cancer, the composition comprising a compound identified by the assay described herein and a physiologically acceptable excipient. In one aspect, the present invention provides a method of screening drug candidates by providing a cell expressing a gene that is up- and down-regulated as in a prostate cancer. In one embodiment, a gene is selected from Tables 1-16. The method further includes adding a drug candidate to the cell and determining the effect of the drug candidate on the expression of the expression profile gene. In one embodiment, the method of screening drug candidates includes comparing the level of expression in the absence of the drug candidate to the level of expression in the presence of the drug candidate, wherein the concentration of the drug candidate can vary when present, and wherein the comparison can occur after addition or removal of the drug candidate. In a preferred embodiment, the cell expresses at least two expression profile genes. The profile genes may show an increase or decrease. Also provided is a method of evaluating the effect of a candidate prostate cancer drug comprising administering the drug to a transgenic animal expressing or over-expressing the prostate cancer modulatory protein, or an animal lacking the prostate cancer modulatory protein, for example as a result of a gene knockout. Moreover, provided herein is a biochip comprising one or more nucleic acid segments of Tables 1-16, wherein the biochip comprises fewer than 1000 nucleic acid probes. Preferably, at least two nucleic acid segments are included. More preferably, at least three nucleic acid segments are included. Furthermore, a method of diagnosing a disorder associated with prostate cancer is provided. The method comprises determining the expression of a gene of Tables 1- 16, in a first tissue type of a first individual, and comparing the distribution to the expression of the gene from a second normal tissue type from the first individual or a second unaffected individual. A difference in the expression indicates that the first individual has a disorder associated with prostate cancer. In a further embodiment, the biochip also includes a polynucleotide sequence of a gene that is not up- and down-regulated in prostate cancer. In one embodiment a method for screening for a bioactive agent capable of interfering with the binding of a prostate cancer modulating protein (prostate cancer modulatory protein) or a fragment thereof and an antibody which binds to said prostate cancer modulatory protein or fragment thereof. In a preferred embodiment, the method comprises combining a prostate cancer modulatory protein or fragment thereof, a candidate bioactive agent and an antibody which binds to said prostate cancer modulatory protein or fragment thereof. The method further includes determining the binding of said prostate cancer modulatory protein or fragment thereof and said antibody. Wherein there is a change in binding, an agent is identified as an interfering agent. The interfering agent can be an agonist or an antagonist. Preferably, the agent inhibits prostate cancer. Also provided herein are methods of eliciting an immune response in an individual. In one embodiment a method provided herein comprises administering to an individual a composition comprising a prostate cancer modulating protein, or a fragment thereof. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-16. Further provided herein are compositions capable of eliciting an immune response in an individual. In one embodiment, a composition provided herein comprises a prostate cancer modulating protein, preferably encoded by a nucleic acid of Tables 1-16, or a fragment thereof, and a pharmaceutically acceptable carrier. In another embodiment, said composition comprises a nucleic acid comprising a sequence encoding a prostate cancer modulating protein, preferably selected from the nucleic acids of Tables 1-16, and a pharmaceutically acceptable carrier. Also provided are methods of neutralizing the effect of a prostate cancer protein, or a fragment thereof, comprising contacting an agent specific for said protein with said protein in an amount sufficient to effect neutralization. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-16. In another aspect of the invention, a method of treating an individual for prostate cancer is provided. In one embodiment, the method comprises administering to said individual an inhibitor of a prostate cancer modulating protein. In another embodiment, the method comprises administering to a patient having prostate cancer an antibody to a prostate cancer modulating protein conjugated to a therapeutic moiety. Such a therapeutic moiety can be a cytotoxic agent or a radioisotope. DETAILED DESCRIPTION OF THE INVENTION In accordance with the objects outlined above, the present invention provides novel methods for diagnosis and prognosis evaluation for prostate cancer (PC), including metastatic prostate cancer, as well as methods for screening for compositions which modulate prostate cancer. Also provided are methods for treating prostate cancer. In addition to the other nucleic acid and peptide sequences, the present invention also relates to the identification of PAA2 as a gene that is highly over expressed in prostate cancer patient tissues. PAA2 sequence is identical to the zinc transporter ZNT4. Results presented herein demonstrate that PAA2/ZNT4 is highly expressed in prostate cancer cells. The prostate gland is unique in that it has the highest capacity of any organ in the body to accumulate zinc. Zinc uptake is regulated by prolactin and testosterone, which induce the expression of a member of the ZIP family of zinc transporters (Costello et al., 1999, J. Biol. Chem. 274:17499-17504). Zinc accumulation in the prostate functions to inhibit citrate oxidation, which results in a decrease in cellular ATP production (Costello and Franklin, 1998, Prostate 35:285-296). Cancer cells are more sensitive to decreased ATP production and have evolved to prevent zinc accumulation. Without wishing to be bound by theory, the up-regulation of ZNT4 in prostate cancer cells may result in protection of the cells from high zinc levels by its ability to pump accumulated zinc out of the cells. The present invention also relates to nucleic acid sequencess encoding PBHl. PBHl is related to human TRPC7 (transient receptor potential-related channels, NP_003298), a putative calcium channel highly expressed in brain (Nagamine et al., Genomics 54:124-131 (1998)). Trp is related to melastatin, a gene down-regulated in metastatic melanomas (Duncan et al., Cancer Res. 58:1515-1520 (1998)), and MTR1, a gene locallized to within the Beckwith-Wiedemann syndrome/Wilm's tumor susceptability region (Prawitt et al., Hum. Mol. Genet. 9:203-216 (2000)). Without wishing to be bound by theory, it is believed that PBHl functions as a calcium channel. As a calcium channel, PBHl is an ideal target for a small molecule therapeutic, or a therapeutic antibody that disrupts channel function. CD20, the target of Rituximab in non-Hodgekin's lymphoma (Maloney et al., Blood 90:2188-2195 (1997); Leget and Czuczman, Curr. Opin. Oncol. 10:548-551 (1998)), is a plasma membrane calcium channel expressed in B cells (Tedder andEngel, Immunol. Today 15:450-454 (1994)). Similarly, a small molecule, or antibody that inhibits or alters a calcium signal mediated by PBHl, will result in the death of prostate cancer cells. PBHl, and other genes of the invention, are also be useful as targets for cytotoxic T-lymphocytes. Genes that are tumor specific, or that are expressed in immune- privileged organs, are currently being used as potential vaccine targets (Van den Eynde and Boon, Int. J. Clin. Lab. Res. 27:81-86 (1997)). The expression pattern of PBHl indicates that it is an ideal target for cytotoxic T-lymphocytes. Thus, therapies that utilize PBHl-specific cytotoxic T-lymphocytes to induce prostate cancer cell death are also provided by this invention. See, e.g., U.S. Patent No. 6,051,227 and WO 00/32231, the disclosures of which are herein incorporated by reference. The present invention is also related to the identification of PAA3 as a gene that is important in the modulation of prostate cancer and or breast cancer. Tables 1-16 provide unigene cluster identification numbers, exemplar accession numbers, or genomic nucleotide position numbers for the nucleotide sequence of genes that exhibit increased or decreased expression in prostate cancer samples. Definitions The term "prostate cancer protein" or "prostate cancer polynucleotide" or "prostate cancer-associated transcript" refers to nucleic acid and polypeptide polymorphic variants, alleles, mutants, and interspecies homologues that: (1) have a nucleotide sequence that has greater than about 60% nucleotide sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater nucleotide sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleotides, to a nucleotide sequence of or associated with a unigene cluster of Tables 1-16; (2) bind to antibodies, e.g., polyclonal antibodies, raised against an immunogen comprising an amino acid sequence encoded by a nucleotide sequence of or associated with a unigene cluster of Tables 1-16, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to a nucleic acid sequence, or the complement thereof of Tables 1-16 and conservatively modified variants thereof or (4) have an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater amino sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acid, to an amino acid sequence encoded by a nucleotide sequence of or associated with a unigene cluster of Tables 1-16. A polynucleotide or polypeptide sequence is typically from a mammal including, but not limited to, primate, e.g., human; rodent, e.g., rat, mouse, hamster; cow, pig, horse, sheep, or other mammal. A "prostate cancer polypeptide" and a "prostate cancer polynucleotide," include both naturally occurring or recombinant forms. A "full length" prostate cancer protein or nucleic acid refers to a prostate cancer polypeptide or polynucleotide sequence, or a variant thereof, that contains all of the elements normally contained in one or more naturally occurring, wild type prostate cancer polynucleotide or polypeptide sequences. For example, a full length prostate cancer nucleic acid will typically comprise all of the exons that encode for the full length, naturally ocurring protein. The "full length" may be prior to, or after, various stages of post-translation processing or splicing, including alternative splicing. "Biological sample" as used herein is a sample of biological tissue or fluid that contains nucleic acids or polypeptides, e.g., of a prostate cancer protein, polynucleotide or transcript. Such samples include, but are not limited to, tissue isolated from primates, e.g., humans, or rodents, e.g., mice, and rats. Biological samples may also include sections of tissues such as biopsy and autopsy samples, frozen sections taken for histologic purposes, blood, plasma, serum, sputum, stool, tears, mucus, hair, skin, etc. Biological samples also include explants and primary and/or transformed cell cultures derived from patient tissues. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish. "Providing a biological sample" means to obtain a biological sample for use in methods described in this invention. Most often, this will be done by removing a sample of cells from an animal, but can also be accomplished by using previously isolated cells (e.g., isolated by another person, at another time, and or for another purpose), or by performing the methods of the invention in vivo. Archival tissues, having treatment or outcome history, will be particularly useful. The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site http://www.ncbi.nlm.nih.gov/BLAST/ or the like). Such sequences are then said to be "substantially identical." This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions, as well as naturally occurring, e.g., polymorphic or allelic variants, and man-made variants. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length. For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters. A "comparison window", as used herein, includes reference to a segment of one of the number of contiguous positions selected from the group consisting typically of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology (Ausubel et al. , eds. 1995 supplement)). Preferred examples of algorithms that are suitable for determining percent sequence identity and sequence similarity include the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al, Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al, J. Mol. Biol. 215:403-410 (1990). BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al, supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, e.g., for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands. The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Ptoc. Natl. Acad. Sci. USA 90:5873- 5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001. Log values may be large negative numbers, e.g., 5, 10, 20, 30, 40, 40, 70, 90, 110, 150, 170, etc. An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, e.g., where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequences. A "host cell" is a naturally occurring cell or a transformed cell that contains an expression vector and supports the replication or expression of the expression vector. Host cells may be cultured cells, explants, cells in vivo, and the like. Host cells may be prokaryotic cells such as E. coli, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells such as CHO, HeLa, and the like (.see, e.g., the American Type Culture Collection catalog or web site, www.atcc.org). The terms "isolated," "purified," or "biologically pure" refer to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein or nucleic acid that is the predominant species present in a preparation is substantially purified. In particular, an isolated nucleic acid is separated from some open reading frames that naturally flank the gene and encode proteins other than protein encoded by the gene. The term "purified" in some embodiments denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Preferably, it means that the nucleic acid or protein is at least 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure. "Purify" or "purification" in other embodiments means removing at least one contaminant from the composition to be purified. In this sense, purification does not require that the purified compound be homogenous, e.g., 100% pure. The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymer. The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ- carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions similarly to a naturally occurring amino acid. Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes. "Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated, e.g., naturally contiguous, sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to another of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes silent variations of the nucleic acid. One of skill will recognize that in certain contexts each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, often silent variations of a nucleic acid which encodes a polypeptide is implicit in a described sequence with respect to the expression product, but not with respect to actual probe sequences. As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.typically conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)). Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e.g., Alberts et al. , Molecular Biology of the Cell (3 rd ed., 1994) and Cantor & Schimmel, Biophysical Chemistry Part I: The Conformation of Biological Macromolecules (1980). "Primary structure" refers to the amino acid sequence of a particular peptide. "Secondary structure" refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains. Domains are portions of a polypeptide that often form a compact unit of the polypeptide and are typically 25 to approximately 500 amino acids long. Typical domains are made up of sections of lesser organization such as stretches of β-sheet and α-helices. "Tertiary structure" refers to the complete three dimensional structure of a polypeptide monomer. "Quaternary structure" refers to the three dimensional structure formed, usually by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms. "Nucleic acid" or "oligonucleotide" or "polynucleotide" or grammatical equivalents used herein means at least two nucleotides covalently linked together. Oligonucleotides are typically from about 5, 6, 7, 8, 9, 10, 12, 15, 25, 30, 40, 50 or more nucleotides in length, up to about 100 nucleotides in length. Nucleic acids and polynucleotides are a polymers of any length, including longer lengths, e.g., 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000, etc. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have alternate backbones, comprising, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press); and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones; non-ionic backbones, and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, Carbohydrate Modifications in Antisense Research, Sanghui & Cook, eds.. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g. to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made. A variety of references disclose such nucleic acid analogs, including, for example, phosphoramidate (Beaucage et al., Tetrahedron 49(10): 1925 (1993) and references therein; Letsinger, J. Org. Chem. 35:3800 (1970); Sprinzl et al., Eur. J. Biochem. 81:579 (1977); Letsinger et al., Nucl. Acids Res. 14:3487 (1986); Sawai et al, Chem. Lett. 805 (1984), Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); and Pauwels et al., Chemica Scripta 26:141 91986)), phosphorothioate (Mag et al., Nucleic Acids Res. 19:1437 (1991); and U.S. Patent No. 5,644,048), phosphorodithioate (Briu et al., J. Am. Chem. Soc. 111:2321 (1989), O-methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide nucleic acid backbones and linkages (see Egholm, J. Am. Chem. Soc. 114:1895 (1992); Meier et al., Chem. Int. Ed. Engl. 31:1008 (1992); Nielsen, Nature, 365:566 (1993); Carlsson et al., Nature 380:207 (1996), all of which are incorporated by reference). Other analog nucleic acids include those with positive backbones (Denpcy et al., Proc. Natl. Acad. Sci. USA 92:6097 (1995); non-ionic backbones (U.S. Patent Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; Kiedrowshi et al., Angew. Chem. Intl. Ed. English 30:423 (1991); Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); Letsinger et al., Nucleoside & Nucleotide 13 : 1597 (1994); Chapters 2 and 3, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook; Mesmaeker et al., Bioorganic & Medicinal Chem. Lett. 4:395 (1994); Jeffs et al., J. Biomolecular NMR 34:17 (1994); Tetrahedron Lett. 37:743 (1996)) and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids (see Jenkins et al., Chem. Soc. Rev. (1995) pp 169-176). Several nucleic acid analogs are described in Rawls, C & E News June 2, 1997 page 35. All of these references are hereby expressly incorporated by reference. Particularly preferred are peptide nucleic acids (PNA) which includes peptide nucleic acid analogs. These backbones are substantially non-ionic under neutral conditions, in contrast to the highly charged phosphodiester backbone of naturally occurring nucleic acids. This results in two advantages. First, the PNA backbone exhibits improved hybridization kinetics. PNAs have larger changes in the melting temperature (T m ) for mismatched versus perfectly matched basepairs. DNA and RNA typically exhibit a 2-4°C drop in T m for an internal mismatch. With the non-ionic PNA backbone, the drop is closer to 7-9°C. Similarly, due to their non-ionic nature, hybridization of the bases attached to these backbones is relatively insensitive to salt concentration. In addition, PNAs are not degraded by cellular enzymes, and thus can be more stable. The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. As will be appreciated by those in the art, the depiction of a single strand also defines the sequence of the complementary strand; thus the sequences described herein also provide the complement of the sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc. "Transcript" typically refers to a naturally occurring RNA, e.g., a pre-mRNA, hnRNA, or mRNA. As used herein, the term "nucleoside" includes nucleotides and nucleoside and nucleotide analogs, and modified nucleosides such as amino modified nucleosides. In addition, "nucleoside" includes non- naturally occurring analog structures. Thus, e.g. the individual units of a peptide nucleic acid, each containing a base, are referred to herein as a nucleoside. A "label" or a "detectable moiety" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide. The radioisotope may be, for example, 3H, 14C, 32P, 35S, or 1251. In some cases, particularly using antibodies against the proteins of the invention, the radioisotopes are used as toxic moieties, as described below. The labels may be incorporated into the prostate cancer nucleic acids, proteins and antibodies at any position. Any method known in the art for conjugating the antibody to the label may be employed, including those methods described by Hunter et al., Nature, 144:945 (1962); David et al., Biochemistry. 13:1014 (1974); Pain et al., J. Immunol. Meth., 40:219 (1981); and Nygren, J. Histochem. and Cvtochem.. 30:407 (1982). The lifetime of radiolabeled peptides or radiolabeled antibody compositions may extended by the addition of substances that stablize the radiolabeled peptide or antibody and protect it from degradation. Any substance or combination of substances that stablize the radiolabeled peptide or antibody may be used including those substances disclosed in US Patent No. 5,961,955. An "effector" or "effector moiety" or "effector component" is a molecule that is bound (or linked, or conjugated), either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds, to an antibody. The "effector" can be a variety of molecules including, e.g., detection moieties including radioactive compounds, fluorescent compounds, an enzyme or substrate, tags such as epitope tags, a toxin; activatable moieties, a chemotherapeutic agent; a lipase; an antibiotic; or a radioisotope emitting "hard" e.g., beta radiation. A "labeled nucleic acid probe or oligonucleotide" is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe. Alternatively, method using high affinity interactions may achieve the same results where one of a pair of binding partners binds to the other, e.g., biotin, streptavidin. As used herein a "nucleic acid probe or oligonucleotide" is defined as a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (i.e., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not functionally interfere with hybridization. Thus, e.g., probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. It will be understood by one of skill in the art that probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly labeled as with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled such as with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence. Diagnosis or prognosis may be based at the genomic level, or at the level of RNA or protein expression. The term "recombinant" when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, e.g., recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all. By the term "recombinant nucleic acid" herein is meant nucleic acid, originally formed in vitro, in general, by the manipulation of nucleic acid, e.g., using polymerases and endonucleases, in a form not normally found in nature. In this manner, operably linkage of different sequences is achieved. Thus an isolated nucleic acid, in a linear form, or an expression vector formed in vitro by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e., using the in vivo cellular machinery of the host cell rather than in vitro manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention. Similarly, a "recombinant protein" is a protein made using recombinant techniques, i.e., through the expression of a recombinant nucleic acid as depicted above. The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not normally found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences, e.g., from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein will often refer to two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein). A "promoter" is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence. An "expression vector" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter. The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence that is determinative of the presence of the nucleotide sequence, in a heterogeneous population of nucleic acids and other biologies (e.g., total cellular or library DNA or RNA). Similarly, the phrase "specifically (or selectively) binds" to an antibody or "specifically (or selectively) immunoreactive with," when referring to a protein or peptide, refers to a binding reaction that is determinative of the presence of the protein, in a heterogeneous population of proteins and other biologies. Thus, under designated immunoassay or nucleic acid hybridization conditions, the specified antibodies or nucleic acid probes bind to a particular protein nucleotide sequences at least two times the background and more typically more than 10 to 100 times background. Specific binding to an antibody under such conditions requires an antibody that is selected for its specificity for a particular protein. For example, polyclonal antibodies raised to a particular protein, polymorphic variants, alleles, orthologs, and conservatively modified variants, or splice variants, or portions thereof, can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with the desired prostact cancer protein and not with other proteins. This selection may be achieved by subtracting out antibodies that cross-react with other molecules. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELIS A immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual (1988) for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity). The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength pH. The T m is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T m , 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background preferably 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65°C, with wash in 0.2x SSC, and 0.1% SDS at 65°C. For PCR, a temperature of about 36°C is typical for low stringency amplification, although annealing temperatures may vary between about 32°C and 48°C depending on primer length. For high stringency PCR amplification, a temperature of about 62°C is typical, although high stringency annealing temperatures can range from about 50°C to about 65°C, depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90°C - 95°C for 30 sec - 2 min., an annealing phase lasting 30 sec. - 2 min., and an extension phase of about 72°C for 1 - 2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. N.Y.). Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in IX SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous reference, e.g., and Current Protocols in Molecular Biology, ed. Ausubel, et al. The phrase "functional effects" in the context of assays for testing compounds that modulate activity of a prostate cancer protein includes the determination of a parameter that is indirectly or directly under the influence of the prostate cancer protein or nucleic acid, e.g., a functional, physical, or chemical effect, such as the ability to decrease prostate cancer. It includes ligand binding activity; cell growth on soft agar; anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and protein expression in cells undergoing metastasis, and other characteristics of prostate cancer cells. "Functional effects" include in vitro, in vivo, and ex vivo activities. By "determining the functional effect" is meant assaying for a compound that increases or decreases a parameter that is indirectly or directly under the influence of a prostate cancer protein sequence, e.g., functional, enzymatic, physical and chemical effects. Such functional effects can be measured by any means known to those skilled in the art, e.g., changes in spectroscopic characteristics (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties for the protein, measuring inducible markers or transcriptional activation of the prostate cancer protein; measuring binding activity or binding assays, e.g. binding to antibodies or other ligands, and measuring cellular proliferation. Determination of the functional effect of a compound on prostate cancer can also be performed using prostate cancer assays known to those of skill in the art such as an in vitro assays, e.g., cell growth on soft agar; anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and protein expression in cells undergoing metastasis, and other characteristics of prostate cancer cells. The functional effects can be evaluated by many means known to those skilled in the art, e.g., microscopy for quantitative or qualitative measures of alterations in morphological features, measurement of changes in RNA or protein levels for prostate cancer-associated sequences, measurement of RNA stability, identification of downstream or reporter gene expression (CAT, luciferase, β-gal, GFP and the like), e.g., via chemiluminescence, fluorescence, colorimetric reactions, antibody binding, inducible markers, and ligand binding assays. "Inhibitors", "activators", and "modulators" of prostate cancer polynucleotide and polypeptide sequences are used to refer to activating, inhibitory, or modulating molecules or compounds identified using in vitro and in vivo assays of prostate cancer polynucleotide and polypeptide sequences. Inhibitors are compounds that, e.g., bind to, partially or totally block activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of prostate cancer proteins, e.g., antagonists. Antisense nucleic acids may seem to inhibit expression and subsequent function of the protein. "Activators" are compounds that increase, open, activate, facilitate, enhance activation, sensitize, agonize, or up regulate prostate cancer protein activity. Inhibitors, activators, or modulators also include genetically modified versions of prostate cancer proteins, e.g., versions with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, antibodies, small chemical molecules and the like. Such assays for inhibitors and activators include, e.g., expressing the prostate cancer protein in vitro, in cells, or cell membranes, applying putative modulator compounds, and then determining the functional effects on activity, as described above. Activators and inhibitors of prostate cancer can also be identified by incubating prostate cancer cells with the test compound and determining increases or decreases in the expression of 1 or more prostate cancer proteins, e.g., 1,"2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50 or more prostate cancer proteins, such as prostate cancer proteins encoded by the sequences set out in Tables 1-16. Samples or assays comprising prostate cancer proteins that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with inhibitors) are assigned a relative protein activity value of 100%. Inhibition of a polypeptide is achieved when the activity value relative to the control is about 80%, preferably 50%, more preferably 25-0%. Activation of a prostate cancer polypeptide is achieved when the activity value relative to the control (untreated with activators) is 110%, more preferably 150%, more preferably 200-500% (i.e., two to five fold higher relative to the control), more preferably 1000-3000% higher. The phrase "changes in cell growth" refers to any change in cell growth and proliferation characteristics in vitro or in vivo, such as formation of foci, anchorage independence, semi-solid or soft agar growth, changes in contact inhibition and density limitation of growth, loss of growth factor or serum requirements, changes in cell morphology, gaining or losing immortalization, gaining or losing tumor specific markers, ability to form or suppress tumors when injected into suitable animal hosts, and/or immortalization of the cell. See, e.g., Freshney, Culture of Animal Cells a Manual of Basic Technique pp. 231-241 (3 rd ed. 1994). "Tumor cell" refers to precancerous, cancerous, and normal cells in a tumor. "Cancer cells," "transformed" cells or "transformation" in tissue culture, refers to spontaneous or induced phenotypic changes that do not necessarily involve the uptake of new genetic material. Although transformation can arise from infection with a transforming virus and incorporation of new genomic DNA, or uptake of exogenous DNA, it can also arise spontaneously or following exposure to a carcinogen, thereby mutating an endogenous gene. Transformation is associated with phenotypic changes, such as immortalization of cells, aberrant growth control, nonmorphological changes, and/or malignancy (see, Freshney, Culture of Animal Cells a Manual of Basic Technique (3 rd ed. 1994)). "Antibody" refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. Typically, the antigen-binding region of an antibody or its functional equivalent will be most critical in specificity and affinity of binding. See Paul, Fundamental Immunology. An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (V L ) and variable heavy chain (V H ) refer to these light and heavy chains respectively. Antibodies exist, e.g., as intact immunoglobulins or as a number of well- characterized fragments produced by digestion with various peptidases. Thus, e.g., pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)' 2> a dimer of Fab which itself is a light chain joined to V H -C H 1 by a disulfide bond. The F(ab)' 2 may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab)' 2 dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (see Fundamental Immunology (Paul ed., 3d ed. 1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty et al, Nature 348:552-554 (1990)) For preparation of antibodies, e.g., recombinant, monoclonal, or polyclonal antibodies, many technique known in the art can be used (see, e.g., Kohler & Milstein, Nature 256:495-497 (1975); Kozbor et al, Immunology Today 4:72 (1983); Cole et al, pp. 77-96 in Monoclonal Antibodies and Cancer Therapy (1985); Coligan, Current Protocols in Immunology (1991); Harlow & Lane, Antibodies, A Laboratory Manual (1988); and Goding, Monoclonal Antibodies: Principles and Practice (2d ed. 1986)). Techniques for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (see, e.g., McCafferty et al., Nature 348:552-554 (1990); Marks et al, Biotechnology 10:779-783 (1992)). A "chimeric antibody" is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity. Identification of prostate cancer-associated sequences In one aspect, the expression levels of genes are determined in different patient samples for which diagnosis information is desired, to provide expression profiles. An expression profile of a particular sample is essentially a "fingerprint" of the state of the sample; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is characteristic of the state of the cell. That is, normal tissue (e.g., normal prostate or other tissue) may be distinguished from cancerous or metastatic cancerous tissue of the prostate, or prostate cancer tissue or metastatic prostate cancerous tissue can be compared with tissue samples of prostate and other tissues from surviving cancer patients. By comparing expression profiles of tissue in known different prostate cancer states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. The identification of sequences that are differentially expressed in prostate cancer versus non-prostate cancer tissue allows the use of this information in a number of ways. For example, a particular treatment regime may be evaluated: does a chemotherapeutic drug act to down-regulate prostate cancer, and thus tumor growth or recurrence, in a particular patient. Similarly, diagnosis and treatment outcomes may be done or confirmed by comparing patient samples with the known expression profiles. Metastatic tissue can also be analyzed to determine the stage of prostate cancer in the tissue. Furthermore, these gene expression profiles (or individual genes) allow screening of drug candidates with an eye to mimicking or altering a particular expression profile; e.g., screening can be done for drugs that suppress the prostate cancer expression profile. This may be done by making biochips comprising sets of the important prostate cancer genes, which can then be used in these screens. These methods can also be done on the protein basis; that is, protein expression levels of the prostate cancer proteins can be evaluated for diagnostic purposes or to screen candidate agents. In addition, the prostate cancer nucleic acid sequences can be administered for gene therapy purposes, including the administration of antisense nucleic acids, or the prostate cancer proteins (including antibodies and other modulators thereof) administered as therapeutic drugs. Thus the present invention provides nucleic acid and protein sequences that are differentially expressed in prostate cancer, herein termed "prostate cancer sequences." As outlined below, prostate cancer sequences include those that are up-regulated (i.e., expressed at a higher level) in prostate cancer, as well as those that are down-regulated (i.e., expressed at a lower level). In a preferred embodiment, the prostate cancer sequences are from humans; however, as will be appreciated by those in the art, prostate cancer sequences from other organisms may be useful in animal models of disease and drug evaluation; thus, other prostate cancer sequences are provided, from vertebrates, including mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, farm animals (including sheep, goats, pigs, cows, horses, etc.) and pets, e.g., (dogs, cats, etc.). Prostate cancer sequences from other organisms may be obtained using the techniques outlined below. Prostate cancer sequences can include both nucleic acid and amino acid sequences. As will be appreciated by those in the art and is more fully outlined below, prostate cancer nucleic acid sequences are useful in a variety of applications, including diagnostic applications, which will detect naturally occurring nucleic acids, as well as screening applications; e.g., biochips comprising nucleic acid probes or PCR microtiter plates with selected probes to the prostate cancer sequences can be generated. A prostate cancer sequence can be initially identified by substantial nucleic acid and/or amino acid sequence homology to the prostate cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions. For identifying prostate cancer-associated sequences, the prostate cancer screen typically includes comparing genes identified in different tissues, e.g., normal and cancerous tissues, or tumor tissue samples from patients who have metastatic disease vs. non metastatic tissue. Other suitable tissue comparisons include comparing prostate cancer samples with metastatic cancer samples from other cancers, such as lung, breast, gastrointestinal cancers, ovarian, etc. Samples of different stages of prostate cancer, e.g., survivor tissue, drug resistant states, and tissue undergoing metastasis, are applied to biochips comprising nucleic acid probes. The samples are first microdissected, if applicable, and treated as is known in the art for the preparation of mRNA. Suitable biochips are commercially available, e.g. from Affymetrix. Gene expression profiles as described herein are generated and the data analyzed. In one embodiment, the genes showing changes in expression as between normal and disease states are compared to genes expressed in other normal tissues, preferably normal prostate, but also including, and not limited to lung, heart, brain, liver, breast, kidney, muscle, colon, small intestine, large intestine, spleen, bone and placenta. In a preferred embodiment, those genes identified during the prostate cancer screen that are expressed in any significant amount in other tissues are removed from the profile, although in some embodiments, this is not necessary. That is, when screening for drugs, it is usually preferable that the target be disease specific, to minimize possible side effects. In a preferred embodiment, prostate cancer sequences are those that are up- regulated in prostate cancer; that is, the expression of these genes is higher in the prostate cancer tissue as compared to non-cancerous tissue. "Up-regulation" as used herein often means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred. All unigene cluster identification numbers and accession numbers herein are for the GenBank sequence database and the sequences of the accession numbers are hereby expressly incorporated by reference. GenBank is known in the art, see, e.g., Benson, DA, et al, Nucleic Acids Research 26:1-7 (1998) and http://www.ncbi.nlm.nih.gov/. Sequences are also available in other databases, e.g., European Molecular Biology Laboratory (EMBL) and DNA Database of Japan (DDBJ). In another preferred embodiment, prostate cancer sequences are those that are down-regulated in prostate cancer; that is, the expression of these genes is lower in prostate cancer tissue as compared to non-cancerous tissue (see, e.g., Tables 8, 12 and 14). "Down- regulation" as used herein often means at least about a 1.5-fold change more preferrably a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being most preferred. Informatics The ability to identify genes that are over or under expressed in prostate cancer can additionally provide high-resolution, high-sensitivity datasets which can be used in the areas of diagnostics, therapeutics, drug development, pharmacogenetics, protein structure, biosensor development, and other related areas. For example, the expression profiles can be used in diagnostic or prognostic evaluation of patients with prostate cancer. Or as another example, subcellular toxicological information can be generated to better direct drug structure and activity correlation (see Anderson, Pharmaceutical Proteomics: Targets, Mechanism, and Function, paper presented at the IBC Proteomics conference, Coronado, CA (June 11-12, 1998)). Subcellular toxicological information can also be utilized in a biological sensor device to predict the likely toxicological effect of chemical exposures and likely tolerable exposure thresholds (see U.S. Patent No. 5,811,231). Similar advantages accrue from datasets relevant to other biomolecules and bioactive agents (e.g., nucleic acids, saccharides, lipids, drugs, and the like). Thus, in another embodiment, the present invention provides a database that includes at least one set of assay data. The data contained in the database is acquired, e.g., using array analysis either singly or in a library format. The database can be in substantially any form in which data can be maintained and transmitted, but is preferably an electronic database. The electronic database of the invention can be maintained on any electronic device allowing for the storage of and access to the database, such as a personal computer, but is preferably distributed on a wide area network, such as the World Wide Web. The focus of the present section on databases that include peptide sequence data is for clarity of illustration only. It will be apparent to those of skill in the art that similar databases can be assembled for any assay data acquired using an assay of the invention. The compositions and methods for identifying and/or quantitating the relative and/or absolute abundance of a variety of molecular and macromolecular species from a biological sample undergoing prostate cancer, i.e., the identification of prostate cancer- associated sequences described herein, provide an abundance of information, which can be correlated with pathological conditions, predisposition to disease, drug testing, therapeutic monitoring, gene-disease causal linkages, identification of correlates of immunity and physiological status, among others. Although the data generated from the assays of the invention is suited for manual review and analysis, in a preferred embodiment, prior data processing using high-speed computers is utilized. An array of methods for indexing and retrieving biomolecular information is known in the art. For example, U.S. Patents 6,023,659 and 5,966,712 disclose a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to one or more protein function hierarchies. U.S. Patent 5,953,727 discloses a relational database having sequence records containing information in a format that allows a collection of partial-length DNA sequences to be catalogued and searched according to association with one or more sequencing projects for obtaining full-length sequences from the collection of partial length sequences. U.S. Patent 5,706,498 discloses a gene database retrieval system for making a retrieval of a gene sequence similar to a sequence data item in a gene database based on the degree of similarity between a key sequence and a target sequence. U.S. Patent 5,538,897 discloses a method using mass spectroscopy fragmentation patterns of peptides to identify amino acid sequences in computer databases by comparison of predicted mass spectra with experimentally-derived mass spectra using a closeness-of-fit measure. U.S. Patent 5,926,818 discloses a multidimensional database comprising a functionality for multi-dimensional data analysis described as on-line analytical processing (OLAP), which entails the consolidation of projected and actual data according to more than one consolidation path or dimension. U.S. Patent 5,295,261 reports a hybrid database structure in which the fields of each database record are divided into two classes, navigational and informational data, with navigational fields stored in a hierarchical topological map which can be viewed as a tree structure or as the merger of two or more such tree structures. See also Mount et al, Bioinformatics (2001); Biological Sequence Analysis: Probabilistic Models of Proteins and Nucleic Acids (Durbin et al., eds., 1999); Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins (Baxevanis & Oeullette eds., 1998)); Rashidi & Buehler, Bioinformatics: Basic Applications in Biological Science and Medicine (1999); Introduction to Computational Molecular Biology (Setubal et al., eds 1997); Bioinformatics: Methods and Protocols (Misener & Krawetz, eds, 2000); Bioinformatics: Sequence, Structure, and Databanks: A Practical Approach (Higgins & Taylor, eds., 2000); Brown, Bioinformatics: A Biologist's Guide to Biocomputing and the Internet (2001); Han & Kamber, Data Mining: Concepts and Techniques (2000); and Waterman, Introduction to Computational Biology: Maps, Sequences, and Genomes (1995). The present invention provides a computer database comprising a computer and software for storing in computer-retrievable form assay data records cross-tabulated, e.g., with data specifying the source of the target-containing sample from which each sequence specificity record was obtained. In an exemplary embodiment, at least one of the sources of target-containing sample is from a control tissue sample known to be free of pathological disorders. In a variation, at least one of the sources is a known pathological tissue specimen, e.g., a neoplastic lesion or another tissue specimen to be analyzed for prostate cancer. In another variation, the assay records cross-tabulate one or more of the following parameters for each target species in a sample: (1) a unique identification code, which can include, e.g., a target molecular structure and/or characteristic separation coordinate (e.g., electrophoretic coordinates); (2) sample source; and (3) absolute and/or relative quantity of the target species present in the sample. The invention also provides for the storage and retrieval of a collection of target data in a computer data storage apparatus, which can include magnetic disks, optical disks, magneto-optical disks, DRAM, SRAM, SGRAM, SDRAM, RDRAM, DDR RAM, magnetic bubble memory devices, and other data storage devices, including CPU registers and on-CPU data storage arrays. Typically, the target data records are stored as a bit pattern in an array of magnetic domains on a magnetizable medium or as an array of charge states or transistor gate states, such as an array of cells in a DRAM device (e.g., each cell comprised of a transistor and a charge storage area, which may be on the transistor). In one embodiment, the invention provides such storage devices, and computer systems built therewith, comprising a bit pattern encoding a protein expression fingerprint record comprising unique identifiers for at least 10 target data records cross-tabulated with target source. When the target is a peptide or nucleic acid, the invention preferably provides a method for identifying related peptide or nucleic acid sequences, comprising performing a computerized comparison between a peptide or nucleic acid sequence assay record stored in or retrieved from a computer storage device or database and at least one other sequence. The comparison can include a sequence analysis or comparison algorithm or computer program embodiment thereof (e.g., FASTA, TFASTA, GAP, BESTFTT) and/or the comparison may be of the relative amount of a peptide or nucleic acid sequence in a pool of sequences determined from a polypeptide or nucleic acid sample of a specimen. The invention also preferably provides a magnetic disk, such as an IBM- compatible (DOS, Windows, Windows95/98/2000, Windows NT, OS/2) or other format (e.g., Linux, SunOS, Solaris, AIX, SCO Unix, VMS, MV, Macintosh, etc.) floppy diskette or hard (fixed, Winchester) disk drive, comprising a bit pattern encoding data from an assay of the invention in a file format suitable for retrieval and processing in a computerized sequence analysis, comparison, or relative quantitation method. The invention also provides a network, comprising a plurality of computing devices linked via a data link, such as an Ethernet cable (coax or lOBaseT), telephone line, ISDN line, wireless network, optical fiber, or other suitable signal transmission medium, whereby at least one network device (e.g., computer, disk array, etc.) comprises a pattern of magnetic domains (e.g., magnetic disk) and/or charge domains (e.g., an array of DRAM cells) composing a bit pattern encoding data acquired from an assay of the invention. The invention also provides a method for transmitting assay data that includes generating an electronic signal on an electronic communications device, such as a modem, ISDN terminal adapter, DSL, cable modem, ATM switch, or the like, wherein the signal includes (in native or encrypted format) a bit pattern encoding data from an assay or a database comprising a plurality of assay results obtained by the method of the invention. In a preferred embodiment, the invention provides a computer system for comparing a query target to a database containing an array of data structures, such as an assay result obtained by the method of the invention, and ranking database targets based on the degree of identity and gap weight to the target data. A central processor is preferably initialized to load and execute the computer program for alignment and/or comparison of the assay results. Data for a query target is entered into the central processor via an I/O device. Execution of the computer program results in the central processor retrieving the assay data from the data file, which comprises a binary description of an assay result. The target data or record and the computer program can be transferred to secondary memory, which is typically random access memory (e.g., DRAM, SRAM, SGRAM, or SDRAM). Targets are ranked according to the degree of correspondence between a selected assay characteristic (e.g., binding to a selected affinity moiety) and the same characteristic of the query target and results are output via an I O device. For example, a central processor can be a conventional computer (e.g., Intel Pentium, PowerPC, Alpha, PA-8000, SPARC, MIPS 4400, MIPS 10000, VAX, etc.); a program can be a commercial or public domain molecular biology software package (e.g., UWGCG Sequence Analysis Software, Darwin); a data file can be an optical or magnetic disk, a data server, a memory device (e.g., DRAM, SRAM, SGRAM, SDRAM, EPROM, bubble memory, flash memory, etc.); an I/O device can be a terminal comprising a video display and a keyboard, a modem, an ISDN terminal adapter, an Ethernet port, a punched card reader, a magnetic strip reader, or other suitable I/O device. The invention also preferably provides the use of a computer system, such as that described above, which comprises: (1) a computer; (2) a stored bit pattern encoding a collection of peptide sequence specificity records obtained by the methods of the invention, which may be stored in the computer; (3) a comparison target, such as a query target; and (4) a program for alignment and comparison, typically with rank-ordering of comparison results on the basis of computed similarity values. Characteristics of prostate cancer-associated proteins Prostate cancer proteins of the present invention may be classified as secreted proteins, transmembrane proteins or intracellular proteins. In one embodiment, the prostate cancer protein is an intracellular protein. Intracellular proteins may be found in the cytoplasm and/or in the nucleus. Intracellular proteins are involved in all aspects of cellular function and replication (including, e.g., signaling pathways); aberrant expression of such proteins often results in unregulated or disregulated cellular processes (see, e.g., Molecular Biology of the Cell (Alberts, ed., 3rd ed., 1994). For example, many intracellular proteins have enzymatic activity such as protein kinase activity, protein phosphatase activity, protease activity, nucleotide cyclase activity, polymerase activity and the like. Intracellular proteins also serve as docking proteins that are involved in organizing complexes of proteins, or targeting proteins to various subcellular localizations, and are involved in maintaining the structural integrity of organelles. An increasingly appreciated concept in characterizing proteins is the presence in the proteins of one or more motifs for which defined functions have been attributed. In addition to the highly conserved sequences found in the enzymatic domain of proteins, highly conserved sequences have been identified in proteins that are involved in protein-protein interaction. For example, Src-homology-2 (SH2) domains bind tyrosine-phosphorylated targets in a sequence dependent manner. PTB domains, which are distinct from SH2 domains, also bind tyrosine phosphorylated targets. SH3 domains bind to proline-rich targets. In addition, PH domains, tetratricopeptide repeats and WD domains to name only a few, have been shown to mediate protein-protein interactions. Some of these may also be involved in binding to phospholipids or other second messengers. As will be appreciated by one of ordinary skill in the art, these motifs can be identified on the basis of primary sequence; thus, an analysis of the sequence of proteins may provide insight into both the enzymatic potential of the molecule and/or molecules with which the protein may associate. One useful database is Pfam (protein families), which is a large collection of multiple sequence alignments and hidden Markov models covering many common protein domains. Versions are available via the internet from Washington University in St. Louis, the Sanger Center in England, and the Karolinska Institute in Sweden (see, e.g., Bateman et al, Nuc. Acids Res. 28:263-266 (2000); Sonnhammer et al, Proteins 28:405-420 (1997); Bateman et al, Nuc. Acids Res. 27:260-262 (1999); and Sonnhammer et al, Nuc. Acids Res. 26:320-322- (1998)). In another embodiment, the prostate cancer sequences are transmembrane proteins. Transmembrane proteins are molecules that span a phospholipid bilayer of a cell. They may have an intracellular domain, an extracellular domain, or both. The intracellular domains of such proteins may have a number of functions including those already described for intracellular proteins. For example, the intracellular domain may have enzymatic activity and/or may serve as a binding site for additional proteins. Frequently the intracellular domain of transmembrane proteins serves both roles. For example certain receptor tyrosine kinases have both protein kinase activity and SH2 domains. In addition, autophosphorylation of tyrosines on the receptor molecule itself, creates binding sites for additional SH2 domain containing proteins. Transmembrane proteins may contain from one to many transmembrane domains. For example, receptor tyrosine kinases, certain cytokine receptors, receptor guanylyl cyclases and receptor serine/threonine protein kinases contain a single transmembrane domain. However, various other proteins including channels and adenylyl cyclases contain numerous transmembrane domains. Many important cell surface receptors such as G protein coupled receptors (GPCRs) are classified as "seven transmembrane domain" proteins, as they contain 7 membrane spanning regions. Characteristics of transmembrane domains include approximately 20 consecutive hydrophobic amino acids that may be followed by charged amino acids. Therefore, upon analysis of the amino acid sequence of a particular protein, the localization and number of transmembrane domains within the protein may be predicted (see, e.g. PSORT web site http://psort.nibb.ac.jp/). Important transmembrane protein receptors include, but are not limited to the insulin receptor, insulin-like growth factor receptor, human growth hormone receptor, glucose transporters, transferrin receptor, epidermal growth factor receptor, low density lipoprotein receptor, epidermal growth factor receptor, leptin receptor, interleukin receptors, e.g. IL-1 receptor, IL-2 receptor, The extracellular domains of transmembrane proteins are diverse; however, conserved motifs are found repeatedly among various extracellular domains. Conserved structure and/or functions have been ascribed to different extracellular motifs. Many extracellular domains are involved in binding to other molecules. In one aspect, extracellular domains are found on receptors. Factors that bind the receptor domain include circulating ligands, which may be peptides, proteins, or small molecules such as adenosine and the like. For example, growth factors such as EGF, FGF and PDGF are circulating growth factors that bind to their cognate receptors to initiate a variety of cellular responses. Other factors include cytokines, mitogenic factors, neurotrophic factors and the like. Extracellular domains also bind to cell-associated molecules. In this respect, they mediate cell-cell interactions. Cell- associated ligands can be tethered to the cell, e.g., via a glycosylphosphatidylinositol (GPI) anchor, or may themselves be transmembrane proteins. Extracellular domains also associate with the extracellular matrix and contribute to the maintenance of the cell structure. Prostate cancer proteins that are transmembrane are particularly preferred in the present invention as they are readily accessible targets for immunotherapeutics, as are described herein. In addition, as outlined below, transmembrane proteins can be also useful in imaging modalities. Antibodies may be used to label such readily accessible proteins in situ. Alternatively, antibodies can also label intracellular proteins, in which case samples are typically permeablized to provide access to intracellular proteins. It will also be appreciated by those in the art that a transmembrane protein can be made soluble by removing transmembrane sequences, e.g., through recombinant methods. Furthermore, transmembrane proteins that have been made soluble can be made to be secreted through recombinant means by adding an appropriate signal sequence. In another embodiment, the prostate cancer proteins are secreted proteins; the secretion of which can be either constitutive or regulated. These proteins have a signal peptide or signal sequence that targets the molecule to the secretory pathway. Secreted proteins are involved in numerous physiological events; by virtue of their circulating nature, they serve to transmit signals to various other cell types. The secreted protein may function in an autocrine manner (acting on the cell that secreted the factor), a paracrine manner (acting on cells in close proximity to the cell that secreted the factor) or an endocrine manner (acting on cells at a distance). Thus secreted molecules find use in modulating or altering numerous aspects of physiology. Prostate cancer proteins that are secreted proteins are particularly preferred in the present invention as they serve as good targets for diagnostic markers, e.g., for blood, plasma, serum, or stool tests. Use of prostate cancer nucleic acids As described above, prostate cancer sequence is initially identified by substantial nucleic acid and/or amino acid sequence homology or linkage to the prostate cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions. Typically, linked sequences on a mRNA are found on the same molecule. The prostate cancer nucleic acid sequences of the invention, e.g., the sequences in Tables 1-16, can be fragments of larger genes, i.e., they are nucleic acid segments. "Genes" in this context includes coding regions, non-coding regions, and mixtures of coding and non-coding regions. Accordingly, as will be appreciated by those in the art, using the sequences provided herein, extended sequences, in either direction, of the prostate cancer genes can be obtained, using techniques well known in the art for cloning either longer sequences or the full length sequences; see Ausubel, et al, supra. Much can be done by informatics and many sequences can be clustered to include multiple sequences corresponding to a single gene, e.g., systems such as UniGene (see, http://www.ncbi.nlm.nih.gov/UniGene/). Once the prostate cancer nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire prostate cancer nucleic acid coding regions or the entire mRNA sequence. Once isolated from its natural source, e.g., contained within a plasmid or other vector or excised therefrom as a linear nucleic acid segment, the recombinant prostate cancer nucleic acid can be further-used as a probe to identify and isolate other prostate cancer nucleic acids, e.g., extended coding regions. It can also be used as a "precursor" nucleic acid to make modified or variant prostate cancer nucleic acids and proteins. The prostate cancer nucleic acids of the present invention are used in several ways. In a first embodiment, nucleic acid probes to the prostate cancer nucleic acids are made and attached to biochips to be used in screening and diagnostic methods, as outlined below, or for administration, e.g., for gene therapy, vaccine, and/or antisense applications. Alternatively, the prostate cancer nucleic acids that include coding regions of prostate cancer proteins can be put into expression vectors for the expression of prostate cancer proteins, again for screening purposes or for administration to a patient. In a preferred embodiment, nucleic acid probes to prostate cancer nucleic acids (both the nucleic acid sequences outlined in the figures and/or the complements thereof) are made. The nucleic acid probes attached to the biochip are designed to be substantially complementary to the prostate cancer nucleic acids, i.e. the target sequence (either the target sequence of the sample or to other probe sequences, e.g., in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization between the target sequence and the single stranded nucleic acids of the present invention. However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by "substantially complementary" herein is meant that the probes are sufficiently complementary to the target sequences to hybridize under normal reaction conditions, particularly high stringency conditions, as outlined herein. A nucleic acid probe is generally single stranded but can be partially single and partially double stranded. The strandedness of the probe is dictated by the structure, composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8 to about 100 bases long, with from about 10 to about 80 bases being preferred, and from about 30 to about 50 bases being particularly preferred. That is, generally whole genes are not used. In some embodiments, much longer nucleic acids can be used, up to hundreds of bases. In a preferred embodiment, more than one probe per sequence is used, with either overlapping probes or probes to different sections of the target being used. That is, two, three, four or more probes, with three being preferred, are used to build in a redundancy for a particular target. The probes can be overlapping (i.e., have some sequence in common), or separate. In some cases, PCR primers may be used to amplify signal for higher sensitivity. As will be appreciated by those in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By "immobilized" and grammatical equivalents herein is meant the association or binding between the nucleic acid probe and the solid support is sufficient to be stable under the conditions of binding, washing, analysis, and removal as outlined below. The binding can typically be covalent or non-covalent. By "non- covalent binding" and grammatical equivalents herein is meant one or more of electrostatic, hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, such as, streptavidin to the support and the non-covalent binding of the biotinylated probe to the streptavidin. By "covalent binding" and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including sigma bonds, pi bonds and coordination bonds. Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules. Immobilization may also involve a combination of covalent and non-covalent interactions. In general, the probes are attached to the biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip. The biochip comprises a suitable solid substrate. By "substrate" or "solid support" or other grammatical equivalents herein is meant a material that can be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, TeflonJ, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silica- based materials including silicon and modified silicon, carbon, metals, inorganic glasses, plastics, etc. In general, the substrates allow optical detection and do not appreciably fluoresce. A preferred substrate is described in copending application entitled Reusable Low Fluorescent Plastic Biochip, U.S. Application Serial No. 09/270,214, filed March 15, 1999, herein incorporated by reference in its entirety. Generally the substrate is planar, although as will be appreciated by those in the art, other configurations of substrates may be used as well. For example, the probes may be placed on the inside surface of a tube, for flow-through sample analysis to minimize sample volume. Similarly, the substrate may be flexible, such as a flexible foam, including closed cell foams made of particular plastics. In a preferred embodiment, the surface of the biochip and the probe may be derivatized with chemical functional groups for subsequent attachment of the two. Thus, e.g., the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxy groups, oxo groups and thiol groups, with amino groups being particularly preferred. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino groups, e.g. using linkers as are known in the art; e.g., homo-or hetero-bifunctional linkers as are well known (see 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used. In this embodiment, oligonucleotides are synthesized as is known in the art, and then attached to the surface of the solid support. As will be appreciated by those skilled in the art, either the 5' or 3' terminus may be attached to the solid support, or attachment may be via an internal nucleoside. In another embodiment, the immobilization to the solid support may be very strong, yet non-covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces covalently coated with streptavidin, resulting in attachment. Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized in situ, using well known photolithographic techniques, such as those described in WO 95/25116; WO 95/35505; U.S. Patent Nos. 5,700,637 and 5,445,934; and references cited within, all of which are expressly incorporated by reference; these methods of attachment form the basis of the Affimetrix GeneChip™ technology. Often, amplification-based assays are performed to measure the expression level of prostate cancer-associated sequences. These assays are typically performed in conjunction with reverse transcription. In such assays, a prostate cancer-associated nucleic acid sequence acts as a template in an amplification reaction (e.g., Polymerase Chain Reaction, or PCR). In a quantitative amplification, the amount of amplification product will be proportional to the amount of template in the original sample. Comparison to appropriate controls provides a measure of the amount of prostate cancer-associated RNA. Methods of quantitative amplification are well known to those of skill in the art. Detailed protocols for quantitative PCR are provided, e.g., in Innis et al., PCR Protocols, A Guide to Methods and Applications (1990). In some embodiments, a TaqMan based assay is used to measure expression. TaqMan based assays use a fluorogenic oligonucleotide probe that contains a 5' fluorescent dye and a 3' quenching agent. The probe hybridizes to a PCR product, but cannot itself be extended due to a blocking agent at the 3' end. When the PCR product is amplified in subsequent cycles, the 5' nuclease activity of the polymerase, e.g., AmpliTaq, results in the cleavage of the TaqMan probe. This cleavage separates the 5' fluorescent dye and the 3' quenching agent, thereby resulting in an increase in fluorescence as a function of amplification (see, e.g., literature provided by Perkin-Elmer, e.g., www2.perkin-elmer.com). Other suitable amplification methods include, but are not limited to, ligase chain reaction (LCR) (see Wu & Wallace, Genomics 4:560 (1989), Landegren et al, Science 241:1077 (1988), and Barringer et al, Gene 89:117 (1990)), transcription amplification (Kwoh et al, Proc. Natl. Acad. Sci. USA 86:1173 (1989)), self-sustained sequence replication (Guatelli et al, Proc. Nat. Acad. Sci. USA 87: 1874 (1990)), dot PCR, and linker adapter PCR, etc. Expression of prostate cancer proteins from nucleic acids In a preferred embodiment, prostate cancer nucleic acids, e.g., encoding prostate cancer proteins are used to make a variety of expression vectors to express prostate cancer proteins which can then be used in screening assays, as described below. Expression vectors and recombinant DNA technology are well known to those of skill in the art (see, e.g., Ausubel, supra, and Gene Expression Systems (Fernandez & Hoeffler, eds, 1999)) and are used to express proteins. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, these expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the prostate cancer protein. The term "control sequences" refers to DNA sequences used for the expression of an operably linked coding sequence in a particular host organism. Control sequences that are suitable for prokaryotes, e.g., include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers. Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is typically accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. Transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the prostate cancer protein. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells. In general, transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences. Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention. In addition, an expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, e.g. in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art (e.g., Fernandez & Hoeffler, supra). In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used. The prostate cancer proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a prostate cancer protein, under the appropriate conditions to induce or cause expression of the prostate cancer protein. Conditions appropriate for prostate cancer protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation or optimization. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculo viral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield. Appropriate host cells include yeast, bacteria, archaebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are Saccharomyces cerevisiae and other yeasts, E. coli, Bacillus sύbtϊlis, Sf9 cells, C129 cells, 293 cells, Neurospora, BHK, CHO, COS, HeLa cells, HUNEC (human umbilical vein endothelial cells), THP1 cells (a macrophage cell line) and various other human cells and cell lines. In a preferred embodiment, the prostate cancer proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include retroviral and adenoviral systems. One expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and PCT/US97/01048, both of which are hereby expressly incorporated by reference. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the S V40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter (see, e.g., Fernandez & Hoeffler, supra). Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. Examples of transcription terminator and polyadenlyation signals include those derived form SV40. The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used. Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei. In a preferred embodiment, prostate cancer proteins are expressed in bacterial systems. Bacterial expression systems are well known in the art. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; e.g., the tac promoter is a hybrid of the tip and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. The expression vector may also include a signal peptide sequence that provides for secretion of the prostate cancer protein in bacteria. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways. These components are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for Bacillus subtϊlis, E. coli, Streptococcus cremoris, and Streptococcus lividans, among others (e.g., Fernandez & Hoeffler, supra). The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others. In one embodiment, prostate cancer proteins are produced in insect cells. Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are. well known in the art. In a preferred embodiment, prostate cancer protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for Saccharomyces cerevisiae, Candida albicans and C. maltosa, Hansenula polymorpha, Kluyveromyces fragilis and K. lactis, Pichia guillerimondii and P. pastoris, Schizosaccharomyces pombe, and Yarrowia lipolytica. The prostate cancer protein may also be made as a fusion protein, using techniques well known in the art. Thus, e.g., for the creation of monoclonal antibodies, if the desired epitope is small, the prostate cancer protein may be fused to a carrier protein to form an immunogen. Alternatively, the prostate cancer protein may be made as a fusion protein to increase expression, or for other reasons. For example, when the prostate cancer protein is a prostate cancer peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression purposes. In a preferred embodiment, the prostate cancer protein is purified or isolated after expression. Prostate cancer proteins may be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample. Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse- phase HPLC chromatography, and chromatofocusing. For example, the prostate cancer protein may be purified using a standard anti-prostate cancer protein antibody column. Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see Scopes, Protein Purification (1982). The degree of purification necessary will vary depending on the use of the prostate cancer protein. In some instances no purification will be necessary. Once expressed and purified if necessary, the prostate cancer proteins and nucleic acids are useful in a number of applications. They may be used as immunoselection reagents, as vaccine reagents, as screening agents, etc. Variants of prostate cancer proteins In one embodiment, the prostate cancer proteins are derivative or variant prostate cancer proteins as compared to the wild-type sequence. That is, as outlined more fully below, the derivative prostate cancer peptide will often contain at least one amino acid substitution, deletion or insertion, with amino acid substitutions being particularly preferred. The amino acid substitution, insertion or deletion may occur at any residue within the prostate cancer peptide. Also included within one embodiment of prostate cancer proteins of the present invention are amino acid sequence variants. These variants typically fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the prostate cancer protein, using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant prostate cancer protein fragments having up to about 100-150 residues may be prepared by in vitro synthesis using established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the prostate cancer protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below. While the site or region for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed prostate cancer variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, e.g., M13 primer mutagenesis and PCR mutagenesis. Screening of the mutants is done using assays of prostate cancer protein activities. Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger. Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the prostate cancer protein are desired, substitutions are generally made in accordance with the amino acid substitution relationships provided in the definition section. The variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analog, although variants also are selected to modify the characteristics of the prostate cancer proteins as needed. Alternatively, the variant may be designed such that the biological activity of the prostate cancer protein is altered. For example, glycosylation sites may be altered or removed. Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those described above. For example, substitutions may be made which more significantly affect: the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the polypeptide's properties are those in which (a) a hydrophilic residue, e.g. seryl or threonyl is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g. lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g. glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g. glycine. Covalent modifications of prostate cancer polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a prostate cancer polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N-or C-terminal residues of a prostate cancer polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking prostate cancer polypeptides to a water-insoluble support matrix or surface for use in the method for purifying anti-prostate cancer polypeptide antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, e.g., l,l-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, e.g., esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N- maleimido-l,8-octane and agents such as methyl-3-((p-azidophenyl)dithio)propioimidate. Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl, threonyl or tyrosyl residues, methylation of the amino groups of the lysine, arginine, and histidine side chains (Creighton, Proteins: Structure and Molecular Properties, pp. 79-86 (1983)), acetylation of the N- terminal amine, and amidation of any C-terminal carboxyl group. Another type of covalent modification of the prostate cancer polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence prostate cancer polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence prostate cancer polypeptide. Glycosylation patterns can be altered in many ways. For example the use of different cell types to express prostate cancer-associated sequences can result in different glycosylation patterns. Addition of glycosylation sites to prostate cancer polypeptides may also be accomplished by altering the amino acid sequence thereof. The alteration may be made, e.g., by the addition of, or substitution by, one or more serine or threonine residues to the native sequence prostate cancer polypeptide (for O-linked glycosylation sites). The prostate cancer amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the prostate cancer polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids. Another means of increasing the number of carbohydrate moieties on the prostate cancer polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330, and in Aplin & Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981). Removal of carbohydrate moieties present on the prostate cancer polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases as described by Thotakura et al., Meth. Enzymol, 138:350 (1987). Another type of covalent modification of prostate cancer comprises linking the prostate cancer polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337. Prostate cancer polypeptides of the present invention may also be modified in a way to form chimeric molecules comprising a prostate cancer polypeptide fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of a prostate cancer polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl-terminus of the prostate cancer polypeptide. The presence of such epitope-tagged forms of a prostate cancer polypeptide can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the prostate cancer polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of a prostate cancer polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule. Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; HIS6 and metal chelation tags, the flu HA tag polypeptide and its antibody 12CA5 (Field et al, Mol. Cell. Biol. 8:2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto (Evan et al, Molecular and Cellular Biology 5:3610-3616 (1985)); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky et al, Protein Engineering 3(6):547-553 (1990)). Other tag polypeptides include the Flag-peptide (Hopp et al, BioTechnology 6:1204-1210 (1988)); the KT3 epitope peptide (Martin et al, Science 255:192-194 (1992)); tubulin epitope peptide (Skinner et al., J. Biol. Chem. 266:15163-15166 (1991)); and the T7 gene 10 protein peptide tag (Lutz-Freyermuth et al, Proc. Natl. Acad. Sci. USA 87:6393-6397 (1990)). Also included are other prostate cancer proteins of the prostate cancer family, and prostate cancer proteins from other organisms, which are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related prostate cancer proteins from humans or other organisms. As will be appreciated by those in the art, particularly useful probe and/or PCR primer sequences include the unique areas of the prostate cancer nucleic acid sequence. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed. The conditions for the PCR reaction are well known in the art (e.g., Innis, PCR Protocols, supra). Antibodies to prostate cancer proteins In a preferred embodiment, when the prostate cancer protein is to be used to generate antibodies, e.g., for immunotherapy or immunodiagnosis, the prostate cancer protein should share at least one epitope or determinant with the full length protein. By "epitope" or "determinant" herein is typically meant a portion of a protein which will generate and/or bind an antibody or T-cell receptor in the context of MHC. Thus, in most instances, antibodies made to a smaller prostate cancer protein will be able to bind to the full-length protein, particularly linear epitopes. In a preferred embodiment; the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity. Methods of preparing polyclonal antibodies are known to the skilled artisan (e.g., Coligan, supra; and Harlow & Lane, supra). Polyclonal antibodies can be raised in a mammal, e.g., by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include a protein encoded by a nucleic acid of the figures or fragment thereof or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation. The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler & Milstein, Nature 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. The immunizing agent will typically include a polypeptide encoded by a nucleic acid of Tables 1- 16 fragment thereof, or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (1986)). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells. In one embodiment, the antibodies are bispecific antibodies. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens or that have binding specificities for two epitopes on the same antigen. In one embodiment, one of the binding specificities is for a protein encoded by a nucleic acid Tables 1-16 or a fragment thereof, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit, preferably one that is tumor specific. Alternatively, tetramer-type technology may create multi valent reagents. In a preferred embodiment, the antibodies to prostate cancer protein are capable of reducing or eliminating a biological function of a prostate cancer protein, as is described below. That is, the addition of anti-prostate cancer protein antibodies (either polyclonal or preferably monoclonal) to prostate cancer tissue (or cells containing prostate cancer) may reduce or eliminate the prostate cancer. Generally, at least a 25% decrease in activity, growth, size or the like is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred. In a preferred embodiment the antibodies to the prostate cancer proteins are humanized antibodies (e.g., Xenerex Biosciences, Mederex, Inc., Abgenix, Inc., Protein Design Labs,Inc.) Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non- human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al, Nature 321:522-525 (1986); Riechmann et al, Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992)). Humanization can be essentially performed following the method of Winter and co-workers (Jones et al, Nature 321:522-525 (1986); Riechmann et al, Nature 332:323-327 (1988); Verhoeyen et al, Science 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Patent No.4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non- human species. Human antibodies can also be produced using various techniques known in the art, including phage display libraries (Hoogenboom & Winter, J. Mol. Biol.227:381 (1991); Marks et al, J. Mol. Biol. 222:581 (1991)). The techniques of Cole et al. and Boerner et al are also available for the preparation of human monoclonal antibodies (Cole et al, Monoclonal Antibodies and Cancer Therapy, p. 77 (1985) and Boerner eta , J. Immunol 147(l):86-95 (1991)). Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, e.g., in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al, Bio Technology 10:779- 783 (1992); Lonberg et al, Nature 368:856-859 (1994); Morrison, Nature 368:812-13 (1994); Fishwild et al, Nature Biotechnology 14:845-51 (1996); Neuberger, Nature Biotechnology 14:826 (1996); Lonberg & Huszar, Intern. Rev. Immunol. 13:65-93 (1995). By immunotherapy is meant treatment of prostate cancer with an antibody raised against prostate cancer proteins. As used herein, immunotherapy can be passive or active. Passive immunotherapy as defined herein is the passive transfer of antibody to a recipient (patient). Active immunization is the induction of antibody and/or T-cell responses in a recipient (patient). Induction of an immune response is the result of providing the recipient with an antigen to which antibodies are raised. As appreciated by one of ordinary skill in the art, the antigen may be provided by injecting a polypeptide against which antibodies are desired to be raised into a recipient, or contacting the recipient with a nucleic acid capable of expressing the antigen and under conditions for expression of the antigen, leading to an immune response. In a preferred embodiment the prostate cancer proteins against which antibodies are raised are secreted proteins as described above. Without being bound by theory, antibodies used for treatment, bind and prevent the secreted protein from binding to its receptor, thereby inactivating the secreted prostate cancer protein. In another preferred embodiment, the prostate cancer protein to which antibodies are raised is a transmembrane protein. Without being bound by theory, antibodies used for treatment, bind the extracellular domain of the prostate cancer protein and prevent it from binding to other proteins, such as circulating ligands or cell-associated molecules. The antibody may cause down-regulation of the transmembrane prostate cancer protein. As will be appreciated by one of ordinary skill in the art, the antibody may be a competitive, non- competitive or uncompetitive inhibitor of protein binding to the extracellular domain of the prostate cancer protein. The antibody is also an antagonist of the prostate cancer protein. Further, the antibody prevents activation of the transmembrane prostate cancer protein. In one aspect, when the antibody prevents the binding of other molecules to the prostate cancer protein, the antibody prevents growth of the cell. The antibody may also be used to target or sensitize the cell to cytotoxic agents, including, but not limited to TNF-cc, TNF-β, DL-l, INF-γ and EL-2, or chemotherapeutic agents including 5FU, vinblastine, actinomycin D, cisplatin, methotrexate, and the like. In some instances the antibody belongs to a sub-type that activates serum complement when complexed with the transmembrane protein thereby mediating cytotoxicity or antigen-dependent cytotoxicity (ADCC). Thus, prostate cancer is treated by administering to a patient antibodies directed against the transmembrane prostate cancer protein. Antibody-labeling may activate a co-toxin, localize a toxin payload, or otherwise provide means to locally ablate cells. In another preferred embodiment, the antibody is conjugated to an effector moiety. The effector moiety can be any number of molecules, including labelling moieties such as radioactive labels or fluorescent labels, or can be a therapeutic moiety. In one aspect the therapeutic moiety is a small molecule that modulates the activity of the prostate cancer protein. In another aspect the therapeutic moiety modulates the activity of molecules associated with or in close proximity to the prostate cancer protein. The therapeutic moiety may inhibit enzymatic activity such as protease or collagenase or protein kinase activity associated with prostate cancer. In a preferred embodiment, the therapeutic moiety can also be a cytotoxic agent. In this method, targeting the cytotoxic agent to prostate cancer tissue or cells, results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with prostate cancer. Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins and their corresponding fragments include diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin and the like. Cytotoxic agents also include radiochemicals made by conjugating radioisotopes to antibodies raised against prostate cancer proteins, or binding of a radionuclide to a chelating agent that has been covalently attached to the antibody. Targeting the therapeutic moiety to transmembrane prostate cancer proteins not only serves to increase the local concentration of therapeutic moiety in the prostate cancer afflicted area, but also serves to reduce deleterious side effects that may be associated with the therapeutic moiety. In another preferred embodiment, the prostate cancer protein against which the antibodies are raised is an intracellular protein. In this case, the antibody may be conjugated to a protein which facilitates entry into the cell. In one case, the antibody enters the cell by endocytosis. In another embodiment, a nucleic acid encoding the antibody is administered to the individual or cell. Moreover, wherein the prostate cancer protein can be targeted within a cell, i.e., the nucleus, an antibody thereto contains a signal for that target localization, i.e., a nuclear localization signal. The prostate cancer antibodies of the invention specifically bind to prostate cancer proteins. By "specifically bind" herein is meant that the antibodies bind to the protein with a K- d of at least about 0.1 mM, more usually at least about 1 μM, preferably at least about 0.1 μM or better, and most preferably, 0.01 μM or better. Selectivity of binding is also important. Detection of prostate cancer sequence for diagnostic and therapeutic applications In one aspect, the RNA expression levels of genes are determined for different cellular states in the prostate cancer phenotype. Expression levels of genes in normal tissue (i.e., not undergoing prostate cancer) and in prostate cancer tissue (and in some cases, for varying severities of prostate cancer that relate to prognosis, as outlined below) are evaluated to provide expression profiles. An expression profile of a particular cell state or point of development is essentially a "fingerprint" of the state. While two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is reflective of the state of the cell. By comparing expression profiles of cells in different states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. Then, diagnosis may be performed or confirmed to determine whether a tissue sample has the gene expression profile of normal or cancerous tissue. This will provide for molecular diagnosis of related conditions. "Differential expression," or grammatical equivalents as used herein, refers to qualitative or quantitative differences in the temporal and/or cellular gene expression patterns within and among cells and tissue. Thus, a differentially expressed gene can qualitatively have its expression altered, including an activation or inactivation, in, e.g., normal versus prostate cancer tissue. Genes may be turned on or turned off in a particular state, relative to another state thus permitting comparison of two or more states. A qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by standard techniques. Some genes will be expressed in one state or cell type, but not in both. Alternatively, the difference in expression may be quantitative, e.g., in that expression is increased or decreased; i.e., gene expression is either upregulated, resulting in an increased amount of transcript, or downregulated, resulting in a decreased amount of transcript. The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by use of Affymetrix GeneChip™ expression arrays, Lockhart, Nature Biotechnology 14: 1675-1680 (1996), hereby expressly incorporated by reference. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, northern analysis and RNase protection. As outlined above, preferably the change in expression (i.e., upregulation or downregulation) is at least about 50%, more preferably at least about 100%, more preferably at least about 150%, more preferably at least about 200%, with from 300 to at least 1000% being especially preferred. Evaluation may be at the gene transcript, or the protein level. The amount of gene expression may be monitored using nucleic acid probes to the DNA or RNA equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, e.g., with antibodies to the prostate cancer protein and standard immunoassays (ELIS As, etc.) or other techniques, including mass spectroscopy assays, 2D gel electrophoresis assays, etc. Proteins corresponding to prostate cancer genes, i.e., those identified as being important in a prostate cancer phenotype, can be evaluated in a prostate cancer diagnostic test. In a preferred embodiment, gene expression monitoring is performed simultaneously on a number of genes. Multiple protein expression monitoring can be performed as well. Similarly, these assays may be performed on an individual basis as well. In this embodiment, the prostate cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of prostate cancer sequences in a particular cell. The assays are further described below in the example. PCR techniques can be used to provide greater sensitivity. In a preferred embodiment nucleic acids encoding the prostate cancer protein are detected. Although DNA or RNA encoding the prostate cancer protein may be detected, of particular interest are methods wherein an mRNA encoding a prostate cancer protein is detected. Probes to detect mRNA can be a nucleotide/deoxynucleotide probe that is complementary to and hybridizes with the mRNA and includes, but is not limited to, oligonucleotides, cDNA or RNA. Probes also should contain a detectable label, as defined herein. In one method the mRNA is detected after immobilizing the nucleic acid to be examined on a solid support such as nylon membranes and hybridizing the probe with the sample. Following washing to remove the non-specifically bound probe, the label is detected. In another method detection of the mRNA is performed in situ. In this method permeabilized cells or tissue samples are contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA. Following washing to remove the non-specifically bound probe, the label is detected. For example a digoxygenin labeled riboprobe (RNA probe) that is complementary to the mRNA encoding a prostate cancer protein is detected by binding the digoxygenin with an anti-digoxygenin secondary antibody and developed with nitro blue tetrazolium and 5-bromo-4-chloro-3- indoyl phosphate. In a preferred embodiment, various proteins from the three classes of proteins as described herein (secreted, transmembrane or intracellular proteins) are used in diagnostic assays. The prostate cancer proteins, antibodies, nucleic acids, modified proteins and cells containing prostate cancer sequences are used in diagnostic assays. This can be performed on an individual gene or corresponding polypeptide level. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes and/or corresponding polypeptides. As described and defined herein, prostate cancer proteins, including intracellular, transmembrane or secreted proteins, find use as markers of prostate cancer. Detection of these proteins in putative prostate cancer tissue allows for detection or diagnosis of prostate cancer. In one embodiment, antibodies are used to detect prostate cancer proteins. A preferred method separates proteins from a sample by electrophoresis on a gel (typically a denaturing and reducing protein gel, but may be another type of gel, including isoelectric focusing gels and the like). Following separation of proteins, the prostate cancer protein is detected, e.g., by immunoblotting with antibodies raised against the prostate cancer protein. Methods of immunoblotting are well known to those of ordinary skill in the art. In another preferred method, antibodies to the prostate cancer protein find use in in situ imaging techniques, e.g., in histology (e.g., Methods in Cell Biology: Antibodies in Cell Biology, volume 37 (Asai, ed. 1993)). In this method cells are contacted with from one to many antibodies to the prostate cancer protein(s). Following washing to remove nonspecific antibody binding, the presence of the antibody or antibodies is detected. In one embodiment the antibody is detected by incubating with a secondary antibody that contains a detectable label. In another method the primary antibody to the prostate cancer protein(s) contains a detectable label, e.g. an enzyme marker that can act on a substrate. In another preferred embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in simultaneous screening for a plurality of prostate cancer proteins. As will be appreciated by one of ordinary skill in the art, many other histological imaging techniques are also provided by the invention. In a preferred embodiment the label is detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in the method. In another preferred embodiment, antibodies find use in diagnosing prostate cancer from blood, serum, plasma, stool, and other samples. Such samples, therefore, are useful as samples to be probed or tested for the presence of prostate cancer proteins. Antibodies can be used to detect a prostate cancer protein by previously described immunoassay techniques including ELISA, immunoblotting (western blotting), immunoprecipitation, BIACORE technology and the like. Conversely, the presence of antibodies may indicate an immune response against an endogenous prostate cancer protein. In a preferred embodiment, in situ hybridization of labeled prostate cancer nucleic acid probes to tissue arrays is done. For example, arrays of tissue samples, including prostate cancer tissue and/or normal tissue, are made. In situ hybridization (see, e.g., Ausubel, supra) is then performed. When comparing the fingerprints between an individual and a standard, the skilled artisan can make a diagnosis, a prognosis, or a prediction based on the findings. It is further understood that the genes which indicate the diagnosis may differ from those which indicate the prognosis and molecular profiling of the condition of the cells may lead to distinctions between responsive or refractory conditions or may be predictive of outcomes. In a preferred embodiment, the prostate cancer proteins, antibodies, nucleic acids, modified proteins and cells containing prostate cancer sequences are used in prognosis assays. As above, gene expression profiles can be generated that correlate to prostate cancer, in terms of long term prognosis. Again, this may be done on either a protein or gene level, with the use of genes being preferred. As above, prostate cancer probes may be attached to biochips for the detection and quantification of prostate cancer sequences in a tissue or patient. The assays proceed as outlined above for diagnosis. PCR method may provide more sensitive and accurate quantification. Assays for therapeutic compounds In a preferred embodiment members of the proteins, nucleic acids, and antibodies as described herein are used in drug screening assays. The prostate cancer proteins, antibodies, nucleic acids, modified proteins and cells containing prostate cancer sequences are used in drug screening assays or by evaluating the effect of drug candidates on a "gene expression profile" or expression profile of polypeptides. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent (e.g., Zlokarnik, et al, Science 279:84-8 (1998); Heid, Genome Res 6:986-94, 1996). In a preferred embodiment, the prostate cancer proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified prostate cancer proteins are used in screening assays. That is, the present invention provides novel methods for screening for compositions which modulate the prostate cancer phenotype or an identified physiological function of a prostate cancer protein. As above, this can be done on an individual gene level or by evaluating the effect of drug candidates on a "gene expression profile". In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent, see Zlokarnik, supra. Having identified the differentially expressed genes herein, a variety of assays may be executed. In a preferred embodiment, assays may be run on an individual gene or protein level. That is, having identified a particular gene as up regulated in prostate cancer, test compounds can be screened for the ability to modulate gene expression or for binding to the prostate cancer protein. "Modulation" thus includes both an increase and a decrease in gene expression. The preferred amount of modulation will depend on the original change of the gene expression in normal versus tissue undergoing prostate cancer, with changes of at least 10%, preferably 50%, more preferably 100-300%, and in some embodiments 300- 1000% or greater. Thus, if a gene exhibits a 4-fold increase in prostate cancer tissue compared to normal tissue, a decrease of about four-fold is often desired; similarly, a 10-fold decrease in prostate cancer tissue compared to normal tissue often provides a target value of a 10-fold increase in expression to be induced by the test compound. The amount of gene expression may be monitored using nucleic acid probes and the quantification of gene expression levels, or, alternatively, the gene product itself can be monitored, e.g., through the use of antibodies to the prostate cancer protein and standard immunoassays. Proteomics and separation techniques may also allow quantification of expression. . In a preferred embodiment, gene expression or protein monitoring of a number of entities, i.e., an expression profile, is monitored simultaneously. Such profiles will typically involve a plurality of those entities described herein.. In this embodiment, the prostate cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of prostate cancer sequences in a particular cell. Alternatively, PCR may be used. Thus, a series, e.g., of microtiter plate, may be used with dispensed primers in desired wells. A PCR reaction can then be performed and analyzed for each well. Expression monitoring can be performed to identify compounds that modify the expression of one or more prostate cancer-associated sequences, e.g., a polynucleotide sequence set out in Tables 1-16. Generally, in a preferred embodiment, a test modulator is added to the cells prior to analysis. Moreover, screens are also provided to identify agents that modulate prostate cancer, modulate prostate cancer proteins, bind to a prostate cancer protein, or interfere with the binding of a prostate cancer protein and an antibody or other binding partner. The term "test compound" or "drug candidate" or "modulator" or grammatical equivalents as used herein describes any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for the capacity to directly or indirectly alter the prostate cancer phenotype or the expression of a prostate cancer sequence, e.g., a nucleic acid or protein sequence. In preferred embodiments, modulators alter expression profiles, or expression profile nucleic acids or proteins provided herein. In one embodiment, the modulator suppresses a prostate cancer phenotype, e.g. to a normal tissue fingerprint. In another embodiment, a modulator induced a prostate cancer phenotype. Generally, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection. Drug candidates encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Preferred small molecules are less than 2000, or less than 1500 or less than 1000 or less than 500 D. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides. In one aspect, a modulator will neutralize the effect of a prostate cancer protein. By "neutralize" is meant that activity of a protein is inhibited or blocked and the consequent effect on the cell. In certain embodiments, combinatorial libraries of potential modulators will be screened for an ability to bind to a prostate cancer polypeptide or to modulate activity. Conventionally, new chemical entities with useful properties are generated by identifying a chemical compound (called a "lead compound") with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis. In one preferred embodiment, high throughput screening methods involve providing a library containing a large number of potential therapeutic compounds (candidate compounds). Such "combinatorial chemical libraries" are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics. A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide (e.g., mutein) library, is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks (Gallop et al, J. Med. Chem. 37(9): 1233-1251 (1994)). Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Patent No. 5,010,175, Furka, Pept. Prot. Res. 37:487-493 (1991), Houghton et al, Nature, 354:84-88 (1991)), peptoids (PCT Publication No WO 91/19735), encoded peptides (PCT Publication WO 93/20242), random bio-oligomers (PCT Publication WO 92/00091), benzodiazepines (U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs et al, Proc. Nat. Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara et al., J. Amer. Chem. Soc. 114:6568 (1992)), nonpeptidal peptidomimetics with a Beta-D-Glucose scaffolding (Hirschmann et al, J. Amer. Chem. Soc. 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen et al, J. Amer. Chem. Soc. 116:2661 (1994)), oligocarbamates (Cho, et al, Science 261: 1303 (1993)), and/or peptidyl phosphonates (Campbell et al, J. Org. Chem. 59:658 (1994)). See, generally, Gordon et al, J. Med. Chem. 37:1385 (1994), nucleic acid libraries (see, e.g., Strategene, Corp.), peptide nucleic acid libraries (see, e.g., U.S. Patent 5,539,083), antibody libraries (see, e.g., Vaughn et al, Nature Biotechnology 14(3):309-314 (1996), and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al, Science 21 A: 1520-1522 (1996), and U.S. Patent No. 5,593,853), and small organic molecule libraries (see, e.g., benzodiazepines, Baum, C&EN, Jan 18, page 33 (1993); isoprenoids, U.S. Patent No. 5,569,588; thiazolidinones and metathiazanones, U.S. Patent No. 5,549,974; pyrrolidines, U.S. Patent Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Patent No. 5,506,337; benzodiazepines, U.S. Patent No. 5,288,514; and the like). Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA). A number of well known robotic systems have also been developed for solution phase chemistries. These systems include automated workstations like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate π, Zymark Corporation, Hopkinton, Mass.; Orca, Hewlett-Packard, Palo Alto, Calif.), which mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use with the present invention. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art. In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis, MO, ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, etc.). The assays to identify modulators are amenable to high throughput screening. Preferred assays thus detect enhancement or inhibition of prostate cancer gene transcription, inhibition or enhancement of polypeptide expression, and inhibition or enhancement of polypeptide activity. High throughput assays for the presence, absence, quantification, or other properties of particular nucleic acids or protein products are well known to those of skill in the art. Similarly, binding assays and reporter gene assays are similarly well known. Thus, e.g., U.S. Patent No. 5,559,410 discloses high throughput screening methods for proteins, U.S. Patent No. 5,585,639 discloses high throughput screening methods for nucleic acid binding (i.e., in arrays), while U.S. Patent Nos. 5,576,220 and 5,541,061 disclose high throughput methods of screening for ligand/antibody binding. In addition, high throughput screening systems are commercially available (see, e.g., Zymark Corp., Hopkinton, MA; Air Technical Industries, Mentor, OH; Beckman Instruments, Inc. FuIIerton, CA; Precision Systems, Inc., Natick, MA, etc.). These systems typically automate entire procedures, including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for various high throughput systems. Thus, e.g., Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like. In one embodiment, modulators are proteins, often naturally occurring proteins or fragments of naturally occurring proteins. Thus, e.g., cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of proteins may be made for screening in the methods of the invention. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially preferred. Particularly useful test compound will be directed to the class of proteins to which the target belongs, e.g., substrates for enzymes or ligands and receptors. In a preferred embodiment, modulators are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. The peptides may be digests of naturally occurring proteins as is outlined above, random peptides, or "biased" random peptides. By "randomized" or grammatical equivalents herein is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. Since generally these random peptides (or nucleic acids, discussed below) are chemically synthesized, they may incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents. In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. For example, in a preferred embodiment, the nucleotides or amino acid residues are randomized within a defined class, e.g., of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc. Modulators of prostate cancer can also be nucleic acids, as defined below. As described above generally for proteins, nucleic acid modulating agents may be naturally occurring nucleic acids, random nucleic acids, or "biased" random nucleic acids. For example, digests of procaryotic or eucaryotic genomes may be used as is outlined above for proteins. In certain embodiments, the activity of a prostate cancer-associated protein is down-regulated, or entirely inhibited, by the use of antisense polynucleotide, i.e., a nucleic acid complementary to, and which can preferably hybridize specifically to, a coding mRNA nucleic acid sequence, e.g., a prostate cancer protein mRNA, or a subsequence thereof. Binding of the antisense polynucleotide to the mRNA reduces the translation and/or stability of the mRNA. In the context of this invention, antisense polynucleotides can comprise naturally-occurring nucleotides, or synthetic species formed from naturally-occurring subunits or their close homologs. Antisense polynucleotides may also have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothioate and other sulfur containing species which are known for use in the art. Analogs are comprehended by this invention so long as they function effectively to hybridize with the prostate cancer protein mRNA. See, e.g., Isis Pharmaceuticals, Carlsbad, CA; Sequitor, Inc., Natick, MA. Such antisense polynucleotides can readily be synthesized using recombinant means, or can be synthesized in vitro. Equipment for such synthesis is sold by several vendors, including Applied Biosystems. The preparation of other oUgonucleotides such as phosphorothioates and alkylated derivatives is also well known to those of skill in the art. Antisense molecules as used herein include antisense or sense oligonucleotides. Sense oligonucleotides can, e.g., be employed to block transcription by binding to the anti-sense strand. The antisense and sense oligonucleotide comprise a single- stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences for prostate cancer molecules. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, e.g., Stein & Cohen (Cancer Res. 48:2659 (1988 and van der Krol et al. (BioTechniques 6:958 (1988)). In addition to antisense polynucleotides, ribozymes can be used to target and inhibit transcription of prostate cancer-associated nucleotide sequences. A ribozyme is an RNA molecule that catalytically cleaves other RNA molecules. Different kinds of ribozymes have been described, including group I ribozymes, hammerhead ribozymes, hairpin ribozymes, RNase P, and axhead ribozymes (see, e.g., Castanotto et al., Adv. in Pharmacology 25: 289-317 (1994) for a general review of the properties of different ribozymes). The general features of hairpin ribozymes are described, e.g., in Hampel et al, Nucl. Acids Res. 18:299-304 (1990); European Patent Publication No. 0 360257; U.S. Patent No. 5,254,678. Methods of preparing are well known to those of skill in the art (see, e.g., WO 94/26877; Ojwang et al, Proc. Natl. Acad. Sci. USA 90:6340-6344 (1993); Yamada et al, Human Gene Therapy 1:39-45 (1994); Leavitt et al, Proc. Natl. Acad. Sci. USA 92:699- 703 (1995); Leavitt et al, Human Gene Therapy 5:1151-120 (1994); and Yamada et al, Virology 205: 121-126 (1994)). Polynucleotide modulators of prostate cancer may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a polynucleotide modulator of prostate cancer may be introduced into a cell containing the target nucleic acid sequence, e.g., by formation of an polynucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition" to methods of treatment. As noted above, gene expression monitoring is conveniently used to test candidate modultors (e.g., protein, nucleic acid or small molecule). After the candidate agent has been added and the cells allowed to incubate for some period of time, the sample containing a target sequence to be analyzed is added to the biochip. If required, the target sequence is prepared using known techniques. For example, the sample may be treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR performed as appropriate. For example, an in vitro transcription with labels covalently attached to the nucleotides is performed. Generally, the nucleic acids are labeled with biotin-FITC or PE, or with cy3 or cy5. In a preferred embodiment, the target sequence is labeled with, e.g., a fluorescent, a chemiluminescent, a chemical, or a radioactive signal, to provide a means of detecting the target sequence's specific binding to a probe. The label also can be an enzyme, such as, alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that can be detected. Alternatively, the label can be a labeled compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence. Unbound labeled streptavidin is typically removed prior to analysis. As will be appreciated by those in the art, these assays can be direct hybridization assays or can comprise "sandwich assays", which include the use of multiple probes, as is generally outlined in U.S. Patent Nos. 5,681,702, 5,597,909, 5,545,730, 5.594.117, 5,591,584, 5,571,670, 5,580,731, 5,571,670, 5,591,584, 5,624,802, 5,635,352, 5.594.118, 5,359,100, 5,124,246 and 5,681,697, all of which are hereby incorporated by reference. In this embodiment, in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex. A variety of hybridization conditions may be used in the present invention, including high, moderate and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allows formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to, temperature, formamide concentration, salt concentration, chaotropic salt concentration pH, organic solvent concentration, etc. These parameters may also be used to control non-specific binding, as is generally outlined in U.S. Patent No. 5,681,697. Thus it may be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding. The reactions outlined herein may be accomplished in a variety of ways. Components of the reaction may be added simultaneously, or sequentially, in different orders, with preferred embodiments outlined below. In addition, the reaction may include a variety of other reagents. These include salts, buffers, neutral proteins, e.g. albumin, detergents, etc. which may be used to facilitate optimal hybridization and detection, and/or reduce nonspecific or background interactions. Reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may also be used as appropriate, depending on the sample preparation methods and purity of the target. The assay data are analyzed to determine the expression levels, and changes in expression levels as between states, of individual genes, forming a gene expression profile. Screens are performed to identify modulators of the prostate cancer phenotype. In one embodiment, screening is performed to identify modulators that can induce or suppress a particular expression profile, thus preferably generating the associated phenotype. In another embodiment, e.g., for diagnostic applications, having identified differentially expressed genes important in a particular state, screens can be performed to identify modulators that alter expression of individual genes. In an another embodiment, screening is performed to identify modulators that alter a biological function of the expression product of a differentially expressed gene. Again, having identified the importance of a gene in a particular state, screens are performed to identify agents that bind and/or modulate the biological activity of the gene product. In addition screens can be done for genes that are induced in response to a candidate agent. After identifying a modulator based upon its ability to suppress a prostate cancer expression pattern leading to a normal expression pattern, or to modulate a single prostate cancer gene expression profile so as to mimic the expression of the gene from normal tissue, a screen as described above can be performed to identify genes that are specifically modulated in response to the agent. Comparing expression profiles between normal tissue and agent treated prostate cancer tissue reveals genes that are not expressed in normal tissue or prostate cancer tissue, but are expressed in agent treated tissue. These agent- specific sequences can be identified and used by methods described herein for prostate cancer genes or proteins. In particular these sequences and the proteins they encode find use in marking or identifying agent treated cells. In addition, antibodies can be raised against the agent induced proteins and used to target novel therapeutics to the treated prostate cancer tissue sample. Thus, in one embodiment, a test compound is administered to a population of prostate cancer cells, that have an associated prostate cancer expression profile. By "administration" or "contacting" herein is meant that the candidate agent is added to the cells in such a manner as to allow the agent to act upon the cell, whether by uptake and intracellular action, or by action at the cell surface. In some embodiments, nucleic acid encoding a proteinaceous candidate agent (i.e., a peptide) may be put into a viral construct such as an adenoviral or retroviral construct, and added to the cell, such that expression of the peptide agent is accomplished, e.g., PCT US97/01019. Regulatable gene therapy systems can also be used. Once the test compound has been administered to the cells, the cells can be washed if desired and are allowed to incubate under preferably physiological conditions for some period of time. The cells are then harvested and a new gene expression profile is generated, as outlined herein. Thus, e.g., prostate cancer tissue may be screened for agents that modulate, e.g., induce or suppress the prostate cancer phenotype. A change in at least one gene, preferably many, of the expression profile indicates that the agent has an effect on prostate cancer activity. By defining such a signature for the prostate cancer phenotype, screens for new drugs that alter the phenotype can be devised. With this approach, the drug target need not be known and need not be represented in the original expression screening platform, nor does the level of transcript for the target protein need to change. In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular • differentially expressed gene as important in a particular state, screening of modulators of either the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "prostate cancer proteins" or a "prostate cancer modulatory protein". The prostate cancer modulatory protein may be a fragment, or alternatively, be the full length protein to the fragment encoded by the nucleic acids of Tables 1-16. Preferably, the prostate cancer modulatory protein is a fragment. In a preferred embodiment, the prostate cancer amino acid sequence which is used to determine sequence identity or similarity is encoded by a nucleic acid of Tables 1-16. In another embodiment, the sequences are naturally occurring allelic variants of a protein encoded by a nucleic acid of Tables 1-16. In another embodiment, the sequences are sequence variants as further described herein. Preferably, the prostate cancer modulatory protein is a fragment of approximately 14 to 24 amino acids long. More preferably the fragment is a soluble fragment. Preferably, the fragment includes a non-transmembrane region. In a preferred embodiment, the fragment has an N-terminal Cys to aid in solubility. In one embodiment, the C-terminus of the fragment is kept as a free acid and the N-terminus is a free amine to aid in coupling, i.e., to cysteine. In one embodiment the prostate cancer proteins are conjugated to an immunogenic agent as discussed herein. In one embodiment the prostate cancer protein is conjugated to BSA. Measurements of prostate cancer polypeptide activity, or of prostate cancer or the prostate cancer phenotype can be performed using a variety of assays. For example, the effects of the test compounds upon the function of the prostate cancer polypeptides can be measured by examining parameters described above. A suitable physiological change that affects activity can be used to assess the influence of a test compound on the polypeptides of this invention. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as, in the case of prostate cancer associated with tumors, tumor growth, tumor metastasis, neovascularization, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e.g., northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as cGMP. In the assays of the invention, mammalian prostate cancer polypeptide is typically used, e.g., mouse, preferably human. Assays to identify compounds with modulating activity can be performed in vitro. For example, a prostate cancer polypeptide is first contacted with a potential modulator and incubated for a suitable amount of time, e.g., from 0.5 to 48 hours. In one embodiment, the prostate cancer polypeptide levels are determined in vitro by measuring the level of protein or mRNA. The level of protein is measured using immunoassays such as western blotting, ELIS A and the like with an antibody that selectively binds to the prostate cancer polypeptide or a fragment thereof. For measurement of mRNA, amplification, e.g., using PCR, LCR, or hybridization assays, e.g., northern hybridization, RNAse protection, dot blotting, are preferred. The level of protein or mRNA is detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein. Alternatively, a reporter gene system can be devised using the prostate cancer protein promoter operably linked to a reporter gene such as luciferase, green fluorescent protein, CAT, or β-gal. The reporter construct is typically transfected into a cell. After treatment with a potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques known to those of skill in the art. In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "prostate cancer proteins." The prostate cancer protein may be a fragment, or alternatively, be the full length protein to a fragment shown herein. In one embodiment, screening for modulators of expression of specific genes is performed. Typically, the expression of only one or a few genes are evaluated. In another embodiment, screens are designed to first find compounds that bind to differentially expressed proteins. These compounds are then evaluated for the ability to modulate differentially expressed activity. Moreover, once initial candidate compounds are identified, variants can be further screened to better evaluate structure activity relationships. In a preferred embodiment, binding assays are done. In general, purified or isolated gene product is used; that is, the gene products of one or more differentially expressed nucleic acids are made. For example, antibodies are generated to the protein gene products, and standard immunoassays are run to determine the amount of protein present. Alternatively, cells comprising the prostate cancer proteins can be used in the assays. Thus, in a preferred embodiment, the methods comprise combining a prostate cancer protein and a candidate compound, and determining the binding of the compound to the prostate cancer protein. Preferred embodiments utilize the human prostate cancer protein, although other mammalian proteins may also be used, e.g. for the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative prostate cancer proteins may be used. Generally, in a preferred embodiment of the methods herein, the prostate cancer protein or the candidate agent is non-diffusably bound to an insoluble support having isolated sample receiving areas (e.g. a microtiter plate, an array, etc.). The insoluble supports may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, teflon™, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety. In a preferred embodiment, the prostate cancer protein is bound to the support, and a test compound is added to the assay. Alternatively, the candidate agent is bound to the support and the prostate cancer protein is added. Novel binding agents include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like. The determination of the binding of the test modulating compound to the prostate cancer protein may be done in a number of ways. In a preferred embodiment, the compound is labeled, and binding determined directly, e.g., by attaching all or a portion of the prostate cancer protein to a solid support, adding a labeled candidate agent (e.g., a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps may be utilized as appropriate. In some embodiments, only one of the components is labeled, e.g., the proteins (or proteinaceous candidate compounds) can be labeled. Alternatively, more than one component can be labeled with different labels, e.g., 125 I for the proteins and a fluorophor for the compound. Proximity reagents, e.g., quenching or energy transfer reagents are also useful. In one embodiment, the binding of the test compound is determined by competitive binding assay. The competitor is a binding moiety known to bind to the target molecule (i.e., a prostate cancer protein), such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding between the compound and the binding moiety, with the binding moiety displacing the compound. In one embodiment, the test compound is labeled. Either the compound, or the competitor, or both, is added first to the protein for a time sufficient to allow binding, if present. Incubations may be performed at a temperature which facilitates optimal activity, typically between 4 and 40°C. Incubation periods are typically optimized, e.g., to facilitate rapid high throughput screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding. In a preferred embodiment, the competitor is added first, followed by the test compound. Displacement of the competitor is an indication that the test compound is binding to the prostate cancer protein and thus is capable of binding to, and potentially modulating, the activity of the prostate cancer protein. In this embodiment, either component can be labeled. Thus, e.g., if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the test compound is labeled, the presence of the label on the support indicates displacement. In an alternative embodiment, the test compound is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the test compound is bound to the prostate cancer protein with a higher affinity. Thus, if the test compound is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate that the test compound is capable of binding to the prostate cancer protein. In a preferred embodiment, the methods comprise differential screening to identity agents that are capable of modulating the activity of the prostate cancer proteins. In this embodiment, the methods comprise combining a prostate cancer protein and a competitor in a first sample. A second sample comprises a test compound, a prostate cancer protein, and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the prostate cancer protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the prostate cancer protein. Alternatively, differential screening is used to identify drug candidates that bind to the native prostate cancer protein, but cannot bind to modified prostate cancer proteins. The structure of the prostate cancer protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect the activity of a prostate cancer protein are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein. Positive controls and negative controls may be used in the assays. Preferably control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound. A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc. which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in an order that provides for the requisite binding. In a preferred embodiment, the invention provides methods for screening for a compound capable of modulating the activity of a prostate cancer protein. The methods comprise adding a test compound, as defined above, to a cell comprising prostate cancer proteins. Preferred cell types include almost any cell. The cells contain a recombinant nucleic acid that encodes a prostate cancer protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells. In one aspect, the assays are evaluated in the presence or absence or previous or subsequent exposure of physiological signals, e.g. hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (i.e. cell-cell contacts). In another example, the determinations are determined at different stages of the cell cycle process. In this way, compounds that modulate prostate cancer agents are identified. Compounds with pharmacological activity are able to enhance or interfere with the activity of the prostate cancer protein. Once identified, similar structures are evaluated to identify critical structural feature of the compound. In one embodiment, a method of inhibiting prostate cancer cell division is provided. The method comprises administration of a prostate cancer inhibitor. In another embodiment, a method of inhibiting prostate cancer is provided. The method comprises administration of a prostate cancer inhibitor. In a further embodiment, methods of treating cells or individuals with prostate cancer are provided. The method comprises administration of a prostate cancer inhibitor. In one embodiment, a prostate cancer inhibitor is an antibody as discussed above. In another embodiment, the prostate cancer inhibitor is an antisense molecule. A variety of cell growth, proliferation, and metastasis assays are known to those of skill in the art, as described below. Soft agar growth or colony formation in suspension Normal cells require a solid substrate to attach and grow. When the cells are transformed, they lose this phenotype and grow detached from the substrate. For example, transformed cells can grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft agar. The transformed cells, when transfected with tumor suppressor genes, regenerate normal phenotype and require a solid substrate to attach and grow. Soft agar growth or colony formation in suspension assays can be used to identify modulators of prostate cancer sequences, which when expressed in host cells, inhibit abnormal cellular proliferation and transformation. A therapeutic compound would reduce or eliminate the host cells' ability to grow in stirred suspension culture or suspended in semi- solid media, such as semi-solid or soft. Techniques for soft agar growth or colony formation in suspension assays are described in Freshney, Culture of Animal Cells a Manual of Basic Technique (3 rd ed., 1994), herein incorporated by reference. See also, the methods section of Garkavtsev et al. (1996), supra, herein incorporated by reference. Contact inhibition and density limitation of growth Normal cells typically grow in a flat and organized pattern in a petri dish until they touch other cells. When the cells touch one another, they are contact inhibited and stop growing. When cells are transformed, however, the cells are not contact inhibited and continue to grow to high densities in disorganized foci. Thus, the transformed cells grow to a higher saturation density than normal cells. This can be detected morphologically by the formation of a disoriented monolayer of cells or rounded cells in foci within the regular pattern of normal surrounding cells. Alternatively, labeling index with ( 3 H)-thymidine at saturation density can be used to measure density limitation of growth. See Freshney (1994), supra. The transformed cells, when transfected with tumor suppressor genes, regenerate a normal phenotype and become contact inhibited and would grow to a lower density. In this assay, labeling index with ( 3 H)-thymidine at saturation density is a preferred method of measuring density limitation of growth. Transformed host cells are transfected with a prostate cancer-associated sequence and are grown for 24 hours at saturation density in non-limiting medium conditions. The percentage of cells labeling with ( 3 H)-thymidine is determined autoradiographically. See, Freshney (1994), supra. Growth factor or serum dependence Transformed cells have a lower serum dependence than their normal counterparts (see, e.g., Temin, J. Natl. Cancer Insti. 37:167-175 (1966); Eagle et al, J. Exp. Med. 131:836-879 (1970)); Freshney, supra. This is in part due to release of various growth factors by the transformed cells. Growth factor or serum dependence of transformed host cells can be compared with that of control. Tumor specific markers levels Tumor cells release an increased amount of certain factors (hereinafter "tumor specific markers") than their normal counterparts. For example, plasminogen activator (PA) is released from human glioma at a higher level than from normal brain cells (see, e.g., Gullino, Angiogenesis, tumor vascularization, and potential interference with tumor growth. in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985)). Similarly, Tumor angiogenesis factor (TAF) is released at a higher level in tumor cells than their normal counterparts. See, e.g., Folkman, Angiogenesis and Cancer, Sem Cancer Biol. (1992)). Various techniques which measure the release of these factors are described in Freshney (1994), supra. Also, see, Unkless et al. , J. Biol. Chem. 249:4295-4305 (1974); Strickland & Beers, J. Biol. Chem. 251:5694-5702 (1976); Whur et al, Br. J. Cancer 42:305- 312 (1980); Gullino, Angiogenesis, tumor vascularization, and potential interference with tumor growth, in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985); Freshney Anticancer Res. 5:111-130 (1985). Invasiveness into Matrigel The degree of invasiveness into Matrigel-or some other extracellular matrix constituent can be used as an assay to identify compounds that modulate prostate cancer- associated sequences. Tumor cells exhibit a good correlation between malignancy and invasiveness of cells into Matrigel or some other extracellular matrix constituent. In this assay, tumorigenic cells are typically used as host cells. Expression of a tumor suppressor gene in these host cells would decrease invasiveness of the host cells. Techniques described in Freshney (1994), supra, can be used. Briefly, the level of invasion of host cells can be measured by using filters coated with Matrigel or some other extracellular matrix constituent. Penetration into the gel, or through to the distal side of the filter, is rated as invasiveness, and rated histologically by number of cells and distance moved, or by prelabeling the cells with 125 I and counting the radioactivity on the distal side of the filter or bottom of the dish. See, e.g., Freshney (1984), supra. Tumor growth in vivo Effects of prostate cancer-associated sequences on cell growth can be tested in transgenic or immune-suppressed mice. Knock-out transgenic mice can be made, in which the prostate cancer gene is disrupted or in which a prostate cancer gene is inserted. Knock- out transgenic mice can be made by insertion of a marker gene or other heterologous gene into the endogenous prostate cancer gene site in the mouse genome via homologous recombination. Such mice can also be made by substituting the endogenous prostate cancer gene with a mutated version of the prostate cancer gene, or by mutating the endogenous prostate cancer gene, e.g., by exposure to carcinogens. A DNA construct is introduced into the nuclei of embryonic stem cells. Cells containing the newly engineered genetic lesion are injected into a host mouse embryo, which is re-implanted into a recipient female. Some of these embryos develop into chimeric mice that possess germ cells partially derived from the mutant cell line. Therefore, by breeding the chimeric mice it is possible to obtain a new line of mice containing the introduced genetic lesion (see, e.g., Capecchi et al, Science 244:1288 (1989)). Chimeric targeted mice can be derived according to Hogan et al, Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory (1988) and Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, ed., IRL Press, Washington, D.C., (1987). Alternatively, various immune-suppressed or immune-deficient host animals can be used. For example, genetically athymic "nude" mouse (see, e.g., Giovanella et al, J. Natl. Cancer Inst. 52:921 (1974)), a SCID mouse, a thymectomized mouse, or an irradiated mouse (see, e.g., Bradley et al, Br. J. Cancer 38:263 (1978); Selby et al, Br. J. Cancer 41:52 (1980)) can be used as a host. Transplantable tumor cells (typically about 10 6 cells) injected into isogenic hosts will produce invasive tumors in a high proportions of cases, while normal cells of similar origin will not. In hosts which developed invasive tumors, cells expressing a prostate cancer-associated sequences are injected subcutaneously. After a suitable length of time, preferably 4-8 weeks, tumor growth is measured (e.g., by volume or by its two largest dimensions) and compared to the control. Tumors that have statistically significant reduction (using, e.g., Student's T test) are said to have inhibited growth. Methods of identifying variant prostate cancer-associated sequences Without being bound by theory, expression of various prostate cancer sequences is correlated with prostate cancer. Accordingly, disorders based on mutant or variant prostate cancer genes may be determined. In one embodiment, the invention provides methods for identifying cells containing variant prostate cancer genes, e.g., determining all or part of the sequence of at least one endogenous prostate cancer genes in a cell. This may be accomplished using any number of sequencing techniques. In a preferred embodiment, the invention provides methods of identifying the prostate cancer genotype of an individual, e.g., determining all or part of the sequence of at least one prostate cancer gene of the individual. This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced prostate cancer gene to a known prostate cancer gene, i.e., a wild-type gene. The sequence of all or part of the prostate cancer gene can then be compared to the sequence of a known prostate cancer gene to determine if any differences exist. This can be done using any number of known homology programs, such as Bestfit, etc. In a preferred embodiment, the presence of a difference in the sequence between the prostate cancer gene of the patient and the known prostate cancer gene correlates with a disease state or a propensity for a disease state, as outlined herein. In a preferred embodiment, the prostate cancer genes are used as probes to determine the number of copies of the prostate cancer gene in the genome. In another preferred embodiment, the prostate cancer genes are used as probes to determine the chromosomal localization of the prostate cancer genes. Information such as chromosomal localization finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in the prostate cancer gene locus. Administration of pharmaceutical and vaccine compositions In one embodiment, a therapeutically effective dose of a prostate cancer protein or modulator thereof, is administered to a patient. By "therapeutically effective dose" herein is meant a dose that produces effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (e.g., Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery; Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992), Dekker, ISBN 0824770846, 082476918X, 0824712692, 0824716981; Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); and Pickar, Dosage Calculations (1999)). As is known in the art, adjustments for prostate cancer degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art. U.S. Patent Application N. 09/687,576, further discloses the use of compositions and methods of diagnosis and treatment in prostate cancer is hereby expressly incorporated by reference. A "patient" for the purposes of the present invention includes both humans and other animals, particularly mammals. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, preferably a primate, and in the most preferred embodiment the patient is human. The administration of the prostate cancer proteins and modulators thereof of the present invention can be done in a variety of ways as discussed above, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, e.g., in the treatment of wounds and inflammation, the prostate cancer proteins and modulators may be directly applied as a solution or spray. The pharmaceutical compositions of the present invention comprise a prostate cancer protein in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol. The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include, but are not limited to, powder, tablets, pills, capsules and lozenges. It is recognized that prostate cancer protein modulators (e.g., antibodies, antisense constructs, ribozymes, small organic molecules, etc.) when administered orally, should be protected from digestion. This is typically accomplished either by complexing the molecule(s) with a composition to render it resistant to acidic and enzymatic hydrolysis, or by packaging the molecule(s) in an appropriately resistant carrier, such as a liposome or a protection barrier. Means of protecting agents from digestion are well known in the art. The compositions for administration will commonly comprise a prostate cancer protein modulator dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of active agent in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs (e.g., Remington's Pharmaceutical Science (15th ed., 1980) and Goodman & Gillman, The Pharmacologial Basis of Therapeutics (Hardman et αZ.,eds., 1996)). Thus, a typical pharmaceutical composition for intravenous administration would be about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to about 100 mg per patient per day may be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ. Substantially higher dosages are possible in topical administration. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art, e.g., Remington's Pharmaceutical Science and Goodman and Gillman, The Pharmacologial Basis of Therapeutics, supra. The compositions containing modulators of prostate cancer proteins can be administered for therapeutic or prophylactic treatments. In therapeutic applications, compositions are administered to a patient suffering from a disease (e.g., a cancer) in an amount sufficient to cure or at least partially arrest the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health. Single or multiple administrations of the compositions may be administered depending on the dosage and frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the agents of this invention to effectively treat the patient. An amount of modulator that is capable of preventing or slowing the development of cancer in a mammal is referred to as a "prophylactically effective dose." The particular dose required for a prophylactic treatment will depend upon the medical condition and history of the mammal, the particular cancer being prevented, as well as other factors such as age, weight, gender, administration route, efficiency, etc. Such prophylactic treatments may be used, e.g., in a mammal who has previously had cancer to prevent a recurrence of the cancer, or in a mammal who is suspected of having a significant likelihood of developing cancer. It will be appreciated that the present prostate cancer protein-modulating compounds can be administered alone or in combination with additional prostate cancer modulating compounds or with other therapeutic agent, e.g., other anti-cancer agents or treatments. In numerous embodiments, one or more nucleic acids, e.g., polynucleotides comprising nucleic acid sequences set forth in Tables 1-16, such as antisense polynucleotides or ribozymes, will be introduced into cells, in vitro or in vivo. The present invention provides methods, reagents, vectors, and cells useful for expression of prostate cancer-associated polypeptides and nucleic acids using in vitro (cell-free), ex vivo or in vivo (cell or organism-based) recombinant expression systems. The particular procedure used to introduce the nucleic acids into a host cell for expression of a protein or nucleic acid is application specific. Many procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, spheroplasts, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Berger & Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology volume 152 (Berger), Ausubel et al, eds., Current Protocols (supplemented through 1999), and Sambrook et al, Molecular Cloning - A Laboratory Manual (2nd ed., Vol. 1-3, 1989. In a preferred embodiment, prostate cancer proteins and modulators are administered as therapeutic agents, and can be formulated as outlined above. Similarly, prostate cancer genes (including both the full-length sequence, partial sequences, or regulatory sequences of the prostate cancer coding regions) can be administered in a gene therapy application. These prostate cancer genes can include antisense applications, either as gene therapy (i.e. for incorporation into the genome) or as antisense compositions, as will be appreciated by those in the art. Prostate cancer polypeptides and polynucleotides can also be administered as vaccine compositions to stimulate HTL, CTL and antibody responses.. Such vaccine compositions can include, e.g., lipidated peptides (see, e.g.,Vitiello, A. et al, J. Clin. Invest. 95:341 (1995)), peptide compositions encapsulated in poly(DL-lactide-co-glycolide) ("PLG") microspheres (see, e.g., Eldridge, et al, Molec. Immunol. 28:287-294, (1991); Alonso et al, Vaccine 12:299-306 (1994); Jones et al, Vaccine 13:675-681 (1995)), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e.g., Takahashi et al, Nature 344:873-875 (1990); Hu et al, Clin Exp Immunol. 113:235-243 (1998)), multiple antigen peptide systems (MAPs) (see, e.g., Tarn, Proc. Natl. Acad. Sci. U.S.A. 85:5409-5413 (1988); Tarn, /. Immunol. Methods 196:17-32 (1996)), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, et al, In: Concepts in vaccine development (Kaufmann, ed., p. 379, 1996); Chakrabarti, et al, Nature 320:535 (1986); Hu et al, Nature 320:537 (1986); Kieny, et al, AIDS Bio Technology 4:790 (1986); Top et al, J. Infect. Dis. 124:148 (1971); Chanda et al, Virology 175:535 (1990)), particles of viral or synthetic origin (see, e.g., Kofler et al, J. Immunol. Methods. 192:25 (1996); Eldridge et al, Sem. Hematol. 30:16 (1993); Falo et al, Nature Med. 7:649 (1995)), adjuvants (Warren et al, Annu. Rev. Immunol. 4:369 (1986); Gupta et al, Vaccine 11:293 (1993)), liposomes (Reddy et al, J. Immunol. 148:1585 (1992); Rock, Immunol. Today 17:131 (1996)), or, naked or particle absorbed cDNA (Ulmer, et al, Science 259:1745 (1993); Robinson et al, Vaccine 11:957 (1993); Shiver et al, In: Concepts in vaccine development (Kaufmann, ed., p. 423, 1996); Cease & Berzofsky, Annu. Rev. Immunol. 12:923 (1994) and Eldridge et al, Sem. Hematol. 30:16 (1993)). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) may also be used. Vaccine compositions often include adjuvants. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, Bortadella pertussis or Mycobacterium tuberculosis derived proteins. Certain adjuvants are commercially available as, e.g., Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants. Vaccines can be administered as nucleic acid compositions wherein DNA or RNA encoding one or more of the polypeptides, or a fragment thereof, is administered to a patient. This approach is described, for instance, in Wolff et. al., Science 247:1465 (1990) as well as U.S. Patent Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO 98/04720; and in more detail below. Examples of DNA-based delivery technologies include "naked DNA", facilitated (bupivicaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (see, e.g., U.S. Patent No. 5,922,687). For therapeutic or prophylactic immunization purposes, the peptides of the invention can be expressed by viral or bacterial vectors. Examples of expression vectors include attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of vaccinia virus, e.g., as a vector to express nucleotide sequences that encode prostate cancer polypeptides or polypeptide fragments. Upon introduction into a host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover et al, Nature 351:456-460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization e.g. adeno and adeno-associated virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the like, will be apparent to those skilled in the art from the description herein (see, e.g., Shata et al, Mol Med Today 6:66-71 (2000); Shedlock et al. Leukoc Biol 68:793-806 (2000); Hipp et al, In Vivo 14:571-85 (2000)). Methods for the use of genes as DNA vaccines are well known, and include placing a prostate cancer gene or portion of a prostate cancer gene under the control of a regulatable promoter or a tissue-specific promoter for expression in a prostate cancer patient. The prostate cancer gene used for DNA vaccines can encode full-length prostate cancer proteins, but more preferably encodes portions of the prostate cancer proteins including peptides derived from the prostate cancer protein. In one embodiment, a patient is immunized with a DNA vaccine comprising a plurality of nucleotide sequences derived from a prostate cancer gene. For example, prostate cancer-associated genes or sequence encoding subfragments of a prostate cancer protein are introduced into expression vectors and tested for their immunogenicity in the context of Class I MHC and an ability to generate cytotoxic T cell responses. This procedure provides for production of cytotoxic T cell responses against cells which present antigen, including intracellular epitopes. In a preferred embodiment, the DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the prostate cancer polypeptide encoded by the DNA vaccine. Additional or alternative adjuvants are available. In another preferred embodiment prostate cancer genes find use in generating animal models of prostate cancer. When the prostate cancer gene identified is repressed or diminished in cancer tissue, gene therapy technology, e.g., wherein antisense RNA directed to the prostate cancer gene will also diminish or repress expression of the gene. Animal models of prostate cancer find use in screening for modulators of a prostate cancer-associated sequence or modulators of prostate cancer. Similarly, transgenic animal technology including gene knockout technology, e.g. as a result of homologous recombination with an appropriate gene targeting vector, will result in the absence or increased expression of the prostate cancer protein. When desired, tissue-specific expression or knockout of the prostate cancer protein may be necessary. It is also possible that the prostate cancer protein is overexpressed in prostate cancer. As such, transgenic animals can be generated that overexpress the prostate cancer protein. Depending on the desired expression level, promoters of various strengths can be employed to express the transgene. Also, the number of copies of the integrated transgene can be determined and compared for a determination of the expression level of the transgene. Animals generated by such methods find use as animal models of prostate cancer and are additionally useful in screening for modulators to treat prostate cancer. Kits for Use in Diagnostic and/or Prognostic Applications For use in diagnostic, research, and therapeutic applications suggested above, kits are also provided by the invention. In the diagnostic and research applications such kits may include any or all of the following: assay reagents, buffers, prostate cancer-specific nucleic acids or antibodies, hybridization probes and or primers, antisense polynucleotides, ribozymes, dominant negative prostate cancer polypeptides or polynucleotides, small molecules inhibitors of prostate cancer-associated sequences etc. A therapeutic product may include sterile saline or another pharmaceutically acceptable emulsion and suspension base. In addition, the kits may include instructional materials containing directions (i.e., protocols) for the practice of the methods of this invention. While the instructional materials typically comprise written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this invention. Such media include, but are not limited to electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. Such media may include addresses to internet sites that provide such instructional materials. The present invention also provides for kits for screening for modulators of prostate cancer-associated sequences. Such kits can be prepared from readily available materials and reagents. For example, such kits can comprise one or more of the following materials: a prostate cancer-associated polypeptide or polynucleotide, reaction tubes, and instructions for testing prostate cancer-associated activity. Optionally, the kit contains biologically active prostate cancer protein. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user. Diagnosis would typically involve evaluation of a plurality of genes or products. The genes will be selected based on correlations with important parameters in disease which may be identified in historical or outcome data. EXAMPLES Example 1: Tissue Preparation, Labeling Chips, and Fingerprints Purifying total RNA from tissue sample using TRIzol Reagent The sample weight is first estimated. The tissue samples are homogenized in 1 ml of TRIzol per 50 mg of tissue using a homogenizer (e.g., Polytron 3100). The size of the generator/probe used depends upon the sample amount. A generator that is too large for the amount of tissue to be homogenized will cause a loss of sample and lower RNA yield. A larger generator (e.g., 20 mm) is suitable for tissue samples weighing more than 0.6 g. Fill tubes should not be overfilled. If the working volume is greater than 2 ml and no greater than 10 ml, a 15 ml polypropylene tube (Falcon 2059) is suitable for homogenization. Tissues should be kept frozen until homogenized. The TRIzol is added directly to the frozen tissue before homogenization. Following homogenization, the insoluble material is removed from the homogenate by centrifugation at 7500 x g for 15 min. in a Sorvall superspeed or 12,000 x g for 10 min. in an Eppendorf centrifuge at 4°C. The cleared homogenate is then transferred to a new tube(s). Samples may be frozen and stored at -60 to -70°C for at least one month or else continue with the purification. The next process is phase separation. The homogenized samples are incubated for 5 minutes at room temperature. Then, 0.2 ml of chloroform per 1ml of TRIzol reagent is added to the homogenization mixture. The tubes are securely capped and shaken vigorously by hand (do not vortex) for 15 seconds. The samples are then incubated at room temp, for 2-3 minutes and next centrifuged at 6500 rpm in a Sorvall superspeed for 30 min. at 4oC. The next process is RNA Precipitation. The aqueous phase is transferred to a fresh tube. The organic phase can be saved if isolation of DNA or protein is desired. Then 0.5 ml of isopropyl alcohol is added per 1ml of TRIzol reagent used in the original homogenization. Then, the tubes are securely capped and inverted to mix. The samples are then incubated at room temp, for 10 minutes an centrifuged at 6500 rpm in Sorvall for 20 min. at 4°C. The RNA is then washed. The supernatant is poured off and the pellet washed with cold 75% ethanol. 1 ml of 75% ethanol is used per 1 ml of the TRIzol reagent used in the initial homogenization. The tubes are capped securely and inverted several times to loosen pellet without vortexing . They are next centrifuged at <8000 rpm (<7500 x g) for 5 minutes at 4°C. The RNA wash is decanted. The pellet is carefully transferred to an Eppendorf tube (sliding down the tube into the new tube by use of a pipet tip to help guide it in if necessary). Tube(s) sizes for precipitating the RNA depending on the working volumes. Larger tubes may take too long to dry. Dry pellet. The RNA is then resuspended in an appropriate volume (e.g., 2 -5 ug/ul) of DEPC H 0. The absorbance is then measured. The poly A+ mRNA may next be purified from total RNA by other methods such as Qiagen' s RNeasy kit. The poly A + mRNA is purified from total RNA by adding the oligotex suspension which has been heated to 37°C and mixing prior to adding to RNA. The Elution Buffer is incubated at 70°C. If there is precipitate in the buffer, warm up the 2 x Binding Buffer at 65°C. The the total RNA is mixed with DEPC-treated water, 2 x Binding Buffer, and Oligotex according to Table 2 on page 16 of the Oligotex Handbook and next incubated for 3 minutes at 65°C and 10 minutes at room temperature. The preparation is centrifuged for 2 minutes at 14,000 to 18,000 g, preferably, at a "soft setting," The supernatant is removed without disturbing Oligotex pellet. A little bit of solution can be left behind to reduce the loss of Oligotex. The supernatant is saved until satisfactory binding and elution of poly A + mRNA has been found. Then, the preparation is gently resuspended in Wash Buffer OW2 and pipetted onto the spin column and centrifuged at full speed (soft setting if possible) for 1 minute. Next, the spin column is transferred to a new collection tube and gently resuspended in Wash Buffer OW2 and centrifuged as described herein. Then, the spin column is transferred to a new tube and eluted with 20 to 100 ul of preheated (70°C) Elution Buffer. The Oligotex resin is gently resuspended by pipetting up and down. The centrifugation is repeated as above and the elution repeated with fresh elution buffer or first eluate to keep the elution volume low. The absorbance is next read to determine the yield, using diluted Elution Buffer as the blank. Before proceeding with cDNA synthesis, the mRNA is precipitated before proceeding with cDNA synthesis, as components leftover or in the Elution Buffer from the Oligotex purification procedure will inhibit downstream enzymatic reactions of the mRNA. 0.4 vol. of 7.5 M NH4OAc + 2.5 vol. of cold 100% ethanol is added and the preparation precipitated at -20°C 1 hour to overnight (or 20-30 min. at -70°C), and centrifuged at 14,000-16,000 x g for 30 minutes at 4°C. Next, the pellet is washed with 0.5 ml of 80% ethanol (-20°C) and then centrifuged at 14,000-16,000 x g for 5 minutes at room temperature. The80% ethanol wash is then repeated. The last bit of ethanol from the pellet is then dried without use of a speed vacuum and the pellet is then resuspended in DEPC H 2 0 at 1 ug/ul concentration. Alternatively the RNA may be purified using other methods (e.g., Qiagen's RNeasy kit). No more than 100 ug is added to the RNeasy column. The sample volume is adjusted to 100 ul with RNase-free water. 350 ul Buffer RLT and then 250 ul ethanol (100%) are added to the sample. The preparation is then mixed by pipetting and applied to an RNeasy mini spin column for centrifugation (15 sec at >10,000 rpm). If yield is low, reapply the flowthrough to the column and centrifuge again. Then, transfer column to a new 2 ml collection tube and add 500 ul Buffer RPE and centrifuge for 15 sec at > 10,000 rpm. The flowthrough is discarded. 500 ul Buffer RPE and is then added and the preparation is centriuged for 15 sec at >10,000 rpm. The flowthrough is discarded, and the column membrane dried by centrifuging for 2 min at maximum speed. The column is transferred to a new 1.5-ml collection tube. 30-50 ul of RNase-free water is applied directly onto column membrane. The column is then centrifuged for 1 min at >10,000 rpm and the elution step repeated. The absorbance is then read to determine yield. If necessary, the material may be ethanol precipitated with ammonium acetate and 2.5X volume 100% ethanol. First Strand cDNA Synthesis The first strand can be make using using Gibco's "Superscript Choice System for cDNA Synthesis" kit. The starting material is 5 ug of total RNA or 1 ug of polyA+ mRNAl. For total RNA, 2 ul of Superscript RT is used; for polyA+ mRNA, 1 ul of Superscript RT is used. The final volume of first strand synthesis mix is 20 ul. The RNA should be in a volume no greater than 10 ul. The RNA is incubated with 1 ul of 100 pmol T7-T24 oligo for 10 min at 70°C followed by addition on ice of 7 ul of: 4ul 5X 1 st Strand Buffer, 2 ul of 0.1M DTT, and 1 ul of lOmM dNTP mix. The preparation is then incubated at 37°C for 2 min before addition of the Superscript RT followed by incubation at 37°C for 1 hour. Second Strand Synthesis For the second strand synthesis, place 1st strand reactions on ice and add: 91 ul DEPC H 2 0; 30 ul 5X 2nd Strand Buffer; 3 ul lOmM dNTP mix; 1 ul 10 U/ul E.coli DNA Ligase; 4 ul 10 U/ul E.coli DNA Polymerase; and 1 ul 2 U/ul RNase H. Mix and incubate 2 hours at 16°C. Add 2 ul T4 DNA Polymerase. Incubate 5 min at 16°C. Add 10 ul of 0.5M EDTA. Cleaning up cDNA The cDNA is purified using Phenol:Chloroform:Isoamyl Alcohol (25:24:1) and Phase-Lock gel tubes. The PLG tubes are centrifuged for 30 sec at maximum speed. The cDNA mix is then transferred to PLG tube. An equal volume of phenol:chloroform:isamyl alcohol is then added, the preparation shaken vigorously (no vortexing), and centrifuged for 5 minutes at maximum speed. The top aqueous solution is transferred to a new tube and ethanol precipitated by adding 7.5X 5M NH4OAc and 2.5X volume of 100% ethanol. Next, it is centrifuged immediately at room temperature for 20 min, maximum speed. The supernatant is removed, and the pellet washed with 2X with cold 80% ethanol. As much ethanol wash as possible should be removed before air drying the pellet; and resuspending it in 3 ul RNase-free water. In vitro Transcription (INF) and labeling with biotin In vitro Transcription (INT) and labeling with biotin is performed as follows: Pipet 1.5 ul of cDΝA into a thin-wall PCR tube. Make ΝTP labeling mix by combining 2 ul T7 lOxATP (75 mM) (Ambion); 2 ul T7 lOxGTP (75 mM) (Ambion); 1.5 ul T7 lOxCTP (75 mM) (Ambion); 1.5 ul T7 lOxUTP (75 mM) (Ambion); 3.75 ul 10 mM Bio-11-UTP (Boehringer-Mannheim/Roche or Enzo); 3.75 ul 10 mM Bio-16-CTP (Enzo); 2 ul lOx T7 transcription buffer (Ambion); and 2 ul lOx T7 enzyme mix (Ambion). The final volume is 20 ul. Incubate 6 hours at 37°C in a PCR machine. The RΝA can be furthered cleaned. Clean-up follows the previous instructions for RNeasy columns or Qiagen' s RNeasy protocol handbook. The cRNA often needs to be ethanol precipitated by resuspension in a volume compatible with the fragmentation step. Fragmentation is performed as follows. 15 ug of labeled RNA is usually fragmented. Try to minimize the fragmentation reaction volume; a 10 ul volume is recommended but 20 ul is all right. Do not go higher than 20 ul because the magnesium in the fragmentation buffer contributes to precipitation in the hybridization buffer. Fragment RNA by incubation at 94 C for 35 minutes in 1 x Fragmentation buffer (5 x Fragmentation buffer is 200 mM Tris-acetate, pH 8.1; 500 mM KOAc; 150 mM MgOAc). The labeled RNA transcript can be analyzed before and after fragmentation. Samples can be heated to 65 °C for 15 minutes and electrophoresed on 1% agarose/TBE gels to get an approximate idea of the transcript size range. For hybridization, 200 ul (10 ug cRNA) of a hybridization mix is put on the chip. If multiple hybridizations are to be done (such as cycling through a 5 chip set), then it is recommended that an initial hybridization mix of 300 ul or more be made. The hybridization mix is: fragment labeled RNA (50 ng/ul final cone); 50 pM 948-b control oligo; 1.5 pM BioB ; 5 pM BioC; 25 pM BioD; 100 pM CRE; 0.1 mg/ml herring sperm DNA; 0.5 mg/ml acetylated BSA; and 300 ul with lxMES hyb buffer. The hybridization reaction is conducted with non-biotinylated IVT (purified by RNeasy columns) (see example 1 for steps from tissue to INT): The following mixture is prepared: INT antisense RΝA; 4 μg: μl Random Hexamers (1 μg/μl): 4 μl H 2 O: ul 14 μl Incubate the above 14 μl mixture at 70°C for 10 min.; then put on ice. The Reverse transcription procedure uses the following mixture: 0.1 M DTT: 3 μl 50X dΝTP mix: 0.6 μl H 2 O: 2.4 μl Cy3 or Cy5 dUTP (ImM): 3 μl SS RT π (BRL): l μl 16 μl The above solution is added to the hybridization reaction and incubated for 30 min., 42°C. Then, 1 μl SSII is added and incubated for another hour before being placed on ice. The 50X dΝTP mix contains 25mM of cold dATP, dCTP, and dGTP, lOmM of dTTP and is made by adding 25 μl each of lOOmM dATP, dCTP, and dGTP; 10 μl of lOOmM dTTP to 15 μl H 2 O. ] RΝA degradation is performed as follows. Add 86 μl H20, 1.5 μl 1M ΝaO-H/ 2 mM EDTA and incubate at 65°C, 10 min.. For U-Con 30, 500 μl TE/sample spin at 7000 g for 10 min, save flow through for purification. For Qiagen purification, suspend u-con recovered material in 500 μl buffer PB and proceed using Qiagen protocol. For DΝAse digestion, add 1 ul of 1/100 dilution of DΝAse/30 ul Rx and incubate at 37°C for 15 min. Incubate at 5 min 95 °C to denature the DNAse. Sample preparation For sample preparation, add Cot-1 DNA, 10 μl; 50X dNTPs, 1 μl; 20X SSC, 2.3 μl; Na pyro phosphate, 7.5 μl; 10 mg/ml Herring sperm DNA; 1 ul of 1/10 dilution to 21.8 final vol. Dry in speed vac. Resuspend in 15 μl H 2 0. Add 0.38 μl 10% SDS. Heat 95°C, 2 min and slow cool at room temp, for 20 min. Put on slide and hybridize overnight at 64°C. Washing after the hybridization: 3X SSC/0.03% SDS: 2 min., 37.5 ml 20X SSC+0.75ml 10% SDS in 250ml H 2 O; IX SSC: 5 min., 12.5 ml 20X SSC in 250ml H 2 O; 0.2X SSC: 5 min., 2.5 ml 20X SSC in 250ml H 2 O. Dry slides and scan at appropiate PMT's and channels. Example 2: Taxol resistant Xenograft Model of Human Prostate Cancer Treatment regimens that include paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) have been particularly successful in treating hormone-refractory prostate cancer in the phase II setting (Smith et al., Semin. Oncol. 26(1 Suppl 2): 109-11 (1999)). However, many patients develop tumors which are initially, or later become, resistant to taxol. To identify genes that may be involved with resistance to taxol, or are regulated in response to taxol resistance, and therefore may be used to treat, or identify, taxol resistance in patients, the following experiments were carried out. The androgen-independent human cell line CWR22R was grown as a xenograft in nude mice (Nagabhushan et al., Cancer Res. 56(13):3042-3046 (1996); Agus et al., J. Natl. Cancer Inst.91(21): 1869-1876 (1999); Bubendorf et al., J. Natl. Cancer Inst. 91(20):1758-1764 (1999)). Initially, these xenograft tumors were sensitive to therapeutic doses of taxol. The mice were treated continuously with sub-therapeutic doses, and the tumors were allowed to grow for 3-4 weeks, before surgical removal of the tumors. The tumor from an individual mouse was then minced, and a small portion was then injected into a healthy nude mouse, establishing a second passage of the tumor. This mouse was then treated continuously with the same sub-therapeutic dose of taxol. This process was repeated 14 times, and a portion of each generation of xenograft tumor was collected. There was increasing resistance to therapeutic doses of taxol with each generation. Bythe end of the process, the tumors were fully resistant to therapeutic doses of taxol. RNA from each generation of tumor was then isolated, and individual mRNA species were quantified using a custom Affymetrix GeneChip® oligonucleotide microarray, with probes to interrogate approximately 35,000 unique mRNA transcripts. Genes were selected that showed a statistically significant up- regulation, or down-regulation, during the subsequent generations of increasingly taxol- resistant tumors. Only one gene was significantly up-regulated, whereas 24 genes were down-regulated; these are presented in Table 10. The gene sequences identified to be overexpressed in prostate cancer may be used to identify coding regions from the public DNA database. The sequences may be used to either identify genes that encode known proteins, or they may be used to predict the coding regions from genomic DNA using exon prediction algorithms, such as FGENESH (Salamov and Solovyev, 2000, Genome Res. 10:516-522). In addition, one of ordinary skill in the art would understand how to obtain the unigene cluster identification and sequence information according to the exemplar accession numbers provided in Tables 1-16. (see, http ://www .ncbi .nlm.nih.gov/UniGene/) . TABLE1 : shows genes, including expression sequence tags, differentially expressed in prostate tumor tissue compared to normal tissue as analyzed using the Affymetrix/Eos HuOl GeneChip array. Shown are the relative amounts of each gene expressed in prostate tumor samples and various normal tissue samples showing the highest expression of the gene. P ey: Unique Eos probeset identifier number ExAccn: Exempla Accession number, Genbank accession number UnigenelD: Unigene number Unigene Title: Unigene gene title R1: Ratio of tumor to normal body tissue Pkey UnigenelD ExAccn Uningene Title R1 131919 Hs.272458 AA121266 ESTs 37.2 120328 Hs.290905 AA196979 ESTs; Weakly similar to (defline not ava 32.6 105201 Hs.31412 M195626 ESTs 30.1 101486 Hs.1852 M24902 acid phosphatase; prostate 25.2 119073 Hs.279477 R32894 ESTs 24.8 133428 Hs.183752 M34376 microseminoprotein; beta- 23.8 128180 Hs.171995 AA595348 kallikrein 3; (prostate specific antigen 21.4 104080 Hs.57771 AA402971 Homo sapiens mRNA for serine protease (T 18.9 127537 Hs.162859 AA569531 ESTs 18.6 131665 Hs.30343 R22139 ESTs 17.4 101050 Hs.1832 K01911 neuropeptide Y 17.3 130771 Hs.1915 N48056 folate hydrolase (prostate-specific memb 17 108153 Hs.40808 M054237 ESTs 16.9 107485 Hs.262476 W63793 S-adenosylmethionine decarboxylase 1 16.7 106155 Hs.33287 AA425309 ESTs 16.5 129534 Hs.11260 R73640 ESTs 16.4 100569 Hs.171995 HG2261-HT2351 Antigen, Prostate Specific, Alt. Splice 16 101889 Hs.181350 S39329 kallikrein 2; prostatic 15.4 135389 Hs.99872 U05237 fetal Alzheimer antigen 15 101506 Hs.62192 M27436 coagulation factor III (thromboplastin; 13.9 134374 Hs.8236 D62633 ESTs 12.7 133944 Hs.7780 AA045870 ESTs 12.5 109141 Hs.193380 AA176428 ESTs 12.3 130974 Hs.2178 X57985 H2B histone family; member Q 11.8 114768 Hs.182339 AA149007 ESTs 11.8 104394 Hs.172129 H46617 yp19h1.r1 Soares breast 3NbHBst Homo sap 11.8 125299 Hs.102720 Z39436 ESTs 11.6 104660 Hs.14846 AA007160 ESTs 11.4 100116 Hs.78045 D00654 actin; gamma 2; smooth muscle; enteric 11 131061 Hs.268744 N64328 ESTs; Moderately similar to KIAA0273 [H. 10.9 126645 126645 AI167942 Homo sapiens BAC clone RG041D11 from 7q2 10.7 135153 Hs.95420 N40141 Homo sapiens mRNA for JM27 protein; comp 10.6 107033 Hs.113314 AA599629 ESTs - 10.6 118417 N66048 ESTs; Weakly similar to polymerase [H.sa 10.5 126758 Hs.293960 W37145 ESTs 102 115674 Hs.8364 AA406542 ESTs 10.1 134989 Hs.92381 AA236324 ESTs; Weakly similar to !!!! ALU CLASS A 10.1 107102 Hs.30652 AA609723 ESTs 10.1 116787 Hs.15641 H28581 ESTs 10.1 115719 Hs.59622 AA416997 ESTs 10 123209 Hs.203270 AA489711 ESTs 9.9 101664 Hs.121017 60752 H2A histone family; member A 9.8 112971 Hs.83883 T17185 ESTs 9.7 102519 Hs.80296 U52969 Purkinje cell protein 4 9.7 117984 Hs.106778 N51919 ESTs 9.7 105840 Hs.22209 AA398533 ESTs 9.4 129523 Hs.274509 M30894 T-cell receptor; gamma cluster 9.4 132964 Hs.167133 AA031360 ESTs 9.2 121853 Hs.98502 AA425887 ESTs 9 115764 Hs.91011 AA421562 anterior gradient 2 (Xenopus laevis; sec 8.9 119617 Hs.55999 W47380 ESTs 8.9 100552 Hs.301946 HG2167-HT2237 Protein Kinase Ht31 , Camp-Dependent 8.9 105627 Hs.23317 AA281245 ESTs 8.8 101461 Hs.76422 M22430 phospholipase A2; group IIA (platelets; 8.7 131725 Hs.31146 AA456264 ESTs; Highly similar to (defline not ava 8.5 124526 Hs.293185 N62096 yz61c5.s1 Soares multiple sclerosis 2NbH 8.5 118528 Hs.49397 N67889 ESTs 8.2 133845 Hs.76704 T68510 ESTs 8.2 133354 Hs.334762 AA055552 ESTs; Weakly similar to KIAA0319 [H.sapi 8.1 105912 Hs.20415 AA402000 ESTs; Weakly similar to GS3786 [H.sapien 8 119018 Hs.278695 N95796 ESTs 8 100394 Hs.66052 D84276 CD38 antigen (p45) 8 114132 Hs.24192 Z38688 ESTs 7.9 116786 Hs.301527 H25836 tumor necrosis factor (ligand) superfami 7.7 106579 Hs.23023 AA456135 ESTs 7.6 128790 Hs.105700 AA291725 secreted frizzled-related protein 4 7.5 114965 Hs.72472 AA250737 ESTs 7.4 112033 Hs.22627 R43162 ESTs 7.1 102398 U42359 Human N33 protein form 1 (N33) gene, exo 7 101201 Hs.2256 L22524 matrix metalloproteinase 7 (matrilysin; 6.9 109272 Hs.288462 AA195718 ESTs 6.9 103145 Hs.169849 X66276 myosin-binding protein C; slow-type 6.9 101803 Hs.155691 M86546 pre-B-cell leukemia transcription factor 6.8 120562 Hs.302267 AA280036 ESTs; Weakly similar to W01 A6.c [C.elega 6.8 109112 Hs.257924 AA169379 ESTs 6.8 109795 Hs.326416 F10707 ESTs 6.7 107532 Hs.173684 Z19643 ESTs; Weakly similar to (defline not ava 6.7 130336 Hs.171995 X07730 kallikrein 3; (prostate specific antigen 6.6 131425 Hs.26691 AA219134 ESTs 6.6 120588 Hs.16193 AA281591 Homo sapiens mRNA; cDNA DKFZp586B211 (fr 6.6 132902 Hs.59838 AA490969 ESTs 6.6 125674 Hs.323378 W28078 H.sapiens mRNA for transmembrane protein 6.6 133724 Hs.75746 U07919 aldehyde dehydrogenase 6 6.5 130343 Hs.278628 AA490262 ESTs; Moderately similar to APXL gene pr 6.5 120215 Hs.108787 Z41050 Homo sapiens Mcd4p homolog mRNA; compiet 6.5 129215 Hs.126085 AA176867 ESTs 6.5 131881 Hs.3383 AA010163 upstream regulatory element binding prot 6.5 133376 Hs.7232 T23670 ESTs 6.4 105376 Hs.8768 AA236559 ESTs; Weakly similar to neuronal thread 6.4 104674 Hs.26289 AA009527 ESTs 6.4 100727 Hs.334786 X07290 Human HF.12 gene mRNA 6.3 130150 Hs.15113 AF000573 homogentisate 1;2-dioxygenase (homogenti 6.3 121770 Hs.278428 AA421714 Homo sapiens mRNA for KIAA0896 protein; 6.3 123475 Hs.250528 AA599267 ESTs; Weakly similar to ANKYRIN; BRAIN V 6.3 133061 Hs.296638 AB000584 prostate differentiation factor 6.3 116429 Hs.279923 AA609710 ESTs; Weakly similar to similar to GTP-b 6.2 101233 Hs.878 L29008 sorbitol dehydrogenase 6.2 104691 Hs.37744 AA011176 ESTs 62 127248 AA325029 EST27953 Cerebellum II Homo sapiens cDNA 6.2 127775 Hs.179902 H04106 ESTs; Weakly similar to (defline not ava 6.2 105500 Hs.222399 AA256485 ESTs 6.1 131463 Hs.2714 X74142 forkhead (Drosophila)-like 1 - 6.1 132116 Hs.40289 AA234767 ESTs 6 130828 Hs.203213 AA053400 ESTs 5.9 115357 Hs.72988 AA281793 ESTs 5.8 105496 Hs.301997 AA256323 ESTs 5.7 116334 Hs.48948 AA491457 ESTs 5.7 107968 Hs.61539 AA034020 ESTs 5.7 120132 Hs.125019 Z38839 ESTs; Weakly similar to III! ALU SUBFAMI 5.6 106375 Hs.289072 AA443993 ESTs 5.6 132550 Hs.170195 AA029597 bone morphogenetic protein 7 (osteogenic 5.6 124777 Hs.140237 R41933 ESTs; Weakly similar to neuronal thread 5.6 100311 Hs.337616 D50640 phosphodiesterase 3B; cGMP-inhibited 5.6 101791 Hs.62354 M83822 Human beige-like protein (BGL) mRNA; par 5.5 117698 Hs.45107 N41002 ESTs 5.5 132387 Hs.281434 R70914 heat shock 70kD protein 1 5.5 122041 Hs.98732 AA431407 Homo sapiens Chromosome 16 BAC clone CIT 5.5 133723 Hs.262476 AA088851 S-adenosylmethionine decarboxylase 1 5.5 113938 W81598 ESTs 5.4 133015 Hs.246315 AA047036 ESTs 5.4 125745 Hs.75722 AI283493 ribophorin II 5.4 107295 Hs.80120 T34527 UDP-N-acetyl-alpha-D-galactosamine:polyp 5.4 108186 Hs.7780 AA056482 ESTs 5.3 100184 Hs.21223 D17408 calponin 1; basic; smooth muscle 5.3 104466 Hs.326392 N25110 Human guanine nucleotide exchange factor 5.3 104033 Hs.98944 AA365031 ESTs 5.3 110844 Hs.167531 N31952 ESTs; Weakly similar to (defline not ava 5.3 129056 Hs.108336 H70627 ESTs; Weakly similar to HI! ALU SUBFAMI 5.3 102805 Hs.25351 U90304 iroquois-class homeodomain protein 5.3 133493 Hs.194369 AA284143 Homo sapiens chromosome 1 atrophin-1 rel 5.3 129184 Hs.109201 W26769 ESTs; Highly similar to (defline not ava 5.2 134158 Hs.79428 U15174 BCL2 adenovirus E1B 19kD-interacting pro 5.2 107240 Hs.159872 D59368 ESTs 5.2 104787 AA027317 ESTs; Weakly similar to HI! ALU SUBFAMI 5.2 123527 Hs.108327 AA608679 damage-specific DNA binding protein 1 (1 5.2 116646 Hs.194228 F03048 ESTs; Moderately similar to !!!! ALU SUB 5.2 101448 Hs.195850 M21389 keratin 5 (epidermolysis bullosa simplex 5.1 116188 Hs.184598 AA464728 ESTs; Weakly similar to III! ALU SUBFAMI 5.1 126259 Hs.281428 Z21472 ESTs; Moderately similar to llll ALU SUB 5.1 105921 Hs.169119 AA402613 ESTs 5.1 103375 Hs.54416 X91868 sine oculis homeobox (Drosophila) homolo 5.1 128871 Hs.106778 AA400271 ESTs; Highly similar to (defline not ava 5.1 112681 Hs.148932 R87331 ESTs; Moderately similar to semaphorin V 5.1 105784 Hs.226434 AA350771 ESTs 5.1 116238 Hs.47144 AA479362 ESTs 5 102913 Hs.80342 X07696 keratin 15 5 103011 Hs.326035 X52541 early growth response 1 5 126023 H58881 yr36d09.r1 Soares fetal liver spleen 1 NF 5 103709 Hs.13804 AA037316 ESTs 5 118981 Hs.39288 N93839 ESTs; Weakly similar to HI! ALU SUBFAMI 5 134807 Hs.89732 X78932 zinc finger protein 273 5 100079 Hs.23311 AB002365 Human mRNA for KIAA0367 gene; partial cd 4.9 132047 Hs.3796 D83492 EphB6 4.9 132880 Hs.177537 AA444369 ESTs 4.9 124049 Hs.74519 F10523 pri ase; polypeptide 2A (58kD) 4.8 133330 Hs.71119 U42360 Human N33 mRNA; complete eds 4.8 104776 AA026349 ESTs 4.8 122593 Hs.128749 AA453310 Homo sapiens alpha-methylacyl-CoA racema 4.8 103912 Hs.143087 AA251078 ESTs 4.8 113961 Hs.26009 W86307 Homo sapiens mRNA for KIAA0860 protein; 4.8 105288 Hs.3585 AA233168 ESTs; Weakly similar to coded for by C. 4.8 135035 Hs.284186 H89575 ESTs 4.8 104144 Hs.183390 AA447439 ESTs; Weakly similar to ZINC FINGER PROT 4.8 129389 Hs.288126 AA621604 ESTs 4.8 125982 R98091 RAE1 (RNA export 1; S.pombe) homolog 4.8 125162 Hs.26243 W44682 ESTs 4.8 103023 Hs.117950 X53793 multifunctional polypeptide similar to S 4.7 129735 W80701 ESTs; Weakly similar to HERV-E envelope 4.7 104479 Hs.106390 N36040 ESTs 4.7 103731 AA070545 zm7c3.r1 Stratagene neuroepitheliu (#93 4.7 126575 Hs.127602 W72416 ESTs - 4.7 124578 Hs.231500 N68321 Human glucose transporter-like protβin-l 4.7 130617 Hs.1674 M90516 glutamine-fructose-6-phosphate transamin 4.7 116752 Hs.91622 H06373 Homo sapiens clone 24456 mRNA sequence 4.7 100279 Hs.82007 D42084 Human mRNA for KIAA0094 gene; partial cd 4.7 126288 Hs.89576 AI479264 ESTs 4.7 131836 Hs.32990 AA610086 ESTs 4.7 106717 Hs.239489 AA465093 TIA1 cytotoxic granule-associated RNA-bi 4.7 114542 Hs.91011 AA055768 ESTs 4.6 103806 AA130614 zo1f2.r1 Stratagene neuroepithelium NT2R 4.6 130529 AA173238 small inducible cytokine A5 (RANTES) 4.6 115675 Hs.82065 AA406546 ESTs 4.6 111386 Hs.293798 N95326 ESTs 4.6 106503 Hs.29679 AA452411 ESTs 4.6 119943 Hs.14158 W86835 copine III 4.6 104459 Hs.100070 M91493 EST 4.6 100774 Hs.89603 HG371-HT1063 Mucin 1, Epithelial, Alt. Splice 6 4.6 100652 Hs.142653 HG2825-HT2949 Ret Transforming Gene 4.6 132015 Hs.3731 D11900 ESTs 4.6 126086 H70975 yr73g01.r1 Soares fetal liver spleen 1 NF 4.6 130888 Hs.173094 F03819 ESTs 4.6 106390 Hs.20166 AA446964 Prostate stem cell antigen 4.6 126959 AA199853 ESTs; Moderately similar to III! ALU SUB 4.5 131584 Hs.29117 X91648 H.sapiens mRNA for pur alpha extended 3' 4.5 104838 Hs.20953 AA039481 ESTs 4.5 125661 R50319 ESTs 4.5 103171 Hs.234726 X68733 alpha-1 -antichymotrypsin 4.5 103928 Hs.199160 AA280085 ESTs 4.5 102899 Hs.75730 X06272 signal recognition particle receptor ('d 4.5 100892 Hs.180789 HG4557-HT4962 Small Nuclear Ribonudeoprotein U1, 1snr 4.5 106167 Hs.7956 AA425906 ESTs 4.5 129404 Hs.317584 AA172056 ESTs 4.5 106990 Hs.24758 AA521354 ESTs 4.5 132316 Hs.44566 U28831 Human protein immuno-reactive with anti- 4.4 132056 Hs.38176 T89386 Homo sapiens mRNA for KIAA0606 protein; 4.4 133718 Hs.198760 X15306 neurofilament; heavy polypeptide (200kD) 4.4 101470 Hs.1846 M22898 tumor protein p53 (Li-Fraumeni syndrome) 4.4 131904 Hs.284296 AA143019 ESTs; Highly similar to surface 4 integr 4.4 105804 Hs.22514 AA383142 ESTs 4.4 122861 Hs.119394 AA464428 ESTs 4.4 111336 Hs.29894 N79565 ESTs 4.4 121944 Hs.98518 AA429278 ESTs 4.4 134401 Hs.211577 AA243746 ESTs; Highly similar to CG1 protein [H.s 4.4 126458 Hs.288969 AA815252 ESTs; Weakly similar to !!!! ALU SUBFAMI 4.4 133435 Hs.323966 T23983 ESTs; Moderately similar to HI! ALU SUB 4.4 105178 Hs.21941 AA187490 ESTs 4.3 127315 AA640834 nr27b06. NCI_CGAP_Pr3 Homo sapiens cDN 4.3 132645 Hs.54424 X87870 H.sapiens mRNA for hepatocyte nudear fa 4.3 116162 Hs.282990 AA461487 ESTs; Weakly similar to F52C12.2 [C.eleg 4.3 118040 Hs.47567 N52876 EST 4.3 130008 Hs.278427 M31423 cerebellar degeneration-related protein 4.3 126607 Hs.114688 W87424 ESTs 4.3 123061 Hs.105130 AA482030 EST 4.3 109391 Hs.184245 AA219699 ESTs 4.3 109175 AA180496 ESTs 4.3 127003 Hs.173540 AA550806 ESTs; Weakly similar to (defline not ava 4.3 102547 Hs.46638 U57911 chromosome 11 open reading frame 8 4.3 134208 Hs.79993 U88871 peroxisomal biogenesis factor 7 4.3 104258 Hs.5462 AF007216 solute earner family 4; sodium bicarbon 4.3 130759 Hs.18946 AA094720 ESTs; Weakly similar to (defline not ava 4.3 132160 Hs.295923 AA281770 seven in absentia (Drosophila) homolog 1 4.3 135062 Hs.93872 AA174183 ESTs 4.3 126510 Hs.334762 R49702 ESTs; Weakly similar to KIAA0319 [Rsapi 4.2 122055 Hs.98747 AA431732 EST 42 133136 Hs.6574 AF007165 suppressin (nudear deformed epidermal a 4.2 109890 Hs.20843 H04649 ESTs 4.2 133294 Hs.69997 R79723 sapiens mRNA for translin associated z 4.2 134436 Hs.83190 S80437 fatty add synthase {3' region} [human, 4.2 107375 Hs.251064 U88573 NBR2 4.2 122223 Hs.27413 AA436158 ESTs - 4.2 103044 Hs.248210 X55777 H.sapiens Mahlavu hepatocellular carano 4.2 120125 Hs.59815 W99362 EST 4.2 128969 Hs.283978 T65327 ESTs; Highly similar to (defline not ava 4.2 129637 Hs.1179 D90359 TATA box binding protein (TBP)-associate 4.2 106566 AA455921 ESTs; Weakly similar to III! ALU SUBFAMI 4.2 112605 Hs.29852 R79220 ESTs 4.2 103364 Hs.279929 X90872 H.sapiens mRNA for gp25L2 protein 4.2 132811 Hs.57419 U25435 transcriptional repressor 4.2 126570 Hs.326292 T79274 ESTs 4.2 116298 Hs.94109 AA489046 ESTs 4.2 103024 Hs.105938 X53961 lactotransferrin 4.1 129133 Hs.108850 R56728 yg95c6.r1 Soares infant brain 1N1B Homo 4.1 133167 Hs.6641 N98707 kinesin family member 5C 4.1 126871 Hs.14051 AA351779 ESTs 4.1 132333 Hs.45032 AA192157 ESTs 4.1 107376 Hs.327179 U90545 solute carrier family 17 (sodium phospha 4.1 128517 Hs.100861 AA280617 ESTs; Weakly similar to p60 katanin [H.s 4.1 130555 Hs.116774 AA450324 ESTs 4.1 105765 Hs.24183 AA343514 ESTs 4.1 126529 Hs.26369 AA133237 ESTs 4.1 125928 Hs.181889 H29730 ESTs 4.1 117280 Hs.172129 N22107 ESTs; Moderately similar to llll ALU SUB 4.1 100234 Hs.3085 D29677 KIAA0054 gene product 4.1 100959 Hs.118127 J00073 actin; alpha; cardiac muscle 4.1 107130 Hs.12913 AA620582 ESTs; Weakly similar to (defline not ava 4.1 105035 Hs.8859 AA128486 ESTs 4.1 126735 Hs.226795 AA808949 glutathione S-transferase pi 4.1 113056 Hs.8036 T26471 ESTs; Moderately similar to III! ALU SUB 4 102460 Hs.211582 U48959 Homo sapiens myosin light chain kinase ( 4 106968 Hs.26813 AA504631 ESTs; Weakly similar to (defline not ava 4 123107 Hs.104207 AA486071 ESTs 4 127256 Hs.267967 AA327550 ESTs; Weakly similar to llll ALU SUBFAMI 4 105329 Hs.22862 AA234561 ESTs 4 115504 Hs.42736 AA291946 ESTs 4 120726 Hs.97293 AA293656 ESTs 4 103576 Hs.94560 Z26317 desmoglein 2 4 127889 Hs.144941 AI147408 ESTs 4 106394 Hs.25320 AA447223 ESTs 4 128046 AA873285 ESTs 4 103391 Hs.114366 X94453 pyrroline-5-carbox late synthetase (glut 4 106448 Hs.27004 AA449455 ESTs 4 126513 Hs.86276 W27601 ESTs; Moderately similar to (defline not 4 129593 Hs.98314 AA487015 ESTs; Weakly similar to HI! ALU SUBFAMI 3.9 110151 Hs.31608 H18836 ESTs 3.9 105344 Hs.8645 AA235303 ESTs 3.9 104791 Hs.301871 AA029046 ESTs 3.9 123442 Hs.111496 AA598803 ESTs 3.9 127800 Hs.79428 AA521047 BCL2/adenovirus E1B 19kD-interacting pro 3.9 114555 Hs.167904 AA058594 ESTs 3.9 122138 Hs.163960 AA435549 ESTs 3.9 129565 Hs.198726 X77777 vasoactive intestinal peptide receptor 1 3.9 103471 Hs.75216 Y00815 protein tyrosine phosphatase; receptor t 3.9 133908 Hs.325474 M83216 caldesmon 1 3.9 105635 Hs.301985 AA281508 ESTs 3.9 134285 Hs.81086 AA460012 solute carrier family 22 (organic cation 3.9 134125 Hs.50421 R38102 KIAA0203 gene product 3.9 125628 Hs.241493 AA418069 natural killer-tumor recognition sequenc 3.9 103695 Hs.186600 AA018758 ESTs 3.9 100642 Hs.182183 HG2743-HT3926 Caldesmon l, Alt. Splice 6, Non-Musde 3.9 104334 Hs.78771 D82614 ESTs 3.9 110242 Hs.19978 H26417 ESTs 3.9 125298 Hs.289008 Z39255 ESTs 3.9 104060 Hs.303193 AA397968 zt87a9.r1 Soares testis NHT Homo sapiens 3.9 105823 Hs.293960 AA398197 ESTs 3.9 126499 Hs.110445 AA315671 ESTs; Moderately similar to unknown [M.m 3.9 130752 Hs.18895 D50927 KIAA0137 gene product 3.8 123494 Hs.112110 AA599786 ESTs 3.8 104846 Hs.32478 AA040154 ESTs 3.8 108921 Hs.71721 AA142913 ESTs - 3.8 115506 Hs.45207 AA292537 ESTs 3.8 100452 Hs.241552 D87742 Human mRNA for KIAA0268 gene; partial cd 3.8 104454 Hs.129228 M84443 galactokinase 2 3.8 108730 Hs.102859 AA126254 ESTs 3.8 131223 Hs.24427 AA247788 ESTs; Highly similar to (defline not ava 3.8 104784 Hs.269228 AA027055 ESTs 3.8 104946 Hs.73848 AA069549 ESTs 3.8 106932 Hs.9394 AA495926 ESTs 3.8 101724 Hs.620 M69225 bullous pemphigoid antigen 1 (230/240kD) 3.8 106140 Hs.14912 AA424524 Homo sapiens mRNA for KIAA0286 gene; par 3.8 128135 Hs.269721 AA913491 ESTs 3.8 120030 Hs.58694 W92051 ESTs 3.8 126457 Hs.50382 AA007489 zh98g04.r1 Soares etaljiver spleen 1NF 3.8 123917 Hs.112969 AA621311 EST 3.7 110714 Hs.17752 H95978 Homo sapiens phosphatidylserinβ-spedfic 3.7 130577 Hs.162 M35410 insulin-like growth factor binding prate 3.7 117667 Hs.44708 N39214 ser-Thr protein kinase related to the my 3.7 126104 Hs.39712 N77278 ESTs; Weakly similar to BONE/CARTILAGE P 3.7 100379 Hs.278721 D82060 Homo sapiens mRNA for membrane protein w 3.7 115646 Hs.305971 AA404352 ESTs 3.7 125792 Hs.193700 AI005388 ESTs; Moderately similar to III! ALU SUB 3.7 102162 Hs.1592 U18291 CDC16 (cell division cycle 16; S. cerevi 3.7 128530 Hs.183475 AA504343 ESTs; Moderately similar to III! ALU SUB 3.7 119940 Hs.272531 W86779 EST 3.7 110769 Hs.23837 N22222 yw34b06.s1 Morton Fetal Cochlea Homo sap 3.7 132914 Hs.60293 AA496037 ESTs 3.7 113594 Hs.15683 T92030 ESTs 3.7 103702 Hs.279952 AA027793 ESTs; Highly similar to (defline not ava 3.7 130780 Hs.19347 AA248406 ESTs 3.7 123288 Hs.291025 AA495836 EST 3.7 120691 Hs.22380 AA291173 ESTs 3.7 103153 Hs.75295 X66534 guanylate cyclase 1; soluble; alpha 3 3.7 129201 Hs.109390 H19969 ESTs 3.7 114798 Hs.54900 AA159181 ESTs 3.7 126801 Hs.7337 AA512902 ESTs 3.7 105503 Hs.31707 AA256616 ESTs 3.7 104260 Hs.194283 AF008192 Homo sapiens putative GR6 protein (GR6) 3.7 125980 Hs.35699 R97219 ESTs 3.7 123255 Hs.105273 AA490890 ESTs 3.6 103862 Hs.6363 AA206625 ESTs 3.6 100696 Hs.121686 HG3162-HT3339 Transcription Factor Iia 3.6 134917 Hs.166994 X87241 FAT tumor suppressor (Drosophila) homolo 3.6 103520 Y10511 H.sapiens mRNA for CD176 protein 3.6 113778 Hs.302738 W15263 ESTs 3.6 101838 Hs.75511 M92934 connective tissue growth factor 3.6 113702 T97307 ESTs; Moderately similar to HI! ALU SUB 3.6 118201 Hs.48428 N59800 EST 3.6 116519 Hs.68554 C20780 EST 3.6 105886 Hs.22983 AA400517 ESTs; Moderately similar to UDP-GLUCOSE: 3.6 106709 Hs.170291 AA464696 ESTs 3.6 127858 Hs.27973 AA806365 oc26h07.s1 NCI_CGAP_GCB1 Homo sapiens cD 3.6 101964 S81578 dioxin-responsive gene {putative polyade 3.6 105508 Hs.326416 AA256680 ESTs 3.6 116844 Hs.337434 H64938 ESTs 3.6 105372 Hs.142296 AA236481 ESTs 3.6 100745 Hs.144630 HG3510-HT3704 V-Erba Related Ear-3 Protein 3.6 127521 Hs.164018 AA809982 ESTs 3.6 110758 Hs.274265 N21365 talin 3.6 107307 Hs.44155 T52099 creatine kinase; mitochondrial 2 (sarcom 3.6 133200 Hs.183639 AA432248 ESTs 3.6 114774 Hs.184325 AA150043 ESTs 3.6 120265 Hs.270696 AA173759 ESTs; Moderately similar to llll ALU SUB 3.6 134359 Hs.199067 M34309 v-erb-b2 avian erythroblastic leukemia v 3.6 116250 Hs.44829 AA480975 ESTs; Moderately similar to III! ALU SUB 3.6 106313 Hs.35841 AA436459 nuclear fador l X (CCAAT-binding transc 3.6 131898 Hs.279780 N52232 ESTs 3.6 133444 Hs.73793 M27281 vascular endothelial growth factor 3.6 128232 Hs.334641 H06296 ESTs 3.6 135357 Hs.79572 AA235803 ESTs . 3.5 457951 AI369384 arylsulfatase D 3.5 108407 AA075519 zm87h9.s1 Stratagene ovarian cancer (#93 3.5 126659 T16245 a disintegrin and metalloproteinase doma 3.5 104189 Hs.301804 AA485805 ESTs 3.5 125956 Hs.129014 N53276 ESTs 3.5 103026 Hs.79386 X54162 Human mRNA for a 64 Kd autoantigen expre 3.5 133011 Hs.171921 AA042990 sema domain; immunoglobulin domain (Ig); 3.5 131379 Hs.26176 R49035 ESTs 3.5 126742 Hs.169359 H64106 yr57e06.r1 Soares fetal liver spleen 1NF 3.5 105560 Hs.306915 AA262783 ESTs 3.5 118472 Hs.42179 N66818 ESTs 3.5 105623 Hs.30127 AA280895 ESTs; Highly similar to HI! ALU SUBFAMI 3.5 120262 Hs.145807 AA172076 ESTs; Moderately similar to III! ALU SUB 3.5 105027 Hs.26771 AA126472 ESTs 3.5 130760 Hs.18953 AA128997 phosphodiesterase 9A 3.5 117473 Hs.155560 N30157 ESTs 3.5 102663 Hs.168075 U70322 karyopherin (importin) beta 2 3.5 126349 Hs.13531 AA442868 ESTs; Weakly similar to (defline not ava 3.5 132154 Hs.41119 N67179 ESTs 3.5 131689 Hs.30696 AA599653 transcription fador-like 5 (basic helix 3.5 127862 Hs.163191 AA765305 EST 3.5 126995 Hs.189810 W26950 Human DNA sequence from PAC 388M5 on chr 3.5 119071 R31180 ESTs 3.5 103941 Hs.96593 AA282978 ESTs 3.5 110721 Hs.31319 H97678 ESTs 3.5 126586 Hs.43086 AA011247 ESTs 3.5 103106 Hs.1857 X62025 phosphodiesterase 6G; cGMP-spedfic; rod 3.5 116357 Hs.90797 AA504806 Homo sapiens clone 23620 mRNA sequence 3.5 105309 Hs.4104 AA233790 ESTs 3.5 130796 Hs.19525 R39390 ESTs 3.5 109101 Hs.52184 AA167708 ESTs 3.5 103134 Hs.2839 X65724 Norrie disease (pseudoglioma) 3.5 131798 Hs.301449 X86098 adenovirus 5 E1 A binding protein 3.5 118535 Hs.49418 N67968 ESTs 3.5 102592 Hs.11223 U62389 Human putative cytosolic NADP-dependent 3.4 125905 Hs.6456 T69868 chaperonin containing TCP1; subunit 2 (b 3.4 109160 Hs.301997 AA179387 ESTs 3.4 105327 Hs.211593 AA234440 ESTs 3.4 106586 Hs.57787 AA456598 ESTs 3.4 122635 AA454085 EST 3.4 132413 Hs.260116 AA132969 metalloprotease 1 (pitrilysin family) 3.4 131938 Hs.34956 AA283620 ESTs 3.4 133871 Hs.182793 AA454597 ESTs 3.4 107175 Hs.292503 AA621751 ESTs; Weakly similar to KIAA0601 protein 3.4 101188 Hs.184298 L20320 cyclin-dependent kinase 7 (homolog of Xe 3.4 126422 Hs.237658 H48518 ESTs; Highly similar to apolipoprotein A 3.4 118475 N66845 ESTs; Weakly similar to HI! ALU CLASS B 3.4 104558 Hs.88959 R56678 ESTs; Weakly similar to III! ALU SUBFAMI 3.4 128307 Hs.132005 AI453794 ESTs 3.4 112254 Hs.25829 R51831 ESTs 3.4 125408 Hs.89578 N72353 yv37e12.r1 Soares fetal liver spleen 1NF 3.4 109834 Hs.175955 H00604 ESTs 3.4 130844 Hs.20191 D12122 seven in absentia (Drosophila) homolog 2 3.4 127143 Hs.20843 AA533553 nj68h04.s1 NCI CGAP Pr10 Homo sapiens cD 3.4 135309 Hs.42500 D25984 ESTs 3.4 125724 Hs.295978 AA083407 stimulated trans-acting factor (50 Da) 3.4 127692 Hs.187983 AI021912 ESTs 3.4 116674 Hs.92127 F04816 ESTs 3.4 134700 Hs.8868 AA481414 golgi SNAP receptor complex member 1 3.4 114846 Hs.166196 AA234929 ESTs 3.4 103649 Hs.155983 Z70219 H.sapiens mRNA for 5'UTR for unknown pro 3.4 134835 Hs.89925 L04569 caldum channel; voltage-dependent; L ty 3.4 130568 Hs.16085 AA232535 ESTs; Highly similar to (defline not ava 3.4 111331 Hs.15978 N78773 ESTs 3.4 106036 Hs.10653 AA412505 ESTs 3.4 130987 Hs.21893 R45698 ESTs 3.4 112814 Hs.35828 R98192 ESTs 3.4 127815 Hs.255015 AA876009 Ob93c10.s1 NCI_CGAP_GCB1 Homo sapiens cD 3.4 100144 Hs.75616 D13643 KIAA0018 gene product 3.4 101129 Hs.247992 L10405 Homo sapiens DNA binding protein for sur 3.4 130874 Hs.20621 T08287 ESTs 3.4 106882 Hs.26994 AA489009 ESTs 3.4 103855 Hs.302267 AA195179 ESTs 3.4 125957 H45213 yo03b08.r1 Soares adult brain N2b5HB55Y 3.3 114048 Hs.146085 W94613 ESTs 3.3 109826 Hs.75354 F13702 ESTs 3.3 125355 Hs.170098 R45630 ESTs; Highly similar to KIAA0372 [H.sapi 3.3 104182 Hs.143792 AA479990 ESTs; Weakly similar to glio a amplified 3.3 100294 Hs.75454 D49396 Human mRNA for Apo1_Human (MER5(Aop1-Mou 3.3 131688 Hs.30692 U24153 p21 (CDKN1A)-activated kinase 2 3.3 116256 Hs.88201 AA481256 ESTs; Weakly similar to (defline not ava 3.3 102034 Hs.230 U05291 fibromodulin 3.3 130072 Hs.14658 R99606 Human chromosome 5q13.1 done 5G8 mRNA 3.3 114615 Hs.159456 AA083812 ESTs; Highly similar to (defline not ava 3.3 128707 Hs.104105 AA136474 Meis (mouse) homolog 2 3.3 115048 Hs.190057 AA252668 ESTs 3.3 125862 Hs.31110 H12084 ESTs 3.3 135142 Hs.24192 R31679 ESTs 3.3 103119 Hs.2877 X63629 cadherin 3; P-cadherin (placental) 3.3 104460 Hs.62604 M91504 ESTs 3.3 100365 Hs.79284 D78611 mesoderm specific transcript (mouse) horn 3.3 131524 Hs.301804 N39152 ESTs 3.3 102165 Hs.159627 U18321 Death associated protein 3 3.3 126966 Hs.182575 R38438 solute carrier family 15 (H+/peptide tra 3.3 124839 Hs.140942 R55784 ESTs 3.3 100709 Hs.100469 HG3264-HT3441 Af-6 (Gb:U02478) 3.3 132967 Hs.61635 AA032221 Homo sapiens BAG clone RG041 D11 from 7q2 3.3 102927 Hs.65114 X12876 keratin 18 3.3 132616 Hs.283558 AA386264 ESTs 3.3 125132 Hs.129781 W15495 ESTs 3.3 111225 Hs.31652 N68989 ESTs 3.3 114956 Hs.87113 AA243681 ESTs 3.3 122235 Hs.112227 AA436475 ESTs 3.3 112325 Hs.12315 R56055 ESTs 3.3 123360 Hs.178604 AA504784 ESTs 3.3 105150 Hs.155995 AA169640 Homo sapiens mRNA for KIAA0643 protein; 3.3 107391 Hs.284294 W02877 ESTs 3.3 113058 Hs.7569 T26893 EST 3.3 134371 Hs.82318 S69790 Brush-1 3.3 125669 Hs.333256 R51308 ESTs; Moderately similar to III! ALU SUB 3.3 111506 Hs.294105 R07726 ESTs 3.3 122974 Hs.194215 AA478625 ESTs 3.3 102369 Hs.299867 U39840 hepatocyte nuclear factor 3; alpha 3.3 120408 Hs.190151 AA235045 ESTs 3.3 117993 Hs.47402 N52039 ESTs; Weakly similar to HI! ALU SUBFAMI 3.3 129586 Hs.11500 AA437118 ESTs 3.3 128138 Hs.126494 AI200825 ESTs 3.3 127265 AA332751 EST37214 Embryo, 8 week I Homo sapiens c 3.3 107674 Hs.41143 AA011027 Homo sapiens mRNA for KIAA0581 protein; 3.2 104866 Hs.293691 AA045342 ESTs 3.2 103427 Hs.250655 X97303 H.sapiens mRNA for Ptg-12 protein 3.2 132990 Hs.334334 AA458761 ESTs 32 127017 Hs.251946 AA740146 ESTs 32 132313 Hs.44481 U13220 forkhead (Drosophila)-like 6 3.2 106880 Hs.32425 AA488889 ESTs 3.2 107039 Hs.169780 AA599751 homologous to yeast nitrogen permease (c 32 120870 Hs.292581 AA357172 ESTs 32 107920 Hs.284207 AA027951 ESTs 3.2 104165 Hs.105116 AA459160 EST 32 107012 Hs.63908 AA598745 ESTs 32 103605 Hs.194657 Z35402 H.sapiens gene encoding E-cadherin, exon 32 124006 Hs.270016 D60302 ESTs 3.2 101300 Hs.74137 L40391 Homo sapiens (done s153) mRNA fragment 3.2 101183 Hs.795 L19779 H2A histone family; member 0 3.2 125596 R25698 yg44h11.ι2 Soares infant brain 1 NIB Homo 32 127261 AA661567 nu86b02.s1 NCI CGAP Atv1 Homo sapiens cD 3.2 120090 Hs.59554 W94591 ESTs 3.2 129393 Hs.166982 D13435 phosphatidylinositol glycan; dass F . 3.2 120923 Hs.97129 AA382283 ESTs 3.2 118907 Hs.274256 N91003 ESTs 3.2 111552 Hs.191185 R09411 ESTs 3.2 104431 Hs.99913 J03019 adrenergic; beta-1-; receptor 3.2 133551 Hs.278634 D63480 Human mRNA for KIAA0146 gene; partial cd 3.2 131615 Hs.192803 D14533 xeroderma pigmentosum; complementation g 3.2 126547 Hs.84072 U47732 transmembrane 4 superfamily member 3 3.2 103172 Hs.116774 X68742 integrin; alpha 1 3.2 113867 Hs.24095 W68845 ESTs 32 133323 Hs.70937 Z83735 H3 histone family; member K 3.2 111597 Hs.189716 R11499 ESTs 3.2 121515 Hs.104696 AA412133 ESTs 3.2 107445 Hs.6639 W28406 ESTs 3.2 106887 Hs.334335 AA489091 ESTs 32 123052 Hs.185766 AA481806 ESTs 3.2 107072 Hs.130760 AA609113 Homo sapiens mRNA; cDNA DKFZp586N0318 (f 32 102214 Hs.32964 U23752 SRY (sex-determining region Y)-box 11 3.2 123147 AA487961 ab11h6.s1 Stratagene lung (#93721) Homo 3.2 125435 Hs.272138 R00940 ye87g03.r1 Soares fetal liver spleen 1NF 3.2 116246 Hs.250646 AA479961 ESTs; Highly similar to ubiquitin-conjug 3.2 105169 Hs.180789 AA180321 Homo sapiens (done S164) mRNA; 3' end o 3.2 134001 Hs.78344 AF001548 yosin; heavy polypeptide 11; smooth mus 3.2 124866 Hs.304389 R68571 ESTs 3.2 133205 Hs.67619 AA089559 Homo sapiens mRNA; chromosome 1 specific 3.2 102986 Hs.182378 X17648 colony stimulating factor 1 (macrophage) 3.2 101232 Hs.242894 L28997 ADP-ribosylation factor-like 1 3.1 132906 Hs.234896 AA142857 ESTs; Highly similar to geminin [H.sapie 3.1 104281 Hs.5669 C14290 ESTs 3.1 123926 Hs.227933 AA621348 ESTs; Highly similar to (defline not ava 3.1 134464 Hs.239720 N79354 ESTs; Weakly similar to Rga [D.melanogas 3.1 105322 Hs.16346 AA234100 ESTs 3.1 100631 Hs.48332 HG2709-HT2805 Serine/Threonine Kinase (Gb225431) 3.1 130791 Hs.199263 AA259102 ESTs; Highly similar to (defline not ava 3.1 131220 Hs.300855 R77200 ESTs 3.1 113237 Hs.123642 T62857 ESTs 3.1 125562 Hs.98968 AI494372 ESTs 3.1 134110 Hs.79136 U41060 Human breast cancer; estrogen regulated 3.1 132393 Hs.47334 W85888 ESTs; Moderately similar to III! ALU SUB 3.1 107439 Hs.296842 W27995 ESTs; Moderately similar to non-muscle m 3.1 125863 Hs.40719 AA299096 Homo sapiens mRNA; cDNA DKFZp564M0916 (f 3.1 105811 Hs.286192 AA394121 ESTs 3.1 129284 Hs.296141 AA104023 ESTs 3.1 125321 Hs.178294 T86652 ESTs 3.1 107332 Hs.183297 T87750 ESTs 3.1 123570 Hs.109653 AA608955 ESTs 3.1 100384 Hs.90800 D83646 matrix metalloproteinase 16 (membrane-in 3.1 109063 Hs.38972 AA161043 tetraspan 1 3.1 133284 Hs.182828 U09367 zinc finger protein 136 (clone pHZ-20) 3.1 131839 Hs.33010 H80622 Homo sapiens mRNA for KIAA0633 protein; 3.1 117606 Hs.44698 N35115 ESTs 3.1 418998 Hs.287849 F13215 ESTs 3.1 125180 Hs.103120 W58344 ESTs 3.1 100789 HG3893-HT4163 Phosphogiucomutase 1, Alt. Splice 3.1 126017 Hs.159440 H60487 ESTs 3.1 132452 Hs.247324 AA005262 Homo sapiens DNA sequence from PAC 262D1 3.1 129077 Hs.108479 H78886 ESTs 3.1 126563 Hs.181368 W26247 U5 snRNP-spedfic protein (220 kD); orth 3.1 129650 Hs.118258 N52554 ESTs 3.1 123465 AA599033 ESTs 3.1 126486 Hs.152316 AA345339 EST51345 Gall bladder II Homo sapiens cD 3.1 126460 Hs.167031 W01616 za36d05.r1 Soares fetal liver spleen 1NF 3.1 118697 Hs.43234 N72094 ESTs 3.1 103860 Hs.38057 AA203742 ESTs 3.1 127968 Hs.124347 AA971439 ESTs 3.1 124984 Hs.223241 T47566 yb15c11.s1 Stratagene placenta (#937225) 3.1 103903 Hs.15220 AA249334 j312.seq.F Human fetal heart, Lambda ZAP 3.1 106697 Hs.22242 AA463737 ESTs 3.1 130892 Hs.20993 AA442604 ESTs; Weakly similar to Ydr374cp [S.cere 3 114032 Hs.35014 W92779 ESTs - 3 128835 Hs.106390 W15528 ESTs 3 103667 Hs.247815 Z80788 H.sapiens H4Λ gene 3 126264 HS250614 N42897 yy13h06.r1 Soares melaπocyte 2NbHM Homo 3 132626 Hs.21275 D25755 ESTs 3 131107 Hs.75354 N87590 ESTs 3 126780 Hs.5811 R12421 ESTs 3 127363 Hs.22116 AA307744 Homo sapiens Cdc14B1 phosphatase mRNA; c 3 103690 Hs.84063 AA016186 ESTs 3 102589 Hs.8867 U62015 Homo sapiens Cyι61 mRNA, complete eds 3 125144 Hs.24336 W37999 ESTs 3 132977 Hs.301404 U28686 RNA binding motif protein 3 3 120714 Hs.146170 AA292689 ESTs 3 101038 Hs.79411 J05249 replication protein A2 (32kD) 3 102856 Hs.248177 X00090 Human histone H3 gene 3 105516 Hs.30738 AA257971 ESTs 3 131137 Hs.33287 U85193 nuclear factor l/B 3 127221 Hs.241551 AI354332 ESTs 3 411888 Hs.24104 R26708 ESTs 3 131684 Hs.3066 U26174 granzyme K (serine protease; granzyme 3; 3 100629 Hs.21291 HG2706-HT2802 Serine/Threonine Kinase (Gb:Z25428) 3 119944 Hs.58915 W86838 EST 3 113801 Hs.118281 W38418 zinc finger protein 266 3 133780 Hs.76152 M14219 decorin 3 104690 Hs.14449 AA010889 ESTs 3 126371 Hs.304139 N57645 EST 3 127635 Hs.116346 AA766903 ESTs 3 128434 Hs.143880 AI190914 ESTs 3 435761 Hs.187555 AA701941 ESTs 3 125025 Hs.50748 T71561 ESTs 3 124940 Hs.103804 R99599 heterogeneous nuclear ribonudeoprotein 3 128742 Hs.251531 D00763 proteaso e (prosome; macropain) subunit; 3 107147 Hs.10450 AA621125 Homo sapiens chromosome 2; 10 repeat reg 3 112068 Hs.22545 R43910 ESTs 3 105346 Hs.263727 AA235465 ESTs; Moderately similar to III! ALU SUB 3 130972 Hs.21739 AA370302 Homo sapiens mRNA; cDNA DKFZp586l1518 (f 3 131230 Hs.274407 AA149987 thymus spedfic serine peptidasβ 3 133743 Hs.75847 N79435 ESTs 3 127402 Hs.227949 AA358869 ESTs; Highly similar to SEC13-RELATED PR 3 117483 Hs.44189 N30426 ESTs 3 123659 Hs.112699 AA609368 ESTs 3 103963 Hs.63290 AA298588 EST114219 HSC172 cells II Homo sapiens c 3 103795 Hs.7367 AA112222 ESTs; Moderately similar to (defline not 3 115092 Hs.80975 AA255903 CD39-like 4 2.9 134831 Hs.89890 S72370 pyruvate cartoxylase 2.9 128579 Hs.101810 AA093378 ESTs; Weakly similar to III! ALU SUBFAMI 2.9 134193 Hs.7980 F09570 ESTs 2.9 123522 Hs.112575 AA608577 ESTs 2.9 107109 Hs.32793 AA609943 ESTs 2.9 134694 Hs.88556 D50405 histone deacetylase 1 2.9 134399 Hs.82689 H99801 tumor rejection antigen (gp96) 1 2.9 134632 Hs.174139 AA398710 H. sapiens RNA for CLCN3 2.9 106683 Hs.14512 AA461495 ESTs 2.9 108555 AA084963 zn13e12.s1 Stratagene hNT neuron (#93723 2.9 100953 Hs.2110 HG945-HT945 Nucleic Acid-Binding Protein (Gb:L12693) 2.9 130597 Hs.16492 AA173998 ESTs; Weakly similar to weakly similar t 2.9 101813 Hs.139226 M87338 replication factor C (activator 1 ) 2 (40 2.9 106636 Hs.286 AA459950 ESTs 2.9 129109 Hs.108708 AA491295 calcium calmodulin-dependent protein kin 2.9 125819 Hs.251871 AA044840 stromal cell-derived factor 1 2.9 106282 Hs.9857 AA433946 ESTs; Weakly similar to (defline not ava 2.9 100386 Hs.301636 D83703 peroxiso al biogenesis factor 6 2.9 114546 Hs.98074 AA056263 ESTs; Moderately similar to HI! ALU SUB 2.9 105914 Hs.9701 AA402224 Homo sapiens growth arrest and DNA-damag 2.9 108552 AA084912 zn11c7.s1 Stratagene hNT neuron (#937233 2.9 126505 Hs.190057 W26894 16a11 Human retina cDNA randomly primed 2.9 134098 Hs.79086 X06323 Human MRL3 mRNA for ribosomal protein L3 2.9 129721 Hs.211539 L19161 eukaiyotic translation initiation fador 2.9 100076 Hs.277422 AB000897 Homo sapiens mRNA for cadherin FIB3, par 2.9 117466 Hs.44104 N29862 ESTs - 2.9 106335 Hs.36688 AA437258 ESTs; Moderately similar to WAP four-dis 2.9 134510 Hs.250870 U25265 protein kinase; mitogen-activated; kinas 2.9 105835 Hs.32995 AA398412 ESTs 2.9 106611 Hs.26267 AA458904 ESTs; Weakly similar to torsinA [H.sapie 2.9 134087 Hs.173824 U51166 thymine-DNA glycosylase 2.9 100641 Hs.182183 HG2743-HT2846 CaWesmon l, Alt. Splice 4, Non-Musde 2.9 104602 R86920 ESTs 2.9 117203 Hs.42738 H99799 ESTs 2.9 131889 Hs.34073 AA401912 BH-protocadherin (brain-heart) 2.9 101707 Hs.155212 M65131 methyl alonyl Coenzyme A mutase 2.9 115271 Hs.5724 AA279422 ESTs 2.9 125812 Hs.287912 H73420 ledin; mannose-binding; 1 2.9 110740 Hs.19762 H99675 ESTs 2.9 103406 Hs.285728 X95677 H.sapiens mRNA for ArgBPIB protein 2.9 104577 Hs.132390 R71539 ESTs 2.9 102772 Hs.161002 U83115 absent in melanoma 1 2.9 131710 Hs.30985 AA233225 ESTs; Highly similar to (defline not ava 2.9 125231 Hs.268903 W84714 ESTs 2.9 127380 Hs.15535 AI417137 Homo sapiens done 24582 mRNA sequence 2.9 104229 Hs.61289 AB002346 inositol phosphate 5'-phosphatase 2 (syn 2.9 126600 Hs.191385 AA699949 ESTs 2.9 125175 Hs.303030 W52355 EST 2.9 103849 Hs.34578 AA187045 ESTs; Weakly similar to III! ALU SUBFAMI 2.9 102126 Hs.78961 U14575 protein phosphatase 1; regulatory (inhib 2.9 124906 Hs.107815 R87647 ESTs 2.9 131148 Hs.303125 C00038 ESTs 2.9 123158 Hs.218329 AA488658 heat shock 70kD protein 1 2.9 133667 Hs.75462 U72649 Human BTG2 (BTG2) mRNA; complete eds 2.9 105182 Hs.18271 AA191014 ESTs; Weakly similar to Ydr372cp [S.cere 2.9 133968 Hs.232068 D15050 Human mRNA for transcription factor AREB 2.9 117425 Hs.336901 N27154 ESTs 2.9 111087 Hs.37637 N59645 ESTs 2.9 129641 Hs.11805 N66066 ESTs 2.9 128639 Hs.102897 N91246 ESTs 2.9 133209 Hs.79265 AA114183 ESTs; Moderately similar to glutamate py 2.9 135154 Hs.267812 AA126433 sorting nexin 4 2.9 126838 Hs.279609 AA858097 pigment epithelium-derived fador 2.9 103803 Hs.106149 AA127696 ESTs 2.9 102139 Hs.2128 U15932 dual specificity phosphatase 5 2.9 128104 AA971000 op67g11.s1 Soares_NFL_T_GBC_S1 Homo sapi 2.8 127834 Hs.337631 AA761415 nz22d08.s1 NCI CGAP GCB1 Homo sapiens cD 2.8 133101 Hs.180952 AA488230 ESTs 2.8 127250 Hs.217916 AI023717 ESTs 2.8 135063 Hs.93883 D10537 myelin protein zero (Charcot-Marie-Tooth 2.8 126323 Hs.68644 N45014 yy80g06.r1 Soares multiple sclerosis 2Nb 2.8 121873 Hs.145696 AA426270 ESTs 2.8 122090 Hs.98684 AA432141 ESTs 2.8 118728 Hs.322645 N73705 ESTs 2.8 135400 Hs.99915 M23263 androgen receptor (dihydrotestosterone r 2.8 125278 Hs.129998 W93523 ESTs 2.8 124387 Hs.109019 N27637 ESTs 2.8 124803 Hs.12186 R45480 cyclin K 2.8 H45968 Hs.32149 H45968 ESTs 2.8 104261 Hs.5409 AF008442 RNA polymerase I subunit 2.8 105366 Hs.282093 AA236356 ESTs 2.8 106070 Hs.5957 AA417761 Homo sapiens done 24416 mRNA sequence 2.8 131356 Hs.25960 M13241 v-myc avian yelocytomatosis viral relat 2.8 112009 Hs.26255 R42714 EST 2.8 133199 Hs-250175 AA609773 Homo sapiens done 23904 mRNA sequence 2.8 110379 Hs.33130 H44825 ESTs 2.8 103890 Hs.72085 AA236843 ESTs; Weakly similar to unknown [S.cerev 2.8 128152 R20353 yg20f10.r1 Soares infant brain INIB Homo 2.8 107008 Hs.23740 AA598710 ESTs 2.8 135243 Hs.97101 AA215333 ESTs 2.8 103058 Hs.184510 X57348 stratifin 2.8 132020 Hs-293845 AA428990 ESTs 2.8 116354 Hs.292566 AA504262 ESTs 2.8 125867 Hs.12372 H98141 ESTs 2.8 120603 Hs.98541 AA282787 ESTs; Highly similar to (defline not ava 2.8 115119 Hs.46847 AA256524 Human DNA sequence from clone 30M3 on ch 2.8 133865 Hs.170290 F09315 discs; large (Drosophila) homolog 5 2.8 109415 Hs.110826 AA227219 Homo sapiens CAGF9 mRNA; partial eds 2.8 128687 Hs.23767 Z38910 ESTs 2.8 109984 Hs.10299 H09594 ESTs; Moderately similar to !!!! ALU SUB 2.8 133179 Hs.66731 U81599 homeo box B13 2.8 115998 Hs.336629 AA448488 ESTs; Weakly similar to zinc finger prat 2.8 112180 Hs.25067 R49116 EST 2.8 120428 Hs.173694 AA236822 ESTs; Moderately similar to (defline not 2.8 106241 Hs.6019 AA430108 ESTs 2.8 131060 Hs.22564 AA160890 myosin VI 2.8 111383 Hs.40919 N94527 ESTs 2.8 102123 Hs.1594 U14518 centromere protein A (17kD) 2.8 102722 Hs.79981 U79242 Human done 23560 mRNA sequence 2.8 129887 Hs.274324 W92041 PCAF associated fador 65 alpha 2.8 126663 Hs.181297 AA714635 ESTs 2.8 104367 Hs. 34342 H17438 ESTs; Weakly similar to seventransmembra 2.8 107316 Hs.193700 T63174 ESTs; Moderately similar to III! ALU SUB 2.8 128059 Hs.145096 AA972446 ESTs 2.8 124447 N48000 ESTs 2.8 111398 Hs.125565 R00086 deafness; X-linked 1; progressive 2.8 134085 Hs.79018 U20979 chromatin assembly factor 1 (150 kDa) 2.8 124788 Hs.100912 R43543 ESTs 2.8 112248 Hs.326416 R51361 ESTs 2.8 121309 Hs.97312 AA402482 ESTs 2.8 103076 Hs.75319 X59618 ribonucleotide reductase M2 polypeptide 2.8 107071 Hs.35198 AA609053 ESTs 2.8 104425 Hs.35380 H88496 ESTs 2.8 132991 Hs.62245 AA446906 solute carrier family 25 (mitochondrial 2.8 104968 Hs.29669 AA084602 ESTs 2.8 121153 Hs.97694 AA399640 ESTs 2.8 131216 Hs.243901 D31058 ESTs 2.8 109682 Hs.22869 F09299 ESTs 2.8 131990 Hs.168818 H77734 ESTs; Moderately similar to roundabout 1 2.8 132027 Hs.181444 N78844 ESTs; Weakly similar to R12C12.6 [C.eleg 2.8 127383 Hs.190478 AA447990 ESTs 2.8 132598 Hs.530 M81379 collagen; type IV; alpha 3 (Goodpasture 2.8 101121 Hs.1313 L09753 tumor necrosis factor (ligand) superfami 2.8 123000 Hs.105640 AA479347 ESTs 2.8 121329 Hs.1755 AA404324 ESTs 2.8 100481 Hs.121489 HG1098-HT1098 Cystatin D 2.7 113803 Hs.283683 W42789 ESTs 2.7 110934 Hs.169001 N48708 ESTs; Weakly similar to cytochrome P-450 2.7 432888 T86823 ESTs 2.7 121802 Hs.188898 AA424328 ESTs 2.7 130396 Hs.155313 AB002331 Human mRNA for KIAA0333 gene; partial cd 2.7 121103 Hs.97697 AA398936 ESTs; Weakly similar to (defline not ava 2.7 131129 Hs.23240 R27296 ESTs 2.7 130943 Hs.272429 D50855 calcium-sensing receptor (hypocalciuric 2.7 134676 Hs.87819 W28051 ESTs; Weakly similar to keratin 9; cytos 2.7 111900 Hs.25318 R39044 ESTs 2.7 106025 Hs.173334 AA412063 ESTs 2.7 126144 Hs.40639 N39696 yx92a07. Soares melanocyte 2NbHM Homo 2.7 103248 Hs.75262 X77383 cathepsin 0 2.7 127230 Hs.274170 H30501 Homo sapiens Opa-interacting protein OIP 2.7 101584 Hs.84072 M35252 transmembrane 4 superfamily member 3 2.7 124131 Hs.167489 H19980 ESTs 2.7 129689 Hs.77873 AA130156 ESTs 2.7 132892 Hs.9973 W92797 ESTs 2.7 120827 Hs.132967 AA347717 ESTs 2.7 134579 Hs.85963 N23222 ESTs; Moderately similar to III! ALU SUB 2.7 106149 Hs.256301 AA424881 ESTs 2.7 132037 Hs.332541 AA203649 ESTs; Weakly similar to HEM45 [H.sapiens 2.7 130542 Hs.179825 U64675 Human sperm membrane protein BS-63 mRNA, 2.7 122851 Hs.99598 AA463627 ESTs 2.7 134983 Hs.196384 D28235 prostaglandin-endoperoxide synthase2 (p 2.7 120537 Hs.160422 AA262790 ESTs 2.7 131036 Hs.174140 X64330 ATP citrate lyase 2.7 133889 Hs.211582 AA099391 ESTs - 2.7 128847 Hs.106529 AA424199 zv81e01.r1 Soares total fetus Nb2HF8 9w 2.7 112755 Hs.306044 R93802 ESTs 2.7 423239 AA323591 EST26392 Cerebellum II Homo sapiens cDNA 2.7 105031 Hs.12321 AA127240 ESTs 2.7 126021 Hs.187516 AA775894 ESTs 2.7 102116 U13706 Human ELAV-like neuronal protein 1 isofo 2.7 133394 Hs.237225 R16759 ESTs; Weakly similar to (defline not ava 2.7 104267 Hs.278439 C00358 ESTs 2.7 107614 Hs.40241 AA004878 ESTs; Highly similar to (defline not ava 2.7 129809 Hs.1259 X55283 asiaioglycoprotein receptor 2 2.7 112109 Hs.283309 R45221 ESTs; Weakly similar to llll ALU SUBFAMI 2.7 128422 T85681 yd60c06.r1 Soares fetal liver spleen 1NF 2.7 109494 Hs.43899 AA233702 ESTs 2.7 118696 Hs.292284 N72086 Homo sapiens RNA polymerase III largest 2.7 106053 Hs.36727 AA416963 ESTs; Highly similar to histone H2A [H.s 2.7 104440 Hs.284380 L20492 gamma-glutamyltransferase 1 2.7 129426 Hs.111323 AA412087 EST; Highly similar to (defline not avai 2.7 123798 AA620411 small inducible cytokine A5 (RANTES) 2.7 106716 Hs.238928 AA464962 ESTs 2.7 103663 Z78291 Z78291 Homo sapiens brain fetus Homo sap 2.7 114162 Hs.22265 Z38909 ESTs 2.7 113063 Hs.5027 T32438 ESTs 2.7 127897 AA773857 af80c09.r1 Soares_NhHMPu_S1 Homo sapiens 2.7 130621 Hs.16803 AA621718 ESTs; Weakly similar to (defline not ava 2.7 116245 Hs.42796 AA479958 ESTs; Highly similar to (defline not ava 2.7 125499 R11878 yf49d11. Soares infant brain 1NIB Homo 2.7 133960 Hs.77899 M19267 tropomyosin 1 (alpha) 2.7 104470 Hs.246358 N28843 ESTs; Weakly similar to Similar to colla 2.7 134982 Hs.92308 N46086 ESTs 2.7 106803 Hs.284295 AA479114 ESTs 2.7 104899 Hs.285574 AA054726 ESTs 2.7 125401 Hs.337585 AI204637 ESTs; Moderately similar to KIAA0350 [H. 2.7 111253 Hs.15768 N70042 ESTs; Moderately similar to III! ALU SUB 2.7 118449 Hs.164478 N66413 ESTs; Weakly similar to (defline not ava 2.7 134507 Hs.84318 M63488 replication protein A1 (70kD) 2.7 121609 Hs.98185 AA416867 EST 2.7 113835 Hs.27475 W56590 ESTs 2.7 113962 Hs.285290 W86375 ESTs; Highly similar to (defline not ava 2.7 121913 Hs.98558 AA428062 ESTs 2.7 108194 Hs.216717 AA057250 ESTs 2.7 130799 Hs.12696 AA464273 ESTs 2.7 123184 Hs.18166 AA489072 Homo sapiens mRNA for KIAA0870 protein; 2.7 103420 Hs.173497 X97065 SEC23-like protein B 2.7 106186 Hs.6315 AA427398 acetylserotonin N-methyltransferase-like 2.7 101349 L77559 Homo sapiens DGS-B partial mRNA 2.7 112954 Hs.6655 T16559 ESTs 2.7 133054 Hs.291079 R07876 ESTs; Weakly similar to unknown [S.cerev 2.7 128131 Hs.25640 AI283162 claudin 3 2.6 101864 Hs.75777 M95787 transgelin 2.6 111948 Hs.26303 R40752 ESTs 2.6 130145 Hs.151051 U07620 protein kinase mitogen-adivated 10 (MAP 2.6 126507 Hs.23964 AI362218 ESTs 2.6 117903 Hs.47111 N50740 ESTs 2.6 116345 Hs.199067 AA496981 ESTs 2.6 132227 Hs.4248 AA412620 ESTs 2.6 125746 Hs.274256 H03574 yj42b06.r1 Soares placenta Nb2HP Homo sa 2.6 105073 Hs.89463 AA137034 ESTs 2.6 102764 U82310 Homo sapiens unknown protein mRNA, parti 2.6 131367 Hs.173933 AA456687 ESTs 2.6 130792 Hs.19500 AA307896 nudear localization signal deleted in v 2.6 107427 Hs.46736 W26975 ESTs 2.6 117477 Hs.44175 N30328 ESTs 2.6 106290 Hs.16364 AA435542 ESTs 2.6 126829 Hs.7910 R11547 ESTs 2.6 118836 Hs.173001 N79820 ESTs 2.6 100147 Hs.136348 D13666 osteoblast specific fador 2 (fasciclin 2.6 104278 Hs.109253 C02582 ESTs; Highly similar to (defline not ava 2.6 135051 Hs.83484 C15324 ESTs 2.6 126081 Hs.227835 AI346024 collagen; type I; alpha 1 - 2.6 123579 AA608983 af5d4.s1 Soares_testis_NHT Homo sapiens 2.6 130115 Hs.149923 M31627 X-box binding protein 1 2.6 101434 Hs.1430 M20218 coagulation factor XI (plasma thrombopla 2.6 122962 Hs.104720 AA478429 ESTs; Moderately similar to III! ALU SUB 2.6 126151 Hs.40808 AA324743 ESTs 2.6 128925 Hs.21851 D61676 Homo sapiens mRNA; cDNA DKFZp586J2118 (f 2.6 128919 Hs.103391 1-27559 insulin-like growth factor binding prate 2.6 130296 Hs.154103 R09286 LIM protein (similar to rat protein kina 2.6 128402 Hs.191637 AA457244 ESTs 2.6 129273 Hs.109968 W63783 ESTs 2.6 125483 Hs.7788 F07759 ESTs 2.6 132953 Hs.321264 AA029927 ESTs 2.6 130963 Hs.21639 U57099 nuclear protein; marker for differential 2.6 120614 Hs.194154 AA284281 ESTs; Weakly similar to III! ALU SUBFAMI 2.6 123251 Hs.103267 AA490858 ESTs; Moderately similar to Rabin3 [R.no 2.6 121710 Hs.96744 AA419011 ESTs 2.6 125428 Hs.851 W74608 ESTs; Highly similar to (defline not ava 2.6 115906 Hs.82302 AA436616 ESTs 2.6 108432 AA076626 Homo sapiens done 23851 mRNA sequence 2.6 126191 Hs.191911 H97728 ESTs 2.6 106164 Hs.281434 AA425773 ESTs 2.6 111519 Hs.268615 R08165 ESTs 2.6 134590 Hs.173840 W58612 ESTs 2.6 102565 U59748 Human desert hedgehog (hDHH) mRNA, parti 2.6 129879 Hs.13109 AA194973 ESTs 2.6 114264 Hs.334609 Z40074 ESTs 2.6 106236 Hs.21104 AA429951 ESTs 2.6 135192 Hs.321709 AF000234 purinergic receptor P2X; ligand-gated to 2.6 109833 Hs.29889 H00580 ESTs 2.6 105756 Hs.8535 AA303088 ESTs; Weakly similar to transformation-r 2.6 121422 Hs.97967 AA406210 ESTs 2.6 130417 Hs.155485 U58522 Human huntingtin interacting protein (HI 2.6 124312 Hs.102329 H94647 ESTs 2.6 108998 Hs.97199 AA156058 ESTs 2.6 127081 Hs.180591 R88362 ESTs; Weakly similar to weak similarity 2.6 129574 Hs.11463 AA458603 ESTs; Weakly similar to (defline not ava 2.6 112410 Hs.26904 R61680 ESTs 2.6 123929 Hs.112981 AA621364 ESTs 2.6 122905 Hs.104835 AA470070 ESTs 2.6 116399 Hs.110637 AA599729 Homo sapiens homeobox protein A10 (HOXA1 2.6 130279 Hs.153934 AA424044 core-binding fador; runt domain; alpha 2.6 130021 Hs.1435 M24470 guanosine monophosphate reductase 2.6 100585 Hs.199160 HG2367-HT2463 Trithorax Homolog Hrx 2.6 104965 Hs.30177 AA084104 ESTs 2.6 117711 Hs.46485 N45201 EST 2.6 124792 Hs.48712 R44357 ESTs 2.6 111299 Hs.74313 N73808 ESTs 2.6 103616 Hs.32971 Z46973 ■ phosphoinositide-3-kinase; dass 3 2.6 133629 Hs.195614 D13642 KIAA0017 gene product 2.6 126484 Hs.169977 AI086782 ESTs 2.6 100858 HG4245-HT4515 Forkhead Family Afx1 2.6 133547 Hs.301927 X02883 T-cell receptor; alpha (V;D;J;C) 2.6 126680 Hs.133865 F07097 ESTs 2.6 125739 Hs.92137 AA428557 v-myc avian myelocytomatosis viral oncog 2.6 102276 Hs.10247 U30999 Human (memc) mRNA, 3'UTR 2.6 105586 Hs.191538 AA279137 ESTs 2.6 103978 Hs.34136 AA307443 ESTs 2.6 125054 Hs.268601 T80622 ESTs; Weakly similar to (defline not ava 2.6 114212 Hs.21201 Z39338 ESTs; Highly similar to (defline not ava 2.6 116959 Hs.40022 H79310 EST 2.6 109228 Hs.306995 AA193366 ESTs 2.6 133989 Hs.78202 U29175 SWI/SNF related; matrix assodated; act! 2.6 100640 Hs.182183 HG2743-HT2845 Caldesmon l, Alt. Splice 3, Non-Muscle 2.6 133093 Hs.285996 AA598749 ESTs 2.6 114306 Hs.6540 Z40861 ESTs 2.6 106060 Hs.171391 AA417287 C-terminal binding protein 2 2.5 107748 Hs.60772 AA017258 EST 2.5 100134 Hs.49 D13264 macrophage scavenger receptor 1 2.5 133969 Hs.78 U13044 GA-binding protein transcription fador; 2.5 130992 Hs.74316 AA455001 ESTs 2.5 127493 Hs.291701 AA808081 oc39a08.s1 NCI CGAP GCB1 Homo sapiens cD 2.5 132869 Hs.203961 N26855 ESTs 2.5 117570 Hs.44583 N34415 EST 2.5 124644 Hs.109654 N91279 ESTs 2.5 103558 Hs.2785 Z19574 keratin 17 2.5 132883 Hs.5897 AA047151 ESTs 2.5 102009 Hs.82643 U02680 protein tyrosine kinase 9 2.5 116058 Hs.20159 AA454156 ESTs 2.5 121989 Hs.193784 AA430O44 ESTs 2.5 131257 Hs.24908 AA256042 ESTs 2.5 100320 Hs.75275 D50916 homolog of yeast (S. cerevisiae) ufd2 2.5 102959 Hs.121524 X15722 glutathione reductase 2.5 132969 Hs.6166 AA047616 ESTs 2.5 130869 Hs.2057 AA128100 uridine monophosphate synthetase (orotat 2.5 129645 Hs.118131 L38928 5;10-methenyitetrahydrofolate synthetase 2.5 126399 Hs.83883 AA128075 zl16d08.r1 Soares_pregnanLuterus_NbHPU 2.5 134069 Hs.78935 U29607 Homo sapiens elF-2-associated p67 homolo 2.5 109816 Hs.61960 F11013 ESTs; Weakly similar to KIAA0176 [H.sapi 2.5 134801 Hs.89695 X02160 insulin receptor 2.5 104232 Hs.10587 AB002351 Human mRNA for KIAA0353 gene; partial cd 2.5 107361 Hs.159486 U72513 Human RPL13-2 pseudogene mRNA; complete 2.5 106057 Hs.289074 AA417067 ESTs 2.5 134252 Hs.80720 AA031782 Homo sapiens mRNA; cDNA DKFZp586B1722 (f 2.5 128062 Hs.105547 AA379500 ESTs 2.5 110009 Hs.6614 H10933 ESTs 2.5 111375 Hs.20432 N93696 ESTs 2.5 122642 Hs.99361 AA454186 ESTs 2.5 127999 Hs.69851 AA837495 ESTs; Weakly similar to Wiskott-Aldrich 2.5 105029 Hs.13268 AA126855 ESTs 2.5 105082 Hs.26765 AA143763 ESTs; Weakly similar to Similarity to S. 2.5 TABLE 1 A show the accession numbers for those primekeys lacking unigenelD's for Table 1. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column. Pkey: Unique Eos probeset identifier number CAT number: Gene duster number Accession: Genbank accession numbers Pkey CATnumber Accessions 108552 111555J AA071210 AA069899 AA071438 AA084912 AA084803 AA079371 AA079370 126023 1596090J H57661 H58881 126086 1606216J H75681 H70975 102565 32479J AB010994 U59748 AA064660 101964 48158_-7 S81578 125499 1562851J H10543 R11878 125596 1708455J R25698 R56582 R56018 118417 37186J AF080229 AF080231 AF080230 AF080232 AF080233 AF080234 BE550633 AI636743 AW614951 BE467547 AI680833 AI633818 N29986 U87592 U87593 U87590 U87591 S46404 U87587 AA463992 AW206802 AI970376 AI583718 AI672574 N25695 AW665466 AI818326 AA126128 AI480345 AW013827 AA248638 AI214968 AA204735 AA207155 AA206262 AA204833 AW003247 AW496808 AI080480 AI631703 AI651023 AI867418 AW818140 AA502500 AI206199 AI671282 AI352545 BE501030 AI652535 BE465762 AA206331 AW451866 AA471088 AA206342 AA204834 AA206100 AW021661 AA332922 N66048 AA703396 H92278 AW139734 H92683 U87589 U87595 H69001 U87594 BE466420 A1624817 BE466611 AI206344 AA574397 AA348354 AI493192 125661 327827J AA491830 R50173 R55192 R50320 AI732306 AI732305 AI820727 AI820728 R55191 R50319 R50227 125957 1583542J H41694 H45213 125982 1766315J R98091 W92898 127248 227560J AA364195 AA325029 AW962050 103731 112052J AA070545 AA131490 AA131373 127261 231687J AA330501 AA661567 127265 232391J AA331503 AA332751 AW962542 126659 1541209J T16245 R19694 F13545 H10299 T66048 T65279 H18006 127315 37938J AF116622 AH 14507 AA640834 AA377999 103806 112618J AA130614AA071410 128104 502608J AA906093AA971000 104602 524482_2 H47610 R86920 128152 297868J F07973 R20353AA442660 128422 1811283J T77794T85681 127897 446527J AA773681 AA773857 106566 120358J BE298210 AI672315 AW086489 BE298417 AA455921 AA902537 BE327124 R14963 AA085210 AW274273 AI333584 AI369742 AI039658 AI885095 AI476470 AI287650 AI885299 AI985381 AW592624 AW340136 AI266556 AA456390 AI310815 AA484951 129735 44573 2 AI950087 N70208 R97040 N36809 A1308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI653832 AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 AI819225 AW205862 AI683338 A1858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA5510G5 W80701 AW613456 AI373032 AI564269 F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226 F04005 123147 219802_-2 AA487961 130529 158447J AA178953AA192740 123579 genbank_AA608983 AA608983 109175 genbank_AA180496 AA180496 100789 tigr--HT4163 S67998 100858 tigr_HT4515 U10072 123798579959J AA620411 AA287491 102116 βntrez_U13706 U13706 102398 entrez U42359 U42359 102764 entrez_U82310 U82310 118475 genbank_N66845 N66845 104776 genbank_AA026349 AA026349 104787 genbank_AA027317 AA027317 113702 genbank_T97307 T97307 113938 genbank_W81598 W81598 122635 genbank_AA454085 AA454085 108407 genbank_AA075519 AA075519 108432 genbank_AA076626 AA076626 108555 genbank_AA084963 AA084963 101349 entrez_L77559 L77559 124447 genbank_N48000 N48000 119071 genbank_R31180 R31180 103520 entrez_Y10511 Y10511 103663 genbank_Z78291 Z78291 128046 877605J AA873285 AI025762 126959 546044J AA199853 AA206355 123465 genbank_AA599033 AA599033 MISSING AT THE TIME OF PUBLICATION TABLE 2: shows a preferred subset of the Accession numbers for genes found in Table 1 which are differentially expressed in prostate tumor tissue compared to normal prostate tissue. Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD: Unigene number Unigene Title: Unigene gene title R1 : Ratio of tumor to normal body tissue (Relaxed ratio (87/70) Pkey ExAccn UnigenelD Unigene Title R1 131919 AA121266 Hs.272458 ESTs 372 120328 AA196979 Hs.290905 ESTs; Weakly similar to (defline not ava 32.6 101486 M24902 Hs.1852 add phosphatase; prostate 252 119073 R32894 Hs.279477 ESTs 24.8 133428 M34376 Hs.183752 microseminoprotein; beta- 23.8 128180 AA595348 Hs.171995 kallikrein 3; (prostate specific antigen 21.4 104080 AA402971 Hs.57771 Homo sapiens mRNA for serine protease (T 18.9 127537 AA569531 Hs.162859 ESTs 18.6 131665 R22139 Hs.30343 ESTs 17.4 101050 K01911 Hs.1832 neuropeptide Y 17.3 130771 N48056 Hs.1915 folate hydrolase (prostate-specific memb 17 107485 W63793 Hs.262476 S-adenosylmethionine decaiboxylase 1 16.7 106155 AA425309 Hs.33287 ESTs 16.5 129534 R73640 Hs.11260 ESTs 16.4 100569 HG2261-HT2351 Antigen, Prostate Specific, Alt. Splice 16 101889 S39329 Hs.181350 kallikrein 2; prostatic 15.4 135389 U05237 Hs.99872 fetal Alzheimer antigen 15 133944 AA045870 Hs.7780 ESTs 12.5 130974 X57985 Hs.2178 H2B histone family; member Q 11.8 114768 AA149007 Hs.182339 ESTs 11.8 104660 AA007160 Hs.14846 ESTs 11.4 131061 N64328 Hs.268744 ESTs; Moderately similar to KIAA0273 [H. 10.9 126645 AI167942 Hs.61635 Homo sapiens BAC done RG041D11 from 7q2 10.7 135153 N40141 Hs.95420 Homo sapiens mRNA for JM27 protein; comp 10.6 107033 AA599629 Hs.113314 ESTs 10.6 118417 N66048 ESTs; Weakly similar to polymerase [H.sa 10.5 126758 W37145 Hs.293960 ESTs 102 107102 AA609723 Hs.30652 ESTs 10.1 116787 H28581 Hs.15641 ESTs 10.1 115719 AA416997 Hs.59622 ESTs 10 123209 AA489711 HS203270 ESTs 9.9 101664 M60752 Hs.121017 H2A histone family; member A 9.8 112971 T17185 Hs.83883 ESTs 9.7 117984 N51919 Hs.106778 ESTs 9.7 129523 M30894 Hs274509 T-cell receptor; gamma cluster 9.4 132964 AA031360 Hs.167133 ESTs 9.2 121853 AA425887 Hs.98502 ESTs 9 119617 W47380 Hs.55999 ESTs 8.9 105627 AA281245 Hs.23317 ESTs 8.8 101461 M22430 Hs.76422 phospholipase A2; group IIA (platelets; 8.7 124526 N62096 Hs-293185 yz61c5.s1 Soares multiple sclerosis_2NbH 8.5 133845 T68510 Hs.76704 ESTs 8.2 133354 AA055552 Hs.334762 ESTs; Weakly similar to KIAA0319 [H.sapi 8.1 119018 N95796 Hs.278695 ESTs 8 100394 D84276 Hs.66052 CD38 antigen (p45) 8 106579 AA456135 Hs.23023 ESTs 7.6 114965 AA250737 Hs.72472 ESTs 7.4 112033 R43162 Hs-22627 ESTs 7.1 102398 U42359 Human N33 protein form 1 (N33) gene, exo 7 101201 L22524 Hs-2256 matrix metalloproteinase 7 (matrilysin; 6.9 101803 M86546 Hs.155691 pre-B-cβll leukemia transcription factor 6.8 120562 AA280036 Hs.302267 ESTs; Weakly similar to W01A6.C [Celega 6.8 109112 AA169379 Hs.257924 ESTs 6.8 109795 F10707 Hs.326416 ESTs 6.7 130336 X07730 Hs.171995 kallikrein 3; (prostate specific antigen 6.6 131425 AA219134 Hs.26691 ESTs 6.6 132902 AA490969 Hs.59838 ESTs 6.6 133724 U07919 Hs.75746 aldehyde dehydrogenase 6 6.5 120215 Z41050 Hs.108787 Homo sapiens Mcd4p homolog mRNA; compiet 6.5 131881 AA010163 Hs.3383 upstream regulatory element binding prot 6.5 100727 X07290 Hs.334786 Human HF.12 gene mRNA 6.3 121770 AA421714 Hs.278428 Homo sapiens mRNA for KIAA0896 protein; 6.3 123475 AA599267 Hs.250528 ESTs; Weakly similar to ANKYRIN; BRAIN V 6.3 133061 AB000584 Hs.296638 prostate differentiation fador 6.3 116429 AA609710 Hs.279923 ESTs; Weakly similar to similar to GTP-b 6.2 101233 L29008 Hs.878 sorbitol dehydrogenase 6.2 104691 AA011176 Hs.37744 ESTs 6.2 127248 AA325029 EST27953 Cerebellum II Homo sapiens CDNA6.2 105500 AA256485 Hs.222399 ESTs 6.1 130828 AA053400 Hs.203213 ESTs 5.9 115357 AA281793 Hs.72988 ESTs 5.8 116334 AA491457 Hs.48948 ESTs 5.7 120132 Z38839 Hs.125019 ESTs; Weakly similarto III! ALU SUBFAMI 5.6 106375 AA443993 Hs.289072 ESTs 5.6 124777 R41933 Hs.140237 ESTs; Weakly similar to neuronal thread 5.6 101791 M83822 Hs.62354 Human beige-like protein (BGL) mRNA; par 5.5 117698 N41002 Hs.45107 ESTs 5.5 122041 AA431407 Hs.98732 Homo sapiens Chromosome 16 BAC done CIT 5.5 133723 AA088851 Hs.262476 S-adenosylmethionine decarboxylase 1 5.5 113938 W81598 ESTs 5.4 133015 AA047036 Hs.246315 ESTs 5.4 108186 AA056482 Hs.7780 ESTs 5.3 104466 N25110 Hs.326392 Human guanine nudeotide exchange fador 5.3 104033 AA365031 Hs.98944 ESTs 5.3 110844 N31952 Hs.167531 ESTs; Weakly similar to (defline not ava 5.3 129056 H70627 Hs.108336 ESTs; Weakly similar to III! ALU SUBFAMI 5.3 133493 AA284143 Hs.194369 Homo sapiens chromosome 1 atrophin-1 rel 5.3 129184 W26769 Hs.109201 ESTs; Highly similar to (defline not ava 5.2 101448 M21389 Hs.195850 keratin 5 (epider olysis bullosa simplex 5.1 116188 AA464728 Hs.184598 ESTs; Weakly similar to !!!! ALU SUBFAMI 5.1 105921 AA402613 Hs.169119 ESTs 5.1 103375 X91868 Hs.54416 sine oculis homeobox (Drosophila) homolo 5.1 128871 AA400271 Hs.106778 ESTs; Highly similar to (defline not ava 5.1 116238 AA479362 Hs.47144 ESTs 5 102913 X07696 Hs.80342 keratin 15 5 103011 X52541 Hs.326035 early growth response 1 5 118981 N93839 Hs.39288 ESTs; Weakly similarto !!!! ALU SUBFAMI 5 TABLE 2 A shows the accession numbers for those primekeys lacking unigenelD's for Table 2. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column. Pkey: Unique Eos probeset identifier number CAT number: Gene duster number Accession: Genbank accession numbers Pkey CAT number Accession 118417 37186J AF080229 AF080231 AF080230 AF080232 AF080233 AF080234 BE550633 AI636743 AW614951 BE467547 AI680833 AI633818 N29986 U87592 U87593 U87590 U87591 S46404 U87587 AA463992 AW206802 AI970376 AI583718 AI672574 N25695 AW665466 AI818326 AA126128 AI480345 AW013827 AA248638 AI214968 AA204735 AA207155 AA206262 AA204833 AW003247 AW496808 AI080480 A1631703 AI651023 AI867418 AW818140 AA502500 AI206199 AI671282 AI352545 BE501030 AI652535 BE465762 AA206331 AW451866 AA471088 AA206342 AA204834 AA206100 AW021661 AA332922 N66048 AA703396 H92278 AW139734 H92683 U87589 U87595 H69001 U87594 BE466420 AI624817 BE466611 AI206344 AA574397 AA348354 AI493192 127248 227560J AA364195 AA325029 AW962050 107033 235652 AI141999 AA730176 R44544 R41778 AW300793 AW966157 AA918501 AA599629 AI082195 AI198537 AW006520 AW236663 AW151420 A1826987 AI810832 AI669102 AI201981 N27331 AA335566 T84622 BE085347 BE085269 102398 entrez_U42359 U42359 113938 genbank_W81598W81598 TABLE 3: shows genes, including expression sequence tags, differentially expressed in prostate tumor tissue compared to normal tissue as analyzed using the Affymetrix/Eos Hu02 GeneChip array. Shown are the relative amounts of each gene expressed in prostate tumor samples and various normal tissue samples showing the highest expression of the gene. Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD: Unigene number Unigene Title: Unigene gene title R1: Ratio of tumor to normal body tissue Pkey ExAccn UnigenelD Unigene Title R1 100131 D12485 Hs.11951 phosphodiesterase l nucleotide pyrophosp 6.3 100235 D29954 Hs.13421 KIAA0056 protein 5.1 100570 HG2261-HT2352 Hs.171995 Antigen, Prostate Specific, Alt Splice 100819 HG4020-HT4290 Hs.2387 Transglutaminase 10.5 101063 L00354 Hs.80247 cholecystokinin 8.5 101247 L33801 Hs.78802 glycogen synthase kinase 3 beta 4.7 101416 M17254 Hs.279477 v-ets avian erythroblastosis virus E26 o 4.7 101447 M21305 Human alpha satellite and satellite 3 ju 11 101485 M24736 Hs.89546 seledin E (endothelial adhesion molecul 9.8 101514 M28214 Hs.123072 RAB3B; member RAS oncogene family 6.2 101626 M57399 Hs.44 pleiotrophin (heparin binding growth fac 8.4 101663 M60750 Hs.2178 H2B histone family; member A 4.9 101758 M77836 Hs.79217 pyrroline-5-caιboxylate reductase 1 5.4 101768 M81118 Hs.78989 7.5 101817 M88163 Hs.152292 SWI/SNF related; matrix assodated; acti 5.5 101888 M99701 Hs.95243 transcription elongation fador A (Sll)- 5.7 102031 U04898 Hs.2156 RAR-related orphan receptor A 132 102052 U07559 Hs.505 ISL1 transcription factor; LIM homeodoma 8.9 102221 U24576 Hs.3844 LIM domain only 4 5.6 102233 U26173 Hs.79334 nudear fador; interieukin 3 regulated 7.4 102302 U33052 Hs.69171 protein kinase C-like 2 8.2 102348 U37519 Hs.87539 aldehyde dehydrogenase 8 5.9 102457 U48807 Hs.2359 dual specificity phosphatase 4 5.1 102473 U49957 Hs.180398 LIM domain-containing preferred transloc 5.7 102669 U71207 Hs.29279 eyes absent (Drosophila) homolog 2 9 102698 U75272 Hs.1867 progastricsin (pepsinogen C) 10.6 102751 U80034 Hs.68583 mitochondrial intermediate peptidase 15.6 102823 U90914 Hs.5057 carboxypeptidase D 4.9 102869 X02544 Hs.572 orosomucoid 1 22.6 103031 X54667 Hs.123114 cystatin S 4.7 103043 X55733 Hs.93379 eukaryotic translation initiation fador 4.9 103093 X60708 Hs.44926 dipeptidylpeptidase IV (CD26; adenosine 5.8 - 103376 X92098 Hs.323378 coated vesicle membrane protein 5.2 103401 X95240 Hs.54431 specific granule protein (28 kDa); cyste 7.4 103613 Z46629 Hs.2316 SRY (sex-determining region Y)-box 9 (ca 5.2 103677 Z83806 H.sapiens mRNA for axonemal dynein heavy 4.9 103962 AA298180 Hs.83243 ESTs 6 104084 AA410529 Hs.30732 ESTs 6.4 104257 AF006265 Hs.9222 estrogen receptor-binding fragment-assoc 6.8 104301 D45332 Hs.6783 ESTs 10.5 104769 AA025887 Hs.293943 ESTs; Weakly similar to !!!! ALU SUBFAMI 6.3 104851 AA040882 Hs.10290 U5 snRNP-spedfic 40 kDa protein (hPrpβ- 4.9 104896 AA054228 Hs.23165 ESTs 5.8 104956 AA074880 Hs20509 ESTs; Weakly similar to hypothetical pro 6.4 104957 AA074919 Hs.10026 ESTs; Weakly similar to ORF YJL063C [S.c 4.8 104967 AA084506 Hs291000 ESTs 6.5 105099 AA150776 Hs.23729 Homo sapiens done 24405 mRNA sequence 7 105298 AA233459 Hs.26369 ESTs 5.1 105304 AA233553 Hs.190325 ESTs 4.7 105370 AA236476 Hs.22791 ESTs; Weakly similar to transmembrane pr 10.3 105427 AA251330 Hs.28248 ESTs 5 105542 AA261858 Hs.266957 ESTs; Weakly similar to heat shock prate 8.8 105628 AA281251 Hs.79828 ESTs; Weakly similar to putative zinc fi 5.5 105640 AA281623 Hs.6685 ESTs; Weakly similar to KIAA0742 protein 8 105645 AA282138 Hs.11325 ESTs 14 105691 AA287097 Hs.289068 transcription fador 4 6.3 105730 AA292701 Hs.5364 DKFZP564I052 protein 4.9 105808 AA393808 Hs.286131 KIAA0438 gene produd 7 105826 AA398243 Hs.194477 ESTs; Moderately similar to similar to N 5 105903 AA401433 Hs.200016 ESTs; Weakly similar to diphosphoinosito 9.9 105906 AA401633 Hs.22380 ESTs 11.5 106065 AA417558 Hs.25206 ESTs 5.1 106094 AA419461 Hs.23317 ESTs 10.9 106157 AA425367 Hs.34892 ESTs 6.6 106184 AA426643 Hs.10762 ESTs 8.5 106211 AA428240 Hs.126083 ESTs 8.4 106213 AA428258 Hs.8769 Homo sapiens mRNA; cDNA DKFZp564E153 (fr 5.7 106272 AA432074 Hs.323099 ESTs 5.8 106369 AA443828 Hs.288856 ESTs 6.3 106400 AA447621 Hs.94109 ESTs 5.4 106474 AA450212 Hs.42484 Homo sapiens mRNA; cDNA DKFZp564C053 (fr 9.2 106507 AA452584 Hs.267819 protein phosphatase 1; regulatory (inhib 5.6 106523 AA453441 Hs.31511 ESTs 4.7 106532 AA453628 Hs.37443 ESTs 4.7 106557 AA455087 Hs.22247 ESTs 5.7 106575 AA456039 Hs. 05421 ESTs 7.2 106618 AA459249 Hs.8715 ESTs; Weakly similar to Similarity with 5.6 106820 AA481037 Hs.12592 ESTs 5.4 106846 AA485223 Hs.34892 ESTs 5.3 106973 AA505141 Hs.11923 Human DNA sequence from done 167A19 on 7.5 107110 AA609952 Hs.12784 KIAA0293 protein 6.1 107127 AA620504 Hs.179898 ESTs 7.1 107159 AA621340 Hs.10600 ESTs; Weakly similar to ORF YKR081C [S.c 5.2 107217 D51095 Hs.35861 DKFZP586E1621 protein 15.1 107365 U78294 Hs.111256 arachidonate 15-lipoxygenase; second typ 4.7 107630 AA007218 Hs.60178 ESTs 5.3 107734 AA016225 Hs.7517 ESTs 4.8 107760 AA018042 Hs.252085 EST 7.6 107997 AA037388 Hs.82223 Human DNA sequence from clone 141H5 on c 10.5 108012 AA039616 Hs.173334 ESTs 6.5 108520 AA084138 Hs.46786 ESTs 7.9 108583 AA088276 Hs.68826 ESTs 5.6 108613 AA100967 Hs.69165 ESTs 6 108664 AA113349 Hs.69588 EST 6.3 108677 AA115629 Hs.118531 ESTs 5.9 108807 AA129968 Hs.49376 ESTs; Weakly similar to PROTEIN PHOSPHAT 5.8 108910 AA136590 ESTs 5 108933 AA147224 Hs.337232 ESTs 12.7 108948 AA149579 Hs.118258 ESTs 6.8 109014 AA156790 Hs.262036 ESTs 15.3 109124 AA171529 Hs.183887 ESTs 6.1 109142 AA176438 Hs.41295 ESTs 5.1 109277 AA196332 Hs.86043 ESTs 5.5 109342 AA213620 Homo sapiens mRNA; cDNA DKFZp586M1418 (f6 109562 F01811 Hs.187931 ESTs; Moderately similar to voltage-gate 10.8 109565 F01930 Hs-23648 ESTs 7 109648 F04600 Hs.7154 ESTs 9.9 109799 F10770 Hs.180378 Homo sapiens done 669 unknown mRNA; com 6.4 109859 H02308 Hs.20792 ESTs 5.3 110181 H20276 Hs.31742 ESTs 16.8 110854 N32919 Hs.27931 ESTs 10 110924 N47938 Hs.12940 yy84a09.s1 Soares_multiple_sderosis_2Nb 5.6 111046 N55514 Hs.318584 ESTs 6.9 111091 N59858 Hs.33032 Homo sapiens mRNA; cDNA DKFZp434N185 (fr 5.2 111157 N66613 Hs.99364 ESTs 5 111164 N66857 Hs.122489 ESTs; Weakly similar to !!!! ALU CLASS C 5.6 111221 N68869 Hs.15119 ESTs 6.2 111348 N90041 Hs.9585 ESTs 5.4 111353 N90430 Hs.6616 ESTs 5.3 111495 R07210 Hs.9683 ESTs 5.8 111540 R08850 Hs.9786 ESTs 6 111579 R10657 Hs.167115 KIAA0830 protein 12.6 111581 R10684 Hs.5794 ESTs 7.1 111734 R25375 Hs.128749 ESTs 6.2 111861 R37460 Hs.25231 ESTs 9.4 111870 R37778 Hs.18685 ESTs; Weakly similar to hypothetical pro 6.5 111937 R40431 Hs.14846 Homo sapiens mRNA; cDNA DKFZp564D016 (fr 4.8 111987 R42036 Hs.6763 KIAA0942 protein 6.4 112184 R49173 Hs.330242 ESTs 5.6 112286 R53765 Hs.158135 KIAA0981 protein 9.3 112380 R59740 Hs.5740 ESTs 4.7 112452 R63841 Hs.157461 ESTs 6 112601 R79111 Hs.78225 annexinAI 5.4 112753 R93696 Hs.169882 ESTs 5.8 112902 T09262 Hs.129190 ESTs 5.1 112984 T23457 Hs.289014 ESTs 4.9 113021 T23855 Hs.129836 KIAA1028 protein 10.8 113083 T40530 Hs.266957 ESTs; Weakly similar to heat shock prate 5.7 113200 T57773 Hs.10263 ESTs 7.3 113494 T88878 Hs.86538 ESTs 8.7 113849 W60439 Hs.8858 ESTs; Moderately similar to cbp146 [M.mu 4.9 113883 W72382 Hs.11958 oxidative 3 alpha hydroxysteroid dehydro 4.7 113950 W85765 Hs.30504 Homo sapiens mRNA; cDNA DKFZp434E082 (fr 6.7 113986 W87462 Hs.21894 ESTs 5.9 113989 W87544 Hs.268828 ESTs 4.7 114124 Z38595 Hs.125019 ESTs; Highly similar to KIAA0886 protein 21.3 114340 Z41395 Hs.143611 ESTs 9.6 114346 Z41450 Hs.130489 ESTs 5.2 114435 AA018216 Hs.164975 Bicaudal D (Drosophila) homolog 1 7.4 114463 AA025370 Hs.40109 KIAA0872 protein 8.2 114652 AA101416 Hs.107149 ESTs; Weakly similar to PTB-ASSOCIATED S 5.4 114721 AA131450 Hs.103822 ESTs 4.8 114730 AA133527 Hs.331328 ESTs; Weakly similar to The KIAA0138 gen 5.1 114833 AA234362 Hs.87159 ESTs; Moderately similar to CGI-66 prate 5.5 114860 AA235112 Hs.42179 ESTs; Moderately similar to similar to m 6.3 114884 AA235811 Hs.293672 ESTs 5.2 114895 AA236177 Hs.76591 KIAA0887 protein 4.7 114908 AA236545 Hs.54973 ESTs 5.2 114932 AA242751 Hs.16218 KIAA0903 protein 5.7 115084 AA255566 Hs.42484 Homo sapiens mRNA; cDNA DKFZp564C053 (fr 5.2 115140 AA258030 Hs.279938 ESTs; Weakly similar to supported by GEN 5.9 115468 AA287061 Hs.48499 ESTs; Highly similar to Bdeight protein 4.7 115583 AA398913 Hs.45231 LDOC1 protein 7.6 115709 AA412519 Hs-58279 ESTs 4.8 115772 AA423972 Hs.131740 ESTs 5 115774 AA424029 Hs.288390 ESTs; Moderately similar to dynamin; int 5.4 115776 AA424038 Hs.81897 ESTs 5 115821 AA427528 Hs.130965 ESTs; Weakly similarto ZINC FINGER PROT 13.7 115955 AA446121 Hs.44198 Homo sapiens BAC done RG054D04 from 7q3 10.6 116024 AA451748 Hs.83883 Human DNA sequence from done 718J7 on c 6.8 116108 AA457566 Hs.28777 ESTs 6 116117 AA459117 Hs.31575 SEC63; endoplasmic reticulum translocon 7.3 116146 AA460701 Hs.15423 ESTs 5.5 116296 AA489033 Hs.62601 Homo sapiens mRNA; cDNADKFZp586K1318 (f 5.7 116379 AA521472 Hs.71252 ESTs 5.9 116393 AA599463 Hs.306051 protein phosphatase 2 (formerly 2A); reg 5.9 116401 AA599963 Hs.59698 ESTs 7.9 116416 AA609219 Hs.39982 ESTs 9.2 116587 D59325 Hs.121429 ESTs 5.2 116601 D80055 Hs.45140 ESTs 4.9 116684 F09156 Hs.66095 ESTs 7.2 116722 F13654 HSFIH32 Stratagene caH-937212 (1992) Horn 5.5 116766 H13260 Hs.95097 ESTs 5.9 117453 N29568 Hs.108319 thyroid hormone receptor-assodated prot 6.9 117557 N33920 Hs.44532 diubiquitin 4.8 117708 N45114 Hs.126280 ESTs 6.3 118001 N52151 Hs.47447 ESTs 11.4 118229 N62339 Hs.166254 heat shock 90kD protein 1 ; alpha 6.2 118599 N69207 Hs.203697 ESTs 5.8 118645 N70358 Hs.125180 growth hormone receptor 7.1 118873 N89881 Hs.44577 ESTs 6 118985 N94303 Hs.55028 ESTs 9.3 119107 R42424 Hs.63841 ESTs 6 119126 R45175 Hs.117183 ESTs 17.9 119271 T16387 Hs.65328 ESTs 6 119367 T78324 Hs.250895 ESTs 5 119721 W69440 Hs.48376 ESTs 15.4 119741 W70205 Hs.43670 kinesin family member 3A 10.1 119780 W72967 Hs.191381 ESTs; Weakly similarto hypothetical pro 5.3 120217 Z41078 Hs.66035 ESTs 4.8 120266 AA173939 Hs.205442 ESTs; Weakly similar to inner centromere 8.8 120294 AA190888 Hs.153881 ESTs; Highly similar to NY-REN-62 antige 4.9 120418 AA236010 Hs.26613 Homo sapiens mRNA; cDNA DKFZp586F1323 (f 4.7 120486 AA253400 Hs.137569 tumor protein 63 kDa with strong homolog 5.6 120524 AA261852 Hs.192905 ESTs 4.9 120571 AA280738 Hs.34892 ESTs 8.8 120596 AA282074 Hs237323 ESTs 6.2 120713 AA292655 Hs.96557 ESTs 9.9 120992 AA398246 Hs.97594 ESTs 16.4 121429 AA406293 Hs.41167 ESTs 6.9 121503 AA412049 HS290347 ESTs 7.6 121512 AA412105 Hs.193736 ESTs 5.8 121816 AA424814 Hs.48827 ESTs 4.6 122027 AA431302 Hs.98721 EST; Weakly similar to N-copine [ sapie 5.6 122294 AA437311 Hs.98927 ESTs 5.7 122411 AA446859 Hs.99083 ESTs 6.5 122791 AA460158 Hs.129836 KIAA1028 protein 12.4 122792 AA460225 Hs.99519 ESTs 5.1 122969 AA478539 Hs.104336 ESTs 4.9 123095 AA485724 Hs.27413 ESTs 5.4 123100 AA485957 Hs.306219 Homo sapiens done 25032 mRNA sequence 5 123295 AA495981 Hs.250830 ESTs 4.7 123311 AA496252 Hs.105069 ESTs 7.4 123583 AA609006 Hs.111240 ESTs 9.1 123619 AA609200 ESTs 4.7 123645 AA609310 Hs.188691 ESTs 4.8 123709 AA609651 Hs.112742 ESTs 7 123968 C14333 Hs.108327 damage-spedfic DNA binding protein 1 (1 5 124178 H45996 Hs.97101 putative G protein-coupled receptor 6.8 124352 N21626 Hs.102406 ESTs 102 124357 N22401 yw37g07.s1 Morton Fetal Cochlea Homo sap 10.6 124515 N58172 Hs.109370 ESTs 142 124911 R88992 Hs.174195 ESTs 4.8 125154 W38419 ESTs 4.7 125992 W01626 za36e07.r1 Soares fetal liver spleen 1NF 5.1 126802 AA947601 Hs.97056 ESTs 5.1 126812 Z36290 Hs.173933 ESTs; Weakly similarto NUCLEAR FACTOR 1 4.6 127080 AA662913 Hs.190173 ESTs 5 127308 AA507628 Hs.334390 ESTs 4.8 - 127370 AI024352 Hs.70337 immunoglobulin superfamily; member 4 4.7 127386 AI457411 Hs.106728 ESTs 4.8 127965 AA828760 Hs-292059 ESTs 4.8 128172 AI400862 Hs265130 ESTs 5 128305 AI039722 Hs279009 ESTs 5.8 128420 A1088155 Hs.41296 ESTs; Weakly similar to unknown [H.sapie 17 128467 AA176446 Hs.180428 ESTs; Weakly similar to hypothetical 43. 4.8 128610 L38608 Hs.10247 activated leucocyte cell adhesion molecu 7.9 128625 AA242816 Hs.102652 ESTs; Weakly similar to Kl AA0437 [H.sapi 8.1 128651 AA446990 Hs.103135 ESTs 6.5 129088 AA215971 Hs.194431 KIAA0992 protein 5.2 129136 N26391 Hs.250723 ESTs 5.1 129171 AA234048 Hs.7753 calumenin 5.8 129229 AA211941 Hs.109643 polyadenylate binding protein-interactin 5.8 129386 N27524 Hs260024 Cdc42 effedor protein 3 52 129467 AA410311 Hs.44208 ESTs 5.1 129564 H22136 Hs.75295 guanylate cydase 1 ; soluble; alpha 3 16.3 129699 AA458578 Hs.12017 KIAA0439 protein; homolog of yeast ubiqu 9.2 129821 F11019 Hs.12696 cortadin SH3 domain-binding protein 8.6 129823 X00948 Hs.105314 relaxiπ 2 (H2) 9.1 129847 W46767 Hs.296178 ESTs; Weakly similar to RNA POLYMERASE I 5.4 129912 AA047344 Hs.107213 ESTs; Highly similar to NY-REN-6 antigen 6.5 129958 1-20591 Hs.1378 annexin A3 5.1 129977 J04076 Hs.1395 early growth response 2 (Krox-20 (Drosop 8.6 130061 U82256 Hs.172851 arginase; type II 7.4 130241 U78313 Hs.153203 MyoD family inhibitor 4.9 130466 N21679 Hs.180059 ESTs 5.8 130541 X05608 Hs.211584 neurofilament; light polypeptide (68kD) 6.7 130619 AA477739 Hs.12532 ESTs 6.4 130925 N71935 Hs.169378 multiple PDZ domain protein 7.9 130938 AA013250 Hs.21398 ESTs; Moderately similar to PUTATIVE GLU 6.2 130971 H20332 Hs.301444 signal sequence receptor; gamma (translo 6.4 131066 F09006 Hs.22588 ESTs 5 131126 F09012 Hs.181326 myotubularin related protein 2 6.4 131310 J02960 Hs.2551 adrenergic; beta-2-; receptor; surface 7.9 131487 AA253220 HS27373 Homo sapiens mRNA; cDNA DKFZp56401763 (f 5.9 131561 X59841 HS294101 pre-B-cell leukemia transcription fador 7.6 131562 U90551 HS28777 H2A histone family; member L 5.1 131579 N62922 Hs.29088 ESTs 11 131629 AA442119 HS238809 ESTs 4.9 131682 AA428368 Hs.30654 ESTs 4.8 131699 R68657 Hs.90421 ESTs; Moderately similar to !!!! ALU SUB 6.5 131795 N32724 Hs.32317 Sox-like transcriptional fador 5.6 132053 H93381 Hs.38085 ESTs; Weakly similar to putative glycine 72 132122 U65092 Hs.40403 Cbp/p300-interading transacfivator; wit 5.6 132191 AA449431 Hs.288361 KIAA0741 gene produd 8 132256 AA608856 Hs.431 murine leukemia viral (bmi-1 ) oncogene h 5.5 132482 AA429478 Hs238126 ESTs; Highly similar to CGI-49 protein [ 6.6 132533 AA021608 Hs.172510 ESTs 5.8 132572 AA448297 Hs237825 signal recognition particle 72kD 6.2 132581 R42266 Hs.52256 ESTs; Weakly similar to beta-TrCP protei 16 132700 N47109 Hs.5521 ESTs 6.8 132701 AA279359 Hs.55220 BCL2-assodated athanogene 2 5.3 132725 L41887 Hs.184167 splidng fador; arginine/serine-rich 7 7.8 132783 N74897 HS278894 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep 5.9 132790 X75535 Hs.168670 peroxisomal famesylated protein 8 132939 U76189 Hs.61152 exostoses (multiple)-like 2 52 133142 F03321 Hs.65874 ESTs 5.2 133342 U29589 Hs.7138 cholinergic receptor; muscarinic 3 10.3 133434 AA278852 Hs.30212 ESTs 5.8 133453 M68941 Hs.73826 protein tyrosine phosphatase; non-recept 4.9 133520 X74331 Hs.74519 primase; polypeptide 2A (58kD) 13.1 133544 T33873 Hs.74624 protein tyrosine phosphatase; receptor t 4.6 133608 D13315 Hs.75207 glyoxalase I 4.8 133626 H75939 Hs.75277 Homo sapiens mRNA; cDNA DKFZp586M141 (fr 5 133633 D21262 Hs.75337 nudeolar phosphoprotein p130 6.3 133797 S66431 Hs.76272 retinoblastoma-binding protein 2 6 133928 N34096 Hs.7766 ubiquitin-conjugating enzyme E2E 1 (homo 5.4 134095 U47414 Hs.79069 cydin G2 5.2 - 134249 N89827 Hs.80667 FIALBP1 associated Eps domain containing 6.5 134321 AA418230 Hs.8172 ESTs 7 134453 X70683 Hs.83484 SRY (sex determining region Y)-box 4 4.7 134542 X57025 Hs.85112 insulin-like growth fador 1 (somatomedi 7.7 134570 U66615 Hs.172280 SWI SNF related; matrix assoα ' ated; adi 6.4 134592 U82613 Hs.289104 Alu-binding protein with zinc finger dom 5.4 134654 W23625 Hs.8739 ESTs; Weakly similar to ORF YGR200C [S.c 5 134666 AA482319 Hs.8752 putative type II membrane protein 5.4 134806 Z49099 Hs.89718 spermine synthase 6.7 134951 AA431480 Hs.169358 ESTs 9.8 135066 X04602 Hs.93913 interieukin 6 (interferon; beta 2) 5.7 135155 AA358268 Hs.166556 ESTs; Moderately similar to transcriptio 4.9 135411 L10333 Hs.99947 reticulon 1 5.3 300023 M10098 AFFX control: 18S ribosomal RNA 4.6 300254 AW079607 Hs.55610 ESTs; Weakly similar to ZnT-3 [ksapiens 7.8 300273 AW013907 Hs.167531 ESTs; Moderately similar to predided us 115 300319 AW157646 Hs.153506 ESTs; Weakly similar to microtubule-adi 8.5 300566 H86709 Hs.326392 son of sevenless (Drosophila) homolog 1 5.8 300578 AI989417 Hs.134289 ESTs 4.4 300671 AI239706 Hs.93810 ESTs 7.9 300675 AA039352 Hs.125034 ESTs; Weakly similar to ORF YDL040C [S.c 4.5 300680 AW468066 Hs.24817 ESTs; Weakly similar to KIAA0986 protein 5.2 300762 AI497778 Hs.20509 ESTs 6.4 300810 AI076890 Hs.146847 ESTs 5.8 300813 AA406411 Hs208341 ESTs; Weakly similar to KIAA0989 protein 10.6 300823 AI863068 Hs.106823 ESTs; Weakly similar to putative zinc fi 5.6 300834 AF109300 Hs.147924 ESTs 6.7 300923 AW136372 Hs.1852 ESTs 7.6 300962 AA593373 HS293744 ESTs 5.5 301015 AA947682 Hs.20252 ESTs; Weakly similar to Chain A; Cdc42hs 7 301042 AI659131 Hs.197733 ESTs 24.9 301242 AW161535 Hs23782 ESTs 11.8 301254 AI049624 Hs.283390 EST duster (not in UniGene) with exon h 4.3 301262 H29500 Hs.7130 ESTs; Moderately similar to N-copine [H. 4.3 301388 AA156879 Hs.262036 ESTs; Weakly similar to ZINC FINGER PROT 6.6 301563 AI802946 Hs.44208 ESTs; Weakly similar to match to ESTs AA 5.7 301656 AW008475 Hs.151258 EST duster (not in UniGene) with exon h 6.8 301689 Z44810 Hs.301789 ESTs; Weakly similar to similar to C.ele 6.3 301783 AL046347 Hs.83937 Homo sapiens PAC done DJ1159004 from 7p 6.2 301805 AI800004 Hs.142846 ESTs; Weakly similar to MesP1 [M.musculu 8.5 301846 R20002 Hs.6823 ESTs; Weakly similar to intrinsic fador 4.6 301891 AF131855 Hs.279591 Homo sapiens done 25056 mRNA sequence 6.3 302005 AI869666 Hs.123119 ESTs 36.8 302056 AI457532 Hs.30488 ESTs; Moderately similar to ROSA26AS [M. 9.5 302067 H05698 Hs222399 ESTs; Weakly similar to protein-tyrosine 5.8 302099 AL021397 Hs.137576 ribosomal protein L34 pseudogene 1 8.8 302147 AB022660 Hs.151717 KIAA0437 protein 5.9 302214 AJ001454 Hs.159425 Homo sapiens mRNA for testican-3 4.3 302236 AI128606 Hs.6557 zinc finger protein 161 4.3 302358 D81150 Hs.322848 EST duster (not in UniGene) with exon h 5.5 302410 NM 004917 Hs.218366 EST duster (not in UniGene) with exon h 26.8 302486 AC003682 Hs.183512 multiple UniGene matches 8.2 302582 NM 000522 Hs.249195 EST duster (not in UniGene) with exon h 6.4 302785 AA425562 Hs.11065 EST duster (not in UniGene) with exon h 5 302792 AA343696 Hs.46821 ESTs; Weakly similar to putative [H.sapi 4.8 302881 AA508353 Hs.105314 relaxin 1 (H1) 78.8 302892 N58545 Hs.42346 histone deacetylase 3 8.5 302970 AW118352 Hs.312679 EST duster (not in UniGene) with exon h 7.4 302977 AW263124 Hs.315111 EST duster (not in UniGene) with exon h 5.5 303029 AF199613 EST duster (not in UniGene) with exon h 4.6 303125 AF161352 Hs.111782 EST duster (not in UniGene) with exon h 5.8 303280 AI571580 Hs.170307 ESTs 4.3 303306 AA215297 Hs.61441 EST duster (not in UniGene) with exon h 6.4 303309 AL134164 Hs.145416 ESTs 6.6 303344 AA255977 Hs250646 ESTs; Highly similar to ubiquitin-conjug 19.5 303380 AA298471 Hs.326567 EST duster (not in UniGene) with exon h 6.6 303401 AA758552 Hs.309497 ESTs 6.8 303525 AW516519 Hs.273294 ESTs 4.8 303526 AA348111 Hs.96900 ESTs 12.1 303540 AA355607 Hs.309490 ESTs; Weakly similar to MMSET type I [H. 8.2 303572 AW338520 Hs.242540 ESTs 8.4 303685 AW500106 Hs.23643 EST duster (not in UniGene) with exon h 4.9 303699 D30891 Hs.19525 EST duster (not in UniGene) with exon h 15.7 303702 AW500748 Hs.224961 ESTs; Weakly similar to 73 kDA subunit o 6.3 303718 AI741397 Hs.114658 ESTs 4.6 303722 AA521510 Hs.145010 ESTs 12.5 303732 AW502405 Hs.125759 ESTs; Weakly similar to tumor suppressor 4.3 303735 AA707750 Hs.169055 ESTs; Weakly similar to ds-Golgi matrix 5.4 303752 AI017286 Hs.5957 EST duster (not in UniGene) with exon h 5.3 303753 AW503733 Hs.9414 ESTs 13 303813 AI275850 Hs.114658 EST duster (not in UniGene) with exon h 7.8 304053 R00493 Hs.125565 translocase of inner mitochondrial membr 4.8 304218 N66373 Hs27973 ESTs; Weakly similar to ZK354.7 [C.elega 6 305200 AA668128 Hs.45207 EST singleton (not in UniGene) with exon 5.7 306716 AI024916 Hs251354 ESTs 5.7 307848 AI364186 EST singleton (not in UniGene) with exon 7.3 307871 AI368665 Hs.31476 EST singleton (not in UniGene) with exon 5.4 308050 AI460O04 Hs.31608 EST singleton (not in UniGene) with exon 8.1 308362 AI613519 Hs.105749 EST singleton (not in UniGene) with exon 5.5 308923 AI863051 Hs.279815 ESTs 4.4 309116 AI927149 Hs29797 ribosomal protein L10 4.5 309375 AW075342 Hs.9271 EST singleton (not in UniGene) with exon 7.4 309674 AW205604 Hs.266009 ESTs; Weakly similar to !!!! ALU SUBFAMI 5 310095 AI921750 Hs.144871 ESTs 5 310098 AI685841 Hs.161354 ESTs 11.6 310250 AI478629 Hs.158465 ESTs 5.8 310365 AI262148 Hs.145569 ESTs 9.7 310382 AI734009 Hs.127699 EST duster (not in UniGene) 10.4 310409 AI612775 Hs.145710 ESTs 4.6 310431 AI420227 Hs.149358 ESTs 72.9 310573 AW292180 Hs.156142 ESTs 7.6 310598 AI338013 Hs.140546 ESTs 9.2 310639 AW269082 Hs.175162 ESTs 4.5 310787 AW262580 Hs.147674 ESTs 4.9 310816 AI973051 Hs.224965 ESTs 7.6 311251 AI655662 Hs.197698 ESTs 41.3 311280 AI767957 Hs.198248 ESTs; Weakly similar to Y38A8.1 gene pro 4.5 311330 AI679524 Hs.201629 ESTs; Moderately similar to !!!! ALU SUB 4.6 311515 AW136713 HS23862 ESTs 5.9 311574 AI824863 HS211420 ESTs 4.8 311587 AI828254 Hs.271019 ESTs 5.8 311596 AI682088 Hs.79375 ESTs 26.4 311631 AI809519 Hs.27133 ESTs 6.4 311688 AW025661 Hs.240090 ESTs 7.4 311783 AI682478 Hs.13528 EST 4.6 311826 AA765470 Hs.85092 ESTs 6.7 311853 AW014013 Hs.107056 ESTs 5.3 311901 R16890 Hs.137135 ESTs 5.6 311932 AW451654 HS257482 ESTs 4.3 312153 AA759250 Hs.118625 cytochrame b-561 11 312182 AA834800 Hs.326263 EST duster (not in UniGene) 16.9 312242 AI380207 Hs.125276 ESTs 4.7 312296 C01367 Hs.127128 ESTs 5.3 312407 R46180 Hs.153485 ESTs 6.2 312424 AA847398 Hs291997 ESTs 4.8 312425 R49353 HS293892 ESTs 52 312480 R68651 Hs.144997 ESTs 9.5 312518 C17785 Hs.182738 ESTs 6.3 312521 AA033609 Hs.239884 ESTs 112 312527 AI695522 Hs.191271 ESTs 4.7 312539 AI004377 HS200360 ESTs 7 312546 AI623511 Hs.118567 ESTs 5.1 312563 AA976064 Hs.180842 ESTs 6.5 312623 AA694607 Hs.176956 EST cluster (not in UniGene) 10.8 312857 AA772279 Hs.126914 ESTs 5 312890 AI813654 Hs.5957 ESTs 5.8 312903 AA939266 Hs.278626 ESTs 7.7 312905 H92571 Hs.234478 ESTs 6.5 312976 AA836271 Hs.125830 ESTs 4.6 312983 AI079278 HS269899 ESTs 5.1 312996 AA249018 Hs.154331 EST duster (not in UniGene) 7 313035 N36417 Hs.144928 ESTs 6.3 313166 AI801098 Hs.151500 ESTs 4.3 313188 AI039702 Hs.179573 collagen; type I; alpha 2 4.8 313218 AA827805 Hs.124296 ESTs 5 313226 AI200281 Hs.123910 ESTs 5.9 313325 AI420611 Hs.127832 ESTs 4.6 313326 AI088120 Hs.122329 ESTs 7.4 313425 AA745689 Hs.186838 ESTs; Weakly similar to similar to zinc 6.3 313499 AI261390 Hs.146085 ESTs 5.6 313540 AI797301 Hs.5740 ESTs 5.9 313568 AW467376 Hs.129640 ESTs 4.3 313569 AI273419 Hs.135146 ESTs; Weakly similar to ZK1058.5 [C.βleg 4.6 313603 AW468119 Hs287631 EST duster (not in UniGene) 6.8 313615 AW295194 Hs.301997 DKFZP434N126 protein 52 313625 AW468402 Hs.254020 ESTs 7.8 313634 AA688292 Hs.337786 ESTs 4.4 313635 AA507227 Hs.6390 ESTs 8.1 313638 AI753075 Hs.104627 ESTs 6.7 313670 C16690 Hs.23767 EST duster (not in UniGene) 4.4 313671 W49823 Hs.104613 ESTs 4.4 313676 AA861697 Hs.120591 EST duster (not in UniGene) 13.4 313703 AI161293 Hs.280380 ESTs; Weakly similar to KIAA0525 protein 10 313712 AA768553 Hs.74170 ESTs 5.2 313800 AW296132 Hs.55098 ESTs 5.4 313979 AI535895 Hs.221024 ESTs 4.3 314121 AI732100 Hs.187619 ESTs 13.6 314123 AW245993 Hs.223394 ESTs 6.4 314171 AI821895 Hs.193481 ESTs 29.4 314188 AL138431 Hs.164243 ESTs 4.6 314219 AL036001 Hs.48376 ESTs 5.7 314236 AA743396 Hs.189023 ESTs 4.9 314237 AA732359 Hs.96264 ESTs 4.4 314284 AA731431 Hs.293464 EST duster (not in UniGene) 6.4 314305 AI280112 Hs.125232 ESTs 5.3 314343 AI754701 Hs.328476 ESTs; Weakly similar to alternatively sp 62 314530 AI052358 Hs.193726 ESTs 4.5 314691 AW207206 Hs.136319 ESTs 17 314695 AW502698 Hs.118152 ESTs 8.9 314785 AI538226 Hs.32976 ESTs 9.4 314801 AA481027 Hs.109045 ESTs; Weakly similar to ORF YGR245c [S.i 314864 AA493811 Hs294068 ESTs 314907 AI672225 Hs.222886 ESTs 19.3 314916 AA548906 Hs.122244 ESTs 4.5 314954 AA521381 Hs.187726 ESTs 5.3 314981 AA524953 Hs.293334 ESTs 4.6 315021 AA533447 Hs.312989 EST duster (not in UniGene) 5.1 315051 AW292425 Hs.163484 EST 15.5 315052 AA876910 Hs.134427 ESTs 20 315073 AW452948 Hs.257631 ESTs 5.3 315084 AI821085 ESTs 82 315214 AI915927 Hs.34771 ESTs 5.4 315220 AI420753 Hs.66731 ESTs 5.1 315278 AI985544 Hs.12450 ESTs 5.8 315282 AI222165 Hs.144923 ESTs 4.5 315368 AW291563 Hs.104696 ESTs 6 315369 AA764918 Hs.256531 ESTs 4.8 315378 AI263393 Hs.145008 ESTs 62 315379 AI378329 Hs.126629 ESTs 5.4 315402 AW293424 Hs.75354 ESTs 5.1 315442 AA977935 Hs.127274 ESTs 6.6 315443 AW003416 Hs.160604 ESTs 5.5 315528 R37257 Hs.184780 ESTs 8.1 315593 AW198103 Hs.158154 ESTs 9.9 315634 AA837085 Hs220585 ESTs 7.8 315705 AW449285 Hs.313636 ESTs 8.9 315707 AI418055 Hs.161160 ESTs 5.1 - 315714 AA744015 Hs.298138 EST duster (not in UniGene) 6.1 315740 T05558 Hs.156880 EST duster (not in UniGene) 6.8 315762 AI391470 Hs.158618 ESTs 5.3 315769 AA744875 Hs.189413 ESTs 5 315843 AA679430 Hs.191897 ESTs 5.7 315990 AI800041 Hs.190555 ESTs 9.2 316012 AA764950 Hs.119898 ESTs 4.3 316036 AA708016 Hs.190389 ESTs 5.9 316055 AA693880 Hs.6947 EST duster (not in UniGene) 6.7 316074 AW517542 HS293273 ESTs 5.5 316100 AW203986 Hs213003 ESTs 5.1 316169 AI127483 Hs.120451 ESTs 82 316442 AA760894 Hs.153023 ESTs 17.1 316491 AA766025 Hs.186854 EST 4.6 316504 AW135854 Hs.132458 ESTs 4.3 316667 AW015940 Hs232234 ESTs 7.6 316854 AA831215 Hs.159066 ESTs; Weakly similar to predided using 5.1 316905 AW138241 HS210846 ESTs 6.4 317008 AW051597 Hs.143707 ESTs 4.4 317019 AA864968 Hs.127699 ESTs 11 317194 AW445167 Hs.126036 ESTs 13.5 317224 D56760 Hs.93029 ESTs 8.7 317404 AI806867 Hs.126594 ESTs 8.7 317501 AA931245 Hs.137097 ESTs 11.1 317543 AI654187 Hs.195704 ESTs 142 317651 AW292779 Hs.169799 ESTs 5.8 317758 AI733277 Hs.128321 ESTs 5.4 317850 N29974 Hs.152982 EST cluster (not in UniGene) 11.4 317869 AW295184 Hs.129142 ESTs; Weakly similar to DEOXYRIBONUCLEAS 13.8 317902 AI828602 Hs211265 ESTs 5.3 317916 AI565071 Hs.159983 ESTs 7.7 318239 AI085198 Hs.164226 ESTs 13.1 318268 AI817736 Hs.182490 ESTs 6.2 318327 AW294013 Hs.200942 ESTs 4.6 318363 R45530 Hs.1440 gam a-aminobutyric acid (GABA) A recepto 6 318428 AI949409 Hs.194591 ESTs 12.3 318464 AI151010 Hs.157774 ESTs 4.3 318524 AW291511 Hs.159066 ESTs 25.9 318540 T30280 Hs.274803 EST cluster (not in UniGene) 7 318591 AW206806 Hs.115325 ESTs 4.8 318615 AI133617 Hs.10177 ESTs 5.5 318646 AW175665 HS278695 ESTs 5.7 318667 AI493742 Hs.165210 ESTs 11 318668 W26276 Hs.136075 ESTs 5.9 318753 AA578265 Hs.7130 copine IV 5.5 319080 Z45131 Hs.23023 ESTs 16.9 319181 F06504 Hs.27384 EST cluster (not in UniGene) 4.6 319191 AF071538 Hs.79414 prostate epithelium-spedfic Ets traπscr 6.6 319233 R21054 Hs.180532 ESTs 4.9 319586 D78808 Hs.283683 ESTs 8.2 319750 AA621606 Hs.117956 ESTs 9.3 319763 AA460775 Hs.6295 ESTs 14.3 319824 AA424266 Hs.123642 EST cluster (not in UniGene) 12.8 319838 AA337642 Hs.95262 nudear fador related to kappa B bindiπ 5.1 319913 AA179304 Hs271586 ESTs; Moderately similar to !!!! ALU SUB 4.3 319964 T80579 HS290270 ESTs 5.8 320076 AI653733 Hs271593 ESTs 8.5 320102 AW296219 Hs.115325 RAB7; member RAS oncogene family-like 1 9.8 320187 T99949 Hs.303428 EST duster (not in UniGene) 9.8 320211 AL039402 Hs.125783 DEME-6 protein 7.9 320324 AF071202 Hs.139336 ATP-binding cassette; sub-family C (CFTR 562 320455 R49889 Hs.24144 EST duster (not in UniGene) 8.3 320464 AI089817 Hs.237146 ESTs 5.4 320561 NM_006953 Hs.159330 EST duster (not in UniGene) 7 320574 AL049443 Hs.161283 Homo sapiens mRNA; cDNA DKFZp586N2020 (f 4.4 320576 AL049977 Hs.162209 Homo sapiens mRNA; cDNA DKFZp564C122 (fr 6.7 320654 AW263086 Hs.118112 ESTs 6 320796 AF038966 Hs.31218 secretory carrier membrane protein 1 13.5 320800 AI681006 Hs.71721 ESTs 62 320813 AW360847 Hs.16578 ESTs 9.3 320853 AI473796 Hs.135904 ESTs 8.1 320856 D59945 Hs.65366 EST duster (not in UniGene) 6 320899 AA633772 Hs.116796 ESTs 9.2 320918 AW195012 Hs.293970 ESTs 5 320973 H19732 Hs.247917 ESTs 5.9 321099 AA018386 Hs.64341 ESTs 4.6 321190 H52462 Hs.163872 EST duster (not in UniGene) 5.8 321318 AB033041 Hs.137507 EST duster (not in UniGene) 8.4 321382 AW372449 Hs.175982 EST duster (not in UniGene) 7.3 321441 AW297633 Hs.118498 ESTs 14.7 321538 H80483 Hs.46903 EST duster (not in UniGene) 9.2 321609 H86021 Hs.182538 ESTs; Weakly similar to hMmTRAIb [H.sapi 4.8 321636 AI791838 Hs.193465 ESTs 5.5 321638 AI356352 Hs.108932 ESTs 4.6 321644 A1204177 HS237396 ESTs 6.6 321681 AA233821 Hs.190173 EST duster (not in UniGene) 4.6 321726 X91221 Hs.144465 EST duster (not in UniGene) 5 321758 U29112 Hs.196151 EST duster (not in UniGene) 6.2 321877 AL109784 Hs.189222 EST duster (not in UniGene) 4.6 321899 N55158 Hs.29468 ESTs 4.6 321902 AA746374 Hs.145010 ESTs 8.2 322007 AW410646 Hs.164649 ESTs 5.1 322055 AL137646 Hs.146001 EST duster (not in UniGene) 4.3 322092 AF085833 Hs.135624 EST duster (not in UniGene) 4.3 322221 AI890619 Hs.179662 nudeosome assembly protein 1 -like 1 4.4 322278 AF086283 EST duster (not in UniGene) 5.8 322303 W07459 Hs.157601 EST duster (not in UniGene) 22 322437 AW393804 Hs.170253 ESTs; Weakly similar to rabaptin-4 [H.sa 4.4 322493 AF143235 Hs.279819 EST duster (not in UniGene) 7.2 322782 AA056060 Hs.202577 EST duster (not in UniGene) 18.4 322811 AA782292 Hs.105872 ESTs 6.9 322818 AW043782 Hs.293616 ESTs 10.7 322826 AI807883 Hs.180059 ESTs 5 322887 AI986306 Hs.86149 ESTs; Weakly similar to KIAA0969 protein 11.9 322889 AA081924 Hs.124918 ESTs 7.1 322924 AA669253 Hs.136075 ESTs 4.5 322982 AI351191 Hs.128430 ESTs 6.6 322994 AA422116 Hs.191461 ESTs 4.7 323040 AA336609 Hs.10862 ESTs 6.9 323041 AL118747 Hs.26691 EST duster (not in UniGene) 8.3 323045 AA148950 Hs.188836 ESTs 4.6 323048 AL118923 Hs.175110 EST duster (not in UniGene) 7.5 323070 AA157726 Hs.264330 ESTs 7.5 323071 AA157867 Hs.5722 ESTs 4.7 323097 Z44354 Hs.296261 guanine nudeotide binding protein (G pr 4.9 323131 AA176982 Hs.270124 EST duster (not in UniGene) 6.1 323136 AL120351 Hs.30177 EST duster (not in UniGene) 4.3 323175 AI827137 Hs.336454 ESTs 6.2 323218 AF131846 Hs.13396 Homo sapiens clone 25028 mRNA sequence 6.3 323226 AF055019 Hs.21906 Homo sapiens done 24670 mRNA sequence 12.6 323236 AA363148 HS293960 ESTs 10.9 323262 AI829770 Hs.190642 ESTs 7.6 323276 AA836452 Hs.323822 ESTs 7.6 323287 AA639902 Hs.104215 ESTs 24.7 323335 AI655499 Hs.161712 ESTs 14.1 323341 AL134875 Hs.108646 ESTs 5.3 323362 AL135067 Hs.117182 ESTs 6.1 323486 C05278 HS299221 ESTs; Moderately similar to [PYRUVATE DE 8.5 323496 AI826801 Hs.300700 ESTs 4.5 323507 H71721 Hs.128387 ESTs 4.4 323545 AI814405 Hs224569 ESTs 5.8 323623 AA314280 Hs.146589 EST duster (not in UniGene) 5 323663 AW263526 HS243023 ESTs 7.7 323691 AA317561 Hs.145599 EST duster (not in UniGene) 5.9 323810 AA740405 Hs.108806 ESTs 62 323846 AA337621 Hs.137635 ESTs 6 323929 AA354940 Hs.145958 ESTs 10.7 323959 AI636775 Hs.6831 ESTs 5.4 323996 AA367032 HS217882 ESTs 5.8 323997 AA844907 Hs.274454 EST duster (not in UniGene) 4.4 324019 AW177009 EST duster (not in UniGene) 4.6 324130 AL046575 Hs.130198 ESTs 11 324295 AI146686 Hs.143691 ESTs 13.7 324296 AI524039 Hs.192524 ESTs 6.8 324307 AA627642 Hs.4994 transducer of ERBB2; 2 (TOB2) 4.9 324330 AA884766 EST duster (not in UniGene) 4.3 324385 F28212 Hs.284247 EST duster (not in UniGene) 4.7 324430 AA464018 Hs.184598 EST duster (not in UniGene) 13.6 324452 AW014022 Hs.170953 ESTs 7.6 324547 AW501974 Hs.74170 ESTs 5.6 324603 AW016378 Hs.292934 ESTs 242 324617 AA508552 Hs.195839 ESTs 54 324618 AI346282 Hs.87159 ESTs 4.6 324620 AA448021 Hs.94109 EST duster (not in UniGene) 5.7 324626 AI685464 ESTs 9 324658 AI694767 Hs.129179 ESTs 22 324676 AW503943 Hs.112451 ESTs 4.9 324691 AI217963 Hs.293341 ESTs; Weakly similar to Pro-a2(Xl) [H.sa 10.6 324696 AA641092 Hs.257339 ESTs 102 324713 AW340249 Hs.163440 ESTs 5.5 324715 AI739168 Hs.131798 EST cluster (not in UniGene) 7.2 324718 AI557019 Hs.116467 ESTs 34.4 324720 AA578904 Hs.292437 ESTs 4.8 324752 AI279919 Hs.272072 ESTs; Moderately similar to !!!! ALU SUB 7.9 324753 AA612626 Hs.144871 EST duster (not in UniGene) 52 324790 AI334367 Hs.159337 ESTs 7.6 324801 AI819924 Hs.14553 ESTs 12.6 324804 AI692552 ESTs 6.5 324845 AA361016 Hs.337533 ESTs 4.5 324888 AI564134 Hs.136102 KIAA0853 protein 4.4 324929 AI741633 Hs.125350 ESTs 6.5 324961 AA613792 EST cluster (not in UniGene) 5.1 325108 AA401863 Hs.22380 ESTs 7.1 326816 CH20 hsgi|6552458 9.6 326997 CH21 hs gi|5867660 4.8 327098 CH21 hsgi|6682516 4.3 328492 CH.07 hs gi|5868455 5.8 329362 CH.X hsgi|5868837 4.3 329929 CH.16_p2 gi|6165201 5.5 329960 CH.16_p2gi|5091594 7.6 330020 CH.16_p2 gi|6671887 6 330211 CH.05_p2 gi|6013592 12.6 330384 M23263 androgen receptor (dihydrotestosterone r 9 330430 HG2261-HT2352 Hs.321110 Antigen, Prostate Specific, Alt. Splice 13.8 330546 U31382 Hs.299867 guanine nucleotide binding protein 4 6 330551 U39840 hepatocyte nuclear fador 3; alpha 4.9 330658 AA319514 Hs.30732 ESTs 6 330700 AA037415 Hs.20999 ESTs 5.5 330704 AA056557 Hs.6759 ESTs 5.1 330705 AA102571 Hs.157078 ESTs 11.7 330706 AA121140 Hs.177576 ESTs; Moderately similarto kynurenine a 14.5 330712 AA167269 Hs.52620 ESTs 5 330725 AA252033 Hs.24052 ESTs; Weakly similar to Hi! ALU SUBFAMI 72 330732 AA281092 Hs.35254 ESTs 4.9 330762 AA449677 Hs.15251 Human DNA sequence from clone 437M21 on 18.5 330763 AA450200 Hs.143187 FK506-binding protein 3 (25kD) 4.3 330772 AA479114 Hs.11356 ESTs 5.8 330786 D60374 EST 4.6 330892 AA149579 Hs.91202 ESTs 15.3 330949 H01458 Hs.142896 ESTs 10.3 330977 H20826 Hs.315181 ESTs 4.4 331017 N24619 Hs.108920 ESTs 11.8 331099 R36671 Hs.14846 ESTs 11.6 331128 R51361 HS268714 ESTs 4.8 331151 R82331 Hs.268838 ESTs 13 331195 T64447 Hs.168439 ESTs 4.9 331320 AA262999 Hs.300141 ESTs 4.8 - 331321 AA278355 Hs.87929 ESTs 6.1 331337 AA287662 Hs.118630 ESTs 92 331348 AA400596 Hs.88143 ESTs 9.9 331359 AA416979 Hs.81897 ESTs 4.3 331383 AA454543 Hs.43543 ESTs 4.6 331422 F10802 Hs.237339 ESTs; Moderately similar to !!!! ALU SUB 4.9 331442 H77381 Hs.41223 ESTs 7.5 331466 N21680 Hs.43455 ESTs 5.4 331479 N27154 Hs.44076 ESTs 6.5 331490 N32912 Hs291039 ESTs; Weakly similar to hypothetical 43. 12.5 331493 N34357 Hs.93817 ESTs 4.6 331561 N62780 Hs.48703 ESTs 9.2 331615 N92352 Hs.5472 ESTs 4.6 331659 W48868 Hs.334305 ESTs 8.7 331696 Z38907 Hs.65949 KIAA0888 protein 10.3 331811 AA404500 Hs.187958 ESTs 4.8 331848 AA417039 Hs.98268 signal recognition particle 72kD 7.5 331873 AA429445 Hs.98640 ESTs 6.5 331889 AA431407 Hs.98802 Homo sapiens Chromosome 16 BAC clone CIT 33.6 331967 AA460158 Hs.99589 KIAA1028 protein 6.8 331974 AA464518 Hs.105322 ESTs 5.3 332043 AA490831 Hs.201591 ESTs 10.8 332076 AA599477 HS291156 ESTs 4.4 332173 F09281 Hs.100725 ESTs 5.5 332247 N58172 ESTs 142 332249 N62096 Hs.194140 ESTs 72 332325 T79428 Hs.339667 ESTs 5.6 332396 AA340504 ESTs; Weakly similar to similarto human 212 332434 N75542 Hs.237731 transcription fador 4 15.3 332493 N95495 Hs.56729 ESTs; Highly similar to GTP-binding prat 7.1 332522 L38503 Hs.178357 glutathione S-transferase theta 2 6.6 332526 AA281753 Hs.17731 inositol 1;4;5-triphosphate receptor; ty 5.8 332530 M31682 Hs.19280 inhibin; beta B (activin AB beta polypep 5.5 332533 M99487 Hs.325825 folate hydrolase (prostate-specific memb 38.1 332538 N48715 Hs20991 ESTs 6.5 332546 D84454 Hs.22587 solute carrier family 35 (UDP-galadose 4.8 332594 AA279313 Hs.32951 methyl CpG binding protein 2 5.6 332610 AA412405 Hs.40513 ESTs; Weakly similar to BETA GALACTOSIDA 5.6 332661 N95742 Hs.6390 ESTs 6.9 332697 T94885 Hs.75725 carboxypeptidase E 24.3 332712 D26070 Hs.79306 inositol 1;4;5-triphosphate receptor; ty 9.9 332716 L00058 Hs.79630 v-myc avian myelocytomatosis viral oncog 5.6 332726 R72029 Hs.83428 synaptophysin-like protein 5 332781 AA233258 ESTs; Weakly similar to D1007.5 [C.elega 4.5 332797 CH22_FGENES.6 2 30.8 332798 CH22 FGENES.6 5 66.8 332799 CH22 FGENES.6 6 19.8 332933 CH22 FGENES.38 7 5.6 332980 CH22 FGENES.54 1 5.5 332984 CH22 FGENES.54 6 4.9 333168 CH22 FGENES.94 1 4.7 333169 CH22 FGENES.94 2 4.4 333452 CH22 FGENES.157 1 4.8 333456 CH22 FGENES.157 5 4.3 333458 CH22 FGENES.157 7 4.6 333611 CH22 FGENES217 6 4.7 333621 CH22 FGENES219 5 5.5 333814 CH22 FGENES282 2 7.1 333849 CH22_FGENES290_8 62 333949 CH22_FGENES.303_5 4.3 333951 CH22 FGENES.303 7 4.9 333955 CH22 FGENES.303 11 5.6 334150 CH22 FGENES.339J 5.1 334223 CH22 FGENES.360_4 20.3 334297 CH22 FGENES.372 3 9.4 334443 CH22 FGENES.387_2 4.6 334444 CH22 FGENES.387_4 5.6 334447 CH22 FGENES.387_7 13.1 334570 CH22 FGENES.405 11 5.4 334749 CH22 FGENES.427J 5.3 334777 CH22 FGENES.430_9 4.7 334960 CH22 FGENES.465_29 5.2 335179 CH22 FGENES.504_9 8.8 335293 CH22 FGENES.527-6 4.7 335550 CH22 FGENES.576J1 5.1 335581 CH22 FGENES.581J9 5.7 335586 CH22 FGENES.581_25 4.3 335809 CH22 FGENES.617-.6 62 335810 CH22 FGENES.617_7 5.8 335822 CH22 FGENES.619_7 7.1 335824 CH22 FGENES.619J1 8.5 335853 CH22 FGENES.626_5 4.3 335886 CH22 FGENES.632_4 4.3 336034 CH22 FGENES.678 5 6.8 336441 CH22 FGENES.827_7 7.6 336624 CH22_FGENES.6-3 43.3 336625 CH22_FGENES.6-4 37.9 336679 CH22_FGENES.43-7 5.3 337577 CH22_C65E1.GENSCAN.8-1 4.9 338255 CH22_EM:AC005500.GENSCAN276-3 13.4 338260 CH22_EM:AC005500.GENSCAN279-10 4.6 338561 CH22_EM:AC005500.GENSCAN.421-5 4.6 338562 CH22_EM:AC005500.GENSCAN.421-6 4.3 338759 CH22_EM:AC005500.GENSCAN.517-6 5.1 338763 CH22_EM:AC005500.GENSCAN.517-16 5.5 338764 CH22_EM:AC005500.GENSCAN.517-17 7.1 TABLE 3 A shows the accession numbers for those primekeys lacking unigenelD's for Table 3. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column. Pkey: Unique Eos probeset identifier number CAT number: Gene duster number Accession: Genbank accession numbers Pkey CAT number Accession 123619 371681J AA602964 AA609200 116722 143512J Z24878 AA494098 F13654AA494040AA143127 103677 41847J Z83806 AJ132091 AJ132090 125992 1589048J H48372 W01626 109342 genbank_AA213620 AA213620 125154 genbank_W38419 W38419 101447 entrez_M21305 M21305 124357 genbankJ.22401 N22401 108910 genbank_AA136590 AA136590 322278 47271J W69304 AF086283 W69200 315084 350959J AI821085 AW973464 AA554802 AI821831 AA657438 AA640756 AA650339 324019 262792J AW177009 AI381610 324330 300543J AA884766 AW974271 AA592975 AA447312 324626 336411_1 AI685464AW971336 AA513587AA525142 303029 37699J AF199613 AF108756 324804 398093J A1692552 AI393343 AI800510 AI377711 F24263 AA661876 324961 376239J AA613792 AW182329T05304AW858385 329362 c_χ_hs 336624 CH22_4071FG_6_3_ 336625 CH22_4072FG_6_4_ 336679 CH22 4157FG_43_7_ 338255 CH22_6856FG_LINK_EM:AC00 338260 CH22_6863FG_UNK_EM:AC00 329929 c16_p2 329960 c16_p2 338561 CH22_7294FG_UNK_EM:AC00 338562 CH22 7295FG_UNK_EM.AC00 338759 CH22_7581FG_LINK_EMAC00 338763 CH22 7585FG_UNK_EM:AC00 338764 CH22 7586FG_LINK_EM:AC00 333168 CH22_400FG_94_1_LINK_EMA 333169 CH22_401FG_94_2_UNK_EMA 333452 CH22_702FG_157_1_LINK_EM: 333456 CH22_706FG_157_5_UNK_EM: 333458 CH22_708FG_157_7_LINK_EM: 333611 CH22_872FG_217_6_LINK_EM: 333621 CH22_882FG_219_5_LINK_EM: 333814 CH22_1083FG_282_2_LINK_EM 333849 CH22_1118FG_290_8_UNK EM 335179 CH22_2515FG--504_9J-INK_EM 333949 CH22_1225FG_303_5_LINK_EM 333951 CH22_1227FG_303_7_LINK_EM 333955 CH22_1231FG_303_11_LINK_E 335293 CH22_2635FG_527_6_LINK_EM 326816 C20_hs 326997 C21_hs 335550 CH22_2905FG_576_11_LINK_E 335581 CH22_2938FG_581_19_LINK_E 335586 CH22_2944FG_581_25_LINK_E 328492 C_7_hs 335809 CH22_3181FG_617_6_LINi EM 335810 CH22_3182FG_617_7_LINK_EM 335822 CH22_3195FG 619_7_LINK_EM 335824 CH22_3197FG 619_11_LINK_E 335853 CH22_3228FG 626_5_LINK_EM 335886 CH22_3261FG 632_4_LINK_EM 330020 c16_p2 330211 C_5_p2 337577 CH22_5864FG_LINK_C65E1.G 307848 AI364186 332797 CH22_13FG_6 2_LINK_C4G1.G 332798 CH22_14FG_6_5_LINK_C4G1.G 332799 CH22_15FG_6 6_LINK_C4G1.G 334150 CH22_1429FG_339_1_LINK_EM 332933 CH22_154FG_38_7_LINK_C20H 332980 CH22_204FG_54_1_LINK_EMΛ 332984 CH22_208FG_54_6_LINK_EMΛ 334223 CH22_1507FG_360_4_LINK_EM 334297 CH22J588FG 372_3_LINK_EM 327098 C21_hs 334443 CH22_1742FG_387 2_LINK_EM 334444 CH22_1743FG_387_4_LINK_EM 334447 CH22J746FG 387_7_LINK_EM 334570 CH22J875FG 405_11_LINK_E 334749 CH22_2061FG 427_1_LINK_EM 334777 CH22_2089FG_430_9_LINK_EM 336034 CH22_3419FG_678_5_LINK_DJ 334960 CH22_2281FG_465_29_UNK_E 336441 CH22_3861FG 827_7_LINK_DJ 330551 9851_2 U39840 NM_004496 AW135607 BE087458 BE087567 AA177116 AW195705 AW750756 AI811008 AI694151 BE348594 AW971075 AI347950 AI201455 AI073898 AA652680 AA613671 AI318364 AA507550 AA693692 AI032599 AA991871 AI269801 AW948974T74639 AA532907 AW949173 330786 53973_3 BE379594 AI192455 AL039862 AI744012 AI761735 AW243181 AI743687 AI928223 AI423022 AI627855 AI636059 AI651571 AW802044 AI826995 AI431733 AI539125 AA863056 AW270910 AI768930 AW008835 AW615183 AW591147 A1695294 AI672106 AA506358 AI308060 AA011556 AA962437 AI935488 BE219625 AI004356 AW151394 AI218466 N66178 AI419784 AW242519 AW946907 D60374 AA989263 AI698799 AA470460 AI824167 332247 372969_1 AA669097 AA513815 AA026798 AA676526 AA704429 AA704269 AW118292 AA579216 N58172 332396 20265 AW579842 BE156562 BE156690 BE156489 BE081033 AK001559 BE149402 M85387 AW367811 AW367798 R17370 AI908947 AA382932 R58449 H18732 AA371231 AW962899 AA713530 AW892946 R53463 H11063 AW068542 Z40761 BE176212 BE176155 W23952 W92188 AW374883 AA303497 AW954769 AA036808 BE168063 AW382073 AW382085 AL041475 H80748 AI078161 BE463983 AI805213 AI761264 W94885 N94502 AI623772 AI419532 AI810302 AI634190 AW002516 AW150777 AI352312 AI367474 AW204807 AI675502 AI337026 AW134715 BE328451 AI123157 AI560020 AI300745 AI608631 AI248873 AA742484 AW051635 H18646 AI245045 AA507111 AI640510 AI925594 AA115747 AA143035 AA151106 332781 32044J AK001764 BE313896 AA380199 AA380151 AA194996 AW118089 AA495871 AW975219 AW085598 AI378909 AW992310 AW992409 AI911857 AA657643 AI804471 AI242589 AI623968 R09556 AI129100 AI206500 AA680094 AA677784 AI023178 AI277519 AA424742 AI240654 AA232846 AI804273 AI382376 AA001729 W90790 BEO90656 AW295015 AI674596 AI431734 AI420517 AW769185 AI128355 AI192474 AI820001 AA001929 AA706925 AI076676 AI499119 AI200493 AI695919 AI376217 W69195 W69261 AW305099 W90320 BE048357 AI658856 AA838534 AA233258 AI753393 AA709227 AI674387 AI872616 TABLE 3B shows the genomic positioning for those primekeys lacking unigene ID's and accession numbers in Table 3. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed. Pkey: Unique number corresponding to an Eos probeset Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (Gl) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. Strand: Indicates DNA strand from which exons were predicted. NLposition: Indicates nudeotide positions of predicted exons. Pkey Ref Strand NLposition 333611 Dunham, . eta . Plus 6548368-6548507 333621 Dunham, . eta . Plus 8597414-8597560 333814 Dunham, . eta . Plus 7894165-7894252 333849 Dunham, . eta . Plus 8018323-8018472 333949 Dunham, . eta . Plus 8589634-8589791 333951 Dunham, . eta . Plus 8592501-8592637 333955 Dunham, . eta . Plus 8597414-8597560 334150 Dunham, .eta . Plus 10529221-10529854 334297 Dunham, . eta . Plus 13420934-13421058 334443 Dunham, . eta . Plus 14298981-14299056 334444 Dunham, . eta . Plus 14306433-14306492 334447 Dunham, . eta . Plus 14308764-14308824 334570 Dunham, . eta . Plus 14994868-14994943 334777 Dunham, . eta . Plus 16259586-16260166 335179 Dunham, . etal . Plus 21634405-21634526 335581 Dunham, . etal . Plus 24976198-24976334 335586 Dunham, . eta . Plus 24990333-24990497 335809 Dunham, . eta . Plus 26310772-26310909 335810 Dunham, . eta . Plus 26314767-26314849 335822 Dunham, . eta . Plus 26364087-26364196 335824 Dunham, . eta . Plus 26376860-26376942 335886 Dunham, . etal Plus 26934235-26934364 336034 Dunham, . etal . Plus 29014404-29014590 336441 Dunham, . etal . Plus 34187606-34187663 337577 Dunham, . eta . Plus 595377-595678 338260 Dunham, . eta Plus 15458919-15459257 332797 Dunham, . etal . Minus 216964-216798 332798 Dunham, . etal . Minus 232147-231974 332799 Dunham, . etal . Minus 232421-232307 332933 Dunham, . eta! Minus 2035790-2035681 332980 Dunham, . eta! Minus 5136165-5136019 332984 Dunham, . etal Minus 2632606-2632457 333168 Dunham, . etal Minus 3729896-3729788 333169 Dunham, . etal Minus 3730864-3730767 333452 Dunham, . eta! Minus 5136165-5136019 333456 Dunham, . etal Minus 2631933-2631797 333458 Dunham, . etal . Minus 5143942-5143806 334223 Dunham, . eta Minus 12734365-12734269 334749 Dunham, . etal Minus 16090686-16090106 334960 Dunham, . etal Minus 20160968-20160795 335293 Dunham, . etal Minus 22316408-22316275 335550 Dunham, . etal Minus 24668714-24668658 335853 Dunham, . eta! Minus 26614629-26614506 336624 Dunham, . etal Minus 227714-227577 336625 Dunham, . etal Minus 229124-229024 336679 Dunham, . etal Minus 2035790-2035681 338255 Dunham, . etal Minus 15242294-15242231 338561 Dunham, . etal . Minus 22311966-22311856 338562 Dunham, . eta! Minus 22312594-22312465 338759 Dunham, . etal Minus 26582475-26582199 338763 Dunham, . etal Minus 26628148-26628009 338764 Dunham, . etal Minus 26641232-26641101 3299605091594 Minus 1031-1162 329929 6165201 Minus 156410-156553 330020 6671887 Plus 172397-172491 326816 6552458 Plus 198354-198436 326997 5867660 Minus 71389-72147 327098 6682516 Minus 1061684-1062361 330211 6013592 Plus 59158-59215 328492 5868455 Minus 46094-46241 329362 5868837 Minus 65688-68173 TABLE 4: shows a preferred subset of the Accession numbers for genes found in Table 3 which are differentially expressed in prostate tumor tissue compared to normal prostate tissue. Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD: Unigene number Unigene Title: Unigene gene title R1: Ratio of tumor to normal body tissue Pkey ExAccn UnigenelD Unigene Title R1 100819 HG4020-HT4290Hs2387 Transglutaminase 10.5 102698 U75272 Hs.1867 progastricsin (pepsinogen C) 10.6 102869 X02544 Hs.572 orasomucoid 1 22.6 105370 AA236476 Hs22791 ESTs; Weakly similar to transmembrane pr 10.3 105645 AA282138 Hs.11325 ESTs 14 106094 AA419461 Hs.23317 ESTs 10.9 109014 AA156790 Hs.262036 ESTs 15.3 109562 F01811 Hs.187931 ESTs; Moderately similar to voltage-gate 10.8 113021 T23855 Hs.129836 KIAA1028 protein 10.8 114124 Z38595 Hs.125019 ESTs; Highly similar to KIAA0886 protein 21.3 122791 AA460158 Hs.129836 KIAA1028 protein 12.4 124352 N21626 Hs.102406 ESTs 102 301042 AI659131 Hs.197733 ESTs 24.9 302005 AI869666 Hs.123119 ESTs 36.8 302410 NM 004917 Hs218366 EST duster (not in UniGene) with exon h 26.8 302881 AA508353 Hs.105314 relaxin 1 (H1) 78.8 303344 AA255977 Hs.250646 ESTs; Highly similar to ubiquitin-conjug 19.5 303753 AW503733 Hs.9414 ESTs 13 310431 AI420227 Hs.149358 ESTs 72.9 311251 AI655662 Hs.197698 ESTs 41.3 311596 AI682088 Hs.79375 ESTs 26.4 312153 AA759250 Hs.118625 cytochrome b-561 11 312521 AA033609 HS239884 ESTs 112 313676 AA861697 Hs.120591 EST duster (not in UniGene) 13.4 314171 AI821895 Hs.193481 ESTs 29.4 314907 AI672225 Hs222886 ESTs 19.3 315051 AW292425 Hs.163484 EST 15.5 315052 AA876910 Hs.134427 ESTs 20 317548 AI654187 Hs.195704 ESTs 142 317869 AW295184 Hs.129142 ESTs; Weakly similar to DEOXYRIBONUCLEAS 13.8 318428 AI949409 Hs.194591 ESTs 12.3 318524 AW291511 Hs.159066 ESTs 25.9 319080 Z45131 HS23023 ESTs 16.9 319763 AA460775 Hs.6295 ESTs 14.3 320324 AF071202 Hs.139336 ATP-binding cassette; sub-family C (CFTR 562 321441 AW297633 Hs.118498 ESTs 14.7 322303 W07459 Hs.157601 EST duster (not in UniGene) 22 322782 AA056060 Hs.202577 EST duster (not in UniGene) 18.4 322818 AW043782 Hs.293616 ESTs 10.7 323287 AA639902 Hs.104215 ESTs 24.7 324603 AW016378 Hs292934 ESTs 242 324617 AA508552 Hs.195839 ESTs 54 324658 AI694767 Hs.129179 ESTs 22 324691 AI217963 Hs.293341 ESTs; Weakly similar to Pro-a2(XI) [H.sa 10.6 324696 AA641092 Hs.257339 ESTs 102 324718 AI557019 Hs.116467 ESTs 34.4 330211 CH.05_p2 gi|6013592 12.6 330430 HG2261-HT2352 Hs.321110 Antigen, Prostate Specific, Alt Splice 13.8 330706 AA121140 Hs.177576 ESTs; Moderately similar to kynurenine a 14.5 330762 AA449677 Hs.15251 Human DNA sequence from done 437M21 < an 18.5 330892 AA149579 Hs.91202 ESTs 15.3 330949 H01458 Hs.142896 ESTs 10.3 331099 R36671 Hs.14846 ESTs 11.6 331151 R82331 Hs268838 ESTs 13 331889 AA431407 Hs.98802 Homo sapiens Chromosome 16 BAC clone CIT 31 332247 N58172 ESTs 142 332396 AA340504 ESTs; Weakly similar to similarto human 212 332533 M99487 Hs.325825 folatθ hydrolase (prostate-spedfic memb 38.1 332697 T94885 Hs.75725 carboxypeptidase E 24.3 332797 CH22 FGENES.6 2 30.8 332798 CH22 FGENES.6_5 66.8 332799 CH22 FGENES.6 6 19.8 334223 CH22 FGENES.360_4 20.3 336624 CH22 FGENES.6-3 43.3 336625 CH22 FGENES.6-4 37.9 TABLE 4A shows the accession numbers for those primekeys lacking unigenelD's for Table 4. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column. Pkey: Unique Eos probeset identifier number CAT number: Gene duster number Accession: Genbank accession numbers Pkey CAT number Accession 336624 CH22_4071FG_6_3_ 336625 CH22_4072FG_6_4_ 330211 c_5_p2 332797 CH22_13FG_6_2_LINK_C4G1.G 332798 CH22_14FG_6_5-LINK_C4G1.G 332799 CH22_15FG_6_6_LINK_C4G1.G 334223 CH22_1507FG_360_4_LINK_EM 332247 372969J AA669097 AA513815 AA026798 AA676526 AA704429 AA704269 AW118292 AA579216 N58172 332396 20265J AW579842 BE156562 BE156690 BE156489 BE081033 AK001559 BE149402 M85387 AW367811 AW367798 R17370 AI908947 AA382932 R58449 H18732 AA371231 AW962899 AA713530 AW892946 R53463 H11063 AW068542 Z40761 BE176212 BE176155 W23952 W92188 AW374883 AA303497 AW954769 AA036808 BE168063 AW382073 AW382085 AL041475 H80748 AI078161 BE463983 AI805213 AI761264 W94885 N94502 AI623772 AI419532 AI810302 AI634190 AW002516 AW150777 AI352312 AI367474 AW204807 AI675502 AI337026 AW134715 BE328451 AI123157 AI560020 AI300745 AI608631 AI248873AA742484 AW051635 H18646 AI245045 AA507111 AI640510AI925594 AA115747 AA143035 AA151106 TABLE 4B shows the genomic positioning for those primekeys lacking unigene ID's and accession numbers in Table 4. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed. Pkey: Unique number corresponding to an Eos probeset Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (Gl) numbers. "Dunham I. et al." refers to the publication entitled The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. Strand: Indicates DNA strand from which exons were predicted. NLposition: Indicates nucleotide positions of predicted exons. Pkey Ref Strand NLposition 332797 Dunham, I. etal. Minus 216964-216798 332798 Dunham, I. etal. Minus 232147-231974 332799 Dunham, I. etal. Minus 232421-232307 334223 Dunham, I. etal. Minus 12734365-12734269 336624 Dunham, I. etal. Minus 227714-227577 336625 Dunham, I. etal. Minus 229124-229024 330211 6013592 Plus 59158-59215 TABLE 5: 1170 GENES UP-REGULATED IN PROSTATE CANCER COMPARED TO NORMAL ADULT TISSUES Table 5 shows 1170 genes up-regulated in prostate cancer compared to normal adult tissues. These were selected from 59680 probesets on the Affymetrix/Eos Hu03 GeneChip array such that the ratio of "average" prostate cancer to "average" normal adult tissues was greater than or equal to 3.44. The "average" prostate cancer level was set to the 85 th percentile amongst 73 prostate cancers. The "average" normal adult tissue level was set to the 85 th percentile amongst 162 non-malignant tissues. In order to remove gene-specific background levels of non-specific hybridization, the 7.5 th percentile value amongst the 162 non-malignant tissues was subtracted from both the numerator and the denominator before the ratio was evaluated. Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD: Unigene numbei r Unigene Title: Unigene gene title R1: Ratio of tumor to normal tissue Pkey ExAccn UnigenelD Unigene Title R1 446057 AI420227 Hs.149358 ESTs, Weakly similar to A46010 X-linked 86.42 400302 N48056 Hs.1915 folate hydrolase (prostate-specific memb 66.46 414569 AF109298 Hs.118258 prostate cancer assodated protein 1 58.36 417407 AA923278 HS290905 ESTs, Weakly similar to protease [H.sapi 56.16 431579 AW971082 HS222886 ESTs, Weakly similar to TRHY_HUMAN TRICH 53.38 409361 NM 005982 I Hs.54416 sine oculis homeobox (Drosophila) homolo 4828 409731 AA125985 Hs.56145 thymosin, beta, identified in neuroblast 4524 400298 AA032279 Hs.61635 six transmembrane epithelial antigen of 43.48 420154 AI093155 Hs.95420 JM27 protein 41.12 433466 AA508353 Hs.105314 relaxin 1 (H1) 39.88 400296 AA305627 Hs.139336 ATP-binding cassette, sub-family C (CFTR 38.42 400292 AA250737 Hs.72472 ESTs 38.00 432887 AI926047 Hs.162859 ESTs 36.48 439176 AI446444 Hs.190394 ESTs, Weakly similar to B28096 line-1 pr 36.45 430722 AW968543 HS203270 ESTs, Weakly similar to ALU1 HUMAN ALU S 3320 437052 AA861697 Hs.120591 ESTs 33.02 418396 AI765805 HS26691 ESTs 32.68 434036 AI659131 Hs.197733 hypothetical protein MGC2849 32.44 407709 AA456135 HS23023 ESTs 32.10 426747 AA535210 Hs.171995 kallikrein 3, (prostate specific antigen 31.80 407168 R45175 ESTs 31.72 440260 AI972867 Hs.7130 copine IV 30.52 421513 X00949 Hs.105314 relaxin 1 (H1) 30.10 416370 N90470 HS203697 ESTs, Weakly similar to I38022 hypotheti 29.68 407122 H20276 Hs.31742 ESTs 2924 400287 S39329 Hs.181350 kallikrein 2, prostatic 28.90 432244 AI669973 Hs.200574 ESTs 28.74 451939 U80456 HS27311 single-minded (Drosophila) homolog 2 28.74 415989 AI267700 Hs.111128 ESTs 28.34 418961 AW967646 Hs.23023 ESTs 27.34 425628 NM 004476 Hs.1915 folate hydrolase (prostate-spedfic memb 27.32 458509 AA654650 HS282906 ESTs 2724 448290 AK002107 HS20843 Homo sapiens cDNA FU11245 fis, done PL 27.16 428336 AA503115 Hs.183752 microseminoprotein, beta- 26.17 450096 AI682088 HS223368 holocarboxylase synthetase (biotin-[prop 25.60 400299 X07730 Hs.171995 kallikrein 3, (prostate specific antigen 24.91 437571 AA760894 Hs.153023 ESTs 24.74 453160 AI263307 Hs.146228 H2B histone family, member L 24.66 453096 AW294631 Hs.11325 ESTs 24.46 425075 AA506324 Hs.1852 add phosphatase, prostate 2423 407202 N58172 Hs.109370 ESTs 24.18 424846 AU077324 Hs.1832 neuropeptide Y 23.57 453370 AI470523 Hs.182356 ATP-binding cassette, sub-family C (CFTR 23.16 422805 AA436989 Hs.121017 H2A histone family, member A 22.52 444917 R68651 Hs.144997 ESTs 2226 408826 AF216077 Hs.48376 Homo sapiens done HB-2 mRNA sequence 22.02 413597 AW302885 Hs.117183 ESTs 21.76 426429 X73114 Hs.169849 myosin-binding protein C, slow-type 21.32 435981 H74319 Hs.188620 ESTs 21.12 432966 AA650114 ESTs 21.07 418848 AI820961 Hs.193465 ESTs 21.06 405685 20.90 443271 BE568568 Hs.195704 ESTs 19.98 418819 AA228776 Hs.191721 ESTs 19.94 420757 X78592 Hs.99915 androgen receptor (dihydrotestosterone r 19.72 418994 AA296520 Hs.89546 selectin E (endothelial adhesion molecul 19.56 429918 AW873986 Hs.119383 ESTs 19.04 415539 AI733881 Hs.72472 ESTs 18.43 450382 AA397658 Hs.60257 Homo sapiens cDNA FU13598 fis, done PL 18.34 418829 AA516531 Hs.55999 NK homeobox (Drosophila), family 3, A 1828 429984 AL050102 Hs.227209 hypothetical protein FU21617 17.82 443822 AI087412 Hs.143611 ESTs, Weakly similar to 20O4399A chromos 17.66 431676 AI685464 HS292638 gb:tt88f04.x1 NCI CGAP Pι28 Homo sapiens 17.64 410330 AW023630 Hs.46786 ESTs 17.52 432441 AW292425 Hs.163484 ESTs 17.41 452792 AB037765 Hs.30652 KIAA1344 protein 17.39 445472 AB006631 Hs.12784 Homo sapiens mRNA for KIAA0293 gene, par 17.00 414565 AA502972 Hs.183390 hypothetical protein FU13590 16.82 430487 D87742 Hs.241552 KIAA0268 protein 16.72 431716 D89053 Hs.268012 fatty-add-Coenzyme A ligase, long-chain 16.60 419536 AA603305 gb:np12d11.s1 NCI CGAP_Pr3 Homo sapiens 16.50 439677 R82331 Hs.164599 ESTs 16.46 449625 NM 014253 Hs.23796 odz (odd Ozrten-m, Drosophila) homolog 1 16.32 408430 S79876 Hs.44926 dipeptidylpeptidase IV (CD26, adenosine 1628 447033 AI357412 Hs.157601 ESTs 16.02 453006 AI362575 Hs.167133 ESTs 15.74 431474 AL133990 Hs.190642 ESTs 15.70 420218 AW958037 Hs.22437 ribosomal protein L4 15.64 408000 L11690 Hs.620 bullous pemphtgoid antigen 1 (230/240kD) 15.54 416208 AW291168 Hs.41295 ESTs, Weakly similar to MUC2_HUMAN MUCIN 15.48 430226 BE245562 Hs.2551 adrenergic, beta-2-, receptor, surface 15.40 415263 AA948033 Hs.130853 ESTs 15.38 432437 W07088 Hs293685 ESTs 1526 428398 AI249368 Hs.98558 ESTs 1521 429900 AA460421 Hs.30875 ESTs 14.90 449156 AF103907 Hs.171353 prostate cancer antigen 3 14.89 411096 U80034 Hs.68583 mitochondrial intermediate peptidase 14.81 435974 U29690 Hs.37744 Homo sapiens beta-1 adrenergic receptor 14.76 444484 AK002126 Hs.11260 hypothetical protein FU11264 14.76 422728 AW937826 Hs.103262 ESTs, Weakly similar to ZN91_HUMAN ZINC 14.60 418601 AA279490 Hs.86368 calmegin 14.56 448999 AF179274 Hs22791 transmembrane protein with EGF-like and 14.55 445885 AI734009 Hs.127699 KIAA1603 protein 14.44 452712 AW838616 gb:RC5-LT0054-140200-013-D01 LT0054 Homo- 1422 432189 AA527941 gb:nh30c04.s1 NCI_CGAP_Pι3 Homo sapiens 14.12 424565 AW102723 Hs.75295 guanylate cydase 1 , soluble, alpha 3 13.78 429290 AF203032 Hs.198760 neurofilament, heavy polypeptide (200kD) 13.57 419264 AA877104 Hs.293672 ESTs, Weakly similar to ALUBJHUMAN HI! 13.40 416445 AL043004 Hs.300678 KIAA0135 protein 13.32 407275 AI364186 gb:qw34h07.x1 NCI_CGAP_Ut4 Homo sapiens 1324 408369 R38438 Hs.182575 solute carrier family 15 (H+/peptide tra 1321 446720 AI439136 Hs.140546 ESTs 13.06 434988 AI418055 Hs.161160 ESTs 13.02 448172 N75276 Hs.135904 ESTs 12.98 416182 NM_004354 Hs.79069 cydin G2 12.94 420544 AA677577 Hs.98732 Homo sapiens Chromosome 16 BAC clone CIT 12.79 445413 AA151342 Hs.12677 CGI-147 protein 12.64 452588 AA889120 Hs.110637 homeo bo AIO 12.62 407819 R42185 HS274803 ESTs 12.60 433444 AW975324 Hs.129816 ESTs 12.60 421059 AI654133 Hs.30212 thyroid receptor interacting protein 15 12.30 420077 AW512260 Hs.87767 ESTs 1224 453930 AA419466 Hs.36727 hypothetical protein FU10903 1222 441610 AW576148 Hs.148376 ESTs 1220 451009 AA013140 Hs.115707 ESTs 12.18 433764 AW753676 Hs.39982 ESTs 12.16 440286 U29589 Hs.7138 cholinergic receptor, muscarinic 3 12.04 443912 R37257 Hs.184780 ESTs 11.92 419526 AI821895 Hs.193481 ESTs 11.91 423073 BE252922 Hs.123119 MAD (mothers against decapentaplegic, Dr 11.87 452784 BE463857 Hs.151258 hypothetical protein FLJ21062 11.86 414422 AA147224 Hs.71814 ESTs 11.76 450203 AF097994 Hs.301528 L-kynurenine/alpha-aminoadipate aminotra 11.68 436679 AI127483 Hs.120451 ESTs, Weakly similar to unnamed protein 11.60 440901 AA909358 Hs.128612 ESTs 11.60 448045 AJ297436 Hs20166 prostate stem cell antigen 11.51 433887 AW204232 Hs.279522 ESTs 1150 434980 AW770553 HS293640 sterol θ-acyltransferase (acyl-Coenzyme 11.38 425905 AB032959 Hs.161700 novel C3HC4 type Zinc finger (ring finge 11.33 434680 T11738 Hs.127574 ESTs 11.32 449650 AF055575 Hs.297647 calcium channel, voltage-dependent, L ty 11.18 431173 AW971198 HS294068 ESTs 11.16 434539 AW748078 Hs.214410 ESTs, Weakly similar to MUC2JHUMAN MUCIN 11.16 410037 AB020725 Hs.58009 KIAA0918 protein 11.14 417708 N74392 Hs.50495 ESTs 11.14 458332 AI000341 HS220491 ESTs 11.12 420381 D50640 Hs.301782 phosphodiesterase 3B, cGMP-inhibited 11.10 425665 AK001050 Hs.159066 hypothetical protein FU10188 11.08 425710 AF030880 Hs.159275 solute carrier family, member 4 11.08 428728 NM 016625 Hs.191381 hypothetical protein 11.04 407021 U52077 gb:Human marineri transposase gene, comp 11.02 410733 D84284 Hs.66052 CD38 antigen (p45) 11.02 401714 10.90 434485 AI623511 Hs.118567 ESTs 10.89 415786 AW419196 HS257924 hypothetical protein FU13782 10.87 452340 NM 002202 Hs.505 ISL1 transcription fador, LIM/homeodoma 10.85 453628 AW243307 Hs.170187 hypothetical protein 10.72 408063 BE086548 Hs.42346 caldneurin-binding protein calsarcin-1 10.67 417687 AI828596 HS250691 ESTs 10.64 434666 AF151103 Hs.112259 T cell receptor gamma locus 10.53 432374 W68815 Hs.301885 Homo sapiens cDNA FU11346 fis, done PL 10.50 428819 AL135623 Hs.193914 KIAA0575 gene produd 10.48 413409 AI638418 Hs.21745 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep 10.44 428775 AA434579 Hs.143691 ESTs 1021 436556 AI364997 Hs.7572 ESTs 1020 441690 R81733 Hs.33106 ESTs 10.14 419852 AW503756 Hs.286184 hypothetical protein dJ551 D2.5 10.10 421991 NM 014918 Hs.110488 KIAA0990 protein 10.04 423698 AA329796 Hs.1098 DKFZp434J1813 protein 10.02 452039 AI922988 Hs.172510 ESTs 10.00 433043 W57554 Hs.125019 ESTs 9.98 433927 AI557019 Hs.116467 small nudear protein PRAC 9.97 445424 AB028945 Hs.12696 cortactin SH3 domain-binding protein 9.96 432240 AI694767 Hs.129179 Homo sapiens cDNA FU13581 fis, clone PL 9.88 433104 AL043002 Hs.128246 ESTs, Moderately similar to unnamed prat 9.84 452744 AI267652 Hs.30504 Homo sapiens mRNA; cDNA DKFZp434E082 (fr 9.82 431217 NM 013427 HS250830 Rho GTPase activating protein 6 9.75 427398 AW390020 Hs.20415 chromosome 21 open reading frame 11 9.70 446896 T15767 HS22452 Homo sapiens mRNA for KIAA1737 protein, 9.70 421470 R27496 Hs.1378 annexin A3 9.64 406554 9.60 401424 9.58 407902 AL117474 Hs.41181 Homo sapiens mRNA; cDNA DKFZp727C191 (fr 9.56 423545 AP000692 Hs.129781 chromosome 21 open reading frame 5 9.54 439024 R96696 Hs.35598 ESTs 9.51 431548 AI834273 Hs.9711 novel protein 9.48 409262 AK000631 Hs.52256 hypothetical protein FU20624 9.45 446271 D82484 Hs.100469 ESTs 9.42 448692 AW013907 HS224276 methy-crotonoyl-Coenzyme A carboxylase 2 926 414140 AA281279 HS23317 hypothetical protein FU14681 9.24 435980 AF274571 Hs.129142 deoxyribonuclease II beta 9.24 421246 AW582962 Hs.300961 CGI-47 protein 9.20 427304 AA761526 Hs.163853 ESTs 9.16 442914 AW188551 Hs.99519 hypothetical protein FLJ14007 9.16 413627 BE182082 Hs.246973 ESTs 9.14 439699 AF086534 Hs.187561 ESTs, Moderately similar to ALU1 HUMAN A 9.10 437718 AI927288 Hs.196779 ESTs 9.07 439820 AL3602O4 HS283853 Homo sapiens mRNA full length insert cDN 9.06 447342 AI199268 Hs.19322 Homo sapiens, Similar to RIKEN cDNA 2010 9.05 446223 BE300091 Hs.119699 hypothetical protein FU12969 9.04 410001 AB041036 Hs.57771 kallikrein 11 9.03 424012 AW368377 Hs.137569 tumor protein 63 kDa with strong homolog 9.03 441791 AW372449 Hs.175982 hypothetical protein FU21159 9.02 448206 BE622585 Hs.3731 ESTs, Moderately similar to 138022 hypot 9.02 414269 AA298489 olfadory receptor, family 51 , subfamily 8.99 442081 AA401863 HS22380 ESTs 8.98 420092 AA814043 Hs.88045 ESTs 8.85 411630 U42349 Hs.71119 Putative prostate cancer tumor suppresso 8.80 421863 AI952677 Hs.108972 Homo sapiens mRNA; cDNA DKFZp434P228 (fr 8.80 454141 AW138413 Hs.182356 ATP-binding cassette, sub-family C (CFTR 8.80 418278 AI088489 Hs.83937 hypothetical protein 8.78 428330 L22524 HS2256 matrix metalloproteinase 7 (matrilysin, 8.76 432415 T16971 Hs.289014 ESTs, Weakly similar to A43932 mucin 2 p 8.75 424906 AI566086 Hs.153716 Homo sapiens mRNA for Hmob33 protein, 3' 8.74 415245 N59650 Hs.27252 ESTs 8.72 442409 BE208843 Hs.129544 hypothetical protein MGC15438 8.70 404571 8.66 418033 W68180 Hs.259855 elongation fador-2 kinase 8.64 456497 AW967956 Hs.123648 ESTs, Weakly similar to AF108460 1 ubinu 8.56 405876 8.54 448807 AI571940 Hs.7549 ESTs 8.52 445372 N36417 Hs.144928 ESTs 8.48 425171 AW732240 Hs.300615 ESTs 8.44 419968 X04430 Hs.93913 interleukin 6 (interferon, beta 2) 8.36 407385 AA610150 HS272072 ESTs, Weakly similarto I38022 hypotheti 8.31 433172 AB037841 Hs.102652 hypothetical protein ASH1 8.30 422631 BE218919 Hs.118793 hypothetical protein FU10688 827 412719 AW016610 Hs.129911 ESTs 8.24 418849 AW474547 Hs.53565 Homo sapiens PIG-M mRNA for mannosyltran 8.22 444922 AI921750 Hs.144871 Homo sapiens cDNA FU13752 fis, done PL 8.22 427674 NM-.003528 Hs2178 H2B histone family, member Q 8.20 432101 AI918950 Hs.11092 EphA3 8.17 416288 H51299 gb:yp07c06.s1 Soares breast 3NbHBst Homo 8.15 404915 8.08 440106 AA864968 Hs.127699 KIAA1603 protein 8.07 442861 AA243837 Hs.57787 ESTs 8.06 452259 AA317439 HS28707 signal sequence receptor, gamma (translo 8.06 443250 AI041530 Hs.132107 ESTs 8.06 437267 AW511443 Hs.258110 ESTs 8.04 452891 N75582 Hs212875 ESTs, Weakly similar to DYH9_HUMAN CILI 8.02 422219 AW978073 regulator of itotic spindle assembly 1 8.00 453049 BE537217 Hs.30343 ESTs 8.00 439731 AI953135 Hs.45140 hypothetical protein FU14084 7.98 408554 AA836381 Hs.7323 nudear receptor cc-repressor HDAC3 comp 7.94 421154 AA284333 HS287631 Homo sapiens cDNA FU14269 fis, clone PL 7.94 430107 AA465293 Hs.105069 ESTs 7.94 433404 T32982 Hs.102720 ESTs 7.93 450813 AI739625 Hs.203376 ESTs 7.90 416239 AL038450 Hs.48948 ESTs 7.85 448212 AI475858 gb:tc87d07.x1 NCI_CGAP_CLL1 Homo sapiens 7.82 449532 W74653 Hs.271593 ESTs, Moderately similar to A47582 B-cel 7.82 413930 M86153 Hs.75618 RAB11A, member RAS oncogene family 7.80 458191 AI420611 Hs.127832 ESTs 7.80 444858 AI199738 Hs208275 ESTs, Weakly similar to ALUAJ.UMAN !!!! 7.78 457498 AI732230 Hs.191737 ESTs 7.78 407235 D20569 Hs.169407 SAC2 (suppressor of actin mutations 2, y 7.76 433759 AA680003 Hs.109363 Homo sapiens cDNA: FU23603 fis, done L 7.74 433805 AA706910 Hs.112742 ESTs 7.74 426485 NM_006207 Hs.170040 platelet-derived growth fador receptor- 7.72 446028 R44714 Hs.106795 Homo sapiens cDNA FU13136 fis, done NT 7.72 418555 AI417215 Hs.87159 hypothetical protein FU12577 7.70 447499 AW262580 Hs.147674 protocadherin beta 16 7.70 419839 U24577 Hs.93304 phospholipase A2, group VII (platelet-ac 7.68 416857 AA188775 Hs.292453 ESTs 7.68 413801 M62246 Hs.35406 ESTs, Highly similar to unnamed protein 7.66 425480 AB023198 Hs.158135 KIAA0981 protein 7.66 420120 AL049610 Hs.95243 transcription elongation fador A (Sll)- 7.64 424099 AF071202 Hs.139336 ATP-binding cassette, sub-family C (CFTR 7.64 446307 T50083 Hs.9094 ESTs 7.63 429220 AW207206 Hs.136319 ESTs 7.59 420345 AW295230 Hs.25231 ESTs 7.54 429208 AA447990 Hs.190478 ESTs 7.54 447247 AW369351 Hs.287955 Homo sapiens cDNA FU13090 fis, clone NT 7.53 440995 T57773 Hs.10263 ESTs 7.53 448706 AW291095 HS21814 interleukin 20 receptor, alpha 7.52 410227 AB009284 Hs.61152 exostoses (multiple)-like 2 7.49 431616 AA508552 Hs.195839 ESTs, Weakly similar to I38022 hypotheti 7.46 434217 AW014795 Hs.23349 ESTs 7.44 431467 N71831 HS256398 Homo sapiens mRNA; cDNA DKFZp434E0528 (f 7.42 448519 AW175665 Hs.244334 Homo sapiens prostein mRNA, complete eds 7.42 446791 A1632278 Hs.34981 ESTs 7.40 419743 AW408762 Hs.127478 Homo sapiens done 24416 mRNA sequence 7.39 445855 BE247129 Hs.145569 ESTs 7.36 425211 M18667 Hs.1867 progastricsin (pepsinogen C) 7.35 419131 AA406293 Hs.301622 ESTs 7.34 400294 N95796 Hs.179809 Homo sapiens prostein mRNA, complete eds 7.33 441736 AW292779 Hs.169799 ESTs 728 427701 AA411101 Hs.221750 nudear autoantigenic sperm protein (his 724 457733 AW974812 Hs.291971 ESTs 7.24 418432 M14156 Hs.85112 insulin-like growth fador 1 (somatomedi 722 441201 AW118822 Hs.128757 ESTs 7.21 419953 BE267154 Hs.125752 ESTs 7.20 419991 AJ000098 Hs.94210 eyes absent (Drosophila) homolog 1 720 425018 BE245277 Hs.154196 E4F transcription fador 1 720 424560 AA158727 Hs.150555 protein predided by done 23733 7.18 435380 AA679001 Hs.192221 ESTs 7.14 420658 AW965215 Hs.130707 ESTs 7.12 408291 AB023191 Hs.44131 KIAA0974 protein 7.10 409110 AA191493 Hs.48778 niban protein 7.10 414485 W27026 Hs.182625 VAMP (vesicle-associated membrane protei 7.10 430039 BE253012 Hs.153400 ESTs, Weakly similar to ALU1 HUMAN ALU S 7.10 450832 AW970602 Hs.105421 ESTs 7.10 417153 X57010 Hs.81343 collagen, type II, alpha 1 (primary oste 7.08 412446 AI768015 Hs.92127 ESTs 7.07 412953 Z45794 Hs.238809 ESTs 7.06 418051 AW192535 Hs.19479 ESTs 7.06 421566 NM_000399 Hs.1395 early growth response 2 (Krox-20 (Drosop 7.04 446999 AA151520 HS279525 hypothetical protein MGC4485 7.04 440529 AW207640 Hs.16478 Homo sapiens cDNA: FU21718 fis, done C 7.04 441111 AI806867 Hs.126594 ESTs 7.01 451027 AW519204 Hs.40808 ESTs 7.00 408432 AW195262 gb:xn67b05.x1 NCI_CGAP_CML1 Homo sapiens 7.00 432223 AA333283 Hs.285336 Homo sapiens, done IMAGE.3460280, mRNA 7.00 444805 AB007899 Hs.12017 homolog of yeast ubiquitin-protein ligas 6.99 414212 AA136569 HS295940 KIAA0187 gene product 6.98 431725 X65724 Hs2839 Nome disease (pseudoglioma) 6.98 449685 AW296669 Hs.66095 ESTs 6.97 447313 U92981 Hs.18081 Homo sapiens done DT1P1B6 mRNA, CAG rep 6.96 424590 AW966399 Hs.46821 hypothetical protein FU20086 6.94 449655 AI021987 Hs.59970 ESTs 6.92 419563 AA526235 Hs.193162 Homo sapiens cDNA FU11983 fis, done HE 6.90 434163 AW974720 HS25206 group XII secreted phospholipase A2 6.89 415809 Z32789 Hs.46601 ESTs 6.86 425782 U66468 Hs.159525 cell growth regulatory with EF-hand doma 6.85 417958 AA767382 Hs.193417 ESTs 6.84 427408 AA583206 Hs2156 RAR-related orphan receptor A 6.79 445873 AA250970 Hs251946 poly(A)-binding protein, cytoplasmic 1-1 6.74 410718 AI920783 Hs.191435 ESTs 6.74 432363 AA534489 gb:nf76g11.s1 NCLCGAP Co3 Homo sapiens 6.74 436521 AW203986 Hs.213003 ESTs 6.73 435604 AA625279 Hs.26892 uncharaderized bone marrow protein BM04 6.73 419083 AI479560 Hs.98613 Homo sapiens cDNA FU12292 fis, done MA 6.72 418245 AA088767 Hs.83883 transmembrane, prostate androgen induced 6.70 420714 BE172704 Hs.222746 KIAA1610 protein 6.70 412707 AW206373 Hs.16443 Homo sapiens cDNA: FU21721 fis, done C 6.67 421896 N62293 Hs.45107 ESTs 6.66 411078 AI222020 Hs.182364 CocoaCrisp 6.66 452465 AA610211 Hs.34244 ESTs 6.66 422763 AA033699 Hs.83938 ESTs, Moderately similar to MAS2_HUMAN M 6.66 444618 AV653785 Hs.300171 ELL-RELATED RNA POLYMERASE II, ELONGATIO 6.64 450164 AI239923 Hs.30098 ESTs 6.63 431060 AF039307 Hs.249171 homeo boxAH 6.62 408031 AA081395 Hs.42173 Homo sapiens cDNA FU10366 fis, done NT 6.62 420285 AA258124 Hs.293878 ESTs, Moderately similar to ZN91_HUMAN Z 6.62 444670 H58373 Hs.37494 hypothetical protein MGC5370 6.62 444489 AI151010 Hs.157774 ESTs 6.60 445685 AW779829 Hs.263436 gb:hn88a05.x1 NCI_CGAP_Kid11 Homo sapien 6.60 435677 AA694142 Hs.293726 ESTs, Weakly similar to TSGA RAT TESTIS 6.59 452221 C21322 Hs.11577 hypothetical protein FLJ22242 6.59 431510 AA580082 Hs.112264 ESTs 6.56 415874 AF091622 Hs.78893 KIAA0244 protein 6.54 418405 AI868282 Hs.11898 ESTs, Highly similar to KIAA1370 protein 6.54 452768 AW069459 Hs.61539 ESTs 6.54 401451 6.52 416289 W26333 ESTs 6.52 431778 AL080276 HS268562 regulator of G-protein signalling 17 6.51 409089 NM 014781 Hs.50421 KIAA0203 gene produd 6.50 442833 AA328153 Hs.88201 ESTs, Weakly similar to A Chain A, Cryst 6.50 431992 NM 002742 Hs.2891 protein kinase C, mu 6.49 418833 AW974899 Hs.292776 ESTs 6.48 429163 AA884766 gb:am20a10.s1 Soares_NFU GBC_S1 Homo s 6.46 430403 AF039390 Hs.241382 tumor necrosis fador (ligand) superfami 6.46 443058 AW451642 Hs.16732 ESTs 6.46 418564 AA631143 Hs.179809 Homo sapiens prostein mRNA, complete eds 6.44 432674 AA641092 HS257339 ESTs, Weakly similar to I38022 hypotheti 6.44 423600 AI633559 Hs.29076 ESTs 6.44 404253 6.42 433610 AA806822 Hs.112547 ESTs 6.42 421552 AF026692 Hs.105700 secreted frizzled-related protein 4 6.41 407118 AA156790 HS262036 ESTs, Weakly similar to Z223_HUMAN ZINC 6.40 408608 N79738 Hs.136102 KIAA0853 protein 6.40 421452 AI925946 Hs.104530 fetal hypothetical protein 6.40 433285 AW975944 Hs.237396 ESTs 6.40 434926 BE543269 Hs.50252 mitochondrial ribosomal protein L32 6.40 446189 H85224 Hs.214013 ESTs 6.40 416806 NM 000288 Hs.79993 peroxisomal biogenesis factor 7 6.38 416467 H57585 Hs.37467 ESTs 6.36 453403 BE466639 Hs.61779 Homo sapiens cDNA FU13591 fis, done PL 6.34 429769 NM 004917 Hs.218366 kallikrein 4 (prostase, enamel matrix, p 6.34 423642 AW452650 Hs.157148 hypothetical protein MGC13204 ' 6.32 425843 BE313280 Hs.159627 death associated protein 3 6.32 439221 AA737106 Hs.32250 ESTs, Moderately similar to 178885 serin 6.32 428194 AA765603 Hs.180877 H3 histone, family 3B (H3.3B) 6.30 431958 X63629 Hs.2877 cadherin 3, type 1 , P-cadherin (placenta 6.30 439366 AF100143 Hs.6540 fibroblast growth factor 13 6.30 452789 AW081626 Hs.242561 ESTs 6.30 416836 D54745 Hs.80247 cholecystokinin 6.30 436962 AW377314 Hs.5364 DKFZP564I052 protein 6.29 433383 AF034837 Hs.192731 double-stranded RNA specific adenosine d 6.29 418636 AW749855 gb:QV4-BT0534-281299-053-c05 BT0534 Homo 626 450728 AW162923 Hs.25363 presenilin 2 (Alzheimer disease 4) 625 440293 AI004193 Hs.22123 ESTs 624 453745 AA952989 Hs.63908 hypothetical protein MGC14726 624 426595 AW971980 Hs.62402 p21/Cdc42 Rac1-adivated kinase 1 (yeast 624 444412 AI147652 Hs.216381 Homo sapiens done HH409 unknown mRNA 624 413384 NM 000401 Hs.75334 exostoses (multiple) 2 622 426320 W47595 Hs.169300 transforming growth fador, beta 2 6.22 423349 AF010258 Hs.127428 homeo boxA9 6.20 429165 AWO09886 Hs.118258 prostate cancer associated protein 1 6.18 424800 AL035588 Hs.153203 MyoD family inhibitor 6.18 409564 AA045857 Hs.54943 fradure callus 1 (rat) homolog 6.16 438796 W67821 Hs.109590 genethonin 1 6.16 425451 AF242769 Hs.157461 mesenchymal stem cell protein DSC54 6.14 451663 AI872360 Hs.209293 ESTs 6.14 413623 AA825721 Hs.246973 ESTs 6.12 452232 AW020603 Hs.271698 radial spoke protein 3 6.12 453390 AA862496 Hs.28482 ESTs 6.12 435542 AA687376 Hs269533 ESTs 6.12 420424 AB033036 Hs.97594 KIAA1210 protein 6.11 407103 AA424881 Hs.256301 hypothetical protein MGC13170 6.10 409734 BE161664 Hs.56155 hypothetical protein 6.10 432686 BE223007 Hs.152460 Homo sapiens cDNA FU12909 fis, clone NT 6.10 438361 AA805666 Hs.1 6217 Homo sapiens cDNA: FU23077 fis, done L 6.10 411479 AW848047 gb:IL3-CT0214-291299-052-A12 CT0214 Homo 6.10 438849 W28948 Hs.10762 ESTs 6.08 452726 AF188527 Hs.61661 ESTs, Weakly similar to AF1746051 F-box 6.08 445895 D29954 Hs.13421 KIAA0056 protein 6.08 440774 AI420611 Hs.127832 ESTs 6.07 422583 AA410506 Hs.118578 KIAA0874 protein 6.06 427500 AW970017 Hs.293948 ESTs, Weakly similar to S65657 alpha-1C- 6.04 443646 AI085198 HS298699 ESTs 6.04 410566 AA373210 Hs.43047 Homo sapiens cDNA FU13585 fis, done PL 6.02 417845 AL117461 Hs.82719 Homo sapiens mRNA; cDNA DKFZp586F1822 (f 6.02 430273 AI311127 Hs.125522 ESTs 6.02 434792 AA649253 Hs.132458 ESTs 6.01 442490 AW965078 Hs.30212 thyroid receptor interacting protein 15 6.01 420026 AI831190 Hs.166676 ESTs 6.00 437782 AI370876 Hs.123163 exportin 1 (CRM1, yeast, homolog) 6.00 447359 NM 012093 Hs.18268 adenylate kinase 5 6.00 447713 AI420733 Hs.207083 ESTs 6.00 451073 AI758905 Hs206063 ESTs 6.00 451640 AA195601 Hs26771 Human DNA sequence from clone 747H23 on 6.00 410889 X91662 Hs.66744 twist (Drosophila) homolog (acrocephalos 5.97 441222 AI277237 Hs.44208 hypothetical protein FU23153 5.96 447732 AI758398 Hs.161318 ESTs 5.96 437756 AA767537 Hs.197096 ESTs 5.95 408829 NM 006042 Hs.48384 heparan sulfate (glucosamine) 3-θ-sulfot 5.94 453911 AW503857 Hs.4007 Sarcolemmal-assodated protein 5.94 414085 AA114016 Hs.75746 aldehyde dehydrogenase 1 family, member 5.93 408875 NM-015434 Hs.48604 DKFZP434B168 protein 5.92 439451 AF086270 HS278554 heterochromatin-like protein 1 5.92 423853 AB011537 Hs.133466 slit (Drosophila) homolog 1 5.91 453060 AW294092 Hs21594 hypothetical protein MGC15754 5.91 420407 AA814732 Hs.145010 lipopolysaccaride-spedfic response 5-li 5.91 450480 X82125 HS25040 zinc finger protein 239 5.90 408446 AW450669 Hs.45068 hypothetical protein DKFZp434H43 5.88 421039 NM 003478 Hs.101299 cullin 5 5.88 451684 AF216751 Hs26813 CDA14 5.88 436063 AK000028 Hs.250867 ribosomal protein S24 5.86 410507 AA355288 Hs271408 transitional epithelia response protein 5.86 420179 N74530 Hs21168 ESTs 5.84 453878 AW964440 Hs.19025 DC32 5.84 452270 AW975014 Hs.26 ferrochelatase (protoporphyria) 5.83 435867 AA954229 Hs.114052 ESTs 5.82 417683 AW566008 Hs.239154 ankyrin repeat, family A (RFXANK-like), 5.82 432005 AA524190 Hs.120777 ESTs, Weakly similar to ELL2_HUMAN RNA P 5.81 406815 AA833930 Hs.288036 tRNA isopentenylpyrophosphate transferas 5.80 437980 R50393 Hs278436 KIAA1474 protein 5.80 425856 AA364908 Hs.98927 hypothetical protein FU13993 5.79 400301 X03635 Hs.1657 estrogen receptor 1 5.78 446261 AA313893 Hs.13399 hypothetical protein FU12615 similar to 5.78 410141 R07775 Hs.287657 Homo sapiens cDNA: FU21291 fis, done C 5.77 427258 AA400091 Hs.39421 ESTs 5.76 419108 AA389724 Hs.191264 ESTs, Weakly similar to ALU7..HUMAN ALU S 5.76 442029 AW956698 Hs.14456 neural precursor cell expressed, develop 5.76 407783 AW996872 Hs.172028 a disintegrin and metalloproteinase doma 5.75 434408 AI031771 Hs.132586 ESTs 5.74 415077 L41607 Hs.934 glucosaminy! (N-acetyl) transferase 2, 1 5.74 432435 BE218886 Hs.282070 ESTs 5.74 433313 W20128 Hs.296039 ESTs 5.73 431740 N75450 Hs.183412 ESTs, Moderately similar to AF116721 67 5.73 412991 AW949013 gb:QV4-FT0005-110500-201-e12 FT0005 Homo 5.72 418852 BE537037 Hs.273294 hypothetical protein FU20069 5.72 418882 NM 004996 Hs.89433 ATP-binding cassette, sub-family C (CFTR 5.72 446867 AB007891 Hs.16349 KIAA0431 protein 5.72 437866 AA156781 Hs.83992 metallothionein 1E (fundional) 5.72 410232 AW372451 Hs.61184 CGI-79 protein 5.70 414452 AA454038 Hs.29032 ESTs 5.70 422762 AL031320 Hs.119976 Human DNA sequence from done RP1-20N2 o 5.70 428730 AA625947 HS25750 ESTs 5.70 431571 AW500486 Hs.180610 splicing factor proline/glutamine rich ( 5.70 433393 AF038564 Hs.98074 itchy (mouse homolog) E3 ubiquitin prote 5.70 450616 AL133067 Hs25214 hypothetical protein 5.70 443774 AL117428 Hs.9740 DKFZP434A236 protein 5.69 446100 AW967109 Hs.13804 hypothetical protein dJ4620232 5.69 419168 AI336132 Hs.33718 Homo sapiens cDNA FU12641 fis, clone NT 5.68 416653 AA768553 Hs.77496 metallothionein 1E (functional) 5.67 452679 Z42387 Hs.4299 transmembrane, prostate androgen induced 5.66 450244 AA007534 Hs.125062 ESTs 5.66 408621 AI970672 Hs.46638 chromosome 11 open reading frame 8 5.65 450325 AI935962 Hs.26289 ESTs 5.65 439671 AW162840 Hs.6641 kinesin family member 5C 5.64 452387 AI680772 Hs.4316 trinucleotide repeat containing 12 5.64 413992 W26276 Hs.136075 RNA, U2 small nudear 5.63 444151 AW972917 Hs.128749 alpha-methylacyl-CoA racemase 5.63 417791 AW965339 Hs.111471 ESTs 5.62 410196 AI936442 Hs.59838 hypothetical protein FU10808 5.60 415123 D60925 ESTs 5.60 429170 NM 001394 Hs.2359 dual specificity phosphatase 4 5.60 434415 BE177494 gb:RC6-HT0596-27030O-011-C05 HT0596 Homo 5.60 440738 AI004650 Hs.225674 WD repeat domain 9 5.60 443830 AI142095 Hs.143273 ESTs 5.60 449603 AI655662 Hs.197698 ESTs 5.60 414342 AA742181 Hs.75912 KIAA0257 protein 5.59 422634 NM 016010 Hs.118821 CGI-62 protein 5.56 435047 AA454985 Hs.54973 cadherin-like protein VR20 5.55 400268 5.55 452055 AI377431 HS293772 hypothetical protein MGC10858 5.54 437073 AI885608 Hs.94122 ESTs 5.54 434072 H70854 Hs283059 Homo sapiens PRO1082 mRNA, complete eds 5.53 418339 AA639902 Hs.104215 ESTs, Moderately similar to SPCN .HUMAN S 5.52 434551 BE387162 HS280858 ESTs, Highly similar to A35661 DNA exds 5.52 439569 AW602166 Hs222399 CEGP1 protein 5.51 441102 AA973905 Hs.16003 intermediate filament protein syncoilin 5.50 448310 AI480316 gb:tm26h09.x1 Soares NFUJ_GBC S1 Homo s 5.50 413173 BE076928 Hs.70980 ESTs 5.48 436246 AW450963 Hs.119991 ESTs 5.48 449300 AI656959 Hs.222165 ESTs 5.48 452823 AB012124 Hs.30696 transcription fador-like 5 (basic helix 5.48 451403 AA885569 Hs.15727 Homo sapiens cDNA FLJ14511 fis, done NT 5.46 417061 AI675944 Hs.188691 Homo sapiens cDNA FU12033 fis, clone HE 5.44 429126 AW172356 Hs.99083 ESTs 5.44 431316 AA502663 Hs.145037 ESTs 5.44 439192 AW970536 Hs.105413 ESTs 5.44 431938 AA938471 Hs.115242 specific granule protein (28 kDa); cystβ 5.44 451552 AA047233 Hs.33810 ESTs 5.43 416991 N36389 Hs295091 KIAA0226 gene product 5.42 427638 AA406411 Hs.208341 ESTs, Weakly similar to KIAA0989 protein 5.42 427718 AI798680 Hs.25933 ESTs 5.42 438710 AA833907 Hs.178724 ESTs, Weakly similar to ALU1_HUMAN ALU S 5.42 406076 AI-390179 Hs.137011 Homo sapiens mRNA; cDNA DKFZp547P134 (fr 5.40 431263 AW129203 Hs.13743 ESTs 5.40 421264 AL039123 Hs.103042 microtubule-assodated protein 1B 5.38 421685 AF189723 Hs.106778 ATPase, Ca++ transporting, type 2C, memb 5.37 408460 AA054726 Hs.285574 ESTs 5.36 409091 AW970386 Hs.269423 ESTs 5.36 421987 AI133161 HS286131 CGI-101 protein 5.36 428002 AA418703 gb:zv98c03.s1 Soares NhHMPu_S1 Homo sapi 5.36 441217 AI922183 Hs213246 ESTs 5.36 426006 R49031 Hs.22627 ESTs 5.35 422806 BE314767 Hs.1581 glutathione S-transferase theta 2 5.34 432281 AK001239 HS274263 hypothetical protein FU10377 5.32 451982 F13036 Hs.27373 Homo sapiens mRNA; cDNA DKFZp56401763 (f 5.32 421129 BE439899 Hs.89271 ESTs 5.31 444042 NM 004915 Hs.10237 ATP-binding cassette, sub-family G (WHIT 5.31 410150 AW382942 Hs.6774 ESTs 5.30 423952 AW877787 Hs.136102 KIAA0853 protein 5.30 452822 X85689 Hs.288617 hypothetical protein FU22621 5.30 447752 M73700 Hs.347 lactotraπsferrin 5.29 441766 R53790 Hs.23294 hypothetical protein FU14393 529 431359 AW993522 Hs292934 ESTs 5.27 427212 AW293849 Hs.58279 ESTs, Weakly similar to ALU7_HUMAN ALU S 527 449916 T60525 HS299221 pyruvate dehydrogenase kinase, isoenzyme 527 454014 AW016670 HS233275 ESTs 527 419714 AA758751 Hs.98216 ESTs 5.26 428845 AL157579 Hs.153610 KIAA0751 gene produd 526 417333 AL157545 Hs.42179 bromodomain and PHD finger containing, 3 5.24 419986 AI345455 Hs.78915 GA-binding protein transcription fador, 524 407182 AA312551 Hs.230157 ESTs 5.22 420111 AA255652 gb:zs21h11.r1 NCI CGAP GCB1 Homo sapiens 522 428058 AI821625 Hs.191602 ESTs 5.22 459551 AI472808 gb:tj70e07.x1 Soares NSF F8 9W OT_PA P S 5.22 432524 AI458020 HS293287 ESTs 5.22 436207 AA334774 Hs.12845 hypothetical protein MGC13159 5.22 410870 U81599 Hs.66731 homeo box B13 5.22 451418 BE387790 Hs.26369 hypothetical protein FLJ20287 5.22 409757 NM 001898 Hs.123114 cystatin SN 521 441124 T97717 Hs.119563 ESTs 5.21 428593 AW207440 Hs.185973 degenerative spermatocyte (homolog Droso 5.21 436401 AI087958 Hs29088 ESTs 5.20 437113 AA744693 gb:ny26c10.s1 NCI CGAP GCB1 Homo sapiens 5.20 450947 AI745400 HS204662 ESTs 520 453279 AW893940 Hs.59698 ESTs 520 445467 AI239832 Hs.15617 ESTs, Weakly similar to ALU4_HUMAN ALU S 5.19 448944 AB014605 HS22599 atrophin-1 interacting protein 1; activi 5.19 412198 AA937111 Hs.69165 ESTs 5.18 422646 H87863 Hs.151380 ESTs, Weakly similar to T16584 hypotheti 5.18 438986 AF085888 HS269307 ESTs 5.18 453954 AW118336 Hs.75251 DEAD/H (Asp-Glu-Ala-Asp/His) box binding 5.18 447541 AK000288 Hs.18800 hypothetical protein FU20281 5.18 434029 AA621763 Hs.170434 Homo sapiens cDNA FU14242 fis, done OV 5.16 459294 AW977286 Hs.169531 RBP1 -like protein 5.16 429441 AJ224172 HS204096 lipophilin B (uteroglobin family member) 5.16 424692 AA429834 Hs.151791 KIAA0092 gene produd 5.15 427359 AW020782 Hs.79881 Homo sapiens cDNA: FU23006 fis, done L 5.15 419872 AI422951 Hs.146162 ESTs 5.15 429422 AK001494 HS202596 Homo sapiens cDNA FU10632 fis, done NT * 5.14 448902 Z45998 HS22543 Homo sapiens mRNA; cDNA DKFZp761I1912 (f 5.14 459055 N23235 Hs.30567 ESTs, Weakly similar to B34087 hypotheti 5.14 431318 AA502700 HS293147 ESTs, Moderately similar to A46010 X-lin 5.14 452953 AI932884 HS271741 ESTs, Weakly similar to A46010 X-linked 5.13 428372 AK000684 Hs.183887 hypothetical protein FU22104 5.12 434401 AI864131 Hs.71119 Putative prostate cancer tumor suppresso 5.12 416434 AW163045 Hs.79334 nudear fador, interieukin 3 regulated 5.11 410268 AA316181 Hs.61635 six transmembrane epithelial antigen of 5.10 417517 AF001176 Hs.82238 POP4 (processing of precursor , S. cerev 5.10 453616 NM 003462 Hs.33846 dynein, axone al, light intermediate pol 5.10 427958 AA418000 Hs.98280 potassium intermediate/small conductance 5.09 407945 X69208 Hs.606 ATPase, Cu++ transporting, alpha polypep 5.08 425154 NM 001851 Hs.154850 collagen, type IX, alpha 1 5.08 412863 AA121673 Hs.59757 zinc finger protein 281 5.06 420807 AA280627 Hs.57846 ESTs 5.06 430568 AA769221 HS270847 delta-tubulin 5.06 433687 AA743991 gb:ny57g01.s1 NCI_CGAP_Pr18 Homo sapiens 5.06 438375 AW015940 Hs.232234 ESTs 5.06 418092 R45154 Hs.106604 ESTs 5.06 418576 AW968159 Hs.289104 Alu-binding protein with zinc finger dom 5.05 413328 Y15723 Hs.75295 guanylate cyclase 1 , soluble, alpha 3 5.04 414271 AK000275 Hs.75871 protein kinase C binding protein 1 5.04 432729 AK000292 Hs.278732 hypothetical protein FU20285 5.04 433433 AI692623 Hs.121513 Homo sapiens clone Z3-1 placenta expres 5.04 439662 H97552 HS269060 ESTs 5.04 439743 AL389956 Hs.283858 Homo sapiens mRNA full length insert cDN 5.04 417511 AL049176 Hs.82223 chordin-like 5.02 437814 AI088192 Hs.135474 ESTs, Weakly similar to DDX9_HUMAN ATP-D 5.02 426342 AF093419 Hs.169378 multiple PDZ domain protein 5.02 429782 NM 005754 Hs220689 Ras-GTPase-activating protein SH3-domain 5.02 429975 AI167145 Hs.165538 ESTs 5.02 436209 AW850417 Hs.254020 ESTs, Moderately similar to unnamed prot 5.02 438571 AW020775 Hs.56022 ESTs 5.02 450223 AA418204 Hs241493 natural killer-tumor recognition sequenc 5.02 408267 AW380525 HS267705 tubulin-spedfic chaperone e 5.01 417730 Z44761 gb:HSC28F061 normalized infant brain cDN 5.00 425465 L18964 Hs.1904 protein kinase C, iota 5.00 430599 NM 004855 Hs.247118 phosphatidylinositol glycan, dass B 5.00 450961 AW978813 Hs.250867 metallothionein 1 E (functional) 5.00 451386 AB029006 Hs.26334 spastic paraplegia 4 (autosomal dominant 5.00 420380 AA640891 Hs.102406 ESTs 4.99 424947 R77952 Hs.239625 ESTs, Weakly similar to alternatively sp 4.99 442653 BE269247 Hs.170226 gb:601185486F1 NIH_MGC_8 Homo sapiens cD 4.98 457211 AW972565 Hs.32399 ESTs, Weakly similar to S51797 vasodilat 4.97 425851 NM 001490 Hs.159642 glucosaminyl (N-acetyl) transferase 1 , c 4.97 446279 AA490770 Hs.182382 ESTs 4.96 433377 AI752713 Hs.43845 ESTs 4.96 450218 R02018 Hs.168640 ankylosis, progressive (mouse) homolog 4.96 412715 NM 000947 Hs.74519 primase, polypeptide 2A (58kD) 4.94 448164 R61680 Hs26904 ESTs, Moderately similar to Z195_HUMAN Z 4.94 420121 AW968271 Hs.191534 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.94 421689 N87820 Hs.106826 KIAA1696 protein 4.93 445808 AV655234 Hs298083 ESTs, Moderately similar to PC4259 ferri 4.92 416533 BE244053 Hs.79362 retinoblastoma-like 2 (p130) 4.92 418049 AA211467 Hs.190488 Homo sapiens, Similar to nudear localiz 4.92 436039 AW023323 Hs.121070 ESTs 4.92 432653 N62096 Hs293185 ESTs, Weakly similar to JC7328 amino ad 4.91 420324 AF163474 Hs.96744 prostate androgen-regulated transcript 1 4.91 403047 4.91 436899 AA764852 HS291567 ESTs 4.90 431117 AF0O3522 HS250500 delta (Drosophila)-like 1 4.90 427617 D42063 Hs.179825 RAN binding protein 2 4.88 428804 AK000713 Hs.193736 hypothetical protein FU20706 4.88 433050 AI093930 Hs.163440 Homo sapiens cDNA: FU21000 fis, clone C 4.88 418575 AA225313 Hs222886 ESTs, Weakly similar to TRHY_HUMAN TRICH 4.86 432615 AA557191 Hs.55028 ESTs, Weakly similar to I54374 gene NF2 4.86 412652 AI801777 Hs.6774 ESTs 4.86 432473 AI202703 Hs.152414 ESTs 4.86 449071 NM 005872 Hs.22960 breast cardnoma amplified sequence 2 - 4.86 450654 AJ245587 Hs.25275 Kruppel-type zinc finger protein 4.85 418866 T65754 Hs.100489 gb:yd 1 c07.s1 Stratagene lung (937210) H 4.85 407596 R86913 gb:yq30f05.r1 Soares fetal liver spleen 4.84 456516 BE172704 Hs.222746 KIAA1610 protein 4.84 426501 AW043782 Hs.293616 ESTs 4.84 448730 AB032983 Hs21894 KIAA1157 protein 4.84 458339 AW976853 Hs.172843 ESTs 4.83 422083 NM 001141 Hs.111256 arachidonate 15-lipoxygenase, second typ 4.82 420159 AI572490 Hs.99785 Homo sapiens cDNA: FU21245 fis, done C 4.82 424103 NM 001918 Hs.139410 dihydrolipoamide branched chain transacy 4.82 449535 W15267 HS23672 low density lipoprotein receptor-related 4.82 422048 NM 012445 HS288126 spondin 2, extracellular matrix protein 4.82 416737 AF154335 Hs.79691 LIM domain protein 4.82 419972 AL041465 Hs.294038 golgin-67 4.81 420235 AA256756 Hs.31178 ESTs 4.81 423412 AF109300 Hs.147924 prostate cancer associated protein 5 4.80 429598 AA811257 Hs.269710 ESTs 4.80 457114 AI821625 Hs.191602 ESTs 4.80 421828 AW891965 Hs.289109 histone deacetylase 3 4.79 424602 AK002055 Hs.301129 hypothetical protein FU11193 4.78 428364 AA426565 Hs.160541 ESTs, Moderately similar to ALU1_HUMAN A 4.78 452335 AW188944 Hs.61272 ESTs 4.78 410765 AI694972 Hs.66180 nucleosome assembly protein 1-like 2 4.77 421040 AA715026 Hs.135280 ESTs 4.76 421518 AI056392 Hs.208819 ESTs 4.76 452560 BE077084 ESTs 4.76 409752 AW963990 gb:EST376063 MAGE resequences, MAGH Homo 4.75 439703 AF086538 Hs.196245 ESTs 4.75 418836 AI655499 Hs.161712 ESTs 4.74 450642 R39773 Hs.7130 copine IV 4.74 419879 Z17805 Hs.93564 Homer, neuronal immediate early gene, 2 4.74 411440 AW749402 gb:QV4-BT0383-281299-061 -c06 BT0383 Homo 4.74 450649 NM 001429 HS297722 E1 A binding protein p300 4.74 408738 NM 014785 Hs.47313 KIAA0258 gene produd 4.73 435020 AW505076 Hs.301855 DiGeorge syndrome critical region gene 8 4.72 411624 BE145964 KIAA0594 protein 4.72 439360 AA448488 Hs.55346 ribosomal protein L44 4.72 440491 R35252 Hs.24944 ESTs, Weakly similar to 2109260A B cell 4.72 442611 BE077155 Hs.177537 hypothetical protein DKFZp761B1514 4.72 443555 N71710 Hs.21398 ESTs, Moderately similar to A Chain A, H 4.72 453800 BE300741 Hs.288416 hypothetical protein FU13340 4.72 457528 AW973791 Hs.292784 ESTs 4.72 416795 AI497778 Hs.168053 HBV pX assodated protein-8 4.71 407302 R74206 Hs.268755 ESTs, Weakly similar to I78885 serine/th 4.71 404721 4.70 426261 AW242243 Hs.168670 peroxisomaifamesylated protein 4.70 431924 AK000850 HS272203 Homo sapiens cDNA FU20843 fis, done AD 4.70 435256 AF193766 Hs.13872 cytokine-like protein C17 4.70 438295 AI394151 Hs.37932 ESTs 4.70 442655 AW027457 Hs.30323 ESTs, Weakly similar to B34087 hypotheti 4.70 415788 AW628686 Hs.78851 KIAA0217 protein 4.69 442760 BE075297 Hs.10067 ESTs, Weakly similar to A43932 mudn 2 p 4.69 432432 AA541323 Hs.115831 ESTs 4.68 454398 AA463437 Hs.11556 Homo sapiens cDNA FU12566 fis, done NT 4.68 452741 BE392914 Hs.30503 Homo sapiens CDNA FU11344 fis, done PL 4.67 424853 BE549737 Hs.132967 Human EST done 122887 mariner transposo 4.67 419706 C04649 Hs.77899 tropomyosin 1 (alpha) 4.66 412088 AI689496 Hs.108932 ESTs 4.65 416276 U41060 Hs.79136 LIV-1 protein, estrogen regulated 4.64 429281 AA830856 HS29808 Homo sapiens cDNA: FU21122 fis, done C 4.64 448207 AI475490 Hs.170577 ESTs 4.64 408374 AW025430 Hs.155591 forkhead bo FI 4.64 447162 BE328091 Hs.157396 ESTs, WeaWy similar to A46010 X-linked 4.64 451900 AB023199 HS27207 KIAA0982 protein 4.63 421437 AW821252 Hs.104336 hypothetical protein 4.63 418624 AI734080 Hs.104211 ESTs 4.63 426172 AA371307 Hs.125056 ESTs 4.62 439831 AW136488 HS25545 ESTs 4.61 452994 AW962597 Hs.31305 KIAA1547 protein - 4.61 457726 AI217477 Hs.194591 ESTs 4.60 434629 AA789081 Hs.4029 glioma-amplified sequence-41 4.60 403764 4.58 410659 AI080175 Hs.68826 ESTs 4.58 432383 AK000144 Hs.274449 Homo sapiens cDNA FL.20137 fis, done CO 4.58 451246 AW189232 Hs.39140 cutaneous T-cell lymphoma tumor antigen 4.58 433234 AB040928 Hs.65366 KIAA1495 protein 4.57 424983 AI742434 Hs.169911 ESTs 4.56 437812 AI582291 Hs.16846 ESTs, Weakly similar to 04HUD1 debrisoqu 4.56 438447 AI082883 Hs.167593 hypothetical protein FU13409; KIAA1711 4.55 434715 BE005346 Hs.116410 ESTs 4.55 447673 AI823987 Hs.182285 ESTs 4.54 408897 N50204 HS283709 lipopolysaccharide specific response-7 p 4.54 436645 AW023424 Hs.156520 ESTs 4.54 421247 BE391727 Hs.102910 general transcription fador IIH, polype 4.53 450377 AB033091 HS24936 KIAA1265 protein 4.53 433644 AW342028 Hs-256112 gb:hb75d03.x1 NCI_CGAP_Ut2 Homo sapiens 4.53 408321 AW405882 Hs.44205 cortistatin 4.53 439225 AA192669 Hs.45032 ESTs 4.52 440348 AW015802 Hs.47023 ESTs 4.52 446351 AW444551 Hs.258532 x 001 protein 4.52 451212 AW902672 Hs.287334 ESTs 4.52 430294 AI538226 Hs.135184 guanine nucleotide binding protein 4 4.52 435005 U80743 Hs.4316 trinucleotWe repeat containing 12 4.52 448072 AI459306 Hs.24908 ESTs 4.50 403721 4.50 451018 AW965599 Hs.247324 mitochondrial ribosomal protein S14 4.50 453070 AK001455 Hs.31575 SEC63, endoplasmic reticulum translocon 4.49 417412 X16896 Hs.82112 interieukin 1 receptor, type I 4.48 439735 AI635386 Hs.142846 hypothetical protein 4.48 435663 AI023707 Hs.134273 ESTs 4.48 424036 AA770688 Hs.81946 H2A histone family, member L 4.48 426386 AA748850 Hs.174877 bladder cancer overexpressed protein 4.48 408622 AA056060 HS202577 Homo sapiens cDNA FU12166 fis, done MA 4.47 444269 AI590346 Hs.146220 ESTs 4.47 430187 AI799909 Hs.158989 ESTs 4.46 427761 AA412205 Hs.140996 ESTs 4.46 430261 AA305127 HS237225 hypothetical protein HT023 4.46 444169 AV648170 Hs.58756 ESTs 4.44 430598 AK001764 HS247112 hypothetical protein FU10902 4.44 412903 BE007967 Hs.155795 ESTs 4.44 417048 AI088775 Hs.55498 geranyigeranyl diphosphate synthase 1 4.44 442710 AI015631 HS23210 ESTs 4.44 457413 AA743462 Hs.165337 ESTs 4.44 400303 AA242758 Hs.79136 LIV-1 protein, estrogen regulated 4.42 443268 AI800271 Hs.129445 hypothetical protein FU12496 4.42 438209 AL120659 Hs.6111 ai l-hydrocaibon receptor nuclear transl 4.42 431724 AA514535 Hs283704 ESTs 4.41 412280 AW205116 Hs.272814 hypothetical protein DKFZp434E1723 4.40 440801 AA906366 Hs.190535 ESTs 4.40 452959 AI933416 Hs.189674 ESTs 4.40 453861 AI026838 Hs.30120 ESTs, Weakly similar to NUCL_HUMAN NUCLE 4.40 417421 AL138201 Hs.82120 nuclear receptor subfamily 4, group A, m 4.40 447270 AC002551 Hs.331 general transcription fador IIIC, polyp 4.38 433641 AF080229 gb:Human endogenous retrovirus K done 1 4.38 447078 AW885727 Hs.301570 ESTs 4.38 424242 AA337476 hypothetical protein MGC13102 4.37 408170 AW204516 Hs.31835 ESTs 4.36 448757 AI366784 Hs.48820 TATA box binding protein (TBP)-associate , 4.36 420021 AA252848 HS293557 ESTs 4.36 449694 AI659790 Hs.253302 ESTs 4.36 453867 AI929383 Hs.108196 hypothetical protein DKFZp434N185 4.36 458712 AI347502 Hs.173066 hypothetical protein FU20761 4.36 417251 AW015242 Hs.99488 ESTs, Weakly similar to YK54_YEAST HYPOT 4.35 434423 NM_006769 Hs.3844 LIM domain only 4 4.35 423427 AL137612 Hs.285848 KIAA1454 protein 4.34 415715 F30364 ESTs 4.33 404561 4.32 422969 AA782536 Hs.122647 N-myristoyltransferase 2 4.32 423685 BE350494 Hs.49753 uveal autoantigen with coiled coil domai 4.32 443977 AL120986 Hs.150627 ESTs, Weakly similar to I38022 hypotheti 4.32 425071 NM 013989 Hs.154424 deiodinase, iodothyronine, type II 4.32 431583 AL042613 HS262476 S-adenosylmethionine decaiboxylase 1 4.31 411379 AI816344 Hs.12554 ESTs, Weakly similar to NPL4 HUMAN NUCLE 4.30 421476 AW953805 Hs21887 ESTs 4.30 425178 H16097 Hs.161027 ESTs 4.30 439262 AA832333 Hs.124399 ESTs 4.30 442818 AK001741 Hs.8739 hypothetical protein FU10879 4.30 421977 W94197 Hs.110165 ribosomal protein 126 homobg 429 437114 AA836641 Hs.163085 ESTs 4.28 420195 N44348 Hs.300794 Homo sapiens cDNA FU11177 fis, done PL 428 418330 BE409405 Hs.94722 ESTs 427 419750 AL079741 Hs.183114 Homo sapiens cDNA FU14236 fis, done NT 426 437065 AL036450 Hs.103238 ESTs 426 455276 BE176479 gb:RC3-HT0585-160300-022-b09 HT0585 Homo 424 416292 AA179233 Hs.42390 nasopharyngeal cardnoma susceptibility 424 423740 Y07701 Hs.132243 aminopeptidase puromydn sensitive 4.24 442023 AI187878 Hs.144549 ESTs 4.24 426764 AA732524 Hs.151464 ESTs, Weakly similar to ALUCJHUMAN III! 423 454058 AI273419 Hs.135146 hypothetical protein FLJ13984 423 456511 AA282330 Hs.145668 ESTs 422 448330 AL036449 Hs207163 ESTs 422 424701 NM 005923 Hs.151988 mitogen-activatθd protein kinase kinase 421 432621 AI298501 Hs.12807 ESTs, Weakly similar to T46428 hypotheti 420 445707 AI248720 Hs.114390 ESTs 420 419910 AA662913 Hs.190173 ESTs, Weakly similar to A46010 X-linked 420 424085 NM 002914 Hs.139226 replication fador C (activator 1) 2 (40 4.20 440749 W22335 Hs.7392 hypothetical protein MGC3199 4.20 442787 W93048 Hs.227203 hypothetical protein MGC2747 420 443414 R54594 HS25209 ESTs 420 443556 AA256769 Hs.94949 methylmalonyl-CoA epimerase 4.20 444170 AW613879 Hs.102408 ESTs 420 446751 AA766998 Hs.85874 Human DNA sequence from clone RP11-16L21 420 421041 N36914 Hs.14691 ESTs, Moderately similar to I38022 hypot 4.19 447476 BE293466 HS20880 ESTs, Weakly similar to I38022 hypotheti 4.19 448543 AW897741 HS21380 Homo sapiens mRNA; cDNA DKFZp586P1124 (f 4.18 410294 AB014515 HS288891 KIAA0615 gene produd 4.18 433607 AA602004 HS23260 ESTs 4.18 435552 AI668636 Hs.193480 ESTs, Moderately similar to ALU6_HUMAN A 4.18 447124 AW976438 Hs.17428 RBPMike protein 4.18 453308 AW959731 Hs.32538 ESTs 4.17 439328 W07411 Hs.118212 ESTs, Moderately similar to ALU3 HUMAN A 4.16 430473 AW130690 HS299842 ESTs 4.16 437257 AI283085 HS290931 ESTs, Weakly similar to YFJ7_YEAST HYPOT 4.16 438018 AK001160 Hs.5999 hypothetical protein FU10298 4.16 443857 AI089292 Hs287621 hypothetical protein FU14069 4.15 446711 AF169692 Hs.12450 protocadherin 9 4.15 419103 Z40229 Hs.96423 hypothetical protein FU23033 4.14 405403 4.14 407378 AA299264 ESTs, Moderately similar to I38022 hypot 4.14 408986 AW298602 Hs.197687 ESTs 4.14 418727 AA227609 Hs.94834 ESTs 4.14 434400 AI478211 Hs.186896 Homo sapiens cDNA FU11417 fis, done HE 4.14 438578 AA811244 Hs.164168 ESTs 4.14 450459 AI697193 HS299254 Homo sapiens cDNA: FU23597 fis, done L 4.14 429887 AW366286 Hs.145696 splidng fador(CC1.3) 4.13 448148 NM_016578 Hs20509 HBV pX assodated protein-8 4.13 450316 W84446 Hs.17850 hypothetical protein MGC4643 4.12 417531 NM_003157 Hs.1087 serine/threonine kinase 2 4.12 431592 R69016 HS293871 hypothetical protein MGC10895s 4.12 432463 AA548518 Hs.186733 ESTs 4.12 433613 AA836126 Hs.5669 ESTs 4.12 434739 AA804487 Hs.144130 ESTs 4.12 438259 AW205969 Hs.131808 ESTs 4.12 425810 AI923627 Hs.31903 ESTs 4.10 432672 AW973775 Hs.130760 myosin phosphatase, target subunit 2 4.10 433345 AI681545 Hs.152982 hypothetical protein FU13117 4.10 432712 AB016247 HS288031 sterol-C5-desaturase (fungal ERG3, delta 4.09 453020 AL162039 Hs.31422 Homo sapiens mRNA; cDNA DKFZp434M229 (fr 4.09 412045 AA099802 Hs.4299 transmembrane, prostate androgen induced 4.09 435114 AA775483 Hs288936 mitochondrial ribosomal protein L9 4.08 443204 AW205878 Hs29643 Homo sapiens cDNA FLJ13103 fis, done NT 4.08 445459 AI478629 Hs.158465 likely ortholog of mouse putative IKK re 4.08 438938 H46212 Hs.137221 ESTs 4.07 454119 BE549773 Hs.40510 uncoupling protein 4 4.06 411000 N40449 HS201619 ESTs, Weakly similar to S38383 SEB4B pro 4.06 418926 AA232658 Hs.87070 UDP-glucose.glycoprotein glucosyltransfe 4.06 424432 AB037821 Hs.146858 protocadherin 10 4.06 449673 AA002064 Hs.18920 ESTs 4.06 429299 AI620463 Hs.99197 hypothetical protein MGC13102 4.06 422174 AL049325 Hs.112493 Homo sapiens mRNA; cDNA DKFZp564D036 (fr 4.05 455497 AA112573 HS285691 Homo sapiens prostein mRNA, complete eds 4.05 415138 C18356 Hs.78045 tissue fador pathway inhibitor 2 4.04 402791 4.04 426792 AL044854 Hs.172329 KIAA0576 protein 4.04 438660 U95740 Hs.6349 Homo sapiens, done IMAGE.3010666, mRNA, 4.04 442768 AL048534 Hs.48458 ESTs, Weakly similar to ALU8_HUMAN ALU S 4.04 447568 AF155655 Hs.18885 CGI-116 protein 4.04 428342 AI739168 Hs.131798 Homo sapiens CDNA FU13458 fis, done PL 4.04 453439 AI572438 Hs.32976 guanine nucleotide binding protein 4 4.02 453857 AL080235 Hs.35861 DKFZP586E1621 protein 4.02 428249 AA130914 Hs.183291 zinc finger protein 268 4.02 432015 AL157504 Hs.159115 Homo sapiens mRNA; cDNA DKFZp586O0724 (f 4.02 445495 BE622641 Hs.38489 ESTs, Weakly similar to 138022 hypotheti 4.02 451746 M86178 ESTs 4.02 452211 AI985513 Hs.233420 ESTs 4.02 453046 AA284040 HS219441 ESTs, Highly similar to CA5B_HUMAN CARBO 4.02 456038 AA203285 Hs.294141 ESTs, Weakly similar to alternatively sp 4.02 452449 AW068658 HS20943 ESTs 4.02 407204 R41933 Hs.140237 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.01 428046 AW812795 Hs.155381 ESTs, Moderately similar to I38022 hypot 4.01 438520 AA706319 Hs.98416 ESTs 4.01 443292 AK000213 Hs.9196 hypothetical protein 4.01 432715 AA247152 Hs.200483 ESTs, Weakly similar to KIAA1074 protein 4.00 403797 4.00 418347 AA216419 Hs.269295 gb:nc16e03.s1 NCI_CGAP_Pr1 Homo sapiens 4.00 419459 AW291128 Hs.278422 DKFZP586G1122 protein 4.00 420911 U77413 Hs.100293 O-linked N-acetylglucosamine (GlcNAc) tr 4.00 425176 AW015644 Hs.301430 TEA domain family member 1 (SV40 transcr 4.00 447505 AL049266 Hs.18724 Homo sapiens mRNA; cDNA DKFZp564F093 (fr 4.00 453773 AL133761 gb:DKFZp761C1413_r1 761 (synonym: hamy2) 4.00 434384 AA631910 Hs.162849 ESTs 3.99 422471 AA311027 Hs.271894 ESTs, Weakly similar to I38022 hypotheti 3.99 427386 AW836261 Hs.177486 ESTs 3.98 433394 AI907753 Hs.93810 cerebral cavernous malformations 1 3.98 441269 AW015206 Hs.178784 ESTs 3.97 419629 AB020695 Hs.91662 KIAA0888 protein 3.96 435008 AF150262 Hs.162898 ESTs 3.96 456649 R74441 Hs.117176 po!y(A)-binding protein, nudear 1 3.96 418723 AA504428 Hs.10487 Homo sapiens, done IMAGE-3954132, mRNA, 3.96 428738 NM 000380 Hs.192803 xeroderma pigmentosum, complementation g 3.95 430456 AA314998 Hs.241503 hypothetical protein 3.95 422017 NM 003877 Hs.110776 STAT induced STAT inhibitor-2 3.95 409960 BE261944 Hs.153028 hexoklnase 1 3.95 455309 AW894017 gb:RC4-NN0027-150400-012-g04 NN0027 Homo 3.95 450295 AI766732 Hs.201194 ESTs 3.94 456660 AA909249 Hs.112282 solute carrier family 30 (zinc transport 3.94 410908 AA121686 Hs.10592 ESTs 3.94 447145 AA761073 Hs.192943 TRAF family member-assodated NFKB activ 3.94 449318 AW236021 Hs.108788 Homo sapiens, Similar to RIKEN cDNA 5730 3.94 449869 W57990 Hs.60059 Homo sapiens cDNA FU11478 fis, done HE 3.94 411887 AW182924 Hs.128790 ESTs 3.93 437531 AI400752 Hs.112259 T cell receptor gamma locus 3.93 452238 F01811 Hs.187931 ESTs 3.93 410486 AW235094 Hs.193424 zinc finger protein 3.92 424882 AI379461 Hs.153636 far upstream element (FUSE) binding prot 3.92 426269 H15302 Hs.168950 Homo sapiens mRNA; cDNA DKFZp566A1046 (f- 3.92 427043 AA397679 Hs.298460 ESTs 3.92 440404 AI015881 Hs.125616 mitochondrial ribosomal protein S5 3.92 452762 AW501435 Hs.171409 v-akt urine thymoma viral oncogene homo 3.92 453058 AW612293 Hs.288684 Homo sapiens cDNA FU11750 fis, clone HE 3.92 423583 AL122055 Hs.129836 KIAA1028 protein 3.92 408001 AA046458 Hs.95296 ESTs 392 419197 N48921 HS27441 KIAA1615 protein 3.91 428695 AI355647 Hs.189999 purinergic receptor (family A group 5) 3.91 401747 3.91 410011 AB020641 Hs.57856 PFTAIRE protein kinase 1 3.91 432205 AI806583 Hs.125291 ESTs 3.91 447857 AA081218 Hs.58608 Homo sapiens cDNA FU14206 fis, done NT 3.91 446494 AA463276 Hs.288906 WW Domain-Containing Gene 3.91 409928 AL137163 Hs.57549 hypothetical protein dJ473B4 3.90 411598 BE336654 Hs.70937 H3 histone family, member A 3.90 424790 AL119344 Hs.13326 ESTs, Weakly similar to 2004399A chromos 3.90 425707 AF115402 Hs.11713 E74-like fador 5 (ets domain transcript 3.90 431325 AW026751 Hs.5794 ESTs, Weakly similar to 2109260A B cell 3.89 451806 NM_003729 Hs.27076 RNA 3'-terminal phosphate cyclase 3.89 401045 3.89 433023 AW864793 Hs.34161 thrombospondin 1 3.89 452160 BE378541 Hs.279815 cysteine sulfinic acid decarboxylase-rel 3.89 437372 AA323968 Hs.283631 hypothetical protein DKFZp547G183 3.89 417067 AJ001417 Hs.81086 solute carrier family 22 (extraneuronal 3.88 410467 AF102546 Hs.63931 dachshund (Drosophila) homolog 3.88 422660 AW297582 Hs237062 hypothetical protein FU22548 similarto 3.88 431930 AB035301 Hs.272211 cadherin 7, type 2 3.88 453047 AW023798 Hs.286025 ESTs 3.88 433891 AA613792 gb:no97h03.s1 NCI_CGAP_Pr2 Homo sapiens 3.88 401785 3.88 431088 AA491824 Hs.196881 ESTs 3.88 451952 AL120173 Hs.301663 ESTs 3.87 422089 AA523172 Hs.103135 ESTs, Weakly similar to SFR4_HUMAN SPLIC 3.87 452277 AL049013 Hs.28783 KIAA1223 protein 3.87 438279 AA805166 Hs.165165 HIV-1 rev binding protein 2 3.86 458229 AI929602 Hs.177 phosphatidylinositol glycan, dass H 3.86 406414 3.86 417193 AI922189 Hs.288390 hypothetical protein FU22795 3.85 413174 AA723564 Hs.191343 ESTs 3.85 433332 AI367347 Hs.127809 Homo sapiens clone TCCCTA00151 mRNA sequ 3.85 411089 AA456454 Hs.118637 cell division cyde 2-like 1 (PITSLRE pr 3.85 412494 AL133900 Hs.792 ADP-ribosylation fador domain protein 1 3.84 413530 AA130158 Hs.19977 ESTs, Moderately similar to ALU8_HUMAN A 3.84 459592 AL037421 Hs208746 ESTs, Moderately similar to pot. ORF I [ 3.84 418329 AW247430 Hs.84152 cystathionine-beta-synthase 3.83 451468 AW503398 Hs210047 ESTs, Moderately similar to I38022 hypot 3.83 434804 AA649530 gb:ns44f05.s1 NCI_CGAP_Alv1 Homo sapiens 3.83 401819 3.82 424179 F30712 Homo sapiens, done IMAGE.4285740, mRNA 3.82 424850 AA151057 Hs.153498 chromosome 18 open reading frame 1 3.82 426472 BE246138 Hs.30853 ESTs 3.82 426625 T78300 Hs.171409 serologically defined colon cancer antig 3.82 427585 D31152 Hs.179729 collagen, type X, alpha 1 (Schmid metaph 3.82 427756 AI376540 Hs.15574 ESTs 3.82 444701 AI916512 Hs.198394 ESTs 3.82 423052 M28214 Hs.123072 RAB3B, member RAS oncogene family 3.82 429259 AA420450 HS292911 ESTs, Highly similar to S60712 band-6-pr 3.82 416111 AA033813 Hs.79018 chromatin assembly factor 1 , subunit A ( 3.82 433586 T85301 gb:yd78d06.s1 Soares fetal liver spleen 3.81 438527 AI969251 Hs.143237 RAB7, member RAS oncogene family-like 1 3.81 410297 AA148710 Hs.159441 lumican 3.81 429898 AW117322 Hs.42366 ESTs 3.81 409079 W87707 Hs.82065 interleukin 6 signal transducer (gp130, 3.80 419423 D26488 Hs.90315 KIAA0007 protein 3.80 429643 AA455889 Hs.187548 FYVE-finger-containing Rab5 effector pro 3.80 431499 NM_001514 HS258561 general transcription factor IIB 3.80 445060 AA830811 Hs.88808 ESTs 3.80 449419 R34910 Hs.119172 ESTs 3.80 450584 AA040403 Hs.60371 ESTs 3.80 426137 AL040683 Hs.167031 DKFZP566D133 protein 3.79 420185 AL044056 Hs.158047 ESTs 3.79 410076 T05387 Hs.7991 ESTs 3.78 444078 BE246919 Hs.10290 U5 snRNP-specific40 kDa protein (hPφ8- 3.78 417318 AW953937 Hs.12891 ESTs 3.78 414664 AA587775 Hs.66295 multi-PDZ-domain-containing protein 3.78 410275 U85658 Hs.61796 transcription fador AP-2 gamma (adivat 3.77 410503 AW975746 Hs.188662 KIAA1702 protein 3.77 434170 AA626509 Hs.122329 ESTs 3.77 421838 AW881089 Hs.108806 Homo sapiens mRNA; cDNA DKFZp566M0947 (f 3.77 425268 AI807883 Hs.156932 Homo sapiens cDNA FU20653 fis, done KA 3.76 431696 AA259068 Hs267819 protein phosphatase 1, regulatory (inhib 3.76 411990 AW963624 Hs.31707 ESTs, Weakly similar to YEW4_YEAST HYPOT 3.76 430291 AV660345 HS238126 CGI-49 protein 3.76 448779 BE042877 Hs.177135 ESTs 3.76 452682 AA456193 Hs.155606 progesterone membrane binding protein 3.75 452598 AI831594 Hs.68647 ESTs, Weakly similar to ALU7JHUMAN ALU S 3.75 439498 AA908731 Hs.58297 CLLL8 protein 3.75 440258 AI741633 Hs.125350 ESTs 3.74 456848 AL121087 Hs.296406 KIAA0685 gene produd 3.74 415082 AA160000 Hs.137396 ESTs, Weakly similar to JC5238 galadosy 3.74 420653 AI224532 Hs.88550 ESTs 3.74 431637 AI879330 Hs.265960 hypothetical protein FU10563 3.74 440411 N30256 Hs.156971 hypothetical protein DKFZp434G1415 3.74 405917 3.74 419440 AB020689 Hs.90419 KIAA0882 protein 3.74 451230 BE546208 Hs.26090 hypothetical protein FU20272 3.73 429597 NM 003816 Hs.2442 a α sintegrin and metalloproteinase do a 3.73 430144 AI732722 Hs.187694 ERGL protein; ERGIC-53-like protein 3.72 438394 BE379623 HS27693 peptidylprolyl isomerase (cyclophilin)-l 3.72 440527 AV657117 Hs.184164 ESTs, Moderately similar to S65657 alpha 3.72 449433 AI672096 Hs.9012 ESTs, Weakly similar to S26650 DNA-bindi 3.72 456228 BE503227 Hs.134759 ESTs 3.72 448663 BE614599 Hs.106823 hypothetical protein MGC14797 3.72 415075 L27479 Hs.77889 Friedreich ataxia region gene X123 3.72 433544 AI793211 Hs.165372 ESTs, Moderately similar to ALU1_HUMAN A 3.71 418293 AI224483 Hs.16063 hypothetical protein FU21877 3.71 449897 AW819642 HS24135 transmembrane protein vezatin; hypotheti 3.71 420297 AI628272 Hs.88323 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.70 423065 R96158 Hs.194606 Homo sapiens, done MGC.5406, mRNA, comp 3.70 429340 N35938 Hs.199429 Homo sapiens mRNA; cDNA DKFZp434M2216 (f 3.70 437777 AA768098 Hs.189079 ESTs 3.70 440351 AF030933 Hs.7179 RAD1 (S. po be) homolog 3.70 443603 BE502601 Hs.134289 ESTs, Weakly similar to KIAA1063 protein 3.70 446965 BE242873 Hs.16677 WD repeat domain 15 3.70 412350 AI659306 Hs.73826 protein tyrosine phosphatase, non-recept 3.70 433852 AI378329 Hs.126629 ESTs 3.70 433142 AL120697 Hs.110640 ESTs 3.69 419994 AA282881 Hs.190057 ESTs 3.69 412628 AI972402 Hs.173902 hypothetical protein MGC2648 3:69 431416 AA532718 Hs.178604 ESTs 3.69 439444 AI277652 Hs.54578 ESTs, Weakly similar to I38022 hypotheti 3.68 414709 AA704703 Hs.77031 Sp2 transcription fador 3.68 447397 BE247676 Hs.18442 E-1 enzyme 3.68 405718 3.68 425217 AU076696 Hs.155174 CDC5 (cell division cycle 5, S. pombe, h 3.68 442242 AV647908 Hs.90424 Homo sapiens cDNA: FU23285 fis, clone H 3.68 424690 BE538356 Hs.151777 eukaryotic translation initiation fador 3.68 421734 AI318624 Hs.107444 Homo sapiens cDNA FU20562 fis, done KA 3.67 427221 L15409 Hs.174007 von Hippel-Lindau syndrome 3.67 439864 AI720078 HS291997 ESTs, Weakly similar to A47582 B-cell gr 3.66 402408 3.66 426327 W03242 Hs.44898 Homo sapiens done TCCCTA00151 mRNA sequ 3.66 427119 AW880562 Hs.114574 ESTs 3.66 427356 AW023482 Hs.97849 ESTs 3.66 452946 X95425 Hs.31092 EphA5 3.66 419078 M93119 Hs.89584 insulinoma-assodated 1 3.66 416295 A1064824 Hs.193385 ESTs 3.65 427144 X95097 Hs.2126 vasoactive intestinal peptide receptor 2 3.65 447500 AI381900 Hs.159212 ESTs 3.65 453127 AI696671 HS294110 ESTs 3.65 423396 AI382555 Hs.127950 bromodomain-containing 1 3.65 419346 AI830417 polybromo 1 3.64 441540 C01367 Hs.127128 ESTs 3.64 446501 AI302616 Hs.150819 ESTs 3.64 459527 AW977556 HS291735 ESTs, Weakly similar to I78885 serine/th 3.63 446320 AF126245 Hs.14791 acyl-Coenzyme A dehydrogenase family, me 3.63 435706 W31254 Hs.7045 GL004 protein 3.63 400110 3.62 410313 R10305 Hs.185683 ESTs 3.62 414713 BE465243 Hs.12664 ESTs 3.62 436279 AW900372 Hs.180793 ESTs, Weakly similar to S65657 alpha-1C- 3.62 439818 AL360137 Hs.19934 Homo sapiens mRNA full length insert cDN 3.62 451797 AW663858 Hs.56120 small indudble cytokine subfamily E, me 3.62 451294 AI457338 HS29894 ESTs 3.62 434194 AF119847 Hs.283940 Homo sapiens PRO1550 mRNA, partial eds 3.62 404939 3.62 408101 AW968504 Hs.123073 CDC2-related protein kinase 7 3.62 435846 AA700870 Hs.14304 ESTs 3.61 432833 N51075 Hs.47191 ESTs 3.61 427276 AA400269 Hs.49598 ESTs 3.61 433495 AW373784 Hs.71 alpha-2-glycoprotein 1, zinc 3.60 403137 3.60 404165 3.60 409571 AA504249 Hs.187585 ESTs 3.60 410561 BE540255 Hs.6994 Homo sapiens cDNA: FU22044 fis, clone H 3.60 412924 BE018422 Hs.75258 H2A histone family, member Y 3.60 434228 Z42047 HS283978 Homo sapiens PR02751 mRNA, complete eds 3.60 436797 AA731491 Hs.178518 hypothetical protein MGC14879 3.60 437162 , AW005505 Hs.5464 thyroid hormone receptor coactivating pr 3.60 437444 H46008 Hs.31518 ESTs 3.60 404210 3.59 446157 BE270828 Hs.131740 Homo sapiens cDNA: FU22562 fis, clone H 3.59 437587 AI591222 Hs.122421 Human DNA sequence from done RP1-187J11 3.58 423147 AA987927 Hs.131740 Homo sapiens cDNA: FU22562 fis, done H 3.57 452226 AA024898 Hs.296002 ESTs 3.56 443775 AF291664 Hs204732 matrix metaltoproteinase 26 3.56 452501 AB037791 Hs.29716 hypothetical protein FU10980 3.56 428647 AA830050 Hs.124344 ESTs 3.56 422443 NM 014707 Hs.116753 histone deacetylase 7B 3.55 447966 AA340605 Hs.105887 ESTs, Weakly similar to Homolog of rat Z 3.55 420892 AW975076 Hs.172589 nudear phosphoprotein similar to S. cer 3.55 420230 AL034344 Hs.298020 forkhead boxCI 3.55 418428 Y12490 Hs.85092 thyroid hormone receptor interador 11 3.54 428949 AA442153 Hs.104744 hypothetical protein DKFZp434J0617 3.54 444929 A1685841 Hs.161354 ESTs 3.54 433339 AF019226 Hs.8036 glioblastoma overexpressed 3.54 424369 R87622 Hs.26714 KIAA1831 protein 3.54 433002 AF048730 HS279906 cydinTI 3.53 435425 H16263 Hs.31416 ESTs 3.53 415621 AI648602 Hs.131189 ESTs 3.53 416974 AF01O233 Hs.80667 RALBP1 assodated Eps domain containing 3.53 405793 3.52 409770 AW499536 gb:UI-HF-BR0p-aji-c-12-0-Ul.r1 IH_MGC_5 3.52 425305 AA363025 Hs.155572 Human done 23801 mRNA sequence 3.52 428939 AW236550 Hs.131914 ESTs 3.52 438388 AA806349 Hs.44698 ESTs 3.52 443703 AV646177 Hs213021 ESTs 3.52 457940 AL360159 Hs.30445 Homo sapiens TRIpartite motif protein ps 3.52 402444 3.52 409643 AW450866 HS257359 ESTs 3.51 418250 U29926 Hs.83918 adenosine monophosphate deaminase (isofo 3.51 432745 AI821926 HS269507 gb:nt78f05.x5 NCI_CGAP_Pι3 Homo sapiens 3.51 414222 AL135173 Hs.878 sorbitol dehydrogenase 3.51 430061 AB037817 HS230188 KIAA1396 protein 3.51 421491 H99999 Hs.42736 ESTs 3.50 422384 AA224077 Hs.42438 Sm protein F 3.50 434565 T52172 ESTs 3.50 438379 N23018 Hs.171391 C-terminal binding protein 2 3.50 439741 BE379646 Hs.6904 Homo sapiens mRNA full length insert cDN 3.50 447311 R37010 Hs.33417 Homo sapiens cDNA: FU22806 fis, clone K 3.50 447805 AW627932 Hs.19614 gemin4 3.50 454265 H03556 Hs.300949 ESTs, Weakly similar to thyroid hormone 3.50 418838 AW385224 Hs.35198 edonudeotide pyrophosphatase/phosphodi 3.50 448804 AW512213 Hs.42500 ADP-ribosylation fador-like 5 3.50 409617 BE003760 Hs.55209 Homo sapiens mRNA; cDNA DKFZp434K0514 (f 3.49 434075 AW003416 Hs.160604 ESTs 3.49 444190 AI878918 Hs.10526 cysteine and glydne-rich protein 2 3.49 435017 AA336522 Hs.12854 angiotensin II, type I receptor-associat 3.48 423445 NM 014324 Hs.128749 alpha-methylacyl-CoA racemase 3.48 420271 AI954365 Hs.42892 ESTs 3.48 443684 AI681307 Hs.166674 ESTs 3.48 444168 AW379879 gb:RC1-HT0256-081199-011-f01 HT0256 Homo 3.48 446074 AA079799 HS29263 hypothetical protein FU11896 3.48 452582 AL137407 Hs.29911 Homo sapiens mRNA; cDNA DKFZp434M232 (fr 3.48 431542 H63010 Hs.5740 ESTs 3.48 432697 AW975050 Hs.293892 ESTs, Weakly similar to ALU4 HUMAN ALU S 3.48 435572 AW975339 Hs239828 ESTs, Weakly similar to GAG2_HUMAN RETRO 3.47 407192 AA609200 gb:af12e02.s1 Soares_testis_NHT Homo sap 3.47 413435 X51405 Hs.75360 carboxypeptidase E 3.46 447210 AF035269 Hs.17752 phosphatidylserine-spedficphospholipas 3.46 447958 AW796524 Hs.68644 Homo sapiens microsomal signal peptklase 3.46 425312 AA354940 Hs.145958 ESTs 3.46 442007 AA301116 Hs.142838 nudeolar phosphoprotein Nopp34 3.46 417455 AW007066 Hs.18949 ESTs, Weakly similar to CA2B_HUMAN COLLA 3.45 426931 NM 003416 Hs.2076 zinc finger protein 7 (KOX 4, clone HF.1 3.45 408739 W01556 Hs.238797 ESTs, Moderately similar to I38022 hypot 3.45 436024 AI800041 Hs.190555 ESTs 3.45 408418 AW963897 Hs.44743 KIAA1435 protein 3.45 409151 AA306105 Hs.50785 SEC22, veside traffi eking protein (S. c 3.44 418626 AW299508 Hs.135230 ESTs 3.44 420560 AW207748 Hs.59115 ESTs 3.44 420686 AI950339 Hs.40782 ESTs 3.44 428870 AA436831 Hs.36049 ESTs 3.44 436754 AI061288 Hs.133437 ESTs 3.44 437960 AI669586 HS222194 ESTs 3.44 452300 AW628045 Hs.28896 Homo sapiens mRNA full length insert cDN 3.44 421887 AW161450 Hs.109201 CGI-86 protein 3.44 TABLE 5A shows the accession numbers for those primekeys lacking a unigenelD in Tables 5, 6, and 7. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column. Pkey: Unique Eos probeset identifier number CAT number Gene cluster number Accession: Genbank accession numbers Pkey CATnumber Accession 407596 1003489J R86913 R86901 H25352 R01370 H43764 AW044451 W21298 408432 1058667J AW195262 R27868 AW811262 409752 1153011 AW963990 AA078196 AW749482 AA077468 BE151571 AA376917 409770 11540481 AW499536 AW499553 AW502138 AW499537 AW502136 AW501743 411440 1245771 AW749402 AW749403 Z45743 R80376 AA093358 411479 1247077J AW848047 AW848202 AW848631 AW848142 AW848702 AW848121 AW848632 AW848140 AW848571 AW848009 AW848067 AW848069 AW848905 AW848214 411624 12521661 BE145964 BE146286 AW854564 412991 1342481 AW949013AA126111 414269 1431331 AA298489 AA137165 415123 15233901 D60925 D60828 D80787 415715 1548818J F30364 F36559 T15435 416288 15859831 H51299 H44619 H46391 R86024 H51892 T72744 416289 15860371 W26333 R05358 H44682 417730 1695795J Z44761 R25801 R11926 R35604 418636 1774021 AW749855 AA225995 AW750208 AW750206 419346 1841291 AI830417AA236612 419536 185688J AA603305 AA244095 AA244183 420111 1907551 AA255652 AA280911 AW967920 AA262684 422219 2135471 AW978073 AW978072 AA807550 AA306567 424179 236389--1 F30712 F35665 AW263888 AI904014 AI904018 AA336927 AA336502 424242 237181 AA337476 AW966227 AA450376 AW960222 AA381051 428002 285602J AA418703 AA418711 BE071915 BE071920 BE071912 429163 3005431 AA884766 AW974271 AA592975 AA447312 432189 3428191 AA527941 AI810608 AI620190 AA635266 432340 3452481 AA534222 AA632632 T81234 432363 3454691 AA534489 AW970240 AW970323 432966 3568391 AA650114 AW974148 AA572946 433586 370470J T85301 AW517087 AA601054 BE073959 433641 371861 AF080229 AF080231 AF080230 AF080232 AF0802-33 AF080234 BE550633 AI636743 AW614951 BE467547 AI680833 AI633818 N29986 U87592 U87593 U87590 U87591 S46404 U87587 AA463992 AW206802 AI970376 AI583718 AI672574 N25695 AW665466 AI818326 AA126128 AI480345 AW013827 AA248638 AI214968 AA204735 AA207155 AA206262 AA204833 AW003247 AW496808 AI080480 AI631703 AI651023 AI867418 AW818140 AA502500 AI206199 AI671282 AI352545 BE501030 AI652535 BE465762 AA206331 AW451866 AA471088 AA206342 AA204834 AA206100 AW021661 AA332922 N66048 AA703396 H92278 AW139734 H92683 U87589 U87595 H69001 U87594 BE466420 AI624817 BE466611 AI206344 AA574397 AA348354 AI493192 433687 3730611 AA743991 AA604852 AW272737 433891 3762391 AA613792 AW182329 T05304 AW858385 434415 3859311 BE177494 AW276909 AA632849 434565 388981 T52172 AF147324T52248 434804 3934811 AA649530 AA659316 H64973 437113 4332341 AA744693 AW750059 444168 5938291 AW379879 AI126285 H12014 448212 755099J AI475858 AW969013 448310 757918J AI480316 AW847535 451746 8833031 M86178 AI813822 D56993 452560 922216J BE077084 AW139963 AW863127 AW806209 AW806204 AW806205 AW806206 AW806211 AW806212 AW806207 AW806208 AW806210 AI907497 452712 928309J AW838616 AW838660 BE144343 AI914520 AW888910 BE184854 BE184784 453773 980699J AL133761 AL133767 455276 1272541J BE176479 BE176678 BE176357 BE176550 AW886079 BE176676 BE176615 BE176555 BE176489 BE176610 BE176362 455309 1278153J AW894017 AW893956 AW894032 TABLE 5B shows the genomic positioning for those primekeys lacking unigene ID's and accession numbers in Tables 5, 6, and 7. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed. Pkey: Unique number corresponding to an Eos probeset Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (Gl) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. Strand: Indicates DNA strand from which exons were predided. NLposition: Indicates nucleotide positions of predided exons. Pkey Ref Strand NLposition 401045 8117619 Plus 90044-90184,91111-91345 401424 8176894 Plus 24223-24428 401451 6634068 Minus 119926-121272 401714 6715702 Plus 96484-96681 401747 9789672 Minus 118596-118816,119119-119244,119609-119761,120422-120990,130161-130381,130468-130593,131097- 131258,131866-131932,132451-132575,133580-134011 401785 7249190 Minus 165776-165996,166189-166314,166408-166569,167112-167268,167387-167469,168634-168942 401819 7467933 Minus 28217-28486 402408 9796239 Minus ■ 110326-110491 402444 9796614 Plus 28391-28517 402791 6137008 Minus 51036-51207 403047 3540153 Minus 59793-59968 403137 9211494 Minus 92349-92572,92958-93084,93579-93712,93949-94072,94591-94748,95214-95337 403721 7528046 Minus 156647-157366 403764 7717105 Minus 118692-118853 403797 8099896 Minus 123065-125008 404165 9926489 Minus 69025-69128 404210 5006246 Plus 169926-170121 404253 9367202 Minus 55675-56055 404561 9795980 Minus 69039-70100 404571 7249169 Minus 112450-112648 404721 9856648 Minus 173763-174294 404915 7341766 Minus 100915-101087 404939 6862697 Plus 175318-175476 405403 6850244 Minus 37491-37670,40951-41031 405685 4508129 Minus 37956-38097 405718 9795467 Plus 113080-113266 405793 1405887 Minus 89197-89453 405876 6758747 Plus 39694-40031 405917 7712162 Minus 106829-107213 406414 9256407 Plus 49593-49850 406554 7711566 Plus 106956-107121 TABLE 6:286 GENES ENCODING EXTRACELLULAR OR CELL SURFACE PROTEINS UP-REGULATED IN PROSTATE CANCER COMPARED TO NORMAL ADULT TISSUES Table 6 shows 286 genes up-regulated in prostate cancer compared to normal adult tissues that are likely to be extracellular or cell-surface proteins. These were selected as for Table 5 and the predicted protein contained a structural domain that is indicative of extracellular localization (e.g. egf, 7tm domains). Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD: Unigene number Unigene Title ι: Unigene gene title R1: Ratio of tumor to normal tissue Pkey ExAccn UnigenelD Uningene Title R1 409361 NM 005982 Hs.54416 sine oculis homeobox (Drosophila) homolo 4828 409731 AA125985 Hs.56145 thymosin, beta, identified in neuroblast 4524 400298 AA032279 Hs.61635 six transmembrane epithelial antigen of 43.48 420154 AI093155 Hs.95420 JM27 protein 41.12 426747 AA535210 Hs.171995 kallikrein 3, (prostate specific antigen 31.80 400299 X07730 Hs.171995 kallikrein 3, (prostate specific antigen 24.91 425075 AA506324 Hs.1852 add phosphatase, prostate 2423 424846 AU077324 Hs.1832 neuropeptide Y 23.57 405685 20.90 420757 X78592 Hs.99915 androgen receptor (dihydrotestosterone r 19.72 418994 AA296520 Hs.89546 sele in E (endothelial adhesion molecul 19.56 452792 AB037765 Hs.30652 KIAA1344 protein 17.39 445472 AB006631 Hs.12784 Homo sapiens mRNA for KIAA0293 gene, par 17.00 414565 AA502972 Hs.183390 hypothetical protein FU13590 16.82 431716 D89053 Hs.268012 fatty-add-Coenzyme A ligase, long-chain 16.60 408430 S79876 Hs.44926 dipeptidylpeptidase IV (CD26, adenosine 1628 408000 L11690 Hs.620 bullous pemphigokJ antigen 1 (230/240kD) 15.54 430226 BE245562 Hs2551 adrenergic, beta-2-, receptor, surface 15.40 444484 AK002126 Hs.11260 hypothetical protein FU11264 14.76 418601 AA279490 Hs.86368 calmegin 1456 448999 AF179274 HS22791 transmembrane protein with EGF-like and 1455 416182 NM 004354 Hs.79069 cydin G2 12.94 420544 AA677577 Hs.98732 Homo sapiens Chromosome 16 BAC done CIT 12.79 445413 AA151342 Hs.12677 CGI-147 protein 12.64 453930 AA419466 Hs.36727 hypothetical protein FLJ10903 1222 440286 U29589 Hs.7138 cholinergic receptor, muscarinic 3 12.04 452784 BE463857 Hs.151258 hypothetical protein FU21062 11.86 450203 AF097994 Hs.301528 L-kynurenine/alpha-aminoadipate aminotra 11.68 448045 AJ297436 Hs.20166 prostate stem cell antigen 1151 449650 AF055575 Hs.23838 caldum channel, voltage-dependent, L ty 11.18 420381 D50640 Hs.337616 phosphodiesterase 3B, cGMP-inhibited 11.10 425665 AK001050 Hs.159066 hypothetical protein FU10188 11.08 425710 AF030880 Hs.159275 solute carrier family, member 4 11.08 428728 NM_016625 Hs.191381 hypothetical protein 11.04 407021 U52077 gb:Human marinerl transposase gene, comp 11.02 410733 D84284 Hs.66052 CD38 antigen (p45) 11.02 452340 NM 002202 Hs.505 ISL1 transcription fador, LIM/homeodoma 10.85 428819 AL135623 Hs.193914 KIAA0575 gene produd 10.48 421991 NM 014918 Hs.110488 KIAA0990 protein 10.04 431217 NM_013427 Hs.250830 Rho GTPase activating protein 6 9.75 421470 R27496 Hs.1378 annexinA3 9.64 409262 AK000631 Hs.52256 hypothetical protein FU20624 9.45 435980 AF274571 Hs.129142 deoxyribonuclease II beta 924 421246 AW582962 Hs.102897 CGI-47 protein 920 410001 AB041036 Hs.57771 kallikrein 11 9.03 441791 AW372449 Hs.175982 hypothetical protein FU21159 9.02 404571 8.66 456497 AW967956 Hs.123648 ESTs, Weakly similar to AF1084601 ubinu 8.56 419968 X04430 Hs.93913 interleukin 6 (interferon, beta 2) 8.36 433172 AB037841 Hs.102652 hypothetical protein ASH1 8.30 422631 BE218919 Hs.118793 hypothetical protein FU10688 827 427674 NM_003528 Hs.2178 H2B histone family, member Q 820 404915 8.08 452259 AA317439 Hs.28707 signal sequence receptor, gamma (translo 8.06 452891 N75582 Hs212875 ESTs, Weakly similar to DYH9_HUMAN CILIA 8.02 439731 AI953135 Hs.45140 hypothetical protein FI-J14084 7.98 419839 U24577 Hs.93304 phospholipase A2, group VII (platelet-ac 7.68 420120 AL049610 Hs.95243 transcription elongation fador A (Sll)- 7.64 424099 AF071202 Hs.139336 ATP-binding cassette, sub-family C (CFTR 7.64 448706 AW291095 Hs.21814 interleukin 20 receptor, alpha 7.52 410227 AB009284 Hs.61152 exostoses (multiple)-like 2 7.49 425211 M18667 Hs.1867 progastricsin (pepsinogen C) 7.35 441736 AW292779 Hs.169799 ESTs 7.28 419991 AJ000098 Hs.94210 eyes absent (Drosophila) homolog 1 720 425018 BE245277 Hs.154196 E4F transcription fador 1 720 424560 AA158727 Hs.150555 protein predided by done 23733 7.18 409110 AA191493 Hs.48778 niban protein 7.10 421566 NM 000399 Hs.1395 early growth response 2 (Krox-20 (Drosop 7.Q4 431725 X65724 Hs.2839 Nome disease (pseudoglioma) 6.98 425782 U66468 Hs.159525 cell growth regulatory with EF-hand doma 6.85 427408 AA583206 Hs.2156 RAR-related orphan receptor A 6.79 435604 AA625279 Hs26892 uncharadenzed bone marrow protein BM04 6.73 415874 AF091622 Hs.78893 KIAA0244 protein 6.54 401451 6.52 431778 AL080276 Hs.268562 regulator of G-protein signalling 17 6.51 409089 NM 014781 Hs.50421 KIAA0203 gene produd 6.50 431992 NM_002742 Hs.2891 protein kinase C, mu 6.49 404253 6.42 421552 AF026692 Hs.105700 secreted frizzled-related protein 4 6.41 416806 NM 000288 Hs.79993 peroxisomal biogenesis fador 7 6.38 431958 X63629 Hs.2877 cadherin 3, type 1, P-cadherin (placenta 6.30 439366 AF100143 Hs.6540 fibroblast growth factor 13 6.30 416836 D54745 Hs.80247 cholecystokinin 6.30 433383 AF034837 Hs.192731 double-stranded RNA spedfic adenosine d 629 450728 AW162923 Hs25363 presenilin 2 (Alzheimer disease 4) 625 413384 NM 000401 Hs.75334 exostoses (multiple) 2 622 423349 AF010258 Hs.127428 homeo boxA9 620 424800 AL035588 Hs.153203 MyoD family inhibitor 6.18 425451 AF242769 Hs.157461 mesenchymal stem cell protein DSC54 6.14 447359 NM 012093 Hs.18268 adenylate kinase 5 6.00 410889 X91662 Hs.66744 twist (Drosophila) homolog (acrocephalos 5.97 408829 NM--006042 Hs.48384 heparan sulfate (glucosamine) 3-θ-sulfot 5.94 453911 AW503857 Hs.4007 Sarcolemmal-assodated protein 5.94 408875 NM 015434 Hs.48604 DKFZP434B168 protein 5.92 450480 X82125 HS25040 zinc finger protein 239 5.90 451684 AF216751 Hs26813 CDA14 5.88 400301 X03635 Hs.1657 estrogen receptor 1 5.78 415077 L41607 Hs.934 glucosaminyl (N-acetyl) transferase 2, 1 5.74 418852 BE537037 Hs.273294 hypothetical protein FU20069 5.72 446867 AB007891 Hs.16349 KIAA0431 protein 5.72 410232 AW372451 Hs.61184 CGI-79 protein 5.70 422762 AL031320 Hs.119976 Human DNA sequence from clone RP1-20N2 o 5.70 450616 AL133067 Hs.302689 hypothetical protein 5.70 408621 AI970672 Hs.46638 chromosome 11 open reading frame 8 5.65 439671 AW162840 Hs.6641 kinesin family member 5C 5.64 410196 AI936442 Hs.59838 hypothetical protein FU10808 5.60 429170 NM 001394 Hs.2359 dual specificity phosphatase 4 5.60 440738 A1004650 Hs.225674 WD repeat domain 9 5.60 414342 AA742181 Hs.75912 KIAA0257 protein 5.59 422634 NM_016010 Hs.118821 CGI-62 protein 5.56 400268 5.55 439569 AW602166 Hs.222399 CEGP1 protein 5.51 452823 AB012124 Hs.30696 transcription factor-like 5 (basic helix 5.48 431938 AA938471 Hs.54431 spedfic granule protein (28 kDa); cyste 5.44 427638 AA406411 Hs.208341 ESTs, Weakly similar to KIAAQ989 protein 5.42 421264 AL039123 Hs.103042 microtubule-assodated protein 1B 5.38 421685 AF189723 Hs.106778 ATPase, Ca++ transporting, type 2C, memb 5.37 421987 AI133161 Hs.286131 CGI-101 protein 5.36 422806 BE314767 Hs.1581 glutathione S-transferase theta 2 5.34 432281 AK001239 Hs.274263 hypothetical protein FU10377 5.32 451982 F13036 Hs.27373 Homo sapiens mRNA; cDNA DKFZp56401763 (f 5.32 444042 NM 004915 Hs.10237 ATP-binding cassette, sub-family G (WHIT 5.31 447752 M73700 Hs.105938 ladotransferrin 5.29 451418 BE387790 Hs.26369 hypothetical protein FU20287 5.22 428593 AW207440 Hs.185973 degenerative spermatocyte (homolog Droso 521 447541 AK000288 Hs.18800 hypothetical protein FLJ20281 5.18 459294 AW977286 Hs.17428 RBPWike protein 5.16 424692 AA429834 Hs.151791 KIAA0092 gene produd 5.15 416434 AW163045 Hs.79334 nudear fador, interleukin 3 regulated 5.11 410268 AA316181 Hs.61635 six transmembrane epithelial antigen of 5.10 417517 AF001176 Hs.82238 POP4 (processing of precursor , S. cerev 5.10 453616 NM 003462 Hs.33846 dynein, axonemal, light intermediate pol 5.10 427958 AA4180O0 Hs.98280 potassium intermediate/small conductance 5.09 407945 X69208 Hs.606 ATPase, Cu++ transporting, alpha polypep 5.08 418576 AW968159 Hs289104 Alu-binding protein with zinc finger dom 5.05 413328 Y15723 Hs.75295 guanylate cyclase 1, soluble, alpha 3 5.04 432729 AK000292 Hs.278732 hypothetical protein FU20285 5.04 426342 AF093419 Hs.169378 multiple PDZ domain protein 5.02 429782 NM 005754 Hs.220689 Ras-GTPase-adivating protein SH3-domain 5.02 436209 AW850417 Hs.254020 ESTs, Moderately similar to unnamed prot 5.02 430599 NM 004855 Hs.247118 phosphatidylinositol glycan, class B 5.00 451386 AB029006 Hs.26334 spastic paraplegia 4 (autosomal dominant 5.00 457211 AW972565 Hs.32399 ESTs, Weakly similar to S51797 vasodilat 4.97 425851 NM 001490 Hs.159642 glucosaminyl (N-acetyl) transferase 1, c 4.97 421689 N87820 Hs.106826 KIAA1696 protein 4.93 416533 BE244053 Hs.79362 retinoblastoma-like 2 (p130) 4.92 432653 N62096 Hs.293185 ESTs, Weakly similar to JC7328 amino aci 4.91 403047 4.91 431117 AF003522 Hs.250500 delta (Drosophila)-like 1 4.90 427617 D42063 Hs.199179 RAN binding protein 2 4.88 428804 AK000713 Hs.193736 hypothetical protein FU20706 4.88 449071 NM 005872 Hs.22960 breast carcinoma amplified sequence 2 4.86 407596 R86913 gb:yq30f05.r1 Soares fetal liver spleen 4.84 456516 BE172704 Hs.222746 KIAA1610 protein 4.84 458339 AW976853 Hs.172843 ESTs 4.83 422083 NM 001141 Hs.111258 arachidonate 15-lipoxygenase, second typ 4.82 449535 W15267 Hs.23672 low density lipoprotein receptor-related 4.82 422048 NM 012445 Hs.288126 spondin 2, extracellular matrix protein 4.82 424602 AK002055 Hs.151046 hypothetical protein FU11193 4.78 410765 AI694972 Hs.66180 nudeosome assembly protein 1-like 2 4.77 419879 Z17805 Hs.93564 Homer, neuronal immediate early gene, 2 4.74 450649 NM 001429 HS25272 E1A binding protein p300 4.74 411624 BE145964 Hs.103283 KIAA0594 protein 4.72 404721 4.70 426261 AW242243 Hs.168670 peroxisomal famesylated protein 4.70 416276 U41060 Hs.79136 LIV-1 protein, estrogen regulated 4.64 408374 AW025430 Hs.155591 forkhead box F1 4.64 451900 AB023199 Hs.27207 KIAA0982 protein 4.63 421437 AW821252 Hs.104336 hypothetical protein 4.63 ■ 434629 AA789081 Hs.4029 glioma-amplified sequence-41 4.60 403764 4.58 421247 BE391727 Hs.102910 general transcription fador IIH, polype 4.53 403721 4.50 453070 AK001465 Hs.31575 SEC63, endoplasmic reticulum translocon 4.49 417412 X16896 Hs.82112 interleukin 1 receptor, type I 4.48 439735 AI635386 Hs.142846 hypothetical protein 4.48 430261 AA305127 Hs.237225 hypothetical protein HT023 4.46 430598 AK001764 Hs.247112 hypothetical protein FU10902 4.44 400303 AA242758 Hs.79136 LIV-1 protein, estrogen regulated 4.42 438209 AL120659 Hs.6111 atyl-hydrocarbon receptor nuclear transl 4.42 417421 AL138201 Hs.82120 nuclear receptor subfamily 4, group A, m 4.40 447270 AC002551 Hs.331 general transcription fador NIC, polyp 4.38 434423 NM-.006769 Hs.3844 LIM domain only 4 4.35 404561 4.32 422969 AA782536 Hs.122647 N-myristoyltransferase 2 4.32 423685 BE350494 Hs.49753 uveal autoantigen with coiled coil domai 4.32 425071 NM 013989 Hs.154424 deiodinase, iodothyronine, type II 4.32 431583 AL042613 Hs262476 S-adenosylmethionine decarboxylase 1 4.31 442818 AK001741 Hs.8739 hypothetical protein FLJ10879 4.30 423740 Y07701 Hs.293007 aminopeptidase puromydn sensitive 4.24 424701 NM 005923 Hs.151988 mitogen-activatβd protein kinase kinase 421 424085 NM 002914 Hs.139226 replication fador C (ad ' wator 1) 2 (40 4.20 410294 AB014515 Hs.323712 KIAA0615 gene produd 4.18 447124 AW976438 Hs.17428 RBPMike protein 4.18 438018 AK001160 Hs.5999 hypothetical protein FU10298 4.16 443857 AI089292 Hs.287621 hypothetical protein FLJ14069 4.15 446711 AF169692 Hs.12450 protocadherin 9 4.15 405403 4.14 448148 NM 016578 Hs.20509 HBV pX associated protein-8 4.13 417531 NM 003157 Hs.1087 serine/threonine kinase 2 4.12 433345 AI681545 Hs.152982 hypothetical protein FU13117 4.10 432712 AB016247 HS288031 sterol-C5-desaturase (fungal ERG3, delta 4.09 435114 AA775483 Hs.288936 mitochondrial ribosomal protein L9 4.08 445459 AI478629 Hs.158465 likely ortholog of mouse putative IKK re 4.08 402791 4.04 438660 U95740 Hs.6349 Homo sapiens, clone IMAGE.3010666, mRNA, 4.04 447568 AF155655 Hs.18885 CGI-116 protein 4.04 452211 AI985513 Hs233420 ESTs 4.02 443292 AK0O0213 Hs.9196 hypothetical protein 4.01 420911 U77413 Hs.100293 O-linked N-acetylglucosamine (GlcNAc) tr 4.00 428738 NM 000380 Hs.192803 xeroderma pigmentosum, complementation g 3.95 430456 AA314998 Hs.241503 hypothetical protein 3.95 437531 AI400752 Hs.112259 T cell receptor gamma locus 3.93 428695 AI355647 Hs.189999 purinergic receptor (family A group 5) 3.91 410011 AB020641 Hs.57856 PFTAIRE protein kinase 1 3.91 446494 AA463276 Hs.288906 WW Domain-Containing Gene 3.91 409928 AL137163 Hs.57549 hypothetical protein dJ473B4 3.90 411598 BE336654 Hs.70937 H3 histone family, member A 3.90 425707 AF115402 Hs.11713 E74-like fador 5 (ets domain transcript 3.90 451806 NM_003729 Hs.27076 RNA3'-terminal phosphate cyclase 3.89 401045 3.89 437372 AA323968 Hs283631 hypothetical protein DKFZp547G183 3.89 417067 AJ001417 Hs.81086 solute carrier family 22 (extraneuronal 3.88 410467 AF102546 Hs.63931 dachshund (Drosophila) homolog 3.88 431930 AB035301 Hs.272211 cadherin7,type2 3.88 453047 AW023798 Hs.286025 ESTs 3.88 401785 3.88 458229 AI929602 Hs.177 phosphatidylinositol glycan, dass H 3.86 406414 3.86 412494 AL133900 Hs.792 ADP-ribosylation fador domain protein 1 3.84 418329 AW247430 Hs.84152 cystathionine-beta-synthase 3.83 424850 AA151057 Hs.153498 chromosome 18 open reading frame 1 3.82 427585 D31152 Hs.179729 collagen, type X, alpha 1 (Schmid metaph 3.82 423052 M28214 Hs.123072 RAB3B, member RAS oncogene family 3.82 416111 AA033813 Hs.79018 chromaβn assembly fador 1 , subunit A ( 3.82 419423 D26488 Hs.90315 KIAA0007 protein 3.80 429643 AA455889 Hs.167279 FYVE-finger-containing Rab5 effedor ' pro 3.80 431499 NM 001514 Hs.258561 general transcription fador IIB 3.80 444078 BE246919 Hs.10290 U5 snRNP-specific40 kDa protein (hPφδ- 3.78 430291 AV660345 Hs238126 CGI-49 protein 3.76 431637 AI879330 Hs.265960 hypothetical protein FU10563 3.74 440411 N30256 Hs.151093 hypothetical protein DKFZp434G1415 3.74 405917 3.74 451230 BE546208 HS26090 hypothetical protein FU20272 3.73 429597 NM 003816 Hs.2442 a disintegrin and metalloproteinase doma 3.73 415075 L27479 Hs.77889 Friedreich ataxia region gene X123 3.72 440351 AF030933 Hs.7179 RAD1 (S. pombe) homolog 3.70 443603 BE502601 Hs.134289 ESTs, Weakly similar to KIAA1063 protein 3.70 446965 BE242873 Hs.16677 WD repeat domain 15 3.70 412350 AI659306 Hs.73826 protein tyrosine phosphatase, non-recept 3.70 433852 AI378329 Hs.126629 ESTs 3.70 447397 BE247676 Hs.18442 E-1 enzyme 3.68 405718 3.68 425217 AU076696 Hs.155174 CDC5 (cell division cycle 5, S. pombe, h 3.68 421734 AI318624 Hs.107444 Homo sapiens cDNA FU20562 fis, done KA 3.67 427221 L15409 Hs.174007 von Hippel-Lindau syndrome 3.67 402408 3.66 452946 X95425 Hs.31092 EphA5 3.66 419078 M93119 Hs.89584 insulinoma-associated 1 3.66 427144 X95097 Hs.2126 vasoactive intestinal peptide receptor 2 3.65 423396 AI382555 Hs.127950 bromodomain-containing 1 3.65 446320 AF126245 Hs.14791 acyl-Coenzyme A dehydrogenase family, me 3.63 404939 3.62 403137 3.60 437162 AW005505 Hs.5464 thyroid hormone receptor coadivating pr 3.60 404210 3.59 443775 AF291664 Hs.204732 matrix metalloproteinase 26 3.56 452501 AB037791 Hs.29716 hypothetical protein FU10980 3.56 422443 NM.014707 Hs.116753 histone deacetylase 7B 3.55 420230 AL034344 Hs.284186 forkhead boxCI 3.55 418428 Y12490 Hs.85092 thyroid hormone receptor interador 11 3.54 433002 AF048730 Hs279906 cydin T1 3.53 405793 3.52 457940 AL360159 Hs.306517 Homo sapiens TRIpartite motif protein ps 3.52 402444 3.52 418250 U29926 Hs.83918 adenosine monophosphate deaminase (isofo 3.51 414222 AL135173 Hs.878 sorbitol dehydrogenase 3.51 422384 AA224077 Hs.42438 Sm protein F 3.50 447805 AW627932 Hs.19614 gemin4 3.50 454265 H03556 Hs.300949 ESTs, Weakly similar to thyroid hormone 3.50 423445 NM 014324 Hs.128749 alpha-methylacyl-CoA racemase 3.48 413435 X51405 Hs.75360 carboxypeptidase E 3.46 447210 AF035269 Hs.17752 phosphatidylserine-spedficphospholipas 3.46 426931 NM 003416 Hs.2076 zinc finger protein 7 (KOX 4, done HF.1 3.45 408418 AW963897 Hs.44743 KIAA1435 protein 3.45 421887 AW161450 Hs.109201 CGI-86 protein 3.44 Table 7: 42 GENES ENCODING SMALL MOLECULE TARGETS UP-REGULATED IN PROSTATE CANCER COMPARED TO NORMAL ADULT TISSUES Table 7 shows 42 genes up-regulated in prostate cancer compared to normal adult tissues that are likely to be small molecule targets. These were selected as for Table 5 and the predicted protein contained a structural domain that is indicative of a drugable structure (e.g. protease, kinase, phosphatase, receptor). The functional domain is indicated for each gene. Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD: Unigene number Unigene Title: Unigene gene title PSDomain: Protein Structural Domain R1 : Ratio of tumor vs. normal tissue Pkey ExAccn UnigenelD Unigene Title PSDomain R1 426747 AA535210 Hs.171995 kallikrein 3, (prostate specific antigen trypsin 31.80 400299 X07730 Hs.171995 kallikrein 3, (prostate specific antigen trypsin 24.91 420757 X78592 Hs.99915 androgen receptor (dihydrotestosterone r Androgen_recep,hormone_rec,zf-C4 19.72 408430 S79876 Hs.44926 dipeptidylpeptidase IV (CD26, adenosine DPPIV N term,Peptidase_S9 1628 430226 BE245562 Hs.2551 adrenergic, beta-2-, receptor, surface 7tm_1 15.40 411096 U80034 Hs.68583 mitochondrial intermediate peptidase Peptidase M3 14.81 440286 U29589 Hs.7138 cholinergic receptor, muscarinic 3 7tm_1 12.04 420381 D50640 Hs.337616 phosphodiesterasβ 3B, cGMP-inhibited PDEase 11.10 407021 U52077 gb:Human marinert transposase gene, comp SET.TransposaseJ 11.02 401424 arginase 9.58 410001 AB041036 Hs.57771 kallikrein 11 trypsin 9.03 428330 L22524 Hs.2256 matrix metalloproteinase 7 (matrilysin, Peptidase_M10 8.76 424099 AF071202 Hs.139336 ATP-binding cassette, sub-family C (CFTR ABC_tran,ABC_membrane 7.64 419991 AJ000098 Hs.94210 eyes absent (Drosophila) homolog 1 Hydrolase 7.20 431992 NM 002742 Hs2891 protein kinase C, mu pkinase,DAG_PE-bind,PH 6.49 447359 NM 012093 Hs.18268 adenylate kinase 5 adenylatekinase 6.00 400301 X03635 Hs.1657 estrogen receptor 1 OesLrecep,zf-C4,hormone_rec 5.78 421685 AF189723 Hs.106778 ATPase, Ca++ transporting, type 2C, memb E1 -E2_ATPase,Hydrolase 5.37 444042 NM 004915 Hs.10237 ATP-binding cassette, sub-family G (WHIT ABCJran 5.31 447752 M73700 Hs.105938 lactotransferrin transferrin,7tm 1 529 407945 X69208 Hs.606 ATPase, Cu++ transporting, alpha polypep E1-E2_ATPase,Hydrolase,HMA 5.08 403047 trypsin 4.91 427617 D42063 Hs.199179 RAN binding protein 2 Ran_BP1 ,zf-RanBP,TPR,pro_isomerase 422083 NM 001141 Hs.111256 arachidonate 15-lipoxygenase, second typ lipoxygenase.PLAT 4.82 449535 W15267 Hs.23672 low density lipoprotein receptor-related ldl_recepLb,ldLrecepLa,EGF 4.82 425071 NM_013989 Hs.154424 deiodinase, iodothyronine, type II T4_deiodinase 4.32 423740 Y07701 HS293007 aminopeptidase puromydn sensitive Peptidase_M1 424 424701 NM 005923 Hs.151988 mitogen-activated protein kinase kinase pkinase 421 424085 NM 002914 Hs.139226 replication fador C (activator 1) 2 (40 AAA,Viral_helicase1 420 417531 NM 003157 Hs.1087 serine/threonine kinase 2 pkinase " 4.12 428695 AI355647 Hs.189999 purinergic receptor (family A group 5) 7tm_1 3.91 410011 AB020641 Hs.57856 PFTAIRE protein kinase 1 pkinase 3.91 424850 AA151057 Hs.153498 chromosome 18 open reading frame 1 IdLrecepLa 3.82 412350 AI659306 Hs.73826 protein tyrosine phosphatase, non-recept Y_phosphatase,Band_41 ,PDZ 3.70 447397 BE247676 Hs.18442 E-1 enzyme Hydrolase 3.68 452946 X95425 Hs.31092 EphA5 EPH_lbd,fn3,pkinase,SAM 3.66 427144 X95097 Hs.2126 vasoactive intestinal peptide receptor 2 7tm_2 3.65 443775 AF291664 Hs.204732 matrix metalloproteinase 26 Peptidase M10 3.56 457940 AL360159 Hs.306517 Homo sapiens TRIpartite motif protein ps SPRY,7tm_1 3.52 418250 U29926 Hs.83918 adenosine monophosphate deaminase (isofo A_deaminase 3.51 413435 X51405 Hs.75360 caiboxypeptidase E Zn_carbθpept 3.46 447210 AF035269 Hs.17752 phosphatidylserine-spedfic phospholipas lipase 3.46 TABLE 8: 136 GENES SIGNIFICANTLY DOWN-REGULATED IN PROSTATE CANCER COMPARED TO NORMAL PROSTATE Table 8 shows 136 genes significantly down-regulated in prostate cancer compared to normal prostate . These were selected from 59680 probesets on the Affymetrix Eos Hu03 GeneChip array such that the ratio of "average" normal prostate to "average" prostate cancer tissues was greater than or equal to 2. The "average" normal prostate level was set to the mean amongst 4 normal prostate tissues. The "average" prostate cancer level was set to the 85 th percentile amongst 73 tumor samples. In order to remove gene-specific background levels of non- specific hybridization, the 10 th percentile value amongst all the tissues was subtracted from both the numerator and the denominator before the ratio was evaluated. Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD: Unigene number Unigene Title: Unigene gene title R1: Ratio of normal prostate to prostate cancer Pkey ExAccn UnigenelD Unigene Title R1 425932 M81650 Hs.1968 semenogelin I 57.69 425545 N98529 Hs.158295 Human mRNA for myosin light chain 3 (MLC 19.70 426752 X69490 Hs.172004 titin 1525 442082 R41823 Hs.7413 ESTs; calsyntenin-2 10.05 407245 X90568 Hs.172004 titin 9.38 422711 D60641 Hs21739 Homo sapiens mRNA; cDNADKFZp586M518 (f 9.05 420813 X51501 Hs.99949 prolactin-induced protein 8.18 411987 AA375975 Hs.183380 "ESTs, Moderately similar to ALU7_HUMAN 7.45 404567 5.62 416030 H15261 Hs.21948 ESTs 5.51 444892 AI620617 Hs.148565 ESTs 527 444573 AW043590 Hs225023 ESTs 520 428068 AW016437 HS233462 ESTs 5.08 437440 AA846804 Hs.123694 ESTs 4.95 404113 4.75 452279 AA286844 Hs.61260 hypothetical protein FU13164 4.75 421058 AW297967 Hs.188181 ESTs 4.63 445592 AV654382 Hs.17947 "ESTs, Weakly similar to K02F3.10[C.ele 4.53 405163 4.49 405227 4.45 454059 NM_003154Hs.37048 statherin 4.45 450152 AI138635 Hs22968 ESTs 4.40 407013 U35637 "gb:Human nebulin mRNA, partial eds" 4.03 403612 4.02 440089 AA864468 Hs.135646 ESTs 4.00 AL119844 Hs.49476 Homo sapiens done TUA8 Cri-du-chat regi 3.98 436726 AA324975 Hs.128993 "ESTs, Weakly similar to KIAA0465 protei 3.95 459367 BE148877 "gb:CM4-HT0244-111199-040-h12 HT0244 Horn 3.95 427318 AF186081 Hs.175783 zinc transporter 3.92 411762 AW860972 "gb:QVO-CT0387-180300-167-h07 CT0387 Horn 3.85 418668 AW407987 Hs.87150 Human done A9A2BR11 (CAC)n/(GTG)n repea 3.75 458311 AF069478 "gb:AF069478 Homo sapiens astrocytoma li 3.61 403649 3.60 419682 H13139 Hs.92282 paired-like homeodomain transcription fa 3.58 412519 AA196241 Hs.73980 "troponin TI, skeletal, slow" 3.51 414206 AW276887 Hs.46609 ESTs 3.45 427419 NM_000200Hs.177888 histatin 3 3.37 420777 AA280223 Hs.130865 ESTs 3.35 428134 AA421773 Hs.161008 ESTs 3.31 450218 R02018 Hs.168640 "Ank, mouse, homolog of 3.30 433474 AI192195 Hs.147174 "EST, Highly similar to ubiquitin-protei 3.30 418833 AW974899 Hs.292776 ESTs 3.26 400440 X83957 Hs.83870 nebulin 3.16 413778 AA090235 Hs.75535 "myosin, light polypeptide 2, regulatory 3.06 423151 AW838068 "gb:QV3-LT0048-010300-109-f02 T0048 Hom 3.05 445060 AA830811 Hs.88808 ESTs 2.98 457065 AI476318 Hs.192480 ESTs 2.95 432456 H00093 "gb:ph8f12u_19/1TV Outward Alu-prime hn 2.92 405678 2.85 406707 S73840 Hs.931 "myosin, heavy polypeptide 2, skeletal m 2.81 444105 AW189097 Hs.166597 ESTs 2.78 433968 AL157518 Hs.90421 PR02463 protein 2.73 438522 AA809431 Hs258886 ESTs 2.73 436562 H71937 Hs.169756 "complement component 1, s subcomponent" 2.68 412417 AA102268 Hs.42175 ESTs 2.67 455590 BE072259 "gb:QV4-BT0536-271299-059-g04 BT0536 Horn 2.65 415380 F07953 Hs.16085 pulative G-protein coupled receptor 2.65 428729 AL162331 Hs.191436 hypothetical protein FU 10619 2.64 408537 AW207734 "gb:UI-H-BI2-age-h-01-0-Ul.s1 NCI_CGAP_S 2.63 424706 AA741336 Hs.152108 transcriptional unit N 143 2.63 413212 BE072092 "gb:PM4-BT0532-160200-003-b11 BT0532 Hom 2.63 406704 M21665 Hs.929 "myosin, heavy polypeptide 7, cardiac mu 2.62 437507 AA758538 Hs.246882 ESTs 2.60 410384 AI933794 Hs.42745 ESTs 2.58 408074 R20723 Hs.124764 ESTs 2.58 436653 AA829828 Hs292402 ESTs 2.52 458090 AI282149 Hs.56213 "ESTs, Highly similar to FXD3_HUMAN FORK 2.51 432003 AI689154 Hs.122972 ESTs 2.50 436915 AA737400 Hs.142230 ESTs 2.50 410028 AW576454 Hs258553 ESTs 2.46 448920 AW408009 Hs.22580 alkylglycerone phosphate synthase 2.45 422046 AI638562 "gb:ts50a10.x1 NCI_CGAP_Ut1 Homo sapiens 2.44 451122 AA015767 Hs.193587 ESTs 2.40 422646 H87863 Hs.151380 ESTs 2.36 451237 AW600293 "gb:ESTOO049 pGEM-T library Homo sapiens 2.36 400001 AFFX control: BioB-3 2.36 415835 Z45365 "gb:HSC2NF061 normalized infant brain cD 2.36 439706 AW872527 Hs.59761 ESTs 2.36 423341 AW242394 Hs.252495 ESTs 2.36 436486 AA742221 Hs.120633 ESTs 2.35 407449 AJ002784 gb:Homo sapiens mRNA; fetal brain cDNA 5 2.33 430573 AA744550 Hs.136345 ESTs 2.32 401974 2.31 443356 AL044498 Hs.133262 "ESTs, Weakly similar to PH0217 reverse 2.31 430751 NM 012471 Hs247868 transient receptor potential channel 5 2.25 439128 AI949371 Hs.153089 ESTs 2.25 448765 R15337 Hs21958 "Homo sapiens CDNAFU10532 fis, done N 225 451130 AI762250 Hs211347 ESTs 224 405420 2.23 455029 AW851258 "gb:IL3-CT0220-160200-066-H06 CT0220 Horn 2.23 438224 AA933999 "gb.on91f04.s1 Soares_NFL_T_GBC S1 Homo 223 407764 BE008347 "gb:CMO-BN0154-080400-325-h04 BN0154 Horn 223 413549 BE252470 "gb:601108292F1 NIH_MGC_16 Homo sapiens 223 437010 AA741368 Hs291434 ESTs 2.23 435111 AI914279 Hs213740 ESTs 2.22 403375 2.21 455060 AW853441 "gb:RC1-CT0252-030100-023-g09 CT0252 Hom 2.21 409792 AW854153 "gb:RC3-CT0254-060400-029-d03 CT0254 Horn 2.20 421154 AA284333 Hs287631 "Homo sapiens cDN A FU 14269 fis, done P 2.19 401963 2.18 435034 AF168711 Hs.159397 xOIO protein 2.18 448996 AW998989 Hs.105749 KIAA0553 protein 2.18 436816 AW297599 Hs255667 ESTs 2.17 442252 AI733395 Hs.129124 ESTs 2.17 419310 AA236233 Hs.188716 ESTs 2.16 418579 H91800 Hs.124156 ESTs 2.16 423315 R54109 Hs26096 ESTs 2.16 432744 AA988835 Hs.38664 ESTs 2.15 424492 AI133482 Hs.165210 ESTs 2.15 424770 AA425562 "gb:zw46e05.r1 Soares_total_fetus_Nb2HF8 2.15 437101 AA744518 Hs.120610 ESTs 2.15 428793 AC004957 Hs298975 "ESTs, Highly similar to collapsin-2-lik 2.15 415708 H56475 "gb:yt87d11.r1 Soares_pineal_gland_N3HPG 2.13 459619 2.12 427506 AK000134 Hs.179100 hypothetical protein FU20127 2.12 452508 AA804174 Hs.184354 ESTs 2.10 410881 AW809157 "gb:RCO-ST0118-041099-031-c07_1 ST0118 Homo sapiens cDNA, mRNA sequence" 2.10 403087 2.10 403869 2.10 445028 D81194 Hs.282499 ESTs 2.10 447884 H29505 "gb:ym60d10. Soares infant brain 1NIB Homo sapiens cDNA clone 5', mRNA sequence" 2.10 414575 H11257 Hs.295233 ESTs 2.09 420351 BE218221 Hs.190044 ESTs 2.08 426998 BE274360 "gb:601121068F1 NIH_MGC_20 Homo sapiens cDNA clone 5', mRNA sequence" 2.08 405455 2.08 423843 AA332652 "gb:EST36627 Embryo, 8 week I Homo sapiens cDNA 5' end similar to similar to monoamine oxidase B, mRNA sequence" 2.08 406135 2.07 427046 BE246180 Hs.121385 ESTs 2.07 403493 2.05 444514 AI682905 Hs.270431 "ESTs, Weakly similarto ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION WARNING ENTRY [H.sapiens]" 2.05 435884 AA701443 Hs.192868 ESTs 2.05 419629 AB020695 Hs.91662 KIAA0888 protein 2.03 405900 ~ 2.03 457350 AW974438 Hs.194136 "ESTs, Moderately similar to AF0914571 zinc finger protein RIN ZF [R.norvegicus]" 2.02 400007 AFFX control: BioDn-5 2.01 406978 M64358 "gb:Human rhom-3 gene, exon." 2.00 TABLE 8A shows the accession numbers for those primekeys lacking a unigenelD in Table 8. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column. Pkey: Unique Eos probeset identifier number CAT number Gene duster number Accession: Genbank accession numbers Pkey CAT number Accessions 407764 1014849 BE008347 BE008320 BE083307 BE083311 AW075968 408537 1064753J AW207734 D60164 D81150 D81078 D61356 AW996804 409792 1154677J AW854153 AW500210 BE145772 AW501310 410881 1225682J AW809157AW812181 AW812175 AW812172 AW812161 AW812165 411762 1256906J AW860972 AW862598 AW862599 AW860988 AW860983 AW860898 AW860925 AW860922 AW860986 AW860984 AW860989 413212 1353792J BE072092 BE072106 BE072086 BE072098 BE072103 413549 1375933_2 BE252470 BE147573 415708 1548209J H56475 F29401 F34552 415835 1558511J Z45365 R25905 H05203 T77496 422046 210744J AI638562 T16929 H13401 F07773 R55836 423151 225415J AW838068 AW837986 AW838067 AA322487 AW837936 423843 232510J AA332652 AA331633 AW999369AW902993 BE170475 AA378845 AW964175 AI475221 424770 243504J AA425562 AI880208 AA346646 N22655 AW811775 AW811786 426998 274259_-1 BE274360 432456 347718_2 H00093 H00079 H00070 H00054 H00049 H00063 AW905306 AW905241 AW905410 AW905307 AW905411 AW905240 AW905210 AW905352 AW905304 AW905239 AW905242 AW905243 H00087 438224 452656J AA933999 AA781181 447884 740749J H29505 R18575 Z43580 T48738 AI435454 BE004683 451237 863269J AW600293 AI767468 455029 1249374J AW851258 AW851435AW851106 AW851421 455060 1251259J AW853441 BE145228 BE145218 BE145162 BE145283 455590 1335127J BE072259 BE072230 BE007911 458311 543550J AF069478 AF069479 AF069480 TABLE 8B shows the genomic positioning for those primekeys lacking unigene ID's and accession numbers in table 8. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed. Pkey: Unique number corresponding to an Eos probeset Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (Gl) numbers. "Dunham I. et al." refers to the publication entitled The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. Strand: Indicates DNA strand from which exons were predided. NLposition: Indicates nudeotide positions of predided exons. Pkey Ref Strand NLposition 401963 3126783 Plus 51382-51521 401974 3126777 Plus 85330-85683 403087 8954241 Plus 169511-169795 403375 9255944 Minus 92554-92795 403493 7341425 Plus 157568-159084 403612 8469060 Minus 94723-94859 403649 8705159 Minus 27141-27247 403869 7280046 Minus 34379-34583 404113 9588571 Minus 13446-13646 404567 7249169 Minus 101320-101501 405163 9966267 Minus 161171-161299 405227 6731245 Minus 22550-22802 405420 7211837 Minus 13428-13582 405455 7656675 Plus 134112-134671 405678 4079670 Plus 151821-152027 405900 6758795 Minus 71181-71535 406135 9164918 Minus 65489-65715 TABLE 9: 1001 GENES SIGNIFICANTLY UP-REGULATED IN NORMAL PROSTATE COMPATED TO PROSTATE CANCER Table 9 shows 1001 genes significantly up-regulated in prostate cancer compared to normal prostate. These were selected from 59680 probesets on the Affymetrix/Eos Hu03 GeneChip array such that the ratio of "average" normal prostate to "average" prostate cancer tissues was greater than or equal to 8.14. The "average" normal prostate level was set to the mean amongst 4 normal prostate tissues. The "average" prostate cancer level was set to the 85 th percentile amongst 73 tumor samples. In order to remove gene-specific background levels of non-specific hybridization, the 10 th percentile value amongst all the tissues was subtracted from both the numerator and the denominator before the ratio was evaluated. Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD: Unigene number Unigene Title: Unigene gene title R1: Ratio of prostate cancer to normal prostate Pkey ExAccn UnigenelD Unigene Title R1 451002 AA013299 Hs.8018 ESTs, Weakly similar to ALU3 HUMAN ALU S 1684.00 435596 AA689465 Hs.188999 ESTs 738.00 443576 AI078027 Hs.169338 ESTs 246.86 434247 AA928116 HS272065 ESTs 245.20 400452 AK000185 gb:Homo sapiens cDNA FU20178 fis, clone 222.00 405932 221.33 427906 AA864330 Hs.166520 ESTs 212.00 443685 AI686550 Hs.174481 ESTs 16320 451554 AI474866 Hs.193237 ESTs 149.45 418323 NM 002118 Hs.1162 major histocompatibility complex, dass 126.11 429480 M36860 Hs.9295 elastin (supravalvular aortic stenosis, 12327 426025 AW138330 HS233778 ESTs 120.00 418917 X02994 Hs.1217 adenosine deaminase 106.75 404407 105.71 442027 AI652926 Hs.128395 ESTs 100.53 433704 AA608684 Hs.121705 ESTs, Moderately similar to ALUC HUMAN ! 94.00 453758 U83527 gb:HSU83527 Human fetal brain (M.Lovett) 89.18 415354 F06495 gb:HSC1AB051 normalized infant brain cDN 87.73 424239 M67439 Hs.143526 dopamine receptor D5 86.82 444143 AW747996 Hs.160999 ESTs 86.43 401672 7726 430590 AW383947 Hs246381 CD68 antigen 68.47 411972 BE074959 gb:PMO-BT0582-310100-001-f08 BT0582 Homo 68.00 448992 AI766053 Hs.188346 ESTs 6126 408828 BE540279 gb:601059857F1 NIH MGC 10 Homo sapiens c 57.71 409653 AW451693 HS220826 ESTs " 56.40 402964 54.67 422673 N59027 gb:yv59d11.r1 Soares fetal liver spleen 54.00 422568 AA372275 Hs279800 Homo sapiens cDNA FU11383 fis, done HE 54.00 438907 R32704 Hs.301298 ESTs 52.96 405172 52.96 444897 AW137088 Hs.144857 ESTs 52.32 458019 AW592931 Hs256298 ESTs 51.63 405275 AB028989 Hs.88500 mitogen-activated protein kinase 8 inter 50.98 457815 AA703679 Hs.106999 ESTs, Weakly similar to SYT5_HUMAN SYNAP 49.60 424385 AA339666 gb:EST44776 Fetal brain I Homo sapiens c 48.90 407172 T54095 gb:ya92c05.s1 Stratagene placenta (93722 47.98 428202 AA424163 Hs.156895 ESTs 46.83 435672 AI700148 HS283626 ESTs 43.57 420283 AA485224 Hs.57734 G protein-coupled receptor kinase-intera 43.00 417016 AA837098 Hs269933 ESTs 42.70 438854 AF074994 HS24240 ESTs 42.67 406134 42.43 457319 AA480895 Hs.201552 ESTs, Weakly similar to T17288 hypotheti 42.31 409314 AA070266 gb:zm69d04.r1 Stratagene neuroepithelium 4225 401124 41.61 429316 AI371157 Hs.178538 ESTs 40.00 420317 AB006628 Hs.96485 KIAA0290 protein 39.64 457586 AW062439 gb:MRO-CT0060-120899-001-f08 CT0060 Homo 39.60 417407 AA923278 Hs.290905 ESTs, Weakly similar to protease [H.sapi 38.73 430269 BE221682 Hs.178364 ESTs 38.06 439602 W79114 Hs.58558 ESTs 36.69 433686 AA604799 Hs.136528 ESTs, Moderately similar to ALU1 HUMAN A 3629 417993 AW963705 Hs.295806 ESTs, Weakly similar to ALU7 HUMAN ALU S 36.18 428214 AA936282 Hs.120397 ESTs 36.10 416908 AA333990 Hs.80424 coagulation fador XIII, A1 polypeptide 36.08 426264 BE314852 Hs.168694 hypothetical protein FU10257 36.00 415911 H08796 Hs.124952 ESTs 36.00 457502 AA076049 Hs274415 Homo sapiens cDNA FU10229 fis, done HE 3523 421566 NM 000399 Hs.1395 early growth response 2 (Krox-20 (Drosop 3520 401468 34.89 458561 AI220150 Hs.211195 ESTs 34.60 433601 BE350738 Hs.123993 ESTs, Weakly similar to T00366 hypotheti 3324 454977 AW848032 gb:IL3-CT0214-231299-053-D11 CT0214 Homo 32.96 402828 32.93 414522 AW518944 Hs.76325 Homo sapiens cDNA: FU23125 fis, done L 31.76 402842 31.68 421245 AA285363 gb:HTH280 HTCDL1 Homo sapiens cDNA 573' 31.59 401631 F05183 Hs.1799 CD1D antigen, d polypeptide 3126 408057 AW139565 gb:UI-H-BI1-aea-d-04-0-Ul.s1 NCI_CGAP_Su 3124 408069 H81795 gb:ys68a10.r1 Soares retina N2b4HR Homo 3120 438694 T87479 Hs.291797 ESTs 31.09 449156 AF103907 Hs.171353 prostate cancer antigen 3 29.78 428796 AU076734 Hs.193665 solute carrier family 28 (sodium-coupled 29.76 452549 AI907039 gb:PM-BT134-020499-566 BT134 Homo sapien 29.59 410129 BE244074 Hs.285531 regulator of Fas-induced apoptosis 29.53 414464 AI870175 Hs.13957 ESTs 29.47 412326 R07566 Hs.73817 Small inducible cytokine A3 (homologous 2922 459081 W07808 gb:zb03a12.r1 Soares fetal lung NbHL19W 2920 448702 AW102670 Hs.122464 ESTs 29.13 451939 U80456 Hs.27311 single-minded (Drosophila) homolog 2 28.74 443412 W84893 Hs.9305 angiotensin receptor-like 1 28.61 457324 AB028990 Hs243901 KIAA1067 protein 2824 424247 X14008 Hs.234734 lysozyme (renal amyloidosis) 28.18 457140 AI279960 Hs.178140 ESTs 28.12 444151 AW972917 Hs.128749 alpha-methylacyl-CoA racemase 28.06 457669 AW104257 Hs.123426 ESTs, Weakly similar to putative serine/ 27.61 412429 AV650262 Hs.75765 GR02 oncogene 27.36 405495 27.33 406516 2725 407997 AW135429 Hs.243577 ESTs 26.96 442115 AW452332 HS257554 ESTs 26.36 409038 T97490 Hs.50002 small inducible cytokine subfamily A (Cy 26.34 402838 26.32 449846 AI979284 HS200552 ESTs - 2621 417153 X57010 Hs.81343 collagen, type II, alpha 1 (primary oste 2620 439792 NM 014856 Hs.6684 KIAA0476 gene produd 25.91 450096 AI682088 Hs.2233δ8 ESTs 25.60 424196 AL133660 Hs.142926 Homo sapiens mRNA; cDNA DKFZp434M0927 (f 25.57 414246 BE391090 Hs.280278 EST 25.57 420848 NM 005188 Hs.99980 Cas-Br-M (murine) ecotropic retroviral t 25.48 424778 AA251048 Hs.153042 lymphocyte antigen 9 25.42 409126 AA063426 gb:zf70c08.s1 Soares_pineaLgland_N3HPG 2525 443936 AW083491 Hs.31196 ESTs 2522 419392 W28573 gbSWO Human retina cDNA randomly prim 25.01 411201 T74588 Hs.8509 ESTs, Weakly similar to C03 HUMAN COMPLE 24.85 422940 BE077458 gb:RC1-BT0606-09050!M)15-b04 BT0606 Homo 24.76 437571 AA760894 Hs.153023 ESTs 24.74 433973 AI014723 Hs.131770 ESTs 24.57 422416 BE019557 Hs.11900 Human DNA sequence from done RP4-583P15 24.53 421552 AF026692 Hs.105700 secreted frizzled-related protein 4 24.49 443668 U25758 Hs.134584 ESTs 24.49 424800 AL035588 Hs.153203 MyoD family inhibitor 24.10 453633 AA357001 Hs.34045 hypothetical protein FU20764 24.04 430565 AL122081 Hs.244343 cad erin related 23 24.00 433694 AI208611 Hs.12066 Homo sapiens cDNA FI-J11720 fis, clone HE 23.89 451045 AA215672 gb:zr96e09.s1 NCI CGAP GCB1 Homo sapiens 23.83 408583 AW449674 Hs.47359 ESTs 23.73 444040 AF204231 Hs.182982 golgin-67 23.62 414182 AA136301 gb:zk93g04.s1 Soares_pregnanLuterus_NbH 23.39 418678 NM 001327 Hs.167379 cancer/testis antigen 2320 408380 AF123050 Hs.44532 diublquitin 22.68 456076 BE243877 Hs.76941 ATPase, Na+/K+ transporting, beta 3 poly 22.65 418299 AA279530 Hs.83968 integrin, beta 2 (antigen CD18 (p95), ly 22.38 444917 R68651 Hs.144997 ESTs 2226 444381 BE387335 Hs.283713 ESTs 22.08 415788 AW628686 Hs.78851 KIAA0217 protein 22.04 410896 AW809637 gb:MR4-ST0124-261099-015-b07 ST0124 Homo 22.00 412978 AI431708 Hs.820 homeo boxCβ 21.95 458418 AV653846 Hs.126261 Homo sapiens Chromosome 16 BAC done CIT 21.94 454791 BE071874 gb:RC2-BT0522-120200-014-a06 BT0522 Homo 21.84 408748 J05500 Hs.47431 spectrin, beta, erythrocytic (indudes s 2126 416011 H14487 gb:ym18c10.r1 Soares infant brain 1NIB H 2124 440474 AI207936 Hs.7195 gamma-aminobutyric add (GABA) A recepto 21.14 447047 AI623698 Hs.246306 Homo sapiens cDNA: FU23529 fis, done L 21.11 426793 X89887 Hs.172350 HIR (histone cell cyde regulation defec 21.10 409841 AW502139 gb:UI-HF-BR0p-ajr-e-05-O-Ul.r1 NIH_MGC_5 21.07 405685 20.90 457359 AI983207 Hs.192481 ESTs, Weakly similar to SYPH HUMAN SYNAP 20.84 423067 AA321355 Hs.285401 ESTs 20.74 422355 AW403724 Hs.140 immunoglobulin heavy constant gamma 3 (G 20.73 401201 20.73 458278 W28912 Hs.129019 ESTs 20.68 439097 H66948 gb:yr86d10.r1 Soares fetal liver spleen 20.67 414875 H42679 Hs.77522 major histocompatibility complex, class 20.66 400926 20.66 451355 NM 004197 Hs.444 serine/threonine kinase 19 20.64 446982 AW500221 Hs.43616 Homo sapiens mRNA for FLJ00029 protein, 20.61 417105 X60992 Hs.81226 CD6 antigen 20.61 405777 20.51 424123 AW966158 Hs.58582 Homo sapiens cDNA FU12702 fis, clone NT 2020 425009 X58288 Hs.154151 protein tyrosine phosphatase, receptor t 20.10 443271 BE568568 Hs.195704 ESTs 19.98 421064 AI245432 Hs.101332 tumor necrosis factor, alpha-induced pro 19.98 418819 AA228776 Hs.191721 ESTs 19.94 457595 AA584854 gb:no09h11.s1 NCI_CGAP_Phe1 Homo sapiens 19.90 404426 19.84 412571 U43143 Hs.74049 fms-related tyrosine kinase 4 19.79 431457 NM--012211 Hs.256297 integrin, alpha 11 19.62 414002 NM_006732 Hs.75678 FBJ murine osteosarcoma viral oncogene h 19.57 418994 AA296520 Hs.89546 Seledin E (endothelial adhesion molecul 19.56 437158 AW090198 Hs.4779 KIAA1150 protein 19.52 437866 AA156781 Hs.83992 ESTs 19.44 417421 AL138201 Hs.82120 nudear receptor subfamily 4, group A, m - 19.34 433057 X15675 Hs.296832 Human pTR7 mRNA for repetitive sequence 1922 421730 AW449808 Hs.164036 glucosamine (N-acetyl)-6-sulfatase (Sanf 1921 456557 AA284477 Hs.96618 ESTs 18.77 440806 AI247422 Hs.129966 ESTs 18.76 439845 AL355743 Hs.56663 Homo sapiens EST from done 41214, full 18.65 416155 AI807264 Hs.205442 ESTs, Weakly similar to AF1176101 inner 18.64 437820 AA769062 Hs.16029 ESTs, Weakly similar to alternatively sp 18.62 450923 AW043951 Hs.38449 ESTs 18.59 418329 AW247430 Hs.84152 cystathionine-beta-synthase 18.58 424537 AI673027 Hs.143271 ESTs 18.55 447742 AF113925 Hs.19405 caspase recruitment domain 4 18.52 415251 R42863 Hs.7124 ESTs 18.47 440770 AA912815 Hs.222078 ESTs 18.40 407711 AI085846 Hs.25522 ESTs 18.32 427157 U51166 Hs.173824 thymine-DNAglycosylase 1828 409847 AW501751 Hs.279733 ESTs 18.15 417240 N57568 Hs.176028 EST 18.13 435732 AF229178 Hs.123136 leudne rich repeat and death domain con 18.12 436896 AW977385 Hs.278615 ESTs 18.12 432485 N90866 Hs.276770 CDW52 antigen (CAMPATH-1 antigen) 17.90 429490 AI971131 Hs.293684 ESTs, Weakly similar to alternatively sp 17.82 429984 AL050102 Hs.227209 DKFZP586F1019 protein 17.82 449214 AI889114 Hs.195663 ESTs 17.75 433867 AK000596 Hs.3618 hippocaldn-like 1 17.72 431735 AW977724 Hs.75968 thymosin, beta 4, X chromosome 17.71 401515 17.67 444045 AI097439 Hs.135548 ESTs 17.58 442754 AL045825 Hs.210197 ESTs 17.55 426559 AB001914 Hs.170414 paired basic amino acid deaving system 17.54 432415 T16971 Hs.289014 ESTs 17.50 427829 AI188225 Hs.127462 ESTs 17.50 432516 R08003 Hs.188013 ESTs 17.44 435259 AA152106 Hs.4859 cydin L ania-6a 17.36 414989 T81668 gb:yd29c04.r1 Soares fetal liver spleen 17.31 444880 AW118683 Hs.154150 ESTs 17.30 417651 R06874 Hs.268628 ESTs 1727 453457 AL037103 Hs270599 ESTs, Weakly similar to unnamed protein 1722 424246 AW452533 Hs.143604 Kaiso 1722 419078 M93119 Hs.89584 insulinoma-assodated 1 17.18 417696 BE241624 Hs.82401 CD69 antigen (p60, early T-cell acth ati 17.14 431117 AF003522 Hs250500 delta (Drosophila)-.ike 1 17.14 455254 AW877015 gb:QV2-PT0010-250300-096-f12 PT0010 Homo 17.14 425782 U66468 Hs.159525 cell growth regulatory with EF-hand doma 17.12 426678 H08170 Hs.113755 ESTs 17.12 426403 NM_000361 Hs.2030 thrombomodulin 17.01 425905 AB032959 Hs.161700 KIAA1133 protein 17.00 438867 AW451157 Hs.181157 ESTs 16.98 420940 AA830664 Hs.143974 ESTs 16.94 459234 AI940425 gb:CMO-CT0052-150799-024-c04 CT0052 Homo 16.92 404756 16.91 422247 U18244 Hs.113602 solute carrier family 1 (high affinity a 16.90 420568 F09247 Hs.167399 protocadherin alpha 5 16.88 443559 AI076765 Hs.269899 ESTs 16.80 438703 AI803373 Hs.31599 ESTs 16.78 411424 AW845985 gb:RC2-CT0163-200999-002-H08 CT0163 Homo 16.70 402895 16.69 422538 NM_006441 Hs.118131 5,10-methenyltetrahydrofolate synthetase 16.68 447108 AW449602 Hs.217953 ESTs, Moderately similar to NK-TUMOR REC 16.65 448520 AB002367 Hs21355 doublecortin and CaM kinase-llke 1 16.54 438567 AW451955 Hs.153065 ESTs 16.52 407811 AW190902 Hs.40098 cysteine knot superfamily 1 , BMP antagon 16.50 410721 R23534 Hs.2730 heterogeneous nudear ribonudeoprotein 16.50 437133 AB018319 Hs.5460 KIAA0776 protein 16.40 408182 AA047854 gb:zf49g04.r1 Soares retina N2b4HR Homo 16.32 417315 AI080042 Hs.180450 ribosomal protein S24 16.30 431840 AA5349Q8 Hs.2860 POU domain, dass 5, transcription fado 1628 439882 AA847856 Hs.124565 ESTs 1620 418277 AW135221 Hs.130812 ESTs 16.09 410688 AW796342 gb:PM2-UM0027-230200-002-h02 UM0027 Homo ' 16.04 420120 AL049610 Hs.95243 transcription elongation fador A (Sll)- 16.04 429597 NM_003816 Hs.2442 a disintegrin and metalloproteinase doma 16.02 447033 AI357412 Hs.157601 EST - not in UniGene 16.02 421684 BE281591 Hs.106768 hypothetical protein FU10511 15.94 408599 AA055800 Hs222933 ESTs 15.93 446012 AV656098 Hs.172382 hypothetical protein FU20001 15.86 409671 AA076769 gb:7B02B10 Chromosome 7 Fetal Brain cDNA 15.85 405934 . 15.84 426108 AA622037 Hs.166468 programmed cell death 5 15.84 416208 AW291168 Hs.41295 ESTs 15.48 410708 AA534370 Hs.154088 Homo sapiens cDNA: FU22756 fis, done K 15.42 447342 AI199268 Hs.19322 ESTs; Weakly similar to III! ALU SUBFAMI 15.38 454563 AW807530 gb:CMO-ST0081-130999-054-d02 ST0081 Homo 15.37 411507 AW850140 gb:IL3-CT0219-261099-023-D11 CT0219 Homo 15.36 438170 AI916685 Hs.194601 ESTs 1529 416292 AA179233 Hs.42390 nasopharyngeal carcinoma susceptibility 1526 406638 M13861 gb:Human T-cell receptor adive beta-cha 1526 446686 AW138043 Hs.156307 ESTs 1525 434485 AI623511 Hs.118567 ESTs 1524 441188 AW292830 HS255609 ESTs 1522 444172 BE147740 Hs.104558 ESTs 1522 409521 BE244854 Hs.159578 Homo sapiens mRNA for FU00020 protein, 15.16 420748 AA279956 Hs.88672 ESTs 15.14 422583 AA410506 Hs.118578 H.sapiens mRNA for ribosomal protein L18 15.14 424240 AB023185 Hs.143535 caldum calmodulin-dependent protein kin 15.12 451118 AI862096 Hs.60640 ESTs 15.12 437495 BE177778 gb:RC1-HT0598-310300-012-f07 HT0598 Homo 15.12 445467 AI239832 Hs.15617 ESTs, Weakly similar to ALU4 HUMAN ALU S 15.06 418305 AW006783 Hs.6686 ESTs 15.03 402812 15.02 436851 AA732480 Hs.293581 ESTs 15.00 400991 15.00 415752 BE314524 Hs.78776 Human putative transmembrane protein (nm 14.96 429900 AA460421 Hs.30875 ESTs 14.90 403683 14.84 430315 NM 004293 Hs239147 guanine deaminase 14.80 451952 AL120173 Hs.301663 ESTs 14.72 424687 J05070 Hs.151733 matrix metalloproteinase 9 (gelatinase B 14.69 447229 BE617135 gb:601441677F1 NIH_MGC_65 Homo sapiens c 14.67 425818 AB021225 Hs.159581 matrix metalloproteinase 17 (membrane-in 14.65 448553 AI638449 Hs.173031 ESTs 14.63 431089 BE041395 Hs283676 ESTs, Weakly similar to unknown protein 14.60 459145 AI903354 gb:RC-BT029-100199-117 BT029 Homo sapien 14.55 449650 AF055575 Hs297647 ESTs, Moderately similar to caldum chan 14.54 400952 14.46 445885 AI734009 Hs.127699 EST duster (not in UniGene) 14.44 407938 AA905097 Hs.85050 phospholamban 14.42 431676 AI685464 HS292638 ESTs 14.40 437210 AA311443 HS293563 Homo sapiens mRNA; cDNA DKFZp586E2317 (f 14.36 451900 AB023199 HS27207 K1AA0982 protein 14.36 445800 AA126419 Hs.301632 ESTs 14.32 412368 AW945992 Hs.181125 immunoglobulin lambda locus 14.31 409055 AW304028 Hs.300578 ESTs 1423 408763 W57550 Hs.301526 Homo sapiens cDNA FU13181 fis, done NT 1422 446734 AL049278 Hs.16074 Homo sapiens mRNA; cDNA DKFZp564l153 (fr 1422 413551 BE242639 Hs.75425 ub-quitin associated protein 1422 421913 AI934365 Hs.109439 osteoglydn (osteoinductive fador, mime 1422 452712 AW838616 gb:RC5-LT0054-140200-013-D01 LT0054 Homo 1422 451468 AW503398 HS210047 ESTs 14.16 406038 Y14443 Hs.88219 zinc finger protein 200 14.14 424909 S78187 Hs.153752 cell division cycle 25B 14.07 434078 AW880709 HS283683 EST 14.07 415254 AI815831 Hs.184378 ESTs 14.05 418196 AI745649 Hs26549 ESTs, Weakly similar to T00066 hypotheti 14.02 410020 T86315 Hs.728 ribonudease, RNase A family, 2 (liver, 13.98 411352 NM 002890 Hs.758 RAS p21 protein activator (GTPase activa 13.98 429848 AF145439 Hs225946 chemokine (C-C motif) receptor 9 13.95 413729 BE159999 gb:QV1-HT0412-270300-123-d10 HT0412 Homo 13.90 400125 - 13.88 420319 AW406289 Hs.96593 hypothetical protein 13.85 448272 AI479094 Hs.170786 ESTs 13.80 422695 AA315158 gb:EST186956 HCC cell line (matastasis t 13.80 424565 AW102723 Hs.75295 guanylate cydase 1 , soluble, alpha 3 13.78 458048 H30340 Hs.173705 Homo sapiens cDNA: FLJ22050 fis, clone H 13.78 408894 AI935400 Hs217286 ESTs 13.76 454093 AW860158 gb:RCO-CT0379-290100-032-b04 CT0379 Homo 13.75 410889 X91662 Hs.66744 twist (Drosophila) homolog (acrocephatos 13.74 457751 AI908236 gb:IL-BT166-180399-010 BT166 Homo sapien 13.72 455131 AW857913 gb:RC0-CT0323-231199-031-b05 CT0323 Homo 13.69 408364 AW015238 Hs.128453 ESTs 13.67 425907 AA365752 Hs.155965 ESTs 13.62 402359 13.60 401044 13.53 409877 AW502498 Hs.157150 ESTs, Weakly similar to zinc finger prat 13.53 423690 AA329648 HS23804 ESTs 13.49 430685 AI690234 Hs.191666 ESTs, Weakly similar to reverse transcri 13.47 414052 AW578849 Hs.283552 ESTs, Weakly similar to unnamed protein 13.46 447858 AW080339 Hs.211911 ESTs 13.44 435716 AI573283 Hs.38458 ESTs 13.44 439120 H56389 gb:y.87c03.r1 Soares_pineal_gland_N3HPG 13.43 402788 13.40 451591 AA886446 Hs.146278 ESTs 13.40 405411 13.38 426558 AW188574 Hs.24218 ESTs 13.34 453506 AA132818 Hs.110407 ESTs, Weakly similar to coded for by C. 13.33 416445 AL043004 Hs.300678 Human serine/threonine kinase mRNA, part 13.32 457084 AI074149 Hs.150905 ESTs, Weakly similar to chondroitin 4-su 13.32 403838 13.32 427337 Z46223 Hs.176663 Fc fragment of IgG, low affinity lllb, r 13.30 434318 AW207552 Hs.116328 ESTs, Weakly similartodJ134E15.1 [H.sa 1328 435193 N41359 Hs.218107 ESTs 1328 414756 AW451101 Hs.159489 ESTs, Moderately similar to hexokinase I 1327 420626 AF043722 Hs.99491 RAS guanyl releasing protein 2 (caldum 1326 420052 AA418850 Hs.44410 ESTs 1325 414020 NM 002984 Hs.75703 small indudble cytokine A4 (homologous 1325 403851 1324 422647 W07492 Hs.157101 ESTs 1321 433598 AI762836 Hs.271433 ESTs, Moderately similar to ALU2 HUMAN A 1321 409065 AB033113 Hs.50187 KIAA1287 protein 1320 435063 R21966 Hs.57734 G protein-coupled receptor kinase-intera 13.19 439367 BE386844 Hs.248746 ESTs 13.17 451957 AI796320 Hs.10299 Homo sapiens cDNA FU13545 fis, clone PL 13.16 420569 AA278362 Hs.289062 Homo sapiens cDNA FU12334 fis, done MA 13.14 447883 BE262802 Hs.4909 dickkopf (Xenopus laevis) homolog 3 13.07 426490 NM 001621 Hs.170087 aryl hydrocaibon receptor 13.06 414789 AA155859 Hs.79708 ESTs 13.05 451418 BE387790 Hs.26369 ESTs 13.04 443494 T99719 Hs270404 Homo sapiens cDNA: FU22389 fis, clone H 13.03 425878 AW964806 Hs.38085 ESTs, Weakly similar to putative glydne 13.02 431912 AI660552 Hs.154903 ESTs, Weakly similar to A56154 Abl subst 13.00 407122 H20276 Hs.31742 ESTs 13.00 456491 AL137466 Hs.97277 Homo sapiens mRNA; cDNA DKFZp434H1322 (f 12.99 448172 N75276 Hs.135904 ESTs 12.98 452144 AA032197 Hs.102558 ESTs 12.96 419953 BE267154 Hs.125752 ESTs 12.96 416182 NM 004354 Hs.79069 cydin G2 12.94 451154 AA015879 Hs.33536 ESTs 12.93 412257 AW903830 gb:CM4-NN1037-250400-155-h04 NN1037 Homo 12.93 449784 AW161319 Hs.12915 ESTs 12.92 432695 D63480 Hs.278634 KIAA0146 protein 12.92 454105 NM 001259 Hs.38481 cydin-dependent kinase 6 12.92 439093 AA534163 Hs.5476 serine protease inhibitor, Kazal type, 5 12.90 416098 H41324 Hs.31581 ESTs, Moderately similar to ST1 B_HUMAN S 12.88 424897 D63216 Hs.153684 frizzled-related protein 12.88 414604 AU076649 Hs.76556 growth arrest and DNA-damage-indudble 3 12.88 414664 AA587775 Hs.66295 Homo sapiens HSPC311 mRNA, partial eds 12.84 452560 BE077084 gb:RC5-BT0603-220200-013-C07 BT0603 Homo 12.84 413869 NM 000878 Hs.75596 interleukin 2 receptor, beta - 12.80 452359 BE167229 Hs.29206 Homo sapiens done 24659 mRNA sequence 12.80 435886 BE265839 Hs.12126 hepatocellular car noma-assodated anti 12.78 445230 U97018 Hs.12451 echinoderm microtubule-assodated protei 12.78 412226 W26786 gb:15d7 Human retina cDNA randomly prime 12.77 446619 AU076643 Hs.313 secreted phosphoprotein 1 (osteopontin, 12.76 447769 AW873704 Hs.48764 ESTs 12.76 414478 AI306389 Hs.76240 adβnylate kinase 1 12.76 425383 D83407 Hs.156007 Down syndrome critical region gene 1-lik 12.68 450704 H85157 Hs.40696 ESTs 12.66 405856 12.66 412935 BE267045 Hs.75064 tubulin-spedficchaperone c 12.65 402802 12.62 452588 AA889120 Hs.110637 Homeo boxAIO 12.62 419978 NM 001454 Hs.93974 forkhead boxJI 12.62 403137 12.60 430226 BE245562 Hs.2551 adrenergic, beta-2-, receptor, surface 1257 448076 AJ133123 Hs.20196 adenylate cydase 9 12.56 450462 F07097 Hs.300828 Homo sapiens mRNA full length insert cDN 12.54 405236 12.52 409292 AA071051 gb:zm58e05.s1 Stratagene fibroblast (937 12.47 421540 AA767669 Hs.10242 ESTs 12.47 425840 AW978731 Hs.301824 ESTs 12.44 443181 AI039201 Hs.54548 ESTs 12.42 452436 BE077546 Hs.31447 ESTs 12.42 455183 AW984111 gb:RCO-HN0007-160300-011-f09 HN0007 Homo 12.40 432887 AI926047 Hs.162859 ESTs 12.37 410494 M36564 Hs.64016 protein S (alpha) 12.36 439024 R96696 Hs.35598 ESTs 12.36 451246 AW189232 Hs.39140 cutaneous T-cell lymphoma tumor antigen 12.36 432892 AL042615 Hs.15995 ESTs 12.35 418982 AI348838 Hs.13073 ESTs 12.35 414516 AI307802 HS279551 ESTs 12.34 440134 BE410734 gb:601301619F1 NIH MGC 21 Homo sapiens c 1229 443873 AL048542 Hs.16291 ESTs 1228 401286 1226 454020 AW962845 HS256527 ESTs 1224 420077 AW512260 Hs.87767 ESTs 1224 443837 AI984625 Hs.9884 spindle pole body protein 1224 407519 X64979 gb:H.sapiens mRNA HTPCRX01 for olfadory 1223 435839 AF249744 Hs25951 Rho guanine nucleotide exchange fador ( 1222 448552 AW973653 Hs.20104 hypothetical protein FU00052 1220 405325 1220 451009 AA013140 Hs.115707 ESTs 12.18 423066 Y18264 Hs.120171 ESTs 12.17 439556 AI623752 Hs.163603 ESTs 12.16 443062 N77999 Hs.8963 Homo sapiens mRNA full length insert cDN 12.15 445873 AA250970 Hs.251946 Homo sapiens cDNA: FLJ23107 fis, clone L 12.14 453542 AW836724 Hs.33190 Homo sapiens mRNA expressed only in plac 12.11 440106 AA864968 Hs.127699 ESTs 12.10 417605 AF006609 Hs.82294 regulator of G-protein signalling 3 12.10 440286 U29589 Hs.7138 cholinergic receptor, muscarinic 3 12.04 420061 AW024937 Hs.29410 ESTs 12.02 458727 AI022813 Hs.92679 Homo sapiens done CDABP0014 mRNA sequen 11.96 445407 AI222658 Hs221889 ESTs, Weakly similar to la costa [D.mela 11.95 418250 U29926 Hs.83918 adenosine monophosphate deaminase (isofo 11.94 414129 AI990287 HS270798 ESTs 11.93 409799 D11928 Hs.76845 phosphoserine phosphatase-like 11.92 438461 AW075485 Hs.286049 phosphoserine aminotransferase 11.92 443912 R37257 Hs.184780 ESTs 11.92 424606 AA343936 gb:EST49786 Gall bladder I Homo sapiens 11.90 434217 AW014795 Hs23349 ESTs 11.90 451533 NM 004657 Hs.26530 serum deprivation response (phosphatidyl 11.90 422423 AF283777 Hs.116481 CD72 antigen 11.89 409398 AW386461 gb:PM4-PT0019-121299-004-F02 PT0019 Homo 11.89 423853 AB011537 Hs.133466 slit (Drosophila) homolog 1 11.82 446180 AI074413 Hs.14220 hypothetical protein FU20450 11.80 414341 D80004 Hs.75909 KIAA0182 protein 11.80 406538 11.79 433253 AW450502 Hs.24218 ESTs - 11.79 447397 BE247676 Hs.18442 E-1 enzyme 11.78 451684 AF216751 Hs.26813 CDA14 11.76 416862 R23765 HS23575 ESTs 11.74 425770 NM 014363 Hs.159492 spastic ataxia of Charlevoix-Saguenay (s 11.72 428826 AL048842 Hs.194019 attradin 11.72 433037 NM 014158 Hs.279938 HSPC067 protein 11.72 447476 BE293466 Hs.20880 ESTs 11.72 452092 BE245374 Hs27842 hypothetical protein FU11210 11.72 412922 M60721 Hs.74870 H2.0 (Drosophila)-like homeo box 1 11.72 401680 NM 005578 Hs.180398 LIM domain-containing preferred transbc 11.69 422576 BE548555 Hs.118554 CGI-83 protein 11.68 450203 AF097994 Hs.301528 L-kynurenine/alpha-aminoadipate aminotra 11.68 410531 AW752953 gb:QVO-CT0224-261099-035-g02 CT0224 Homo 11.67 425917 W28517 Hs.117167 Homo sapiens cDNA: FU23067 fis, done L 11.66 418693 AI750878 Hs.87409 thrambospondin 1 11.64 400557 11.62 416188 BE157260 Hs.79070 v-myc avian myelocytomatosis viral oncog 11.60 419047 AW952771 Hs.90043 ESTs 11.59 420441 AI986160 Hs.88446 ESTs 11.59 400885 11.57 409853 AW502327 gb:UI-HF-BROp-aka-a-07-0-Ul.r1 NIH_MGC_5 11.56 400802 11.56 434540 NM 016045 Hs.5184 TH1 drosophila homolog 1155 431449 M55994 Hs.256278 tumor necrosis fador receptor superfami 11.55 425928 S55736 Hs238852 ESTs, Weakly similar to hypothetical pro 1154 434701 AA460479 Hs.4096 KIAA0742 protein 11.53 434228 Z42047 Hs.283978 ESTs; KIAA0738 gene produd 11.52 420729 AW964897 Hs290825 ESTs 11.52 428328 AA426080 Hs.98489 ESTs 11.50 433887 AW204232 HS279522 ESTs 11.50 414812 X72755 Hs.77367 monokine induced by gamma interferon 11.46 457718 F18572 HS22978 ESTs 11.44 452260 AA453208 Hs.28726 RAB9, member RAS oncogene family 11.42 459029 AA131376 Hs285203 fibroblast growth fador 12 11.42 456267 AI127958 Hs.83393 cystatin E/M 11.39 433285 AW975944 Hs.237396 ESTs 11.38 449186 AW291876 Hs.196986 ESTs 11.37 447861 AI434593 Hs.164294 ESTs 11.37 456023 R00028 gb:ye70a06.s1 Soares fetal liver spleen 11.36 439444 AI277652 Hs.54578 ESTs 11.31 401163 11.31 430886 L36149 Hs.248116 chemokine (C motif) XC receptor 1 1128 450784 AW246803 Hs.47289 ESTs 1128 452391 AL044829 Hs.29331 carnitine palmitoyltransferase I, muscle 1127 449625 NM 014253 Hs.23796 odz (odd Oz ten-m, Drosophila) homolog 1 1126 456827 AA075687 Hs.147176 epidermal growth fador receptor substra 1124 439328 W07411 Hs.118212 ESTs, Moderately similar to ALU3_HUMAN A 1124 432093 H28383 gb:yl52c03.r1 Soares breast 3NbHBst Homo 1124 407335 AA631047 Hs.158761 Homo sapiens cDNA FU13054 fis, clone NT 1123 442501 AA315267 Hs.23128 ESTs 1122 429746 AJ237672 Hs.214142 5,10-methylenetetrahydrofolate reductase 1121 422858 R35398 gb:yg64g10.r1 Soares infant brain 1 NIB H 1120 415156 X84908 Hs.78060 phosphorylase kinase, beta 1120 446713 AV660122 Hs.282675 ESTs 1120 452221 C21322 Hs.11577 ESTs 1120 418261 W78902 HS293297 ESTs 11.17 433332 AI367347 Hs.127809 ESTs 11.16 434539 AW748078 Hs.214410 ESTs 11.16 413471 BE142098 gb:CM4-HT0137-220999-017-d11 HT0137 Homo 11.14 410037 AB020725 Hs.58009 KIAA0918 protein 11.14 405601 11.13 458332 AI000341 Hs.220491 ESTs 11.12 427654 AA410183 Hs.137475 ESTs 11.12 427138 N77624 Hs.173717 phosphatidic acid phosphatase type 2B 11.10 431475 AI567669 HS287316 ESTs 11.10 425710 AF030880 Hs.159275 solute earner family, member 4 11.08 413748 AW104057 Hs.19193 ESTs 11.07 409208 Y0O093 Hs.51077 integrin, alpha X (antigen CD11C (p150), 11.07 457278 W92745 Hs.193324 ESTs - 11.03 407021 U52077 gb:Human marinerl transposase gene, comp 11.02 445701 AF055581 Hs.13131 lymphocyte adaptor protein 11.02 408338 AW867079 gb:MR1-SN0033-120400-002-c10 SN0033 Homo 10.95 401030 BE382701 Hs.25960 v-myc avian myelocytomatosis viral relat 10.95 437891 AW006969 Hs.6311 hypothetical protein FU20859 10.94 453874 AW591783 Hs.36131 collagen, type XIV, alpha 1 (undulin) 10.94 421562 AA530994 Hs.105803 ghrelin precursor 10.92 413431 AW246428 Hs.75355 ub-quitin-conjugating enzyme E2N (homolo 10.92 400132 10.92 436420 AA443966 Hs.31595 ESTs 10.90 424880 NM 000328 Hs.153614 retinitis pigmentosa GTPase regulator 10.88 433264 D85782 Hs.3229 cysteine dioxygenase, type I 10.88 429842 AI366213 Hs.173422 KIAA1605 protein 10.87 412405 AW948126 gb:RC0-MT0013-28030 O31-a12 MT0013 Homo 10.85 400615 10.80 425018 BE245277 Hs.154196 E4F transcription fador 1 10.80 456011 BE243628 gb:TCBAP1D1053 Pediatric pre-B cell acut 10.79 455982 BE176862 gb:RC4-HT0587-170300-012-a04 HT0587 Homo 10.74 450418 BE218418 Hs.201802 ESTs 10.73 412490 AW803564 Hs.288850 ESTs 10.72 436962 AW377314 Hs.5364 DKFZP564I052 protein 10.70 437743 AI383497 Hs.131811 ESTs, Weakly similar to ALU1_HUMAN ALU S 10.70 449967 R40978 Hs.271498 ESTs, Moderately similar to ALU1 HUMANA 10.70 449590 AA694070 Hs.268835 ESTs 10.68 446035 NM 006558 Hs.13565 Sam68-like phosphotyrosine protein, T-ST 10.68 426530 U24578 Hs.170250 complement component 4A 10.66 428600 AW863261 Hs.15036 ESTs, Highly similar to AF161358 1 HSPC0 10.64 420090 AA220238 Hs.94986 ribonudease P (38kD) 10.64 451593 AF151879 Hs.26706 CGI-121 protein 10.62 438893 AF075031 HS29327 ESTs 10.62 459324 AW080953 gb:xc28c12.x1 NCI_CGAP_Co18 Homo sapiens 10.61 439883 AL359652 Hs.171096 Homo sapiens EST from done DKFZp434A041 10.58 406513 AA715328 Hs.291205 ESTs 10.57 407826 AA128423 Hs.40300 calpain 3, (p94) 10.57 419550 D50918 Hs.90998 KIAA0128 protein; septin 2 10.56 428522 R10184 Hs.191987 ESTs, Weakly similar to ALU1 HUMAN ALU S 10.56 459526 AI142350 Hs.146735 EST 10.55 411448 AA178955 Hs.271439 ESTs 10.54 410102 AW248508 Hs.279727 ESTs; 10.52 406577 10.52 408405 AK001332 Hs.44672 hypothetical protein FU10470 10.51 428966 AF059214 Hs.194687 cholesterol 25-hydroxylase 10.50 400880 10.48 415875 AA894876 Hs.5687 protein phosphatase 1 B (formerly 2C), ma 10.48 434715 BE005346 Hs.116410 ESTs 10.46 406851 AA609784 Hs.180255 major histocompatibility complex, class 10.44 413409 AI638418 Hs.21745 ESTs 10.44 418489 U76421 Hs.85302 adenosine deaminase, RNA-spedfic, B1 (h 10.44 419465 AW500239 Hs.21187 Homo sapiens cDNA: FUI23068 fis, done L 10.44 419544 AI909154 gb:QV-BT200-010499-007 BT200 Homo sapien 10.44 432180 Y18418 Hs.272822 RuvB (E coli homolog)-like 1 10.44 413822 R08950 Hs.272044 ESTs, Weakly similar to ALU1_HUMAN ALU S 10.42 437446 AA788946 Hs.16869 ESTs, Moderately similar to CA1C RAT COL 10.41 415701 NM 003878 Hs.78619 gamma-glutamyl hydrolase (conjugase, fol 10.41 443790 NM_003500 Hs.9795 acyl-Coenzyme A oxidase 2, branched chai 10.40 458873 AW150717 Hs296176 STAT induced STAT inhibitor 3 10.38 415082 AA160000 Hs.137396 ESTs 10.37 429124 AW505086 Hs.196914 minor histocompatibility antigen HA-1 10.36 417187 AB011151 Hs.81505 KIAA0579 protein 10.34 426827 AW067805 Hs.172665 methylenetetrahydrofolate dehydrogenase 10.34 424280 NM 000030 Hs271366 alanine-glyoxylate aminotransferase homo 10.33 446099 T93096 Hs.17126 ESTs 10.32 423445 NM 014324 Hs.128749 alpha-methylacyl-CoA racemase 10.31 409995 AW960597 Hs.30164 ESTs 10.30 432242 AW022715 Hs.162160 ESTs, Weakly similar to ALU4_HUMAN ALU S 10.30 406394 AA172106 Hs.110950 Rag C protein 10.30 406189 1029 422283 AW411307 Hs.114311 CDC45 (cell division cyde 45, S.cerevis 1026 401598 AA172106 Hs.110950 Rag C protein - 1026 456995 T89832 Hs.170278 ESTs 1026 416511 NM_006762 Hs.79356 Lysosomal-associated multispanning membr 1024 427274 NM_005211 Hs.174142 colony stimulating fador 1 receptor, fo 1024 401384 1023 456226 D13168 Hs.82002 endothelin receptor type B 1022 426928 AF037062 Hs.172914 retinol dehydrogenase 5 (11-dsand 9-cis 1021 423032 AI684746 Hs.119274 ESTs 1020 436556 AI364997 Hs.7572 ESTs 1020 418400 BE243026 Hs.301989 KIAA0246 protein 10.19 437401 AA757196 Hs.121190 ESTs 10.19 403690 10.17 423790 BE152393 gb:CM2-HT0323-171199-033-a08 HT0323 Homo 10.16 434094 AA305599 Hs238205 hypothetical protein PRO2013 10.16 434967 AW975009 HS292274 ESTs 10.16 432827 Z68128 Hs.3109 Rho GTPase activating protein 4 10.16 432660 AI288430 Hs.64004 ESTs 10.14 452234 AW084176 Hs.223296 ESTs 10.14 445629 AI245701 gb:qk31f05.x1 NCI CGAP Kid3 Homo sapiens 10.13 457236 AA626142 Hs.179991 ESTs, Weakly similar to KPCE_HUMAN PROTE 10.13 444605 AI174603 Hs.254105 enolase l, (alpha) 10.12 450313 AI038989 Hs.24809 hypothetical protein FLJ10826 10.12 407482 NM 006056 10.12 449971 AA807346 Hs.288581 Homo sapiens cDNA FL-14296 fis, clone PL 10.11 441201 AW118822 Hs.128757 ESTs 10.10 435157 AW014605 Hs.179872 ESTs 10.10 417308 H60720 Hs.81892 KIAA0101 gene produd 10.09 442582 AI204266 Hs.179303 ESTs 10.05 437252 AI433833 Hs.164159 ESTs, Weakly similar to ALU1_HUMAN ALU S 10.04 448663 BE614599 Hs.106823 H.sapiens gene from PAC 426I6, similar t 10.04 434467 BE552368 Hs.231853 Homo sapiens cDNA FU13445 fis, clone PL 10.04 423698 AA329796 Hs.1098 DKFZp434J1813 protein 10.02 412707 AW206373 Hs.16443 Homo sapiens cDNA: FL 21721 fis, done C 10.00 414658 X58528 Hs.76781 ATP-binding cassette, sub-family D (ALD) 10.00 421832 NM 016098 Hs.108725 HSPC040 protein 10.00 423554 M90516 Hs.1674 glutamine-frudose-6-phosphate transamin 10.00 452039 AI922988 Hs.172510 ESTs 10.00 434673 AW137442 Hs.136965 ESTs 10.00 427978 AA418280 Hs.180040 Homo sapiens cDNA: FLJ22439 fis, done H 10.00 457803 BE501815 Hs.198011 ESTs 9.99 428279 AA425310 Hs.155766 ESTs 9.98 444412 AI147652 Hs.216381 Homo sapiens done HH409 unknown mRNA 9.98 417049 N72394 Hs.44862 ESTs 9.96 427509 M62505 Hs.2161 complement component 5 receptor 1 (C5a I 9.96 445424 AB028945 Hs.12696 cortactin SH3 domain-binding protein 9.96 443678 AW009605 Hs.231923 ESTs 9.96 447567 AW474513 Hs.224397 ESTs, Weakly similar to B48013 proline-r 9.94 414709 AA704703 Hs.77031 Sp2 transcription factor 9.94 434596 T59538 gb:yb65g12.s1 Stratagene ovary (937217) 9.94 427630 BE276115 Hs.144980 ESTs, Weakly similar to CA13_HUMAN COLLA 9.93 416111 AA033813 Hs.79018 chromatin assembly fador 1 , subunit A ( 9.92 423349 AF010258 Hs.127428 homeo boxA9 9.92 424308 AW975531 Hs.154443 minichromosome maintenance deficient (S. 9.92 416814 AW192307 Hs.80042 dolichyl-P-Glc:Man9GlcNAc2-PP-dolichylgl 9.90 417986 AA481003 Hs.97128 ESTs 9.90 425174 D87450 Hs.154978 KIAA0261 protein 9.90 438171 AW976507 Hs.293515 ESTs 9.90 421984 AW972187 Hs.110443 hypothetical protein FU22215 9.89 408597 NM 005291 Hs.46453 G protein-coupled receptor 17 9.88 413907 AI097570 Hs.71222 ESTs 9.87 451296 AW801383 Hs.118578 H.sapiens mRNA for ribosomal protein L18 9.86 433409 AI278802 HS25661 ESTs 9.85 450360 AW117416 Hs.245484 ESTs 9.85 433104 AL043002 Hs.128246 ESTs, Moderately similar to unnamed prat 9.84 449824 AI962552 Hs226765 ESTs 9.84 452744 AI267652 Hs.30504 Homo sapiens mRNA; cDNA DKFZp434E082 (fr 9.82 431066 AF026273 Hs.249175 interleukin-1 receptor-associated kinase 9.82 426457 AW894667 Hs.169965 chimerin (chimaerin) 1 9.80 443371 AI792888 Hs.145489 ESTs 9.80 437159 AL050072 gb:Homo sapiens mRNA; cDNA DKFZp566E1346 - 9.75 425242 D13635 Hs.155287 KIAA0010 gene produd 9.74 447498 N67619 Hs.43687 ESTs 9.74 426759 AI590401 Hs.21213 ESTs 9.73 435129 AI381659 Hs.267086 ESTs 9.72 437672 AW748265 Hs.5741 flavohemoprotein b5+b5R 9.72 438209 AL120659 Hs.6111 KIAA0307 gene produd 9.72 438440 AA807228 Hs.225161 ESTs 9.72 449720 AA311152 Hs.288708 ESTs; Weakly similar to KIAA0226 [H.sapi 9.72 414291 AI289619 Hs.13040 ESTs 9.72 436206 AK001451 Hs.265561 CD2-assodated protein 9.70 446896 T15767 Hs22452 Homo sapiens cDNA: FU21084 fis, done C 9.70 412667 AW977540 HS269254 ESTs 9.70 423301 S67580 Hs.1645 cytochrome P450, subfamily IVA, polypept 9.67 440757 AW118645 Hs.160004 ESTs 9.67 441412 AI393657 Hs.159750 ESTs 9.66 421044 AF061871 Hs.101302 collagen, type XII, alpha 1 9.66 414726 BE466863 Hs.280099 ESTs 9.66 418485 R91679 Hs.124981 ESTs 9.66 433480 X02422 Hs.181125 immunoglobulin lambda locus 9.65 441530 AI248301 Hs.127112 ESTs 9.65 433533 D53304 Hs.65394 ESTs 9.65 421470 R27496 Hs.1378 annexin A3 9.64 438613 C05569 Hs.243122 hypothetical protein FU13057 similar to 9.64 429324 AA488101 Hs.199245 inactivation escape 1 9.62 450244 AA007534 Hs.125062 ESTs 9.62 407660 AW063190 Hs.279101 ESTs 9.61 406554 9.60 426404 AA377607 Hs.273138 ESTs 9.58 447045 AW392394 Hs.278569 KIAA0064 gene produd 9.58 449894 AK001578 Hs.24129 hypothetical protein FU10716 9.58 448376 AI494332 Hs.196963 ESTs 9.58 407902 AL117474 Hs.41181 Homo sapiens mRNA; cDNA DKFZp727C191 (fr 9.56 446572 AV659151 HS282961 ESTs 9.56 459245 BE242623 Hs.31939 manic fringe (Drosophila) homolog 9.55 423545 AP000692 Hs.129781 chromosome 21 open reading frame 5 9.54 414697 BE266134 Hs.76927 translocase of outer mitochondrial membr 9.54 410846 AW807057 gb:MR4-ST0062-031199-018-b03 ST0062 Homo 9.52 421181 NM 005574 Hs.184585 LIM domain only 2 (rhombotin-like 1) 9.52 427308 D26067 Hs.174905 KIAA0033 protein 9.52 415995 NM_004573 Hs.994 phospholipase C, beta 2 9.51 434846 AW295389 Hs.119768 ESTs 9.51 414342 AA742181 Hs.75912 Homo sapiens cDNA: FU22199 fis, done H 9.50 416959 D28459 Hs.80612 ubiquitin-conjugating enzyme E2A (RAD6 h 9.50 443123 AA094538 Hs.6588 ESTs 9.50 439312 AA833902 Hs.270745 ESTs 9.48 449375 R07114 HS271224 ESTs 9.48 436357 AJ132085 gb.Homo sapiens mRNA for axonemal dynein 9.44 458723 AW137726 Hs.244352 ESTs, Moderately similar to laminin alph 9.44 457526 AW450584 Hs.192131 ESTs, Weakly similar to RIBB [H.sapiens] 9.43 404741 9.43 422409 NM 005428 Hs.116237 vav l oncogene 9.43 403708 9.42 408806 AW847814 Hs.289005 Homo sapiens cDNA: FU21532 fis, done C 9.42 417380 T06809 gb:EST04698 Fetal brain, Stratagene (cat 9.42 422501 AA354690 Hs.144967 ESTs 9.42 426197 AA004410 Hs.167835 acyl-Coenzyme A oxidase 1 , palmitoyl 9.42 452624 AU076606 Hs.30054 coagulation factor V (proaccelerin, labi 9.42 412110 AW893569 gb:RCO-NN0021-040400-021-c10 NN0021 Homo 9.41 414158 AA361623 Hs288775 Homo sapiens cDNA FU13900 fis, done TH 9.41 408101 AW968504 Hs.123073 CDC2-related protein kinase 7 9.40 414171 AA360328 Hs.865 RAP1A, member of RAS oncogene family 9.40 415947 U04045 Hs.78934 mutS (E. coli) homolog 2 (colon cancer, 9.40 426959 BE262745 gb:601153869F1 NIH MGC 19 Homo sapiens c 9.39 417519 AI689987 Hs.177669 ESTs, Weakly similar to RMS1 HUMAN REGUL 9.39 457181 BE514362 Hs296422 FK506-binding protein 3 (25kD) 9.39 402835 9.38 404632 9.38 446566 H95741 Hs.17914 Homo sapiens cDNA: FU22801 fis, clone K 9.37 455369 AW903533 gb:CM1-NN1031-060400-178-d05 NN1031 Homo - 9.37 444001 AI095087 Hs.152299 ESTs, Moderately similar to ALU5 HUMAN A 9.36 458191 AI420611 Hs.127832 ESTs 9.36 431374 BE258532 Hs.251871 CTP synthase 9.34 429327 AA283981 Hs.199248 prostaglandin E receptor 4 (subtype EP4) 9.33 407061 X97748 gbRsapiens PTX3 gene promotor region. 9.33 416967 BE616731 Hs.80645 interferon regulatory fador 1 9.33 423013 AW875443 Hs.22209 secreted modular calcium-binding protein 9.33 439461 AA693960 Hs.103158 ESTs 9.33 418830 BE513731 Hs.88959 Human DNA sequence from done 967N21 on 9.32 422763 AA033699 Hs.83938 ESTs, Moderately.similar to MASP-2 [H.sa 9.32 442739 NM 007274 Hs.8679 cytosolic acyl coenzyme A thioester hydr 9.32 452859 AI300555 Hs.288158 Homo sapiens cDNA: FU23591 fis, done L 9.32 403237 9.32 415000 AW025529 Hs239812 ESTs, Weakly similar to CALM.HUMAN CALMO 9.31 417951 AW976410 Hs289069 Homo sapiens cDNA: FU21016 fis, done C 9.30 419066 Z98492 Hs.6975 PRO1073 protein 9.30 448443 AW167128 Hs.231934 ESTs 9.30 405125 9.30 409768 AW499566 gb:UI-HF-BR0p-aji-h-03-0-Ul.r1 NIH MGC_5 928 453708 AI191811 Hs.54629 ESTs 9.28 442271 AF000652 Hs.8180 syndecan binding protein (synteπin) 9.27 410055 AJ250839 Hs.58241 gene for serine/threonine protein kinase 9.26 448692 AW013907 Hs.224276 ESTs, Moderately similar to predicted us 9.26 417381 AF164142 Hs.82042 solute carrier family 23 (nucleobase tra 9.25 422497 D29642 Hs.1528 KIAA0053 gene produd 9.25 414140 AA281279 Hs.23317 ESTs 9.24 435980 AF274571 Hs.129142 ESTs; Weakly similar to DEOXYRIBONUCLEAS 9.24 458530 BE395035 Hs.199889 ESTs, Weakly similar to KIAA0874 protein 9.24 402585 9.24 420819 AA280700 gb:zs95h11.s1 NCI CGAP GCB1 Homo sapiens 9.23 444755 AA431791 Hs.183001 ESTs 9.22 411630 U42349 Hs.71119 Putative prostate cancer tumor suppresso 9.22 421246 AW582962 Hs.300961 ESTs, Highly similarto AF151805 1 CGI-4 920 421924 BE514514 Hs.109606 coronin, adin-binding protein, 1A 9.19 414888 AL039185 Hs.77558 thyroid hormone receptor interador 7 9.18 434267 AI206589 Hs.116243 ESTs 9.17 409213 U61412 Hs.51133 PTK6 protein tyrosine kinase 6 9.17 428242 H55709 Hs.2250 leukemia inhibitory fador (cholinergic 9.16 451736 AW080356 Hs.293684 ESTs, Weakly similar to alternatively sp 9.15 413627 BE182082 Hs.246973 ESTs 9.14 416134 AA528402 Hs.74861 adivated RNA polymerase II transcriptio 9.14 449251 AW151660 Hs.31444 ESTs 9.14 452813 U54727 Hs.191445 ESTs 9.14 443622 AI911527 Hs.11805 ESTs 9.14 413260 BE075281 gb:PM1-BT0585-290200-005-d07 BT0585 Homo 9.12 413450 Z99716 Hs.75372 N-acetylgaladosaminidase, alpha- 9.12 446442 BE221533 Hs.257858 ESTs 9.12 438540 AA810021 Hs.136906 ESTs 9.12 426251 M24283 Hs.168383 Intercellular adhesion molecule 1 (CD54) 9.11 410290 AA402307 Hs.73818 ubiquinol-cytochrome c reductase hinge p 9.10 437398 AA913736 Hs.126715 ESTs 9.10 421559 NM 014720 Hs.105751 Ste20-related serine/threonine kinase 9.10 439699 AF086534 Hs.187561 ESTs, Moderately similar to ALU1 HUMAN A 9.10 430799 C19035 Hs.164259 ESTs 9.09 424544 M88700 Hs.150403 dopa decarboxylase (aromatic L-amino ad 9.08 453942 AW190920 Hs.19928 ESTs 9.08 425844 T68073 Hs.159628 serine (or cysteine) proteinase inhibito 9.08 434658 AI624436 Hs.194488 ESTs 9.07 453999 BE328153 Hs240087 ESTs 9.06 436490 R71543 Hs.18713 ESTs 9.05 409192 AA065131 Hs233439 ESTs, Weakly similar to ALU7--HUMAN ALU S 9.05 446223 BE300091 Hs.119699 hypothetical protein FU12969 9.04 447247 AW369351 Hs.287955 Homo sapiens cDNA FLJ13090 fis, done NT 9.04 450094 AI174947 Hs295789 Homo sapiens mRNA; cDNA DKFZp564D1164 (f 9.04 432012 AW301344 Hs.195969 ESTs 9.04 422520 AU076730 Hs.117977 kinesin2 (60-70kD) 9.02 418650 BE386750 Hs.86978 prolylendopeptidase 9.02 423008 M81590 Hs.123016 5-hydroxytιyptamine (serotonin) receptor 9.02 436476 AA326108 Hs.53631 ESTs - 9.02 448206 BE622585 Hs.3731 ESTs 9.02 431574 AW572659 Hs.261373 adenosine A2b receptor pseudogene 9.01 443453 R99876 Hs.269882 ESTs 9.01 435472 AW972330 Hs.283022 triggering receptor expressed on myeloid 9.01 420337 AW295840 Hs.14555 Homo sapiens cDNA: FLJ21513 fis, done C 9.00 449810 AB008681 Hs.23994 activin A receptor, type IIB 9.00 406780 AA902386 Hs.286 ribosomal protein L4 8.99 429169 AW341130 Hs.197757 ESTs, Moderately similar to FGFE_HUMAN F 8.99 421326 AF051428 Hs.103504 estrogen receptor 2 (ER beta) 8.97 425491 AA883316 Hs.255221 ESTs 8.96 425516 BE000707 Hs.29567 ESTs 8.96 439773 AI051313 Hs.143315 ESTs 8.96 443247 BE614387 Hs.47378 ESTs 8.96 456623 AI084125 Hs.108106 transcription factor 8.95 438707 L08239 Hs.5326 porcupine 8.95 402240 8.95 444152 AI125694 Hs.149305 Homo sapiens cDNA FLJ14264 fis, clone PL 8.95 409842 AW501756 gb:UI-HF-BR0p-ajm-c-09-O-Ul.r1 NIH MGC 5 8.94 416277 W78765 Hs.73580 ESTs 8.94 456697 AI908006 Hs.111334 ferritin, light polypeptide 8.94 410762 AF226053 Hs.66170 HSKM-B protein 8.92 412942 AL120344 Hs.75074 mitogen-adivated protein kinase-adivat 8.92 442320 AI287817 Hs.129636 ESTs 8.92 449673 AA002064 Hs.18920 ESTs 8.91 411486 N85785 Hs.181165 eukaryotic translation elongation fador 8.90 437916 BE566249 Hs.20999 Homo sapiens cDNA: FLJ23142 fis, clone L 8.90 442732 AA257161 Hs.8658 hypothetical protein DKFZp434E0321 8.89 419741 NM 007019 Hs.93002 ubiquitin carrier protein E2-C 8.89 411499 AW849292 gb:IL3-CT0215-020300-090-E06 CT0215 Homo 8.89 431154 AW971228 Hs.290259 ESTs 8.89 414922 D00723 Hs.77631 glycine cleavage system protein H (amino 8.88 418036 Z37976 Hs.83337 latent transforming growth fador beta b 8.87 406422 8.87 422926 NM 016102 Hs.121748 ring finger protein 16 8.87 435220 D50030 Hs.104 HGFadivator 8.86 418203 X54942 Hs.83758 CDC28 protein kinase 2 8.86 418613 AA744529 Hs.86575 mitogen-adivated protein kinase kinase 8.85 439250 H66566 HS271711 ESTs 8.85 432359 AA076049 Hs274415 Homo sapiens cDNA FU10229 fis, done HE 8.84 450000 AI952797 Hs.10888 Homo sapiens cDNA: FU21559 fis, clone C 8.83 425657 T89839 Hs.119471 ESTs 8.83 425694 U51333 Hs.159237 hexokinase 3 (white cell) 8.82 419972 AL041465 Hs.294038 ESTs, Moderately similar to ALU2_HUMAN A 8.82 436396 AI683487 Hs299112 Homo sapiens cDNA FU11441 fis, clone HE 8.82 413413 D82520 Hs.301834 Homo sapiens cDNA FU10952 fis, clone PL 8.82 428807 AA435997 Hs.104930 ESTs 8.82 415839 R40611 Hs.137565 ESTs 8.81 419553 N34145 HS250614 ESTs 8.80 420309 AW043637 Hs.21766 ESTs 8.80 421863 AI952677 Hs.108972 Homo sapiens mRNA; cDNA DKFZp434P228 (fr 8.80 447965 AW292577 Hs.94445 ESTs 8.80 459172 BE063380 gb:PMO-BT0275-291099-002-g10 BT0275 Homo 8.80 403259 8.78 411534 AW850473 gb:IL3-CT0219-280100-061 -B11 CT0219 Homo 8.78 456161 BE264645 Hs282093 Homo sapiens cDNA: FU21918 fis, clone H 8.77 413654 AA331881 Hs.75454 peroxiredoxin 3 8.76 401744 8.76 425348 AL137477 Hs.155912 cadherin-like24 8.76 423396 AI382555 Hs.127950 bromodomain-containing 1 8.75 450649 NM 001429 Hs297722 Human DNA sequence from done RP1-85F18 8.75 408331 NM 007240 Hs.44229 dual specificity phosphatase 12 8.74 423872 AB020316 Hs.134015 uronyl 2-sulfotransferase 8.74 424906 AI566086 Hs.153716 Homo sapiens mRNA for Hmob33 protein, 3 1 8.74 427596 AA449506 Hs.179765 Homo sapiens mRNA; cDNADKFZp586H1921 (f 8.73 432488 AA551010 HS216640 ESTs 8.72 448980 AL137527 Hs22703 Homo sapiens mRNA; cDNA DKFZp434P1018 (f 8.72 429455 AI472111 HS292507 ESTs 8.71 429855 AW385597 Hs.138902 ESTs, Weakly similarto B34087 hypotheti 8.71 441746 H59955 Hs.127829 ESTs 8.70 411945 AL033527 Hs.92137 v-myc avian myelocytomatosis viral oncog 8.70 413492 D87470 Hs.75400 KIAA0280 protein 8.70 435706 W31254 Hs.7045 GL004 protein 8.70 433741 AA609019 Hs.159343 ESTs 8.70 426340 Z97989 Hs.169370 FYN oncogene related to SRC, FGR, YES 422779 AA317036 Hs.41989 ESTs 8.67 449785 AI225235 Hs288300 Homo sapiens cDNA: FU23231 fis, clone C 8.67 420144 AA811813 Hs.119421 ESTs 8.66 420235 AA256756 Hs.31178 ESTs 8.66 432606 NM 002104 Hs.3066 granzyme K (serine protease, granzyme 3; 8.66 425762 BE244076 Hs.159578 Homo sapiens mRNA for FU00020 protein, 8.65 427448 BE246449 Hs2157 Wiskott-Aldrich syndrome (eczema-thrambo 8.64 418033 W68180 Hs259855 Homo sapiens cDNA FU12507 fis, clone NT 8.64 429084 AJ001443 Hs.195614 splicing fador 3b, subunit 3, 130kD 8.64 417094 NM 006895 Hs.81182 histamine N-methyltransferase 8.64 457277 NM 004736 Hs227656 xenotropic and polytropic retrovirus rec 8.63 422631 BE218919 Hs.118793 hypothetical protein FU10688 8.63 410679 AW795196 Hs.215857 ring finger protein 14 8.63 431585 BE242803 Hs.262823 hypothetical protein FU10326 8.62 401851 8.62 401866 8.62 407783 AW996872 Hs.172028 a disintegrin and metalloproteinase doma 8.62 408242 AA251594 Hs.43913 PIBF1 gene produd 8.62 422250 AW408530 Hs.113823 ClpX (caseinolytic protease X, E. coli) 8.62 430259 BE550182 Hs.127826 RalGEF-like protein 3, mouse homolog 8.62 452598 AI831594 Hs.68647 ESTs, Weakly similar to ALU7 HUMAN ALU S 8.62 419541 AW749617 gb:RC3-BT0502-130100-012-g07 BT0502 Homo 8.60 428839 AI767756 Hs.82302 ESTs 8.60 429328 AA829402 Hs.47939 ESTs 8.60 451491 AI972094 Hs.286221 Homo sapiens cDNA FU13741 fis, done PL 8.60 452561 AI692181 Hs.49169 KIAA1634 protein 8.60 420027 AF009746 Hs.94395 ATP-binding cassette, sub-family D (ALD) 8.60 435205 X54136 Hs.181125 immunoglobulin lambda locus 8.60 430900 U91939 Hs.248123 G protein-coupled receptor 25 8.60 405074 8.59 437991 AI479773 Hs.181679 ESTs 8.59 436346 BE328882 Hs.193096 ESTs, Moderately similar to U119_HUMAN U 8.58 411079 AA091228 gb:cchn2152.seq.F Human fetal heart, Lam 8.57 418452 BE379749 Hs.85201 C-type (calcium dependent, carbohydrate- 8.56 429109 AL008637 Hs.196352 neutrophil cytosolic fador 4 (40kD) 8.56 448019 AW947164 Hs.195641 ESTs 8.56 449865 AW204272 Hs.199371 ESTs 8.55 431180 H55883 gb:yq94h03.r1 Soares fetal liver spleen 8.54 445988 BE007663 Hs.13503 inactivation escape 2 8.54 405876 8.54 407235 D20569 Hs.169407 SAC2 (suppressor of actin mutations 2, y 8.54 414807 AI738616 Hs.77348 hydroxyprostaglandin dehydrogenase 15-(N 8.54 425671 AF193612 Hs.159142 lunatic fringe (Drosophila) homolog 8.54 452413 AW082633 Hs.212715 ESTs 8.54 421620 AA446183 Hs.91885 ESTs 8.53 444539 AI955765 Hs.146907 ESTs 8.52 415102 M31899 Hs.77929 excision repair cross-complementing rode 8.51 405552 8.51 418068 AW971155 Hs.293902 ESTs, Weakly similar to prolyl 4-hydroxy 8.50 420133 AA426117 Hs.14373 ESTs 8.50 438887 R68857 Hs.265499 ESTs 8.50 446468 AI765890 Hs.16341 ESTs; Moderately similar to !!!! ALU SUB 8.50 446585 AV659397 Hs.282948 ESTs 8.50 441896 AW891873 gb:CM3-NT0090-040500-173-b02 NT0090 Homo 8.50 437718 AI927288 Hs.196779 ESTs 8.48 420656 AA279098 Hs.187636 ESTs 8.48 429303 AW137635 Hs.44238 ESTs 8.48 450624 AL043983 Hs.125063 Homo sapiens cDNA FU13825 fis, clone TH 8.48 452573 AI907957 Hs287622 Homo sapiens cDNA FU14082 fis, done HE 8.48 456341 AA229126 Hs.122647 N-myristoyitransferasθ2 8.48 423024 AA593731 Hs.75613 CD36 antigen (collagen type I receptor, 8.47 446985 AL038704 Hs.156827 ESTs, Weakly similar to ALU1_HUMAN ALU S 8.46 431778 AL080276 Hs.268562 regulator of G-protein signalling 17 8.46 400268 - 8.46 421828 AW891965 Hs289109 dimethylarginine dimethylaminohydrolase 8.45 417022 NM_014737 Hs.80905 Ras association (RalGDS/AF-6) domain fam 8.44 421029 AW057782 Hs.293053 ESTs 8.44 425171 AW732240 Hs.300615 ESTs 8.44 459070 AI814302 gb:wj71c12.x1 NCI_CGAP_Lu19 Homo sapiens 8.42 406006 8.42 412643 AW971239 Hs.293982 ESTs 8.42 424775 AB014540 Hs.153026 SWAP-70 protein 8.42 446848 AW136083 Hs.195266 ESTs, Weakly similar to S59501 interfero 8.42 448043 AI458653 Hs.201881 ESTs 8.41 407183 AA358015 gb:EST66864 Fetal lung III Homo sapiens 8.40 412324 AW978439 Hs.69504 ESTs 8.40 419594 AA013051 Hs.91417 topoisomerase (DNA) II binding protein 8.40 430968 AW972830 gb:EST384925 MAGE resequences, MAGL Homo 8.40 431689 AA305688 Hs267695 UDP-Gal:betaGlcNAc beta 1,3-galadosyltr 8.40 438582 AI521310 Hs.283365 ESTs, Weakly similar to ALU5_HUMAN ALU S 8.40 447685 AL122043 Hs.19221 hypothetical protein DKFZp566G1424 8.40 459119 AW844498 Hs.289052 Homo sapiens LENG8 mRNA, variant C, part 8.38 400817 8.37 425265 BE245297 gb:TCBAP1 E2482 Pediatric pre-B cell acut 8.37 409385 AA071267 gb:zm61g01.r1 Stratagene fibroblast (937 8.36 439121 BE047779 Hs.44701 ESTs 8.36 419968 X04430 Hs.93913 interleukin 6 (interferon, beta 2) 8.36 408327 AW182309 Hs.249963 ESTs, Highly similar to dJ1170K4.4 [H.sa 8.35 403976 8.34 448064 AA379036 gb:EST91809 Synovial sarcoma Homo sapien 8.33 442914 AW188551 Hs.99519 Homo sapiens cDNA FU14007 fis, clone Y7 8.33 428032 AW997704 Hs.11493 Homo sapiens cDNA FU13536 fis, done PL 8.32 434194 AF119847 Hs.283940 Homo sapiens PRO1550 mRNA, partial eds 8.32 458677 AW937670 Hs.254379 ESTs 8.32 420925 NM 015698 Hs.100391 T54 protein 8.30 416475 T70298 gb:yd26g02.s1 Soares fetal liver spleen 8.30 416852 AF283776 Hs.80285 Homo sapiens mRNA; cDNA DKFZp586C1723 (f 8.30 430676 AF084866 gb.Homo sapiens envelope protein RIC-3 ( 8.30 428455 AI732694 Hs.98520 ESTs 8.29 435343 AW194962 Hs.199028 ESTs 8.29 450783 BE266695 gb:601190242F1 NIH_MGC_7 Homo sapiens cD 8.29 404946 828 422942 AF054839 Hs.122540 tetraspan 2 8.28 453716 AA037675 Hs.152675 ESTs 8.28 437098 AA744488 Hs.132842 ESTs, Moderately similar to ALU1_HUMAN A 8.28 443907 AU076484 Hs.9963 TYRO protein tyrosine kinase binding pro 8.27 401930 AF106069 Hs.23168 ubiquitin spedfic protease 15 8.26 446554 AA151730 Hs.301789 ESTs, Weakly similar to similar to C.ele 8.26 426290 AB007918 Hs.169182 KIAA0449 protein 8.25 419904 AA974411 Hs.18672 ESTs 825 413886 AW958264 Hs.103832 ESTs, Weakly similar to TRHY HUMAN TRICH 8.24 424738 AI963740 Hs.46826 ESTs 8.24 427359 AW020782 Hs.79881 Homo sapiens cDNA: FU23006 fis, done L 8.24 424534 D87682 Hs.150275 KIAA0241 protein 8.24 424429 U63830 Hs.146847 TRAF family member-asso ated NFKB activ 8.24 442604 BE263710 Hs.279904 ESTs 8.22 442992 AI914699 Hs.13297 ESTs 8.22 427210 BE396283 Hs.173987 eukaryotic translation initiation fador 8.22 457229 BE222450 Hs.266390 ESTs 8.21 423730 AA330214 gb:EST33935 Embryo, 12 week II Homo sapi 8.21 411928 AA888624 Hs.19121 adaptor-related protein complex 2, alpha 820 416051 AA835868 Hs25253 Homo sapiens cDNA: FU20935 fis, done A 8.20 417231 R40739 HS21326 ESTs 8.20 422049 W25760 Hs.77631 glydne deavage system protein H (amino 820 427528 AU077143 Hs.179565 minichromosome maintenance deficient (S. 820 458776 AV654978 Hs.19904 cystathionase (cystathionine gamma-lyase 8.19 417687 AI828596 Hs.250691 ESTs 8.18 423218 NM_015896 Hs.167380 BLu protein 8.18 425397 J04088 Hs.156346 topoisomerase (DNA) II alpha (170kD) 8.18 406964 M21305 Hs247946 Human alpha satellite and satellite 3 ju 8.18 402401 U42349 Hs.71119 Putative prostate cancer tumor suppresso 8.18 423397 NM_001838 Hs.1652 chemokine (C-C motif) receptor 7 8.18 427857 AL133017 Hs.2210 thyroid hormone receptor interador 3 - 8.17 401519 8.17 447188 H65423 Hs.17631 Homo sapiens cDNA FU20118 fis, done CO 8.16 424704 AI263293 Hs.152096 cytochrome P450, subfamily IIJ (arachido 8.16 435854 AJ278120 Hs.4996 DKFZP564D166 protein 8.14 448556 AW885606 Hs.5064 ESTs 8.14 449217 AA278536 Hs23262 ribonudease, RNase A family, k6 8.14 453124 AI139058 HS23296 ESTs 8.14 442812 AI018406 Hs.131284 ESTs 8.14 421129 BE439899 Hs.89271 ESTs 8.14 TABLE 9A shows the accession numbers for those primekeys lacking a unigenelD in Table 9. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column. Pkey: Unique Eos probeset identifier number CAT number: Gene duster number Accession: Genbank accession numbers Pkey CAT number Accession 408057 1035720_-1 AW139565 408069 103655J H81795Z42291 R20973 AA046920 408182 104479J AA047854 AA057506 AA053841 408338 1052148J AW867079 AW867086 AW182772 408828 108463J BE540279 AW410659 AA057857 R77693 BE278674 409126 110159J AA063426 AW962323 AW408063AA063503 AA772927 AW753492 BE175371 AA311147 409292 111586J AA071051 AA070584AA069938 AA102136 AA074430 409314 111841J AA070266AA084967AA126998 409385 112523J AA071267T65940 T64515 AA071334 409398 1126716J AW386461 AW876408 AW386672AW386599AW876258 AW386619 AW386289AW876136 AW876203AW876213AW876301 AW876295 AW876349 AW876365 AW876160 AW876369 AW876352 AW876271 409671 114731J AA076769 AA076781 AI087968 409768 1154035J AW499566 AW502378 AW499522 AW502046 AW502671 AW501917 AW501868AW501721 AW502813 409841 1156088J AW502139 AW502432 AW502235 AW501683 AW502647 409842 1156119J AW501756 AW502096 AW502465 AW501715 409853 1156226J AW502327AW502488 AW501829 AW502625 AW502687 410531 1207200J AW752953 H88044 BE156092 410688 1216101J AW796342 AW796356 BE161430 410846 1223902J AW807057 AW807054 AW807189 AW807193 AW807369 AW807429 AW807364 AW807365 AW807078 AW807256 AW807180 AW807331 410896 1226053J AW809637 AW809697 AW810554 AW809707 AW809885 AW810000 AW810088 AW809742 AW809816 AW809749 AW809639 AW809722 AW809836 AW809774 AW810023 AW810013 AW809813 AW809660 AW809728 AW809768 AW809951 AW809657 AW809954 411079 123128J AA091228 H71860 H71073 411424 1245497J AW845985 AW845991 AW845962 411499 1248105J AW849292 AW849431 AW849422 AW849428 AW849420 AW849424 AW849427 411507 1248607J AW850140 AW850195 AW850192 411534 1248827J AW850473 AW850471 AW850431 AW850523 411972 1268491J BE074959 AW880160 412110 1277844J AW893569 AW893571 AW893588 AW893593 412226 1284289J W26786 AW998612 AW902272 412257 1285376J AW903830 BE071916 412405 1293012J AW948126 AW948139 AW948196 AW948145 AW948162 AW948134 AW948127 AW948124 AW948153 AW948157 AW948125 AW948131 AW948158 AW948164 AW948151 413260 1356003J BE075281 BE075219 BE075123 BE075119 BE075046 413471 1371778J BE142098 BE142092 413729 1385114J BE159999 BE160056 BE160107 BE160139 414182 142409J AA136301 AI381776 AA136321 414989 1511339J T81668C19040C17569 415354 1534763J F06495 R24336 R13046 416011 1566439J H14487 50911 Z43216 416475 1596398J T70298 H58072 R02750 417380 1672461J T06809 N75735 419392 1843934_-1 W28573 419541 185724J AW749617 R64714AA244138AA244137 BE094019 419544 185760.2 AI909154 AA526337AA244193AI909153 420819 196721J AA280700 AW975494 AA687385 421245 200620J AA285363 AA285333 AA285359 AA285326 AA285350 422673 219674J N59027AA314694 N53937 R08100 422695219996J AA315158AW961298 N76067AW802759AI858495W04474 422858222209J R35398BE252178AA318153 422940223106J BE077458 AA337277AA319285 423730231462J AA330214AW962519T54709 423790232031J BE152393AA330984 BE073904 424385238731J AA339666AW952809AA349119 424606241409J AA343936 AA344060AW963081 425265249175J BE245297AA353976AW505023 426959273830_-1 BE262745 43067632168J AF084866 AF084870 AF084864 AF084867 AF084869 AF084865 AF084868 AW818206 AW812038 BE144813 BE144812 AW812041 AW812040 AW812067 BE061583 BE061604 T05808 AI352469 AA580921 BE141783 BE141782 BE061601 AW814393 AW885029 430968 326269J AW972830 AA527647 AA489820 AA570362 431180 328906J H55883 AW971249 AA493900 H55788 432093 341283 H28383 AW972670 H28359 AA525808 434596 38937J T59538 T59589 T59598 T59542 AF147374 436357 41842J AJ132085 Z83805 437159 43393J AL050072 AW900148 437495 43765J BE177778 BE177779 AL390180 AA359908 439097 46858J H66948 AF085954 H66949 439120 46879J H56389AF085977H56173 440134 48675J BE410734 BE560117 BE270054 BE296330 BE267957 AI003007 BE545259 441896 52842J AW891873 AW891897 BE564764 445629 645767J AI245701 BE272724 447229 71288J BE617135 AW504051 AW504283 448064 74761J AA379036 AA150589 AI696854 BE621316 450783 84655J BE266695 BE265474 N53200 BE267333 451045 85673J AA215672 AI696628 AA013335 H86334 AA017006 452549 921802J AI907039 AI907081 452560 922216J BE077084 AW139963 AW863127 AW806209 AW806204 AW806205 AW806206 AW806211 AW806212 AW806207 AW806208 AW806210 AI907497 452712 928309J AW838616 AW838660 BE144343 AI914520 AW888910 BE184854 BE184784 453758980026J U83527AL120938 U83522 4540931007366J AW860158 AW862385 AW860159 AW862386 AW862341 AW821869 AW821893 AW062660 AW062656 4545631224342J AW807530 AW807540 AW807537 AW846086 BE141634 AW846089 AW807499 AW807533 AW838499 454791 1234759J BE071874 BE071882 AW820782 AW821007 454977 1247099J AW848032 AW848630 AW848478 AW848623 AW848484 AW848169 AW848830 AW848149 AW848119 AW848893 AW848903 AW848407 455131 1254674J AW857913 AW857916 AW857914AW861627AW861626 AW861624 455183 1259023J AW984111 AW863918 AW863856 4552541266449J AW877015 AW877133 AW876978 AW877071 AW876988 AW877069 AW877063 AW877013 4553691285173J6 AW903533 AW903516 AW903562 BE085202 BE085215 BE085214 BE085209 BE085172 BE085175 BE085193 BE085211 BE085199 455982 1396849J BE176862 BE176876 BE176947BE176878 456011 1410860J BE243628 BE246081 BE247016BE241984 BE241534BE246091 BE245679BE243620BE245998 BE242329 BE241417 BE241457BE242522 BE241989 BE241464 456023 1416335J R00028BE247630 457586 360505J AW062439AW751554AA579463 457595 364225_-1 AA584854 457751 399422J AI908236 AA663731 459070 883688J AI814302 AI814428 459081 889426J W07808 AI822066 459145 918957J AI903354 AI903489 AI903488 459172 921149J BE063380 BE063346 AI906097 459234 945240 -1 AI940425 TABLE 9B shows the genomic positioning for those primekeys lacking unigene ID's and accession numbers in Table 9. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed. Pkey: Unique number corresponding to an Eos probeset Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (Gl) numbers. "Dunham I. et al." refers to the publication entitled The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. Strand: Indicates DNA strand from which exons were predicted. NLposition: Indicates nucleotide positions of predicted exons. Pkey Ref Strand NLposition 400452 8113550 Minus 90308-90505 400557 9801261 Plus 208453-208528,209633-209813 400615 9908994 Plus 118036-118166,118681-118807 400802 8567867 Minus 174571-174856 400817 8569994 Plus 170793-170948 400880 9931121 Plus 29235-29336,36363-36580 400885 9958187 Minus 58242-58733 400926 7651921 Minus 52033-52158,53956-54120,54957-55052,55420-55480,56452-56666,57221-57718 400952 7658481 Plus 192667-192826,194387-194876 400991 8096825 Plus 159197-159320 401044 8117619 Plus 73501-73674 4011248570296 Minus 124181-124391 401163 6981820 Plus 5302-5545 401201 9743387 Minus 138534-138629,139234-139294,140121-140335,142033-142479 401286 9801342 Minus 147036-147318 401384 6850939 Minus 58360-58545 401468 6433826 Plus 13056-13482 401515 7630851 Plus 29929-30126 401519 6649315 Plus 157315-157950 401672 9838136 Plus 128526-128704,130755-130860 401744 2576349 Plus 14595-14751 401851 7770425 Minus 146443-146664,147794-147971,148351-148480,148980-149111,149801-149949 401866 8018106 Plus 73126-73623 4022407690131 Plus 104382-104527,106136-106372 402359 9211204 Minus 40403-41961 402585 9908890 Minus 174893-175050,183210-183435 402788 9796102 Plus 98273-101430 402802 3287156 Minus 53242-53432 402812 6010110 Plus 25026-2509125844-25920 402828 8918414 Plus 69071-69642 402835 9187337 Plus 26961-27101 402838 9369121 Minus 32589-32735,35478-35666 402842 9369121 Minus 76355-76479 402895 9967547 Plus 85537-85671,86379-86469 402964 9581599 Minus 46624-46784 403137 9211494 Minus 92349-92572,92958-93084,93579-93712,93949-94072,94591-94748,95214-95337 403237 7637807 Plus 7271-7527 403259 7770585 Plus 4693-4857 403683 7331517 Plus 217175-217446 403690 7387384 Minus 78627-79583 403708 5705981 Minus 134394-134812 403838 4176355 Plus 19197-19502 403851 7708872 Plus 22733-23007 403976 7657840 Plus 24755-24969 404407 7329316 Minus 48154-48499 404426 7407959 Plus 77842-77954 404632 9796668 Plus 45096-45229 404741 8574139 Plus 143025-143467 404756 7706327 Plus 82849-83627 404946 7382189 Plus 134445-134750 405074 7770440 Plus 44340-44559,44790-45059 405125 8247873 Plus 137113-137814 405172 9966752 Plus 153027-153262 4052367249076 Minus 151699-151915 405325 6094661 Minus 25818-26380 405411 3451356 Minus 17503-17778,18021-18290 405495 8050952 Minus 72182-72373 405552 1552506 Plus 45199-45647 405601 5815493 Minus 147835-147935,149220-149299 405685 4508129 Minus 37956-38097 405777 7263187 Minus 104773-105051 405856 7653009 Plus 101777-102043 405876 6758747 Plus 39694-40031 405932 7767812 Minus 123525-123713 405934 6758795 Plus 159913-160605 406006 8247801 Minus 42640-42776 406134 9163473 Plus 153291-153452 406189 7289992 Minus 22007-22234 406422 9256411 Plus 163003-163311 406516 7711422 Minus 128375-128449,128560-128784 406538 7711478 Plus 35196-35367,38229-38476,40080-40216,43522-43840 406554 7711566 Plus 106956-107121 406577 7711730 Plus 11377-11509 TABLE 10." shows genes, including expression sequence tags differentially expressed in taxol resistant prostate tumor xenografts as compared to taxol sensitive prostate tumor xenografts. The genes are indicated as either being upregulated or downregulated during the induction of taxol resistance in sequential passages of the grafts. Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD: Unigene number Unigene Title: Unigene gene title Eos: Internal Eos name F00-F14: passage number Pkey ExAccn UnigenelD UnigenTitle Eos Resp.FOO FOO F02 F02 F05 F05 F07 F09 F10 F11 F13 F14 117921 N51002 Hs.47170 Liprin A2 PM28UP 1 9 8 9 32 20 34 122 1(55 82 71 111 112971 T17185 Hs.4299 ESTs CHA1 down 290 281 267 335 270 284 150 157 83 89 49 75 126645 AI167942 Hs.61635 STEAP PAAδdown 106 111 103 71 34 67 33 14 2 1 1 1 119018 N95796 Hs.179809 ESTs PAB2 down 765 841 757 909 742 704 478 428 253 175 228 238 110844 N31952 Hs.167531 ESTs PAV7down 175 192 147 141 123 129 73 65 55 48 54 84 100654 HG2841-HT2969 Hs.75442 Albumin, A PM01 down 666 605 504 728 357 445 602 187 117 127 117 11! 100655 HG2841-HT2970 Hs.75442 Albumin, A PM02down 620 653 486 688 368 386 606 175 101 95 115 97 102076 U09579 Hs252437 cydiπ-dep PM03down 101 94 143 190 105 107 88 40 34 31 46 22 102208 U22961 Hs.75442 albumin PM04down 495 424 323 518 252 296 467 188 169 143 165 145 103739 AA075779 mitochondr PM05down 75 190 606 230 378 106 218 88 69 192 69 99 107036 AA599690 Hs.15725 SBBI48 PMOδdown 87 124 115 188 132 111 66 71 49 70 38 50 108242 AA062746 ESTs PM07down 14 20 252 13 22 43 193 10 10 104 21 18 108282 AA065143 solute car PM08down 27 54 178 73 108 37 53 24 14 53 15 34 108679 AA115963 beta-1-glo PM09down 680 893 1292 656 869 389 1 74 118 662 359 409 108731 AA126313 Hs.107476 ATPsyntha PMIOdown lO 19 185 25 60 1 32 3 7 14 1 1 110675 H89355 Hs.6598 adrenergic PM11 down 207 334 237 239 231 220 119 145 93 64 56 124 115412 AA283804 Hs.193552 ESTs PM12down 146 316 282 271 340 334 115 238 100 196 83 207 115844 AA430124 Hs234607 MDM2 PM13down 49 93 94 154 132 91 23 54 23 76 14 41 120588 AA281591 Hs.16193 ESTs PM14down 80 157 58 141 159 127 39 83 35 37 16 46 132349 Y00705 Hs.181286 serine pro PM15down 146 217 214 150 106 128 177 85 54 63 66 56 132888 AA490775 Hs.5920 N-acetylma PM16down 92 150 132 178 126 139 53 94 48 67 41 80 132967 AA032221 Hs.61635 STEAP PM17down 224 208 203 215 205 180 132 65 68 50 48 63 133063 AA283085 Hs.64065 ESTs PM18down 85 148 161 150 92 108 42 99 42 65 29 126 134374 D62633 Hs.8236 ESTs PM19down 230 240 194 212 231 189 89 123 107 95 68 91 135400 M23263 Hs.99915 androgen r PM20down 36 167 99 178 132 101 23 71 26 122 14 44 TABLE 11 : shows genes, including expression sequence tags that are up-regulated in prostate tumor tissue compared to normal prostate tissue as analyzed using Affymetrix/Eos HuOl GeneChip array. Shown are the ratios of "average" normal prostate to "average" prostate cancer tissues. Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank! accession number UnigenelD: Unigene number Unigene Title ι: Unigene gene title R1: Background subtraded normal prostate : prostate tumor tissue Pkey ExAccn UnigenelD Unigene Title R1 101336 L49169 Hs.75678 FBJ murine osteosarcoma viral oncogene homolog B 0.012 130642 M63438 Hs.156110 Immunoglobulin kappa variable 1D-8 0.015 133512 X01677 Hs.195188 glyceraldehyde-3-phosphate dehydrogenase 0.017 133436 H44631 Hs.737 immediate early protein 0.017 129292 X13810 Hs.1101 POU domain; class 2; transcription fador 2 0.019 100610 HG2566-HT4792 Microtubule-Assodated Protein Tau, Alt. Splice " 3, Exon 8 0.02 133448 M34516 Hs.170116 immunoglobulin lambda-like polypeptide 3 0.021 125193 W67577 Hs.84298 CD74 antigen (invariant polypeptide of major histocompatibility complex; class II antigen-assodated) 0.022 133456 T49257 Hs.183704 ubiquitin C 0.022 134546 AA459310 Hs.8518 Homo sapiens mRNA; cDNA DKFZp586L1722 (from done DKFZp586L1722) 0.023 102131 U15085 Hs.1162 major histocompatibility complex; dass II; DM beta 0.023 101375 M13560 Hs.84298 CD74 antigen (invariant polypeptide of major histocompatibility complex; dass II antigen-assodated) 0.023 100674 HG3033-HT3194 Spliceosomal Protein Sap 62 0.024 134365 R32377 Hs.82240 syntaxin 3A 0.027 132335 D60387 Hs.189885 ESTs 0.027 110303 H37901 Hs.32706 ESTs 0.028 131678 N59162 Hs.30542 ESTs 0.028 116599 D80046 Hs.250879 ESTs 0.029 133769 M17733 Hs.75968 thymosin; beta 4; X chromosome 0.029 107904 AA026648 Hs.61389 ESTs 0.03 129427 T80746 Hs.111334 ferritin; light polypeptide 0.03 105987 AA406631 Hs.110299 mitogen-adivated protein kinase kinase 7 0.03 131466 F03233 Hs.27189 ESTs 0.032 102859 X00274 Hs.76807 Human HLA-DR alpha-chain mRNA 0.032 134626 S82198 Hs.8709 caldecrin (serum calcium decreasing fador; elastase IV) 0.032 134170 M63138 Hs.79572 cathepsin D (iysosomal aspartyl protease) 0.033 131713 X57809 Hs.181125 immunogbbulin lambda gene duster 0.034 100748 HG3517-HT3711 Alpha-1-Antitrypsin, 5' End 0.034 118769 N74496 ESTs 0.034 111734 R25375 Hs.126916 ESTs 0.036 109221 AA192755 Hs.85840 ESTs; Weakly similar to stac [H.sapiens] 0.036 133846 AA480073 Hs.76719 U6 snRNA-assodated Sm-like protein 0.036 135281 AA401575 Hs.97757 ESTs 0.037 119073 R32894 Hs.45514 v-ets avian erythroblastosis virus E26 oncogene related 0.037 100760 HG3576-HT3779 Major Histocompatibility Complex, Class li Beta W52 0.037 101426 M19483 Hs.25 ATP synthase; H + transprtng; mitochndri F1 complex; beta polypept 0.038 129568 AA428025 Hs.114360 transforming growth fador beta-stimulated protein TSC-22 0.038 130900 Z38468 Hs.21036 ESTs; Moderately similar to F25965_3 [H.sapiens] 0.039 133879 M13829 Hs.77183 v-raf murine sarcoma 3611 viral oncogene homolog 1 0.039 100627 HG2702-HT2798 Serine/Threonine Kinase (Gb225424) 0.039 129424 M55593 Hs.111301 matrix metalloproteinase 2 (gelatinase A; 72kD gelatinase; 72kD type IV collagenase) 0.039 128652 AA621245 Hs.103147 ESTs; Weakly similar to similar to SP.YR40 BACSU [C.elegans] 0.039 129979 T72635 Hs.13956 ESTs 0.039 133468 X03068 Hs.73931 major histocompatibility complex; dass II; DQ beta 1 0.04 102636 U67092 Human ataxia-telangiectasia locus protein (ATM) gene, exons 1a, 1b, 2, 3 and 4, partial eds 0.04 129536 M33493 Hs.184504 tryptase; alpha 0.04 133599 M64788 Hs.75151 RAP1; GTPase activating protein 1 0.041 102104 U12139 Human alphal (XI) collagen (COL11A1) gene, 5' region and exon 1 0.041 131340 AA478305 Hs.25817 Homo sapiens chromosome 19; cosmid R27216 0.041 130446 X79510 Hs.155693 protein tyrosine phosphatase; non-receptor type 21 0.042 101352 L77701 Hs.16297 COX17 (yeast) homolog; cytochrome c oxidase assembly protein 0.042 122593 AA453310 Hs.128749 alpha-methylacyl-CoA racemase 0.042 130181 R39552 Hs.151608 Homo sapiens done 23622 mRNA sequence 0.042 134071 Z14093 Hs.78950 branched chain keto acid dehydrogenase E1; alpha polypeptide (maple syrup urine disease) 0.042 108129 AA053252 Hs.185848 ESTs; Weakly similar to !! ALU SUBFAMILY J WARNING ENTRY !! [H.sapiens] 0.043 130511 L32137 Hs.1584 cartilage oligomeric matrix protein (pseudoachondroplasia; epiphyseal dysplasia 1; multiple) 0.043 133336 AA291456 Hs.71190 ESTs 0.043 132982 L02326 Hs.198118 immunoglobulin lambda-like polypeptide 2 0.044 131880 AA047034 Hs.33818 RecQ protein-like 5 0.044 130540 U35234 Hs.159534 protein tyrosine phosphatase; receptor type; S 0.044 133467 AA258595 Hs.73931 major histocompatibility complex; class II; DQ beta 1 0.044 101191 1-20688 Hs.83656 Rho GDP dissociation inhibitor (GDI) beta 0.044 101860 M95610 Hs.37165 collagen; type IX; alpha 2 0.044 102799 U88898 Human endogenous retroviral H proteaseΛntegrase-derived ORF1 mRNA, complete eds, and putative envelope prot mRNA, partial eds 0.044 107200 D20350 Hs.5628 ESTs 0.044 101166 L14927 Hs2099 lipocalin 1 (protein migrating faster than albumirfrtearprealbumin) 0.044 134289 M54915 Hs.81170 pim-1 oncogene 0.044 135329 AA436026 Hs.98858 ESTs 0.044 124950 T03786 Hs.151531 protein phosphatase 3 (formerly 2B); catalytic subunit; beta isoform (calcineurin A beta) 0.044 102919 X12447 Hs.183760 aldolase A; frudose-bisphosphate 0.044 100574 HG2279-HT2375 Triosephosphate Isomerase 0.045 131286 AA450092 Hs.25300 Homo sapiens dones 24718 and 24825 mRNA sequence 0.045 102675 U72512 Human B-cell receptor assodated protein (hBAP) alternatively spliced mRNA, partial 3'UTR 0.045 131332 R50487 Hs.25717 ESTs 0.045 101634 M57731 Hs.75765 GR02 oncogene 0.046 113118 T47906 Hs.220512 ESTs 0.046 124884 R77276 Hs.120911 ESTs 0.046 130523 W76097 Hs.214507 ESTs 0.046 110244 H26742 Hs.25367 ESTs; Weakly similar to ALR [H.sapiens] 0.046 131932 AA454980 Hs.25601 chromodomain helicase DNA binding protein 3 0.046 132509 H09751 Hs.5038 neuropathy target esterase 0.046 133372 AA291139 Hs.72242 ESTs 0.046 100817 HG4011-HT4804 Dystrophin-Assodated Glycoprotein, 50 Kda, Alt. Splice 2 0.047 106746 AA476436 Hs.7991 ESTs 0.047 135401 L14813 Hs.169271 carboxyl ester lipase-like (bite salt-stimulated lipase-like) 0.047 130479 R44163 Hs.12457 Homo sapiens clone 23770 mRNA sequence 0.047 102589 U62015 Hs.8867 cysteine-rich; angiogenic inducer; 61 0.047 121521 AA412165 Hs.97358 EST 0.048 135340 AA425137 Hs.99093 Homo sapiens chromosome 19; cosmid R28379 0.048 132336 AA342422 Hs.45073 ESTs 0.048 115368 AA282133 Hs.88960 ESTs; Weakly similar to similar to collagen [C.elegans] 0.048 101278 L38487 Hs.110849 estrogen-related receptor alpha 0.048 103284 X80200 Hs.8375 TNF receptor-assodated fador 4 0.048 100564 HG2239-HT2324 Potassium Channel Protein.(Gb211585) 0.048 133132 Z40883 Hs.65588 ESTs; Weakly similar to dJ393P122 [H.sapiens] 0.048 121811 AA424535 Hs.98416 ESTs 0.048 129613 AA279481 Hs.238831 ESTs; Weakly similar to collagen alpha 1 (XVIII) chain [M.musculus] 0.049 132468 S79854 Hs.49322 deiodinase; iodothyronine; type III 0.049 120111 W95841 Hs.136031 ESTs 0.049 103668 Z83741 Hs.248174 H2A histone family; member M 0.049 130386 F10874 Hs.234249 mitogen-adivated protein kinase 8 interacting protein 1 0.049 104275 C02170 Hs.39387 ESTs; Weakly smlr to weak smlrity to ribosomal prot L14 [C.elegans] 0.049 106305 AA436146 Hs.12828 ESTs 0.05 116431 AA609878 Hs.55289 ESTs; Weakly smlr to 110 KD CELL MEMBRANE GLYCOPROTEIN [H.sapiens] 0.813 120339 AA206465 Hs.256470 EST 0.05 114427 AA017063 ESTs; Highly similar to Miz-1 protein [ sapiens] 0.05 118821 N79070 Hs.94789 ESTs 0.05 118979 N93798 Hs.43666 protein tyrosine phosphatase type IVA; member 3 0.05 107495 W78776 Hs.90375 ESTs 0.051 120240 Z41732 Hs.66049 ESTs 0.051 114331 Z41309 Hs.12400 ESTs 0.051 130947 R40037 Hs.21506 ESTs 0.052 129242 W81679 Hs.5174 ribosomal protein S17 0.052 131413 AA482390 Hs.26510 ESTs; Modly smlr to vacuolar prot sorting homotag r-vps33b [R.norvegicus] 0.052 112304 R54798 Hs.26239 ESTs 0.052 101416 M17254 Hs.45514 v-ets avian erythroblastosis virus E26 oncogene related 0.052 131201 AA426304 Hs.24174 ESTs 0.052 101054 K02405 Hs.73933 Human MHC dass II HLA-DQ-beta mRNA (DR7 DQw2); complete eds 0.052 101306 L41143 Hs.232069 T-cell leukemia translocation altered gene 0.053 129311 T55087 yb45c08. Stratagene fetal spleen (#937205) Homo sapiens cDNA clone IMAGE:741265 1 , mRNA sequence. 0.053 129942 U95301 Hs.144442 phospholipase A2; group X 0.053 119210 R93340 Hs.92995 ESTs 0.053 101046 K01160 Accession not listed in Genbank 0.053 114086 Z38266 Hs.12770 Homo sapiens PAC clone DJ0777O23 from 7p14-p15 0.053 110171 H19964 Hs.31709 ESTs 0.053 101004 J04101 HS248109 v-ets avian erythroblastosis virus E26 oncogene homolog 1 0.053 129715 N58479 Hs.12126 ESTs; Weakly similar to LR8 [H.sapiens] 0.053 101581 M34996 Hs.198253 major histocompatibility complex; dass II; DQ alpha 1 0.053 113285 T66830 Hs.182712 ESTs 0.053 127537 AA569531 Hs.162859 ESTs 0.054 100813 HG3995-HT4265 Cpg-Enriched Dna, Clone S19 0.054 101841 M93107 Hs.76893 3-hydroxybutyrate dehydrogenase (heart; mitochondria!) 0.054 135053 R77159 Hs.93678 ESTs 0.054 101419 M17886 Hs.177592 ribosomal protein; large; P1 0.054 119724 W69468 Hs.47622 ESTs 0.055 102673 U72509 Human alternatively spliced B8 (B7) mRNA, partial sequence 0.055 129877 AA248589 Hs.13094 ESTs; Weakly similar to ORF YGR101W [S.cerevisiae] 0.055 114788 AA156737 Hs.103904 EST 0.055 123812 AA620607 Hs.111591 ESTs 0.055 117669 N39237 Hs.44977 ESTs 0.055 123782 AA610111 Hs.162695 EST 0.055 102395 U41767 Hs.92208 a disintegrin and metalloproteinase domain 15 (metargidin) 0.055 133795 M12529 Hs.169401 apolipoprotein E 0.055 123193 AA489228 Hs.136956 ESTs 0.056 132595 AA253369 Hs.155742 glyoxylate redudase/hydroxypyruvate reductase 0.056 104161 AA456471 Hs.7724 KIAA0963 protein 0.056 115330 AA281145 Hs.88827 ESTs 0.056 112893 T08000 Hs.194684 bassoon (presynaptic cytomatrix protein) 0.056 133475 L29217 Hs.73987 CDC-like kinase 3 0.056 128699 K03207 Hs.103972 praline-rich protein BstNI subfamily 4 0.056 102940 X13956 Hs.24998 Hu 12S RNA induced by poly(ri); poly(rC) and Newcastle disease virus 0.056 131299 AA431464 HS25426 ESTs; Weakly similar to unknown [H.sapiens] 0.057 102495 U51240 Hs.79356 Lysosomal-assodated multispanning membrane protein-5 0.057 129594 R70379 Hs.115396 Human germline IgD chain gene; C-region; C-delta-1 domain 0.057 118593 N69020 HS207689 EST 0.057 126702 U54602 Hs2785 keratin 17 0.057 124386 N27368 Hs.212414 sema domain; immunoglobulin domain (Ig); short basic domain; secreted; (semaphorin) 3E 0.057 130538 M20786 Hs.159509 alpha-2-plasmin inhibitor 0.057 114299 Z40782 Hs.22920 similarto S68401 (cattle) glucose induced gene 0.057 115604 AA400378 Hs.49391 ESTs 0.057 106052 AA416947 Hs.6382 ESTs; Highly similar to KIAA0612 protein [H.sapiens] 0.057 131730 U05681 Hs.31210 B-cell CLL/lymphoma3 0.057 131285 AA479498 Hs.25274 ESTs; Modly smlr to putative seven pass transmembrane prot [H.sapiens] 0.058 129705 X78706 Hs.12068 carnitine acetyltransferase 0.058 123175 AA489010 Hs.178400 ESTs 0.058 103592 Z30644 Hs.123059 chloride channel Kb 0.058 118196 N59478 Hs.48396 ESTs; Moderately similar to tumor necrosis fador-alpha -induced protein B12 [H.sapiens] 0.058 104886 AA053348 Hs.144626 growth differentiation fador 11 0.058 104250 AF000575 Hs.105928 leukocyte immunoglobulin-like receptor; subfamily B (with TM and ITIM domains); member 3 0.058 113301 T67452 Hs.13104 EST 0.058 110441 H50302 Hs.19845 ESTs; Highly smlr to prot phosphatase 2A BR gamma subunit [H.sapiens] 0.058 125297 Z39215 Hs.159409 ESTs 0.058 135258 AA292423 Hs.97272 ESTs; Weakly similar to dJ281H82 [H.sapiens] 0.058 130633 T92363 Hs.178703 ESTs 0.058 112006 R42607 HS22241 hypothetical protein 0.058 130805 U12194 Hs.170238 sodium channel; voltage-gated; type I; beta polypeptide 0.058 134907 D80002 Hs.178292 KIAA0180 protein 0.058 132619 AA404565 Hs.53447 ESTs; Moderately similar to kinesin light chain 1 [M.musculus] 0.058 135115 N35489 Hs.94653 neurochondrin 0.058 100531 HG1872-HT1907 Major Histocompatibility Complex, Dg 0.058 124530 N62256 Hs.102727 EST 0.058 119960 W87533 Hs.32699 ESTs; Moderately similar to LIV-1 protein [H.sapiens] 0.058 132793 AA478999 Hs.56966 KIAA0906 protein 0.058 101076 L04270 Hs.1116 fymphotoxin beta receptor (TNFR superfamily; member 3 0.058 130655 N92934 Hs.17409 cysteine-rich protein 1 (intestinal) 0.058 134458 AA192614 Hs.83577 cysteine and glydne-rich protein 3 (cardiac LIM protein) 0.058 105904 AA401452 Hs.32060 ESTs 0.059 132878 AA026793 Hs.58679 ESTs; Weakly similar to 4F2 CD98 light chain [M.musculus] 0.059 121828 AA425166 Hs.98497 ESTs 0.059 133418 U76366 Hs.172727 TreacherCollins-Franceschetti syndrome 1 0.059 129317 N46244 Hs.110373 ESTs 0.059 130153 D85815 Hs.15114 ras homolog gene family; member D 0.059 124403 N31745 Hs.102493 ESTs 0.059 127683 AA668123 Hs.134170 ESTs 0.059 129814 W20070 Hs.168625 KIAA0979 protein 0.059 131770 D59682 Hs.31833 ESTs 0.06 117557 N33920 Hs.44532 diubiquitin 0.06 103522 Y10514 H.sapiens mRNA for CD152 protein ~ 0.06 120029 W91960 Hs.250640 sequence-specific single-stranded-DNA-binding protein 0.06 102135 U15460 Hs.41691 activating transcription fador B 0.06 123617 AA609183 Hs.181131 ESTs 0.06 112136 R46100 Hs.9739 ESTs 0.061 133725 V00563 Hs.179543 immunoglobulin mu 0.061 102069 U09196 Hs.82520 Hu 1.1 kb mRNA upregltd in retinoic add treated HL-60 neutrophilic cells 0.061 106555 AA455000 Hs.16725 ESTs 0.061 123269 AA491226 Hs.105280 ESTs; Weakly similar to dJ963K232 [H.sapiens] 0.061 109088 AA166837 Hs.72620 DKFZP434I114 protein 0.O61 129399 AA263028 Hs.111076 malate dehydrogenase 2; NAD (mitochondria!) 0.061 129375 W79850 Hs.11081 ESTs; Weakly similar to HPBRII-7 protein [H.saptens] 0.061 135271 AA397763 Hs.97562 ESTs 0.061 132958 W90398 Hs.6147 KIAA1075 protein 0.061 129364 AA477106 Hs.110757 DNA segment on chromosome 21 (unique) 2056 expressed sequence 0.061 123427 AA598548 Hs.112471 ESTs 0.061 105236 AA219179 Hs.19105 translocase of inner mitochondrial membrane 17 (yeast) homolog B 0.061 101012 J04444 Hs.697 cytochrome c-1 0.062 134791 L18983 Hs.89655 protein tyrosine phosphatase; receptor type; N 0.062 133700 K01396 Hs.75621 protease inhibitor 1 (anti-elastase); alpha-1-antitrypsin 0.062 123887 AA621065 Hs.112943 ESTs 0.062 129363 H05704 Hs.110746 H sapiens HCR (a-helix coiled-coil rod ho ologue) mRNA; complete eds 0.062 105719 AA291644 Hs.36793 ESTs 0.062 124226 H62396 Hs.190266 ESTs 0.062 117437 N27645 yw5e3.s1 Weizmann Olfadory Epithelium H sapiens cDNA done IMAGE2556763' smlr to contains L1.t3 L1 repetitive element ;, mRNA seq 0.062 132741 AA394133 Hs.55898 ESTs; Highly similar to OASIS protein [M.musculus] 0.062 134437 M26041 Hs.198253 major histocompatibility complex; dass II; DQ alpha 1 0.062 107664 AA010594 Hs.5326 ESTs; Moderately similar to pim-1 protein [H.sapiens] 0.062 120844 AA349417 Hs.96917 ESTs 0.062 101574 M34182 Hs.158029 protein kinase; cAMP-dependent; catalytic; gamma 0.062 131219 C00476 Hs.24395 small inducible cytokine subfamily B (Cys-X-Cys); member 14 (BRAK) 0.062 103495 Y09022 Hs.153591 Not56 (D. melanogaster)-like protein 0.062 129607 AA404594 Hs.11607 ESTs 0.062 106467 AA450040 Hs.154162 ADP-ribosylation fador-like 2 0.062 128841 T16358 Hs.106443 ESTs 0.062 100515 HG1723-HT1729 Macrophage Scavenger Receptor, Alt. Splice 2 0.062 119332 T54095 ESTs; Weakly similar to I! ALU SUBFAMILY J WARNING ENTRY I! [H.sapiens] 0.062 134516 AA171939 Hs.23413 ESTs 0.062 135012 X73608 Hs.93029 sparc/osteonedin; cwcv and kazal-like domains proteoglycan (testican) 0.063 103575 Z26256 H.sapiens isoform 1 gene for L-type ca -ium channel, exon 1 0.063 115514 AA297739 Hs.55609 ESTs; Weakly similar to ISOLEUCYL-TRNA SYNTHETASE; CYTOPLASMIC [H.sapiens] 0.063 103996 AA321355 EST2393 Bone marrow Homo sapiens cDNA 5' end, mRNA sequence 0.063 110505 H55992 Hs.20495 DKFZP434F011 protein 0.063 133912 X62744 Hs.77522 major histocompatibility complex; dass II; DM alpha 0.063 129581 M3360O Hs.180255 major histocompatibility complex; dass II; DR beta 1 0.063 130139 R38280 Hs.150922 BCS1 (yeast homotog)-like 0.064 105817 AA397825 Hs.5307 synaptopodin 0.064 134658 AA410617 Hs.178009 ESTs 0.064 100306 D50495 Hs.80598 transcription elongation fador A (Sll); 2 0.064 100277 D42053 Hs.75890 site-1 protease (subtilisin-like; sterol-regulated; cleaves sterol regulatory element binding proteins) 0.064 133116 D61259 Hs.6529 ESTs 0.064 134909 AA521488 Hs.90998 KIAA0128 protein 0.064 130319 X74794 Hs.154443 minichromosome maintenance deficient (S. cerevisiae) 4 0.064 132057 AA102489 Hs.173484 ESTs 0.064 108334 AA070473 zm7c8.s1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA done IMAGE-53993', mRNA sequence 0.064 129763 F10815 Hs.12373 KIAA0422 protein 0.064 135112 T67464 Hs.94617 ESTs; Weakly similar to predided using Genefinder [C.elegans] 0.064 122269 AA436856 Hs.98910 ESTs 0.064 133082 AA457129 Hs.6455 RuvB (E cofi homolog)-like 2 0.064 113213 T58607 ya94a02.s1 Stratagene placenta (#937225) Homo sapiens cDNA clone IMAGE-692903', mRNA sequence. 0.065 106228 AA429290 Hs.17719 ESTs 0.065 130192 Y12661 Hs.171014 VGF nerve growth factor inducible 0.065 104894 AA054087 Hs.18858 phospholipase A2; group IVC (cytosolic; calcium-independent) 0.065 103508 Y10141 H.sapiens DAT1 gene, partial, VNTR 0.065 128474 U40671 Hs.100299 ligase III; DNA; ATP-dependent - 0.065 134012 AA417821 Hs.237924 ESTs; Highly similar to CGI-69 protein [ sapiens] 0.065 134536 AA457735 Hs.850 IMP (inosine monophosphate) dehydrogenase 1 0.065 111714 R23146 Hs.23466 ESTs 0.065 110521 H57060 Hs.108268 ESTs 0.065 103282 X80198 Hs.77628 steroidogenic acute regulatory protein related 0.065 113921 W80730 Hs.28355 ESTs 0.065 129331 N93465 Hs.110453 ESTs; Highly similar to CGI-38 protein [H.saptens] 0.065 111316 N74597 Hs.180535 ESTs; Weakly similar to mitogen inducible gene mig-2 [H.saptens] 0.065 135138 AA036794 Hs.95196 ESTs; Weakly similar to T20B12.3 [C.elegans] 0.065 107289 T10792 Hs.172098 ESTs 0.065 121405 AA406083 Hs.98007 ESTs 0.065 124965 T16275 Hs.106359 ESTs 0.065 106595 AA456933 Hs.174481 ESTs 0.066 100106 AF015910 Homo sapiens unknown protein mRNA, partial eds 0.066 134715 AA282757 Hs.89040 prepronodceptin 0.066 135367 AA480109 Hs.9963 TYRO protein tyrosine kinase binding protein 0.066 111533 R08548 Hs.251651 EST 0.066 128509 R53109 Hs247362 dimethylarginine dimethylaminohydrolase 2 0.066 101030 J05037 Hs.76751 serine dehydratase 0.066 102753 U80226 Human gamma-aminobutyric add transaminase mRNA, partial eds 0.067 126991 R31652 Hs.821 biglycan 0.067 109583 F02322 HS26135 ESTs 0.067 119241 T12559 Hs.221382 ESTs 0.067 130569 AA156597 HS256441 EST; Moderately similar to CGI-136 protein [H.sapiens] 0.067 112926 T10316 Hs.4302 ESTs 0.067 120495 AA256073 Hs.190626 ESTs 0.067 130931 AA278412 HS21346 ESTs; Weakly similar to F42C5.7 gene produd [C.elegans] 0.067 129982 M87789 Hs.140 immunoglobulin gamma 3 (Gm marker) 0.067 133832 H03387 Hs.241305 estrogen-responsive B box protein 0.067 110697 H93721 Hs.20798 ESTs 0.067 121183 AA400138 Hs.97703 ESTs 0.067 130953 U12707 Hs.2157 Wiskott-Aldrich syndrome (ecezema-thrombocytopenia) 0.067 102218 U24183 Hs.75160 phosphofrudokinase; usde 0.067 114181 Z39079 Hs.8021 KIAA1058 protein 0.067 116581 D51287 Hs.82148 ribosomal protein S12 0.067 132498 T87708 Hs.50098 ESTs 0.068 103788 AA096014 Hs.9527 ESTs; Highly similar to HSPC013 [H.sapiens] 0.068 102459 U48936 Human amiloride-sensitive epithelial sodium channel gamma subunit mRNA, 5' end, partial eds 0.068 100373 D79999 Hs.77225 ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase)-like 1 0.068 132717 AA203321 Hs.151696 DKFZP727G051 protein 0.068 128863 D87462 Hs.106674 BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase) 0.068 115193 AA262029 Hs.88218 ESTs 0.068 124558 N66046 Hs.141605 ESTs 0.069 117225 N20392 Hs.42846 ESTs 0.069 110665 H83380 Hs.32757 ESTs 0.069 132905 U70663 Hs.182965 Kruppel-like fador 4 (gut) 0.069 105778 AA348910 Hs.153299 DOM-3 (C. elegans) homolog Z 0.069 134770 R72079 Hs.89575 CD79B antigen (immunoglobulin-associated beta) 0.069 123097 AA485869 Hs.105671 ESTs 0.069 100750 HG3523-HT4899 Prato-Oncogene C-Myc, Alt. Splice 3, Orf 114 0.069 125091 T91518 ye20f05.s1 Stratagene lung (#937210) H sapiens cDNA done IMAGE: 3' similar to contains Alu repetitive element;contains MER12 repetitive element; mRNA sequence. 0.069 100756 HG3565-HT3768 Zinc Finger Protein (Gb:M88357) 0.069 113483 T87768 Hs.16439 ESTs 0.069 101119 L09708 Hs.2253 complement component 2 0.069 102286 U31628 Hs.12503 interleukin 15 receptor; alpha 0.07 135349 D83174 Hs.9930 collagen-binding protein 2 (colligen 2) 0.07 100991 J03764 Hs.82085 plasminogen activator inhibitor; type I 0.07 133675 AA443720 Hs.7551 ESTs; Weakly similar to T25G3.1 [C.elegans] 0.07 105422 AA251014 Hs.12210 ESTs 0.07 102932 X13334 Hs.75627 CD14 antigen 0.07 119147 R58878 Hs.65739 ESTs 0.07 104900 AA055048 Hs.180481 ESTs; Weakly similar to ACROSIN PRECURSOR [H.sapiens] 0.07 133185 AA481404 Hs.6686 ESTs 0.07 115496 AA290674 Hs.71819 eukaryotic translation initiation fador 4E binding protein 1 0.07 121005 AA398332 Hs.97613 ESTs 0.07 124869 R69088 Hs.28728 ESTs; Weakly similar to F55A12.9 [C.elegans] ~ 0.071 129154 N23673 Hs.108969 mannosidase; alpha; class 2B; member 1 0.071 112161 R48295 ESTs; Wkly smlr to !! ALU SUBFAMILY J WARNING ENTRY II [H.sapiens] 0.071 125251 W87486 Hs.141464 ESTs 0.071 134298 J00116 Hs.81343 collagen; type II; alpha 1 (primary osteoarthritis; spondyloepiphyseal dysplasia; congenital) 0.071 119745 W70264 Hs.58093 ESTs 0.071 131306 AA232686 Hs.25489 ESTs 0.071 107776 AA018820 Hs.221147 ESTs 0.071 134271 AA199630 Hs.184456 ESTs; Wkly smlr to 1! ALU SUBFAMILY SX WARNING ENTRY !! [H.sapiens] 0.071 101798 M85220 Accession not listed in Genbank 0.071 135402 S76942 Hs.99922 dopamine receptor D4 0.071 118742 N74052 Hs.50424 EST 0.071 131867 N64656 Hs.3353 Homo sapiens done 24940 mRNA sequence 0.071 102923 X12517 Hs.1063 small nuclear ribonudeoprotein polypeptide C 0.072 100775 HG371-HT26388 Mudn 1 , Epithelial, Alt. Splice 9 0.072 111020 N54361 Hs.185726 ESTs 0.072 134224 X80822 Hs.163593 ribosomal protein L18a 0.072 124059 F13673 Hs.99769 ESTs 0.072 133972 AA160743 Hs.78019 Homo saptens clone 24432 mRNA sequence 0.072 129681 AA436009 Hs.178186 ESTs; Weakly similar to WASP-famity protein [H.sapiens] 0.072 103065 X58399 Hs.81221 Human L2-9 transcript of unreatranged immunoglobulin V(H)5 pseudogene 0.072 124966 T19271 Hs.155560 calnexin 0.072 112270 R53021 Hs.203358 ESTs 0.072 116704 F10183 Hs.66140 EST 0.072 129890 M13699 Hs.111461 ceruloplasmin (ferroxidase) 0.072 127345 AA972008 Hs.166253 ESTs; Highly similar to KIAA0476 protein [H.sapiens] 0.072 112436 R63 90 Hs.28391 ESTs 0.072 114531 AA053033 Hs.203330 ESTs 0.072 135122 H99080 Hs.94814 ESTs 0.072 103934 AA281338 Hs.134200 Homo sapiens mRNA; cDNA DKFZp564C186 (from done DKFZp564C186) 0.072 109363 AA215369 Hs.185764 ESTs; Weakly similar to hypothetical protein [H.sapiens] 0.072 112647 R83329 Hs.33403 ESTs 0.073 127083 Z44079 Hs.91608 otoferiin 0.073 133027 AA402624 Hs.63236 synudein; gamma (breast cancer-spedfic protein 1 ) 0.073 122086 AA432121 Hs.250986 EST 0.073 110405 H47542 Hs.33962 ESTs 0.073 128697 AB002344 Hs.103915 KIAA0346 protein 0.073 112221 R50380 Hs.25670 ESTs 0.073 100478 HG1067-HT1067 Mudn (Gb:M22406) 0.073 115598 AA400129 Hs.65735 ESTs 0.073 132491 AA227137 Hs.4984 KIAA0828 protein 0.073 101655 M60299 Human alpha- 1 collagen type II gene, exons 1, 2 and 3 0.073 106018 AA411887 Hs.34737 ESTs 0.073 129683 W05348 Hs.158196 DKFZP434B103 protein 0.073 134137 F10045 Hs.79347 KIAA0211 gene produd 0.073 114008 W89128 Hs.19872 ESTs 0.073 107653 AA010210 Hs.47041 ESTs 0.073 104798 AA029462 Hs.17235 ESTs 0.073 134082 L16991 Hs.79006 deoxythymidylate kinase 0.073 119180 R80413 Hs.92520 ESTs 0.073 107741 AA016982 Hs.64341 ESTs 0.073 133683 AA335223 Hs.75558 pepsinogen 5; group I (pepsinogen A) 0.073 111694 R22035 Hs.23331 ESTs 0.073 120764 AA338729 Hs.133096 ESTs 0.073 119389 T88826 Hs.90973 ESTs 0.074 100929 HG688-HT688 Major Histocompatibility Complex, Class li, Dr Beta 2 (Gb:X65561) 0.074 119388 T88798 plasminogen adivator inhibitor; type I 0.074 133019 AF009674 Hs.184434 axin 0.074 105185 AA191495 Hs.189937 ESTs 0.074 133413 S72043 Hs.73133 metallothionein 3 (growth inhibitory fador (neurotrcphic)) 0.074 101017 J04599 Hs.821 biglycan 0.074 132865 K02765 Hs.251972 complement component 3 0.074 110882 N36001 Hs.17348 ESTs; Wkly smlr to !! ALU SUBFAMILY SQ WARNING ENTRY !! [H.saptens] 0.074 129197 T90303 Hs.109308 ESTs; Wkly smlr to leucine-rich glioma-inactivated prot precursor [H.sapiens] 0.074 101184 L19871 Hs.460 activating transcription fador 3 0.075 134910 AA431320 Hs.9100 ESTs 0.075 119411 T96621 HS203656 EST 0.075 102000 U01824 Hs.380 solute carrier family 1 (glial high affinity glutamate transporter); member 2 0.075 114691 AA121893 Hs.103779 ESTs; Weakly similar to envelope protein [H.saptens] 0.075 134179 U53204 Hs.79706 plectin 1; intermediate filament binding protein; 500kD 0.075 134503 U34880 Hs.84183 diptheria toxin resistance protein required for diphthamide biosynthesis (Saccharomyces)-like 1 0.075 129719 N66396 Hs.167766 ESTs; Moderately similar to Pro-a2(XI) [H.sapiens] 0.075 113916 W80464 Hs.31928 ESTs; Wkly smlr to alternatively spliced produd using exon 13A [H.saptens] 0.075 113897 W73926 Hs.4947 ESTs 0.075 129697 R00841 Hs.172069 DKFZP434C212 protein 0.075 112078 R44155 Hs.112218 ESTs 0.075 121980 AA429886 Hs.110407 ESTs; Weakly similar to coded for by C. elegans cDNA yk173c12.5 [C.elegans] 0.075 100898 HG4638-HT5050 Spliceosomal Protein Sap 49 0.075 121626 AA416974 Hs.98174 ESTs 0.075 133670 AA243416 Hs.75470 hypothetical protein; expressed in osteoblast 0.075 131879 AA017161 Hs.33792 ESTs 0.075 100254 D38037 Hs.77643 FK506-binding protein 1B (12.6 kD) 0.075 133194 AA291726 Hs.67201 ESTs 0.075 106081 AA418394 Hs.25354 ESTs 0.075 115544 AA351433 Hs.66187 Homo sapiens done 23700 mRNA sequence 0.076 119955 W87460 Hs.58989 ESTs 0.076 104407 H61361 Hs.102171 immunoglobulin superfamily containing leucine-rich repeat 0.076 135019 X58431 Hs.98428 Human Hox22 gene for a homeobox protein 0.076 114815 AA161488 Hs.103931 DKFZP434B0335 protein 0.076 119471 W31352 Hs.55445 ESTs 0.076 117788 N48292 Hs.46849 ESTs 0.076 119406 T95064 Hs.193771 EST 0.076 130777 R61742 HS256554 ESTs 0.076 130494 L13197 Hs.75874 pregnancy-associated plasma protein A 0.076 104107 AA424111 Hs.12598 T-cell lymphoma invasion and metastasis 2 0.076 121483 AA411981 Hs.25274 ESTs; Modly smlr to putative seven pass transmembrane prot [H.saptens] 0.076 104451 M13299 Hs.102119 blue cone pigment 0.076 118027 N52770 Hs.75968 thymosin; beta 4; X chromosome 0.076 109419 AA227560 Hs.86987 receptor-interacting serine-threonine kinase 3 0.076 115783 AA424487 Hs.72289 ESTs; Weakly similar to LIV-1 protein [H.sapiens] 0.076 110585 H62223 Hs.133526 ESTs; Wkly smlr to !!!ALU SUBFAMILY SB1 WARNING ENTRY !!![H.sapiens] 0.076 123165 AA488863 Hs.105216 ESTs; Weakly smlr to "ALU SUBFAMILY J WARNING ENTRY !! [H.saptens] 0.077 103966 AA303166 Hs.127270 ESTs 0.077 109549 F01528 Hs.21192 Homo sapiens done 25155 mRNA sequence 0.077 106730 AA465520 Hs.22313 ESTs 0.077 120310 AA193676 Hs.118926 DKFZP586K0919 protein 0.077 104078 AA402801 Hs.222010 ESTs 0.077 117624 N35978 Hs.82364 ESTs 0.077 112421 R62441 Hs.23127 ESTs 0.077 106958 AA497026 Hs.22059 ESTs 0.077 129984 W92811 Hs.183927 ESTs; Weakly similar to I! ALU SUBFAMILY J WARNING ENTRY I! [H.sapiens] 0.077 122044 AA431456 Hs.98736 EST 0.077 123280 AA491285 Hs.175144 ESTs 0.077 115710 AA412535 Hs.55235 sphingomyelin phosphodiesterase 2; neutra I membrane (neutral sphingomyelinase) 0.077 134129 D87444 Hs.79305 KIAA0255 gene produd 0.077 129321 AA224502 Hs.206501 Homo sapiens done 643 unknown mRNA; complete sequence 0.078 130513 AA460257 Hs.15866 ESTs 0.078 100996 J03909 Hs.14623 interferon; gamma-inducibte protein 30 0.078 128358 AI095718 Hs.135015 ESTs 0.078 128544 R59352 Hs.119273 KIAA0296 gene produd 0.078 106040 AA412681 Hs.125139 ESTs 0.078 106495 AA452113 Hs.32454 ESTs; Moderately similar to KIAA0544 protein [H.sapiens] 0.078 131833 R40899 Hs.32973 glycine receptor; beta 0.078 119219 R97176 Hs.110783 ESTs 0.078 135415 X60655 Hs.99967 even-skipped homeo box 1 (homolog of Drosophila) 0.078 109457 AA232646 Hs.68061 ESTs; Weakly similar to sphingosine kinase [M.musculus] 0.078 117137 H96670 Hs.42221 ESTs 0.078 107094 AA609614 Hs.5241 ESTs 0.078 130165 T90529 Hs.251613 EST 0.078 124072 H05252 Hs.101637 EST; Weakly similar to hypothetical protein [H.sapiens] 0.078 126151 AA324743 Hs.40808 ESTs 0.078 119035 R01779 Hs.7740 ESTs 0.078 110157 H18987 Hs.169731 ESTs 0.078 128515 AA149044 Hs.10086 ESTs; Highly similar to HYPOTHETICAL PROTEIN KIAA0195 [H.sapiens] 0.078 133069 U94836 Hs.6430 protein with polyglutamine repeat 0.078 112209 R49644 Hs.24865 ESTs 0.078 133361 R28279 Hs.71848 Human done 23548 mRNA sequence 0.078 134714 U89922 Hs.890 lymphotoxin beta (TNF superfamily; member 3) 0.078 129905 T86796 Hs.132875 ESTs; Weakly similar to predided using Genefinder [C.elegans] 0.079 120421 AA236166 Hs.132957 ESTs; Weakly similar to chondromodulin-l precursor [H.sapiens] 0.079 100885 HG4490-HT4876 Proline-Rich Protein Prb4, Allele 0.079 102789 U86759 Hs.158336 netrin 2 (chicken)-like ' 0.079 120139 Z39273 Hs.77876 Human DNA from chromosome 19-spedfic cosmid R30923; genomic sequence 0.079 135238 U76343 Hs.96970 Human liver GABA transport protein mRNA; 3' end 0.079 129618 N54845 Hs.173030 ESTs 0.079 132960 AA609742 Hs.6150 KIAA0521 protein 0.079 108751 AA127063 Hs.203717 ESTs 0.079 134060 D42039 Hs.78871 KIAA0081 protein 0.079 111338 N79778 Hs.35094 extracellular matrix protein 2; female organ and adipocyte specific 0.079 112345 R56880 Hs.26563 ESTs 0.079 126456 WO0881 za56d02.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE2965475', mRNA sequence. 0.079 128937 Z39939 Hs.10726 ESTs 0.079 103485 Y08409 HS248415 thyroid hormone responsive SP0T14 (rat) homolog 0.079 111202 N68280 Hs.107922 ESTs 0.079 132625 AA429890 Hs.166066 dsplatin resistance associated 0.079 103434 X98085 Hs.54433 tenasdn R (restridin; janusin) 0.079 102616 U65581 Hs.159191 ribosomal protein L3-like 0.079 102667 U70867 Hs.83974 solute earner family 21 (prostaglandin transporter); member 2 0.079 111422 R01127 Hs.19104 ESTs 0.079 101411 M16938 Hs.820 homeo box C6 0.08 113267 T65058 Hs.12725 ESTs; Weakly similar to I! ALU SUBFAMILY J WARNING ENTRY I! [H.sapfens] 0.08 103559 Z19585 Hs.75774 thrombospondin 4 0.08 131588 AA258613 Hs.29189 KIAA1021 protein 0.08 107821 AA020991 Hs.172856 ESTs 0.08 134278 H82839 Hs.81001 ESTs; Weakly similar to DY3.6 [C.elegans] 0.08 120893 AA369800 Hs.97058 EST; Highly similar to CMP-N-acety!neuraminic add hydroxylase [H.sapiens] 0.08 108786 AA128999 zo8f12.s1 Stratagene neuroepithelium NT2RAMI 937234 Homo sapiens cDNA done IMAGE.5671193', mRNA sequence 0.08 106890 AA489245 Hs.88500 KIAA1066 protein; JSAP1 homolog (mouse); JIP3 homolog (mouse) 0.08 119760 W72267 Hs.58219 ESTs 0.08 132999 Y00787 Hs.624 interleukin 8 0.08 129156 AA028195 Hs.108973 dolichyl-phosphate mannosyltransferase polypeptide 2; regulatory subunit 0.08 121171 AA400008 Hs.161814 ESTs 0.08 103864 AA207264 Hs.181077 ESTs; Weakly similar to Miller-Dieker lissencephaly gene [H.sapiens] 0.08 128591 AA255537 Hs.102057 ESTs; Weakly similar to O-linked GlcNAc transferase [H.sapiens] 0.08 122172 AA435753 Hs.161854 EST 0.08 112802 R97647 Hs.174855 EST 0.08 107723 AA015967 Hs.60680 EST 0.08 113011 T23737 Hs.1600 chaperonin containing TCP1; subunit 5 (epsilon) 0.081 131279 AA089853 Hs25197 STIP1 homology and U-Box containing protein 1 0.081 103190 X7O083 Hs.58414 filamin C; gamma (actin-binding ρrotein-280) 0.081 103956 AA292411 Hs.233348 ESTs 0.081 112706 R89828 Hs.138493 ESTs 0.081 126126 M85370 EST01884 Fetal brain, Stratagene (cat#936206) Homo sapiens cDNA done HFBCH10, mRNA sequence. 0.081 130094 H43286 Hs.167017 gamma-aminobutyricadd (GABA) B receptor; 1 0.081 100800 HG3945-HT4215 Phospholipid Transfer Protein 0.081 108675 AA115240 Hs.61816 ESTs 0.081 129420 AA234259 Hs.99816 ESTs 0.081 129666 M77349 Hs.118787 transforming growth fador; beta-induced; 68kD 0.081 101645 M59807 Hs.943 natural kilter cell transcript 4 0.081 130536 T17045 Hs.159492 spastic ataxia of Chartevoix-Saguenay (sacsin) 0.081 107732 AA016181 Hs.59752 ESTs 0.081 123071 AA482593 Hs.104285 ESTs 0.081 113537 T90457 Hs.191293 ESTs 0.081 101250 L34060 Hs.79133 cadherin 8 0.081 122521 AA449433 Hs.149227 ESTs; Weakly similar to PROLINE-RICH PROTEIN MP-3 [M.musculus] 0.081 133914 N32811 Hs.77542 ESTs 0.081 102038 U05659 Hs.477 hydroxysteroid (17-beta) dehydrogenase 3 0.081 110336 H40338 Hs.174094 ESTs; Weakly similarto !! ALU SUBFAMILY J WARNING ENTRY !! [H.sapfens] 0.081 118637 N70274 Hs.49822 ESTs 0.081 117966 N51589 Hs.94012 ESTs 0.082 104424 H87671 Hs.182320 ESTs; Weakly similar to Mouse 19.5 mRNA; complete eds [M.musculus] 0.082 100361 D78361 Hs.125078 Human mRNA for ornithine decarboxylase antizyme; ORF 1 and ORF 2 0.082 112974 T17291 Hs.101174 microtubute-associated protein tau 0.082 132832 D63482 Hs.57734 KIAA0148 gene produd 0.082 132039 Z39489 Hs.3781 Homo sapiens BAC clone RG118D07 from 7q31 0.082 113272 T65383 Hs.12807 ESTs 0.082 104924 AA058532 Hs.28774 ESTs 0.082 111061 N58054 Hs.36859 ESTs 0.082 129269 R45977 Hs.163593 ribosomal protein L18a 0.082 102453 U48437 Hs.74565 amyloid beta (A4) precursor-like protein 1 0.082 126204 AI080388 Hs.134296 ESTs 0.082 116615 D80666 Hs.45203 ESTs 0.082 128856 AA219552 Hs.204144 ESTs; Modly smlr to tumor necrosis fador-alpha-induced prot B12 [H.sapiens] 0.082 112776 R95850 Hs.34494 ESTs 0.082 105494 AA256273 Hs.29288 Homo sapiens mRNA; cDNA DKFZp434P174 (from done DKFZp434P174) 0.082 117000 H84718 Hs.112236 ESTs; Weakly similar to repressor protein [H.saptens] 0.082 112656 R85260 Hs.133151 transient receptor potential channel 7 0.082 128963 J03890 Hs.1074 surfactant; pulmonary-assodated protein C 0.083 116957 H79292 Hs.39960 ESTs 0.083 101057 K03430 Human complement C1q B-chain gene, exon A+1 0.083 121948 AA429452 Hs.98582 ESTs 0.083 130822 M80647 Hs2001 thromboxane A synthase 1 (platelet; cytochrome P450; subfamily V) 0.083 122743 AA458674 Hs.99478 EST 0.083 114569 AA063316 zm2d1.s1 Stratagene cornea! stroma (#937222) Homo sapiens cDN A done IMAGE.5129473' similar to TR.Ε198281 E198281 THIOREDOXIN REDUCTASE ;contains Alu repetitive element;, mRNA sequence 0.083 132270 U70671 Hs.43509 ataxin 2 related protein 0.083 108126 AA052951 Hs.47413 ESTs 0.083 102880 X04325 Hs2679 gap junction protein; beta 1; 32kD (connexin 32; Charcot-Marie-Tooth neuropathy; X-linked) 0.083 115365 AA282089 Hs.88599 ESTs 0.083 114529 AA052980 Hs.206704 ESTs 0.083 135017 AA249586 Hs.9315 ESTs; Weakly similar to NEURONAL OLFACTOMEDIN-RELATED ER LOCALIZED PROTEIN [H.sapiens] 0.083 123776 AA610071 Hs.112813 ESTs 0.083 114454 AA021091 Hs.226208 ESTs 0.083 101246 L33799 Hs.202097 procollagen C-endopeptidase enhancer 0.083 107366 U78310 Hs.13501 pescadillo (zebrafish) homolog 1; containing BRCT domain 0.083 132779 T89601 Hs.95497 ESTs; Weakly similar to GLUCOSE TRANSPORTER TYPE 5; SMALL INTESTINE [Rsapiens] 0.083 129709 AA112209 Hs.1209 acyl-Coenzyme A dehydrogenase; long chain 0.083 115244 AA278767 Hs.914 Human mRNA for SB classll histocompatibility antigen alpha-chain 0.083 123253 AA490878 Hs.111334 ferritin; light polypeptide 0.083 128469 T23724 Hs.258677 EST 0.083 132220 AA431847 Hs.42409 ESTs; Highly similar to CGI-146 protein [H.sapiens] 0.083 111664 R17939 Hs.22344 ESTs 0.083 102354 U38268 Human cytochrome b pseudogene, partial eds 0.084 112828 R98774 Hs.194338 ESTs 0.084 110410 H47868 Hs.34024 ESTs 0.084 102620 U66052 Human done W2-6 mRNA from chromosome X 0.084 102550 U58087 Hs.14541 cullin 1 0.084 108417 AA075716 zm89e5.s1 Stratagene ovarian cancer (#937219) H sapiens cDNA clone IMAGE:545123' similarto gb:X14723 CLUSTERIN PRECURSOR (HUMAN);, mRNA sequence 0.084 113299 T67285 Hs.13089 ESTs 0.084 117869 N49947 Hs.46990 ESTs 0.084 113734 T98484 Hs.18377 EST 0.084 133325 C00424 Hs.7101 periodontal ligament fibroblast protein 0.084 123368 AA505022 Hs.124838 ESTs 0.084 101615 M55153 Hs.8265 transglutaminase 2 (C polypeptide; protein-glutamine -gamma-glutamyltransferase) 0.084 119352 T65972 Hs.193365 ESTs; Moderately similar to alternatively spliced produd using exon 13A [H.sapiens] 0.084 123828 AA620686 Hs.112884 EST 0.084 103611 Z38133 Hs.113973 myosin; heavy polypeptide 8; skeletal muscle; perinatal 0.084 131289 AA485697 Hs.25334 ESTs; Weakly similar to ION CHANNEL HOMOLOG RIC PRECURSOR [M.musculus] 0.084 128678 T15896 Hs.103535 ESTs 0.084 130814 AA256695 Hs.19813 ESTs 0.084 133391 X57579 Hs.727 inhibin; beta A (activin A; activin AB alpha polypeptide) 0.084 129322 AA437153 Hs.110407 ESTs; Weakly similar to coded for by C. elegansrcDNA yk173c12.5 [C.elegans] 0.084 109284 AA196995 Hs.86092 ESTs 0.084 116689 F09222 Hs.66099 ESTs 0.085 100545 HG2147-HT2217 Mucin 3, Intestinal (Gb:M55405) 0.085 102634 U66711 Hs.77667 lymphocyte antigen 6 complex; locus E 0.085 111735 R25389 Hs.23856 ESTs; Weakly similar to FAST kinase [H.sapiens] 0.085 105181 AA190676 Hs.10974 ESTs; Moderately similar to unknown [R.norvegicus] 0.085 122681 AA455350 Hs.99401 EST 0.085 114543 AA056121 Hs.158419 ESTs 0.085 133597 AA425908 Hs.75139 partner of RAC1 (arfaptin 2) 0.085 121064 AA398647 Hs.97406 ESTs 0.085 122231 AA436369 Hs.197728 ESTs; Weakly similar to ZINC FINGER PROTEIN 135 [H.sapiens] 0.085 100309 D50550 Hs.95659 lethal giant laivae (Drosophila) homolog 1 0.085 101727 M73481 Hs.73883 gastrin-reteasing peptide receptor 0.085 131226 AA165400 Hs.24476 ESTs 0.085 133580 AA095041 Hs.181073 ESTs 0.085 102792 U87964 Hs.227576 GTP binding protein 1 0.085 104976 AA086480 Hs.183669 ESTs; Weakly similar to !! ALU SUBFAMILY J WARNING ENTRY I! [H.sapiens] 0.085 120865 AA350631 Hs.96963 EST 0.085 106080 AA418046 Hs.35124 ESTs 0.085 128571 AA416619 Hs.101661 ESTs 0.085 101838 M92934 Hs.75511 connective tissue growth fador 0.085 128514 H84261 Hs.100843 ESTs; Weakly similar to similar to GTP-binding protein [C.elegans] 0.085 123099 AA485931 Hs.79 aminoacylase 1 0.085 134067 Y08200 Hs.78920 Rab geranylgeranyltransferase; alpha subunit 0.085 116967 H80336 Hs.40124 EST 0.085 110053 H12586 Hs.89563 nudear cap binding protein 1; 80kD 0.085 114395 AA007313 Hs.110155 ESTs 0.085 107465 W44681 Hs251385 murine retrovirus integration site 1 homolog 0.085 101983 S85655 Hs.75323 prohibitin 0.085 112544 R70948 Hs.29153 ESTs 0.086 111423 R01165 Hs.188507 ESTs 0.086 127918 AA806043 Hs.115396 Human germline IgD chain gene; C-region; C-delta-1 domain 0.086 107300 T40348 Hs.90488 ESTs 0.086 134947 R51194 yj71a08.r1 Soares breast 2NbHBst Homo sapiens cDNA done 1MAGE:154166 5' similar to gb:L11284 DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (HUMAN);, mRNA sequence. 0.086 124579 N68345 Hs.127179 ESTs; Weakly similar to TERATOCARCINOMA-DERIVED GROWTH FACTOR 1 [H.sapiens] 0.086 130471 Z68280 Hs.183706 addudn 1 (alpha) 0.086 116596 D60755 Hs.92955 ESTs 0.086 105069 AA136345 Hs23617 ESTs; Weakly similar to ZFOC1 gene produd [H.sapiens] 0.086 102491 U51010 Human nicotinamide N-methyltransferase gene, exon 1 and 5' flanking region 0.086 130069 AA055896 Hs.146428 collagen; type V; alpha 1 0.086 130234 AA280413 Hs.157441 spleen focus forming virus (SFFV) proviral integration oncogene spil 0.086 120540 AA262992 Hs.96417 ESTs 0.086 122508 AA449221 HS20432 ESTs 0.086 128054 AI205718 Hs.125416 ESTs 0.086 133020 AA053248 Hs.185182 ESTs; Highly similar to 40S RIBOSOMAL PROTEIN S10 [H.sapiens] 0.086 130056 AA017356 Hs.171900 armadillo repeat gene deletes in velocardiofadal syndrome 0.086 130504 U48865 Hs.158323 CCAAT/enhancer binding protein (C/EBP); epsilon 0.086 133978 W73859 Hs.78061 transcription fador 21 0.086 105265 AA227941 Hs.26088 ESTs 0.086 133035 T15965 Hs.6333 ESTs 0.086 100768 HG3636-HT3846 Myosin, Heavy Polypeptide 9, Non-Muscle 0.086 129338 T56800 Hs.47274 Homo sapiens mRNA; cDNA DKFZp564B176 (from done DKFZp564B176) 0.086 132789 W23761 Hs.56876 ESTs 0.086 116099 AA456309 Hs.58831 regulator of Fas-induced apoptosis 0.086 100721 HG3355-HT3532 Peroxisome Proliferator Activated Receptor (Gb230972) 0.087 112569 R73150 Hs.75270 GTP-binding protein homologous to Saccharomyces cerevisiae SEC4 0.087 130645 AA020942 Hs.17200 STAM-like protein containing SH3 and ITAM domains 2 0.087 100751 HG3527-HT3721 Luteinizing Hormone, Beta Subunit 0.087 134550 M27161 Hs.85258 CD8 antigen; alpha polypeptide (p32) 0.087 130885 AA338646 Hs20912 adenomatous polyposis coli like 0.087 101446 M21302 Hs.56306 small proline-rich protein 2A 0.087 116287 AA487856 Hs.155829 KIAA0676 protein 0.087 134034 X89267 Hs.78601 uropo hyrinogen decarboxylase 0.087 130860 U66061 Hs241395 protease; serine; 1 (trypsin 1) 0.087 109901 H04992 Hs.30499 ESTs 0.087 107537 Z20777 Hs.9857 ESTs; Weakly similar to peroxisomal short-chain alcohol dehydrogenase [H.sapiens] 0.087 133232 AA496030 Hs.6845 ESTs 0.087 108559 AA085161 zn12c5.s1 Stratagene hNT neuron (#937233) H sapiens cDNA done IMAGE.547283' similar to TR:G 1151228 G1151228 LPG1P. ;, mRNA seq 0.087 121288 AA401735 Hs.97340 EST 0.087 108844 AA132916 Hs.177961 Human Chromosome 16 BAC done CIT987SK-A-388D4 0.087 129874 AA406488 Hs.181551 ESTs 0.087 105139 AA164543 Hs.110082 ESTs 0.088 124789 R43803 Hs.78110 ESTs; Weakly similar to F17A92 [C.elegans] 0.088 115923 AA441929 Hs.38205 ESTs 0.088 123640 AA609292 Hs.112681 ESTs 0.088 131607 AA351409 Hs.172740 microtubule-assodated protein; RP/EB family; member 3 0.088 130064 T67053 Hs.181125 immunoglobulin lambda gene cluster 0.088 108752 AA127070 Hs.71055 ESTs 0.088 124249 H68077 Hs.108211 ESTs 0.088 100109 AJ000480 Hs.143513 phosphoprotein regulated by mitogenic pathways 0.088 104642 AA004662 Hs.184245 KIAA0929 protein Msx2 interacting nudear target (MINT) homolog 0.088 131752 AA453311 Hs.31566 ESTs 0.088 114727 AA132545 Hs.190202 ESTs 0.088 120965 AA398089 Hs.179715 ESTs 0.088 100396 D84361 Hs.151123 Human mRNA for p52 and p64 isoforms of N-Shc; complete eds 0.088 106218 AA428451 Hs.91146 DKFZP586E0820 protein 0.088 111562 R09567 Hs.187569 ESTs 0.088 121219 AA400606 Hs.144344 EST 0.088 101187 L20316 Hs208 glucagon receptor 0.088 101513 M28210 Hs27744 RAB3A; member RAS oncogene family 0.088 116454 AA621071 Hs.42034 ESTs; Moderately similar to T-complex protein 10A [H.sapfens] 0.088 116171 AA463434 Hs.42658 ESTs 0.089 117500 N31909 Hs.44278 ESTs 0.039 119978 W88623 Hs.59190 EST 0.089 132005 D58231 Hs.173091 DKFZP434K151 protein 0.089 109914 H05529 Hs.194704 leucine-rich; glioma inactivated 1 0.089 130370 M55265 Hs.155140 casein kinase 2; alpha 1 polypeptide 0.089 104262 AF009801 Hs.105941 bagpipe homeobox (Drosophila) homolog 1 0.089 129708 AA417181 Hs.120858 ESTs 0.089 106398 AA447545 Hs.18268 adenylate kinase 5 0.089 120884 AA365356 Hs.97041 ESTs 0.089 130404 X72012 Hs.76753 endoglin (Osler-Rendu-Weber syndrome 1) 0.089 114072 Z38184 Hs.123633 ESTs 0.089 131470 X54938 Hs.2722 inositol 1;4;5-trisphosphate 3-kinase A 0.089 124573 N67935 Hs.194703 adaptor-related protein complex 4; mu 1 subunit 0.089 114717 AA131240 Hs.252014 EST 0.089 133806 M12759 Hs.76325 Human lg J chain gene 0.09 130470 AA398552 Hs.15711 KIAA0639 protein 0.09 133182 Z80787 Hs.240135 H4 histone family; member J 0.09 116036 AA452572 Hs.43866 ESTs 0.09 132404 AA393903 Hs.4768 ESTs 0.09 122695 AA456048 Hs.99403 ESTs; Moderately similar to undulin 2 [H.sapiens] 0.09 125975 AA495891 Hs.152290 ESTs; Highly similar to PACAP type-3/VIP type-2 receptor [H.saptens] 0.09 110783 N23669 Hs.26407 ESTs 0.09 129860 AA410343 Hs.129826 tetraspan transmembrane 4 super family 0.09 120740 AA302650 Hs.96654 EST 0.09 119564 W38206 Accession not listed in Genbank 0.09 134474 AA054746 Hs.8379 ESTs 0.09 119014 N95435 Hs.55144 ESTs 0.09 109791 F10669 Hs.13228 DRE-antagonist modulator; calsenilin 0.09 117605 N35073 Hs.44433 ESTs 0.09 121589 AA416627 Hs.191598 ESTs 0.09 104326 D81655 Hs.143067 ESTs 0.09 129861 N69507 Hs.129849 DKFZP564M182 protein 0.09 102795 U88667 Hs.198396 ATP-binding cassette; sub-family A (ABC1); member 4 0.09 119626 W49499 Hs.184456 ESTs; Wkly smlr to I! ALU SUBFAMILY SX WARNING ENTRY !! [H.sapiens] 0.09 110516 H56894 Hs.37368 EST 0.09 105382 AA236853 Hs.111801 Homo sapiens mRNA; cDNA DKFZp564H2023 (from done DKFZp564H2023) 0.09 123754 AA609964 Hs.102021 ESTs 0.09 108008 AA039430 Hs.61920 ESTs 0.09 121057 AA398619 Hs.142375 ESTs; Moderately similar to putative envelope protein [H.sapiens] 0.091 123675 AA609474 Hs.112713 EST 0.091 135194 C20975 Hs.9613 ESTs; Highly similar to angiopofetin-related protein [H.sapiens] 0.091 127070 AA641812 Hs.190037 ESTs 0.091 134051 S67070 Hs.78846 heat shock 27kD protein 2 0.091 133382 AA112532 Hs.7247 ESTs 0.091 103615 Z46967 Hs.115460 calicin 0.091 118457 N66593 Hs.49230 EST 0.091 118504 N67334 Hs.50158 ESTs 0.091 112915 T10176 Hs.4254 ESTs 0.091 132088 AA470121 Hs.243960 HLA-B assodated transcript-3 0.091 101504 M27288 Hs.248156 oncostatin M 0.091 112550 R71391 Hs.29074 ESTs 0.091 128551 H09058 Hs.237323 N-acetylglucosamine-phosphate mutase; DKFZP434B187 protein 0.091 112879 T03541 Hs.115960 ESTs 0.091 127079 AI364691 Hs.128628 ESTs; Moderately similar to CL3BC [R.norvegicus] 0.091 101993 U01062 Hs.77515 inositol 1;4;5-triphosphate receptor; type 3 0.091 113020 T23830 Hs.7303 ESTs; Weakly similar to PROHIBITIN [ksapiens] 0.091 120465 AA251505 Hs.130861 ESTs 0.091 130152 U32645 Hs.151139 E74-like fador 4 (ets domain transcription fador) 0.091 104941 AA065169 Hs.17805 ESTs 0.091 110090 H16076 Hs.6915 ESTs 0.091 135375 AA480888 Hs.99741 ESTs; Weakly similar to BRAIN PROTEIN H5 [H.sapiens] 0.091 123799 AA620418 Hs.112861 ESTs 0.092 118966 N93438 Hs.76907 ESTs; Highly similar to HSPC002 [Rsapiens] 0.092 116969 H80633 Hs.143038 ESTs 0.092 125147 W38150 Accession not listed in Genbank 0.092 100836 HG4113-HT4383 Olfadory Receptor Or17-201 0.092 114726 AA132509 Hs.103827 EST 0.092 107311 T57738 Hs.174112 ESTs 0.092 112863 T03148 Hs.4610 EST 0.092 129290 AA521407 Hs.110095 ESTs 0.092 103384 X92762 Hs.79021 tafazzin (cardiomyopathy; dilated 3A (X-linked); endocardial fibroelastosis 2; Barth syndrome) 0.092 112508 R68213 Hs.28847 ESTs 0.092 111863 R37495 HS23578 ESTs 0.092 131184 AA452705 Hs.23954 ESTs; Weakly similar to KIAA0584 protein [H.sapiens] 0.092 107420 W26567 Hs.4775 ESTs 0.092 111768 R27606 Hs.24185 ESTs 0.092 112290 R53940 Hs.26016 ESTs 0.092 130581 AA481982 Hs.16258 ESTs; Weakly similar to RAS-RELATED PROTEIN RAB-5A [H.sapiens] 0.092 120744 AA302772 Hs.228649 EST 0.093 112226 R50761 Hs.25738 ESTs 0.093 116154 AA460951 Hs.57100 ESTs 0.093 102640 U67674 Hs.194783 solute carrier family 10 (sodium/bile acid cotransporter family); member 2 0.093 129797 X53595 Hs.1252 apolipoprotein H (beta-2-glycoprotein I) 0.093 102705 U77180 Hs.50002 small indudble cytokine subfamily A (Cys-Cys); member 19 0.093 132408 AA035547 Hs.47822 KIAA0380 gene produd; RhoA-spedfic guanine nudeotide exchange fador 0.093 108441 AA079079 zm97c9.s1 Stratagene colon HT29 (#937221) Homo sapiens cDNA done IMAGE:5458723 1 similar to contains element MER22 MER22 repetitive element ;, mRNA sequence 0.093 108145 AA054133 Hs.63085 ESTs 0.093 106466 AA449990 Hs.76057 lysophospholipase II 0.093 101697 M64358 Human rhom-3 gene, exon 0.093 121294 AA401958 Hs.240170 ESTs; Moderately similar to alternatively spliced produd using exon 13A [H.sapiens] 0.093 117824 N49065 Hs.125201 ESTs; Weakly similar to B7 [M.musculus] 0.093 115771 AA422049 Hs.40780 ESTs 0.093 102303 U33053 Hs.2499 protein kinase C-like 1 0.093 131405 U79255 Hs.26468 amyloid beta (A4) precursor protein-binding; family A; member 2 (X11-like) 0.093 112909 T10069 Hs.101094 ESTs 0.093 124173 H41281 Hs.107619 ESTs 0.093 112488 R66896 Hs.28788 ESTs 0.093 130554 X59303 Hs.159637 valyl-tRNA synthetase 2 0.093 106413 AA447964 Hs.6311 ESTs 0.093 111711 R22891 Hs.7093 ESTs 0.094 117595 N34933 Hs.44664 EST 0.094 113813 W45174 Hs.31382 ESTs 0.094 107769 AA018449 Hs.125220 Homo sapiens DNA from chromosome 19-cosmids R30102:R29350:R27740 containing MEF2B; genomic sequence 0.094 114966 AA250743 Hs.92198 ESTs; Highly similar to caldum-regulated heat stable protein CRHSP-24 [H.sapiens] 0.094 130297 H94949 Hs.171955 trophinin-assisting protein (tastin) 0.094 109589 F02429 Hs.6581 ESTs 0.094 112592 R77631 Hs.29126 ESTs 0.094 102314 U34038 Hs.154299 coagulation factor II (thrombin) receptor-like 1 0.094 116128 AA459915 Hs.112193 mutS (E. coli) homolog 5 0.094 106809 AA479704 Hs.220324 Human DNA sequence from done 283E3 on chromosome 1p3621-36.33. Contains the alternatively spliced gene for Matrix Metalloproteinase in the Female Reproductive trad MIFR1; -2; MMP21/22A; -B and -C; a novel gene; the alternatively spliced CDC2L2 gene for 0.094 130607 AA043894 Hs.16603 ESTs 0.094 120592 AA281929 Hs.143974 ESTs 0.094 117230 N20535 Hs.43265 melastatin 1 0.094 105948 AA404597 Hs.7133 ESTs 0.094 101333 L47738 Hs.80313 p53 inducible protein 0.094 101909 S69265 . Homo sapiens mRNA for PLE21 protein; complete eds 0.094 106959 AA497031 Hs.8657 ESTs; Highly similar to CTG7a [H.sapiens] 0.094 127034 AA352389 ESTs; Wkly smlr to glucose-6-phosphatase catalytic subunit [R.noivegicus] 0.095 134430 H52105 Hs.8309 KIAA0747 protein 0.095 120342 AA207105 Hs.45068 Homo sapiens mRNA; cDNA DKFZp434l143 (from clone DKFZp434l143) 0.095 104450 L77564 Hs.103978 serine/threonine kinase 22B (spermiogenesis associated) 0.095 130902 AA424530 HS21061 ESTs 0.095 102708 U77594 Hs.37682 retinoic acid receptor responder (tazarotene induced) 2 0.095 107373 U85773 Hs.154695 phosphomaπnomutase 2 0.095 123569 AA608952 Hs.195292 ESTs; Weakly similar to RNA helicase HDB/DICE1 [H.saptens] 0.095 102687 U73379 Hs.93002 ubiquitin carrier protein E2-C 0.095 128888 AA034951 Hs.106893 ESTs 0.095 100283 D43642 Hs.2430 transcription fador-like 1 0.095 102747 U79303 Hs.82482 protein predided by done 23882 0.095 107798 AA019346 Hs.60918 EST 0.095 123565 AA608907 Hs.112614 EST 0.095 116010 AA449450 Hs.56421 ESTs; Weakly similar to Similarity to H.infiuenza ribonuclease PH [C.elegans] 0.095 117155 H97536 Hs.42391 EST 0.095 133094 AA115572 Hs.64746 chloride intracellular channel 3 0.095 113174 T54659 Hs.9779 ESTs 0.095 102016 U03270 Hs.122511 centrin; EF-hand protein; 1 0.095 130126 AB002318 Hs.150443 KIAA0320 protein 0.095 134813 X14767 Hs.89768 gamma-aminobutyric acid (GABA) A receptor; beta 1 0.095 132055 N69440 Hs.38132 ESTs 0.095 122229 AA436198 Hs.103902 ESTs 0.096 127574 AA907314 Hs.188905 ESTs 0.096 134432 AA053022 Hs.8312 ESTs 0.096 128052 AA878398 Hs.190491 ESTs 0.096 101637 M58285 Hs.132834 hematopoietic protein 1 0.096 103386 X92972 Hs.80324 protein phosphatase 6; catalytic subunit 0.096 133079 AA477561 Hs.6449 ESTs 0.096 120328 AA196979 Hs.104129 ESTs; Weakly similar to protease [H.sapiens] 0.096 107640 AA009615 Hs.257808 ESTs 0.096 123389 AA521176 Hs.221231 ESTs 0.096 103222 " X74795 Hs.77171 minichromosome maintenance defident (S. cerevisiae) 5 (cell division cycle 46) 0.096 111704 R22450 Hs.23396 ESTs; Highly similar to ZINC FINGER PROTEIN 140 [H.sapiens] 0.096 126856 AA306523 EST177475 Jurkat T-cells VI Homo sapiens cDNA 5' end, mRNA sequence. 0.733 127071 AA250806 ESTs 0.096 114550 AA056755 Hs.151714 ESTs 0.096 125955 AI356943 Hs.143761 ESTs 0.096 134363 M37033 Hs.82212 CD53 antigen 0.096 128550 W76492 Hs.170142 ESTs 0.096 122598 AA453465 Hs.99329 ESTs 0.096 118898 N90703 Hs.4236 KIAA0478 gene produd 0.096 117661 N39092 Hs.44940 ESTs 0.096 120996 AA398281 Hs.143684 ESTs 0.096 123388 AA521172 Hs.134417 ESTs 0.096 106700 AA463929 Hs.28701 ESTs 0.096 112962 T16814 Hs.6828 ESTs 0.096 121262 AA401372 Hs.97723 ESTs 0.096 134551 R44839 Hs.8526 i-beta-1;3-N-acetylgIucosaminyltransferase 0.096 112060 R43754 Hs.21164 ESTs 0.096 134678 AA039935 Hs.182595 dynein; axonemal; light polypeptide 4 0.096 100855 HG4234-HT4504 Methylenetetrahydrofolate Reductase 0.097 132414 N91193 Hs.48145 ESTs 0.097 112900 T08758 Hs.3813 ESTs 0.097 115989 AA447777 Hs.93135 ESTs 0.097 103561 Z21488 Hs.143434 contadin 1 0.097 131087 AA009738 Hs.22824 ESTs; Weakly similar to p160 myb-binding protein [M.musculus] 0.097 120293 AA190859 Hs.191428 ESTs 0.097 111830 R36081 Hs.25085 EST 0.097 113654 T95770 Hs.17666 ESTs 0.097 132675 AA179338 Hs.5476 serine proteinase inhibitor 0.097 120182 Z40125 Hs.91968 ESTs 0.097 132879 U16282 Hs.5881 ELL gene (11-19 lysine-rich leukemia gene) 0.097 134211 AA056681 Hs.80021 ESTs; Weakly similar to 62D9.p [D.melanogaster] 0.097 115448 AA284845 Hs.165051 ESTs 0.097 118118 N56901 Hs.47995 ESTs 0.097 107598 AA004528 Hs.169444 ESTs 0.097 128933 H01824 Hs.760 GATA-binding protein 2 0.097 114892 AA235988 Hs.86024 ESTs 0.097 101922 S75168 Hs.274 megakaryocyte-assodated tyrosine kinase 0.097 105444 AA252374 Hs.19333 ESTs; Weakly similar to ATP(GTP)-binding protein [Ksapiens] 0.097 128155 AA926843 Hs.143302 ESTs 0.097 116276 AA485870 Hs.44914 ESTs 0.097 111964 R41227 Hs.21860 ESTs 0.097 135100 AA398926 Hs.251108 Homo sapiens mRNA; chromosome 1 spedfic transcript KIAA0493 0.097 124872 R69251 Hs.101506 EST 0.097 103084 X59932 Hs.77793 c-src tyrosine kinase 0.097 124138 H23199 Hs.107010 ESTs 0.098 130048 R31745 Hs.211612 SEC24 (S. cerevisiae) related gene family; member A 0.098 100208 D26129 Hs.78224 ribonudease; RNase A family; 1 (pancreatic) 0.098 123537 AA608775 Hs.112589 ESTs 0.098 118999 N95019 Hs.55092 ESTs 0.098 119847 W80384 Hs.9853 ESTs 0.098 112819 R98618 Hs.35984 ESTs 0.098 131080 J05008 Hs.2271 eπdothelin 1 0.098 127353 AA190853 Hs.155360 ESTs 0.098 132068 X66365 Hs.38481 cydin-dependent kinase 6 0.098 105744 AA293436 Hs.12909 ESTs 0.098 133680 M92357 Hs.101382 tumor necrosis factor; alpha-induced protein 2 0.098 122899 AA469960 Hs.178420 ESTs; Highly similar to WASP interacting protein [H.sapiens] 0.098 128700 U59286 Hs.103982 small indudble cytokine subfamily B (Cys-X-Cys); member 11 0.098 104393 H46486 Hs.226499 nesca protein 0.098 123320 AA496792 Hs.139572 EST 0.098 129169 N31641 Hs.109058 ribosomal protein S6 kinase; 90kD; polypeptide 5 0.098 135093 U51333 Hs.159237 hexokinase 3 (white cell) 0.098 113269 T65159 Hs.85044 ESTs 0.098 124283 H86783 Hs.194136 ESTs; Moderately similar to zinc finger protein RIN ZF [R.norvegicus] 0.098 114376 GMCSF Accession not listed in Genbank 0.099 100881 HG4458-HT4727 Immunoglobulin Heavy Chain, Vdjc Regions (Gb:L23563) 0.099 116572 D45654 Hs.65582 DKFZP586C1324 protein 0.099 123956 AA621747 Hs.112847 EST 0.099 100818 HG4018-HT4288 Opioid-Binding Cell Adhesion Molecule 0.099 132754 W47419 Hs.56007 Human DNA from chromosome 19-spedfic cosmid F25965; genomic sequence 0.099 112741 R93080 Hs.35035 ESTs 0.099 112748 R93299 Hs.166492 ESTS 0.099 130858 S57235 Hs.246381 CD68 antigen 0.099 124870 R69233 Hs.101504 ESTs 0.099 125304 Z39833 Hs.124940 GTP-binding protein 0.099 121297 AA401995 Hs.97860 ESTs 0.099 128602 AA046103 Hs.102367 ESTs 0.099 124062 H00440 Hs.144524 ESTs; Weakly similar to signal transducer and adivator of transcription 2 [M.musculus] 0.099 100547 HG2149-HT2219 Mucin (Gb:M57417) 0.099 105652 AA282505 Hs.19015 ESTs 0.099 133390 AA459945 Hs.72660 KIAA0585 protein 0.099 133503 M33195 Hs.743 Fc fragment of IgE; high affinity I; receptor for; gamma polypeptide 0.099 109461 AA232667 Hs.58210 ESTs 0.099 102068 U09117 Hs.80776 phospholipase C; delta 1 0.099 113464 T86931 Hs.16295 ESTs 0.099 104240 AB002368 Hs.70500 KIAA0370 protein 0.099 121113 AA399109 Hs.161813 ESTs 0.1 122896 AA469952 Hs.97899 ESTs; Weakly similar to dal2; len:343; CAI: 0.17f ALC_YEAST P25335 ALLANTOICASE [S.cerevisiae] 0.1 102405 U43148 Hs.159526 patched (Drosophila) homolog 0.1 103599 Z33905 Hs.81218 receptor-associated protein of the synapse; 43kD 0.1 121079 AA398719 Hs.14169 ESTs; Weakly similar to CREB-binding protein [H.sapiens] 0.1 115820 AA427487 Hs.39619 ESTs; Weakly similar to RETICULOCALBIN 1 PRECURSOR [Ksapiens] 0.781 125106 T95766 Hs.189760 ESTs 0.1 131373 N68116 Hs.26146 Down syndrome critical region gene 3 0.1 120224 Z41239 Hs.106960 ESTs 0.1 133090 AA448228 Hs.6468 ESTs 0.1 132300 AA133244 Hs.44234 ESTs 0.1 113129 T49384 Hs.8988 EST 0.1 110638 H73197 Hs.17241 ESTs 0.1 131364 R53255 Hs.26010 ESTs 0.1 105370 AA236476 Hs.22791 ESTs; Weakly similar to transmembrane protein with EGF-like and two follistatin-like domains 1 [H.saptens] 0.238 TABLE 11 A shows the accession numbers for those primekeys lacking unigenelD's for Table 11. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column. Pkey: Unique Eos probeset identifier number CAT number: Gene duster number Accession: Genbank accession numbers Pkey CAT number Accession 100610 19864J AW161357 AI879062 AI928938 AW161097 AW161167 BE314465 AA351715 F07096AA179034 F08510 F00653 AI936671 AA476718 AW772454 AI807703 R44253 AA976667 AI985186 AI650254 H38942 R84829 AA018724 AA001000 H85934 AA019126 H85609 AA017000 AA339355 AW950556 D51397 AA213981 BE548002 AI056359 AA001560 AW952113 AA317769 AI857477 AI857475 AW249771 AW162661 H38943 AA018628 R85885 AI984613 AI934765 AI796172 AW157488 AI929191 R85523 D51221 D53851 H85610AI749674 F21582 AA323145 AA019127AA687444T06745AI699293 H29532 AA214029 AA223656 NM_016834 X14474 R19697 H09695 R17455 R13812 R19056 A1681231 AI590200 R37671 AA861828 AI990023 AI935669 AW005821 AA324581 H17335 R37659 R42802 R46242 R60936 R59731 H28993 AA479907 R44570 AI890696 AA308884 AA507078 R41274 AI365507T16348 AI560453 F03259 F04722 T16312 AA016O81 AW073061 BE314824 W28930 R44098 R51045 100674 21517_2 AW403342 AW248986 BE561709 AA357312 BE311834 BE389496 BE294887 AW732696 BE047868 AI702383 BE019155 AI702367 BE408966 BE280458 BE313759 BE513492 BE535404 BE280258 AC005263 NM_007165121990 AW732711 AI564920 AW249094 BE265365 AW607186 AW607346 BE005217 H27211 U46230 BE260066 BE207043 BE546782 AW248659 108559 41469_9 AA085228 AA085161 100721 19818J L40904 NM_005037 X90563 AB005526 H21596 AA088517 100748 41861J X06096 X05826 100750 15759J BE157260 BE157265 R48118 H43827 Z17877 AW379070 AW291778 M20605 J03253 M14206 V00568 AI860465 AW296022 M13930 AL047400 J00120 BE018476 AW675223 T26980 F06694 R22709 R24720 H22753 AI903100 AI903094 AW937823 X00364 D10493 K01904 K01906 K00535 L00058 AA410662 AW384760 AA304930 AI680985 XO0198 H58025 AW998901 AV653447 N31654 AW610357 AW610369 AW862480 BE223010 AW384172 AW384219 AW384171 AW384218 AA298522 BE140421 AW945162 AW751711 AA514409 AW747912 AI214214 W87741 AA972406 AA554513 BE302087 AI249030 AA477850 AV653129 AI281360 AI274110 W87861 AA641366 X66258 AI051600 AA877139 AA527483 AA857219 AI250782 AA625531 AA807892 AI278811 AI224033 H24033 AA593396 AW129709 R45453 N22772 AA235530T29737AI016409 AI688907 AA568370 AA722760 AI539329 AA550843 AW674698 AI538452 AI538453 AI337957 AA477744 AA464600 AI140319 AW949294 AI339781 AI828736 AA923634 AA344094 AI278350 AA975567 AA908416 AA857170 AW023520 R43413 R48004 F02958 AI989439 R11207 AA737307 D10493 AW950652 AI093842 AI474024 AA703369 R11264 M13930 M13930 M13930 M13930 M13930 J00120 M13930 M13930 X00364 J00120 R19507 AA639812 100751 24700J N32759 N29730 N30831 N32604 N31955 AI206390 H87574 R23494 AI186215 N30036 AI741512 J00117 NM_000737 AI453626 AA330974 AI188729 AI188604 AI188964 N30276 AI188947 AI188830 AI188303 AI200457 AI219166 AI192459 AI183280 AI189275 AI188639 AI186353 AI189616 AI184224 AI130720 AI188454 AI188391 AI148857 AI192447 AI209155 AI190013 AI206355 AI188721 AI189429 AI189364 AI186330 AI431595 AI189595 AI188781 AI148647 AI200022 AI221552 AI220923 AI188728 AA233034 AI189807 AI189641 AI219044 AI148774 AI200658 W71989 AI207360 AI188824 AI200559 AI200270 AA644163 AI199943 AI151301 AI189555 AI262724 AI148590 AI148695 AI126906 AI149163 K03183 K03189 AI189842 AI221014 N30608 AI186465 AI220865 AI188498 AI138226 AI189968 AI221019 AI138197 AI149426 AI148904 AI186218 AI188348 AI160579 AI198460 AI149039 AI160936 AI219055 AI184784 AI221580 AI161082 AI160814 AI123896 AI417614 AI126101 AI188872 AI149571 AI168533 A1149072 AI149467 AI131286 N30684 AI160705 AI160692 AI149559 AI273580 AI189442 AI138448 AI149591 N27302 AA400910 AI138431 AI138435 AI128407 N30216 AI128296 AI219589 AI188492 AI149447 AI168482 H95374 AI219009 N31616 AI276216 N32233 AI291937 N30741 AI188689 N27111 R23214 AI221605 AI184348 AI200375 H94451 N26397 AI871881 AA232905 N30833 AI220780 H94446 N30822 H87464 R68815 N30290 AI128424 H12587 T47334 H87631 H87156 AI219133 AI868741 AA330859 H86993 AA330413 H93656 N30817 T90191 H93668 AI200054 H95207T47316 H95381 T49170 R00880T49171 N27381 H94107 R63352T85053 AW451899 H95142 N30313 H94015 H86987 T28278 N29701 C18834 AA331267 AA330939 AI654493 N27073 N29831 R68113 N30758 R26086 N32108 H95135 AA330414 AA330978 AI219422 AI189453 AI199951 X00264 NM_000894 AA371909 AA063496 T29543 AA371971 AA372026 AA371978 AA371346 AI051683 AI186418 AI220659 AI189068 AI219266 AI186552 AI188715 AI149156 100760 1334_7 AW794626 M27126 M27014 100775 18179_3 J05581 M61170 T27692 M34088 M34089 AW860335 AW579047 AW610437 AW610386 AW610422 AW610473 AW579078 AW604897 AW860163 AW579067 AW862410 AI816584 AW177757 AW602769 AI909790 AW860331 AI909787 AI909811 AI909813 AW845083 AI905920 AW387919 BE140766 AI909279 AW369405 AA429321 AA429320 AA367451 AA847972 AW001137 AI567905T84561 AI631295 AA151351 H02932 AI884519 AA367457 AW369421 AI678846 AW391803AI610869 AW192838 AI922289 AI952140 A1910233 AI479474 AW001395 AA488073 AI985760 AW130017 AI858369 AA627845 AW081805 AA158865 AI624443 AA344985 AA569793 R72486 AI589329 AI903204 AI269893 AA641284 AI279932 AA149270 AI697120 AA729146 AI589353 AA480067 AI923310 AA530908 AI275395 AA425062 AA580280 AA889527 AA158866 AW131341 AA573028 AA877326 T29335 AW951288 H04235 AA099243 AA994659 AI659618 AA887919 AI299297 AW001116 AW263844 AI270578 AA970828 AW572126 AA775299 AW369449 AW369398 AW369452 AI933677 AI870710 AI092911 AI582464 AI497674 AA937026 AA885865 L38597 AA908325 AW369432 AW026623 AA627778 AI264942 AA932409 AI187328 AI672970 AI886098 AW440471 AW138860 AI866858 AI802528 AI926172 AW243914 AI933690 AA996114 AA536189 AW009937 AI918060 AI270379 A1973169 AW175638 AW369413 100800 24735J NM_006227 L26232 R50649 AU077024 AL008726 AA411079 R35151 BE278153 BE278139 AI459777 R88036 Z43210 F07326 AF052157 R17844 BE615476 T82160 R71985 H21963 AA299158 AW368246 R48123 R50628 R70441 H27245 H72015 R72345 R39392 AI909738 BE612778 BE613234 D52116 D52136 D52132 D52067 D51922 D51995 D51905 N34249 N25459 AA464436 AA297350 AA297466 R81736 H02737 AW582505 R27523 AI834241 AW130867 W72668 W76426 AA358363 R50262 AW473860 H52335 H43953 H21964 T39505 AI887517 AW156925 AW839850 H02628 AW007705 AI561008 F22392 R71279 AA995433 R50725 W24462 R71931 AA464437 AW591731 R25667 R52695 R50810 AI560805 AI089266 H68386 H41353 H28590 AW001860 AI141623 AA250773 AI284778 AW511412 AW083975 AA130377 AW026047 R50551 R81494 AI357668 AI078272 F32666 F36981 AW304865 H43906 AA931068 R48010 AI540217 AI017339 AI291812 AI741954 AA458490 AI088378 AA298764 H61168 AA358362 AA298725 AA298515 AA464148 AA443538 R43046 AA084314 T40641 T47608 T48940 AI082477 AW470145 N92284 AI758958 AA298512 AA284586 AI597777 AA480277 AI932559 AI869081 AA476615 AA503651 AI656024 AW168522 AI682051 AI689106 AI274592 AI520917 BE258916 BE615861 BE280282 R53386 BE278255 BE278398 T47607 AA477662 H68385 100817 19648J L34355 L46810 NM_000023 U08895 AA424260 AI097272 AA424162 N79764 F19290 F25278 AI479385 AA460662 AA432059 AW016935 F25770 F32549 F36677 F33016 F35992 F36010 AW172497 AA835076 F28727 AA211643 AA453282 100818 19604.3 U79251 AA843851 R38201 R66461 R44908 AA683289 H17477 R37364 R52832AW298336 AA351391 NM_002545 L34774 AA296886 AW967001 T28889 R13451 T77331 AL119196 AL118830 H08459 AW892812 AW905838 H17585 R52878 100881 458J27 BE561958 BE561728 BE397612 BE514391 BE269037 BE514207 BE562381 BE514256 BE514403 BE514250 BE397832 BE269598 BE559865 BE396881 BE560031 BE514199 BE560037 BE560454 100885 12707_3 X07881 NM_006249 X07637 AA376715 AA376677 X07715 X07704 S80916 100898 8542 1 BE387614 R51501 AA199714 AW674779 F08178 BE269071 AA376313 H08264 AA380420 H18785 AL042151 BE277758 BE267438 NM J05850 L35013 BE540833 BE390902 BE391494 BE277459 BE385592 BE390612 BE384263 BE387779 BE388647 BE537373 BE547158 AW409585 AW374033 AW602185 AA355725 AW577548 AW935015 AW935160 W40232 AW938647 AW374332 AA434040 BE293488 AL138361 BE560260 AI745075 AA317980 AW949382 AI834311 AI653582 AI831042 AI361878 AA618606 AA729052 AI424969 AA199715 AW769374 AI828422 AW044307 AI862816 AI203583 AW084461 AW514655 AA831883 AA290672 AA831286 AA578510 AW089965 AW150746 AA292743 H22232 AI469275 AW439312 AA292744 AW471443 AI473989 AA593336 AA464070 AI678937 AW069451 AA970763 AA610480 AA593328 AA464009 AA768985 AI298928 AA436600 AA464718 AA699361 D61482 D55935 AI369591 AA470695 AI809135 AA640627 AI568446 R51502 W45467 AI655316 AA463934 AW168609 AW518663 BE045525 Z41251 AI868091 AA908160 AI026697 AI886259 AI612932 AA215437 AI956014 BE541087 BE255652 BE265878 BE394102 W27502 102459 3556J U48936 L36592 X87160 NMJXJ1039 AL036606 AL036420 U35630 AW298574 126126 1630017J W80551 M85370 102620 16821_37 AA976427 U66052 102673 24986_6 AI457548 U72509 102675 5145_4 U72512 T98357 R31335 F18090 102753 2226J L32961 NM_000663 U80226 S75578 AA425061 AA429317 AI815143 AA910669 AI286022 AI286019 102799 34624_4 U88896 U88898 AA916056 T03285 AI341594 AI359534 AI634031 U88897 127034 51148- 2 BE397750 AA232171 BE562900 BE384894 BE242228 BE206819 BE261742 AA296468 AW959763 BE276164 BE264109 BE392626 BE256735 AA301453 N55872 H01676 AA292746 AA427485 AA496400 AA352389 103522 21640J Y10518 Y10514 Z83935 Y10508 AK000055 Y10519 AI142012 AI681175 BE222219 AA890586 BE504347 BE328064 N63044 N51226 AI151248 AI521996 AI924777 AW375954 AI860275 W00549 AI742673 AW612288 AI763062 AA632510 AI087347 AI088070 AI214349 AA890297 AI494156 AI698598 AA631658 AA504593 AA860733 AI266761 AW663214 AW771231 AA639610 AI769806 AI769746 AW014326 AI288611 127071 188097J AA250806 AA459220 126456 291965J AA429212 W00881 119388 1762256J T88798 R92430 126856 20669 1 AI084125 AI083773 AI479687 AI939609 AI968662 AF129507 NM 513282 AW971840 AW298508 AA744240 AA811217 AA827671 AA811055 AA806567 AA488977 AA908902 AI637637 AA927056 AI870139 AW340492 AA488755 AA129794 AA306523 AA354253 BE256277 AC053467 AW962084 103996 224545J AA321355 AW964592 R23284 H73883 R23382 N47914 C01377 H04668 AW606248 R34447 AA847136 AI684489 AI523112 AW044269 AI379138 N29366 AA761543 N79248 AA960845 AA768316 AI147926 AI718599 AI880620 R67467 AI216016 AI738663 H04648 113213 23798J NM_001395 Y08302 A1434619 AI470328 AI261807 AW024965 AI806537 AI830549 A1640337 AI219065 AW271700 AW028488 AI133339 AI859205 R51175 U87167 BE379324 BE392008 AA340819 AA343110 T57275 D59164 AW299312 AI434422 AI936390 AW024975 R40262 AW269126 R09430 T56590 AI367247 AI253132 BE464248 T58658 AW207785 T58607 134947 844579J R51194 AI732276 R53587 AI820697 129311 16078J AK0O0526 BE550084 W30689 AW271859 AA411456 AI341551 AA242990 AA243027 H87046 D20360 AI184053 AA146956 AI721023 AI718944 AA146955 F18215 AA903890 AI7O0355 AI075430 AA411584 AA878210 AI476760 AW945637 AA630596 AA431522AA301989AI909058D12149 N41960BE222214AA609922AA828176AA393359AA398693AW024956 BE467805AW298623AW264085AI024454AI024719AI431927T55087AI611014T54920AA131253AI436344 114427 9724_2 AA017176AI359979AA047836AA017063AA016303AA001545 114569 110077J AA063315AA063316 100106 15621_-5 AF015910 100515 342 1 AA305746 D90187T63943AW951154 T29182 AI734941 D13264 AI299239 Z18812 AW299859 W24476 AA933064 AA489759 100531 46038J AW888554 AW607282 AA319986 M28590 100545 22955 11 M55405 AW752552 100574 17320J2 AA326895 M10036 NM_000365 N84665 H69414 N84657 AA380453 AA329743 AA357367 AA188770 AA376532 AA353653 AA158953 AA083176 BE537313 AA181433 D53373 R57376 AA206698 R14807 H18899 H11191 H93892 R25593 T61134 N93285 AA083081 AA831789 H13137AA497014 AA079330 AA182861 H13138W47161 R62913 AA687089AA211112 AA429237 AL035923 AA100070 AW392898 AI566433 AA866006 AA214002 AW392865 N79454 AA197181 AI680371 AA176501 AA737967 AI089225 F34874 AW571437 AI620620 AA573489 AA423816 AA164917 AA458455 T47072 AI569087 AI261656 AA730919 AI633441 AW195182 AI351622 AW243465 AI872649 AI359227 AA987941 AI693770 T47073 AW779948 AW510580 AI635626 AW627601 AA864326 AA953578 AI341418 BE222853 AI241963 AI094663 AA928380 AA493373 AW043762 AI377783 AW958987 BE619760 AA385240 BE277975 BE280095 AW631443 AA581048 BE618715 BE299610 C14874 BE559858 BE378455 BE618290 BE544585 AI525575 BE548897 BE267110 AA804738 BE269821 AA918133 BE277647 AA599947 BE280735 BE390239 N74150 T12504 AI208197 AW955527 AA113897 N40081 H73835 H70393 AI434041 W22950 AM 92661 BE264461 W26486 AA626424 AA196694 T69209 AA857976 AI540287 AA410599 AA864287 AW950564 AA013320 T49283 AI541438 AW804703 AA335534 AA335659 BE562269 BE618802 BE277850 BE546413 BE280994 AA204813 BE561694 BE543524 BE253647 AW001452 W19116 BE542508 AA205894 BE254875 BE270033 AI525906 BE251792 AA975700 BE272138 AW607671 N87686 M10036 BE515060 BE298607 AI745178 U47924 H03193 100627 tigr_HT2798 Z25424 100756 tigr_HT3768 M88357 100768 tigr_HT3846 L29141 M69180 M81105 100813 tigr_HT4265 L33999 100836 tigr_HT4383 U04688 100855 tigr_HT4504 U09806 102104 entrez_U12139 U12139 125091 genbank_T91518 T91518 100929 tigr_HT688 X65561 125147 _entre?_W38150 W38150 102354 entre?_U38268 U38268 102491 entrez_U51010 U51010 102636 entrez_U67092 U67092 118769 genbank_N74496 N74496 101046 entre?_K01160 K01160 101057 entrez_K03430 K03430 108334 genbank.AA070473 AA070473 108417 483241J AA070853 AA075749 AA075716 108441 genbank_AA079079 AA079079 108786 genbank_AA128999 AA128999 101655 entrez_M60299 M60299 101697 entrez_M64358 M64358 117437 genbank_N27645 N27645 101798 entrez_M85220 M85220 101909 entrez_S69265 S69265 103508 entrez_Y10141 Y10141 103575 entrez_Z26256 Z26256 119332 genbank_T54095 T54095 112161 genbank M8295 R48295 119564 NOT_FOUND_entrez_W38206 W38206 114376 NOT_FOUND_entrez_GMCSF GMCSF 100478 tigr_HT1067 M22406 100547 tigr_HT2219 M57417 100564 tigr_HT2324 Z11585 TABLE 12: shows genes, including expression sequence tags, that are down-regulated in prostate tumor tissue compared to normal prostate tissue as analyzed using Affymetrix/Eos HuOl GeneChip array. Shown are the ratios of "average" normal prostate to "average" prostate cancer tissues. Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD: Unigene number Unigene Title: Unigene gene title R1 : Background subtraded normal prostate : prostate tumor tissue Pkey ExAccn UnigenelD Unigene Title R1 100522 HG1763-HT1780 Prolactin-lnduced Protein 17.4 130803 M81650 Hs.1968 semenogelin 1 16.785 118068 N53943 Hs.13743 ESTs _ 13225 114251 Z39898 Hs.21948 ESTs 12.7 112134 R46025 Hs.7413 ESTs ' 8.735 101436 M20642 Hs.158295 Human alkali myosin light chain 3 mRNA; complete eds 8.175 104028 AA361094 Hs.221128 ESTs 8.15 108944 AA149204 Hs.175783 ESTs; Highly similar to growth arrest inducible gene produd [H.sapiens] 7.535 103838 AA174173 Hs.12622 ESTs 7.212 120469 AA251741 Hs25882 DKFZP586M1824 protein 7.175 110279 H29231 Hs.27384 ESTs 6.701 127472 AA761378 Hs.192013 ESTs 6.642 133301 N35229 Hs.7037 pallid (mouse) homolog; pallidin 6.411 102457 U48807 Hs.2359 dual specificity phosphatase 4 6.395 114011 W90385 Hs.15082 ESTs 6.15 101249 L33881 Hs.1904 protein kinase C; iota 6 123265 AA491209 Hs.105265 ESTs; Weakly similar to reverse transcriptase [M.musculus] 6 119322 T49655 Hs.241569 ESTs; Modly smlr to !! ALU SUBFAMILY SQ WARNING ENTRY !! [H.sapiens] 5.95 101673 M61906 Hs.6241 phosphoinositide-3-kinase; regulatory subunit; polypeptide 1 (p85 alpha) 5.925 115586 AA399218 Hs.92423 ESTs 5.7 120590 AA281780 Hs.111441 ESTs; Weakly similar to similar to Kruppel-like zinc finger protein [C.elegans] 5.7 109748 F10192 HS248323 Tubulin; alpha; brain-specific 5.625 134727 X80507 Hs.8939 yes-associated protein 65 kDa 5.5 129171 AA234048 Hs.7753 calumenin 5.486 120390 AA233122 Hs.111460 ESTs; Highly similar to multifunctional calcium calmodulin-dependent protein kinase II delta2 isoform [H.sapiens] 5.4 131699 R68657 Hs.90421 ESTs; Modly smlr to !! ALU SUBFAMILY SX WARNING ENTRY !! [H.sapiens] 5279 104490 N71503 Hs.43087 ESTs; Weakly similar to dysferiin [H.sapiens] 5266 102124 U14528 Hs.29981 solute carrier family 26 (sulfate transporter); member 2 5.151 109280 AA196635 Hs.86081 ESTs 5.134 109707 F09739 Hs.185701 Homo sapiens mRNA full length insert cDNA done EUROIMAGE 21920 5.075 108087 AA045709 Hs.40545 ESTs 5.075 135006 M21665 Hs.929 myosin; heavy polypeptide 7; cardiac muscle; beta 5.055 119182 R80664 Hs.77067 ESTs - 5.033 129806 R62444 Hs.173373 KIAA0931 protein 4.675 101435 M20543 Hs.1288 adin; alpha 1 ; skeletal musde 4.626 125954 R93943 yt72d 2.r1 Soares retina N2b4HR Homo saptens cDNA done IMAGE2757355', 4.6 113989 W87544 Hs.221184 ESTs 4.559 104432 J03460 Hs.99949 proladin-induced protein 4.451 112326 R56068 Hs.4268 ESTs 4.45 119063 R16833 Hs.53106 ESTs; Weakly similar to !! ALU SUBFAMILY J WARNING ENTRY I! [H.sapiens] 4.45 130376 R40873 Hs.155174 KIAA0432 gene produd 4.301 122484 AA448286 Hs.98074 ESTs; Highly similar to atrophin-1 interacting protein 4 [H.sapiens] 4.2 104142 AA447006 ESTs; Moderately similar to !! ALU SUBFAMILY SQ WARNING 4.175 129413 N32787 Hs.11123 ESTs; Moderately similar to hypothetical protein 2 [H.saptens] 4.1 103678 Z84483 Human DNA sequence from PAC 46H23, BRCA2 gene region chromosome 13q12-134.05 114266 Z40186 Hs.26409 ESTs 4.05 115206 AA262491 Hs.186572 ESTs 4.048 123723 AA609749 Hs.112759 ESTs; Highly similar to unknown protein [R.norvegicus] 4.041 129130 H97993 Hs.172788 ESTs; Weakly similar to KIAA0512 protein [H.sapiens] 4.028 120217 Z41078 Hs.66035 ESTs 4.028 108536 AA084524 zn19d8.s1 Stratagene neuroepithelium NT2RAMI 937234 Homo sapiens cDNA 4.023 134460 AA400030 Hs.8360 ESTs; Weakly similar to I! ALU CUSS B WARNING ENTRY !! [H.sapiens] 3.925 120418 AA236010 Hs.26613 Homo saptens mRNA; cDNA DKFZp586F1323 (from done DKFZp586F1323) 3.91 132783 N74897 Hs.5683 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 15 3.889 125052 T80174 Hs.222779 ESTs; Moderately similar to similar to NEDD-4 [ sapiens] 3.85 108600 AA099585 Hs.41175 ESTs 3.833 103099 X61100 Hs.8248 NADH dehydrogenase (ubiquinone) Fe-S protein 1 (75kD) (NADH-coenzyme 3.818 134948 H06773 Hs.93850 protein kinase; AMP-adivated; gamma 2 non-catalytic subunit 3.792 120511 AA258144 Hs.221576 ESTs 3.779 111861 R37460 Hs.25231 ESTs 3.768 113966 W86600 Hs.9842 ESTs 3.75 131649 AA481254 Hs.30120 ESTs 3.708 129775 R94659 Hs.12420 ESTs 3.707 110191 H20568 Hs.27182 phospholipase A2-activating protein 3.7 112678 R87160 Hs.33665 ESTs 3.7 127115 AA375791 Hs.131894 ESTs 3.674 132892 W92797 Hs.59378 DKFZP434G162 protein 3.653 115023 AA252079 Hs.63931 dachshund (Drosophila) homolog 3.625 114932 AA242751 Hs.16218 KIAA0903 protein 3.62 106865 AA487228 Hs.19479 ESTs 3.614 134480 AA024664 Hs.83916 NADH dehydrogenase (ubiquinone) 1 alpha subcomptex; 5 (13kD; B13) .- 3.613 124780 R42493 HS220839 ESTs 3.6 130631 AA025399 Hs.169737 ESTs 3.592 134154 AA211320 Hs.79404 neuron-specific protein 3.568 104160 AA455706 Hs.99722 ESTs; Weakly similar to 78 KD GLUCOSE REGUUTED PROTEIN PRECURSOR 3.559 105524 AA258158 Hs.22153 ESTs; Weakly similar to KIAA0352 [H.sapfens] 3.542 110168 H19673 Hs.176586 ESTs 3.525 109480 AA233299 Hs.72158 ESTs 3.522 109585 F02367 Hs.27252 ESTs 3.5 115134 AA257107 Hs.194331 ESTs 3.5 116083 AA455653 Hs.44581 ESTs; Weakly similar to HEAT SHOCK 70 KD PROTEIN 6 [H.sapiens] 3.459 120524 AA261852 Hs.192905 ESTs 3.45 116932 H74330 Hs.150000 ESTs 3.425 130746 AA256976 Hs.18800 ESTs; Weakly similar to KIAA0579 protein [H.sapiens] 3.42 107513 X05451 Hs.158295 Human alkali myosin light chain 3 mRNA; complete eds 3.417 118641 N70298 Hs.49829 ESTs 3.407 126584 AI028384 Hs.127331 ESTs 3.399 105134 AA159953 Hs.22895 ESTs; Weakly similar to arylsulfatase B precursor [H.sapiens] 3.325 123502 AA600116 Hs.112526 ESTs 3.318 132389 N50866 Hs.47135 ESTs 3.317 105691 AA287097 Hs.75356 transcription fador 4 3.315 131505 H85897 Hs27755 ESTs 3.309 120775 AA342104 Hs.96777 EST 3.3 105579 AA278824 Hs.19218 ESTs 3295 128190 AA946876 Hs.148376 ESTs 3292 100819 HG4020-HT4290 Transglutaminase 3.288 130217 D29956 Hs.152818 ubiquitin specific protease 8 3273 130068 AA608903 Hs.106220 KIAA0336 gene produd 3269 134719 L07515 Hs.89232 chromobox homolog 5 (Drosophila HP1 alpha) 3.266 110277 H29209 Hs.151231 ESTs; Highly similar to FYVE finger-containing phosphoinositide kinase [M.musculus] 3.26 127354 AA41B880 Hs.185797 ESTs " 3212 129173 R60523 Hs.109087 ESTs 3.197 127464 AA970504 Hs.146103 ESTs 3.179 124923 R94500 Hs.108046 ESTs 3.175 122465 AA448164 Hs.99153 ESTs; Highly similar to CGI-73 protein [Ksapiens] 3.151 122027 AA431302 Hs.98721 EST; Weakly similar to N-copine [H.sapiens] 3.151 103329 X85134 Hs.72984 retinoblastoma-binding protein 5 3.15 129937 M95767 Hs.135578 chitobiase; di-N-acetyl- 3.15 134197 AA057341 Hs.87889 helicase-moi 3.15 107764 AA018219 Hs.226923 ESTs 3.125 121775 AA421773 Hs.161008 ESTs 3.125 114768 AA149007 Hs.182339 Ets homologous fador 3.12 132381 N48818 Hs.46884 ESTs 3.11 123105 AA485973 Hs.143947 ESTs 3.104 121176 AA400080 Hs.97774 ESTs 3.1 125053 T80620 Hs.186473 ESTs 3.075 105909 AA401739 Hs.5111 ESTs 3.066 119767 W72562 Hs.58119 ESTs 3.057 115776 AA424038 Hs.58197 ESTs 3.056 111713 R22988 Hs.220950 ESTs 3.05 115301 AA280047 Hs.43948 ESTs 3.05 118448 N66412 Hs.49189 ESTs 3 106586 AA456598 Hs.256269 ESTs 2.995 110415 H48239 Hs29739 ESTs; Weakly similar to RAS-REUTED PROTEIN RAB-3A [H.sapiens] 2.979 105173 AA182030 Hs.8364 ESTs 2.978 101102 L07594 Hs.79059 transforming growth fador; beta receptor III (betaglycan; 300kD) 2.976 110543 H58383 Hs.258544 ESTs 2.976 125593 R24464 Hs.202949 KIAA1102 protein 2.964 100824 HG4058-HT4328 Oncogene Aml1-Evi-1, Fusion Adivated 2.957 106822 AA481068 Hs.31835 ESTs 2.95 131963 D11930 Hs.3592 ESTs 2.95 111221 N68869 Hs.15119 ESTs 2.936 113620 T93795 Hs.17252 EST 2.917 105220 AA210695 Hs.17212 ESTs 2.917 123234 AA490227 Hs.105252 ESTs 2.904 125250 W87465 Hs222926 ESTs; Weakly similar to D20922 [C.elegans] 2.9 116196 AA465160 Hs.63386 ESTs 2.9 122100 AA432243 Hs.41086 ESTs; Weakly similar to OXYSTEROL-BINDING PROTEIN [H.sapiens] 2.896 111712 R22905 Hs.113716 ESTs 2.895 126589 W78107 Hs.187698 ESTs; Weakly similar to Yer140wp [S.cerevisiae] 2.895 111132 N64378 Hs.13149 ESTs; Highly similar to unknown function [H-sapiens] 2.894 115307 AA280300 Hs.191346 ESTs 2.886 AA152263 Hs.18827 KIAA0849 protein 2.883 129486 H03686 Hs220689 Ras-GTPase-adivating protein SH3-domain-binding protein 2.879 119805 W73788 Hs.43213 ESTs 2.875 125721 R59881 Hs.7503 ESTs 2.871 103704 AA028171 Hs.153688 ESTs 2.868 128420 AI088155 Hs.14146 ESTs; Weakly similar to unknown [H.sapiens] 2.866 120571 AA280738 Hs.128679 ESTs 2.863 123059 AA482019 Hs238202 EST 2.86 129462 D84239 Hs.111732 lgG Fc binding protein 2.856 125166 W45491 Hs.172609 nudeobindin 1 2.854 125992 W01626 za36e07.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA done 2.852 109431 AA227972 Hs.43635 ESTs 2.85 105077 AA142919 Hs.5558 ESTs 2.847 131388 R34531 Hs.92200 KIAA0480 gene produd 2.846 121080 AA398720 Hs.177953 ESTs 2.838 112575 R73816 Hs.17385 ESTs 2.836 130244 R26206 Hs.153293 KIAA0701 protein 2.825 134698 AA427783 Hs.77910 3-hydroxy-3-methylglutaryl-Coenzyme A synthase l (soluble) 2.816 116355 AA504356 Hs.88650 ESTs 2.813 115316 AA280627 Hs.57846 ESTs 2.806 129677 U48736 Hs.198891 serine/threonine-protein kinase PRP4 homolog 2.8 130971 H20332 Hs28707 signal sequence receptor; gamma (translocon-associated protein gamma) 2.799 115054 AA252863 Hs.87729 ESTs 2.795 130285 AA063546 Hs202968 ESTs 2.792 124308 H93575 Hs227146 Homo sapiens mRNA; cDNA DKFZp564J142 (from done DKFZp564 142) 2.783 125502 AA732329 Hs.191959 ESTs 2.778 114800 AA159825 Hs.131887 ESTs; Weakly similar to ORF YNI227C [S.cerevisiae] 2.768 128625 AA242816 Hs.102652 ESTs; Weakly similar to KIAA0437 [H.saptens] 2.766 130159 H51098 Hs.151310 PDZ domain protein (Drosophila inaD-like) 2.75 107127 AA620504 Hs22119 ESTs 2.742 113547 T90746 Hs.15233 ESTs 2.734 104639 AA004622 Hs.18214 ESTs 2.727 127609 AA622559 Hs.150318 ESTs 2.726 106922 AA490964 Hs.10056 ESTs 2.725 124825 R52088 yg85c3.s1 Soares infant brain 1 NIB Homo sapiens cDNA done 2.725 124333 H98683 Hs.154054 ESTs 2.708 117634 N36421 Hs.107854 ESTs; Weakly similar to SODIUM- AND CHLORIDE-DEPENDENTGLYCINE TRANSP 2.706 101609 M54927 Hs.1787 proteolipid protein 1 (Pelizaeus-Merzbacher disease; spastic paraplegia 2; uncomplicated) 2.704 117142 H96908 Hs.42251 ESTs 2.7 112602 R79147 Hs203365 ESTs 2.695 106828 AA481505 Hs.13797 ESTs 2.68 124377 N25996 Hs.179833 ESTs 2.675 101026 J04970 carboxypeptidase M 2.675 124560 N66393 ' Hs.102754 ESTs 2.675 124066 H02494 Hs.101615 ESTs 2.671 130281 R12777. Hs.15395 ESTs; Weakly similar to ARGINYL-TRNA SYNTHETASE [H.saptens] 2.66 110949 N49602 Hs.13308 ESTs 2.65 111031 N54839 Hs.221085 ESTs; Highly similar to mediator [H.sapiens] 2.633 121770 AA421714 Hs.11469 KIAA0896 protein 2.63 134132 U32519 Hs.220689 Ras-GTPase-adivating protein SH3-domain-binding protein 2.626 112424 R62452 Hs.191265 ESTs 2.625 122544 AA451679 Hs.194410 ESTs 2.625 134425 X90568 Hs.172004 titin 2.624 111114 N63391 Hs.9238 ESTs 2.619 116119 AA459242 Hs.44445 ESTs; Weakly similar to Kelch motif containing protein [H.sapiens] 2.615 112079 R44164 Hs.23014 ESTs 2.6 123033 AA481271 Hs.193945 ESTs 2.591 124196 H52617 Hs.144167 ESTs 2.586 125873 H14437 yl25a04.r1 Soares breast 3NbHBst Homo sapiens cDNA done 2.58 117684 N40184 Hs.45050 ESTs 2.575 134938 D30037 Hs.168326 phosphotidylinositol transfer protein; beta 2.575 131822 AA215647 Hs.200332 ESTs 2.568 135185 U71203 Hs.96038 Ric (Drosophila)-like; expressed in many tissues 2.564 117690 N40467 Hs.93834 ESTs 2.557 118807 N78582 Hs.50732 protein kinase; AMP-adivated; beta 2 non-catalytic subunit 2.552 121369 AA405657 Hs.128791 Human DNA sequence from clone 967N21 on chromosome 20p12.3-13. Contains 2.55 114860 AA235112 Hs.106227 ESTs; Moderately similar to similar to murine RNA-binding protein [H.sapiens] 2.549 121857 AA426017 Hs.62694 ESTs; Highly similar to DNA-REPAIR PROTEIN COMPLEMENTING 2.548 110190 H20560 Hs.244624 ESTs 2.548 132573 AA045333 Hs.51743 ESTs; Weakly similar to I! ALU SUBFAMILY SB2 WARNING ENTRY !! [H.sapiens] 2.542 109706 F09729 Hs.12780 ESTs 2.537 135109 AA410391 Hs.94592 klotho 2.525 132810 R37027 Hs.5737 KIAA0475 gene produd 2.525 124879 R73588 Hs.101533 ESTs 2.525 103840 AA174190 Hs.50932 ESTs 2.525 119066 R22196 Hs.34492 ESTs 2.519 114833 AA234362 Hs.87310 ESTs; Moderately similar to CGI-66 protein [H.sapiens] 2.507 112998 T23555 Hs.103288 ESTs 2.5 123312 AA496258 Hs.99601 ESTs 2.499 121873 AA426270 Hs.145696 splicing fador (CC1.3) 2.491 123321 AA496884 Hs.23972 ESTs 2.491 107760 AA018042 Hs.95078 EST 2.483 102580 U60808 Hs.152981 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1 2.481 103053 X56741 Hs.5947 mel transforming oncogene (derived from cell line NK14)- RAB8 homolog 2.475 124756 R38100 Hs.106294 ESTs 2.475 112936 T15665 Hs.6185 ESTs; Weakly similar to BcDNA.GH12174 [D.melanogaster] 2.475 125178 W58202 Hs.125731 ESTs 2.475 112423 R62447 Hs22123 ESTs 2.471 123515 AA600323 Hs.112535 EST 2.462 102842 U95020 Hs21903 caldu channel; voltage-dependent; beta 4 subunit 2.457 102400 U42390 Hs.171957 triple fundional domain (PTPRF interacting) 2.455 113187 T56056 Hs.9992 ESTs 2.452 131687 L11066 Hs.3069 heat shock 70kD protein 9B (mortalin-2) 2.448 115314 AA280583 Hs256501 ESTs 2.437 128211 AI206427 Hs.166707 ESTs; Highly similar to Ran-binding protein 2 [H.sapiens] 2.43 134281 L11005 Hs.81047 aldehyde oxidase 1 2.425 115985 AA447709 Hs.132094 ESTs; Moderately similar to putative transcription fador CA150 [H.sapfens] 2.425 111348 N90041 Hs.9585 ESTs 2.418 129430 AA258842 Hs.197877 Homo sapiens clone 23777 putative transmembrane GTPase mRNA; partial eds 2.418 133863 C13990 Hs.76930 synuclein; alpha (non A4 component of amyloid precursor) 2.417 111164 N66857 Hs.14808 ESTs; Weakly similar to I! ALU CUSS C WARNING ENTRY !! [H.sapiens] 2.416 132143 AA257056 Hs.7972 KIAA0871 protein 2.412 130330 M55047 Hs.154679 synaptotagmin 1 2.408 114219 Z39451 Hs.27389 ESTs 2.406 117101 H94043 Hs.24341 DKFZP58611419 protein 2.403 125433 AA034325 Hs.54320 ESTs 2.4 111099 N62506 Hs.21958 ESTs 2.4 120323 AA195405 Hs.110347 Homo sapiens mRNA for alpha integrin binding protein 80; partial 2.397 118624 N69998 HS21801 ESTs 2.394 123570 AA608955 Hs.109653 ESTs 2.389 123562 AA608893 Hs.190065 ESTs 2.388 131546 AA262821 Hs.28578 muscleblind (Drosophila)-like 2.385 103143 X66141 Hs.75535 myosin; light polypeptide 2; regulatory; cardiac; slow 2.384 123645 AA609310 Hs.188691 ESTs 2.383 130123 AA001835 Hs.150390 zinc finger protein 262 2.379 131682 AA428368 Hs.30654 ESTs 2.378 115909 AA436666 Hs.59761 ESTs 2.375 125168 W45574 Hs.252497 ESTs 2.372 123973 C14805 Hs.182151 ESTs 2.361 135197 U76456 Homo sapiens tissue inhibitor of metalloproteinase 4 mRNA, complete eds 2.357 118689 N71545 Hs.184544 ESTs 2.357 107734 AA016225 Hs.93386 ESTs 2.354 124590 N69220 Hs.41381 ESTs; Weakly similar to ubiquitin hydrolyzing enzyme I [H.sapiens] 2.35 111163 N66850 Hs.17606 ESTs 2.348 112349 R58877 Hs.22665 ESTs; Moderately similar to dJ83L6.1 [H.sapiens] 2.345 129076 AA262179 Hs.169343 ESTs 2.345 134238 R81509 Hs.184571 splidng fador; arginine/serine-rich 11 2.341 116766 H13260 Hs.95097 ESTs 2.336 106331 AA436853 Hs.34795 ESTs 2.333 129003 AA443752 Hs.10784 ESTs 2.332 132368 AA599814 Hs.46637 ESTs; Weakly similar to cDNA EST yk289g5.5 comes from this gene [C.etegans] 2.332 124697 R06273 Hs.186467 ESTs; Modly smlr to I! ALU SUBFAMILY J WARNING ENTRY I! [H.sapiens] 2.322 120273 AA176688 Hs.221139 ESTs 2.313 127110 AA304993 Hs.100861 ESTs; Weakly similar to p60 katanin [H.sapfens] 2.307 105450 AA252621 Hs.93842 ESTs 2.301 119819 W74371 Hs.58383 ESTs 2.297 102302 U33052 Hs.69171 protein kinase C-like 2 2.288 130596 N74353 Hs.16475 ESTs 2.282 114161 Z38904 Hs.22385 ESTs; Weakly similar to KIAA0970 protein [H.saptens] 2.278 130542 U64675 Human sperm membrane protein BS-63 mRNA, complete eds 2.277 104491 N71513 Hs.39328 ESTs 2275 116988 H82527 ys69e12.s1 Soares retina N2b4HR Homo sapiens cDNA clone 2.275 126823 AA370120 Hs.7870 ESTs; Weakly similar to Ylr350wp [S.cerevisiae] 2.273 108800 AA129731 Hs.90424 ESTs 2.273 101310 L41607 Hs.934 glucosaminyl (N-acetyl) transferase 2; l-branching enzyme 2269 126842 W19498 Hs.21085 ESTs 2.255 127251 AA936428 Hs.128638 ESTs 2.251 124647 N91947 Hs.125033 ESTs 2.249 127112 AI143906 Hs.125103 ESTs 2247 101973 S82597 Hs.80120 UDP-N-acetyl-alpha-D-galadosamine:polypeptide 2.246 120999 AA398302 Hs.127437 ESTs 2.245 130225 AA599583 Hs.15299 HMBA-indudble 2.243 119980 W88678 Hs.249247 heterogeneous nudear protein similar to rat helix destabilizing protein 2.243 124222 H61053 HS222844 ESTs 224 129199 H90914 Hs.128629 ESTs 2236 106802 AA479101 Hs.16570 ESTs; Weakly similar to !! ALU SUBFAMILY SQ WARNING ENTRY !! [H.sapiens] 2231 126160 N90960 Hs247277 ESTs; Weakly similar to transformation-related protein [H.sapiens] 2.229 104627 AA001976 Hs.19603 ESTs 2.228 106474 AA450212 Hs.42484 Homo sapiens mRNA; cDNA DKFZp564C053 (from clone DKFZp564C053) 2.226 113096 T40927 Hs.8345 ESTs 2.225 135336 AA452822 Hs.99027 ESTs 2.225 135344 R62976 Hs.168491 ESTs; Moderately similar to TRF1-interading ankyrin-related 2.225 126156 AA508354 Hs.118448 ESTs; Moderately similar to AKT3 protein kinase [H.sapiens] 2.222 128885 AA397841 Hs.180141 cofilin 2 (musde) 2.218 107900 AA026385 Hs.176600 ESTs; Moderately similar to I! ALU SUBFAMILY SB2 WARNING 2217 114481 AA033562 Hs.151572 ESTs 2212 109292 AA199828 Hs.188662 ESTs 2.212 104257 AF006265 Hs.9222 estrogen receptor-binding fragment-assodated gene 9 2.209 132932 T15482 Hs.6093 ESTs 2204 127392 AA262728 Hs.14896 Homo sapiens done 24590 mRNA sequence 2.204 104641 AA004652 Hs.18564 ESTs 22 122529 AA449828 Hs.99229 ESTs 2.195 124307 H93562 Hs.162395 proline synthetase co-transcribed (baderial homolog) 2.193 133601 S95936 Hs.75155 transferrin 2.193 119904 W85709 Hs.128927 ESTs; Weakly similar to !! ALU SUBFAMILY SP WARNING ENTRY I! [H.sapiens] 2.192 100348 D64109 Hs.4994 transducer of ERBB2; 2 (TOB2) 2.185 126871 AA351779 Hs200334 ESTs 2.18 127793 AI298835 Hs.30445 ESTs; Weakly similar to transcription regulator Staf-50 [H.sapiens] 2.178 105149 AA169253 Hs.8958 ESTs 2.177 121367 AA405648 zw39g8.s1 Soares total_fetus_Nb2HF8_9wH saptens cDNA done IMAGE.7724782.177 111836 R36228 Hs.25119 ESTs 2.175 133394 R16759 Hs.237225 ribosomal protein S5 pseudogene 1 2.175 123207 AA489697 Hs.145053 ESTs 2.175 129801 F11087 HS239666 ESTs 2.175 103393 X94612 Hs.41749 protein kinase; cGMP-dependent; type II 2.161 132415 AA043223 Hs.4815 nudix (nudeoside diphosphate linked moiety X)-type motif 3 2.157 106369 AA443828 Hs.25324 ESTs 2.157 122963 AA478446 Hs.69559 KIAA1096 protein 2.156 133473 M19309 Hs.73980 troponin T1 ; skeletal; slow 2.155 134257 C06270 Hs.8078 Homo sapiens mRNA; cDNA DKFZp586L081 (from done DKFZp586L081 ) 2.155 135156 AA056012 Hs.9552 binder of Art Two 2.151 104055 AA393755 Hs.117211 ESTs; Highly similar to CGI-62 protein [H.sapiens] 2.15 102313 U33921 HSU33921 Clontech adult lung cDNA library (HL1158a) Homo sapiens cDNA 2.15 109788 F10638 Hs.12432 Homo sapiens clone 24407 mRNA sequence 2.15 103507 Y10032 Hs.159640 serum glucocorticoid regulated kinase 2.15 116000 AA448710 Hs.41327 ESTs 2.15 105858 AA399164 Hs.227676 ESTs; Moderately similar to !! ALU SUBFAMILY SQ 2.137 103153 X66534 Hs.75295 guanylate cyclase 1 ; soluble; alpha 3 2.137 126202 AA652238 Hs.199726 ESTs 2.135 115955 AA446121 Hs.44198 Homo sapiens B AC done RG054D04 from 7q31 2.134 104164 AA458770 Hs27023 KIAA0917 protein 2.132 108692 AA121270 Hs.82960 ESTs 2.128 122878 AA465341 Hs.99640 ESTs 2.126 134771 L13939 Hs.89576 adaptor-related protein complex 1 ; beta 1 subunit 2.125 104298 D31120 Hs.40368 adaptor-related protein complex 1 ; sigma 2 subunit 2.125 104840 AA039595 Hs.42458 Homo sapiens mRNA; cDNA DKFZp586C1817 (from done DKFZp586C1817) 2.125 122180 AA435798 Hs.98835 ESTs; Moderately similar to putative ring zinc finger protein 2.125 131012 H01992 Hs.202949 KIAA1102 protein 2.125 134092 H17490 Hs.7905 ESTs; Highly similar to sorting nexin 9 [H.sapiens] 2.123 118617 N69666 Hs.183413 ESTs; Modtly smlr to I! ALU SUBFAMILY J WARNING ENTRY I! [H.sapiens] 2.123 107155 AA621202 Hs.7946 DKFZP586D1519 protein 2.12 130925 N71935 Hs.169378 multiple PDZ domain protein 2.12 135167 U63717 Hs.95821 osteoclast stimulating fador 1 2.118 105952 AA405263 Hs.181400 ESTs 2.109 110308 H38148 Hs.32775 ESTs 2.108 116368 AA521186 Hs.94217 ESTs 2.107 132939 U76189 Hs.61152 exostoses (multiple)-like 2 2.102 117881 N50073 Hs.84926 ESTs; Highly similar to B-IND1 protein [M.musculus] 2.1 121723 AA419622 Hs.104800 ESTs; Weakly similar to Mouse 19.5 mRNA; complete eds [M.musculus] 2.096 103500 Y09443 Hs22580 alkylglycerone phosphate synthase 2.094 121429 AA406293 Hs.193498 ESTs 2.093 134632 AA398710 Hs.174139 chloride channel 3 2.091 129785 F10980 Hs.184780 ESTs 2.09 111065 N58193 Hs.18740 ESTs; Weakly similar to 1-evidence 2.089 114710 AA129931 Hs.79081 protein phosphatase 1 ; catalytic subunit; gamma isoform 2.083 132711 N73702 HS238927 ESTs 2.083 133377 R05490 Hs.7239 SEC24 (S. cerevisiae) related gene family; member B 2.079 124773 R40923 Hs.106604 ESTs 2.078 117759 N47587 Hs.97345 ESTs; Weakly similar to TROPOMODULIN [H.sapiens] 2.076 127386 AI457411 Hs.106728 ESTs 2.076 101167 L15309 Hs.193677 zinc finger protein 141 (clone pHZ-44) 2.075 109597 F02582 Hs.14474 ESTs 2.074 124390 N29325 Hs.7535 ESTs; Highly similar to COBW-like placental protein [H:sapiens] 2.07 116225 AA478609 Hs.47278 Human Chromosome 16 BAC done CIT987SK-A-735G6 2.07 131243 R16667 Hs24752 spectrin SH3 domain binding protein 1 2.069 130557 T90830 Hs.15981 ESTs; Weakly similar to line-1 protein ORF2 [H.sapiens] 2.067 134103 D14826 Hs.155924 cAMP responsive element modulator 2.064 108833 AA131866 Hs.61661 ESTs; Weakly similar to DY3.6 [C.elegans] 2.063 112286 R53765 Hs.158135 KIAA0981 protein 2.063 125624 AA165411 zq49a01.r1 Stratagene hNT neuron (#937233) Homo sapiens cDNA clone 2.061 124612 N72200 Hs.13913 ESTs 2.058 116335 AA495830 Hs.87013 ESTs 2.057 112248 R51361 HS23423 ESTs 2.056 115789 AA424754 Hs.43149 ESTs 2.056 107029 AA599219 Hs.187492 ESTs; Weakly similar to ALR [H.sapiens] 2.056 110294 H30270 Hs.165062 ESTs 2.054 120532 AA262354 Hs.186648 ESTs 2.054 118180 N59249 Hs.48349 ESTs 2.052 132018 AA293194 Hs.3737 ESTs 2.052 132617 AA171913 Hs.5338 carbonic anhydrase XII 2.05 131526 N36167 Hs.28274 ESTs 2.05 113254 T64438 Hs.11449 DKFZP5640123 protein 2.05 122785 AA459978 Hs.99508 ESTs 2.05 107203 D20426 Hs.5656 EST 2.05 105713 AA291321 Hs.184319 ESTs; Moderately similar to KIAA1006 protein [H.saptens] 2.046 129385 D82675 Hs.110950 Homo sapiens done 25007 mRNA sequence 2.042 119116 R43845 Hs.64595 DKFZP566E2346 protein 2.04 116405 AA600253 Hs.55601 ESTs; Highly similar to host cell fador 2 [H.sapiens] 2.04 125924 AA526849 Hs.82109 syndecan 1 2.039 105599 AA279442 Hs.143460 protein kinase C; nu 2.037 119741 W70205 Hs.43670 kinesin family member 3A 2.037 101449 M21494 Hs.118843 creatine kinase; muscle 2.036 107109 AA609943 Hs.32793 ESTs 2.034 117040 H89112 yw25e5.s1 Morton Fetal Cochlea Homo sapiens cDNA done IMAGE25328 2.034 132906 AA142857 Hs.234896 ESTs; Highly similar to geminin [H.sapiens] 2.031 105479 AA255546 HS23467 ESTs 2.027 102031 U04898 Hs2156 RAR-related orphan receptor A 2.027 119846 W80363 Hs.58446 ESTs 2.024 124809 R46482 Hs.106875 ESTs 2.024 130286 AA041548 Hs.154023 KIAA0573 protein 2.023 124457 N50114 Hs.128704 ESTs 2.017 125144 W37999 Hs.24336 ESTs 2.017 120581 AA281257 Hs.125868 ESTs 2.014 104931 AA062731 Hs.108319 thyroid hormone receptor-assodated protein; 150 kDa subunit 2.012 120548 AA278846 Hs.187634 ESTs 2.011 113933 W81362 Hs.30567 ESTs 2.011 123072 AA485041 Hs.104308 ESTs 2.009 123648 AA609323 Hs.112689 ESTs 2.008 116875 H67749 Hs.161022 EST 2.003 103179 X69398 Hs.82685 CD47 antigen (Rh-related antigen; integrin-associated signal transducer) 1.995 103478 Y07755 Hs.38991 S100 caldum-binding protein A2 1.995 111007 N53378 Hs22543 ESTs 1.995 120470 AA251797 zs11f3.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone 1.989 112280 R53457 Hs26040 ESTs; Weakly similar to fatty add omega-hydroxylase [H.sapiens] 1.989 114127 Z38652 Hs.106961 ESTs; Weakly similar to TYL [H.sapiens] 1.988 129863 AA151005 Hs.129872 sperm surface protein 1.988 106320 AA436608 ESTs 1.988 108933 AA147224 Hs.71814 ESTs 1.986 105906 AA401633 HS22380 ESTs 1.982 109029 AA157911 Hs.72200 ESTs 1.982 118470 N66769 Hs.82781 ESTs 1.975 115358 AA281886 Hs.88923 ESTs 1.975 115257 AA279060 Hs.193516 B-cell CLL/lymphoma 10 1.974 126879 AA719776 zh38g04.s1 Soares_pineal_gland N3HPG Homo sapiens cDNA done IMAGE.4143901.974 109547 F01479 Hs26966 ESTs 1.973 127111 AA805726 HS220509 ESTs 1.969 101266 L36645 Hs.73964 EphA4 1.966 129319 AA037467 Hs.30340 ESTs 1.965 106211 AA428240 Hs.126083 ESTs 1.962 112753 R93696 Hs.169882 ESTs 1.961 120489 AA255538 Hs.190504 ESTs 1.959 129699 AA458578 Hs.12017 KIAA0439 protein; homolog of yeast ubiquitin-protein ligase Rsp5 1.956 105425 AA251129 HS24416 ESTs 1.953 134740 L37362 Hs.89455 opioid receptor; kappa 1 1.95 109324 AA210700 Hs.86405 Homo sapiens mRNA; cDNA DKFZp564P056 (from clone DKFZp564P056) 1.95 124303 H93043 Hs.107070 ESTs 1.95 102337 U36922 Human fork head domain protein (FKHR) mRNA, 3' end 1.948 109441 AA228100 Hs.86998 nudear fador of adfvated T-cells 5 1.946 127364 AA179573 Hs.90061 progesterone binding protein 1.942 105255 AA227498 Hs.3623 ESTs 1.942 130672 L19783 Hs.177 phosphatidylinositol glycan; class H 1.942 104301 D45332 Hs.6783 ESTs 1.94 132442 R62589 Hs.167419 ESTs 1.939 105519 AA258063 HS23438 ESTs 1.937 132902 AA490969 Hs.168147 ESTs 1.936 118873 N89881 Hs.44577 ESTs 1.936 114124 Z38595 Hs.125019 ESTs; Highly similar to KIAA0886 protein [ saptens] 1.934 115075 AA255486 Hs.88045 ESTs 1.933 110695 H93463 Hs.124777 ESTs 1.931 105360 AA236209 Hs.187626 ESTs 1.931 124998 T56013 Hs.77910 3-hydroxy-3-methylglutaryl-Coβnzyme A synthase 1 (soluble) 1.929 121816 AA424814 Hs.187509 ESTs 1.927 111717 R23241 Hs.110776 STAT induced STAT inhibitor-2 1.925 128874 H06245 Hs.106801 ESTs 1.925 109391 AA219699 Hs.184245 KIAA0929 protein Msx2 interading nudear target (MINT) homolog 1.913 126129 H82165 Hs.40334 ESTs 1.911 115553 AA369027 Hs.71414 ESTs 1.905 113811 W44928 Hs.4878 ESTs 1.905 108345 AA070906 zm66d1.s1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA done 1.904 120472 AA251875 Hs.104472 ESTs; Weakly similar to Gag-Pol polyprotein [M.musculus] 1.903 116602 D80063 Hs.241673 EST 1.901 121121 AA399371 Hs.189095 ESTs; Weakly similar to zinc finger protein SALL1 [H.sapiens] 1.9 125330 AA401804 Hs.114574 ESTs 1.896 130095 F01831 Hs.14838 ESTs 1.894 119782 W72982 Hs.58262 ESTs 1.894 104115 AA428090 Hs.26102 ESTs 1.893 131313 C17938 Hs.22370 Homo sapiens mRNA; cDNA DKFZp564O0122 (from done DKFZp564O0122) 1.891 105583 AA278907 Hs24549 ESTs 1.891 122825 AA461195 Hs.99580 ESTs 1.887 119495 W35390 Hs.55533 ESTs 1.886 130309 AA134289 Hs.15423 Homo saptens BAC clone RG114B19 from 7q31.1 1.886 125628 AA418069 Hs.241493 natural killer-tumor recognition sequence 1.886 110611 H66947 Hs.14671 ESTs; Highly similar to gene ERCC5 protein [H.sapiens] 1.885 117301 N22569 Hs.43215 ESTs 1.884 131406 N92239 Hs.26471 Wnt inhibitory fador-1 1.881 126428 AA013312 Hs.64988 ESTs 1.881 120285 AA182882 Hs.111110 tttin-cap (telet onin) 1.878 112724 R91753 Hs.17757 ESTs 1.878 103121 X63679 Hs.4147 translocating chain-associating membrane protein 1.875 124381 N26765 Hs.109008 ESTs 1.875 117226 N20468 Hs.177322 ESTs; Weakly similar to putative p150 [H.sapiens] 1.875 105610 AA279991 Hs.124691 ESTs; Weakly similar to trithorax homologue 2 [H.saptens] 1.875 111229 N69113 Hs.110855 ESTs 1.875 120627 AA285079 Hs.190474 ESTs 1.873 107048 AA600012 Hs.10669 ESTs; Moderately similar to KIAA0400 [H.saptens] 1.872 104041 AA381902 Hs.197114 RNA binding protein 1.872 115162 AA258366 Hs227806 ras GTPase adivating protein-like 1.872 102239 U26726 Hs.1376 hydroxysteroid (11-beta) dehydrogenase 2 1.87 100043 M10098 AFFX control: 18S ribosomal RNA 1.868 120296 AA191353 Hs22385 ESTs; Weakly similar to KIAA0970 protein [H.sapiens] 1.867 129011 S72869 Hs.107932 DNA segment; single copy; probe pH4 (transforming sequence; thyroid-1; 1.867 134851 R44479 Hs.90232 KIAA0552 gene produd 1.866 117392 N26175 Hs.93405 ESTs 1.864 114530 AA053027 Hs.191797 ESTs 1.863 123541 AA608794 Hs.112592 ESTs 1.863 124890 R78618 Hs.34145 ESTs; Weakly similar to RAS-REUTED PROTEIN RAB-8 [H.sapiens] 1.862 105299 AA233511 Hs.194720 ATP-binding cassette; sub-family G (WHITE); member 2 1.861 103560 Z20656 Hs.182787 myosin; heavy polypept 6; cardiac muscle; alpha (cardiomyopathy; hypertrophie 1) 1.861 113073 T33637 Hs.6841 ESTs 1.86 120407 AA235040 Hs.107283 ESTs 1.859 103892 AA243523 Hs.17155 ESTs - 1.858 123795 AA620381 Hs.70488 ESTs 1.857 108524 AA084323 Hs.68138 ESTs 1.857 113953 W85812 Hs.187554 ESTs 1.856 110721 H97678 Hs.31319 ESTs 1.856 129426 AA412087 Hs.168272 EST; Highly smlr to prot inhibitor of activated STAT prot PIASx-alpha [H.sapiens] 1.853 112102 R44840 Hs.21303 ESTs 1.852 118502 N67317 Hs.50150 ESTs 1.852 107619 AA004955 Hs.60015 ESTs 1.851 100438 D87446 Hs.75912 KIAA0257 protein 1.85 120652 AA287312 Hs.191648 ESTs 1.85 121643 AA417078 Hs.193767 ESTs 1.843 117387 N26011 Hs.53810 ESTs 1.843 132084 Y12394 Hs.3886 kaiyopherin alpha 3 (importin alpha 4) 1.843 124449 N48593 Hs.121820 ESTs 1.841 120263 AA173440 Hs.193919 ESTs 1.838 127226 AA731036 Hs.3463 ribosomal protein S23 1.838 111837 R36447 Hs.24453 ESTs 1.835 128727 M64174 Hs.50651 Janus kinase 1 (a protein tyrosine kinase) 1.834 114439 AA018937 Hs.128629 ESTs 1.833 102332 U35637 Human nebulin mRNA, partial eds 1.83 126579 W72979 Hs.146082 ESTs 1.83 102341 U37122 Hs.8110 adducin 3 (gamma) 1.83 114246 Z39848 Hs.12079 ESTs 1.828 131757 D17532 Hs.316 DEAD H (Asp-Glu-Ala-Asp/His) box polypeptide 6 (RNA helicase; 54kD) 1.823 108904 AA136521 Hs.71148 ESTs; Weakly similar to putative p150 [H.sapiens] 1.823 115084 AA255566 Hs.42484 Homo sapiens mRNA; cDNA DKFZp564C053 (from clone DKFZp564C053) 1.823 131957 AA609008 Hs.183232 ESTs 1.822 100131 D12485 Hs.11951 phosphodiesterase l/nudeotide pyrophosphatase 1 (homologous to mouse Ly-41 antigen) 1.822 124163 H30539 Hs.189838 ESTs 1.821 118204 N59859 Hs.48443 ESTs 1.821 107727 AA016021 Hs.173091 DKFZP434K151 protein 1.82 100357 D78156 Hs.241548 RAS p21 protein activator 2 1.82 116295 AA489016 Hs.91216 ESTs; Highly similar to partial CDS; human putative tumor suppressor [ sapiens] | 1.82 124833 R54112 Hs.128697 ESTs 1.817 122587 AA453255 Hs.6968 ESTs 1.817 114359 Z41589 Hs.153483 ESTs; Moderately similar to H1 chloride channel [H.sapiens] 1.815 111289 N72253 Hs.238246 ESTs 1.813 110826 N30068 Hs.15347 ESTs 1.812 104106 AA422123 Hs.42457 ESTs 1.811 130043 AA055404 Hs.193953 ESTs; Weakly similar to I! ALU SUBFAMILY J WARNING ENTRY !! [H.sapfens] 1253 115864 AA432080 Hs.81200 ESTs 1.81 129737 AA056140 Hs.122684 ESTs 1.81 124477 N53158 Hs.102682 ESTs 1.809 100782 HG3740-HT4010 Basic Transcription Fador 2, 34 Kda Subunit 1.806 106101 AA421053 Hs.34395 ESTs 1.806 115479 AA287596 zs52h09.s1 NCI CGAP 6CB1 H sapiens cDNA clone IMAGE.701153 1.804 116104 AA456635 Hs.78524 ESTs 1.804 114173 Z39050 Hs.21963 ESTs 1.804 132632 N59764 Hs.5398 guanine-monophosphate synthetase 1.803 119135 R49548 Hs.169681 death effedor domain-containing 1.802 131559 N91087 Hs.28728 ESTs; Weakly similar to F55A12.9 [C.elegans] 1.801 126922 AA177138 Hs.161671 ESTs 1.8 117375 N25427 Hs.108812 ESTs 1.8 103571 Z25535 Hs.211608 nudeoporin 153kD 1.8 105978 AA406367 Hs.15973 ESTs 1.8 125904 H22372 Hs.163586 ESTs 1.799 133883 AA397915 Hs.77221 choline kinase 1.798 105777 AA348412 Hs23096 ESTs 1.797 110166 H19480 Hs.174309 ESTs 1.796 105038 AA130273 Hs.7584 ESTs; Weakly similar to hypothetical protein; similar to [Ksapiens] 1.796 105427 AA251330 Hs28248 ESTs 1.795 115278 AA279757 Hs.67466 ESTs; Weakly similar to BACN32G11.d [D.melanogaster] 1.794 133104 L13698 Hs.65029 growth arrest-specific 1 1.794 131170 N48674 Hs.23796 Human DNA sequence from done 1052M9 on chromosome Xq25. Contains the 1.792 100136 D13540 Hs22868 protein tyrosine phosphatase; non-receptor type 11 1.791 127263 AA331157 EST35035 Embryo, 6 week, subtraded (total cDNA) I Homo sapiens cDNA 1.79 114157 Z38878 Hs.24979 ESTs 1.79 125601 AI096717 Hs.247043 KIAA0525 protein 1.788 118472 N66818 Hs.42179 ESTs 1.787 112456 R63925 Hs.28464 ESTs 1.787 130236 N69682 Hs.51957 SC35-interading protein 1 1.786 133297 AA600057 Hs.70266 KIAA0905 protein 1.784 125650 R40096 Hs.176578 ESTs 1.784 132056 T89386 Hs.38176 KIAA0606 protein; SCN Circadian Oscillatory Protein (SCOP) 1.783 129093 AA262710 Hs.108614 KIAA0627 protein 1.783 123176 AA489020 Hs.193424 ESTs 1.782 106340 AA441792 Hs.22857 chord domain-containing protein 1 1.781 100598 HG2463-HT2559 Guanine Nucleotide-Binding Protein G25k 1.779 104038 AA374532 EST86676 HSC172 cells I Homo saptens cDNA5' end, mRNA sequence 1.778 122235 AA436475 Hs.190104 ESTs 1.777 105104 AA151771 Hs.76941 ATPase; Na K + transporting; bete 3 polypeptide 1.776 107601 AA004636 Hs.50223 ESTs 1.776 131467 W68255 HS27194 DKFZP434K171 protein 1.776 118449 N66413 Hs.172466 ESTs; Weakly similar to KIAA0775 protein [H.sapiens] 1.776 107969 AA034030 Hs.155212 methylmalonyl Coenzyme Amutase 1.775 115527 AA342079 HS252055 ESTs 1.775 132471 T16305 Hs.49349 beta-site APP-cleaving enzyme 1.775 105966 AA406105 Hs.5344 adaptor-related protein complex 1 ; gamma 1 subunit 1.774 127548 AA373091 Hs.93832 Homo sapiens done 24483 unknown mRNA; parital eds 1.774 106217 AA428379 Hs.24870 ESTs 1.773 131214 N26777 Hs.172635 ESTs 1.773 106295 AA435664 Hs.8583 similar to APOBEC1 1.773 106328 AA436705 Hs.28020 KIAA0766 gene produd 1.772 124661 N93797 Hs.3090 EphB1 1.772 122988 AA479166 Hs.105633 ESTs 1.772 115504 AA291946 Hs.42736 ESTs 1.771 105168 AA180208 Hs.16606 ESTs; Highly similar to CGI-32 protein [H.sapiens] 1.767 129153 AA188618 Hs.181461 ariadne; Drosophila; homolog of 1.766 105829 AA398290 Hs.21965 ESTs 1.764 101811 M86917 Hs.24734 oxysterol binding protein 1.764 100138 D13628 Hs.2463 aπgiopofetin 1 1.764 124704 R07335 ye96c1.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 1.763 122314 AA442257 Hs.192076 ESTs 1.762 109865 H02566 Hs.191268 Homo sapiens mRNA; cDNA DKFZp434N174 (from done DKFZp434N174) 1.761 106206 AA428069 Hs.89519 KIAA1046 protein 1.758 107135 AA620782 Hs.23247 ESTs 1.757 105760 AA338960 Hs.28170 ESTs 1.756 106288 AA435536 Hs.24336 ESTs 1.756 103968 AA304566 Hs.3542 ESTs 1.756 129559 AA234945 Hs.11360 ESTs 1.756 117885 N50112 Hs.47023 ESTs 1.754 107032 AA599472 Hs.247309 sucdnate-CoA ligase; GDP-forming; beta subunit 1.754 124807 R45963 Hs.233811 ESTs; Weakly similar to ORF2 [M.musculus] 1.753 100276 D42047 Hs.82432 KIAA0089 protein 1.753 110924 N47938 yy84a09.s1 Soares_multiple_sderosis_2NbHMSP Homo saptens cDNA clone 1.751 133002 AF006082 Hs.62461 ARP2 (adin-related protein 2; yeast) homolog 1.751 132530 AA455917 Hs.50785 SEC22; vesicle trafficking protein (S. cerevisiae)-like 1 1.75 110759 N21671 Hs.19025 ESTs 1.75 106138 AA424515 Hs.33264 ESTs 1.75 107348 U43701 Hs.184776 ribosomal protein I23a 1.75 115867 AA432162 Hs.165986 DKFZP586B2022 protein 1.749 135398 AA194075 Hs.99908 nuclear receptor coactivator 4 1.747 113783 W19222 Hs.7041 ESTs; Weakly similar to I! ALU SUBFAMILY SQ WARNING ENTRY !! [H.sapiens] 1.747 134898 X98330 Hs.90821 ryanodine receptor 2 (cardiac) 1.745 132215 T10132 Hs.4236 KIAA047B gene produd 1.744 104229 AB002346 Hs.61289 synaptojanin 2 1.743 116166 AA461556 Hs202949 KIAA1102 protein 1.743 115433 AA284252 Hs.58372 ESTs 1.743 114908 AA236545 Hs.54973 ESTs 1.742 127425 AA470941 Hs.143162 ESTs 1.741 131089 Z38807 Hs.22870 ESTs 1.739 113498 T88908 Hs.189746 ESTs 1.738 116710 F10577 Hs.70312 ESTs 1.735 127210 R51476 yg76f04.r1 Soares infant brain 1 NIB Homo sapiens cDNA done 1.733 120554 AA279654 Hs.194524 ESTs 1.733 129940 U18242 Hs.13572 caldum modulating ligand 1.732 117023 H88157 Hs.41105 ESTs 1.731 111700 R22212 Hs.23361 ESTs 1.731 116911 H72240 Hs.39292 ESTs; Moderately similar to KIAA0745 protein [H.sapiens] 1.731 106025 AA412063 Hs.6065 ESTs 1.728 108626 AA101984 Hs.61697 G-protein coupled receptor 1.726 111614 R12581 Hs.191146 ESTs 1.726 134134 L76703 Hs.173328 protein phosphatase 2; regulatory subunit B (B56); epsilon isoform 1.725 106886 AA489086 Hs.36545 ESTs 1.725 117998 N52136 Hs.93828 ESTs 1.725 121204 AA400422 Hs.55896 ESTs 1.725 121342 AA404995 Hs.192480 ESTs 1.725 131129 R27296 Hs.23240 ESTs 1.725 116235 AA479181 Hs.186726 ESTs 1.725 102423 U44754 Hs.179312 small nuclear RNA activating complex; polypeptide 1 ; 43kD 1.724 110273 H29050 Hs.24096 ESTs 1.722 108758 AA127395 Hs.222414 ESTs 1.722 110672 H88477 Hs.191178 ESTs 1.721 120271 AA176404 Hs.111092 ESTs; Weakly similar to ZINC FINGER PROTEIN 136 [H.sapiens] 1.72 100227 D28915 Hs.82316 interferon-induced; hepatitis C-associated microtubular aggregate prot (44kD) 1.719 129232 W69459 Hs.109655 sex comb on midteg (Drosophila)-like 1 1.719 134663 W73367 Hs.8750 ESTs 1.717 104902 AA055475 Hs.104143 dathrin; light polypeptide (Lea) 1.717 120582 AA281290 Hs.125287 ESTs; Weakly similar to BC331191 1 [H.sapiens] 1.717 134891 F03517 Hs.90787 ESTs 1.716 106219 AA428567 Hs26613 Homo sapiens mRNA; cDNA DKFZp586F1323 (from done DKFZp586F1323) 1.715 116372 AA521311 Hs.13854 ESTs 1.713 107570 AA001870 Hs237323 N-acetylglucosamine-phosphate mutase; DKFZP434B187 protein 1.713 106198 AA427816 Hs.11803 ESTs 1.712 125136 W31479 Hs.129051 ESTs 1.712 104973 AA085676 Hs.6763 KIAA0942 protein 1.712 128710 J04813 Hs.104117 cytochrome P450; subfamily IIIA (niphedipine oxidase); polypeptide 5 1.711 123994 D20899 Hs.107127 Homo saptens mRNA; cDNA DKFZp564G022 (from done DKFZp564G022) 1.711 127871 AA766511 Hs.128848 ESTs 1.71 116089 AA455933 Hs.41324 ESTs 1.709 123337 AA504153 Hs.132797 ESTs; Weakly similar to ORF YGLOSOw [S.cerevisiae] 1.708 123619 AA609200 Hs.162686 ESTs 1.708 104781 AA026617 Hs21610 ESTs; Highly similar to BAH-assodated protein 1 [H.sapiens] 1.707 115114 AA256468 Hs.88148 ESTs 1.705 117852 N49408 Hs.136102 KIAA0853 protein 1.705 127644 T57570 Hs.77039 ribosomal protein S3A 1.704 111359 N91273 Hs.27179 ESTs 1.702 131721 L36644 Hs.31092 EphA5 1.7 132438 F08925 Hs.48610 ESTs 1.7 132476 N67192 Hs.49476 Homo sapiens done TUA8 Cri-du-chat region mRNA 1.7 130990 F02488 Hs.21917 KIAA0768 protein 1.7 128499 AA487503 Hs.100636 ESTs 1.698 120780 AA342337 Hs.241569 ESTs; Modtly smlr to I! ALU SUBFAMILY SQ WARNING ENTRY I! [H.sapiens] 1.697 132920 L06133 Hs.606 ATPase; Cu++ transporting; alpha polypeptide (Menkes syndrome) 1.696 135037 U77948 Hs.184122 general transcription fador II; i 1.696 110024 H11297 Hs.31050 ESTs 1.695 134415 AA329274 Hs.82911 protein tyrosine phosphatase type IVA; member 2 1.694 102223 U24685 Hs.148226 Human anti ' -B cell autoantibody IgM heavy chain variable V-D-J region (VH4) gene; done E11 ; VH4-63 non-produdive rearrangement 1.694 126712 AA205862 Hs.7942 ESTs 1.694 101507 M27492 Hs.82112 interleukin 1 receptor; type I 1.692 106291 AA435551 Hs.30824 ESTs 1.691 116826 H58691 Hs.8215 ESTs; Weakly similarto double-stranded RNA-binding nudear protein DRSBP76 [ saptens] 1.69 135339 D59269 Hs.127842 Homo sapiens mRNA full length insert cDNA done EUROIMAGE 783648 1.69 118250 N62602 yz75b6.s1 Soares_multiple_sderosis_2NbHMSP Homo sapiens cDNA done IMAGE288851 3' similarto contains Alu repetitive element;, mRNA sequence 1.689 106470 AA450116 Hs.186180 ESTs 1.688 108203 AA057678 Hs.63408 ESTs 1.687 119748 W70313 Hs.126906 ESTs 1.686 116576 D51228 Hs.79404 neuron-spedfic protein 1.683 123035 AA481392 Hs.105166 ESTs 1.683 126668 AA011616 Hs.184086 ESTs 1.681 101512 M28209 Hs250716 RAB1; member RAS oncogene family 1.678 102704 U76638 Hs.54089 BRCA1 associated RING domain 1 1.677 126218 AA256386 Hs.13649 Novel human gene mapping to chomosome 13; similarto rat RhoGAP 1.676 111180 N67277 Hs.9403 ESTs 1.676 105937 AA404342 Hs.173531 ESTs 1.675 114118 Z38520 Hs.175930 ESTs 1.675 109203 AA190634 Hs.108787 endoplasmic reticulum membrane protein 1.675 125245 W86608 Hs.7243 ubiquitin specific protease 24 1.675 102906 X06956 Hs.75318 tubulin; alpha 1 (testis spedfic) 1.675 125914 AA262925 Hs.180034 deavage stimulation fador; 3' pre-RNA; subunit 3; 77kD 1.674 134294 U63289 Hs.81248 CUG triplet repeat; RNA-binding protein 1 1.674 109742 F10108 Hs.183333 ESTs 1.673 134674 D63876 Hs.87726 KIAA0154 protein 1.673 104079 AA402937 Hs.103238 ESTs 1.671 107554 AA001386 Hs.59844 ESTs 1.671 132439 AA243139 Hs.4863 Homo sapiens done 25088 mRNA sequence 1.669 124515 N58172 Hs.109370 ESTs 1.668 124300 H92575 Hs.105959 ESTs; Weakly similar to !! ALU SUBFAMILY SQ WARNING ENTRY I! [H.sapiens] 1.668 126809 AA743475 Hs.171693 ESTs 1.667 106095 AA419547 Hs.11713 ESTs 1.664 101754 M77142 Hs.239489 TIA1 cytotoxic granule-associated RNA-binding protein 1.663 105188 AA192306 Hs.23926 ESTs 1.663 113582 T91371 Hs.16824 EST 1.661 119559 W38197 Accession not listed in Genbank 1.661 119961 W87535 Hs.59015 ring finger protein 9 1.657 123255 AA490890 Hs.105273 ESTs 1.657 111078 N59230 Hs.186574 ESTs 1.655 113082 T40528 Hs.8246 ESTs 1.654 119589 W44692 Hs.124177 ESTs 1.652 104308 D53639 Hs.77904 ribosomal protein S26 1.65 103073 X59417 Hs.74077 proteasome (prosome; macropain) subunit; alpha type; 6 1.65 124424 N35314 Hs.107265 ESTs 1.65 128890 AA096157 Hs.182364 ESTs; Weakly similar to 25 kDa trypsin inhibitor [H.saptens] 1.65 119400 T92767 ye27d06.s1 Stratagene lung (#937210) Homo sapiens cDNA done IMAGE:1189553', mRNA sequence. 1.65 131631 AA486868 Hs.29802 slit (Drosophila) homolog 2 1.65 118229 N62339 Hs.180532 heat shock 90kD protein 1 ; alpha 1.649 118533 N67954 Hs.49413 ESTs 1.648 130666 AA476307 Hs.194035 KIAA0737 gene produd 1.647 103093 X60708 Hs.44926 dipeptidylpeptidase IV (CD26; adenosine deaminase complexing protein 2) 1.647 128667 U69140 Hs.103419 fasdculation and elongation protein zeta2 (zygin II) 1.646 112933 T15530 HS221439 ESTs 1.646 114546 AA056263 Hs.132747 ESTs 1.645 126705 AA579377 Hs.180532 heat shock 90kD protein 1 ; alpha 1.644 114399 AA007595 Hs.220937 ESTs 1.642 118836 N79820 Hs.50854 ESTs 1.64 100401 D85423 Homo sapiens mRNA for Cdc5, partial eds 1.64 105681 AA284865 Hs.171228 KIAA1040 protein 1.639 132526 AA460128 Hs.5074 similar to S. pombe dim1+ 1.639 133809 AA034002 Hs.76359 catalase 1.639 115968 AA447083 Hs.134522 ESTs 1.637 116370 AA521256 Hs.236204 ESTs; Moderately similar to NUCLEAR PORE COMPLEX PROTEIN NUP107 [R.norvegicus] 1.631 109644 F04477 Hs.204802 ESTs; Moderately similar to GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE; LIVER [Ksapiens] 1.627 103427 X97303 sapiens mRNA for Ptg-12 protein 1.627 132186 T33888 Hs.221040 KIAA1038 protein 1.626 131428 U17838 Hs26719 PR domain containing 2; with ZNF domain 1.626 126638 AA649257 Hs.188602 ESTs 1.625 114503 AA039568 Hs.188083 ESTs 1.625 121242 AA400857 Hs.97509 EST 1.625 122414 AA446885 Hs.99087 ESTs; Moderately similar to ZINC FINGER PROTEIN 141 [H.sapfens] 1.625 110632 H72344 Hs.171635 ESTs 1.624 111389 N95837 Hs.169111 ESTs; Weakly similar to L82A [D.melanogaster] 1.624 112449 R63802 Hs.124186 ring finger protein 2 1.623 113070 T33464 Hs.6298 ESTs 1.622 107229 D59284 Hs.34644 ESTs 1.618 132710 W93726 Hs.55279 protease inhibitor 5 (maspin) 1.617 124664 N94814 Hs.33540 ESTs; Weakly similar to KIAA0765 protein [H.sapiens] 1.617 130166 AA350690 Hs.151411 KIAA0916 protein 1.616 125040 T78451 Hs.199961 ESTs 1.615 132972 H39627 Hs.164967 ESTs; Weakly similar to I! ALU SUBFAMILY SB WARNING ENTRY !! [H.sapiens] 1.615 115873 AA433916 Hs.90093 heat shock 70kD protein 4 1.611 120408 AA235045 Hs.190151 ESTs 1.61 120934 AA383773 Hs.191500 ESTs 1.61 115259 AA279071 Hs.13453 splicing fador3b; subunit 1; 155kD 1.609 134330 D20113 Hs.8185 ESTs; Highly similar to CGI-44 protein [H.sapiens] 1.607 115117 AA256492 Hs.49007 poly(A) polymerase 1.606 125162 W44682 Hs.109896 ESTs 1.605 103946 AA285246 Hs.111650 ESTs; Weakly similar to Prt1 homolog [H.saptens] 1.604 133389 AA166917 Hs.72639 ESTs 1.603 115528 AA342301 Hs.53929 ESTs; Weakly similar to I! ALU CUSS B WARNING ENTRY !! [H.sapiens] 1.602 129704 W81301 Hs.12064 ubiquitin specific protease 22 1.602 109313 AA206800 Hs.86276 ESTs; Moderately similar to zinc finger protein dp [H.sapiens] 1.601 130457 U58091 Hs.155976 cullin 4B 1.6 123076 AA485211 Hs.190046 ESTs 1.6 115113 AA256460 Hs.44610 ESTs 1.6 117731 N46433 Hs.46609 ESTs 1.6 123344 AA504338 Hs.171857 ESTs 1.599 131798 X86098 Hs.3238 adenovirus 5 E1 A binding protein 1.597 125370 AA256743 Hs.151791 KIAA0092 gene produd 1.596 114918 AA236813 Hs.72324 ESTs; Highly similar to unknown [H.saptens] 1.596 114807 AA160805 Hs.199832 ESTs 1.596 105103 AA151593 Hs.10130 ESTs 1.594 125004 T60120 yb68f02.s1 Stratagene ovary (#937217) Homo sapiens cDNA clone IMAGE763473', mRNA sequence. 1.592 105658 AA282914 Hs.10176 ESTs 1.589 110455 H52172 yt85e8.s1 Soares_pinea|_gland_N3HPG Homo sapiens cDNA clone IMAGE23111 3' similar to contains Alu repetitive element;, mRNA sequence 1.589 119780 W72967 Hs.191381 ESTs; Weakly similarto hypothetical protein [H.sapfens] 1.587 126983 AA211537 zn55d01 ,r1 Stratagene muscle 937209 Homo sapiens cDNA done IMAGE.562081 5\ mRNA sequence. 1.586 134675 AA250745 Hs.87773 protein kinase; cAMP-dependent; catalytic; beta 1.584 105431 AA252033 Hs.15036 ESTs; Weakly similar to !! ALU SUBFAMILY J WARNING ENTRY !! [H.sapiens] 1.584 120187 Z40251 Hs.56974 ESTs 1.584 115830 AA428137 Hs.86434 ESTs 1.581 135069 AA456311 Hs.93961 ESTs; Weakly similar to !! ALU CUSS A WARNING ENTRY !! [ sapiens] 1.581 122997 AA479295 Hs.106290 Kelch motif containing protein 1.581 119707 W67569 Hs.44143 ESTs; Weakly similar to SNF2alpha protein [H.sapiens] 1.58 131934 D80948 Hs.34922 ESTs 1.58 106141 AA424558 Hs.9302 phosducin-like 1.58 115271 AA279422 Hs.5724 ESTs 1.579 131468 R27598 Hs.27197 KIAA0797 protein 1.577 131165 R98173 Hs23763 Max-interacting protein 1.575 117273 N21680 Hs.43047 ESTs 1.575 101569 M33772 Hs.182421 troponin C2; fast 1.575 116127 AA459703 Hs.79070 v-myc avian myelocytomatosis viral oncogene homolog 1.575 120022 W90625 Hs.58432 ESTs 1.575 117512 N32157 Hs.82207 ESTs 1.574 106511 AA452865 Hs.206713 UDP-Gal:betaGlcNAc bete 1 ;4- galadosyltransførase; polypeptide 2 1.573 116415 AA609204 Hs.27973 KIAA0874 protein 1.573 127879 AA810215 Hs.189079 ESTs 1.571 125211 W72798 Hs.103177 ESTs; Wkly smlr to cDNA EST EMBLD32579 comes from this gene [C.elegans] 1.571 114746 AA135638 Hs.223756 ESTs 1.571 122698 AA456112 Hs.99410 ESTs 1.57 116765 H12636 Hs.121585 ESTs; Weakly similar to reverse transcriptase [H.sapiens] 1.568 130895 AA609828 Hs.21015 ESTs; Highly similar to tetracycline transporter-like protein [M.musculus] 1.568 114338 Z41366 Hs.40109 KIAA0872 protein 1.567 111005 N53076 Hs.5996 ESTs 1.567 128135 AA913491 Hs.189143 ESTs; Modrtiy smlr to !! ALU SUBFAMILY J WARNING ENTRY !! [H.sapiens] 1.567 112046 R43365 Hs22273 ESTs 1.566 132160 AA281770 Hs.184081 seven in absentia (Drosophila) homolog 1 1.566 111568 R10153 Hs.20561 ESTs 1.566 127775 H04106 Hs.179902 ESTs; Weakly similar to NG22 [H.saptens] 1.566 115359 AA281936 Hs.88914 ESTs 1.566 121845 AA425734 Hs.165066 ESTs; Weakly similar to hypothetical protein [H.sapiens] 1.565 127854 AA769520 ESTs; Weakly similar to REGUUTOR OF MITOTIC SPINDLE ASSEMBLY 1 [H.sapiens] 1.564 120287 AA187679 Hs.111114 ESTs 1.563 114940 AA243012 Hs.75928 ESTs 1.562 126716 AA031700 Hs251962 ESTs 1.562 134161 U97188 Hs.79440 IGF-II mRNA-binding protein 3 1.561 125390 H95094 Hs.75187 translocase of outer mitochondrial membrane 20 (yeast) homolog 1.561 115334 AA281244 Hs.65300 ESTs 1.559 113721 T97931 Hs.18190 EST 1.558 114895 AA236177 Hs.76591 KIAA0887 protein 1.558 119341 T62571 Hs.146388 microtubule-associated protein 7 1.558 108012 AA039616 Hs.61933 ESTs 1.558 130335 AA156499 Hs.8454 protein kinase; cAMP-dependent; regulatory; type II; alpha 1.557 134351 R82074 Hs.82109 syndecan 1 1.557 133300 D51401 Hs.70333 ESTs 1.553 106920 AA490899 Hs24462 ESTs 1.553 118744 N74075 Hs.94293 EST 1.552 126489 W20016 Hs.144228 ESTs; Weakly similar to ZINC FINGER PROTEIN 83 [H.sapiens] 1.55 115913 AA436720 Hs.65487 ESTs 1.55 107868 AA025234 Hs.61260 ESTs 1.55 134520 N21407 Hs.257325 ESTs 1.55 109703 F09684 Hs.24792 ESTs; Weakly similar to ORF YOR283w [S.cerevisiae] 1.55 120288 AA187938 Hs.55189 ESTs; Weakly similar to F25B5.3 [C.elegans] 1.548 106356 AA443277 Hs.31034 peroxisomal biogenesis fador 11 A 1.548 129460 AA235627 Hs.11171 APG5 (autophagy 5; S. cerevisiae)-like 1.547 133950 D11961 Hs.77823 ESTs 1.546 128172 AI400862 Hs.142607 ESTs 1.546 114162 Z38909 Hs.22265 ESTs 1.545 101803 M86546 Hs.155691 pre-B-cell leukemia transcription fador 1 1.544 113617 T93630 Hs.17207 ESTs 1.542 104896 AA054228 Hs.23165 ESTs 1.541 114477 AA032013 Hs.144260 EST 1.54 110731 H98653 Hs.188006 KIAA0878 protein 1.54 130367 Z38501 Hs.8768 ESTs; Wkly smlr to I! ALU SUBFAMILY SQ WARNING ENTRY I! [H.sapiens] 1.538 130539 L07044 Hs.250857 Homo sapiens calcium calmodulin-dependent protein kinase II mRNA; partial eds 1.538 134921 W60186 Hs.169487 Kreisler (mouse) maf-related teudne zipper homolog 1.537 130583 W24957 Hs.16281 ESTs; Moderately similar to similar to C.elegans protein encoded in cosmid T20D3 [H.sapfens] 1.537 133723 AA088851 Hs.75744 S-adenosylmethionine decaiboxylase 1 1.537 106450 AA449469 Hs.11859 ESTs 1.536 104120 AA429838 Hs.89519 KIAA1046 protein 1.536 100533 HG1879-HT1919 Ras-Like Protein Tc10 1.535 130664 R09049 Hs.17625 ESTs 1.535 127122 AA279153 Hs.190049 ESTs 1.535 134264 T03391 Hs.8087 ESTs 1.535 132319 AA418662 Hs.44625 ESTs 1.535 115465 AA286941 Hs.43691 ESTs 1.533 125003 T59442 Hs.100445 ESTs 1.532 102273 U30888 Hs.75981 ubiquitin spedfic protease 14 (tRNA-guanine transglycosylase) 1.532 121875 AA426299 Hs.98510 ESTs 1.532 114366 Z41747 Hs.469 succinate dehydrogenase complex; subunit A; flavoprotein (Fp) 1.531 132944 AA054515 Hs.6127 ESTs; Weakly similar to prostate-specific transglutaminase [H.sapiens] 1.53 111199 N68210 Hs.29822 ESTs 1.53 113494 T88878 Hs.258738 ESTs 1.529 129515 AA490882 Hs.112227 ESTs 1.528 133124 AA156049 Hs.65490 ESTs 1.528 104785 AA027163 Hs.7942 ESTs 1.526 105595 AA279408 Hs.25866 ESTs 1.526 130198 U67156 Hs.151988 mitogen-activated protein kinase kinase kinase 5 1.526 114297 Z40758 Hs.173091 DKFZP434K151 protein 1.525 112876 T03488 Hs.4842 ESTs 1.525 127500 AA525014 Hs.162115 ESTs 1.525 120519 AA258585 Hs.129887 cadherin 19 (NOTE: redefinition of symbol) 1.525 119859 W80702 Hs.58461 ESTs 1.525 129944 L00389 Hs.1361 cytochrome P450; subfamily I (aromatic compound-indudble); polypeptide 2 1.524 118864 N89670 Hs.42148 ESTs; Weakly similar to Su(P) [D.melanogaster] 1.523 123964 C13961 Hs.210115 EST 1.523 111676 R19414 Hs.166459 ESTs 1.522 128332 AI079523 Hs.134173 ESTs 1.522 130455 X17059 Hs.155956 N-acetyltransferase 1 (arylamine N-acetyltransferase) 1.521 125181 W58461 Hs.12396 ESTs 1.521 127093 AA768241 oa72d02.s1 NCI_CGAP_GCB1 Homo sapiens cDNA done IMAGE:13177953', mRNA sequence. 1.521 132156 AA157401 Hs.4113 S-adenosylhomocysteine hydrolase-like 1 1.521 125303 Z39821 Hs.107295 ESTs 1.52 132697 AA281951 Hs.5518 Homo sapiens mRNA; cDNA DKFZp566J2146 (from done DKFZp566J2146) 1.52 117086 H93135 Hs.41840 ESTs 1.519 113355 T79203 Hs.14480 ESTs 1.518 108621 AA101811 Hs.69506 ESTs 1.518 109384 AA219172 Hs.86849 EST 1.518 128510 X94703 Hs.100816 RAB28; member RAS oncogene family 1.517 132968 N77151 Hs.61638 myosin X 1.515 117035 H88798 Hs.41182 ESTs 1.515 116781 H22985 Hs.52132 ESTs 1.513 108677 AA115629 Hs.118531 ESTs 1.513 130214 H78003 Hs.15266 ESTs 1.513 134700 AA481414 Hs.8868 golgi SNAP receptor complex member 1 1.512 116618 D80783 Hs.45224 ESTs 1.508 126257 N99638 tumor necrosis fador receptor superfamily; member 10b 1.508 125859 AA806808 Hs.118797 ubiquitin-conjugating enzyme E2D 3 (homologous to yeast UBC4/5) 1.508 113837 W57698 Hs.8888 ESTs 1.507 114317 Z41038 Hs.469 sucdnate dehydrogenase complex; subunit A; fiavoprotein (Fp) 1.507 100311 D50640 Hs.184653 phosphodiesterase 3B; cGMP-inhibited 1.507 126802 AA947601 Hs.97056 ESTs 1.506 128661 R82837 Hs.103329 KIAA0970 protein 1.506 134194 AA233231 Hs.79828 ESTs 1.506 108953 AA149652 Hs.42128 ESTs 1.504 133240 D31161 Hs.68613 ESTs 1.502 132671 X76302 Hs.54649 putative nucleic add binding protein RY-1 1.501 132609 Z48923 Hs.53250 bone mo phogenetic protein receptor; type II (serine/threonine kinase) 1.501 105574 AA278678 Hs.258567 ESTs 1.5 113718 T97782 Hs.256268 ESTs 1.5 127824 AI208365 Hs.127811 ESTs 1.5 130132 U55936 Hs.184376 synaptosomal-assodated protein; 23kD 1.5 127394 AA453224 ESTs; Weakly similar to !! ALU SUBFAMILY J WARNING ENTRY !! [H.saptens] 1.5 100485 HG1111-HT1111 Ras-Like Protein Tc21 1.5 101078 L04510 Hs.792 ADP-ribosylation factor domain protein 1 ; 64kD 1.5 128611 AA456845 Hs.102471 KIAA0680 gene produd 1.5 TABLE 12A shows the accession numbers for those primekeys lacking unigenelD's for Table 12. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column. Pkey: Unique Eos probeset identifier number CAT number. Gene duster number Accession: Genbank accession numbers Pkey CAT number Accession 108536 119811 AA084524 AA339253 AW966289 117040 46956J AW9706 0AA503323 H89218AF086031 H89112 100782 18457J AA355435 NM_001516 Z30093 T28405 AW949486 AA461142 AA410532 AI652073 AA521208 AI970141 AI968234 AI026102 AA713583 AW135876 AA936614 AA770300 AI242635 AA377033 AW960263 AW607683 AI273603 AA410287 AI040513 AA460838 AI803916 AW294095 AW449680 AW798677 AW675048 BE542116 AL120521 100819 3022J L34840 NM_003241 U31905 AI546931 AI791616 AI973065 AI792321 AI546937 AI685880 AI732835 AI682360 AA420653 AA564047 A1682323 A1824614 AI659889 AI680052 A1970887 AI623108 AA420692 AI418074 AA631018 AI810595 AW291463 AW449930 AI668908 AI970818 100824 5 36 AI393237 AI521317 AI761348 AF025841 D43968 AW994987 L34598 AF025841 D89789 D89788 D89790 AW998932 AI971742 AI310238 X90976 AW139668 AW674280 AI365552 AA877452 AV657554 C75229 AA376077 AI798056 AW609213 W25586 H30149 BE075089 BE075190 AW580858 H99598 AA425238 AA133916 AW363478 BE158121 BE158127 AW467960 BE158135 BE158126 BE158145 N92860 AA847246 AI961688 AI361423 AA878154 AA043767 AI863712 AI559226 AW339007 AI371266 AI368901 AA046624 AA134739 AW449154 AA130232 AI458720 AA962511 AI700627 R70437 AW004008 AA045229 AI671572 H99599 AA043768 AI685454 AI871685 N29937 X90977 AA524240 AI142114 AI825750 AI567805 AI631365 AI347893 AA134740 F20669 AA046707 AW793216 AW963298 AW959380 AA363265 AI784593 AI268201 R69451 AV657618AI695588 125004 264197J BE312163 AJ230798 AA374482 AI926059 AA622653 AI860704 BE139185 AW296884 T60238 T60120 102313 27608J U33921 AI190489 AA573311 102337 553_1 AI814663 AA806761 AA765241 AA019317 AA092255 AA035405 T85079 AA890151 AI373959 T85080 BE153728 AA740848 BE080682 AL048137 AW182316 AI699468 AW274481 AW407538 AA306562 AW950024 AW949943 AL045703 AW843196 W25132 BE612794 AA304266 AW958054 H25673 AV646563 AV646573 BE172990 AW593488 AA385181 AA164998 AI246476 AA345406 AI277554 AA134749 AA856624 BE613247 AA299003 AL048138 AA028121 T92510 AI923835 AW020440AI401594AI889401 N93290 AA044247 AA028100AI582845AA811151 AI741811 AI925878 AA448277 AA172221 AI214783 BE220793 AA022746 AI082882 AA022849 AI928385 AA573472 AI420686 AW072902 AI799493 AI873506 AI468977 AH 92079 AI468976 AA044272 AW015701 AW316979 AA933042 AA609017 AI318393 AI424571 AI934945 AA172023 AW050917 AA846180 AA134748 AI003947 AI766769 AW006697 AA653517 AW575680 AI474214 AA401478 U36922 AA927064 AA868000 D62654 T91745 AW500202 AA194764 AA746346 AA130464 AW117498 AA054526 N26432 H02534 H04964 AW303367 BE300931 AI218049 AI208073 AW182749 AA983630 AI147585 AA194765 AA054534 AA922720 AI436585 AI346535 AA134269 AA280923 AA897422 AA019559 AW274010 AA035406 AA917879 H99327 W32908 AI216046 AW496823 AA019414 H82288 W35284 AI936621 AI767113 AA866177 AW367874 H82398 AF032885 AW300151 AW467069 AA809346 AI188507 AI494178 AA872752 AI631631 U02310 NM--002015 AA815006 AI382453 AW197658 AI761654 AI804396 AI382221 AI813640 AI439635 AI523901 AW517242 AI221705 AW298104 AW204560 AW573095 AW028783 AW014650 AI766744 AI808294 AI698758 AI041809 AI766667 AI479103 AA872797 AA769305 AA765080 AA334166 AI472322 124704 292319 1 R07335 R07640 116988 185904 1 AW953679 AW953680 AA244436 H82527 AA361046 AA244483 H82526 124825 330773J AA501669 R52088 110455 46874J H52576 AF085971 H52172 126257 182217 1 N99638 AW973750 AA328271 H90994 AA558020 AA234435 N59599 R94815 125624 154135 AW968363 AA465492 R34539 AA165411 104038 264235 1 AA374532 AA421255 103427 43892J BE514383 AA071273 AW247987 AW673286 BE312102 AW749824 BE071985 AW577383 BE071945 BE072005 AW577355 BE071965 AW239231 BE072000 BE071960 AW577360 AW749830 AW373020 X97303 AW999522 BE000192 BE562219 BE266655 BE264970 104142 113242 1 AA074713 AA447006 127093 47721J AW977549 AA256038 AL365415 AW500455 AA768241 AW968097Z17849 AA256104 125873 10492J AW271838 AL133605 C01646 H29959 AA999896 D60676 AW999454 AW961176 AA315244 H14437 AW386118 N46512 AW272021 AI768516 BE466421 AI082809 AI804454 AA905101 AW173368 N38942 AW614169 AI080483 N29489 AI500550 AA994475 AA614464 AA707368 AA593145 AA569473 AW627815 AI828244 N63226 N42300 125954 4457J NM_016353 AB023584 W44753 R09585 AA382865 R23772 AI814257 AA974046 AK001608 AI935638 AW440609 AI420022 AA777386 AA806969 AI554876 AI584006 AI688556 AI688634 AI697997 AI014540 AI806683 AI741202 AW263154 AW297238 AI149951 AI589076 AW082158 AW614265 AA931887 AA781969 R09490 AA484643 AI207121 AI088390 AI538065 AI619547 AI741925 AI702846 H40846 R93943 AW747979 AA461348 U30163 AA326023 AI535992 AW242870 AI244025 AI222558 W38425 AW473630 AI624599 AI921226 AI683152 AI096458 AI123822 AW170802 C16447 AI337674 D25726 AW339366 AW771259 AA461174 125992 1589048J H48372 W01626 127210 15307_6 AA305278 AA223833 110924 6443J AW058463 AF195766 AA680145 T86901 W60373 W60281 NM_007222 AF106862 AI000795AA167188 AW884503 AW891313 AW891332 AW891312 AI984924 AI123518 N75170 AA131614 H25330 AI913358 AI742277 W25576 R58771 AW445159 AW888628 AW888627 AW274674 AI088482 N52314 N34282 AW001769 AI338943 T66784 AI288963 AW468676 AW237528 H25289 N71690 AA610128 AI143458 AI082599 N49144 AA854773 AW663411 AW610151 N47938 AW601626 AA167189 AA918304 AA805205 BE069496 AA652836 BE069499 AI699298 AW249926 AW888578 BE567635 T10726 AW604715 D54245 D53062 D55610 D55555 AA301376 AI133498 N77788 AI936320 AW090734 AI269977 N50828 AA550814 AI421993 AI005384 N50813 D60292 D59349 AA131710 D81698 D81699 127263 232161J AA331156 AA331157 AA331155 135197 29440J U76456 NM_003256 AF057532 AA193414 AW293304 AW963378 AA313095 AI359841 AI969312 AI080163 AW448926 AI671136 BE466399 AI637967 AI671873 AW196583 AW071635 AI634427 AW296872 AW292470 AA193650 127394 304844J BE161832 AA453224 AA485772 126879 1860_2 D90391 M55575 AI652268 AA719776 126983 171841J AA524886 AW971347 AA211537 120470 188975J AW971327 AA524988 AW628653 AA251797 127854 443883J AW976796 AA769520 121367 280429J AA432071 AA405648 AW000908 T16347 106320 6435J AB028957 AL120001 AI267678 H10928 R19844 AW970334 AA393182 F05472 F11711 H09908 N50250 AI815411 BE463679 D61468 AW970253 D60889 C15548 D61011 D60867 AI815795 AA534831 D81386 AW235039 AI382158 D81174 AA416899 AA852310 H09789 H10929 H09813 F09369 R44721 D51515 Z38456 R14004 T66255 F12148 F12139 AW351702 M85350 AI018713 AW972450 AW972645 AA514964 T66172 F09785 F09776 AA436608 T05327 T07118 AA339352 115479 201515J AW301608 N46706 AA649093 AA287595 AW811753 AA287596 N39260 101026 11075 1 NM_001874 J04970 T91426 AW205201 T84979 AA255727 AA847837 R02164T91339 AV651884 AV651835 AV651350 AV650118 AV651338 A1272002 AI367796 AA830651 AA262112 AW151198 100401 24827J AU076696 AA219720 AL135197 AA305877 N56376 AA318063 AA130725 AW954903 BE541230 AW383312 U86753 D85423 AI679458 AI122932 AB007892 AI583919 BE160134 F08104 R34903 F13440 AA095444 AA262453 AA191036 R17895 T81266 BE149776 AI279537 AI143113 AA361072 AW959030 AW268817 AA811533 BE275179 AI221677 T65147 R49293 AA249176 BE000290 AA768053 F09494 BE092645 BE172099 Z41177 AA044750 AI909768 BE140795 BE140574 AW845210 AW752452 BE243244 AA843664 AI300080 BE169032 AW189979 BE004869 AA621872 AI951772 AI678897 AI926598 N62813 AI350912 AW608791 AI309602 AI983138 AW875592 AI655073 AW875626 AA130606 AI370827 C75528 C75554 AW263335 AI344426 BE004788 AA576220 AA604824 AI431405 AA749378 R38882 AW955075 AA173821 C75657 AA219672 AW768408 R43141 AI431414 AA483343 AI673792 T17294 AW770187 N74285 AI476404 AI088288 AA654152 AW974864 BE617311 BE243328 BE168049 130542 28089_3 U64675 AW167507 AW167508 BE218568 AA779360 W85722 AL044843 BE159404 AF012086 AW898611 AW898610 BE159405 BE092191 AW890826 AW369841 AW368064 AW606702 AL044731 R82691 AA419346 AA416558 H96045 AL040450 AI640531 AI808434 AL046613 AW855784 AW362469 AL048881 AL049015 AA094272 AA888908 AA417294 AW237786 R59793 AL044916 D82402 AI216854 AI079342 H96406 AL037845 AI915900 AA972133 AI478783 T31074 Z21135 Z21396 AA352182 R13918 AA430178 C17811 AI371824 AI742256 AA926801 N79156 AA350610 AA081971 N83639 R35544 AA312292 AW952080 N42322 AA171957 AA565297 R89207 AA504106 AI630782 AA826482 AI301579 T36241 AW966618 Z28426 AL043480 AI124636 AA393449 T19504 AW887823 AI289814 N53979 AL043571 AI632764 AI859613 AI986308 AI683212 AI984499 AI133258 C05898 AW512761 AI041260 BE466240 Z19161 AI351190 N67549 AI373374 AA400873 AW440914 AW514879 AA770146 AI358754 R51113 AI283773 AA649886 T30543 D54358 R37750 T03358 T15451 T15880 AA999689 N67396 AI056289 T85597 N62441 R89099 R00035 T85596 R61335 R00128 N63359 AI535964 100485 30576_2 AI207768 M31468 NM_012250 W01322 AA253280 AA253233 AA293148 AW582106 R79880 AA459547 AA363459 AA234396 N31669 H44468 AA434587 AW363088 AW993541 108345 112277_6 AA070906 AA070934 100522 19669J X51501 NM_002652 Y10179 J03460 AI791618 AI821473 AA916588 AA564296 AA916110 AI972286 AI420470 AI568790 AI597724 AW205207 AI659305 AI791620 AA532383 AI821475 AA526498 100533 32905J NM_012249 M31470 AL043108 AA262561 AA178883 T29433 AA313329 W48807 AW404323 AA453560 AW403227 H94816 W17101 AA165152 W23989 AA091310 100598 23902 AL121734 D54896 AA424269 BE242906 AA362118 BE018454 AI280348 AL048769 M35543 AA757734 AI128865 H20289 H23728 AI203445 H41481 H18237 H44081 H92839 AI928621 H75675 D51148 AI796198 AW390453 D55579 D54145 D53996 D54015 R37664 H17541 AA668681 T65061 R15867 AW468123 R16049 H69030 AA054226 H16070 F09655 R92144T03521 R05473 H92840 AA018186 R91707 102332 14745_3 U35637AA112989 Z19308 118250 genbank_N62602 N62602 103678 entre?_Z84483 Z84483 119400 genbank_T92767 T92767 119559 entre*_W38197 W38197 MISSING AT THE TIME OF PUBLICATION TABLE 13: shows genes, including expression sequence tags, up-regulated in prostate tumor tissue compared to normal prostate tissue as analyzed using Affymetrix/Eos Hu02 GeneChip array. Shown are the ratios of "average" normal prostate to "average" prostate cancer tissues. Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD: Unigene number Unigene Title: Unigene gene title R1: Background subtraded normal prostate : prostate tumor tissue Pkey ExAccn UnigenelD Unigene Title R1 333516 CH22 FGENES.173J 0.028 337954 CH22_EM:AC005500.GENSCAN.96-3 0.029 332496 R73299 Hs.204354 ras homolog gene family; member B 0.03 337944 CH22 EM.AC005500.GENSCAN.89-7 0.033 334111 CH22 FGENES.330J0 0.033 333657 CH22 FGENES241 2 0.034 327718 CH.04 hsgi|6525284 0.034 336355 CH22_FGENES.817_5 0.035 322011 AL137354 EST cluster (not in UniGene) 0.035 336377 CH22_FGENES.821_5 0.036 300254 AW079607 Hs.188417 ESTs; Weakly similar to ZnT-3 [H.saptens] 0.037 330096 CH.19_p2 gi|6015278 0.037 335191 CH22 FGENES.507_6 0.038 334040 CH22 FGENES.322_8 0.039 333586 CH22 FGENES204 2 0.04 333295 CH22 FGENES.132 2 0.042 313326 AI088120 Hs.122329 ESTs 0.043 329517 CH.10_p2 gi|3983513 0.043 333403 CH22 FGENES.144_21 0.043 335226 CH22 FGENES.513 11 0.044 335976 CH22 FGENES.652J1 0.045 333637 CH22 FGENES.229 2 0.046 334582 CH22 FGENES.407_5 0.046 336437 CH22 FGENES.826_4 0.047 337461 CH22_FGENES.782-1 0.047 302892 N58545 Hs.6975 histone deacetylase 3 0.049 338689 CH22 EM.AC005500.GENSCAN.475-3 0.049 334721 CH22_FGENES.421_32 0.049 305867 AA864572 EST singleton (not in UniGene) with exon hit 0.049 335498 CH22 FGENES.571_7 0.05 311596 AI682088 Hs223368 ESTs 0.05 326959 CH21 hsgi|6469836 0.051 311688 AW025661 HS240090 ESTs 0.052 317298 AI922374 Hs.158549 ESTs 0.052 332984 CH22_FGENES.54_6 0.052 321039 AW247083 EST duster (not in UniGene) 0.053 335844 CH22 FGENES.623 4 0.053 325371 CH.12 hs gi|5866920 0.054 335667 CH22 FGENES.590J8 0.054 333635 CH22 FGENES.228_2 0.054 336736 CH22 FGENES.110-2 0.055 335893 CH22 FGENES.635 1 0.055 333170 CH22 FGENES.94 5 0.055 329768 CH.14_p2 gi|6015501 0.055 334030 CH22_FGENES.320_2 0.055 323359 AA234172 Hs.137418 ESTs 0.055 300453 AW051431 Hs.113029 ribosomal protein S25 0.055 334262 CH22_FGENES.367_12 0.055 306590 AI000246 EST singleton (not in UniGene) with exon hit 0.055 331087 R22520 Hs23398 ESTs 0.055 338620 CH22 EM.AC005500.GENSCAN.450-18 0.056 339045 CH22_DA59H18.GENSCAN28-5 0.056 308023 AI452732 EST singleton (not in UniGene) with exon hit 0.057 339067 CH22 DA59H18.GENSCAN.33-3 0.057 335689 CH22 FGENES.596 4 0.057 339069 CH22 DA59H18.GENSCAN.33-5 0.057 338176 CH22 EM:AC005500.GENSCAN219-4 0.057 328159 CH.06 hs gi|5868065 0.058 335655 CH22 FGENES.590 6 0.058 336371 CH22 FGENES.820 1 0.058 336558 CH22 FGENES.842 3 0.059 337738 CH22 EM.AC000097.GENSCAN.100-4 0.059 334273 CH22 FGENES.369 2 0.059 335889 CH22 FGENES.633 3 0.059 327807 CH.05 hs gi|5867968 0.059 333315 CH22 FGENES.138 7 0.059 338825 CH22 DJ246D7.GENSCAN.4-6 0.06 337612 CH22 C20H12.GENSCAN.22-5 0.06 333897 CH22 FGENES293 4 0.06 335990 CH22 FGENES.655 4 0.06 334264 CH22 FGENES.367J5 0.06 338653 CH22_EM:AC005500.GENSCAN.460-39 0.061 322303 W07459 EST cluster (not in UniGene) 0.061 333498 CH22 FGENES.168 8 0.061 336522 CH22_FGENES.839_3 0.061 301357 AW295677 Hs.137840 ESTs; Moderately similar to HOMEOBOX PROTEIN SIX1 [Rsapiens] 0.062 305917 AA876469 Hs.181357 laminin receptor 1 (67kD; ribosomal protein SA) 0.062 336143 CH22 FGENES.705 5 0.063 333493 CH22_FGENES.168_2 0.063 332533 M99487 Hs.1915 folate hydrolase (prostate-spedfic membrane antigen) 1 0.063 325844 CH.16 hs gi|6552453 0.063 336402 CH22 FGENES.823 17 0.063 335767 CH22_FGENES.607_1 0.064 301893 T80334 EST cluster (not in UniGene) with exon hit 0.064 324019 AW177009 EST cluster (not in UniGene) 0.064 305801 AA845997 EST singleton (not in UniGene) with exon hit 0.064 335188 CH22 FGENES.507 3 0.065 337533 CH22 FGENES.828-2 0.065 333311 CH22 FGENES.138 3 0.065 335668 CH22_FGENES.590_19 0.065 306786 AI041589 EST singleton (not in UniGene) with exon hit 0.066 306365 AA962086 EST singleton (not in UniGene) with exon hit 0.066 306249 AA933840 EST singleton (not in UniGene) with exon hit 0.066 335018 CH22 FGENES.474 6 0.066 333594 CH22 FGENES210 3 0.066 333900 CH22 FGENES293 7 0.066 325207 CH.10 hs gi|6552430 0.067 329888 CH.15_p2 gi|6067149 0.067 326238 CH.17 hsgi|5867260 0.067 333658 CH22 FGENES241 4 0.067 335809 CH22_FGENES.617_6 0.068 307427 AI243437 EST singleton (not in UniGene) with exon hit 0.068 318428 AI949409 Hs.224583 ESTs 0.069 327005 CH.21 hs gi|5867664 0.069 330463 HG998-HT998 Sulfotransferase, Phenol-Preferring 0.069 333318 CH22 FGENES.138 10 0.07 333313 CH22 FGENES.138_5 0.07 325937 CH.16 hs gi|5867132 0.07 335663 CH22 FGENES.590 14 0.07 335349 CH22_FGENES.539_2 0.07 303396 AA224470 Hs.25426 ESTs; Weakly similar to unknown [H.sapiens] 0.07 332603 N66681 Hs.33470 ESTs 0.07 333310 CH22_FGENES.138_2 0.071 309924 AW340812 EST singleton (not in UniGene) with exon hit 0.071 336340 CH22_FGENES.814_15 0.071 308025 AI453365 Hs.172928 collagen; type I; alpha 1 0.071 306805 AI055966 EST singleton (not in UniGene) with exon hit 0.071 335499 CH22 FGENES.571 8 0.071 329669 CH.14_p2 gi|6272129 0.071 321666 D28390 EST duster (not in UniGene) 0.071 338174 CH22_EM:AC005500.GENSCAN219-2 0.072 336556 CH22_FGENES.842_1 0.072 305451 AA738105 Hs.140 immunoglobulin gamma 3 (Gm marker) 0.072 336684 CH22 FGENES.46-1 0.072 326943 CH.21 hsgi|6004446 0.073 333947 CH22 FGENES.303 1 0.074 333214 CH22 FGENES.104 5 0.074 331917 AA446572 Hs.174007 ESTs; Moderately similar to !!!! ALU SUBFAMILY J WARNING 0.074 339102 CH22_DA59H18.GENSCAN.44-9 0.074 328122 CH.06_hs gi|5868031 0.075 332250 N62712 Hs.226223 KIAA0618 gene produd 0.075 328506 CH.07 hsgi|5868471 0.075 331756 AA291468 Hs.98504 ESTs 0.075 335193 CH22 FGENES.507 8 0.076 317729 AA971718 Hs.128141 ESTs 0.076 304515 AA458708 Hs.251577 hemoglobin; alpha 2 0.076 313644 AI565766 Hs.124960 ESTs 0.076 326145 CH.17 hs gi|5867204 0.076 336394 CH22_FGENES.823_6 0.077 306516 AA989542 EST singleton (not in UniGene) with exon hit 0.077 300629 AA152119 Hs.155101 ATP synthase; H+ transporting; mitochondrial F1 complex; alpha subunit; isoform 1; cardiac muscle 0.077 333160 CH22 FGENES.91 2 0.077 337490 CH22_FGENES.799-5 0.077 305403 AA723748 EST singleton (not in UniGene) with exon hit 0.077 331747 AA281765 Hs.193689 ESTs 0.077 332792 CH22_FGENES.3_2 0.078 330513 M81057 Hs.180884 caiboxypeptidase B1 (tissue) 0.078 308905 AI859636 Hs.8102 ribosomal protein S20 0.078 337419 CH22 FGENES.759-4 0.078 333459 CH22 FGENES.157 8 0.078 334851 CH22_FGENES.440_3 0.078 329046 CH.X_hsgi|5868569 0.078 327879 CH.06_hs gi|5868142 0.079 305830 AA857665 EST singleton (not in UniGene) with exon hit 0.079 302928 AL137719 EST duster (not in UniGene) with exon hit 0.079 304321 AA136698 Hs.113029 ribosomal protein S25 0.079 326390 CH.19 hs gi|5867340 0.079 335230 CH22 FGENES.514 2 0.08 334622 CH22 FGENES.412 6 0.08 335331 CH22_FGENES.535_4 0.08 304753 AA578840 Hs.77961 major histocompatibility complex; class l; B 0.08 301863 AI418863 EST duster (not in UniGene) with exon hit 0.081 336561 CH22 FGENES.842 6 0.081 335611 CH22_FGENES.583_5 0.081 305060 AA635771 EST singleton (not in UniGene) with exon hit 0.081 306051 AA905130 EST singleton (not in UniGene) with exon hit 0.082 308289 AI571211 EST singleton (not in UniGene) with exon hit 0.082 334365 CH22 FGENES.378 13 0.082 335496 CH22_FGENES.571_4 0.082 332634 S38953 Human unidentified gene complementary to P450c21 gene; partial eds 0.082 337824 CH22_EM:AC005500.GENSCAN.13-18 0.082 335822 CH22 FGENES.619 7 0.082 334758 CH22 FGENES.428_7 0.082 309641 AW194230 Hs.253100 EST 0.082 333064 CH22 FGENES.75_7 0.083 338695 CH22 EM.AC005500.GENSCAN.477-25 0.083 331809 AA402482 Hs.97312 ESTs 0.083 326138 CH.17 hs gi|5867203 0.083 328304 CH.07_hs gi|6004478 0.083 330570 U60276 Hs.165439 arsA (baderial) arsenite transporter; ATP-binding; homolog 1 0.083 334305 CH22 FGENES.373_8 0.083 335885 CH22 FGENES.632_3 0.083 325839 CH.16 hsgi|6552452 0.083 333531 CH22_FGENES.175_18 0.084 330385 AA449749 Hs.31386 ESTs; Highly similar to secreted apoptosis related protein 1 [H.sapiens] 0.084 323305 AA811351 Hs25307 Homo saptens dona 24812 mRNA sequence 0.084 331698 Z39929 Hs.65843 ESTs 0.084 335888 CH22_FGENES.633_2 0.084 306008 AA894390 EST singleton (not in UniGene) with exon hit 0.084 334249 CH22_FGENES.365_15 0.084 318303 AW451197 Hs.113418 ESTs 0.084 330171 CH.02_p2 gi|6648220 0.084 336662 CH22_FGENES.41-1 0.085 320506 AI815668 Hs.157476 sud -associated nβurotrophic factor target 2 (FGFR signalling adaptor) 0.085 316974 AI740721 Hs.128292 ESTs 0.085 336492 CH22 FGENES.832 9 0.085 335750 CH22 FGENES.602 4 0.085 335676 CH22 FGENES.594 1 0.086 336093 CH22 FGENES.691 2 0.086 310932 AI933861 Hs.222852 ESTs 0.086 335160 CH22 FGENES.502 4 0.086 334306 CH22 FGENES.373 9 0.086 334793 CH22 FGENES.433 5 0.086 333936 CH22 FGENES.301 2 0.087 336413 CH22 FGENES.823 35 0.087 333775 CH22 FGENES272 6 0.087 335971 CH22_FGENES.652_4 0.087 301737 AI815981 EST cluster (not in UniGene) with exon hit 0.087 339101 CH22 DA59H18.GENSCAN.44-6 0.087 327612 CH.04 hsgi|6525283 0.087 326241 CH.17 hsgi|5867260 0.088 338386 CH22 EM:AC005500.GENSCAN.331-4 0.088 327762 CH.05_hsgi|5867961 0.088 305266 AA679772 EST singleton (not in UniGene) with exon hit 0.088 334359 CH22 FGENES.378 4 0.088 335500 CH22 FGENES.571 10 0.088 329687 CH.14_p2 gi|6117856 0.088 333654 CH22_FGENES240_2 0.088 324430 AA464018 EST cluster (not in UniGene) 0.088 325999 CH.16 hs gi|5867073 0.089 334832 CH22 FGENES.439 1 0.089 339115 CH22 DA59H18.GENSCAN.49-3 0.089 300896 AI916902 Hs.213882 ESTs 0.089 328784 CH.07 hs gi|5868309 0.089 335044 CH22 FGENES.480 1 0.089 329791 CH.14_p2 gi|6469354 0.089 333656 CH22 FGENES240 4 0.089 326180 CH.17 hs gi|5867211 0.089 333391 CH22 FGENES.144 6 0.089 338324 CH22_EM:AC005500.GENSCAN.306-3 0.089 305396 AA721052 EST singleton (not in UniGene) with exon hit 0.089 337483 CH22 FGENES.795-7 0.09 326424 CH.19_hsgi|5867369 0.09 306454 AA977992 EST singleton (not in UniGene) with exon hit 0.09 338893 CH22 DJ32I10.GENSCAN.7-6 0.09 327470 CH.02 hsgi|5867772 0.09 333165 CH22 FGENES.91_7 0.09 307155 AI186738 Hs.182426 ribosomal protein S2 0.09 330717 AA233926 Hs.23635 ESTs 0.09 335334 CH22 FGENES.535J0 0.09 335907 CH22 FGENES.636 2 0.09 333885 CH22_FGENES292_7 0.09 331034 N51868 Hs.31965 ESTs; Moderately similar to 40S RIBOSOMAL PROTEIN S20 [H.sapiens] 0.09 304660 AA534416 Hs.162185 ESTs 0.09 328217 CH.06 hs gi|5868096 0.091 336068 CH22 FGENES.684 13 0.091 302833 AA295381 Hs.44423 ESTs 0.091 328668 CH.07 hs gi|5868254 0.091 335309 CH22 FGENES.532_2 0.091 338481 CH22_EM:AC005500.GENSCAN.377-5 0.091 306286 AA936892 EST singleton (not in UniGene) with exon hit 0.091 305070 AA639783 EST singleton (not in UniGene) with exon hit 0.091 304870 AA594811 Hs.119122 : ribosomal protein L13a 0.091 303856 AA968589 Hs.944 glucose phosphate isomerase 0.091 323789 AI459812 Hs.170460 ESTs; Weakly similar to KIAA0990 protein [H.sapiens] 0.092 334910 CH22_FGENES.455 3 0.092 326382 CH.19_hs gi|5867327 0.092 332467 AA489630 Hs.119004 KIAA0665 gene produd 0.092 338534 CH22 EM.AC005500.GENSCAN.402-7 0.092 336449 CH22 FGENES.829 6 0.092 333709 CH22 FGENES250 24 0.092 336559 CH22 FGENES.842 4 0.092 333230 CH22 FGENES.107 10 0.093 333133 CH22 FGENES.83 9 0.093 334885 CH22_FGENES.451_11 0.093 330605 X02419 Hs.77274 plasminogen activator; urokinase 0.093 336392 CH22 FGENES.823 4 0.093 334083 CH22 FGENES.327 38 0.093 325469 CH.12 hs gi|6017034 0.093 331077 R09531 Hs.19039 ESTs 0.093 303701 AW500732 EST duster (not in UniGene) with exon hit 0.093 334218 CH22 FGENES.358 3 0.093 336542 CH22 FGENES.840 6 0.093 337151 CH22 FGENES.546-1 0.093 333642 CH22 FGENES231 2 0.093 336863 CH22 FGENES297-4 0.093 334680 CH22 FGENES.419 2 0.093 326365 CH.18 hsgi|5867297 0.093 338952 CH22 DJ32I10.GENSCAN23-22 0.093 337539 CH22 FGENES.832-4 0.094 333546 CH22 FGENES.180 2 0.094 335258 CH22 FGENES.518 3 0.094 336786 CH22 FGENES.168-19 0.094 321644 AI204177 Hs.237396 ESTs 0.094 335943 CH22 FGENES.646 17 0.094 327918 CH.06_hs gi|5868165 0.094 306398 AA970548 EST singleton (not in UniGene) with exon hit 0.094 335671 CH22 FGENES.592 3 0.094 335033 CH22_FGENES.475_11 0.094 338277 CH22 EM.AC005500.GENSCAN290-2 0.094 332061 AA504812 Hs.192824 early B-celi factor 0.094 305153 AA654582 Hs.77039 ribosomal protein S3A 0.094 333880 CH22_FGENES292_2 0.094 323940 AI864428 Hs.170880 ESTs 0.094 313779 AA648796 Hs.129771 I ESTs 0.095 323109 AA169345 EST duster (not in UniGene) 0.095 332930 CH22 FGENES.38 4 0.095 335368 CH22_FGENES.543_6 0.095 303887 R72672 Hs.193484 ESTs; Weakly similar to Similarity with yeast gene L3502.1 [C.elegans] 0.095 336223 CH22_FGENES.727_3 0.095 311280 AI767957 Hs.197737 ESTs; Weakly similar to Y38A8.1 gene produd [C.etegans] 0.095 337256 CH22,FGENES.648-3 0.095 308814 AI819263 EST singleton (not in UniGene) with exon hit 0.095 334659 CH22 FGENES.418.-7 0.095 335895 CH22_FGENES.635_3 0.095 321697 AW388061 Hs.4953 golgi autoantigen; golgin subfamily a; 3 0.095 336010 CH22_FGENES.668_8 0.096 302824 U21260 EST duster (not in UniGene) with exon hit 0.096 333612 CH22_FGENES217_7 0.096 304823 AA584837 EST singleton (not in UniGene) with exon hit 0.096 335665 CH22_FGENES.590_16 0.096 306518 AA989598 EST singleton (not in UniGene) with exon hit 0.096 335243 CH22 FGENES.516 0.096 335436 CH22 FGENES.559_5 0.096 300243 AI420256 Hs.161271 ESTs 0.096 332810 CH22_FGENES.7_12 0.097 308612 AI735634 EST singleton (not in UniGene) with exon hit 0.097 335818 CH22 FGENES.618_6 0.097 325838 CH.16 hsgi|6552452 0.097 337462 CH22 FGENES.795-6 0.097 336645 CH22 FGENES.26-1 0.097 337293 CH22 FGENES.675-1 0.098 329893 CH.15_p2gi|6525313 0.098 326533 CH.19 hsgi|5867441 0.098 334905 CH22_FGENES.452_20 0.098 306347 AA961144 EST singleton (not in UniGene) with exon hit 0.098 336676 CH22 FGENES.43-4 0.098 339166 CH22 DA59H18.GENSCAN.69-7 0.098 335774 CH22 FGENES.607 10 0.098 339216 CH22 FF113D11.GENSCAN.6-11 0.098 335311 CH22 FGENES.532 4 0.098 329632 CH.11_p2 gi|6729060 0.098 328595 CH.07 hs gi|5868224 0.098 326928 CH.21 hsgi|6456782 0.098 315234 AI079680 Hs.120770 ESTs 0.098 306082 AA908508 EST singleton (not in UniGene) with exon hit 0.098 305710 AA826544 EST singleton (not in UniGene) with exon hit 0.098 318540 T30280 EST cluster (not in UniGene) 0.099 337553 CH22_C4G1.GENSCAN.2-1 0.099 320951 AA344069 Hs.202699 neurexophilin 4 0.099 303845 T08033 EST cluster (not in UniGene) with exon hit 0.099 338981 CH22_DA59H18.GENSCAN2-5 0.099 321313 R87365 Hs.26058 ESTs; Weakly similar to p532 [H.sapiens] 0.099 328348 CH.07 hs gi|5868383 0.099 332203 H49388 Hs.102082 EST 0.099 301780 R07064 EST duster (not in UniGene) with exon hit 0.099 332095 AA608838 Hs.162681 EST 0.099 333227 CH22 FGENES.107 5 0.099 316442 AA760894 Hs.153023 ESTs 0.099 326001 CH.16 hs gi|5867073 0.099 334363 CH22 FGENES.378 11 0.099 338895 CH22 DJ32I10.GENSCAN.9-2 0.099 327460 CH.02_hs gi[6004455 0.099 332705 T59161 Hs.76293 thymosin; beta 10 0.1 307806 AI351739 EST singleton (not in UniGene) with exon hit 0.1 322800 F25037 Hs.225175 ESTs 0.1 304918 AA602697 EST singleton (not in UniGene) with exon hit 0.1 334327 CH22 FGENES.375 4 0.1 318359 AI097439 Hs.135548 ESTs 0.1 326644 CH20 hs gi|5867559 0.1 334454 CH22 FGENES.388 3 0.1 327959 CH.06 hs gi|5868210 0.1 323783 AA330586 Hs.131819 ESTs 0.1 309198 AI955915 Hs.248038 major histocompatibility complex; dass I; C 0.1 339265 CH22 BA354I12.GENSCAN.10-3 0.1 320576 AL049977 Hs.162209 Homo sapiens mRNA; cDNADKFZp564C122 (from done DKFZp564C122) 0.1 338132 CH22 EM.AC005500.GENSCAN200-2 0.1 333163 CH22 FGENES.91 5 0.101 337584 CH22_C20H12.GENSCAN.5-1 0.101 307588 AI285535 EST singleton (not in UniGene) with exon hit 0.101 336969 CH22 FGENES.378-2 0.101 327535 CH.02 hsgi|6525279 0.101 328732 CH.07 hsgi|5868289 0.101 336686 CH22 FGENES.46-3 0.101 335777 CH22 FGENES.607 13 0.101 332944 CH22 FGENES.47_3 0.101 333174 CH22 FGENES.95J 0.101 336380 CH22_FGENES.821_8 0.101 330571 U60800 Hs.79089 sema domain; immunoglobulin domain (Ig); cytoplasmic domain; (semaphorin) 4D 0.101 331789 AA398721 Hs.186749 ESTs 0.101 338915 CH22 DJ32I10.GENSCAN.12-1 0.101 334844 CH22 FGENES.439_24 0.101 336642 CH22 FGENES.23-4 0.101 334906 CH22 FGENES.452_21 0.101 333188 CH22_FGENES.98_8 0.101 300088 AW299993 EST duster (not in UniGene) with exon hit 0.101 329373 CH.X hsgi|6682537 0.102 331120 R46576 Hs.23239 ESTs 0.102 335856 CH22 FGENES.628J 0.102 331888 AA431337 Hs.98017 ESTs 0.102 333154 CH22 FGENES.89 4 0.102 335989 CH22_FGENES.655_2 0.102 304385 AA235602 EST singleton (not in UniGene) with exon hit 0.102 338016 CH22_EM:AC005500.GENSCAN.133-1 0.102 335190 CH22 FGENES.507 5 0.102 318595 T39486 Hs.6137 ESTs 0.102 333697 CH22_FGENES250_11 0.102 306526 AA989713 EST singleton (not in UniGene) with exon hit 0.103 328734 CH.07_hs gi|5868289 0.103 307294 AI205612 Hs.73742 ribosomal protein; large; PO 0.103 327424 CH.02 hs gi|5867751 0.103 335872 CH22 FGENES.630 3 0.103 333572 CH22 FGENES.189 1 0.103 334774 CH22_FGENES.430 6 0.103 338660 CH22 EM.AC005500.GENSCAN.462-1 0.103 326713 CH20 hsgi!5867595 0.103 333994 CH22 FGENES.310 18 0.103 335800 CH22 FGENES.613 4 0.103 318113 AI187943 Hs.132322 ESTs 0.103 337278 CH22 FGENES.665-1 0.103 336386 CH22 FGENES.822 6 0.103 334790 CH22_FGENES.432_15 0.103 303778 AW505368 EST duster (not in UniGene) with exon hit 0.104 336524 CH22_FGENES.839 5 0.104 328936 CH.08 hsgi|586850O 0.104 335102 CH22 FGENES.494 7 0.104 300935 AA513644 Hs.222815 ESTs; Weakly similar to Wiskott-Aldrich Syndrome protein [H.sapiens] 0.104 307581 AI284415 EST singleton (not in UniGene) with exon hit 0.104 317301 AW291683 Hs.226056 ESTs 0.104 335330 CH22 FGENES.535 3 0.104 337968 CH22 EM:AC005500.GENSCAN.103-2 0.104 335627 CH22 FGENES.584 7 0.104 336274 CH22 FGENES.762 2 0.104 334730 CH22 FGENES.424 5 0.105 334409 CH22 FGENES.383 6 0.105 327237 CH.01 hsgi|5867544 0.105 333321 CH22_FGENES.138_13 0.105 303181 AA452366 EST duster (not in UniGene) with exon hit 0.105 333738 CH22 FGENES261 2 0.105 338255 CH22_EM:AC005500.GENSCAN276-3 0.105 334282 CH22_FGENES.369_12 0.105 330190 CH.05_p2gi|6165182 0.105 310748 AW014249 Hs.158698 ESTs 0.105 338150 CH22 EM.AC005500.GENSCAN207-2 0.105 336719 CH22 FGENES.82-6 0.105 330228 CH.05_p2 gi|6013527 0.105 327801 CH.05_hsgi|5867924 0.105 330525 S75168 Hs.274 megakaryoeyte-assodated tyrosine kinase 0.105 334972 CH22_FGENES.468 2 0.105 335111 CH22 FGENES.494J9 0.106 334483 CH22 FGENES.395 5 0.106 328829 CH.07_hsgi|5868337 0.106 302753 M74299 EST duster (not in UniGene) with exon hit 0.106 334512 CH22 FGENES.398J0 0.106 330024 CH.16_p2 gi|6671908 0.106 321030 AI769930 Hs.233617 Homo sapiens (done B3B3E13) Huntington's disease candidate region 0.107 338410 CH22 EM.AC005500.GENSCAN.341-6 0.107 334353 CH22 FGENES.376_5 0.107 338276 CH22 EM.AC005500.GENSCAN.288-9 0.107 329053 CH.X hs gi|5868574 0.107 336560 CH22 FGENES.842_5 0.107 332158 AA621363 Hs.112980 EST 0.107 336447 CH22_FGENES.829_4 0.107 333703 CH22_FGENES250_17 0.107 326207 CH.17_hsgi|5867222 0.107 333232 CH22_FGENES.108_1 0.107 334802 CH22_FGENES.435_1 0.107 303784 AA704983 EST cluster (not in UniGene) with exon hit 0.107 338847 CH22 DJ246D7.GENSCAN.10-2 0.107 339407 CH22 DJ579N16.GENSCAN.1-9 0.108 337635 CH22 C20H12.GENSCAN.32-8 0.108 334650 CH22_FGENES.417_17 0.108 308511 AI687580 EST singleton (not in UniGene) with exon hit 0.108 333392 CH22 FGENES.144 8 0.108 325840 CH.16_hs gi|6552452 0.108 315044 AW205664 Hs.129568 ESTs 0.108 333298 CH22 FGENES.133 4 0.108 335157 CH22 FGENES.501 7 0.108 333305 CH22 FGENES.137 2 0.108 326379 CH.19 hsgi|5867327 0.108 335050 CH22_FGENES.482_1 0.108 305185 AA663985 HS.24803E 1 major histocompatibility complex; class 1; C 0.108 335658 CH22 FGENES.590 9 0.108 323040 AA336609 Hs.10862 ESTs 0.108 337326 CH22 FGENES.699-6 0.108 339262 CH22 BA354I12.GENSCAN.9-6 0.108 321202 H54052 Hs.163639 ESTs; Weakly similar to INTERCELLULAR ADHESION MOLECULE-1 PRECURSOR [H.sapiens] 0.109 331792 AA398968 Hs.97548 EST 0.109 333806 CH22_FGENES278_2 0.109 321325 AB033100 EST duster (not in UniGene) 0.109 331373 AA435513 Hs.178170 ESTs; Weakly similar to DUAL SPECIFICITY PROTEIN PHOSPHATASE 3 0.87 328775 CH.07 hs gi|5868309 0.109 335105 CH22 FGENES.494 10 0.109 300975 AI283548 Hs.149668 ESTs 0.109 324893 T31940 EST duster (not in UniGene) 0.109 333397 CH22 FGENES.144 15 0.109 336484 CH22 FGENES.831 3 0.109 335507 CH22 FGENES.571 22 0.109 336373 CH22 FGENES.820 3 0.109 336188 CH22 FGENES.717 12 0.109 313455 AW081702 Hs.137329 ESTs 0.109 335185 CH22_FGENES.506_4 0.109 306814 AI066577 EST singleton (not in UniGene) with exon hit 0.109 311130 AI632322 Hs.195306 ESTs 0.109 310882 AW080339 Hs.211911 ESTs 0.109 323383 AI346359 Hs.135209 ESTs 0.11 300212 AW135925 Hs.184552 : biphenylhydrolase-like (serine hydrolase; breast epithelial mudn-assoc. 0.11 325675 CH.14 hs gi|5867014 0.11 330095 CH.19_p2 gi|6015278 0.11 331942 AA453261 Hs.99309 ESTs 0.11 334723 CH22 FGENES.421 34 0.11 333614 CH22 FGENES217 9 0.11 337316 CH22_FGENES.692-1 0.11 305057 AA635626 Hs.62954 fenitin; heavy polypeptide 1 0.11 338704 CH22 EM:AC005500.GENSCAN.480-3 0.11 335385 CH22 FGENES.543 27 0.11 338012 CH22 EM.AC005500.GENSCAN.128-10 0.11 329449 CH.Y hsgi|5868886 0.11 338980 CH22 DA59H18.GENSCAN2-4 0.11 336553 CH22 FGENES.841 10 0.111 330021 CH.16_p2 gi|6671889 0.111 327579 CH.03 hs gi|5867824 0.111 333099 CH22 FGENES.79 4 0.111 337076 CH22_FGENES.453-4 0.111 331388 AA456852 Hs.43543 suppressor of white apricot homolog 2 0.111 306674 AI005542 Hs.180414 heat shock 70kD protein 10 (HSC71) 0.111 305949 AA884409 EST singleton (not in UniGene) with exon hit 0.111 330748 AA419217 Hs.15911 DKFZP586E1422 protein 0.111 333780 CH22_FGENES273_2 0.111 323676 AI702835 EST duster (not in UniGene) 0.111 308952 AI868157 Hs.224226 EST 0.111 309338 AW026946 Hs.181165 > eukaryotic translation elongation fador 1 alpha 1 0.111 329317 CH.X hsgi|6381976 0.112 333518 CH22_FGENES.173_3 0.112 306982 AI127883 EST singleton (not in UniGene) with exon hit 0.112 336225 CH22 FGENES.728 2 0.112 333698 CH22 FGENES250 12 0.112 302173 AI417947 Hs.14068 ESTs 0.112 335510 CH22 FGENES.571 25 0.112 328042 CH.06 hs gi|5902482 0.112 336512 CH22_FGENES.834_7 0.112 328541 CH.07 hs gi|5868486 0.112 311265 AW205118 Hs.199214 ESTs 0.112 323218 AF131846 Hs.13396 Homo sapiens done 25028 mRNA sequence 0.112 302002 AF013956 Hs.123085 chromobox homolog 4 (Drosophila Pc class) 0.112 315088 AA557351 Hs.152446 1 ESTs; Moderately similar to MULTIFUNCTIONAL PROTEIN ADE2 0.112 312581 AI937242 Hs.176590 ESTs 0.112 322246 AW384710 Hs.125258 ESTs 0.112 333659 CH22 FGENES241_5 0.113 327510 CH.02 hsgi|6117815 0.113 336520 CH22 FGENES.839 1 0.113 338682 CH22 EM:AC005500.GENSCAN.472-1 0.113 334508 CH22_FGENES.398_6 0.113 322533 T59538 EST cluster (not in UniGene) 0.113 306873 AI086929 EST singleton (not in UniGene) with exon hit 0.113 336040 CH22_FGENES.679_2 0.113 303898 T23215 EST duster (not in UniGene) with exon hit 0.113 312011 AW294868 Hs.187226 i ESTs 0.113 335186 CH22 FGENES.506_5 0.113 333607 CH22_FGENES216_2 0.113 305549 AA773530 EST singleton (not in UniGene) with exon hit 0.113 333686 CH22 FGENES249_4 0.113 334352 CH22 FGENES.376_3 0.113 338195 CH22 EM.AC005500.GENSCAN233-18 0.114 333588 CH22 FGENES206 2 0.114 339233 CH22 BA354I12.GENSCAN2-3 0.114 337455 CH22_FGENES.777-1 0.114 309101 AI925108 EST singleton (not in UniGene) with exon hit 0.114 328522 CH.07_hs gi|5868477 0.114 323999 AI537333 Hs.252782 ESTs 0.114 333517 CH22 FGENES.173_2 0.114 329935 CH.16_p2 gi|6165200 0.114 326226 CH.17 hs gi|5867230 0.114 335890 CH22 FGENES.633..4 0.114 336715 CH22 FGENES.77-1 0.114 327640 CH.04 hsgi|5867890 0.114 338842 CH22_DJ246D7.GENSCAN.7-1 0.114 306534 AA991487 EST singleton (not in UniGene) with exon hit 0.114 336597 CH22_FGENES266_1 0.114 321010 Y17456 Hs.227150 Homo sapiens LSFR2 gene; last exon 0.114 302294 AA159213 Hs.5337 isodtrate dehydrogenase 2 (NADP+); mitochondrial 0.114 324895 N44238 Hs.77515 inositol 1;4;5-triphosphate receptor; type 3 0.114 327358 CH.01_hs gi|6552411 0.114 308792 AI815153 Hs.19518£ I glyceraldehyde-3-phosphate dehydrogenase 0.115 325886 CH.16 hs gi|5867087 0.115 336850 CH22_FGENES272-11 0.115 305858 AA863103 EST singleton (not in UniGene) with exon hit 0.115 302569 AC004472 multiple UniGene matches 0.115 336158 CH22 FGENES.707_2 0.115 327866 CH.06 hs gi|5868131 0.115 339157 CH22 DA59H18.GENSCAN.67-3 0.115 339258 CH22 BA354I12.GENSCAN.8-3 0.115 336129 CH22 FGENES.701J7 0.115 333684 CH22 FGENES249_2 0.115 309618 AW190162 Hs.184776 ribosomal protein L23a 0.115 312926 AA954097 Hs.127523 ESTs 0.115 302640 AB035698 EST duster (not in UniGene) with exon hit 0.115 328968 CH.08 hsgi|6456775 0.115 327902 CH.06_hsgi|5868158 0.115 321927 AJ223366 EST duster (not in UniGene) 0.115 335962 CH22 FGENES.651_4 0.115 334927 CH22_FGENES.460_1 0.115 330535 U11872 Human interleukin-8 receptor type B (IL8RB) mRNA, splice variant IL8RB1 0.856 328591 CH.07_hs gi[5868227 0.115 334902 CH22 FGENES.452 16 0.115 328525 CH.07_hsgi|5868482 0.115 325870 CH.16 hsgi|6682492 0.116 337522 CH22_FGENES.819-1 0.116 305079 AA641329 EST singleton (not in UniGene) with exon hit 0.116 327343 CH.01 hs gi|6017017 0.116 333918 CH22 FGENES296 7 0.116 333600 CH22 FGENES213 2 0.116 335846 CH22 FGENES.623 6 0.116 333510 CH22 FGENES.171 4 0.116 327629 CH.04 hsgi|5867872 0.116 333470 CH22 FGENES.161 6 0.116 326855 CH20 hsgi|6552460 0.116 327008 CH21 hsgi|5867664 0.117 337480 CH22 FGENES.795-3 0.117 336425 CH22 FGENES.824 10 0.117 321964 AL079687 Hs.171065 ESTs 0.117 335651 CH22_FGENES.590_2 0.117 308164 AI521574 Hs.18116- i eukaryotic translation elongation fador 1 alpha 1 0.117 337927 CH22_EM:AC005500.GENSCAN.80-3 0.117 300341 H45095 Hs.153524 ESTs 0.117 300154 AI245127 Hs.179331 I ESTs 0.117 306295 AA937331 EST singleton (not in UniGene) with exon hit 0.117 329670 CH.14_p2 gi|6272129 0.117 335612 CH22_FGENES.583_6 0.117 307845 AI363450 EST singleton (not in UniGene) with exon hit 0.117 330401 D28383 Human mRNA for ATP synthase B chain, 5'UTR (sequence from the 5'cap to the start codon) 0.117 327127 CH.21 hsgi|6682520 0.117 333843 CH22 FGENES.290 1 0.117 331083 R17762 Hs.22292 ESTs 0.117 329140 CH.X hsgi|6017060 0.117 339338 CH22 BA354I12.GENSCAN27-3 0.117 331974 AA464518 Hs.99616 ESTs 0.117 338631 CH22 EM.AC005500.GENSCAN.454-2 0.117 330299 CH.06_p2 gi|2905881 0.117 330351 CH.09_p2 gi|3056622 0.117 305377 AA715714 Hs.181357 laminin receptor 1 (67kD; ribosomal protein SA) 0.117 333106 CH22 FGENES.79 12 0.117 338514 CH22 EM-AC005500.GENSCAN.392-4 0.117 327335 CH.01 hsgi|5902477 0.117 301970 AB028962 Hs.120245 KIAA1039 protein 0.118 326339 CH.17_hsgi|6056311 0.118 330612 X15673 Hs.93174 Human endogenous retrovirus pHE.1 (ERV9) 0.118 334178 CH22 FGENES.350 6 0.118 328008 CH.06 hsgi|5902482 0.118 329976 CH.16_p2 gi|4878063 0.118 320952 AA897432 Hs.130411 ESTs 0.118 305621 AA789095 EST singleton (not in UniGene) with exon hit 0.118 337850 CH22 EM:AC005500.GENSCAN.34-3 0.118 333626 CH22 FGENES.224 2 0.118 337672 CH22 EM.AC000097.GENSCAN.67-1 0.118 328803 CH.07 hs gi|6004475 0.118 325922 CH.16 hs gi|5867122 0.118 334489 CH22 FGENES.397 1 0.118 320638 R54766 Hs.101120 ESTs 0.118 321932 AA569229 EST duster (not in UniGene) 0.118 336958 CH22_FGENES.367-1 0.118 332082 AA600176 Hs.112345 ESTs 0.118 306004 AA889992 EST singleton (not in UniGene) with exon hit 0.118 336803 CH22_FGENES.194-1 0.118 309107 AI925823 EST singleton (not in UniGene) with exon hit 0.118 336859 CH22 FGENES.293-9 0.118 337935 CH22 EM.AC005500.GENSCAN.85-6 0.118 326492 CH.19 hsgi|5867422 0.118 327289 CH.01 hs gi|5867481 0.119 325818 CH.14 hs gi|6682490 0.119 310787 AW262580 Hs.159040 ESTs 0.119 330028 CH.16_p2 gi|6671908 0.119 325317 CH.11 hs gi|5866878 0.119 335279 CH22 FGENES.523 7 0.119 331720 AA192173 Hs.221530 ESTs 0.119 329186 CH.X hs gi|5868711 0.119 316012 AA764950 Hs.119898 ESTs 0.119 338316 CH22 EM.AC005500.GENSCAN.304-2 0.119 326033 CH.17 hs gi|5867178 0.119 334745 CH22 FGENES.426 3 0.119 333051 CH22_FGENES.73_5 0.119 301763 R01279 EST cluster (not in UniGene) with exon hit 0.12 304502 AA454809 Hs.172928 collagen; type I; alpha 1 0.12 335680 CH22_FGENES.594_5 0.12 304678 AA543556 EST singleton (not in UniGene) with exon hit 0.12 335441 CH22 FGENES.560 4 0.12 336187 CH22_FGENES.717_11 0.12 309422 AW087175 EST singleton (not in UniGene) with exon hit 0.12 336047 CH22_FGENES.679_9 0.12 309651 AW195850 EST singleton (not in UniGene) with exon hit 0.12 308547 AI695385 Hs.201903 EST 0.12 304443 AA399444 EST singleton (not in UniGene) with exon hit 0.12 336245 CH22_FGENES.746_3 0.12 302703 H72333 EST cluster (not in UniGene) with exon hit 0.12 335690 CH22 FGENES.596 5 0.12 328941 CH.08 hs gi|6456765 0.12 333873 CH22 FGENES291_9 0.12 317246 AW105092 Hs.155690 ESTs 0.12 339288 CH22 BA354I12.GENSCAN.16-6 0.12 337996 CH22 EM.AC005500.GENSCAN.116-3 0.12 333304 CH22_FGENES.137_1 0.121 308332 AI591235 EST singleton (not in UniGene) with exon hit 0.121 329319 CH.X_hs gi|6381976 0.121 302086 X57138 multiple UniGene matches 0.121 333290 CH22 FGENES.129 2 0.121 323825 AI793080 Hs.123525 ESTs; Weakly similar to NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN PRECURSOR [R.nonegicus] 0.121 330575 U64105 Hs.252280 Rho guanine nucleotide exchange fador (GEF) 1 0.121 305274 AA679990 Hs.181165 eukaryotic translation elongation fador 1 alpha 1 0.121 333647 CH22_FGENES235_2 0.121 302251 AA333340 EST duster (not in UniGene) with exon hit 0.121 329777 CH.14_p2 gi|6002090 0.121 333155 CH22 FGENES.89 5 0.121 326122 CH.17 hs gi|5867194 0.121 335310 CH22 FGENES.532 3 0.121 335453 CH22_FGENES.562_13 0.122 305103 AA643329 Hs.111334 ferritin; light polypeptide 0.122 337284 CH22 FGENES.667-2 0.122 337418 CH22 FGENES.758-4 0.122 313073 AI963740 Hs.46826 ESTs 0.122 303759 AW504164 EST duster (not in UniGene) with exon hit 0.122 300017 M33197 AFFX control: GAPDH 0.122 316725 AW135084 Hs.127264 ESTs 0.122 330738 AA293153 Hs.120980 nudear receptor co-repressor 2 0.122 336466 CH22 FGENES.829 25 0.122 335956 CH22 FGENES.647 3 0.122 315308 AA780564 Hs.189053 ESTs 0.122 338925 CH22 DJ32I10.GENSCAN.14-3 0.122 334969 CH22_FGENES.466_2 0.122 322050 AL137589 EST duster (not in UniGene) 0.122 339084 CH22 DA59H18.GENSCAN.38-2 0.122 338323 CH22 EM.AC005500.GENSCAN.306-2 0.122 337003 CH22 FGENES.419-7 0.122 325470 CH.12 hsgi|6017034 0.123 336503 CH22 FGENES.833 10 0.123 330786 D60374 HS258712 EST 0.123 329446 CH.Y_hs gi|5868886 0.123 303326 AA229433 Hs.222634 ESTs; Moderately similar to ubiquitin-like protein / ribosomal protein S30 0.123 309067 AI916313 Hs.212788 EST 0.123 317464 AA968472 Hs.130463 ESTs 0.123 328755 CH.07_hsgi|5868301 0.123 326036 CH.17 hs gi|5867178 0.123 327208 CH.01 hs gi|5867447 0.123 326124 CH.17 hs gi|5916395 0.123 327509 CH.02 hs gi|6117815 0.123 338398 CH22_EM:AC005500.GENSCAN.336-5 0.123 304652 AA527782 Hs.84298 CD74 antigen (invariant polypeptide of major histocompatibility complex; class I! antigen-associated) 0.123 335797 CH22 FGENES.612 6 0.124 336714 CH22 FGENES.76-29 0.124 327204 CH.01 hs gi|5867447 0.124 331881 AA430672 Hs.123778 ESTs 0.124 306971 AI126509 EST singleton (not in UniGene) with exon hit 0.124 336174 CH22 FGENES.710 1 0.124 336126 CH22 FGENES.701 13 0.124 329129 CH.X_hsgi|6588026 0.124 303049 AW407562 EST duster (not in UniGene) with exon hit 0.124 335778 CH22 FGENES.607 14 0.124 336601 CH22 FGENES.369 2 0.124 334340 CH22 FGENES.375 17 0.124 337436 CH22_FGENES.767-1 0.124 306013 AA896990 EST singleton (not in UniGene) with exon hit 0.124 339213 CH22 FF113D11.GENSCAN.6-8 0.124 335355 CH22 FGENES.541 2 0.124 336552 CH22 FGENES.841 9 0.124 336384 CH22 FGENES.822 4 0.124 310485 AI286202 Hs.149800 ESTs 0.125 335840 CH22 FGENES.622 3 0.125 336444 CH22_FGENES.827_10 0.125 315703 N36070 EST duster (not in UniGene) 0.125 327763 CH.05 hsgi|5867961 0.125 336383 CH22 FGENES.822 3 0.125 333496 CH22 FGENES.168 6 0.125 328662 CH.07 hsgi|6004473 0.125 338986 CH22 DA59H18.GENSCAN.5-1 0.125 328311 CH.07 hsgi|5868371 0.125 337241 CH22 FGENES.644-2 0.125 336933 CH22 FGENES.350-7 0.125 313483 AW294432 Hs.144252 ESTs 0.125 326116 CH.17 hs gi|5867193 0.125 330450 HG363-HT363 Epidermal Growth Fador Receptor-Related Protein 0.125 307491 AI268539 EST singleton (not in UniGene) with exon hit 0.125 331852 AA418988 Hs.98314 Homo sapiens mRNA; cDNA DKFZp586L0120 (from done DKFZp586L0120) 0.125 330462 HG944-HT944 Dopamine Receptor D4 0.125 304410 AA284508 EST singleton (not in UniGene) with exon hit 0.125 336385 CH22 FGENES.822 5 0.125 336793 CH22 FGENES.176-3 0.125 326243 CH.17 hs gi|5867261 0.125 327266 CH.01_hsgi|5867462 0.125 320753 AF070579 Hs.181544 Homo sapiens clone 24487 mR A sequence 0.125 336960 CH22 FGENES.369-5 0.125 329667 CH.14_p2 gi|6272129 0.125 328163 CH.06 hsgi|5868071 0.125 336534 CH22 FGENES.839 16 0.125 339289 CH22_BA354l12.GENSCAN.16-9 0.126 309230 AI970747 EST singleton (not in UniGene) with exon hit 0.126 339190 CH22 FF113D11.GENSCAN.1-2 0.126 337086 CH22 FGENES.458-14 0.126 319233 R21054 Hs.211522 ESTs 0.126 339396 CH22 BA232E17.GENSCAN.6-8 0.126 331930 AA449077 Hs.179765 Homo sapiens mRNA; cDNA DKFZp586H1921 (from done DKFZp586H192 0.126 308099 AI475914 EST singleton (not in UniGene) with exon hit 0.126 338477 CH22 EM:AC005500.GENSCAN.373-5 0.126 334286 CH22 FGENES.369 16 0.126 317245 AI025039 Hs.131732 ESTs 0.126 335249 CH22 FGENES.516 10 0.126 333327 CH22_FGENES.138_20 0.126 304240 AA009802 EST singleton (not in UniGene) with exon hit 0.126 335464 CH22 FGENES.562 26 0.126 335236 CH22 FGENES.515 8 0.126 334154 CH22_FGENES.340_4 0.126 309257 AI984183 EST singleton (not in UniGene) with exon hit 0.126 310015 AI220122 Hs.201981 ESTs; Weakly similar to breast carcinoma-associated antigen [H.saptens] 0.126 328280 CH.07_hs gi|5868352 0.126 305744 AA831819 EST singleton (not in UniGene) with exon hit 0.126 327430 CH.02_hs gi|5867754 0.126 328323 CH.07_hs gi|5868373 0.126 333274 CH22 FGENES.123 2 0.126 337193 CH22 FGENES.575-3 0.127 334820 CH22 FGENES.437 2 0.127 328706 CH.07_hs gi|5868270 0.127 331228 W67267 Hs.174911 ESTs 0.127 307205 AM92479 EST singleton (not in UniGene) with exon hit 0.127 337123 CH22 FGENES.519-3 0.127 326201 CH.17 hs gi|5867216 0.127 335276 CH22 FGENES.523 2 0.127 331202 T81115 Hs.191136 ESTs 0.127 330532 U03187 Hs.121544 interleukin 12 receptor; beta 1 0.127 321235 N49521 EST cluster (not in UniGene) 0.127 301743 F12605 Hs.204529 ESTs; Weakly similar to reverse transcriptase [H.sapiens] 0.127 328175 CH.06_hs gi|5868073 0.127 306407 AA971985 EST singleton (not in UniGene) with exon hit 0.127 327145 CH.01 hs gi|5867548 0.127 327649 CH.04 hs gi|5867899 0.127 335142 CH22 FGENES.498 12 0.127 333909 CH22_FGENES295_2 0.127 330608 X04325 HS2679 gap junction protein; beta 1; 32kD (connexin 32; Charcot-Marie-Tooth neuropathy; X-linked) 0.127 330158 CH21_p2 gi|6580367 0.127 320153 AF064594 Hs.120360 phospholipase A2; group VI 0.127 314407 AA098835 Hs.224432 ESTs 0.127 333383 CH22 FGENES.143 22 0.127 320663 AI734242 HS244473 ESTs 0.128 326233 CH.17 hsgi|5867232 0.128 326598 CH.20 hsgi|5867634 0.128 335174 CH22_FGENES.504_4 0.128 319843 H29920 Hs.99486 ESTs; Weakly similar to aralarl [H.sapiens] 0.128 335458 CH22 FGENES.562 18 0.128 332997 CH22 FGENES.58 4 0.128 334188 CH22 FGENES.352 3 0.128 329759 CH.14_p2 gi|6048280 0.128 330348 CH.09_p2 gi|4544475 0.128 326958 CH21_hsgi|6469836 0.128 305263 AA679467 EST singleton (not in UniGene) with exon hit 0.128 337693 CH22 EM.AC000097.GENSCAN.78-14 0.128 326812 CH.20 hs gi|6682504 0.128 333237 CH22 FGENES.108 7 0.128 333699 CH22_FGENES250_13 0.128 311496 AI768677 Hs.209888 ESTs; Weakly similar to phosphatidylserine synthase-2 [M.musculus] 0.128 336499 CH22_FGENES.833_4 0.128 320087 AF032387 Hs.113265 small nuclear RNA ad ' rvating complex; polypeptide 4; 190kD 0.128 309989 AI184186 Hs.197813 ESTs 0.128 301490 AW298468 Hs.250461 ESTs 0.128 337011 CH22 FGENES.427-6 0.128 315052 AA876910 Hs.134427 ESTs 0.128 301611 W22172 Hs.59038 ESTs 0.128 336497 CH22_FGENES.833_2 0.129 302068 Y16280 Hs.132049 endothelin type b receptor-like protein 2 0.129 334502 CH22_FGENES.397_18 0.129 304332 AA158884 EST singleton (not in UniGene) with exon hit 0.129 304522 AA465405 EST singleton (not in UniGene) with exon hit 0.129 312407 R46180 Hs.15348- i ESTs 0.129 310098 AI685841 Hs.161354 ESTs 0.129 301119 AF142579 EST duster (not in UniGene) with exon hit 0.129 309268 AI985821 Hs.62954 fenitin; heavy polypeptide 1 0.129 330989 H42142 Hs.226396 i DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 19 (Dbp5; yeast; homolog) 0.129 336949 CH22 FGENES.361-4 0.129 330115 CH.19_p2 gi|6015202 0.129 339212 CH22 FF113D11.GENSCAN.6-7 0.129 326951 CH21_hs gi|6004446 0.129 305165 AA662939 EST singleton (not in UniGene) with exon hit 0.129 308238 AI559492 EST singleton (not in UniGene) with exon hit 0.129 337140 CH22_FGENES.537-5 0.13 321758 U29112 EST cluster (not in UniGene) 0.13 304619 AA515554 Hs.119598 ribosomal protein L3 0.13 312469 AA745289 Hs.173088 ESTs 0.13 339017 CH22 DA59H18.GENSCAN20-6 0.13 330116 CH.19_p2 gi|6015202 0.13 333312 CH22 FGENES.138 4 0.13 338004 CH22 EM.AC005500.GENSCAN.121-1 0.13 314141 AA232134 Hs.190028 I ESTs 0.13 300509 AI239845 Hs.128494 ESTs; Weakly similar to EG.95B72 [D.melanogaster] 0.13 338530 CH22 EM.AC005500.GENSCAN.398-11 0.13 335968 CH22_FGENES.652_1 0.13 314121 AI732100 Hs.187619 ESTs 0.13 337593 CH22 C20H12.GENSCAN.6-8 0.13 332881 CH22_FGENES.33_1 0.13 305836 AA858043 EST singleton (not In UniGene) with exon hit , 0.13 339059 CH22_DA59H18.GENSCAN.30-5 0.13 305610 AA782319 EST singleton (not in UniGene) with exon hit 0.13 305852 AA862455 EST singleton (not in UniGene) with exon hit 0.13 327409 CH.02 hs gi|5867750 0.13 312751 AI613089 Hs.164178 ESTs 0.13 308726 AI799268 Hs.209929 ' EST 0.13 325961 CH.16 hsgi|5867147 0.13 311159 AW025919 Hs.197636 ESTs 0.13 322715 AA057230 Hs.182135 ESTs 0.13 336441 CH22 FGENES.827 7 0.13 336339 CH22_FGENES.814_12 0.13 306911 AI095365 EST singleton (not in UniGene) with exon hit 0.13 333613 CH22 FGENES217 8 0.13 338489 CH22_EM:AC005500.GENSCAN.384-17 0.131 326904 CH.21 hsgi|5867684 0.131 337337 CH22 FGENES.717-1 0.131 326752 CH20_hs gi|5867615 0.131 303977 AW512978 EST singleton (not in UniGene) with exon hit 0.131 301373 AA595235 EST duster (not in UniGene) with exon hit 0.131 338448 CH22 EM.AC005500.GENSCAN.359-22 0.131 333774 CH22 FGENES272 5 0.131 332986 CH22 FGENES.54 8 0.131 335362 CH22 FGENES.541 12 0.131 335896 CH22 FGENES.635 4 0.131 337825 CH22 EM.AC005500.GENSCAN.13-19 0.131 325257 CH.11 hs gi|5866895 0.131 331188 T50240 Hs.167837 ESTs 0.131 330645 Y08302 Hs.144879 dual specificity phosphatase 9 0.131 331760 AA292721 Hs.154434 ESTs; Weakly similar to unknown [H.sapiens] 0.131 322995 AA513829 Hs.29797 ribosomal protein L10 0.131 335497 CH22 FGENES.571 5 0.131 334824 CH22 FGENES.437 6 0.131 319480 R06933 Hs.184221 ESTs 0.131 334842 CH22 FGENES.439 21 0.131 333335 CH22 FGENES.139 4 0.131 317252 AA905178 Hs.130124 ESTs 0.131 329034 CH.X_hs gi|5868561 0.131 305186 AA664230 EST singleton (not in UniGene) with exon hit 0.131 335755 CH22_FGENES.604_4 0.131 302143 H15270 Hs.189847 putative neuronal cell adhesion molecule 0.131 334939 CH22 FGENES.465 3 0.131 318994 C15110 Hs.17802 ESTs 0.131 334498 CH22 FGENES.397 14 0.131 333413 CH22 FGENES.146 2 0.132 329676 CH.14_p2 gi|6272128 0.132 327277 CH.01_hs gi|5867473 0.132 305022 AA627416 EST singleton (not in UniGene) with exon hit 0.132 336805 CH22_FGENES.196-3 0.132 320121 T93657 EST duster (not in UniGene) 0.132 334761 CH22 FGENES.428 10 0.132 339400 CH22 BA232E17.GENSCAN.7-6 0.132 330301 CH.06_p2 gi|2905862 0.132 316822 AA827691 Hs.129967 ESTs; Weakly similar to neuronal thread protein AD7oNTP [H.sapiens] 0.132 328020 CH.06 hsgi|5902482 0.132 325327 CH.11_hs gi|5866875 0.132 321163 AA209530 EST duster (not in UniGene) 0.132 336393 CH22 FGENES.823 5 0.132 325905 CH.16_hs gi|5867104 0.132 305237 AA676286 HS2186 eukaiyotic translation elongation fador 1 gamma 0.132 339046 CH22_DA59H18.GENSCAN28-6 0.132 325375 CH.12 hs gi|5866920 0.132 333961 CH22 FGENES.304 7 0.132 335450 CH22_FGENES.562_8 0.133 302286 R58438 EST duster (not in UniGene) with exon hit 0.133 335116 CH22 FGENES.496 3 0.133 327333 CH.01_hs gi|5902477 0.133 308070 AI470948 EST singleton (not in UniGene) with exon hit 0.133 308311 AI581855 EST singleton (not in UniGene) with exon hit 0.133 320813 AW360847 Hs.208839 ESTs 0.133 323665 AW248307 EST duster (not in UniGene) 0.133 328318 CH.07_hs gi|5868373 0.133 320603 R51419 EST duster (not in UniGene) 0.133 332791 CH22_FGENES.3_1 0.133 314976 AA524725 Hs.162108 ESTs 0.133 303309 AL134164 HS224868 ESTs 0.133 320581 R39753 Hs.170187 ESTs 0.133 333944 CH22 FGENES.302 2 0.133 317992 AI733512 Hs.130901 ESTs 0.133 330935 F02383 Hs.26492 beta-1;3-glucuronyltransferase 3 (glucuronosyltransferase I) 0.133 336659 CH22 FGENES.36-5 0.133 338887 CH22_DJ32i10.GENSCAN.6-10 0.133 305273 AA679979 Hs.181165 i eukaryotic translation elongation fador 1 alpha 1 0.133 333566 CH22_FGENES.183_2 0.134 316952 AW450033 Hs.163312 ESTs 0.134 333818 CH22_FGENES283 1 0.134 328687 CH.07_hsgi|5868262 0.134 302879 H11802 EST duster (not in UniGene) with exon hit 0.134 336557 CH22 FGENES.842 2 0.134 335222 CH22 FGENES.513 5 0.134 338094 CH22 EM.AC005500.GENSCAN.179-3 0.134 337384 CH22 FGENES.745-1 0.134 327360 CH.01 hs gi|6552411 0.134 328132 CH.06 hs gi 5868038 0.134 323604 AI751438 Hs.182827 ESTs; Weakly similar to !!!! ALU SUBFAMILY SQ WARNING ENTRY HI! 0.134 337591 CH22_C20H12.GENSCAN.6-6 0.134 307018 AI140639 EST singleton (not in UniGene) with exon hit 0.134 326896 CH.21 hs gi|5867680 0.134 333479 CH22 FGENES.163 5 0.134 337915 CH22 EM.AC005500.GENSCAN.61-3 0.134 335110 CH22 FGENES.494 18 0.134 333481 CH22 FGENES.163 9 0.134 327512 CH.02_hs gi|6117815 0.134 300096 AW328639 Hs.83575 ESTs; Weakly similar to ZC328.3 [C.elegans] 0.134 330163 CH.02_p2 gi|6042042 0.135 335752 CH22 FGENES.604 1 0.135 334857 CH22 FGENES.443 1 0.135 301872 H84730 EST duster (not in UniGene) with exon hit 0.135 337529 CH22 FGENES.823-29 0.135 335734 CH22 FGENES.601 4 0.135 337551 CH22_FGENES.847-8 0.135 309078 AI920965 Hs.77961 major histocompatibility complex; class I; B 0.135 335513 CH22 FGENES.571 28 0.135 339078 CH22_DA59H18.GENSCAN.37-6 0.135 321907 N56660 Hs.148722 ESTs; Weakly similar to large tumor suppressor 1 [H.sapiens] 0.135 337189 CH22 FGENES.571-32 0.135 329635 CH.12_p2 gi|5302817 0.135 308601 AI719930 EST singleton (not in UniGene) with exon hit 0.135 305020 AA627248 Hs.2064 vimentin 0.135 333894 CH22_FGENES.293_1 0.135 322465 AA137152 Hs.3784 ESTs; Highly similar to phosphoserine aminotransferase [H.saptens] 0.135 305601 AA780975 EST singleton (not in UniGene) with exon hit 0.135 332186 H10781 Hs.141051 I ESTs; Moderately similar to HI! ALU SUBFAMILY SB WARNING ENTRY 0.135 327822 CH.05 hs gi|5867968 0.135 310087 AI393914 Hs.160624 ESTs; Weakly similar to similar to CR16; SH3 domain binding protein 0.135 328752 CH.07 hs gi|5868298 0.135 337611 CH22 C20H12.GENSCAN.19-4 0.135 334470 CH22 FGENES.394 1 0.136 335115 CH22 FGENES.496 2 0.136 328730 CH.07_hs gi|5868289 0.136 330350 CH.09_p2 gi|3056622 0.136 336971 CH22_FGENES.378-6 0.136 308258 AI565612 EST singleton (not in UniGene) with exon hit 0.136 326745 CH.20 hsgi|5867611 0.136 335440 CH22_FGENES.560_3 0.136 320257 AA330746 EST duster (not in UniGene) 0.136 328677 CH.07 hsgi|5868256 0.136 329731 CH.14_p2 gi|6065783 0.136 315950 AA700553 Hs.206974 ESTs 0.136 330049 CH.17_p2 gi|4567182 0.136 337070 CH22 FGENES.448-3 0.136 304095 H11324 Hs.31059 EST 0.136 309304 AW005527 Hs.232820 EST 0.136 333458 CH22 FGENES.157 7 0.136 329899 CH.15_p2 gi|6563505 0.136 322202 AI275056 Hs.200133 ESTs 0.136 333991 CH22_FGENES.310_15 0.136 318617 AW247252 Hs.75514 nudeoside phosphorylase 0.136 310623 AI341586 Hs.195588 ESTs 0.136 330489 M23323 Hs.3003 CD3E antigen; epsilon polypeptide (TiT3 complex) 0.136 309646 AW194694 EST singleton (not in UniGene) with exon hit 0.136 331068 R00071 Hs.191199 ESTs 0.136 334285 CH22_FGENES.369_15 0.136 332178 F13689 Hs.100725 EST 0.136 305724 AA827608 EST singleton (not in UniGene) with exon hit 0.136 303158 AL138110 Hs.8594 Homo sapiens mRNA containing (CAG)4 repeat; clone CZ-CAG-7 0.136 334543 CH22 FGENES.403 8 0.136 335384 CH22 FGENES.543 26 0.136 336527 CH22 FGENES.839_8 0.136 334951 CH22 FGENES.465 20 0.136 325882 CH.16_hs gi|5867087 0.137 305134 AA653159 EST singleton (not in UniGene) with exon hit 0.137 307058 AI148709 EST singleton (not in UniGene) with exon hit 0.137 331943 AA453418 Hs.178272 ! ESTs 0.137 331116 R44780 Hs.22634 ESTs 0.137 306094 AA908877 EST singleton (not in UniGene) with exon hit 0.137 333561 CH22_FGENES.180_18 0.137 321439 H61962 EST duster (not in UniGene) 0.137 324594 AA497090 EST duster (not in UniGene) 0.137 337926 CH22 EM.AC005500.GENSCAN.77-4 0.137 337353 CH22 FGENES.726-1 0.137 331836 AA412295 Hs.104774 EST 0.137 308981 AI873242 EST singleton (not in UniGene) with exon hit 0.137 329424 CH.Y hs gi|5868879 0.137 325829 CH.15 hs gi|5867052 0.137 331845 AA416863 Hs.98183 ESTs 0.137 333854 CH22_FGENES290_13 0.137 306591 AI000248 EST singleton (not in UniGene) with exon hit 0.137 328948 CH.08 hsgi|6456765 0.137 338935 CH22 DJ32I10.GENSCAN.18-12 0.137 325960 CH.16_hsgi|5867147 0.137 328377 CH.07_hs gi|5868390 0.138 308851 AI829820 EST singleton (not in UniGene) with exon hit 0.138 314620 AA424352 Hs.210586 i ESTs 0.138 337592 CH22 C20H12.GENSCAN.6-7 0.138 338684 CH22 EM.AC005500.GENSCAN.472-3 0.138 331800 AA400498 Hs.97543 ESTs 0.138 304587 AA505535 EST singleton (not in UniGene) with exon hit 0.138 333981 CH22_FGENES.310_4 0.138 332452 AA040369 Hs.11170 SYT interading protein 0.138 305752 AA835278 EST singleton (not in UniGene) with exon hit 0.138 311947 T65554 Hs.251591 EST 0.138 333783 CH22 FGENES273 5 0.138 337406 CH22 FGENES.754-14 0.138 327976 CH.06 hs gi|5868212 0.138 325593 CH.13 hs gi|5866992 0.138 339425 CH22_DJ579N16.GENSCAN.14-4 0.138 304475 AA428879 EST singleton (not in UniGene) with exon hit 0.138 309488 AW131104 EST singleton (not in UniGene) with exon hit 0.138 337532 CH22_FGENES.827-6 0.138 317234 AA904448 Hs.126368 ESTs 0.138 312261 AA854425 Hs.144455 ESTs 0.138 328927 CH.08 hs gi|5868500 0.138 336424 CH22_FGENES.824_9 0.138 326667 CH.20 hs gi|6552455 0.138 325988 CH.16_hsgi|5867064 0.138 318446 AW300287 EST duster (not in UniGene) 0.139 336511 CH22 FGENES.834 6 0.139 335204 CH22_FGENES.508_13 0.139 303244 AA147472 EST duster (not in UniGene) with exon hit 0.139 330870 AA115804 Hs.187593 ESTs 0.139 329376 CH.X_hs gi|5868859 0.139 304703 AA563898 EST singleton (not in UniGene) with exon hit 0.139 333653 CH22_FGENES239_2 0.139 306799 AI051696 EST singleton (not in UniGene) with exon hit 0.139 304872 AA595289 EST singleton (not in UniGene) with exon hit 0.139 330812 AA013001 Hs.60563 ESTs 0.139 329568 CH.10_p2 gi|3962490 0.139 319210 AA253074 Hs.146261 ESTs 0.139 334320 CH22 FGENES.374 5 0.139 300860 AI916949 Hs.149748 ESTs; Weakly similar to weak similarity to collagens [C.elegans] 0.139 305866 AA864533 EST singleton (not in UniGene) with exon hit 0.139 312943 AA984364 Hs.119064 ESTs 0.139 330523 M99439 Hs.83958 transdudn-like enhancer of split 4; homolog of Drosophila E(sp1 ) 0.139 312708 AI076204 Hs.135440 ESTs 0.139 309366 AW072970 EST singleton (not in UniGene) with exon hit 0.139 303273 AA316069 EST duster (not in UniGene) with exon hit 0.139 317484 AW274696 Hs.143921 ESTs 0.139 333239 CH22_FGENES.111_1 0.139 307126 AI184951 EST singleton (not in UniGene) with exon hit 0.139 316813 AA826505 Hs.124517 ESTs 0.139 331746 AA281365 Hs.121640 ESTs; Weakly similar to KIAA0386 [H.saptens] 0.139 308558 AI700145 Hs.172182 poly(A)-binding protein; cytoplasmic 1 0.139 310784 AW086142 Hs.159017 ESTs 0.139 323831 AA335715 Hs.200299 ESTs 0.139 307692 AI318342 EST singleton (not in UniGene) with exon hit 0.139 310570 AI318327 EST duster (not in UniGene) 0.139 327934 CH.06_hs giJ5868184 0.139 305232 AA670052 Hs.195188 glyceraldehyde-3-phosphate dehydrogenase 0.139 334756 CH22 FGENES.428 5 0.139 331938 AA451867 Hs.99255 ESTs 0.139 301393 AI474722 Hs.150898 ESTs; Weakly similar to KIAA0644 protein [H.sapiens] 0.139 312005 T78450 Hs.13941 ESTs 0.139 338431 CH22 EM:AC005500.GENSCAN.351-4 0.14 331214 T90496 Hs.16757 ESTs 0.14 333601 CH22 FGENES213 4 0.14 323481 AA278449 Hs.137429 ESTs 0.14 336911 CH22 FGENES.344-4 0.14 338157 CH22_EM:AC005500.GENSCAN209-5 0.14 327845 CH.05_hs gi|6531962 0.14 319109 Z45662 Hs.90797 Homo sapiens done 23620 mRNA sequence 0.14 334763 CH22 FGENES.428 12 0.14 329384 CH.X_hs gi|5868869 0.14 302996 AF054663 EST cluster (not in UniGene) with exon hit 0.14 323751 AW452656 Hs.209824 ESTs 0.14 329916 CH.16_p2 gi[6223624 0.14 301993 N49826 Hs.18602 ESTs 0.14 338129 CH22 EM.AC005500.GENSCAN.197-2 0.14 325704 CH.14 hsgi|5867028 0.14 335656 CH22 FGENES.590 7 0.14 331673 W72366 Hs.40033 ESTs 0.14 316807 AI018331 Hs.172444 ESTs; Highly similar to transcription regulator [M.musculus] 0.14 310743 AW449754 Hs.158665 ESTs 0.14 326941 CH.21 hs gi|6004446 0.14 328809 CH.07 hs gi|5868327 0.14 323855 AI653164 Hs.128665 ESTs 0.14 304705 AA564064 EST singleton (not in UniGene) with exon hit 0.14 325666 CH.14 hs gi|6469822 0.14 333747 CH22 FGENES.265 6 0.14 318287 AW015616 Hs.143321 ESTs 0.141 332972 CH22_FGENES.51_5 0.141 305704 AA825266 EST singleton (not in UniGene) with exon hit 0.141 315699 AW182805 Hs.189183 ESTs; Weakly similar to Nodi [H.sapiens] 0.141 327296 CH.01 hs gi|5867492 0.141 336400 CH22 FGENES.823 15 0.141 321033 H26214 Hs.20733 ESTs; Weakly similar to HI! ALU SUBFAMILY SX WARNING ENTRY 0.141 316522 AI475995 Hs.122910 ESTs 0.141 335715 CH22 FGENES.599 15 0.141 335959 CH22 FGENES.650 2 0.141 333259 CH22 FGENES.118 7 0.141 337382 CH22_FGENES.744-8 0.141 322346 AA227618 Hs.10882 HMG-box containing protein 1 0.141 325378 CH.12 hs gi|5866920 0.141 338500 CH22 EM.AC00550O.GENSCAN.390-1 0.141 338460 CH22 EMAC005500.GENSCAN.362-5 0.141 315279 AW511138 Hs.256581 ESTs 0.141 314439 AI539443 Hs.137447 ESTs 0.141 333624 CH22 FGENES.222 3 0.141 329237 CH.X_hsgi|5868729 0.141 330117 CH.19_p2 gi|6015201 0.141 338017 CH22 EM.AC005500.GENSCAN.134-1 0.141 337854 CH22 EM.AC005500.GENSCAN.38-12 0.142 329984 CH.16_p2 gi|4646193 0.142 305004 AA622328 Hs.162762 EST 0.142 302815 N40373 EST cluster (not in UniGene) with exon hit 0.142 327823 CH.05 hs gi|5867968 0.142 326753 CH20 hs gi|5867616 0.142 301201 AA904482 Hs.197775 ESTs 0.142 334303 CH22 FGENES.373 6 0.142 326453 CH.19 hs gi|5867399 0.142 311050 AI864581 Hs.215477 ESTs 0.142 308740 AI802711 Hs.210337 EST; Weakly similar to aldolase A [H.saptens] 0.142 331003 H63959 Hs.142722 ESTs 0.142 338010 CH22 EM.AC005500.GENSCAN.128-8 0.142 336326 CH22 FGENES.812 4 0.142 318100 R44308 Hs.242302 ESTs 0.142 320641 R55421 EST duster (not in UniGene) 0.142 325855 CH.16_hs gi 5867067 0.142 330425 HG1728-HT1734 Non-Specific Cross Reading Antigen (Gb:D90277), AIL Splice Form 2 0.142 324583 AA425411 Hs.22581 ESTs 0.142 326268 CH.17 hsgi|5867267 0.142 331390 AA460341 Hs.45008 ESTs 0.142 338904 CH22 DJ32I10.GENSCAN.10-16 0.143 333096 CH22_FGENES.79 1 0.143 331919 AA446869 Hs.119316 ESTs 0.143 312214 AI248004 Hs.125187 ESTs 0.143 323198 AW179174 Hs.7984 ESTs 0.143 316107 AI204001 Hs.184014 ribosomal protein L31 0.143 301335 AA885317 Hs.190511 ESTs 0.143 337392 CH22_FGENES.747-3 0.143 325543 CH.12_hs gi|6682452 0.143 305903 AA873085 EST singleton (not in UniGene) with exon hit 0.143 332707 L35594 Hs.174185 phosphodiesterase l/nudeotide pyrophosphatase 2 (autotaxin) 0.143 337913 CH22 EM.AC005500.GENSCAN.59-10 0.143 301436 AA961061 Hs.131696 ESTs 0.143 335078 CH22 FGENES.486 5 0.143 338451 CH22_EM:AC005500.GENSCAN.359-39 0.143 302777 AJ230640 EST cluster (not in UniGene) with exon hit 0.143 330464 J03068 Hs.78223 N-acylaminoacyl-peptide hydrolase 0.143 330988 H41411 Hs.33855 ESTs 0.143 328939 CH.08 hs gi|6004481 0.143 308015 AI440174 Hs.228907 EST; Weakly similar to GUANINE NUCLEOTIDE-BINDING PROTEIN BETASUBUNIT-LIKE PROTEIN 12.3 [H.sapiens] 0.143 328504 CH.07_hsgi|5868471 0.143 332599 AA402891 Hs.32951 solute carrier family 29 (nucleoside transporters); member 2 0.143 335744 CH22_FGENES.601_15 0.143 322394 AF077208 EST duster (not in UniGene) 0.143 323892 AL042661 EST cluster (not in UniGene) 0.143 318443 AI939323 Hs.157714 ESTs; Weakly similar to NEURONAL ACETYLCHOLINE RECEPTOR PROTEIN; ALPHA-5 CHAIN PRECURSOR [H.sapiens] 0.143 336568 CH22 FGENES.843 7 0.143 330958 H08815 Hs.159824 EST 0.143 327672 CH.04 hs gi|5867843 0.143 335900 CH22 FGENES.635 8 0.144 336044 CH22_FGENES.679_6 0.144 318845 AI815951 Hs.33183 ESTs; Weakly similar to estrogen-responsive finger protein; efp [H.sapiens] 0.144 333483 CH22 FGENES.165 2 0.144 333337 CH22_FGENES.139_6 0.144 305993 AA889197 EST singleton (not in UniGene) with exon hit 0.144 335719 CH22 FGENES.599 22 0.144 325682 CH.14 hsgi|6138923 0.144 327350 CH.01 hsgi|6249563 0.144 339291 CH22 BA354I12.GENSCAN.18-1 0.144 326358 CH.18 hsgi|5867293 0.144 330316 CH.08_p2 gi|6007576 0.144 308150 AI499346 Hs.174131 ribosomal protein L6 0.144 338065 CH22 EM-AC005500.GENSCAN.164-1 0.144 339009 CH22 DA59H18.GENSCAN.18-7 0.144 327776 CH.05 hsgi|5867964 0.145 336664 CH22_FGENES.41-8 0.145 321921 AF070619 EST duster (not in UniGene) 0.145 319346 T70147 Hs.12024 ESTs 0.145 304265 AA062892 EST singleton (not in UniGene) with exon hit 0.145 303818 Z45986 Hs.250178 copine ll 0.145 327498 CH.02 hsgi|6017023 0.145 335227 CH22 FGENES.513J3 0.145 339022 CH22_DA59H18.GENSCAN22-1 0.145 302597 H55661 Hs.33026 ESTs; Weakly similar to similar to Enterococcus faecalis TRAB [Celegans] 0.145 308550 AI697008 Hs.201811 EST 0.145 302175 AA262760 Hs.156015 Homo sapiens chromosome 19; cosmid R29381 0.145 303252 AA156760 EST duster (not in UniGene) with exon hit 0.145 337414 CH22_FGENES.757-2 0.145 310382 AI734009 EST duster (not in UniGene) 0.145 329333 CH. -hsgi|5868806 0.145 336857 CH22_FGENES291-7 0.145 332565 AA234896 Hs.25272 E1A binding protein p300 0.145 318634 AI928098 Hs.156832 ESTs 0.145 336318 CH22 FGENES.801 1 0.145 310960 AI923551 Hs.170843 ESTs 0.145 335346 CH22 FGENES.537 2 0.145 331196 T65416 Hs.12826 ESTs 0.145 337607 CH22_C20H12.GENSCAN.17-3 0.146 331206 T84096 Hs.15284 ESTs 0.146 301793 T80698 EST cluster (not in UniGene) with exon hit 0.146 319590 AA210878 EST duster (not in UniGene) 0.146 311394 A1695374 Hs.256231 ESTs 0.146 324773 AA632554 Hs.163401 ESTs 0.146 324841 AI142359 Hs.155316 ESTs 0.146 332260 N70088 Hs.138467 ESTs 0.146 329276 CH.X hs gi|5868762 0.146 335887 CH22 FGENES.633 1 0.146 338294 CH22 EM.AC005500.GENSCAN297-1 0.146 336993 CH22 FGENES.409-4 0.146 334135 CH22 FGENES.336 2 0.146 326251 CH.17_hsgi|5867263 0.146 337396 CH22 FGENES.749-1 0.146 339167 CH22 DA59H18.GENSCAN.69-8 0.146 316838 AW135418 Hs.161210 ESTs 0.146 325313 CH.11 hs gi|5866865 0.146 331047 N66918 Hs.32205 ESTs 0.146 323915 AL043362 EST duster (not in UniGene) 0.146 302747 AF062275 EST cluster (not in UniGene) with exon hit 0.146 306317 AA947909 EST singleton (not in UniGene) with exon hit 0.146 334399 CH22 FGENES.382 5 0.146 326472 CH.19 hs gil5867404 0.146 333061 CH22 FGENES.75 4 0.146 337072 CH22 FGENES.448-5 0.146 334328 CH22_FGENES.375_5 0.146 327039 CH21 hs gi|6531965 0.146 325576 CH.12 hsgi[6552443 0.147 315935 AI075804 Hs.132660 ESTs 0.147 319638 AA323758 EST duster (not in UniGene) 0.147 334501 CH22 FGENES.397 17 0.147 338238 CH22_EM:AC005500.GENSCAN264-4 0.147 308636 AI744063 EST singleton (not in UniGene) with exon hit 0.147 336567 CH22 FGENES.843 6 0.147 335819 CH22 FGENES.619 2 0.147 336950 CH22_FGENES.361-8 0.147 307055 AI148477 EST singleton (not in UniGene) with exon hit 0.147 315134 AW504854 Hs.126714 ESTs 0.147 335834 CH22 FGENES.621 1 0.147 327870 CH.06_hsgi|5868131 0.147 323802 AA332011 Hs.250138 protein phosphatase 2C; magnesium-dependent; catalytic subunit 0.147 329412 CH.X_hsgi|6682553 0.147 323791 AA333068 EST duster (not in UniGene) 0.147 324126 AA385315 EST duster (not in UniGene) 0.147 327865 CH.06 hs gi|5868130 0.147 333445 CH22 FGENES.154 2 0.147 321302 AA021351 Hs.158497 KIAA0724 gene produd 0.147 336744 CH22_FGENES.118-9 0.147 323731 AA323414 EST cluster (not in UniGene) 0.148 320289 H07989 EST duster (not in UniGene) 0.148 305488 AA749000 EST singleton (not in UniGene) with exon hit 0.148 305592 AA780594 Hs.62954 ferritin; heavy polypeptide 1 0.148 304094 H11295 EST singleton (not in UniGene) with exon hit 0.148 325040 AW296368 EST duster (not in UniGene) 0.148 339034 CH22 DA59H18.GENSCAN26-2 0.148 334504 CH22 FGENES.398 2 0.148 334778 CH22_FGENES.431_2 0.148 320148 U77494 Hs.119687 RAN binding protein 8 0.148 303584 AW173759 Hs.203401 ESTs 0.148 325826 CH.15_hs gi|5867048 0.148 331192 T55182 Hs.152571 ESTs; Highly similar to IGF-II mRNA-binding protein 2 [H.sapiens] 0.148 325785 CH.14_hs gi|6381957 0.148 333166 CH22 FGENES.91 8 0.148 336548 CH22 FGENES.841_5 0.148 337552 CH22 C4G1.GENSCAN.1-4 0.148 331775 AA382742 Hs.97151 EST 0.148 338936 CH22_DJ32l10.GENSCAN.19-6 0.148 331869 AA428554 Hs.104894 ESTs; Weakly similar to fibronedin precursor [H.sapiens] 0.148 332865 CH22 FGENES28 5 0.148 328663 CH.07 hsgi|6004473 0.148 328436 CH.07_hs gi|5868417 0.148 311158 AI634864 Hs.250789 ESTs; Highly similar to similar to NEDD-4 [H.sapiens] 0.148 336942 CH22 FGENES.354-2 0.148 302262 R53169 Hs.246091 ESTs 0.149 333296 CH22 FGENES.132_3 0.149 333365 CH22 FGENES.142_2 0.149 311706 AW452392 Hs.252854 ESTs 0.149 337109 CH22 FGENES.489-2 0.149 315062 AW173300 Hs.190201 ESTs 0.149 333454 CH22 FGENES.157_3 0.149 334784 CH22 FGENES.432_9 0.149 333255 CH22 FGENES.118_3 0.149 337518 CH22_FGENES.814-7 0.149 320651 AA489268 EST cluster (not in UniGene) 0.149 323437 AA287567 EST duster (not in UniGene) 0.149 328761 CH.07 hs gi|5868302 0.149 328787 CH.07 hs gi[5868309 0.149 335261 CH22 FGENES.520_2 0.149 300827 R16689 Hs.106004 ESTs 0.149 339263 CH22 BA354I12.GENSCAN.10-1 0.149 337412 CH22 FGENES.756-6 0.149 334414 CH22 FGENES.384 1 0.149 332931 CH22_FGENES.38_5 0.149 310801 AW270980 Hs.106346 novel centiosomal protein RanBPM 0.149 305216 AA669056 EST singleton (not in UniGene) with exon hit 0.149 314779 AA470122 Hs.190261 ESTs 0.149 338414 CH22_EM:AC005500.GENSCAN.341-27 0.149 303342 AW247361 EST duster (not in UniGene) with exon hit 0.149 337509 CH22_FGENES.806-4 0.149 306631 AI001149 EST singleton (not in UniGene) with exon hit 0.149 302533 L36149 Hs248116 chemokine (C motif) XC receptor 1 0.149 336536 CH22 FGENES.839J8 0.149 324666 T32458 Hs.14285 ESTs 0.149 310173 AI767433 Hs.170013 ESTs 0.149 333595 CH22 FGENES211 2 0.149 335975 CH22_FGENES.652_9 0.15 306654 AI003654 EST singleton (not in UniGene) with exon hit 0.15 335025 CH22 FGENES.475 3 0.15 328711 CH.07_hs gi 5868271 0.15 328274 CH.07_hs gi 5868219 0.15 325505 CH.12 hs gi 6682451 0.15 329641 CH.14_p2 gi 6468233 0.15 304955 AA613504 EST singleton (not in UniGene) with exon hit 0.15 339103 CH22 DA59H18.GENSCAN.44-10 0.15 329636 CH.12_p2 gi|5302817 0.15 310118 AI203293 Hs.157489 ESTs 0.15 326056 CH.17_hsgi|5867184 0.15 303773 AA769074 EST cluster (not in UniGene) with exon hit 0.15 303153 U09759 Hs.8325 mitogen-adi. rated protein kinase 9 0.15 TABLE 13A shows the accession numbers for those primekeys lacking unigenelD's for Table 13. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column. Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers Pkey CAT number Accession 322050 24275J AL137589 AA423949 BE222949 BE222694 AI199615 AW873116 AI277950 AW044290 AW630096 321439 1599424J H61962 W01567 N75711 321666 13653_22 BE259906 AA232518 AA013359 AL035788 AW160822 BE387134 BE002954 BE391839 AW161565 AI878841 BE616458 BE409981 BE387308 BE297436 BE315536 AA206924 R12012 AA214169 BE312812 BE387093 H11710 BE312009 BE260569 AA343566 AA219526 R34757 AA219749 BE336733 AA219751 AW411099 AA232408 BE018716 BE398089 AA206253 AA053487 AA114224 AV655868 AW732566 BE394087 AW732574 AA313442 BE336875 AA070548 BE259840 BE019828 AW732341 AA299916 BE019253 BE018238 BE387109 AA232304 BE255589 AW732585 AA181436 AA308777 AA075802 AW732521 AA314526 AA226747 BE409513 AA206168 BE388292 BE298782 BE387086 AA305310 AV652723 AA314918 BE615510 AW951763 BE398104 BE385195 BE407165 BE391336 BE390187 BE389189 BE540650 BE249884 BE385985 BE274245 BE391124 BE260080 AA182600 BE512821 BE390090 BE279398 BE279589 BE263454 BE515194 BE293569 BE272531 BE388814 BE384659 BE271685 BE561043 BE278449 BE302572 AW239076 AI750583 AA376179 AA112632 BE266324 BE266614 R13105 AA132286 BE296305 AI220355 AA205606 AA219527 AA219519 AW804310 AA083286 BE171208 T19693 AA338328 BE185868 AA903024 T92162 AA330119 BE410404 BE314668 300088 622937J AW576245 BE207878 AW299993 AI199558 AI285442 AW299994 AW394242 AW394184 322303 704603J AI357412 AI870708 AI590539 W07459 322394 27492J AW068287 AA310079 BE336702 AA356318 AA306059 AA346785 AW402633 AA311210 AW402909 N76879 AW402913 AW401920 AA321636 AA354474 C17297 C16938 AA311774 M29871 NM_002872 Z82188 AW405674 H94176 R89281 AA214723 AI014482 AW949347 T27749 AW804226 AW796964 AW404581 AF077208 NM_014029 W68830 W79652 AA353375 AW575218 AA552192 AA521232 AA702695 AA033975 AW407827 AA829948 N94402 AW628604 AI523308 N57605 AA641662 H42477 N52784 AI753478 AA768493 AA845729 W47391 N55270 AI090117 R89282 BE206172 AA076650 AA595650 AI218931 BE049397 AI433110 W74114 H94277 AI358627 AI085221 AI862818 AA835967 AW103905 AI640644 AA835507 AA856887 AA694392 AW337542 AI524410 BE045500 AI440060 AI358801 AW028238 AW205248 AI718264 R48618 AA357358 AI695002 AA897549 AW081065 AI433360 AI810783 AI620963 Z82188 AA360224 321758 44275J U29112 AI656540 AI364875 AI656246 AI990940 323109 155498J AA169345 AI762857 AI949997 AI809601 AI681948 AI221079 AW167404 AI347614 AI611090 AI023472 AI347683 AI027467 AW591788 AI380665 AA835735 AA836654 AI244028 AW193159 AI500112 AI918722 AI738693 AI702308 AA805365 AI766842 322533 38937J T59538 T59589 T59598 T59542 AF147374 321921 34680 AF070619 R20302 T80358 321927 21620J AJ223366 BE305086 AW820106 AA621983 BE305208 AI738475 AI380189 AW590847 AI127232 AA622706 AI380858 AA621975 AI587036 AA665743 AW204003 AI692234 AI002242 AI692219 AW137282 AW268783 AW295910 AI308015 AW301462 AI318288 AI31857S AI318117 AI345591 AI249650 AI246934 AI246864 AI246971 AW268311 AI249654 BE041907 AW732776 321932 265316J N72324 N52825 W19526 BE143464 AA376060 306971 14694_7 M83667 NM_005195 S63168 M83667 AW068039 AW630649 AI338577 AI018125 AI269878 AW242440 AI887823 AI342581 BE222416 AI582847 AI651011 AI660815 AI699574 BE550201 AI926996 AW665855 AI827752 AI761857 BE328168 BE222451 AI762201 AW000929 AW007207 BE042962 BE551843 BE465373 AI279179 AI949945 BE551862 AW051667 BE328076 BE222296 AW007229 AW772332 AI279801 AI934526 AI631938 AI770103 BE041412 AI417900 AI692655 AI869943 AW270119 AI431739 AI703347 AW770568 AW025473 AI701497 AI128026 BE328147 AW203980 BE046793 AW087704 AI674597 A1650732 AI813691 AI472092 AI695224 AI241217 AW207746 AI206840 AI271362 AI631788 AI911883 AI914619 AI380585 AI767501 AI823759 AI564116 AI190991 AI377369 AI814122 AI221623 AI354793 AI081988 AI391740 AI337435 BE467366 AI824347 AI565325 AI280038 AI640455 AI819744 BE467803 BE327524 AI149402 AI313187 BE219684 AW611948 AW665821 AI091260AW044492 BE220366 AW025381 AW183264 AI694865 AI498474 AI129780 AI202028 AI566792 BE220659 AI928040 AI830696 AI493021 AW612488 AI913152 BE042965 AI631837 AI693873 AI498925 AI768668 AI401544 BE327023 AI693383 AI769874 AI744003 AW082273 AI686501 AI798177 AI985196 AI090033 AI432342 AI689918 AI638308 BE468080 BE219588 AI912119 BE219787 AW005392 BE326564 AI589039 AI860187 AI758143 AI338168 AI702936 BE221985 AI498727 AI918196 AI279735 AW771497 AI860133 AW237834 AW661759 AW028111 BE503416 AI360180 AW611715 AI871777 BE045447 BE326444 AI266547 AI800237 AI823315 AI478368 AI264281 AI675841 AI690041 AI498018 AI554124 AI239893 AI864054 AI280099 AI192815 AI620465 AI080201 AW002057 BE500986 AI341131 AI818991 AI566137 AI123403 BE219192 AW183844 AI499842 AW137971 AW138720 AW015526 AW138160 AW243163 AW138705 AW139927 AW140006 AW138810 AW137450 AW206970 AW135419 AW205974 AA043494 BE465106 AW139955 AI741112 BE326942 AA043506 AI079957 AI942432 AI392902 AI097047 AI470599 AA514553 AA984008 N47949 AI654114 AA884832 AI796752 AI765290 AI301155 AW470358 BE222764 AI823569 AI651188 AI692695 AI476643 BE504307 AI767573 BE219719 AI932249 AW467075 AI913633 BE221966 AI091025 AA969215 AI799810 AA931170 BE048559 AI809606 AI138614 AI739456 AI674605 AW772068 AI089286 AI625787 AI263418 AW008638 AI928389 AW628997 AI470010 AI914168 AI760003 AI203050 AI334069 AI694788 BE045337 AI948659 AI912982 AI867131 AI192102 AI767583 AI347518 AI566005 AI625884 AI215888 AI633904 AW182265 AW614357 AI128030 AI343685 AI914283 AI985003 AI823578 AI493053 AI380285 AI633895 AI267880 AI538162 AI991552 BE219479 BE219296 AI302178 AW779296 AI913805 AI631644 AI566772 AI985498 AI942289 AI935659 AI339092 AI247432 AI686472 AI766886 AI017228 AI333272 AW301668 AI972218 AW082027 AI632974 AI474761 AI766127 AW236578 AW000966 AI870734 AI222399 AI871249 AI703448 BE464210 AI768037 AI871585 AI767871 AI738757 AI220732 AI681633 AI768783 AI684463 AI307339 AI263203 AW665264 BE463969 AI768786 AI439118 AI127913 BE218324 AI672342 BE220052 AI796163 AI221662 AW197672 AW025300 AI769681 AW612448 BE219757 AW072420 AI669980 AI830418 AW204353 AA047011 AA913868 AI739146 AI669954 AW470507 AW614835 AW302151 AW772372 AI762427 AW339902 AW303370 BE464775 AW299818 AW236072 AW195060 AW274737 AW263062 AW183846 AI868894 AW300493 AW172509 AW516876 AW593773 AW299474 AW303546 AI817323 AI823624 AI694005 AI934589 AI343479 AI861825 AI962726 AI765845 AW080318 AI640227 AI763042 AI768903 AW235386 AA738489 AW341293 AA588585 BE221732 AI914179 AW611669 AI572789 AW194735 AW236122 AW236007 AW612789 AW197501 AW195046 AI797145 AI864423 AI458934 AI342848 AI693227 AI912642 AI689993 AA932572 AA740269 AW470392 AW086020 AI221701 T69326 T70461 AI765579 AI338263 AI431721 AI394249 AI186462 AI823571 AI953665 AI497954 AI761057 AI678228 AI640302 AI948742 AA594626 AA883155 AI972682 AI804774 AI300407 AI433524 AA897341 AI401175 AI291071 AA021213 AI126509 AI948955 AI218835 AA903938 AA502610 AI498320 AA584267 AA935285 AI476253 AA489658 AA975053 AA715326 AA557139 AA126417 AA971455 AA557319 AI499738 AA911438 AI913637 AA494506 N90793 AI990724 AA131667 AA128164 AA046840 AI262557 AA131729 AA594926 T59467 AA436907 AA044630 A1589177 AI279237 AI880498 AI431822 AA708934 AW612558 AI634069 W03610 AI192272 BE550862 AI400879 AA708507 AI128003 AI375308 AI271423 AI199552 AA125977 AI366498 AA458662 AI694382 AA044627 AI636263 AI796270 T90146 AW014724 AI870812 AI948781 AA369965 AI094721 AW271817 AI262898 AI244680 T69252 AI934148 AA046357 W19109 AA028157 AW021924 AA253491 AI189397 AI934388 D58282 W21323 W24288 AI682972 AA293683 AA284566 AV659511 AA434184 H87089 AA040038 N57464 AA343709 AW805815 R89837 301119 33384J BE621320 BE266806 BE276582 AW516729 AF142579 AW451687 AK000069 AA325236 BE168997 W73105 AA715365 BE278873 AA808894 AA386371 AW517942 AW750993 BE140314 BE392384 BE621757 AA318192 BE548173 AW152607 AW166898 AA352215 AW841506 T59802 AF147378 AA335719 AW956069 T59668 AA826362 AI961329 AI290469 AW197375 AI805651 AA160748 AA581089 A1968889 AA581100 AA501478 AI621069 AA468534 AA503715 AA658457 AI144504 BE387827 AA159880 324019 262792J AW177009 AI381610 323437 189513J AA287567 AA252404 AW967735 AA287568 AA761222 AA865644 AA831245 307845 198O4J0 BE514807 R43224 AI363450 AA450226 AF030942 324126 272259J AA385315 AI627453 AI050695 AI348281 309101 7570J AI340462 AI583268 AA079086 AI950777 AI301866 AI925108 AW876954 AW877000 AA525418 AA888549 AI934220 AW380220 AA804858 AI927576 T61151 AW384053 BE391691 AA533856 AA248400T48202 N57156 R68346 R26020 AL050332 W30806 H61369 AA092592 AA230324 BE271217 AW372903 T48772 AA358002 AA094302 AA559856 AW373308 AW373315 AW373297 AW373311 AW373314 AW373309 AW877055 AW770140 AW379805 A1581609 AW364144 AA078921 AA715432 AA654210 AI004899 AA602209 W47464 AA506588 R26822 AU076528 AI535743 AI535704 AI535681 315703 119175J AA402307 D60405 D61237 D59891 AW964877 AA325215 AI459739 N36070 N25658 AA083684 AW293368 AI761958 AI741205 AI693175 AW873603 AI143269 AI187124 N25199 H19323 AI650842 AW316825 AA083842 AA935650 AW298404 AI472001 AI648568 R17676 R41625 AI123237 R17677 AI206866 F36920 AI654713 F34084 AA618029 AI915139 AW275194 AW514577 D80420 AW149850 Z40953 AI867861 AA927547 AA974344 AI825793 AI635565 AI652157 BE504748 AW295759 F16800 AW839796 F01781 AA909730 AA984010 301373 368214J AA595235 AW973839 T03040 323665 54093J AW248307AA313452AW951927AA355961 BE566O80 323676 220254J AI702835 AI758919 AI685405 AI952108 AI299207 AI400767 AW105389 AI952710 AA845312 AI784118 AI537315 302086 23306J X57138 NM_003514 Z98744 BE253911 BE256314 A1095013 A1138475 323731 226193J AA323414 AW664013 AI809377 AI276041 AW296883 AI798340 323791 232336J AA333068 AA331863 AA331838 AW962531 AA331442 325040 23854J AW296368 AA247632 AK002030 R15304T08775 AW975664AI186801 AA730688 AW190918 AI141176AW513211 AI275071 AA988601 BE042933 BE045713 AW087176 324430 312113J AA464018 AA464079 AA468142 323892 477253J AA846318 W15478 AL042661 309488 1030131J AW131104 BE246610 302251 27216.4 AA333340 AW955834 R49755 U33428 . 302286 22717_6 R58438 AA358612 323915 110063J AL043362 AA350031 AW751972 BE549118 324594 330528J AA497090 AI351879 AI350914 301737 65_1 AI815981 AF287269 BE260960 BE263991 AA311733 F12145 F07345 Z43604 T29948 H64102 Z43611 T35364 N40667 AI909783 AW751045 AA160594 AI816064 AI307240 AI951554 AA641031 AA293045 AI942492 AI687077 R78689 H12368 AA894728 AI124930 AI423498 AA777759 AA614585 AW071822 T66288 AI418558 H21480 AI335011 AI051728 AA293436 AW302233 AW188628 N26393 AI076557 AI311022 AW451505 H62593 Z39666 H12315 AI761351 AI364142 F02935 AW571491 T35366AI240745 H64151 AA503793AA831948AI627686AI761531 F03591 F09782 301763 1688575J R01279 R05896 T86522 301780 18597_2 R05735 BE349600 R37388 N79751 R10115 AA702039 AA836147 AA505716 AI049661 AI499239 R54072 AI023394 AA827710 W60285 W500038 AI884786 AA827191 AA810075 AW005088 R70248 AI858560 AW078678 AA631306 H52839 AW085835 AI656182 AA737178 AW136923 AA281028 AA570316 AA722871 AA362737 AI217268 BE242373 R01113 AA628946 AI394527 AW402308 AI361110 AI917585 T99639 AA805326 N44577 AI394021 AW403385 T23949 AI497766 T96602 AA834947 AI693908 Z33450 T92127 BE541896 AI933301 BE251540 BE252269 N50968 AI695531 AW575523 AW296889 N93796 N89924 AI361804 AI085251 AA810694 BE303011 AA743784 R13478 AA358771 AA325294 AW964880 BE258953 R54116 AW881039 AW602593 301793 239325J BE265837 AA340632 T96304 T96075 T72780 H51978 R09868 303049 102592J AW408042 AW407562 BE172835 BE396893 BE269184 AA045741 BE004187 AW751261 W74283 301863 19477J BE263301 AI418863 NM_005194 X52560 AW328683 BE298869 D63161 301872 27494_4 H84730T73262 301893 6561J T80334 BE292758 AK000854 H16996 BE253691 R88508 AA357663 AW955288 AW579550 N98864 AA595201 AI742967 AA602658 AI091433 AA813367 AI983217 AW298007 AI628490 AI708037 AI560654 AI032983 R88509 R38972 AI687783 AI560153 AW874581 N69891 AA993617 H51180 AI269042 AI281358 AW591213 AI017724 AI262859 H16997 R38991 AI804355 AI868988 AI669525 AW023081 AL047848 310382 653318J A1734009 AI263076 AW272255 AI792912 303181 74060_2 AA452366 AA351338 BE262590 BE262591 AA074050 AA389667 BE161346 302569 17513_2 AC004472 BE312721 BE273942 F11928 T65358 BE612432 BE261576 BE179884 324893 4670 1 AA324119 AW246199 BE395368 BE261676 BE382334 BE394701 BE304548 T31940 BE398128 BE398019 BE296693 BE379564 BE269460 BE397065 Z42029 BE305028 AK000549 BE536182 BE314372 AW393349 T50987 AA069735 BE386997 AW381699 T51050 W95025 AA477678 AA348306 AW956831 AW06291& AL040397 BE305160 AA315419 AW249929 AA295944 AI635946 AI870259 AI951125 AW028250 AI885184 AW873113 AI077544 AW025091 AI817594 AI401718 AW008245 AI499064 AA599687 AI016890 AA765638 W93340 AA588708 AW519173 R51917 AA676778 AI084871 AA687684 AI860840 AI811921 AW514730 AA477561 N78845 AA779894 AA778559 AI968953 T16188 T32828 AA991426 AI474472 AI473542 AI828972 AW247906 AA977415 AW591489 AA8760O8 AW191893 AA074278 AW874099 Z40196 AW083615 F01544 T55984 AI290413 AI972167 AI365049 T36028 AI042568 BE560076 W17119 AA196376 T47999 R54309 303244 9334J AK001269 AL354613 AA147472 AA490803 BE207628 AW816113 AA085574 AW503392 AA299910 AW750305 BE079539 BE079484 BE512838 AK001593 AW968772 AW967440 AW206280 AA251270 AI627886 AA303599 AA147473 BE206616 AA490611 AA715039 AW590866 AW590447 AI864512 AA204731 AA894490 BE001136 AA612785 AA237035 AA149960 Z44257 R12986 AA448446 AI734041 AA422167 BE220551 R66041 R32927 R32942 AA258773 AW386142 R53730 N54624 AW880296 AA253485 AW954441 H98989 AW614348 AI654838 AA779793 AW237213 N66635 AI186812 AA947479 BE158011 AI859480 AW805579 N52010 AA806305 AI628445 AW270990 AA778165 AA149949 AI650728 AA749108 AA687257 AI261661 AA747442 AA481351 AA206339 AA903407 AW473306 AI688930 AA262281 AA448310 AA748820 AI347430 BE465692 R32839 AW510564 AA436408 AA257971 AA253362 AA938330 AA513150 AA976840 AA687117 AI281547 AA046243 R32825 AI631554 AW139818 AI244536 R52946 AW235443 R40183 AA299909 AA811958 AI302918 Z40213 BE158047 BE158060 AA767245 AW748159 AW50O735 AA094074 303252 149690_3 AW393348 AW393350 AW386713 AW384705 303273 67758J AA316069 BE274224 AL120803 BE170052 BE170039 AI906340 BE091310 AA491506 AW836675 AW863111 302640 21194 AW973784 AW843642 AA557573 AA578088 AI125161 AA349349 AI372794 BE312586 BE312777 T32148 AW239077 AI905357 Z42685 AW298772 R18578 AA780425 AA325971 AI372793 R10658 AA295021 AW885349 AW885288 BE271987 AW366519 AA349350 AA233207 R88464 AA434299 R02058 R00019 R54563 Z44886 R20150 AW368328 AW368321 AW802152 W79803 H12809 AA028951 AW367382 AA295247 H46355 AA905620 R54564 H12765 AW950608 AA028952 AA366908 AI085652 R43207 R77954 AI672848 T28547 AA427734 AA572853 AA769934 AI242108 R00020 R02059 R10659 AI185270 AI041890 NM_000080 X66403 F03854 AI652442 AI766431 AA976913 AI989882 AA471024 AI802727 AI824112 F02169 AI890843 BE250876 BE252859 AL157418 R78326 303342 189722J AW068570 AW247361 AA252638 AI751982 BE260758 BE293073 AW293303 302703 7075J AB040951 AK002094 AA676593 W44644 N42376 Z45942 AW841844 BE541378 AA358274 AA213391 T88771 NM 015493 AL117489 N88248 N31714 N36273 N31721 AW576263 AA449380 AI366135 AA551576 AW149789 Z17418 AW474331 AA056181 AI753611 AA046428 AA488007AA300764 N44732 AA377697AA346752AA485787AA894546 AA115295 AA299914 R88096 AA367342 AW884666 W84522 AA426325 AI983849 AA873315 AA873307 AI355170 AA534678 AA969227 AI127202 AW083323 AI338244 AW020877 AA780019 N33426 AW069314 N63079 AI926527 AA115270 AW886601 AI357402 AA599312 AI460358 AI926969 AA429402 N33197 AW886733 R88205 N52803 AW021988 AA213392 BE139656 AI142383 AA427844 AA954743 AA233622 AW073382 AA426326 AA493560 AA425133 N24819 AI419516 AI571515 AI147373 AI628677 AI214877 AA992123 H71599 AA029095 AA622262 AW117398 AW275286 AI911337 " AA864950 T94173 AI475634 AI701411 AI287696 T94091 AA505746 AI184310 AI350967 AI083596 W74274 AI954381 AI832767 AI368443 AA195578 AW874416 AI005421 AW014339 AA908660 AI350791 AW241382 AI473104 AI275186 AA515528 AA194897 AA782901 AW069414 F20248 AA426011 AI305169 AI832109 A1570082 AW072984 AI492474 AA919076 AL049024 W79889 N42400 AA625435 AW963887 AA233420 318446 604736J AW779971 AW300287 AW152002 AW069505 AI866447 AI298231 AI146920 AI692267 AI872876 302815 42200J BE397032 AJ292529 N40373 N34073 AA321112 AW959902 AA258103 AW860213 BE549059 BE296027 BE296657 AA300789 AI971491 AW513665 AA909530 AI951045 AW058103 AI971506 AI061239 AA600054 AI000807 AA969975 AA281492 AW593654 AA321111 AW298633 AI278754 AI863862 AI285506 AA989727 F33114 T16079 AI762625 AI492103 AW770346 AW026768 AI468710 AI499987 AA310412 AA622784 AA642297 AI866427 302879 36555J H11802T66097AF042831 318540 1018709_2 R42185 AW939055 T30280 Z43366 R54166 302928 22118J AA938905 AA574056 AA714466 AI805592 AI123431 AA229723 AA620759 AI004450 AW299820 AI949299 AW874308 AA626037 A974112 AA931563 AF073924 AA995769 AI766441 AI367730 AI081342 AA235800 AA235801 AI138970 AA719797 AA759343 X89673 AA759344 AA312909 X87825 Y10529 AC006271 AA758739 BE501015 AA909905 AF065857 AC006271 AA970044 304332 28696_41 AA158883 AA171835 AA187049 AA143546 BE299538 BE614280 BE621705 BE299684 BE619550 BE613099 BE619558 BE514331 BE617716 BE612920 BE615742 BE258739 BE621539 AI434511 BE546696 BE614324 BE379359 BE250106 BE250681 BE299592 BE300272 BE616805 BE397385 BE562024 BE271246 BE250556 BE280311 BE561995 BE618755 BE276126 BE546275 BE311547 BE262155 BE281082 BE513087 BE546891 BE514289 BE397389 BE267442 BE545455 ' BE614483 BE293447 BE270710 BE281071 BE267458 BE542095 BE262701 BE513634 BE548116 BE299546 BE619604 BE512885 BE616638 BE266173 BE258933 BE259710 BE268569 BE563861 BE614871 BE537509 BE250108 BE515323 BE538868 BE250081 BE277706 BE410127 BE619445 BE250753 BE304969 BE616348 BE546878 BE544962 BE410346 BE267256 X17206 NM_002952 BE304541 BE619171 BE259655 BE549186 BE314944 BE613101 BE378069 BE621110 BE542752 BE257029 BE531315 BE619306 BE267328 BE259439 BE297093 BE280651 BE407684 BE250201 BE312819 BE535432 BE279917 BE312626 BE531118 BE378744 BE275370 BE250195 BE409980 BE274432 BE266637 BE279321 BE622382 BE280232 BE263816 BE378977 BE300145 BE250204 BE547609 BE264377 BE266688 BE259746 BE260829 BE619517 BE388097 BE264025 BE618945 BE614758 BE312249 BE294359 BE531121 BE622300 BE615109 BE544354 BE614998 BE393239 BE297520 BE393221 BE278818 BE279309 BE265476 BE618772 BE615185 BE265144 BE249837 BE312230 BE407843 BE253884 BE407645 BE615804 BE619058 BE559512 BE383249 BE613497 BE294351 BE295062 BE622385 BE390654 BE535438 BE563186 BE396374 BE270842 BE386110 BE260368 BE250186 BE265875 BE537229 BE253369 BE256997 BE269482 BE264959 BE279072 AA662160 BE280733 AA858428 BE561308 BE267285 BE561422 BE563181 BE304614 BE295437 BE619424 BE275863 BE394315 BE408109 BE541866 BE253772 BE618236 BE535261 BE296490 BE278212 BE563154 BE257245 BE262274 BE513032 BE378567 BE394152 BE618947 BE269302 BE546516 BE536792 BE615187 BE261186 BE615367 BE619289 BE261184T49376 AL031671 BE273400 BE563457 BE545597 BE615169 AA150323 AA158723 AA079033 BE313333 AA160100 BE271115 BE294302 BE273051 BE273048 BE622390 AA837947 BE387721 AW973277 AA808731 BE280792 AA160444 BE256723AI745420AA643017 BE549441 BE293858 AW975249 AI620819 AW089494 AI434549 BE305231 AA081262 BE280101 AA522507 AI950880 AA187460 BE386860 AW859229 BE170489 BE620149 BE548218 AA316696 AA484426 AI567740 AA160605 AW939805 AA089573 BE300194 BE391331 AW975419 H26808 BE545544 BE615974 AW800241 BE616222 W17343 BE387865 T53697 C03943 BE617637 BE315130 T52942 T50588 N74693 AA187107T59919 AW797397 AA206447 AA854619 T57175 AI570296 AW517964 AA158269 AI282220 W25297 AI580710 BE262453 AI185868 AA526485 AI288051 AI582513 AA100675 AW615567 BE395354 AI472725 BE314881 BE621281 N99921 AI282689 AI432725 AW732011 AA872254 BE205807 T59435 AI282712 AA650505 AI004374 AA725260 BE313161 T60173 AI371260 BE385641 AW751812 AA078827 AI491858 AI433622 AA219118 AI002092 AA996003 AA064604 AI250287 AI304397 AI453213 AA653630 AI524573 AI440306 H48802 AA157843 AA715629 AW973788 AA932493 A1347563 AA181309 T67880 AA643033 AW467498 AA115904 AA935410 AA483032 AA084568 W25246 AI567588 AA155732 AA158614 AA888319 AA158568 AA188422 AI309183 AA084817 AA157995 AI859659 AA188008 AI287379 AI540675 AA085212 AW028391 AA173297 BE256792 AA182854 BE378771 BE538571 AA079037 BE281597 AA643926 W81011 AA159344 AA320691 AA877597 T57107 AW263819 AI690413 AI619605 AI687579 AA970560 AI368942 AI927104 AW419220 AI620051 AA128490 AA120825 AA079520 AA199648 AW188403 BE045224 AW265533AA074338AA102685AW779399AA192451 AA182771 AW366812 BE281418AA211094AA131073AA487924 AW674848 AI568103 AA171934 F30349 AW088785 AA581370 AA205482 AW352296 AW517565 AI376249 AA158884 AI340509 T59965 AA085193 AA071570 AI874045 AA852755 BE045217 AW189428 AA211141 AA652134 AI497729 AA994817 AI811459 BE535857 AW769697 AW167892 AW149305 AI864981 AW272126 AW023245 AI439266 AI953196 AA160912 AI718580 BE537547 AA501448 AA069308 L07393 AA353007 AA079235 AI539140 AA740154 W58341 AA888403 BE299000 AA196413 BE613327 BE261523 AA866599 AW844713 AI691159 AI079975 AW327479 BE180731 AA984805 303701 1155179J AW500732 AW504061 303759 447287J AA774672 AW504164 303773 356632J AA769074 AA570769 AA808585 AA808682 303778 174437J AW505368 AA218610 F11852T65345 AA397806 303784 414659J BE297711 AW505574 AA704983 303845 50211_2 F07942 T08033 303898 162688_3 BE386266 BE148823 T23215 AI906290 AA299906 BE207197 AW074114 AI760368 AI005358 AW662201 AA188988 AI690711 AA775103 AW072931 AI684269 AW129364 AW615634 AI049941 AW874040 AI352633 AA188989 AI287775 AA868774AA599660 20121 452027J AA780365 AA909233 AI275542 319590 171338J AA210878 AA215684 R11101 305186 17456_1 M13560 AA336951 AA161015 R72814 T69687 R75705 T61319 AA158454 R50579 T56649 AI214156 T70375 R31655 H64997 AW800487 H49110 AA634206 H42384 H21783 AI560152 AA664230 H42302 R48708 AA013277 T61901 T92417 AA875985 T61962 T63055 AA430725 AA458964 AA578746 AI582385 T63000 AI499875 H64998 AA022538 AI364804 AI865211 AI439714 AI224059 AI249917 T59258 AA477806 AA715834 AA916120 R38304 R35899 R82985 H25524 H82984 AW516728 T54642 AA079866 H27555 AA455820 T63919 R79450 AI431241 AA937349 AA127213 AA421729 H61196 T63894 AA013050 AA079133 W96364 AA487926 AI762796 H26377 AI433386 AI865423 AW371475 R98189 AA643978 AI718204 AW381954 AI862735 319638 226485J AA323758 R12731 R14082 320257 163534J R17531 AW960899 AA338366 AW673294 BE047729 BE047722 AA330746 AW841797 H05030 AI142105 R12654 320289 115941J H07989 AJ239462 H24544 AA078369 R74153 304703 33971_42 BE512926 BE304794 AA129140 AA052922 AA092258 BE378058 BE615391 BE615218 BE616188 AI214126 H05675 W56857 AI028525 BE617241 BE531271 AW856227 T56489 AA322005 AW794148 AF170577 BE615738 AA005138 L76930 L76932 L76933 X95410 AW389462 BE563092 AW997937 AA263158 AI520992 AW947350 AA522535 AW945921 AV653776 AW884835 AW947338 AI687178 AW945799 AI905627 AW948449 AV653751 AW945924 AA563898 AW945810 AW945832 AW371449 AW945864 AW948447 AW945910 AA643002 AA522680 AA522715 AA578840 AA523279 AA826150 AW945809 AW405998 AA551909 R23173 AA595545 AW389497 AI933770 AI125053 AI471803 AW795856 AW796937 W30675 H70317 H68296 T59240 AA397650 H59852 AA938072 AA978010 R35643 T89735 AW361585 AW196153 AI538069 AA604540 AI434259 R49181 T58717 AW062486 AW796966 AI648384 R77733 AI623502 BE171342 BE171303 R35658 AW974883 AW149898 AI500045 AI540710 AI540392 AW009172 AW277199 AI371312 AI500096 AI470297 AW372940 AW844562 AW844560 AW797965 AI691146 X07062 AW799199 H60666 AA837684 AF130734 T25952 AI933771 AI914860 AW391925 AW793843 AW795012 AW366709 AW750987 AW750985 R35765 AW844942 AW750986 H64920 R34651 X86703 321039 26338_2 BE018103 BE018083 BE293253 AW247083 BE207643 BE514793 BE183238 AA376427 AW273850 AW043786 BE439973 AL045428 AI889050 AA026496 AI422924 AI884485 W96068 AA020872 F37119 AA714378 AA021107 AA011141 AI554001 AI375841 AI469097 AA335219 AW967315 AI692177 AA410448 AI568858 AA582647 AA026419 AA281639 AW515248 AW007777 AA010840 AW188439 AI805423 AI148210 BE301590 AA744414 AA745392 AW167423 AA622659 AW000878 AI432387 AA760930 BE047189 AA021605 AV658045 AI093347 AA588594 H63143 AA639556 AI308976 AA379270 AA633407 AI874329 AI206484 AI493895 AI694103 AI249682 AA973765 AA872445 AI125446 AA287272 AW069761 AA682569 AW009712 BE542774 R50167 BE301574 AA991202 AA502006 AI219819 AW074373 AA617996 AI521242 F25241 AW615812 R16774 AA335218 AW673800 H26778 AI468557 AI886986 AI560759 AI460075 AA502968 AA503273 AA610680 AA287274 AA554020 AA284889 AA916636 AW469457 AW273250 AW673708 AW512948 AL041071 AI446042 AA903535 BE172441 AI282411 AW265021 AA810799 AI559865 AA729332AW004611 AW129451 AA659019 BE208239 AA610825 H03511 BE383995 R16474 AA281701 AW009244 AA287424AA558139 AW364081 306051 19085_3 F08147 AW408359 AW949429 R23785 AW247442 AA305512 T29095 AA905130 BE246361 BE244981 AA220199 BE504058 X80878 AA533727 AA608601 AW005964 AI811627 AI367037 AI277985 AI493719 AI277848 AA854982 AW247298 AI216345 AI041295 AI887378 AA781241 AI674270 AW628959 AI383083 BE504391 AA729421 AA552188 AA373387 AW880360 AW875262 AW875369 AW581540 AW875358 AW581568 R23735 AW134768 321163 171122J W03912 AW971410 AA506385 AA209530 H73495 H48629 W56149 321235 1102181J H56752 AW340384 N49521 320603 4297J AA853680 AK001668 BE386425 BE563549 BE296124 BE298950 R51419 U46295 BE147292 AA360056 R48018 AW845348 N47383 AI817280 AI671902 AA988104 AA479464 N56996 AI192374 AI927558 AA659888 AI799903 AA548397 AI161167 AI656333 AI418829 AW592671 BE327906 AW513346 AI888579 AW469410 AW512809 D25682 AA576079 AA479354 T30342 R51307 T16044 H29063 AW079357 AI339477 R47914 AI986068 AI870O65 AI868489 AI521099 AI582732 AA995540 AW957299 AA352608 AA676752 AA410510 AA358874 AI865724 AA853679 A1699265 AW188789 N47380 AA233715 320641 185591J BE258194 R55421 R55643 H42362 AA243884 320651 58648J AW886407 AA489268 R57015 R58094 BE077459 BE077423 BE546995 AW849216 T69383 AW938111 H60337 BE221073 321325 28266J AB033100 AA347036 BE260325 AW961669 AL047207 AA347037 AI766894 AA601045 AI559897 AW139033 AW274622 AW172884 AW089070 AA804340 AW798925 305704464759_-1 AA825266 322011 23158J AL137354 AL043375 306407 AA971985 306454 AA977992 306516 AA989542 306518 AA989598 306526 AA989713 306534 AA991487 306590 AI000246 306591 AI000248 306631 AI001149 306654 AI003654 306786 AI041589 306799 AI051696 308023 AI452732 308070 AI470948 AI475914 306805 AI055966 306814 AI066577 306873 AI086929 306911 AI095365 306982 AI127883 308238 AI559492 308258 AI565612 308289 AI571211 308311 AI581855 308332 AI591235 308511 AI687580 308601 AI719930 308612 AI735634 308636 AI744063 308814 AI819263 308851 AI829820 308981 A1873242 310570 1071946J A1318327 AI318328 AI318495 305022 AA627416 305060 AA635771 305070 AA639783 305079 AA641329 305134 AA653159 303977 AW512978 305216 AA669056 305263 AA679467 305266 AA679772 305396 AA721052 305403 AA723748 305488 AA749000 305549 AA773530 305601 AA780975 305610 AA782319 305621 AA789095 305710 AA826544 305724 AA827608 305744 AA831819 305752 AA835278 307018 AI140639 307055 AI148477 307058 AI148709 305801 AA845997 305830 AA857665 305836 AA858043 305852 AA862455 305858 AA863103 305866 AA864533 305867 AA864572 307126 AI184951 305903 AA873085 328803 c_7_hs 328809 c 7 hs 305949 AA884409 328829 c_7_hs 330021 c16_p2 330024 c16_p2 330028 c16_p2 330049 c17_p2 305993 AA889197 330095 c19_p2 330096 c19_p2 307205 AI192479 307427 AI243437 307491 AI268539 307581 AI284415 307588 AI285535 337672 CH22 6002FG. UNK_EM:AC0O 337693 CH22 6030FG_ LINK EM:ACOO 337738 CH22_6083FG. LINK EM.ACOO 307692 AI318342 307806 AI351739 309107 AI925823 309230 AI970747 339338 CH22_8300FG. UNK_BA354I1 309257 AI984183 309366 AW072970 309422 AW087175 325207 c10 hs 325257 c11_hs 309646 AW194694 309651 AW195850 325313 c11_hs 309924 AW340812 334030 CH22 1308FG 320 2 LINK EM 334040 CH22J318FG_322_8_LINK_EM 334083 CH22 1361FG 327 38_LINK_E 332810 CH22 26FG 7 12 LINK_C65E1 302747 32813 1 AF062275 L03830 302753 33029 1 M74299 M74302 M74303 302777 33803J AJ230640 AJ230648 304094 H11295 302824 35372 1 U21260 U21258 302996 41196J AF054663 AF124197 R70292 325870 c16 hs 304240 AA009802 304410 AA284508 304443 AA399444 304475 AA428879 304522 AA465405 304678 AA548556 304705 AA564064 306004 AA889992 306008 AA894390 306013 AA896990 306082 AA908508 336174 CH22_3567FG_710_1_LINK_DA 306094 AA908877 304823 AA584837 304872 AA595289 304918 AA602697 304955 AA613504 306249 AA933840 306286 AA936892 306295 AA937331 306317 AA947909 306347 AA961144 306365 AA962086 306398 AA970548 330401 entrez D28383 D28383 330463 460_2 NM 001055 AA332948 U2630 BE168856 AA376730 H12694 AA810348 AA621972 AI818950 AV645367 AI819966 AA910602 AW512449 H67893 AI310497 AI304330 AI339217 AW193588 AW438688 AI818970 AW316799 AA906527 AA777570 N47673 AI336428 AW945133 AI038606 R29692 AW194197 AI304748 H12639 AA053178 AA493213 AA676958 AA113154 AI313469 AI368239 R93183 W24532 U52852 U54701 AL046864 AA365795 330535 1374_-8 U11872 33263410404_2 U24488 NM_007116 TABLE 13B shows the genomic positioning for those primekeys lacking unigene ID's and accession numbers in Table 13. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed. Pkey: Unique number corresponding to an Eos probeset Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (Gl) numbers Strand: Indicates DNA strand from which exons were predicted. NLposition: Indicates nudeotide positions of predided exons. Pkey Ref Strand NLposition 332791 Plus 72720-73315 332792 Plus 73381-73768 332810 Plus 304296-304384 332944 Plus 2414825-2414932 332972 Plus 2572152-2572236 333133 Plus 3360058-3360195 333154 Plus 3615887-3616019 333155 Plus 3616832-3617003 333227 Plus 3992866-3992968 333230 Plus 3995507-3996507 333298 Plus 4581537-4581947 333304 Plus 4629943-4630242 333305 Plus 4630388-4630645 333365 Plus 4786883-4787283 333383 Plus 4907179-4907277 333391 Plus 4916697-4916780 333392 Plus 4918294-4918433 333397 Plus 4922466-4922635 333403 Plus 4925140-4925256 333413 Plus 4943824-4943974 333445 Plus 5097827-5097885 333479 Plus 5272855-5272939 333481 Plus 5286358-5286505 333483 Plus 5297945-5298105 333516 Plus 5570204-5570390 333517 Plus 5570729-5570925 333518 Plus 5571761-5572025 333531 Plus 5622622-5622684 333566 Plus 5954226-5954473 333572 Plus 6026896-6027189 333586 Plus 6246834-6247314 333588 Plus 6255445-6255779 333594 Plus 6308990-6309450 333595 Plus 6323103-6323348 333600 Plus 6355629-6355925 333601 Plus 6360075-6360442 333607 Plus 6504431-6504690 333612 Plus 6549563-6549697 333613 Plus 6550643-6550748 333614 Plus 6551227-6551389 333624 Plus 6595146-6595244 333626 Plus 6614174-6614467 333635 Plus 6663683-6663973 333637 Plus 6674968-6675134 333642 Plus 6708760-6709139 333647 Plus 6772502-6772779 333653 Plus 6811130-6811392 333654 Plus 6816731-6816993 333656 Plus 6822087-6822406 333657 Plus 6831369-6831445 333658 Plus 6835282-6835474 333659 Dunham, I. etal. Plus 6836179-6836248 333684 Dunham, I. etal. Plus 7169561-7169742 333686 Dunham, I. etal. Plus 7177117-7177302 333697 Dunham, I. etal. Plus 7203859-7203934 333698 Dunham, I. etal. Plus 7205279-7205383 333699 Dunham, I. etal. Plus 7206101-7206175 333703 Dunham, I. etal. Plus 7215559-7215663 333709 Dunham, I. etal. Plus 7229730-7229835 333747 Dunham, I. etal. Plus 7605884-7606206 333774 Dunham, I. etal. Plus 7716509-7716636 333775 Dunham, I. etal. Plus 7729983-7730149 333806 Dunham, I. etal. Plus 7877475-7877666 333843 Dunham, I. etal. Plus 7978762-7978887 333854 Dunham, I. etal. Plus 8029446-8029524 333873 Dunham, I. etal. Plus 8133266-8133429 333880 Dunham, I. etal. Plus 8151923-8152133 333885 Dunham, I. etal. Plus 8154352-8154437 333918 Dunham, I. etal. Plus 8307124-8307215 333947 Dunham, I. etal. Plus 8579888-8579966 333961 Dunham, I. etal. Plus 8617999-8618104 333981 Dunham, I. etal. Plus 8782374-8782643 333991 Dunham, I. etal. Plus 8837419-8837551 333994 Dunham, I. etal. Plus 8852749-8852894 334030 Dunham, I. etal. Plus 9288463-9288782 334083 Dunham, I. etal. Plus 9837016-9837081 334111 Dunham, I. etal. Plus 10279365-10279531 334135 Dunham, I. etal. Plus 10457085-10457183 334218 Dunham, I. etal. Plus 12680289-12680378 334249 Dunham, I. etal. Plus 13190430-13190574 334262 Dunham, I. etal. Plus 13231452-13231581 334264 Dunham, I. etal. Plus 13234447-13234544 334327 Dunham, I. etal. Plus 13577413-13577496 334328 Dunham, I. etal. Plus 13589868-13589936 334340 Dunham, I. etal. Plus 13642407-13642522 334454 Dunham, I. etal. Plus 14326506-14326738 334504 Dunham, I. etal. Plus 14510206-14510398 334508 Dunham, I. etal. Plus 14514936-14515122 334512 Dunham, I. etal. Plus 14545933-14546366 334582 Dunham, I. etal. Plus 15026255-15026371 334659 Dunham, I. etal. Plus 15460624-15460726 334721 Dunham, I. etal. Plus 15796816-15796987 334723 Dunham, I. etal. Plus 15805317-15805399 334730 Dunham, I. etal. Plus 15967830-15967934 334774 Dunham, I. etal. Plus 16251857-16252178 334778 Dunham, I. etal. Plus 16276180-16276395 334851 Dunham, I. etal. Plus 17820110-17820810 334885 Dunham, I. etal. Plus 19233667-19233787 334902 Dunham, I. etal. Plus 19317083-19317195 334905 Dunham, I. etal. Plus 19322553-19322680 334906 Dunham, I. etal. Plus 19323493-19323590 334910 Dunham, I. etal. Plus 19398155-19398684 335018 Dunham, I. etal. Plus 20688288-20688415 335025 Dunham, I. etal. Plus 20743941-20744050 335033 Dunham, I. etal. Plus 20753188-20753314 335044 Dunham, I. etal. Plus 20842088-20842682 335142 Dunham, I. etal. Plus 21465105-21465186 335157 Dunham, I. etal. Plus 21543302-21544341 335160 Dunham, I. etal. Plus 21573388-21573497 335174 Dunham, I. etal. Plus 21631301-21631447 335188 Dunham, I. etal. Plus 21669118-21669328 335190 Dunham, I. etal. Plus 21680807-21680876 335191 Dunham, I. etal. Plus 21681110-21681183 335193 Dunham, . etal. Plus 21692208-21692362 335204 Dunham, . etal. Plus 21750636-21750726 335222 Dunham, I etal. Plus 21885542-21885608 335226 Dunham, I . etal. Plus 21890838-21890930 335227 Dunham, I . etal. Plus 21892145-21892289 335309 Dunham, .etal. Plus 22500158-22500276 335310 Dunham, I etal. Plus 22500714-22500831 335311 Dunham, I. etal. Plus 22501602-22501676 335355 Dunham, I. etal. Plus 22779222-22779516 335362 Dunham, I. etal. Plus 22809167-22809461 335368 Dunham, I. etal. Plus 22843040-22843184 335384 Dunham, I. etal. Plus 22918150-22918263 335385 Dunham, I. etal. Plus 22919072-22919339 335436 Dunham, I. etal. Plus 23427793-23427923 335440 Dunham, I. etal. Plus 23458702-23459017 335441 Dunham, I. etal. Plus 23460632-23460724 335450 Dunham, I. etal. Plus 23480190-23480270 335453 Dunham, I. etal. Plus 23483333-23483459 335458 Dunham, i. etal. Plus 23490034-23490143 335464 Dunham, I. etal. Plus 23500331-23500496 335496 Dunham, I. etal. Plus 24164386-24164545 335497 Dunham, I. etal. Plus 24167666-24167869 335498 Dunham, I.etal. Plus 24172082-24172161 335499 Dunham, I. etal. Plus 24176698-24176869 335500 Dunham, I. etal. Plus 24178236-24178326 335507 Dunham, I. etal. Plus 24219973-24220039 335510 Dunham, I.etal. Plus 24222975-24223118 335513 Dunham, I. etal. Plus 24224272-24224496 335627 Dunham, I. etal. Plus 25150005-25150061 335651 Dunham, I. etal. Plus 25317560-25317696 335655 Dunham, I. etal. Plus 25333211-25333369 335656 Dunham, I. etal. Plus 25333601-25333751 335658 Dunham, I. etal. Plus 25336315-25336406 335663 Dunham, I. etal. Plus 25342680-25342802 335665 Dunham, I. etal. Plus 25344096-25344287 335667 Dunham, I. etal. Plus 25345735-25345856 335668 Dunham, I. etal. Plus 25346313-25346447 335689 Dunham, I. etal. Plus - 25454350-25454604 335690 Dunham, I. etal. Plus 25455442-25455625 335715 Dunham, I. etal. Plus 25565941-25566052 335719 Dunham, I. etal. Plus 25593936-25594101 335734 Dunham, I. etal. Plus 25688723-25688869 335744 Dunham, I. etal. Plus 25716483-25716615 335809 Dunham, I. etal. Plus 26310772-26310909 335819 Dunham, I. etal. Plus 26356341-26356470 335822 Dunham, I.etal. Plus 26364087-26364196 335872 Dunham, I. etal. Plus 26820760-26820943 335885 Dunham, I.etal. Plus 26933436-26933534 335968 Dunham, I. etal. Plus 27743843-27744029 335971 Dunham, I. etal. Plus 27752808-27753017 335975 Dunham, I. etal. Plus 27801321-27801391 335976 Dunham, I. etal. Plus 27809041-27809187 335989 Dunham, I. etal. Plus 27983788-27983860 335990 Dunham, I. etal. Plus 27988532-27988608 336010 Dunham, I. etal. Plus 28570239-28570330 336093 Dunham, I.etal. Plus 29556922-29557002 336126 Dunham, I. etal. Plus 30057891-30058105 336129 Dunham, I. etal. Plus 30062259-30062348 336187 Dunham, I. etal. Plus 30433494-30433585 336188 Dunham, I. etal. Plus 30434870-30435004 336225 Dunham, I. etal. Plus 30833614-30833788 336371 Dunham, I. etal. Plus 33968108-33968204 336373 Dunham, I. etal. Plus 33976308-33976504 336377 Dunham, I. etal. Plus 33994489-33994599 336380 Dunham, I. etal. Plus 33995323-33995434 336383 Dunham, I. etal. Plus 34005784-34005964 336384 Dunham, I. etal. Plus 34007429-34007559 336385 Dunham, i. etal. Plus 34007879-34008159 336386 Dunham, I. etal. Plus 34012965-34013115 336441 Dunham, I. etal. Plus 34187606-34187663 336444 Dunham, I. etal. Plus 34190585-34190718 336484 Dunham, I. etal. Plus 34237425-34237505 336497 Dunham, I. etal. Plus 34267190-34267245 336499 Dunham, I. etal. Plus 34267504-34267572 336503 Dunham, I. etal. Plus 34271306-34271372 336548 Dunham, I. etal. Plus 34353881-34354826 336552 Plus 34356420-34356527 336553 Plus 34356683-34356753 336567 Plus 34428228-34428395 336568 Plus 34428521-34428637 336659 Plus 1896402-1896478 336715 Plus 3110198-3110314 336803 Plus 6106904-6106990 336805 Plus 6126661-6126786 336850 Plus 7745284-7745355 336857 Plus 8130457-8130612 336911 Plus 11035818-11035984 336949 Plus 12818687-12818891 336950 Plus 12875843-12875912 336958 Plus 13203550-13203973 336993 Plus 15096270-15096324 337076 Plus 19338177-19338679 337109 Plus 21166580-21166650 337123 Plus 22052874-22052942 337151 Plus 23106433-23106510 337189 Plus 24225887-24225954 337241 Plus 27280182-27280313 337337 Plus 30395182-30395285 337353 Plus 30804624-30804780 337384 Plus 31333399-31333580 337396 Plus 31585902-31586067 337414 Plus 31953012-31953205 337418 Plus 32014049-32014131 337461 Plus 32803968-32804028 337480 Plus 33219714-33219779 337482 Plus 33227865-33227946 337483 Plus 33237292-33237427 337490 Plus 33318571-33318644 337522 Plus 33963188-33963979 337532 Plus 34187269-34187366 337552 Plus 19497-19600 337584 Plus 945236-945452 337611 Plus 1482883-1483016 337672 Plus 3331236-3331313 337693 Plus 3575975-3576153 337738 Plus 3865738-3865814 337926 Plus 6286377-6286470 337927 Plus 6343033-6343172 337935 Plus 6534661-6534782 337944 Plus 6589383-6589450 337954 Plus 6831483-6831620 337996 Plus 7445532-7445633 338004 Plus 7601363-7601520 338016 Plus 7863131-7863310 338174 Plus 12771102-12771268 338176 Plus 12774072-12774223 338238 Plus 14661936-14662015 338277 Plus 16167622-16167962 338294 Plus 16463958-16464539 338316 Plus 17089711-17089988 338323 Plus 17154655-17154792 338324 Plus 17155309-17155574 338386 Plus 18611213-18611407 338398 Plus 18953492-18953581 338410 Plus 19292807-19292916 338414 Plus 19345573-19345660 338460 Plus 20233372-20233488 338481 Plus 20942659-20942873 338489 Plus 21142605-21143049 338500 Plus 21253847-21253974 338514 Plus 21379420-21379655 338530 Plus 21636361-21636509 338620 Plus 23540239-23540334 338631 Plus 23711167-23711241 338653 Plus 24219427-24219509 338660 Dunham, I. etal. Plus 24387122-24387266 338704 Dunham, I. etal. Plus 25230432-25230548 338847 Dunham, I. etal. Plus 27995337-27995420 338887 Dunham, I. etal. Plus 28465244-28465384 338895 Dunham, I. etal. Plus 28598893-28599135 338915 Dunham, I. etal. Plus 28824881-28824977 338925 Dunham, I. etal. Plus 28883892-28884036 338936 Dunham, I. etal. Plus 29148022-29148160 338952 Dunham, I. etal. Plus 29418831-29418968 338980 Dunham, I. etal. Plus 29896789-29896874 338981 Dunham, I. et.al. Plus 29897917-29898008 338986 Dunham, I. etal. Plus 30007287-30007415 339009 Dunham, I. et.al. Plus 30348477-30348598 339017 Dunham, I. etal. Plus 30420896-30421090 339045 Dunham, I. etal. Plus 30744286-30744356 339046 Dunham, I. etal. Plus 30746269-30746420 339059 Dunham, I. etal. Plus 30814655-30814801 339067 Dunham, I. etal. Plus 30869347-30869412 339069 Dunham, I. etal. Plus 30880975-30881070 339078 Dunham, I. etal. Plus 30914310-30914423 339084 Dunham, I. etal. Plus 30944556-30944803 339101 Dunham, I. etal. Plus 31158047-31158123 339102 Dunham, I. etal. Plus 31169321-31169563 339103 Dunham, I. etal. Plus 31170343-31170454 339115 Dunham, I. etal. Plus 31459869-31459927 339157 Dunham, I. etal. Plus 32131701-32131833 339166 Dunham, I. et.al. Plus 32210902-32211006 339167 Dunham, I. et.al. Plus 32213567-32213730 339288 Dunham, I. etal. Plus 33169611-33169691 339289 Dunham, I. etal. Plus 33186756-33186903 339291 Dunham, I. etal. Plus 33205057-33205247 339407 Dunham, I. etal. Plus 34189461-34189620 332865 Dunham, I. etal. Minus 1391482-1391218 332881 Dunham, I. etal. Minus 1563520-1563184 332930 Dunham, I. etal. Minus 2022565-2022497 332931 Dunham, I. etal. Minus 2023651-2023562 332984 Dunham, I. etal. Minus 2632606-2632457 332986 Dunham, etal. Minus 2635398-2635206 332997 Dunham, etal. Minus 2710509-2710375 333051 Dunham, etal. Minus 2991973-2991840 333061 Dunham, etal. Minus 3029631-3029527 333064 Dunham, I. etal. Minus 3030722-3030623 333096 Dunham, I. etal. Minus 3184234-3184118 333099 Dunham, I. etal. Minus 3206796-3206674 333106 Dunham, I. etal. Minus 3230744-3230547 333160 Dunham, I. etal. Minus 3654893-3654678 333163 Dunham, I. etal. Minus 3665124-3664962 333165 Dunham, I. etal. Minus 3674052-3673905 333166 Dunham, I. etal. Minus 3694664-3694567 333170 Dunham, I. etal. Minus 3733394-3733299 333174 Dunham, I. etal. Minus 3764284-3764210 333188 Dunham, I. etal. Minus 3826990-3826863 333214 Dunham, I. etal. Minus 3966559-3966437 333232 Dunham, I. etal. Minus 4001551-4001365 333237 Dunham, I. et.al. Minus 4003326-4003219 333239 Dunham, I. et.al. Minus 4095861-4094462 333255 Dunham, I. etal. Minus 4297883-4297716 333259 Dunham, I. etal. Minus 4306769-4306639 333274 Dunham, I. etal. Minus 4389146-4388954 333290 Dunham, I. etal. Minus 4530734-4530554 333295 Dunham, I. etal. Minus 45492904549198 333296 Dunham, I. etal. Minus 4550766-4550644 333310 Dunham, I. etal. Minus 4637315-4637232 333311 Dunham, I. etal. Minus 4637933-4637844 333312 Dunham, I. etal. Minus 4638794-4638635 333313 Dunham, I. etal. Minus 4639397-4639277 333315 Dunham, I. etal. Minus 5405980-5405876 333318 Dunham, I. etal. Minus 4642636-4642564 333321 Dunham, I. etal. Minus 4649080-4648934 333327 Dunham, I. etal Minus 4657947-4657828 333335 Dunham, I. etal Minus 4672656-4672564 333337 Dunham, I. etal Minus 46779304677841 333454 Dunham, I. etal Minus 5137007-5136880 333458 Dunham, I. eta! Minus 5143942-5143806 333459 Dunham, I. etal Minus 5144548-5144344 333470 Dunham, I. etal Minus 5223319-5223088 333493 Dunham, I. etal Minus 4637315-4637232 333496 Dunham, I. etal Minus 5404643-5404523 333498 Dunham, I. etal Minus 5405980-5405876 333510 Dunham, I. etal Minus 5557628-5557469 333546 Dunham, I. etal Minus 5886643-5886442 333561 Dunham, I. etal Minus 5903659-5903590 333738 Dunham, I. etal Minus 7552160-7552084 333780 Dunham, I. etal Minus 7750367-7750277 333783 Dunham, I. et.al Minus 7751850-7751777 333818 Dunham, I. etal Minus 7911959-7911762 333894 Dunham, I. etal Minus 8188855-8188709 333897 Dunham, I. etal Minus 8194390-8194284 333900 Dunham, I. etal Minus 8200268-8200122 333909 Dunham, I. et.al Minus 8229639-8229477 333936 Dunham, I. etal Minus 8512805-8512564 333944 Dunham, I. et.al Minus 8557051-8556936 334040 Dunham, I. etal Minus 9342995-9342934 334154 Dunham, I. etal Minus 10570714-10570572 334178 Dunham, I. et.al Minus 11755052-11754971 334188 Dunham, I. etal Minus 11925963-11925834 334273 Dunham, I. etal Minus 13265608-13265522 334282 Dunham, I. etal Minus 13285293-13285178 334285 Dunham, I. etal Minus 13289990-13289793 334286 Dunham, I. etal Minus 13291759-13291569 334303 Dunham, I. etal Minus 13454331-13454217 334305 Dunham, I. etal Minus 13456310-13456209 334306 Dunham, I. etal Minus 13461157-13461049 334320 Dunham, I. etal Minus 13496857-13496717 334352 Dunham, I. etal Minus 13675908-13675828 334353 Dunham, I. etal Minus 13683722-13683596 334359 Dunham, I. etal Minus 13728664-13728534 334363 Dunham, I. etal Minus 13740004-13739812 334365 Dunham, I. etal Minus 13742078-13741971 334399 Dunham, I. etal Minus 14186289-14186163 334409 Dunham, I. etal Minus 14195181-14195075 334414 Dunham, I. etal Minus 14234033-14233932 334470 Dunham, I. etal . Minus 14389581-14389442 334483 Dunham, I. etal Minus 14428355-14428281 334489 Dunham, I. etal . Minus 14455428-14454288 334498 Dunham, I. eta . Minus 14483789-14483700 334501 Dunham, I. eta . Minus 14487509-14487356 334502 Dunham, I. eta . Minus 14488605-14488526 334543 Dunham, I. eta . Minus 14834496-14834116 334622 Dunham, I. eta . Minus 15191678-15191609 334650 Dunham, I. eta . Minus 15371251-15371178 334680 Dunham, I. eta . Minus 15520047-15519887 334745 Dunham, I. eta . Minus 16049960-16049653 334756 Dunham, I. eta . Minus 16128678-16128528 334758 Dunham, I. eta . Minus 16132368-16132233 334761 Dunham, I. eta . Minus 16138424-16138319 334763 Dunham, I. eta . Minus 16148136-16148077 334784 Dunham, I. eta . Minus 16294548-16294360 334790 Dunham, I. eta . Minus 16307576-16307509 334793 Dunham, I. eta . Minus 16330748-16330681 334802 Dunham, I. eta . Minus 16413158-16413026 334820 Dunham, I. eta . Minus 16764338-16764249 334824 Dunham, I. eta . Minus 16857777-16857674 334832 Dunham, i. eta . Minus 17173957-17173760 334842 Dunham, I. eta . Minus 17464352-17464181 334844 Dunham, I. eta . Minus 17503891-17503768 334857 Dunham, I. eta . Minus 18488368-18488242 334927 Dunham, I.eta . Minus 19988711-19987853 334939 Dunham, . et.al. Minus 20131162-20131054 334951 Dunham, . et.al. Minus 20147708-20147502 334969 Dunham, .etal. Minus 20188176-20188020 334972 Dunham, .etal. Minus 20294734-20294611 335050 Dunham, .etal. Minus 20884109-20883951 335078 Dunham, .etal. Minus 21059529-21059458 335102 Dunham, .etal. Minus 21313841-21313598 335105 Dunham, . etal. Minus 21320563-21320440 335110 Dunham, .etal. Minus 21334136-21333811 335111 Dunham, . etal. Minus 21335946-21335809 335115 Dunham, . etal. Minus 21388250-21388146 335116 Dunham, .et.al. Minus 21388573-21388414 335185 Dunham, I .etal. Minus 21651593-21651522 335186 Dunham, I .etal. Minus 21656436-21656338 335230 Dunham, .etal. Minus 21899517-21898678 335236 Dunham, . etal. Minus 21915016-21914870 335243 Dunham, . etal. Minus 21933519-21933365 335249 Dunham, . etal. Minus 21950851-21950669 335258 Dunham, .etal. Minus 22043431-22043262 335261 Dunham, .etal. Minus 22063937-22063772 335276 Dunham, . etal. Minus 22154036-22153937 335279 Dunham, .etal. Minus 22168834-22168638 335330 Dunham, .etal. Minus 22556589-22556422 335331 Dunham, .et.al. Minus 22556823-22556708 335334 Dunham, .etal. Minus 22560390-22560136 335346 Dunham, .etal. Minus 22641097-22640918 335349 Dunham, .etal. Minus 22661861-22661271 335611 Dunham, .etal. Minus 25070825-25070706 335612 Dunham, .etal. Minus 25072328-25072142 335671 Dunham, .etal. Minus 25358629-25358533 335676 Dunham, .etal. Minus 25395274-25395152 335680 Dunham, .et.al. Minus 25402437-25402361 335750 Dunham, .etal. Minus 25732501-25731972 335752 Dunham, .etal. Minus 25757026-25756890 335755 Dunham, .etal. Minus 25763806-25763747 335767 Dunham, .etal. Minus 25819547-25819218 335774 Dunham, .etal. Minus 25883733-25883572 335777 Dunham, .etal. Minus 25885770-25885599 335778 Dunham, .etal. Minus 25886469-25886334 335797 Dunham, .etal. Minus 25958182-25958030 335800 Dunham, . etal. Minus 25985373-25985280 335818 Dunham, .etal. Minus 26323886-26323744 335834 Dunham, . etal. Minus 26391707-26391530 335840 Dunham, .etal. Minus 26420596-26420538 335844 Dunham, .etal. Minus 26433427-26433344 335846 Dunham, .etal. Minus 26436727-26436621 335856 Dunham, .etal. Minus 26662452-26662346 335887 Dunham, .etal. Minus 26939225-26938782 335888 Dunham, . etal. Minus 26943037-26942820 335889 Dunham, . etal. Minus 26946988-26946901 335890 Dunham, . etal. Minus 26949087-26948665 335893 Dunham, . etal. Minus 26973898-26973747 335895 Dunham, . etal. Minus 26975307-26975239 335896 Dunham, . etal. Minus 26977639-26977558 335900 Dunham, . etal. Minus 26980354-26980238 335907 Dunham, . etal. Minus 27013352-27013273 335943 Dunham, . etal. Minus 27446610-27446378 335956 Dunham, . etal. Minus 27653729-27653635 335959 Dunham, . etal. Minus 27682313-27682145 335962 Dunham, . etal. Minus 27704276-27704144 336040 Dunham, .etal. Minus 29036458-29036300 336044 Dunham, .etal. Minus 29043828-29043727 336047 Dunham, .etal. Minus 29050617-29050466 336068 Dunham, .etal. Minus 29252077-29251969 336143 Dunham, . etal. Minus 30135948-30135854 336158 Dunham, .etal. Minus 30163730-30163610 336174 Dunham, . etal. Minus 30241988-30241839 336223 Dunham, i.etal. Minus 30816306-30816195 336245 Dunham, 1.etal. Minus 31420569-31420509 336274 Minus 32085468-32085303 336318 Minus 33364452-33364338 336326 Minus 33567328-33567201 336339 Minus 33798479-33798330 336340 Minus 33812069-33811915 336355 Minus 33874750-33874649 336392 Minus 34015868-34015736 336393 Minus 34016145-34015951 336394 Minus 34016457-34016298 336400 Minus 34023437-34023298 336402 Minus 34024090-34023981 336413 Minus 34046702-34046576 336424 Minus 34055549-34055491 336425 Minus 34058544-34058446 336437 Minus 34074154-34074090 336447 Minus 34198207-34197996 336449 Minus 34204707-34204577 336466 Minus 34213195-34213046 336492 Minus 34255578-34255437 336511 Minus 34277480-34277351 336512 Minus 34278373-34278275 336520 Minus 34319184-34319101 336522 Minus 34320169-34320056 336524 Minus 34321055-34320921 336527 Minus 34322071-34321966 336534 Minus 34326797-34326620 336536 Minus 34327678-34327538 336542 Minus 34331316-34331183 336556 Minus 34375244-34374907 336557 Minus 34375443-34375341 336558 Minus 34375825-34375698 336559 Minus 34376430-34376261 336560 Minus 34376814-34376596 336561 Minus 34377168-34376928 336597 Minus 7627912-7627757 336601 Minus 13265853-13265654 336642 Minus 1304281-1304212 336645 Minus 1351268-1351168 336662 Minus 2158060-2157993 336664 Minus 1993558-1993481 336676 Minus 2022565-2022497 336684 Minus 2158060-2157993 336686 Minus 2160698-2160486 336714 Minus 3094026-3093871 336719 Minus 3331631-3331503 336736 Minus 4093128-4093041 336744 Minus 4333001-4332848 336786 Minus 5419973-5419873 336793 Minus 5631345-5631237 336859 Minus 8201756-8201561 336863 Minus 8396673-8396425 336933 Minus 11760045-11759981 336942 Minus 12027537-12027455 336960 Minus 13267243-13267172 336969 Minus 13725722-13725643 336971 Minus 13732308-13732221 337003 Minus 15523541-15523422 337011 Minus 16106423-16106080 337070 Minus 19034423-19034321 337072 Minus 19077452-19077323 337086 Minus 19657011-19656881 337140 Minus 22649450-22649388 337193 Minus 24594969-24594874 337256 Minus 27659956-27659876 337278 Minus 28429017-28428848 337284 Minus 28491414-28491094 337293 Minus 28846334-28845873 337316 Minus 29657129-29656997 337326 Minus 30017199-30017069 337382 Dunham, I.etal Minus 31233666-31233579 337392 Dunham, I.etal Minus 31442311-31442229 337406 Dunham, I.etal Minus 31864840-31864588 337412 Dunham, I.etal Minus 31916487-31916312 337419 Dunham,I.etal Minus 32021496-32021170 337436 Dunham, I.etal Minus 32257869-32257739 337455 Dunham, I.etal Minus 32434517-32434425 337509 Dunham, I.etal Minus 33414613-33414498 337518 Dunham, I.etal Minus 33796750-33796647 337529 Dunham, I.etal Minus 34043668-34043546 337533 Dunham, I.etal Minus 34193388-34193261 337539 Dunham, I.etal Minus 34254490-34254322 337551 Dunham, etal. Minus 34524446-34524362 337553 Dunham, etal. Minus 24230-24160 337591 Dunham, etal. Minus 1006414-1006184 337592 Dunham, etal. Minus 1007791-1007634 337593 Dunham,I.etal. Minus 1009460-1009291 337607 Dunham, I. etal. Minus 1355719-1355637 337612 Dunham, I. etal. Minus 1570235-1570142 337635 Dunham, I.etal. Minus 2169690-2169569 337824 Dunham, I.etal. Minus 45595404559266 337825 Dunham, I.etal. Minus 45671554567005 337850 Dunham, I.etal. Minus 5077143-5076943 337854 Dunham, I.etal. Minus 5153435-5153272 337913 Dunham, I.etal. Minus 6149843-6149786 337915 Dunham, I. etal. Minus 5922748-5922690 337968 Dunham, I.etal. Minus 7095797-7095680 338010 Dunham, I. etal. Minus 7754282-7754184 338012 Dunham, I. et.al. Minus 7761421-7761351 338017 Dunham, I. etal. Minus 7864521-7864401 338065 Dunham, I.etal. Minus 7235048-7234950 338094 Dunham, I.etal. Minus 9595602-9595440 338129 Dunham, I.etal. Minus 10915338-10915237 338132 Dunham, I.etal. Minus 10989617-10989530 338150 Dunham, I.etal. Minus 11478551-11478355 338157 Dunham, I.etal. Minus 11731444-11731375 338195 Dunham, I.etal. Minus 13484103-13483972 338255 Dunham, I.etal. Minus 15242294-15242231 338276 Dunham, I.etal. Minus 16109555-16109398 338431 Dunham, I.etal. Minus 19747608-19747496 338448 Dunham,I.etal. Minus 20151152-20151054 338451 Dunham, I. etal. Minus 20174286-20174193 338477 Dunham, I.etal. Minus 20821897-20821838 338534 Dunham, I.etal. Minus 21771238-21771170 338682 Dunham, I.etal. Minus 24800712-24800461 338684 Dunham,I.etal. Minus 24827522-24827428 338689 Dunham, I.etal. Minus 24893073-24892972 338695 Dunham, I.etal. Minus 25104153-25104016 338825 Dunham, I. etal. Minus 27664798-27664712 338842 Dunham, I.etal. Minus 27824238-27824079 338893 Dunham, I.etal. Minus 28491807-28491631 338904 Dunham,I.etal. Minus 28766345-28766253 338935 Dunham, I.etal. Minus 29071537-29071461 339022 Dunham, I.etal. Minus 30523414-30523289 339034 Dunham, I.etal. Minus 30621603-30621422 339190 Dunham, I.etal. Minus 32403103-32402985 339212 Dunham, I.etal. Minus 32494335-32494210 339213 Dunham, I. etal. Minus 32496590-32496440 339216 Dunham, I.etal. Minus 32504250-32504109 339233 Dunham, I.etal. Minus 32751331-32751238 339258 Dunham, I.etal. Minus 32934756-32934615 339262 Dunham, I.etal. Minus 32971258-32971090 339263 Dunham, I. etal. Minus 32974634-32974452 339265 Dunham, I.etal. Minus 32975943-32975806 339338 Dunham, I.et.al. Minus 33468728-33468606 339396 Dunham, I.etal. Minus 34017306-34017205 339400 Dunham, I. etal. Minus 34045024-34044940 339425 Dunham, I.eta!. Minus 34407911-34407798 3252076552430 Plus 140049-140170 o © CΛ H U α. fiϊllilffff|ϊϊ|lϊϊϊϊϊ|fllϊϊ|fi?ϊϊ|ϊiϊlϊiϊϊϊϊϊ|ffi.ϊϊflflfϊ|li?ϊ|ϊ|ϊϊϊϊ|fl o rT) © CΛ H U α. α.222α.α.2α.22α.α.α.α α.α.2α.222ι---.α.2α-.α-.2 2i- £2i-L2α:22i-Li£2222i£222 CL 222i--:i-C2i--:i£α.222i£2cLα.α---.2ι-.22 3283775868390 Plus 16947-17023 3284365868417 Plus 203760-203904 3285045868471 Plus 47064-47217 3285065868471 Plus 60716-60830 3285225868477 Plus 1972307-1972452 3285255868482 Plus 12387-14313 328541 5868486 Plus 130956-131050 3286626004473 Plus 1184773-1184855 3286636004473 Plus 1185279-1186634 3288036004475 Minus 291716-291948 3283046004478 Minus 3884-3952 3289275868500 Minus 428829-428893 3289365868500 Minus 1352202-1352259 3289396004481 Minus 131139-131320 328941 6456765 Minus 9817-9885 3289486456765 Plus 28227-28413 3289686456775 Plus 117442-118283 3303166007576 Minus 119761-119931 3303503056622 Minus 26413-26820 330351 3056622 Minus 27522-27614 3303484544475 Minus 19855-19962 3290345868561 Minus 32819-32939 3290465868569 Plus 18971-19030 3290535868574 Plus 426453-426541 3291865868711 Minus 13108-13225 3292375868729 Plus 133238-133339 3292765868762 Minus 222629-222709 3293335868806 Plus 392666-392746 3293765868859 Plus 52356-52694 3293845868869 Minus 116524-116662 3291406017060 Plus 290842-290905 3293176381976 Plus 614823-615209 3293196381976 Plus 721390-721470 3291296588026 Plus 144569-144712 3293736682537 Minus 38950-39301 3294126682553 Minus 68948-69041 3294245868879 Plus 362196-362344 3294465868886 Plus 84776-84899 3294495868886 Plus 97697-97771 TABLE 14: shows genes, including expression sequence tags, down-regulated in prostate tumor tissue compared to normal prostate tissue as analyzed using Affymetrix/Eos Hu02 GeneChip array. Shown are the ratios of "average" normal prostate to "average" prostate cancer tissues. Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession numbe UnigenelD: Unigene number Unigene Title: Unigene gene title R1: Background subtracted normal prostate : prostate tumor tissue Pkey ExAccn UnigenelD Unigene Title R1 331328 AA281133 Hs.88808 ESTs 18.53 320875 D60641 Hs.131921 ESTs 14.55 300994 AI251936 Hs.146298 ESTs 12.17 323461 AA418762 Hs.190044 ESTs 10.55 301015 AA947682 Hs.217173 ESTs; Weakly similar to Chain A; Cdc42hs-Gdp Complex [H.sapiens] 10.17 319419 AA543096 Hs.13648 ESTs; Highly similar to mitogen-induced [M.musculus] 92 323486 C05278 Hs.166800 ESTs; Moderately similar to [PYRUVATE DEHYDROGENASE(LIPOAMIDE)] KINASE ISOZYME 4 PRECURSOR [H.sapiens] 8.87 324882 AW419080 Hs.250645 ESTs 8 330569 U57796 Hs.57679 zinc finger protein 192 7.88 330126 CH.21_p2 gi|6093735 7.8 316265 AA737400 Hs.142230 ESTs 7.7 323045 AA148950 Hs.188836 ESTs 7.64 320668 R58399 Hs.146217 ESTs 7.4 330769 AA465192 Hs.16514 ESTs 7.15 312614 AI766732 Hs.201194 ESTs 7 314790 AW341754 Hs.189305 ESTs 6.83 309979 AW452118 Hs.257533 EST 6.74 314236 AA743396 Hs.189023 ESTs 6.49 329192 CH.X_hs gi|5868716 6.1 324307 AA627642 Hs.4994 transducer of ERBB2; 2 (TOB2) 5.99 303685 AW500106 EST cluster (not in UniGene) with exon hit 5.82 314921 AW452382 Hs.257564 ESTs 5.8 315840 AA679001 Hs.192221 ESTs 5.68 332776 AA034364 Hs.256551 ESTs; Weakly similar to III! ALU CLASS B WARNING ENTRY III! [H.sapiens] 5.43 313533 AW298141 Hs.157975 ESTs 5.4 303494 F30712 EST cluster (not in UniGene) with exon hit 5.35 317490 AI627358 Hs.148367 ESTs 5.31 332546 D84454 Hs.21899 solute carrier family 35 (UDP-galactose transporter); member 2 5.25 334719 CH22_FGENES.421_30 5.25 300679 AA813958 Hs.207727 ESTs; Moderately similar to KIAA0071 [H.sapiens] 522 311811 AI625304 Hs.190312 ESTs 522 315310 A 511298 Hs.256067 ESTs 5.19 312871 H86747 Hs.227602 KIAA1116 protein 5.11 324715 AI739168 EST cluster (not in UniGene) 4.97 313870 AW206435 Hs.146057 ESTs 4.97 321453 N50080 Hs.117827 ESTs 4.78 316160 AW197887 Hs.253353 ESTs 4.63 313833 AA766825 EST cluster (not in UniGene) 4.58 315850 AW270550 Hs.116957 ESTs 4.53 303124 AF161350 EST cluster (not in UniGene) with exon hit 4.46 323346 AL134932 Hs.143607 ESTs 4.4 301383 AA913591 Hs.126480 ESTs 4.35 324513 AW501678 Hs.164577 ESTs 4.28 303480 AA331906 EST cluster (not in UniGene) with exon hit 4.25 323591 AA301270 EST cluster (not in UniGene) 4.22 313603 AW468119 EST cluster (not in UniGene) 4.2 317863 AI733395 Hs.129124 ESTs 4.1 312381 R42049 Hs.195473 ESTs 4.08 317514 AW451570 Hs.126850 ESTs 4.03 319750 AA621606 Hs.117956 ESTs 4.03 322520 T55958 EST cluster (not in UniGene) 4 314754 AW026761 Hs.134374 ESTs 4 316088 AI990652 Hs.208973 ESTs 4 318473 AI939339 Hs.146883 ESTs 3.96 307848 AI364186 EST singleton (not in UniGene) with exon hit 3.95 300730 AW449204 Hs.257125 ESTs 3.94 303034 W60843 Hs.31570 ESTs 3.93 324668 AI679131 Hs.201424 ESTs 3.9 324674 AA541323 Hs.115831 ESTs 3.88 300547 N53442 Hs.143443 ESTs 3.83 316100 AW203986 Hs.213003 ESTs 3.79 314801 AA481027 Hs.127336 ESTs; Weakly similar to ORF YGR245c [S.cerevisiae] 3.75 320856 D59945 EST cluster (not in UniGene) 3.74 313188 AI039702 Hs.179573 collagen; type I; alpha 2 3.73 314187 AA804409 Hs.118920 ESTs 3.73 311826 AA765470 Hs.122826 ESTs 3.7 302358 D81150 EST cluster (not in UniGene) with exon hit 3.68 311441 Z38720 Hs.151014 ESTs 3.66 321914 AA011603 EST cluster (not in UniGene) 3.59 332216 H95082 Hs.102332 EST 3.52 324771 AA631739 EST cluster (not in UniGene) 3.5 323691 AA317561 EST cluster (not in UniGene) 3.49 303525 AW516519 Hs.115130 ESTs 3.47 309709 AW242630 EST singleton (not in UniGene) with exon hit 3.46 300038 AFFX control: MurlL4 3.38 316526 AI088192 Hs.135474 ESTs; Weakly similar to ATP-DEPENDENT RNA HELICASE A [H-sapiens] 3.36 313029 AA731520 Hs.170504 ESTs 3.35 304356 AA196027 Hs.195188 glyceraldehyde-3-phosphate dehydrogenase 3.34 314610 AI948688 Hs.191805 ESTs 3.33 329815 CH.14_p2 gi|6624888 3.32 314949 AI745387 Hs.239124 ESTs 3.31 300598 N53574 Hs.158932 ESTs 3.3 329218 CH.X_hsgi|586872δ 3.28 315706 AW440742 Hs.155556 ESTs 3.28 303751 AW503637 EST cluster (not in UniGene) with exon hit 325 307783 AI347274 EST singleton (not in UniGene) with exon hit 3.25 321414 AA324975 Hs.128993 ESTs; Weakly similar to KIAA0465 protein [H.sapiens] 325 312187 AA700439 Hs.188490 ESTs 3.25 334061 CH22_FGENES.327_14 323 336036 CH22 FGENES.678 7 323 321477 H67818 Hs.222059 ESTs 3.21 315760 AW139383 Hs.245437 ESTs 32 316733 AA811713 Hs.163222 ESTs 3.2 300855 AW235248 Hs.79828 ESTs 32 323611 AA304986 Hs.145704 ESTs 3.19 314138 AA740616 EST cluster (not in UniGene) 3.17 316774 AA814859 EST cluster (not in UniGene) 3.16 308884 AI833131 Hs.179100 ESTs 3.11 331317 AA258222 Hs.87757 ESTs 3.1 317221 AI989538 Hs.191074 ESTs 3.08 316386 AA749062 Hs.180285 ESTs 3.08 321040 H26953 EST cluster (not in UniGene) 3.08 308828 AI824829 EST singleton (not in UniGene) with exon hit 3.08 300778 AA236233 Hs.188716 ESTs 3.07 316667 AW015940 Hs.232234 ESTs 3.07 324614 AW503101 EST cluster (not in UniGene) 3.07 316468 AW293046 Hs.255158 ESTs 3.07 300671 AI239706 Hs.189886 ESTs 3.06 314301 AW297967 Hs.188181 ESTs 3.05 312335 AW043620 Hs.236993 ESTs 3.03 322957 AA247755 EST cluster (not in UniGene) 3.01 316848 AA830053 Hs.126798 ESTs 3.01 313473 AA009660 Hs.251948 ESTs; Moderately similar to T07D3.7 [C.elegans] 2.99 318518 T27119 EST cluster (not in UniGene) 2.98 313383 AI076370 Hs.134037 ESTs 2.97 331389 AA458637 Hs.152207 ESTs 2.96 304257 AA053294 EST singleton (not in UniGene) with exon hit 2.95 309917 AW340014 EST singleton (not in UniGene) with exon hit 2.95 319661 H08035 Hs.21398 ESTs; Moderately similar to PUTATIVE GLUC0SAMINE-6-PH0SPHATE ISOMERASE [H.sapiens] 2.95 321253 AI699484 EST cluster (not in UniGene) 2.93 321193 AA149508 Hs.103288 ESTs 2.93 332864 CH22_FGENES.28_4 2.92 300027 M11507 AFFX control: transferrin receptor 2.91 324330 AA884766 EST cluster (not in UniGene) 2.88 320014 AA137114 Hs.170291 ESTs 2.88 333916 CH22_FGENES.296_5 2.88 318885 Z43272 EST cluster (not in UniGene) 2.87 318146 AI040125 Hs.150521 ESTs 2.87 323348 AA233056 Hs.191518 ESTs 2.85 305703 AA825148 Hs.21229 F-box protein Fbwlb 2.84 335862 CH22 FGENES.629 7 2.83 317672 AW205409 Hs.127748 ESTs 2.82 323416 AI610397 Hs.159560 ESTs 2.81 312652 AI419909 Hs.160994 ESTs 2.81 324094 AA382603 EST cluster (not in UniGene) 2.81 319761 R84237 EST cluster (not in UniGene) 2.8 317013 AA864458 Hs.135645 ESTs 2.8 317383 AA913887 Hs.126511 ESTs 2.78 314659 AW277121 Hs-254881 ESTs 2.78 312479 AI950844 Hs.128738 ESTs; Weakly similar to non-lens beta gamma-ciystallin like protein [H.sapiens] 2.77 332808 CH22 FGENES.7 10 2.75 311824 AW293826 Hs.250610 ESTs 2.75 321992 C06003 Hs.116456 ESTs 2.73 316074 AW517542 Hs.208382 ESTs 2.73 309839 AW296076 EST singleton (not in UniGene) with exon hit 2.73 312071 AA683529 Hs.143119 ESTs 2.73 312684 AW294020 Hs.117721 ESTs 2.72 332668 AA062971 Hs.181161 ESTs; Weakly similarto INHIBITOR OF APOPTOSIS PROTEIN 1 [M.musculus] 2.72 322139 H53744 EST cluster (not in UniGene) 2.72 304168 H77679 EST singleton (not in UniGene) with exon hit 2.72 325602 CH.13 hs gi|5866994 2.71 319885 R59096 Hs.136698 ESTs 2.71 300611 N75450 EST cluster (not in UniGene) with exon hit 2.71 316854 AA831215 Hs.159066 ESTs; Weakly similar to predicted using Geneflnder [C.elegans] 2.69 318208 AI091458 Hs.134559 ESTs 2.68 331623 R38715 Hs.153529 Homo sapiens clone 24540 mRNA sequence 2.68 324616 AI823999 Hs.162000 ESTs 2.68 304968 AA614308 EST singleton (not in UniGene) with exon hit 2.67 314912 AI431345 Hs.161784 ESTs 2.67 300767 AW193466 Hs.136525 ESTs 2.67 313453 AI057369 Hs.122536 ESTs 2.65 320600 AA135565 Hs.250739 ESTs 2.65 301180 AI308989 Hs.156939 ESTs 2.65 324825 AA704457 Hs.255738 ESTs; Moderately similar to gag [H.sapiens] 2.65 300336 AW292417 Hs.255074 ESTs; Moderately similar to high-risk human papilloma viruses E6 oncoproteins targeted protein E6TP1 alpha [H.sapiens] 2.64 317850 N29974 EST cluster (not in UniGene) 2.64 339047 CH22_DA59H18.GENSCAN.28-7 2.64 324580 AA492588 EST cluster (not in UniGene) 2.63 321142 AI817933 Hs.209584 ESTs 2.62 319478 R06841 EST cluster (not in UniGene) 2.62 300793 AI248571 Hs.186837 ESTs 2.61 313733 AA836116 EST cluster (not in UniGene) 2.6 326505 CH.19_hs gi|5867435 2.6 314987 AW015506 Hs.130730 ESTs 2.6 303114 AF090948 EST cluster (not in UniGene) with exon hit 2.59 318709 H24244 Hs.240763 ESTs; Weakly similar to /prediction 2.58 312878 AI209108 Hs.143946 ESTs 2.57 329224 CH.X_hsgi|5868728 2.56 328018 CH.06_hs gi|5902482 2.56 323231 AA324437 Hs.177230 ESTs 2.55 312887 AW157377 Hs.132910 ESTs 2.55 315183 AW136134 Hs.220277 ESTs 2.55 300259 AI479011 Hs.170783 ESTs 2.54 313240 AI743261 Hs.131860 ESTs 2.54 316697 AW293174 Hs.252627 ESTs 2.53 313966 AI807551 Hs.189061 ESTs 2.53 331263 AA015718 ze31a12.s1 Soares retina N2b4HR Homo sapiens cDNA clone IMAG&365743', mRNA sequence . 2.51 310683 AW055233 Hs.160870 ESTs 2.5 302566 AA085996 Hs.248572 Human PAC clone DJ404F18 from Xq23 2.5 302697 AJ001408 EST cluster (not in UniGene) with exon hit 2.5 308362 AI613519 EST singleton (not in UniGene) with exon hit 2.49 322347 AF086538 EST cluster (not In UniGene) 2.49 316240 AA974253 Hs.1203 9 ESTs 2.49 323208 AA203415 Hs.136200 ESTs 2.48 321643 W76005 Hs.32094 ESTs 2.48 330723 AA243617 Hs.31082 ESTs; Highly similar to db83 [R.no-vegicus] 2.48 323455 AA256675 Hs.200438 ESTs; Weakly similar to atypical PKC specific binding protein [R.norvegicus] 2.47 308383 AI624497 EST singleton (not in UniGene) with exon h ' rt 2.47 328744 CH.07 hs gi|5868290 2.47 332344 W45574 Hs.252497 ESTs 2.47 328121 CH.06 hs gi|5868031 2.47 321915 AI670955 Hs.200151 ESTs 2.46 314954 AA521381 Hs.187726 ESTs 2.45 302821 AA188868 Hs.173933 ESTs; Weakly similar to NUCLEAR FACTOR 1 X [H.sapiens] 2.45 329454 CH.Y hsgi|5868887 2.45 336605 CH22 FGENES.420 4 2.45 300664 AI444628 Hs.256809 ESTs 2.44 323362 AL135067 Hs.117182 ESTs 2.44 300024 M10098 AFFX control: 18S ribosomal RNA 2.44 325026 AI671168 Hs.12285 ESTs 2.43 324510 AI148353 Hs.120849 ESTs 2.43 313389 AI765182 Hs.119903 ESTs 2.43 301309 M78276 Hs.255917 ESTs 2.43 313570 AA041455 Hs.209312 ESTs 2.43 316504 AW135854 Hs.132458 ESTs 2.42 319401 R01342 EST cluster (not in UniGene) - 2.42 312827 AI744361 Hs.205591 ESTs; Weakly similar to zinc finger protein Png-1 [M.musculus] 2.42 327871 CH.06 hs gi|5868131 2.41 337173 CH22_FGENES.565-3 2.41 302948 AA465635 EST cluster (not in UniGene) with exon hit 2.41 324303 AL118754 EST cluster (not in UniGene) 2.4 315527 AI791138 Hs.116768 ESTs 2.4 315979 AA830515 Hs-2229 7 ESTs 2.4 331310 AA253351 Hs.44439 STAT induced STAT inhibitor-4 2.4 321095 AA017595 Hs.32844 ESTs 2.4 308561 AI701559 EST singleton (not in UniGene) with exon hit 2.39 313035 N36417 Hs.144928 ESTs 2.37 322114 AA643791 Hs.191740 ESTs 2.37 313671 W49823 Hs.145553 ESTs 2.37 303211 AA099548 Hs.191436 ESTs; Highly similar to dJI 118D24.4 [H.sapiens] 2.37 301256 AA932948 EST cluster (not in UniGene) with exon hit 2.36 338165 CH22_EM:AC005500.GENSCAN.212-3 2.36 324692 AA557952 EST cluster (not in UniGene) 2.35 318587 AA779704 Hs.168830 ESTs 2.35 312378 R41582 Hs.109219 retinal degeneration B beta 2.35 318625 T48446 Hs.193 62 ESTs 2.35 305181 AA663726 Hs.116922 EST 2.35 300815 AA286678 EST cluster (not in UniGene) with exon hit 2.34 324063 AW292740 Hs.254815 ESTs 2.34 315859 AA682305 Hs.133268 ESTs 2.33 305092 AA642912 EST singleton (not in UniGene) with exon hit 2.33 306598 AI000320 EST singleton (not in UniGene) with exon hit 2.33 300307 AI651016 Hs.246311 ESTs 2.33 321348 Z49979 EST cluster (not in UniGene) 2.33 325112 AI903770 Hs.124344 ESTs 2.32 336679 CH22_FGENES.43-7 2.32 321383 AJ002574 EST cluster (not in UniGene) 2.32 337357 CH22_FGENES.730-6 2.31 300680 AW468066 Hs.257712 ESTs; Weakly similar to K1AA0986 protein [H.sapiens] 2.31 327120 CH.21_hsgi|6531970 2.31 302761 AW250553 EST cluster (not in UniGene) with exon hit 2.3 312132 AI475490 Hs.170577 ESTs 2.3 315639 AA827652 EST cluster (not in UniGene) 2.3 312189 T95594 Hs.187435 ESTs 2.3 306537 AA991705 EST singleton (not in UniGene) with exon hit 2.3 327061 CH.21_hsgi|6531965 2.3 315391 AA759098 Hs.192007 ESTs 2.3 322384 AI968646 Hs.33862 ESTs 2.29 323206 AA203339 Hs.220750 ESTs 2.29 318110 AI680915 Hs.201379 ESTs 2.28 335250 CH22_FGENES.516 11 2.28 331696 Z38907 Hs.91662 KIAA0888 protein 228 318327 AW294013 Hs.200942 ESTs 228 324980 AA969121 Hs.254296 ESTs 2.28 319429 AI608881 Hs.11482 ESTs; Highly similar to junctionai adhesion molecule [H.sapiens] 2.28 310601 AI970543 Hs.192605 ESTs 228 318905 Z43395 EST cluster (not in UniGene) 228 323442 AA252753 Hs.164039 ESTs 227 304428 AA342250 Hs.99819 ubiquitin specific protease 16 227 313352 AW292127 Hs.144758 ESTs 2.27 316491 AA766025 Hs.238794 EST 227 317751 AI697668 Hs.202241 ESTs 226 314136 AA229781 Hs.221962 ESTs 2.26 306665 AI004614 Hs.130577 EST 226 303946 AW474196 Hs.221604 ESTs 2.25 313435 AA769123 EST cluster (not in UniGene) 2.25 317679 AA968799 Hs.150289 ESTs 225 322370 AA330095 EST cluster (not in UniGene) 225 306620 AI000929 EST singleton (not in UniGene) with exon hit 224 329109 CH.X_hs gi|5868626 2.24 311043 AI871209 Hs.177128 ESTs 2.24 300228 AI458372 Hs.158748 ESTs; Weakly similar to synapsln lb [M.musculus] 2.24 307223 AI193698 Hs.184776 ribosomal protein L23a 2.24 309023 AI888045 EST singleton (not in UniGene) with exon hit 2.23 310749 AI493675 Hs.170332 ESTs 2.23 316769 AI914939 Hs.212184 ESTs 2.22 320409 AA356195 EST cluster (not in UniGene) 2.21 333149 CH22 FGENES.87 8 2.21 324951 M86125 Hs.137487 ESTs 2.21 321939 AI791617 Hs.145068 ESTs 2.2 320594 AI863952 Hs.169436 arginyltransferase 1 22 320722 R67430 Hs.172787 ESTs 22 321781 D78667 EST cluster (not in UniGene) 22 328903 CH.08_hsgi|5868514 2.2 303889 T19204 EST cluster (not in UniGene) with exon hit 2-2 325045 T08845 EST cluster (not in UniGene) 2.2 312828 AI865455 Hs-211818 ESTs; Moderately similarto III! ALU SUBFAMILY J WARNING ENTRY III! [H.sapiens] 2.19 335109 CH22_FGENES.494 15 2.18 330878 AA131471 Hs.71440 ESTs 2.18 311289 AI971362 Hs.231945 ESTs 2.18 304608 AA513456 EST singleton (not in UniGene) with exon hit 2.18 337393 CH22_FGENES.747-4 2.18 332812 CH22_FGENES.7_14 2.18 327665 CH.04_hs gi|5867839 2.18 314581 AW504859 Hs.237849 ESTs 2.17 326508 CH.19_hsgi|6682496 2.17 301242 AW161535 Hs.258803 ESTs 2.17 312780 AI765651 Hs.172900 ESTs 2.17 315954 AW276810 Hs.254859 ESTs 2.16 311179 AI880843 Hs.223333 ESTs 2.16 315320 AI084182 Hs.186895 ESTs 2.16 313017 AI015203 Hs.118015 ESTs 2.16 312430 AW139117 Hs.117494 ESTs 2.15 300864 AA406539 Hs.190958 ESTs 2.15 314753 AA463262 EST cluster (not in UniGene) 2.15 322574 AF156548 EST cluster (not in UniGene) 2.15 321409 C03864 EST cluster (not in UniGene) 2.15 321205 AA002047 EST cluster (not in UniGene), 2.14 320406 AA353895 Hs.152983 HUS1 (S. pombe) checkpoint homolog 2.14 337646 CH22_EM:AC000097.GENSCAN.11-2 2.13 303084 AF174008 EST cluster (not in UniGene) with exon hit 2.13 312185 AA654772 Hs.186564 ESTs 2.13 306813 AI066544 EST singleton (not in UniGene) with exon hit 2.13 314465 AA602917 Hs.156974 ESTs 2.12 318168 AI821782 Hs.220587 ESTs; Moderately similar to III! ALU SUBFAMILY ! I [H.sapiens] 2.12 315990 AI800041 Hs.190555 ESTs 2.11 320712 R66867 EST cluster (not in UniGene) 2.11 318487 AI167877 Hs.143716 ESTs 2.11 317462 AW015206 Hs.178784 ESTs 2.11 304384 AA235482 Hs.62954 ferritin; heavy polypeptide 1 2.11 314544 AA399018 Hs.250835 ESTs 2.1 319881 T72744 EST cluster (not in UniGene) 2.1 328078 CH.06 hs gi|5868008 2.1 317354 AW090770 Hs.192271 ESTs 2.1 308617 AI738720 EST singleton (not in UniGene) with exon hit 2.09 311568 AW439969 Hs.218177 ESTs 2.09 313605 AI761786 Hs.204674 ESTs 2.09 314289 AA848118 Hs-221216 ESTs 2.08 332933 CH22 FGENES.38 7 2.08 325498 CH.12_hsgi|5866967 2.08 313659 AW296067 Hs.124106 ESTs 2.08 324596 AW149321 Hs.105411 ESTs 2.08 324783 AA640770 EST cluster (not in UniGene) 2.07 302696 AA347452 EST cluster (not in UniGene) with exon hit 2.07 313418 AW450674 Hs.114696 ESTs 2.06 326920 CH.21 hsgi|6456782 2.06 327574 CH.03 hsgi|5867818 2.06 323207 AI052795 Hs.192201 ESTs 2.06 303753 AW503733 Hs.170315 ESTs 2.05 305235 AA670480 EST singleton (not in UniGene) with exon hit 2.05 316055 AA693880 EST cluster (not in UniGene) 2.05 317194 AW445167 Hs.126036 ESTs 2.05 319565 AW408683 Hs.32922 ESTs 2.05 335146 CH22_FGENES.499_2 2.05 301475 AI678183 Hs.170917 prostaglandin E receptor3 (subtype EP3) 2.04 312442 AA120970 Hs.143199 ESTs 2.04 322502 R62925 Hs.243665 ESTs 2.04 303693 AA290875 Hs.30120 ESTs 2.04 310179 AI215643 Hs.171381 ESTs 2.03 321121 W23285 EST cluster (not in UniGene) 2.03 331330 AA282197 Hs.89002 ESTs; Highly similar to CGI-07 protein [H.sapiens] 2.03 306557 AA994530 EST singleton (not in UniGene) with exon hit 2.03 317865 AI298794 Hs.129130 ESTs 2.03 318667 AI493742 Hs.165210 ESTs 2.02 318042 AW294522 Hs.149991 ESTs 2.02 323818 AW245528 Hs.134754 ESTs 2.02 331286 AA137062 Hs.103853 ESTs 2.01 311262 AI989942 Hs.232150 ESTs 2.01 335601 CH22_FGENES.581_41 2.01 311351 AI682303 Hs-201274 ESTs 2.01 312996 AA249018 EST cluster (not in UniGene) 2.01 328190 CH.06 hsgi|5868077 2 338030 CH22 EM-AC005500.GENSCAN.148-16 2 333940 CH22 FGENES.301 6 2 328227 CH.06_hsgi|5868105 2 331481 N27448 Hs.43944 EST 2 335288 CH22_FGENES.527_1 2 307513 AI274307 EST singleton (not in UniGene) with exon hit 2 323316 AL134620 EST cluster (not in UniGene) 2 319479 R21945 Hs.256153 ESTs 2 303482 AA502583 Hs.197271 ESTs 2 327489 CH.02 hsgi|6004459 1.99 323935 AW175841 Hs.192183 ESTs 1.99 309575 AW168096 Hs.195188 glyceraldehyde-3-phosphate dehydrogenase 1.99 337043 CH22 FGENES.439-19 1.98 312897 AI828174 Hs.227049 ESTs 1.98 307881 AI370434 EST singleton (not in UniGene) with exon hit 1.98 328656 CH.07 hsgi|6004473 1.98 314569 AA813784 Hs.123001 ESTs 1.98 332783 W45302 Hs.87889 helicase-moi 1.98 315259 AA701499 Hs.148115 ESTs 1.98 313171 N67879 Hs.157695 ESTs 1.97 318060 AI241421 Hs.132236 ESTs 1.97 332256 N66393 Hs.102754 ESTs 1.97 312110 AI962180 Hs.226803 ESTs 1.97 335864 CH22 FGENES.629 9 1.97 320389 W00545 Hs.171785 ESTs 1.97 314065 AA868267 Hs.85524 ESTs 1.96 323086 H15474 Hs.12214 Homo sapiens clone 23716 mRNA sequence 1.96 323919 AA862973 Hs.220704 ESTs 1.96 310750 AI373163 Hs.170333 ESTs 1.96 309435 AW090537 EST singleton (not in UniGene) with exon hit 1.96 300129 AW028820 EST cluster (not in UniGene) with exon hit 1.96 320130 AI820675 Hs.203804 ESTs 1.95 323787 AW373446 Hs.169885 ESTs; Weakly similar to cDNA EST EMBLT02216 comes from this gene [C.elegans] 1.95 338112 CH22 EM.AC005500.GENSCAN.185-24 1.95 313625 AW468402 Hs-254020 ESTs 1.95 325240 CH.10_hsgi|5866848 1.95 331833 AA412102 Hs.250911 interleukin 13 receptor; alpha 1 1.95 332252 N63882 za21f9.s1 Soares fetal liver spleen 1 NFLS Homo sapiens cDNA clone IMAGE.2932253', mRNA sequence 1.95 300279 AW237425 Hs.253817 ESTs 1.95 326023 CH.17_hs gi|5867245 1.95 321609 H86021 Hs.198800 ESTs; Weakly similar to hMmTRAIb [H.sapiens] 1.94 324183 AA402453 Hs.113011 ESTs 1.94 336276 CH22 FGENES.762 5 1.94 334913 CH22 FGENES.456 3 1.94 325417 CH.12 hs gi|5866925 1.94 318489 AW043590 Hs.225023 ESTs 1.94 318455 AI148763 EST cluster (not in UniGene) 1.94 306890 AI092235 EST singleton (not in UniGene) with exon hit 1.94 315073 AW452948 Hs-257631 ESTs 1.94 321289 R84687 Hs.226306 ESTs 1.94 308521 AI689808 EST singleton (not in UniGene) with exon hit 1.93 306382 AA968967 EST singleton (not in UniGene) with exon hit 1.93 331320 AA262999 Hs.42788 ESTs 1.93 324279 AA501412 Hs.191688 ESTs; Weakly similar to Pro-Pol-dUTPase polyprotein [M.musculus] 1.93 309577 AW168753 EST singleton (not in UniGene) with exon hit 1.93 327014 CH.21_hs gi|5867664 1.93 303488 AW025860 EST cluster (not in UniGene) with exon hit 1.93 306561 AA995223 Hs.129559 EST 1.92 330694 AA019806 Hs.108447 spinocerebellar ataxia 7 (olivopontocerebellar atrophy with retinal degeneration) 1.92 313083 N50545 Hs.159200 ESTs 1.92 327752 CH.05_hsgi|5867949 1.92 318674 AA295490 EST cluster (not in UniGene) 1.92 301267 AW297762 Hs-255690 ESTs 1.91 332092 AA608787 Hs.112590 ESTs 1.91 323509 AL036947 EST cluster (not in UniGene) 1.91 321452 AA317554 EST cluster (not in UniGene) 1.91 311483 AI765013 Hs.209128 ESTs 1.91 300976 AI246374 Hs.185861 ESTs 1.91 323715 AA322155 EST cluster (not in UniGene) 1.91 313800 AW296132 Hs.166674 ESTs 1.91 332029 AA489697 Hs.145053 ESTs 1.91 304013 AW518573 Hs.156110 Immunoglobulin kappa variable 1D-8 1.91 322019 AA354549 Hs.41181 Homo sapiens mRNA; cDNA DKFZp727C191 (from clone DKFZp727C191) 1.91 334150 CH22 FGENES.339 1 1.9 310094 AW450967 Hs.235240 ESTs 1.9 316218 AW207642 Hs.174021 ESTs 1.9 324774 AI031771 Hs.132586 ESTs 1.9 326507 CH.19jιs gi|5867435 1.9 314570 AA405696 EST cluster (not in UniGene) 1.9 336268 CH22 FGENES.758 2 1.9 315278 AI985544 Hs.116429 ESTs 1.9 325824 CH.15_hs gi|5867048 1.9 316277 AA737780 Hs.213392 ESTs 1.9 323181 AA418583 Hs.143621 ESTs 1.9 301438 AA961643 Hs.127716 ESTs 1.89 307050 AI147341 Hs.146734 EST 1.89 306830 AI075803 EST singleton (not in UniGene) with exon h ' rt 1.89 302426 AL049925 Hs.225984 DKFZP547G0910 protein 1.89 320127 H72615 Hs.17268 ESTs 1.89 337736 CH22_EM:AC000097.GENSCAN.100-2 1.89 331319 AA262755 Hs.194264 ESTs 1.88 310767 AI377505 Hs.158835 ESTs 1.88 314880 AI732169 Hs.105429 ESTs 1.88 312539 AI004377 Hs.200360 ESTs 1.88 309674 AW205604 Hs.168034 ESTs; Weakly similar to HI! ALU SUBFAMILY SP WARNING ENTRY III! [H.sapiens] 1. 314621 AI627478 Hs.187670 ESTs 1.88 319495 AI972145 Hs.192756 ESTs 1.88 313472 AA007374 EST cluster (not in UniGene) 1.88 302705 U09060 EST cluster (not in UniGene) with exon hit 1.88 329511 CH.10_p2 gi|3983514 1.88 317140 AI699412 Hs.201925 ESTs 1.87 302598 AI815985 Hs.129683 ubiquitin-conjugating enzyme E2D 1 (homologous to yeast UBC4/5) 1.87 301153 AA725670 Hs.120485 ESTs; Weakly similar to serine/threonine kinase with SH3 domain; leucine zipper domain and proline rich domain [H.sapiens] 1.87 332222 N28271 Hs.176618 ESTs 1.87 330703 AA055475 Hs.104143 clathrin; light polypeptide (Lea) 1.87 318470 AI159863 Hs.143713 ESTs 1.87 314014 AW291847 Hs.121715 ESTs; Weakly similar to HP protein [H.sapiens] 1.87 300370 AI827817 EST cluster (not in UniGene) with exon hit 1.86 312329 R84768 Hs.13399 Homo sapiens done 25032 mRNA sequence 1.86 325587 CH.12_hs gi|6682462 1.86 310237 AI884313 Hs.158906 ESTs 1.86 318872 R13085 EST cluster (not in UniGene) 1.86 303431 AA317915 EST cluster (not in UniGene) with exon hit 1.86 338427 CH22 EM.AC005500.GENSCAN.349-1 1.86 300452 AI352293 Hs.191098 ESTs 1.85 321279 H85330 Hs.146060 ESTs 1.85 301690 F05865 Hs.249180 ubiquitin-conjugating enzyme E2E 2 (homologous to yeast UBC4/5) 1.85 307932 AJ230822 EST singleton (not in UniGene) with exon hit 1.85 318292 AI679966 Hs.150603 ESTs 1.85 310254 AI239811 Hs.157491 ESTs 1.85 311790 AW016437 Hs.233462 ESTs 1.84 314248 AA278347 Hs.126078 ESTs 1.84 335586 CH22 FGENES.581 25 1.84 339209 CH22_FF113D11.GENSCAN.6-4 1.84 307954 AI419692 EST singleton (not in UniGene) with exon hit 1.84 302549 AF055136 Hs.248162 tectorin alpha 1.84 321629 H87213 Hs.158092 ESTs 1.84 301239 AA807558 EST cluster (not in UniGene) with exon hit 1.84 332434 N75542 Hs.75356 transcription factor 4 1.84 327192 CH.01_hsgi|5867445 1.83 310214 AI220072 Hs.165893 ESTs 1.83 320516 R33857 Hs.181479 ESTs; Weakly similar to E-SELECTIN PRECURSOR [H.sapiens] 1.83 324231 W60827 EST cluster (not in UniGene) 1.83 336616 CH22 FGENES.613 5 1.83 328799 CH.07_hsgi|5868316 1.83 324661 AW504161 EST cluster (not in UniGene) 1.83 313190 AA766707 Hs.153039 ESTs 1.83 301979 L28168 Hs.121495 potassium voltage-gated channel; Isk-related family; member 1 1.82 302099 AL021397 Hs.137576 ribosomal protein L34 pseudogene 1 1.82 320187 T99949 EST cluster (not in UniGene) 1.82 320791 R78808 Hs.93961 ESTs; Weakly similar to III! ALU CLASS A WARNING ENTRY III! [H.sapiens] 1.82 305733 AA829535 Hs.84298 CD74 antigen (invariant polypept of MHC; class II antigen-associated) 1.82 308280 AI569349 Hs.180920 ribosomal protein S9 1.81 321533 W78877 Hs.40111 ESTs 1.81 312946 AI915122 Hs.204087 ESTs; Weakly similar to F33D11.9b [C.elegans] 1.81 319474 H90265 Hs.100638 ESTs 1.81 329519 CH.10_p2 gi|3983510 1.81 324685 AA220982 EST cluster (not in UniGene) 1.81 320697 N62937 Hs.139181 ESTs 1.81 329246 CH.X_hsgi[5868732 1.81 332000 AA481271 Hs.193945 ESTs 1.81 310811 AI420990 Hs.161303 ESTs 1.81 325866 CH.16_hs gi|5867076 1.81 322064 Z78343 EST cluster (not in UniGene) 1.8 333712 CH22_FGENES.251J 1.8 313457 AA576052 Hs.193223 ESTs 1.8 321591 H85687 Hs.117927 ESTs 1.8 330260 CH.05_p2 gi|6671884 1.8 311080 AI656320 Hs.197711 ESTs 1.8 329522 CH.10_p2 gi|3983507 1.8 322889 AA081924 Hs.211417 ESTs 1.8 300175 AI275011 Hs.204877 ESTs 1.8 330976 H20560 Hs.244624 ESTs 1.8 300208 AI341180 Hs.196115 ESTs; Weakly similar to FIBRILLIN 1 PRECURSOR [H.sapiens] 1.79 319635 R17531 EST cluster (not in UniGene) 1.79 313454 AA730673 Hs.188634 ESTs 1.79 303093 AI4O0310 Hs.148958 ESTs 1.79 309815 AW292760 EST singleton (not in UniGene) with exon hit 1.79 326506 CH.19 hs gi|5867435 1.79 319845 AA649011 Hs.187902 ESTs 1.79 300290 AI623739 Hs.186387 ESTs 1.79 312180 AI248285 Hs.118348 ESTs 1.79 313058 D81015 Hs.125382 ESTs 1.79 330120 CH.19_p2 gi|6671864 1.78 328412 CH.07_hsgi|5868405 1.78 302345 NM 000565 EST cluster (not in UniGene) with exon hit 1.78 308100 AI475949 EST singleton (not in UniGene) with exon hit 1.78 311386 AW205705 Hs.207514 ESTs 1.78 330282 CH.05_p2 gi|6671910 1.78 318856 Z43011 Hs.21169 ESTs 1.78 312486 AA845630 Hs.117904 ESTs 1.78 325450 CH.12_hs gi|5866941 1.78 321206 H54178 Hs.226469 ESTs 1.78 330977 H20826 Hs.31783 ESTs 1.78 303487 AA333666 EST cluster (not in UniGene) with exon hit 1.77 310398 AI264671 Hs.164166 ESTs 1.77 313230 AI540166 Hs.129563 ESTs 1.77 317747 AI683782 Hs.128245 ESTs 1.77 303381 AL038841 Hs.163313 ESTs; Weakly similar to III! ALU SUBFAMILY SB WARNING ENTRY III! [H.sapiens] 1.77 336123 CH22 FGENES.701 8 1.77 300185 AI286182 Hs.208484 ESTs 1.77 316002 AW451733 Hs.119824 ESTs 1.77 319850 AA001811 Hs.83722 ESTs 1.77 329941 CH.16_p2 gi|6165199 1.77 328329 CH.07_hsgi|5868375 1.77 322934 AI493054 Hs.158968 ESTs 1.77 325902 CH.16 hsgi|5867101 1.76 322239 W01813 Hs.12109 WD40 protein Ciaol 1.76 303530 AI274851 Hs.258744 ESTs 1.76 300980 AI025527 Hs.222097 ESTs 1.76 331909 AA437300 Hs.178210 ESTs 1.76 321553 H92449 Hs.116406 ESTs 1.76 301618 T52760 EST cluster (not in UniGene) with exon hit 1.76 319592 AA627356 Hs.163315 ESTs 1.76 318511 T26528 Hs.227175 ESTs; Weakly similar to III! ALU SUBFAMILY SQ WARNING ENTRY III! [H.sapiens] 1.76 327183 CH.01 hsgi|5867442 1.76 313516 AA029058 Hs.135145 ESTs 1.76 318644 AI752482 EST cluster (not in UniGene) 1.76 321632 AA419617 EST cluster (not in UniGene) 1.76 324657 AW451142 Hs.255628 ESTs 1.76 300437 AW449374 Hs-257149 ESTs 1.75 319775 AA504429 Hs.6211 ethyl-CpG binding domain protein 1 1.75 314775 AI149880 Hs.188809 ESTs 1.75 337460 CH22_FGENES.780-5 1.75 309849 AW297444 EST singleton (not in UniGene) with exon hit 1.75 301471 AA995014 Hs.129544 ESTs; Weakly similar to ORF YLL027w [S.cerevisiae] 1.75 312739 AI318426 Hs.155925 ESTs 1.75 319995 H15355 Hs.60887 ESTs 1.75 326495 CH.19 hs gi|5867423 1.75 337497 CH22_FGENES.801-4 1.75 322633 AA004534 Hs.153981 ESTs 1.75 332177 F10812 Hs.101433 ESTs 1.75 326930 CH.21_hsgi|6456782 1.75 316893 AA837332 EST cluster (not in UniGene) 1.75 324826 AA704806 Hs.143842 ESTs 1.75 311269 AI656924 Hs.174257 ESTs 1.75 309375 AW075342 EST singleton (not in UniGene) with exon hit 1.75 314171 AI821895 Hs.193481 ESTs 1.75 311684 AI990741 Hs.252809 ESTs 1.75 334387 CH22 FGENES.380 1 1.75 312195 AI300101 Hs.252222 ESTs 1.75 315707 AI418055 Hs.161160 ESTs 1.74 324349 AW501470 EST cluster (not in UniGene) 1.74 300724 AI762929 Hs.206134 ESTs; Weakly similar to similar to reverse transcriptase [C.elegans] 1.74 309906 AW339340 EST singleton (not in UniGene) with exon hit 1.74 303714 AW501336 EST cluster (not in UniGene) with exon hit 1.74 318704 Z24981 EST cluster (not in UniGene) 1.74 303027 AF111178 EST cluster (not in UniGene) with exon hit 1.74 322601 W92924 EST cluster (not in UniGene) 1.74 319382 H93199 Hs.33665 ESTs 1.74 315858 AA737345 EST cluster (not in UniGene) 1.74 332243 N55484 Hs.220540 ESTs; Highly similar to ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR [H.sapiens] 1.74 330951 H02566 Hs.191268 Homo sapiens mRNA; cDNA DKFZp434N174 (from clone DKFZp434N174) 1.74 324044 AL045752 Hs.211519 ESTs 1.73 320630 AA199847 EST cluster (not in UniGene) 1.73 327288 CH.01 hsgi|5867481 1.73 314986 AI201367 Hs.142860 ESTs 1.73 319078 H17255 Hs.144515 ESTs 1.73 326278 CH.17_hs gi|5867269 1.73 302552 H49792 EST cluster (not in UniGene) with exon hit 1.73 322322 AF086431 EST cluster (not in UniGene) 1.73 327075 CH.21 hs gi|6531965 1.73 317392 AI797588 Hs.145459 ESTs 1.73 300810 AI076890 Hs.186949 ESTs 1.73 315978 AA830893 Hs.119769 ESTs 1.73 323903 AA773580 Hs.193598 ESTs 1.73 330803 AA004699 Hs.150580 putative translation initiation factor 1.73 309845 AW296802 Hs.255580 EST 1.73 314963 AI689617 Hs.200934 ESTs 1.73 311710 F09774 Hs.175971 ESTs 1.73 315315 AI984592 Hs.15088 ESTs 1.73 300378 AA663560 Hs.235873 ESTs; Weakly similar to K11C4.2 [C.elegans] 1.73 316141 AW303457 EST cluster (not in UniGene) 1.72 319826 T71739 Hs.75442 albumin 1.72 312961 AI033922 Hs.122517 ESTs 1.72 334379 CH22_FGENES.379_11 1.72 305854 AA862733 EST singleton (not in UniGene) with exon hit 1.72 313031 N34927 Hs.186566 ESTs 1.72 329728 CH.14_p2 gi|6065785 1.72 312090 N57692 Hs.118064 ESTs 1.72 323341 AL134875 Hs.192386 ESTs 1.72 302077 AA310580 Hs.132898 Homo sapiens chromosome 11; BAC CIT-HSP-311e8 (BC269730) containing the tiFENI gene 1.71 310766 AI971438 Hs.158824 ESTs 1.71 311450 AI809985 Hs-203340 ESTs 1.71 311792 AW238064 Hs.253909 ESTs 1.71 321500 H71999 EST cluster (not in UniGene) 1.71 311948 T78791 Hs.241569 ESTs; Moderately smlr to III) ALU SUBFAMILY SQ WARNING ENTRY III! [H.sapiens] 1. 302270 R56151 EST cluster (not in UniGene) with exon hit 1.71 329089 CH.X_hsgi|5868614 1.71 322331 AF086467 EST cluster (not in UniGene) 1.71 318235 AI080361 Hs.134217 ESTs 1.71 304561 AA489792 EST singleton (not in UniGene) with exon hit 1.71 312681 AI028149 Hs.193124 pyruvate dehydrogenase kinase; isoenzyme 3 1.71 310250 AI478629 Hs.158465 ESTs 1.71 338178 CH22_EM:AC005500.GENSCAN.219-6 1.71 338910 CH22_DJ32I10.GENSCAN.11-2 1.71 321225 AL080073 Hs.251414 Homo sapiens mRNA; cDNADKFZp564B1462 (from clone DKFZp564B1462) 1.7 322289 AA534550 Hs.539 ribosomal protein S29 1.7 319802 AI701489 Hs.202501 ESTs 1.7 314022 AW452420 Hs.248678 ESTs 1.7 314937 AA515602 Hs.152330 ESTs 1.7 300580 AA761322 Hs.220538 ESTs 1.7 304398 AA262785 EST singleton (not in UniGene) with exon hit 1.7 313421 AW339515 Hs.163700 ESTs 1.7 309763 AW270182 EST singleton (not in UniGene) with exon hit 1.7 322092 AF085833 EST cluster (not in UniGene) 1.7 315603 AA764768 Hs.121158 ESTs 1.7 325031 T08597 EST cluster (not in UniGene) 1.7 327157 CH.01_hs gi|5866841 1.7 314809 AI741461 Hs.161904 ESTs 1.7 320361 H67220 Hs.146406 nitrilase 1 1.69 324721 AW402302 Hs.43616 ESTs 1.69 328624 CH.07_hs gi|5868246 1.69 303344 AA255977 Hs.250646 ESTs; Highly similar to ubiquitin-conjugating enzyme [M.musculus] 1.69 328960 CH.08_hsgi|6456775 1.69 315702 AA657501 Hs.146315 ESTs 1.69 302385 AJ224172 Hs.204096 lipophilin B (uteroglobin family member); prostatein-like 1.68 319699 R14537 EST cluster (not in UniGene) 1.68 309506 AW137700 EST singleton (not in UniGene) with exon hit 1.68 330417 D84424 Hs.57697 hyaluronan synthase 1 1.68 315296 AA876905 Hs.125286 ESTs 1.68 328538 CH.07_hs gi|5868485 1.68 323923 AA354146 EST cluster (not in UniGene) 1.68 320303 AL079289 Hs.137154 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 35971 1.68 302967 AI927068 Hs.110853 ESTs; Weakly similar to R10D12.12 [C.elegans] 1.68 310695 AI472124 Hs.157757 ESTs 1.68 307512 AI273815 Hs.242463 keratin 8 1.68 338506 CH22_EM:AC005500.GENSCAN.390-10 1.68 331722 AA195405 Hs.110347 Homo sapiens mRNA for alpha integrin binding protein 80; partial 1.68 301431 R05385 EST cluster (not in UniGene) with exon hit 1.68 318853 Z42977 Hs.21062 ESTs 1.68 323032 AW244073 Hs.145946 ESTs 1.68 317538 AW137772 Hs.185980 ESTs 1.68 325780 CH.14_hsgi|6381953 1.67 321739 AL080280 EST cluster (not in UniGene) 1.67 319808 T58960 EST cluster (not in UniGene) 1.67 313443 AA249037 EST cluster (not in UniGene) 1.67 331366 AA424754 Hs.43149 ESTs 1.67 316443 AI797592 Hs.207407 ESTs 1.67 322878 AA081820 EST cluster (not in UniGene) 1.67 330320 CH.08_p2 gi|5932415 1.67 329081 CH-X_hsgi|5868602 1.67 334026 CH22_FGENES.318_3 1.67 317791 AI801500 Hs.128457 ESTs 1.67 322235 AF086106 EST cluster (not in UniGene) 1.66 331148 R73816 Hs.17385 ESTs 1.66 325452 CH.12_hsgi|5866941 1.66 315106 AW452184 Hs.232100 ESTs 1.66 326014 CH.16_hs gi|5867160 1.66 307130 AI185234 EST singleton (not in UniGene) with exon hit 1.66 300943 AA524545 Hs.224630 ESTs 1.66 319402 W21298 EST cluster (not in UniGene) 1.66 310889 AI457946 Hs.170437 ESTs; Weakly similar to hyperpolarization-activated; cyclic nucleotide-gated channel 2 [H.sapiens] 1.66 323371 AL135118 EST cluster (not in UniGene) 1.66 335568 CH22 FGENES.581 4 1.66 320654 AW263086 Hs.118112 ESTs 1.66 338983 CH22_DA59H18.GENSCAN.3-1 1.65 330002 CH.16_p2 gi|6623963 1.65 315343 AW205477 Hs.179891 ESTs 1.65 334487 CH22 FGENES.395_9 1.65 312169 AI064824 Hs.193385 ESTs 1.65 309668 AW204480 Hs.253414 EST 1.65 309518 AW148928 Hs.248895 EST 1.65 307965 AI421641 EST singleton (not in UniGene) with exon hit 1.65 316787 AW369770 Hs.130351 ESTs 1.65 300835 AA401858 Hs.224843 ESTs 1.65 338763 CH22 EM-.AC005500.GENSCAN.517-16 1.65 303327 AA232729 Hs.154302 ESTs 1.65 313231 AW139993 Hs.163682 ESTs 1.65 334073 CH22_FGENES.327_28 1.65 319901 T77136 Hs.8765 RNA helicase-related protein 1.65 326530 CH.19_hsgi|5867441 1.65 301126 AI802877 Hs.210843 ESTs; Weakly similar to dJ1039K52 [H.sapiens] 1.65 314043 AA827082 EST cluster (not in UniGene) 1.65 304387 AA236027 EST singleton (not in UniGene) with exon hit 1.65 322932 AA099732 EST cluster (not in UniGene) 1.65 337272 CH22_FGENES.660-1 1.64 332694 AA262768 Hs.243901 KIAA1067 protein 1.64 318996 Z44266 EST cluster (not in UniGene) 1.64 315336 AW342028 Hs.256112 ESTs 1.64 313329 AW293704 Hs.122658 ESTs 1.64 318088 AW295409 Hs.137945 ESTs 1.64 313835 AI538438 Hs.159087 ESTs 1.64 320035 AA378974 Hs.130720 ESTs; Weakly similar to CELLULAR NUCLEIC ACID BINDING PROTEIN [H.sapiens] 1.64 309372 AW074330 EST singleton (not in UniGene) with exon hit 1.63 324157 AW402236 EST cluster (not in UniGene) 1.63 323929 AA354940 Hs.145958 ESTs 1.63 302490 AA885502 Hs.187032 ESTs 1.63 333942 CH22_FGENES.301_8 1.63 327459 CH.02_hsgi|5867772 1.63 301918 AA476777 EST cluster (not in UniGene) with exon hit 1.63 315664 AI744068 Hs.160712 ESTs 1.63 304405 AA282572 . EST singleton (not in UniGene) with exon hit 1.63 310624 AI341594 Hs.157522 ESTs; Moderately similar to env protein [H.sapiens] 1.63 319250 F11623 EST cluster (not in UniGene) 1.63 310608 AI962234 Hs.196102 ESTs 1.63 317348 AI348076 Hs.831 3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase (hydroxymethylglutaricaciduria) 1.63 306513 AA989230 EST singleton (not in UniGene) with exon hit 1.63 320807 AA086110 Hs.188536 Homo sapiens clone 24838 mRNA sequence 1.63 303710 AI269069 Hs.250852 ESTs; Highly similar to ubiquitin hydrolyzing enzyme I [H.sapiens] 1.63 328291 CH.07_hs gi|5868363 1.63 304236 W93278 EST singleton (not in UniGene) with exon hit 1.63 317683 AI791700 Hs.127893 ESTs 1.63 311960 AW440133 Hs.189690 ESTs 1.62 312834 AI028309 Hs.114246 ESTs 1.62 325326 CH.11 hsgi|5866875 1.62 313663 AI953261 Hs.169813 ESTs 1.62 327526 CH.02 hs gi|6381882 1.62 300429 AW449679 Hs.156739 ESTs; Highly similar to XG GLYCOPROTEIN PRECURSOR [H.sapiens] 1.62 305169 AA663131 EST singleton (not in UniGene) with exon hit 1.62 316621 AI021996 Hs.122138 ESTs 1.62 329666 CH.14_p2 gi|6272129 1.62 318035 AI744130 Hs.131201 ESTs 1.62 300492 AL031709 multiple UniGene matches 1.62 316532 AI307229 Hs.184304 ESTs 1.62 332048 AA496019 Hs.201591 ESTs 1.62 307113 AI183686 EST singleton (not in UniGene) with exon hit 1.62 319127 N49476 EST cluster (not in UniGene) 1.62 331155 R87650 Hs.33439 ESTs; Weakly similar to III! ALU SUBFAMILY J WARNING ENTRY llll [H.sapiens] 1.61 338220 CH22_EM:AC005500.GENSCAN.246-9 1.61 315763 AW515270 Hs.118342 ESTs 1.61 323571 AA984133 Hs.153260 c-Cbl-interacting protein " 1.61 312240 R28628 Hs.203669 ESTs 1.61 304569 AA490934 EST singleton (not in UniGene) with exon hit 1.61 313179 AI076101 Hs.131704 ESTs 1.61 326858 CH.20_hsgi|6552462 1.61 317276 AI823847 Hs.129986 ESTs 1.61 312572 AA350125 Hs.187499 ESTs 1.61 311932 AW451654 Hs.257482 ESTs 1.61 302103 AA452310 Hs.26090 ESTs; Weakly similar to T20B12.1 [C.elegans] 1.61 308413 A1636253 Hs.196511 EST 1.61 310077 AI620617 Hs.148565 ESTs 1.61 337780 CH22_EM:AC000097.GENSCAN.121-2 1.61 327796 CH.05jιs gi|5867982 1.61 308352 AI610791 EST singleton (not in UniGene) with exon hit 1.61 324539 AI378032 Hs.125892 ESTs 1.61 303232 AA437414 EST cluster (not in UniGene) with exon hit 1.61 337884 CH22_EM:AC005500.GENSCAN.54-2 1.61 303620 AA397546 Hs.119151 ESTs 1.61 303481 AA336839 EST cluster (not in UniGene) with exon hit 1.61 314481 AA548589 Hs.105846 ESTs 1.61 300327 AI908894 Hs.245893 ESTs 1.6 323473 AA262442 EST cluster (not in UniGene) 1.6 326154 CH.17 hs gi|5867170 1.6 331920 AA446885 Hs.99087 - ESTs; Moderately similar to ZINC FINGER PROTEIN 141 [H.sapiens] 1.6 323827 AW406878 EST cluster (not in UniGene) 1.6 322452 W56710 EST cluster (not in UniGene) 1.6 310597 AI739071 Hs.158515 ESTs 1.6 307871 AI368665 EST singleton (not in UniGene) with exon hit 1.6 322215 AF088005 EST cluster (not in UniGene) 1.6 318420 AI139857 Hs.143837 ESTs 1.6 332217 H98987 Hs.102383 EST 1.6 324937 M79230 Hs.192398 ESTs 1.6 320543 AF052176 Hs.158529 Homo sapiens clone 24457 mRNA sequence 1.6 300674 AW467388 EST cluster (not in UniGene) with exon hit 1.6 315193 AI241331 Hs.131765 ESTs 1.6 319713 R24204 EST cluster (not in UniGene) 1.6 301210 AI379982 Hs.158944 ESTs 1.6 309365 AW072861 EST singleton (not in UniGene) with exon hit 1.6 321403 AW451454 Hs.247568 adenylate kinase 3 1.6 321908 AA376936 Hs.20998 ESTs 1.6 303349 AA382661 EST cluster (not in UniGene) with exon hit 1.6 324338 AL138357 Hs.247514 ESTs 1.6 310599 AW300144 EST cluster (not in UniGene) 1.6 333193 CH22 FGENES.98 15 1.6 336433 CH22 FGENES.825 12 1.6 312097 AI352096 Hs.157169 ESTs 1.6 311445 AW204237 Hs.192703 ESTs; Weakly similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens ] 1.59 317736 AI361722 Hs.192410 ESTs 1.59 308147 AI498991 EST singleton (not in UniGene) with exon hit 1.59 313489 AA017492 Hs.135655 ESTs 1.59 316289 AA902488 Hs.122952 ESTs 1.59 326983 CH.21 hs gi|5867657 1.59 314781 AW205298 Hs.202372 ESTs 1.59 328397 CH.07 hs gi|5868397 1.59 331970 AA461084 Hs.187677 ESTs 1.59 321744 N91419 Hs.12028 ESTs 1.59 310509 AI292181 Hs.150036 ESTs 1.59 315921 AI147545 Hs.114172 ESTs 1.59 322049 AI928242 Hs.144383 ESTs 1.59 301161 AA731518 EST cluster (not in UniGene) with exon hit 1.59 300548 AI026836 Hs.114689 ESTs 1.59 319142 F07366 EST cluster (not in UniGene) 1.59 313526 AW152263 Hs.249243 ESTs 1.59 305937 AA883238 EST singleton (not in UniGene) with exon hit 1.58 330123 CH.19_p2 gi|6671869 1.58 327819 CH.05 hs gi|5867968 1.58 318250 AI478814 Hs.134603 ESTs 1.58 306760 AI034094 Hs.169476 tubulin; alpha; ubiquitous 1.58 322358 AA220235 Hs.246836 ESTs 1.58 317866 AI690269 Hs.201345 ESTs 1.58 320725 AA703319 Hs.120967 ESTs 1.58 311332 AW292247 Hs.255052 ESTs 1.58 334893 CH22_FGENES.452_7 1.58 318730 AA398215 EST cluster (not in UniGene) 1.58 315889 AW271639 Hs.221744 ESTs 1.58 303702 AW500748 Hs.224961 ESTs; Weakly similar to 73 kDA subunit of cleavage and polyadenylation specificity factor [H.sapiens] 1.57 315086 AI492660 Hs.170935 ESTs 1.57 332514 AA156499 Hs.8454 protein kinase; cAMP-dependent; regulatory; type II; alpha 1.57 335549 CH22 FGENES.576J0 1.57 329532 CH.10_p2 gi|3983505 1.57 323140 AA180467 EST cluster (not in UniGene) 1.57 313166 AI801098 Hs.151500 ESTs 1.57 337896 CH22 EM.AC005500.GENSCAN.56-3 1.57 330658 AA319514 Hs.211093 ESTs 1.57 324585 AI823969 Hs.132678 ESTs 1.57 317151 AW298195 Hs.255735 ESTs 1.57 308818 AI819700 Hs.208231 EST 1.57 326547 CH.19 hsgi|5867307 1.57 318833 H06234 Hs.24888 ESTs 1.57 320488 R31386 EST duster (not in UniGene) 1.57 306929 AI124514 EST singleton (not in UniGene) with exon hit 1.57 338083 CH22 EM:AC005500.GENSCAN.174-1 1.57 316868 AI660898 Hs.195602 ESTs 1.57 310937 AI472880 Hs.170480 ESTs 1.57 328638 CH.07 hs gi|6004473 1.57 310074 AI651039 Hs.148559 ESTs 1.56 327058 CH-21 hs gi|6531965 1.56 320076 AI653733 Hs.204079 ESTs 1.56 322345 AF086529 EST cluster (not in UniGene) 1.56 314731 AI745498 Hs.204579 ESTs 1.56 318687 H49619 Hs.127301 ESTs 1.56 303841 AI934464 EST duster (not in UniGene) with exon hit 1.56 302370 AJ009849 Hs.199297 Homo sapiens GNAS1 gene encoding NESP55 1.56 322571 AF156271 EST duster (not in UniGene) 1.56 318050 AI052093 Hs.133132 ESTs 1.56 303388 AL039604 EST duster (not in UniGene) with exon hit 1.56 323758 AA833858 EST duster (not in UniGene) 1.56 328369 CH.07 hs gi|5868388 1.56 329415 CH.Y hsgi|5868874 1.56 303915 AW468839 Hs.257767 EST 1.56 338794 CH22 EM.AC005500.GENSCAN.528-1 1.56 303074 AA243481 Hs.127320 ESTs; Weakly similar to KIAA0346 [H.sapiens] 1.56 318807 F08434 EST cluster (not in UniGene) 1.56 334287 CH22 FGENES.369 17 1.56 311928 AW024798 Hs.233374 ESTs 1.55 304592 AA505833 Hs.162017 EST 1.55 300785 AA682913 Hs.247179 ESTs; Weakly similar to KIAA0319 [H.sapiens] 1.55 304921 AA603092 EST singleton (not in UniGene) with exon hit 1.55 324605 AW502851 Hs.249978 ESTs 1.55 324473 AW501163 EST duster (not in UniGene) 1.55 300566 H86709 Hs.21371 son of sevenless (Drosophila) homolog 1 1.55 314165 AA761265 Hs.221281 ESTs 1.55 302868 AA157392 EST duster (not in UniGene) with exon hit 1.55 314034 AI299137 Hs.154214 ESTs 1.55 325389 CH.12 hsgi|5866921 1.55 331849 AA417078 Hs.193767 ESTs 1.55 320536 AA331732 Hs.137224 ESTs 1.55 303347 AA258033 EST duster (not in UniGene) with exon hit 1.55 315769 AA744875 Hs.189413 ESTs 1.55 317031 AA973297 Hs.126101 ESTs 1.55 300203 AI827065 Hs.224877 ESTs 1.55 304037 T26438 EST singleton (not in UniGene) with exon hit 1.55 322613 AW160507 EST duster (not in UniGene) 1.54 317987 AW138174 Hs.130651 ESTs 1.54 322313 AF086386 EST duster (not in UniGene) 1.54 323992 AW411383 Hs.169688 ESTs 1.54 325303 CH.11 hsgi]5866908 1.54 312701 AI457663 Hs.128127 ESTs 1.54 304787 AA582678 EST singleton (not in UniGene) with exon hit 1.54 305849 AA861571 EST singleton (not in UniGene) with exon hit 1.54 314557 AA401367 Hs.128647 ESTs 1.54 316507 AI381515 Hs.158381 ESTs 1.54 315023 AA533505 Hs.185844 ESTs 1.54 314920 AA513406 Hs.152307 ESTs 1.54 323097 Z44354 Hs.180950 guanine nucleotide binding protein (G protein); q polypeptide 1.54 325043 W27919 Hs.32944 inositol polyphosphate-4-phosphatase; type I; 107kD 1.54 307892 AI376086 Hs.158759 EST 1.54 324573 AA491600 Hs.161942 ESTs 1.54 313092 AI923673 Hs.212827 ESTs 1.54 324696 AA641092 Hs.257339 ESTs 1.54 303019 AF098363 EST duster (not in UniGene) with exon hit 1.54 317158 AI459140 Hs.129109 ESTs 154 309536 AW151933 EST singleton (not in UniGene) with exon hit 154 301568 AI146423 Hs.146709 ESTs 153 315674 AA651923 Hs.191850 ESTs 1.53 321861 N79341 EST duster (not in UniGene) 1.53 310890 AI184510 Hs.143728 ESTs 1.53 330036 CH.17_p2 gi|6042048 1.53 316907 AA843868 Hs.190567 ESTs 1.53 312299 AA972712 Hs.174818 ESTs 1.53 331128 R51361 Hs.23423 ESTs 1.53 305177 AA663591 EST singleton (not in UniGene) with exon hit 1.53 337685 CH22 EM:AC000097.GENSCAN.77-1 1.53 335290 CH22_FGENES.527_3 1.53 308896 AI858667 EST singleton (not in UniGene) with exon hit 1.53 307944 AI418246 EST singleton (not in UniGene) with exon hit 1.53 300867 AW340374 Hs.121033 neural precursor cell expressed; devebpmentelly down-regulated 1 1.53 335320 CH22 FGENES.534 7 1.53 329841 CH.14_p2 gi|6672062 1.53 317916 AI565071 Hs.159983 ESTs 1.53 332901 CH22_FGENES.36_2 1.53 305413 AA724659 EST singleton (not in UniGene) with exon hit 1.53 316707 AI016387 Hs.184406 ESTs 1.53 313693 AW469180 Hs.170651 ESTs 1.53 316101 AA922236 Hs.221037 ESTs 1.53 320796 AF038966 Hs.184543 secretory carrier membrane protein 1 1.53 307451 AI248615 EST singleton (not in UniGene) with exon hit 1.53 323648 AI679968 Hs.152060 ESTs 1.53 331482 N27515 Hs.40296 ESTs 1.53 318059 AI023175 Hs.167022 ESTs 1.53 325958 CH.16 hs gi|5867142 1.53 315736 AA664265 Hs.230213 ESTs 1.53 314740 AW015667 Hs.119427 ESTs 1.52 314117 AA224368 Hs.185164 ESTs 1.52 301646 AA313954 EST duster (not in UniGene) with exon hit 1.52 338752 CH22_EM:AC005500.GENSCAN.513-10 1.52 309314 AW009312 EST singleton (not in UniGene) with exon hit 1.52 301445 A1208364 Hs.128233 ESTs; Weakly similar to REGULATOR OF CHROMOSOME CONDENSATION [H.sapiens] 1.52 308501 AI685263 Hs.201150 EST 1.52 312330 AA635305 Hs.121574 ESTs 1.52 318040 AI018150 Hs.148781 ESTs 1.52 336205 CH22 FGENES.719 10 1.52 325701 CH.14 hs gi|5867028 152 315009 AW189460 Hs.208358 ESTs 1.52 303121 AW407585 Hs.27769 ESTs; Weakly similar to mCAC [M.musculus] 1.52 309271 AI986221 EST singleton (not in UniGene) with exon hit 1.52 328385 CH.07_hsgi|5868395 1.52 307700 AI318545 EST singleton (not in UniGene) with exon hit 1.52 314591 AW103292 Hs.245328 ESTs 1.52 304484 AA432067 Hs.258373 ESTs 1.52 304382 AA232873 EST singleton (not in UniGene) with exon hit 1.52 304232 W52674 EST singleton (not in UniGene) with exon hit 1.52 309853 AW298169 Hs.57553 tousled-like kinase 2 1.52 312504 AW207346 Hs.143202 ESTs 1.52 313134 N63406 Hs.258697 ESTs 1.52 330391 AF015950 Hs.115256 telomerase reverse transcriptase 1.52 314342 AI873046 Hs.258775 ESTs 151 305977 AA887293 EST singleton (not in UniGene) with exon hit 1.51 301165 N85789 Hs.224155 ESTs; Weakly similar to PTERIN-4-ALPHA-CARBlNOLAMlNE DEHYDRATASE [H.sapiens] 1.51 300613 AI932294 Hs.249604 ESTs; Weakly similar to B-CELL LYMPHOMA 6 PROTEIN [Rsapiens] 1.51 324124 AI554212 Hs.185664 ESTs; Weakly similar to SERINE/THREONINE-PROTEIN KINASE NRK2 [H.sapiens] 1.51 308037 AI458207 Hs.174181 ESTs 1.51 323909 AL043148 Hs.186257 ESTs 1.51 315464 AW139500 Hs.116135 ESTs 1.51 306700 AI022056 EST singleton (not in UniGene) with exon hit 1.51 337976 CH22_EM:AC005500.GENSCAN.107-1 1.51 306855 AI083982 EST singleton (not in UniGene) with exon hit 1.51 311045 AI569399 Hs.174746 ESTs 1.51 315010 AA531082 Hs.240049 ESTs 151 310205 AW025248 Hs.202445 ESTs 1.51 310759 AW135924 Hs.224883 ESTs 151 310954 AW449044 Hs.171298 ESTs 1.51 312019 T77046 Hs.188750 ESTs 1.51 334773 CH22_FGENES.430 5 1.51 332043 AA490831 Hs.125056 ESTs 1.51 322950 AA296219 EST duster (not in UniGene) 1.51 337920 CH22_EM:AC005500.GENSCAN.67-3 1.51 328993 CH.09_hsgi|5868536 1.51 309245 AI972447 EST singleton (not in UniGene) with exon hit 1.51 312172 AI222168 Hs.191168 ESTs 1.51 304039 T47349 EST singleton (not in UniGene) with exon hit 15 301329 AI149653 Hs.190496 ESTs 1.5 313376 AI949246 Hs.200381 ESTs 1.5 324248 AW504918 EST cluster (not in UniGene) 1.5 308771 AI809301 EST singleton (not in UniGene) with exon hit 1.5 334935 CH22_FGENES.464_3 1.5 319764 AA019827 EST duster (not in UniGene) 1.5 318519 T27135 EST duster (not in UniGene) 1.5 332807 CH22_FGENES.7_9 1.5 322310 AF086376 EST duster (not in UniGene) 1.5 324557 AA489166 Hs.156933 ESTs 1.5 332118 AA609585 Hs.162689 EST 1.5 319539 R09027 EST duster (not in UniGene) 1.5 313149 AW291092 Hs.201058 ESTs 15 329722 CH.14_p2 gi|6065785 1.5 323514 AA861209 EST cluster (not in UniGene) 15 308078 AI472621 EST singleton (not in UniGene) with exon hit 1.5 337965 CH22 EM.AC005500.GENSCAN.100-10 15 335905 CH22 FGENES.635 13 1.5 TABLE 14A shows the accession numbers for those primekeys lacking unigenelD's for Table 14. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column. Pkey: Unique Eos probeset identifier number CAT number: Gene duster number Accession: Genbank accession numbers Pkey CAT number Accession 322064 234514J BE261397 Z78343 BE176419 AA383657 N90640 AA334052 AW955761 BE536232 AA374087 AA584776 321409 197898J N71838 AA282003 T54072 AA761419 H92966 AI831371 AI095435 AI690247 R99331 AW964110 AA975590 AA346128 H94196 C03864 322092 46678J AF085833 R69689 AW341677 AA923375 BE327566 AW630415 R69601 AW615339 321452 212379_2 AW962489 H64300 AA329527 313603 199797J AA284333 AW468119 AA284334 AA810992 320856 36098J AB040928 T94673 AI289313 AI536039 Z44366 BE141499 D60116 D61488 D59945 AA419503 R28090 R72986 H03255 AI189112 AI912312 AW511018 AI401349 AW470144 C14624 AI335797 Z40300 AI014456 D60269 D60115 T16722 AI370673 D60270 322139 46806J H53744 AF075088 H53797 321500 552826J BE004271 A1248023 AI022157 H71999 313733 441212J AA766346 AA809877 AA836116 AW469598 AW977404 322215 47002J AF088005 N51816 N51731 322235 47070J AF086106 AI193589 AW665594 N71795 AA722627 AW665373 AI300251 321632 286374J AW812795 AA419617 H87827 AW299775 AW382168 AW382133 BE171659 AW392392 BE171641 AA541393 313833 120893J AA766825 AA811180 AA085906 AI762946 AW977820 322310 47376J AF086376 W77804 W72689 AA837735 322313 47386J AF086386 W77947W72708 322322 47434J AF086431 AA886756 AI557237 322331 47467J AF086467W81444W81445 322345 47537J W95298 AF086529 AI912190 AW294159 AI458747 W94782 322347 47545J AF086538 W95969 AI631911 W95835 322370 187612J AA330095 W25112 AA249401 321739 43998J AL080280 T73124 H02689 AL080281 321781 1511778J D78667 D78871 C18258 314570 280469J AA904776 AA405696 AA405962 300129 635249J AW028820AI219068 322452 497108_2 AI147202W56755 W56710 321861 1651920J N79341 99082 N47551 323140 159551J AA180467AA449184AA464831 AA505048 322520 38916J T55958 T57205 AF147346 321914 85114J AA011603 N58604 58611 322571 22297 1 NM_016102 AF156271 AA781868 AW152318 AW770403 AA909463 AA482996 AA758672 322574 39412J AF156548 AA639797 AI675267 AI825497 AI823355 314753 311451J AA463262 AA463615 AW160405 AW407583 300370 3910_2 AW136181 AA581939 AK001221 AA694538 AA424043 AI016272 AA098960 AA884473 AI356180 BE391633 AA437086 AI277866 AA098827 AA992680 BE172624 AA424101 AA320776 AW962967 N77431 AW858960 AW858897 T85649 AA357743 AI827817 AI905672 322601 577912J A1082395 W92924 BE048524 AW005302 AI084474 AI369330 AI827710 AW135506 AW298694 322613 34330J AW160507 NMJ313367 AF191338 AA384939 AI445790 AA730309 BE397003 BE267753 AI979163 N50386 AW583671 AW583608 BE074466 BE074479 BE074471 AW976283 AA604393 AW162122 W73648 A1823475 N75898 W73713 AW470099 AW513236 AW025055 AW613115 AI923379 W58081 AW664525 AW196795 AI143619 AI565152 AA025406 AA505846 AI685494 AA829964 N59156 N59163 R15442 AA826919 AI610221 AI200120 AA603279 AW150822 AI189513 AI807122 AI016368 AI335868 AW583389 AI193892 AI956157 AI628879 AW591589 AW583446 AI955406 AW148396 AI340255 AI867942 AA748525 AA876991 Z38516 AI874002 AI869474 N63100 AA429094 AA082443 316055 409389J AW105663 AA693880 AW517398 AI768507 BE220851 AW978538 AA831489 323316 981458J BE219300 BE327455 AL134620 R36741 R17996 300492 25768J AL031709 AI249061 AA907658 AI420444 316141 423880_2 AW303457AA972713 AA724265 323371 117336_2 N45114 N51465 BE087338 AI083551 AL135118 BE395609 307700 30923J1 BE280998 BE254670 BE294951 BE564979 AW405364AA069256AA129837 AI559667 BE281405AW410850 BE041153 AI254811 AW301340 AI613335 AW301411 AI609469 AI611607 AI611616 AI377623 AI335509 AI613544 BE043165 AI371663 AI340452 AI612066 AW072890 AI254558 AI349884 AI370095 AI613383 AI611946 AI613353 AI307414 AI318229 AI612685 AW305327 AW268924 AI370063 AI349292 BE049068 AI369098 AW274098 AI344845 AW075187 AI053401 AI345220 BE138515 AI613386 AI583302 AW301955 AI349661 AI307432 AI054168 AI223913 AI612081 AI348942 AI334539 AI309366 AI370098 AI252360 AW086316 AW268911 AW073482 AI379802 AI224284 AI053661 AI334538 A1309369 AI309688 AI310023 AI492709 AI335418 A1053999 AI366989 AW073478 AI247058 AI249584 AI305875 AI308585 AW071272 AI271487 AI340719 AI366995 AI223673 AW271066 AI611936 AW071296 AI270796 AI254385 AI251393 AI252562 AW268236 AI254858 AW071317 AI309102 AI609897 AW268971 AI583267 AI792484 AW075168 BE138443 AI254126 AI309822 AI310872 AI611953 AI251054 AW276658 AI335405 AW075039 AI311768 AI612028 AW271895 AI612005 AI312240 AW271082 AI371642 AI334879 AI310194 AI310772 AI345419 AI334675 AI223914 AI284707 AI284813 AI349140 AI254853 AI313094 AI310170 AI309499 AI312476 AI376484 AI335467 AI340802 AI309815 AI310168 AI611446 AI345824 BE327775 AI318545 F17185 AW614950 308362 792518J AW998989 AI613519 307783 697809J AI347274AW844024 301161 427238J AA731518 AA765714 324094 270098J BE395109 AW663898 AW237041 AI492154 BE046906 AI651285 AI983290 AW002590 AI201040 F32424 AA992272 AW271836 309023 4737J AF180681 NM_015313 AA229509 AA225792 AA216413 AI888045 BE005205 AB002380 T55518 BE276097 AW380669 BE142836 AW370976 AA479384 R96425 AI680999 AA595138 H54582 AI022709 T55440 AI041769 AA861144 AW392028 AA479287 AA824634 AI638446 H54691 R96382 AA770352 AI640467 AW293491 AA779138 R28298 AA970562 C15590 R84455 AA020769 AL036394 H80566 BE548861 AA301207 AW959414 AI284253 AA043173 W52429 BE544571 R24852 Z42603 F13120 R24340 R24326 T75305 H70110 N56255 AA334210 F11453 AW947285 H80345 AA298992 AW380931 AI267175 Z45421 AW380981 W86113 AA663590 AA167577 BE566760 BE169166 AA449904 AA459205 N31126 W03564 N31208 AW993277 N44765 AW605275 D61449 W68572 AA258190 D60496 AW992964 U46277 H04097 AA370360 AW957211 AA159775 AI631243 H83367 H21671 D61077 AW392712 N21112 H98522 N45298 N83629 AI393509 AW022043 AA744886 AI580482 AA723286 AI422244 AI423984 D62804 AI088349 AA587890 AI144172 N33275 BE074397 H03399 D62578 AI056639 AI829918 AA579584 AI089460 AI350124 W68573 A1580828 H98897 AI570468 H83715 W86114 AA923123 D57445 AA043174 AW337721 AI266551 AI140017 AW022356 D79855 D79650 D79393 D60495 AA788666 AA693443 AW516977 W60139 AI628156 AW473223 AI608892 AA159670 AW440366 AI421529 T50751 AI174374 AA912234 AA724248 AW780400 AA907218 H80514 D57452 AA863419 AA552618 D29614 R44556 T16452 R44935 Z41132 D29188 H69692 AI250176 AI078860 AA370359 AW183108 H74200 AA258183 F10723 C00323 R86148 AA860570 AW130073 AL079946 AA410327 AA532614 AA234500 AI151507 AA410288 AW969839 AA483232 AI383200 AA236540 AI807672 H73441 323473 193878J AA262442 AA768862 AA262443 315639 392767J AA827650 AA827652 AW629526 BE044585 AW974451 AA761439 AA648505 AA765803 322878 117013J AA081820AA082191 AA079811 301239 457668J AA807558 AA827117AW629567 301256 16720J NM_016603 AF251038 AI124624 AA776579 AW298470 AI304868 AW082724 AI348442 BE218336 N20641 AI018013 AW858832 AW978157 AA815187 AA932948 AF157316 AI444958 W00848 W02935 AI434933 N26335 AA428681 AW371059 AI651612 AW134937 AW968911 AA488815 AL157523 W48766 AW936954 AW936941 AW579205 AW936886 AW936889 N74541 AW936953 AW578421 AW604352 AW367088 AW849258 AW849453 AW371606 AI554921 W49785 H99814 AA805957 AA904606 AW206696 BE169229 AA333951 AA190704 AW936944 AA463219 AA430306 AW805704 N48503 BE222307AI638612 BE550045 AI805304AI690987AA776841 H12690AW183731 AI380760 AI636261 AA812641 AW592656 AI686132 AA843424 H99220 AW084996 AW128879 AI800871 AA610135 AA191524 AI150076 AI474530 AA748461 N29013 AA746372 N59606 300611 337193J N75450 AA877636 AW137945 W05248 AA514763 AW972399 AI758397 AW195051 324157 247225_2 AW402931 BE393099 323509 967739J AL036947T93676T85475 323514 197787J AA641735 AA281881 AA861209 AA934756 AA835887 AA641795 AA748822 AW295703 300674 466093J AW467388 AA826954 322932 39838 1 AF168711 AA099732 BE019157 AI380212 BE298159 AA249097 AA305112 AW962349 AW962353 AW401801 BE292961 AI439469 AA442919 AI630537 AA724473 AI814288 AW966815 AI376871 AI860202 AI683132 AA099733 AW627633 AI754022 BE206347 AW183349 AI378222 BE178926 AI473282 W52944 AW752469 AW966817 323591 209807J AA301270 AA301379 AA301366 322950 10774J R85652 AA114024 AA296219 AA375304 AW963796 AW885952 AW020969 AA114025 AI804930 BE350971 AI765355 AW317067 AW974763 H85930 AW172600 AI310231 AW612019 D62908 D62864 AA652738 AI674617 AI494064 AW138666 AI147620 AI147629 AW611793 AI668922 AI971005 AI864742 AA174171 322957 29014J AK001701 AA134337 AA356202 BE163251 AW875175 AW875181 AW875177 BE163389 AK000741 AA247755 AA120819 AW868040 AA309118 AW962348 AA471267 AW996843 AK001452 BE005344 BE617899 AA186588 AA120820 AW363311 AA648105 N71529 BE168417 AW673900 AI858160 AA134338 AA659697 N22162 AI335437 AI311237 AI343171 AI336661 AW268074 AW274348 AA935005 AW576295 AW262626 AW593153 AA730055 AA662650 AA782687 AW894855 AI933533 AW193002 AW899448 AW890142 AW812670 AA085664 AA334191 BE178085 BE180553 AA389680 AA984772 AA442527 W26560 BE384359 AA847210 AW304931 AI669606 AA085613 AW197240 AI632828 AA581646 AW129348 AI017643 AW089030 D20893 AI382955 AI557148 AW499979 324231 975669J W60827 AL079968 AL047234 324248 977901J AW504918 N55410 AL118584AW839266 323691 221757J AA317561 AI793000AW235111 AI793178 AA767397 AI263113AA719462 315858 406384J AA737345 AA682286 AI799378 301431 569736J R05385 AI061251 324303 233842 AL118754 AA333202 H38001 324330 300543J AA884766 AW974271 AA592975 AA447312 300815 41537_2 BE152396 BE152395 AA287515 BE001834 AA286678 AW406477 324349 1154015_1 AW501470 AW502931 AW499500 323715 225129J AA322155 AA326396 AA326538 309314 23273_-3 AW009312 323758 229624J AA833858 AW978090 AA327679 AA810436 309375 127_1 AF286598 AW075342 AB028994AL043713 AW378914AA340650 N57166 AW956914 R17961 AA336481 BE393734 AW977867 AW294638 AA927857 AA961627 AW303969 AW894416 AA812119 AA912758 AA424355 AA490582 W30941 AA476693 AA131029 AA127777 AL043714 AA496984 T51117 AA127722 AA594012 AI492876 N76483 AW119061 BE464926 AW303419 AI972370 AI768172 AI826550 AI435432 AI379516 AA778421 AI276089 AA424521 N59361 AA723153 AA723176 AI867487 AA090677 AI827221 AI351027 W02732 AI810729 AA142848 AI082110 N59379 N29744 AI283747 AI148665 AW779845 AI382967 F34319 AI369934 AI282438 AW183449 AA863467 AA813469 AI092645 AI870701 AA863119 325031 266373_2 T65475 R07576 T17017 F08143 Z43546 325045 1534945J T08845Z43538 F06691 324473 38795 1 BE560824 BE513941 AW238907 AA580852 AW501176 BE241846 AW501163 AW751433 AW501340 BE241715 AI910774 323827 235506J AW406878 AW966560 AW966151 AW966496 AA336174 AA335376 AA335537 302270 1734192J R56151 W91936 301618 10967_5 T52761 T52760 301646 42154 1 AJ277841 AI630669 AI804370 Z41939 AW751251 AA299456 Z44739 AW860471 230158 AW105391 H56997 W84688 AA491201 W84636 AA706815 AI131055 AA483636 AI005075 AW340034 AI332372 AW118195 AI338932 AI191968 AA693932 AI189982 AI193225 AA884163 AA594562 W37747 AA249754 AA746131 AI916540 AI832188 AW946555 AA833838 Z40564 AA861563 F01447 AA887937 AI933559 AW973250 AA566018 AA313954 323923 249295J AA354146 AI184230 AA643525 324580 328264J AA492588 AA492498 AA492571 316774 463723J AA814859 AA814857 AI582623 309577 6483_6 AW902251 AW168753 302345 29533J X12830 NM_000565 AW503691 X58298 S72848 AA193347 AW503481 AW177946 AW178192 AW178188 AA285233 AA410577 AA193465 AW177939 AW365459 BE221693 302358 1064753J AW207734 D60164 D81150 D81078 D61356 AW996804 324614 215437J AW503101 AA309184 N56323 R70998 324661 385257J AW504161 AW503601 AW505509 324685 41003J AF226667 AA207032 AA100804 AA121287 AA488316 AI808218 AW419048 AI911097 AW132123 AA502311 AW089948 AA100952 AI075431 AW083432 AI990554 BE466029 F28643 AF086422 W79581 AW439007 F37179 W79780 AW439035 AA731381 AW750380 AA251012 AW589846 AA730238 AA329792 AW087255 AA220982 AA082469 AA877260 AA232380 BE298910 324692 351987J AA557952 AA677593 AA618150 316893 473541J AW979189 AA837332 AA856946 AA876935 303027 21796J AF111178 NM 005708 AF105267 AW590040 AI979280 AA001322 BE146329 AA702430 AA702429 AA694221 AI206348 AI206285 AW770197 AA923032 AI379586 AA701165 AW594643 AA001909 AW002368 324715 290035_2 AI739168 AA426249 AI199636 AW505198 AW977291 AA824583 AA883419 AA724079 AI015524 AI377728 AW293682 AI928140 AA731438 AI092404 AI085630 AA731340 324771 385085J AA631739 AA768584 AW134477 324783 389615J AA640770 AI683112 AA913009 303114 37417J AF090948 AI064898 AM 11182 303124 21112J AB018257 BE148640 AA081832 AK001915 AF150217 AF161350 AI219174 AW074664 D60040 AA346065 H28750 AW151783 BE613360 BE612628 BE502031 AW183790 AA992580 AA505815 AI310432 AI678015 AW592679 AA879181 AA806708 AI744110 H24681 C16064 D62900 AI285033 AA346064 AI865123 AW467798 BE221231 AL120676 N89877 AI928370 AI358387 AA748486 AV647478 AV647460 AA312313 AI279340 AW505099 302552 82290J AA005122 H49792 301918 316229J AA476777T86049 303232 20474J AA437414 AA131479 AA086182 AB037775 AW161063 AW514393 AA332331 AW136197 BE150789 AA425533 AA249605 N88308 AI016201 BE004662 AA291027 R57587 AA424277 AA476391 W07532 T97036 AA218898 AW162629 R57770 W01278 W90204 W90156 AL119197 R84513 AA280103 AA334994 AW965504 AA460868 AA447470 AW138594 W38898 W90028 AI078353 W90078 AA699696 N35523 AA704225 AA035059 AW134892 AA115140 AI142854 H90084 AA826342 AA460694 N46339 AA425344 N56953 AA035569 A1761083 AI658696 AI524818 AI338965 AW069249 AW299871 BE464061 AI189720 AW340682 AI423380 AI275122 H17532 N80735 AA826343 AI039694 BE328398 AI192947 AW271286 AI623122 AI922902 AW293087 N22141 AA730657 AW316610 N26473 F06663 Z43610 H14783 R59761 H11540 AI265915 AI681773 AI091748 BE220636 AW841861 AI702181 AI468447 AA907544 AI273941 AW244034 R37769 AA446663 T96929 BE045884 AA476341 H89994 H29043AW051211 N49522 AA306977 302696 33570 AK000738 AA347452 AW961713 H70832 AI750643 AA362887 AW955588 W44974 AA279599 AW298762 AA452666 AA443355 AI337273AA446931 AI752977AA661554 W42674 AI292172 R41163AA621381 AI244157 30269743219J AJ001409AJ001410 309917 57485_2 AW340014 AW866993 AV651649 303347 192210J AA258033 AA459485 303349 193138J AA382661 AW958642 AA259088 310599 690880J AW300144AI338491 AI798381 BE220076 303388 969232 1 AL039604 AL039497 302761 45074 AW250553 L07876 Z36843 R30693 AI190097 AW965317 318455 606341J AH48763 AI903763 AI903753 AI903762 AI903800 AI9O3801 317850 363835J AI681545 AI951714 AI570397 AW873588 AA836396 AI359986 AI499790 AA773477 AI951615 T07547 AW304709 AF114041 BE176629 Z44580 T30422 T32690 AW953065 H10602 303431 32082J NM_000539 AA019013 AA019367 AA056154 H38735 AA057003 AA021051 H38102 AA015774 AA059291 AA019439 H84843 H83375 AA019914 AA017288 R84449 W26519 H38258 AA018736 H84147 AA018577 AA059353 U49742 H38767 AA318341 AA317553 H86646 H91989 AA317398 AA317378 W29024 W23034 T27877 AW950059 AA017195 R84262 AA057177 H89941 AA019904 H84662 AA015775 AA019368 AA020976 H37900 C20733 H38682 H85197 AA018578 AA017252 AA019440 AA059059 H38651 H84148 AA018560 W25754 C20752 AA317915 AW952115 AA317369 AA019845 R85402 AA019492 AA017196 AA056093 AA056094 AA058836 AA056155 W25957 W23027 AA056159 W23043 W21890 W28951 AA317978 W26459 AA317265 319127 1653640J N49476 Z45911 R21061 303480 232749J AA331906 AA332484 303431 31534 1 AK001952 AA336839 AW249271 BE247287 AF182002 BE613472 AW962673 AA332235 AW849937 AW849814 H49893 AA477148 AW968944 AF182003 AW007897 BE246145 W76100 AI480141 AW410205 AA609339 AI209111 AW000979 AA330280 AW961554 W72865 H49894 AA514317 AA620407 AA504522 AW472833 AA716609 AW129282 AA347351 AA628378 AW589860 AI636696 AA464632 AA464533 AW874189 AA757076 AA479654 AW517910 AW292357 AW872638 AW262288 AI910666 AW513749 AW238771 AA215797 BE387073 303487 20890 1 BE143533 AW850432 AK000042 AA333666 AA385314 AW966616 AW793068 AW793414 AA361103 AW390841 AA040095 AW385058 AW799162 AI383115 AI990745 AI653703 BE503693 AW150758 AI949919 AW190450 AW512348 AI625970 AW501057 N52954 AI281378 AI401710 AI648409 AW002659 AI687639 AI093943 R33960 AA040062 AI926267 AI240425 AI520911 AI093428 R52943 303488 36085 1 AI040372 AB040915 W40569 BE158910 BE158914 D63226 AW025860 AW583088 AA334307 AA210942 AW753212 AW805322 AA362635 BE158911 AW891225 AW994862 AA805451 R28541 AA229347 N48266 AI377788 R28682 R36122 AA811941 AI240742AI632001 T99965 W01976 AW891205 AW891177T97433 C15571 AA346850AA504293W07500 AI694503 AA489216 AA327725 AW959917 AA694146 N68514 AI076285 AW016246 T07783 AA642400 AA716133 AA805332 R00312 AA705021 AW498605 AW891723 AW891906 AA808025 N29039 N74897 W60393 AA810184 AI627460 AW057516 AA807436 AA760966 AI359295 N78642 N20662 AA830300 W81705 AA832258 AW891718 AI811796 AW515523 Z41735 AA449978 AW891714 AI684539 AW891896 AW071701 AI890916 AI924994 AI039743 AA888524 AA244214 AI015736 AI270105 AI865077 303494 236389J F30712 F35665 AW263888 AI904014 AI904018 AA336927 AA336502 319142 164820J H08370 Z46168 F07366 AA193168 AA193138 302868 12593J AK000290 AI476034 AA465309 BE148761 AW303607 AW958665 AW469635 AI819365 AI243857 AW469326 AA157110 AA278626 AA496257 AA306656 F29732 AA831859 AA312210 AA564476 AA579065 AA769522 AA740386 AI205635 AA491643 AA810400 AA417708 AI567332 AA157392 N53817 AA374229 318518 1205335J R68545 T27119 R25687 AW750672 3185194347411 H13364T27135 R61679 AA746905 30416872494_-10 H77679 30294821445J AB038995 NM_016530 AK001111 AA465635 AW968716 U66624 AA885459 AA703019 AI040266 AI018689 AI692886 AI125372 AI376796 AI192040 N58161 AL133607 AW503673 AW505479 AA362265 AJ404571 3192502443511 F11623 H17552 AA347728 318644177001 BE311816 AK000916 AW868037 AW868039 AF228527 AI752482 AW868041 AA077049 AI201537 W55873 AA206019 AA077918 AW968729 AI978828 AW139620 AI093053 AW204025 AI418805 AA598926 AA586345 AA045669 BE314455 AA045668 318674204968J W01166 AW996900 BE184300 Z44887 T34535 R51495 AW886575 AA295490 AA295162 AA295163 AW937125 T56951 30423220640_2 BE386106 W52674 30368580881 AW500106 BE241915 AW503971 NM J16542 AB040057 AA313812 AK000556 W16504 AI822088 AA259107 AA191319 BE085957 AA309584 BE122687 AW952435 T84469 BE088194 BE088132 AA328562 BE092674 AA263102 T39634 AW992380 R79391 R24392 H03060 AW675066 AI299952 AW020325 D25953 N75199 AA361425 AW612302 AW236333 AW673897 AW953686 N22323 AA649166 AI377099 H03061 AI660072 AW276405 AA809779 AI803430 AW297484 AW510384 AA814816 AA371522 D63035 AA953567 R79392 R24282 AA876831 AW297542 AI699023 AA992652 AI041436 318704799152J AI631602 AW589676 Z28684 Z24981 318730275116 Z32887 BE349923 AA398215 AA399231 3037141155758J AW501336 AW501337 304387183612J AA236027 BE003275 304398101691 AA195509 BE394661 AV660757AA489161 BE165972 AW503705 AA262785 AF123320Z78357 NM_014171 AF161488 AA248971 BE568575 AA461410 AA165108 AI637731 H75454 AA372934 AW339334 BE568754 BE564697 BE567299 AI681606 BE537269 AW197204 AA290890 AI189393 AW292463 AW470227 F27399 AW611942 BE566888 AW301701 AI675761 AI628429 AA164711 AI797753 AI656879 AI912690 AI675277 AI695099 AI094095 AW014158 BE091059 AI201748 AW236961 AI038003 AI083606 AA401606 AI079405 AI073516 AI655537 AA401475 AI814532 AI079862 AI093789 AI422084 AI216476 AI392760 AA926998 AA781782 Z25198 AI086377 AI185511 AI185539 Z28843 AI223792 AI379563 AA706253 AI433798 AI921885 H75455 AW025269 AI224100 AI083611 AI225057 AW196334 AI572254 AA761628 AI472801 AA283784 303751 468554J AA830149 AW978407 M85983AW503637 319401 1323199J W00973 N56457 AW992226 T84921 R01342 319402 1003489 1 R86913 R86901 H25352 R01370 H43764 AW044451 W21298 318807 1536467J F08434Z42573 H28810 319478 765461 1 AI524124 R06841 R06842 318872 153458ΪJ Z43108 F06295 R13085 318885 94880_2 AA742999 Z43272 AA345258 AW956677 AA031942 303841 79133 1 W19657 BE616760 BE259848 BE382680 BE615587 AI934464 AA322745 T07155 AW961174 AA307302 Z41888 AA621992 AA188400 AW770608 AI147458 AI148408 AI696291 AA972591 303889 1777183J T19204T36109 T36107 319539 63198J R09027 AA344892 AA329574 AW955648 AW978708 AI567804 AI378935 AW014657 AI804134 R08922 N92947 BE546788 318905 1536408J F08365Z43395 R54298 320187 396254J T99949 AA654769 AA664550 AW975264 318996 65715J Z44266 H06384 AV655948 319635 163534J R17531 AW960899 AA338366 AW673294 BE047729 BE047722 AA330746 AW841797 H05030 AI142105 R12654 319699 747196_1 AI458682 H24240 R14537 R18426 AW867082 319713 1699356J R24204 R15712T84695 319761 75324_2 AW630974 BE005208 R84237 AA724997 AA334867 AW955777 R18816 319764 88596J AA019827 R18947 H46852 319808 7069_3 T58960 AA609180 AA621130 AI927236 AA431075 321040 193331J AA261830 AW967855 H26953 AA262478 320409 43709 1 AA226869 AA296516 AW959753 AA186390 AL359619 AA356195 AA148427 R22748 AI033624 BE548853 H95327 AW579751 BE561649 AA397533 BE617136 AA236444 T89946 AA247450 N55777 W38725 AI743846 AI808406 AA922229 AI051464 W04713 R11251 W19656 AI042319 AA489276 AI224533 H95274 AW269958 T89311 AI890088 AI862754 AI830968 AI669336 AI589780 AA534557 AW273839 AI338155 AI126632 N83542 BE046048 AA807028 AA848107 AW167978 AA976930 AA148428 AI289304 AI524262 AI625961 AA773469 AI222288 AI280054 AI242371 AA227222 AA973329 AA296517 AA829436 AA234526 AI149769 AI567865 AA936939 AI590681 AW469308 AI689531 AA486419 AI422051 AI057252 AA626941 AI475352 AW247913 AI222370 AA670122 AW198034 AA486418 AI363794 AA380739 319881 1585983J H51299 H44619 H46391 R86024 H51892 T72744 320488 368456J AI817336 R32883 AA595590 AI743065 R31386 321121 1545647J W23285 H42714 F25381 F37215 321205 81249J AA002047 N72537 H54142 H81580 321253 375160J AA610649 AI699484 H59558 314043 155125J AA827082 AA732246AA167611 AA830741 320630 17685_2 AA199847 AA410224 R53323 AW936567 AW936569 AW936568 AW936571 313435 443527J AA769123 AA831715 AW977666 W92553 313443 82292J AA005125 W95019 W93335 AA249037 313472 82811_1 AA007374 AA007466 AI816886 321348 41762 Z49979 D61703 U30168 314138 179960J AA740616 AA654854 AA229923 320712 57156_2 R66867 R65678 R82673 W73128 R83101 321383 41924J AW968556 AJ238555 AW968731 AJ002574 AA459446 H70260 AW977557 AA767351 AW268572 AA810719 AI698677 AI300460 AA907450 AA649224 T07415 AI536896 BE018515 AI279865 BE047421 312996 187327J AW368634 AI702169 AI245179 AW368646 BE545574 AA249018 AW368633 N27553 306513 AA989230 306537 AA991705 306557 AA994530 306598 AI000320 306620 AI000929 306700 AI022056 308078 AI472621 306813 AI066544 306830 AI075803 306855 AI083982 329722 c14_p2 329728 c14_p2 306890 AI092235 308100 AI475949 308147 AI498991 306929 AI124514 308352 AI610791 308383 AI624497 308521 AI689808 308561 AI701559 308617 AI738720 308771 AI809301 308828 AI824829 308896 AI858667 30301941850J AF098363 AF098365 30308444211_1 AF174008 AF174027 AF174106 305092 AA642912 305169 AA663131 305177 AA663591 305235 AA670480 305413 AA724659 305849 AA861571 305854 AA862733 307113 AI183686 307130 AI185234 305937 AA883238 305977 AA887293 307451 AI248615 307513 AI274307 307848 AI364186 307871 AI368665 307881 AI370434 307932 AJ230822 307944 AI418246 307954 AI419692 307965 AI421641 309245 AI972447 309271 AI986221 309365 AW072861 309372 AW074330 309435 AW090537 309506 AW137700 309536 AW151933 309709 AW242630 325417 c12 hs 325450 c12 hs 325452 c12_hs 309815 AW292760 309839 AW296076 309849 AW297444 309906 AW339340 302705 31765J U09060U09061 304037 - T26438 304039 T47349 304236 W93278 304257 AA053294 304382 AA232873 304405 AA282572 304561 AA489792 304569 AA490934 304787 AA582678 304921 AA603092 327819 c_5_hs 304968 AA614308 306382 AA968967 33126347479J AW780192 AA015718W02571 332252 1663967J N63882T91174 TABLE 14B shows the genomic positioning for those primekeys lacking unigene ID's and accession numbers in Table 14. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed. Pkey: Unique number corresponding to an Eos probeset Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (Gl) numbers Strand: Indicates DNA strand from which exons were predided. NLposition: Indicates nudeotide positions of predided exons. Pkey Ref Strand NLposition 332807 Dunham, I. etal. Plus 297686-297808 332808 Dunham, . etal. Plus 298277-298360 332812 Dunham, . etal. Plus 309688-310561 332901 Dunham, . etal. Plus 1841954-1842090 333149 Dunham, . etal. Plus 3574317-3574413 333916 Dunham, . etal. Plus 8298994-8299169 334026 Dunham, . etal. Plus 9196549-9196681 334061 Dunham, . etal. Plus 9686941-9687077 334073 Dunham, . etal. Plus 9792201-9792374 334150 Dunham, . etal. Plus 10529221-10529854 334379 Dunham, . etal. Plus 13908356-13908467 334719 Dunham, . etal. Plus 15778859-15779026 334773 Dunham, . etal. Plus 16235169-16235328 334893 Dunham, . etal. Plus 19302753-19302881 334935 Dunham, . etal. Plus 20108247-20108373 335146 Dunham, . etal. Plus 21491292-21491457 335320 Dunham, . etal. Plus 22542132-22542246 335568 Dunham, . etal. Plus 24935021-24935655 335586 Dunham, . etal. Plus 24990333-24990497 335601 Dunham, . etal. Plus 25044923-25045157 336036 Dunham, . etal. Plus 29019796-29019877 336123 Dunham, . etal. Plus 30051089-30051186 336268 Dunham, . etal. Plus 31997555-31998040 337173 Dunham, . etal. Plus 23624127-23624224 337460 Dunham, . etal. Plus 32536159-32536395 337685 Dunham, . etal. Plus 3547161-3547245 337736 Dunham, . etal. Plus 3850500-3850643 337780 Dunham, . etal. Plus 41137934113990 337965 Dunham, . etal. Plus 7034267-7034392 337976 Dunham, . etal. Plus 7166011-7166119 338030 Dunham, . etal. Plus 8072708-8072827 338112 Dunham, . etal. Plus 10391398-10391600 338165 Dunham, .etal. Plus 12205719-12205875 338178 Dunham, . etal. Plus 12800037-12800181 338427 Dunham, . etal. Plus 19685043-19685354 338506 Dunham, . etal. Plus 21221871-21221953 338794 Dunham, . etal. Plus 27114697-27114763 338910 Dunham, . etal. Plus 28795375-28795551 339047 Dunham, . etal. Plus 30760793-30760968 332864 Dunham, . etal. Minus 1390386-1390296 332933 Dunham, . etal. Minus 2035790-2035681 333193 Dunham, . etal. Minus 3832993-3832494 333712 Dunham, . etal. Minus 7286177-7286073 333940 Dunham, . etal. Minus 8523830-8523671 333942 Dunham, . etal. Minus 8552629-8552330 334287 Dunham, . etal. Minus 13294116-13293871 334387 Dunham, . etal. Minus 13946021-13945781 334487 Dunham, .etal. Minus 14432191-14432132 334913 Dunham, . etal. Minus 19463909-19453815 335109 Dunham, . etal. Minus 21325792-21325667 335250 Dunham, . etal. Minus 21952922-21952826 335288 Dunham,.I.etal Minus 22304275-22303770 335290 Dunham,.I.etal Minus 22309950-22309891 335549 Dunham,.I.etal Minus 24666203-24666128 335862 Dunham,.l.eta! Minus 26690300-26690125 335864 Dunham,.I.etal Minus 26694537-26694382 335905 Dunham„, I. et.al Minus 26988888-26988719 336205 Dunhami,, I. etal Minus 30477456-30477311 336276 Dunham,, I. etal Minus 32093320-32093181 336433 Dunhami,, I. etal Minus 34067540-34067425 336605 Dunham,, I. etal Minus 15616509-15616358 336616 Dunhami,, I. etal Minus 26021027-26020848 336679 Dunhami,, I. etal Minus 2035790-2035681 337043 Dunhami,, I. etal Minus 17407330-17407251 337272 Dunhami,,I. etal Minus 28241476-28241307 337357 Dunham,.I.etal Minus 30906179-30906109 337393 Dunhami,, I.etal Minus 31471747-31471569 337497 Dunhami,, I. etal Minus 33371317-33371258 337646 Dunham„, I. etal Minus 2648689-2648632 337920 Dunhami,, I. etal Minus 6051648-6051510 338083 Dunhami,, I. etal Minus 9318438-9318301 338220 Dunhami,, I. etal Minus 14166440-14166104 338752 Dunhamι,, I. etal Minus 26421374-26421135 338763 Dunhami,, I. etal Minus 26628148-26628009 338983 Dunhami,, I. etal Minus 29908865-29908702 339209 Dunham,, I. etal Minus 32492953-32492593 325240 5866848 Minus 32301-32650 329532 3983505 Plus 42937-43014 329522 3983507 Minus 35265-35458 329519 3983510 Plus 18407-18597 329511 3983514 Plus 20965-21325 325326 5866875 Plus 47726-48024 325303 5866908 Minus 73556-73630 325389 5866921 Plus 239672-239759 325417 5866925 Minus 110635-110745 325450 5866941 Minus 435379-435552 325452 5866941 Minus 704103-704202 325498 5866967 Plus 173372-173930 325587 6682462 Plus 126724-126967 325602 5866994 Plus 79122-79251 325701 5867028 Minus 72936-73046 325780 6381953 Plus 63634-63873 329722 6065785 Minus 112713-112992 329728 6065785 Minus 207544-207741 3296666272129 Plus 98307-98446 329815 6624888 Minus 68431-68720 329841 6672062 Minus 40181-40331 325824 5867048 Minus 42450-42833 325866 5867076 Minus 94358-94628 325902 5867101 Minus 127729-127842 325958 5867142 Plus 53437-53550 326014 5867160 Minus 10358-10447 329941 6165199 Minus 34319-34411 330002 6623963 Plus 46097-46158 326154 5867170 Minus 7103-7179 326023 5867245 Plus 171799-171896 326278 5867269 Pius 75250-75903 330036 6042048 Plus 117120-117216 326547 5867307 Minus 623677-623870 326495 5867423 Plus 11843-11930 326507 5867435 Minus 13038-13111 326505 5867435 Minus 8818-8949 326506 5867435 Minus 9368-9509 326530 5867441 Minus 303000-303122 326508 6682496 Plus 78904-79112 330120 6671864 Minus 127553-127656 330123 6671869 Minus 35311-35406 326858 6552462 Minus 69337-69670 326983 5867657 Minus 16023-16581 327014 5867664 Plus 1017630-1017788 3269306456782 Plus 606950-607705 3269206456782 Minus 42425-42519 3270586531965 Plus 2384268-2384835 327061 6531965 Minus 3486389-3486673 3270756531965 Plus 4041318-4041431 3271206531970 Minus 6-1088 330126 6093735 Plus 82458-82623 327157 5866841 Minus 44084746 3271835867442 Plus 84317-84531 327192 5867445 Minus 194652-194764 327288 5867481 Plus 48583-48773 327469 5867772 Plus 145549-145708 327489 6004459 Minus 57796-58015 327526 6381882 Minus 97010-97123 3275745867818 Plus 68767-69126 327665 5867839 Plus 141736-141900 327752 5867949 Plus 93721-94421 327819 5867968 Minus 92202-92717 327796 5867982 Plus 85267-85405 330260 6671884 Plus 4520345269 330282 6671910 Plus 39824114 328078 5868008 Plus 72807-72865 328121 5868031 Pius 153782-153850 328190 5868077 Plus 21082-21165 328227 5868105 Minus 21082-21242 327871 5868131 Minus 88889-89221 328018 5902482 Minus 542547-543133 328624 5868246 Minus 120666-120836 328744 5868290 Plus 138639-138722 328799 5868316 Minus 80771-80923 328291 5868363 Minus 144244-144434 328329 5868375 Plus 191709-192239 328369 5868388 Plus 75371-75583 328385 5868395 Plus 369952-370155 328397 5868397 Plus 344967-345063 328412 5868405 Plus 86427-86519 328538 5868485 Plus 38144243 328656 6004473 Plus 792616-792729 328638 6004473 Plus 294618-294903 328903 5868514 Plus 23625-24468 3289606456775 Plus 38547-38837 330320 5932415 Minus 54458-54697 328993 5868536 Plus 49160-50084 329081 5868602 Plus 93368-93510 329089 5868614 Plus 25805-26923 329109 5868626 Plus 102168-102273 329192 5868716 Plus 166936-167020 329218 5868726 Minus 71408-71707 3292245868728 Plus 27422-27664 329246 5868732 Minus 250541-250792 329415 5868874 Plus 1011438-1011818 329454 5868887 Plus 51342-51593 TABLE 15: 169 GENES WITH SEQUENCE INFORMATION DEPICTED IN TABLE 16 Table 15 depicts UnigenelD, UnigeneTitle, Primekey, Predicted Cellular Localization, and Exemplar Accession for all of the sequences in Table 16. The information in Table 15 is linked by EosCode to Table 16. Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD: Unigene number Unigene Title: Unigene gene title EosCode: Internal Eos name Localization: Predicted cellular localization of gene product Pkey ExAccn UnigenelD UnigeneTitle EosCode Localization 100394 D84276 Hs.66052 CD38 antigen (p45) PBC1 plasma membrane 100452 D87742 Hs.241552 KIAA0268 protein PAB7 not determined 101249 L33881 Hs.1904 protein kinase C, iota OAA1 cytoplasmic 101485 M24736 selectin E (endothelial adhesion molecul ACC5 plasma membrane " 101514 M28214 Hs.123072 RAB3B, member RAS oncogene family PFJ2 cytoplasmic 101851 M94250 Hs.82045 midkine (neurite growth-promoting factor LBH9 102398 U42359 gb:Human N33 protein form 1 (N33) gene, PDG3 102522 U53347 Hs.183556 solute carrier family 1 (neutral amino a PFJ4 plasma membrane 102669 U71207 Hs.29279 eyes absent (Drosophila) homolog 2 LEM9 cytoplasmic 103119 X63629 Hs.2877 cadherin 3, type 1 , P-cadherin (placenta LBG2 plasma membrane 103709 AA037316 Hs.13804 hypothetical protein dJ462023.2 PD06 104080 AA402971 Hs.57771 kallikrein 11 PBA6 secreted 104144 AA447439 Hs.183390 hypothetical protein FU13590 PDM3 104691 AA011176 Hs.37744 Homo sapiens beta-1 adrenergic receptor PAV1 plasma membrane 105370 AA236476 Hs.22791 transmembrane protein with EGF-like and PDM9 plasma membrane 106149 AA424881 Hs.256301 hypothetical protein MGC13170 PD08 106579 AA456135 Hs.23023 ESTs PAA4 plasma membrane 107102 AA609723 Hs.30652 KIAA1344 protein PAA3 not determined 107217 D51095 DKFZP586E1621 protein PDG8 108153 AA054237 Hs.40808 ESTs PBF1 plasma membrane 109014 AA156790 Hs.262036 ESTs, Weakly similar to Z223.HUMAN ZINC PDG7 109112 AA169379 Hs.257924 hypothetical protein FU13782 BCU4 not determined 109890 H04649 Hs.20843 Homo sapiens cDNA FU11245 fis, clone PL PDG4 110151 H18836 Hs.31608 hypothetical protein FU20041 PAV9 plasma membrane 112971 T17185 Hs.83883 transmembrane, prostate androgen induced CHA1 not determined 113021 T23855- Hs.129836 KIAA1028 protein PD03 114908 AA236545 Hs.54973 cadherin-like protein VR20 PFJ6 plasma membrane 114965 AA250737 Hs.72472 ESTs BCY2 mitochondrial 116393 AA599463 hypothetical protein MGC2648 PDV3 secreted 116416 AA609219 Hs.39982 ESTs OAB6 117698 N41002 Hs.45107 ESTs PDT9 ER 117984 N51919 Hs.106778 ATPase, Ca++ transporting, type 2C, memb PAJ5 not determined 118985 N94303 Hs.55028 ESTs, Weakly similar to I54374 gene NF2 PDM8 119018 N95796 Hs.278695 Homo sapiens prostein mRNA, complete eds -PAB2 plasma membrane 119126 R45175 Hs.117183 ESTs PBF8 120992 AA398246 Hs.97594 KIAA1210 protein PDG5 121710 AA419011 prostate androgen-regulated transcript 1 PDV5 121913 AA428062 ESTs; protease inhibitor 15 (PI15) BCU7 vesicular 122041 AA431407 Hs.98732 Homo sapiens Chromosome 16 BAC clone CIT PAZ1 not determined 122593 AA453310 Hs.128749 alpha-methylacyl-CoA racemase PD01 123209 AA489711 Hs.203270 ESTs, Weakly similar to ALU1_HUMAN ALU S PAA2 plasma membrane 124526 N62096 Hs.293185 ESTs, Weakly similar to JC7328 amino aci PAV4 plasma membrane 126399 AA128075 transmembrane, prostate androgen induced PDY4 126645 AI167942 Hs.61635 six transmembrane epithelial antigen of PAA5 plasma membrane 126966 R38438 Hs.182575 solute earner family 15 (H-t peptide tra PD05 plasma membrane 127537 AA569531 Hs.162859 ESTs PAA6 not determined 128790 AA291725 Hs.105700 secreted frizzled-related protein 4 BCX2 secreted 129109 AA491295 Hs.108708 calcium/cal odulin-dependent protein kin PFJ7 129184 W26769 Hs.109201 CGI-86 protein PAV6 vesicular 129389 AA621604 spondin 2, extracellular matrix protein CJA5 not determined 129404 AA172056 ESTs PAB4 129534 R73640 Hs.11260 hypothetical protein FI-J11264 PAJ3 secreted 130760 AA128997 Hs.18953 phosphodiesterase 9A PEE6 nuclear 131425 AA219134 Hs.26691 ESTs PBA7 132964 AA031360 ESTs PAA7 plasma membrane 132967 AA032221 Hs.61635 six transmembrane epithelial antigen of PM17 plasma membrane 133179 U81599 Hs.66731 homeo box B13 PFJ5 nuclear 133330 U42360 Hs.71119 Putative prostate cancer tumor suppresso PDM1 plasma membrane 133520 X74331 Hs.74519 primase, polypeptide 2A (58kD) PDM2 133724 U07919 Hs.75746 aldehyde dehydrogenase 1 family, member PDT1 mitochondrial 133724 U07919 Hs.75746 aldehyde dehydrogenase 1 family, member PDT1 mitochondrial 133944 AA045870 Hs.7780 Homo sapiens mRNA; cDNA DKFZp564A072 (fr PAB9 cytoplasmic 134110 U41060 Hs.79136 LIV-1 protein, estrogen regulated BCR4 plasma membrane 301805 AI80OO04 Hs.142846 hypothetical protein PEU4 nuclear 302005 AI869666 Hs.123119 MAD (mothers against decapentaplegic, DrPBJΘ cytoplasmic 302881 AA508353 Hs.105314 relaxin 1 (H1) PBH3 secreted 303506 AA340605 Hs.105887 ESTs, Weakly similar to Homolog of rat Z PEG4 303699 D30891 Hs.19525 hypothetical protein FU22794 PBM4 not determined 303753 AW503733 Hs.9414 KIAA1488 protein PBY3 not determined 308050 AI460004 Hs.31608 hypothetical protein FU20041 PEU5 plasma membrane 310382 AI734009 Hs.127699 KIAA1603 protein PCQ8 310431 AI420227 Hs.149358 ESTs, Weakly similar to A46010 X-linked PBH1 plasma membrane., 310573 AW292180 Hs.156142 ESTs PEN3 plasma membrane 310598 AI338013 Hs.140546 ESTs PCW3 310816 AI973051 HS224965 ESTs PET5 311596 AI682088 Hs.79375 hotacarboxylase synthetase (biotin-[prop PBH8 313676 AA861697 Hs.120591 ESTs PBY2 314121 AI732100 Hs.187619 ESTs PBY1 314691 AW207206 Hs.136319 ESTs BFF8 not determined 314785 AI538226 Hs.32976 guanine nucleotide binding protein 4 CB07 cytoplasmic 314907 AI672225 Hs.222886 ESTs, Weakly similar to TRHY_HUMAN TRICH PBM2not determined 315051 AW292425 ESTs PBM9 315052 AA876910 Hs.134427 ESTs PBJ7 plasma membrane 316442 AA760894 Hs.153023 ESTs PBJ9 317548 AI654187 Hs.195704 ESTs PBQ6 317869 AW295184 Hs.129142 deoxyribonuclease II beta PBQ7 318524 AW291511 Hs.159066 hypothetical protein FU10188 PBJ1 cytoplasmic 319191 AF071538 prostate epithelium-specific Ets transcr PEN1 319763 AA460775 Hs.6295 ESTs, Weakly similar to T17248 hypotheti PE07 320324 AF071202 Hs.139336 ATP-binding cassette, sub-family C (CFTR PBH5 plasma membrane 320561 NM_006953Hs.159330 uroplakiπ 3 PEL9 plasma membrane 320796 AF038966 Hs.31218 secretory carrier membrane protein 1 PBY4 not determined 321441 AW297633 Hs.118498 Homo sapiens LUCA-15 protein mRNA, splic PBY8 not determined 322303 W07459 Hs.157601 ESTs CBF9 secreted 322782 AA056O60 Hs.202577 Homo sapiens cDNA FU12166 fis, clone MA PBQ1 not determined 322818 AW043782 Hs.293616 ESTs PCQ7 plasma membrane 323226 AF055019 Hs.21906 Homo sapiens clone 24670 mRNA sequence PCI2 not determined 323287 AA639902 Hs.104215 ESTs, Moderately similar to SPCNJHUMAN S PBJ5 324295 AI146686 Hs.143691 ESTs PBQ9 not determined 324430 AA464018 Hs.184598 Homo sapiens cDNA: FU23241 fis, clone C PBY6 not determined 324603 AW016378 Hs.292934 ESTs PBM3 324617 AA508552 Hs.195839 ESTs, Weakly similar to I38022 hypotheti PBH4 cytoplasmic 324626 AI685464 Qb:tt88f04.x1 NCI_CGAP_Pι28 Homo sapiens -PCW6 324658 AI694767 Hs.129179 Homo sapiens cDNA FU13581 fis, clone PL PBJ4 plasma membrane 324718 AI557019 Hs.116467 small nuclear protein PRAC CBK1 nuclear 330211 PBJ2 not determined 330546 U31382 Hs.299867 guanine nucleotide binding protein 4 PEW1 cytoplasmic 330762 AA449677 Hs.15251 hypothetical protein PBM1 not determined 330790 T48536 Hs.122764 TMPRSS2, transmembrane protease, serine PEL3 plasma membrane 330892 AA149579 Hs.91202 ESTs PBQ4 plasma membrane 331099 R36671 Hs.14846 Homo sapiens mRNA; cDNA DKFZp564D016 (fr PCQ1 cytoplasmic 331490 N32912 Hs.291039 ESTs PCI4 nuclear 331889 AA431407 Hs.98802 ESTs, Moderately similar to T14342 NSD1 PBH7 not determined 332247 N58172 gb:za21f09.s1 Soares fetal liver spleen PBQ5 nuclear 332396 AA340504 gb:hw31a09.x1 NCI_CGAP_Kid11 Homo sapien PBJ8 not determined 332697 T94885 transgelin2 PBQ8 secreted 332798 PBH2 nuclear 334447 PBY9 not determined 338255 PBY7 not determined 401424 PFG2 mitochondrial 407122 H20276 Hs.31742 ESTs PEW7 408430 S79876 Hs.44926 dipeptidylpeptidase IV (CD26, adenosine PEZ3 plasma membrane 408826 AF216077 Hs.48376 Homo sapiens clone HB-2 mRNA sequence PEY1 409262 AK000631 Hs.52256 hypothetical protein FU20624 PFG1 nuclear 409361 NM_005982Hs.54416 sine oculis homeobox (Drosophila) homolo PEW3 nuclear 411096 U80034 Hs.68583 mitochondrial intermediate peptidase PEZ9 mitochondrial 413125 BE244589 Hs.75207 glyoxalase l PFJ3 cytoplasmic 413623 AA825721 Hs.246973 ESTs 0BH6 414422 AA147224 Hs.337232 Homeo box A13 PFC6 415263 AA948033 Hs.130853 ESTs PEZ5 417153 X57010 Hs.81343 "collagen, type II, alpha 1 (primary ost PFJ1 secreted 418601 AA279490 Hs.86368 calmegin PFA1 ER 418848 AI820961 Hs.193465 ESTs PEY4 418882 NM_004996Hs.89433 ATP-binding cassette, sub-family C (CFTR 0BH2 419839 U24577 Hs.93304 "phospholipase A2, group VII (platelet-a PFH9 secreted 421887 AW161450 Hs.109201 CGI-86 protein PFH2 plasma membrane 422083 NM_001141 Hs.111256 "arachidonate 15-lipoxygenase, second ty PFH5 cytoplasmic 424565 AW102723 Hs.75295 guanylate cyclase 1 , soluble, alpha 3 PFA3 425071 NM_013989Hs.154424 "deiodinase, iodothyronine, type II" PFH6 secreted 425710 AF030880 solute carrier family, member 4 PFD4 plasma membrane 427958 AA418000 Hs.98280 potassium intermediate/small conductance PFH1 plasma membrane 428819 AL135623 Hs.193914 KIAA0575 gene product PFD6 nuclear 429900 AA460421 Hs.30875 ESTs PEZ7 429918 AW873986 Hs.119383 ESTs PEY5 430226 BE245562 Hs.2551 adrenergic, beta-2-, receptor, surface PEZ4 plasma membrane 431217 NM_013427Hs.250830 Rho GTPase activating protein 6 PFG6 nuclear 431716 D89053 Hs.268012 fatty-add-Coenzyme A ligase, long-chain PEZ1 431992 NM_002742Hs.2891 protein kinase C, mu PFH4 cytoplasmic 432189 AA527941 gb:nh30c04.s1 NCI_CGAP_Pr3 Homo sapiens PFA2 432244 AI669973 Hs.200574 ESTs PEW8 432437 W07088 Hs.293685 ESTs PFG3 432966 AA650114 Hs.325198 ESTs PEY3 439176 AI446444 Hs.190394 ESTs, Weakly similar to B28096 line-1 pr PEW5 440260 AI972867 Hs.7130 copine lV PEW6 440901 AA909358 Hs.128612 ESTs PFC8 445424 AB028945 cortactin SH3 domain-binding protein PEZ6 446320 AF126245 Hs.14791 "acyl-Coenzyme A dehydrogenase family, m PFH7 447210 AF035269 phosphatidylserine-specificphospholipas PFH8 449156 AF103907 Hs.171353 prostate cancer antigen 3, non-coding DD PEZ8 449625 NM_014253 odz (odd Oz/ten-m, Drosophila) homolog 1 PEZ2 plasma membrane 449650 AF055575 Hs.23838 calcium channel, voltage-dependent, Lty PFD2 plasma membrane 451939 U80456 Hs.27311 single-minded (Drosophila) homolog 2 PFJ8 451982 F13036 Hs-27373 Homo sapiens mRNA; cDNA DKFZp56401763 (f PFG9plasma membrane 452039 AI922988 ESTs PFD8 452340 NM 002202HS.505 ISL1 transcription factor, LIM/homeodoma PFG4 nuclear 452784 BE463857 Hs.151258 hypothetical protein FU21062 PFC5 cytoplasmic 452946 X95425 Hs.31092 EphAδ PFH3 plasma membrane TABLE 15A shows the accession numbers for those primekeys lacking a unigenelD in Table 15. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column. Pkey: Unique Eos probeset identifier number CAT number Gene cluster number Accession: Genbank accession numbers Pkey CAT number Accession 116393 131543J AI972402 AI634409 AI523716 AI799749 W44518 AI424438 AI688513AI971048AI686324AW013854AA588483AA528111 AI627428 AI582200 AI669296 AI826926 AI620526 AI669958 AI972458 AI924500 AA512903 W44517 AA335363 AW238997 BE300165 BE250665 AA284195 AA523420 W52834 AI471970 AI952824 AW003820 AW009463 AA669796 AA114966 AI653342 AA115038 AI342150 AI092100 AI968211 W51994 AI804005 AI201420 AI123210 AI738405 AI674964 AI970341 AW027500 AI493316 AI333193 AI139353 AA599463 AI656163 AI804200 AI365321 AI990213 AI657011 AA650025 AI968810 AI341978 AA599839 AW592602 AA644289 AI468578 AI565265 AI565228 BE221535 AW973052 101485 18113_1 AA296520 AL021940 M30640 NM_000450 M24736 M61894 AL047443 H39560 AI694691 AA916787 AI214796 AA939085 AI150616 AA412553 AA412545 AI051015 T27654 AA694430 126399 17331J AA088767 AF224278 AA128075 AL035541 AA027926 AI761441 AI972096 AW071693 AI742327 AI377498 AI804815 AI640802 AI885001 AI921394 AA595115 N71820 AI921217 AW007283 AI457828 AI369306 AA917446 AI493698 AA088701 AA126899 A1936228 AW204238 AI039567 AI925027 BE138909 AW452945 AW135998 AA310984 AA027860 AW073519 AI537597 AA953976 AI521341 AW273569 AW050740 AA536113 AA559064 AI474392 AW135709 AA535181 AW572959 AA570597 AI905464 AI677810 AI587642 AW975102 AA424310 AA482527 N64192 AA658276 AW889117 AA486591 AW889172 AI381990 AI381991 AI673419 AI990950 AA487031 AI272934 AI150565 AA229168 AW316722 AI142707 BE222396 AA614168 AA122026 AW338227 AA632457 AI968726 AW369662 AA512956 AA541675 AA451748 AI250993 BE146418 AA122025 132964 94346J AI362575 AI805082 AW263421 AI432462 AA135870 AA031360 AA031604 AA298475 AA298464 129389 21074J NM_012445 AB027466 BE407510 BE047605 AA047125 AW084003 AA149494 AA149490 AA292528 AA570505 AA526186 AW006250 AW007762 AI341557 AI799666 AI972710 AI377966 AI962810 AI084783 AI458032 AI190971 AW148913 AA372354 AW970032 AW007426 AA650188 AI123203 AI122890 AI280975 W73595 W73495 AI863238 AA374109 AA603986 AW149089 AW957523 AI307748 AI921067 AI336463 F24537 AI380460 AI367500 AI189309 AI814701 AI766921 AW572106 AA037024 AW072576 AA578293 AI288103 AA235454 AW450642 AA574230 AW294024 AI589229 AI580733 AW512227 AA877009 AI660255 AW188597 AA558228 AI572782 AA658397 AI274628 AI866359 AA864573 AI264439 AA621604 AW515493 AW243333 Z39737 AI567038 AA573997 AA573559 AW236431 AI652870 AI684973 AA034505 AA047126 129404 156454J AI267700 AI720344 AA191424 AI023543 AI469633 AA172056 AW958465 AA172236 AW953397 AA355086 107217 9836J AL080235 AA031750 D81382 AI480231 AI095947 AI560953 BE010721 AI870290 AA374945 AA125792 D51527 D51556 AI685541 D51559 AW117286 AA195741 AI675138 AW593439 AI201885 T30590 AW952100 D51095 AA523864 W70O43 AA987586 AI421515 AI205532 AA127069 AI337367 D51595 AI453785 AW075677 AW088359 C14287 C14284 121710 19266J AF163474 NM_016590 AF163475 AI761105 AI770098 AA410580 AA411616 AI590343 AI739050 AL050198 AI862645 AA419104 AA513809 AA333032 AI816915 AW139625 AA640889 AI311391 AI627693 AW135514 AA419011 AI269149 AI245259 AI970008 AI970017 AW139445 AA569503 AI761072 AI766179 AI759995 AI300776 AI870129 AW150770 AA226501 AA226220 121913 291015J AI249368 AI742316 AA428062 AA442089 AI864189 BE349478 AI803475 AI584049 BE552085 AI088609 AI264197 AI886144 AI129474 AI307145 BE181300 AW058403 AI696838 AW748598 AA442196 AI216428 102398 entrez_U42359U42359 315051 347217J AW292425 BE467167 AI702953 BE550961 BE222309 AI299348 AI693336 AA541708 324626 336411J AI685464 AW971336AA513587AA525142 319191 16065J NM_012391 AF071538 AB031549 AI685592 AI745526 AA662204AW130657M662164 AW971121 AI668916 AA513274 AI991223 AI979170 AW298436 AA639821 AI859010 AW513942 AI687669 AA662521 AA548598 AI345056 AI305374 BE043418 AI432856 AI334840 AI379796 AI492693 AI307915 BE042082 AI307834 AI307858 AI309488 BE042210 AI435670 AI371605 AI862491 AI284563 AI306872 AI255044 AI254601 AI251236 A1473073 AI473042 AI432760 AI435664 AI336826 AI289365 AI369096 AI862274 AI334871 AI349863 AI250405 AI377617 AI309895 AI313017 AI862291 AI311936 AI378718 AI305722 AI306769 AI308888 AI334565 AI862296 AI344230AI435685 AI344087 AI378696 AI311209 AI435775 AI310611 AI311154AI432289 AI431561 AI492681 AI432867 AI335288 AI492796 AI432769 AI310299 AI432273 AI379820 AI275319 AI435753 AI609441 AI432767 AI369100 AI311420 AI349974 AI247157 AI334677 AI270910 AI224320 AI305608 AI334489 AI377152 AI350012 AI370086 AI335053 AI306781 AI306750 AI334849 AI334874 AI340380 AI307876 AI305974 AI305972 AI311521 AI334872 AI862509 AI311498 AI335051 AI289684 AI310859 AI311862 AI862483 AI492775 AI307906 AI492708 AI289693 AI340373 AI307910 AI311359 AI435653 AI334865 AI311492 AI492809 AI492690 AI431576 AI862268 AI311879 AI308435 AI492792 AI862512 AI275321 AI431568 AI431564 AI307885 AI307926 AI435692 AI435778 AI310182 AI308894 AI492707 AI492713 AI308560 AI307829 AI343234 AI580598 AW472796 AI340918 AI310243 AI309368 AI307920 A1289665 AI306777 AW086318 AW086292 AW086378 AI310027 AI275293 AI369082 AI340900 AI306749 AI371558 AW086287 BE043803 AI306793 AI306272 AI287948 AI270917 AI284816 AI336813 AI284546 AI308044 AI275290 AI270872 AI306795 AI289687 AI223570 AI305303 AI289677 AI287742 AI275284 AI306812 AI336701 AI371554 AI378719 AI344988 AI223631 AI335141 AI343222 AI284568 AI305357 AI275270 AI345932 AI436549 AI307925 AI311502 AI344238 AI343182 AI308508 AI305988 AI270790 AI379792 AI305647 AI305410 AI432251 AI436517 AI343227 AI305534 AI340387 AI271043 AI305499 AI271046 AI305962 AI289465 AI305378 AI289725 AI310848 AI305848 AI289362 AI252964 AI307049 AI310831 AI306993 AI306796 AI224659 AI305969 AI349855 AI306164 AI306948 AI284676 AI309155 AI343202 AI432785 AI306815 AI369081 AI270885 AI289699 AI435704 AI309647 AI305716 AI311281 AI287927 AI472995 AI340423 AI270958 AI307069 AI305364 AI270807 AI275306 AI311890 AI275263 AI432750 AI289371 AI432861 AI255113 AI305709 AI473008 AI311168 AI309711 AI377164 AI271201 AI289560 AI309710 AI306195 AI311201 AI287741 AI271066 AI432876 AI275281 AI379795 AI472972 AI311967 AI306826 AI305465 AI270792 AI473019 AI305340 AI270922 AI305995 AI305462 AI254144 AI270969 AI473012 AI305390 AI275278 AI223644 AI289692 AI250318 AI305372 AI289691 AI250521 AI306283 AI306814 AI307933 AI473160 AI432903 AI223720 AI254979 AI334862 AI306926 AI289541 AI432248 AI435722 AI435698 AI432859 AI310683 AI473175 AI335144 AI289467 AI436489 AI306928 AI473033 AI305763 AI307868 AI307882 AI348959 AI435736 AI432857 AI432896 AI435735 AI432283 AI473086 AI432863 AI473081 AI432825 AI307840 AI473164 AI432885 AI473166 AI472982 AI435734 AI473060 AI473171 AI432279 AI432882 AI334670 AI436512 AI432827 AI432852 AI473051 AI473077 AI435697 AI271509 AI492781 AI472983 AI473018 AI432897 AI473043 AI432871 AI436536 AI473157 AI349715 AI432777 AI473016 AI473158 AI340369 AI307941 AI432773 AI377146 AI492791 AI270950 AI305342 AI284604 AI306269 AI284811 AI270811 AI289347 AI334869 AI334852 AI311759 AI250382 AI309520 AI289550 AI305721 AI340870 AI270901 AI308575 AI307904 AI340715 AI270941 AI309808 AI246867 AI473014 AI307039 AI289360 AI473069 AI492786 AI344013 AI305876 AI436510 AI340742 AI473028 AI307891 BE041871 BE041268 BE042340 BE041946 BE041783 AI306173 AI201948 AI926972 AI275769 338255 CH22_6856FG_LINK_EM:AC00 330211 C_5_p2 332798 CH22_14FG_6_5_LINK_C4G1.G 334447 CH22_1746FG_387_7_LINK_EM 332247 372969J AA669097 AA513815 AA026798 AA676526 AA704429 AA704269 AW118292 AA579216 N58172 332396 20265J AW579842 BE156562 BE156690 BE156489 BE081033 AK001559 BE149402 M85387 AW367811 AW367798 R17370 AI908947 AA382932 R58449 H18732 AA371231 AW962899 AA713530 AW892946 R53463 H11063 AW068542 Z40761 BE176212 BE176155 W23952 W92188 AW374883 AA303497 AW954769 AA036808 BE168063 AW382073 AW382085 AL041475 H80748 AI078161 BE463983 AI805213 AI761264 W94885 N94502 AI623772 AI419532 AI810302 AI634190 AW002516 AW150777 AI352312 AI367474 AW204807 AI675502 AI337026 AW134715 BE328451 AI123157 AI560020 AI300745 AI608631 AI248873 AA742484 AW051635 H18646 AI245045 AA507111 AI640510 AI925594 AA115747 AA143035 AA151106 332697 13699J X51405 NM_001873 T11322 AL118886 BE328175 AW136009 BE467445 AW470313 AA774852 BE504139 AW501046 AA082792 AW389231 AA370044 R36841 AA371457 C04813 R25791 R25556 AW895854 AW903819 AW895671 AW895677 BE159723 AW895664 AW895597 AW895595 AW895665 AW888518 AI903724 F06081 F08503 AL119462 AW895730 AW888516 R26511 R26489 AA334126 AA327626 N85713 AW895998 AA223622 F05468 AA370749 W05590 M78202 AA371073 AW498607 R15017 T16991 AA001282 AA001 38 AA551566 AA330159 AI922855 AA383512 AA029603 D82246 D82171 T94933 H56545 AA348060 AA176888 R96764 AW451817 AA385766 AA452618 AI690057 AA988822 BE549928 AA150901 W57992 AW899925 C05281 AA932042 AA370980 AW962877 W04741 AA369982 AW385948 AA922466 N75882 AI422070 AI361256 AI680224 D57122 T94885 R53266 R46713 T19071 AW796277 AA325333 F04719 F02334 AA358146 AA626597 AA358304 AW028099 AL119570 D57290 D58273 D57796 N48555 AI361969 AA329457 D57225 AW024046 AA992606 AW022118 AW021538 AA935845 H89870 H56546 AW961219 AA453239 AW837541 N45521 BE218029 AA318877 AA327740 AW961809 T92139 D53216 D52365 D53363 D53312 D53116 AI547267 AA679935 AW026552 AW026418 AW190507 AI927710 AW244108 D50948 AW054991 AW021063 AW022511 AA493436 AI365636 BE464751 AW149384 AA102442 AW771368 AI818251 AI126368 D51049 AI421542 AI559467 AW079779 AW021048 AW023969 AW044214 AI458264 AA027274 AI620254 AW028917 BE219511 AA326242 N67561 AI971273 AA878328 D57131 AA770662 AI309299 AI796767 AA613338 W58076 AI566287 AI445573 AI880260 AA001919 AW339259 AI492610 AI492611 R97692 AI301425 AA722603 D58361 AI350323 AA973926 AI431263 AA516126 AA865467 AI925177 N39443 AA001943 AI299371 AI082412 AA665090 AA583433 H89871 AA977231 AI362219 AI056096 AI270446 N67524 N22103 AW614224 AA744054 AW243622 AI613188 AI929173 AI350243 AI362138 AA744004 AA176661 D56787 AI955625 AI393109 AI094769 AI479728 AI423107 AI955617 AI034036 AI582196 AW264534 AI418961 AA570761 AI343538 AA650341 AA992503 AA770004 AL039666 AI862675 AW190335 AA610274 AW418627 BE467472 D56786 T28749 AI217610 AI359556 T23523 AL040189 AA846222 AA651636 D51280 AI888986 AI521167 AI340177 AW612815 AI625285 AA621607 AA177059 AA229768 AA829788 AI749682 AW190631 N75299 AA230089 AI915632 BE069542 AA890020 AA528397 AA995390 BE503860 AA570812 AW339396 AI197986 AI203725 AI282379 AA670375 AA461513 F01728 AW243599 C00856 N75567 R95995 AA150932 -R95961 AA648060 AA933800 AA927073 AA101126 AA864190 T93566 BE167472 425710 25529J AF030880 NM.000441 AC002467 AA385554 H23053 AW891838 AI139968 AA653057 AI695233 432189 342819J AA527941 AI810608 AI620190AA635266 445424 6391J AB028945 T77648 F13328 AL157605 Z46212 AA304736 F11855 T66098 T30174 AW954164 AW176301 AW748243 AA456428 AI369958 AA938565 AW959613 Z42008 AA994779 AI683909 F11019 F10926 AI769597 AI752550 T65015 AI884314 AA643954 Z41838 AW020147 AI038822 AW571822 AA299781 AA894928 AF131790 BE005411 AI902476 AW082695 AA464384 R42750 AW902301 AA464273 R05837 Z38294 H41098 AL134507 M86079 447210 7119 1 AF035269 AF035268 NM_015900 T96213 U37591 AA156832 AA299371 AI084325 H95977 AI765967 BE221465 AA156726 AI969563 AW024539 AI436791 AI949451 AA843093 AI452756 AA824232 AI306667 T96131 AW207447 AW243556 AW957032 AI084332 H95978 U30998 449625 8113J NM_014253 AF100772 BE088769 AL022718 BE161779 AW863569 BE161640 AL039060 BE168542 AW296554 AA323193 AA235370 AW779760 N48674 AI375997 R45432 D59344 AI203107 F07491 R35360 R25094 AI913631 AI498402 T61382 AI016320 N45526 T61415 AA331486 452039 89513J AI922988 H05475 AA021608 AW169947 AA913750 Z41614 AW8O0O12 TABLE 15B shows the genomic positioning for those primekeys lacking unigene ID's and accession numbers in Table 15. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed. Pkey: Unique number corresponding to an Eos probeset Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (Gl) numbers. "Dunham I. et al." refers to the publication entitled The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. Strand: Indicates DNA strand from which exons were predicted. NLposition: Indicates nucleotide positions of predicted exons. Pkey Ref Strand NLposition 334447 Dunham, I. etal. Plus 14308764-14308824 332798 Dunham, I. etal. Minus 232147-231974 338255 Dunham, I. etal. Minus 15242294-15242231 330211 6013592 Plus 59158-59215 401424 8176894 Plus 24223-24428 TABLE 11 AND SEQUENCE LISTING SEQID N0.1 BCU4 DNA SEQUENCE _ Nucleic Add Accession* NM.024915 J Coding sequence: 13-1890 (underlined sequences correspond to start and slop codons) 1 11 21 3 1 41 51 I I I I I I ATTGGATCAA ACATQTCACA AGAGTCGGAC AATAATAAAA GACTAGTGGC CTTAGTGCCC 60 0 ATGCCCAGTG ACCCTCCATT CAATACCCGA AGAGCCTACA CCAGTGAGGA TGAAGCCTGG 120 AAGTCATACT TGGAGAATCC CCTGACAGCA GCCACCAAGG CCATGATGAT CATTAATGGT 180 GATGAGGACA GTGCTGCTGC CCTCGGCCTG CTCTATGACT ACTACAAGGT TCCTCGAGAC 240 AAGAGGCTGC TGTCTGTAAG CAAAGCAAGT GACAGCCAAG AAGACCAGGA GAAAAGAAAC 3 00 _ TGCCTTGGCA CCAGTGAAGCCCAGAGTAATTTGAGTGGAG GAGAAAACCG AGTGCAAGTC 3 60 5 CTAAAGACTG TTCCAGTGAA CCTTTCCCTA AATCAAGATC ACCTGGAGAA TTCCAAGCGG 420 GAACAGTACA GCATCAGCTT CCCCGAGAGC TCTGCCATCA TCCCGGTGTC GGGAATCACG 480 GTGGTGAAAG CTGAAGATTT CACACCAGTT TTCATGGCCC CACCTGTGCA CTATCCCCGG 540 GGAGATGGGG AAGAGCAACG AGTGGTTATC TTTGAACAGA CTCAGTATGA CGTGCCCTCG 600 CTGGCCACCCACAGCGCCTATCTCAAAGAC GACCAGCGCAGCACTCCGGACAGCACATAC 660 0 AGCGAGAGCTTCAAGGACGCAGCCACAGAG AAATTTCGGAGTGCTTCAGT GGGGCTGAG 720 GAGTACATGT ATGATCAGAC ATCAAGTGGC ACATTTCAGT ACACCCTGGA AGCCACCAAA 780 TCTCTCCGTC AGAAGCAGGG GGAGGGCCCC ATGACCTACC TCAACAAAGG ACAGTTCTAT 840 GCCATAACAC TCAGCGAGAC CGGAGACAAC AAATGCTTCC GACACCCCAT CAGCAAAGTC 900 AGGAGTGTGG TGATGGTGGTCTTCAGTGAA GACAAAAACAGAGATGAACAGCTCAAATAC 960 5 TGGAAATACTGGCACTCTCG GCAGCATACG GCGAAGCAGAGGGTCCTTGACATTGCCGAT 1020 TACAAGGAGA GCTTTAATAC GATTGGAAAC ATTGAAGAGA TTGCATATAA TGCTGTTTCC 1080 TTTACCTGGG ACGTGAATGA AGAGGCGAAG ATTTTCATCA CCGTGAATTG CTTGAGCACA 1140 GATTTCTCCT CCCAAAAAGG GGTGAAAGGA CTTCCTTTGA TGATTCAGAT TGACACATAC 1200 AGTTATAACA ATCGTAGCAATAAACCCATTCATAGAGCTTATTGCCAGATCAAGGTCTTC 1260 0 TGTGACAAAG GAGCAGAAAG AAAAATCCGA GATGAAGAGC AGAAGCAGAA CAGGAAGAAC 1 3 20 GGGAAAGGCC AGGCCTCCCA AACTCAATGC AACAGCTCCT CTGATGGGAA GTTGGCTGCC 1 3 80 ATACCTTTAC AGAAGAAGAG TGACATCACC TACTTCAAAA CCATGCCTGA TCTCCACTCA 1440 CAGCCAGTTC TCTTCATACC TGATGTTCAC TTTGCAAACC TGCAGAGGAC CGGACAGGTG 1500 TATTACAACA CGGATGATGA ACGAGAAGGTGGCAGTGTCCTTGTTAAACG GATGTTCCGG 1560 5 CCCATGGAAG AGGAGTTTGG TCCGGTGCCT TCAAAGCAGA TGAAAGAAGA AGGGACAAAG 1620 CGAGTGCTCT TGTACGTGAG GAAGGAGACT GACGATGTGT TCGATGCATT GATGTTGAAG 1680 TCTCCCACAG TGATGGGCCT GATGGAAGCG ATATCTGAGA AATATGGGCT GCCCGTGGAG 1 40 AAGATAGCAA AGCTTTACAA GAAAAGCAAA AAAGGCATCT TGGTGAACAT GGATGACAAC 1800 ATCATCGAGC ACTACTCGAA CGAGGACACC TTCATCCTCA ACATGGAGAG CATGGTGGAG 1860 GGCTTCAAGG TCACGCTCATGGAAATCTAQCCCTGGGTTTGGCATCCGCTTTGGCTGGAG 1920 CTCTCAGTGC GTTCCTCCCT GAGAGAGACA GAAGCCCCAG CCCCAGAACC TGGAGACCCA 1980 TCTCCCCCAT CTCACAACTG CTGTTACAAG ACCGTGCTGG GGAGTGGGGC AAGGGACAGG 2040 CCCCACAGTC GGTGTGCTTG GCCCATCCAC TGGCACCTAC CACGGAGCCG AAGCCTGAGC 2100 CCCTCAGGAA GGTGCCTTAG GCCTGTTGGA TTCCTATTTA TTGCCCACCT TTTCCTGGAG 2160 5 CCCAGGTCCAGGCCCGCCAGGACTCTGCAGGTCACTGCTAGCTCCAGATGAGACCGTCCA 2220 GCGTTCCCCC TTCAAGAGAA ACACTCATCC CGAACAGCCT AAAAAATTCC CATCCCTTCT 2280 TTCTCACCCC TCCATATCTA TATCTCCCGA GTGGCTGGAC AAAATGAGCT ACGTCTGGGT 2340 GCAGTAGTTA TAGGTGGGGC AAGAGGTGGA TGCCCACTTT CTGGTCAGAC ACCTTTAGGT 2400 TGCTCTGGGG AAGGCTGTCTTGCTAAATACCTCCAGGGTTCCCAGCAAGTGGCCACCAGG 2460 0 CCTTGTACAG GAAGACATTC AGTCACCGTG TAATTAGTAA CACAGAAAGT CTGCCTGTCT 2520 GCATTGTACA TAGTGTTTAT AATATTGTAA TAATATATTT TACCTGTGGT ATGTGGGCAT 2580 GTTTACTGCC ACTGGCCTAG AGGAGACACA GACCTGGAGA CCGTTTTAAT GGGGGTTTTT 2640 GCCTCTGTGC CTGTTCAAGA GACTTGCAGG GCTAGGTAGA GGGCCTTTGG GATGTTAAGG 2700 TGACTGCAGCTGATGCCAAG ATGGACTCTG CAATGGGCATACCTGGGGGCTCGTTCCCTG 2760 5 TCCCCAGAGG AAGCCCCCTC TCCTTCTCCA TGGGCATGAC TCTCCTTCGA GGCCACCACG 2820 TTTATCTCAC AATGATGTGT TTTGCCTGAC TTTCCCTTTG CGCTGTCTCG TGGGAAAGGT 2880 CATTCTGTCT GAGACCCCAG CTCCTTCTCC AGCTTTGGCT GCGGGCATGG CCTGAGCTTT 2940 CTGGAGAGCC TCTGCAGGGG GTTTGCCATC AGGGCCCTGT GGCTGGGTCT GCTGCAGAGC 3000 TCCTTGGCTATCAGGAGAATCCTGGACACTGTACTGTGCCTCCCAGTTTACAAACACGCC 3060 0 CTTCATCTCA AGTGGCCCTTTAAAAGGCC GCTGCCATGTGAGAGCTGTGAACAGCTCAG 3120 CTCTGAGTCG GCAGACTGGG GCTTCCTCCT GGGCCACCAG ATGGAAAGGG GGTATTGTTT 3180 GCCTCACTCC TGGATGCTGC GTTTTAAGGA AGTGAGTGAG AAAGAATGTG CCAAGATACC 3240 TGGCTCCTGT GAAACCAGCC TCAGGAGGGA AACTGGGAGA GAGAAGCTGT GGTCTCCTGC 3300 TACATGCCCT GGGAGCTGGA AGAGAAAAAC ACTCCCCTAA ACAATCGCAA AATGATGAAC 3360 5 CATCATGGGC CACTGTTCTC TTTGAGGGGA CAGGTΓTAGG GGTTTGCGTT CGCCCTTGTG 3420 GGCTGAAGCA CTAGCTTTTT GGTAGCTAGA CACATCCTGC ACCCAAAGGT TCTCTACAAA 3480 GGCCCAGATT TGTTTGTAAA GCACTTTGAC TCTTACCTGG AGGCCCGCTC TCTAAGGGCT 3540 TCCTGCGCTC CCACCTCATC TGTCCCTGAG ATGCAGAGCA GGATGGAGGG TCTGCTTCTA 3600 GCTCAGCTGTTTCTCCTTGA GGTTGCGGAG GAATTGAATTGAATGGGACAGAGGGCAGGT 3660 0 GCTGTGGCCA AGAAGATCTC CGAGCAGCAG TGACGGGGCA CCTTGCTGTG TGTCCTCTGG 3720 GCATGTTAAC CCTTCTGTGG GGCCAAAGGT TTGCATCGTG GATCCAGCTG TGCTCCAGTC 3780 TGTCCCCTCC TCCTCCACTC TGACTGCCAC GCCCCGGACC AGCAGCTTGG GGACCCTCCA 3840 GGGTACTAAT GGGGCTCTGT TCTGAGATGG ACAAATTCAG TGTTGGAAAT ACATGTTGTA 3900 CTATGCACTT CCCATGCTCC TAGGGTTAGG AATAGTTTCA AACATG ATTG GCAG ACATAA 3960 5 CAACGGCAAA TACTCGGACT GGGGCATAGG ACTCCAGAGT AGGAAAAAGA CAAAAGATTT -1020 GGCAGCCTGA CACAGGCAAC CTACCCCTCT CTCTCCAGCC TCTTTATGAA ACTGTTTGTT 4080 TGCCAGTCCT GCCCTAAGGC AGAAGATGAA TTGAAGATGC TGTGCATGTT TCCTAAGTCC 4140 TTGAGCAATC ATGGTGGTGA CAATTGCCAC AAGGGATATG AGGCCAGTGC CACCAGAGGG 4200 TGGTGCCAAG TGCCACATCC CTTCCGATCC ATTCCCCTCT GTATCCTCGG AGCACCCCAG 4260 TTTGCCTTTG ATGTGTCCGC TGTGTATGTT AGCTGAACTT TGATGAGCAA AATTTCCTGA 4320 GCGAAACACT CCAAAGAGAT AGGAAAACTT GCCGCCTCTT CTTTTTTGTC CCTTAATCAA 4380 ACTCAAATAA GCTTAAAAAA AATCCATGGA AGATCATGGA CATGTGAAAT GAGCATTTTT 4440 5 TTCTTTTCTT TTTTTTTTTT TTTTTTTAAC AAAGTCTGAA CTGAACAGAA CAAGACTTTT 4500 TCCTCATACA TCTCCAAATT GTTTAAACTT ACTTTATGAG TGTTTGTTTA GAAGTTCGGA 4560 CCAACAGAAA AATGCAGTCA GATGTCATCT TGGAATTGGT TTCTAAAAGA GTAAGGCATG 4620 TCCCTGCCCA GAAACTTAGG AAGCATGAAA TAAATCAAAT GTTTATTTTC CTTCTTATTT 4680 AAAATCATGC TAATGCAACA GAAATAGAGG GTTTGTGCCA AATGCTATGA ACGGCCCTTT 4740 10 CTTAAAG ACA AGCAAGGGAG ATTGATATAT GTACAATTTG CTCTCATGTT TTT SEQ ID N0:2 BCU4 Protein sequence: Protein Accession*: NP.079191.1 15 1 11 21 31 41 51 I I I I I I MSQESDNNKR VA VPMPSD PPFNTRRAYT SEDEAWKSYL ENPLTAATKA MMIINGDEDS 60 AAALGLLYDY YKVPRDKRLLSVSKASDSQEDQEKRNCLGT SEAQSNLSGG ENRVQVLKTV 120 20 PVNLSLNQDH ENSKREQYS ISFPESSAIIPVSGΓΓWKA EDFΓPVFMAPPVHYPRGDGE i80 EQRVVIEEQT QYDVPSLATH SAYLKDDQRS TPDSTYSESF KDAATEKFRS ASVGAEEYMY 240 DQTSSGTFQY TLEATKSLRQ KQGEGPMTY NKGQFYAITL SETGDNKCFR HPISKVRS VV 300 MVVFSEDKNR DEQLKYWKYW HSRQHTAKQR VLDIADYKES FNTIGNIEEI AYNAVSFTWD 360 VNEEAKMT VNCLSTDFSS QKGVKGLPLM IQIDTYSYNN RSNKPIHRAY CQIKVFCDKG 420 25 AERKIRDEEQ KQNRKNGKGQ ASQTQCNSSS DGKLAAIP Q KKSDITYFKT MPDLHSQPV 480 FIPDVHFAN QRTGQVYYNT DDEREGGSVL VKRMFRPMEE EFGPVPSKQM KEEGTKRVLL 540 YVRKETDDVF DALMLKSPTV MGLMEAISEK YGLPVEKIAK LYKKSKKGIL VNMDDNIIEH 600 YSNEDTFILN MESMVEGFKV TLMEI 30 SEQ ID N0:3 BCU7 DNA SEQUENCE VARIANT 1: Nucleic Acid Accession #: AA428062 Coding sequence: 1-777 (entire sequence represents open reading frame) 35 1 11 21 31 41 51 I I I I I I ATGATAGCAA TCTCTGCCGT CAGCAGTGCA CTCCTGTTCT CCCTTCTCTG TGAAGCAAGT 60 ACCGTCGTCC TACTCAATC CACTGACTCA TCCCCGCCAA CCAATAATTT CACTGATATT 120 40 GAAGCAGCTC GAAAGCACA ATTAGATTCA GCGGATATCC CCAAAGCCAG GCGGAAGCGC 180 TACATTTCGC AGAATGACAT GATCGCCATT CT GATTATC ATAATCAAGT TCGGGGCAAA 240 GTGTTCCCAC CGGCAGCAAA TATGGAATAT ATGGTTTGGG ATGAAAATCT TGCAAAATCG 300 GCAGAGGCTT GGGCGGCTAC TTGCATT GG GACCA GGAC CTTCT ACTT ACTGAGATTT 360 TTGGGCCAAA ATCTATCTGT ACGCACTGGA AGATATCGCT CTATTCTCCA GTTGGTCAAG 420 45 CCATGGTATG AGAAGTGAA AGAT ATGCT TTTCCATATC CCCAGGATTG CAACCCCAGA 480 TGTCCTATGA GATGTTTTGG TCCCAGTGC ACACATATA CGCAGATGGT TTGGGCCACT 540 TCCAATCGGA TAGGATGCGC AATTCATGCT TGCCAAAACA TGAATGTTTG GGGATCTGTG 600 GGCGACGG CAGTT ACTT GGTATGCAAC TA GCCCCAA AGGGCAATTG GATTGGAGAA 660 __ GCACCATATA AAGTAGGGGT ACCATG CA TCT GTCCTC CAAGTTATGG GGGATCTTGT 720 50 ACTGACAATC TGTGTTTTCC AGGAGT ACG TCAAACTACC TGTACTGGTT TAAATAA SEQ ID 1.0:4 BCU7 DNA SEQUENCE VARIANT 2: Nucleic Acid Accession #: AA428062 Coding sequence: 1 -777 (entire sequence represents open reading frame) 55 1 11 21 31 41 51 O.nU A ITGATAGCAA T ICTCTGCCGT C IAGCAGTGCA C 'TCCTGTTCT C ! CCTTCTCTG T IGAAGCAAGT 60 ACCGTCGTCC TACTCAATTC CACTGACTCA TCCCCGCCAA CCAATAATTT CACTGATATT 120 GAAGCAGCTC TGAAAGCACA ATTAGATTCA GCGGATATCC CCAAAGCCAG GCGGAAGCGC 180 TACATTTCGC AGAATGACAT GATCGCCATT CTTGATTATC ATAATCAAGT TCGGGGCAAA 240 ,_ GTGTTCCCAC CGGCAGCAAA TATGGAATAT ATGGTTTGGG ATGAAAATCT TGCAAAATCG 300 65 GCAGAGGCTT GGGCGGCTAC TTGCATTTGG GACCATGGAC CTTCTTACTT ACTGAGATTT 3 60 TTGGGCCAAA ATCTATCTGT ACGCACTGGA AGATATCGCT CTATTCTCCA GTTGGTCAAG 420 CCATGGTATG ATGAAGTGAA AGATTATGCT TTTCCATATC CCCAGGATTG CAACCCCAGA 480 TGTCCTATGA GATGTTTTGG TCCCATGTGC ACACATTATA CGCAGATGGT TTGGGCCACT 540 __ TCCAATCGGA TAGGATGCGC AATTCATACT TGCCAAAACA TGAATGTTTG GGGATCTGTG 600 70 TGGCGACGTG CAGTTTACTT GGTATGCAAC TATGCCCCAA AGGGCAATTG GATTGGAGAA 660 GCACCATATA AAGTAGGGGT ACCATGTTCA TCTTGTCCTC CAAGTTATGG GGGATCTTGT 720 ACTGACAATC TGTGTTTTCC AGGAGTTACG TCAAACTACC TGTACTGGTT TAAATAA _ SEQ ID NO:5 BCU7 Protein sβmmnce Variant 1: 75 Protein Accession #: none 1 11 21 31 41 51 I I I I I I MIAISAVSSA L FS CEAS TWLLNSTDS SPPTNNFTDI EAALKAQLDS ADIPKARRKR 60 YISQNDMIAI LDYHNQVRGK VFPPAANMEY MVWDENLAKS AEA AATCI DHGPSYLLRF 120 LGQNLSVRTG RYRSILQLVK PWYDEVKDYA FPYPQDCNPR CPMRCFGPMC THYTQMVWAT 180 SNRIGCAIHA CQNMNVWGSV WRRAVYLVCN YAPKGN IGE APYKVGVPCS SCPPSYGGSC 240 TDNLCFPGVT SNY Y FK SEQ ID NO:6 BCU7 Protein sequence Vanaπt 2: Protein Accession #: none 1 11 21 31 41 51 I I I I I I MIAISAVSSA LFSL CEAS T LLNSTDS SPPTNNFTDI EAALKAQ DS ADIPKARRKR 60 YISQNDMIAI LDYHNQVRGK VFPPAANMEY MVWDENLAKS AEAWAATCIW DHGPSYLLRF 120 LGQNLSVRTG RYRSILQLVK PWYDEVKDYA FPYPQDCNPR CPMRCFGPMC THYTQMVWAT 180 SNRIGCAIHT CQNMNVWGSV WRRAVYLVCN YAPKGNWIGE APYKVGVPCS SCPPSYGGSC 240 TDNLCFPGVT SNYLYWFK SEQ ID N0:7 BCX2 DNA SEQUENCE Nucleic Acid Accession #: NM_003014 Coding sequence: 238-1278 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I GGCGGGTTCG CGCCCCGAAG GCTGAGAGCTGGCGCTGCTCGTGCCCTGTG TGCCAGACGG 60 CGGAGCTCCG CGGCCGGACC CCGCGGCCCCGCTTTGCTGCCGACTGGAGTTTGGGGGAAG 120 AAACTCTCCTGCGCCCCAGA AGATTTCTTCCTCGGCGAAG GGACAGCGAA AGATGAGGGT 180 GGCAGGAAGA GAAGGCGCTT TCTGTCTGCC GGGGTCGCAG CGCGAGAGGG CAGTGCCATQ 240 TTCCTCTCCA TCCTAGTGGC GCTGTGCCTG TGGCTGCACC TGGCGCTGGG CGTGCGCGGC 300 GCGCCCTGCG AGGCGGTGCG CATCCCTATG TGCCGGCACA TGCCCTGGAA CATCACGCGG 360 ATGCCCAACC ACCTGCACCACAGCACGCAG GAGAACGCCATCCTGGCCATCGAGCAGTAC 420 GAGGAGCTGG TGGACGTGAA CTGCAGCGCC GTGCTGCGCT TCTTCTTCTG TGCCATGTAC 480 GCGCCCATTT GCACCCTGGA GTTCCTGCAC GACCCTATCA AGCCGTGCAA GTCGGTGTGC 540 CAACGCGCGC GCGACGACTG CGAGCCCCTC ATGAAGATGT ACAACCACAG CTGGCCCGAA 600 AGCCTGGCCTGCGACGAGCTGCCTGTCTATGACCGTGGCGTGTGCATTTCGCCTGAAGCC 660 ATCGTCACGG ACCTCCCGGA GGATGTTAAGTGGATAGACATCACACCAGA CATGATGGTA 720 CAGGAAAGGC CTCTTGATGT TGACTGTAAA CGCCTAAGCC CCGATCGGTG CAAGTGTAAA 780 AAGGTGAAGC CAACTTTGGC AACGTATCTC AGCAAAAACT ACAGCTATGT TATTCATGCC 840 AAAATAAAAG CTGTGCAGAG GAGTGGCTGC AATGAGGTCA CAACGGTGGT GGATGTAAAA 900 GAGATCTTCA AGTCCTCATCACCCATCCCTCGAACTCAAG TCCCGCTCATTACAAATTCT 960 TCTTGCCAGTGTCCACACATCCTGCCCCATCAAGATGTTCTCATCATGTGTTACGAGTGG 1020 CGTTCAAGGA TGATGCTTCT TGAAAATTGC TTAGTTGAAA AATGGAGAGA TCAGCTTAGT 1080 AAAAGATCCA TACAGTGGGA AGAGAGGCTG CAGGAACAGC GGAGAACAGT TCAGGACAAG 1140 AAGAAAACAG CCGGGCGCAC CAGTCGTAGT AATCCCCCCA AACCAAAGGG AAAGCCTCCT 1200 GCTCCCAAAC CAGCCAGTCC CAAGAAGAAC ATTAAAACTA GGAGTGCCCA GAAGAGAACA 1260 AACCCGAAAA GAGTGTiϊΔGC TAACTAGTTTCCAAAGCGGAGACTTCCGAC TTCCTTACAG 1320 GATGAGGCTG GGCATTGCCT GGGACAGCCT ATGTAAGGCC ATGTGCCCCT TGCCCTAACA 1380 ACTCACTGCA GTGCTCTTCA TAGACACATC TTGCAGCATT TTTCTTAAGG CTATGCTTCA 1440 GTTTTTCTTT GTAAGCCATC ACAAGCCATA GTGGTAGGTT TGCCCTTTGG TACAGAAGGT 1500 GAGTTAAAGCTGGTGGAAAAGGCTTATTGCATTGCATTCAGAGTAACCTGTGTGCATACT 1560 CTAGAAGAGTAGGGAAAATAATGCTTGTTACAATTCGACCTAATATGTGCATTGTAAAAT 1620 AAATGCCATA TTTCAAACAA AACACGTAAT ΪTmϊACAG TATGTTTTAT TACCTTTTGA 1680 TATCTGTTGT TGCAATGTTA GTGATGTTTT AAAATGTGAT GAAAATATAA TGTTTTTAAG 1740 AAGGAACAGT AGTGGAATGA ATGTTAAAAG ATCTTTATGT GTTTATGGTC TGCAGAAGGA 1800 TTTTTGTGATGAAAGGGGATTTTTTGAAAAATTAGAGAAGTAGCATATGG AAAATrATAA 1860 TGTGTTTTTTTACCAATGACTTCAGTTTCTGTTTTTAGCTAGAAACTTAAAAACAAAAAT 1920 AATAATAAAG AAAAATAAAT AAAAAGGAGA GGCAGACAAT GTCTGGATTC CTGTTTTTTG 1980 GTTACCTGAT TTCCATGATC ATGATGCTTC TTGTCAACAC CCTCTT AAGC AGCACCAGAA 2040 ACAGTGAGTT TGTCTGTACC ATTAGGAGTT AGGTACTAAT TAGTTGGCTA ATGCTCAAGT 2100 ATTTTATACC CACAAGAGAG GTATGTCACT CATCTTACTT CCCAGGACAT CCACCCTGAG 2160 AATAATTTGA CAAGCTTAAA AATGGCCTTC ATGTGAGTGC CAAATTTTGT TTTTCTTCAT 2220 TTAAATATTT TCTTTGCCTA AATACATGTG AGAGGAGTTA AATATAAATG TACAGAGAGG 2280 AAAGTTGAGT TCCACCTCTG AAATGAGAAT TACTTGACAG TTGGGATACT TTAATCAGAA 2340 AAAAAGAACT TATTTGCAGC ATTTTATCAA CAAATTTCAT AATTGTGGAC AATTGGAGGC 2400 ATTTATTTTA AAAAACAATT TTATTGGCCT TTTGCTAACA CAGTAAGCAT GTATTTTATA 2460 AGGCATTCAA TAAATGCACA ACGCCCAAAG GAAATAAAAT CCTATCTAAT CCTACTCTCC 2520 ACTACACAGA GGTAATCACT ATTAGTATTT TGGCATATTA TTCTCCAGGT GTTTGCTTAT 2580 GCACTTATAA AATGATTTGA ACAAATAAAA CTAGGAACCT GTATACATGT GTTTCATAAC 2640 CTGCCTCCTT TGCTTGGCCC TTTATTGAGA TAAGTTTTCC TGTCAAGAAA GCAGAAACCA 2700 TCTCATTTCTAACAGCTGTG TTATATTCCATAGTATGCATTACTCAACAA ACTGTTGTGC 2760 TATTGGATAC TTAGGTGGTT TCTTCACTGA CAATACTGAA TAAACATCTC ACCGGAATTC SEQ ID N0:8 BCX2 Protein sequence: Protein Accession* NP_003005.1 1 11 21 31 41 51 I I I I I I IFLSπ.VA ^ LHLA 5VRGAPCEAVRIPMCRHMPWNrrRMPNHLHHSTQENAILAIEQ 60 YEELVDVNCS AVLRFFFCAM YAPICTLEFL HDPIKPCKSV CQRARDDCEP LMKMYNHSWP 120 ESLACDELPV YDRGVCISPE AIVTDLPEDV KWTDITPDMM VQERPLDVDC KRLSPDRCKC 180 KKVKPTLATY LSKNYSYVIH AKIKAVQRSG CNEVTTVVDV KEIFKSSSPI PRTQVPLITN 240 SSCQCPHILP HQD VLIMCYE WRSRMMLLEN CLVEKWRDQL SKRSIQWEER LQEQRRTVQD 300 5 KKKTAGRTSR SNPPKPKGKP PAPKPASPKK NIKTRSAQKR TNPKRV SEQ ID N0:9 CBK1 DNA SEQUENCE Nucleic Acid Accession * N JJ32391 10 Coding sequence: 129~302 (underlined sequences correspond to start and slop codons) 11 21 31 41 51 15 I I I I I GTCCTTCCTC TCCTAGCCTA AGGCGTGCAA ACAGAGCGCC ACTGGGAGGC TGAAACCTTT 60 AGGCCGATGC TTGCTTGCAA GGTCAGGCAA GCTGGATTCT GGTCCCCACC TTTGCAGAGA 120 GAACAGCGAT GTTGTGCGCC CATTTCTCAG ATCAAGGACC GGCCCATCTT ACTACCTCCA 180 AGAGTGCΪTT TCTCTCTAAT AAGAAAACAT CTACTTTGAA ACATCTACTG GGCGAGACCA 240 GGAGTGATGβ CTCAGCCTGT AATTCTGGAA TTTCGGGAGG CCGAGGCAGG AAGATTCCTT 300 20 GAGCACAGGA GTTCCAGACC AGCCTGGGCA ATGTAGCAAG ACGCTGTCTC TATTTATACA 360 ATAAAATTTT TTTAAAAAAG G 25 SEQ ID N0:1Q CBK1 Protein sequence: Protein Accession* NP_115767 _ _. 1 11 21 31 41 51 30 i i i i i i MLCAHFSDQG PAHLTTSKSA FLSNKKTSTL KHLLGETRSD GSACNSGISG GRGRKIP SEQID 0:11 CHA1 DNA SEQUENCE Nucleic Acid Accession* NMJK0182 35 Coding sequence: 96-854 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 40 I I I I I TCCTTGGGTT CGGGTGAAAG CGCCTGGGGG TTCGTGGCCA TGATCCCCGA GCTGCTGGAG 60 AACTGAAGGC GGACAGTCTC CTGCGAAACC AGGCAATGGC GGAGCTGGAG TTTGTTCAGA 120 TCATCATCAT CGTGGTGGTG ATGATGGTGA TGGTGGTGGT GATCACGTGC CTGCTGAGCC 180 ACTACAAGCT GTCTGCACGG TCCTTCATCA GCCGGCACAG CCAGGGGCGG AGGAGAGAAG 240 ATGCCCTGTC CTCAGAAGGA TGCCTGTGGC CCTCGGAGAG CACAGTGTCA GGCAACGGAA 300 45 TCCCAGAGCC GCAGGTCTAC GCCCCGCCTC GGCCCACCGA CCGCCTGGCC GTGCCGCCCT 360 TCGCCCAGCG GGAGCGCTTC CACCGCTTCC AGCCCACCTA TCCGTACCTG CAGCACGAGA 420 TCGACCTGCC ACCCACCATC TCGCTGTCAG ACGGGGAGGA GCCCCCACCC TACCAGGGCC 480 CCTGCACCCT CCAGCTTCGG GACCCCGAGC AGCAGCTGGA ACTGAACCGG GAGTCGGTGC 540 GCGCACCCCC AAACAGAACC ATCTTCGACA GTGACCTGAT GGATAGTGCC AGGCTGGGCG 600 50 GCCCCTGCCC CCCCAGCAGT AACTCGGGCA TCAGCGCCAC GTGCTACGGC AGCGGCGGGC 660 GCATGGAGGG GCCGCCGCCC ACCTACAGCG AGGTCATCGG CCACTACCCG GGGTCCTCCT 720 TCCAGCACCA GCAGAGCAGT GGGCCGCCCT CCTTGCTGGA GGGGACCCGG CTCCACCACA 780 CACACATCGC GCCCCTAGAG AGCGCAGCCA TCTGGAGCAA AGAGAAGGAT AAACAGAAAG 840 GACACCCTCT CTAGGGTCCC CAGGGGGGCC GGGCTGGGGC TGCGTAGGTG AAAAGGCAGA 900 55 ACACTCCGCG CTTCTTAGAA GAGGAGTGAG AGGAAGGCGG GGGGCGCAGC AACGCATCGT 960 GTGGCCCTCC CCTCCCACCT CCCTGTGTAT AAATATTTAC ATGTGATGTC TGGTCTGAAT 1020 GCACAAGCTA AGAGAGCTTG CAAAAAAAAA AAGAAAAAAG AAAAAAAAAA ACCACGTTTC 1080 TTTGTTGAGC TGTGTCTTGA AGGCAAAAGA AAAAAAATTT CTACAGTAAA AAAAAAAAAA 1140 A 60 SEQ ID N0.12 CHA1 Protein sequence: Protein Accession* NP_064567 65 1 11 21 31 41 51 I I I I I I MAELEFVQII IIWVMMVMV WITCLLSHY KLSARSFISR HSQGRRREDA LSSEGCLWPS 60 ESTVSGNGIP EPQVYAPPRP TDRLAVPPFA QRERFHRFQP TYPYLQHEID LPPTISLSDG 120 __ EEPPPYQGPC TLQLRDPEQQ LELNRESVRA PPNRTIFDSD LMDSARLGGP CPPSSNSGIS 180 70 ATCYGSGGRM EGPPPTYSEV IGHYPGSSFQ HQQSSGPPSL LEGTRLHHTH IAPLESAAIW 240 SKEKDKQKGH PL SEQ ID NO:13C A5 DNA SEQUENCE 75 Nucleic Acid Accession*: NM_012445 Coding sequence: 276-1271 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 80 I GCACGAGGGA AGAGGGTGAT CCGACCCGGG GAAGGTCGCT GGGCAGGGCG AGTTGGGAAA 60 GCGGCAGCCC CCGCCGCCCC CGCAGCCCCT TCTCCTCCTT TCTCCCACGT CCTATCTGCC 120 TCTCGCTGGA GGCCAGGCCG TGCAGCATCG AAGACAGGAG GAACTGGAGC CTCATTGGCC 180 GGCCCGGGGC GCCGGCCTCG GGCTTAAATA GGAGCTCCGG GCTCTGGCTG GGACCCGACC 240 GCTGCCGGCC GCGCTCCCGC TGCTCCTGCC GGGTGATGGA AAACCCCAGC CCGGCCGCCG 300 CCCTGGGCAA GGCCCTCTGC GCTCTCCTCC TGGCCACTCT CGGCGCCGCC GGCCAGCCTC 360 TTGGGGGAGA GTCCATCTGT TCCGCCAGAG CCCCGGCCAA ATACAGCATC ACCTTCACGG 420 GCAAGTGGAG CCAGACGGCC TTCCCCAAGC AGTACCCCCT GTTCCGCCCC CCTGCGCAGT 480 GGTCTTCGCT GCTGGGGGCC GCGCATAGCT CCGACTACAG CATGTGGAGG AAGAACCAGT 540 10 ACGTCAGTAA CGGGCTGCGC GACTTTGCGG AGCGCGGCGA GGCCTGGGCG CTGATGAAGG 600 AGATCGAGGC GGCGGGGGAG GCGCTGCAGA GCGTGCACGC GGTGTTTTCG GCGCCCGCCG 660 TCCCCAGCGG CACCGGGCAG ACGTCGGCGG AGCTGGAGGT GCAGCGCAGG CACTCGCTGG 720 TCTCGTTTGT GGTGCGCATC GTGCCCAGCC CCGACTGGTT CGTGGGCGTG GACAGCCTGG 780 ACCTGTGCGA CGGGGACCGT TGGCGGGAAC AGGCGGCGCT GGACCTGTAC CCCTACGACG 840 15 CCGGGACGGA CAGCGGCTTC ACCTTCTCCT CCCCCAACTT CGCCACCATC CCGCAGGACA 900 CGGTGACCGA GATAACGTCC TCCTCTCCCA GCCACCCGGC CAACTCCTTC TACTACCCGC 960 GGCTGAAGGC CCTGCCTCCC ATCGCCAGGG TGACACTGGT GCGGCTGCGA CAGAGCCCCA 1020 GGGCCTTCAT CCCTCCCGCC CCAGTCCTGC CCAGCAGGGA CAATGAGATT GTAGACAGCG 1080 CCTCAGTTCC AGAAACGCCG CTGGACTGCG AGGTCTCCCT GTGGTCGTCC TGGGGACTGT 1140 20 GCGGAGGCCA CTGTGGGAGG CTCGGGACCA AGAGCAGGAC TCGCTACGTC CGGGTCCAGC 1200 CCGCCAACAA CGGGAGCCCC TGCCCCGAGC TCGAAGAAGA GGCTGAGTGC GTCCCTGATA 1260 ACTGCGTCTA AGACCAGAGC CCCGCAGCCC CTGGGGCCCC CGGAGCCATG GGGTGTCGGG 1320 GGCTCCTGTG CAGGCTCATG CTGCAGGCGG CCGAGGCACA GGGGGTTTCG CGCTGCTCCT 1380 GACCGCGGTβ AGGCCGCGCC GACCATCTCT GCACTGAAGG GCCCTCTGGT GGCCGGCACG 1440 25 GGCATTGGGA AACAGCCTCC TCCTTTCCCA ACCTTGCTTC TTAGGGGCCC CCGTGTCCCG 1500 TCTGCTCTCA GCCTCCTCCT CCTGCAGGAT AAAGTCATCC CCAAGGCTCC AGCTACTCTA 1560 AATTATGGTC TCCTTATAAG TTATTGCTGC TCCAGGAGAT TGTCCTTCAT CGTCCAGGGG 1620 CCTGGCTCCC ACGTGGTTGC AGATACCTCA GACCTGGTGC TCTAGGCTGT GCTGAGCCCA 1680 CTCTCCCGAG GGCGCATCCA AGCGGGGGCC ACTTGAGAAG TGAATAAATG GGGCGGTTTC 1740 30 GGAAGCGTCA GTGTTTCCAT GTTATGGATC TCTCTGCGTT TGAATAAAGA CTATCTCTGT 1800 TGCTCAC 35 SEQ ID NO:14 CJA5 Protein sequence: Protein Accession * NP_036-77 11 21 31 41 51 40 I " I I I I MENPSPAAAL GKALCALLLA TLGAAGQPLG GESICSARAP AKYSITFTGK WSQTAFPKQY 60 PLFRPPAQWS SLLGAAHSSD YSMWRKNQYV SNGLRDFAER GEAWALMKEI EAAGEALQSV 120 HAVFSAPAVP SGTGQTSAEL EVQRRHSLVS FWRIVPSPD WFVGVDSLDL CDGDRWREQA 180 ALDLYPYDAG TDSGFTFSSP NFATIPQDTV TEITSSSPSH PANSFYYPRL KALPPIARVT 240 LVRLRQSPRA FIPPAPVLPS RDNEIVDSAS VPETPLDCEV SLWSSWGLCG GHCGRLGTKS 300 45 RTRYVRVQPA NNGSPCPELE EEAECVPDNC V SEQ ID N0.15 LBH9 DNA SEQUENCE Nucleic Acid Accession* NM_002391 50 Coding sequence: 26-457 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I CGGGCGAAGC AGCGCGGGCA GCGAGATGCA GCACCGAGGC TTCCTCCTCC TCACCCTCCT 60 55 CGCCCTGCTG GCGCTCACCT CCGCGGTCGC CAAAAAGAAA GATAAGGTGA AGAAGGGCGG 120 CCCGGGGAGC GAGTGCGCTG AGTGGGCCTG GGGGCCCTGC ACCCCCAGCA GCAAGGATTG 180 CGGCGTGGGT TTCCGCGAGG GCACCTGCGG GGCCCAGACC CAGCGCATCC GGTGCAGGGT 240 GCCCTGCAAC TGGAAGAAGG AGTTTGGAGC CGACTGCAAG TACAAGTTTG AGAACTGGGG 300 TGCGTGTGAT GGGGGCACAG GCACCAAAGT CCGCCAAGGC ACCCTGAAGA AGGCGCGCTA 360 60 CAATGCTCAG TGCCAGGAGA CCATCCGCGT CACCAAGCCC TGCACCCCCA AGACCAAAGC 420 AAAGGCCAAA GCCAAGAAAG GGAAGGGAAA GGACTAGACG CCAAGCCTGG ATGCCAAGGA 480 GCCCCTGGTG TCACATGGGG CCTGGCCACG CCCTCCCTCT CCCAGGCCCG AGATGTGACC 540 CACCAGTGCC TTCTGTCTGC TCGTTAGCTT TAATCAATCA TGCCCTGCCT TGTCCCTCTC 600 ACTCCCCAGC CCCACCCCTA AGTGCCCAAA GTGGGGAGGG ACAAGGGATT CTGGGAAGCT 660 65 TGAGCCTCCC CCAAAGCAAT GTGAGTCCCA GAGCCCGCTT TTGTTCTTCC CCACAATTCC 720 ATTACTAAGA AACACATCAA ATAAACTGAC TTTTTCCCCC CAATAAAAGC TCTTCTTTTT 780 TAATAT 70 SEQ ID N0:16 LBH9 Protein sequence: Protein Accession * NP_002382 1 11 21 31 41 51 ,-_. I I I I I I /D MQHRGFLLLT LLALLALTSA VAKKKDKVKK GGPGSECAEW AWGPCTPSSK DCGVGFREGT 60 CGAQTQRIRC RVPCNWKKEF GADCKYKFEN WGACDGGTGT KVRQGTLKKA RYNAQCQETI 120 RVTKPCTPKT KAKAKAKKGK GKD SEQ ID N0:17 LEM9 DNA SEQUENCE Nucleic Acid Accession* NM_005244 Coding sequence: 1-1617 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I 1 ATGGTAGAAC TAGTGATCTC ACCCAGCCTC ACTGTAAACA GCGATTGTCT GGATAAACTG 60 AAGTTTAACC GTGCTGACGC TGCTGTGTGG ACTCTGAGTG ACAGACAAGG CATCACCAAA 120 TCGGCCCCCC TGAGAGTGTC CCAGCTCTTC TCCAGATCTT GCCCACGTGT CCTCCCCCGC 180 CAGCCTTCCA CAGCCATGGC AGCCTACGGC CAGACGCAGT ACAGTGCGGG GATCCAGCAG 240 GCTACCCCCT ATACAGCTTA CCCACCTCCA GCACAAGCCT ATGGAATCCC TTCCTACAGC 300 ATCAAGACAG AAGACAGCTT GAACCATTCC CCTGGCCAGA GTGGATTCCT CAGCTATGGC 360 TCCAGCTTCA GCACCTCACC CACTGGACAG AGCCCATACA CCTACCAGAT GCACGGCACA 420 ACAGGGTTCT ATCAAGGAGG AAATGGACTG GGCAACGCAG CCGGTTTCGG GAGTGTGCAC 480 CAGGACTATC CTTCCTACCC CGGCTTCCCC CAGAGCCAGT ACCCCCAGTA TTACGGCTCA 540 TCCTACAACC CTCCCTACGT CCCGGCCAGC AGCATCTGCC CTTCGCCCCT CTCCACGTCC 600 ACCTACGTCC TCCAGGAGGC ATCTCACAAC GTCCCCAACC AGAGTTCCGA GTCACTTGCT 660 GGTGAATACA ACACACACAA TGGACCTTCC ACACCAGCGA AAGAGGGAGA CACAGACAGG 720 CCGCACCGGG CCTCCGACGG GAAGCTCCGA GGCCGGTCTA AGAGGAGCAG TGACCCGTCC 780 CCGGCAGGGG ACAATGAGAT TGAGCGTGTG TTCGTGTGGG ACTTGGATGA GACAATAATT 840 ATTTTTCACT CCTTACTCAC GGGGACATTT GCATCCAGAT ACGGGAAGGA CACCACGACG 900 TCCGTGCGCA TTGGCCTTAT GATGGAAGAG ATGATCTTCA ACCTTGCAGA TACACATCTG 960 TTCTTCAATG ACCTGGAGGA TTGTGACCAG ATCCACGTTG ATGACGTCTC ATCAGATGAC 1020 AATGGCCAAG ATTTAAGCAC ATACAACTTC TCCGCTGACG GCTTCCACAG TTCGGCCCCA 1080 GGAGCCAACC TGTGCCTGGG CTCTGGCGTG CACGGCGGCG TGGACTGGAT GAGGAAGCTG 1140 GCCTTCCGCT ACCGGCGGGT GAAGGAGATG TACAATACCT ACAAGAACAA CGTTGGTGGG 1200 TTGATAGGCA CTCCCAAAAG GGAGACCTGG CTACAGCTCC GAGCTGAGCT GGAAGCTCTC 1260 ACAGACCTCT GGCTGACCCA CTCCCTGAAG GCACTAAACC TCATCAACTC CCGGCCCAAC 1320 TGTGTCAATG TGCTGGTCAC CACCACTCAA CTAATTCCTG CCCTGGCCAA AGTCCTGCTA 1380 TATGGCCTGG GGTCTGTGTT TCCTATTGAG AACATCTACA GTGCAACCAA GACAGGGAAG 1440 GAGAGCTGCT TCGAGAGGAT AATGCAGAGA TTCGGCAGAA AAGCTGTCTA CGTGGTGATC 1500 GGTGATGGTG TGGAAGAGGA GCAAGGAGCG AAAAAGCACA ACATGCCTTT CTGGCGGATA 1560 TCCTGCCACG CAGACCTGGA GGCACTGAGG CACGCCCTGG AACTGGAGTA TTTATAG SEQ ID N0:18 LEM9 Protein sequence- Protein Accession* NP_005235 11 21 31 41 51 I I I I I MVELVISPSL TV SDCLDKL KFNRADAAVW TLSDRQGITK SAPLRVSQLF SRSCPRVLPR 60 QPSTAMAAYG QTQYSAGIQQ ATPYTAYPPP AQAYGIPSYS IKTEDSLNHS PGQSGFLSYG 120 SSFSTSPTGQ SPYTYQMHGT TGFYQGGNGL GNAAGFGSVH QDYPSYPGFP QSQYPQYYGS 180 SYNPPYVPAS SICPSPLSTS TYVLQEASHN VPNQSSESLA GEYNTHNGPS TPAKEGDTDR 240 PHRASDGKLR GRSKRSSDPS PAGDNEIERV FVWDLDETII IFHSLLTGTF ASRYGKDTTT 300 SVRIGLMMEE MIFNLADTHL FFNDLEDCDQ IHVDDVSSDD NGQDLSTYNF SADGFHSSAP 360 GANLCLGSGV HGGVDWMRKL AFRYRRVKEM YNTYKNNVGG LIGTPKRETW LQLRAELEAL 420 TDLWLTHSLK ALNLINSRPN CVNVLVTTTQ LIPALAKVLL YGLGSVFPIE NIYSATKTGK 480 ESCFERIMQR FGRKAVYWI GDGVEEEQGA KKHNMPFWRI SCHADLEALR HALELEYL SEQ ID N0:190AA1 DNA SEQUENCE Nxleic Acid Accession* NM_002740 Coding sequence: 17β-1968 (undeιiιnedsequencescorrespondtostartandstopcodons) 11 21 31 41 51 I I I I I CCGCGGTTCC GGCTGCTCCG GCGAGGCGAC CCTTGGGTCG GCGCTGCGGG CGAGGTGGGC 60 AGGTAGGTGG GCGGACGGCC GCGGTTCTCC GGCAAGCGCA GGCGGCGGAG TCCCCCACGG 120 CGCCCGAAGC GCCCCCCGCA CCCCCGGCCT CCAGCGTTGA GGCGGGGGAG TGAGGAGATG 180 CCGACCCAGA GGGACAGCAG CACCATGTCC CACACGGTCG CAGGCGGCGG CAGCGGGGAC 240 CATTCCCACC AGGTCCGGGT GAAAGCCTAC TACCGCGGGG ATATCATGAT AACACATTTT 300 GAACCTTCCA TCTCCTTTGA GGGCCTTTGC AATGAGGTTC GAGACATGTG TTCTTTTGAC 360 AACGAACAGC TCTTCACCAT GAAATGGATA GATGAGGAAG GAGACCCGTG TACAGTATCA 420 TCTCAGTTGG AGTTAGAAGA AGCCTTTAGA CTTTATGAGC TAAACAAGGA TTCTGAACTC 480 TTGATTCATG TGTTCCCTTG TGTACCAGAA CGTCCTGGGA TGCCTTGTCC AGGAGAAGAT 540 AAATCCATCT ACCGTAGAGG TGCACGCCGC TGGAGAAAGC TTTATTGTGC CAATGGCCAC 600 ACTTTCCAAG CCAAGCGTTT CAACAGGCGT GCTCACTGTG CCATCTGCAC AGACCGAATA 660 TGGGGACTTG GACGCCAAGG ATATAAGTGC ATCAACTGCA AACTCTTGGT TCATAAGAAG 720 TGCCATAAAC TCGTCACAAT TGAATGTGGG CGGCATTCTT TGCCACAGGA ACCAGTGATG 780 CCCATGGATC AGTCATCCAT GCATTCTGAC CATGCACAGA CAGTAATTCC ATATAATCCT 840 TCAAGTCATG AGAGTTTGGA TCAAGTTGGT GAAGAAAAAG AGGCAATGAA CACCAGGGAA 900 AGTGGCAAAG CTTCATCCAG TCTAGGTCTT CAGGATTTTG ATTTGCTCCG GGTAATAGGA 960 AGAGGAAGTT ATGCCAAAGT ACTGTTGGTT CGATTAAAAA AAACAGATCG TATTTATGCA 1020 ATGAAAGTTG TGAAAAAAGA GCTTGTTAAT GATGATGAGG ATATTGATTG GGTACAGACA 1080 GAGAAGCATG TGTTTGAGCA GGCATCCAAT CATCCTTTCC TTGTTGGGCT GCATTCTTGC 1140 TTTCAGACAG AAAGCAGATT GTTCTTTGTT ATAGAGTATG TAAATGGAGG AGACCTAATG 1200 TTTCATATGC AGCGACAAAG AAAACTTCCT GAAGAACATG CCAGATTTTA CTCTGCAGAA 1260 ATCAGTCTAG CATTAAATTA TCTTCATGAG CGAGGGATAA TTTATAGAGA TTTGAAACTG 1320 GACAATGTAT TACTGGACTC TGAAGGCCAC ATTAAACTCA CTGACTACGG CATGTGTAAG 1380 GAAGGATTAC GGCCAGGAGA TACAACCAGC ACTTTCTGTG GTACTCCTAA TTACATTGCT 1440 CCTGAAATTT TAAGAGGAGA AGATTATGGT TTCAGTGTTG ACTGGTGGGC TCTTGGAGTG 1500 CTCATGTTTG AGATGATGGC AGGAAGGTCT CCATTTGATA TTGTTGGGAG CTCCGATAAC 1560 CCTGACCAGA ACACAGAGGA TTATCTCTTC CAAGTTATTT TGGAAAAACA AATTCGCATA 1620 CCACGTTCTC TGTCTGTAAA AGCTGCAAGT GTTCTGAAGA GTTTTCTTAA TAAGGACCCT 1680 AAGGAACGAT TGGGTTGTCA TCCTCAAACA GGATTTGCTG ATATTCAGGG ACACCCGTTC 1740 TTCCGAAATG TTGATTGGGA TATGATGGAG CAAAAACAGG TGGTACCTCC CTTTAAACCA 1800 AATATTTCTG GGGAATTTGG TTTGGACAAC TTTGATTCTC AGTTTACTAA TGAACCTGTC 1860 CAGCTCACTC CAGATGACGA TGACATTGTG AGGAAGATTG ATCAGTCTGA ATTTGAAGGT 1920 TTTGAGTATA TCAATCCTCT TTTGATGTCT GCAGAAGAAT GTGTCTGATC CTCATTTTTC 1980 AACCATGTAT TCTACTCATG TTGCCATTTA ATGCATGGAT AAACTTGCTG CAAGCCTGGA 2040 TACAATTAAC CATTTTATAT TTGCCACCTA CAAAAAAACA CCCAATATCT TCTCTTGTAG 2100 ACTATATGAA TCAATTATTA CATCTGTTTT ACTATGAAAA AAAAATTAAT ACTACTAGCT 2160 TCCAGACAAT CATGTCAAAA TTTAGTTGAA CTGGTTTTTC AGTTTTTAAA AGGCCTACAG 2220 ATGAGTAATG AAGTTACCTT TTTTGTTTAA AAAAAAAAAA G SEQ ID 1.0:20 OAA1 Protein sequence: Protein Accession #: NP M2731 11 21 31 41 51 I I I I I MSHTVAGGGS GDHSHQVRVK AYYRGDIMIT HFEPSISFEG LCNEVRDMCS FDNEQLFTMK 60 WIDEEGDPCT VSSQLELEEA FRLYELNKDS ELLIHVFPCV PERPGMPCPG EDKSIYRRGA 120 RRWRKLYCAN GHTFQAKRFN RRAHCAICTD RIWGLGRQGY KCINCKLLVH KKCHKLVTIE 180 CGRHSLPQEP VMPMDQSSMH SDHAQTVIPY NPSSHESLDQ VGEEKEAMNT RESGKASSΞL 240 GLQDFDLLRV IGRGSYAKVL LVRLKKTDRI YAMKWKKEL VNDDEDIDWV QTEKHVFEQA 300 SNHPFLVGLH SCFQTESRLF FVIEYVNGGD LMFHMQRQRK LPEEHARFYS AEISI-ALNYL 360 HERGIIYRDL KLDNVLLDSE GHIKLTDYGM CKEGLRPGDT TSTFCGTPNY IAPEILRGED 420 YGFSVDWWAL GVLMFEMMAG RSPFDIVGSS DNPDQNTEDY LFQVILEKQI RIPRSLSVKA 480 ASVLKSFLNK DPKERLGCHP QTGFADIQGH PFFRNVDWDM MEQKQWPPF KPNISGEFGL 540 DNFDSQFTNE PVQLTPDDDD IVRKIDQSEF EGFEYINPLL MSAEECV SEQ ID N0:21 0BH2 DNA SEQUENCE Nucleic Acid Accession #: L05628 Coding sequence: 197-4792 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I CCAGGCGGCG TTGCGGCCCC GGCCCCGGCT CCCTGCGCCG CCGCCGCCGC CGCCGCCGCC 60 GCCGCCGCCG CCGCCGCCAG CGCTAGCGCC AGCAGCCGGG CCCGATCACC CGCCGCCCGG 120 TGCCCGCCGC CGCCCGCGCC AGCAACCGGG CCCGATCACC CGCCGCCCGG TGCCCGCCGC 180 CGCCCGCGCC ACCGGCATGG CGCTCCGGGG CTTCTGCAGC GCCGATGGCT CCGACCCGCT 240 CTGGGACTGG AATGTCACGT GGAATACCAG CAACCCCGAC TTCACCAAGT GCTTTCAGAA 300 CACGGTCCTC GTGTGGGTGC CTTGTTTTTA CCTCTGGGCC TGTTTCCCCT TCTACTTCCT 360 CTATCTCTCC CGACATGACC GAGGCTACAT TCAGATGACA CCTCTCAACA AAACCAAAAC 420 TGCCTTGGGA TTTTTGCTGT GGATCGTCTG CTGGGCAGAC CTCTTCTACT CTTTCTGGGA 480 AAGAAGTCGG GGCATATTCC TGGCCCCAGT GTTTCTGGTC AGCCCAACTC TCTTGGGCAT 540 CACCACGCTG CTTGCTACCT TTTTAATTCA GCTGGAGAGG AGGAAGGGAG TTCAGTCTTC 600 AGGGATCATG CTCACTTTCT GGCTGGTAGC CCTAGTGTGT GCCCTAGCCA TCCTGAGATC 660 CAAAATTATG ACAGCCTTAA AAGAGGATGC CCAGGTGGAC CTGTTTCGTG ACATCACTTT 720 CTACGTCTAC TTTTCCCTCT TACTCATTCA GCTCGTCTTG TCCTGTTTCT CAGATCGCTC 780 ACCCCTGTTC TCGGAAACCA TCCACGACCC TAATCCCTGC CCAGAGTCCA GCGCTTCCTT 840 CCTGTCGAGG ATCACCTTCT GGTGGATCAC AGGGTTGATT GTCCGGGGCT ACCGCCAGCC 900 CCTGGAGGGC AGTGACCTCT GGTCCTTAAA CAAGGAGGAC ACGTCGGAAC AAGTCGTGCC 960 TGTTTTGGTA AAGAACTGGA AGAAGGAATG CGCCAAGACT AGGAAGCAGC CGGTGAAGGT 1020 TGTGTACTCC TCCAAGGATC CTGCCCAGCC GAAAGAGAGT TCCAAGGTGG ATGCGAATGA 1080 GGAGGTGGAG GCTTTGATCG TCAAGTCCCC ACAGAAGGAG TGGAACCCCT CTCTGTTTAA 1140 GGTGTTATAC AAGACCTTTG GGCCCTACTT CCTCATGAGC TTCTTCTTCA AGGCCATCCA 1200 CGACCTGATG ATGTTTTCCG GGCCGCAGAT CTTAAAGTTG CTCATCAAGT TCGTGAATGA 1260 CACGAAGGCC CCAGACTGGC AGGGCTACTT CTACACCGTG CTGCTGTT G TCACTGCCTG 1320 CCTGCAGACC CTCGTGCTGC ACCAGTACTT CCACATCTGC TTCGTCAGTG GCATGAGGAT 1380 CAAGACCGCT GTCATTGGGG CTGTCTATCG GAAGGCCCTG GTGATCACCA ATTCAGCCAG 1440 AAAATCCTCC ACGGTCGGGG AGATTGTCAA CCTCATGTCT GTGGACGCTC AGAGGTTCAT 1500 GGACTTGGCC ACGTACATTA ACATGATCTG GTCAGCCCCC CTGCAAGTCA TCCTTGCTCT 1560 CTACCTCCTG TGGCTGAATC TGGGCCCTTC CGTCCTGGCT GGAGTGGCGG TGATGGTCCT 1620 CATGGTGCCC GTCAATGCTG TGATGGCGAT GAAGACCAAG ACGTATCAGG TGGCCCACAT 1680 GAAGAGCAAA GACAATCGGA TCAAGCTGAT GAACGAAATT CTCAATGGGA TCAAAGTGCT 1740 AAAGCTTTAT GCCTGGGAGC TGGCATTCAA GGACAAGGTG CTGGCCATCA GGCAGGAGGA 1800 GCTGAAGGTG CTGAAGAAGT CTGCCTACCT GTCAGCCGTG GGCACCTTCA CCTGGGTCTG 1860 CACGCCCTTT CTGGTGGCCT TGTGCACATT TGCCGTCTAC GTGACCATTG ACGAGAACAA 1920 CATCCTGGAT GCCCAGACAG CCTTCGTGTC TTTGGCCTTG TTCAACATCC TCCGGTTTCC 1980 CCTGAACATT CTCCCCATGG TCATCAGCAG CATCGTGCAG GCGAGTGTCT CCCTCAAACG 2040 CCTGAGGATC TTTCTCTCCC ATGAGGAGCT GGAACCTGAC AGCATCGAGC GACGGCCTGT 2100 CAAAGACGGC GGGGGCACGA ACAGCATCAC CGTGAGGAAT GCCACATTCA CCTGGGCCAG 2160 GAGCGACCCT CCCACACTGA ATGGCATCAC CTTCTCCATC CCCGAAGGTG CTTTGGTGGC 2220 CGTGGTGGGC CAGGTGGGCT GCGGAAAGTC GTCCCTGCTC TCAGCCCTCT TGGCTGAGAT 2280 GGACAAAGTG GAGGGGCACG TGGCTATCAA GGGCTCCGTG GCCTATGTGC CACAGCAGGC 2340 CTGGATTCAG AATGATTCTC TCCGAGAAAA CATCCTTTTT GGATGTCAGC TGGAGGAACC 2400 ATATTACAGG TCCGTGATAC AGGCCTGTGC CCTCCTCCCA GACCTGGAAA TCCTGCCCAG 2460 TGGGGATCGG ACAGAGATTG GCGAGAAGGG CGTGAACCTG TCTGGGGGCC AGAAGCAGCG 2520 CGTGAGCCTG GCCCGGGCCG TGTACTCCAA CGCTGACATT TACCTCTTCG ATGATCCCCT 2580 CTCAGCAGTG GATGCCCATG TGGGAAAACA CATCTTTGAA AATGTGATTG GCCCCAAGGG 2640 GATGCTGAAG AACAAGACGC GGATCTTGGT CACGCACAGC ATGAGCTACT TGCCGCAGGT 2700 GGACGTCATC ATCGTCATGA GTGGCGGCAA GATCTCTGAG ATGGGCTCCT ACCAGGAGCT 2760 GCTGGCTCGA GACGGCGCCT TCGCTGAGTT CCTGCGTACC TATGCCAGCA CAGAGCAGGA 2820 GCAGGATGCA GAGGAGAACG GGGTCACGGG CGTCAGCGGT CCAGGGAAGG AAGCAAAGCA 2880 AATGGAGAAT GGCATGCTGG TGACGGACAG TGCAGGGAAG CAACTGCAGA GACAGCTCAG 2940 CAGCTCCTCC TCCTATAGTG GGGACATCAG CAGGCACCAC AACAGCACCG CAGAACTGCA 3000 GAAAGCTGAG GCCAAGAAGG AGGAGACCTG GAAGCTGATG GAGGCTGACA AGGCGCAGAC 3060 AGGGCAGGTC AAGCTTTCCG TGTACTGGGA CTACATGAAG GCCATCGGAC TCTTCATCTC 3120 CTTCCTCAGC ATCTTCCTTT TCATGTGTAA CCATGTGTCC GCGCTGGCTT CCAACTATTG 3180 GCTCAGCCTC TGGACTGATG ACCCCATCGT CAACGGGACT CAGGAGCACA CGAAAGTCCG 3240 GCTGAGCGTC TATGGAGCCC TGGGCATTTC ACAAGGGATC GCCGTGTTTG GCTACTCCAT 3300 GGCCGTGTCC ATCGGGGGGA TCTTGGCTTC CCGCTGTCTG CACGTGGACC TGCTGCACAG 3360 CATCCTGCGG TCACCCATGA GCTTCTTTGA GCGGACCCCC AGTGGGAACC TGGTGAACCG 3420 CTTCTCCAAG GAGCTGGACA CAGTGGACTC CATGATCCCG GAGGTCATCA AGATGTTCAT 3480 GGGCTCCCTG TTCAACGTCA TTGGTGCCTG CATCGTTATC CTGCTGGCCA CGCCCATCGC 3540 CGCCATCATC ATCCCGCCCC TTGGCCTCAT CTACTTCTTC GTCCAGAGGT TCTACGTGGC 3600 TTCCTCCCGG CAGCTGAAGC GCCTCGAGTC GGTCAGCCGC TCCCCGGTCT ATTCCCATTT 3660 CAACGAGACC TTGCTGGGGG TCAGCGTCAT TCGAGCCTTC GAGGAGCAGG AGCGCTTCAT 3720 CCACCAGAGT GACCTGAAGG TGGACGAGAA CCAGAAGGCC TATTACCCCA GCATCGTGGC 3780 CAACAGGTGG CTGGCCGTGC GGCTGGAGTG TGTGGGCAAC TGCATCGTTC TGTTTGCTGC 3840 CCTGTTTGCG GTGATCTCCA GGCACAGCCT CAGTGCTGGC TTGGTGGGCC TCTCAGTGTC 3900 TTACTCATTG CAGGTCACCA CGTACTTGAA CTGGCTGGTT CGGATGTCAT CTGAAATGGA 3960 AACCAACATC GTGGCCGTGG AGAGGCTCAA GGAGTATTCA GAGACTGAGA AGGAGGCGCC 4020 CTGGCAAATC CAGGAGACAG CTCCGCCCAG CAGCTGGCCC CAGGTGGGCC GAGTGGAATT 4080 CCGGAACTAC TGCCTGCGCT ACCGAGAGGA CCTGGACTTC GTTCTCAGGC ACATCAATGT 4140 CACGATCAAT GGGGGAGAAA AGGTCGGCAT CGTGGGGCGG ACGGGAGCTG GGAAGTCGTC 4200 CCTGACCCTG GGCTTATTTC GGATCAACGA GTCTGCCGAA GGAGAGATCA TCATCGATGG 4260 CATCAACATC GCCAAGATCG GCCTGCACGA CCTCCGCTTC AAGATCACCA TCATCCCCCA 4320 GGACCCTGTT TTGTTTTCGG GTTCCCTCCG AATGAACCTG GACCCATTCA GCCAGTACTC 4380 GGATGAAGAA GTCTGGACGT CCCTGGAGCT GGCCCACCTG AAGGACTTCG TGTCAGCCCT 4440 TCCTGACAAG CTAGACCATG AATGTGCAGA AGGCGGGGAG AACCTCAGTG TCGGGCAGCG 4500 CCAGCTTGTG TGCCTAGCCC GGGCCCTGCT GAGGAAGACG AAGATCCTTG TGTTGGATGA 4560 GGCCACGGCA GCCGTGGACC TGGAAACGGA CGACCTCATC CAGTCCACCA TCCGGACACA 4620 GTTCGAGGAC TGCACCGTCC TCACCATCGC CCACCGGCTC AACACCATCA TGGACTACAC 4680 AAGGGTGATC GTCTTGGACA AAGGAGAAAT CCAGGAGTAC GGCGCCCCAT CGGACCTCCT 4740 GCAGCAGAGA GGTCTTTTCT ACAGCATGGC CAAAGACGCC GGCTTGGTGT_GAGCCCCAGA 4800 GCTGGCATAT CTGGTCAGAA CTGCAGGGCC TATATGCCAG CGCCCAGGGA GGAGTCAGTA 4860 CCCCTGGTAA ACCAAGCCTC CCACACTGAA ACCAAAACAT AAAAACCAAA CCCAGACAAC 4920 CAAAACATAT TCAAAGCAGC AGCCACCGCC ATCCGGTCCC CTGCCTGGAA CTGGCTGTGA 4980 AGACCCAGGA GAGACAGAGA TGCGAACCAC C SEQ ID NO:22 OBH2 Protein sequence: Protein Accession * AAB46616 11 21 31 41 51 I I I I I I MALRGFCSAD GSDPLWDWNV TWNTSNPDFT KCFQNTVLVW VPCFYLWACF PFYFLYLSRH 60 DRGYIQMTPL NKTKTALGFL LWIVCWADLF YSFWERSRGI FLAPVFLVSP TLLGITTLLA 120 TFLIQLERRK GVQSSGIMLT FWLVALVCAL AILRSKIMTA LKEDAQVDLF RDITFYVYFS 180 LLLIQLVLSC FSDRSPLFSE TIHDPNPCPE SSASFLSRIT FWWITGLΓVR GYRQPLEGSD 240 LWSLNKEDTS EQWFVLVKN WKKECAKTRK QPVKWYSSK DPAQPKESSK VDANEEVEAL 300 IVKSPQKEWN PSLFKVLYKT FGPYFLMSFF FKAIHDLMMF SGEQILKLLI KFVNDTKAPD 360 WQGYFYTVLL FVTACLQTLV LHQYFHICFV SGMRIKTAVI GAVYRKALVI TNSARKSSTV 420 GE-CVNI-MSVD AQRFMDLATY INMIWSAPLQ VILALYLLWL NLGPSVLAGV AVKVLMVFVN 480 AVMAMKTKTY QVAHMKSKDN RIKLMNEILN GIKVLKLYAW ELAFKDKVLA IRQEELKVLK 540 KSAYLSAVGT FTWVCTPFLV ALCTFAVYVT IDENNILDAQ TAFVSLALFN ILRFPLNILP 600 MVISSIVQAS VSLKRLRIFL SHEELEPDSI ERRPVKDGGG TNSITVRNAT FTWARSDPPT 660 LNGITFSIPE GALVAWGQV GCGKSSLLSA LLAEMDKVEG HVAIKGSVAY VPQQAWIQND 720 SLRENILFGC QLEEPYYRSV IQACALLPDL EILPSGDRTE IGEKGVNLSG GQKQRVSLAR 780 AVYSNADIYL FDDPLSAVDA HVGKHIFENV IGPKGMLKNK TRILVTHSMS YLPQVDVIIV 840 MSGGKISEMG SYQELLARDG AFAEFLRTYA STEQEQDAEE NGVTGVSGPG KEAKQMENGM 900 LVTDSAGKQL QRQLSSSSSY SGDISRHHNS TAELQKAEAK KEETWKLMEA DKAQTGQVKL 960 SVYWDYMKAI GLFISFLSIF LFMCNHVSAL ASNYWLSLWT DDPIVNGTQE HTKVRLSVYG 1020 ALGISQGIAV FGYSMAVSIG GILASRCLHV DLLHSILRSP MSFFERTPSG NLVNRFSKEL 1080 DTVDSMIPEV IKMFMGSLFN VIGACIVILL ATPIAAIIIP PLGLIYFFVQ RFYVASSRQL 1140 KRLESVSRSP VYSHFNETLL GVSVIRAFEE QERFIHQSDL KVDENQKAYY PSIVANRWLA 1200 VRLECVGNCI VLFAALFAVI SRHSLSAGLV GLSVSYSLQV TTYLNWLVRM SSEMETNIVA 1260 VERLKEYSET EKEAPWQIQE TAPPSSWPQV GRVEFRNYCL RYREDLDFVL RHIMVTINGG 1320 EKVGIVGRTG AGKSSLTLGL FRINESAEGE IIIDGINIAK IGLHDLRFKI TIIPQD1?VLF 1380 SGSLRMNLDP FSQYSDEEVW TSLELAHLKD FVSALPDKLD HECAEGGENL SVGQRQLVCL 1440 ARALLRKTKI LVLDEATAAV DLETDDLIQS TIRTQFEDCT VLTIAHRLNT IMDYTRVIVL 1500 DKGEIQEYGA PSDLLQQRGL FYSMAKDAGL V SEQ ID NO:23 PAA2 DNA SEQUENCE Nucleic Acid Accession* NM.013309 Coding sequence: 1-1290 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 ATGGCCGGCT CTGGCGCGTG GAAGCGCCTC AAATCTATGC TAAGGAAGGA TGATGCGCCG 60 CTGTTTTTAA ATGACACCAG CGCCTTTGAC TTCTCGGATG AGGCGGGGGA CGAGGGGCTT 120 TCTCGGTTCA ACAAACTTCG AGTTGTGGTG GCCGATGACG GTTCCGAAGC CCCGGAAAGG 180 CCTGTTAACG GGGCGCACCC GACCCTCCAG GCCGACGATG ATTCCTTACT GGACCAAGAC 240 TTACCTTTGA CCAACAGTCA GCTGAGTTTG AAGGTGGACT CCTGTGACAA CTGCAGCAAA 300 CAGAGAGAGA TACTGAAGCA GAGAAAGGTG AAAGCCAGGT TGACCATTGC TGCCGTTCTG 360 TACTTGCTTT TCATGATTGG AGAACTTGTA GGTGGATACA TTGCAAATAβ CCTAGCAATC 420 ATGACAGATG CACTTCATAT GTTAACTGAC CTAAGCGCCA TCATACTCAC CCTGCTTGCT 480 TTGTGGCTAT CATCAAAATC ACCAACCAAA AGATTCACCT TTGGATTTCA TCGCTTAGAG 540 GTTTTGTCAG CTATGATTAG TGTGCTGTTG GTGTATATAC TTATGGGATT CCTCTTATAT 600 GAAGCTGTGC AAAGAACTAT CCATATGAAC TATGAAATAA ATGGAGATAT AATGCTCATC 660 ACCGCAGCTG TTGGAGTTGC AGTTAATGTA ATAATGGGGT TTCTGTTGAA CCAGTCTGGT 720 CACCGTCACT CCCATTCCCA CTCCCTGCCT TCAAATTCCC CTACCAGAGG TTCTGGGTGT 780 GAACGTAACC ATGGGCAGGA TAGCCTGGCA GTGAGAGCTG CATTTGTACA TGCTTTGGGA 840 GATTTGGTAC AGAGTGTTGG TGTGCTAATA GCTGCATACA TCATACGATT CAAGCCAGAA 900 TACAAGATTG CTGATCCCAT CTGTACATAC GTATTTTCAT TACTTGTGGC TTTTACAACA 960 TTTCGAATCA TATGGGATAC AGTAGTTATA ATACTAGAAG GTGTGCCAAG CCATTTGAAT 1020 GTAGACTATA TCAAAGAAGC CTTGATGAAA ATAGAAGATG TATATTCAGT CGAAGATTTA 1080 AATATCTGGT CTCTCACTTC AGGAAAATCT ACTGCCATAG TTCACATACA GCTAATTCCT 1140 GGAAGTTCAT CTAAATGGGA GGAAGTACAG TCCAAAGCAA ACCATTTATT ATTGAACACA 1200 TTTGGCATGT ATAGATGTAC TATTCAGCTT CAGAGTTACA GGCAAGAAGT GGACAGAACT 1260 TGTGCAAATT GTCAGAGTTC TAGTCCCTGA SEQ ID N0.24 PAA2 Protein sequence: Protein Accession* NP_037441 11 21 31 41 51 I I I I I I MAGSGAWKRL KSMLRKDDAP LFLNDTSAFD FSDEAGDEGL SRFNKLRVW ADDGSEAPER 60 PVNGAHPTLQ ADDDSLLDQD LPLTNSQLSL KVDSCDNCSK QREILKQRKV KARLTIAAVL 120 YLLFMIGELV GGYIANSLAI MTDALHMLTD LSAIILTLLA LWLSSKSPTK RFTFGFHRLE 180 VLSAMISVLL VYILMGFLLY EAVQRTIHMN YEINGDIMLI TAAVGVAVNV IMGFLLNQSG 240 HRHSHSHSLP SNSPTRGSGC ERNHGQDSLA VRAAFVHALG DLVQSVGVLI AAYIIRFKPE 300 YKIADPICTY VFSLLVAFTT FRIIWDTWI ILEGVPSHLN VDYIKEALMK IEDVYSVEDL 360 NIWSLTSGKS TAIVHIQLIP GSSSKWEEVQ SKANHLLLNT FGMYRCTIQL QSYRQEVDRT 420 CANCQSSSP SEQ ID N0.25 PAA3 DNA SEQUENCE Nucleic Acid Accession* AB037765 Coding sequence: 375-2798 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I GCCGAGTCGG TGGCGGCTGC AGGCTGGGAG GGAGAAGTGC TACGCCTTTG CAGGTTGGCG 60 AAGTGGTTCC AGGCTACCCG GCTAGTCTGG CACGGCCCCG TCTTCTGCCT CCTCCTCCGT 120 CGCGTGGCGG CGGGAACTGT TGGCCGCGCG GCCTCGGGAA CGGCCCAGGT CCCCGCCCGC 180 AGGTCCCGGG CAGATAACAT AGATCATCAG TAGAAAACTT CTTGAAGTTG TTCAAGAAAA 240 ATTTGAAAGT AGCAAAATAG AAAATAAAGA ATTAACAGCA GATACAGAGG ACAGCATGGA 300 AGTGTTGTCT TAGGAAACAG AACACAGCAG TGAAAAAACA GACAAAATCC GCTCAGATAC 360 AACTGCAGCT GATAATGTTT TCCGGCTTCA ATGTCTTTAG AGTTGGGATC TCTTTTGTCA 420 TAATGTGCAT TTTTTACATG CCAACAGTAA ACTCTTTACC AGAACTGAGT CCTCAGAAAT 480 ATTTTAGTAC ATTGCAACCA GGTCTTGAAG AACTGAATGA GGCTGTTAGA CCTCTGCAGG 540 ACTATGGAAT TTCAGTTGCC AAGGTTAATT GTGTCAAAGA AGAAATATCA AGATACTGTG 600 GAAAAGAAAA GGATTTGATG AAAGCATATT TATTCAAGGG CAACATATTG CTCAGAGAAT 660 TCCCTACTGA CACCTTGTTT GATGTGAATG CCATTGTCGC CCATGTTCTC TTTGCTCTTC 720 TTTTTAGTGA AGTGAAATAT ATTACCAACC TGGAAGACCT TCAGAACATA GAAAATGCTC 780 TGAAAGGAAA AGCAAATATT ATATTCTCAT ATGTAAGAGC CATTGGAATA CCAGAGCACA 840 GAGCAGTCAT GGAAGCCGGT TTTGTGTATG GGACTACATA CCAATTTGTC TTAACCACAG 900 AAATTGCCCT TTTGGAAAGT ATTGGCTCTG AGGATGTGGA ATATGCACAT CTCTACTTTT 960 TTCATTGTAA ACTAGTCTTG GACTTGACCC AGCAATGTAG AAGAACACTA ATGGAACAGC 1020 CATTGACTAC ACTGAACATT CACCTGTTTA TTAAGACAAT GAAAGCACCT CTGTTGACTG 1080 AAGTTGCTGA AGATCCTCAA CAAGTTTCAA CTGTCCATCT CCAACTGGGC TTACCACTGG 1140 TTTTTATTGT TAGCCAACAG GCTACTTATG AAGCTGATAG AAGAACTGCA GAATGGGTTG 1200 CTTGGCGTCT TCTGGGAAAA GCAGGAGTTC TACTCTTGTT AAGGGACTCT TTGGAAGTGA 1260 ACATTCCTCA AGATGCTAAT GTGGTCTTCA AAAGAGCAGA AGAGGGAGTT CCAGTGGAAT 1320 TTTTGGTATT ACATGATGTT GATTTAATAA TATCTCATGT GGAAAATAAT ATGCACATTG 1380 AGGAAATACA AGAAGATGAA GACAATGACA TGGAAGGTCC AGATATAGAT GTTCAGGATG 1440 ATGAAGTGGC AGAAACTGTT TTCAGAGATA GGAAGAGAAA ATTACCTTTG GAACTTACAG 1500 TGGAACTAAC AGAAGAAACA TTTAATGCAA CAGTGATGGC TTCTGACAGC ATAGTACTCT 1560 TCTATGCTGG TTGGCAAGCA GTATCCATGG CATTTTTGCA ATCCTATATT GATGTGGCAG 1620 TTAAACTGAA AGGCACATCT ACTATGCTTC TTACTAGAAT AAACTGTGCA GATTGGTCTG 1680 ATGTATGTAC TAAGCAAAAT GTTACTGAAT TTCCTATCAT AAAGATGTAC AAGAAAGGCG 1740 AGAACCCAGT ATCTTATGCT GGAATGTTAG GAACCAAAGA TCTCCTAAAA TTTATCCAGC 1800 TCAACAGGAT TTCATATCCA GTGAATATAA CATCGATCCA AGAAGCAGAA GAATATTTAA 1860 GTGGGGAATT ATATAAAGAC CTCATCTTGT ATTCTAGTGT GTCAGTATTG GGACTATTTA 1920 GTCCAACCAT GAAAACAGCA AAAGAAGATT TTAGTGAAGC AGGAAACTAC CTAAAAGGAT 1980 ATGTTATCAC TGGAATTTAT TCTGAAGAAG ATGTTTTGCT ACTGTCAACC AAATATGCTG 2040 CAAGTCTTCC AGCCCTGCTG CTTGCCAGAC ACACAGAAGG CAAAATAGAG AGCATCCCAC 2100 TAGCTAGCAC ACATGCACAA GACATAGTTC AAATAATAAC AGATGCACTA CTGGAAATGT 2160 TTCCGGAAAT CACTGTGGAA AATCTTCCCA GTTATTTCAG ACTTCAGAAA CCATTATTGA 2220 TTTTGTTCAG TGATGGCACT GTAAATCCTC AATATAAAAA AGCAATATTG ACACTGGTAA 2280 AGCAGAAATA CTTGGATTCA TTTACTCCAT GCTGGTTAAA TCTAAAGAAT ACTCCAGTGG 2340 GGAGAGGAAT CTTGCGGGCA TATTTTGATC CTCTGCCTCC CCTTCCTCTT CTTGTTTTGG 2400 TGAATCTGCA TTCAGGTGGC CAAGTATTTG CATTTCCTTC AGACCAGGCT ATAATTGAAG 2460 AAAACCTTGT ATTGTGGCTG AAGAAATTAG AAGCAGGACT AGAAAATCAT ATCACAATTT 2520 TACCTGCTCA AGAATGGAAA CCTCCTCTTC CAGCTTATGA TTTTCTAAGT ATGATAGATG 2580 CCGCAACATC TCAACGTGGC ACTAGGAAAG TTCCCAAGTG TATGAAAGAA ACAGATGTGC 2640 AGGAGAATGA TAAGGAACAA CATGAAGATA AATCGGCAGT CAGAAAAGAA CCGATTGAAA 2700 CTCTGAGAAT AAAGCATTGG AATAGAAGTA ATTGGTTTAA AGAAGCAGAA AAATCATTTA 2760 GACGTGATAA AGAGTTAGGA TGCTCAAAAG TGAACTAATT TTATAGGGCT GTGGTTTCCA 2820 AAATTTTTTT GGCATGATAG ACTTAATTTA TTTCCTTAAA GAATAATATT AAATCATTTC 2880 AAGTTTGCAG ACTAGTGCCA TCCAATAGAA TTATAATATA AGTCACATAT TTTATTTAAA 2940 ATTTTCTAGT AACTACATTA AACAAAGTAA AAGTGAGCAG GGCAAAATAA TTTTGATATT 3000 ACTTTTCACC CAGTAGTATA CCCAAAATAG CGAAATATAG AAATTATTAA TGAGATATTT 3060 TACATCCTTT TTTGTACCAA GTCTTCTAAA TGCAGTACAT ATTTTATACT TACTGCATTT 3120 CTTACTTCCG AGTAGCCATA TTTCAAGTGT TCATTGCCAC ATGTGGCCTG TGACTACTGT 3180 ATTGGACAGT TCAGTACTAG ACAAAAACTA GCATAATTAA CTTAGTTCTA GCCATGATTT 3240 CTATTTGGAT TAAAATTAAA CTCTAATCAC AGTTAACTCC ACAGTGCATT CATGCAGCTG 33 00 ACAGTTATAT TTGTTTTATT GGAGTCATGA TATTAAAATC AGCGTTTGTC AACCTCAGGG 3360 GATATTTAGC AATTGTCGGG AGACATTTTT GATGTCATGA CTAGGGCAGT TATTGACATT 3420 TAGTGAGTAG AGGCCATGGA TCCTGCTAAA TAACCTGCAT TGGACAGCGC CCCACAACAA 3480 AGAATTATCC TGCCCGAAAT GGTAGTCGTG CCAAGGCTGA GTAACCTTGT GTTAAAAGTA 3540 ACCTGTGGCA GACTAGGTTT CCAGAATTTC CTGGTTCTGC TCACGTATCA TGTTTGAAAA 3600 AATTTTGGCT ATTAAAGATA TGTATTAGAT GGTCTTATCC TGATTATTAC CTGGATACAA 3660 CTTGATCTTT TCTAATATTT TCAGAAAGTG ATGGGATAAC CCTAGAAGAG GACTCAGAAT 3720 GATATTTATA TTTTAAGTGA GTCTTAAAAC CTCCTCTTAT TTCTACAAGT TATATGGCTA 3780 AATTTCAGAT TGAACAGGGA TTCAGCATTC TGCCATCTCC TCATGGAAAG AGAGGCTCCC 3840 TCATCTGAAG CGTCTCTGAA ATCTACCCTT GCAAGCTTCA GACAAATCAβ TTGATCTCCC 3900 TGAGCCACAC GGCCTCATTC TGTGAGGGAG GGAAAGATTA GCCAAAGAGT TAATTTTCAT 3960 TCCAAATCAC TTAGCTGTTA GACTGATCTG TTTGTAGCAG TTGTTTGTCT CATTTTTGCT 4020 CTGTGCATTT TTTGAGACAT TTGTTGAGAA TATTCTATTT GGTGCTCTAC TGTATTTTTC 4080 TTTTTAATAT CTACTTGATA TCTTGTTCTT TAAATTTTCT TCACATATGG TTTGCCTGAT 4140 ACAACTGATT TTTATAACTG AAATTTAAGG AATCTAACAG CTAAAACTCA GTAAGTGCAT 4200 MTATTTCCTT ATAACATAGA CCCGTTGCTA CTCTCAGCAC CCTCTCCTCA ATTTTTTTTC 4260 CTGTAGCATG TGATGCCTGA TTAAACTCAT TTTCATTTGC TTTTATTTCT AATATGGGAA 4320 CAATGAGAGT GAACTCTAAA TATAGGTTGT AGTAATAAAA CATCATTAGC CTAATTATTA 4380 GAAAATGCTA ATTAAGTACC AGCACATAGA AACATGAAAT TGCTTAGTCA TTGTACCTTT 4440 GTCAGCAATT TTGACAGTCA TTAATGTTTG TCATAATTTT AAATAAAGTG TCTGGGTTTC 4500 AGAATACCTT CAAAAAAAAA AAAAAA SEQ ID NO:26 PAA3 Protein sequence: Protein Accession* BAA92582 11 21 31 41 51 MFSGFNVFRV GISFVIMCIF YMPTVNSLPE LSPQKYFSTL QPGLEELNEA VRPLQDYGIS 60 VAKVNCVKEE ISRYCGKEKD LMKAYLFKGN ILLREFPTDT LFDVNAIVAH VLFALLFSEV 120 KYITNLEDLQ NIENALKGKA NIIFSYVRAI GIPEHRAVME AGFVYGTTYQ FVLTTEIALL 180 ESIGΞEDVEY AHLYFFHCKL VLDLTQQCRR TLMEQPLTTL NIHLFIKTMK APLLTEVAED 240 PQQVSTVHLQ -LGLPLVFIVS QQATYEADRR TAEWVAWRLL GKAGVLLLLR DSLEVNIPQD 300 ANWFKRAEE GVPVEFLVLH DVDLIISHVE NNMHIEEIQE DEDNDMEGPD IDVQDDEVAE 360 TVFRDRKRKL PLELTVELTE ETFNATVMAS DSIVLFYAGW QAVSMAFLQS YIDVAVKLKG 420 TSTMLLTRIN CADWSDVCTK QNVTEFPIIK MYKKGENPVS YAGMLGTKDL LKFIQLNRIS 480 YPVNITSIQE AEEYLSGELY KDLILYSSVS VLGLFSPTMK TAKEDFSEAG NYLKGYVITG 540 IYSEEDVLLL STKYAASLPA LLLARHTEGK IESIPLASTH AQDIVQIITD ALLEMFPEIT 600 VENLPSYFRL QKPLLILFSD GTVNPQYKKA ILTLVKQKYL DSFTPCWLNL KNTPVGRGIL 660 RAYFDPLPPL PLLVLVNLHS GGQVFAFPSD QAIIEENLVL WLKKLEAGLE NHITILPAQE 720 WKPPLPAYDF LSMIDAATSQ RGTRKVPKCM KETDVQENDK EQHEDKSAVR KEPIETLRIK 780 HWNRSNWFKE AEKSFRRDKE LGCSKVN SEQ ID N0.27 PAA5 DNA SEQUENCE Nucleic Acid Accession* NM_012449 Coding sequence: 66-1085 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I CCGAGACTCA CGGTCAAGCT AAGGCGAAGA GTGGGTGGCT GAAGCCATAC TATTTTATAG 60 AATTAATGGA AAGCAGAAAA GACATCACAA ACCAAGAAGA ACTTTGGAAA ATGAAGCCTA 120 GGAGAAATTT AGAAGAAGAC GATTATTTGC ATAAGGACAC GGGAGAGACC AGCATGCTAA 180 AAAGACCTGT GCTTTTGCAT TTGCACCAAA CAGCCCATGC TGATGAATTT GACTGCCCTT 240 CAGAACTTCA GCACACACAG GAACTCTTTC CACAGTGGCA CTTGCCAATT AAAATAGCTG 300 CTATTATAGC ATCTCTGACT TTTCTTTACA CTCTTCTGAG GGAAGTAATT CACCCTTTAG 360 CAACTTCCCA TCAACAATAT TTTTATAAAA TTCCAATCCT GGTCATCAAC AAAGTCTTGC 420 CAATGGTTTC CATCACTCTC TTGGCATTGG TTTACCTGCC AGGTGTGATA GCAGCAATTG 480 TCCAACTTCA TAATGGAACC AAGTATAAGA AGTTTCCACA TTGGTTGGAT AAGTGGATGT 540 TAACAAGAAA GCAGTTTGGG CTTCTCAGTT TCTTTTTTGC TGTACTGCAT GCAATTTATA 600 GTCTGTCTTA CCCAATGAGG CGATCCTACA GATACAAGTT GCTAAACTGG GCATATCAAC 660 AGGTCCAACA AAATAAAGAA GATGCCTGGA TTGAGCATGA TGTTTGGAGA ATGGAGATTT 720 ATGTGTCTCT GGGAATTGTG GGATTGGCAA TACTGGCTCT GTTGGCTGTβ ACATCTATTC 780 CATCTGTGAG TGACTCTTTG ACATGGAGAG AATTTCACTA TATTCAGAGC AAGCTAGGAA 840 TTGTTTCCCT TCTACTGGGC ACAATACACG CATTGATTTT TGCCTGGAAT AAGTGGATAG 900 ATATAAAACA ATTTGTATGG TATACACCTC CAACTTTTAT GATAGCTGTT TTCCTTCCAA 960 TTGTTGTCCT GATATTTAAA AGCATACTAT TCCTGCCATG CTTGAGGAAG AAGATACTGA 1020 AGATTAGACA TGGTTGGGAA GACGTCACCA AAATTAACAA AACTGAGATA TGTTCCCAGT 1080 TGTAGAATTA CTGTTTACAC ACATTTTTGT TCAATATTGA TATATTTTAT CACCAACATT 1140 TCAAGTTTGT ATTTGTTAAT AAAATGATTA TTCAAGGAAA AAAAAAAAAA AAAAA SEQ ID N0:28 PAA5 Protein sequence Protein Accession * NP_036581 11 21 31 41 51 I I I MESRKDITNQ EELWKMKPRR NLEEDDYLHK DTGETSMLKR FVLLHLHQTA HADEFDCPSE 60 LQHTQELFPQ WHLPIKIAAI IASLTFLYTL LREVIHPLAT SHQQYFYKIP ILVINKVLPM 120 VSITLLALVY LPGVIAAΓVQ LHNGTKYKKF PHWLDKWMLT RKQFGLLSFF FAVLHAIYSL 180 SYPMRRSYRY KLLNWAYQQV QQNKEDAWIE HDVWRMEIYV SLGIVGLAIL ALLAVTSIPS 240 VSDSLTWREF HYIQSKLGIV SLLLGTIHAL IFAWNKWIDI KQFVWYTPPT FMIAVFLPIV 3 00 VLIFKSILFL PCLRKKILKI RHGWEDVTKI NKTEICSQL SEQ ID N0:29 PAA7 DNA SEQUENCE Nucleic Acid Accession* NM_0 3 0774 Coding sequence: 1-963 (undedined sequences correspond to start and stop codons) 11 21 31 41 51 1 I I I I ATGAGTTCCT GCAACTTCAC ACATGCCACC TTTGTGCTTA TTGGTATCCC AGGATTAGAG 60 AAAGCCCATT TCTGGGTTGG CTTCCCCCTC CTTTCCATGT ATGTAGTGGC AATGTTTGGA 120 AACTGCATCG TGGTCTTCAT CGTAAGGACG GAACGCAGCC TGCACGCTCC GATGTACCTC 180 TTTCTCTGCA TGCTTGCAGC CATTGACCTG GCCTTATCCA CATCCACCAT GCCTAAGATC 240 CTTGCCCTTT TCTGGTTTGA TTCCCGAGAG ATTAGCTTTG AGGCCTGTCT TACCCAGATG 300 TTCTTTATTC ATGCCCTCTC AGCCATTGAA TCCACCATCC TGCTGGCCAT GGCCTTTGAC 360 CGTTATGTGG CCATCTGCCA CCCACTGCGC CATGCTGCAG TGCTCAACAA TACAGTAACA 420 GCCCAGATTG GCATCGTGGC TGTGGTCCGC GGATCCCTCT TTTTTTTCCC ACTGCCTCTG 480 CTGATCAAGC GGCTGGCCTT CTGCCACTCC AATGTCCTCT CGCACTCCTA TTGTGTCCAC 540 CAGGATGTAA TGAAGTTGGC CTATGCAGAC ACTTTGCCCA ATGTGGTATA TGGTCTTACT 600 GCCATTCTGC TGGTCATGGG CGTGGACGTA ATGTTCATCT CCTTGTCCTA TTTTCTGATA 660 ATACGAACGG TTCTGCAACT GCCTTCCAAG TCAGAGCGGG CCAAGGCCTT TGGAACCTGT 720 GTGTCACACA TTGGTGTGGT ACTCGCCTTC TATGTGCCAC TTATTGGCCT CTCAGTGGTA 780 CACCGCTTTG GAAACAGCCT TCATCCCATT GTGCGTGTTG TCATGGGTGA CATCTACCTG 840 CTGCTGCCTC CTGTCATCAA TCCCATCATC TATGGTGCCA AAACCAAACA GATCAGAACA 900 CGGGTGCTGG CTATGTTCAA GATCAGCTGT GACAAGGACT TGCAGGCTGT GGGAGGCAAG 960 TGACCCTTAA CACTACACTT CTCCTTATCT TTATTGGCTT GATAAACATA ATTATTTCTA 1020 ACACTAGCTT ATTTCCAGTT GCCCATAAGC ACATCAGTAC TTTTCTCTGG CTGGAATAGT 1080 AAACTAAAGT ATGGTACATC TACCTAAAGG ACTATTATGT GGAATAATAC ATACTAATGA 1140 AGTATTACAT GATTTAAAGA CTACAATAAA ACCAAACATG CTTATAACAT TAAGAAAAAC 1200 AATAAAGATA CATGATTGAA ACCAAGTTGA AAAATAGCAT ATGCCTTGGA GGAAATGTGC 1260 TCAAATTACT AATGATTTAG TGTTGTCCCT ACTTTCTCTC TCTTTTTTCT TTCTTTTTTT 1320 TTTATTATGG TTAGCTGTCA CATACAACTT TTTTTTTTTT TGAGATGGGG TCTCGCTCTG 1380 TCACCAGGCT GGAGTGCAGT GGCGCGATCT CGGCTCACTG CAACCTCCAC ATCCCATGTT 1440 GAAGTAATTC TTCTGCCTCA GCCTCCCGAG TAGCTGGGAC TAGAGGAACG TGCCACCATG 1500 ACTGGCTAAT TTTCTGTATT TTTTAGTAGA GACAGAGTTT CACCATGTTG GCCAGGATGG 1560 TCTCGATCTC CTGACCTTGT GATCCACCCG CCTCAGCCTC CCAAAGTGTT GGGATTACAG 1620 GTGTGAACCA CTGTGCCCGG CCTGTGTACA ACTTTTTAAA TAGGGAATAT GATAGCTTCG 1680 CATGGTGGTG TGCACCTATA GCCCCCACTG CCTGGAAAGC TGAGGTGGGA GAATCGCTTG 1740 AGTCCAGGAG TTTGAGGTTA CAGTGATCCA CGATCGTACC ACTACACTCC AGCCTGGGCA 1800 ACAGAGCAAG ACCCTGTCTC AAAGCATAAA ATGGAATAAC ATATCAAATG AAACAGGGAA 1860 AATGAAGCTG ACAATTTATG GAAGCCAGGG CTTGTCACAG TCTCTACTGT TATTATGCAT 1920 TACCTGGGAA TTTATATAAG CCCTTAATAA TARTGCCAAT GAACATCTCA TGTGTGCTCA 1980 CAATGTTCTG GCACTATTAT AAGTGCTTCA CAGGTTTTAT GTGTTCTTCG TAACTTTATG 2040 GAGTAGGTAC CATTTGTGTC TCTTTATTAT AAGTGAGAGA AATGAAGTTT ATATTATCAA 2100 GGGGACTAAA GTCACACGGC TTGTGGGCAC TGTGCCAAGA TTTAAAATTA AATTTGATGG 2160 TTGAATACAG TTACTTAATG ACCATGTTAT ATTGCTTCCT GTGTAACATC TGCCATTTAT 2220 TTCCTCAGCT GTACAAATCC TCTGTTTTCT CTCTGTTACA CACTAACATC AATGGCTTTG 2280 TACTTGTGAT GAGAGATAAC CTTGCCCTAG TTGTGGGCAA CACATGCAGA ATAATCCTGT 2340 TTTACAGCTG CCTTTCGTGA TCTTATTGCT TGCTTTTTTC CAGATTCAGG GAGAATGTTG 2400 TTGTCTATTT GTCTCTTACA TCTCCTTGAT CATGTCTTCA TTTTTTAATG TGCTCTGTAC 2460 CTGTCAAAAA TTTTGAATGT ACACCACATG CTATTGTCTG AACTTGAGTA TAAGATAAAA 2520 TAAAATTTTA TTTTAAATTT T SEQ ID NO:30 PAA7 PROTEIN SEQUENCE Protein Accession* NP_l 10401 11 21 31 41 51 I I I I I MSSCNFTHAT FVLIGIPGLE KAHFWVGFPL LSMYWAMFG NCIWFIVRT ERSLHAPMYL 60 FLCMLAAIDL ALSTSTMPKI LALFWFDSRE ISFEACLTQM FFIHALSAIE STILLAMAFD 120 RYVAICHPLR HAAVLNNTVT AQIGIVAWR GSLFFFPLPL LIKRLAFCHS NVLSHSYCVH 180 QDVMKLAYAD TLPNWYGLT AILLVMGVDV MFISLSYFLI IRTVLQLPSK SERAKAFGTC 240 VSHIGWLAF YVPLIGLSW HRFGNSLHPI VRWMGDIYL LLPFVINPII YGAKTKQIRT 300 RVLAMFKISC DKDLQAVGGK SEQ ID N0:31 PAV6 DNA SEQUENCE Nucleic Acid Accession ft XM_0508 3 7 Coding sequence: 1 -1020 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I ATGAACTGGG AGCTGCTGCT GTGGCTGCTG GTGCTGTGCG CGCTGCTCCT GCTCTTGGTG 60 CAGCTGCTGC GCTTCCTGAG GGCTGACGGC GACCTGACGC TACTATGGGC CGAGTGGCAG 120 GGACGACGCC CAGAATGGGA GCTGACTGAT ATGGTGGTGT GGGTGACTGG AGCCTCGAGT 180 GGAATTGGTG AGGAGCTGGC TTACCAGTTG TCTAAACTAG GAGTTTCTCT TGTGCTGTCA 240 GCCAGAAGAG TGCATGAGCT GGAAAGGGTG AAAAGAAGAT GCCTAGAGAA TGGCAATTTA 300 AAAGAAAAAG ATATACTTGT TTTGCCCCTT GACCTGACCG ACACTGGTTC CCATGAAGCG 360 GCTACCAAAG CTGTTCTCCA GGAGTTTGGT AGAATCGACA TTCTGGTCAA CAATGGTGGA 420 ATGTCCCAGC GTTCTCTGTG CATGGATACC AGCTTGGATβ TCTACAGAAA GCTAATAGAG 480 CTTAACTACT TAGGGACGGT GTCCTTGACA AAATGTGTTC TGCCTCACAT GATCGAGAGG 540 AAGCAAGGAA AGATTGTTAC TGTGAATAGC ATCCTGGGTA TCATATCTGT ACCTCTTTCC 600 ATTGGATACT GTGCTAGCAA GCATGCTCTC CGGGGTTTTT TTAATGGCCT TCGAACAGAA 660 CTTGCCACAT ACCCAGGTAT AATAGTTTCT AACATTTGCC CAGGACCTGT GCAATCAAAT 720 ATTGTGGAGA ATTCCCTAGC TGGAGAAGTC ACAAAGACTA TAGGCAATAA TGGAGACCAG 780 TCCCACAAGA TGACAACCAG TCGTTGTGTG CGGCTGATGT TAATCAGCAT GGCCAATGAT 840 TTGAAAGAAG TTTGGATCTC AGAACAACCT TTCTTGTTAG TAACATATTT GTGGCAATAC 900 ATGCCAACCT GGGCCTGGTG GATAACCAAC AAGATGGGGA AGAAAAGGAT TGAGAACTTT 960 AAGAGTGGTG TGGATGCAGA CTCTTCTTAT TTTAAAATCT TTAAGACAAA ACATGACTGA SEQ ID NO:32 PAV6 Protein sequence Protein Accession*: XP_050837 11 21 31 41 51 MNWELLLWLL VLCALLLLLV QLLRFLRADG DLTLLWAEWQ GRRPEWELTD MWWVTGASS 60 GIGEELAYQL. SKLGVSLVLS ARRVHELERV KRRCLENGNL KEKDILVLPL DLTDTGSHEA 120 ATKAVLQEFG RIDILVNNGΒ MSQRSLCMDT SLDVYRKLIE LNYLGTVSLT KCVLPHMIER 180 KQGKΓVTVNS ILGIISVPLS IGYCASKHAL RGFFNGLRTE LATYPGIΓVS NICPGPVQSN 240 IVENSLAGEV TKTIGNNGDQ SHKMTTSRCV RLMLISMAND LKEVWISEQP FLLVTYLWQY 300 MPTWAWWITN KMGKKRIENFKSGVDADSSY FKIFKTKHD SEQ ID NO:33 PBA6 DNA SEQUENCE Nucleic Acid Accession* NM_006853 Coding sequence: 26-874 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I AGGAATCTGC GCTCGGGTTC CGCAGATGCA GAGGTTGAGG TGGCTGCGGG ACTGGAAGTC 60 ATCGGGCAGA GGTCTCACAG CAGCCAAGGA ACCTGGGGCC CGCTCCTCCC CCCTCCAGGC 120 CATGAGGATT CTGCAGTTAA TCCTGCTTGC TCTGGCAACA GGGCTTGTAG GGGGAGAGAC 180 CAGGATCATC AAGGGGTTCG AGTGCAAGCC TCACTCCCAG CCCTGGCAGG CAGCCCTGTT 240 CGAGAAGACG CGGCTACTCT GTGGGGCGAC GCTCATCGCC CCCAGATGGC TCCTGACAGC 300 AGCCCACTGC CTCAAGCCCC GCTACATAGT TCACCTGGGG CAGCACAACC TCCAGAAGGA 360 GGAGGGCTGT GAGCAGACCC GGACAGCCAC TGAGTCCTTC CCCCACCCCG GCTTCAACAA 420 CAGCCTCCCC AACAAAGACC ACCGCAATGA CATCATGCTG GTGAAGATGG CATCGCCAGT 480 CTCCATCACC TGGGCTGTGC GACCCCTCAC CCTCTCCTCA CGCTGTGTCA CTGCTGGCAC 540 CAGCTGCCTC ATTTCCGGCT GGGGCAGCAC GTCCAGCCCC CAGTTACGCC TGCCTCACAC 600 CTTGCGATGC GCCAACATCA CCATCATTGA GCACCAGAAG TGTGAGAACG CCTACCCCGG 660 CAACATCACA GACACCATGG TGTGTGCCAG CGTGCAGGAA GGGGGCAAGG ACTCCTGCCA 720 GGGTGACTCC GGGGGCCCTC TGGTCTGTAA CCAGTCTCTT CAAGGCATTA TCTCCTGGGG 780 CCAGGATCCG TGTGCGATCA CCCGAAAGCC TGGTGTCTAC ACGAAAGTCT GCAAATATGT 840 GGACTGGATC CAGGAGACGA TGAAGAACAA TTAGACTGGA CCCACCCACC ACAGCCCATC 900 ACCCTCCATT TCCACTTGGT GTTTGGTTCC TGTTCACTCT GTTAATAAGA AACCCTAAGC 960 CAAGACCCTC TACGAACATT CTTTGGGCCT CCTGGACTAC AGGAGATGCT GTCACTTAAT 1020 AATCAACCTG GGGTTCGAAA TCAGTGAGAC CTGGATTCAA ATTCTGCCTT GAAATATTGT 1080 GACTCTGGGA ATGACAACAC CTGGTTTGTT CTCTGTTGTA TCCCCAGCCC CAAAGACAGC 1140 TCCTGGCCAT ATATCAAGGT TTCAATAAAT ATTTGCTAAA TGAGTG SEQ ID NO:34 PBA6 PROTEIN SEQUENCE Protein Accession*: NP_006844 1 11 21 31 41 51 I I I I I I MRILQLILLA LATGLVGGET RIIKGFECKP HSQPWQAALF EKTRLLCGAT LIAPRWLLTA 60 AHCLKPRYIV HLGQHNLQKE EGCEQTRTAT ESFPHPGFNN SLPNKDHRND IMLVKMASPV 120 SITWAVRPLT LSSRCVTAGT SCLISGWGST SSPQLRLPHT LRCANITIIE HQKCENAYPG 180 NITDTMVCAS VQEGGKDSCQ GDSGGPLVCN QSLQGIISWG QDPCAITRKP GVYTKVCKYV 240 DWIQETMKNN SEQ ID NO:35 PBC1 DNA SEQUENCE Nucleic Acid Accession* NM_001775 Coding sequence: 70-972 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I CTAAAGCTCT CTTGCTGCCT AGCCTCCTGC CGGCCTCATC TTCGCCCAGC CAACCCCGCC 60 TGGAGCCCTA_ TGGCCAACTG CGAGTTCAGC CCGGTGTCCG GGGACAAACC CTGCTGCCGG 120 CTCTCTAGGA GAGCCCAACT CTGTCTTGGC GTCAGTATCC TGGTCCTGAT CCTCGTCGTG 180 GTGCTCGCGG TGGTCGTCCC GAGGTGGCGC CAGACGTGGA GCGGTCCGGG CACCACCAAG 240 CGCTTTCCCG AGACCGTCCT GGCGCGATGC GTCAAGTACA CTGAAATTCA TCCTGAGATG 300 AGACATGTAG ACTGCCAAAG TGTATGGGAT GCTTTCAAGG GTGCATTTAT TTCAAAACAT 360 CCTTGCAACA TTACTGAAGA AGACTATCAG CCACTAATGA AGTTGGGAAC TCAGACCGTA 420 CCTTGCAACA AGATTCTTCT TTGGAGCAGA ATAAAAGATC TGGCCCATCA GTTCACACAG 480 GTCCAGCGGG ACATGTTCAC CCTGGAGGAC ACGCTGCTAG GCTACCTTGC TGATGACCTC 540 ACATGGTGTG GTGAATTCAA CACTTCCAAA ATAAACTATC AATCTTGCCC AGACTGGAGA 600 AAGGACTGCA GCAACAACCC TGTTTCAGTA TTCTGGAAAA CGGTTTCCCG CAGGTTTGCA 660 GAAGCTGCCT GTGATGTGGT CCATGTGATG CTCAATGGAT CCCGCAGTAA AATCTTTGAC 720 AAAAACAGCA CTTTTGGGAG TGTGGAAGTC CATAATTTGC AACCAGAGAA GGTTCAGACA 780 CTAGAGGCCT GGGTGATACA TGGTGGAAGA GAAGATTCCA GAGACTTATG CCAGGATCCC 840 ACCATAAAAG AGCTGGAATC GATTATAAGC AAAAGGAATA TTCAATTTTC CTGCAAGAAT 900 ATCTACAGAC CTGACAAGTT TCTTCAGTGT GTGAAAAATC CTGAGGATTC ATCTTGCACA 960 TCTGAGATCT_ GAGCCAGTCG CTGTGGTTGT TTTAGCTCCT TGACTCCTTG TGGTTTATGT 1020 CATCATACAT GACTCAGCAT ACCTGCTGGT GCAGAGCTGA AGATTTTGGA GGGTCCTCCA 1080 CAATAAGGTC AATGCCAGAG ACGGAAGCCT TTTTCCCCAA AGTCTTAAAA TAACTTATAT 1140 CATCAGCATA CCTTTATTGT GATCTATCAA TAGTCAAGAA AAATTATTGT ATAAGATTAG 1200 AATGAAAATT GTATGTTAAG TTACTTCCTT TAG SEQ ID NO:36 PBC1 Protein sequence Protein Accession*: NP_001766 11 21 31 41 51 I I I MANCEFSPVS GDKPCCRLSR RAQLCLGVSI LVLILWVLA WVPRWRQTW SGPGTTKRFP 60 ETVLARCVKY TEIHPEMRHV DCQSVWDAFK GAFISKHPCN ITEEDYQPLM KLGTQTVPCN 120 KILLWSRIKD LAHQFTQVQR DMFTLEDTLL GYLADDLTWC GEFNTSKINY QSCPDWRKDC 180 SNNPVSVFWK TVSRRFAEAA CDWHVMLNG SRSKIFDKNS TFGSVEVHNL QPEKVQTLEA 240 WVIHGGREDS RDLCQDPTIK ELESIISKRN IQFSCKNIYR PDKFLQCVKN PEDSSCTSEI SEQ ID NO:37 PBH1 DNA SEQUENCE Nucleic Acid Accession* XML017718 Coding sequence: 1-3315 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I ATGTCCTTTC GGGCAGCCAG GCTCAGCATG AGGAACAGAA GGAATGACAC TCTGGACAGC 60 ACCCGGACCC TGTACTCCAG CGCGTCTCGG AGCACAGACT TGTCTTACAG TGAAAGCGAC 120 TTGGTGAATT TTATTCAAGC AAATTTTAAG AAACGAGAAT GTGTCTTCTT TACCAAAGAT 180 TCCAAGGCCA CGGAGAATGT GTGCAAGTGT GGCTATGCCC AGAGCCAGCA CATGGAAGGC 240 ACCCAGATCA ACCAAAGTGA GAAATGGAAC TACAAGAAAC ACACCAAGGA ATTTCCTACC 300 GACGCCTTTG GGGATATTCA GTTTGAGACA CTGGGGAAGA AAGGGAAGTA TATACGTCTG 360 TCCTGCGACA CGGACGCGGA AATCCTTTAC GAGCTGCTGA CCCAGCACTG GCACCTGAKA 420 ACACCCAACC TGGTCATTTC TGTGACCGGG GGCGCCAAGA ACTTCGCCCT GAAGCCGCGC 480 ATGCGCAAGA TCTTCAGCCG GCTCATCTAC ATCGCGCAGT CCAAAGGTGC TTGGATTCTC 540 ACGGGAGGCA CCCATTATGG CCTGATGAAG TACATCGGGG AGGTGGTGAG AGATAACACC 600 ATCAGCAGGA GTTCAGAGGA GAATATTGTG GCCATTGGCA TAGCAGCTTG GGGCATGGTC 660 TCCAACCGGG ACACCCTCAT CAGGAATTGC GATGCTGAGG GCTATTTTTT AGCCCAGTAC 720 CTTATGGATG ACTTCACAAG AGATCCACTG TATATCCTGG ACAACAACCA CACACATTTG 780 CTGCTCGTGG ACAATGGCTG TCATGGACAT CCCACTGTCG AAGCAAAGCT CCGGAATCAG 840 CTAGAGAAGT ATATCTCTGA GCGCACTATT CAAGATTCCA ACTATGGTGG CAAGATCCCC 900 ATTGTGTGTT TTGCCCAAGG AGGTGGAAAA GAGACTTTGA AAGCCATCAA TACCTCCATC 960 AAAAATAAAA TTCCTTGTGT GGTGGTGGAA GGCTCGGGCC AGATCGCTGA TGTGATCGCT 1020 AGCCTGGTGG AGGTGGAGGA TGCCCTGACA TCTTCTGCCG TCAAGGAGAA GCTGGTGCGC 1080 TTTTTACCCC GCACGGTGTC CCGGCTGCCT GAGGAGGAGA CTGAGAGTTG GATCAAATGG 1140 CTCAAAGAAA TTCTCGAATG TTCTCACCTA TTAACAGTTA TTAAAATGGA AGAAGCTGGG 1200 GATGAAATTG TGAGCAATGC CATCTCCTAC GCTCTATACA AAGCCTTCAG CACCAGTGAG 1260 CAAGACAAGG ATAACTGGAA TGGGCAGCTG AAGCTTCTGC TGGAGTGGAA CCAGCTGGAC 1320 TTAGCCAATG ATGAGATTTT CACCAATGAC CGCCGATGGG AGTCTGCTGA CCTTCAAGAA 1380 GTCATGTTTA CGGCTCTCAT AAAGGACAGA CCCAAGTTTG TCCGCCTCTT TCTGGAGAAT 1440 GGCTTGAACC TACGGAAGTT TCTCACCCAT GATGTCCTCA CTGAACTCTT CTCCAACCAC 1500 TTCAGCACGC TTGTGTACCG GAATCTGCAG ATCGCCAAGA ATTCCTATAA TGATGCCCTC 1560 CTCACGTTTG TCTGGAAACT GGTTGCGAAC TTCCGAAGAG GCTTCCGGAA GGAAGACAGA 1620 AATGGCCGGG ACGAGATGGA CATAGAACTC CACGACGTGT CTCCTATTAC TCGGCACCCC 1680 CTGCAAGCTC TCTTCATCTG GGCCATTCTT CAGAATAAGA AGGAACTCTC CAAAGTCATT 1740 TGGGAGCAGA CCAGGGGCTG CACTCTGGCA GCCCTGGGAG CCAGCAAGCT TCTGAAGACT 1800 CTGGCCAAAG TGAAGAACGA CATCAATGCT GCTGGGGAGT CCGAGGAGCT GGCTAATGAG 1860 TACGAGACCC GGGCTGTTGA GCTGTTCACT GAGTGTTACA GCAGCGATGA AGACTTGGCA 1920 GAACAGCTGC TGGTCTATTC CTGTGAAGCT TGGGGTGGAA GCAACTGTCT GGAGCTGGCG 1980 GTGGAGGCCA CAGACCAGCA TTTCATCGCC CAGCCTGGGG TCCAGAATTT TCTTTCTAAG 2040 CAATGGTATG GAGAGATTTC CCGAGACACC AAGAACTGGA AGATTATCCT GTGTCTGTTT 2100 ATTATACCCT TGGTGGGCTG TGGCTTTGTA TCATTTAGGA AGAAACCTGT CGACAAGCAC 2160 AAGAAGCTGC TTTGGTACTA TGTGGCGTTC TTCACCTCCC CCTTCGTGGT CTTCTCCTGG 2220 AATGTGGTCT TCTACATCGC CTTCCTCCTG CTGTTTGCCT ACGTGCTGCT CATGGATTTC 2280 CATTCGGTGC CACACCCCCC CGAGCTGGTC CTGTACTCGC TGGTCTTTGT CCTCTTCTGT 2340 GATGAAGTGA GACAGTGGTA CGTAAATGGG GTGAATTATT TTACTGACCT GTGGAATGTG 2400 ATGGACACGC TGGGGCTTTT TTACTTCATA GCAGGAATTG TATTTCGGCT CCACTCTTCT 2460 AATAAAAGCT CTTTGTATTC TGGACGAGTC ATTTTCTGTC TGGACTACAT TATTTTCACT 2520 CTAAGATTGA TCCACATTTT TACTGTAAGC AGAAACTTAG GACCCAAGAT TATAATGCTG 2580 CAGAGGATGC TGATCGATGT GTTCTTCTTC CTGTTCCTCT TTGCGGTGTG GATGGTGGCC 2640 TTTGGCGTGG CCAGGCAAGG GATCCTTAGG CAGAATGAGC AGCGCTGGAG GTGGATATTC 2700 CGTTCGGTCA TCTACGAGCC CTACCTGGCC ATGTTCGGCC AGGTGCCCAG TGACGTGGAT 2760 GGTACCACGT ATGACTTTGC CCACTGCACC TTCACTGGGA ATGAGTCCAA GCCACTGTGT 2820 GTGGAGCTGG ATGAGCACAA CCTGCCCCGG TTCCCCGAGT GGATCACCAT CCCCCTGGTG 2880 TGCATCTACA TGTTATCCAC CAACATCCTG CTGGTCAACC TGCTGGTCGC CATGTTTGGC 2940 TACACGGTGG GCACCGTCCA GGAGAACAAT GACCAGGTCT GGAAGTTCCA GAGGTACTTC 3000 CTGGTGCAGG AGTACTGCAG CCGCCTCAAT ATCCCCTTCC CCTTCATCGT CTTCGCTTAC 3060 TTCTACATGG TGGTGAAGAA GTGCTTCAAG TGTTGCTGCA AGGAGAAAAA CATGGAGTCT 3120 TCTGTCTGCT GTTTCAAAAA TGAAGACAAT GAGACTCTGG CATGGGAGGG TGTCATGAAG 3180 GAAAACTACC TTGTCAAGAT CAACACAAAA GCCAACGACA CCTCAGAGGA AATGAGGCAT 3240 CGATTTAGAC AACTGGATAC AAAGCTTAAT GATCTCAAGG GTCTTCTGAA AGAGATTGCT 3300 AATAAAATCA AATGA SEQ ID N0:38 PBH1 Protein sequence Protein Accession* XP_017718 11 21 31 41 51 MSFRAARLSM RNRRNDTLDS TRTLYSSASR STDLSYSESD LVNFIQANFK KRECVFFTKD 60 SKATENVCKC GYAQSQHMEO TQINQSEKWN YKKHTKEFPT DAFGDIQFET LGKKGKYIRL 120 SCDTDAEILY ELLTQHWHLK TPNLVISVTG GAKNFALKPR MRKIFSRLIY IAQSKGAWIL 180 TGGTHYGLMK YIGEWRDNT ISRSSEENIV AIGIAAWGMV SNRDTLIRNC DAEGYFLAQY 240 LMDDFTRDPL YILDNNHTHL LLVDNGCHGH PTVEAKLRNQ LEKYISERTI QDSNYGGKIP 300 IVCFAQGGGK ETLKAINTSI KNKIPCWVE GSGQIADVIA SLVEVEDALT SSAVKEKLVR 360 FLPRTVSRLP EEETESWIKW LKEILECSHL LTVIKMEEAG DEΓVSNAISY ALYKAFSTSE 420 QDKDNWNGQL KLLLEWNQLD LANDEIFTND RRWESADLQE VMFTALIKDR PKFVRLFLEN 480 GLNLRKFLTH DVLTELFSNH FSTLVYRNLQ IAKNSYNDAL LTFVWKLVAN FRRGFRKEDR 540 NGRDEMDIEL HDVSPITRHP LQALFIWAIL QNKKELSKVI WEQTRGCTLA ALGASKLLKT 600 I-AKVKNDINA AGESEELANE YETRAVELFT ECYSSDEDLA EQLLVYSCEA WGGSNCLELA 660 VEATDQHFIA QPGVQNFLSK QWYGEISRDT KNWKIILCLF IIPLVGCGFV SFRKKPVDKH 720 KKLLWYYVAF FTSPFWFSW NWFYIAFLL LFAYVLLMDF HSVPHPPELV LYSLVFVLFC 780 DEVRQWYVNG VNYFTDLWNV MDTLGLFYFI AGIVFRLHSS NKSSLYSGRV IFCLDYIIFT 840 LRLIHIFTVS RNLGPKIIML QRMLIDVFFF LFLTAVWMVA FGVARQGILR QNEQRWRWIF 900 RSVIYEPYLA MFGQVPSDVD GTTYDFAHCT FTGNESKPLC VELDEHNLPR FPEWITIPLV 960 CIYMLSTNIL LVNLLVAMFG YTVGTVQENN DQVWKFQRYF LVQEYCSRLN IPFPFIVFAY 1020 FYMWKKCFK CCCKEKNMES SVCCFKNEDN ETLAWEGVMK ENYLVKINTK ANDTSEEMRH 1080 RFRQLDTKLN DLKGLLKEIA NKIK SEQ ID N0.39 PBH3 DNA SEQUENCE Nucleic Acid Accession* XMJH1804 Coding sequence: 1-558 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I ATGCCTCGCC TGTTCTTGTT CCACCTGCTA GAATTCTGTT TACTACTGAA CCAATTTTCC 60 AGAGCAGTCG CGGCCAAATG GAAGGACGAT GTTATTAAAT TATGCGGCCG CGAATTAGTT 120 CGCGCGCAGA TTGCCATTTG CGGCATGAGC ACCTGGAGCA AAAGGTCTCT GAGCCAGGAA 180 GATGCTCCTC AGACACCTAG ACCAGTGGCA GAAATTGTAC CATCCTTCAT CAACAAAGAT 240 ACAGAAACTA TAATTATCAT GTTGGAATTC ATTGCTAATT TGCCACCGGA GCTGAAGGCA 300 GCCCTATCTG AGAGGCAACC ATCATTACCA GAGCTACAGC AGTATGTACC TGCATTAAAG 360 GATTCCAATC TTAGCTTTGA AGAATTTAAG AAACTTATTC GCAATAGGCA AAGTGAAGCC 420 GCAGACAGCA ATCCTTCAGA ATTAAAATAC TTAGGCTTGG ATACTCATTC TCAAAAAAAG 480 AGACGACCCT ACGTGGCACT GTTTGAGAAA TGTTGCCTAA TTGGTTGTAC CAAAAGGTCT 540 CTTGCTAAAT ATTGCTGA SEQ ID NO;4Q PBH3 PROTEIN SEQUENCE Protein Accession * NP-.008842 1 11 21 31 41 51 I I I I I I MPRLFLFHLL EFCLLLNQFS RAVAAKWKDD VIKLCGRELV RAQIAICGMS TWSKRSLSQE 60 DAPQTPRFVA EIVPSFINKD TETIIIMLEF IANLPPELKA ALSERQPSLP ELQQYVPALK 120 DSNLSFEEFK KLIRNRQSEA ADSNPSELKY LGLDTHSQKK RRPYVALFEK CCLIGCTKRS 180 LAKYC SEQ ID N0:41 PBH5 DNA SEQUENCE Nucleic Acid Accession #: NM_005845 Coding sequence: 1-3978 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I ATGCTGCCCG TGTACCAGGA GGTGAAGCCC AACCCGCTGC AGGACGCGAA CCTCTGCTCA 60 CGCGTGTTCT TCTGGTGGCT CAATCCCTTG TTTAAAATTG GCCATAAACG GAGATTAGAG 120 GAAGATGATA TGTATTCAGT GCTGCCAGAA GACCGCTCAC AGCACCTTGG AGAGGAGTTG 180 CAAGGGTTCT GGGATAAAGA AGTTTTAAGA GCTGAGAATG ACGCACAGAA GCCTTCTTTA 240 ACAAGAGCAA TCATAAAGTG TTACTGGAAA TCTTATTTAG TTTTGGGAAT TTTTACGTTA 300 ATTGAGGAAA GTGCCAAAGT AATCCAGCCC ATATTTTTGG GAAAAATTAT TAATTATTTT 360 GAAAATTATG ATCCCATGGA TTCTGTGGCT TTGAACACAG CGTACGCCTA TGCCACGGTG 420 CTGACTTTTT GCACGCTCAT TTTGGCTATA CTGCATCACT TATATTTTTA TCACGTTCAG 480 TGTGCTGGGA TGAGGTTACG AGTAGCCATG TGCCATATGA TTTATCGGAA GGCACTTCGT 540 CTTAGTAACA TGGCCATGGG GAAGACAACC ACAGGCCAGA TAGTCAATCT GCTGTCCAAT 600 GATGTGAACA AGTTTGATCA GGTGACAGTG TTCTTACACT TCCTGTGGGC AGGACCACTG 660 CAGGCGATCG CAGTGACTGC CCTACTCTGG ATGGAGATAG GAATATCGTG CCTTGCTGGG 720 ATGGCAGTTC TAATCATTCT CCTGCCCTTG CAAAGCTGTT TTGGGAAGTT GTTCTCATCA 780 CTGAGGAGTA AAACTGCAAC TTTCACGGAT GCCAGGATCA GGACCATGAA TGAAGTTATA 840 ACTGGTATAA GGATAATAAA AATGTACGCC TGGGAAAAGT CATTTTCAAA TCTTATTACC 900 AATTTGAGAA AGAAGGAGAT TTCCAAGATT CTGAGAAGTT CCTGCCTCAG GGGGATGAAT 960 TTGGCTTCGT TTTTCAGTGC AAGCAAAATC ATCGTGTTTG TGACCTTCAC CACCTACGTG 1020 CTCCTCGGCA GTGTGATCAC AGCCAGCCGC GTGTTCGTGG CAGTGACGCT GTATGGGGCT 1080 GTGCGGCTGA CGGTTACCCT CTTCTTCCCC TCAGCCATTG AGAGGGTGTC AGAGGCAATC 1140 GTCAGCATCC GAAGAATCCA GACCTTTTTG CTACTTGATG AGATATCACA GCGCAACCGT 1200 CAGCTGCCGT CAGATGGTAA AAAGATGGTG CATGTGCAGG ATTTTACTGC TTTTTGGGAT 1260 AAGGCATCAG AGACCCCAAC TCTACAAGGC CTTTCCTTTA CTGTCAGACC TGGCGAATTG 1320 TTAGCTGTGG TCGGCCCCGT GGGAGCAGGG AAGTCATCAC TGTTAAGTGC CGTGCTCGGG 1380 GAATTGGCCC CAAGTCACGG GCTGGTCAGC GTGCATGGAA GAATTGCCTA TGTGTCTCAG 1440 CAGCCCTGGG TGTTCTCGGG AACTCTGAGG AGTAATATTT TATTTGGGAA GAAATACGAA 1500 AAGGAACGAT ATGAAAAAGT CATAAAGGCT TGTGCTCTGA AAAAGGATTT ACAGCTGTTG 1560 GAGGATGGTG ATCTGACTGT GATAGGAGAT CGGGGAACCA CGCTGAGTGG AGGGCAGAAA 1620 GCACGGGTAA ACCTTGCAAG AGCAGTGTAT CAAGATGCTG ACATCTATCT CCTGGACGAT 1680 CCTCTCAGTG CAGTAGATGC GGAAGTTAGC AGACACTTGT TCGAACTGTG TATTTGTCAA 1740 ATTTTGCATG AGAAGATCAC AATTTTAGTG ACTCATCAGT TGCAGTACCT CAAAGCTGCA 1800 AGTCAGATTC TGATATTGAA AGATGGTAAA ATGGTGCAGA AGGGGACTTA CACTGAGTTC 1860 CTAAAATCTG GTATAGATTT TGGCTCCCTT TTAAAGAAGG ATAATGAGGA AAGTGAACAA 1920 CCTCCAGTTC CAGGAACTCC CACACTAAGG AATCGTACCT TCTCAGAGTC TTCGGTTTGG 1980 TCTCAACAAT CTTCTAGACC CTCCTTGAAA GATGGTGCTC TGGAGAGCCA AGATACAGAG 2040 AATGTCCCAβ TTACACTATC AGAGGAGAAC CGTTCTGAAG GAAAAGTTGG TTTTCAGGCC 2100 TATAAGAATT ACTTCAGAGC TGGTGCTCAC TGGATTGTCT TCATTTTCCT TATTCTCCTA 2160 AACACTGCAG CTCAGGTTGC CTATGTGCTT CAAGATTGGT GGCTTTCATA CTGGGCAAAC 2220 AAACAAAGTA TGCTAAATGT CACTGTAAAT GGAGGAGGAA ATGTAACCGA GAAGCTAGAT 2280 CTTAACTGGT ACTTAGGAAT TTATTCAGGT TTAACTGTAG CTACCGTTCT TTTTGGCATA 2340 GCAAGATCTC TATTGGTATT CTACGTCCTT GTTAACTCTT CACAAACTTT GCACAACAAA 2400 ATGTTTGAGT CAATTCTGAA AGCTCCGGTA TTATTCTTTG ATAGAAATCC AATAGGAAGA 2460 ATTTTAAATC GTTTCTCCAA AGACATTGGA CACTTGGATG ATTTGCTGCC GCTGACGTTT 2520 TTAGATTTCA TCCAGACATT GCTACAAGTG GTTGGTGTGG TCTCTGTGGC TGTGGCCGTG 2580 ATTCCTTGGA TCGCAATACC CTTGGTTCCC CTTGGAATCA TTTTCATTTT TCTTCGGCGA 2640 TATTTTTTGG AAACGTCAAG AGATGTGAAG CGCCTGGAAT CTACAACTCG GAGTCCAGTG 2700 TTTTCCCACT TGTCATCTTC TCTCCAGGGG CTCTGGACCA TCCGGGCATA CAAAGCAGAA. 2760 GAGAGGTGTC AGGAACTGTT TGATGCACAC CAGGATTTAC ATTCAGAGGC TTGGTTCTTG 2820 TTTTTGACAA CGTCCCGCTG GTTCGCCGTC CGTCTGGATG CCATCTGTGC CATGTTTGTC 2880 ATCATCGTTG CCTTTGGGTC CCTGATTCTG GCAAAAACTC TGGATGCCGG GCAGGTTGGT 2940 TTGGCACTGT CCTATGCCCT CACGCTCATG GGGATGTTTC AGTGGTGTGT TCGACAAAGT 3000 GCTGAAGTTG AGAATATGAT GATCTCAGTA GAAAGGGTCA TTGAATACAC AGACCTTGAA 3060 AAAGAAGCAC CTTGGGAATA TCAGAAACGC CCACCACCAG CCTGGCCCCA TGAAGGAGTG 3120 ATAATCTTTG ACAATGTGAA CTTCATGTAC AGTCCAGGTG GGCCTCTGGT ACTGAAGCAT 3180 CTGACAGCAC TCATTAAATC ACAAGAAAAG GTTGGCATTG TGGGAAGAAC CGGAGCTGGA 3240 AAAAGTTCCC TCATCTCAGC CCTTTTTAGA TTGTCAGAAC CCGAAGGTAA AATTTGGATT 3300 GATAAGATCT TGACAACTGA AATTGGACTT CACGATTTAA GGAAGAAAAT GTCAATCATA 3360 CCTCAGGAAC CTGTTTTGTT CACTGGAACA ATGAGGAAAA ACCTGGATCC CTTTAATGAG 3420 CACACGGATG AGGAACTGTG GAATGCCTTA CAAGAGGTAC AACTTAAAGA AACCATTGAA 3480 GATCTTCCTG GTAAAATGGA TACTGAATTA GCAGAATCAG GATCCAATTT TAGTGTTGGA 3540 CAAAGACAAC TGGTGTGCCT TGCCAGGGCA ATTCTCAGGA AAAATCAGAT ATTGATTATT 3600 GATGAAGCGA CGGCAAATGT GGATCCAAGA ACTGATGAGT TAATACAAAA AAAAATCCGG 3660 GAGAAATTTG CCCACTGCAC CGTGCTAACC ATTGCACACA GATTGAACAC CATTATTGAC 3720 AGCGACAAGA TAATGGTTTT AGATTCAGGA AGACTGAAAG AATATGATGA GCCGTATGTT 3780 TTGCTGCAAA ATAAAGAGAG CCTATTTTAC AAGATGGTGC AACAACTGGG CAAGGCAGAA 3840 GCCGCTGCCC TCACTGAAAC AGCAAAACAG GTATACTTCA AAAGAAATTA TCCACATATT 3900 GGTCACACTG ACCACATGGT TACAAACACT TCCAATGGAC AGCCCTCGAC CTTAACTATT 3960 TTCGAGACAG CACTGTGA SEQ ID NO:42 PBH5 PROTEIN SEQUENCE Protein Accession # NP_005836 11 21 31 41 51 I I I I ML VYQEVKP NPLQDANLCS RVFFWWLNPL FKIGHKRRLE EDDMYSVLPE D IRSQHLGEEL 60 QGFWDKEVLR AENDAQKPSL TRAIIKCYWK SYLVLGIFTL IEESAKVIQP IFLGKIINYF 120 ENYDPMDSVA LNTAYAYATV LTFCTLILAI LHHLYFYHVQ CAGMRLRVAM CHMIYRKALR 180 LSNMAMGKTT TGQIVNLLSN DVNKFDQVTV FLHFLWAGPL QAIAVTALLW MEIGISCLAG 240 MAVLIILLPL QSCFGKLFSS LRSKTATFTD ARIRTMNEVI TGIRIIKMYA WEKSFSNLIT 300 NLRKKEISKI LRSSCLRGMN LASFFSASKI ΓVFVTFTTYV LLGSVITASR VFVAVTLYGA 360 VRLTVTLFFP SAIERVSEAI VSIRRIQTFL LLDEISQRNR QLPSDGKKMV HVQDFTAFWD 420 KASETPTLQG LSFTVRPGEL LAWGPVGAG KSSLLSAVLG ELAPSHGLVS VHGRIAYVSQ 480 QPWVFSGTLR SNILFGKKYE KERYEKVIKA CALKKDLQLL EDGDLTVIGD RGTTLSGGQK 540 ARVNLARAVY QDADIYLLDD PLSAVDAEVS RHLFELCICQ ILHEKITILV THQLQYLKAA 600 SQILILKDGK MVQKGTYTEF LKSGIDFGSL LKKDNEESEQ PPVPGTPTLR NRTFSESSVW 660 SQQSSRPSLK DGALESQDTE NVPVTLSEEN RSEGKVGFQA YKNYFϊlAGAH WIVFIFLILL 720 NTAAQVAYVL QDWWLSYWAN KQSMLNVTVN GGGNVTEKLD LNWYLGIYSG LTVATVLFGI 780 ARSLLVFYVL VNSSQTLHNK MFESILKAPV LFFDRNPIGR ILNRFSKDIG HLDDLLPLTF 840 LDFIQTLLQV VGWSVAVAV IPWIAIPLVP LGIIFIFLRR YFLETSRDVK RLESTTRSPV 900 FSHLSSSLQG LWTIRAYKAE ERCQELFDAH QDLHSEAWFL FLTTSRWFAV RLDAICAMFV 960 IIVAFGSLIL AKTLDAGQVG LALSYALTLM GMFQWCVRQS AEVENMMISV ERVIEYTDLE 1020 KEAPWEYQKR PPPAWPHEGV IIFDNVNFMY SPGGPLVLKH LTALIKSQEK VGIVGRTGAG 1080 KSSLISALFR LSEPEGKIWI DKILTTEIGL HDLRKKMSII PQEFVLFTGT MRKNLDPFNE 1140 HTDEELWNAL QEVQLKETIE DLPGKMDTEL AESGSNFSVG QRQLVCLARA ILRKNQILII 1200 DEATANVDPR TDELIQKKIR EKFAHCTVLT IAHRLNTIID SDKIMVLDSG RLKEYDEPYV 1260 LLQNKESLFY KMVQQLGKAE AAALTETAKQ VYFKRNYPHI GHTDHMVTNT SNGQPSTLTI 1320 FETAL SEQ ID N0.43 PBQ7 DNA SEQUENCE Nucleic Acid Accession* NM_021233 Coding sequence 34-1119 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I ATGGGGAAAG TGTCCTGCTG TGGCATGAAA TAAATGAAAC AGAAAATGAT GGCAAGACTG 60 CTAAGAACAT CCTTTGCTTT GCTCTTCCTT GGCCTCTTTG GGGTGCTGGG GGCAGCAACA 120 ATTTCATGCA GAAATGAAGA AGGGAAAGCT GTGGACTGGT TTACTTTTTA TAAGTTACCT 180 AAAAGACAAA ACAAGGAAAG TGGAGAGACT GGGTTAGAGT ACCTGTACCT AGACTCTACA 240 ACTAGAAGCT GGAGGAAGAG TGAGCAACTA ATGAATGACA CCAAGAGTGT TTTGGGAAGG 3 00 ACATTACAAC AGCTATATGA AGCATATGCC TCTAAGAGTA ACAACACAGC CTATCTAATA 360 TACAATGATG GAGTCCCTAA ACCTGTGAAT TACAGTAGAA AGTATGGACA CACCAAAGGT 420 TTACTGCTGT GGAACAGAGT TCAAGGGTTC TGGCTGATTC ATTCCATCCC TCAGTTTCCT 480 CCAATTCCGG AAGAAGGCTA TGATTATCCA CCCACAGGGA GACGAAATGG ACAAAGTGGC 540 ATCTGCATAA CTTTCAAGTA CAACCAGTAT GAGGCAATAG ATTCTCAGCT CTTGGTCTGC 600 AACCCCAACG TCTATAGCTG CTCCATCCCA GCCACCTTTC ACCAGGAGCT CATTCACATG 660 CCCCAGCTGT GCACCAGGGC CAGCTCATCA GAGATTCCTG GCAGGCTCCT CACCACACTT 720 CAGTCGGCCC AGGGACAAAA ATTCCTCCAT TTTGCAAAGT CGGATTCTTT TCTTGACGAC 780 ATCTTTGCAG CCTGGATGGC TCAACGGCTG AAGACACACT TGTTAACAGA AACCTGGCAG 840 CGAAAAAGAC AAGAGCTTCC TTCAAACTGC TCCCTTCCTT ACCATGTCTA CAATATAAAA 900 GCAATTAAAT TATCACGACA CTCTTATTTC AGTTCTTATC AAGATCACGC CAAGTGGTGT 960 ATTTCCCAAA AGGGCACCAA AAATCGCTGG ACATGTATTG GAGACCTAAA TCGGAGTCCA 1020 CACCAAGCCT TCAGAAGTGG AGGATTCATT TGTACCCAGA ATTGGCAAAT TTACCAAGCA 1080 TTTCAAGGAT TAGTATTATA CTATGAAAGC TGTAAGTAAA CTTGGTGAAA GGACACAGGT SEQ ID NO:44 PBQ7 Protein sequence Protein Accession* NP_067056 1 11 21 31 41 51 I I I I I I - MMARLLRTSF ALLFLGLFGV LGAATISCRN EEGKAVDWFT FYKLPKRQNK ESGETGLEYL 60 YLDSTTRSWR KSEQLMNDTK SVLGRTLQQL YEAYASKSNN TAYLIYNDGV PKPVNYSRKY 120 GHTKGLLLWN RVQGFWLIHS IPQFPPIPEE GYDYPPTGRR NGQSGICITF KYNQYEAIDS 180 QLLVCNPNVY SCSIPATFHQ ELIHMPQLCT RASSSEIPGR LLTTLQSAQG QKFLHFAKSD 240 SFLDDIFAAW MAQRLKTHLL TETWQRKRQE LPSNCSLPYH VYNIKAIKLS RHSYFSSYQD 300 HAKWCISQKG TKNRWTCIGD LNRSPHQAFR SGGFICTQNW QIYQAFQGLV LYYESCK SEQ ID N0.45 PCQ8 DNA SEQUENCE Nucleic Acid Accession* XM_030453 Coding sequence 89-1273 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I CGGTGCCCTG GGGTGGAATA TCCCCTACGA ATTTAACCAA GCGGACTTTA ATGCCACTGT 60 GCAGTTCATC CAAAACCACT TGGATGACAT GGATGTCAAA AAGGGTGTCT CCTGGACCAC 120 CATCCGCTAC ATGATAGGAG AGATTCAATA TGGAGGCAGA GTCACTGACG ACTATGATAA 180 GAGATTGTTG AACACATTTG CTAAGGTTTG GTTCAGTGAA AATATGTTTG GACCAGATTT 240 CAGTTTTTAC CAAGGATACA ATATTCCAAA ATGCAGCACA GTGGATAACT ATCTTCAGTA 300 TATCCAGAGT TTGCCTGCCT ATGACAGCCC TGAGGTGTTT GGGCTGCACC CCAATGCTGA 360 CATCACCTAC CAGAGCAAGC TGGCCAAGGA CGTGCTGGAC ACCATCCTAG GCATCCAACC 420 CAAGGACACC TCTGGTGGAG GGGATGAGAC CCGGGAGGCG GTGGTGGCCC GGCTGGCTGA 480 TGATATGCTG GAGAAGCTGC CCCCAGACTA TGTCCCCTTT GAAGTAAAAG AGAGGCTGCA 540 GAAGATGGGG CCATTCCAGC CTATGAACAT TTTCCTCAGG CAGGAAATAG ACAGAATGCA 600 AAGGGTACTC AGCCTTGTCC GCAGCACCCT CACTGAGCTG AAACTTGCTA TTGATGGCAC 660 CATCATCATG AGCGAAAATC TGCAAGATGC ATTGGATTGC ATGTTTGATG CTAGAATCCC 720 TGCTTGGTGG AAAAAAGCTT CTTGGGTTTT TAGTACACTG GGTTTCTGGT TTACTGAACT 780 TATAGAAAGA AACAGCCAGT TTACCTCGTG GGTTTTCAAT GGCCGACCTC ACTGCTTTTG 840 GATGACGGGT TTTTTTAACC CCCAGGGATT TTTAACTGCA ATGCGACAGG AAATAACTCG 900 GGCCAACAAA GGCTGGGCTC TGGACAATAT GGTGCTTTGC AATGAAGTCA CCAAATGGAT 960 GAAGGACGAC ATTTCTACCC CTCCCACAGA GGGTGTCTAT GTCTATGGCT TATATCTTGA 1020 AGGTGCTGGC TGGGACAAGA GGAACATGAA ACTCATTGAA TCAAAGCCAA AAGTGCTCTT 1080 TGAGTTGATG CCTGTCATAA GGATTTATGC AGAAAACAAT ACTTTACGAG ATCCTCGGTT 1140 TTACTCCTGT CCCATCTATA AGAAGCCAGT TCGAACGGAC TTGAACTACA TTGCCGCTGT 1200 GGATCTCAGG ACAGCCCAGA CCCCTGAACA CTGGGTGCTC CGTGGGGTTG CCCTTCTCTG 1260 TGATGTCAAG TAACATGTGG GGAGTGTCCC CACCCAATGC TTTGGAAAAT GCAAGATCTA 1320 AATTATTGTA ACCTTTATTT CTGTATGACT GCTGGACAGT GTATGTTAGG TCGTTTATGC 1380 AATTAATGAG CTGCATAGGT TTTCCCCACT CCTTAATTGG ATGCTTATAT TTTACTTGTT 1440 TCATCATTAG TGACCAATGT CTGAGTTTGT TGAAAATGTT ATTTAGTGAT ATAAAAGTAA 1500 ATTTACAGCA TCCTAATGAA GTGTGGCCCT CAAATCCACA GTAGTATATT TTCTTCTTAC 1560 TTCGCTCCGA AGACTGACTG TGATTATAAC AGCAAATATA TTTGCATGTG GACAAAGATT 1620 AGATGGCAAG ATAGAAAAAT AAGAACAGAT GTGATAGCAA GAATTATAGT TGGCTTGAAA 1680 AAATGTGATG ATCAGGAGAA AAAATAAAAA AAGGGTAGAA ATATTAGACG GTGCGTAGGG 1740 ACTTTCTATG GACTTTTATT AATTAGGAAA CATTATCAAA GGAACTTTTC ACGTATTTTT 1800 CTTTAAATTC TGGTTAGATG TTATTAATAA TTCTTCATCT AACCTACTGA CTAGAAAATA 1860 TAGTCAGTAC TAAATTAGAA TTGTGGTTTA TAAACTTTTG GTTAGCTCTG GATCTGTATA 1920 ACTGCATTTT TTTGGATAAA CAGTTTTTGG TAGGTGGATA CCGGGAGACA AGTGTGGGTC 1980 CCTCTCACTG GGCTTCATTC TGTGGACCAG GATCATTATT TCATGCTCAT GATCATGAGA 2040 GTTAGGACTG AGTGGCTCCT GTGACTCCCA CCATCTTAGA TGATACTGTT TTCTTGTGAG 2100 TTCTTTCTTT TGGTGTGGAT TAGTATATCA GTTGATTTGT GTGAATTGTG GTGAAACAAT 2160 CATTTCATTT TGAAAAGCAA GTAATGAAAA TGTCAGCATC ATAGGAATTA ATAAAATGTT 2220 TTTACTAAAA AAAAAAAAAA AAA SEQ ID NO: 46 PCQ8 Protein sequence Protein Accession * BAB 15543 1 11 21 31 41 51 l l l l MDVKKGVSWT TIRYMIGEIQ YGGRVTDDYD KRLLNTFAKV WFSENMFGPD FΞFYQGYNIP 60 KCSTVDNYLQ YIQSLPAYDS PEVFGLHPNA DITYQSKLAK DVLDTILGIQ PKDTSGGGDE 120 TREAWARLA DDMLEKLPPD YVPFEVKERL QKMGPFQPMN IFLRQEIDRM QRVLSLVRST 180 LTELKLAIDG TIIMSENLQD ALDCMFDARI PAWWKKASWV FSTLGFWFTE LIERNSQFTS 240 WVFNGRPHCF WMTGFFNPQG FLTAMRQEIT RANKGWALDN MVLCNEVTKW MKDDISTPPT 300 EGVYVYGLYL EGAGWDKRNM KLIESKPKVL FELMPVIRIY AENNTLRDPR FYSCPIYKKP 360 VRTDLNYIAA VDLRTAQTPE HWVLRGVALL CDVK SEQ ID NO:47 PDG5 DNA SEQUENCE Nucleic Acid Accession* AB033036 Coding sequence: 68-3349 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I GGAGCAGCCT ACAACTTCAC AACCAGAAAC CACTACCCCT CAGGGGTTGC TTTCAGATAA 60 AGATGACATG GGAAGGAGAA ATGCTGGCAT AGATTTCGGA TCCAGAAAAG CATCAGCAGC 120 ACAGCCCATA CCTGAAAACA TGGACAATTC CATGGTTAGT GATCCACAAC CATACCATGA 180 AGATGCAGCT TCTGGAGCTG AGAAGACAGA AGCCAGAGCT TCTCTCTCAC TGATGGTGGA 240 AAGCCTTTCT ACAACCCAAG AGGAGGCCAT TCTCTCAGTA GCAGCAGAGG CTCAGGTGTT 300 TATGAATCCT TCTCATATCC AGTTAGAAGA TCAAGAAGCT TTCAGCTTTG ATTTACAAAA 360 GGCCCAATCC AAAATGGAGT CAGCCCAGGA TGTTCAAACT ATCTGCAAAG AAAAGCCTTC 420 TGGAAATGTT CACCAGACCT TTACAGCAAG TGTTTTGGGT ATGACAAGTA CTACAGCCAA 480 AGGAGATGTT TATGCCAAGA CTCTGCCTCC CAGAAGCCTT TTTCAGTCCT CAAGGAAGCC 540 TGATGCTGAA GAAGTCTCCT CAGATTCAGA GAATATTCCT GAGGAGGGGG ATGGTTCTGA 600 AGAACTGGCT CATGGTCACT CTTCCCAGTC CTTGGGGAAG TTTGAAGATG AACAAGAAGT 660 CTTCTCAGAA TCAAAAAGTT TTGTTGAGGA CTTGAGCAGC TCTGAGGAGG AGCTGGACCT 720 CAGATGCCTC TCCCAGGCTT TAGAGGAGCC TGAAGATGCA GAAGTCTTCA CAGAATCAAG 780 CAGTTATGTT GAAAAGTACA ACACTTCTGA TGATTGCAGC AGCTCAGAGG AAGACCTGCC 840 TCTCAGACAC CCTGCTCAGG CCTTGGGAAA GCCCAAAAAC CAACAAGAAG TCTCCTCTGC 900 TTCAAATAAT ACTCCTGAAG AGCAGAATGA TTTTATGCAG CAGCTGCCTT CCAGATGCCC 960 TTCTCAGCCC ATTATGAATC CTACTGTTCA GCAACAAGTC CCCACCAGTT CAGTGGGCAC 1020 TTCTATAAAA CAGAGCGATT CCGTGGAGCC AATCCCTCCA AGACACCCTT TCCAGCCATG 1080 GGTGAACCCT AAAGTGGAGC AAGAAGTTTC CTCATCTCCA AAGAGCATGG CTGTTGAAGA 1140 GAGCATTTCT ATGAAGCCTC TGCCTCCTAA ACTTCTTTGC CAGCCCTTGA TGAATCCTAA 1200 AGTTCAACAA AACATGTTCT CAGGTTCAGA GGACATTGCT GTTGAGAGAG TCATTTCTGT 1260 GGAGCCACTA CTCCCCAGAT ATTCTCCTCA GTCCTTGACA GATCCTCAAA TCCGGCAAAT 1 3 20 CTCAGAAAGC ACAGCTGTTG AGGAAGGCAC TTATGTGGAA CCGCTGCCTC CCAGATGCCT 1380 TTCCCAGCCC TCGGAGAGGC CTAAGTTCCT GGACTCAATG AGTACTTCTG CAGAATGGAG 1440 CAGTCCTGTG GCACCAACAC CTTCCAAATA CACTTCCCCG CCATGGGTGA CCCCTAAATT 1500 TGAGGAACTG TATCAACTCT CTGCACATCC AGAAAGCACT ACTGTTGAAG AGGACATTTC 1560 TAAGGAGCAG CTGCTTCCCA GACATCTTTC CCAGTTGACT GTGGGAAATA AAGTCCAGCA 1620 ACTGTCCTCA AATTTCGAGC GGGCTGCTAT TGAGGCAGAC ATTTCTGGGA GTCCATTGCC 1680 TCCCCAATAT GCTACCCAGT TCTTAAAGAG GTCTAAAGTT CAGGAAATGA CCTCACGACT 1740 AGAGAAAATG GCTGTTGAAG GCACTTCTAA CAAATCACCG ATTCCCAGGC GTCCGACCCA 1800 GTCATTCGTG AAATTTATGG CACAGCAAAT CTTTTCAGAG AGCTCTGCTC TTAAGAGGGG 1860 CAGTGATGTG GCACCTCTGC CTCCCAATCT TCCTTCCAAA TCTTTATCAA AGCCTGAAGT 1920 CAAGCACCAA GTTTTCTCAG ATTCAGGGAG TGCTAATCCT AAGGGAGGCA TTTCTTCAAA 1980 GATGCTACCT ATGAAGCACC CTTTACAGTC CTTGGGGAGG CCTGAAGACC CACAGAAAGT 2040 TTTCTCTTAT TCAGAGAGAG CTCCTGGGAA GTGCAGCAGT TTTAAAGAGC AGCTGTCTCC 2100 CAGGCAGCTT TCCCAGGCCT TGAGGAAACC TGAGTATGAG CAAAAAGTCT CCCCTGTTTC 2160 TGCCAGTTCT CCTAAAGAGT GGAGGAATTC TAAAAAGCAG CTGCCTCCCA AACATTCTTC 2220 10 CCAAGCCTCA GATAGGTCTA AATTCCAGCC ACAGATGTCA TCAAAGGGCC CAGTGAATGT 2280 ACCTGTAAAG CAGAGCAGCG GTGAGAAGCA CCTGCCTTCA AGTAGTCCTT TCCAGCAACA 2340 GGTTCATTCA AGTTCTGTGA ATGCTGCTGC TAGGCGATCT GTTTTTGAGA GCAATTCTGA 2400 CAATTGGTTC CTAGGAAGAG ATGAAGCTTT TGCAATCAAA ACCAAGAAAT TCAGCCAAGG 2460 TTCCAAAAAC CCCATAAAGA GCATTCCAGC CCCTGCTACC AAACCTGGGA AGTTCACCAT 2520 15 TGCTCCTGTC AGGCAAACAT CCACTTCTGG GGGCATTTAC TCTAAGAAAG AAGATCTTGA 2580 GAGTGGTGAT GGTAATAATA ACCAGCATGC AAACCTATCC AATCAGGATG ATGTTGAAAA 2640 GCTTTTTGGA GTTCGACTGA AAAGAGCCCC TCCCTCGCAG AAGTATAAGA GTGAGAAACA 2700 AGATAACTTC ACCCAGCTTG CTTCAGTGCC CTCGGGCCCA ATTTCATCCT CTGTAGGCAG 2760 GGGACATAAA ATCAGAAGCA CTTCCCAGGG GCTCCTGGAT GCTGCAGGGA ACCTCACCAA 2820 20 AATATCTTAC GTTGCAGATA AGCAACAGAG CAGGCCCAAA TCTGAAAGCA TGGCCAAGAA 2880 GCAACCTGCT TGCAAGACCC CAGGAAAGCC TGCTGGTCAA CAGTCAGATT ATGCTGTCTC 2940 AGAGCCGGTT TGGATAACTA TGGCAAAGCA GAAGCAGAAG AGTTTCAAGG CCCACATTTC 3000 TGTGAAAGAG CTGAAAACTA AGAGCAATGC TGGAGCCGAT GCTGAGACTA AGGAGCCTAA 3060 ATATGAGGGA GCTGGCTCTG CAAATGAAAA CCAACCTAAA AAGATGTTCA CTTCCAGTGT 3120 25 CCATAAACAG GAGAAGACAG CACAGATGAA GCCACCTAAG CCTACAAAAT CAGTTGGATT 3180 TGAAGCTCAG AAGATACTGC AAGTTCCTGC CATGGAAAAA GAAACCAAAC GATCTTCAAC 3240 TCTCCCAGCC AAGTTCCAGA ACCCAGTTGA GCCAATTGAG CCTGTCTGGT TCTCACTGGC 3300 CAGGAAGAAA GCCAAAGCAT GGAGCCACAT GGCAGAAATC ACGCAATAAA GAGCTCTTGT 3360 GTGGAGCATC AGCATTTATT TTATTTAGTT TTTTTTTTTT TTTTTTTTTT GAGACAGAGT 3420 30 CTCGCTCTGT TACCCAGATT GGAGTGCAGT GGCGCGATCT CCGCTCACTG CAAGCTCCGC 3 480 CTCCCGGGTT CACGCCACTC TCCCGCCTCA GTCTCCCGAC TAGCTGGGAC TACAGGCGCC 3 540 CGCCATCACG CCCGGCTAAT TTTGTTTTCG TATTTTTAGT AGAGACGGGG TTTCACCATG 3600 TTGGCCAGGA TGGTCTTGAT CTCCTGACCT CGTGATCCGC CCGCCTCAGC CTCCCAAAAG 3660 CTGGGATTAC AGGCGTGAGC CACCGCGCCC GGCCAAGCAT CAGCGTTTTA AATGATAATT 3720 35 GCTAATAGCT GTATTAATTC TATGTAGTGA TCTTTTTACT GTGACCACTT GTATTAAGCA 3780 AAATAAGTAT TAAGCAAACT AAGAATTTAT TAAGCAAAAT AAGAATTTAT TAAGCAAAAT 3 840 AGCCTTAGAA ATGCAAATTA AAACATAATT ATTTGAATGA AATAAATGCC ATGAATGCTT 3 900 AACCTTCCAC GTAGTCACTG CCAGCACCCA GAAACCCAGC ATTTCCTCTA TTAAAACTAT 3 960 CGAAAACATT TGCACTGCTG TAAAATTGCA AAATCTTTAA CTTTGGACAA TGTGCTTTAG 4020 40 AAGGGAGAAA GCAAAAACAT TTTGTTGGAG CAACTAGAAA ATTGTCATTT CCCTCAACCA 4080 AATAAAGTAA TTCTAATGGA AACATTCAGA TGATTTGACC TAAAGATTGβ CCTTTAGGTT 4140 TTATGAGCCT AGATAGATGC CGCAATTATT TGGTTGTTGC TCTAAGCTTT GCAAGGGATC 4200 CTAAAAGAGG CGGTGGAAGT GAAAATTCTG GGTCTCCAAG AAAATTTCTG CACAGCCAGT 4260 TCTCCAATCA GCCTATCACC CCTTGAAACA TCTTCCCTGT GTCCCTGGGG GCCCCTGATG 4320 45 CTTTCTCCTT GGGTGATAGT AACATGCAGA GCACTTACAC AAAGCTCCCT CTTTGGACAT 4380 ACCCCACGTC GACCTGTCAC AGGCCTGGCT GTAGCGAGCA CCTCCCTATG ACGCAGAATG 4440 CTTCTTGGGA ATTATCTTAC TCCTCTGGAG GGTTAGTCCA TCAATGTTTT GCTTCTTGTC 4500 CCAATACTAC TGTGACCCTC TCTGATCGCA CAGAAATCAC TGCCTATCAC ATATATCCTG 4560 TTAAGCACTG AAGACCCTAT TGAAATTAGA GTTCTACAGA TGCCAAAAGC TGTACTTTCC 4620 50 ATCAGGCAGA TGGCAAGCTT ACTGCCTTGA TGCACATCTβ GAGCCACTGG AGCTCCTTCC 4680 TCTCTGGTTC CAGCATTAAG GTGGAGAACT CCATGTAGCT TCTTGTCCTT TCCCCTCAGC 4740 TGTCTTTGCT TCACAAGGTT TTAGCCCAAA GCAAGAGTGC AATCCCAAAG CCACAGAGAA 4800 ATGAACTTTC CGCTACCTGG AAGCTTTAAG TGAGTAAATC AGCTTTTCCC CTCTCATTCC 4860 TAGAGGCACA CACCTCAAAA GTTACTAGGC TGGAGAGACC CTACCTTCCA GTGACCCACT 4920 55 CATCCCCCAG CCACGGAGAA GAGGGAAGAC CAAAAAGGGA GAGTGAGAAA GAGGATGAGA 4980 GGGATGGTCA GCTGTGAGGG GAGGGGGCAA GTGGCCCAGC AAATGTTGAT GCCTCCCTTC 5040 CCATCTTGCC ACACGGTCTT TTTCTTTTGT AGCACAGCCT CCATTAATAA CTCCTCGGCT 5100 GAGGATGAAG ATGTAGGCAC CTTTACCCCC AGAGCCAGTT CCTTAATTGG CTGGCTTTCT 5160 GAGATGCAGA CCACCCTAGA ATCTCATCTA GGTTCACTAG AAGTTAGTTA AATCTTCCTT 5220 60 TCTCTGTCTT TCTCTTCATT CCATCCCCCA AACCCACCAA ACACTAAGGG AGAGCTCCCT 5280 TTGGATGTCT GGGCAGTAAA CCTAGCTCAT TTTTCTAGGA GACCCAGAAG TGACTTCTGA 5340 GTAGTTATCA CTGTGTCTGC CTCTGTTACA CTGTGCTGCT TTGCTTAAAC AGAAATGCAG 5400 GCCTGGACAT CTGACTGTGC CTTTATATTC TGAGTGGGGT GCTGCCCCAT GCAAAAAAAT 5460 CCAGAGAGGT AGTGAGGTGT CAGAGCTAAA CACTTGGTGC TGGGTTTTGT TGATGCTGGT 5520 65 ATAATGTGAC ACAGTACAAT TACATGCTAA ATTTTGCATT TTCTCTATAT AACATCTATT 5580 TTTCCTGATA CTGTGCCTTT GCCATTTTGA TAATGCTATT TTGATTGAGT GAATTTTATT 5640 TCCTTTGTAT TCCCATAGTG AACAATATAT TAAGGTAGAT GCCCTTTATC TGGGTACTCC 5700 TGGTAGATTA GCTGTTACAC CTCCCTTCCC TTTTTTACAG TGAACCTGTA TTCAGTTATT 5760 GTCACTCTGA GAACTCTCCA ATAACAATTT CTTTTCCACA GTTAACAACA CAGCTGTTAC 5820 70 ACCTCCCTTC CTTTTTTTCA CAGTGAACCT GTATTCAGCT ATTCTCACTC TGAGAACTCT 5880 CCAATAACAA TTTCTTTTCC ACAGTTAACA ACAAAGTTCT GTTTTTAAAT GAAGAGATTA 5940 AGTTCTTTTT AAATGCCTAA AGGCATATTC TGACAACTTT TCTACTTCTT TAACTTTTTT 6000 GATTTAAGAT ATATGCAAAG CAAATAAATT CAATAAAGCC T 75 SEQ ID NO:48 PDG5 Protein sequence Protein Accession* BAA86524 1 11 21 31 41 51 θ anU E IQPTTSQPET T ITPQGLLSDK D IDMGRRNAGI D IFGSRKASAA Q IPIPENMDNS M 'VSDPQPYHE 60 DAASGAEKTE ARASLSLMVE SLSTTQEEAI LSVAAEAQVF MNPSHIQLED QEAFSFDLQK 120 AQSKMESAQD VQTICKEKPS GNVHQTFTAS VLGMTSTTAK GDVYAKTLPP RSLFQSSRKP 180 DAEEVSSDSE NIPEEGDGSE ELAHGHSSQS LGKFEDEQEV FSESKSFVED LSSSEEELDL 240 RCLSQALEEP EDAEVFTESS SYVEKYNTSD DCSSSEEDLP LRHPAQALGK PKNQQEVSSA 300 SNNTPEEQND FMQQLPSRCP SQPIMNPTVQ QQVPTSSVGT SIKQSDSVEP IPPRHPFQPW 360 VNPKVEQEVS SSPKSMAVEE SISMKPLPPK LLCQPLMNPK VQQNMFSGSE DIAVERVISV 420 EPLLPRYSPQ SLTDPQIRQI SESTAVEEGT YVEPLPPRCL SQPSERPKFL DSMSTSAEWS 480 SPVAPTPSKY TSPPWVTPKF EELYQLSAHP ESTTVEEDIS KEQLLPRHLS QLTVGNKVQQ 540 LSSNFERAAI EADISGSPLP PQYATQFLKR SKVQEMTSRL EKMAVEGTSN KSPIPRRPTQ 600 SFVKFMAQQI FSESSALKRG SDVAPLPPNL PSKSLSKPEV KHQVFSDSGS ANPKGGISSK 660 MLPMKHPLQS LGRPEDPQKV FSYSERAPGK CSSFKEQLSP RQLSQALRKP EYEQKVSFVS 720 ASSPKEWRNS KKQLPPKHSS QASDRSKFQP QMSSKGPVNV PVKQSSGEKH LPSSSPFQQQ 780 VHSSSVNAAA RRSVFESNSD NWFLGRDEAF AIKTKKFSQG SKNPIKSIPA PATKPGKFTI 840 AFVRQTSTSG GIYSKKEDLE SGDGNNNQHA NLSNQDDVEK LFGVRLKRAP PSQKYKSEKQ 900 DNFTQLASVP SGPISSSVGR GHKIRSTSQG LLDAAGNLTK ISYVADKQQS RPKSESMAKK 960 QPACKTPGKP AGQQSDYAVS EPVWITMAKQ KQKSFKAHIS VKELKTKSNA GADAETKEPK 1020 YEGAGSANEN QPKKMFTSSV HKQEKTAQMK PPKPTKSVGF EAQKILQVPA MEKETKRSST 1080 LPAKFQNFVE PIEPVWFSLA RKKAKAWSHM AEITQ SEQ ID NO:49 PAB7 DNA SEQUENCE Nucleic Acid Accession*: D87742 Coding sequence: 208-3582 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I GCTTTCCTTT CTAAAGTAGA AGAGGATGAT TATCCCTCTG AAGAACTACT AGAGGATGAA 60 AACGCTATAA ATGCAAAACG GTCTAAAGAA AAAAACCCTG GGAATCAGGG CAGGCAGTTT 120 GATGTTAATC TGCAAGTCCC TGACAGAGCA GTTTTAGGGA CCATTCATCC AGATCCAGAA 180 ATTGAAGAAA GCAAGCAAGA AACTAGTATG ATTTTGGATA GTGAAAAAAC AAGTGAGACT 240 GCTGCCAAAG GGGTCAACAC AGGAGGCAGG GAACCAAATA CAATGGTGGA AAAAGAACGC 300 CCTCTGGCAG ATAAGAAAGC ACAGAGACCA TTTGAACGAA GTGACTTTTC TGACAGCATA 3 60 AAAATTCAGA CTCCAGAATT AGGTGAAGTG TTTCAGAATA AAGATTCTGA TTATCTGAAβ 420 AACGACAACC CTGAGGAACA TCTGAAGACC TCAGGGCTTG CAGGGGAGCC TGAGGGAGAA 480 CTCTCAAAAG AGGACCATGG GAACACAGAG AAGTACATGG GCACAGAAAG CCAGGGGTCT 540 GCTGCTGCAG AACCTGAAGA TGACTCGTTC CACTGGACTC CACATACAAG TGTAGAGCCA 600 GGGCATAGTG ACAAGAGGGA GGACTTACTT ATCATAAGCA GCTTCTTTAA AGAACAACAG 660 TCTTTGCAGC GGTTCCAGAA GTACTTTAAT GTCCATGAGC TGGAAGCCTT GCTACAAGAA 720 ATGTCATCAA AACTGAAGTC AGCGCAGCAG GAGAGCCTGC CCTATAATAT GGAAAAAGTC 780 CTAGATAAGG TCTTCCGTGC TTCTGAGTCA CAAATTCTGA GCATAGCAGA AAAAATGCTT 840 GATACTCGTG TGGCTGAAAA TAGAGATCTG GGAATGAACG AAAATAACAT ATTTGAAGAG 900 GCTGCAGTGC TTGATGACAT TCAAGACCTC ATCTATTTTG TCAGGTACAA GCACTCCACA 960 GCAGAGGAGA CAGCCACACT GGTGATGGCA CCACCTCTAG AGGAAGGCTT GGGTGGAGCA 1020 ATGGAAGAGA TGCAACCACT GCATGAAGAT AATTTCTCAC GAGAGAAGAC AGCAGAACTT 1080 AATGTGCAGG TTCCTGAAGA ACCCACCCAC TTGGACCAAC GTGTGATTGG GGACACTCAT 1140 GCCTCAGAAG TGTCACAGAA GCCAAATACT GAGAAAGACC TGGACCCAGG GCCAGTTACA 1200 ACAGAAGACA CTCCTATGGA TGCTATTGAT GCAAACAAGC AACCAGAGAC AGCCGCCGAA 1260 GAGCCGGCAA GTGTCACACC TTTGGAAAAC GCAATCCTTC TAATATATTC ATTCATGTTT 1320 TATTTAACTA AGTCGCTAGT TGCTACATTG CCTGATGATG TTCAGCCTGG GCCTGATTTT 1380 TATGGACTGC CATGGAAACC TGTATTTATC ACTGCCTTCT TGGGAATTGC TTCGTTTGCC 1440 ATTTTCTTAT GGAGAACTGT CCTTGTTGTG AAGGATAGAG TATATCAAGT CACGGAACAG 1500 CAAATTTCTG AGAAGTTGAA GACTATCATG AAAGAAAATA CAGAACTTGT ACAAAAATTG 1560 TCAAATTATG AACAGAAGAT CAAGGAATCA AAGAAACATG TTCAGGAAAC CAGGAAACAA 1620 AATATGATTC TCTCTGATGA AGCAATTAAA TATAAGGATA AAATCAAGAC ACTTGAAAAA 1680 AATCAGGAAA TTCTGGATGA CACAGCTAAA AATCTTCGTG TTATGCTAGA ATCTGAGAGA 1740 GAACAGAATG TCAAGAATCA GGACTTGATA TCAGAAAACA AGAAATCTAT AGAGAAGTTA 1800 AAGGATGTTA TTTCAATGAA TGCCTCAGAA TTTTCAGAGG TTCAGATTGC ACTTAATGAA 1860 GCTAAGCTTA GTGAAGAGAA GGTGAAGTCT GAATGCCATC GGGTTCAAGA AGAAAATGCT 1920 AGGCTTAAGA AGAAAAAAGA GCAGTTGCAG CAGGAAATCG AAGACTGGAG TAAATTACAT 1980 GCTGAGCTCA GTGAGCAAAT CAAATCATTT GAGAAGTCTC AGAAAGATTT GGAAGTAGCT 2040 CTTACTCACA AGGATGATAA TATTAATGCT TTGACTAACT GCATTACACA GTTGAATCTG 2100 TTAGAGTGTG AATCTGAATC TGAGGGTCAA AATAAAGGTG GAAATGATTC AGATGAATTA 2160 GCAAATGGAG ■AAGTGGGAGG TGACCGGAAT GAGAAGATGA AAAATCAAAT TAAGCAGATG 2220 ATGGATGTCT CTCGGACACA GACTGCAATA TCGGTAGTTG AAGAGGATCT AAAGCTTTTA 2280 CAGCTTAAGC TAAGAGCCTC CGTGTCCACT AAATGTAACC TGGAAGACCA GGTAAAGAAA 2340 TTGGAAGATG ACCGCAACTC ACTACAAGCT GCCAAAGCTG GACTGGAAGA TGAATGCAAA 2400 ACCTTGAGGC AGAAAGTGGA GATTCTGAAT GAGCTCTATC AGCAGAAGGA GATGGCTTTG 2460 CAAAAGAAAC TGAGTCAAGA AGAGTATGAA CGGCAAGAAA GAGAGCACAG GCTGTCAGCT 2520 GCAGATGAAA AGGCAGTTTC GGCTGCAGAG GAAGTAAAAA CTTACAAGCG GAGAATTGAA 2580 GAAATGGAGG ATGAATTACA GAAGACAGAG CGGTCATTTA AAAACCAGAT CGCTACCCAT 2640 GAGAAGAAAG CTCATGAAAA CTGGCTCAAA GCTCGTGCTG CAGAAAGAGC TATAGCTGAA 2700 GAGAAAAGGG AAGCTGCCAA TTTGAGACAC AAATTATTAG AATTAACACA AAAGATGGCA 2760 ATGCTGCAAβ AAGAACCTGT GATTGTAAAA CCAATGCCAG GAAAACCAAA TACACAAAAC 2820 CCTCCACGGA GAGGTCCTCT GAGCCAGAAT GGCTCTTTTG GCCCATCCCC TGTGAGTGGT 2880 GGAGAATGCT CCCCTCCATT GACAGTGGAG CCACCCGTGA GACCTCTCTC TGCTACTCTC 2940 AATCGAAGAG ATATGCCTAG AAGTGAATTT GGATCAGTGG ACGGGCCTCT ACCTCATCCT 3000 CGATGGTCAG CTGAGGCATC TGGGAAACCC TCTCCTTCTG ATCCAGGATC TGGTACAGCT 3060 ACCATGATGA ACAGCAGCTC AAGAGGCTCT TCCCCTACCA GGGTACTCGA TGAAGGCAAG 3120 GTTAATATGG CTCCAAAAGG GCCCCCTCCT TTCCCAGGAG TCCCTCTCAT GAGCACCCCC 3180 ATGGGAGGCC CTGTACCACC ACCCATTCGA TATGGACCAC CACCTCAGCT CTGCGGACCT 3240 TTTGGGCCTC GGCCACTTCC TCCACCCTTT GGCCCTGGTA TGCGTCCACC ACTAGGCTTA 3300 AGAGAATTTG CACCAGGCGT TCCACCAGGA AGACGGGACC TGCCTCTCCA CCCTCGGGGA 3360 TTTTTACCTβ GACACGCACC ATTTAGACCT TTAGGTTCAC TTGGCCCAAG AGAGTACTTT 3420 ATTCCTGGTA CCCGATTACC ACCCCCAACC CATGGTCCCC AGGAATACCC ACCACCACCT 3480 GCTGTAAGAG ACTTACTGCC GTCAGGCTCT AGAGATGAGC CTCCACCTGC CTCTCAGAGC 3540 ACTAGCCAGG ACTGTTCACA GGCTTTAAAA CAGAGCCCAT. AAAACTATGA CCTCTGAGGT 3600 TTCATTGGAA AGAAAGTGTA CTGTGCATTA TCCATTACAG TAAAGGATTT CATTGGCTTC 3660 AAAATCCAAA AGTTTATTTT AAAAGGTTTG TTGTTAGAAC TAAGCTGCCT TGGCAGTGTG 3720 CATTTTTGAG CCAAACAATT CAAAAATGTC ATTTCTTCCC TAAATAAAAA TCACCTTTTA 3780 AGCTAGAGCG TCCTTACAAC TTTGAAATGT GCAATAAAGA ATACCTGTGT TTTAGCTAAT 3840 GTAGCATATG TAATTGCAAA ATGATTTAGA ATGTCATGAA AAATATGAAC ATTTCCTGTG 3900 GAAATGCTTT AAGAACATGT ATTTCCATTA TCCTATTTTT AGTGTACACC AGCTGAATAC 3960 GGAGCAATGG TGTTTATAAG CGTTTTTTTA AACTATCTGG TCACAAAGAC TGTTACGCTA 4020 AAAATGTTTA CTAAAAGATC ACTAAACTAT CTCCCCTCTT GCTGAAGTTC TTTGTAGTAA 4080 TAGCTCATAA AAATTTGTTT ATTAATATTT CCCAAGTGTC TGTTGACTCA TTGGACTGTT 4140 ATGAGGCTTG TGCCATTTGG GGAACATGTA AACTCAGGCT CCCAGAACTG AAGATGGTGG 4200 CTGGTGGCAC ACTTCCGGCT GCTCCTCCGT CACCTGTGAA CTCTACAAGT GATGTCTTTT 4260 TATTTCAAAG AAGTTTATTT CCCACTTGTA TAGCATTCAC ATGCTTTCTT TACGATCCTC 4320 ATTGTCTATT TGAGAATGGT TTTCTGAGAG TGAGTTTACA TTAGTAGCAA GAGTTGTTTG 4380 ACCTGATGTT CCATTGTTTT TACCATTCCT GTAGAAAAAG GGTGCACAAC AGAAAAATGA 4440 AAATGATGTG TCATGGCCAT AAAAGTATAG AAATCTTTAA AAATTTTAAA ATGTACAGTC 4500 CCTTATCTAT CTTTCCCATT CCTTGCCACT GATTTTTGAG GAATATAATA AAAAGATTGG 4560 AAGAGTATAA TGCCATGAGA AAGAATGATT TAGGACTGTG AGGGTTATAA CATGCCCTAG 4620 GTCAGCAACC AAGGGTTGAA ATCAGTTCTG TTTTAGGGGG AAATGGGGGG GGCGACAGAT 4680 ATTATTCCAA AATTAATATT AATTAATATT TAAACGTTGG TGTTTTTATT TAAAAATCAG 4740 TAACTAACCA TCTGGAATTG CACCATACTT AAAGTCTTAT CCATTACTAC ACTGTCTTTA 4800 AAACAATGTT TCTTTAAATA CTCTACAACG TTTCTAAGAA CGAACTTCAG ACATTTTAAT 4860 TACAGTAATA ATAGCACTCC TTTTAAGGAG TTTCAGATCC ACACTAAAAC TAAAATCATA 4920 AAAGGCTGAT ACTTTTGTTT GCTGCTAGGC TATATTCTTC CATTCTTTGA AGTCCTATGA 4980 TGTAATATTT TTGAAACCTA GTGTATGTCT TGTCACTGTT GTGATATTTA ATCGATTAAG 5040 AATACCTTGT AAAAAGGAGC AAAAGCTTCA ATGTGAAACA ATTTTCTCTC TTTATACTAA 5100 ACAACTGAAG ATAGATAGTT TAGAAAGATA AGGACCTTTG AAAGAAGACA ACTCTGTCAA 5160 AGTTCATAAG GAATATAAAA ATTCTTCAGG AAAAGAGAAT TCAATCTATA TGTCCTCCCG 5220 TTTAATATCA AGAATAGAAG AAATTAAGAG GAAAACTCCA CAGAAGAGCA TAGGCCACTT 5280 TTAGCCATGT AAAAATAAGA TTAAGTCACA AATACAACTT TTGAATTTAC CTGTCAATAT 5340 CTCTTTAGGA CACAAAACAA TGCTGAAGTT AATATAATTT CTAATTTTAA ATGTCATTTA 5400 AGTGTAGATT ATGCCATCTA GGAAGGTAAG TAGGAAAGGT AAATTAAATC TATTTTTAAA 5460 ATTCAAAATA TTAGAGTATT TTTCCCCTCT AAAGCCTTTT TTGGTGATTA TTCTGTATCT 5520 GACATAATTG AGAAACTGGT AAGCTGTAAA GATTCCAGTG TAGCTTCTCT GAGAAGTTGT 5580 GAGCCAGTCC ATAACTGCTT CCTCACATCC ATCTGATTGC ACCATTTCTG CAGCAAACCC 5640 CAAAGCAGGG TGCCAATATG CAGATGGCAT AGGGAGTATC ATCCCTCAGC CAAATCACTT 5700 TTCCATCTCT AAAGTTTCAT CTATTTTGGA AGTCATCTCC AACTAATTGT GTCTGGATTT 5760 AGTTGCTAAA ATTGTCTTAT TTATTTATGA AGCAGCAATA TTCAGCCTGA AAGCATTTCT 5820 GCCATAGTTG TTGTAGTTAT ATCGCCAATG GCTGATTTTT TTCATTGGAA AGTAAATTTA 5880 AGTAATTCGT GGGATGTGGT ATATTCTGTG TCAACTTCAA GATAATCACT CATTTTCTCG 5940 TTATATTCAG GTCTGAATTA AAGTTAAGTT AATCAC SEQ ID NO:50 PAB7 Protein sequence Protein Accession*: BAA13448 11 21 31 41 51 I I I I I AFLSKVEEDD YPSEELLEDE NAINAKRSKE KNPGNQGRQF DVNLQVPDRA VLGTIHPDPE 60 IEESKQETΞM ILDSEKTSET AAKGVNTGGR EPNTMVEKER PLADKKAQRP FERSDFSDSI 120 KIQTPELGEV FQNKDSDYLK NDNPEEHLKT SGLAGEPEGE LSKEDHGNTE KYMGTESQGS 180 AAAEPEDDSF HWTPHTSVEP GHSDKREDLL IISSFFKEQQ SLQRFQKYFN VHELEALLQE 240 MSSKLKSAQQ ESLPYNMEKV LDKVFRASES QILSIAEKML DTRVAENRDL GMNENNIFEE 300 AAVLDDIQDL IYFVRYKHST AEETATLVMA PPLEEGLGGA MEEMQPLHED NFSREKTAEL 360 NVQVPEEPTH LDQRVIGDTH ASEVSQKPNT EKDLDPGFVT TEDTPMDAID ANKQPETAAE 420 EPASVTPLEN AILLIYSFMF YLTKSLVATL PDDVQPGPDF YGLPWKPVFI TAFLGIASFA 480 IFLWRTVLW KDRVYQVTEQ QISEKLKTIM KENTELVQKL SNYEQKIKES KKHVQETRKQ 540 NMILSDEAIK YKDKIKTLEK NQEILDDTAK NLRVMLESER EQNVKNQDLI SENKKSIEKL 600 KDVISMNASE FSEVQIALNE AKLSEEKVKS ECHRVQEENA RLKKKKEQLQ QEIEDWSKLH 660 AELSEQIKSF EKSQKDLEVA LTHKDDNINA LTNCITQLNL LECESESEGQ NKGGNDSDEL 720 ANGEVGGDRN EKMKNQIKQM MDVSRTQTAI SWEEDLKLL QLKLRASVST KCNLEDQVKK 780 LEDDRNSLQA AKAGLEDECK TLRQKVEILN ELYQQKEMAL QKKLSQEEYE RQEREHRLSA 840 ADEKAVSAAE EVKTYKRRIE EMEDELQKTE RSFKNQIATH EKKAHENWLK ARAAERAIAE 900 EKREAANLRH KLLELTQKMA MLQEEPVIVK PMPGKPNTQN PPRRGPLSQN GSFGPSPVSG 960 GECSPPLTVE PPVRPLSATL NRRDMPRSEF GSVDGPLPHP RWSAEASGKP SPSDPGSGTA 1020 TMMNSSSRGS SPTRVLDEGK VNMAPKGPPP FPGVPLMSTP MGGPVPPPIR YGPPPQLCGP 1080 FGPRPLPPPF GPGMRPPLGL REFAPGVPPG RRDLPLHPRG FLPGHAPFRP LGSLGPREYF 1140 IPGTRLPPPT HGPQEYPPPP AVRDLLPSGS RDEPPPASQS TSQDCSQALK QSP SEQ ID N0:51 PAB9 DNA SEQUENCE Nucleic Acid Accession*: NM_006457 Coding sequence: 84-1874 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I AGACTGAGGC GGAGGCAGCC CCGCGCCGCG CCGGACCCGA GCATATTTCA TTTTCTGTCA 60 TTGGACTTTG AGCCATTAGA ACCATGAGCA ACTACAGTGT GTCACTGGTT GGCCCAGCTC 120 CTTGGGGTTT CCGGCTGCAG GGCGGTAAGG ATTTCAACAT GCCTCTGACA ATCTCTAGTC 180 TAAAAGATGG CGGCAAGGCA GCCCAGGCAA ATGTAAGAAT AGGCGATGTG GTTCTCAGCA 240 TTGATGGAAT AAATGCACAA GGAATGACTC ATCTTGAAGC CCAGAATAAG ATTAAGGGTT 300 GTACAGGCTC TTTGAATATG ACTCTGCAAA GAGCATCTGC TGCACCCAAG CCTGAGCCGG 360 TTCCTGTTCA AAAGGGAGAA CCTAAAGAAG TAGTTAAACC TGTGCCCATT ACATCTCCTG 420 CTGTGTCCAA AGTCACTTCC ACAAACAACA TGGCCTACAA TAAGGCACCA CGGCCTTTTG 480 GTTCTGTGTC TTCACCAAAA GTCACATCCA TCCCATCACC ATCGTCTGCC TTCACCCCAG 540 CCCATGCGAC CACCTCATCA CATGCTTCCC CTTCACCCGT GGCTGCCGTC ACTCCTCCCC 600 TGTTCGCTGC ATCTGGACTG CATGCTAATG CCAATCTTAG TGCTGACCAG TCTCCATCTG 660 CACTGAGCGC TGGTAAAACT GCAGTTAATG TCCCACGGCA GCCCACAGTC ACCAGCGTGT 720 GTTCCGAGAC TTCTCAGGAG CTAGCAGAGG GACAGAGAAG AGGATCCCAG GGTGACAGTA 780 AACAGCAAAA TGGCCCACCA AGAAAACACA TTGTGGAGCG CTATACAGAG TTTTATCATG 840 TACCCACTCA CAGTGATGCC AGCAAGAAGA GACTGATTGA GGATACTGAA GACTGGCGTC 900 CAAGAACTGG AACAACTCAG TCTCGCTCTT TCCGAATCCT TGCCCAGATC ACTGGGACTG 960 AACATTTGAA AGAATCTGAA GCCGATAATA CAAAGAAGGC AAATAACTCT CAGGAGCCTT 1020 CTCCGCAGTT GGCTTCCTTG GTAGCTTCCA CACGGAGCAT GCCCGAGAGC CTGGACAGCC 1080 CAACCTCTGG CAGACCAGGG GTTACCAGCC TCACAACTGC AGCTGCCTTC AAGCCTGTAG 1140 GATCCACTGG CGTCATCAAG TCACCAAGCT GGCAACGGCC AAACCAAGGA GTACCTTCCA 1200 CTGGAAGAAT CTCAAACAGC GCTACTTACT CAGGATCAGT GGCACCAGCC AACTCAGCTT 1260 TGGGACAAAC CCAGCCAAGT GACCAGGACA CTTTAGTGCA AAGAGCTGAG CACATTCCAG 1320 CAGGGAAACG AACTCCGATG TGCGCCCATT GTAACCAGGT CATCAGAGGA CCATTCTTAG 1380 TGGCACTGGG GAAATCTTGG CACCCAGAAG AATTCAACTG CGCTCACTGC AAAAATACAA 1440 TGGCCTACAT TGGATTTGTA GAGGAGAAAG GAGCCCTGTA TTGTGAGCTG TGCTATGAGA 1500 AATTCTTTGC CCCTGAATGT GGTCGATGCC AAAGGAAGAT CCTTGGAGAA GTCATCAATβ 1560 CGTTGAAACA AACTTGGCAT GTTTCCTGTT TTGTGTGTGT AGCCTGTGGA AAGCCCATTC 1620 GGAACAATGT TTTTCACTTβ GAGGATGGTG AACCCTACTG TGAGACTGAT TATTATGCCC 1680 TCTTTGGTAC TATATGCCAT GGATGTGAAT TTCCCATAGA AGCTGGTGAC ATGTTCCTGG 1740 AAGCTCTGGG CTACACCTGG CATGACACTT GCTTTGTATG CTCAGTGTGT TGTGAAAGTT 1800 TGGAAGGTCA GACCTTTTTC TCCAAGAAGG ACAAGCCCCT GTGTAAGAAA CATGCTCATT 1860 CTGTGAATTT TTGAAAGTCA ACAGTTCAGG AGAAGAGAAG GAATTTGAAG AGAAAAAGGA 1920 AAATTAAAAT TACTAATTAA TTTTTAGATT CAATATTTAT ATGGAGTTTT GAAAAATAAT 1980 AGTGGCCCTG AAGGAATAAA TTCCAGCTTT AAAAACCAAG TCTGAGGAAA TATTTGGCTT 2040 CATAAAGTAA AGAGACGGTT TGGCATTTAT TATTACTTTT TCCTGTATTT TATGCCCATA 2100 AAATAAGCTT TATAAAAACC AATTTCCTGA TGGACTATTA AATTCATCTT AGAATAAATT 2160 AGTGAAGAAT TTAATTTTAG AATAAATAAT CCAATCTGAA ATAATTATAC CTTCTTTCCT 2220 TGTTAGGTAG TTATGAGTAA ATCTGCAAAA GGCAATGAAA ATGCCTTAAA TTTTATCAAT 2280 AACAGAATTA TTGTATTTAA AAAAAAACTA ATACTTATCT TTAAAATAGT AAATAGGATT 2340 TTAAACAGAG AATTTTATCA GTAATAGGTG TCAGTTTTTA AAAAATTGCT TGTAGGCTGA 2400 GCGCGGTGGC TCACGCCTGT AATCCCAGCA CTTTGGGAGG CCAAGGTGGG TGGACCACAT 2460 GAGGTCAGGA GTTTGAGATC AGCCTGGCCA ACATGGTGAA ACCCCATCTC TACTAAAAAT 2520 ACAAAAATTA GCCGGACGCA GTGGCACGCG CCTGTAATCC CAGCTACTCA AGAGGCTGAG 2580 GCACGAGAAT CACTTGAACC CGGGAGGGAG AGGTTGCAGT GAGCCAAGAT CGTACCACTG 2640 CACTCCAGCC TGGGTGACAG AGTGAGACTC CGTCTCCAAA AAAAAACTTT GCTTGTATAT 2700 TATTTTTGCC TTACAGTGGA TCATTCTAGT AGGAAAGGAC AATAAGATTT TTTATCAAAA 2760 TGTGTCATGC CAGTAAGAGA TGTTATATTC TTTTCTTATT TCTTCCCCAC CCAAAAATAA 2820 GCTACCATAT AGCTTATAAG TCTCAAATTT TTGCCTTTTA CTAAAATGTG ATTGTTTCTG 2880 TTCATTGTGT ATGCTTCATC ACCTATATTA GGCAAATTCC ATTTTTTCCC TTGCGCTAAG 2940 GTAAAGATTT AATTAAATAA TTTTGGCCTC TCATAGTTTT CTCTCTCTTT AAAGAGAATA 3000 AATAGAGGGC CAGGTGTGGT GGCTCACGCC TGTGATCCCA GCACTTTGGG AGGCCAAGAC 3060 GGGCGGATCA TGAGGTCAAG AGATCAAGAT CATCCTGGCC AACATGGTGA AACCCTGTCT 3120 CTACTAAAAA TACAAAAATG AGCTGGGCAT GGTGGGGCGT GCCTGTAGTC CCATGTACTT 3180 GGGAGGCTGA GGCAGGAAAA TTCTTGAACC CAGGAGACGG AAGTTGCAGT GAGCTGAGAT 3240 CACACCACTG CACTCCAGCC TGGTGACAGA GCAAGACTCC GGCTCTT SEQ ID NO:52 PAB9 Protein sequence Protein Accession* NPJM6448 11 21 31 41 51 I I I I I I 1 MSNYSVSLVG PAPWGFRLQG GKDFNMPLTI SSLKDGGKAA QANVRIGDW LSIDGINAQG 60 61 MTHLEAQNKI KGCTGSLNMT LQRASAAPKP EPVPVQKGEP KEWKFVPIT SPAVSKVTST 120 121 NNMAYNKAPR PFGSVSSPKV TSIPSPSSAF TPAHATTSSH ASPSFVAAVT PPLFAASGLH 180 181 ANANLSADQS PSALSAGKTA VNVPRQPTVT SVCSETSQEL AEGQRRGSQG DSKQQNGPPR 240 241 KHIVERYTEF YHVPTHSDAS KKRLIEDTED WRPRTGTTQS RSFRILAQIT GTEHLKESEA 300 301 DNTKKANNSQ EPSPQLASLV ASTRSMPESL DSPTSGRPGV TSLTTAAAFK PVGSTGVIKS 360 361 PSWQRPNQGV PSTGRISNSA TYSGSVAPAN SALGQTQPSD QDTLVQRAEH IPAGKRTPMC 420 421 AHCNQVIRGP FLVALGKSWH PEEFNCAHCK NTMAYIGFVE EKGALYCELC YEKFFAPECG 480 481 RCQRKILGEV INALKQTWHV SCFVCVACGK PIRNNVFHLE DGEPYCETDY YALFGTICHG 540 541 CEFPIEAGDM FLEALGYTWH DTCFVCSVCC ESLEGQTFFS KKDKPLCKKH AHSVNF SEQ ID N0:53 PBH7 DNA SEQUENCE Nucleic Acid Accession*: AA431407 Coding sequence: 1-864 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I ATGGCCAACT GTAAAATGAC CAAAAGCATC AGGTTCCCTG CCCTGGAGCA CTGCTATACT 60 GGCGGGGAGG TCGTGTTGCC CAAGGATCAG GAGGAGTGGA AAAGACGGAC GGGCCTTCTG 120 CTCTACGAGA ACTATGGGCA GTCGGAAACG GGACTAATTT GTGCCACCTA CTGGGGAATG 180 AAGATCAAGC CGGGTTTCAT GGGGAAGGCC ACTCCACCCT ATGACGTCCA GTTTCATATG 240 GAGGCCTCAG TTGAAAACTG CATTATTGTG AGCATGAACA CCGCTGACCC TGGCAGCCAG 300 GGCATCACAC ACAGCCTCTT GCTACAGGTC ATTGATGACA AGGGCAGCAT CCTCCCACCT 360 AACACAGAAG GAAACATTGG CATCAGAATC AAACCTGTCA GGCCTGTGAG CCTCTTCATG 420 TGCTATGAGG GTGACCCAGA GAAGACAGCT AAAGTGGAAT GTGGGGACTT CTACAACACT 480 GGGGACAGAG GAAAGATGGA TGAAGAGGGC TACATTTGTT TCCTGGGGAG GAGTGATGAC 540 ATCATTAATG CCTCTGGGTA TCGCATCGGG CCTGCAGAGG TTGAAAGCGC TTTGGTGGAG 600 CACCCAGCGG TGGCGGAGTC AGCCGTGGTG GGCAGCCCAG ACCCGATTCG AGGGGAGGTG 660 GTGAAGGCCT TTATTGTCCT GACCCCACAG TTCCTGTCCC ATGACAAGGA TCAGCTGACC 720 AAGGAACTGC AGCAGCATGT CAAGTCAGTG ACAGCCCCAT ACAAGTACCC AAGGAAGGTG 780 GAGTTTGTCT CAGAGCTGCC AAAAACCATC ACTGGCAAGA TTGAACGGAA GGAACTTCGG 840 AAAAAGGAGA CTGGTCAGAT GTAATCGGCA GTGAACTCAG AACGCACTGC ACACCTGAGG 900 CAAATCCCTG GCCACTTTAG TCTCCCCACT ATGGTGAGGA CGAGGGTGGG GCATTGAGAG 960 TGTTGATTTG GGAAAGTATC AGGAGTGCCA TGATTCCAAT GTTTTCCTTC TTTTAAATTA 1020 AATTCAGTTG CTCTGCTTCC TCCAAGTCCT CTGTATCTTT AGAATTTCCC AGGTGAGCAC 1080 TCATAACGCA AGTAATAAAA TACTGATATC AACAA SEQ ID NO:54 PBH7 Protein sequence Protein Accession * FGENESH predicted 11 21 31 41 51 I I I I I MANCKMTKSI RFPALEHCYT GGEWLPKDQ EEWKRRTGLL LYENYGQSET GLICATYWGM 60 KIKPGFMGKA TPPYDVQFHM EASVENCIIV SMNTADPGSQ GITHSLLLQV IDDKGSILPP 120 NTEGNIGIRI KFVRPVSLFM CYEGDPEKTA KVECGDFYNT GDRGKMDEEG YICFLGRSDD 180 IINASGYRIG PAEVESALVΞ HPAVAESAW GSPDPIRGEV VKAFIVLTPQ FLSHDKDQLT 240 KELQQHVKSV TAPYKYPRKV EFVSELPKTI TGKIERKELR KKETGQM SEQ ID NO:55 PBJ5 DNA SEQUENCE Nucleic Acid Accession * AF388200 Coding sequence: 33-137 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I GAGAGAGGGA GGCAGAAGAG GAAGTCAGAG CGATGTGCTG TGAAATCTAC TACCGTTTGC 60 TGGTTTTGAA AATGGAGAAA AAGAGTGAGG AACTGAGAAA CATGGATGGC CTTGGGAACG 120 TGGAAAAGGG TCACTGAAAT GGGACGACAT_ GAACTCAAGG AGGCTATTTA TGACCATGTC 180 ATTTGCAACA TCAAGAAAGC TTATCTGGAG TGAAAGTAAA TGAGACCAAC AGAGATAAGA 240 GACCCGGAGA AATCCTGGTT ACACTGCTTG AATCCTGTCA GTCCTATACT GGAGTCCTGT 300 TAATACAAAA TAATAGTAAT AATCCCTCTC TTTCTTATGT TTATGCCAAC TTCAACAAAA 360 AGAAACTTGA CTAAGAGACA ATATAAGAAC TTAATGTGTA ATTAAGAAAG AACTCTCCAC 420 CACGGGGAAT GTGAAAGGTA TATGAGTCCC TTTTCACGAT GCGATGTCAT GTCTTTTAAA 480 TAAGCCATAC TTTATGTTCA ATAAAAAGAG AATAAGCAGG A SEQ ID N0:56 PBJ5 Protein sequence Protein Accession * AAK83352 1 11 21 31 41 51 l l l l MCCEIYYRLL VLKMEKKSEE LRNMDGLGNV EKGH SEQ ID N0:57 PBJ7 DNA SEQUENCE Nucleic Acid Accession *: AA876910 Coding sequence: 1-2064 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I ATGGACAGTT GCCTGCAACA T 1ATGAGAGAC CTACTTTACC TCCTTCAGGA GCTCAGGTGT 60 TTAAATCCAG CTACACTACT CCCTGATCCA GACTCCACTA CTCCTGTTCA TGACTGTCAG 120 GATCTGTTGG AAACTACCAA AACTGGCCAA CCTGATCTTC AAGATGTGCC CCTAGAAAAG 180 GCAGATGCCA CTGTGTTCAC AGATGGTAGC AGCTTCCTCG AGCAGGGAGA ACGAAAAGCT 240 GTTTCTTTTC CACAGCCAGA TCTGCCTGAC AATCCCACAT ACTCAACAGA AGAAGAAAAA 300 CTGGCTTCAG ATGTTGGAGC AAATAAAAAT CAGGAAGGAC GTGTATTCGC AAACACTACT 360 TGGAGGGCCG GTACCTCCAA GGAAGTCTCC TTTGCAGTTG ATTTATGTGT ACTGTTCCCA 420 GAGCCAGCTC GTACCCATGA AGAGCAACAT AATTTGCCGβ TCATAGGAGC AGGAAGTGTC 480 GACCTTGCAG CAGGATTTCG ACACTCTGGG AGCCAAACTG GATGTGGAAG CTCCAAAGGT 540 GCAGAAAAAG GGCTCCAAAA TGTTGACTTT TACCTCTCTC CTGGAAATCA CCCTGACGCT 600 AGCTGTAGAG ATACTTACCA GTTTTTCTGC CCTGATTCGA CATCTGTAAC TTTAGCCACC 660 TACTCTGGGG GATCAACTAG ATCTTCAACT CTTTCCATAA GTCGTGTTCC TCATCCTAAA 720 TTATGTACTA GAAAAAATTG TAATCCTCTT ACTATAACTβ TCCATGACCC TAATGCAGCT 780 CAATGGTATT ATGGCATGTC ATGGGGATTA AGACTTTATA TCCCAGGATT TGATGTTGGG 840 ACTATGTTCA CCATCCAAAA GAAAATCTTG GTCTCATCGA GCTCCCCCAA GCCAATCGGG 900 CCTTTAACTG ATCTAGGTGA CCCTATATTC CAGAAACACC CTGACAAAGT TGATTTAACT 960 GTTCCTCTGC CATTCTTAGT TCCTAGACCC CAGCTACAAC AACAACATCT TCAACCCAGC 1020 CTAATGTCTA TACTAGGTGG AGTACACCAT CTCCTTAACC TCACCCAGCC TAAACTAGCC 1080 CAAGATTGTT GGCTATGTTT AAAAGCAAAA CCCCCTTATT ATGTAGGATT AGGAGTAGAA 1140 GCCACACTTA AACGTGGCCC TCTATCTTGT CATACACGAC CCCGTGCTCT CACAATAGGA 1200 GATGTGTCTG GAAATGCTTC CTGTCTGATT AGTACCGGGT ATAACTTATC TGCTTCTCCT 1260 TTTCAGGCTA CTTGTAATCA GTCCCTGCTT ACTTCCATAA GCACCTCAGT CTCTTACCAA 1320 GCACCCAACA ATACCTGGTT GGCCTCCACC TCAGGTCTCA CTCGCTGCAT TAATGGAACT 1380 GAACCAGGAC CTCTCCTGTG CGTGTTAGTT CATCTACTTC CCCAGGTATA TGTGTACAGT 1440 GGACCAGAAG GACGACAACT CATCGCTCCC CCTCAGTTAC ATCCCAGGTT GCACCAAGCT 1500 GTCCCACTTC TGGTTCCCCT ATTGGCTGGT CTTAGCATAG CTGGATCAGC AGCCATTGGT 1560 ACGGCTGCCC TCGTTCAAGG AGAAACTGGA CTAATATCCC TGTCTCAACA GGTCGATGCT 1620 GATTTTAGTA ACCTCCAGTC TGCCATAGAT ATACTACATT CCCAGGTAGA GTCTCTGGCT 1680 GAAGTAGTTC TTCAAAACTG CCGATGCTTA GATCTGCTAT TCCTCTCTCA AGGAGGTTTA 1740 TGTCCAGCTC TAGGAGAAAG TTGTTGCTTC TATGCCAATC AATCTGGAGT CATAAAAGGT 1800 ACAGTAAAAA AAGTTCGAGA AAATCTAGAT AGGCACCAAC AAGAACGAGA AAATAACATC 1860 CCCTGGTATC AAAGCATGTT TAACTGGAAC CCATCGCTAA CTACTTTAAT CACTGGGTTA 1920 GCTGGACCTC TCCTCATCCT ACTATTAAGT TTAATTTTTG GGCCTTGTAT ATTAAATTCG 1980 TTTCTTAATT TTATAAAACA ACGCATAGCT TCTGTCAAAC TTACGTATCT TAAGACTCAA 2040 TATGACACCC TTGTTAATAA CTGA SEQ ID N0:58 PBJ7 Protein sequence Protein Accession* FGENESH predicted 11 21 31 41 51 I I I I I I MDSCLQHMRD LLYLLQELRC LNPATLLPDP DSTTPVHDCQ DLLETTKTCQ PDLQDVPLEK 60 ADATVFTDGS SFLEQGERKA VSFPQPDLPD NPTYSTEEEK LASDVGANKN QEGRVFANTT 120 WRAGTSKEVS FAVDLCVLFP EPARTHEEQH NLPVIGAGSV DI-AAGFGHSG SQTGCGSSKG 180 AEKGLQNVDF YLCPGNHPDA SCRDTYQFFC PDWTCVTLAT YSGGSTRSST LSISRVPHPK 240 LCTRKNCNPL TITVHDPNAA QWYYGMSWGL RLYIPGFDVG TMFTIQKKIL VSWSSPKPIG 300 PLTDLGDPIF QKHPDKVDLT VPLPFLVPRP QLQQQHLQPS LMSILGGVHH LLNLTQPKLA 360 QDCWLCLKAK PPYYVGLGVE ATLKRGPLSC HTRPRALTIG DVSGNASCLI STGYNLSASP 420 FQATCNQSLL TSISTSVSYQ APNNTWLACT SGLTRCINGT EPGPLLCVLV HVLPQVYVYS 480 GPEGRQLIAP PELHPRLHQA VPLLVPLLAG LSIAGSAAIG TAALVQGETC LISLSQQVDA 540 DFSNLQSAID ILHSQVESLA EWLQNCRCL DLLFLSQGGL CAALGESCCF YANQSGVIKG 600 TVKKVRENLD RHQQERENNI PWYQSMFNWN PWLTTLITCL AGPLLILLLS LIFGPCILNS 660 FLNFIKQRIA SVKLTYLKTQ YDTLVNN SEQ ID 0.59 PCQ1 DNA SEQUENCE Nucleic Acid Accession * NM_019005 Coding sequence: 182-1885 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 TCATCGTGGA AATTTCTTGA AACCGCTCTC GTAATTTGCC ACGTGCTGTT GCAAATATTC 60 TCGTGAATGA ACACAGAATC AGCATGGCTT TCCTTTGCTG AGAAATCACT GATGGGAAGT 120 GAGACTTGTT AAACTTGAAA GTGAATGGAC CTGAGTGGAC CCTTTGATCA CATCAGTAAA 180 CATGAGCGGT ACCAAACCTG ATATTTTATG GGCACCACAC CATGTTGATA GATTTGTTGT 240 GTGTGACTCA GAACTAAGTC TTTATCATGT GGAATCTACT GTGAATTCAG AACTCAAAGC 300 TGGATCTTTA CGTTTATCTG AAGACTCTGC AGCTACATTA CTGTCAATAA ATTCAGATAC 360 ACCCTATATG AAATGTGTTG CCTGGTATCT TAATTATGAT CCTGAATGTC TGCTGGCAGT 420 TGGACAAGCA AATGGTCGAG TTGTACTTAC AAGCCTTGGT CAAGATCATA ACTCAAAGTT 480 CAAAGATTTG ATAGGAAAAG AGTTTGTTCC AAAACATGCA CGACAATGTA ATACCCTTGC 540 CTGGAATCCA CTGGATAGTA ACTGGCTAGC TCCTGGTTTA GATAAGCACA GAGCTCACTT 600 TTCAGTGCTA ATATGGGATA TCTGCAGCAA ATATACTCCT GATATAGTTC CCATGGAAAA 660 AGTGAAACTT TCAGCAGGTG AAACTCAAAC AACATTATTA GTAACAAAAC CACTTTATGA 720 GTTAGGACAG AATGATGCTT GTCTGTCTCT TTGTTGGCTT CCACGAGACC AGAAACTTCT 780 CCTTGCTCGT ATGCATCGTA ACCTAGCTAT ATTTGATCTT CGGAATACAA GCCAAAAGAT 840 GTTCGTAAAT ACAAAAGCTG TTCAGGGTGT GACGGTAGAC CCATATTTCC ACGATCGTCT 900 TGCTTCCTTC TATGAAGGTC AGGTTGCAAT ATGGGATCTT AGAAAATTTG AGAAGCCAGT 960 TTTGACATTG ACTGAGCAAC CAAAACCCTT AACAAAAGTA GCATGGTGTC CCACTAGGAC 1020 TGGTCTACTT GCCACTTTAA CAAGGGATAG TAATATTATT AGATTGTATC ATATGCAGCA 1080 TACACCCACT CCCATTGGGG ATGAAACTCA ACCCACAATA ATTCAAAGAA GTGTGCAACC 1140 TTGTGACAAT TACATTGCTT CCTTTCCGTG GCATCCAACA AGTCAAAATC GAATGATAGT 1200 TGTAACTCCC AACCGAACAA TGTCAGACTT CACTGTTTTT GAAAGGATAT CTCTTGCCTC 1260 GAGCCCAATT ACATCTTTAA TGTGGGCTTG TGGTCGTCAT TTATATGAAT GTACGGAAGA 1320 AGAAAATGAT AATTCTTTAG AAAAAGATAT AGCAACGAAG ATGCGTCTTC GGGCTTTATC 1380 AAGGTATGGA CTTGATACAG AGCAGGTGTG GAGGAACCAC ATTTTAGCTG GAAATGAAQA 1440 TCCACAGCTC AAGTCACTCT GGTATACTCT GCACTTTATG AAGCAATACA CAGAAGATAT 1500 GGATCAGAAA TCTCCAGGCA ACAAAGGATC ATTGGTTTAT GCAGGAATTA AATCAATTGT 1560 AAAGTCATCG TTGGGAATGG TGGAAAGCAG CAGACATAAT TGGAGTGGGT TGGATAAGCA 1620 AAGTGATATT CAAAACTTAA ATGAAGAGAG AATCTTAGCT TTACAGCTTT GTGGGTGGAT 1680 AAAGAAAGGA ACGGATGTAG ACGTGGGGCC ATTTTTGAAC TCCCTTGTAC AAGAAGGGGA 1740 ATGGGAAAGA GCTGCTGCTC TCGCATTGTT CAACTTGGAT ATTCGCCGAG CAATCCAAAT 1800 CCTCAATCAA GGGGCATCTT CTGAAAAAGG CAGGAGATCT GAATCTCAAT GTGGTAGCAA 1860 TGGCTTTATC GGGTTATACG GATGAGAAGA ACTCCCTTTC GAGAGAAATG TGTAGCACAC 1920 TGCGATTACA GCTAAATAAC CCGTATTTGT GTGTCATCTT TGCATTTCTG ACAAGTGAAA 1980 CAGGATCTTA CGATGGAGTT TTGTATGAAA ACAAAGTTGC AGTACGTGAC AGAGTGGCAT 2040 TTGCTTCTAA ATTCCTTAGT GATACTCAGA TACATCGAAA AGTTGACCAA TGAAATGAAA 2100 GAGGCTGGAA ATTTGGAAGG AATTTTGCTT ACAGGCCTTA CTAAAGATGG AGTGGACTTA 2160 ATCGAGAGTT ATGTTGATAG AACTGGAGAT GTTCAAACAG CAAGTTACTG TATGTTACAG 2220 GGTTCACCTT TAGATGTTCT TAAAGATCAA AGGGTTCAGT ACTGGATTGA GAATTATAGA 2280 AATTTATTAG ATGCCTGGAG GTTTTGGCAT AAACGAGCTG AATTTGATAT TCACAGGAGT 2340 AAGTTGGATC CCAGTTCCAA GCCTTTAGCA CAAGTTTTTG TGAGTTCCAA TTTCTGTGGC 2400 AAGTCAATCT CCTACAGCTG TTCAGCTGTG CCTCATCAGG GCAGAGGTTT TAGTCAGTAT 2460 GGTGTCAGTG GCTCACCAAC GAAATCTAAA GTCACAAGTT GTCCTGGCTG TCGAAAACCA 2520 CTTCCTCGAT GTGCGCTTTβ TCTCATTAAT ATGGGAACAC CAGTTTCTAG CTGTCCTGGA 2580 GGAACCAAAT CAGATGAAAA AGTCGACTTG AGCAAGGACA AAAAATTAGC CCAATTTAAC 2640 AACTGGTTTA CATGGTGTCA TAATTGCAGG CACGGTCGAC ATGCTCGACA TATCCTTAGT 2700 TGGTTCAGGG ACCATCCAGA GTCCCCTGTC TCTGCATGCA CGTGTAAATC TATCCAGTTC 2760 GATACAACGG GGAATCTGGT ACCTGCAGAG ACTGTCCAGC CATAAAATCT TACCACCTTA 2820 AGAGAACCCT TCAAGTGTGG AGCTTTCTAG TAGGTGTCCT TCATAGCTCA GAAACATACC 2880 TCAGAACAAG CCATTCATGA CTTACCTGTA ATGGGAAAAT AAATCATTCT ATCAGAAAAA 2940 AAAAAAAAAA AAAAAAAAAA SEQ ID NO:60 PCQ1 Protein sequence Protein Accession* NP_061878 11 21 31 41 51 I I I I I MSGTKPDILW APHHVDRFW CDSELSLYHV ESTVNSELKA GSLRLSEDSA ATLLSINSDT 60 PYMKCVAWYL NYDPECLLAV GQANGRWLT SLGQDHNSKF KDLIGKEFVP KHARQCNTLA 120 WNPLDSNWLA AGLDKHRADF SVLIWDICSK YTPDIVPMEK VKLSAGETET TLLVTKPLYE 180 LGQNDACLSL CWLPRDQKLL LAGMHRNLAI FDLRNTSQKM FVNTKAVQGV TVDPYFHDRV 240 ASFYEGQVAI WDLRKFEKPV LTLTEQPKPL TKVAWCPTRT GLLATLTRDS NIIRLYDMQH 300 T1?TPIGDETE PTIIERSVQP CDNYIASFAW HPTSQNRMIV VTPNRTMSDF TVFERISLAW 360 SPITSLMWAC GRHLYECTEE ENDNSLEKDI ATKMRLRALS RYGLDTEQVW RNHILAGNED 420 PQLKSLWYTL HFMKQYTEDM DQKSPGNKGS LVYAGIKSIV KSSLGMVESS RHNWSGLDKQ 480 SDIQNLNEER ILALQLCGWI KKGTDVDVGP FLNSLVQEGE WERAAAVALF NLDIRRAIQI 540 LNEGASSEKG RRSESQCGSN GFIGLYG SEQ ID N0:61 PDQ3 DNA SEQUENCE Nucleic Acid Accession* U42359 Coding sequence: 563-775 (underlined sequences correspond to start and stop codons) 11 21 3 1 41 51 I I I I I TTGTACATCT TAACAACCTT AAGCTGTACA AATAGANCAA TAATATCTAA ATGGTGTCAT 60 GATCAGCCCA CAGTACACAT CATTGATGAG AATTTCACTG GTCTCAACCT TTCTCATGCT 120 GAGTCCTCGC TTTGTAAAAT GACTTATAAA GGTCCAAGGA TTTAGAGATG ATTAAGAGAT 180 AAGCTGGCAT TCTGTAAAGG CACCATCGTC TATCCCCTGT CTTATCTAGA TAAAGAATGT 240 AGTGCTAAAT CTTGTAATAA TATTGTACAA ATGGAAATTC AATCTTAAGG ATTATTTTTT 300 CCATATTGTT GTATTTCATT GTGGTCTATT GGAAAGTGAT CTGGACTTTG AGTGAGAAGA 360 TGTGATTTGG ACCATGGCAC TTAAAAACTC TATAACCTCA GGCAAGTCTT TTAATCTTCT 420 CTGAGCCTCA GTTTTCCTCA TTTTTCAAAT ATAGAGAGTA TAACATTTAT CTCATAAGAC 480 AAGTTCTAGT AAATTACTGT TTTACAAATG TAAGATAACT TTTAACTGTG AGATTCCATA 540 TTCCAGTCTT ACATTATTAT GTTTATCTCC CACAGGGAGA AGTCCTCAGA TAAAAATGTC 600 TACCAAAAGA CTGACACGTG GAGTTAATCA TTTGACAGAT GCAAATCCTT CCACCCCCAA 660 CAAATATACT TTCTTTAACT TCTCTCTGGG TATCACTTAG GGAAAAAAAG GCAGGCAACA 720 AAATATTTTT TAATTCTATC TTAGGAAAAA TTGTAGNCAA ATCTTTTTNT CCCATTAACA 780 AATAATCTAA GCCTTAATAT TCAAGGGGTA ATAAAAATAC AAAGTCTTCC AAACAGGTAA 840 CTTACTTCAA AACTTT SEQ ID N0:62 PDG3 Protein sequence Protein Accession* AAB18375 11 21 31 41 51 I I I I I MGARGAPSRR RQAGRRLRYL PTCSFPFLLL LLLLCIQLGG GQKKKENLLA EKVEQLMEWS 60 SRRSIFRMNG DKFRKFIKAP PRNYSMIVMF TALQPQRQCS VCRQANEEYQ ILANSWRYSS 120 AFCNKLFFSM VDYDEGTDVF QQLNMNSAPT FXHXPPKGRP KRADTFDLQR IGFAAEQLAK 180 WIADRTDVHI RVFRPPNYSG TIALALLVSL VGGLLYXRRN NLEFIYNKtfG WAMVSLCIVF 240 AMTSGQMWNH IRGPPYAHKN PHNGQVSYIH GSSQAQFVAE SHIILVLNAA ITMGMVLLNE 300 AATSKGDVGK RRIICLVGLG LWFFFSFLL SIFRSKYHGY PYSDLDFE SEQ ID N0:63 PDG8 DNA SEQUENCE Nucleic Acid Accession*: ALO80235 Coding sequence: 245453 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I GGTCGCCGCA CCGGCCGCCT CCGGCCCGCC GCCGCCCCCA GCGCCGCCGC CGCCACCGCC 60 GGGGCGCCCA CCGCGCTGCC AGCCTACCCC GCGGCCGAGC CGCCCGGGCC GCTGTGGCTG 120 CAGGGCGAGC CGCTGCATTT CTGCTGCCTA GACTTCAGCC TGGAGGAGCT GCAGGGCGAG 180 CCGGGCTGGC GGCTGAACCG TAAGCCCATT GAGTCCACGC TGGTGGCCTC CTTCATGACC 240 CTGGTCATCG TGGTGTGGAG CGTGGCCGCC CTCATCTGGC CGGTGCCCAT CATCGCCGGC 300 TTCCTCCCCA ACGGCATGGA ACAGCGCCGG ACCACCGCCA GCACCACCGC AGCCACCCCC 360 GCCGCAGTGC CCGCAGGGAC CACCGCAGCC GCCGCCGCCG CCGCCGCTCC CGCCGCCGCC 420 GCGGCCGTCA CTTCGGGGGT GGCGACCAAG TGACCCGCTC CGCTCCTCCC TGTGTCCGTC 480 CTGTGTCCGC GCGCGCGGGT GCCTTTCCCG CCGGGGACTC GGCCGGTCTC CTTCGTGCTG 540 TAGTTATCGT TAGTTCCTCT TCCCGAGATG GGGCCGCCGA GAGACCCCAG CGCCTTTCAA 600 AAGCAAGGTT TGTGCTGCGC TTCCAGTTCC GAAAAGCAGA TGTTTAAGCC CTTGGACTGA 660 GGGTGGGATC GCAGCTCCGA AGACGGAGAG GAGGGAAATG GGGCCCTTTC CCCTCTATTG 720 CATCCCCCTG CCCGACTCCT TCCCCGCACC CACGTGCCCT AGATTCATGG CAGAAAATGA 780 CCAAATCCTC TGTATTTGTT TTATATATTT AATAACTGTT TTAAATGAAA GTTTTAGTAA 840 AAAAAATACA AAACAAAAAG ATTAAATTGC TATTGCTGTA GTAAGAGAAG CTCTTTGTAT 900 CTGAACATAG TTGTATTTGA AATTTGTGGT TTTTTAATTT ATTTAAAATT GGGGGGAGGG 960 CATCGGAAGG ATTTAACACC GATATATTGT TACCGCTCAA AATGAACTTT ATCAACCTTT 1020 TCCAAGTTGA TCTATCCAGT GACGTCGCCT GGTGGGCGTT TCTTCTTCTA CTTATGTGGT 1080 TTTTTGGCTT TTAATACAGA CATTTTCCTC CAAAAAAAAA AAAAAAAAGG SEQ ID NO:64 PDG8 Protein sequence Protein Accession * CAB45781 1 11 21 31 41 51 1 inU G 'RRTGRLRPA A 'APSAAAATA G 'APTALPAYP A 'AEPPGPLWL Q 'GEPLHFCCL D 'FSLEELQGE 60 PGWRLNRKPI ESTLVACFMT LVIWWSVAA LIWPVPIIAG FLPNGMEQRR TTASTTAATP 120 AAVPAGTTAA AAAAAAAAAA AAVTSGVATK _ SEQ ID NO:65 PD 1 DNA SEQUENCE 15 Nucleic Acid Accession*: NMJM6765 Coding sequence: 149-1195 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 0 I I I I I CGGCCGCGGC CCGGGTCCCT CGCAAAGCCG CTGCCATCCC GGAGGGCCCA GCCAGCGGGC 60 TCCCGGAGGC TCGCCGGGCA GGCGTGGTGC GCGGTAGGAG CTGGGCGCGC ACGGCTACCG 120 CGCGTGGAGG AGACACTGCC CTGCCGCGAT GGGGGCCCGG GGCGCTCCTT CACGCCGTAG 180 GCAAGCGGGG CGGCGGCTCC GGTACCTGCC CACCGGGAGC TTTCCCTTCC TTCTCCTGCT 240 5 GCTGCTGCTC TGCATCCAGC TCGGGGGAGG ACAGAAGAAA AAGGAGAATC TTTTAGCTGA 300 AAAAGTAGAG CAGCTGATCG AATCGAGTTC CAGACGCTCA ATCTTCCGAA TCAATCGTGA 360 TAAATTCCGA AAATTTATAA AGGCACCACC TCGAAACTAT TCCATGATTG TTATGTTCAC 420 TGCTCTTCAG CCTCAGCGGC AGTGTTCTGT GTGCAGGCAA GCTAATGAAG AATATCAAAT 480 ACTGGCGAAC TCCTGGCGCT ATTCATCTGC TTTTTCTAAC AAGCTCTTCT TCAGTATCGT 540 0 GGACTATGAT GAGGGGACAG ACGTTTTTCA GCAGCTCAAC ATGAACTCTG CTCCTACATT 600 CAYGCATTTW CCTCCAAAAG GCAGACCTAA GAGAGCTGAT ACTTTTGACC TCCAAAGAAT 660 TGGATTTGCA GCTGAGCAAC TAGCAAAGTG GATTGCTGAC AGAACGGATG TTCATATTCG 720 GGTTTTCAGA CCACCCAACT ACTCTGGTAC CATTCCTTTG GCCCTGTTAG TGTCGCTTGT 780 TGGAGGTTTG CTTTATTNGA GAAGGAACAA CTTCGAGTTC ATCTATAACA AGACTGGTTG 840 5 GGCCATGGTG TCTCTGTGTA TAGTCTTTGC TATGACTTCT GGCCAGATCT GGAACCATAT 900 CCGTGGACCT CCATATGCTC ATAAGAACCC ACACAATCGA CAAGTGAGCT ACATTCATGG 960 GAGCAGCCAG GCTCAGTTTG TGGCAGAATC ACACATTATT CTGGTACTGA ATGCCGCTAT 1020 CACCATGGGG ATGGTTCTTC TAAATCAAGC AGCAACTTCG AAAGGCGATG TTGGAAAAAG 1080 ACGGATAATT TGCCTAGTCG GATTCGGCCT GGTGGTCTTC TTCTTCAGTT TTCTACTTTC 1140 0 AATATTTCGT TCCAAGTACC ACGGCTATCC TTATAGTCAT CTGGACTTTG AGTGAGAAGA 1200 TGTGATTTGG ACCATCGCAC TTAAAAACTC TATAACCTCA GCTTTTTAAT TAAATCAAGC 1260 CAAGTGGGAT TTGCATAAAG TGAATGTTTA CCATGAAGAT AAACTGTTCC TCACTTTATA 1320 CTATTTTGAA TTCATTCATT TCATTGTGAT CAGCTAGCTT ATTCTTCTGT ACTTTTTTTA 1380 AACTGTGGGT TTTCCTAGTA AATTTAATTT ACAGAAATCA ATGGTAGCAT TTAGTAATCT 1440 5 ACAAAGGAAA TATCAAAGTG TTTTTCAAGC CTGTTATATY CAGTCTGTKC CACAGGATTG 1500 CAATAAATGA CAATGTAATT A SEQ ID NO:66 PDM1 Protein sequence: 0 Protein Accession* NP_006756 11 21 31 41 51 I I I I I MGARGAPSRR RQAGRRLRYL PTGSFPFLLL LLLLCIQLGG GQKKKENLLA EKVEQLMEWS 60 5 SRRSIFRMNG DKFRKFIKAP PRNYSMIVMF TALQPQRQCS VCRQANEEYQ ILANSWRYSS 120 AFCNKLFFSM VDYDEGTDVF QQLNMNSAPT FXHXPPKGRP KRADTFDLQR IGFAAEQLAK 180 WIADRTDVHI RVFRPPNYSG TIALALLVSL VGGLLYXRRN NLEFIYNKTG WAMVSLCrVF 240 AMTSGQMWNH IRGPPYAHKN PHNGQVSYIH GSSQAQFVAE SHIILVLNAA ITMGMVLLNE 300 AATSKGDVGK RRIICLVGLG LWFFFSFLL SIFRSKYHGY PYSDLDFE 0 SEQ ID N0.67 PDM2 DNA SEQUENCE Nucleic Acid Accession* NM_000947 Coding sequence: 88-1617 (underlined sequences correspond to start and stop codons) 5 11 21 31 41 51 GGTTTCATAT GAACTCTCCC GCCACCCGGG AACAGCTCGC TGCCACCGTT TGTGTTTTCC 60 0 GAGTTTGTAT TCTTGCAGGT GACCAAGATG GAGTTTTCTG GAAGAAAGCG GAGGAAGCTG 120 AGGTTGGCAG GTGACCAGAG GAATGCTTCC TACCCTCATT GCCTTCAGTT TTACTTGCAG 180 CCACCTTCTG AAAACATATC TTTAACAGAA TTTCAAAACT TGGCTATTGA TAGAGTTAAA 240 TTGTTAAAAT CAGTTGAAAA TCTTGGAGTG AGCTATCTCA AAGGAACTGA ACAATACCAG 300 AGTAAGTTGG AGAGTGAGCT TCGGAAGCTC AAGTTTTCCT ACAGAGAGAA GCTAGAAGAT 360 5 GAATATGAAC CACGAAGAAG AGATCATATT TCTCATTTTA TTTTGCGGCT TGCTTATTGC 420 CAGTCTGAAG AACTTAGACG CTGGTTCATT CAACAAGAAA TGGATCTCCT TCGATTTAGA 480 TTTAGTATTT TACCCAAGGA TAAAATTCAG GATTTCTTAA AGGATAGCCA ATTGCAGTTT 540 GAGGCTATAA GTGATGAAGA GAAGACTCTT CGAGAACAGG AGATTGTTGC CTCATCACCA 600 AGTTTAAGTG GACTTAAGTT GGGGTTCGAG TCCATTTATA AGATCCCTTT TGCTGATCCT 660 0 CTGGATTTCT TTCGAGGAAG GAAAGTCTAT TTGGAAGATG GCTTTGCTTA CGTACCACTT 720 AAGGACATTG TGGCAATCAT CCTGAATCAA TTTAGAGCCA AACTGTCCAA GGCTTTGGCA 780 TTAACAGCCA GGTCCTTGCC TGCTCTGCAG TCTGATGAAA GACTTCAGCC TCTGCTCAAT 840 CACCTCAGTC ATTCCTACAC TCGCCAAGAT TACAGTACCC AGGGAAATGT TGGGAAGATT 900 TCTTTAGATC AGATTGATTT GCTTTCTACC AAATCCTTCC CACCTTCCAT GCGTCAGTTA 960 CATAAAGCCT TGCGGGAAAA TCACCATCTT CGTCATGGAG GCCGAATGCA GTATCGCCTA 1020 TTTCTGAAGG GCATTGGTTT AACTTTGGAA CAGGCATTGC AGTTCTGGAA GCAAGAATTT 1080 ATCAAAGGAA AGATGGATCC AGACAAGTTT GATAAAGGTT ACTCTTACAA CATCCGTCAC 1140 AGCTTTGGAA AGGAAGGCAA GAGGACAGAC TATACACCTT TCAGTTGCCT GAAGATTATT 1200 CTGTCCAATC CACCAAGCCA AGGGGATTAT CATGGGTGCC CATTCCGTCA CAGTGATCCA 1260 GAGCTGCTGA AGCAAAAGTT GCAGTCATAC AAGATCTCTC CTGGAGGGAT AAGCCAGATT 1320 TTGGATTTAβ TAAAGGGGAC ACATTACCAG GTAGCCTCTC AAAAATACTT TGAGATGATA 1380 CACAATGTGβ ATCATTGTGG CTTTTCTTTG AATCATCCTA ATCAGTTCTT TTGTGAGAGC 1440 CAACGTATTC TAAATGGTGG TAAAGACATA AAGAAGGAAC CTATCCAACC AGAAACTCCT 1500 CAACCCAAAC CAAGTCTCCA GAAAACCAAG GATGCATCAT CTGCTCTGGC CTCTTTAAAT 1560 TCCTCTCTGG AAATGGATAT GGAAGGACTA GAAGATTACT TTAGTCAAGA TTCTTAGGCA 1620 GTTTTATAAC CCTTTTTCCT CAATAGCCTG TTTCCTGTTT TTAAGATTTT GCCTTTGTTG 1680 TTGAAAAAGG GTTTCACTGT CACCAAGGCT TAGTGCAGTG ACACAATTAC AGCTGATTGC 1740 AGCCTTGACC TTCCCAGCTC AAGTGATCCT CCTACCTCAG CCTCCCAAGT AGTTAGGACA 1800 CACAGGTGTG CACCTCATAT CCAGATAATT TTTTTCAATT TTTTTTTCTA GAGGTGGGGG 1860 GTCTCCCTAT GTTGCCCAGG CAGATCTCAG ACTCCTGGGC TCAAGCGATC CTCACACCTC 1920 AGCGTCCCAG AGTGCTGGGA TTACAGTTGT GAGCCACTGT GCCTGGCCTT TTTTTTTTTT 1980 TAACCTTTTC GTTTAACTTC TCTCTTCACT GCATCCCAAT CCATCTACAG GCATGCACAC 2040 TTATTAGGAA AGGAGGTTTG AGGTAACAAC AGAGACTTTC ACTATATTTT GCTTTGACAβ 2100 AAGGAAAGAG GAGGAGTTTC TATTAAAATC TCTCACTTGA GTGATGTCAT TTAAGTCCTA 2160 TTTTAGGAGA TAAAAACAGC TTTGGGGACT GGTTAAAGTC CCCCAGAAAC TACAATAAAG 2220 AACAACTTTT GTTTTAACTC TTAATCACTT TGTAATTTTG ACTCAATCCT TTTCTGGACC 2280 ATTTTTGTTA ATAAATATCA AAGTGT SEQ ID NO:68 PDM2 Protein sequence: Protein Accession #: NP_000938 11 21 31 41 51 I I I I I I MEFSGRKRRK LRLAGDQRNA SYPHCLQFYL QPPSENISLT EFENLAIDRV KLLKSVENLG 60 VSYVKGTEQY QSKLESELRK LKFSYREKLE DEYEPRRRDH ISHFILRLAY CQSEELRRWF 120 IQQEMDLLRF RFSILPKDKI QDFLKDSQLQ FEAISDEEKT LREQEIVASS PSLSGLKLGF 180 ESIYKIPFAD ALDLFRGRKV YLEDGFAYVP LKDIVAIILN EFRAKLSKAL ALTARSLPAV 240 QSDERLQPLL NHLSHSYTGQ DYSTQGNVGK ISLDQIDLLS TKSFPPCMRQ LHKALRENHH 300 LRHGGRMQYG LFLKGIGLTL EQALQFWKQE FIKGKMDPDK FDKGYSYNIR HSFGKEGKRT 360 DYTPFSCLKI ILSNPPSQGD YHGCPFRHSD PELLKQKLQS YKISPGGISQ ILDLVKGTHY 420 QVACQKYFEM IHNVDDCGFS LNHPNQFFCE SQRILNGGKD IKKEPIQPET PQPKPSVQKT 480 KDASSALASL NSSLEMDMΞG LEDYFSEDS SEQ ID N0.69 PD 3 DNA SEQUENCE Nucleic Acid Accession* NM_024840 Coding sequence: 108-491 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I AATTCATACA GGAGAGAAGT CATATATATG CAGTCATTGT GGAAAAGGCT TCATCAAGAA 60 GTCTCGGCTC ATTAATCATC AGAGAGTTCA TACAGGAGAG AAACCACATG GATGCAGCCT 120 GTGTGGGAAG GCCTTCTCCA AAAGGTCCAG GCTCACTGAA CACCAGAGAA CTCATACAGG 180 AGAGAAGCCC TATCAATGCA CTGAATGTGA CAAAGCATTC CGCTGGAAAT CACAGCTCAA 240 TGCACATCAG AAAGCTCACA CAGGAGAGAA GTCATATATA TGCCGTGATT GTGGAAAAGG 300 CTTCATTCAG AAGGGAAATC TCATTGTACA TCAGCGAATT CATACTGGAG AAAAACCCTA 360 TATATGCAAT GAATGTGGAA AAGGCTTCAT CCAAAAGGGC AACCTCCTTA TTCATCGACG 420 TACTCACACT GGAGAGAAAC CCTATGAATG CAATGAATGT GGGAAAGGCT TCAGCCAGAA 480 GACATGTTTA ATATCCCATC AGAGATTTCA CACAGGAAAG ACACCCTTTG TATGTACTCA 540 GTGTGGAAAA TCCTGCTCAC ACAAGTCAGG TCTCATTAAC CACCAGAGAA TTCACACAGG 600 AGAGAAACCC TATACATGCA GTCACTGTGG GAAAGCTTTC AGAGATAAAT CATGTCTCftA 660 CAGACATCGG AGAACTCATA CAGGGGAGAG ACCGTATGGA TGCTCTGATT GTGGGAAAGC 720 TTTCTCCCAC TTCTCATGCC TTGTTTATCA TAAGGGAATG CTGCATGCAA GAGAGAAATC 780 TGTAGGTTCA GTCAAATTGG AAAATCCTTG CTCAGAGAGT CATAGCTTAT CACATACACG 840 TGATCTCATA CAGGATAAAG ACTCTGTTAA CATGGTCACT CTGCAGATGC CTTCTGTGGC 900 AGCTCAGACC TCATTAACTA ACAGTGCGTT CCAAGCAGAG AGCAAAGTAG CCATTGTCAG 960 CCAGCCTGTT GCCAGAAGTT CAGTCTCAGC AGATAGTAGA ATTTGCACAG AATAAAAACC 1020 ATATGAATGC AGTGAATCTG GTAGTGCTTT CAGTGATCAA TTACATCATA TGTCACAAAA 1080 AACACAGAGG AACAAACTGA TATATTCAAG GTGGAAAGCC CTTGAATAAA ACCTTATGGC 1140 TAATAAGCAT ATACTCAGAG AAAAATAGTA TGAAGTGGAG ACTCGGAAAT TCTTTTATGG 1200 GAAGATAGAT CTTCTCATCA GTGACCATAG ATCACATCTT CAGTGAGCTT ATAGTTGGTA 1260 GAAATATAAT GATCATGGAA AAGTCCTTGT TCAGAAACAG TACGCCAGTA GGTATCAGGG 1320 GGTTTACACA GGAGAGAAAC TTTTGGAAGA CCTTTGAAGG CTATGAATGT GGCAGGGTTG 1380 CTAGTGGTAC ATTCTGCCTT ATCCTCAGAG GGAATCATAT AGAAATAAAA CTATGAAAAT 1440 GTAACTAGAA CATCTTCATC AAAATATGAA AGAACACACG AAGCAAATAA GCCCTGTGAA 1500 AAGGAGTATT TTAGAGATTT CGATCAGAAA TCTAACATCA TTATATGGCA GATAATATAC 1560 AGGATGTGTA TTTTAGGACA ATATACCTTG AATCACTAGT TGATATGTCA ATGACTAATT 1620 AAAAGGGGTT GTCAGTGTTA CACATCATTG GTTAAATTTA TAGCACAATG TACCTCTTCC 1680 CCCTTTTTTG ATAAGAGTCT TCTATTCCCA ACCAAGATCA TTATATGATT AGCTCTTCTC 1740 TTTCTTTGAT TCCAAATTTC TTCACTTGTT ATTTCAGACT ACTGAAGCTC TTCAAAAGGA 1800 AAAATGTATT TAATTTAATA ATGTAACACA ACAAGTTTCG ATGTGTTTAA CTTTATAAAT 1860 AATCACCCCA GAGGAATCAA GTTCAAAACT TCTCAATAAC C SEQ ID NO:70 PD 3 Protein saπiiBn fi: Protein Accession* NP 079116 1 11 21 31 41 51 I I I I I I MDAACVGRPS PKGPGSLNTR ELIQERSPMN ALNVTKHSAG NHSSMHIRKL TQERSHIYAV 60 IVEKASFRRE ISLYISEFIL EKNPIYAMNV EKASSKRATS LFIDVLTLER NPMNAMNVGK 120 ASARRHV - SEQ ID N0:71 PDM8 DNA SEQUENCE Nucleic Acid Accession*: NM.018455 Coding sequence: 341-955 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I i I I I AATTTCGGCA CGGGGGGGAG GCACAGTGAG TCCACTGGGG CACGGCAGCG TCTAAGCCAC 60 AAGCCGACTG ACATAAGCCA GGTCCTAACG GAGCCTATGT GTAAGTCCAC TACTGGTGCA 120 AGGTTGCACA CTTCTAAGAA GAGCGGCGTG GGGGGCTCGG CGACCTTCGC TTCAGTCGCT 180 CCCCCGTGCA GTCCCCTCTG CCCAAGACAC AGCCTGATGC TTGTGCTCCG GTCGGCGGAC 240 TTGGAGGCGG CGGGAACTGC AATTGGTGGC TTTGAAGGGC GGCGAGCGGG AACAGCTCTT 300 GAGGAGTCAG ACTGCAGGAG ATGTGGGCCG TGCCAAAGAG ATGGATCAGA CTGTTGCTGA 360 GTTCATCAAG AGGACCATCT TGAAAATCCC CATGAATCAA CTGACAACAA TCCTGAAGGC 420 CTGGGATTTT TTGTCTGAAA ATCAACTGCA GACTGTAAAT TTCCGACAGA GAAAGGAATC 480 TGTAGTTCAG CACTTGATCC ATCTGTGTCA GGAAAAGCGT GCAAGTATCA GTGATGCTGC 540 CCTCTTAGAC ATCATTTATA TGCAATTTCA TCAGCACCAG AAAGTTTGGG ATGTTTTTCA 600 GATGAGTAAA GGACCAGGTG AAGATCTTGA CCTTTTTCAT ATGAAACAAT TTAAAAATTC 660 GTTCAAGAAA ATTCTTCAGA GAGCATTAAA AAATCTGACA GTCAGCTTCA GAGAAACTGA 720 GGAGAATGCA GTCTGGATTC GAATTGCCTG GGGAACACAG TACACAAAGC CAAACCAGTA 780 CAAACCTACC TACGTGGTGT ACTACTCCCA GACTCCGTAC GCCTTCACGT CCTCCTCCAT 840 GCTCAGGCGC AATACACCGC TTCTGGGTCA GGAGTTAGAA GCTACTGGGA AAATCTACCT 900 CCGACAAGAG GAGATCATTT TAGATATTAC CGAAATGAAG AAAGCTTGCA ATTAGTGAAC 960 ATGAAAGGAA AATAAAAATT CCTCACAGTC AAAAAAAAAA AAAAA SEQ ID NO:72 PDM8 Protein sequence: Protein Accession* NP_060925 1 11 21 31 41 51 I I I I I I MDETVAEFIK RTILKIPMNE LTTILKAWDF LSENQLQTVN FRQRKESWQ HLIHLCEEKR 60 ASISDAALLD IIYMQFHQHQ KVWDVFQMSK GPGEDVDLFD MKQFKNSFKK ILQRALKNVT 120 VSFRETEENA VWIRIAWGTQ YTKPNQYKPT YWYYSQTPY AFTSSSMLRR NTPLLGQELE 180 ATGKIYLRQE EIILDITEMK KACN . SEQ ID NO:73PDM9 DNA SEQUENCE Nucleic Acid Accession* NM_016192 Coding sequence: 1-1125 (undedined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I ATGGTGCTGT GGGAGTCCCC GCGGCAGTGC AGCAGCTGGA CACTTTCCGA GGGCTTTTGC 60 TGGCTGCTGC TGCTGCCCGT CATGCTACTC ATCGTAGCCC GCCCGGTCAA GCTCGCTGCT 120 TTCCCTACCT CCTTAAGTGA CTGCCAAACG CCCACCGGCT GGAATTCCTC TGGTTATGAT 180 GACAGAGAAA ATGATCTCTT CCTCTGTGAC ACCAACACCT GTAAATTTGA TGGGGAATGT 240 TTAAGAATTG GAGACACTGT GACTTGCGTC TGTCAGTTCA AGTCCAACAA TGACTATGTG 300 CCTGTGTGTG GCTCCAATGG GGAGAGCTAC CAGAATGAGT GTTACCTGCG ACAGGCTGCA 360 TGCAAACAGC AGAGTGAGAT ACTTGTGGTG TCAGAAGGAT CATGTCCCAC AGATGCAGGA 420 TCAGGATCTG GAGATGGAGT CCATGAAGGC TCTGGAGAAA CTAGTCAAAA GGAGACATCC 480 ACCTGTGATA TTTGCCAGTT TGGTGCAGAA TGTCACGAAG ATGCCGAGGA TGTCTGGTGT 540 GTGTGTAATA TTGACTGTTC TCAAACCAAC TTCAATCCCC TCTGCGCTTC TGATGGGAAA 600 TCTTATCATA ATGCATGCCA AATCAAAGAA GCATCGTCTC AGAAACAGGA GAAAATTGAA 660 GTCATGTCTT TGGGTCGATG TCAAGATAAC ACAACTACAA CTACTAAGTC TGAAGATGGG 720 CATTATGCAA GAACAGATTA TGCAGAGAAT GCTAACAAAT TAGAAGAAAG TGCCAGAGAA 780 CACCACATAC CTTGTCCGGA ACATTACAAT GGCTTCTGCA TGCATGGGAA GTGTGAGCAT 840 TCTATCAATA TGCAGGAGCC ATCTTGCAGG TGTGATGCTC GTTATACTGG ACAACACTGT 900 GAAAAAAAGG ACTACAGTCT TCTATACGTT GTTCCCGGTC CTGTACGATT TCAGTATGTC 960 TTAATCGCAG CTGTGATTGG AACAATTCAG ATTGCTGTCA TCTCTGTGGT GGTCCTCTGC 1020 ATCACAAGGA AATGCCCCAG AAGCAACAGA ATTCACAGAC AGAAGCAAAA TACAGGGCAC 1080 TACAGTTCAG ACAATACAAC AAGAGCGTCC ACGAGGTTAA TCTGA SEQ ID NO:74 PDM9 Protein sequence: Protein Accession* NP_057276 11 21 31 41 51 I I I I I I 1 MVLWESPRQC SSWTLCEGFC WLLLLPVMLL IVARPVKLAA FPTSLSDCQT PTGWNCSGYD 60 61 DRENDLFLCD TNTCKFDGEC LRIGDTVTCV CQFKCNNDYV FVCGSNGESY QNECYLRQAA 120 121 CKQQSEILW SEGSCATDAG SGSGDGVHEG SGETSQKETS TCDICQFGAE CDEDAEDVWC 180 181 VCNIDCSQTN FNPLCASDGK SYDNACQIKE ASCQKQEKIE VMSLGRCQDN TTTTTKSEDG 240 241 HYARTDYAEN ANKLEESARE HHIPCPEHYN GFCMHGKCEH SINMQEPSCR CDAGYTGQHC 300 301 EKKDYSVLYV VPGPVRFQYV LIAAVIGTIQ IAVICVWLC ITRKCPRSNR IHRQKQNTGH 360 361 YSSDNTTRAS TRLI SEQ ID NO:75 PD01 DNA SEQUENCE Nucleic Acid Accession* NM_014324 Coding sequence: 89-1237 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I ' I GGCGCCGGGA TTGGGAGGGC TTCTTGCAGG CTGCTGGGCT GGGGCTAAGG GCTGCTCAGT 60 TTCCTTCAGC GGGGCACTGG GAAGCGCCAT _GGCACTGCAG GGCATCTCGG TCGTGGAGCT 120 GTCCGGCCTG GCCCCGGGCC GTNTCTGTGC TATGGTCCTG GCTGACTTCG GGGCGCGTCT 180 GGTACGCGTG GACCGGCCCG GCTCCCGCTA CGACGTGAGC CGCTTCGGCC GGGGCAAGCG 240 CTCGCTAGTG CTGGACCTGA AGCAGCCGCG GGAGCCGCGT GCTCCGGCGT CTCTGCAAGC 3 00 GGTCGGATGT GCTGCTGGAG CCCTTCCGCC GCGGTGTCAT GGAGAAACTC CAGCTGGGCC 360 CAGAGATTCT GCAGCGGGAA AATCCAAGGC TTATTTATGC CAGGCTGAGT GGATTTGGCC 420 AGTTCAGGAA AGCTTCTGCC GGTTAGCTGG CCACGATATC AACTATTTGG CTTTGTCAGG 480 TGTTCTCTCA AAAATTGGCA GAAGTGGTGA GAATCCGTAT GCCCCGCTGA ATCTCGTGGC 540 TGACTTTGCT GGTGGTGGCC TTATGTGTCC ACTGGGCATT ATAATGGCTC TTTTTGACCG 600 CACACGCACT GACAAGGGTC AGGTCATTCA TGCAAATATC GTGGAAGGAA CAGCATATTT 660 AAGTTCTTTT CTCTGGAAAA CTCAGAAATC GAGTCTGTGG GAAGCACCTC GAGGACAGAA 720 CATGTTGGAT GGTGGAGCAC CTTTCTATAC GACTTACAGG ACAGCAGATG GGGAATTCAT 780 GGCTGTTGGA GCAATAGAAC CCCAGTTCTA CGAGCTGCTC ATCAAAGGAC TTGGACTAAA 840 GTCTGATGAA CTTCCCAATC AGATGAGCAC GGATGATTCG CCAGAAATGA AGAAGAAGTT 900 TGCAGATGTA TTTGCAAAGA AGACGAAGGC AGAGTGGTGT CAAATCTTTG ACGGCACAGA 960 TCCCTGTGTG ACTCCGGTTC TGACTTTTGA GGAGGTTGTT CATCATGATC ACAACAAGGA 1020 ACGGGGCTCG TTTATCACCA GTGAGGAGCA GGACGTCAGC CCCCGCCTTG CACCTCTGCT 1080 GTTAAACACC CCAGCCATCC CTTCTTCCAA AGGGGATCCT TTCATAGGAG AACACACTCA 1140 GGAGATACTT GAAGAATTTG GATTCAGCCG AGAAGAGATT TATCAGCTTA ACTCAGATAA 1200 AATCATTGAA AGTAATAAGG TAAAAGCTAG TCTCTAACTT CCAGGCCCAC GGCTCAAGTC 1260 AATTTGAATA CTGCATTTAC AGTGTAGAGT AACACATAAC ATTGTATCCA TGGAAACATG 1320 GAGGAACAGT ATTACAGTCT CCTACCACTC TAATCAAGAA AAGAATTACA GACTCTGATT 1380 CTACAGTGAT GATTGAATTC TAAAAATGGT TATCATTAGG GCTTTTGATT TATAAAACTT 1440 TGGGTACTTA TACTAAATTA TGGTAGTTAT TCTGCCTTCC AGTTTGCTTG ATATATTTGT 1500 TGATATTAAG ATTCTTGACT TATATTTTCA ATGGGTTCTA GTGAAAAAGG AATGATATAT 1560 TCTTGAAGAC ATCGATATAC ATTTATTTAC ACTCTTGATT CTACAATGTA GAAAATGAGG 1620 AAATGCCACA AATTGTATGG TCATAAAAGT CACGTCAAAC AGAGTGATTG GTTGCATCCA 1680 GGCCTTTTGT CTTGGTGTTC ATGATCTCCC TCTAAGCACA TTCCAAACTT TAGCAACAGT 1740 TATCACACTT TGTAATTTGC AAAGAAAAGT TTCACCTGTA TTGAATCAGA ATGCCTTCAA 1800 CTGAAAAAAA CATATCCAAA ATAATCAGGA AATGTGTTGG CTCACTACGT AGAGTCCAGA 1860 GGGACAGTCA GTTTTAGGGT TGCCTGTATC CAGTAACTCG GGGCCTGTTT CCCCGTGGGT 1920 CTCTGGGCTG TCAGCTTTCC TTTCTCCATG TGTTTGATTT CTCCTCAGGC TGGTAGCAAG 1980 TTCTGGATCT TATACCCAAC ACACAGCAAC ATCCAGAAAT AAAGATCTCA GGACCCCCCA 2040 AAAAAAAAAA AAAAAAAAAA AAAAAAAA SEQ ID NO:76 PD01 Protein sequence: Protein Accession* NP_055139 1 11 21 31 41 51 I I . I I I I 1 MALQGISWE LSGLAPGRXC AMVLADFGAR WRVDRPGSR YDVSRLGRGK RΞLVLDLKQP 60 61 REPRAAASVQ AVGCAAGALP PRCHGETPAG PRDSAAGKSK AYLCQAEWIW FVQESFCRLA 120 121 GHDINYLALS GVLSKIGRSG ENPYAPLNLV ADFAGGGLMC ALGIIMALFD RTRTDKGQVI 180 181 DANMVEGTAY LSSFLWKTQK SSLWEAPRGQ NMLDGGAPFY TTYRTADGEF MAVGAIEPQF 240 241 YELLIKGLGL KSDELPNQMS TDDWPEMKKK FADVFAKKTK AEWCQIFDGT DACVTFVLTF 300 301 EEWHHDHNK ERGSFITSEE QDVSPRLAPL LLNTPAIPSS KGDPFIGEHT EEILEEFGFS 360 361 REEIYQLNSD KIIESNKVKA SL SEQ ID NO:77 PD03 DNA SEQUENCE Nucleic Acid Accession * AB028951 Coding sequence: 97-1128 (undedined sequences correspond to start and stop codons) 11 21 31 41 51 I I I GTTAAATCCT TACTTTACCA GATTCTTGAT GGTATCCATT ACCTCCATGC AAATTGGGTG 60 CTTCACAGAG ACTTGAAACC AGCAAATATC CTAGTAATGG GAGAAGGTCC TCAGAGGGGG 120 AGAGTCAAAA TAGCTGACAT GGGTTTTGCC AGATTATTCA ATTCTCCTCT AAAGCCACTA 180 GCAGATTTGG ATCCAGTAGT TGTGACATTT TGGTATCGGG CTCCAGAACT TTTGCTTCGT 240 GCAAGGCATT ATACAAAGGC CATTCATATA TGGGCAATAG GTTGTATATT TGCTGAATTG 300 TTGACTTCGG AACCTATTTT TCACTGTCGT CAGGAAGATA TAAAAACAAG CAATCCCTTT 360 CATCATGATC AACTGGATCG GATATTTAGT GTCATCGGGT TTCCTCCAGA TAAAGACTGG 420 GAAGATATTA GAAAGATGCC AGAATATCCC ACACTTCAAA AAGACTTTAG AAGAACAACG 480 TATGCCAACA GTAGCCTCAT AAAGTACATC GAGAAACACA AGGTCAAGCC TGACAGCAAA 540 GTGTTCCTCT TGCTTCAGAA ACTCCTCACC ATCGATCCAA CCAAGAGAAT TACCTCGGAG 600 5 CAAGCTCTCC AGGATCCCTA TTTTCAGGAG GACCCTTTCC CAACATTAGA TGTATTTCCC 660 GGCTGCCAGA TTCCATACCC CAAACGAGAA TTCCTTAATG AAGATCATCC TGAAGAAAAA 720 GGTGACAAGA ATCAGCAACA GCAGCAGAAC CAGCATCAGC AGCCCACAGC CCCTCCACAG 780 CAGGCAGCAG CCCCTCCACA GGCGCCCCCA CCACAGCAGA ACAGCACCCA GACCAACGGG 840 ACCGCAGGTG GGGCTGGGGC CGGGGTCGGG GGCACCGGAG CAGGGTTGCA GCACAGCCAG 900 10 GACTCCAGCC TGAACCAGGT GCCTCCAAAC AAGAAGCCAC GGCTAGGGCC TTCAGGCGCA 960 AACTCAGGTG GACCTGTCAT GCCCTCGGAT TATCAGCACT CCAGTTCTCG CCTGAATTAC 1020 CAAAGCAGCG TTCAGGGATC CTCTCAGTCC CAGAGCACAC TTGGCTACTC TTCCTCGTCT 1080 CAGCAGAGCT CACAGTACCA CCCATCTCAC CAGGCCCACC GGTACTGACC AGCTCCCGTT 1140 GGGCCAGGCC AGCCCAGCCC AGAGCACAGG CTCCAGCAAT ATCTCTGCAT TGAAAAGAAC 1200 15 CAAAAAAATG CAAACTATGA TGCCATTTAA AACTCATACA CATGGGAGGA AAACCTTATA 1260 TACTCAGCAT TGTCCAGGAC TGATAGCTCT TCTTTATTCA CTTAAAGAAG ATTCTTGTGA 1320 AGTTTCCCCA GCACCCCTTC CCTGCATGTG TTCCATTGTG ACTTCTCTGA TAAAGCGTCT 1380 GATCTAATCC CAGCACTTCT GTAACCTTCA GCATTTCTTT GAAGGATTTC CTGGTCCACC 1440 TTTCTCATGC TGTAGCAATC ACTATGGTTT ATCTTTTCAA AGCTCTTTTA ATAGGATTTT 1500 20 AATGTTTTAG AAACAGGATT CCAGTGGTGT ATAGTTTTAT ACTTCATGAA CTGATTTAGC 1560 AACACAGGTA AAAATGCACC TTTTAAAGCA CTACGTTTTC ACAGACAATA ACTGTTCTCC 1620 TCATGGAAGT CTTAAACAGA AACTGTTACT GTCCCAAAGT ACTTTACTAT TACGTTCGTA 1680 TTTATCTAGT TTCAGGGAAG GTCTAATAAA AAGACAAGCG GTGGGACAGA GGGAACCTAC 1740 _ _ AACCAAAAAC TGCCTAGATC TTTGCAGTTA TGTGCTTTAT GCCACGAAGA ACTGAAGTAT 1800 25 GTGGTAATTT TTATAGAATC ATTCATATGG AACTGAGTTC CCAGCATCAT CTTATTCTGA 1860 ATAGCATTCA GTAATTAAGA ATTACAATTT TAACCTTCAT GTAGCTAAGT CTACCTTAAA 1920 AAGGGTTTςA AGAGCTTTGT ACAGTCTCGA TGGCCCACAC CAAAACGCTG AAGAGAGTAA 1980 CAACTCCACT AGGATTTCTG TAAGGAGTAA TTTTGATCAA AAGACGTCTT ACTTCCCTTT 2040 GAAGGAAAAG TTTTTAGTGT GTATTGTACA TAAAGTCGGC TTCTCTAAAG AACCATTGGT 2100 30 TTCTTCACAT CTCGGTCTGC GTGAGTAACT TTCTTGCATA ATCAAGGTTA CTCAAGTAGA 2160 AGCCTGAAAA TTAATCTGCT TTTAAAATAA AGAGCAGTCT TCTCCATTCG TATTTGTATT 2220 AGATATAGAG TGACTATTTT TAAAGCATGT TAAAAATTTA GGTTTTATTC ATGTTTAAAG 2280 TATGTATTAT GTATCCATAA TTTTCCTGTT GTTACTGAAA CTTAATTCTA TCAAGAATCT 2340 TTTTCATTCC ACTGAATGAT TTCTTTTGCC CCTAGGAGAA AACTTAATAA TTGTCCCTAA 2400 35 AAACTATCGG CGGATAGTAT AAGACTATAC TAGACAAAGT GAATATTTCC ATTTCCATTA 2460 TCTATCAATT AGTGGCTGAG TTCTTTCTTA GCTGCTTTAA GGAGCCCCTC ACTCCCCAGA 2520 GTCAAAAGGA AATGTAAAAA CTTAGAGCTC CCATTGTAAT GTAAGGGGCA AGAAATTTCT 2580 GTTCTTCTCA ATCCTACTAG CAGCACCAGC CTTGTTTTAA ATGTTTTCTT GAGCTAGAAG 2640 AAATAGCTGA TTATTGTATA TGCAAATTAC ATGCATTTTT AAAAACTATT CTTTCTGAAC 2700 40 TTATCTACCT GGTTATGATA CTGTGGGTCC ATACACAAGT AAAATAAGAT TAGACAGAAG 2760 CCAGTATACA TTTTCCACTA TTGATCTCAT ACTGTAGCCA GCCAGGACCT TACTGATCTC 2820 AGCATAATAA TGCTCACTAA TAATGAAGTC TGCATAGTCA CACTCATCAA GACTGAAGAT 2880 GAAGCAGGTT ACGTGCTCCA TTGGAAGGAG TTTCTGATAG TCTCCTGCTG TTTTACCCCT 2940 TCCATTTTTT AAAATAAGAA ATTAGCAGCC CTCTGCATAA TGTAGCTGCC TATATGCAGT 3000 45 TTTATCCTCT GCCCTAAAGC CTCACTCTCC AGAGCTGTTG GTCATCAGAT GCTTATTGCA 3060 CCCTCACCAT GTGCCTGGTG CCCTGCTGGG TAGAGAACAC AGAGGACAGG GCATACTTCT 3120 TGTCCTTAAG GAGCTTGTGA TCTGTGACAG TAAGCCCTCC TGGGATGTCT GTCCCATGTG 3180 ATTGACTTAC AAGTGAAACT GTCTTATAAT ATGAAGGTCT TTTTGTTTAC TTCTAAACCC 3240 ACTTGGGTAG TTACTATCCC CAAATCTGTT CTGTAAATAA TATTATGGAA GGGTTTCTAT 3300 50 GTCAGTCTAC CTTAGAGAAA GCCAGTCATT CAATATCACA AAAGGCATTC ACGTATCTTT 3360 GAAATGTTCA CAGGAGCCTT TTAACAACAA CTGGGTGGTC CTTGTAGGCA GAACATACTC 3420 TCCTAAGTGG TTGTAGGAAA TTGCAAGGAA -AATAGAAGGT CTGTTCTTGC TCTCAAGGAG 3480 GTTACCTTTA ATAAAAGAAG ACAAACCCAG ATAGATATCT AAACCAAAAT ACTATGCCCC 3540 _ _ TTAATACTTT ATAAGCAGCA TTGTTAAATA GTTCTTACGC TTATACATTC ACAGAACTAC 3600 55 CCTCTTTTCC TTCTATATAA TGACTTTTGC TGGCAGAACT GAAATATAAA CTGTAAGGGG 3660 ATTTCGTCAG TTCCTCCCAG TATACAATAT CCTCCAGGAC ATAGCCAGAA ATCTCCATTC 3720 CACACATGAC TGAGTTCCTA TCCCTGCACT GGTACTGGCT CTTTTCTCCT CTTTCCTTGC 3780 CTCAGGGTTC GTGCTACCCA CTGATTCCCT TTACCCTTAG TAATAATTTT GGATCATTTT 3840 - Λ CTTTCCTTTA AAGGGGAACA AAGCCTTTTT TTTTTTTGAG ACGGAGTGTT GCTCTGTCAC 3900 60 CCAAGCTGGA GTGCAGTGGC ACGATCTTGG CTCACTCCAA CCTCCACCTT CCAGGTTCAA 3960 GTGATTCTCC TGCCTCAGCC TCCCGAGTAG CTGGGACTAC GGGCACGCAC CACCACGTCT 4020 GGCTAATTTT TCTATTTTTA GTAGAGATGG GGTTTCACCC TATTGGTCAG GCTGGTCTTG 4080 AATTCCTCAC CTCAGGTCAT CCGCCTGTCT CGGCCTCCCG AAGTGCTGGG ATTATAGGTG 4140 £ c TGAGCCACCG CACCCAGTTG GGAACAAAGC CTTTTTAACA CACGTAAGGG CCCTCAAACC 4200 65 GTGGGACCTC TAAGGAGACC TTTGAAGCTT TTTGAGGGCA AACTTTACCT TTGTCGTCCC 4260 CAAATGATCG CATTTCTCTT TGAAATTTAT TAGATACTCT TATGTCCCCC AAGGGTACAG 4320 GAGGGGCATC CCTCAGCCTA TGGGAACACC CAAACTAGGA GGGGTTATTG ACAGGAAGGA 4380 ATCAATCCAA GTGAAGGCTT TCTGCTCTTC GTCTTACAAA CCAGTTTCAG AGTTAGCTTT 4440 CTGGGGAGGT GTGTGTTTCT GAAAGGAATT CAAGTGTTCC AGGACAGATG AGCTCAAGGT 4500 70 AAGGTAGCTT TGGCAGCAGG GCTGATACTA TGAGGCTGAA ACAATCCTTG TGATGAAGTA 4560 GATCATGCAG TGACATACAA AGACCAAGGA TTATGTATAT TTTTATATCT CTGTGGTTTT 4620 GAAACTTTAG TACTTAGAAT TTTGGCCTTC TGCACTACTC TTTTGCTCTT ACGAACATAA 4680 TGGACTCTTA AGAATGGAAA GGGATGACAT TTACCTATGT GTCCTGCCTC ATTCCTGGTG 4740 _ AAGCAACTGC TACTTGTTCT CTATGCCTCT AAAATCATGC TCTTTTCTCT GCTAAAGGTA 4800 75 AAAGAAAAGA AAAAAATAGT TGGAAAATAA GACATGCAAC TTGATGTGCT TTTGAGTAAA 4860 TTTATGCAGC AGAAACTATA CAATCAAGGA AGAATTCTAT GGAAATTACA AATCCAAAAC 4920 TCTATGATGA TGTCTTCCTA GGGAGTAGAG AAAGGCAGTG AAATGGCAGT TAGACCAACA 4980 GAGGCTTCAA GGATTCAAGT ACAAGTAATA TTTTGTATAA AACATAGCAG TTTAGGTCCC 5040 OΛ CATAATCCTC AAAAATAGTC ACAAATATAA CAAAGTTCAT TCTTTTAGGG TTTTTAAAAA 5100 80 ACGTCTTCTA CCTAAGGCCA TACTTACTCT TCTATGCTAT CACTGCAAAG GGGTCATATG 5160 TATGTATTAT ATAAAAAAAA AAACCCTTAA TGCACTGTTA TCTCCTAAAT ATTTAGTAAA 5220 TTAATACTAT TTAATTTTTT TAAAGATTTC TCTGTGTAGA CACTAAAAGT ATTACACAAA 5280 ATCTGGACTG AAGGTGTCCT TTTTAACAAC AATTTAAAGT ACTTTTTATA TATGTTATGT 5340 AGTATATCCT TTCTAAACTG CCTAGTTTGT ATATTCCTAT AATTCCTATT TGTGAAGTCT 5400 ACCTGTTCTT GTCTCTTTTT TCAGTCATTT TCTCCACGCA TCCCCCTTTA TATGGTTATA 5460 GAGATGACTC TAGCTTTTCG TGCTCCACTG CGAGGTTTGT GCTCAGAGCC GCTGCACCCC 5520 AGCGAGGCCT GCTCCATGGA GTGCAGGACG AGCTACTGCT TTGGAGCGAG GGTTTCCTCC 5580 TTTTGAGTTG ACCTCACTTC CTTCTTCAAA TGACTGTTAA AACTAAAATA AATTACATTG 5640 CATTTATTTT ATATTCTTGG TTCAAATAAA ATTTAATTGA CTTTG SEQ ID NO:78 PD03 Protein sequence: Protein Accession *: BAA82980 60 120 180 VFLLLQKLLT MDPTKRITSE QALQDPYFQE DPLPTLDVFA GCQIPYPKRE FLNEDDPEEK 240 GDKNQQQQQN QHQQPTAPPQ QAAAPPQAPP PQQNSTQTNG TAGGAGAGVG GTGAGLQHSQ 300 DSSLNQVPPN KKPRLGPSGA NSGGPVMPSD YQHSSSRLNY QSSVQGSSQS QSTLGYSSSS 360 QQSSQYHPSH QAHRY SEQ ID N0.79 PD05 DNA SEQUENCE Nucleic Acid Accession*: XMJX.2922 Coding sequence: 1-2190 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I ATGAATCCTT TCCAGAAAAA TGAGTCCAAG GAAACTCTTT TTTCACCTGT CTCCATTGAA 60 GAGGTACCAC CTCGACCACC TAGCCCTCCA AAGAAGCCAT CTCCGACAAT CTCTGGCTCC 120 AACTATCCAC TGAGCATTGC CTTCATTGTG GTGAATGAAT TCTGCGAGCG CTTTTCCTAT 180 TATGGAATGA AAGCTGTGCT GATCCTGTAT TTCCTGTATT TCCTGCACTG GAATGAAGAT 240 ACCTCCACAT CTATATACCA TGCCTTCAGC AGCCTCTGTT ATTTTACTCC CATCCTCGGA 300 GCAGCCATTG CTGACTCGTG GTTGGGAAAA TTCAAGACAA TCATCTATCT CTCCTTCGTG 360 TATGTGCTTG GCCATGTGAT CAAGTCCTTG GGTGCCTTAC CAATACTGGG AGGACAAGTG 420 GTACACACAG TCCTATCATT GATCGGCCTG AGTCTAATAG CTTTGGGGAC AGGAGGCATC 480 AAACCCTGTG TGGCAGCTTT TGGTGGAGAC CAGTTTGAAG AAAAACATGC AGAGGAACGG 540 ACTAGATACT TCTCAGTCTT CTACCTGTCC ATCAATGCAG GGAGCTTGAT TTCTACATTT 600 ATCACACCCA TGCTGAGAGG AGATGTGCAA TGTTTTGGAG AAGACTGCTA TGCATTGGCT 660 TTTGGAGTTC CAGGACTGCT CATGGTAATT GCACTTGTTG TGTTTGCAAT GGGAAGCAAA 720 ATATACAATA AACCACCCCC TGAAGGAAAC ATAGTGGCTC AAGTTTTCAA ATGTATCTGG 780 TTTGCTATTT CCAATCGTTT CAAGAACCGT TCTGGAGACA TTCCAAAGCG ACAGCACTGG 840 CTAGACTGGG CAGCTGAGAA ATATCCAAAG CAGCTCATTA TGGATGTAAA GGCACTGACC 900 AGGGTACTAT TCCTTTATAT CCCATTGCCC ATGTTCTCGG CTCTTTTGGA TCAGCAGGGT 960 TCACGATGGA CTTTGCAAGC CATCAGGATC AATAGGAATT TGGGGTTTTT TGTGCTTCAG 1020 CCGGACCAGA TGCAGGTTCT AAATCCCTTT CTGGTTCTTA TCTTCATCCC GTTGTTTGAC 1080 TTTGTCATTT ATCGTCTGGT CTCCAAGTGT GGAATTAACT TCTCATCACT TAGGAAAATC 1140 GCTGTTGGTA TCATCCTAGC GTCCCTGGCA TTTGCAGTTG CGGCAGCTCT AGAGATAAAA 1200 ATAAATGAAA TGGCCCCAGC CCAGTCAGGT CCCCAGGAGG TTTTCCTACA AGTCTTGAAT 1260 CTGGCAGATG ATGAGGTGAA GGTGACAGTG GTGGGAAATG AAAACAATTC TCTGTTCATA 1320 GAGTCCATCA AATCCTTTCA GAAAACACCA CACTATTCCA AACTCCACCT GAAAACAAAA 1380 AGCCAGGATT TTCACTTCCA CCTGAAATAT CACAATTTGT CTCTCTACAC TGAGCATTCT 1440 GTGCAGGAGA AGAACTGGTA CAGTCTTCTC ATTCGTGAAG ATGGGAACAG TATCTCCAGC 1500 ATGATGGTAA AGGATACAGA AAGCAAAACA ACCAATGGGA TGACAACCGT GAGGTTTGTT 1560 AACACTTTGC ATAAAGATCT CAACATCTCC CTCAGTACAG ATACCTCTCT CAATGTTGGT 1620 GAAGACTATG GTGTCTCTGC TTATAGAACT GTGCAAAGAG GAGAATACCC TGCAGTGCAC 1680 TGTAGAACAG AAGATAAGAA CTTTTCTCTG AATTTGGGTC TTCTAGACTT TGGTCCAGCA 1740 TATCTGTTTC TTATTACTAA TAACACCAAT CAGGGTCTTC AGGCCTGGAA GATTCAAGAC 1800 ATTCCAGCCA ACAAAATGTC CATTGCGTGG CAGCTACCAC AATATGCCCT GGTTACAGCT 1860 GGGGAGGTCA TGTTCTCTCT CACAGGTCTT GAGTTTTCTT ATTCTCAGGC TCCCTCTAGC 1920 ATGAAATCTG TGCTCCAGGC AGCTTGGCTA TTGACAATTG CAGTTGGGAA TATCATCGTG 1980 CTTGTTGTGG CACAGTTCAG TGGCCTGGTA CAGTGGGCCG AATTCATTTT GTTTTCCTCC 2040 CTCCTGCTGG TGATCTGCCT GATCTTCTCC ATCATGGGCT ACTACTATGT TCCTGTAAAG 2100 ACAGAGGATA TGCGGGGTCC AGCAGATAAG CACATTCCTC ACATCCAGGG GAACATGATC 2160 AAACTAGAGA CCAAGAAGAC AAAACTCTGA SEQ ID NO:80 PD05 Protein sequence: Protein Accession*: χp_002922 11 21 31 41 51 MNPFQKNESK ETLFSPVSIE EVPPRPPSPP KKPSPTICGS NYPLSIAFIV VNEFCERFSY 60 YGMKAVLILY FLYFLHWNED TSTSIYHAFS SLCYFTPILG AAIADSWLGK FKTIIYLSLV 120 YVLGHVIKSL GALPILGGQV VHTVLSLIGL SLIALGTGGI KPCVAAFGGD QFEEKHAEER 180 TRYFSVFYLS INAGSLISTF ITPMLRGDVQ CFGEDCYALA FGVPGLLMVI ALWFAMGSK 240 IYNKPPPEGN IVAQVFKCIW FAISNRFKNR SGDIPKRQHW LDWAAEKYPK QLIMDVKALT 300 RVLFLYIPLP MFWALLDQQG SRWTLQAIRM NRNLGFFVLQ PDQMQVLNPF LVLIFIPLFD 360 FVIYRLVSKC GINFSSLRKM AVGMILACLA FAVAAAVEIK INEMAPAQSG PQEVFLQVLN 420 LADDEVKVTV VGNENNSLLI ESIKSFQKTP HYSKLHLKTK SQDFHFHLKY HNLSLYTEHS 480 VQEKNWYSLV IREDGNSISS MMVKDTESKT TNGMTTVRFV NTLHKDVNIS LSTDTSLNVG 540 EDYGVSAYRT VQRGEYPAVH CRTEDKNFSL NLGLLDFGAA YLFVITNNTN QGLQAWKIED 600 IPANKMSIAW QLPQYALVTA GEVMFSVTCL EFSYSQAPSS MKSVLQAAWL LTIAVGNIIV 660 LVVAQFSGLV QWAEFILFSC LLLVICLIFS IMGYYYVPVK TEDMRGPADK HIPHIQGNMI 720 KLETKKTKL SEQ ID N0:81 PD06 DNA SEQUENCE Nucleic Acid Accession*: NM_020448 Coding sequence: 1-1221 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I ATGGACGGAT CCCACAGCGC AGCCCTGAAG CTGCAGCAGC TGCCTCCCAC AAGTAGCTCC 60 AGCGCCGTAA GCGAGGCCTC CTTCTCCTAC AAGGAAAACC TGATTGGCGC CCTCTTGGCG 120 ATCTTCGGGC ACCTCGTGGT CAGCATTGCA CTTAACCTCC AGAAGTACTG CCACATCCGC 180 CTGGCAGGCT CCAAGGATCC CCGGGCCTAT TTCAAGACCA AGACATGGTC GCTGGGCCTG 240 TTCCTGATGC TTCTGGGCGA GCTGGGTGTG TTCGCCTCCT ACGCCTTCGC GCCGCTGTCA 300 CTCATCGTGC CCCTCAGCGC AGTTTCTGTG, ATAGCTAGTG CCATCATAGG AATCATATTC 360 ATCAAGGAAA AGTCGAAACC GAAAGACTTT CTCAGGCGCT ACGTCTTGTC CTTTGTTGGC 420 TCCGGTTTCG CTGTCGTGGG TACCTACCTG CTCGTGACAT TCGCACCCAA CAGTCACGAG 480 AAGATGACAG GCGAGAATCT CACCAGGCAC CTCGTGAGCT GGCCTTTCCT TTTGTACATC 540 CTGGTGGAGA TCATTCTGTT CTGCTTGCTG CTCTACTTCT ACAAGGAGAA GAACGCCAAC 600 AACATTGTCG TCATTCTTCT CTTGGTGGCG TTACTTCGCT CCATGACAGT GGTGACAGTC 660 AAGGCCGTGG CTCGGATGCT TGTCTTGTCC ATTCAAGGGA ACCTGCAGCT TGACTACCCC 720 ATCTTCTACG TCATGTTCGT GTGCATGGTG GCAACCGCCG TCTATCAGGC TGCGTTTTTC 780 AGTCAAGCCT CACAGATGTA CGACTCCTCT TTGATTGCCA GTGTCGGCTA CATTCTGTCC 840 ACAACCATTG CTATCACAGC AGGTGCAATA TTTTACCTGG ACTTCATCGG GGAGGACGTG 900 CTGCACATCT GCATGTTTGC ACTGGGGTGC CTCATTGCAT TCTTCGGCGT CTTCTTAATC 960 ACGCGTAACA GGAAGAAGCC CATTCCATTT GAGCCCTATA TTTCCATGGA TGCCATCCCA 1020 GGTATGCAGA ACATCCACGA TAAAGGGATG ACTGTCCAGC CTCAACTTAA AGCTTCTTTT 1080 TCCTATCGGG CTCTGGAAAA CAATGACAAC ATTTCTGAGA TCTACGCTCC TCCCACCCTG 1140 CCAGTCATGC AAGAAGAGCA CGGCTCCAGA AGTGCCTCTG GGGTCCCCTA CCGAGTCCTA 1200 GAGCACACCA AGAAGGAATG A SEQ ID NO:82 PD06 Protein sequence Protein Accession* NP_065181 11 21 31 41 51 I I I I I MDGSHSAALK LQQLPPTSSS SAVSEASFSY KENLIGALLA IFGHLWSIA LNLQKYCHIR 60 LAGSKDPRAY FKTKTWWLGL FLMLLGELGV FASYAFAPLS LIVPLSAVSV IASAIIGIIF 120 IKEKWKPKDF LRRYVLSFVG CGLAWGTYL LVTFAPNSHE KMTGENVTRH LVSWPFLLYM 180 LVEIILFCLL LYFYKEKNAN NIWILLLVA LLGSMTWTV KAVAGMLVLS IQGNLQLDYP 240 IFYVMFVCMV ATAVYQAAFL SQASQMYDSS LIASVGYILS TTIAITAGAI FYLDFIGEDV 300 LHICMFALGC LIAFLGVFLI TRNRKKPIPF EPYISMDAMP GMQNMHDKGM TVQPELKASF 360 SYGALENNDN ISEIYAPATL PVMQEEHGSR SASGVPYRVL EHTKKE SEQ ID NC.83 PD08 DNA SEQUENCE Nucleic Acid Accession* NM.032712 Coding sequence: 555-908 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 CACTCATTAA GAACAGAGGA GGCTGCCTGT TACTCCTGGT GTTCCATCCC TCCAGACACT 60 CTGCTGTTTC CTGCCTAGGC GTGGCTGCAG CCATGGCTAG GAAAGCGCTG CCACCCACCC 120 ACCTGGGCCA GAGCTGGTTC TGCTCCTGCT GCAGGGACAC TGAGCTGGCT ATCTCGGCGC 180 TTCGGGCAAG AACTGCAACA GGCTCTCCTG GGTCCTCCAG GTGTACAGCC GGGCCCCTGC 240 CTTGTGCCTC AGCTCTCGAG AGCTGCTGCT GCCGGGTGAC CTGATCCAAC CTGATAAGGT 300 GCCATCTTCA GCTACCACTG CAAGGCCCTG AGGGCAACAG CAGCACGGCA CTGCCCACCC 360 GGCTGCTGAT GGCCTGGTGC CAGCTGGGAG TCCTCCCGGC ACTTCGAGGC CACTCAGCCA 420 CCCTTCCAGC CCCAGCCCAC CATCGACAGG GGTATCCAGC TTCCTCCTCA ACCTCGTCCT 480 CTGCCCCTGA GCCAGTGACG CCCAAGGACA TGCCTGTTAC CCAGGTCCTG TACCAGCACT 540 AGCTGGTCAA GGGCATGACA GTGCTGGAGG CCGTCTTGGA GATCCAGGCC ATCACTGGCA 600 GCAGGCTCCT CTCCATGGTG CCAGGGCCCG CCAGGCCACC AGGCTCATGC TGGGACCCAA 660 CCCAGTGCAC AAGGACTTGG CTGCTGAGCC ACACACCCAG GAGAAGGTCG ATAAGTGGGC 720 TACCAAGGGC TTCCTGCAGG CTAGGGGAGG AGCCACCCCC GCTTCCCTAT TGTGACCAGG 780 CCTATGGGGA GGAGCTGTCC ATACGCCACC GTGAGACCTG GGCCTGGCTC TCAAGGACAG 840 ACACCGCCTG GCCTGGTGCT CCAGGGGTGA AGCAGGCCAG AATCCTGGGG GAGCTGCTCC 900 TGGTTTGAGC TGCATTCAGG AAGTGCGGGA CATCGTAGGG GAGGCAAAAA GCCTTGGGCA 960 CTACCCTCCC TGTGGAGCTG TTCGGTCTCC GTCGAGCTAG CCACACCCTG ACACCATGTT 1020 CAAGGGTACC GGAAGAGAAG GGTGTCTGCC CCCAACCTCC CCTGTCGGTG TCACTGGCCA 1080 GATCTCATGA GGGAAGCAGG CCTTGTGAGT GGACACTGAC CATCAGTCCC TGGGGGGAGT 1140 GATCCCCCAG GCATCGTGTG CCATGTTβCA CTTCTGCCCA GGCAGCAGGG TGGGTGGGTA 1200 CCATCGGTGC CCACCCCTCC ACCACATGGG GCCCCAAAGC ACTGCAGGCC AAGCAGGGCA 1260 ACCCCACACC CTTGACATAA AAGCATCTTG AAGCTTTTAA AAAAAAAAAA AAAAAA SEQ ID NO:84 PD08 Protein sequence Protein Accession* NPJi β ioi 11 21 31 41 51 I I I I I I MTVLEAVLEI QAITGSRLLS MVPGPARPPG SCWDPTQCTR TWLLSHTPRR RWISGLPRAS 60 CRLGEEPPPL PYCDQAYGEE LSIRHRETWA WLSRTDTAWP GAPGVKQARI LGELLLV SEQ ID NO:85 PDT1 DNA SEQUENCE Nucleic Acid Accession* NM_000693 Coding sequence: 53-1591 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I AGCCGGTGCG CCGCAGACTA GGGCGCCTCG GGCCAGGGAG CGCGGAGGAG CCATCGCCAC 60 CGCTAACGGG GCCGTGGAAA ACGGGCAGCC GGACGGGAAG CCGCCGGCCC TGCCGCGCCC 120 CATCCGCAAC CTCGAGGTCA AGTTCACCAA GATATTTATC AACAATGAAT GGCACGAATC 180 CAAGAGTCGG AAAAAGTTTC CTACATGTAA CCCTTCAACT CGGGAGCAAA TATGTCAAGT 240 GGAAGAAGGA GATAAGCCCG ACGTGGACAA GGCTGTGGAG GCTGCACAGG TTGCCTTCCA 300 GAGGGGCTCG CCATGGCGCC GGCTGGATGC CCTGAGTCGT GGGCGGCTCC TGCACCAGCT 360 GGCTGACCTG GTGGAGAGGG ACCGCGCCAC CTTGGCCGCC CTGGAGACGA TGGATACAGG 420 GAAGCCATTT CTTCATGCTT TTTTCATCGA CCTGGAGGGC TGTATTAGAA CCCTCAGATA 480 CTTTGCAGGG TGGGCAGACA AAATCCAGGG CAAGACCATC CCCACAGATG ACAACGTCGT 540 ATGCTTCACC AGGCATGAGC CCATTGGTGT CTCTCGGGCC ATCACTCCAT GGAACTTCCC 600 CCTGCTGATC CTGGTCTGGA AGCTCGCACC CGCCCTCTGC TGTGGGAACA CCATGGTCCT 660 GAAGCCTCCG GAGCAGACAC CTCTCACCGC CCTTTATCTC GGCTCTCTGA TCAAAGAGGC 720 CGGGTTCCCT CCAGGAGTGG TGAACATTCT GCCAGGATTC GGGCCCACAG TGGGAGCAGC 780 AATTTCTTCT CACCCTCAGA TCAACAAGAT CGCCTTCACC GGCTCCACAG AGGTTGGAAA 840 ACTGGTTAAA GAAGCTCCGT CCCGGAGCAA TCTGAAGCGG GTGACGCTGG AGCTGGGGGG 900 GAAGAACCCC TCCATCGTGT GTCCGGACGC TGACTTGGAC TTGGCAGTGG AGTGTGCCCA 960 TCAGGGAGTG TTCTTCAACC AAGGCCAGTG TTGCACGGCA GCCTCCAGGG TGTTCGTGGA 1020 GGAGCAGGTC TACTCTCAGT TTGTCAGGCG GAGCGTGGAG TATGCCAAGA AACGGCCCGT 1080 GGGAGACCCC TTCGATCTCA AAACAGAACA GGGGCCTCAG ATTGATCAAA AGCAGTTCGA 1140 CAAAATCTTA GAGCTGATCG AGAGTCGGAA GAAGGAAGGG GCCAAGCTGG AATGCGGGGG 1200 CTCAGCCATG GAAGACAAGG GGCTCTTCAT CAAACCCACT GTCTTCTCAG AAGTCACAGA 1260 CAACATGCGG ATTGCCAAAG AGGAGATTTT CGGGCCAGTG CAACCAATAC TGAAGTTCAA 1320 AAGTATCGAA GAAGTGATAA AAAGAGCGAA TAGCACCGAC TATGGACTCA CAGCAGCCGT 1380 GTTCACAAAA AATCTCGACA AAGCCCTGAA GTTGGCTTCT GCCTTAGAGT CTGGAACGGT 1440 CTGGATCAAC TGCTACAACG CCCTCTATGC ACAGGCTCCA TTTGGTGGCT TTAAAATGTC 1500 AGGAAATGGC AGAGAACTAG GTGAATACGC TTTGGCCGAA TACACAGAAG TGAAAACTGT 1560 CACCATCAAA CTTGGCGACA AGAACCCCTC AAGGAAAGGC GGGGCTCCTT CCTCAAACAT 1620 CGGACGGCGG AATGTGGCAG ATGAAATGTC CTGGAGGAAA AAAATGACAT TTCTGACCTT 1680 CCCGGGACAC ATTCTTCTGβ AGGCTTTACA TCTACTCGAG TTGAATGATT GCTGTTTTCC 1740 TCTCACTCTC CTGTTTATTC ACCAGACTGG GGATGCCTAT AGGTTGTCTC TGAAATCGCA 1800 GTCCTGCCTG GGGAGGGAGC TGTTGGCCAT TTCTGTGTTT CCCTTTAAAC CAGATCCTGG 1860 AGACAGTCAG ATACTCAGGG CGTTGTTAAC AGGGAGTGGT ATTTGAAGTG TCCAGCAGTT 1920 GCTTGAAATG CTTTCCCGAA TCTCACTCCA GTAAGAATGT GGGAAAACCC CCTGTCTGTT 1980 CTGCAAGCAG GGCTCTTGCA CCAGCGGTCT CCTCAGGGTG GACCTCCTTA CAGAGCAAGC 2040 CACGCCTCTT TCCGAGGTGA AGGTGGGACC ATTCCTTCGG AAAGGATTCA CAGTAAGGTT 2100 TTTTGGTTTT TCTTTTTTGT TTTCTTGTTT TTAAAAAAAG GATTTCACAG TCAGAAAGTT 2160 TTGGTTAGTC CATACCGTGG AAGGGCGCCA GGGTCTTTGT GGATTGCATG TTGACATTGA 2220 CCGTCAGATT CGGCTTCAAA CCAATACTGC CTTTCGAATA TGACAGAATC AATAGCCCAG 2280 AGAGCTTAGT CAAAGACGAT ATCACGGTCT ACCTTAACCA AGGCACTTTC TTAAGCAGAA 2340 AATATTGTTG AGGTTACCTT TGCTGCTAAA GATCCAATCT TCTAACGCCA CAACAGCATA 2400 GCAAATCCTA GGATAATTCA CCTCCTCATT TGACAAATCA GAGCTCTAAT TCACTTTAAC 2460 AAATTACGCA TTTCTATCAC GTTCACTAAC AGCTTATGAT AAGTCTCTCT AGTCTTCCTT 2520 TTCTCCAGTT- CTGTTACCCA ATTTAGATTA GTAAAGCGTA CACAACTGGA AAGACTGCTG 2580 TAATAACACA GCCTTGTTAT TTTTAAGTCC TATTTTCATA TTAATTTCTG ATTAGTTAGT 2640 AAATAACACC TGGATTCTAT GGAGGACCTC GGTCTTCATC CAAGTGGCCT GAGTATTTCA 2700 CTGGCAGGTT GTGAATTTTT CTTTTCCTCT TTGGGAATCC AAATCATCAT GTGCAATTTC 2760 ATGTTTTAAC TTCGGAAACT GAAAGTGTTC CCATATAGCT TCAAAAACAA AAACAAATGT 2820 GTTATCCGAC GGATACTTTT ATCGTTACTA ACTAGTACTT TCCTAATTGG GAAAGTAGTG 2880 CTTAAGTTTG CAAATTAAGT TGGGGAGGGC AATAATAAAA TGAGGGCCCG TAACAGAACC 2940 AGTGTGTGTA TAACGAAAAC CATGTATAAA ATGGGCCTAT CACCCTTGTC AGAGATATAA 3000 ATTACCACAT TTGGCTTCCC TTCATCAGCT AACACTTATC ACTTATACTA CCAATAACTT 3060 GTTAAATCAG GATTTGGCTT CATACACTGA ATTTTCAGTA TTTTATCTCA AGTAGATATA 3120 GACACTAACC TTGATAGTGA TACGTTAGAG GGTTCCTATT CTTCCATTGT ACGATAATCT 3180 CTTTAATATG AAATGCTACA TTATTTATAA TTGGTAGAGT TATTGTATCT TTTTATAGTT 3240 GTAAGTACAC AGAGGTGGTA TATTTAAACT TCTGTAATAT ACTGTATTTA GAAATGGAAA 3300 TATATATAGT GTTAGGTTTC ACTTCTTTTA AGGTTTACCC CTGTGGTGTG GTTTAAAAAT 3360 CTATAGGCCT GGGAATTCCG ATCCTAGCTC CAGATCGCAT CCCACAATGC GAGAATGATA 3420 AAATAAAATT GGATATTTGA GA SEQ ID NO:86 PDT1 PROTEIN SEQUENCE Protein Accession *: NP_0O0684 11 21 31 41 51 I I I I MATANGAVEN GQPDGKPPAL PRPIRNLEVK FTKIFINNEW HESKSGKKFA TCNPSTREQI 60 CEVEEGDKPD VDKAVEAAQV AFQRGSPWRR LDALSRGRLL HQLADLVERD RATLAALETM 120 DTGKPFLHAF FIDLEGCIRT LRYFAGWADK IQGKTIPTDD NWCFTRHEP IGVCGAITPW 180 NFPLLMLVWK LAPALCCGNT MVLKPAEQTP LTALYLGSLI KEAGFPPGW NIVPGFGPTV 240 GAAISSHPQI NKIAFTCSTE VGKLVKEAAS RSNLKRVTLE LGGKNPCIVC ADADLDLAVE 300 CAHQGVFFNQ GQCCTAASRV FVEEQVYSEF VRRSVEYAKK RPVGDPFDVK TEQGPQIDQK 360 QFDKILELIE SGKKEGAKLE CGGSAMEDKG LFIKPTVFSE VTDNMRIAKE EIFGFVQPIL 420 KFKSIEEVIK RANSTDYGLT AAVFTKNLDK ALKLASALES GTVWINCYNA LYAQAPFGGF 480 KMSGNGRELG EYALAEYTEV KTVTIKLGDK NP SEQ ID NO:87 PDV3 DNA SEQUENCE Nucleic Acid Accession* NM_032642 Coding sequence: 184-1263 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 GACCATTAGC AGGCACCCAG GCCTGTCTTT GGCTCGGAAA CGGTGGCCCC CAATGTAGCC 60 TAGTTTGAAC CTAGGAACTG CAGGACCAGA GAGATTCCAC TGGAGCCTGA TGGACGGGTG 120 ACAGAGGGAA CCCTACTCTG GAAACTGTCA GTCCCAGGGC ACTGGGGAGG GCTCAGGCCG 180 ACCATGCCCA GCCTGCTGCT GCTGTTCACG GCTGCTCTGC TCTCCAGCTG GGCTCAGCTT 240 CTGACAGACG CCAACTCCTG GTGGTCATTA GCTTTGAACC CGGTCCAGAG ACCCGAGATG 300 TTTATCATCG GTGCCCAGCC CGTCTCCAGT CAGCTTCCCG GGCTCTCCCC TCGCCAGAGG 360 AAGCTGTCCC AATTGTACCA GGAGCACATC GCCTACATAG GGGAGGGAGC CAAGACTGGC 420 ATCAAGGAAT GCCAGCACCA GTTCCGGCAG CGGCGGTCGA ATTGCAGCAC AGCGGACAAC 480 GCATCTGTCT TTCGGAGAGT CATGCAGATA GGCAGCCGAβ AGACCGCCTT CACCCACGCG 540 GTGAGCGCCG CGGGCGTGGT CAACGCCATC AGCCGGGCCT GCCGCGAGGG CGAGCTCTCC 600 ACCTGCGGCT GCAGCCGGAC GGCGCGGCCC AAGGACCTGC CCCGGGACTG GCTCTCGGGC 660 GGCTGTGGGG ACAACGTGGA GTACGGCTAC CGCTTCGCCA AGGAGTTTCT GGATCCCCGG 720 GAGCGAGAGA AGAACTTTGC CAAAGGATCA GAGGAGCAGG GCCGGGTGCT CATCAACCTG 780 CAAAACAACG AGGCCGGTCG CAGGGCTGTG TATAAGATCG CAGACGTAGC CTGCAAATGC 840 CACGGCGTCT CGGGGTCCTG CAGCCTCAAG ACCTCCTGGC TGCAGCTGGC CGAGTTCCGC 900 AAGGTCGGGG ACCGGCTGAA GGAGAAGTAC GACAGCGCGG CCGCCATGCG CGTCACCCGC 960 AAGGGCCGGC TGGAGCTGGT CAACAGCCGC TTCACCCAGC CCACCCCGGA GGACCTGGTC 1020 TATGTGGACC CCAGCCCCGA CTACTGCCTG CGCAACGAGA GCACGGGCTC CCTCGGCACG 1080 CAGGGCCGCC TCTGCAACAA GACCTCGGAG GGCATGGATG GCTGTGAGCT CATGTGCTGC 1140 GGGCGTGGCT ACAACCAGTT CAAGAGCGTG CAGGTGGAGC GCTGCCACTG CAAGTTCCAC 1200 TCGTGCTGCT TCGTCAGGTG TAAGAAGTGC ACGGAGATCG TGGACCAGTA CATCTGTAAA 1260 TAGCCCGGAG GGCCTGCTCC CGGCCCCCCC TGCACTCTCC CTCACAAAGG TCTATATTAT 1320 ATAAATCTAT ATAAATCTAT TTTATATTTG TATAAGTAAA TGGGTGGGTG CTATACAATG 1380 GAAAGATCAA AATGGAAAGG AAGAGCTTAT TTAAGAGACG CTGGAGATCT CTGAGGAGTG 1440 GACTTTGCTG GTTCTCTCCT CTTGGTGGGT GGGAGACAGG GCTTTTTCTC TCCCTCTCGC 1500 GAGGACTCTC AGGATCTAGG GACTTGGAAA TATTTACTGT CTGTCCACCA CGGCCTCGAG 1560 GAGGGAGGTT GTGGTTGGAT GGAGGAGATG ATCTTGTCTG GAAGTCTAGA GTCTTTGTTG 1620 GTTAGAGGAC TGCCTGTGAT CCTGGCCACT AGGCCAAGAG GCCCTATGAA GGTGGCGGGA 1680 ACTCAGCTTC AACCTCGATG TCTTCAGGGT CTTCTCCAGA ATCTAGATGG GTTCCGTAAG 1740 AGGCCTGGTG CTCTCTTACT CTTTCATCCA CGTGCACTTG TGCGGCATCT GCAGTTTACA 1800 GGAACGGCTC CTTCCCTAAA ATGAGAAGTC CAAGGTCATC TCTCGCCCAG TGACCACAGA 1860 GAGATCTGCA CCTCCCGGAC TTCAGGCCTG CCTTTCCAGC GAGAATTCTT CATCCTCCAC 1920 GGTTCACTAG CTCCTACCTC AAGAGGAAAG GGGGCCATTT GACCTGACAT GTCAGGAAAG 1980 CCCTAAACTG AATGTTTGCG CCTGGGCTGC AGAAGCCAGG GTCCATCACC AGGCTGCGTG 2040 GACGTTATAC TGTCTTCCCC CACCCCCGGG GAGGGGAAGC TTGAGCTGCT GCTCTCACTC 2100 CTCCACCGAG GGAGGCCTCA CAAACCACAG GACGCTGCAA CGGGTCAGGC TGGCGGGCCC 2160 GGCGTGCTCA TCATCTCTGC CCCAGGTGTA CGGTTTCTCT CTGACATTAA ATGCCCTTCA 2220 TGGAAAAAAA AAAAAGAAAA AAAAAAAAAA AA SEQ ID N0.88 PDV3 Protein sequence Protein Accession* NP_116031 11 21 31 41 51 I I I I I MPSLLLLFTA ALLSSWAQLL TDANSWWSLA LNPVQRPEMF IIGAQFVCSQ LPGLSPGQRK 60 LCQLYQEHMA YIGEGAKTGI KECQHQFRQR RWNCSTADNA SVFGRVMQIG SRETAFTHAV 120 SAAGWNAIS RACREGELST CGCSRTARPK DLPRDWLWGG CGDNVEYGYR FAKEFVDARE 180 REKNFAKGSE EQGRVLMNLQ NNEAGRRAVY KMADVACKCH GVSGSCSLKT CWLQLAEFRK 240 VGDRLKEKYD SAAAMRVTRK GRLELVNSRF TQPTPEDLVY VDPSPDYCLR NESTGSLGTQ 300 GRLCNKTSEG MDGCELMCCG RGYNQFKSVQ VERCHCKFHW CCFVRCKKCT EIVDQYICK- SEQ ID N0:89 PDT9 DNA SEQUENCE Nucleic Acid Accession*: NM_0 33 280 Coding sequence: 58-636 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 GGCAGCCGTC TGTGCCACCC AGAGCCGGCG GGCCGCTAGG TCCCCGGAGA CCCTGCTATG 60 GTGCGTGCGG GCGCCGTGGG GGCTCATCTC CCCGCGTCCG GCTTGGATAT CTTCGGGGAC 120 CTGAAGAAGA TGAACAAGCG CCAGCTCTAT TACCAGGTTT TAAACTTCGC CATGATCGTC 180 TCTTCTGCAC TCATGATATG GAAAGGCTTG ATCGTGCTCA CAGGCAGTGA GAGCCCCATC 240 GTGGTCGTCC TGAGTGGCAG TATGGAGCCG GCCTTTCACA GAGGAGACCT CCTGTTCCTC 300 ACAAATTTCC GGGAAGACCC AATCAGAGCT GGTCAAATAG TTGTTTTTAA AGTTGAAGGA 360 CGAGACATTC CAATAGTTCA CAGAGTAATC AAAGTTCATC AAAAAGATAA TCGAGACATC 420 AAATTTCTGA CTAAAGGAGA TAATAATCAA GTTCATGATA GAGGCTTCTA CAAAGAAGGC 480 CAGAACTGGC TGGAAAAGAA GGACGTGGTG GGAAGAGCAA GAGGGTTTTT ACCATATGTT 540 GGTATGGTCA CCATAATAAT GAATGACTAT CCAAAATTCA AGTATGCTCT TTTGGCTGTA 600 ATGGGTGCAT ATCTGTTACT AAAACGTGAA TCCTAAAATC AGAAGCAGTT CCTGGGACCA 660 GATTGAAATC AATTCTGTTG AAAAAGAGAA AAACTAATAT ATTTGAGATG TTCCATTTTC 720 TGTATAAAAG GGAACAGTGT GGAGATGTTT TTGTCTTGTC CAAATAAAAG ATTCACCAGT 780 AAAAAAAAAA AAAA SEQ ID NO:90 PDT9 Protein seouence Protein Accession* NP_150596 1 11 21 31 41 51 I I I I I I MVRAGAVGAH LPASGLDIFG DLKKMNKRQL YYQVLNFAMI VSSALMIWKG LIVLTGSESP 60 IVWLSGSME PAFHRGDLLF LTNFREDPIR AGEIWFKVE GRDIPIVHRV IKVHEKDNGD 120 IKFLTKGDNN EVDDRGLYKE GQNWLEKKDV VGRARGFLPY VGMVTIIMND YPKFKYALLA 180 VMGAYVLLKR ES SEQ ID N0:91 PDV5 DNA SEQUENCE Nucleic Acid Accession * NM_016590 Coding sequence: 691-975 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I GATTACTCAC ACAGTCTTGA AGATGCAATG TCAGCTATTT AGGACAGAAA CATCCAAGGC 60 CGTGTCAGAA CTCAATTACG ACTACATATG CATTAAGGCA GGAACTGGCA GGCCTCAGGG 120 TACGCCAACT ATAGGACTCG TCCTTCTCGT ACGCTGGGCT ATAATCTATC AAACTGAGCT 180 CCAGAGCCAβ CCAATCACTT AGCTCCTCAT AACAAGTCTA ACTGGCTCTβ GAAAGCTGAA 240 AGGGCTCCAC TGGAACAACA CAGATCAGAT ATTCTACACA TTAATCTACT TATCTGGAAT 300 CACTTTGCCT CTAAAGGCCA GAGAAAAATC ACAGCTTCCT TGTCGGAGGG GAAAAGGACA 360 GGTGATCTCβ GGAAAACGCA GCTACACCTG GAGCAAGGTC TCTTCCCGGC TTGGCAATCT 420 CAGCTGTGCC GGCGCTACGG GACCCGAGCC GTCCCAGAAA CCAAAGGGCA GGCACGGCAG 480 CAAACGCCTG AGTCCTGCTG CCTTCGGTGA CTATATGAGA ATGGAAACTT CTAAGGAAGC 540 CAGGTTGTTA GAATTGTTAC CCCCTTTACT CAGAGATAAC ATAGATTATC CAGGCTCAGA 600 TGGAAAACAA GCCCTTTATT GAATTTTCAA CACAGACTCC CTCCTTCTCA TCTCCTTAAT 660 AAAATTTCAT TAAAATCCCC TTGAACTCCC ATGTTCAAAT CTCCATTTGT TGACAGACAA 720 AGCCAACAAT ACTCTAAACT GAGGCCTGCA AGTCATTTCA TTTGTATTTT TGTCCAGAAA 780 TTTCCCATAG GAAGACTTCA CCTCCTACAA CTCCGAAGAA AACCCTTACT GTCCAAGACC 840 GTCACCAGCA ACCATCCGCA GTCATTCAAG TGGAAGCTTT CACAGCTTTT GTACATTCTC 900 TGTGTCAATA TACAACTGAG TTACAGACTG TCCCCTGGCT CCCTGACCCT TACAAACACT 960 AAAAGTTTTG TTTGACTCAA CTTCAAGCTG CTCATCTGTT AGTAAGTGAT GTTCACTCCA 1020 GAACACATTC ATGATCAGAA CTTTCTAAAA GACCAGCACT GCTCTTCCCC TCCTATAATC 1080 ATAATAATCA TGATAACCTG AAACATGTTA CTGGGACTCG ACATTTTTCT GGGGATTGAA 1140 ATCTTTAGTC CTTCGAGCTG TCACATAGCA GGGGCAACCT CACACTGAAA CAAAGGAAGT 1200 GATGTCCCAT TATTATCCAC CCTGAGCCAC CATAATATCC TGTTTACATT TATTTTCTTC 1260 AGCCTGTGCA AAACAAAGCA ATGGAAAAGG AAACTAAAAA ATATACATAC TAGTACCATT 1320 ATCTTCTTTT GCCTAAAATT ACTAATGCAC CACGTCAGTC TGCTTCCTTC AGGCATCATT 1380 CTCAATTCAT CAGGACTTGT ATTAGCAGGT TCTGGCTAGA GAGACTATCT CCTGTCATCA 1440 CGATCAATTA ATGTTTTCTG GTGATCACAT CAGGCCCTAT CTAAGAAGCT CATGGTATAC 1500 AAGGGTCACC CAAATAGCTG AGTGCAGTCC TTCCTCATAT TTCCTTCATC TTAACCCCGC 1560 AAACAAGAAT TAAGATGATC CCAATAAAAG AAAAATTGCT CAGGAAACTC AACCTTTTTC 1620 TGAACCAAGC ACTCTCAGCA AATCTCAGGT ATTAGAGCAA CTATGGTTGA TTGAAAAGTG 1680 TCTCAAAATC TGGGCCAAGA ATCATTGCTA GGTCCATAAG CTAATTTGTC TGGCCTTCCC 1740 ATTTACGTAA GCCAAAGAAA GTCACTCATG AGTAAACTAT AGAAAACGTT CAGACCCATC 1800 CTGTTAGTAT GTCAAATCAA CTAAGACTGG CAGGGTATTA ACTCCATTCC AGGTGACATG 1860 GATAAAGAGC CCCATTATTT TCACAGTGCC AGCCTCTACC TAAGGAAACC CTAGACCTTG 1920 GAACCAGTTT CCTGGTAGGG AACTGCTGAC AGTTTCAATG CTGACAGTTC GAGCCAATGC 1980 CTCATAGTGT AAACTGAAAG AAAAATAGTT GCTTTTTAAA ATCTCAGCAA GAAGGCCTGC 2040 CTCATCTTAA CAAAGCAAAA AAAAATGCTT TAATTCAAAT TAAAAATCAT GATACTAAAA 2100 AAAAAAAA SEQ ID NO:92 PDV5 Protein sequence Protein Accession * NP_057674 1 11 21 31 41 51 I I I I I I - MQCQLFRTET SKAVSELNYD YICIKAGTGR PQGTPTIGLV LLVRWAHYE TELQSQPIT SEQ ID NO:93 PEE6 DNA SEQUENCE Nucleic Acid Accession* NM_002606 Coding sequence: 61-1842 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I GTA I I CGCGGCGGCT GGCGTCGGGA AAGTACA AAAAGTCCGA GTCCAGCCGC CGGGCGCAGG 60 ATGGGATCCG GCTCCTCCAG CTACCGGCCC AAGGCCATCT ACCTGGACAT CGATGGACGC 120 ATTCAGAAGG TAATCTTCAG CAAGTACTGC AACTCCAGCG ACATCATGGA CCTGTTCTGC 180 ATCGCCACCG GCCTGCCTCG GAACACGACC ATCTCCCTGC TGACCACCGA CGACGCCATG 240 GTCTCCATCβ ACCCCACCAT GCCCGCGAAT TCAGAACGCA CTCCGTACAA AGTGAGACCT 300 GTGGCCATCA AGCAACTCTC CGCTGGTGTC GAGGACAAGA GAACCACAAG CCGTCGCCAG 360 TCTGCTGAGA GACCACTCAG GGACAGACGG GTTCTGGGCC TGGAGCAGCC CCGGAGGGAA 420 GGAGCATTTG AAAGTGGACA GGTAGAGCCC AGGCCCAGAG AGCCCCAGGG CTGCTACCAG 480 GAAGGCCAGC GCATCCCTCC AGAGAGAGAA GAATTAATCC AGAGCGTGCT GGCGCAGGTT 540 GCAGAGCAGT TCTCAAGAGC ATTCAAAATC AATGAACTGA AAGCTCAAGT TGCAAATCAC 600 TTGGCTGTCC TAGAGAAACG CGTGGAATTG GAAGGACTAA AAGTGGTGGA GATTGAGAAA 660 TGCAAGAGTC ACATTAAGAA GATGAGGGAG GAGCTCGCGG CCAGAAGCAG CAGGACCAAC 720 TGCCCCTGTA AGTACAGTTT TTTGGATAAC CACAAGAAGT TGACTCCTCG ACGCGATGTT 780 CCCACTTACC CCAAGTACCT GCTCTCTCCA GAGACCATCG AGGCCCTGCG GAAGCCGACC 840 TTTGACGTCT GGCTTTGGGA GCCCAATGAG ATGCTGAGCT GCCTGGAGCA CATGTACCAC 900 GACCTCGGGC TCGTCAGGGA CTTCAGCATC AACCCTGTCA CCCTCAGGAG GTGGCTGTTC 960 TGTGTCCACG ACAACTACAG AAACAACCCC TTCCACAACT TCCGGCACTC CTTCTGCGTG 1020 GCCCAGATCA TGTACAGCAT GGTCTCGCTC TCCAGTCTCC AGGAGAAGTT CTCACAAACG 1080 GATATCCTGA TCCTAATCAC AGCGGCCATC TCCCACGATC TGGACCATCC CGGCTACAAC 1140 AACACGTACC AGATCAATGC CCGCACAGAG CTGGCGGTCC GCTACAATGA CATCTCACCG 1200 10 CTGGAGAACC ACCACTGCGC CGTGGCCTTC CAGATCCTCG CCGAGCCTCA GTGCAACATC 1260 TTCTCCAACA TCCCACCTGA TGGGTTCAAG CAGATCCGAC AGGGAATGAT CACATTAATC 1320 TTGGCCACTG ACATGGCAAG ACATCCAGAA ATTATGGATT CTTTCAAAGA GAAAATGGAG 1380 AATTTTGACT ACAGCAACGA GGAGCACATG ACCCTGCTCA AGATGATTTT GATAAAATGC 1440 TGTGATATCT CTAACGAGGT CCGTCCAATG GAAGTCGCAG AGCCTTGGGT GGACTCTTTA 1500 15 TTAGAGGAAT ATTTTATGCA GAGCGACCGT GAGAAGTCAG AAGGCCTTCC TGTGGCACCG 1560 TTCATCGACC GAGACAAAGT GACCAAGGCC ACAGCCCAGA TTCGGTTCAT CAAGTTTGTC 1620 CTGATCCCAA TGTTTGAAAC AGTGACCAAG CTCTTCCCCA TGGTTGAGGA GATCATGCTC 1680 CAGCCACTTT GGGAATCCCG AGATCGCTAC GAGGAGCTCA AGCGGATAGA TGACGCCATC 1740 AAAGAGTTAC AGAAGAAGAC TGACAGCTTG ACGTCTGGGG CCACCGAGAA GTCCAGAGAG 1800 20 AGAAGCAGAG ATGTCAAAAA CAGTGAAGGA GACTGTGCCT_ GAGGAAAGCG GGGGGCGTGG 1860 CTGCAGTTCT GGACGGGCTG GCCGAGCTGC GCGGGATCCT TGTGCAGGGA AGAGCTGCCC 1920 TGGGCACCTG GCACCACAAG ACCATGTTTT CTAAGAACCA TTTTGTTCAC TGATACAAAA 1980 AAAAAAAAAA A 25 SEQ ID NO:94 PEE6 Protein sequence Protein Accession* NP_002597 11 21 31 41 51 30 I I I I I MGSGSSSYRP KAIYLDIDGR IQKVIFSKYC NSSDIMDLFC IATGLPRNTT ISLLTTDDAM 60 VSIDPTMPAN SERTPYKVRP VAIKQLSAGV EDKRTTSRGQ SAERPLRDRR WGLEQPRRE 120 GAFESGQVEP RPREPQGCYQ EGQRIPPERE ELIQSVLAQV AEQFSRAFKI NELKAEVANH 180 LAVLEKRVEL EGLKWEIEK CKSDIKKMRE ELAARSSRTN CPCKYSFLDN HKKLTPRRDV 240 PTYPKYLLSP ETIEALRKPT FDVWLWEPNE MLSCLEHMYH DLGLVRDFSI NPVTLRRWLF 300 35 CVHDNYRNNP FHNFRHCFCV AQMMYSMVWL CSLQEKFSQT DILILMTAAI CHDLDHPGYN 360 NTYQINARTE LAVRYNDISP LENHHCAVAF QILAEPECNI FSNIPPDGFK QIRQGMITLI 420 LATDMARHAE IMDSFKEKME NFDYSNEEHM TLLKMILIKC CDIΞNEVRPM EVAEPWVDCL 480 LEEYFMQSDR EKSEGLFVAP FMDRDKVTKA TAQIGFIKFV LIPMFETVTK LFPMVEEIML 540 QPLWESRDRY EELKRIDDAM KELQKKTDSL TSGATEKSRE RSRDVKNSEG DCA 40 SEQ ID NO-95 PEG4 DNA SEQUENCE Nucleic Acid Accession*: none Coding sequence: 41-559 (underlined sequences correspond to start and stop codons) 45 11 21 31 41 51 CAGTCACAGG CGAGAGCCYT GGGATCCACC GGCCAGAGGC ATCCTGCTCC TCCTCACGCT 60 TCCCCTCCTC GGGGGCCCCA CCTGGGCAGG GAAGATGTAT GGCCCTGGAG GAGGCAAGTA 120 TTTCAGCACC ACTGAAGACT ACGACCATGA AATCACAGGG CTGCGGGTGT CTGTAGGTCT 180 50 TCTCCTGGTC AAAAGTGTCC AGGTGAAACT TCGAGACTCC TGGGACGTGA AACTGGGAGC 240 CTTAGGTGGG AATACCCAGG AAGTCACCCT GCAGCCAGGC GAATACATCA CAAAAGTCTT 300 TGTCGCCTTC CAAGCTTTCC TCCGGGGTAT GGTCATGTAC ACCAGCAAGG ACCGCTATTT 360 CTATTTTGGG AAGCTTGATG GCCAGATCTC CTCTGCCTAC CCCAGCCAAG AGGGGCAGGT 420 GCTGGTCGGC ATCTATGGCC AGTATCAACT CCTTGGCATC AAGAGCATTG GCTTTGAATG 480 55 GAATTATCCA CTAGAGGAGC CGACCACTGA GCCACCAGTT AATCTCACAT ACTCAGCAAA 540 CTCACCCGTC GGTCGCTAGG GTGGGGTATG GGGCCATCCG AGCTGAGGCC ATCTGTGTGG 600 TGGTGGCTGA TGGTACTGGA GTAACTGAGT CGGGACGCTG AATCTCAATC CACCAATAAA 660 TAAAGCTTCT GCAGAATCAG TGAAAAAAAA A 60 SEQ ID NO:96 PEG4 Protein sequence Protein Accession* FGENESH predicted 1 11 21 31 41 51 A OD< M I LLLLTLALL G ' GPTWAGKMY G ' PGGGKYFST T ' EDYDHEITG L I RVSVGLLLV K ' SVQVKLGDS 60 WDVKLGALGG NTQEVTLQPG EYITKVFVAF QAFLRGMVMY TSKDRYFYFG KLDGQISSAY 120 PSQEGQVLVG IYGQYQLLGI KSIGFEWNYP LEEPTTEPFV NLTYSANSPV GR 70 SEQ ID NO:97 PE 9 DNA SEQUENCE Nucleic Acid Accession * NMJJ06953 Coding sequence: 33-896(undertlned sequences correspond to start and stop codons) 11 21 31 41 51 75 I I I CCGTTCCGCG CTCTGGCGGC TCCTCCCGGG CGATGCCTCC G ICTCTGGGCC CITGCTGGCCC 60 TCGGCTGCCT GCGGTTCGGC TCGGCTGTGA ACCTGCAGCC CCAACTGGCC AGTGTGACTT 120 TCGCCACCAA CAACCCCACA CTTACCACTC TGGCCTTCGA AAAGCCTCTC TGCATGTTTC 180 ACAGCAAAGA GGCCCTCACT GGCACCCACG AGGTCTACCT GTATGTCCTG GTCGACTCAG 240 80 CCATTTCCAG GAATGCCTCA GTCCAAGACA GCACCAACAC CCCACTGGGC TCAACGTTCC 300 TACAAACAGA GGGTGGGAGG ACAGGTCCCT ACAAAGCTGT GGCCTTTGAC CTCATCCCCT 360 GCAGTCACCT GCCCAGCCTC GATCCCATTG GGGATGTCTC CAAGGCCTCA CAGATCCTCA 420 ATGCCTACCT GGTCAGGGTC GGTGCCAACG GGACCTGCCT GTGGGATCCC AACTTCCAGG 480 GCCTCTGTAA CGCACCCCTG TCGGCAGCCA CGGAGTACAG GTTCAAGTAT GTCCTGGTCA 540 ATATGTCCAC GGGCTTCGTA GAGGACCAGA CCCTCTGGTC GGACCCCATC CGCACCAACC 600 AGCTCACCCC ATACTCGACG ATCGACACGT GGCCAGGCCG GCGGAGCGGA GGCATGATCG 660 TCATCACTTC CATCCTGGGC TCCCTCCCCT TCTTTCTACT TGTGGGTTTT GCTGGCGCCA 720 TTGCCCTCAG CCTCGTGGAC ATGGGGAGTT CTGATGGGGA AACGACTCAC GACTCCCAAA 780 TCACTCAGGA GGCTGTTCCC AAGTCGCTGG GGGCCTCGGA GTCTTCCTAC ACGTCCGTGA 840 ACCGGGGGCC GCCACTCGAC AGGGCTCAGG TGTATTCCAG CAAGCTCCAA GACTCAGCCC 900 AGCACCACCC CTGGGCAGCA GCATCCTCCT CTCTCGCCTT GCCCCAGGCC CTCCAGCGGT 960 GGTTGTCACA CCCTGACTTC AGGGAAGGTG AAACAGGGCT TGTCCCTCCA ACTGCAGGAA 1020 AACCCTTAAT AAAATCTTCT GATGAGTTCT AAAAAAAAA SEQ ID NO:98 PEL9 Protein sequence Protein Accession * NP_008884 1 11 21 31 41 51 I I I I I I MPPLWALLAL GCLRFGSAVN LQPQLASVTF ATNNPTLTTV ALEKPLCMFD SKEALTGTHE 60 VYLYVLVDSA ISRNASVQDS TNTPLGSTFL QTEGGRTGPY KAVAFDLIPC SDLPSLDAIG 120 DVSKASQILN AYLVRVGANG TCLWDPNFQG LCNAPLSAAT EYRFKYVLVN MSTGLVEDQT 180 LWSDPIRTNQ LTPYSTIDTW PGRRSGGMIV ITSILGSLPF FLLVGFAGAI ALSLVDMGSS 240 DGETTHDSQI TQEAVPKSLG ASESSYTSVN RGPPLDRAEV YSSKLQD SEQ ID NO:99 PEN1 DNA SEQUENCE Nucleic Acid Accession*: NM H2391 Coding sequence: 416-1423 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 GTCTGACTTC CTCCCAGCAC ATTCCTGCAC TCTGCCGTGT CCACACTGCC CCACAGACCC 60 AGTCCTCCAA GCCTGCTGCC AGCTCCCTGC AAGCCCCTCA GGTTGGGCCT TGCCACGGTG 120 CCAGCAGGCA GCCCTGGGCT GGGGGTAGGG GACTCCCTAC AGGCACGCAG CCCTGAGACC 180 TCAGAGGGCC ACCCCTTGAG GGTCGCCAGG CCCCCAGTGG CCAACCTGAG TGCTGCCTCT 240 GCCACCAGCC CTGCTGGCCC CTGGTTCCGC TGGCCCCCCA GATGCCTGGC TCAGACACGC 300 CAGTGGCCTC AGCTGCCCAC ACCTCTTCCC GGCCCCTGAA GTTGGCACTC CAGCAGACAG 360 CTCCCTGGGC ACCAGGCAGC TAACAGACAC AGCCGCCAGC CCAAACAGCA GCGGCATGGG 420 CAGCGCCAGC CCGGGTCTGA GCAGCGTATC CCCCAGCCAC CTCCTGCTGC CCCCCGACAC 480 GGTGTCGCGG ACAGGCTTGG AGAAGGCGGC AGCGGGGGCA GTCGGTCTCG AGAGACGGGA 540 CTGGAGTCCC AGTCCACCCG CCACGCCCGA GCAGGGCCTG TCCGCCTTCT ACCTCTCCTA 600 CTTTGACATG CTCTACCCTC AGGACAGCAG CTGGGCAGCC AAGGCCCCTC GGGCCAGCAG 660 TCGGGAGGAG CCACCTCAGG AGCCTGAGCA GTGCCCGGTC ATTGACAGCC AAGCCCCAGC 720 GGGCAGCCTC GACTTGGTGC CCGGCGGGCT GACCTTGGAG GAGCACTCGC TGGAGCAGGT 780 GCAGTCCATG GTGGTGGGCG AAGTCCTCAA GGACATCGAG ACGGCCTGCA AGCTGCTCAA 840 CATCACCGCA GATCCCATGG ACTGGAGCCC CAGCAATGTG CAGAAGTGGC TCCTGTGGAC 900 AGAGCACCAA TACCGGCTGC CCCCCATGGG CAAGGCCTTC CAGGAGCTGG CGGGCAAGGA 960 GCTGTGCGCC ATGTCGGAGG AGCAGTTCCG CCAGCGCTCG CCCCTGGGTC GGGATGTGCT 1020 GCACGCCCAC CTGGACATCT GGAAGTCAGC GGCCTGGATG AAAGAGCGGA CTTCACCTCG 1080 GGCGATTCAC TACTGTCCCT CGACCAGTGA GGAGAGCTGG ACCGACAGCG AGGTCGACTC 1140 ATCATGCTCC GGGCAGCCCA TCCACCTCTG GCAGTTCCTC AAGGAGTTGC TACTCAAGCC 1200 CCACAGCTAT GGCCGCTTCA TTAGGTGGCT CAACAAGGAG AAGGGCATCT TCAAAATTGA 1260 GGACTCAGCC CAGGTGGCCC GGCTCTCGGG CATCCGCAAG AACCGTCCCG CCATGAACTA 1320 CGACAAGCTC AGCCGCTCCA TCCGCCAGTA TTACAAGAAG GGCATCATCC GGAAGCCAGA 1380 CATCTCCCAG CGCCTCGTCT ACCAGTTCGT GCACCCCATC TGAGTGCCTC GCCCAGGGCC 1440 TGAAACCCGC CCTCAGGGGC CTCTCTCCTG CCTCCCCTGC CTCAGCCAGG CCCTGAGATG 1500 GGGGAAAACG GGCAGTCTGC TCTGCTGCTC TGACCTTCCA GAGCCCAAGG TCAGGGAGGG 1560 GCAACCAACT GCCCCAGGGG GATATCGGTC CTCTGGGGCC TTCGGGACCA TGGGGCAGGG 1620 GTGCTTCCTC CTCAGGCCCA GCTCCTCCCC TCGAGGACAG AGGGAGACAG GGCTGCTCCC 1680 CAACACCTGC CTCTCACCCC AGCATTTCCA GAGCAGAGCC TACAGAAGGG CAGTGACTCG 1740 ACAAAGGCCA CAGGCAGTCC AGGCCTCTCT CTGCTCCATC CCCCTGCCTC CCATTCTGCA 1800 CCACACCTGG CATGGTGCAG GGAGACATCT GCACCCCTGA GTTGGGCAGC CAGGAGTGCC 1860 CCCGGGAATG GATAATAAAG ATACTAGAGA ACTG SEQ ID NO:100 PEN1 Protein sequence Protein Accession*: NP_03652 3 11 21 31 41 51 I I I I I MGSASPGLSS VSPSHLLLPP DTVSRTCLEK AAAGAVGLER RDWSPSPPAT PEQGLSAFYL 60 SYFDMLYPED SSWAAKAPGA SSREEPPEEP EQCPVIDSQA PAGSLDLVPG GLTLEEHSLE 120 QVQSMWGEV LKDIETACKL LNITADPMDW SPSNVQKWLL WTEHQYRLPP MGKAFQELAG 180 KELCAMSEEQ FRQRSPLGGD VLHAHLDIWK SAAWMKERTS PGAIHYCAST SEESWTDSEV 240 DSSCSGQPIH LWQFLKELLL KPHSYGRFIR WLNKEKGIFK IEDSAQVARL WGIRKNRPAM 300 NYDKLSRSIR QYYKKGIIRK PDISQRLVYQ FVHPI SEQ ID N0.101 PEN3 DNA SEQUENCE Nucleic Acid Accession* NM.000742 Coding sequence: 555-2144 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 GAGAGAACAG CGTGAGCCTC TCTGCTTCTC TGCTGAGCCC TCATCCCCTC CTGGGGCCAG 60 GCTTGGGTTT CACCTGCAGA ATCGCTTCTC CTGGGCTCCC TGGGCTGTCC TCAGTCGCAC 120 CTCCATCAAG CCGTTCTGGC TGCCAGAGCT GGACAGCCCC AGGAAAACCC ACCTCTCTGC 180 AGAGCTTCCC CAGCTGTCCC CGGGAAGCCA AATGCCTCTC ATGTAAGTCT TCTGCTCGAC 240 GGGGTGTCTC CTAAACCCTC ACTCTTCAGC CTCTCTTTGA CCATGAAATG AAGTGACTGA 300 GCTCTATTCT GTACCTGCCA CTCTATTTCT GGGGTGACTT TTGTCAGCTG CCCAGAATCT 360 CCAAGCCAGG CTGGTTCTCT GCATCCTTTC AATGACCTGT TTTCTTCTGT AACCACAGGT 420 TCGGTCGTGA GAGGAAGCCT CGCAGAATCC AGCAGAATCC TCACAGAATC CAGCAGCAGC 480 TCTGCTGGGG ACATGGTCCA TGGTCCAACC CACAGCAAAG CCCTGACCTG ACCTCCTGAT 540 GCTCAGGAGA AGCCATGGGC CCCTCCTCTC CTCTGTTCCT GTCCTTCACA AAGCTCAGCC 600 TGTGGTGGCT CCTTCTGACC CCAGCAGGTC GAGAGGAAGC TAAGCGCCCA CCTCCCAGGG 660 CTCCTGGAGA CCCACTCTCC TCTCCCAGTC CCACGGCATT GCCGCAGGGA GGCTCGCATA 720 CCGAGACTGA GGACCGGCTC TTCAAACACC TCTTCCGGGG CTACAACCGC TGGGCGCGCC 780 CGGTGCCCAA CACTTCAGAC GTGGTGATTG TGCGCTTTCG ACTCTCCATC GCTCAGCTCA 840 TCGATGTGGA TGAGAAGAAC CAAATGATGA CCACCAACGT CTGGCTAAAA CAGGAGTGGA 900 GCGACTACAA ACTGCGCTGG AACCCCGCTG ATTTTGGCAA CATCACATCT CTCAGGGTCC 960 CTTCTCAGAT GATCTGGATC CCCGACATTG TTCTCTACAA CAATGCAGAT GGGGAGTTTG 1020 CAGTGACCCA CATGACCAAG GCCCACCTCT TCTCCACGGG CACTGTGCAC TCGGTGCCCC 1080 CGGCCATCTA CAAGAGCTCC TGCAGCATCG ACGTCACCTT CTTCCCCTTC GACCAGCAGA 1140 ACTGCAAGAT GAAGTTTGGC TCCTGGACTT ATGACAAGGC CAAGATCGAC CTGGAGCAGA 1200 TCGAGCAGAC TGTGGACCTC AAGGACTACT GGGAGAGCGG CGAGTCGGCC ATCGTCAATG 1260 CCACGGGCAC CTACAACAGC AAGAAGTACG ACTGCTGCGC CGAGATCTAC CCCGACGTCA 1320 CCTACGCCTT CGTCATCCGG CGGCTGCCGC TCTTCTACAC CATCAACCTC ATCATCCCCT 1380 GCCTGCTCAT CTCCTGCCTC ACTGTGCTGG TCTTCTACCT GCCCTCCGAC TGCGGCGAGA 1440 AGATCACGCT GTGCATTTCG GTGCTCCTGT CACTCACCGT CTTCCTGCTG CTCATCACTG 1500 AGATCATCCC GTCCACCTCG CTGGTCATCC CGCTCATCGG CGAGTACCTC CTGTTCACCA 1560 TGATCTTCGT CACCCTGTCC ATCGTCATCA CCGTCTTCGT GCTCAATGTG CACCACCGCT 1620 CCCCCAGCAC CCACACCATC CCCCACTGGG TGCGGGGGGC CCTTCTGGGC TGTGTGCCCC 1680 GGTGGCTTCT GATGAACCGG CCCCCACCAC CCGTCGAGCT CTGCCACCCC CTACGCCTGA 1740 AGCTCAGCCC CTCTTATCAC TGGCTGGAGA GCAACGTGGA TGCCGAGGAG AGGGAGGTCG 1800 TGGTGGAGGA GGAGGACAGA TGGGCATGTG CAGGTCATGT GGCCCCCTCT GTCGGCACCC 1860 TCTGCAGCCA CGGCCACCTG CACTCTCGGG CCTCAGGTCC CAAGGCTGAG GCTCTGCTCC 1920 AGGAGGGTCA GCTGCTGCTA TCACCCCACA TGCAGAAGGC ACTGGAAGGT GTCCACTACA 1980 TTGCCGACCA CCTGCGGTCT GAGGATCCTG ACTCTTCGGT GAAGGAGGAC TGGAAGTATG 2040 TTGCCATCGT CATCGACAGG ATCTTCCTCT GGCTGTTTAT CATCGTCTGC TTCCTGGGGA 2100 CCATCGGCCT CTTTCTGCCT CCGTTCCTAG CTGGAATGAT CTCACTGCAC CTCCCTCGAG 2160 CTGGCTCCCA GGGCAAAGGG GAGGGTTCTT GGATGTGGAA GGGCTTTGAA CAATGTTTAβ 2220 ATTTCGAGAT GAGCCCAAAG TGCCAGGGAG AACAGCCAGG TGAGGTGGGA GGTTGGAGAG 2280 CCAGGTGAGG TCTCTCTAAG TCAGGCTGGG GTTGAAGTTT GGAGTCTGTC CGAGTTTCCA 2340 GGGTCCTGAG CTGTATGGTC CAGCAGGGGA GTAATAAGGG CTCTTCCGGA AGGGGAGGAA 2400 GCGGGAGGCA GGCCTGCACC TGATGTGGAG GTACAGGCAG ATCTTCCCTA CCGGGGAGGG 2460 ATGGATGGTT GGATACAGGT GGCTGGGCTA TTCCATCCAT CTGGAAGCAC ATTTGAGCCT 2520 CCAGGCTTCT CCTTGACGTC ATTCCTCTCC TTCCTTGCTG CAAAATGGCT CTGCACCAGC 2580 CGGCCCCCAG GAGGTCTGGC AGAGCTGAGA GCCATGGCCT GCAGGGGCTC CATATGTCCC 2640 TACGCGTCCA GCAGGCAAAC AAGA SEQ ID NO:102 PEN3 Protein sequence Protein Accession* NPJJ00733 1 11 21 31 41 51 I I I I I I MGPSCPVFLS FTKLSLWWLL LTPAGGEEAK RPPPRAPGDP LSSPSPTALP QGGSHTETED 60 RLFKHLFRGY NRWARFVPNT SDWIVRFGL SIAQLIDVDE KNQMMTTNVW LKQEWSDYKL 120 RWNPADFGNI TSLRVPSEMI WIPDIVLYNN ADGEFAVTHM TKAHLFSTCT VHWVPPAIYK 180 SSCSIDVTFF PFDQQNCKMK FGSWTYDKAK IDLEQMEQTV DLKDYWESGE WAIVNATGTY 240 NSKKYDCCAE IYPDVTYAFV IRRLPLFYTI NLIIPCLLIS CLTVLVFYLP SDCGEKITLC 300 ISVLLSLTVF LLLITEIIPS TSLVIPLIGE YLLFTMIFVT LSIVITVFVL NVHHRSPSTH 360 TMPHWVRGAL LGCVPRWLLM NRPPPPVELC HPLRLKLSPS YHWLESNVDA EEREVWEEE 420 DRWACAGHVA PSVGTLCSHG HLHSGASGPK AEALLQEGEL LLSPHMQKAL EGVHYIADHL 480 RSEDADSSVK EDWKYVAMVI DRIFLWLFII VCFLGTIGLF LPPFLAGMI SEQ ID NO:103 PEU4 DNA SEQUENCE Nucleic Acid Accession*: NM_018670 Coding sequence: 87-893 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I CACGAGGCTG I I I I GAAGGGGCCA CTTCACACCT CGGGCTCGGC ATAAAGCGGC CGCCGGCCGC 60 CGGCCCCCAG ACGCGCCGCC GCTCCCATGG CCCAGCCCCT GtGCCCGCCG CTCTCCGAGT 120 CCTGGATGCT CTCTGCGGCC TGGGGCCCAA CTCGGCGGCC GCCGCCCTCC GACAAGGACT 180 GCGGCCGCTC CCTCGTCTCG TCCCCAGACT CATGGGGCAG CACCCCAGCC GACAGCCCCG 240 TGGCGAGCCC CGCGCGGCCA GGCACCCTCC GGGACCCCCG CGCCCCCTCC GTAGGTAGGC 300 GCGGCGCGCG CAGCAGCCGC CTGGGCAGCG GGCAGAGGCA GAGCGCCAGT GAGCGGGAGA 360 AACTGCGCAT GCGCACGCTG GCCCGCGCCC TGCACGAGCT GCGCCGCTTT CTACCGCCGT 420 CCGTGGCGCC CGCGGGCCAG AGCCTGACCA AGATCGAGAC GCTGCGCCTG GCTATCCGCT 480 ATATCGGCCA CCTGTCGGCC GTCCTAGGCC TCAGCGAGGA GAGTCTCCAG CGCCGGTCCC 540 GGCAGCGCGG TGACGCGGGG TCCCCTCGGG GCTGCCCGCT GTGCCCCGAC GACTGCCCCG 600 CGCAGATGCA GACACGGACG CAGGCTGAGG GGCAGGGGCA GGGGCGCGGG CTGGGCCTGG 660 TATCCGCCGT CCGCGCCGGG GCGTCCTCGG GATCCCCGCC TGCCTGCCCC GGAGCCCGAG 720 CTGCACCCGA GCCGCGCGAC CCGCCTGCGC TGTTCGCCGA GGCGGCGTGC CCGGAAGGGC 780 AGGCGATCGA GCCAAGCCCA CCGTCCCCGC TCCTTCCGGG CGACGTGCTC GCTCTCTTGG 840 AGACCTGGAT GCCCCTCTCG CCTCTGGAGT GGCTGCCTGA GGAGCCCAAG TCACAAGGGA 900 CAACTGACGC CGTCTCTGTG AGCACCGAGG CTTTTTGGCC TCAGCACCTT CGAAGTCGTT 960 CCTTCGCAGA CTCCCTTTCC TGGAAGAGGG CACGGGCGAT CCCGACGGGG GCATTCCTCC 1020 GGGTGAGAGC CGTCCCCACC GCGGCGGCCC TTCTCAGCCC CTCCCTCCAT GGAGGGACCC 1080 ATAGGGCTAG ACACTTTGAG GCAAGCAGGA GGCTCTCCCT AATGTGAATT TATTTATTTG 1140 TGAATAAACT GTACTCGTGT CAAAAAAAAA AAAAAAAAAA A SEQ ID NO:104 PEU4 Protein sequence Protein Accession * NP_061140 1 11 21 31 41 51 I I I I I I MAQPLCPPLS ESWMLSAAWG PTRRPPPSDK DCGRSLVSSP DSWGSTPADS FVASPARPGT 60 LRDPRAPSVG RRGARSSRLG SGQRQSASER EKLRMRTLAR ALHELRRFLP PSVAPAGQSL 120 TKIETLRLAI RYIGHLSAVL GLSEESLQRR CRQRGDAGSP RGCPLCPDDC PAQMQTRTQA 180 EGQGQGRGLG LVSAVRAGAS WGSPPACPGA RAAPEPRDPP ALFAEAACPE GQAMEPSPPS 240 PLLPGDVLAL LETWMPLSPL EWLPEEPK SEQ ID NO:105 PEU5 DNA SEQUENCE Nucleic Acid Accession* NM H7636 Coding sequence: 324-3374 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I CCACGGAGAA GCCCACCGAT GCCTACGGAG AGCTCGACTT CACGGGGGCC GGCCGCAAGC 60 ACAGCAATTT CCTCCGGCTC TCTGACCGAA CGGATCCAGC TGCAGTTTAT AGTCTGGTCA 120 CACGCACATC GGGCTTCCGT GCCCCGAACC TGGTGGTGTC AGTGCTGGGG GGATCGGGGG 180 GCCCCGTCCT CCAGACCTGG CTGCAGGACC TGCTGCGTCG TCGGCTGGTG CGGGCTGCCC 240 AGAGCACAGG AGCCTGGATT GTCACTGGGG GTCTCCACAC GGGCATCGGC CGGCATGTTG 300 GTGTGGCTGT ACGGGACCAT CAGATGGCCA GCACTGGGGG CACCAAGGTG GTGGCCATGG 360 GTGTGGCCCC CTGGGGTGTC GTCCGGAATA GAGACACCCT CATCAACCCC AAGGGCTCGT 420 TCCCTGCGAG GTACCGGTGG CGCGGTGACC CGGAGGACGG GGTCCAGTTT CCCCTCGACT 480 ACAACTACTC GGCCTTCTTC CTGGTGGACG ACGGCACACA CGGCTCCCTG GGGGGCGAGA 540 ACCGCTTCCG CTTGCGCCTG GAGTCCTACA TCTCACAGCA GAAGACGGGC GTCGGAGGGA 600 CTGGAATTGA CATCCCTGTC CTGCTCCTCC TGATTCATCG TCATGAGAAG ATGTTGACGC 660 GAATAGAGAA CGCCACCCAG GCTCAGCTCC CATGTCTCCT CGTCGCTGGC TCAGGGGGAG 720 CTGCGGACTG CCTGGCGGAG ACCCTGGAAG ACACTCTGGC CCCAGGGAGT GGGGGAGCCA 780 GGCAAGGCGA AGCCCGAGAT CGAATCAGGC GTTTCTTTCC CAAAGGGGAC CTTGAGGTCC 840 TCCAGGCCCA GGTCGAGAGG ATTATGACCC GGAAGGAGCT CCTGACAGTC TATTCTTCTG 900 AGGATGGGTC TGAGGAATTC GAGACCATAG TTTTGAAGGC CCTTGTGAAG GCCTGTGGGA 960 GCTCGGAGGC CTCAGCCTAC CTGGATGAGC TGCGTTTGGC TGTCGCTTGG AACCGCGTGG 1020 ACATTGCCCA GAGTCAACTC TTTCGGGGGG ACATCCAATG GCGGTCCTTC CATCTCGAAG 1080 CTTCCCTCAT GGACGCCCTG CTGAATCACC GGCCTCAGTT CGTCCGCTTG CTCATTTCCC 1140 ACGGCCTCAG CCTGGGCCAC TTCCTGACCC CGATGCGCCT GGCCCAACTC TACAGCGCGG 1200 CGCCCTCCAA CTCGCTCATC CGCAACCTTT TGGACCAGGC GTCCCACAGC GCAGGCACCA 1260 AAGCCCCAGC CCTAAAAGGG GGAGCTCCGG AGCTCCGGCC CCCTGACGTG GGGCATCTGC 1320 TGAGGATGCT GCTGGGGAAG ATGTGCGCGC CGAGGTACCC CTCCGGGGGC GCCTGGGACC 1380 CTCACCCAGG CCAGGGCTTC GGGGAGAGCA TGTATCTGCT CTCGGACAAG GCCACCTCGC 1440 CGCTCTCGCT GGATGCTGGC CTCGGGCAGG CCCCCTGGAG CGACCTGCTT CTTTGGGCAC 1500 TGTTGCTCAA CAGGGCACAG ATCGCCATGT ACTTCTGGGA GATCGGTTCC AATCCAGTTT 1560 CCTCAGCTCT TGGGGCCTGT TTGCTGCTCC GGGTGATCGC ACGCCTGGAG CCTCACGCTG 1620 AGGAGGCAGC ACGGAGGAAA GACCTGGCGT TCAAGTTTCA GGGGATGGGC GTTGACCTCT 1680 TTGGCGAGTC CTATCGCAGC AGTGAGGTGA GGGCTGCCCG CCTCCTCCTC CGTCGCTGCC 1740 CGCTCTGGGG GGATGCCACT TGCCTCCAGC TGGCCATCCA AGCTGACGCC CGTCCCTTCT 1800 TTGCCCAGGA TGGGGTACAG TCTCTCCTCA CACAGAAGTC GTGGGGAGAT ATGGCCAGCA 1860 CTACACCCAT CTGGGCCCTG GTTCTCGCCT TCTTTTGCCC TCCACTCATC TACACCCGCC 1920 TCATCACCTT CAGGAAATCA GAAGAGGAGC CCACACGGGA GGAGCTAGAG TTTGACATGG 1980 ATAGTGTCAT TAATGGGGAA GGGCCTGTCG GGACGGCGGA CCCAGCCGAG AAGACGCCGC 2040 TGGGGGTCCC GCGCCAGTCG GGCCGTCCGG GTTGCTGCGG GGGCCGCTGC GGGGGGCGCC 2100 GGTGCCTACG CCGCTGGTTC CACTTCTGGG GCGCGCCGGT GACCATCTTC ATGGGCAACG 2160 TGGTCAGCTA CCTGCTGTTC TTGCTGCTTT TCTCGCGGGT GCTGCTCGTG GATTTCCAGC 2220 CGGCGCCGCC CGGCTCCCTG GAGCTCCTGC TCTATTTCTG GGCTTTCACG CTGCTGTGCG 2280 AGGAACTCCG CCAGGGCCTG AGCGGAGGCG GGGGCAGCCT CGCCAGCGGG GGCCCCGGGC 2340 CTGGCCATGC CTCACTGAGC CAGCGCCTCC GCCTCTACCT CGCCGACAGC TCGAACCAGT 2400 GCGACCTAGT GGCTCTCACC TGCTTCCTCC TCGGCGTGGG CTGCCGGCTG ACCCCGGGTT 2460 TGTACCACCT GGGCCGCACT GTCCTCTGCA TCGACTTCAT GGTTTTCACG GTCCGGCTGC 2520 TTCACATCTT CACGGTCAAC AAACAGCTGG GGCCCAAGAT CGTCATCGTG AGCAAGATGA 2580 TGAAGGACGT GTTCTTCTTC CTCTTCTTCC TCGGCGTGTG GCTGGTAGCC TATGGCGTGG 2640 CCACGGAGGG GCTCCTGAGG CCACGGGACA GTGACTTCCC AAGTATCCTC CGCCGCGTCT 2700 TCTACCGTCC CTACCTGCAG ATCTTCGGGC AGATTCCCCA GGAGGACATG GACGTGGCCC 2760 TCATCGAGCA CAGCAACTGC TCGTCGGAGC CCGGCTTCTG GGCACACCCT CCTCGGGCCC 2820 AGGCGGGCAC CTGCGTCTCC CAGTATGCCA ACTGGCTGGT GGTGCTGCTC CTCGTCATCT 2880 TCCTGCTCGT GGCCAACATC CTGCTGGTCA ACTTCCTCAT TGCCATGTTC AGTTACACAT 2940 TCGGCAAAGT ACAGGGCAAC AGCGATCTCT ACTGGAAGGC GCAGCGTTAC CGCCTCATCC 3000 GGGAATTCCA CTCTCGGCCC GCGCTGGCCC CGCCCTTTAT CGTCATCTCC CACTTGCGCC 3060 TCCTGCTCAG GCAATTGTGC AGGCGACCCC GGAGCCCCCA GCCGTCCTCC CCGGCCCTCG 3120 AGCATTTCCG GGTTTACCTT TCTAAGGAAG CCGAGCGGAA GCTGCTAACG TGGGAATCGG 3180 TGCATAAGGA GAACTTTCTC CTGGCACGCG CTAGGGACAA GCGGGAGAGC GACTCCGAGC 3240 GTCTGGAGCG CACGTCCCAG AAGGTCGACT TGGCACTGAA ACAGCTGGGA CACATCCGCG 3300 AGTACGAACA GCGCCTGAAA GTCCTGGAGC GGGAGGTCCA GCAGTGTAGC CGCGTCCTCG 3360 GGTGGGTGAC GTAGGCCGTT AGCAGCTCTG CCATGTTCCC CTCAGGTGGG CCGCCACCCC 3420 TTGACCTGCA TGGGTCCAAA GAGTGAGCCA TGCTCGCGGA TTTTAAGGAG AAGCCCCCAC 3480 AGGGGATTTT GCTCTTAGAG TAAGGCTCAT GTGGGCCTCG GCCCCCGCAC CTGGTGGCCT 3540 TGTCCTTGAG GTGAGCCCCA TGTCCATCTG GGCCACTCTC AGGACCACCT TTCGGAGTCT 3600 CATCCTTACA AACCACAGCA TGCCCGGCTC CTCCCAGAAC CAGTCCCAGC CTGGGAGGAT 3660 CAAGGCCTGG ATCCCGGGCC GTTATCCATC TGGAGGCTCC AGGGTCCTTC GGGTAACAGG 3720 GACCACAGAC CCCTCACCAC TCACAGATTC CTCACACTCG GGAAATAAAG CCATTTCAGA 3780 GGAAAAAAAA AAAAAAAAAA AAAAAAAAAA SEQ ID NO:106 PEU5 Protein sequence Protein Accession * NP_060106 11 21 31 41 51 I I I I I MASTGGTKW AMGVAPWGW RNRDTLINPK GSFPARYRWR GDPEDGVQFP LDYNYSAFFL 60 VDDGTHGCLG GENRFRLRLE SYISQQKTCV GGTGIDIPVL LLLIDGDEKM LTRIENATQA 120 QLPCLLVAGS GGAADCLAET LEDTLAPGSG GARQGEARDR IRRFFPKGDL EVLQAQVERI 180 MTRKELLTVY SSΞDGSEEFE TIVLKALVKA CGSSEASAYL DELRLAVAWN RVDIAQSELF 240 RGDIQWRSFH LEASLMDALL NDRPEFVRLL ISHGLSLGHF LTPMRLAQLY SAAPSNSLIR 300 NLLDQASHSA GTKAPALKGG AAELRPPDVG HVLRMLLGKM CAPRYPSGGA WDPHPGQGFG 360 ESMYLLSDKA TSPLSLDAGL GQAPWSDLLL WALLLNRAQM AMYFWEMGSN AVSSALGACL 420 LLRVMARLEP DAEEAARRKD LAFKFEGMGV DLFGECYRSS EVRAARLLLR RCPLWGDATC 480 LQLAMQADAR AFFAQDGVQS LLTQKWWGDM ASTTPIWALV LAFFCPPLIY TRLITFRKSE 540 EEPTREELEF DMDSVINGEG PVGTADPAEK TPLGVPRQSG RPGCCGGRCG GRRCLRRWFH 600 FWGAFVTIFM GNWSYLLFL LLFSRVLLVD FQPAPPGSLE LLLYFWAFTL LCEELRQGLS 660 GGGGSLASGG PGPGHASLSQ RLRLYLADSW NQCDLVALTC FLLGVGCRLT PGLYHLGRTV 720 LCIDFMVFTV RLLHIFTVNK QLGPKIVIVS KMMKDVFFFL FFLGVWLVAY GVATEGLLRP 780 RDSDFPSILR RVFYRPYLQI FGQIPQEDMD VALMEHSNCS SEPGFWAHPP GAQAGTCVSQ 840 YANWL LLL VIFLLVANIL LVNLLIAMFS YTFGKVQGNS DLY KAQRYR LIREFHSRPA 900 LAPPFIVISH LRLLLRQLCR RPRSPQPSSP ALEHFRVYLS KEAERKLLTW ESVHKENFLL 960 ARARDKRESD SERLERTSQK VDLALKQLGH IREYEQRLKV LEREVQQCSR VLGWVT SEQ ID NO:107 PEW3 DNA SEQUENCE Nucleic Acid Accession* NM_005982 Coding sequence: 276-1130 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I GGTAGCAGCA TCCACCGGGC GGGAGGTCGG AGGCAGCAAG GCCTTAAAGG CTACTGAGTG 60 CGCCGGCCGT TCCGTGTCCA GAACCTCCCC TACTCCTCCG CCTTCTCTTC CTTGGCCGCC 120 CACCGCCAAG TTCCGACTCC GGTTTTCGCC TTTCCAAAGC CTAAGGAGGA GGTTAGGAAC 180 AGCCGCGCCC CCCTCCCTGC GGCCGCCGCC CCCTGCCTCT CGGCTCTGCT CCCTGCCGCG 240 TGCGCCTCGG CCGTGCGCCC CGGCAGGCGC CAGCCATGTC GATGCTGCCG TCGTTTGGCT 300 TTACGCAGGA GCAAGTGGCG TGCGTGTCCG AGGTTCTGCA GCAAGGCGGA AACCTCGAGC 360 GCCTGGGCAG GTTCCTGTGG TCACTGCCCG CCTCCGACCA CCTCCACAAG AACGAGAGCG 420 TACTCAAGGC CAAGGCGGTC GTCGCCTTCC ACCGCGGCAA CTTCCGTGAG CTCTACAAGA 480 TCCTGGAGAG CCACCAGTTC TCGCCTCACA ACCACCCCAA ACTGCAGCAA CTGTGGCTGA 540 AGGCGCATTA CGTGGAGGCC GAGAAGCTGC GCGGCCGACC CCTGGGCGCC GTGGGCAAAT 600 ATCGGGTGCG CCGAAAATTT CCACTGCCGC GCACCATCTG GGACGGCGAG GAGACCAGCT 660 ACTGCTTCAA GGAGAAGTCG AGGGGTCTCC TGCGGGAGTG GTACGCGCAC AATCCCTACC 720 CATCGCCGCG TGAGAAGCGG GAGCTCGCCG AGGCCACCGG CCTCACCACC ACCCAGGTCA 780 GCAACTGGTT TAAGAACCGG AGGCAAAGAG ACCGGGCCGC GGAGGCCAAG GAAAGGGAGA 840 ACACCGAAAA CAATAACTCC TCCTCCAACA AGCAGAACCA ACTCTCTGCT CTCGAAGGGG 900 GCAAGCCGCT CATGTCCAGC TCAGAAGAGG AATTCTCACC TCCCCAAAGT CCAGACCAGA 960 ACTCGGTCCT TCTGCTGCAG GGCAATATGG GCCACGCCAG GAGCTCAAAC TATTCTCTCC 1020 CGGGCTTAAC AGCCTCGCAG CCCAGTCACG GCCTGCAGAC CCACCAGCAT CAGCTCCAAG 1080 ACTCTCTGCT CGGCCCCCTC ACCTCCAGTC TGGTGGACTT GGGGTCCTAA GTGGGGAGGG 1140 ACTGGGGCCT CGAAGGGATT CCTGGAGCAG CAACCACTGC AGCGACTAGG GACACTTGTA 1200 AATAGAAATC AGGAACATTT TTGCAGCTTG TTTCTGGAGT TGTTTGCGCA TAAAGGAATG 1260 GTGGACTTTC ACAAATATCT TTTTAAAAAT CAAAACCAAC AGCGATCTCA AGCTTAATCT 1320 CCTCTTCTCT CCAACTCTTT CCACTTTTCC ATTTTCCTTC CCAATGCAGA GATCAGGG SEQ ID NO:108 PEW3 Protein sequence Protein Accession*: NP_005973 1 11 21 31 41 51 I I I I I I MSMLPSFGFT QEQVACVCEV LQQGGNLERL GRFLWSLPAC DHLHKNESVL KAKAWAFHR 60 GNFRELYKIL ESHQFSPHNH PKLQQLWLKA HYVEAEKLRG RPLGAVGKΪR VRRKFPLPRT 120 IWDGEETSYC FKEKSRGVLR EWYAHNPYPS PREKRELAEA TGLTTTQVSN WFKNRRQRDR 180 AAEAKERENT ENNNSSSNKQ NQLSPLEGGK PLMSSSEEEF SPPQSPDQNS VLLLQGNMGH 240 ARSSNYSLPG LTASQPSHGL QTHQHQLQDS LLGPLTSSLV DLGS SEQ ID NO:109 PFJ8 DNA SEQUENCE Nucleic Acid Accession* N _005069 Coding sequence: 57-2060 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I GGGGCTCCGC GGGCCTGGAG CACGGCCGGG TCTAATATGC CCGGAGCCGA GGCGCGATQA 60 AGGAGAAGTC CAAGAATGCG GCCAAGACCA GGAGGG AGAA GGAAAATGGC GAGTTTTACG 120 5 AGCTTGCCAA GCTGCTCCCG CTGCCGTCGG CCATCACTTC GCAGCTGGAC AAAGCGTCCA 180 TCATCCGCCT CACCACGAGC TACCTGAAGA TGCGCGCCGT CTTCCCCGAA GGTTTAGGAG 240 ACGCGTGGGG ACAGCCGAGC CGCGCCGGGC CCCTGGACGG CGTCGCCAAG GAGCTGGGAT 300 CGCACTTGCT GCAGACTTTG GATGGATTTG TTTTTGTGGT AGCATCTGAT GGCAAAATCA 360 TGTATATATC CGAGACCGCT TCTGTCCATT TAGGCTTATC CCAGGTGGAG CTCACGGGCA 420 10 ACAGTATTTA TGAATACATC CATCCTTCTG ACCACGATGA GATGACCGCT GTCCTCACGG 480 CCCACCAGCC GCTGCACCAC CACCTGCTCC AAGAGTATGA GATAGAGAGG TCGTTCTTTC 540 TTCGAATGAA ATGTGTCTTG GCGAAAAGGA ACGCGGGCCT GACCTGCAGC GGATACAAGG 600 TCATCCACTG CAGTGGCTAC TTGAAGATCA GGCAGTATAT GCTGGACATG TCCCTGTACG 660 ACTCCTGCTA CCAGATTGTG GGGCTGGTGG CCGTGGGCCA GTCGCTGCCA CCCAGTGCCA 720 15 TCACCGAG AT CAAGCTGTAC AGTAAC ATGT TCATGTTCAG GGCCAGCCTT GACCTGA AGC 780 TGATATTCCT GGATTCCAGG GTGACCGAGG TGACGGGTTA CGAGCCGCAG GACCTGATCG 840 AGAAGACCCT ATACCATCAC GTGCACGGCT GCGACGTGTT CCACCTCCGC TACGCACACC 900 ACCTCCTGTT GGTGAAGGGC CAGGTCACCA CCAAGTACTA CCGGCTGCTG TCCAAGCGGG 960 GCGGCTGGGT GTGGGTGCAG AGCTACGCCA CCGTGGTGCA CAACAGCCGC TCGTCCCGGC 1020 20 CCCACTGCAT CGTGAGTGTC AATTATGTAC TCACGGAGAT TGAATACAAG GAACTTCAGC 1080 TGTCCCTGGA GCAGGTGTCC ACTGCCAAGT CCCAGGACTC CTGGAGGACC GCCTTGTCTA 1140 CCTCACAAGA AACTAGGAAA TTAGTGAAAC CCAAAAATAC CAAGATGAAG ACAAAGCTGA 1200 GAACAAACCC TTACCCCCCA CAGCAATACA GCTCGTTCCA AATGGACAAA CTGGAATGCG 1260 GCCAGCTCGG AAACTGGAGA GCCAGTCCCC CTGCAAGCGC TGCTGCTCCT CCAGAACTGC 1320 25 AGCCCCACTC AGAAAGCAGT GACCTTCTGT ACACGCCATC CTACAGCCTG CCCTTCTCCT 1380 ACCATTACGG ACACTTCCCT CTGGACTCTC ACGTCTTCAG CAGCAAAAAG CCAATGTTGC 1440 CGGCCAAGTT CGGGCAGCCC CAAGGATCCC CTTGTGAGGT GGCACGCTTT TTCCTGAGCA 1500 CACTGCCAGC CAGCGGTGAA TGCCAGTGGC ATTATGCCAA CCCCCTAGTG CCTAGCAGCT 1560 _ CGTCTCCAGC TAAAAATCCT CCAGAGCCAC CGGCGAACAC TGCTAGGCAC AGCCTGGTGC 1620 30 CAAGCTACGA AGCGCCCGCC GCCGCCGTGC GCAGGTTCGG CGAGGACACC GCGCCCCCGA 1680 GCTTCCCGAG CTGCGGCCAC TACCGCGAGG AGCCCGCGCT GGGCCCGGCC AAAGCCGCCC 1740 GCCAGGCCGC CCGGGACGGG GCGCGGCTGG CGCTGGCCCG CGCGGCACCC GAGTGCTGCG 1800 CGCCCCCGAC CCCCGAGGCC CCGGGCGCGC CGGCGCAGCT GCCCTTCGTG CTGCTCAACT 1860 ACCACCGCGT GCTGGCCCGG CGCGGACCGC TGGGGGGCGC CGCACCCGCC GCCTCCGGCC 1920 35 TGGCCTGCGC TCCCGGCGGC CCCGAGGCGG CGACCGGCGC GCTGCGGCTC CGGCACCCGA 1980 GCCCCGCCGC CACCTCCCCG CCCGGCGCGC CCCTGCCGCA CTACCTGGGC GCCTCGGTCA 2040 TCATCACCAA CGGGAGGTQA CCCGCTGGCC GCCCGCGCCA GGAGCCTGGA CCCGGCCTCC 2100 CGGGGCTGCG GCGCCACCGA GCCCGGCAAA TGCGCACGAC CTACATTAAT TTATGCAGAG 2160 ACAGCTGTTT GAATTGGACC CCGCCGCCGA CTTGCGGATT TCCACCGCGG AGGCCCCGCG 2220 40 CGCCGGTGCC GAGGGCCGAG GAGCGCCCGG GTCCGGGCAG GTGACCGCCC GCCTCTGTCC 2280 TGCGAGGGCC GGTGCGACCC AGTTGCTGGG GGCTTGGTTT CCTCACCTTG AAATCGGGCT 2340 TCACGCGTCT TGCCTTGTCC CCAACGTTCC ACAACAGTCC CGCTGGGGGA TTGAAGCGGT 2400 TTCACTCCGC AAATATCCTC CACTTTCAGG AGGGAAAACC CACCCTACCA CAGTCCGCTC 2460 TTCCAAGTGG ACGGCAGACC TGGGAGGGGA CGCCTGTGTC ACGAGCCCTT TTAGATGCTT 2520 45 AGGTGAAGGC AGAAGTGATG ATTGTAAGTC CCATGAATAC ACAACTCCAC TGTCTTTAAA 2580 AGTCATTCAA GAGTCTCATT ATTTTTGTTT TTATTTAACC CTTTCTTCAA TACAAAAAGC 2640 CAACAAACCA AGACTAAGGG GGTGACCATG CAATTCCATT TTGTGTCTGT GAACATAGGT 2700 GTGCTTCCCA AATACATTAA CAAGCTCTTA CTTCCCCCTA ACCCCTATGA ACTCTTGATA 2760 ACACCAAGAG TAGCACCTTC AGAATATATT GAATAGGCAT TAAATGCAAA AATATATATG 2820 50 TAGCCAGACA GTTTATGAGA ATGACCCTGT CAAGCTTCAT TATTACGTGG CAAAATCCCT 2880 CTGGCCCACA CAGATCTGTA ATTCACTAGG CTCGTGTTTG CTACAAATAG TGCTAATAAA 2940 GTTAAATTGC ACGTGCAATA CGGAACACTG TCAATGGACT GCACCTTGTG AAGGAAAAAC 3000 ATGCTTAAGG GGGTGTAATG AAAATGATGT AGACATTTTA AGCATTTTCT ACACAGCGAG 3060 AAAACTTCGT AAGAACATGT TACGTGTGCA ACAGGTAAAC AGAAATCCTT TCATAAAGCA 3120 55 CCAGCAGTGTTTAAAAAATG AGCTTCCATTAATTTTTACT TTTTATGGGT TTTGCTTAAA 3180 GATCTCAACA TGGAAAAATC CTGTCATGGC TCTGAACTGC ACAATGCATT GAACCGCCGT 3240 CCTTCAATTT TCTTCACACT ATCAACACTG CAGCATTTTG CTGCTTTATC AAAATGGTTT 3300 ATTTTAGGAA ACTTTTTCCA CCTTTCTGAA TGGAAAGAGG TTTTCACAAA TGTTTTAAAC 3360 ^ TCATCGTTCT AAAATCAAGT GCACCTACAC CAACTGCTCTCAAAATGTGA ACTGACTTTT 3420 60 ΪTΠΎΠTIT TΠTGCCAAC CCΓGTGTCAC TTAGTGAGGA CCTGACACAA TCCCTACAGG 3480 GTGTCTGTCA GTGGGCCTCA TGGTAAGAGT CACAATTTGC AAATTTAGGA CCGTGGGTCA 3 540 TGCAGCGAAG GGGCTGGATG GTAGGAAGGG ATGTGCCCGC CTCTCCACGC ACTCAGCTAT 3600 ACCTCATTCA CAGCTCCTTG TGAGTGTGTG CACAGGAAAT AAGCCGAGGG TATTATTTTT 3660 TTATGTTCAT GAGTCTTGTA ATTAAACCGT GAT cTTGAA AGGTGTAGGTTTGATTACTA 3720 65 GGAGATACCA CCGACATTTT TCAATAAAGT ACTGCAAAAT GCTTTTGTGT CTACCTTGTT 3780 ATTAACTTTT GGGGCTGTAT TTAGTAAAAA TAAATCAAGG CTATCGGAGC AGTTCAATAA 3840 CAAAGGTTAC TGTTGAGAAA AAAGACCCTA TCATAGATTT ACAAG 70 SEQ ID N0:110 PFJ8 Protein sequence: Protein Accession*: NP_005060.1 1 11 21 31 41 51 75 I I I I I I MKEKSKNAAK TRREKENGEF YELAKLLPLP SAITSQLDKA SIIRLTTSYL KMRAVFPEGL 60 GDAWGQPSRA GPLDGVAKEL GSHLLQTLDG FVFVVASDGK IMYISETASV HLGLSQVELT 120 GNSIYEYIHP SDHDEMTAVL TAHQPLHHHL LQEYEIERSF FLRMKCVLAK RNAGLTCSGY 180 KVIHCSGYLK IRQYMLDMSL YDSCYQIVGL VAVGQSLPPS AITEIKLYSN MFMFRASLDL 240 KLIFLDSRVT EVTGYEPQD IEKTLYHHVH GCDVFHLRYA HHLLLVKGQV TTKYYRLLSK 300 RGGWVWVQSY ATWHNSRSS RPHCIVSVNY VLTEIEYKEL QLSLEQVSTA KSQDSWRTAL 360 STSQETRKLV KPKNTKMKTK LRTNPYPPQQ YSSFQMDKLE CGQLGNWRAS PPASAAAPPE 420 LQPHSESSDL LYTPS YSLPF S YHYGHFPLD SHVFSSKKPM LPAKFGQPQG SPCEVARFFL 480 STLPASGECQ WHYANPLVPS SSSPAKNPPE PPANTARHSL VPSYEAPAAA VRRFGEDTAP 540 PSFPSCGHYR EEPALGPAKA ARQAARDGAR LALARAAPEC CAPPTPEAPG APAQLPFVLL 600 NYHRVLARRG PLGGAAPAAS GLACAPGGPE AATGALRLRH PSPAATSPPG APLPHYLGAS 660 VHTNGR SEQ ID N0:111 PFJ7 DNA SEQUENCE Nucleic Acid Accession * NM_006549 Coding sequence: 1-1254 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I ΩAACGGAC GCTGCATCTG CCCGTCCCTG CCCTACTCAC CCGTCAGCTC CCCGCAGTCC 60 TCGCCTCGGC TGCCCCGGCG GCCGACAGTG GAGTCTCACC ACGTCTCCAT CACGGGTATG 120 CAGGACTGTG TGCAGCTGAA TCAGTATACC CTGAAGGATG AAATTGGAAA GGGCTCCTAT 180 GGTGTCGTCA AGTTGGCCTA CAATGAAAAT GACAATACCT ACTATGCAAT GAAGGTGCTG 240 TCCAAAAAGA AGCTGATCCG GCAGGCCGGC TTTCCACGTC GCCCTCCACC CCGAGGCACC 300 CGGCCAGCTC CTGGAGGCTG CATCCAGCCC AGGGGCCCCA TTGAGCAGGT GTACCAGGAA 360 ATTGCCATCC TCAAGAAGCT GGACCACCCC AATGTGGTGA AGCTGGTGGA GGTCCTGGAT 420 GACCCCAATG AGGACCATCT GTACATGGTG TTCGAACTGG TCAACCAAGG GCCCGTGATG 480 GAAGTGCCCA CCCTCAAACC ACTCTCTGAA GACCAGGCCC GTTTCTACTT CCAGGATCTG 540 ATCAAAGGCA TCGAGTACTT ACACTACCAG AAGATCATCC ACCGTGACAT CAAACCTTCC 600 AACCTCCTGG TCGGAGAAGA TGGGCACATC AAGATCGCTG ACTTTGGTGT GAGCAATGAA 660 TTCAAGGGCA GTGACGCGCT CCTCTCCAAC ACCGTGGGCA CGCCCGCCTTCATGGCACCC 720 GAGTCGCTCT CTGAGACCCG CAAGATCTTC TCTGGGAAGG CCTTGGATGT TTGGGCCATG 780 GGTGTGACAC TATACTGCTT TGTCTTTGGC CAGTGCCCAT TCATGGACGA GCGGATCATG 840 TGTTTACACA GTAAGATCAA GAGTCAGGCC CTGGAATTTC CAGACCAGCC CGACATAGCT 900 GAGGACTTGA AGGACCTGAT CACCCGTATG CTGGACAAGA ACCCCGAGTC GAGGATCGTG 960 GTGCCGGAAA TCAAGCTGCA CCCCTGGGTC ACGAGGCATG GGGCGGAGCC GTTGCCGTCG 1020 GAGGATGAGA ACTGCACGCT GGTCGAAGTG ACTGAAGAGG AGGTCGAGAA CTCAGTCAAA 1080 CACATTCCCA GCTTGGCAAC CGTGATCCTG GTGAAGACCA TGATACGTAA ACGCTCCTTT 1140 GGGAACCCAT TCGAGGGCAG CCGGCGGGAG GAACGCTCAC TGTCAGCGCC TGGAAACTTG 1200 CTCACCAAAA AACCAACCAG GGAATGTGAG TCCCTGTCTG AGCTCAAGAC CJASAAAATA 1260 AGTCCCCTTC CTGCCTGTTG CAAAGTAACG TAAGAGTTCC CTCACCCGAG TGGATGCAGA 1320 CGTTCTTGCT GTCAGCCACC TTCCTTCATA CACATAGCCA GCCCAGGGTG ACCAGAACGT 1380 CCCAGGACAG ATGAGGCTTT GTGTCCTTAT GAGAGTGGGA GAACCTGGTG GGCACCCCTG 1440 GTGCAGGTGC TGTGGTGGGT GGGGACCCCA CTGCCTTTCC CACTGAGCAC ATCATGGCTA 1500 CCTGACTTGG TGGGAGTTCC ATTCAGTCAC TTCTGTTTCTTAAACATAGC TTTACTGAGG 1560 TACAATTCAC ATACCATGTA ATTCACCCAC GGGAAGTGTA TGATTCAGTG GTTTCTAATA 1620 CACACTTCTG CAGCCATTAC CACCGTCAAC TTTACGACAT TTTCATCAGC CCAAGAAGAC 1680 ACCCTACACT CCTTAGCTGT CCCCATCCAA CTCCCCCACC CCAGTAACCA CTCAGAATAG 1740 GTATGGATTT GCCTATTCTG GACGTTTCGT ATAAATGGCG TCATACACTA AAAAAAAAAA 1800 AAAA SEQ ID N0:112 PFJ7 Protein sequence: Protein Accession* NP_006540.1 1 11 21 31 41 51 I I I I I I MNGRCICPSL PYSPVSSPQS SPRLPRRPTV ESHHVSITGM QDCVQLNQYT LKDEIGKGSY 60 GVVKLAYNEN DNTYYAMKVL SKKKLIRQAG FPRRPPPRGT RPAPGGCIQPRGPIEQVYQE 120 ILKKLDHP NVVKLVEVLD DPNEDHLYMV FELVNQGPVM EVPTLKPLSEDQARFYFQDL 180 KGIEYLHYQ KIIHRDIKPS NLLVGEDGHI KIADFGVSNE FKGSDALLSN TVGTPAFMAP 240 ESLSETRKIF SGKALDVWAM GVTLYCFVFG QCPFMDERIM CLHSKIKSQA LEFPDQPDIA 300 EDLKDLITRM LDKNPESRIV VPEIKLHPWV TRHGAEPLPS EDENCTLVEV TEEEVENSVK 360 HIPSLATVIL VKTMIRKRSF GNPFEGSRRE ERSLS APGNL LTKKPTRECE SLSELKT SEQ ID N0:113 PFJ6 DNA SEQUENCE Nucleic Acid Accession* NM_021810 Coding sequence: 1 -429 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I ATSAAACCTC TGATATGGAC ATGGTCAGATGTTGAAGGCC AGAGGCCGGC TCTGCTCATC 60 TGCACAGCTG CAGCAGGACC CACGCAGGGA GTTAAGGGTT ATGGCAAGCC CTTTGAGCCA 120 AGAAGTGTGA AAAACATACA CTCTACTCCT GCTTACCCAG ATGCCACAAT GCACAGACAA 180 CTCCTGGCTC CGGTGGAAGG AAGGATGGCA GAGACATTGA ATCAGAAACT CCATGTTGCC 240 AATGTGCTGG AAGATGACCC CGGCTACCTA CCTCACGTCT ACAGCGAGGA AGGGGAGTGT 300 GGAGGGGCCC CATCCCTCAG CTCTCTGGCC AGCTTGGAAC AGGAGTTGCA ACCTGATTTG 360 CTGGACTCTT TGGGTTCAAA AGCGACTCCG TTTGAGGAAA TATATTCAGA GTCAGGTGTT 20 CCTTCCTAA 5 SEQ ID NO:114 PFJ6 Protein sequence: Protein Accession*: NPJ68582.1 1 11 21 31 41 51 , n I I I I I I 1 U MKPLIWTWSD VEGQRPALLI CTAA AGPTQG VKGYGKPFEP RS VKNIHSTP AYPDATMHRQ 60 LLAPVEGRMA ETLNQKLHVA NVLEDDPGYL PHVYSEEGEC GGAPSLSSLA SLEQELQPDL 120 LDSLGSKATP FEEIYSESGV PS 15 SEQ ID NO:115 PFJ5 DNA SEQUENCE Nucleic Acid Accession #: NM_006361 Coding sequence: 131-985 (underlined sequences correspond to start and stop codons) 20 1 11 21 31 41 51 I I I I I I CGAATGCAGG CGACTTGCGA GCTGGGAGCG ATTTAAAACG CTTTGGATTC CCCCGGCCTG 60 GGTGGGGAGA GCGAGCTGGG TGCCCCCTAG ATTCCCCGCC CCCGCACCTC ATGAGCCGAC 120 CCTCGGCTCC ATGGAGCCCG GCAATTATGC CACCTTGGAT GGAGCCAAGG ATATCGAAGG 180 25 CTTGCTGGGA GCGGGAGGGG GGCGGAATCT GGTCGCCCAC TCCCCTCTGA CCAGCCACCC 240 AGCGGCGCCT ACGCTGATGC CTGCTGTCAA CTATGCCCCC TTGGATCTGC CAGGCTCGGC 300 GGAGCCGCCA AAGCAATGCC ACCCATGCCC TGGGGTGCCC CAGGGGACGT CCCCAGCTCC 360 CGTGCCTTAT GGTTACTTTG GAGGCGGGTA CTACTCCTGC CGAGTGTCCC GGAGCTCGCT 420 GAAACCCTGT GCCCAGGCAG CCACCCTGGC CGCGTACCCC GCGGAGACTC CCACGGCCGG 480 30 GGAAGAGTAC CCCAGTCGCC CCACTGAGTT TGCCTTCTAT CCGGGATATC CGGGAACCTA 540 CCACGCTATG GCCAGTTACC TGGACGTGTC TGTGGTGCAG ACTCTGGGTG CTCCTGGAGA 600 ACCGCGACAT GACTCCCTGT TGCCTGTGGA CAGTTACCAG TCTTGGGCTC TCGCTGGTGG 660 CTGGAACAGC CAGATGTGTT GCCAGGGAGA ACAGAACCCA CCAGGTCCCT TTTGGAAGGC 720 AGCATTTGCA GACTCCAGCG GGCAGCACCC TCCTGACGCC TGCGCCTTTC GTCGCGGCCG 780 35 CAAGAAACGC ATTCCGTACA GCAAGGGGCA GTTGCGGGAG CTGGAGCGGG AGTATGCGGC 840 TAACAAGTTC ATCACCAAGG ACAAGAGGCG CAAGATCTCG GCAGCCACCA GCCTCTCGGA 900 GCGCCAGATT ACCATCTGGT TTCAGAACCG CCGGGTCAAA GAGAAGAAGG TTCTCGCCAA 960 GGTGAAGAAC AGCGCTACCC CTTAAGAGAT CTCCTTGCCT GGGTGGGAGG AGCGAAAGTG 1020 GGGGTGTCCT GGGGAGACCA GAAACCTGCC AAGCCCAGGC TGGGGCCAAG GACTCTGCTG 1080 40 AGAGGCCCCT AGAGACAACA CCCTTCCCAG GCCACTGGCT GCTGGACTGT TCCTCAGGAG 1140 CGGCCTGGGT ACCCAGTATG TGCAGGGAGA CGGAACCCCA TGTGACAGGC CCACTCCACC 1200 AGGGTTCCCA AAGAACCTGG CCCAGTCATA ATCATTCATC CTCACAGTGG CAATAATCAC 1260 GATAACCAGT 45 SEQ ID N0:116 PFJS Protein sequence' Protein Accession #: NP_006352.1 50 1 11 21 31 41 51 I I I I I I MEPGNYATLD GAKDIEGLLG AGGGRNLVAH SPLTSHPAAP TLMPAVNYAP LDLPGSAEPP 60 KQCHPCPGVP QGTSPAPVPY GYFGGGYYSC RVSRSSLKPC AQAATLAAYP AETPTAGEEY 120 PSRPTEFAFY PGYPGTYHAM ASYLDVSVVQ TLGAPGEPRH DSLLPVDSYQ SWALAGGWNS 180 55 QMCCQGEQNP PGPFWKAAFA DSSGQHPPDA CAFRRGRKKR IPYSKGQLRELEREYAANKF 240 ITKDKRRKIS AATSLSERQI TIWFQNRRVK EKKVLAKVKN SATP 60 SEQ ID NO:117PFJ4 DNA SEQUENCE Nucleic Acid Accession #: N _005628 Coding sequence: 591-2216 (underlined sequences correspond to start and stop codons) „ 1 11 21 31 41 51 65 i i i i i i GTAACCGCTA CTCCCGGACA CCAGACCACC GCCTTCCGTA CACAGGGGCC CGCATCCCAC 60 CCTCCCGGAC CTAAGAGCCT GGGTCCCCTG TTTCCGGAGG TCCGCTTCCC GGCCCCCAGA 120 TTCTGGC ATC CCAGCCCTCA GTGTCCAAGA CCCAGGCAGC CCGGGTCCCC GCCTCCCGGA 180 - n TCCAGGCGTC CGGGATCTGC GCCACCAGAA CCTAGCCTCC TGCAGACCTC CGCCATCTGG 240 70 GGGCACTCAA CCTCCTGGAG CCAAGGGCCC CACGTCCCAC CCAGAGAAAC TCTCGTATTC 300 CCAGCTCCTA GGGCCAAGGA ACCCGGGCGC TCCGAACTCC CAGCTTTCGG ACATCTGGCA 360 CACGGGGCAG AGCAGAGAAG CTCAGCGCCC AGCCTGGGGA ATTTAAACAC TCCAGCTTCC 420 AAGAGCCAAG GAACTTCAGT GCTGTGAACT CACAACTCTA AGGAGCCCTC CAAAGTTCCA 480 GTCTCCAGGT GCTGTTACTC AACTCAGTCC TAGGAACGTC GGGTCCTGGG AAGGAGCCCA 540 75 AGCGCTCCCA GCCAGCTTCC AGGCGCTAAG AAACCCCGGT GCTTCCCATC ATGGTGGCCG 600 ATCCTCCTCG AGACTCCAAG GGGCTCGCAG CGGCGGAGCC CACCGCCAAC GGGGGCCTGG 660 CGCTGGCCTC CATCGAGGAC CAAGGCGCGG CAGCAGGCGG CTACTGCGGT TCCCGGGACC 720 AGGTGCGCCG CTGCCTTCGA GCCAACCTGC TTGTGCTGCT GACAGTGGTG GCCGTGGTGG 780 CCGGCGTGGC GCTGGGACTG GGGGTGTCGG GGGCCGGGGG TGCGCTGGCG TTGGGCCCGG 840 AGCGCTTGAG CGCCTTCGTC TTCCCGGGCG AGCTGCTGCT GCGTCTGCTG CGGATGATCA 900 TCTTGCCGCT GGTGGTGTGC AGCTTGATCG GCGGCGCCGC CAGCCTGGAC CCCGGCGCGC 960 TCGGCCGTCT GGGCGCCTGG GCGCTGCTCT TTTTCCTGGT CACCACGCTG CTGGCGTCGG 1020 _ CGCTCGGAGT GGGCTTGGCG CTGGCTCTGC AGCCGGGCGC CGCCTCCGCC GCCATCAACG 1080 5 CCTCCGTGGG AGCCGCGGGC AGTGCCGAAA ATGCCCCCAG CAAGGAGGTG CTCGATTCGT 1140 TCCTGGATCT TGCGAGAAAT ATCTTCCCTT CCAACCTGGT GTCAGCAGCC TTTCGCTCAT 1200 ACTCTACCAC CTATGAAGAG AGGAATATCA CCGGAACCAG GGTGAAGGTG CCCGTGGGGC 1260 AGGAGGTGGA GGGGATGAAC ATCCTGGGCT TGGTAGTGTT TGCCATCGTC TTTGGTGTGG 1320 CGCTGCGGAA GCTGGGGCCT GAAGGGGAGC TGCTTATCCG CTTCTTCAAC TCCTTCAATG 1380 10 AGGCCACCAT GGTTCTGGTC TCCTGGATCA TGTGGTACGC CCCTGTGGGC ATCATGTTCC 1440 TGGTGGCTGG CAAGATCGTG GAGATGGAGG ATGTGGGTTT ACTCTTTGCC CGCCTTGGCA 1500 AGTACATTCT GTGCTGCCTG CTGGGTCACG CCATCCATGG GCTCCTGGTA CTGCCCCTCA 1560 TCTACTTCCT CTTCACCCGC AAAAACCCCT ACCGCTTCCT GTGGGGCATC GTGACGCCGC 1620 _ TGGCCACTGC CTTTGGGACC TCTTCCAGTT CCGCCACGCT GCCGCTGATG ATGAAGTGCG 1680 15 TGGAGGAGAA TAATGGCGTG GCCAAGCACA TCAGCCGTTT CATCCTGCCC ATCGGCGCCA 1740 CCGTCAACAT GGACGGTGCC GCGCTCTTCC AGTGCGTGGC CGCAGTGTTC ATTGCACAGC 1800 TCAGCCAGCA GTCCTTGGAC TTCGTAAAGA TCATCACCAT CCTGGTCACG GCCACAGCGT 1860 CCAGCGTGGG GGCAGCGGGC ATCCCTGCTG GAGGTGTCCT CACTCTGGCC ATCATCCTCG 1920 AAGCAGTCAA CCTCCCGGTC GACCATATCT CCTTGATCCTGGCTGTGGAC TGGCTAGTCG 1980 20 ACCGGTCCTG TACCGTCCTC AATGTAGAAG GTGACGCTCT GGGGGCAGGA CTCCTCCAAA 2040 ATTATGTGGA CCGTACGGAG TCGAGAAGCA CAGAGCCTGA GTTGATACAA GTGAAGAGTG 2100 AGCTGCCCCTGGATCCGCTG CCAGTCCCCA CTGAGGAAGG AAACCCCCTC CTCAAACACT 2160 ATCGGGGGCC CGCAGGGGAT GCCACGGTCG CCTCTGAGAA GGAATCAGTC ATGIAAACCC 2220 CGGGAGGGAC CTTCCCTGCC CTGCTGGGGG TGCTCTTTGG ACACTGGATT ATGAGGAATG 2280 25 GATAAATGGA TGAGCTAGGG CTCTGGGGGTCTGCCTGCAC ACTCTGGGGA GCCAGGGGCC 2340 CCAGCACCCT CCAGGACAGG AGATCTGGGA TGCCTGGCTG CTGGAGTACA TGTGTTCACA 2400 AGGGTTACTC CTCAAAACCC CCAGTTCTCA CTCATGTCCC CAACTCAAGG CTAGAAAACA 2460 GCAAGATGGA GAAATAATGT TCTGCTGCGT CCCCACCGTG ACCTGCCTGG CCTCCCCTGT 2520 CTCAGGGAGC AGGTCACAGG TCACCATGGG GAATTCTAGC CCCCACTGGG GGGATGTTAC 2580 30 AACACCATGC TGGTTATTTT GGCGGCTGTA GTTGTGGGGG GATGTGTGTG TGCACGTGTG 2640 TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG TTCTGTGACC TCCTGTCCCC ATGGTACGTC 2700 CCACCCTGTC CCCAGATCCC CTATTCCCTC CACAATAACA GAAACACTCC CAGGGACTCT 2760 GGGGAGAGGC TGAGGACAAA TACCTGCTGT CACTCCAGAG GACATTTTTT TTAGCAATAA 2820 AATTGAGTGT CAACTATTTA AAAAAAAAAA AAAAAA 35 SEQ ID N0:118 PFJ4 Protein sequence: Protein Accession* NP_005619.1 40 1 11 21 31 41 51 I I I I I I MVADPPRDSK GLAAAEPTAN GGLALASBED QGAAAGGYCG SRDQVRRCLR ANLLVLLTVV 60 AWAGVALGL GVSGAGGALA LGPERLSAFV FPGELLLRLL RMIILPLWC SUGGAASLD 120 PGALGRLGA ALLFFLVTTL ASALGVGLA LALQPGAASAAINASVGAAG SAENAPSKEV 180 45 U-»SFU)LARNπTSNLVSAA FRSYSTTYEERNITGTRVKV PVGQEVEGMN ILGLVVFAIV 240 FGVALRKLGP EGELLIRFFN SFNEATMVLV SWIMWYAPVG IMFLVAGKIV EMEDVGLLFA 300 RLGKYILCCL LGHAIHGLLV LPLIYFLFTR KNPYRFLWGI VTPLATAFGT SSSS ATLPLM 360 MKCVEENNGV AKHISRFILP IGATVNMDGA ALFQCVAAVF IAQLSQQSLD FVKI-T-LVT 420 ATASSVGAAG IPAGGVLTLA IILEAVNLPV DHISLILAVD WLVDRSCTVLNVEGDALGAG 480 50 LLQNYVDRTE SRSTEPELIQ VKSELPLDPLPVPTEEGNPLLKHYRGPAGD ATVASEKESV 540 M 55 SEQ ID N0.119PFJ3 DNA SEQUENCE Nucleic Acid Accession* NM_006708 Coding sequence: 88-642 (underlined sequences correspond to start and stop codons) ^ - 1 11 21 31 41 51 60 I I I I I I CTAGTTAAGG CGGCACAGGG CCGAGGCGTA GTGTGGGTGA CTCCTCCGTT CCTTGGGTCC 60 CGTCGTCTGT GATACTGCAG TTCAGCCATG GCAGAACCGC AGCCCCCGTC CGGCGGCCTC 120 ACGGACGAGG CCGCCCTCAG TTGCTGCTCC GACGCGGACC CCAGTACCAA GGATTTTCTA 180 TTGCAGCAGA CCATGCTACG AGTGAAGG AT CCTAAGAAGT CACTGG ATTT TTATACTAGA 240 65 GTTCTTGGAA TGACGCTAAT CCAAAAATGT GATTTTCCCA TTATGAAGTT TTCACTCTAC 300 TTCTTGGCTT ATGAGGATAA AAATGACATC CCTAAAGAAA AAGATGAAAA AATAGCCTGG 360 GCGCTCTCCA GAAAAGCTAC ACTTGAGCTG ACACACAATT GGGGCACTGA AGATGATGCG 420 ACCCAGAGTT ACCACAATGG CAATTCAGAC CCTCGAGGAT TCGGTCATAT TGGAATTGCT 480 GTTCCTGATG TATACAGTGC TTGTAAAAGG TTTGAAGAAC TGGGAGTCAA ATTTGTGAAG 540 70 AAACCTGATG ATGGTAAAAT GAAAGGCCTG GCATTTATTC AAGATCCTGA TGGCTACTGG 600 ATTGAAATTT TGAATCCTAA CAAAATGGCA ACCTTAATGT AgTGCTGTGA GAATTCTCCT 660 TTGAGATTTC AGAAGAAAGG AAACAATGTG ATTCAAGATA TTTACATACC AGAAGCATCT 720 AGGACTGATG GATCACTGTC CCGATTCAAA TTATTCTTCA GTCCATTTCC CCTTCCTATT 780 TCAGCTGTTC CTITTCACCr AACTGTTCAG TCATTCTGGTTTTCAAGCAG TGCTTTATCT 840 75 CATGTCCTTG AATATAGTTG TGTAACITrA TrπTTAGGT AATAATTAGA ACAGTTCCCT 900 TCAGAGGCTG CATTTGCCTT CTTCTGCCAC CTAAATATTA CTTCCCTTCA AATCTGCCTT 960 TGAATCATCA TTTTTAAAAA AAAATTAACA TGTTTTTGTT GTAGTTATCT TCTGGGGTTT 1020 CAATTCCTCA GAAACAACTT TTTTCACAAC GGAAAGGAAA GAACACTAGT GTTCTTTCAG 1080 TAAAGTACAA AGTGTTTATT TTACAAAAGA GTAGGTACTC TTGAGAGCAA TTCAAATCAT 1140 GCTGACAAGG ATACTGATAG AAAAAGTGAT TTCTTCTTAT TATAAAGTAC ATTTAAAGTT 1200 CAAGGACTAA CCTTATTTAT TTGGGAAAGG GGAGGAGGAA GGAAATGATA TGGTACCCAG 1260 ACACTGGGCT AGGCTGCAAC TTTATCTCAT TTAATACTCC CAGCTGTCAT GTGAGAAAGA 1320 AAGCAGGCTA GGCATGTGAAATCACTTTCA TGGATTATTA ATGGATTTAA GAGGGCATCA 1380 5 ATCAGCTCAA CTCAAGATTT CATAATCATTTTTAGTATTT AGATTGTGCC TCAAAGTTGT 1440 AGTACCTCAC AATACCTCCA CTGGTTTCCT GTTGTAAAAA CCTTCAGTGA GTTTGACCAT 1500 TGTGCTCTTG GCTCTTGGGC TGGAGTACCG TGGTGAGGGA GTAAACACTA GAAGTCTTTA 1560 GTACAAAACT GCTCTAGGGA CACCTGGTGA TTCCTACACA AGTGATGTTT ATATTTCTCA 1620 TAAAGAGTCT TCCCTATCCC AAGGTCTTCA TGATGCCAGT AGCCATATAT GATAAATTAT 1680 0 GTTCAGTGAT AACTTAGTTA TCAGAA ATCA GCTCAGTGGT CTTCCCCGCC ATGATTCACA 1740 TTTGATGAGT TTTTAAAAAT CAAAGTGATT TTGAAAATCT CTAATGGCTC AGAAAATAAA 1800 AACATCCAGT TTGTGGATGA CTATATTTAG ATTTCTCTAG ACTCTAGTGG AAGACCTTTG 1860 GAAAGGCCAT GCCAACCGTG CTTGTACTGC TAGAAGCACT TTATGTTTCC TTTTTGGGTG 1920 AAATGGATTT ATGTGAGTGC TTTAAACAAA TAGCAATACT TATAGACTGA AATAAAATGA 1980 5 A ACTTCAAAT AAG SEQ ID NO:120 PFJ3 Protein sequence: Protein Accession* NP 006699.1 20 1 II 21 31 41 51 I I I I I i MAEPQPPSGG LTDEAALSCC SDADPSTKDF LQQTMLRVK DPKKSLDFYT RVLGMTLIQK 60 CDFPIMKFSLYFLAYEDKND IPKEKDEKIAWALSRKATLE THNWGTEDDATQSYHNGNS 120 25 DPRGFGHIGI AVPDVYSACK RFEELGVKFV KKPDDGKMKG LAHQDPDGY WIEILNPNKM 180 ATLM 50 SEQ ID N0:121 PFJ2 DNA SEQUENCE Nucleic Acid Accession* NM_002867 Coding sequence: 70-729 (underlined sequences correspond to start and stop codons) , _ 1 11 21 31 41 51 55 I I I I I I CCGACGCCAG GTCCTGCCGT CCCGCCGACC GTCCGGGAGC GAACCCGTCG TCCCGCACTG 60 GAGTCCGCGA TGGCTTCAGT GACAGATGGT AAACATGGAG TCAAAGATGC CTCTGACCAG 120 AATTTTGACT ACATGTTTAA ACTGCTTATC ATTGGCAACA GCAGTGTTGG CAAGACCTCC 180 TTCCTCTTGC GCTATGCTGATGACACGTTC ACCCCAGCCTTCGTTAGCAC CGTGGGCATC 240 10 GACTTCAAGG TGAAGACAGTCTACCGTCACGAGAAGCGGGTGAAACTGCA GATCTGGGAC 300 ACAGCTGGGC AGGAGCGGTA CCGGACCATC ACAACAGCCT ATTACCGTGG GGCCATGGGC 360 TTCATTCTGA TGTATGACAT CACCAATGAA GAGTCCTTCA ATGCTGTCCA AGACTGGGCT 420 ACTCAGATCA AGACCTACTC CTGGGACAAT GCACAAGTTA TTCTGGTGGG GAACAAGTGT 480 GACATGGAGGAAGAGAGGGTTGTTCCCACTGAGAAGGGCCAGCTCCTTGCAGAGCAGCTT 540 1-5 GGGTTTGATTTCTTTGAAGC CAGTGCAAAG GAGAACATCA GTGTAAGGCA GGCCTTTGAG 600 CGCCTGGTGG ATGCCATTTG TGACAAGATG TCTGATTCGC TGGACACAGA CCCGTCGATG 660 CTGGGCTCCT CCAAGAACAC GCGTCTCTCG GACACCCCAC CGCTGCTGCA GCAGAACTGC 720 TCATGCT_2C AAGGCCCACC TTCCTGACCT CCCCTCATTG TGGCCCCACA CCCAAGTCTG 780 CTTCTCCCTG TTACACACTG TCCGCTCT >0 SEQ ID NO:122 PFJ2 Protein sequence: Protein Accession* NP_002858.1 1 11 21 31 41 51 I I I I I I MASVTDGKHG VKDASDQNFD YMFKLLIIGN SSVGKTSFLL RYADDTFTPA FVSTVGIDFK 60 VKTVYRHEKR VKLQIWDTAG QERYRTITTA YYRGAMGFIL MYDITNEESF NAVQDWATQI 120 KTYSWDNAQV ILVGNKCDME EERWPTEKG QLLAEQLGFD FFEASAKENI SVRQAFERLV 180 DAICDKMSDS LDTDPSMLGS SKNTRLSDTP PLLQQNCSC SEQ ID NO:123 PFJ1 DNA SEQUENCE Nucleic Acid Accession*: NM.001844 Coding sequence: 1584621 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I 1 I I I ACGCAGAGCG CTGCTGGGCT GCCGGGTCTC CCGCTTCCTC CTCCTGCTCC AAGGGCCTCC 60 TGCATGAGGG CGCGGTAGAG ACCCGGACCC GCGCCGTGCT CCTGCCGTTT CGCTGCGCTC 120 CGCCCGGGCC CGGCTCAGCC AGGCCCCGCG GTGAGCCATQ ATTCGCCTCG GGGCTCCCCA 180 GTCGCTGGTG CTGCTGACGC TGCTCGTCGC CGCTGTCCTT CGGTGTCAGG GCCAGGATGT 240 CCAGGAGGCT GGCAGCTGTG TGCAGGATGG GCAGAGGTAT AATGATAAGG ATGTGTGGAA 300 GCCGGAGCCC TGCCGGATCT GTGTCTGTGA CACTGGGACT GTCCTCTGCG ACGACATAAT 360 CTGTGAAGAC GTGAAAGACT GCCTCAGCCC TGAGATCCCC TTCGGAGAGT GCTGCCCCAT 420 CTGCCCAACT GACCTCGCCA CTGCCAGTGG GCAACCAGGA CCAAAGGGAC AGAAAGGAGA 480 ACCTGGAGAC ATCAAGGATA TTGTAGGACC CAAAGGACCT CCTGGGCCTC AGGGACCTGC 540 AGGGGAACAA GGACCCAGAG GGGATCGTGG TGACAAAGGT GAAAAAGGTG CCCCTGGACC 600 TCGTGGCAGA GATGGAGAAC CTGGGACCCC TGGAAATCCT GGCCCCCCTG GTCCTCCCGG 660 CCCCCCTGGT CCCCCTGGTC TTGGTGGAAA CTTTGCTGCC CAGATGGCTG GAGGATTTGA 720 TGAAAAGGCT GGTGGCGCCC AGTTGGGAGT AATGCAAGGA CCAATGGGCC CCATGGGACC 780 TCGAGGACCT CCAGGGCCTG CAGGTGCTCC TGGGCCTCAA GGATTTCAAG GCAATCCTGG 840 TGAACCTGGT GAACCTGGTG TCTCTGGTCC CATGGGTCCC CGTGGTCCTC CTGGTCCCCC 900 TGGAAAGCCT GGTGATGATG GTGAAGCTGG AAAACCTGGA AAAGCTGGTG AAAGGGGTCC 960 GCCTGGTCCT CAGGGTGCTC GTGGTTTCCC AGGAACCCCA GGCCTTCCTG GTGTCAAAGG 1020 TCACAGAGGT TATCCAGGCC TGGACGGTGC TAAGGGAGAG GCGGGTGCTC CTGGTGTGAA 1080 GGGTGAGAGT GGTTCCCCGG GTGAGAACGG ATCTCCGGGC CCAATGGGTC CTCGTGGCCT 1140 GCCTGGTGAA AGAGGACGGA CTGGCCCTGC TGGCGCTGCG GGTGCCCGAG GCAACGATGG 1200 TCAGCCAGGC CCCGCAGGTC CTCCGGGTCC TGTCGGTCCT GCTGGTGGTC CTGGCTTCCC 1260 TGGTGCTCCT GGAGCCAAGG GTGAAGCCGG CCCCACTGGT GCCCGTGGTC CTGAAGGTGC 1320 TCAAGGTCCT CGCGGTGAAC CTGGTACTCC TGGGTCCCCT GGGCCTGCTG GTGCCTCCGG 1380 TAACCCTGGA ACAGATGGAA TTCCTGGAGC CAAAGGATCT GCTGGTGCTC CTGGCATTGC 1440 TGGTGCTCCT GGCTTCCCTG GGCCACGGGG TCCTCCTGGC CCTCAAGGTG CAACTGGTCC 1500 TCTGGGCCCG AAAGGTCAGA CGGGTGAACC TGGTATTGCT GGCTTCAAAG GTGAACAAGG 1560 CCCCAAGGGA GAACCTGGCC CTGCTGGCCC CCAGGGAGCC CCTGGACCCG CTGGTGAAGA 1620 AGGCAAGAGA GGTGCCCGTG GAGAGCCTGG TGGCGTTGGG CCCATCGGTC CCCCTGGAGA 1680 AAGAGGTGCT CCCGGAAACC GCGGTTTCCC AGGTCAAGAT GGTCTGGCAG GTCCCAAGGG 1740 AGCCCCTGGA GAGCGAGGGC CCAGTGGTCT TGCTGGCCCC AAGGGAGCCA ACGGTGACCC 1800 TGGCCGTCCT GGAGAACCTG GCCTTCCTGG AGCCCGGGGT CTCACTGGCC GCCCTGGTGA 1860 TGCTGGTCCT CAAGGCAAAG TTGGCCCTTC TGGAGCCCCT GGTGAAGATG GTCGTCCTGG 1920 ACCTCCAGGT CCTCAGGGGG CTCGTGGGCA GCCTGGTGTC ATGGGTTTCC CTGGCCCCAA 1980 AGGTGCCAAC GGTGAGCCTG GCAAAGCTGG TGAGAAGGGA CTGCCTGGTG CTCCTGGTCT 2040 GAGGGGTCTT CCTGGCAAAG ATGGTGAGAC AGGTGCTGCA GGACCCCCTG GCCCTGCTGG 2100 ACCTGCTGGT GAACGAGGCG AGCAGGGTGC TCCTGGGCCA TCTGGGTTCC AGGGACTTCC 2160 TGGCCCTCCT GGTCCCCCAG GTGAAGGTGG AAAACCAGGT GACCAGGGTG TTCCCGGTGA 2220 AGCTGGAGCC CCTGGCCTCG TGGGTCCCAG GGGTGAACGA GGTTTCCCAG GTGAACGTGG 2280 CTCTCCCGGT GCCCAGGGCC TCCAGGGTCC CCGTGGCCTC CCCGGCACTC CTGGCACTGA 2340 TGGTCCCAAA GGTGCATCTG GCCCAGCAGG CCCCCCTGGC GCACAGGGCC CTCCAGGTCT 2400 TCAGGGAATG CCTGGCGAGA GGGGAGCAGC TGGTATCGCT GGGCCCAAAG GCGACAGGGG 2460 TGACGTTGGT GAGAAAGGCC CTGAGGGAGC CCCTGGAAAG GATGGTGGAC GAGGCCTGAC 2520 AGGTCCCATT GGCCCCCCTG GCCCAGCTGG TGCTAACGGC GAGAAGGGAG AAGTTGGACC 2580 TCCTGGTCCT GCAGGAAGTG CTGGTGCTCG TGGCGCTCCG GGTGAAGGTG GAGAGACTGG 2640 CCCCCCCGGA CCAGCGGGAT TTGCTGGGCC TCCTGGTGCT GATGGCCAGC CTGGGGCCAA 2700 GGGTGAGCAA GGAGAGGCCG GCCAGAAAGG CGATGCTGGT GCCCCTGGTC CTCAGGGCCC 2760 CTCTGGAGCA CCTGGGCCTC AGGGTCCTAC TGGAGTGACT GGTCCTAAAG GAGCCCGAGG 2820 TGCCCAAGGC CCCCCGGGAG CCACTGGATT CCCTGGAGCT GCTGGCCGCG TTGGACCCCC 2880 AGGCTCCAAT GGCAACCCTG GACCCCCTGG TCCCCCTGGT CCTTCTGGAA AAGATGGTCC 2940 CAAAGGTGCT CGAGGAGACA GCGGCCCCCC TGGCCGAGCT GGTGAACCCG GCCTCCAAGG 3000 TCCTGCTGGA CCCCCTGGCG AGAAGGGAGA GCCTGGAGAT GACGGTCCCT CTGGTGCCGA 3060 AGGTCCACCA GGTCCCCAGG GTCTGGCTGG TCAGAGAGGC ATCGTCGGTC TGCCTGGGCA 3120 ACGTGGTGAG AGAGGATTCC CTGGCTTGCC TGGCCCATCG GGTGAGCCCG GCAAGCAGGG 3180 TGCTCCTGGA GCATCTGGAG ACAGAGGTCC TCCTGGCCCC GTGGGTCCTC CTGGCCTGAC 3240 GGGTCCTGCA GGTGAACCCG GACGAGAGGG AAGCCCCGGT GCTGATGGCC CCCCTGGCAG 3300 AGATGGCGCT GCTGGAGTCA AGGGTGATCG TGGTGAGACT GGTGCTGTGG GAGCTCCTGG 33 60 AGCCCCTGGG CCCCCTGGCT CCCCTGGCCC CGCTGGTCCA ACTGGCAAGC AAGGAGACAG 3420 AGGAGAAGCT GGTGCACAAG GCCCCATGGG ACCCTCAGGA CCAGCTGGAG CCCGGGGAAT 3480 CCAGGGTCCT CAAGGCCCCA GAGGTGACAA AGGAGAGGCT GGAGAGCCTG GCGAGAGAGG 3540 CCTGAAGGGA CACCGTGGCT TCACTGGTCT GCAGGGTCTG CCCGGCCCTC CTGGTCCTTC 3600 TGGAGACCAA GGTGCTTCTG GTCCTGCTGG TCCTTCTGGC CCTAGAGGTC CTCCTGGCCC 3660 CGTCGGTCCC TCTGGCAAAG ATGGTGCTAA TGGAATCCCT GGCCCCATTG GGCCTCCTGG 3720 TCCCCGTGGA CGATCAGGCG AAACCGGTCC TGCTGGTCCT CCTGGAAATC CTGGGCCCCC 3780 TGGTCCTCCA GGTCCCCCTG GCCCTGGCAT CGACATGTCC GCCTTTGCTG GCTTAGGCCC 3840 GAGAGAGAAG GGCCCCGACC CCCTGCAGTA CATGCGGGCC GACCAGGCAG CCGGTGGCCT 3900 GAGACAGCAT GACGCCGAGG TGGATGCCAC ACTCAAGTCC CTCAACAACC AGATTGAGAG 3960 CATCCGCAGC CCCGAGGGCT CCCGCAAGAA CCCTGCTCGC ACCTGCAGAG ACCTGAAACT 4020 CTGCCACCCT GAGTGGAAGA GTGGAGACTA CTGGATTGAC CCCAACCAAG GCTGCACCTT 4080 GGACGCCATG AAGGTTTTCT GCAACATGGA GACTGGCGAG ACTTGCGTCT ACCCCAATCC 4140 AGCAAACGTT CCCAAGAAGA ACTGGTGGAG CAGCAAGAGC AAGGAGAAGA AACACATCTG 4200 GTTTGGAGAA ACCATCAATG GTGGCTTCCA TTTCAGCTAT GGAGATGACA ATCTGGCTCC 4260 CAACACTGCC AACGTCCAGA TGACCTTCCT ACGCCTGCTG TCCACGGAAG GCTCCCAGAA 4320 CATCACCTAC CACTGCAAGA ACAGCATTGC CTATCTGGAC GAAGCAGCTG GCAACCTCAA 4380 GAAGGCCCTG CTCATCCAGG GCTCCAATGA CGTGGAGATC CGGGCAGAGG GCAATAGCAG 4440 GTTCACGTAC ACTGCCCTGA AGGATGGCTG CACGAAACAT ACCGGTAAGT GGGGCAAGAC 4500 TGTTATCGAG TACCGGTCAC AGAAGACCTC ACGCCTCCCC ATCATTGACA TTGCACCCAT 4560 GGACATAGGA GGGCCCGAGC AGGAATTCGG TGTGGACATA GGGCCGGTCT GCTTCTTGTA 4620 AAAACCTGAA CCCAGAAACA ACACAATCCG TTGCAAACCC AAAGGACCCA AGTACTTTCC 4680 AATCTCAGTC ACTCTAGGAC TCTGCACTGA ATGGCTGACC TGACCTGATG TCCATTCATC 4740 CCACCCTCTC ACAGTTCGGA CTTTTCTCCC CTCTCTTTCT AAGAGACCTG AACTGGGCAG 4800 ACTGCAAAAT AAAATCTCGG TGTTCTATTT ATTTATTGTC TTCCTGTAAG ACCTTCGGGT 4860 CAAGGCAGAG GCAGGAAACT AACTGGTGTG AGTCAAATGC CCCCTGAGTG ACTGCCCCCA 4920 GCCCAGGCC A GAAG ACCTCC CTTCAGGTGC CGGGCGCAGG AACTGTGTGT GTCCTACAC A 4980 ATGGTGCTAT TCTGTGTCAA ACACCTCTGT ATTTTTTAAA ACATCAATTG ATATTAAAAA 5040 TGAAAAGATT ATTGGAAAGT SEQ ID N0.124 PF.HProteln sequent-a: Protein Accession* NP-.001835.2 1 11 21 31 41 51 1 1 1 1 1 1 MKLGAPQSL VLLTLLVAAV LRCQGQDVQE AGSCVQDGQR YNDKDVWKPE PCRICVCDTG 60 TVLCDDHCE DVKDCLSPEI PFGECCPICP TDLATASGQP GPKGQKGEPG DIKDIVGPKG 120 PPGPQGPAGE QGPRGDRGDK GEKGAPGPRG RDGEPGTPGN PGPPGPPGPP GPPGLGGNFA 180 AQMAGGFDEK AGGAQLGVMQ GPMGPMGPRG PPGPAGAPGP QGFQGNPGEP GEPGVSGPMG 240 PRGPPGPPGKPGDDGEAGKP GKAGERGPPG PQGARGFPGT PGLPGVKGHR GYPGLDGAKG 3 00 EAGAPG VKGE SGSPGENGSP GPMGPRGLPG ERGRTGPAGA AGARGNDGQP GPAGPPGPVG 360 PAGGPGFPGA PGAKGEAGPT GARGPEGAQG PRGEPGTPGS PGPAGASGNP GTDGIPGAKG 420 SAGAPGIAGA PGFPGPRGPP GPQGATGPLG PKGQTGEPGI AGFKGEQGPK GEPGPAGPQG 480 APGPAGEEGK RGARGEPGGV GPIGPPGERG APGNRGFPGQ DGLAGPKGAP GERGPSGLAG 540 PKGANGDPGR PGEPGLPGAR GLTGRPGDAG PQGKVGPSGA PGEDGRPGPP GPQGARGQPG 600 VMGFPGPKGA NGEPGKAGEK GLPGAPGLRG LPGKDGETGA AGPPGPAGPA GERGEQGAPG 660 PSGFQGLPGP PGPPGEGGKP GDQGVPGEAG APGLVGPRGE RGFPGERGSP GAQGLQGPRG 720 1PGTPGTDGP KGASGPAGPP GAQGPPGLQG MPGERGAAGI AGPKGDRGDV GEKGPEGAPG 780 KDGGRGLTGP IGPPGPAGAN GEKGEVGPPG PAGSAGARGA PGERGETGPP GPAGFAGPPG 840 ADGQPGAKGE QGEAGQKGDA GAPGPQGPSG APGPQGPTGV TGPKGARGAQ GPPGATGFPG 900 AAGRVGPPGS NGNPGPPGPP GPSGKDGPKG ARGDSGPPGR AGEPGLQGPA GPPGEKGEPG 960 DDGPSGAEGP PGPQGLAGQR GIVGLPGQRG ERGFPGLPGP SGEPGKQGAP GASGDRGPPG 1020 PVGPPGLTGP AGEPGREGSP GADGPPGRDG AAGVKGDRGE TGAVGAPGAP GPPGSPGPAG 1080 PTGKQGDRGE AGAQGPMGPS GPAGARGIQG PQGPRGDKGE AGEPGERGLK GHRGFTGLQG 1140 LPGPPGPSGD QGASGPAGPS GPRGPPGPVG PSGKDGANGIPGPIGPPGPR GRSGETGPAG 1200 PPGNPGPPGPPGPPGPGIDM SAFAGLGPRE KGPDPLQYMR ADQAAGGLRQ HDAEVDATLK 1260 SLNNQDESIR SPEGSRKNPA RTCRDLKLCH PEWKSGDYWI DPNQGCTLDA MKVFCNMETG 1320 ETCVYPNPAN VPKKNWWSSK SKEKKHIWFG ETINGGFHFS YGDDNLAPNT ANVQMTELRL 1380 LSTEGSQNIT YHCKNSIAYL DEAAGNLKKA LLIQGSNDVE IRAEGNSRFT YTALKDGCTK 1440 HTGKWGKTVI EYRSQKTSRL PIIDIAPMDI GGPEQEFGVD IGPVCFL SEQ ID NO:125 PFH9 DNA SEQUENCE Nucleic Acid Accession* NM_005084 Coding sequence: 162-1487(underlιned sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I GCTGGTCGGA GGCTCGCAGT GCTGTCGGCG AGAAGCAGTC GGGTTTGGAG CGCTTGGGTC 60 GCGTTGGTGC GCGGTGGAAC GCGCCCAGGG ACCCCAGTTC CCGCGAGCAG CTCCGCGCCG 120 CGCCTGAGAG ACTAAGCTGA AACTGCTGCT CAGCTCCCAA GAT_!GTGCCA CCCAAATTGC 180 ATGTGCTTTT CTGCCTCTGC GGCTGCCTGG CTGTGGTTTA TCCTTTTGAC TGGCAATACA 240 TAAATCCTGT TGCCCATATG AAATCATCAG CATGGGTCAA CAAAATACAA GTACTGATGG 300 CTGCTGCAAG CrrrGGCCAA ACTAAAATCC CCCGGGGAAATGGGCCTTAT TCCGTTGGTT 360 GTACAGACT AATGTTTGAT CACACTAATA AGGGCACCTT CTTGCGTTTA TATTATCCAT 420 CCCAAGATAA TGATCGCCTT GACACCCTTT GGATCCCAAA TAAAGAATAT TTTTGGGGTC 480 TTAGCAAATT TCTTGGAACA CACTGGCTTA TGGGCAACAT TTTGAGGTTA CTCTTTGGTT 540 CAATGACAAC TCCTGCAAAC TGGAATTCCC CTCTGAGGCC TGGTGAAAAA TATCCACTTG 600 TTGTTTTTTC TCATGGTCΓT GGGGCATTCA GGACACTTTA TTCTGCTATT GGCATTGACC 660 TGGCATCTCA TGGGTTTATA GTTGCTGCTG TAGAACACAG AGATAGATCT GCATCTGCAA 720 CTTACTATTT CAAGGACCAA TCTGCTGCAG AAATAGGGGA CAAGTCTTGG CTCTACCTTA 780 GAACCCTGAA ACAAGAGGAG GAGACACATA TACGAAATGA GCAGGTACGG CAAAGAGCAA 840 AAGAATGTTC CCAAGCTCTC AGTCTGATTC TTGACATTGA TCATGGAAAG CCAGTGAAGA 900 ATGCATTAGA TTTAAAGTTT GATATGGAAC AACTGAAGGA CTCTATTGAT AGGGAAAAAA 960 TAGCAGTAATTGGACATTCTTTTGGTGGAG CAACGGTTAT TCAGACTCTTAGTGAAGATC 1020 AGAGATTCAG ATGTGGTATT GCCCTGGATG CATGGATGTT TCCACTGGGT GATGAAGTAT 1080 ATTCCAGAAT TCCTCAGCCC crCTTTTTTA TCAACTCTGA ATATTTCCAA TATCCTGCTA 1140 ATATCATAAA AATGAAAAAA TGCTACTCAC CTGATAAAGA AAGAAAGATG ATTACAATCA 1200 GGGGTTCAGT CCACCAGAAT TTTGCTGACT TCACTTTTGC AACTGGCAAA ATAATTGGAC 1260 ACATGCTCAA ATTAAAGGGA GACATAGATT CAAATGTAGC TATTGATCTTAGCAACAAAG 1320 CTTCATTAGC ATTCTTACAA AAGCATTTAG GACTTCATAA AGATTTTGAT CAGTGGGACT 1380 GCTTGATTGA AGGAGATGAT GAGAATCTTA TTCCAGGGAC CAACATTAAC ACAACCAATC 1440 AACACATCAT GTTACAGAAC TCTTCAGGAA TAGAGAAATA CAATTAβGAT TAAAATAGGT 1500 TTTTT SEQ ID NO:126 PFH9 Protein sequence: Protein Accession* NP_005075.1 1 11 21 31 41 51 I I I I I I MVPPKLHVLF CLCGCLAVVY PFDWQYINPV AHMKSSAWVN KIQVLMAAAS FGQTKIPRGN 60 GPYSVGCTDLMFDHTNKGTF RLYYPSQDN DRLDTLWIPN KEYFWGLSKFLGTHWLMGNI 120 LRIJJFGSMTT PANWNSPLRP GEKYPLVVFS HGLGAFRTLY SAIGIDLASH GFIVAAVEHR 180 DRSASATYYF KDQSAAEIGD KSWLYLRTLKQEEETHIRNE QVRQRAKECS QALSLILDID 240 HGKPVKNALD LKFDMEQ KD SIDREKIAVI GHSFGGATVI QTLSEDQRFR CGIALDAWMF 300 PLGDEVYSRI PQPLFFINSE YFQYPANIIK MKKCYSPDKE RKMITIRGSV HQNFADFTFA 360 TCKHGHMLK LKGDIDSNVA IDLSNKASLA FLQKHLGLHK DFDQWDCLIE GDDENLIPGT 420 NINTTNQHIM LQNSSGIEKY N SEQ ID NO:127PFH8 DNA SEQUENCE 5 Nucleic Acid Accession* N _015900 Coding sequence: 32-1402 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 ι n I I I I I I I U CACG AGCGGC ACGAGGATTT CCAGCTCAGC GAJ≤CCCCCA GGTCCCTGGG AGAGCTGCTT 60 CTGGGTGGGG GGCCTCATTT TGTGGCTCAG CGTTGGAAGT TCAGGGGATG CACCTCCTAC 120 CCCACAGCCA AAGTGCGCTG ACTTCCAGAG CGCCAACCTT TTTGAAGGCA CCGATCTCAA 180 AGTCCAGTTT CTCCTCTTTG TCCCTTCGAA TCCTAGCTGT GGGCAGCTAG TAGAAGGAAG 240 CAGTGACCTC CAAAACTCTG GGTTCAATGC GACTCTGGGA ACCAAACTAA TTATCCATGG 300 15 ATTCAGGGTT TTAGGA ACAA AGCCTTCCTG G ATTGACACA TTTATTAGAA CCCTTCTGCG 360 TGCAACGAAT GCTAATGTGA TTGCCGTGGA CTGGATTTAT GGGTCTACAG GAGTCTACTT 420 CTCAGCTGTG AAAAATGTGA TTAAGTTGAG CCTCGAGATC TCCCTTTTCC TCAATAAACT 480 CCTGGTGCTG GGTGTGTCGG AATCCTCAAT CCACATCATT GGTGTTAGCC TGGGGGCCCA 540 CGTTGGGGGC ATGGTGGGAC AGCTCTTCGG AGGCCAGCTG GGACAGATCA CAGGCCTGGA 600 20 CCCCGCTGGA CCTGAGTACA CCAGGGCCAG TGTGGAAGAG CGCTTGGATG CTGGAGATGC 660 CCTCTTCGTG GAAGCCATCC ACACAGACAC CGACAATTTG GGTATTCGGA TTCCCGTTGG 720 ACATGTGGAC TACTTCGTCA ACGGAGGCCA AGACCAACCT GGCTGCCCCA CCTTCTTTTA 780 CGCAGGTTAT AGTTATCTGA TCTGTGATCA CATGAGGGCT GTGCACCTCT ACATCAGCGC 840 CCTGGAGAAT TCCTGTCCAC TGATGGCCTT TCCCTGTGCC AGCTACAAGG CCTTCCTTGC 900 25 TGGACGCTGT CTGGATTGCT TTAACCCTTT TCTGCTTTCC TGCCCAAGGA TAGGACTGGT 960 GGAACAAGGT GGTGTCAAGA TAGAGCCGCT CCCCAAGGAA GTGAAAGTCT ACCTCCTGAC 1020 TACTTCCAGT GCTCCGTACT GCATGCATCA CAGCCTCGTG GAGTTTCACT TGAAGGAACT 1080 GAGAAACAAG GACACCAACA TCGAGGTTAC CTTCCTTAGC AGTAACATCA CCTCTTCATC 1140 TAAGATCACC ATACCTAAGC AGCAACGCTA TGGGAAAGGA ATCATAGCCC ATGCCACCCC 1200 30 ACAATGCCAG ATAAACCAAG TGAAATTCAA GTTTCAGTCT TCCAACCGAG TTTGGAAAAA 1260 AGACCGGACT ACCATTATTG GGAAGTTCTG CACTGCCCTT TTGCCTGTCA ATGACAGAGA 1320 AAAGATGGTC TGCTTACCTG AACCAGTGAA CTTACAAGCA AGTGTGACTG TTTCCTGTGA 1380 CCTGAAGATA GCCTGTGTGT AGTTTAACCT GGGCAGGACA CATCTCCCTG CATTTTTTTT 1440 TΠTΠTΠ GAGAGAGAGG TGTGATGAGG GATGTGTGTG TGCAGCTTAT TGTAGACCAT 15OO 35 TACTACTAAG GAGAAAAGCA AAGCTCTTTC TTATTTTCCT CATAATCAGC TACCCTGGAG 1560 GGGAGGGAGA ACTCATTTTA CAGAACTTGG TTTCCTTTGC CGATCTTATG TACATACCCA 1620 TΠTAGCTTT CCCATGCATA CTΓAACTGCA CTTGCTTTAT CTCCTTGGGC ATTCGTACTT 1680 AGGATTCAAT AGAAACATGT ACAGGGTAAA CAATTTTTTA AAAATAAAAC TTCATGGAGT 1740 AAAAAAAAAA AAAAAAAA 40 SEQ ID NO:128 PFH8 Protein sequence: Protein Accession* NPJJ56984.1 45 1 11 21 31 41 51 I I I I I I MPPGPWESCF WVGGLELWLS VGSSGDAPPT PQPKCADFQS ANLFEG TOLK VQFLLFVPSN 60 PSCGQLVEGS SDLQNSGFNA TLGTKLIIHG FRVLGTKPSW IDTFIRTLLR ATNANVIAVD 120 WIYGSTGVYFSAVKNVIKLS LEISLFLNKLLVLGVSESSIHπGVSLGAHVGGMVGQLFG 180 50 GQLGQITGLDPAGPEYTRAS VEERLDAGDALFVEAIHTDTDNLGIRIPVG HVDYFVNGGQ 240 DQPGCPTFFY AGYS YLICDH MRAVHLYIS A LENSCPLMAF PCAS YKAFLA GRCLDCFNPF 300 LLSCPRIGLV EQGGVKIEPL PKEVKVYLLT TSSAPYCMHH SLVEFHLKEL RNKDTNIEVT 360 FLSSNiTsss KΠTPKQQRY GKGΠAHATP QCQINQVKFK FQSSNRVWKK DRTTΠGKFC 420 TALLPVNDRE KMVCLPEPVN LQAS VTVSCD LKIACV SEQ ID NO:129 PFH7 DNA SEQUENCE ,_ Nucleic Acid Accession* NM_014384 60 Coding sequence: 89-1336 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 _____ f I i i i ϊ 05 CGTTGCCGGG TCGCAGGTCC CGCCAGTGCG AGCGCAACGG AGGTCGAAGG CGTTCAGACT 60 CTTAGCTGAA CGCGGAGCTG CGGCGGCTA iCTGTGGAGC GGCTGCCGGC GTTTCGGGGC 120 GCGCCTCGGC TGCCTGCCCG GCGGTCTCCG GGTCCTCGTC CAGACCGGCC ACCGGAGCTT 180 GACCTCCTGC ATCGACCCTT CCATGGGACT TAATGAAGAG CAGAAAGAAT TTCAAAAAGT 240 GGCCTTTGACTTTGCTGCCC GAGAGATGGC TCCAAATATG GCAGAGTGGG ACCAGAAGGA 300 70 GCTGTTCCCAGTGGATGTGATGCGGAAGGC AGCCCAGCTAGGCTTCGGAG GGGTCTACAT 360 ACAAACAGAT GTGGGCGGGT CTGGGCTGTC ACGTCTTGAT ACCTCTGTCA TTTTTGAAGC 420 CTTGGCTACA GGCTGCACCA GCACCACAGC CTATATAAGC ATCCACAACA TGTGTGCCTG 480 GATGATTGAT AGCTTCGGAA ATGAGGAACA GAGGCACAAA TTTTGCCCAC CGCTCTGTAC 540 CATGGAGAAG TTTGCTTCCT ACTGCCTCAC TGAACCAGGA AGTGGG AGTG ATGCTGCCTC 600 75 TCTTCTGACCTCCGCTAAGA AACAGGGAGA TCATTACATCCTCAATGGCTCCAAGGCCTT 660 CATCAGTGGT GCTGGTGAGT CAGACATCTA TGTGGTCATG TGCCGAACAG GAGGACCAGG 720 CCCCAAGGGC ATCTCATGCA TAGTTGTTGA GAAGGGGACC CCTGGCCTCA GCTTTGGCAA 780 GAAGGAGAAA AAGGTGGGGT GGAACTCCCA GCCAACACGA GCTGTGATCT TCGAAGACTG 840 TGCTGTCCCT GTGGCCAACA GAATTGGGAG CGAGGGGCAG GGCTTCCTCA TTGCCGTGAG 900 AGGACTGAAC GGAGGGAGGA TCAATATTGC TTCCTGCTCC CTGGGGGCTG CCCACGCCTC 960 TGTCATCCTC ACCCGAGACC ACCTCAATGT CCGGAAGCAG TTTGGAGAGC CTCTGGCCAG 1020 TAACCAGTAC TTGCAATTCA CACTGGCTGA TATGGCAACA AGGCTGGTGG CCGCGCGGCT 1080 GATGGTCCGC AATGCAGCAG TGGCTCTGCA GGAGGAGAGG AAGGATGCAG TGGCCTTGTG 1140 CTCCATGGCC AAGCTCTTTG CTACAGATGA ATGCTTTGCC ATCTGCAACC AGGCCTTGCA 1200 GATGCACGGG GGCTACGGCT ACCTGAAGGA TTACGCTGTT CAGCAGTACG TGCGGGACTC 1260 CAGGGTCCAC CAGATTCTAG AAGGTAGCAA TGAAGTGATG AGGATACTGA TCTCTAGAAG 1320 CCTGCTTCAG GAGTAGAACC CACACTTGTT CTGGCCTGGT GTTCAGTGCG ACTGCAGTCA 1380 GTGTTGAGTG GTGCCATGTG GGCCGCTCTA TTCCAAAGGA ATCATGGATT AGACCCAAGG 1440 GCTGAGCTCC TCTAGGGCAG GACCTGCACC CTGTGTGTTG GCACCAGCAT CGGGTCTTGG 1500 ACTGGGGCAG AATCCCCAGT GGAACCGGAA GAGCTGGACT GATGAGAAAC ATCAGAAGAA 1560 CACATACTAC CTTGTTTTCC TAATGCCAGA AGGGTGACCA GTGAAGATTC ACCGTCAAAC 1620 CATGAAAGTC CTTTCTTGGA TCCACTTTAT CTTGATTAGT CTGCATTTTA CTAGTTCACT 1680 GGATCCCTCC TCTAGGGGCC TGGGGACTTT CACTGATGCT CTTCCTGATT CTAGAGCAAA 1740 GGTGTGGGAA GGGGAAATGG AGGAATGCCC TCCTGTCTGT GTCGTTCTCTGTGCCACAGC 1800 TACAGATGCA GAAGGTTTCT CTGGATAGCA CACCTCTGAA TGTAAATCAT GATAAAATGG 1860 ATATTTGGAA ACTTACTCCT AAGCTGTGAT GTAGGGTGTA TTTCTACTTC TGGACTGCCT 1920 CAATATCAAG GGCTGAGACT TTTGAATGTT GAATATTCGT TGGGTTTCAT GTTAAGACGC 1980 CTGTGGTCCA GGAGTGCTAT TCAGTGTTTC TGTTCCTGAT AAACACTTTG AATATTTTTT 2040 TGTGTTTTTG TTTCCTTTTC TGAAGCTGTT CCTCCTTTTA AATAITITT A ATCACATTGA 2100 TAAAATCTAT CCTTCATCCA CCTCTGGTTC TACTATAGTT GATTTTTATT TTAAATGTTT 2160 AATTGTATTT GATTAAACAC TTAACTGGAT TTTGGAATAA TAAAACTCTC GTCCAATTTG 2220 GCTTTTAAAA AAAAAAAA SEQ ID NO:130 PFH7 Protein sequence: Protein Accession * NP_055199.1 1 11 21 31 41 51 I I I I I I MLWSGCRRFG ARLGCLPGGL RVLVQTGHRS LTSCEDPSMG LNEEQKEFQK VAFDFAAREM 60 APNMAEWDQK ELFPVDVMRK AAQLGFGGVY IQTDVGGSGL SRLDTSVIFE ALATGCTSTT 120 AYISIHNMCA WMIDSFGNEE QRHKFCPPLC TMEKFASYCLTEPGSGSDAA SLLTSAKKQG 180 DHYILNGSKA HSGAGESDI YVVMCRTGGP GPKGISCIW EKGTPGLSFG KKEKKVGWNS 240 QPTRAVIFED CAVPVANRIG SEGQGFLIAV RGLNGGRINI ASCSLGAAHA SVILTRDHLN 300 VRKQFGEPLA SNQYLQFTLA DMATRLVAAR LMVRNAAVAL QEERKDAVAL CSMAKLFATD 360 ECFAICNQAL QMHGGYGYLK DYAVQQYVRD SRVHQILEGS NEVMRILISR SLLQE SEQ ID N0:131 PFH6 DNA SEQUENCE Nucleic Acid Accession* N _013989 Coding sequence: 707-1105(undertined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I GCCTGCAGAG AGAGGCACTT TGCACCACAG ACAGATAGCA AGAAGGGAAA GACAGAGAGT 60 GAGAAAAAAG AGGAGTCAGT CGCTCCTGGG GAAGGGAGAG AGTGAGACTG GGAGAAAGAG 120 AAGCACAGAA AGTGTGTGTA AAACGGAGTA AAGAAAGAAA AAAAAAAAAC TACCCTTAAA 180 GCACATTTAA AAAAAAAAAA CTCTGGCAAT TCAAGAAAGA AACAGGCTAC GTTTAAAGAG 240 CATAGAGACA ATGAAAGGCT AAAGAAAATT TTAAAATCTC TGCCACAGTC TCATAGGTGC 300 TTGGAAATGA AAGTAGAACT GCCTGTCTTT AACGGACTCT GACAGAGGTA ACTGGATTAG 360 GGACGAGTAC GCCAGCTTTT TTTTrrTTTT TTTTTTTTTT TTTAACATCT TAAATCCTGA 420 AAAAAAAAAA AAAAAAAAAA AAAAGGCAGC AGCTCCGAAT TGAATGAATT GATGGGCACA 480 CTCCAACTGC TGGGCTGGAG AGACTGGACT TAGTCTTGCC ATTTCTGCTT CTTTGAAAGA 540 GGAGACAACT TGGGCTTCCT TTTAATTTAG TITI ITITCC CCTTCTCCCC CAACCCCCAA 600 CCTTCCCCCT TACCTCCCCC ACCCCCTTTA TCACCACCCC CCTTTTAAAT AAGAGGGTGA 660 AGGGGAACCA GAGCGCACAA GGGAACTGAC TCAGGAGGCA GAGAAGATSG GCATCCTCAG 720 CGTAGACTTG CTGATCACAC TGCAAATTCT GCCAGTTTTT TTCTCCAACT GCCTCT CCT 780 GGCTCTCTAT GACTCGGTCA TTCTGCTCAA GCACGTGGTG CTGCTGTTGA GCCGCTCCAA 840 GTCCACTCGC GGAGAGTGGC GGCGCATGCT GACCTCAGAG GGACTGCGCT GCGTCTGGAA 900 GAGCTTCCTC CTCGATGCCT ACAAACAGGT GAAATTGGGT GAGGATGCCC CCAATTCCAG 960 TGTGGTGCAT GTCTCCAGTA CAGAAGGAGG TGACAACAGT GGCAATGGTA CCCAGGAGAA 1020 GATAGCTGAG GGAGCCACAT GCCACCTTCT GACTTTGCC AGCCCTGAGC GCCCACTAGT 1080 GGTCAACTTT GGCTCAGCCA CT__iACCTCC TTTCACGAGC CAGCTGCCAG CCTTCCGCAA 1140 ACTGGTGGAA GAGTTCTCCT CAGTGGCTGA CTTCCTGCTG GTCTACATTG ATGAGGCTCA 1200 TCCATCAGAT GGCTGGGCGA TACCGGGGGA CTCCTCTTTG TCTTTTGAGG TGAAGAAGCA 1260 CCAGAACCAG GAAGATCGAT GTGCAGCAGC CCAGCAGCTTCTGGAGCGTT TCTCCTTGCC 1320 GCCCCAGTGC CGAGTTGTGG CTGACCGCAT GGACAATAAC GCCAACATAG CTTACGGGGT 1380 AGCCTTTGAA CGTGTGTGCA TTGTGCAGAG ACAGAAAATT GCTTATCTGG GAGGAAAGGG 1440 CCCCTTCTCC TACAACCTTC AAGAAGTCCG GCATTGGCTG GAGAAGAATT TCAGCAAGAG 1500 ATGAAAGAAA ACTAGATTAG CTGGTTAAAG GTATGATTAT AAGAGAGCTT ATTGTTTTAA 1560 AAAGTTATAT AAAGGCAAGG AAATTAAGAA CTGAATCCAT ATTTCAACAG AGCCCTATTG 1620 GCTTACTGAA AGACAGGAGT TTATCTATCG GAAGAACATG AATCTCTAAC AGCTCCATAC 1680 TTCTTTCACT ACTCAAATGG CATTGGGCTG AGTAAGTAAC CATATCACCT CTCTTCTTAG 1740 TAAAAAGCCC TATGTGAAAA GATCCCAAGA TGGAGAGGAA GAAACGCTAA TTCAGCATGT 1800 GTTCATTCTG CATTGAGAAG GAACTGATAC ATCTGATGCA TGCTTTGAGA CCAGAAGAAA 1860 AGACTTACCT GAATAATTAC TACATTAGGG AAGCTACTGT CTACGTTAAG ATAAAGGGTA 1920 TTGCCTTGGC TCTATTTGGC ATGGATGGAG CCCAGTTGGA AAATTCCCAA ATATTACAAC 1980 AAGTCCTTGA ACCCAGGCCA TGTGGTTAGA CGTTGGTGTT AAGGTTAGAC CTTATGTTAG 2040 AGTCATTTCT GATGTTCCAG CTTCTAGCCA TGTAGTGCTC TCAGTCTTCA TACCCCAGAA 2100 ATTATTGGTA TATTTGTAGA TACCGAGAAT GATCCCTCAG TCTGAGAGGT TAGAATGATC 2160 ATCTGTAATC TGAGGGTTAA TTTCTAGGCA GGTGGAGAGA GTGGTAAAAA AGAAATGAAA 2220 TTGACAAGCT AGGAAAGAGG AGGCAGAAAG ATTTGGAAAA TTCACAGAGT TTCACCCTTA 2280 AGCTGTAGAG AGTGGGTCAC ATTTGTTAGC CACGGAAACA TAGAAACATA CACAAGGCCA 2340 GAAAAAGAAG AAGGAGCTCA ACTAAAAGTG GCATAGAGAA TACACATATA AAAACAATAT 2400 ATTTGTCATA TGCTCCTAGA GAGGAGAAAG GGGTGATTGA AAGAAAAAAA AATACTTAAA 2460 TATTTGTAAT TGTGAGGGGTTTCTTTTGGA AATAATTACT TTTGAACCATGTATGTGGTA 2520 TGTATATTTT CAGTGGGTTA ATTATACCCC ATGATACCTA TTAAAGGAAA ACCAGTGGGT 2580 CTGGTGGTGC TGGTCTTTTC CTCCCCATTC CTACAATTTC TATGTGGCCC AAGTCATTCC 2640 TAATCTTGGT CTCTATAGCA GTGTTCTCTC TGAATGCTGA GCTGAAGAAA TTATACGTAC 2700 ATACACACAT ACATACATAC ATACAAATAT ATGTATATAT ATTCTCAGCT GCTGCGGGAG 2760 GTAGGTACCA TGGCCATTCA GCACAGCCTT GATTTCCTCC CAAAGTAGGT GAGCTATAGT 2820 GAAGAATAGG TGCAAACAAA CAAGCTTACT TCCATTGCAA AATAGAAGAA GAGGAAGTTA 2880 GAGATAATTC TGATCAATCA TTTTGGAGGC TTTGTTATAA GGCAACCCCC GGTATATCAT 2940 GGAATTTCCA TTGACATTTG AATTTGGACT TGGATCTTCC CTTGGTCCCA TTAGCTGAGG 3000 TTTAGTAATC TAAAGTCCCT ATAGTATATG ATTATAATGC TATTTTAAAA AATATATATA 3060 TAAAATATTT TTΓTCTTTTT AAAATAGACA CTATAGTΠT ACCCATAAGTAATATTTAAA 3120 GATTATAGCT CCCAAAAGAA TGGACCAACC ACTTTCGTAT CATAATTTCT TTTTGGTAAA 3180 TATGAGACTA TTATGAAATC ATAGTATATG ATTGTATTTA AAGGTACAAT CAAAGGATCT 3240 TTTGTCCATT CCATTAATAA CTGAATAAAA AATAAATAAA ATGGATAGAA AAAAACTAAA 3300 GTTGAAAATA CATTCTTAAA CTAGTTGTCT GAAATGAGAA AAGAGTG AGA ACTAGGTGTG 3360 CAAGAACCAA ACGTATTTTA TTTTATTTTT TAAATGGGAG CAACATATCA GTCGTGTCAC 3420 CAGCTGGTAT ATTGTGTAAA TATTAAAGCT CCATTGGGAC TGATTTTTCA TGGCAACATC 3480 AGCTTTCTAA TGTTCTAAAT TCTATAAAAA CCACCCACAA AGAAACAAAG CAAATTTCAT 3540 TATCTAATGA GTTGCTGGAA AATCATATTG AGAATAATTA TTTCAGATTC CTCAGTTGTT 3600 AACTTCTACA TTCAAGGGCT TATCTCTGCC CCCATTGATT TTTAACCTCA AAATGGTGTG 3660 AGATTTACTG TGGAACCCTA AAGCAGTAAA ATAAAAAACC TGGTTGCAGC ACATTCACAC 3720 TGTTGTCCTT AAAATTCCCC T 11 1TTCTCT ATGTACGATA AAGTAACAGT ATGTCAGATA 3780 AGCCGGTGGG GGGATGAGAT TAGGCTGAGG CAGTGCTAGT CAACTGGGGG AAAAGGATGA 3840 TGGAAAAATC ACCCAGTTGT GCTATATTTT TAAAGAAGGA GGTCGTTTAT GTGTGCAGAC 3900 AATTCTCCCT GAGGTTAGCC CAATGGAGAA ATGAAGCAGA GGAAGGAAAC ATAGAAAGAC 3960 ATGGGCTATC AGGGAGGAAG ATGTTCAATA GAACATGCAA GAATTTCTGG AAGAAAGGCT 4020 GTGGAAGGGC CAATGGAGAA AATGAATGGA CAAAGCTCAG GAATCCCTAC GCTATGTAGA 4080 ATGTTCTTGG TGTTATCAGG GTTAAGCCCT GTAATTATGT AACCTATTTA TCGCAACATG 4140 AATTTTTATG ATTTCTTGTG ATGTATTCTT TTATGAAATT AACAAGAACT CATTATTTTG 4200 AGGTAGAGGA AAATCAATGC TTTATCTGAT ATGCTGAGAA ATTATTAGAT TGCCAATACT 4260 CATGTGCGTT TCATGTGTTT TATAAGGTTT GTTCCTTTGA AGAATTGTAG TTCTTAGTCC 4320 CACAGGGAAA TGTGTATCTA TTTATATATC ATAGTATAAA TCTATGATAT ATTTATATCA 4380 TATATAAAAG TCTGAGTTCT CTTTCTTAGT CCCTAATCAT GTTTCTCCCA TAGGCTGTGT 4440 . TTACATGGAG CTATCGGTTT AGCCTTTTAA GCTTCATTAG CTTGTCTATT ATTGAAATAG 4500 TTTCCAAGAA ATTTTAGATA TTATCATAAC ATCTGGGTCT ACTCAAACAC TTATTGTTTG 4560 AAAGACTTAT GTCTTGGACC TATCAAAAAC TGACTTTATT TATTGCTTAG TGAAAATACT 4620 AGTGGGATCA ACAATGATTT TCTTGAATGG GCATGAATGG AGATGCCCGC ACAGTAATGT 4680 AGAAATGTTT CATACAGCTA TTAAAATGTA ACTGACCTCC TTAGAGGCAG ATTAGTAACT 4740 GTTCCTACTT TGTATAGCTA AGTGACAGTC ACTTAACTTA CATGACTTTC TTTTTTCACA 4800 TTGGGTCTCT GGTCCTGTGT CTTCACCTCA TTTATAGCAC GTCTCCTTGA TTTTTGGTAG 4860 TATCAACTTC CCAGTGATCT GTTCAGTTAA GTTCTTCTCC CGTTAACCAG GAAGTGCTTA 4920 TTCTCTCATC ACAGTGGGAA GAATAGCCTA TTGTCTTTCA TTTTGCCTGA GTGTATTTTA 4980 CTATTTGGGC TCTGAAATAA AAATTATGAA ATATGGTGAG GTCACATGTT GGTGCTGCCT 5040 TGCTGCATAA AATTCTAGGA GGGCAGGTTA GGAGACAGTT ATGTATGGCC TTTCGGGAAA 5100 ATTCAAAGGG TGGGATTACA AGGGTGTTCC TCAGGCATGC CCCTATGGGC CCTATGTGGA 5160 AGCAAGAAGA ATTGACTGAT TTACAGGACT TCTCTTTATG TCAATCTTAA GAGGATGGAT 5220 GAATCTGGAC ATTTGTTCCA CCCGACCTCT GACTGATGGT TTGGAAAATA ACTTTAATTA 5280 GGATCATATG ACCATTGAAA AAGGAAAAAT GTAGACTCTG ACTTCCGTCC CACTGAAGGA 5340 TTAATGAAAA CCTTTACTAG CATTTAGAGC TTTTCAGAAC ATCCCCACTG TCATGTGTCT 5400 CAGCAGTGGA GACTGCAAGT AAGGCTTTTA ATTTTAGGAG GTTTTTTTTT TTTTTTTTTT 5460 TTCCCCTAAA TGGTATGGCC AAAAGTCAGA GTTAAAATAT ATATAGTTAG ATTCGAACTT 5520 CCTCCTTCAC TCTAAAAATA GAATCCAAAC CCACTCTTCA TATATGCTTC CAGAATGGGG 5580 CTTAAGTACC AATCTCTGCT TTGCAATGGG CACAATCTTG GTCATGTCCT GAGGCTCTCT 5640 AAGAAAAGAG AGGATCTAGG ATGGGAGAGC TAGAAAGTTG CTAACTGGGA AGAACAAGGC 5700 CCTGAGGGGT TGGTCTACCA ATCTGGGAAG ATTTG AAAAC AAACTTCTCG CAACTGAAGG 5760 AAGGCTGAAG GCTGCTGCAA GTCATTGAGT GACTTTAGGA TGAGCAAAAC ATTGGGCCAC 5820 TTCCTAATGC CCTATGTGTA TAGTACCAGA AGCAAGGTCT CAGACTTAAC AGACCCAGCT 5880 CTGTTCCAAG GTGAGTCTGA ACCAATAGAA AGCAAACATG TGCAGATATC CAAACAAGAC 5940 TGCTCATGCA AGTCGGGGCT GGCTACCCGT CTTAGGCAGC AACAGCAGAG CTCCAGGGAG 6000 CTTATTCAAT ATTTACTGAG ACTTCGAAGA CCCAGCAGAT GTTTAATGAA GTCACTATTT 6060 TGGCTCAAAC CCTCCACTTC TCCCCCTCCC CTCAAAAAGC CAACAGGTAA ACACATAAAT 6120 GAAAGAAACC CACAGAAGGG GATGGGAAAT AAAGAAAATT CTCTCAAGAC TTCTCCAGGC 6180 CCATGTCACT GGTCAGCGTG GTTTTTATGT GTATTAGGAT TGGGGGATGT GAAGAAATAA 6240 GTATCCAGTA CTTTATAACC AAAGCAATTA AATGATATTG GGGTAGGGAA TGTTGGCCAG 6300 TTTTGTTTAG TTTTGCCATC ACATTGTCAC CC AGACCTCA CCTAGCCCCA AGTAATCGGG 6360 CGCCCCGAAG AGGGAGACAG AGATGTGCCA GAGTTGACCC AGTGTGCGGA TGATAACTAC 6420 TGACGAAAGA GTCATCGACC TCAGTTAGTG GTTGGATGTA GTCACATTAG TTTGCCTCTC 6480 CCCATCTTTG TCTCCCTGGC AAGGAGAATA TGCGGGACAT GATGCTAAGA GCCCTGGGTA 6540 AATGTGGTGA GAATGCACGC GTGCATATGC TACACATATG TGCTTCTCAG TTGCAGAAAA 6600 TGAACTGCTT TGGGAGATTA TCAGTAGAAA GAGTGTTATC ATATTGGTGC TGAGTGCTAT 6660 GTGTGCTTAT ACAATTTGTT CTTGTATTTT AATAAACTTT GAATAAAAGA ATAAAAAAAA 6720 AAAAAAAAAA AAAAA 5 SEQ ID NO:132 PFH6 Protein sequence: Protein Accession*: NP_054644.1 1 11 21 31 41 51 ι n I I I I I I 1U MGILS\TJLU TLQILPVFFS NCLFLALYDS VILLKHVVLLLSRSKSTRGEWRRMLTSEGL 60 RCVWKSFLLD AYKQVKLGED APNSSVVHVS STEGGDNSGN GTQEKIAEGA TCHLLDFASP 120 ERPLVVNFGS ATXPPFTSQL PAFRKLVEEF SSVADFLLVY IDEAHPSDGW AIPGDSSLSF 180 EVKKHQNQED RCAAAQQLLE RFSLPPQCRV VADRMDNNAN IAYGVAFERV C-VQRQKIAY 240 LGGKGPFSYN LQEVRHWLEK NFSKRXKKTR LAG _ - SEQ ID NO:133PFH5 DNA SEQUENCE 20 Nucleic Acid Accession* NMJM1141 Coding sequence: 72-2102 (underlined sequences correspond to start and stop codons) 1 11 11 31 41 51 e . I I I I I I 25 CAGGCGTGTC CCAGGGGGAG CCCCGCTCTG CAGCCCTGTG CGCCGTAGAG AGCTGGACTT 60 AGGCTGGCAG C QGCCGAG TTCAGGGTCA GGGTGTCCAC CGGAGAAGCC TTCGGGGCTG 120 GCACATGGGA CAAAGTGTCT GTCAGCATCG TGGGGACCCG GGGAGAGAGC CCCCCACTGC 180 CCCTGGACAA TCTCGGCAAG GAGTTCACTG CGGGCGCTGA GGAGGACTTC CAGGTGACGC 240 TCCCGGAGGA CGTAGGCCGA GTGCTGCTGC TGCGCGTGCA CAAGGCGCCC CCAGTGCTGC 300 30 CCCTGCTGGG GCCCCTGGCC CCGGATGCCTGGTTCTGCCG CTGGTTCCAG CTGACACCGC 360 CGCGGGGCGG CCACCTCCTC TTCCCCTGCT ACCAGTGGCT GGAGGGGGCG GGGACCCTGG 420 TGCTGCAGGA GGGTACAGCC AAGGTGTCCT GGGCAGACCA CCACCCTGTG CTCCAGCAAC 480 AGCGCCAGGA GGAGCTTCAG GCCCGGCAGG AGATGTACCA GTGGAAGGCT TACAACCCAG 540 GTTGGCCTCACTGCCTGGATGAAAAGACAGTGGAAGACTTGGAGCTCAATATCAAATACT 600 35 CCACAGCCAAGAATGCCAAC TTTTATCTAC AAGCTGGCTCTGCTTTTGCA GAGATGAAAA 660 TCAAGGGGTT GCTGGACCGC AAGGGGCTCT GGAGGAGTCT GAATGAGATG AAAAGGATCT 720 TCAACTTCCG GAGGACCCCA GCAGCTGAGC ACGCATTTGA GCACTGGCAG GAGGATGCCT 780 TCTTCGCCTC CCAGTTCCTG AATGGTCTCA ACCCTGTCCT GATCCGCCGC TGTCACTACC 840 TCCCAAAGAA CTTCCCCGTC ACTGATGCCA TGGTGGCCTC ATTGTTGGGT CCTGGGACCA 900 0 GCTTGCAGGCTGAGCTAGAG AAGGGCTCCC TGTTCTTGGTGGATCACGGC ATCCTCTCTG 960 GCATCCAGAC CAATGTCATT AATGGGAAGC CGCAGTTCTC TGCGGCCCCA ATGACCCTGC 1020 TATACCAGAG CCCAGGCTGC GGGCCGCTGC TGCCTCTCGC CATCCAGCTC AGCCAGACCC 1080 CCGGCCCAAA CAGCCCCATC TTCCTGCCCA CTGATGACAA GTGGGACTGG TTGCTGGCCA 1140 AGACCTGGGTGCGCAATGCC GAGTTCTCCTTCCATGAGGCCCTCACGCACCTGCTGCACT 1200 5 CACATCTGCTGCCTGAGGTCTTCACCCTGG CTACCCTGCG TCAGCTGCCC CACTGCCACC 1260 CTCTCTTCAA GCTGCTGATC CCGCACACCC GATACACCCT GCACATCAAC ACACTCGCCC 1320 GGGAGCTGCT TATCGTGCCA GGGCAGGTGG TGGACAGGTC CACAGGCATC GGCATTGAAG 1380 GCTTCTCTGA GTTGATACAG AGGAACATGA AGCAGCTGAA CTATTCTCTC CTGTGTCTGC 1440 CTGAGGATAT CCGGACCCGA GGAGTTGAAG ACATCCCAGG CTACTACTAC CGTGATGATG 1500 0 GGATGCAGATTTGGGGTGCA GTGGAACGCTTTGTCTCTGAAATCATCGGTATCTACTACC 1560 CAAGTGATGA GTCTGTCCAA GATGACAGAG AGCTCCAGGC CTGGGTCAGA GAGATCTTCT 1620 CCAAGGGCTT CCTAAACCAG GAGAGCTCAG GTATCCCTTC CTCACTGGAG ACCCGGGAAG 1680 CCCTGGTGCA GTATGTCACC ATGGTGATAT TCACCTGCTC AGCCAAGCAT GCGGCTGTCA 1740 GTGCAGGGCAGTTTGACTCC TGTGCTTGGA TGCCCAACCTGCCACCCAGCATGCAGCTGC 1800 5 CACCACCCACCTCCAAAGGCCTGGCAACATGCGAGGGCTTCATAGCCACCCTCCCACCTG 1860 TCAATGCCAC ATGTGATGTC ATCCTTGCTC TCTGGTTGCT GAGCAAGGAG CCTGGAGACC 1920 AAAGGCCCCT GGGCACCTAT CCGGATGAGC ACTTCACAGA GGAGGCCCCT CGGCGGAGCA 1980 TCGCCACCTT CCAGAGCCGC CTGGCCCAGA TCTCGAGGGG CATCCAGGAG CGGAACCGGG 2040 GCCTGGTGCT GCCCTACACC TACCTAGACC CTCCCCTCAT CGAGAACAGC GTCTCCATCT 2100 0 AAATCCCAGG GGAACACAGG CCCAGATGAC ATCCCTTTGA CCACATCGCT CTAGGATAAC 2160 TGGCACCCAG AGAAAAGGAC TCCTCAGAAA AAACAGGCCC CCATGTGCCT CTCCTGGGAC 2220 AACCAGACTC TGTAACTCAC CCCCACCACC ATACACACAC ACAAAAACAG AAACAAAATC 2280 AAAACAGAGA AAGCAGAAAA TCTACCAAGA ACAGAGTCTC AGGACAGAAC CACTGAGTCT 2340 TTTGGAGGCT CCAAGCCTCA A AGTGCCCGC AGAGCCCACC TTGAGGGTTT TGCTAGTTGG 2400 5 TTTTGTΠTG CGTTTACAGC CGTGGGGGGA AGCACATAAT CCCGCCCCAG GGCCCACTAG 2460 CATCCACTGA TTGGACCTTA TGGTCACCCA ACTCAAGGAC AGCCACCAAG AAGTGGCTGC 2520 CAAAGAGACT GGGCGCAGTG GCTCATGCCC ATAATCCCAG CACTTTGGGA GATGGAGGCG 2580 GGAAAATCAT TTGAGGTCAG AAGTTCAAGG CCAGCCTGGA CGACATAGCG AGACTCCACC 2640 TCTACCAAAA AATAAAAATT AAAAAACAAA AAAAAAAAAA AAAAA 0 SEQ ID N0:134 PFH5 Protein sequence: Protein Accession* NP M1132.1 5 1 11 21 31 41 51 I I I I I I MAEFRVRVST GEAFGAGTWD KVSVSIVGTR GESPPLPLDN LGKEFTAGAE EDFQVTLPED 60 VGRVLLLRVH KAPPVLPLLG PLAPDAWFCR WFQLTPPRGG HLLFPCYQWL EGAGTLVLQE 120 GTAKVSWADH HPVLQQQRQE ELQARQEMYQ WKAYNPGWPH CLDEKTVEDL ELNIKYSTAK 180 NANFYLQAGS AFAEMKIKGL LDRKGLWRSL NEMKRIFNFR RTPAAEHAFE HWQEDAFFAS 240 QFLNGLNPV IRRCHYLPKN FPVTDAMVAS LLGPGTSLQA ELEKGSLFLV DHGILSGIQT 300 NVINGKPQFS AAPMTLLYQS PGCGPLLPLA IQLSQTPGPN SPIFLPTDDK WDWLLAKTWV 360 RNAEFSFHEA LTHLLHSHLL PEVFTLATLR QLPHCHPLFK LL-PHTRYTL HIN TLARELL 420 IVPGQVVDRS TGIGIEGFSE UQRNMKQLN YSLLCLPEDI RTRGVEDIPG YYYRDDGMQI 480 WGAVERFVSE πGIYYPSDE SVQDDRELQA WVREIFSKGF LNQESSGIPS SLETREALVQ 540 YVTMVIFTCS AKHAAVSAGQ FDSCAWMPNL PPSMQLPPPT SKGLATCEGF IATLPPVNAT 600 CDVILALWLL SKEPGDQRPL GTYPDEHFTE EAPRRSIATF QSRLAQISRG IQERNRGLVL 660 PYTYLDPPU ENSVSI SEQ ID NO:135 PFH4 DNA SEQUENCE Nucleic Acid Accession*: N J302742 Coding sequence: 236-2974 (underiined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I GAATTCCTTC TCTCCTCCTC CTCGCCCTTC TCCTCGCCCT CCTCCTCCTC CTCGCCCTCC 60 CCTCCCGATC CTCATCCCCTTGCCCTCCCC CAGCCCAGGG ACTTTTCCGG AAAGTTTTTA 120 TTTTCCGTCT GGGCTCTCGG AGAAAGAAGC TCCTGGCTCA GCGGCTGCAA AACTTTCCTG 180 CTGCCGCGCC GCCAGCCCCC GCCCTCCGCT GCCCGGCCCT GCGCCCCGCC GAGCGATQAG 240 CGCCCCTCCG GTCCTGCGGC CGCCCAGTCC GCTGCTGCCC GTGGCGGCGG CAGCTGCCGC 300 AGCGGCCGCC GCACTGGTCC CAGGGTCCGG GCCCGGGCCC GCGCCGTTCTTGGCTCCTGT 360 CGCGGCCCCG GTCGGGGGCA TCTCGTTCCA TCTGCAGATC GGCCTGAGCC GTGAGCCGGT 420 GCTGCTGCTG CAGGACTCGT CCGGGGACTA CAGCCTGGCG CACGTCCGCG AGATGGCTTG 480 CTCCATTGTC GACCAGAAGT TCCCTGAATG TGGTTTCTAC GGAATGTATG ATAAGATCCT 540 GCTTTTTCGC CATGACCCTA CCTCTGAAAA CATCCTTCAG CTGGTGAAAG CGGCCAGTGA 600 TATCCAGGAA GGCGATCTTA TTGAAGTGGTCTTGTCACGTTCCGCCACCTTTGAAGACTT 660 TCAGATTCGT CCCCACGCTC TCTTTGTTCA TTCATACAGA GCTCCAGCTT TCTGTGATCA 720 CTGTGGAGAA ATGCTGTGGG GGCTGGTACG TCAAGGTCTT AAATGTGAAG GGTGTGGTCT 780 GAATTACCAT AAGAGATGTG CATTTAAAAT ACCCAACAAT TGCAGCGGTG TGAGGCGGAG 840 AAGGCTCTCA AACGTTTCCC TCACTGGGGT CAGCACCATC CGCACATCAT CTGCTGAACT 900 CTCTACAAGT GCCCCTGATG AGCCCCTTCT GCAAAAATCA CCATCAGAGT CGTTTATTGG 960 TCGAGAGAAG AGGTCAAATT CTCAATCATA CATTGGACGA CCAATTCACC TTGACAAGAT 1020 TTTGATGTCT AAAGTTAAAG TGCCGCACAC ATTTGTCATC CACTCCTACA CCCGGCCCAC 1080 AGTGTGCCAG TACTGCAAGA AGCTTCTGAA GGGGCTTTTC AGGCAGGGCT TGCAGTGCAA 1140 AGATTGCAGA TTCAACTGCC ATAAACGTTG TGCACCGAAA GTACCAAACA ACTGCCTTGG 1200 CGAAGTGACC ATTAATGGAG ATTTGCTTAG CCCTGGGGCA GAGTCTGATG TGGTCATGGA 1260 AGAAGGGAGT GATGACAATG ATAGTGAAAG GAACAGTGGG CTCATGGATG ATATGGAAGA 1320 AGCAATGGTC CAAGATGCAG AGATGGCAAT GGCAGAGTGC CAGAACGACA GTGGCGAGAT 1380 GCAAGATCCA GACCCAGACC ACGAGGACGC CAACAGAACC ATCAGTCCAT CAACAAGCAA 1440 CAATATCCCA CTCATGAGGG TAGTGCAGTC TGTCAAACAC ACGAAGAGGA AAAGCAGCAC 1500 AGTCATGAAA GAAGGATGGA TGGTCCACTA CACCAGCAAG GACACGCTGC GGAAACGGCA 1560 CTATTGGAGA TTGGATAGCA AATGTATTAC CCTCTTTCAG AATGACACAG GAAGCAGGTA 1620 CTACAAGGAA ATTCCTTTAT CTGAAATTTT GTCTCTGGAA CCAGTAAAAA CTTCAGCTTT 1680 AATTCCTAAT GGGGCCAATC CTCATTGTTT CGAAATCACT ACGGCAAATG TAGTGTATTA 1740 TGTGGGAGAA AATGTGGTCA ATCCTTCCAG CCCATCACCA AATAACAGTG TTCTCACCAG 1800 TGGCGTTGGT GCAGATGTGG CCAGGATGTG GGAGATAGCC ATCCAGCATG CCCTTATGCC 1860 CGTCATTCCC AAGGGCTCCT CCGTGGGTAC AGGAACCAAC TTGCACAGAG ATATCTCTGT 1920 GAGTATTTCA GTATCAAATT GCCAGATTCA AGAAAATGTG GACATCAGCA CAGTATATCA 1980 GATTTTTCCT GATGAAGTAC TGGGTTCTGG ACAGTTTGGA ATTGTTTATG GAGGAAAACA 2040 TCGTAAAACA GGAAGAGATG TAGCTATTAA AATCATTGAC AAATTACGATTTCCAACAAA 2100 ACAAGAAAGC CAGCTTCGTA ATGAGGTTGC AATTCTACAG AACCTTCATC ACCCTGGTGT 2160 TGTAAATTTG GAGTGTATGT TTGAGACGCC TGAAAGAGTG TTTGTTGTTA TGGAAAAACT 2220 CCATGGAGAC ATGCTGGAAA TGATCTTGTC AAGTGAAAAG GGCAGGTTGC CAGAGCACAT 2280 AACGAAGTTT TTAATTACTC AGATACTCGT GGCTTTGCGG CACCTTCATT TTAAAAATAT 2340 CGTTCACTGT GACCTCAAAC CAGAAAATGT GTTGCTAGCC TCAGCTGATC CTTTTCCTCA 2400 GGTGAAACTT TGTGATTTTG GTTTTGCCCG GATCATTGGA GAGAAGTCTTTCCGGAGGTC 2460 AGTGGTGGGT ACCCCCGCTT ACCTGGCTCC TGAGGTCCTA AGGAACAAGG GCTACAATCG 2520 CTCTCTAGAC ATGTGGTCTG TTGGGGTCAT CATCTATGTA AGCCTAAGCG GCACATTCCC 2580 ATTTAATGAA GATGAAGACA TACACGACCA AATTCAGAAT GCAGCTTTCA TGTATCCACC 2640 AAATCGCTGG AAGGAAATAT CTCATGAAGC CATTGATCTT ATCAACAATT TGCTGCAAGT 2700 AAAAATGAG A AAGCGCTACA GTGTGGATAA GACCTTG AGC CACCCTTGGC TACAGGACTA 2760 TCAGACCTGG TTAGATTTGC GAGAGCTGGA ATGCAAAATC GGGGAGCGCT ACATCACCCA 2820 TGAAAGTGAT GACCTGAGGT GGGAGAAGTA TGCAGGCGAG CAGCGGCTGC AGTACCCCAC 2880 ACACCTGATC AATCCAAGTG CTAGCCACAG TGACACTCCT GAGACTGAAG AAACAGAAAT 2940 GAAAGCCCTC GGTGAGCGTG TCAGCATCCT C__AGTTCCA TCTCCTATAA TCTGTCAAAA 3000 CACTGTGGAA CTAATAAATA CATACGGTCA GGTTTAACAT TTGCCTTGCA GAACTGCCAT 3060 TATTTTCTGT CAGATGAGAA CAAAGCTGTT AAACTGTTAG CACTGTTGAT GTATCTGAGT 3120 TGCCAAGACA AATCAACAGA AGCATTTGTA TTTTGTGTGA CCAACTGTGT TGTATTAACA 3180 AAAGTTCCCT GAAACACGAA ACTTGTTATT GTGAATGATT CATGTTATAT TTAATGCATT 3240 AAACCTGTCT CCACTGTGCC TTTGCAAATC AGTGTTTTTC TTACTGGAGC TTCATTTTGG 3300 TAAGAGACAG AATGTATCTG TGAAGTAGTT CTGTTTGGTG TGTCCCATTG GTGTTGTCAT 3360 TGTAAACAAA CTCTTGAAGA GTCGATTATT TCCAGTGTTC TATGAACAAC TCCAAAACCC 3420 ATGTGGGAAA AAAATGAATG AGGAGGGTAG GGAATAAAAT CCTAAGACAC AAATGCATGA 3480 ACAAGTTTTA ATGTATAGTT TTGAATCCTT TGCCTGCCTG GTGTGCCTCA GTATATTTAA 3540 ACTCAAGACA ATGCACCTAG CTGTGCAAGA CCTAGTGCTC TTAAGCCTAA ATGCCTTAGA 3600 AATGTAAACT GCCATATATA ACAGATACAT TTCCCTCTTT CTTATAATAC TCTGTTGTAC 3660 TATGGAAAAT CAGCTGCTCA GCAACCTTTC ACCTTTGTGT ATTTTTCAAT AATAAAAAAT 3720 ATTCTTGTCA AAAAAAAAAA AA 5 SEQ ID N0:136 PFH4 Protein sequence: Protein Accession * NP.002733.1 1 11 21 31 41 51 10 I I I I I I MSAPPVLRPP SPLLPVAAAA AAAAAALVPG SGPGPAPFLA PVAAPVGGIS FHLQIGLSRE 60 PVLLLQDSSG DYSLAHVREM ACSIVDQKFP ECGFYGMYDK ILLFRHDPTS ENILQLVKAA 120 SDIQEGDLIE VVLSRSATFE DFQIRPHALF VHSYRAPAFC DHCGEMLWGL VRQGLKCEGC 180 GLNYHKRCAFKIPNNCSGVR RRRLSNVSLTGVSTIRTSSA ELSTSAPDEP LLQKSPSESF 240 15 IGREKRSNSQ S YIGRPIHLD KILMSKVKVP HTFVIHS YTR PTVCQYCKKL LKGLFRQGLQ 300 CKDCRFNCHK RCAPKVPNNC LGEVTINGDL LSPGAESDVV MEEGSDDNDS ERNSGLMDDM 360 EEAMVQDAEM AMAECQNDSG EMQDPDPDHE DANRTISPST SNNIPLMRVV QSVKHTKRKS 420 STVMKEGWMV HYTSKDTLRK RHYWRLDSKC ITLFQNDTGS RYYKEIPLSE ILSLEPVKTS 480 ALIPNGANPH CFEΠTANVV YYVGENVVNP SSPSPNNSVLTSGVGADVAR MWEIAIQHAL 540 20 MPVBPKGSSV GTGTNLHRDISVSISVSNCQIQENVDISTVYQIFPDEVLG SGQFGIVYGG 600 KHRKTGRDVA IKIDDKLRFP TKQESQLRNE VAILQNLHHP GW LECMFE TPERVFVVME 660 KLHGDMLEMI SSEKGRLPE HITKFLITQI LVALRHLHFK NIVHCDLKPE NVLLAS ADPF 720 PQVKLCDFGF ARUGEKSFR RSVVGTPAYL APEVLRNKGY NRSLDMWSVG VIIYVSLSGT 780 FPFNEDEDIHDQIQNAAFMYPPNPWKEISHEAIDLINNLLQVKMRKRYSV DKTLSHPWLQ 840 25 DYQTW LRELECKIGERYITHESDDLRWE KYAGEQRLQY PTHLINPSAS HSDTPETEET 900 EMKALGERVS IL 30 SEQ ID N0.137PFH3 DNA SEQUENCE Nucleic Acid Accession*: X95425 Coding sequence: 712-3825 (underlined sequences correspond to start and stop codons) _ _ 1 11 21 31 41 51 35 I I I I I I AATGGTCAGT CAATACATTA TAACATAATA CACCAAATGC TAGAATAGAA GGGGAGGGGG 60 GCACACATAA TGACTCACTG CTGGAAGAAG GGTGCATCAG TGAATTAAAA AATGTCCCTC 120 CCCTCTTCAG CACTCAGCGC GCAGCTATTT CCTTCTGCCA GTCTCTTTGA ACTCTGGATC 180 TTTGCTTTTG CTCGCTGCTC CCTGTTTTTCATTCTCCAC ATTTTCTCAATCCTCTTTCT 240 40 TTATCC- rAG CCACCCTGCTTTTTTCCTCCTTTTTTAAAA AATCGGAGATTTCGTCTTAA 300 AATGATTTGT CTTCCTTACC TTCGTCCATT TCAACACTGA AGGCTGCAAA GAACTTCACC 360 TTTCCCCTAG TGGTATTTAA AAATTCTCAA TCCGTAAAAA GTCTTTTTGA AAGGCAAAGG 420 AACAGGACCC AGACCCTCTC GACACCCTTG ATCCGAGTCA GATCTGCACT AGCAACCAGA 480 ACTAATATTTCATTTAACCC ACCAAAAGGG GGAGGCGAGAGGAGCCAGAAGCAAACTTCA 540 5 TCTGTCTCAG ACGGATCCGTGGTTCCTACATTTGGAGGAG CCGCGTGTCAGAAGGCGTAG 600 GACCCCAAGG GGGGACAAGG AGGACTCCCG AGTCTCCCTT CTCCGCTCTC CGAGACCGAA 660 GAGGTGGACT GAGCCGCTCG GGACAGCGGC ACCGGAGGAG GCTCGGAGAA G<_I_CGGGGC 720 TCGGGGCCCC GGGGTGCGGG ACACCGGCGG CCCCCAAGCG GCGGCGGCGA CACCCCCATC 780 ACCCCAGCGTCCCTGGCCGG CTGCTACTCTGCACCTCGACGGGCTCCCCTCTGGACGTGC 840 50 CTTCTCCTGTGCGCCGCACTCCGGACCCTCCTGGCCAGCCCCAGCAACGAAGTGAATTTA 900 TTGGATTCAC GCACTGTCAT GGGGGACCTG GGATGGATTG CTTTTCCAAA AAATGGGTGG 960 GAAGAGATTG GTGAAGTGGA TGAAAATTAT GCCCCTATCC ACACATACCA AGTATGCAAA 1020 GTGATGGAAC AGAATCAGAA TAACTGGCTT TTGACCAGTT GGATCTCCAA TGAAGGTGCT 1080 TCCAGAATCTTCATAGAACTCAAATTTACCCTGCGGGACTGCAACAGCCTTCCTGGAGGA 1140 55 CTGGGGACCTGTAAGGAAAC CTTTAATATGTATTACTTTGAGTCAGATGA TCAGAATGGG 1200 AGAAACATCA AGGAAAACCA ATACATCAAA ATTGATACCA TTGCTGCCGA TGAAAGCTTT 1260 ACAGAACTTG ATCTTGGTGA CCGTGTTATG AAACTGAATA CAGAGGTCAG AGATGTAGGA 1320 CCTCTAAGCA AAAAGGGATT TTATCTTGCT TTTCAAGATG TTGGTGCTTG CATTGCTCTG 1380 -. Λ GTTTCTGTGCGTGTATACTATAAAAAATGCCCTTCTGTGGTACGACACTTGGCTGTCTTC 1440 60 CCTGACACCATCACTGGAGCTGATTCTTCC CAATTGCTCG AAGTGTCAGG CTCCTGTGTC 1500 AACCATTCTG TGACCGATGA ACCTCCCAAA ATGCACTGCA GCGCCGAAGG GGAGTGGCTG 1560 GTGCCCATCG GGAAATGCAT GTGCAAGGCA GGATATGAAG AGAAAAATGG CACCTGTCAA 1620 GTGTGCAGAC CTGGGTTCTT CAAAGCCTCA CCTCACATCC AGAGCTGCGG CAAATGTCCA 1680 CCTCACAGTT ATACCC ATG A GG AAGCTTC A ACCTCTTGTG TCTGTG AAAA GGATTATTTC 1740 65 AGGAGAGAGT CTGATCCACC CACAATGGCA TGCACAAGAC CCCCCTCTGC TCCTCGGAAT 1800 GCCATCTCAA ATGTTAATGA AACTAGTGTC TTTCTGGAAT GGATTCCGCC TGCTGACACT 1860 GGTGGAAGGA AAGACGTGTC ATATTATATT GCATGCAAGA AGTGCAACTC CCATGCAGGT 1920 GTGTGTGAGG AGTGTGGCGG TCATGTCAGG TACCTTCCCC GGCAAAGCGG CCTGAAAAAC 1980 ACCTCTGTCATGATGGTGGA TCTACTCGCTCACACAAACTATACCTTTGA GATTGAGGCA 2040 70 GTGAATGGAG TGTCCGACTT GAGCCCAGGA GCCCGGCAGT ATGTGTCTGT AAATGTAACC 2100 ACAAATCAAG CAGCTCCATC TCCAGTCACC AATGTGAAAA AAGGGAAAAT TGCAAAAAAC 2160 AGCATCTCTT TGTCTTGGCA AGAACCAGAT CGTCCCAATG GAATCATCCT AGAGTATGAA 2220 ATCAAGCATT TTGAAAAGGA CCAAGAGACC AGCTACACGA TTATCAAATC TAAAGAGACA 2280 ACTATTACTG CAGAGGGCTT GAA ACCAGCT TCAGTTTATG TCTTCCAAAT TCGAGCACGT 2340 75 ACAGCAGCAG GCTATGGTGT CTTCAGTCGA AGATTTGAGT TTGAAACCAC CCCAGTGTTT 2400 GCAGCATCCA GCGATCAAAG CCAGATTCCT GTAATTGCTG TGTCTGTGAC AGTAGGAGTC 2460 ATTTTGTTGG CAGTGGTTAT CGGCGTCCTC CTCAGTGGAA GTTGCTGCGA ATGTGGCTGT 2520 GGGAGGGCTT CTTCCCTGTG CGCTGTTGCC CATCCAATCC TAATATGGCG GTGTGGCTAC 2580 AGCAAAGCAA AACAAGATCC AGAAGAGGAA AAGATGCATT TTCATAATGG GCACATTAAA 2640 CTGCCAGGAG TAAGAACTTA CATTGATCCA CATACCTATG AGGATCCCAA TCAAGCTGTC 2700 CACGAATTTG CCAAGGAGAT AGAAGCATCA TGTATCACCA TTGAGAGAGT TATTGGAGCA 2760 GGTGAATTTG GTGAAGTTTG TAGTGGACGT TTGAAACTAC CAGGAAAAAG AGAATTACCT 2820 GTGGCTATCA AAACCCTTAA AGTAGGCTAT ACTGAAAAGC AACGCAGAGA TTTCCTAGGT 2880 GAAGCAAGTA TCATGGGACA GTTTGATCAT CCTAACATCA TCCATTTAGA AGGTGTGGTG 2940 ACCAAAAGTA AACCAGTGAT GATCGTGACA GAGTATATGG AGAATGGCTC TTTAGATACA 3000 TTTTTGAAGA AAAACGATGG GCAGTTCACT GTGATTCAGC TTGTTGGCAT GCTGAGAGGT 3060 ATCTCTGCAG GAATGAAGTA CCTTTCTGAC ATGGGCTATG TGCATAGAGA TCTTGCTGCC 3120 AGAAACATCT TAATCAACAG TAACCTTGTG TGCAAAGTGT CTGACTTTGG ACTTTCCCGG 3180 GTACTGGAAG ATGATCCCGA GGCAGCCTAC ACCACAAGGG GAGGAAAAAT TCCAATCAGA 3240 TGGACTGCCC CAGAAGCAAT AGCTTTCCGA AAGTTTACTT CTGCCAGTGA TGTCTGGAGT 3300 TATGGAATAG TAATGTGGGA AGTTGTGTCT TATGGAGAGA GACCCTACTG GGAGATGACC 3360 AATCAAGATG TGATTAAAGC GGTAGAGGAA GGCTATCGTC TGCCAAGCCC CATGGATTGT 3420 CCTGCTGCTC TCTATCAGTT AATGCTGGAT TGCTGGCAGA AAGAGCGAAA TAGCAGGCCC 3480 AAGTTTGATG AAATAGTCAA CATGTTGG AC AAGCTG ATAC GTAACCCAAG TAGTCTG AAG 3540 ACGCTGGTTA ATGCATCCTG CAGAGTATCT AATTTATTGG CAGAACATAG CCCACTAGGA 3600 TCTGGGGCCT ACAGATCAGT AGGTGAATGG CTAGAGGCAA TCAAGATGGG CCGGTATACA 3660 GAGATTTTCA TGGAAAATGG ATACAGTTCA ATGGACGCTG TGGCTCAGGT GACCTTGGAG 3720 GATTTGAGAC GGCTTGGAGTGACTCTTGTC GGTCACCAGA AGAAGATCATGAACAGCCTT 3780 CAAGAAATGA AGGTGCAGCT GGTAAACGGA ATGGTGCCATTGTAACTTCA TGTAAATGTC 3840 GCTTCTTCAA GTGAATGATT CTGCACTTTG TAAACAGCAC TGAGATTTAT TTTAACAAAA 3900 AAA SEQ ID NO:138 PFH3 Protein sequence: Protein Accession *: CAA64700.1 1 11 21 31 41 51 I I I I I I MRGSGPRGAG HRRPPSGGGD TPITPASLAG CYSAPRRAPL WTCLLLCAAL RTLLASPSNE 60 VNLLDSRTVM GDLGWIAFPK NGWEEIGEVD ENYAPIHTYQ VCKVMEQNQN WLLTSWISN 120 EGASRIFIEL KFTLRDCNSLPGGLGTCKET FNMYYFESDD QNGRNIKENQ IKIDTIAAD 180 ESFTEUJLGD RVMKI-NTEVR DVGPLSKKGFYLAFQDVGAC IALVSVRVYY KKCPSVVRHL 240 AVEPDTITGA DSSQLLEVSG SCVNHSVTDE PPKMHCSAEG EWLVPIGKCM CKAGYEEKNG 300 TCQVCRPGFF KASPHIQSCG KCPPHSYTHE EASTSCVCEK DYFRRESDPP TMACTRPPSA 360 PRNAISNVNE TSVFLEW1PP ADTGGRKDVS YYIACKKCNS HAGVCEECGG HVRYLPRQSG 420 LKNTSVMMVD LAHTN TRAIEAVNGVSDLSTOARQYVSV^R TTNQAAPS PVTNVKKGKI 480 AKNSISLSWQ EPDRPNGΠLEYEIKHFEKD QETSYTΠKS KETTΓΓAEGLKPASVYVFQI 540 RARTAAGYGV FSRRFEFETT PVFAASSDQS QIPVIAVS VT VGVHI-AWI GVLLSGSCCE 600 CGCGRASSLC AVAHPILIWR CGYSKAKQDP EEEKMHFHNG HIKLPGVRT IDPHTYEDPN 660 QAVHEFAKEI EASCITIERV IGAGEFGEVC SGRLKLPGKR ELPVAIKTLK VGYTEKQRRD 720 FLGEASIMGQ FDHPNIIHI^GVVTKSKPVM IVTEYMENGS DTFI-KKNDG QFrVIQLVGM 780 IJIGISAGMKY I-SDMGYVHRD AARNILINS NLVCKVSDFGLSRVLEDDPEAAYTTRGGKI 840 PIRWTAPEAI AFRKFTSASD VWSYGIVMWE VVSYGERPYW EMTNQDVIKA VEEGYRLPSP 900 MDCPAALYQL MLDCWQKERN SRPKFDEIVN MLDKLIRNPS SLKTLVNASC RVSNLLAEHS 960 PLGSGAYRSV GEWLEAIKMG RYTEIFMENG YSSMDAVAQV TLEDLRRLGV TLVGHQKKIM 1020 NSLQEMKVQLVNGMVPL SEQ ID NO:139 PFH2 DNA SEQUENCE Nucleic Acid Accession * NM.016029 Coding sequence: 78-1097 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I i CTGCGATCCC GCAGGGCAGC GACGCGACTC TGGTGCGGGC CGTCTTCTTC CCCCCGAGCT 60 GGGCGTGCGC GGCCGCAATG AACTGGGAGC TGCTGCTGTG GCTGCTGGTG CTGTGCGCGC 120 TGCTCCTGCT CTTGGTGCAG CTGCTGCGCT TCCTGAGGGC TGACGGCGAC CTGACGCTAC 180 TATGGGCCGA GTGGCAGGGA CGACGCCCAG AATGGGAGCT GACTGATATG GTGGTGTGGG 240 TGACTGG AGC CTCGAGTGGA ATTGGTGAGG AGCTGGCTTA CCAGTTGTCT AAACTAGGAG 300 TTTCTCTTGT GCTGTCAGCC AGAAGAGTGC ATGAGCTGGA AAGGGTGAAA AGAAGATGCC 360 TAGAGAATGG CAATTTAAAA GAAAAAGATA TACTTGTTTT GCCCCTTGAC CTGACCGACA 420 CTGGTTCCCA TGAAGCGGCT ACCAAAGCTG TTCTCCAGGA GTTTGGTAGA ATCGACATTC 480 TGGTCAACAA TGGTGGAATG TCCCAGCGTT CTCTGTGCAT GGATACCAGC TTGGATGTCT 540 ACAGAAAGCT AATAGAGCTT AACTACTTAG GGACGGTGTC CTTGACAAAA TGTGTTCTGC 600 CTCACATGAT CGAGAGGAAG CAAGGAAAGATTGTTACTGTGAATAGCATC CTGGGTATCA 660 TATCTGTACC TCTTTCCATT GGATACTGTG CTAGCAAGCA TGCTCTCCGG GGTTTTTTTA 720 ATGGCCTTCG AACAGAACTT GCCACATACC CAGGTATAAT AGTTTCTAAC ATTTGCCCAG 780 GACCTGTGCA ATCAAATATT GTGGAGAATT CCCTAGCTGG AGAAGTCACA AAGACTATAG 840 GCAATAATGG AGACCAGTCC CACAAGATGA CAACCAGTCG TTGTGTGCGG CTGATGTTAA 900 TCAGCATGGC CAATGATTTG AAAGAAGTTT GGATCTCAGA ACAACCTTTC TTGTTAGTAA 960 CATATTTGTG GCAATACATG CCAACCTGGG CCTGGTGGAT AACCAACAAG ATGGGGAAGA 1020 AAAGGATTGA GAACTTTAAG AGTGGTGTGG ATGCAGACTCTTCTTATTTT AAAATCTTTA 1080 AGACAAAACA TGACΪSΔAAA GAGCACCTGT ACTTTTCAAG CCACTGGAGG GAGAAATGGA 1140 AAACATGAAA ACAGCAATCT TCTTATGCTT CTGAATAATC AAAGACTAAT TTGTGATTTT 1200 ACTTTTTAAT AGATATGACT TTGCTTCCAA CATGGAATGA AATAAAAAAT AAATAATAAA 1260 AGATTGCCATGAATCTTGCA AA SEQ ID N0:140 PFH2 Protein sequence: Protein Accession*: NP.057113.1 1 11 21 31 41 51 I I I I I I MNWELLLWLL VLCALLLLLV QLLRFLRADG DLTLLWAEWQ GRRPEWELTD MVVWVTGASS 60 GIGEELAYQL SKLGVSLVLS ARRVHELERV KRRCLENGNL KEKDILVLPL DLTDTGSHEA 120 ATKAVLQEFG RIDILVNNGG MSQRSLCMDT SLDVYRKLIE LNYLGTVSLT KCVLPHMIER 180 KQGKIVTVNS ILGIISVPLS IGYCASKHAL RGFFNGLRTE LATYPGIIVS NICPGPVQSN 240 IVENSLAGEV TKTIGNNGDQ SHKMTTSRCV RLMLISMAND LKEVWISEQP FLLVTYLWQY 300 MPTWAWWITN KMGKKRIENF KSGVDADSSY FKIFKTKHD SEQ ID N0:141 PFH1 DNA SEQUENCE Nucleic Acid Accession* N _021614 Coding sequence: 1-1740 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I AΪQAGCAGCT GCAGGTACAA CGGGGGCGTC ATGCGGCCGC TCAGCAACTT GAGCGCGTCC 60 CGCCGGAACC TGCACGAGAT GGACTCAGAG GCGCAGCCCC TGCAGCCCCC CGCGTCTGTC 120 GGAGGAGGTG GCGGCGCGTC CTCCCCGTCT GCAGCCGCTG CCGCCGCCGC CGCTGTTTCG 180 TCCTCAGCCC CCGAG ATCGT GGTGTCTAAG CCCGAGCACA ACAACTCCAA CAACCTGGCG 240 CTCTATGGAA CCGGCGGCGG AGGCAGCACT GGAGGAGGCG GCGGCGGTGG CGGGAGCGGG 3 00 CACGGCAGCA GCAGTGGCAC CAAGTCCAGC AAAAAGAAAA ACCAGAACAT CGGCTACAAG 360 CTGGGCCACC GGCGCGCCCT GTTCGAAAAG CGCAAGCGGC TCAGCGACTA CGCGCTCATC 420 TTCGGCATGT TCGGCATCGT GGTCATGGTC ATCGAGACCG AGCTGTCGTG GGGCGCCTAC 480 GACAAGGCGTCGCTGTATTC CTTAGCTCTG AAATGCCTTA TCAGTCTCTCCACGATCATC 540 CTGCTCGGTC TGATCATCGTGTACCACGCC AGGGAAATAC AGTTGTTCATGGTGGACAAT 600 GGAGCAGATG ACTGGAGAAT AGCCATGACT TATGAGCGTA TTTTCTTCAT CTGCTTGGAA 660 ATACTGGTGT GTGCTATTCA TCCCATACCT GGGAATTATA CATTCACATG GACGGCCCGG 720 CTTGCCTTCT CCTATGCCCC ATCCACAACC ACCGCTGATG TGGATATTAT TTTATCTATA 780 CCAATGTTCT TAAGACTCΓA TCTGATTGCC AGAGTCATGC TTTTACATAG CAAACTTTTC 840 ACTGATGCCT CCTCTAGAAG CATTGGAGCA CTTAATAAGA TAAACTTCAA TACACGTTTT 900 GTTATGAAGA CTTTAATGAC TATATGCCCA GGAACTGTAC TCTTGGTTTT TAGTATCTCA 960 TΓATGGATAA TΓGCCGCATG GACTGTCCGA GCTTGTGAAA GGTACCATGA CAACAGGAT 1020 GTTACTAGCA ACTTCCTTGG AGCGATGTGG TTGATATCAA TAACTTTTCT CTCCATTGGT 1080 TATGGTGACA TGGTACCTAA CACATACTGT GGAAAAGGAG TCTGCTTACTTACTGGAATT 1140 ATGGGTGCTG GTTGCACAGC CCTGGTGGTA GCTGTAGTGG CAAGGAAGCT AGAACTTACC 1200 AAAGCAGAAA AACACGTGCA CAATTTCATG ATGGATACTC AGCTGACTAA AAGAGTAAAA 1260 AATGCAGCTG CCAATGTACT CAGGGAAACA TGGCTAATTT ACAAAAATAC AAAGCTAGTG 1320 AAAAAGATAG ATCATGCAAA AGTAAGAAAA CATCAACGAA AATTCCTGCA AGCTATTCAT 1380 CAATTAAGAA GTGTAAAAAT GGAGCAGAGG AAACTGAATG ACCAAGCAAA CACTTTGGTG 1440 GACTTGGCAAAGACCCAGAA CATCATGTATGATATGATTTCTGACTTAAACGAAAGGAGT 1500 GAAGACTTCG AGAAGAGGAT TGTTACCCTG GAAACAAAAC TAGAGACTTT GATTGGTAGC 1560 ATCCACGCCC TCCCTGGGCT CATAAGCCAG ACCATCAGGC AGCAGCAGAG AGATTTCATT 1620 GAGGCTCAGA TGGAGAGCTA CGACAAGCAC GTCACTTACA ATGCTGAGCG GTCCCGGTCC 1680 TCGTCCAGGA GGCGGCGGTC CTCTTCCACA GCACCACCAA CTTCATCAGA GAGTAGCTAG SEQ ID NO:142 PFH1 Protein sequence: Protein Accession* NP_067627 1 11 21 31 41 51 I I I I I I MSSCRYNGGV MRPLSNLSAS RRNLHEMDSE AQPLQPPASV GGGGGASSPS AAAAAAAAVS 60 SSAPEIWSK PEHNNSNNLA LYGTGGGGST GGGGGGGGSG HGSSSGTKSS KKKNQNIGYK 120 LGHRRALFEKRKRLSDYALIFGMFGIWMV IETELSWGAY DKASLYSLALKCL1SLSTII 180 LLGLIIVYHAREIQLFMVDN GADDWRIAMTYERIFFICLE ILVCAIHPIPGNYTFTWTAR 240 LAFSYAPSTT TADVDIILSI PMFLRLYLIA RVMLLHSKLF TDASSRSIGA LNKINFNTRF 300 VMKTLMTICP GTVLLVFSIS LWIIAAWTVR ACERYHDQQD VTSNFLGAMW LISITFLSIG 360 YGDMVPNTYC GKGVCLLTGI MGAGCTALVV AVVARKLELT KAEKHVHNFM MDTQLTKRVK 420 NAAANVI SETWLIYKNTKLV KKIDHAKVRKHQRKFLQAIHQLRSVKMEQR KLNDQANTLV 480 DLAKTQNMY DMISDLNERS EDFEKRIVT ETKLETLIGS IHALPGLISQTIRQQQRDFI 540 EAQMESYDKH VTYNAERSRS SSRRRRSSST APPTSSESS SEQ ID NO:143PFG9 DNA SEQUENCE Nucleic Acid Accession *: AI-110139, coding region is FGENESH predicted Coding sequence: 1-1896 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I SCGCGCCG TGCCGCTGCC CGCCCCGCTC CTGCCGCTGC TGCTGCTCGC GCTCCTGGCC 60 GCTCCCGCCG CCCGCGCCAG CAGAGCCGAG TCCGTCTCCG CGCCGTGGCC CGAACCCGAG 120 CGCGAGTCGC GGCCACCGCC CGGCCCGGGG CCCGGGAACA CCACCCGGTT TGGGTCTGGG 180 GCGGCGGGCG GCAGCGGCAG CTCCAGCTCC AACAGCAGTG GCGACGCCTT GGTGACCCGC 240 ATTTCCATCC TCCTCCGCGA CCTACCCACC CTCAAGGCAG CCGTGATCGT GGCGTTCGCC 300 TTTACCACCC TCCTCATCGC CTGCCTGCTG CTGCGCGTCT TCAGGTCGGG AAAGAGGTTA 360 AAGAAGACAC GCAAGTATGA TATCATCACC ACTCCAGCAG AGCGAGTGGA AATGGCGCCA 420 CTAAATGAAG AGGATGATGA AGATGAGGAC TCCACAGTAT TCGACATCAA ATACAGAGTG 480 TCCTTGCCGG CTGCACTGAG ACGTCAGCTG CCAGGGTGCC AGACGCTACT GACAGTTCCT 540 GTGCCCCCAC CCTTCATCCT CGACATTGAC CTTCCAGCAA GATGCAGTGG AAGGCCTGAT 600 GGTGGAATCA GACCTGGTAA AACCTGTTTC CCAGCCTGGT GGCATCCTGT GGAAAGTTGG 660 TCAGCTGCAA CCTGGGGTGT GAAGGACTGG ACCTGGAAGC CCTCTTGCGT CGGAGGTGTT 720 GAAACCAAAA CGAACGTTAT GTATAAAACC CCAGCTCCA CGTGCGTGTC AGGCATCTGC 780 TCAGACTGTC ACTGGCAAGC TCGTTTCCAC GTCACCACAA TGGAGTTGCTTCTGCCACCC 840 TTTGGGCATC CCTTTAAAGT GCCCCCTACT TCTACTCCCC ATGGTTTTCG ACAACTGCAG 900 CTGAATCTCA TGGAAAAGCT GGATTCCTCT GCCTTACGCA GAAACACCCG GGCTCCATCT 960 GCCAGGTGCT TGCCACTGGT CCTGGCAGAA ATGGCGGCTG CTGAAAGTGA CCTTCCAAAT 1020 CCTTGGTGGC ACTTCAGCGC CACAGGCTCT CCAATAAAAA CCCTTTACAC ACAAACCATG 1080 AGTACCTTGG GCTrGGATGTTTTCTGTGGT GCCGGCCAGC GGGGCACCTTTTGTGAAGAC 1140 AGAGCAGTGA CTAAGGTTCT CCAGGGTAGC TCTTTCTCCA AACAGCTGCG CTGGAAGCCA 1200 GCCCTAGAGA GTGGGTTTCC CCATCATCTC AGGCTTCTCA GAGAGTGTCC TCCGCTGAGC 1260 ACCCATCCTG TCAGGTTGGC TCGTTCAGAT GCCCGGGGAC AAGCCAGCCT GACGGGGAGG 1320 AGGGTGTTTC GGCGTCCGCG GCAGTCTCTG CATGGCGGAG GGTCAGCGGG TACCGCAACT 1380 TGCCTTITGG TTTTGAAGAT TCTGTTGAGG CGCCATCCTC ACCTTGACCTCTTCTACAAA 1440 ATCTGTCTCC CCTGCTGTGC CGTGGAACAC CTACGGGAAG CCAAGAGAAG CTCAGTGACT 1500 GTCCTTGCGT CATTTGAGCA GAGCCCACAA AAGGCAGCTG CTGCCCACGG GGAGCCTGTC 1560 AAACGAGGGC CCAGTGGGCA ATTGACCAGA CACACATGCC CTGGCTGGGG GATCACACAT 1620 GCGAACCTGC AGACAATTCC AGATACCCAA GGCCAGGAAG GCCCACGTGA GGATGTCACT 1680 CACCCTGGAG GAGACTTGGA TGGGGTGGCA AATTTCTATT TGGAGGAAGA GGGTTTCCAG 1740 GATGGCAGAT GCCAGAAGAT GGTCCTGATG TCTGAGGAAG GGCCACCTAG TTTGACAGGA 1800 TGTGAGAGGC TCACAGGTTC CCATCACTTC TCCAGCCATT CCAAGTCTTG GTCCTTCCTT 1860 TCCCCCCGAC AGCCCCTGTT TCTGTCCAGG CCCTGA SEQ ID NO.-144 PFG9 Protein sequence: Protein Accession *: none available, FGENESH predicted 1 11 21 31 41 51 I I I I I I MRAVPLPAPL LPLLLLALLA APAARASRAE SVSAPWPEPE RESRPPPGPG PGNTTRFGSG 60 AAGGSGSSSS NSSGDALVTR ISILLRDLPT LKAAVIVAFA FTTLLIACLL LRVFRSGKRL 120 KKTRKYDITΓ TPAERVEMAP LNEEDDEDED STVFDIKYRV SLPAALRRQL PGCQTLLTVP 180 VPPPFILDID LPARCSGRPD GGIRPGKTCF PAWWHPVES W S AATWGVKDW TWKPSCVGGV 240 ETKTN\TWYKTPAPSCVSGIC SIX;HWQARIΉ VTTMELLLPP FGHPFKVPPT STPHGFRQLQ 300 LNLMEKLDSS ALRRNTRAPS ARCLPLVLAE MAAAESDLPN PWWHFSATGS PIKTLYTQTM 360 STLGLDVFCG AGQRGTFCED RAVTKVLQGS SFSKQLRWKP ALESGFPHHL RLLRECPPLS 420 THPVRLARSD ARGQASLTGR RVFRRPRQSL HGGGSAGTAT CLLVLKILLR RHPHLDLFYK 480 ICLPCCAVEH LREAKRSSVT VLASFEQSPQ KAAAAHGEPV KRGPSGQLTR HTCPGWG-TH 540 ANLQΉPDTQ GQEGPREDVT HPGGDLDGVA NFYLEEEGFQDGRCQKMVLM SEEGPPSLTG 600 CERLTGSHHF SSHSKSWSFL SPRQPLFLSR P SEQ ID NO:145 PFG6 DNA SEQUENCE Nucleic Acid Accession*: NM.013427 Coding sequence: 875-3799 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 GGCTGGGCTG CGAATAGCGT GTTCCTCTCC GGCGGAACAC ACACACCCGG CCTTGGGGCT 60 GTCTCCTGAA GCTCCCTCCT CCACGGAGAG CGCTGAGCGC CGCCGGGAAT TCCATCCCAC 120 CGTGGGCACG CAGTCTTTGG AGGTCCCGGG CGCAGCACGC TCGGTGTCCC CACACTGCAG 180 CAAGACAGAG ACCCCGCGGG AACCTTGAGC TTGGAACAAC CCTTGAGCCT CTGCAGTCGG 240 AAGAGTGGGC GCAGCAGCCC AGCGGAGGCC AGGCGCGCAA CCTCGGGCGC CGGGGCAAGG 300 AGAGAGTGCA GGGAGGCGCA GCTCAGGCGC CCGGCTCAGG AGCGGGAGGA AGTTCTCGCG 360 GCGCCGGGAG CGCGGTGGAC GCGCCCTGGG CGCACGCCCA GGCAGCCTTC TCCCTGGCCC 420 TGGGGACTGT CCTCGGGCGG CAAGGAGGAG CTTGCTGGAG TCTTAGAGGC CATCCAGAGC 480 CAGCGAGCAG GAGCGCTGCG TCTCCCGCCT CAGCTAGGAA GGGGGAGTGG CGCTGGCAGG 540 CTGGAGCTGG GAACCCAGCG AGCGCCTGAC CTTCCTCCTC CTCTTCCTGA CCCTCTTCGC 600 GTCTTGGGCT CCGGAGGAAG GTTCTAGCGG CTGCAGGAGG TCCCCAGACC CATTTTCCTA 660 GAAGGCTGGT GATGGATCTG CTGCTCCTGC CGCCGCCGGG GCACTTGGAG CGCACCGGCG 720 GCGCGTGAGC TGGGCTTTGC TCTCCACCGC CCTGGGCAAA CCCCGGGCCA GCCCCGCCTG 780 GCACCTTTGC CTGAGTCCCT TTCGGTTCCC GACCCAAAGC CACCAGCGTC CAGGGAGGGA 840 GGAGGAGGTG GTCCTCAGGTGCAGCCCCGC CGAGATQTCC GCGCAGAGCC TGCTCCACAG 900 CGTCTTCTCC TGTTCCTCGC CCGCTTCAAG TAGCGCGGCC TCGGCCAAGG GCTTCTCCAA 960 GAGGAAGCTG CGCCAG ACCC GCAGCCTGG A CCCGGCCCTG ATCGGCGGCT GCGGGAGCGA 1020 CGAGGCGGGC GCGGAGGGCA GTGCGCGGGG AGCCACGGCG GGCCGCCTCT ACTCCCCATC 1080 ACTCCCAGCC GAGAGTCTCG GCCCTCGCTT GGCGTCCTCT TCCCGGGGTC CGCCCCCCAG 1140 GGCCACCAGG CTACCGCCTC CTGGACCTCT TTGCTCGTCC TTCTCCACAC CCAGCACCCC 1200 GCAGGAGAAG TCACCATCCG GCAGCTTTCA CTTTGACTAT GAGGTTCCCC TGGGTCGCGG 1260 CGGCCTCAAG AAGAGCATGG CCTGGGACCT GCCTTCTGTC CTGGCCGGGC CAGCCAGTAG 1320 CCGAAGCGCT TCCAGCATCC TCTGTTCATC CGGGGGAGGC CCCAATGGCA TCTTCGCTTC 1380 TCCTAGGAGG TGGCTCCAGC AGAGGAAGTT CCAGTCCCCA CCCGACAGTC GCGGGCACCC 1440 5 CTACGTCGTG TGGAAATCCG AGGGTGATTT CACCTGGAAC AGCATGTCAG GCCGCAGTGT 1500 GCGGCTGAGG TCAGTCCCCA TCCAGAGTCT CTCAGAGCTG GAGAGGGCCC GGCTGCAGGA 1560 AGTGCCTTTT TATCAGTTGC AACAGGACTG TGACCTGAGC TGTCAGATCA CCATTCCCAA 1620 AGATGGACAA AAGAGAAAGA AATCTTTAAG AAAGAAACTG GATTCACTAG GAAAGGAGAA 1680 AAACAAAGAC AAAGAATTCA TCCCACAGGC ATTTGGAATG CCCTTATCCC AAGTCATTGC 1740 10 GAATGACAGG GCCTATAAAC TCAAGCAGGA CTTGCAGAGG GACGAGCAGA AAGATGCATC 1800 TGACTTTGTG GCTTCCCTCC TCCCATTTGG AAATAAAAGA CAAAACAAAG AACTCTCAAG 1860 CAGTAACTCA TCTCTCAGCT CAACCTCAGA AACACCGAAT GAGTCAACGT CCCCAAACAC 1920 CCCGGAACCG GCTCCTCGGG CTAGGAGGAG GGGTGCCATG TCAGTGGATT CTATCACCGA 1980 TCTTGATGAC AATCAGTCTC GACTACTAGA AGCTTTACAA CTTTCCTTGC CTGCTGAGGC 2040 15 TCAAAGTAAA AAGGAAAAAG CCAGAGATAA GAAACTCAGTCTGAATCCTA TTTACAGACA 2100 GGTCCCTAGG CTGGTGGACA GCTGCTGTCA GCACCTAGAA AAACATGGCC TCCAGACAGT 2160 GGGGATATTC CGAGTTGGAA GCTCAAAAAA GAGAGTGAGA CAATTACGTG AGGAATTTGA 2220 CCGTGGGATT GATGTCTCTC TGGAGGAGGA GCACAGTGTT CATGATGTGG CAGCCTTGCT 2280 GAAAGAGTΓC CTGAGGGACA TGCCAGACCC CCTTCTCACC AGGGAGCTGT ACACAGCTTT 2340 20 CATCAACACT CTCTTGTTGG AGCCGGAGGA ACAGCTGGGC ACCTTGCAGC TCCTCATATA 2400 CCTTCTACCT CCCTGCAACT GCGACACCCT CCACCGCCTG CTACAGTTCC TCTCCATCGT 2460 GGCCAGGCAT GCCGATGACA ACATCAGCAA AGATGGGCAA GAGGTCACTG GGAATAAAAT 2520 GACATCTCTA AACTTAGCCA CCATATTTGG ACCCAACCTG CTGCACAAGC AGAAGTCATC 2580 AGACAAAGAA TTCTCAGTTC AGAGTTCAGC CCGGGCTGAG G AGAGCACGG CCATCATCGC 2640 25 TGTTGTGCAA AAGATGATTG AAAATTATGA AGCCCTGTTC ATGGTTCCCC CAGATCTCCA 2700 GAACGAAGTG CTGATCAGCC TGTTAGAGAC CGATCCTGAT GTCGTGGACT ATTTACTCAG 2760 AAGAAAGGCT TCCCAATCAT CAAGCCCTGA CATGCTGCAG TCGGAAGTTT CCTTTTCCGT 2820 GGGAGGGAGG CATTCATCTA CAGACTCCAA CAAGGCCTCC AGCGGAGACA TCTCCCCTTA 2880 TGACAACAAC TCCCCAGTGC TGTCTGAGCG CTCCCTGCTG GCTATGCAAG AGGACGCGGC 2940 30 CCCGGGGGGC TCGGAGAAGC TTTACAGAGTGCCAGGGCAG TTTATGCTGG TGGGCCACTT 3000 GTCGTCGTCA AAGTCAAGGG AAAGTTCTCC TGGACCAAGG CTTGGGAAAG ATCTGTCAGA 3060 GGAGCCTTTC GATATCTGGG GAACTTGGCA TTCAACATTA AAAAGCGGAT CCAAAGACCC 3120 AGGAATGACA GGTTCCTCTG GAGACATTTT TGAAAGCAGC TCCCTAAGAG CGGGGCCCTG 3180 CTCCCTTTCT CAAGGGAACC TGTCCCCAAA TTGGCCTCGG TGGCAGGGGA GCCCCGCAGA 3240 35 GCTGGACAGC GACACGCAGG GGGCTCGGAG GACTCAGGCC GCAGCCCCCG CGACGGAGGG 3300 CAGGGCCCAC CCTGCGGTGT CGCGCGCCTG CAGCACGCCC CACGTCCAGG TGGCAGGGAA 3360 AGCCGAGCGG CCCACGGCCA GGTCGGAGCA GTACTTGACC CTGAGCGGCG CCCACGACCT 3420 CAGCGAGAGT GAGCTGGATG TGGCCGGGCT GCAGAGCCGG GCCACACCTC AGTGCCAAAG 3480 ACCCCATGGG AGTGGGAGGG ATGACAAGCG GCCCCCGCCT CCATACCCGG GCCCAGGGAA 3540 40 GCCCGCGGCA GCGGCAGCCT GGATCCAGGG GCCCCCGGAA GGCGTGGAGA CACCCACGGA 3600 CCAGGGAGGC CAAGCAGCCG AGCGAGAGCA GCAGGTCACG CAGAAAAAAC TGAGCAGCGC 3660 CAACTCCCTG CCAGCGGGCG AGCAGGACAG TCCGCGCCTG GGGGACGCTG GCTGGCTCGA 3720 CTGGCAGAGA GAGCGCTGGC AGATCTGGGA GCTCCTGTCG ACCGACAACC CCGATGCCCT 3780 GCCCGAGACG CTGGTCTQAG CCCGCACCCA GCCGAGCCCC CCCTGCCCCG AGCCCCCCGC 3840 45 CCTCCAGCCC AGGGGGGACC GTGGGTGGTG GCCACTGGCA CACTTAQTGT TCTTCTTTCA 3900 CACTTCTCAA AAGTGACACA AGAGAAATCC AGTTCACCTACAGAGGTAGA GCACTCACGC 3960 CCCCGCCATT GAGAATAAGG TTCCATTGCG TAGCCAGCCT TAGGAAAAAC AAACAGAACC 4020 CAAACCAGAT GGCAATGTCC AATCTAAAAA CGTCCCTCTT GGCTCTATAA TATAAGATAC 4080 AACTCTTGCT TGGTATAGCC TAACCGTATT TATGTGTCTT CGGTTTTGAC TATTGTGTAT 4140 50 TCTGTAACAG ATTATGTATA ATCATATATG ATATATTCAC AAAGAGAAAA CAAAAGGAAC 4200 TTTTAAAAAA AAAATCACTT CACTTATATT AAGCAATGAG ATATACTAAA CAATGAGATT 4260 CTATAGAATG TTCTAGAATG TGCACAAGCG GGTTTCTGTG CTTTTGCCAT AGCTTTATAA 4320 CTGGGGATAA CCCTTCCTTC GATACCAAAC ACTAACAAGA GGAAGCAGAA TATGAGAAGC 4380 CATATTTTTA CATAGGAGTC AGATACAAAA AGAAAAATCA CTGAATGCTT TTAGATATTG 4440 55 AATACGTTTT CAGGAAAATG CTAAATCΓGA TAGATΓACGA AATATATTTT TAGAACTTGT 4500 TTAGAAAGGA TTCAGTTAAC CAAACAAGAA AAAGGCAGTG CCTCACAAAG AAATTAAGAA 4560 GTTGTCCGTC CCACGTTACA TCAAATTCAG TTTTATATAG GCCATATATA ATATATATTT 4620 ATAATGTATA ATTTTTATGT ATTTTTCAAA ACTACAAACT GGAATCCAAC TATAAAGTGT 4680 , _ TTAAGAATCT ACACAGAATA TTCAAATTAT AGAACATGTT TTTTCCCTTT GCCCCATAAT 4740 60 CAGTATTTGC CAAATTACAT GCAATTCCTT AAAAACTAAA TCACATTGGT AAAAGGCCTA 4800 CAGCTTTGTA CTTACATTGT GCCAAAGGCT GAGGAAATGT TTTCTTTCGA ATTTTTATGT 4860 GTATTGTAAA ATGTTCTACC GTACTTTAGT AGTTTGAAGT TTTCAAGTGC ATAACTATTT 4920 TTGACCAGCA GAAGGCGATA CGCTTCAGTA TTTTATGCAA TΠTTTTTCA CTTCGAAGGG 4980 AAAGTGTATT ATAAAAAAAG ATTTTTTTTT TTTAAAACAT GCTACTCTTA ATTTTCATGT 5040 65 TGGTGATGAA ATTCCCAGTG GTGTTTCTTA AGGTTCTATC TTGTGCCATG ATGAATAAAA 5100 AGTTAAGCAA AAAAAAAAAA AAAAAAAAAA AAA __ SEQ ID NO:146 PFG6 Protein sequence: 70 Protein Accession*: NP_038286.1 1 11 21 31 41 51 I I I I I I SAQSLLHSV FSCSSPASSS AASAKGFSKR LRQTRSLDP ALIGGCGSDE AGAEGSARGA 60 75 TAGRLYSPSL PAESLGPRLA SSSRGPPPRA TRLPPPGPLC SSFSTPSTPQ EKSPSGSFHF 120 DYEVPLGRGG LKKSMAWDLP SVLAGPASSR SASSILCSSG GGPNGIFASP RRWLQQRKFQ 180 SPPDSRGHPY VVWKSEGDFT WNSMSGRSVR LRSVPIQSLS ELERARLQEV PFYQLQQDCD 240 LSCQπ-PKD GQKRKKSLRK KLDSUJKEKN KDKEFIPQAF GMPLSQVIAN DRAYKLKQDL 300 QRDEQKDASD FVASLLPFGN KRQNKELSSS NSSLSSTSET PNESTSPNTP EPAPRARRRG 360 AMSVDSITDL DDNQSRLLEA QLSLPAEAQ SKKEKARDKK LSLNPIYRQV PRLVDSCCQH 420 LEKHGLQTVG IFRVGSSKKR VRQLREEFDR GIDVSLEEEH SVHDVAALLK EFLRDMPDPL 480 LTRELYTAH NTLLLEPEEQ LGTLQLLIYL LPPCNCDTLH RLLQFLSIVA RHADDNISKD 540 GQEVTGNKMT SLNLATIFGP NLLHKQKSSD KEFSVQSSAR AEESTAΠAWQKMIENYEA 600 5 LFMVPPDLQN EVLISLLETD PDVVDYLLRR KASQSSSPDM LQSEVSFSVG GRHSS TDSNK 660 ASSGDISPYD NNSPVLSERS LLAMQEDAAP GGSEKLYRVP GQFMLVGHLS SSKSRESSPG 720 PRLGKDLSEE PFDIWGTWHS TLKSGSKDPG MTGSSGDIFE SSSLRAGPCS LSQGNLSPNW 780 PRWQGSPAEL DSDTQGARRT QAAAPATEGR AHPAVSRACS TPHVQVAGKA ERPTARSEQY 840 LTLSGAHDLS ESELDVAGLQ SRATPQCQRP HGSGRDDKRP PPPYPGPGKP AAAAAWIQGP 900 10 PEGVETPTDQ GGQAAEREQQ VTQKKLSSAN SLPAGEQDSP RLGDAGWLDW QRERWQIWEL 960 LSTDNPDALP ETLV 15 SEQ ID N0:147PFG4 DNA SEQUENCE Nucleic Acid Accession*: NM_002202 Coding sequence: 240-1289 (underlined sequences correspond to start and stop codons) 20 1 11 21 31 41 51 C I CCCC I GAG ICC GCGCCGAGTC TGCCGCCGCC GCAGCGCCTC CGCTCCGCCA ACTCCGCCGG 60 CTTAAATTGG ACTCCTAGAT CCGCGAGGGC GCGGCGCAGC CGAGCAGCGG CTCTTTCAGC 120 ATTGGCAACC CCAGGGGCCA ATATTTCCCA CTTAGCCACA GCTCCAGCATCCTCTCTGTG 180 25 GGCTGTTCAC CAACTGTACA ACCACCATTT CACTGTGGAC ATTACTCCCTCTTACAGATA 240 IgGGAGACAT GGGAGATCCA CCAAAAAAAA AACGTCTGAT TTCCCTATGT GTTGGTTGCG 300 GCAATCAGAT TCACGATCAG TATATTCTGA GGGTTTCTCC GGATTTGGAA TGGCATGCGG 360 CATGTTTGAA ATGTGCGGAG TGTAATCAGT ATTTGGACGA GAGCTGTACA TGCTTTGTTA 420 GGGATGGGAA AACCTACTGT AAAAGAGATT ATATCAGGTT GTACGGGATC AAATGCGCCA 480 30 AGTGCAGCAT CGGCTTCAGC AAGAACGACT TCGTGATGCG TGCCCGCTCC AAGGTGTATC 540 ACATCGAGTG TTTCCGCTGT GTGGCCTGCA GCCGCCAGCT CATCCCTGGG GACGAATTTG 600 CGCTTCGGGA GGACGGTCTC TTCTGCCGAG CAGACCACGA TGTGGTGGAG AGGGCCAGTC 660 TAGGCGCTGG CGACCCGCTC AGTCCCCTGC ATCCAGCGCG GCCACTGCAA ATGGCAGCGG 720 AGCCCATCTC CGCCAGGCAG CCAGCCCTGC GGCCCCACGT CCACAAGCAG CCGGAGAAGA 780 35 CCACCCGCGT GCGGACTGTG CTGAACGAGA AGCAGCTGCA CACCTTGCGG ACCTGCTACG 840 CCGCAAACCC GCGGCCAGAT GCGCTCATGA AGGAGCAACT GGTAGAGATG ACGGGCCTCA 900 GTCCCCGTGT GATCCGGGTC TGGTTTCAAA ACAAGCGGTG CAAGGACAAG AAGCGAAGCA 960 TCATGATGAA GCAACTCCAG CAGCAGCAGC CCAATGACAA AACTAATATC CAGGGGATGA 1020 CAGGAACTCC CATGGTGGCT GCCAGTCCAG AGAGACACGA CGGTGGCTTA CAGGCTAACC 1080 40 CAGTGGAAGT ACAAAGTTAC CAGCCACCTT GGAAAGTACT GAGCGACTTC GCCTTGCAGA 1140 GTGACATAGA TCAQCCTGCT TTTCAGCAAC TGGTCAATTT TTCAGAAGGA GGACCGGGCT 1200 CTAATTCCAC TGGCAGTGAA GTAGCATCAA TGTCCTCTCA ACTTCCAGAT ACACCTAACA 1260 GCATGGTAGC CAGTCCTATT GAGGCAJGAG GAACATTCAT TCTGTATTTT TπTCCCTGT 1320 TGGAGAAAGTGGGAAATTATAATGTCGAAC TCTGAAACAA AAGTATTTAA CGACCCAGTC 1380 45 AATGAAAACT GAATCAAGAA ATGAATGCTC CATGAAATGC ACGAAGTCTG TTTAATGAC 1440 AAGGTGATAT GGTAGCAACA CTGTGAAGAC AATCATGGGA TTTTACTAGA ATTAAACAAC 1500 AAACAAAACG CAAAACCCAG TATATGCTAT TCAATGATCT TAGAAGTACT GAAAAAAAAA 1560 GACGTTTTTA AAACGTAGAG GATTTATATT CAAGGATCTC AAAGAAAGCA TTTTCATTTC 1620 ACTGCACATCTAGAGAAAAA CAAAAATAGA AAATTTTCTA GTCCATCCTA ATCTGAATGG 1680 50 TGCTGTTTCT ATATTGGTCA TTGCCTTGCCAAACAGGAGC TCCAGCAAAA GCGCAGGAAG 1740 AGAGACTGGC CTCCTTGGCT GAAAGAGTCC TTTCAGGAAG GTGGAGCTGC ATTGGTTTGA 1800 TATGTTTAAA GTTGACTTTA ACAAGGGGTT AATTGAAATC CTGGGTCTCT TGGCCTGTCC 1860 TGTAGCTGGT TTATΠTTTA CTTTGCCCCC TCCCCACTTT TTTTGAGATC CATCCTTTAT 1920 C\AGAAGTCTGAAGCGACTA TAAAGGTTTT TGAATTCAGA TTTAAAAACC AACTTATAAA 1980 55 GCATTGCAAC AAGGTTACCT CTATTTTGCC ACAAGCGTCT CGGGATTGTG TTTGACTTGT 2040 GTCTGTCCAA GAACTTTTCC CCCAAAGATG TGTATAGTTA TTGGTTAAAA TGACTGTTTT 2100 CTCTCTCTAT GGAAATAAAA AGGAAAAAAA AAAGGAAACT TTTTTTGTTT GCTCTTGCAT 2160 TGCAAAAATT ATAAAGTAAT TTATTATTTA TTGTCGGAAG ACTTGCCACT TTTCATGTCA 2220 TTTGACATIT TTTGTTTGCTGAAGTGAAAA AAAAAGATAA AGGTTGTACG GTGGTCTTTG 2280 60 AATTATATGT CTAATTCTAT GTGTTTTGTC TTTTTCTTAA ATATTATGTG AAATCAAAGC 2340 GCCATATGTA GAATTATATC TTCAGGACTA TTTCACTAAT AAACATTTGG CATAGAT 65 SEQ ID NO:148 PFG4 Protein sequence: Protein Accession #: NP_002193.1 1 11 21 31 41 51 - n I I I I I I /I) MGDPPKKKRL ISLCVGCGNQ IHDQYILRVS PDLEWHAAC KCAECNQYLD ESCTCFVRDG 60 KTYCKRDYIR LYGIKCAKCS IGFSKNDFVM RARSKVYHIE CFRCVACSRQ IPGDEFALR 120 EDGLFCRADH DVVERASLGA GDPLSPLHPA RPLQMAAEPI SARQPALRPH VHKQPEKTTR 180 VRTVLNEKQL HTLRTCYAAN PRPDALMKEQ LVEMTGLSPR V1RVWFQNKR CKDKKRSIMM 240 „ _ KQLQQQQPND KTN1QGMTGT PMVAASPERH DGGLQANPVE VQSYQPPWKV LSDFALQSDI 300 75 DQPAFQQLVN FSEGGPGSNS TGSEVASMSS QLPDTPNSMV ASPIEA SEQ ID NO:149 PFG2 DNA SEQUENCE Nucleic Acid Accession* NM_001172 Coding sequence: 39-1103 (underlined sequences correspond to start and stop codons) 5 1 11 21 31 41 51 I I I I I I GCGGAGCTCT GCCTTGGAG A TTCTCAGTGC TGCGG ATCAT__TCCCTAAGG GGCAGCCTCT 60 CGCGTCTCCT CCAGACGCGA GTGCATTCCA TCCTGAAGAA ATCCGTCCAC TCCGTGGCTG 120 TGATAGGAGC CCCGTTCTCA CAAGGGCAGA AAAGAAAAGG AGTGGAGCAT GGTCCCGCTG 180 10 CCATAAGAGA AGCTGGCTTG ATGAAAAGGCTCTCCAGTTTGGGCTGCCAC CTAAAAGACT 240 TTGGAGATTT GAGTTTTACT CCAGTCCCCA AAGATGATCT CTACAACAAC CTGATAGTGA 300 ATCCACGCTC AGTGGGTCTT GCCAACCAGG AACTGGCTGA GGTGGTTAGC AGAGCTGTGT 360 CAGATGGCTA CAGCTGTGTC ACACTGGGAG GAGACCACAG CCTGGCAATC GGTACCATTA 420 GTGGCCATGC CCGACACTGC CCAGACCTTT GTGTTGTCTG GGTTGATGCC CATGCTGACA 480 15 TCAACACACC CCTTACCACTTCATCAGGAA ATCTCCATGG ACAGCCAGTTTCATTTCTCC 540 TCAGAGAACT ACAGGATAAG GTACCACAAC TCCCAGGATT TTCCTGGATC AAACCTTGTA 600 TCTCTTCTGC AAGTATTGTG TATATTGGTC TGAGAGACGT GGACCCTCCT GAACATTTTA 660 TTTTAAAGAA CTATGATATC CAGTATTTTT CCATGAGAGA TATTGATCGA CTTGGTATCC 720 AGAAGGTCATGGAACGAACA TTTGATCTGCTGATTGGCAA GAGACAAAGA CCAATCCATT 780 20 TGAGTTTTGATATTGATGCA TTTGACCCTACACTGGCTCCAGCCACAGGAACTCCTGTTG 840 TCGGGGGACT AACCTATCGA GAAGGCATGT ATATTGCTGA GGAAATACAC AATACAGGGT 900 TGCTATCAGC ACTGGATCTT GTTGAAGTCA ATCCTCAGTT GGCCACCTCA GAGGAAGAGG 960 CGAAGACTAC AGCTAACCTG GCAGTAGATG TGATTGCTTC AAGCTTTGGT CAGACAAGAG 1020 AAGGAGGGCATATTGTCTATGACCAACTTCCTACTCCCAG TTCACCAGAT GAATCAGAAA 1080 25 ATCAAGCACG TGTGAGAATT TAGGAGACAC TGTGCACTGA CATGTTTCAC AACAGGCATT 1140 CCAGAATTAT GAGGCATTGA GGGGATAGAT GAATACTAAA TGGTTGTCTG GGTCAATACT 1200 GCCTTAATGA GAACATTTAC ACATTCTCAC AATTGTAAAG TTTCCCCTCT ATTTTGGTGA 1260 CCAATACTAC TGTAAATGTA TTTGGTTTTT TGCAGTTCAC AGGGTATTAA TATGCTACAG 1320 TACTATGTAAATTTAAAGAAGTCATAAACA GCATTTATTA CCTTGGTATATCATACTGGT 1380 30 CTTGTTGCTG TTGTTCCITCACATTTAAGTGGTTTTTCATCTTTCCTCCCTCCTCCCACA 1440 GCCTGGCTAT ACAGTGCATC CTTGAACTGT CAGCCCACAG CAGCAATATG CTTATTCTAT 1500 CCACATCCCT AACATCATGC ATTCACAAGG TCAAAGTTCT GGTCCACAAA CCCTTCCCTA 1560 TAGAAGTTCA ATGGCTGCGA AAGAATTTGT AGTAAACCAG GCCTCCCAGG ATGGCGAGCT 1620 CCAGTAAGATGATAATGGAAAGCAGCAGCTTGTTGGTTGTCACTCTACAA AGAGAAGCAA 1680 35 AGTGGGGAGTAGTCAGAAGTTTGGATAACCTTCCTTCTAA ACATTTGGGG GTTAGACCTG 1740 GGACCACGGC TGGATACTCT GAGGCTGTAT GTTTGATCAC ACAGCCACTT AGCAGGAAGT 1800 ACTCATAAGG TTCTTTAGCT GTCACTTAGG GATAACACTG TCTACCTCAC AGAAATGTTA 1860 AACTGAGACA ATAAAACCCA AAGCAT 40 SEQ ID NO:150 PFG2 Protein sequence: Protein Accession*: NP_001163.1 . _ 1 11 21 31 41 51 45 I I I I I I MSLRGSLSRL LQTRVHSELK KSVHSVAVIG APFSQGQKRK GVEHGPAAIR EAGLMKRLSS 60 LGCHLKDFGD LSFTPVPKDD LYNNLIVNPR SVGLANQELA EVVSRAVSDG YSCVTLGGDH 120 SLAIGTISGH ARHCPDLCVV WVDAHADINT PLTTSSGNLH GQPVSFLLRE LQDKVPQLPG 180 FSWIKPCISS ASIVYIGIJRD VDPPEHFILKNYDIQYFSMRDIDRLGIQKVMERTFDLLIG 240 50 KRQRPI-HLSFDωAFDPTI PATGTPVVGG TΥREGMYIAEEIHNTGLLS ALDLVEVNPQ 300 LATSEEEAKT TANLAVDVIA SSFGQTREGG HIVYDQLPTP SSPDESENQA RVRI 55 SEQ ID N0:151 PFG1 DNA SEQUENCE Nucleic Acid Accession* N _017906 Coding sequence: 80-1255 (underlined sequences correspond to start and stop codons) ,_ 1 11 21 31 41 51 60 i i i i i i AATTATATAT TTTTACTCTA TGTTTCTCTA CATGTTTTTT TCTTTCCGTT GCTGGCGGAA 60 GAGGCACGTG CGCTGCTGAA TSGAGCTGGT CGCTGGTTGC TACGAGCAGG TCCTCTTTGG 120 GTTCGCTGTA CACCCGGAGC CCAAGGCTTG CGGCGACCAC GAGCAATGGA CTCTTGTGGC 180 TGACTTCACTCACCATGCTCACACTGCCTCCTTGTCAGCA GTAGCTGTAA ATAGTCGTTT 240 65 TGTGGTCACTGGGAGCAAAG ATGAAACAATTCACATTTATGACATGAAAA AGAAGATTGA 300 GCATGGGGCT CTAGTGCATC ACAGTGGTAC AATAACTTGC CTGAAATTCT ATGGCAACAG 360 GCATTTAATC AGTGGAGCGG AAGATGGACT CATCTGTATC TGGGATGCAA AGAAATGGGA 420 ATGCCTGAAG TCAATTAAAG CTCACAAAGG ACAGGTGACC TTCCTTTCTA TTCACCCATC 480 TGGCAAGTTG GCCCTGTCGG TTGGTACAGA TAAAACTTTA AGAACGTGGA ATCTTGTAGA 540 70 AGGAAGATCA GCATTCATAA AAAATATAAA ACAAAATGCT CACATAGTAG AATGGTCCCC 600 AAGAGGAGAG CAGTATGTAG TTATCATACA GAATAAAATA GACATCTATC AGCTTGACAC 660 TGCATCCATT AGTGGCACCA TCACAAATGA AAAGAGAATT TCCTCTGTTA AATTTCTTTC 720 AGAGTCTGTC CTTGCAGTGG CTGGAGATGA AGAAGTTATA AGGTTTTTTG ACTGTGATTC 780 ACTAGTGTGC CTCTGCGAAT TTAAAGCTCA TGAAAACAGG GTAAAGGACA TGTTCAGTTT 840 75 TGAAATTCCA GAGCATCATGTTATTGTTTC AGCATCGAGTGATGGTTTCATCAAAATGTG 900 GAAGCTTAAG CAGGATAAGA AAGTTCCCCC ATCTTTACTC TGTGAAATAA ACACTAATGC 960 CAGGCTGACG TGTCTTGGAG TGTGGCTAGA CAAAGTGGCA GACATGAAAA GCCTTCCTCC 1020 AGCTGCAGAG CCTTCTCCTG TAAGTAAAGA ACAGTCCAAA ATTGGCAAAA AGGAGCCTGG 1080 TGACACAGTG CACAAAGAAG AAAAGCGGTC AAAACCTAAC ACAAAGAAAC GCGGTTTAAC 1140 AGGTGACAGT AAGAAAGCAA CAAAAGAAAG TGGCCTGATA TCAACCAAGA AGAGGAAAAT 1200 GGTAGAAATG TTGGAAAAGA AGAGGAAAAA GAAGAAAATA AAAACAATGC AGT_JAATCAC 1260 AGATGTCTCC TGAAAGAACT CTTTTAGATG AAATCATTCT ACTCAAATGT ACCTTAATTT 1320 TTTTTTTTCC CTGAGTAAAA GCAAGAAATT TCTTCCTTTG GAAAAAATAT ATATATTAAA 1380 AAACCACTTT TAGATGGTTT TTTTTAAAAA AAAAAAAAAA ACTGGTAAAA TTACTTTTGG 1440 CAGACAGTGT TTTATGAATT ATGTATCATG TTGATATATA ATATGTTAAT GTGTCATGTA 1500 ATTTTTACTT TGTACAAAGC AAATAAAGAT CTTTCTCAAA AAAAAAAAAA AAAA SEQ ID NO:152 PFG1 Protein sequence: Protein Accession*: NP.060376.1 1 11 21 31 41 51 i i i i i i MELVAGCYEQ VLFGFAVHPE PKACGDHEQW TLVADFTHHA HTASLSAVAV NSRFVVTGSK 60 DETIHIYDMK KKIEHGALVH HSGTITCLKF YGNRHLISGA EDGLICIWDA KKWECLKSIK 120 AHKGQVTFLS IHPSGKLALS VGTDKTLRTW NLVEGRSAFI KNIKQNAHIV EWSPRGEQYV 180 VHQNKIDIYQLDTASISGTITNEKRISSV KFLSESVLAV AGDEEVIRFFDCDSLVCLCE 240 FKAHENRVKDMFSFEIPEHH VIVSASSDGFIKMWKLKQDK KVPPS--XCEINTNARLTCLG 300 VWLDKVADMK SLPPAAEPSP VSKEQSKIGK KEPGDTVHKE EKRSKPNTKK RGLTGDSKKA 360 TKESGLISTK KRKMVEMLEK KRKKKKIKTM Q SEQ ID NO:153 PFD6 DNA SEQUENCE Nucleic Acid Accession *: N _01 668 Coding sequence: 110-2953 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I GATGTCTTGG ACATGCTCTG GCTGGCTAAT CTCCATGTTC TAGCCGACTG AAAATACGGT 60 GGCCAAGTGG ATGGTGTGCT TATTTGCAGT CTAAAGAAAT TTCCTTTTGA___TGGCAGAA 120 AATCGAGGATGTGGAGTGGAGACCCCAGACTTACTTGGAG CTGGAGGGTC TGCCTTGCAT 180 CCTGATCTTC AGTGGGATGG ACCCGCATGG GGAGTCCTTG CCGAGGTCTT TGAGGTACTG 240 TGACCTGCGA TTGATAAACT CCTCCTGCTT GGTGAGAACA GCCTTGGAGC AGGAGCTGGG 300 CCTGGCTGCC TACTTTGTGA GCAACGAGGT TCCCTTGGAG AAGGGGGCTA GGAACGAGGC 360 CTTGGAGAGT GATGCTGAGA AGCTGAGCAG CACAGACAAC GAGGATGAGG AGCTGGGGAC 420 AGAAGGCTCTACCTCGGAGA AGAGAAGCCCCATGAAAAGGGAGAGGTCCC GCTCCCACGA 480 CTCAGCATCCTCATCCCTCTCCTCCAAGGCTTCCGGTTCAGCGCTCGGTG GCGAGTCCTC 540 GGCTCAGCCC ACAGCACTCC CCCAGGGAGA GCATGCCAGG TCGCCCCAGC CCCGTGGCCC 600 CGCAGAGGAG GGCAGAGCCC CTGGTGAGAA ACAGAGGCCC CGGGCAAGTC AGGGGCCACC 660 CTCGGCCATC AGCAGGCACA GTCCCGGGCC GACGCCCCAG CCCGACTGTA GCCTCAGGAC 720 CGGCCAGAGG AGCGTCCAGG TGTCGGTCACCTCGTCGTGCTCCCAGCTGTCCTCCTCCTC 780 GGGCTCATCCTCCTCATCCG TGGCGCCCGCTGCCGGCACG TGGGTCCTGC AGGCCTCCCA 840 GTGCTCCTTG ACCAAGGCCT GCCGCCAGCC ACCCATTGTC TTCTTGCCCA AGCTCGTGTA 900 CGACATGGTT GTGTCCACTG ACAGCAGTGG CCTGCCCAAG GCCGCCTCCC TCCTGCCCTC 960 CCCCTCGGTC ATGTGGGCCA GCTCTTTCCG CCCCCTGCTC AGCAAGACCA TGACATCCAC 1020 CGAGCAGTCCCTCTACTACCGGCAGTGGACGGTGCCCCGGCCCAGCCACA TGGACTACGG 1080 CAACCGGGCCGAGGGCCGCG TGGACGGCTTCCACCCCCGCAGGCTGCTGCTCAGCGGCCC 1140 CCCTCAGATC GGGAAGACAG GTGCCTACCT GCAGTTCCTC AGTGTCCTGT CCAGGATGCT 1200 TGTTCGGCTC ACAGAAGTGG ATGTCTATGA CGAGGAGGAG ATCAATATCA ACCTCAGAGA 1260 AGAATCTGAC TGGCATTATC TCCAGCTTAG CGACCCCTGG CCAGACCTGG AGCTGTTCAA 1320 GAAGTTGCCCTTTGACTACATCATTCACGACCCGAAGTATGAAGATGCCA GCCTGATTTG 1380 TTCGCACTAT CAGGGTATAA AGAGTGAAGA CAGAGGGATG TCCCGGAAGC CGGAGGACCT 1440 TTATGTGCGG CGTCAGACGG CACGGATGAG ACTGTCCAAG TACGCAGCGT ACAACACTTA 1500 CCACCACTGT GAGCAGTGCC ACCAGTACAT GGGCTTCCAC CCCCGCTACC AGCTGTATGA 1560 GTCCACCCTG CACGCCTTTG CCTTCTCTTA CTCCATGCTA GGAGAGGAGA TCCAGCTGCA 1620 CTTCATCATCCCCAAGTCCAAGGAGCACCA CTTTGTCTTCAGCCAACCTG GAGGCCAGCT 1680 GGAGAGCATG CGACTACCCC TCGTGACAGA CAAGAGCCAT GAATATATAA AAAGTCCGAC 1740 ATTCACTCCA ACCACCGGCC GTCACGAACA TGGGCTCTTT AATCTGTACC ACGCXATGGA 1800 CGGTGCCAGC CATTTGCACG TGCTGGTTGT CAAGGAATAC GAGATGGCAA TTTATAAGAA 1860 ATATTGGCCC AACCACATCA TGCTGGTGCT CCCCAGTATC TTCAACAGTG CTGGAGTTGG 1920 TGCTGCTCATTTCCTCATCA AGGAGCTGTC CTACCATAACCTGGAGCTCG AGCGGAACCG 1980 GCAGGAGGAG CTGGGAATCA AGCCGCAGGA CATCTGGCCT TTCATTGTGA TCTCTGATGA 2040 CTCCTGCGTG ATGTGGAACG TGGTGGATGT CAACTCTGCT GGGGAGAGAA GCAGGGAGTT 2100 CTCCTGGTCG GAAAGGAACG TGTCTTTGAA GCACATCATG CAGCACATCG AGGCGGCCCC 2160 CGACATCATG CACTACGCCC TGCTGGGCCT GCGGAAGTGG TCCAGCAAGA CCCGGGCCAG 2220 CGAGGTGCAA GAGCCCTTCT CCCGCTGCCA CGTGCACAAC TTCATCATCC TGAACGTGGA 2280 CCTGACCCAGAACGTGCAGTACAACCAGAACCGGTTCCTGTGTGACGATG TAGACTTCAA 2340 CCTGCGGGTG CACAGCGCCG GCCTCCTGCT CTGCCGGTTC AACCGCTTCA GCGTGATGAA 2400 GAAGCAGATC GTGGTGGGCG GCCACAGGTC CTTCCACATC ACATCCAAGG TGTCTGATAA 2460 CTCTGCCGCG GTCGTGCCGG CCCAGTACAT CTGTGCCCCG GACAGCAAGC ACACGTTCCT 2520 CGCAGCGCCC GCCCAGCTCC TGCTGGAG AA GTTCCTGCAG CACCACAGCC ACCTCTTCTT 2580 CCCGCTGTCCCTGAAGAACC ATGACCACCC AGTGCTGTCTGTCGACTGTTACCTGAACCT 2640 GGGATCTCAG ATTTCTGTTT GCTATGTGAG CTCCAGGCCC CACTCTTTAA ACATCAGCTG 2700 CTCGGACTTG CTGTTCAGTG GGCTGCTGCT GTACCTCTGT GACTCTTTTG TGGGAGCTAG 2760 CTΠTTGAAA AAGTTTCATT TTCTGAAAGG TGCGACGTTG TGTGTCATCT GTCAGGACCG 2820 GAGCTCACTG CGCCAGACGG TCGTCCGCCT GGAGCTCGAG GACGAGTGGC AGTTCCGGCT 2880 GCGCGATGAG TTCCAGACCG CCAATGCCAG GGAAGACCGG CCGCTCTTTT TTCTGACGGG 2940 ACGACACATC J___GGAAGAC AGCGGCGAGT TTTCTGAAGA GATGAGTGCT CAGAGCCCTC 3000 ATGCTGTTGA GGCTAAAGGG AGGCCTGGAA CGGTGGGGCG TTTGACTGGA ATGGACCCCA 3060 GGGACTGTCC AGGTGCAGCC CCTCCTAGTA CACATGGGCC CCCGAGGCCG TGGTCCTGGG 3120 5 AGCCAGGAAG ACTCCGCAGT GGGTGAGAAT GAAAACTTGA GACTCCCAAG TTCTGGGCCA 3180 GCCCATTGCT CTGGGCTGTT TTAAAGCCCA TTTCACGAGG AACAAAGATT TACTTCCTGT 3240 CCTGCCATTC GTGTGCTTCC ATGGACAAAC CTGATTTTTT TCTCTTAGTT CTAAAGAATC 3300 TTGGGTTATT TTGTAGCGGT GCCAGTATTT CAGTAGATGG GATTTCAGCC AAGTAGGTTC 3360 CCCTGTAACC TCCTACAAAG CAATATTCCA AAGGAACATT TTAACTGTAA AGGCTGGAGA 3420 10 CAAGAAAAAA TAAGTAGATC GTTTTAATAA CAATTATTTA ATTGCCTATA AGTTTGCTGT 3480 TTCAGAGGCT AGCCCAAAGG CATCAAATTT AATAAAGTTA AACAAATTGA TTTACTTCAG 3540 AGCAAATATG ATCCTATTAA AATAATATAG GGTAAATACC CTACCTCTTA GAAAGGGCAA 3600 AAATGCAAAG AAGCTTTCTT TAAAACTAAA AGGGTTTTTT GGGGGGGGAG TTGGCGGGGA 3660 GGAAATAAGG CTAACAGAGG TTGACCTAAA ATTAGCCTTA CAAAGGAGAA AGGACCACAT 3720 15 TGCTTACTTG AAAC AGACAA TG AAAACA AC CAAAGTGATA TATAAAATAG TTGATG AGAA 3780 CTAGACTTAT GACTGTAGTT TACTAGAGTT TAGTTTTCAG TTGCTGAAGT AGCTCATTTT 3840 CTCTTACTAA TGTTTGGTTC CTCAGGGAAG AATCTCACTT GACTAGAGAG GAGGTGGGAA 3900 CAGAAGAGAG AAGGAGGCAG GGAGATGTAT TTCTTAGGGC TCACCCCTTC ACAGACTGAC 3960 AGAATGGTTT TGTπTGTTT TGTTTTGTTT TGTTTTGTTT TTGAGATGGA CTCTAGCTCT 4020 20 GTCACCCAGG CTGGAGTGCA GTGGTGCGAT CTCGGCTCAC TGCAAGCTCC GCCTCCCGGG 4080 TTCTCACCAT TCTCCTGCCT CAGCCTCCCG AGTAGCTGGG ACTACAGGCG CCCACCACCA 4140 CGCCCGGCTA ATTTTTTGTA TTTTTTAGTA GAGACGGGGT TTCACCATGT TAGCCAGGAT 4200 GGTCTCGATC TCCTGACCTC GTGATCCGCC CGCCTCGGCC TCCCAAAGTG CTGGGATTAC 4260 AGGCGTGAGC CACCGTGCCT GCCCCAGAAT GGTTTTTAAA GCCACAGTTG AGAGGCCACC 4320 25 CATTGCCCGG CGCCTGGACA GTGATCATCT TGTTCATCTT GTTCAGTCCT TTCTTGTGTG 4380 ATTGGAATTA TTCATCCCCT TTGAAAGATG AGAAGGTTGA GATGCAAAGA GTCTACCTTT 4440 CCAAGTTCTC ACTGCTGGAA AGAGCTAGAA GCACAGTTCA AAGTTCTGGC TTCTGGACTC 4500 TGCAGTCCAG GTCTCCCTTC TCCCACTTGC CTACCCTCAA TGCCACACTG TTTTTGAAGT 4560 GGCCCATAAC TTGAAGGAAA AGTTTAAAGA CAGTTCAATT TAATCATCAG AATGCATTCT 4620 30 TTTTTTTTTC GGAGACGGAG TTTCACTCTT GCTGCCCAGG CTGGAGTGCA ATGGTGCAAT 4680 GATCTCGGCT CACTGCAACC TCTGCCTCCT GGGTTCAAGT GATTCTCCAG CCTCAGCCTC 4740 CCGAGTAGCT GGGATTATGG GCGCCCACCA CCATGCCCAG CTAATTTTTG TATTTTTTTT 4800 TTTTAGTAGA GATGGGGTTT CGCCAGGTTG GCCAGGCTGG TCTTGTGAAC TCCTGGCCTC 4860 AGGTGATCTG CCCACCTCAT CCTCCAAAAG TGCTGGGATT ACAGGCATGA GCCACTGCGC 4920 35 CTGGCCTCAG AATGCATTCT TACACATCTA TCCTAGACAT TTATAAGCAC TCTAATGGAT 4980 AACAATCCAA GAATAAATGA TTGTAAAAGA TGATGCCGAA GAGTTGATGT CAATCTTTTT 5040 TTCCTAAGAA AAAAAGTCCG CGAGTATTAA ATATTTAGAT CAATGTTTAT AAAATGATTA 5100 CTTTGTATAT CTCATTATTC CTATTTTGGA ATAAAAACTG ACCTTCTTTA ATCATATACT 5160 TGTCTTTTGT AAATAGCAGC TTTTGTGTCA TTCTCCCCAC TTTATTAGTT AATTTAAATT 5220 40 GGAAAAAACC CTCAAACTAA TATTCTTGTC TGTTCCAGTC TTATAAATAA AACTTATAAT 5280 GCATG 45 SEQ ID NO:154 PFD6 Protein sequence: Protein Accession* NP_055483.1 1 11 21 31 41 51 <n I I I I I I 5U MWQKIED\ΕW RPQTYLELEG U<:iLIFSGM DPHGKLPRS IJlYCDLRLIN SSCLVRTALE 60 QELGLAAYFV SNEVPLEKGA RNEALESDAE KLSSTDNEDE ELGTEGSTSE KRSPMKRERS 120 RSHDSASSSL SSKASGSALG GESSAQPTAL PQGEHARSPQ PRGPAEEGRA PGEKQRPRAS 180 QGPPSAISRH SPGPTPQPDC SLRTGQRSVQ VSVTSSCSQL SSSSGSSSSS VAPAAGTWVL 240 QASQCSLTKA CRQPPIVFLP KLVYDMV VST DSSGLPKAAS LLPSPS VMWA SSFRPLLSKT 300 55 MTSTEQSLYY RQWTVPRPSH MDYGNRAEGR VDGFHPRRLL SGPPQIGKTGAYLQFLSVL 360 SRMLVRLTEV DVYDEEEINI NLREESDWHY LQLSDPWPDL ELFKKLPFDY -OHDPKYEDA 420 SLICSHYQGI KSEDRGMSRK PEDLYVRRQT ARMRLSKYAA YNTYHHCEQC HQYMGFHPRY 480 QLYESTLHAF AFSYSMLGEE IQLHFIIPKS KEHHFVFSQP GGQLESMRLP LVTDKSHEYI 540 KSPTFTPTTG RHEHGLFNLY HAMDGASHLH VLVVKEYEMA rYKKYWPNHI MLVLPSIFNS 600 60 AGVGAAHFLI KELSYHNLELERNRQEELGI KPQDIWPFIV ISDDSCVMWN VVDVNSAGER 660 SREFSWSERN VSLKHIMQHI EAAPDIMHYA LLGLRKWSSK TRASEVQEPF SRCHVHNFH 720 LNVDLTQNVQ YNQNRFLCDD VDFNLRVHSA GLLLCRFNRF SVMKKQIVVG GHRSFHITSK 780 VSDNSAAWP AQYICAPDSK HTFLAAPAQL LLEKFLQHHS HLFFPLSLKN HDHPVLSVDC 840 YLNLGSQISV CYVSSRPHSL NISCSDLLFS GLLLYLCDSF VGASFLKKFH FLKGATLCVI 900 65 CQDRSSLRQT VVRLELEDEW QFRLRDEFQT ANAREDRPLF FLTGRHI SEQ ID NO:155 PFC6 DNA SEQUENCE Nucleic Acid Accession*: NM_000522 70 Coding sequence: 1-1167 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I „_. i_ieACAGCCT CCGTGCTCCT CCACCCCCGC TGGATCGAGC CCACCGTCAT GTTTCTCTAC 60 75 GACAACGGCG GCGGCCTGGT GGCCGACGAG CTCAACAAGA ACATGGAAGG GGCGGCGGCG 120 GCTGCAGCAG CGGCTGCAGC GGCGGCGGCT GCCGGGGCCG GGGGCGGGGG CTTCCCCCAC 180 CCGGCGGCTG CGGCGGCAGG GGGCAACTTC TCGGTGGCGG CCGCGGCCGC GGCTGCGGCG 240 GCCGCCGCGG CCAACCAGTG CCGCAACCTG ATGGCGCACC CGGCGCCCTT GGCGCCAGGA 300 GCCGCGTCCG CCTACAGCAG CGCCCCCGGG GAGGCGCCCC CGTCGGCTGC CGCCGCTGCT 360 GCCGCGGCTG CCGCTGCAGC CGCCGCCGCC GCCGCCGCGT CGTCCTCGGG AGGTCCCGGC 420 CCGGCGGGCC CGGCGGCGGC AGAGGCGGCC AAGCAATGCA GCCCCTGCTC GGCAGCGGCG 480 CAGAGCTCGT CGGGGCCCGC GGCGCTGCCC TATGGCTACT TCGGCAGCGG CTACTACCCG 540 TGCGCCCGCA TGGGCCCGCC CCCCAACGCC ATCAAGTCGTGCCCCCAGCC CCCCTCGGCC 600 GCCGCCGCCG CCGCCTTCGC GGACAAGTAC ATGGATACCG CCGGCCCAGC TGCCGAGGAG 660 TTCAGCTCCC GCGCTAAGGA GTTCGCGTTC TACCACCAGG GCTACGCAGC CGGGCCTTAC 720 CACCACCATC AGCCCATGCC TGGCTACCTG GATATGCCAG TGGTGCCGGG CCTCGGGGGC 780 CCCGGCGAGT CGCGCCACGA ACCCTTGGGT CTTCCCATGG AAAGCTACCA GCCCTGGGCG 840 CTGCCCAACG GCTGGAACGG CCAAATGTAC TGCCCCAAAG AGCAGGCGCA GCCTCCCCAC 900 CTCTGGAAGTCCACTCTGCC CGACGTGGTC TCCCATCCCTCGGATGCCAG CTCCTATAGG 960 AGGGGGAGAA AGAAGCGCGT GCCTTATACC AAGGTGCAAT TAAAAGAACT TGAACGGGAA 1020 TACGCCACGA ATAAATTCAT TACTAAGGAC AAACGGAGGC GGATATCAGC CACGACGAAT 1080 CTCTCTGAGC GGCAGGTCAC AATCTGGTTC CAGAACAGGA GGGTTAAAGA GAAAAAAGTC 1140 ATCAACAAAC TGAAAACCAC TAGTTAA SEQ ID NO:156 PFC6 Protein sequence: Protein Accession * NP M0513.1 1 11 21 31 41 51 I I I I I I MTASVLLHPR WIEPTVMFLY DNGGGLVADE LNKNMEGAAA AAAAAAAAAA AGAGGGGFPH 60 PAAAAAGGNF SVAAAAAAAA AAAANQCRNL MAHPAPLAPG AASAYSSAPG EAPPSAAAAA 120 AAAAAAAAAA AAASSSGGPG PAGPAAAEAA KQCSPCSAAA QSSSGPAALP YGYFGSGYYP 180 CARMGPPPNA IKSCPQPPSA AAAAAFADKY DTAGPAAEEFSSRAKEFAF YHQGYAAGPY 240 HHHQPMPGYL DMP PGLGG PGESRHEPLG LPMESYQPWA LPNGWNGQMY CPKEQAQPPH 300 LWKSTLPDW SHPSDASSYR RGRKKRVPYT KVQLKELERE YATNKHTKD KRRRISATTN 360 LSERQVTIWF QNRRVKEKKV -NKLKTTS SEQ ID N0:157 PFA3 DNA SEQUENCE Nucleic Acid Accession * AW102723 Coding sequence: 523-2676 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I CCCTTATGGC GATTGGGCGG CTGCAGAGAC CAGGACTCAG TTCCCCTGCC CTAGTCTGAG 60 CCTAGTGGGT GGGACTCAGC TCAGAGTCAG TTTTCAGAAG CAGGTTTCAG TTGCAGAGTT 120 TTCCTACACT TTTCCTGCGC TAGAGCAGCG AGCAGCCTGG AACAGACCCA GGCGGAGGAC 180 ACCTGTGGGG GAGGGAGCGC CTGGAGGAGC TTAGAGACCC CAGCCGGGCG TGATCTCACC 240 ATGTGCGGAT TTGCGAGGCG CGCCCTGGAG CTGCTAGAGA TCCGGAAGCA CAGCCCCGAG 300 GTGTGCGAAG CCACCAAGAC TGCGGCTCTT GGAGAAAGCG TGAGCAGGGG GCCACCGCGG 360 TCTCCGGCCTGTCTGCACCC TGTCGCCTGA GCTGCCTGAC AGTGACAATG ACATCCCAGT 420 TACCAGTGTC CTTGAATTGA TAGTGGCTTC TGTTTGTCAG TCTCATATAA GAACTACAGC 480 TCATCAGGAG GAGATCGCAG CAGGGTAAGA GACACCAACA CCATGTTCTG CACGAAGCTC 540 AAGGATCTCA AGATCACAGG AGAGTGTCCT TTCTCCTTAC TGGCACCAGG TCAAGTTCCT 600 AACGAGTCTT CAGAGGAGGC AGCAGGAAGC TCAGAGAGCT GCAAAGCAAC CGTGCCCATC 660 TGTCAAGACA TTCCTGAGAA GAACATACAA GAAAGTCTTC CTCAAAGAAA AACCAGTCGG 720 AGCCGAGTCTATCTTCACAC TTTGGCAGAG AGTATTTGCAAACTGATTTT CCCAGAGTTT 780 GAACGGCTGA ATGTTGCACT TCAGAGAACA TTGGCAAAGC ACAAAATAAA AGAAAGCAGG 840 AAATCTTTGG AAAGAGAAGA CTTTGAAAAA ACAATTGCAG AGCAAGCAGT GCAGCAGAGT 900 CCAGTGGAGT TATCAAAGAA TCTCTTGGTG AAGAGGTTTT TAAAATATGT TACGAGGAAG 960 ATG AAAAC AT CCTTGGGGTG GTTGGAGGCA CCCTTAAAGA TTTTTAAACA GCTTCAGTAC 1020 CCTTCTGAAA CAGAGCAGCC ATTGCCAAGA AGCAGGAAAA AGGGGCAGCT TGAGGACGCC 1080 TCCATTCTAT GCCTGG ATAA GGAGGATGAT TTTCTACATG TTTACTACTT CTTCCCTAAG 1140 AGAACCACCT CCCTGATTCT TCCCGGCATC ATAAAGGCAG CTGCTCACGT ATTATATGAA 1200 ACGGAAGTGG AAGTGTCGTT AATGCCTCCC TGCTTCCATA ATGATTGCAG CGAGTTTGTG 1260 AATCAGCCCTACTTGTTGTA CTCCGTTCAC ATGAAAAGCA CCAAGCCATC CCTGTCCCCC 1320 AGCAAACCCC AGTCCTCGCT GGTGATTCCC ACATCGCTATTCTGCAAGAC ATTTCCATTC 1380 CATTTCATGT TTGACAAAGA TATGACAATT CTGCAATTTG GCAATGGCAT CAGAAGGCTG 1440 ATGAACAGGA GAGACTTTCA AGGAAAGCCT AATTTTGAAT ACTTTGAAAT TCTGACTCCA 1500 AAAATCAACC AGACCTTTAG CGGGATCATG ACTATGTTGA ATATGCAGTT TGTTGTACGA 1560 GTGAGGAGATGGGACAACTC TGTGAAGAAA TCTTCAAGGG TTATGGACCT CAAAGGCCAA 1620 ATGATCTACA TTGTTGAATC CAGTGCAATC TTGTTTTTGG GGTCACCCTG TGTGGACAGA 1680 TTAGAAGATT TTACAGGACG AGGGCTCTAC CTCTCAGACA TCCCAATTCA CAATGCACTG 1740 AGGGATGTGG TCTTAATAGG GGAACAAGCC CGAGCTCAAG ATGGCCTGAA GAAGAGGCTG 1800 GGGAAGCTGA AGGCTACCCT TG AGCAAGCC CACCAAGCCC TGGAGGAGGA GAAG AAAAAG 1860 ACAGTAGACC TTCTGTGCTC CATATTTCCC TGTGAGGTTG CTCAGCAGC GTGGCAAGGG 1920 CAAGTTGTGC AAGCCAAGAA GTTCAGTAAT GTCACCATGC TCTTCTCAGA CATCGTTGGG 1980 TTCACTGCCA TCTGCTCCCA GTGCTCACCG CTGCAGGTCA TCACCATGCT CAATGCACTG 2040 TACACTCGCT TCGACGAGCA GTGTGGAGAG CTGGATGTCT ACAAGGTGGA GACCATTGCG 2100 ATGCCTATTG TGTGGCTTGG GGGATTACAC AAAGAGAGTG ATACTCATGC TGTTCAGATA 2160 GCGCTGATGG CCCTGAAGAT G ATGG AGCTC TCTG ATGAAG TTATGTCTCC CCATGGAG AA 2220 CCTATCAAGA TGCGAATTGG ACTGCACTCT GGATCAGTTT TTGCTGGCGT CGTTGGAGTT 2280 AAAATGCCCC GTTACTGTCT TTTTGGAAAC AATGTCACTC TGGCTAACAA ATTTGAGTCC 2340 TGCAGTGTAC CACGAAAAAT CAATGTCAGC CCAACAACTT ACAGATTACT CAAAGACTGT 2400 CCTGGTTTCG TGTTTACCCC TCGATCAAGG GAGGAACTTC CACCAAACTT CCCTAGTGAA 2460 ATCCCCGGAA TCTGCCATTT TCTGGATGCT TACCAACAAG GAACAAACTC AAAACCATGC 2520 TTCCAAAAGA AAGATGTGGA AGATGCAAGC CAATTTTTTA GGCAAAGCAT CAGGAATAGA 2580 TTAGCAACCT ATATACCTAT TTATAAGTCT TTGGGGTTTG ACTCATTGAA GATGTGTAGA 2640 GCCTCTGAAA GCACTTTAGG GATTGTAGAT GGCTAACAAG CAGTATTAAA ATTTCAGGAG 2700 CCAAGTCACA ATCTTTCTCC TGTTTAACAT GACAAAATGT ACTCACTTCA GTACTTCAGC 2760 TCTTCAAGAA AAAAAAAAAA ACCTTAAAAA GCTACTTTTG TGGGAGTATT TCTATTATAT 2820 AACCAGCACT TACTACCTGT ACTCAAAATT CAGCACCTTG TACATATATC AGATAATTGT 2880 AGTCAATTGT ACAAACTGAT GGAGTCACCT GCAATCTCAT ATCCTGGTGG AATGCCATGG 2940 TTATTAAAGT GTGTTTGTGA TAGTTGTCGT CAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 3000 AAAA SEQ ID NO.-158 PFA3 Protein sequence: Protein Accession * NP.000847.1 1 11 21 31 41 51 I I I I I I MFCTKLKDLK UGECPFSLL APGQVPNESS EEAAGSSESC KATVPICQDI PEKNIQESLP 60 QRKTSRSRVY LHTLAESICKLIFPEFERLN VALQRTLAKH KIKESRKSLEREDFEKTIAE 120 QAVQQSPVELSKNLLVKRFLKYVTRKMKTS LGWLEAPLKIFKQLQYPSETEQPLPRSRKK 180 GQLEDASILC IJ ) KEDDI1XIV YYFFPKRTTS ILPGΠKAA AHVLYETEVE VSLMPPCFHN 240 DCSEFVNQPY LLYSVHMKST KPSLSPSKPQ SSLVIPTSLF CKTFPFHFMF DKDMTTLQFG 300 NGIRRLMNRR DFQGKPNEEY FEILTPKINQ TFSGIMTMLN MQFWRVRRW DNSVKKSSRV 360 MDLKGQMIYIVESSAILFLG SPCVDRLEDFTGRGLYLSDIPIHNALRDVV LIGEQARAQD 420 GLKKRLGKLKATLEQAHQALEEEKKKTVDLLCSIFPCEVA QQLW<2GQVVQAKKFSNVTML 480 FSDIVGFTAI CSQCSPLQVI TMLNALYTRF DQQCGELD VY KVETIAMPIV WLGGLHKESD 540 THAVQIALMA LKMMELSDEV MSPHGEPIKM RIGLHSGSVF AGVVGVKMPR YCLFGNNVTL 600 ANKFESCSVP RKINVSPTTY RLLKDCPGFV FTPRSREELP PNFPSEIPGI CHFLDAYQQG 660 TNSKPCFQKK DVEDASQFFR QSIRNRLATY IPIYKSLGFD SLKMCRASES TLGIVDG SEQ ID NO:159 PFA1 DNA SEQUENCE Nucleic Acid Accession *: N JM4362 Coding sequence: 102-1934 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I CGCCGGCGGG ACTGGTCTGA AGAGACGCGG GGACAAAGTG GCAACGACTT GGACATCTGA 60 GCTGTCACTG CCGAAAACAG GCCGCAAGAG AGATAATCAA TATGCATTTC CAAGCCTTTT 120 GGCTATGTTT GGGTCTTCTG TTCATCTCAA TTAATGCAGA ATTTATGGAT GATGATGTTG 180 AGACGGAAGA CTTTGAAGAA AATTCAGAAG AAATTGATGT TAATGAAAGT GAACTTTCCT 240 CAGAGATTAA ATATAAGACA CCTCAACCTA TAGGAGAAGT ATATTTTGCA GAAACTTTTG 300 ATAGTGGAAG GTTGGCTGGA TGGGTCTTAT CAAAAGCAAA GAAAGATGAC ATGGATGAGG 360 AAATTTCAAT ATACGATGGAAGATGGGAAA TTGAAGAGTTGAAAGAAAAC CAGGTACCTG 420 GTGACAGAGG ACTGGTATTA AAATCTAGAG CAAAGCATCA TGCAATATCT GCTGTATTAG 480 CAAAACCATT CATTTTTGCT GATAAACCCT TGATAGTTCA ATATGAAGTA AATTTTCAAG 540 ATGGTATTGA TTGTGGAGGT GCATACATTA AACTCCTAGC AGACACTGAT GATTTGATTC 600 TGGAAAACTT TTATGATAAA ACATCCTATA TCATTATGTT TGGACCAGAT AAATGTGGAG 660 AAGATTATAA ACTTCATTTT ATCTTCAGAC ATAAACATCC CAAAACTGGA GTΠTCGAAG 720 AGAAACATGC CAAACCTCCA GATGTAGACCTTAAAAAGTTCTTTACAGAC AGGAAGACTC 780 ATCTTTATAC CCTTGTGATG AATCCAGATG ACACATTTGA GGTGTTAGTT GATCAAACAG 840 TΓGTAAACAA AGGAAGCCTC CTAGAGGATG TGGTTCCTCC TATCAAACCT CCCAAAGAAA 900 TTGAAGATCC CAATGATAAA AAACCTGAGG AATGGGATGA AAGAGCAAAA ATTCCTGATC 960 CTTCTGCCGT CAAACCAGAA GACTGGGATG AAAGTGAACC TGCCCAAATA GAAGATTCAA 1020 GTGTTGTTAA ACCTGCTGGCTGGCTTGATGATGAACCAAA ATTTATCCCTGATCCTAATG 1080 CTGAAAAACC TGATGACTGG AATGAAGACA CGGATGGAGA ATGGGAGGCA CCTCAGATTC 1140 TTAATCCAGC ATGTCGGATT GGGTGTGGTG AGTGGAAACC TCCCATGATA GATAACCCAA 1200 AATACAAAGG AGTATGGAGA CCTCCACTGG TCGATAATCC TAACTATCAG GGAATCTGGA 1260 GTCCTCGAAA AATTCCTAATCCAGATTATTTCGAAGATGA TCATCCATTTCTTCTGACTT 1320 CITrCAGTGCTCTTGGTTTA GAGCTTTGGTCTATGACCTC TGATATC ACTTTGATAATT 1380 TTATTATCTG TTCGGAAAAG GAAGTAGCAG ATCACTGGGC TGCAGATGGT TGGAGATGGA 1440 AAATAATGAT AGCAAATGCT AATAAGCCTG GTGTATTAAA ACAGTTAATG GCAGCTGCTG 1500 AAGGGCACCC ATGGCTTTGG TTGATTTATC TTGTGACAGC AGGAGTGCCA ATAGCATTAA 1560 TTACTTCATT TTGTTGGCCA AGAAAAGTAA AGAAAAAACA TAAAGATACA GAGTATAAAA 1620 AAACCGACAT ATGTATACCA CAAACAAAAG GAGTACTAGA GCAAGAAGAA AAGGAAGAGA 1680 AAGCAGCCCT GGAAAAACCA ATGGACCTGG AAGAGGAAAA AAAGCAAAAT GATGGTGAAA 1740 TGCTTGAAAA AGAAGAGGAA AGTGAACCTG AGGAAAAGAG TGAAGAAGAA ATTGAAATCA 1800 TAGAAGGGCA AGAAGAAAGT AATCAATCAA ATAAGTCTGG GTCAGAGGAT GAGATGAAAG 1860 AAGCAGATGA GAGCACAGGA TCTGGAGATG GGCCGATAAA GTCAGTACGC AAAAGAAGAG 1920 TACGAAAGGA CT__\ACTAGA TTGAAATATT TTTAATTCCCGAGAGGATGTTTGGCATTGT 1980 AAAAATCAGC ATGCCAGACC TGAACTTTAA TCAGTCTGCA CATCCTGTTT CTAATATCTA 2040 GCAACATTAT ATTCTTTCAG ACATTTATTT TAGTCCTTCA TTTCCGAGGA AAAAGAAGCA 2100 ACTTTGAAGT TACCTCATCT TTGAATTTAG AATAAAAGTG GCACATTACA TATCGGATCT 2160 AAGAGATTAATACCATTAGA AGTTACACAGTTTTAGTTGTTTGGAGATAGTTTTGGTTTG 2220 TACAGAACAA AATAATATGT AGCAGCTTCA TTGCTATTGG AAAAATCAGT TATTGGAATT 2280 TCCACTTAAA TGGCTATACA ACAATATAAC TGGTAGTTCT ATAATAAAAA TGAGCATATG 2340 TTCTGTTGTG AAGAGCTAAA TGCAATAAAG TTTCTGTATG GTTGTTTGAT TCTATCAACA 2400 ATTGAAAGTG TTGTATATGA CCCACATTTA CCTAGTTTGT GTCAAATTAT AGTTACAGTG 2460 AGTTGTTTGC TTAAATTATA GATTCCTTTA AGGACATGCC TTGTTCATAA AATCACTGGA 2520 TTATATTGCA GCATATTTTA CATTTGAATA CAAGGATAAT GGGTTTTATC AAAACAAAAT 2580 GATGTACAGA TTTTTTTTCA AGTTTTTATA GTTGCTTTAT GCCAGAGTGG TTTACCCCAT 2640 TCACAAAATT TCTTATGCAT ACATTGCTAT TGAAAATAAA ATTTAAATAT TTTTTCATCC 2700 TGAAAAAAAA SEQ ID NO:160PFA1 Protein sequence: Protein Accession* NP M4353.1 10 1 11 21 31 41 51 I I I I I I MHFQAFWLCL GLLFISINAE FMDDDVETED FEENSEEIDV NESELSSEIK YKTPQPIGEV 60 YFAETEDSGR LAGWVLSKAK KDDMDEEISI YDGRWEIEEL KENQVPGDRG LVLKSRAKHH 120 AISAVLAKPF BFADKPLIVQ YEVNFQDGID CGGAYIKLLA DTDDLILENF YDKTSYIIMF 180 15 GPDKCGEDYK LHFiraHKHP KTGVFEEKHA KPPDVDLKKFFTDRKTHLYT LVMNPDDTFE 240 VLVDQTVVNK GSLLEDVVPP IKPPKEIEDP NDKKPEEWDE RAKIPDPSAV KPEDWDESEP 300 AQIEDSSVVK PAGWLDDEPK F-PDPNAEKP DDWNEDTDGE WEAPQILNPA CRIGCGEWKP 360 PMIDNPKYKG VWRPPLVDNP NYQGIWSPRK IPNPDYFEDD HPFLLTSFSA LGLELWSMTS 420 DIYFDNHIC SEKEVADHWA ADGWRWKIMI ANANKPGVLK QLMAAAEGHP WLWLIYLVTA 480 20 GVPIAUTSFCWPRKVKKKH KDTEYKKTDI CIPQTKGVLE QEEKEEKAAL EKPMDLEEEK 540 KQNDGEMLEK EEESEPEEKS EEEIEIIEGQ EESNQSNKSG SEDEMKEADE STGSGDGPIK 600 SVRKRRVRKD 25 SEQ ID N0.161 PEZ9 DNA SEQUENCE Nucleic Acid Accession * NM_005932 Coding sequence: 75-2216 (underlined sequences correspond to start and stop codons) Λ Λ 1 11 21 31 41 51 30 I i I i i i GCGGAGCGCG CGCTCCCAGC GAAAGCAGCA GGGCAGGGAT CTGCGTTGGA GGAAGGGACT 60 GCTCTGGTGC TAGAATGCTG TGCGTCGGAA GGCTGGGCGG CTTGGGAGCC AGAGCAGCAG 120 CTCTGCCGCC CCGCCGGGCG GGCCGGGGAA GCCTCGAAGC CGGGATCCGG GCCCGAAGGG 180 TCAGCACCAG CTGGTCTCCC GTGGGCGCCG CCTTCAATGT CAAGCCCCAG GGCAGCCGCT 240 35 TGG ACCTGTT CGGCGAGCGG GCGCGTCTTT TTGGAGTTCC TGAGCTGAGT GCCCCAGAAG 300 GATTTCATAT TGCACAAGAA AAAGCCTTGA GAAAGACAGA ATTGCTTGTG GACCGTGCAT 360 GTTCCACCCC ACCTGGGCCC CAGACCGTGC TGATCTTCGA TGAGCTCTCG GATTCCTTAT 420 GCAGAGTGGC CGACTTGGCT GATTTTGTGA AAATCGCTCA CCCTGAGCCA GCATTCAGAG 480 AAGCTGCGGA AGAAGCTTGT AGAAGTATTG GCACCATGGT AGAGAAGTTG AACACAAATG 540 40 TGGATTTATA TCAAAGTTTG CAAAAATTAC TAGCTGATAA AAAACTTGTG GATTCCCTTG 600 ATCCAGAAAC AAGGCGAGTG GCTGAACTGT TTATGTTTGA TTTTGAAATT AGTGGAATCC 660 ATCTAGACAA ACAAAAGCGT AAAAGAGCAG TGGACCTCAA TGTTAAAATC TTGGATTTGA 720 GTAGTACATT TCTTATGGGA ACCAATTTTC CCAACAAGAT TGAGAAGCAT CTCTTACCAG 780 AACACATTCG TCGTAACTTT ACATCTGCTG GGGATCATAT CATAATTGAT GGTCTCCACG 840 45 CAGAATCACC AGATGACTTG GTGCGAGAAG CTGCTTATAA AATΓTTTCTTTATCCCAATG 900 CTGGTCAATT GAAATGTTTA GAAGAATTGC TCAGCAGCAG AGATCTTCTG GCAAAGTTGG 960 TGGGGTATTC CACGTTTTCT CACAGGGCTC TCCAAGGAAC GATAGCTAAA AATCCAGAGA 1020 CTGTCATGCA GTTCCTTGAA AAACTATCTG ACAAACTTTC TGAAAGAACT CTGAAAGATT 1080 TTGAGATGAT ACGAGGGATG AAAATGAAAC TGAATGCTCA AAATTCCGAA GTAATGCCCT 1140 50 GGGACCCCCCTTACTACAGTGGTGTGATTC GTGCAGAAAG GTATAATATT GAGCCCAGCC 1200 TATATTGCCC GTTTTTCTCT CTTGGAGCAT GCATGGAAGG CCTGAATATT TTGCTTAACA 1260 GACTGTTGGG GATTTCATTA TATGCAGAGC AGCCTGCAAA AGGAGAGGTG TGGAGCGAAG 1320 ATGTCCGAAA ACTGGCTGTT GTTCATGAAT CTGAAGGATT GTTGGGGTAC ATTTACTGTG 1380 ATTTTTTTCA GCGAGCAGAC AAACCACATC AGGATTGCCA TTTCACTATC CGTGGAGGCA 1440 55 GACTAAAGGA AGATGGAGAC TATCAACTCC CACTTGTAGT TCTTATGCTG AATCTTCCCC 1500 GTTCCTCAAG GAGTTCTCCA ACTTTGCTAA CTCCTGGCAT GATGGAAAAT CTTTTCCATG 1560 AAATGGGACA TGCCATGCAT TCAATGCTAG GACGTACTCG TTACCAACAC GTCACTGGGA 1620 CCAGGTGCCC TACTGATTTT GCTGAGGTTC CTTCTATTCT GATGGAGTAC TTTGCAAATG 1680 ATTATCGAGT AGTTAACCAA TTTGCCAGAC ATTATCAGAC TGGACAGCCA CTGCCAAAAA 1740 60 ATATGGTGTC TCGTCTTTGT GAATCTAAAA AGGTTTGTGC TGCAGCTGAT ATGCAACTTC 1800 AGGTCπTTA TGCCACTCTG GATCAAATCT ACCATGGGAA GCATCCCCTG AGGAATTCAA 1860 CCACAGACAT TCTCAAGGAA ACACAAGAGA AATTCTATGG CCTACCATAT GTTCCAAATA 1920 CTGCCTGGCA GCTGCGATTC AGCCACCTCG TGGGGTATGG TGCTAGATAT TACTCTTACC 1980 TCATGTCCAG AGCGGTCGCC TCCATGGTTT GGAAGGAGTG TTTTCTACAG GATCCTTTCA 2040 65 ACAGGGCTGC CGGGGAGCGC TATCGCAGGG AGATGCTGGC CCACGGTGGA GGCAGGGAGC 2100 CCATGCTCAT GGTTGAAGGT ATGCTTCAGA AGTGTCCTTC TGTTGATGAC TTCGTAAGTG 2160 CCCTCGTTTC CGACTTGGAT CTGGACTTCG AAACTTTCCT CATGGATTCT GAATAAAAGA 2220 AACACTCTAC ACCTCTAATC AAGGTCATGT AGTAATGACT TTGTTATAAA TGCTACAGCT 2280 GTGAGAGCTT GTTTCTGATT GTTTCATTGT TCGCTTCTGT AATTCTGAAA AACTTTAAAC 2340 70 TGGTAGAACT TGGAATAAAT AATTTGTTTT AATTAAAAAA AAAAAAAAAA AA SEQ ID NO:162 PEZ9 Protein spn.ifiry-e: Protein Accession* NP_005923.1 75 1 11 21 31 41 51 I I I I I I MLCVGRLGGL GARAAALPPR RAGRGSLEAG IRARRVSTSW SPVGAAFNVK PQGSRLDLFG 60 ERARLFGVPE LSAPEGFHIA QEKALRKTEL LVDRACSTPP GPQTVLIFDE LSDSLCRVAD 120 LADFVKIAHP EPAFREAAEE ACRSIGTMVE KLNTNVDLYQ SLQKLLADKK LVDSLDPETR 180 RVAELFMFDF EISGIHLDKQ KRKRAVDLNV KILDLSSTFL MGTNFPNKIE KHLLPEHKR 240 NFTSAGDHII IDGLHAESPD DLVREAAYKI FLYPNAGQLK CLEELLSSRD LLAKLVGYST 300 FSHRALQGTIAKNPETVMQFLEKLSDKLSERTLKDFEMIR GMKMKLNAQN SEVMPWDPPY 360 YSGVIRAERY NIEPSLYCPFFSLGACMEGLNILLNRLLGISLYAEQPAKG EVWSEDVRKL 420 AVVHESEGLL GYIYCDFFQR ADKPHQDCHF TIRGGRLKED GDYQLPLVVL MLNLPRSSRS 480 SPTLLTPGMM ENLFHEMGHA MHSMLGRTRY QHVTGTRCPT DFAEVPSILM EYFANDYRVV 540 NQFARHYQTG QPLPKNMVSR LCESKKVCAA ADMQLQVFYA TLDQIYHGKH PLRNSTTDIL 600 KETQEKFYGL PYVPNTAWQL RFSHLVGYGA RYYSYLMSRA VASMVWKECF LQDPFNRAAG 660 ERYRREMLAH GGGREPMLMV EGMLQKCPSV DDFVS ALVSD LDLDFETFLM DSE SEQ ID NO:163 PEZ8 DNA SEQUENCE Nucleic Acid Accession* AF103907 Coding sequence: none (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I ACAGAAGAAA TAGCAAGTGCCGAGAAGCTG GCATCAGAAAAACAGAGGGG AGATTTGTGT 60 GGCTGCAGCC GAGGGAGACC AGGAAGATCT GCATGGTGGG AAGGACCTGA TGATACAGAG 120 GAATTACAAC ACATATACTT AGTGTTTCAA TGAACACCAA GATAAATAAG TGAAGAGCTA 180 GTCCGCTGTG AGTCTCCTCA GTGACACAGG GCTGGATCAC CATCGACGGC ACTTTCTGAG 240 TACTCAGTGC AGCAAAGAAA GACTACAGAC ATCTCAATGG CAGGGGTGAG AAATAAGAAA 300 GGCTGCTGACTTTACCATCTGAGGCCACAC ATCTGCTGAAATGGAGATAA TTAACATCAC 360 TAGAAACAGC AAGATGACAA TATAATGTCT AAGTAGTGAC ATGTTTTTGC ACATTTCCAG 420 CCCCTTTAAA TATCCACACA CACAGGAAGC ACAAAAGGAA GCACAGAGAT CCCTGGGAGA 480 AATGCCCGGC CGCCATCTTG GGTCATCGAT GAGCCTCGCC CTGTGCCTGG TCCCGCTTGT 540 GAGGGAAGGA CATT AG AAAA TGAATTGATG TGTTCCTTAA AGGATGGGCA GGAAAACAGA 600 TCCTGTTGTGGATATTTATTTGAACGGGATTACAGATTTGAAATGAAGTC ACAAAGTGAG 660 CATTACCAAT GAGAGGAAAA CAGACGAGAA AATCTTGATG GCTTCACAAG ACATGCAACA 720 AACAAAATGG AATACTGTGA TGACATGAGG CAGCCAAGCT GGGGAGGAGA TAACCACGGG 780 GCAGAGGGTC AGGATTCTGG CCCTGCTGCC TAAACTGTGC GTTCATAACC AAATCATTTC 840 ATATTTCTAACCCTCAAAAC AAAGCTGTTG TAATATCTGATCTCTACGGTTCCTTCTGGG 900 CCCAACATTCTCCATATATCCAGCCACACTCATTTTTAATATTTAGTTCC CAGATCTGTA 960 CTGTGACCTT TCTACACTGT AGAATAACAT TACTCATTTT GTTCAAAGAC CCTTCGTGTT 1020 GCTGCCTAAT ATGTAGCTGA CTGTTTTTCC TAAGGAGTGT TCTGGCCCAG GGGATCTGTG 1080 AACAGGCTGG GAAGCATCTC AAGATCTTTC CAGGGTTATA CTTACTAGCA CACAGCATGA 1140 TCATTACGGAGTGAATTATC TAATCAACATCATCCTCAGTGTCTTTGCCCATACTGAAAT 1200 TCATTTCCCA CTTTTGTGCC CATTCTCAAG ACCTCAAAATGTCATTCCAT TAATATCACA 1260 GGATTAACTT TTTTTTTTAA CCTGGAAGAA TTCAATGTTA CATGCAGCTA TGGGAATTTA 1320 ATTACATATT TTGTTTTCCA GTGCAAAGAT GACTAAGTCC TTTATCCCTC CCCTTTGTTT 1380 GATTTTTTTT CCAGTATAAA GTTAAAATGC TTAGCCTTGT ACTGAGGCTG TATACAGCAC 1440 AGCCTCTCCCCATCCCTCCA GCCTTATCTGTCATCACCATCAACCCCTCC CATACCACCT 1500 AAACAAAATCTAACTTGTAA TTCCTTGAAC ATGTCAGGACATACATTATTCCTTCTGCCT 1560 GAGAAGCTCT TCCTTGTCTC TTAAATCTAG AATGATGTAA AGTTTTGAAT AAGTTGACTA 1620 TCTTACTTCA TGCAAAGAAG GGACACATAT GAGATTCATC ATCACATGAG ACAGCAAATA 1680 CTAAAAGTGT AATTTGATTA TAAGAGTTTA GATAAATATA TGAAATGCAA GAGCCACAGA 1740 GGGAATGTTTATGGGGCACG TTTGTAAGCCTGGGATGTGA AGCAAAGGCAGGGAACCTCA 1800 TAGTATCTTATATAATATACTTCATTTCTC TATCTCTATCACAATATCCAACAAGCTTTT 1860 CACAGAATTC ATGCAGTGCA AATCCCCAAA GGTAACCTTT ATCCATTTCA TGGTGAGTGC 1920 GCTTTAGAAT TTTGGCAAAT CATACTGGTC ACTTATCTCA ACTTTGAGAT GTGTTTGTCC 1980 TTGTAGTTAA TTGAAAGAAA TAGGGCACTC TTGTGAGCCA CTTTAGGGTT CACTCCTGGC 2040 AATAAAGAAT TTACAAAGAG CTACTCAGGA CCAGTTGTTA AGAGCTCTGT GTGTGTGTGT 2100 GTGTGTGTGT GAGTGTACAT GCCAAAGTGT GCCTCTCTCT CTTGACCCAT TATTTCAGAC 2160 TTAAAACAAG CATGTTTTCA AATGGCACTA TGAGCTGCCA ATGATGTATC ACCACCATAT 2220 CTCATTATTC TCCAGTAAAT GTGATAATAA TGTCATCTGT TAACATAAAA AAAGTTTGAC 2280 TTCACAAAAG CAGCTGGAAA TGGACAACCA CAATATGCAT AAATCTAACT CCTACCATCA 2340 GCTACACACT GCTTGACATA TATTGTTAGA AGCACCTCGC ATTTGTGGGT TCTCTTAAGC 2400 AAAATACTTG CATTAGGTCT CAGCTGGGGC TGTGCATCAG GCGGTTTGAG AAATATTCAA 2460 TTCTCAGCAG AAGCCAGAAT TTGAATTCCC TCATCTTTTA GGAATCATTT ACCAGGTTTG 2520 GAGAGGATTC AGACAGCTCA GGTGCTTTCA CTAATGTCTC TGAACTTCTG TCCCTCTITG 2580 TGTTCATGGA TAGTCCAATA AATAATGTTA TCTTTGAACT GATGCTCATA GGAGAGAATA 2640 TAAG AACTCT GAGTG ATATC AACATTAGGG ATTCAAAGAA ATATTAGATT TAAGCTCACA 2700 CTGGTCAAAA GGAACCAAGA TACAAAGAAC TCTGAGCTGT CATCGTCCCC ATCTCTGTGA 2760 GCCACAACCA ACAGCAGGAC CCAACGCATG TCTGAGATCC TTAAATCAAG GAAACCAGTG 2820 TCATGAGTTG AATTCTCCTA TTATGGATGC TAGCTTCTGG CCATCTCTGG CTCTCCTCTT 2880 GACACATATT AGCTTCTAGC CTTTGCTTCC ACGACTTTTA TCTTTTCTCC AACACATCGC 2940 TTACCAATCC TCTCTCTGCT CTGTTGCTTT GGACTTCCCC ACAAGAATTT CAACGACTCT 3000 CAAGTCTT-TCTTCCATCCC CACCACTAAC CTGAATGCCTAGACCCTTATTTTTATTAAT 3060 TTCCAATAGA TGCTGCCTAT GGGCTATATT GCTTTAGATG AACATTAGAT ATTTAAAGCT 3120 CAAGAGGTTC AAAATCCAAC TCATTATCTT CTCTTTCTTT CACCTCCCTG CTCCTCTCCC 3180 TATATTACTG ATTGCACTGA ACAGCATGGT CCCCAATGTA GCCATGCAAA TGAGAAACCC 3240 AGTGGCTCCT TGTGGTACAT GCATGCAAGA CTGCTGAAGC CAGAAGGATG ACTGATTACG 3300 CCTCATGGGT GGAGGGGACC ACTCCTGGGC CTTCGTGATT GTCAGGAGCA AGACCTGAGA 3360 TGCTCCCTGC CTTCAGTGTC CTCTGCATCT CCCCTTTCTA ATGAAGATCC ATAGAATTTG 3420 CTACATTTGA GAATTCCAAT TAGGAACTCA CATGTTTTAT CTGCCCTATC AATTTTTTAA 3480 ACTTGCTGAA AATTAAGTTT TTTCAAAATC TGTCCTTGTA AATTACTTTT TCTTACAGTG 3540 TCTTGGCATA CTATATCAAC TTTGATTCTT TGTTACAACT TTTCTTACTC TTTTATCACC 3600 AAAGTGGCTT TTATTCTCTT TATTATTATT ATTTTCTTTT ACTACTATAT TACGTTGTTA 3660 TTATTTTGTT CTCTATAGTA TCAATTTATT TGATTTAGTT TCAATTTATT TTTATTGCTG 3720 ACTTTTAAAA TAAGTGATTC GGGGGGTGGG AGAACAGGGG AGGGAGAGCA TTAGGACAAA 3780 TACCTAATGC ATGTGGGACT TAAAACCTAG ATGATGGGTT GATAGGTGCA GCAAACCACT 3840 5 ATGGCACACG TATACCTGTG TAACAAACCT ACACATTCTG CACATGTATC CCAGAACGTA 3900 AAGTAAAATT TAAAAAAAAG TGA Λ PEZ8 Protein sequence: 0 Protein Accession #: none SEQ ID NO:164 PEZ6 DNA SEQUENCE Nucleic Acid Accession *: AB028945 _ Coding sequence: 1-3765 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I AJSATGATGA ACGTCCCCGG CGGAGGAGCG GCCGCGGTGA TGATGACGGG CTACAATAAT 60 GGTCGCTGTC CCCGGAATTC TCTCTACAGT GACTGCATTA TTGAGGAGAA GACGGTGGTC 120 0 CTGCAGAAAA AAGACAATGAGGGCTTTGGA TTCGTGCTTC GAGGGGCCAA AGCTGACACA 180 CCCATTGAAG AATTCACACC AACACCGGCT TTCCCAGCCC TACAGTACCT GGAGTCCGTG 240 GATGAAGGTG GGGTGGCGTG GCAAGCCGGA CTAAGGACCG GGGACTTCTT GATTGAGGTT 300 AACAATGAGA ATGTTGTCAA AGTCGGCCAC AGGCAGGTGG TGAACATGAT CCGGCAGGGA 360 GGGAATCACC TGGTCCTTAA GGTGGTCACG GTGACCAGGA ATCTGGACCC CGACGACACC 420 5 GCCAGGAAGA AAGCTCCCCC GCCTCCAAAG CGGGCACCGA CCACAGCCCT CACCCTGCGC 480 TCCAAGTCCA TGACCTCGGA GCTGGAGGAG CTCGTGGATA AAGATAAACC CGAGGAGATA 540 GTCCCGGCCT CCAAGCCCTC CCGCGCTGCT GAGAACATGG CTGTGGAACC GAGGGTGGCG 600 ACCATCAAGC AGCGGCCCAG CAGCCGGTGC TTCCCGGCGG GCTCAGACAT GAACTCTGTG 660 TACGAACGCC AAGGAATCGC CGTGATGACG CCCACTGTTC CTGGGAGCCC AAAAGCCCCG 720 0 TTTCTGGGCATCCCTCGAGG TACGATGCGA AGGCAGAAAT CAATAGACAG CAGAATCTTT 780 CTATCAGGAA TAACAGAGGA AGAGCGGCAG TTTCTGGCTC CTCCAATGCT GAAGTTCACC 840 AGAAGCCTGT CCATGCCGGA CACCTCTGAG GACATCCCCC CTCCACCGCA GTCTGTGCCC 900 CCGTCCCCAC CACCACCTTC CCCAACCACT TACAACTGCC CCAAGTCCCC AACTCCAAGA 960 GTCTACGGGA CGATTAAGCC TGCGTTCAAT CAGAATTCTG CCGCCAAGGT GTCCCCCGCC 1020 5 ACCAGGTCCG ACACCGTGGC CACCATGATG AGGGAGAAGG GGATGTACTT CAGGAGAGAG 1080 CTGGACCGCT ACTCCTTGGA CTCTGAAGAC CTCTACAGTC GGAATGCCGG CCCGCAAGCC 1140 AACTTCCGCA ACAAGAGAGG CCAGATGCCA GAAAACCCAT ACTCAGAGGT GGGGAAGATC 1200 GCCAGCAAAG CCGTCTACGT CCCCGCCAAG CCCGCCAGGC GGAAGGGGAT GCTGGTGAAG 1260 CAGTCCAACG TGGAGGACAG CCCCGAGAAG ACGTGCTCCA TCCCTATCCC GACCATCATC 1320 0 GTGAAGGAGC CGTCCACCAG CAGCAGCGGC AAGAGCAGCC AGGGCAGCAG CATGGAGATC 1380 GACCCCCAGG CCCCGGAGCC ACCGAGCCAG CTGCGGCCTG ACGAAAGCCT GACCGTCAGC 1440 AGCCCCTTTG CCGCCGCCAT CGCCGGAGCC GTCCGCGACC GTGAGAAGCG GCTGGAAGCC 1500 AGGAGGAACT CCCCGGCCTT CCTCTCCACA GACCTGGGGG ATGAGGATGT GGGCCTGGGG 1560 CCACCCGCCC CCAGGACGCG GCCCTCCATG TTCCCCGAGG AGGGGGATTT TGCTGACGAG 1620 5 GACAGCGCTG AGCAGCTGTC ATCCCCCATG CCGAGTGCCA CGCCCAGGGA GCCCGAAAAC 1680 CATTTCGTGG GTGGCGCCGA GGCCAGTGCT CCGGGTGAGG CTGGGAGGCC GCTGAATTCC 1740 ACGTCCAAAG CCCAGGGGCC CGAGAGCAGC CCAGCAGTGC CCTCCGCGAG CAGCGGCACA 1800 GCCGGCCCCG GGAATTATGT CCACCCACTC ACAGGGCGGC TGCTTGATCC CAGCTCCCCG 1860 CTGGCCCTGG CACTCTCCGC AAGGGACCGA GCCATGAAGG AGTCTCAACA GGGACCCAAA 1920 0 GGGGAGGCCC CCAAGGCCGA CCTCAACAAA CCTCTTTACA TTGATACCAA AATGCGGCCC 1980 AGCCTGGATG CCGGCTTCCC TACGGTCACC AGGCAGAACA CCCGGGGACC CCTGAGGCGG 2040 CAGGAGACGG AGAACAAGTA CGAGACCGAC CTGGGCCGAG ACCGGAAAGG CGATGACAAG 2100 AAGAACATGC TGATCGACAT CATGGACACG TCCCAGCAGA AGTCGGCTGG CCTGCTGATG 2160 GTGCACACCG TGGACGCCAC TAAGCTGGAC AACGCCCTGC AGGAAG AGGA CGAGAAGGCA 2220 5 GAGGTGGAGA TGAAGCCAGA CAGCTCGCCG TCCGAGGTGC CAGAAGGTGT TTCCGAAACC 2280 GAAGGTGCTT TACAGATCTC CGCTGCCCCC GAGCCCACCA CCGTGCCCGG CAGAACCATC 2340 GTCGCGGTGG GCTCCATGGA AGAGGCGGTG ATTTTGCCAT TCCGCATCCC TCCTCCCCCT 2400 CTGGCATCCG TGGACTTGGA TGAGGATTTT ATTTTTACAG AGCCATTGCC TCCTCCCCTG 2460 GAATTTGCAA ATAGTTTTGA TATCCCCGAT GACCGGGCAG CTTCTGTCCC GGCTCTCTCA 2520 0 GACTTAGTGA AGCAGAAGAA AAGCGACACC CCTCAGTCCC CTTCGTTGAA CTCCAGCCAA 2580 CCAACCAACT CTGCAGACAG CAAGAAGCCA GCCAGTCTTT CAAACTGTCT GCCTGCCTCA 2640 TTCCTGCCAC CCCCTGAAAG CTTTGACGCC GTCGCCGACT CTGGGATCGA GGAGGTGGAC 2700 AGCCGGAGTA GCAGCGACCA CCACCTCGAG ACGACCAGCA CTATCTCCAC CGTGTCTAGC 2760 ATCTCCACCC TGTCTTCCGA AGGTGGAGAG AATGTGGACA CCTGCACAGT CTATGCAGAT 2820 5 GGGCAAGCAT TTATGGTTGA CAAACCCCCA GTACCTCCTA AGCCAAAAAT GAAGCCCATC 2880 ATTCACAAAA GCAATGCACT TTATCAAGAC GCGCTCGTGG AAGAAGATGT AGATAGCTTT 2940 GTTATCCCCC CGCCCGCTCC CCCGCCCCCG CCGGGCAGTG CCCAGCCTGG GATGGCCAAG 3000 GTTCTCCAGC CAAGGACCTC CAAGTTGTGG GGCGACGTCA CAGAGATCAA AAGCCCGATT 3060 CTCTCAGGCC CAAAGGCAAA CGTTATTAGT GAATTGAACT CTATCCTACA GCAAATGAAC 3120 0 CGAGAGAAAT TGGCAAAGCC GGGGGAAGG A CTGG ATTCAC CAATGGGAGC CAAGTCCGCC 3180 AGCCTCGCTC CAAGAAGCCC GGAGATCATG AGCACCATCT CAGGTACACG GAGCACGACG 3240 GTCACCTTCA CTGTTCGCCC CGGCACCTCC CAGCCCATCA CCCTGCAGAG CCGGCCCCCC 3300 GACTATGAAA GCAGGACCTC AGGAACAAGA CGTGCCCCAA GCCCTGTGGT CTCGCCAACA 3360 GAGATGAACA AAGAGACCCT GCCCGCCCCC CTGTCTGCTG CCACCGCCTC TCCTTCTCCC 3420 5 GCTCTCTCAG ATGTCTTTAG CCTTCCAAGC CAGCCCCCTT CTGGGGATCT ATTTGGCTTG 3480 AACCCAGCGG GACGCAGTAG GTCGCCATCC CCCTCGATAC TGCAACAGCC AATCTCAAAT 3540 AAGCCTTTTA CAACTAAACC TGTCCACCTG TGGACTAAAC CAGATGTGGC CGATTGGCTG 3600 GAAAGTCTAA ACTTGGGTGA ACATAAAGAG GCCTTCATGG ACAATGAGAT CGATGGCAGT 3660 CACTTACCAA ACCTGCAGAA GGAGGACCTC ATCGATCTTG GGGTAACTCG AGTCGGGCAC 3720 AGAATGAACA TAGAAAGGGC TTTGAAACAG CTGCTGGACA GATAAGGACG GCTGCTCTCC 3780 ACCTCGCAGA CTGCTCTTGT TATAAGTAGA GATGGGCTCG TGCTGAAACA TCTGAATGCC 3840 AAGCGAAGTC TGTGAGCATC AACCCCACTC CATGGGTTTG TCTCCTGGTA GCCAAAGAAA 3900 TACTGAGTTG TGTCCACAAC ATGGCTGGGT CTTCAGACCC CTGGCTCACC ATGTGGGTGT 3960 5 CTTGGGCAGT TTCTATCACA CATGGGACAA GGGGAGGGAG TTTTTCTAAC ATGGAAAAAG 4020 ATTCCCAGCC TGCCGCCCAG CATGCAGGTG GCCTCGCTTT GCCGGGTCCG AGAGGCTCCC 4080 CGTCAATTTT GCACGGGATC CTAGCTCTTG TAGGCAGACA CCAGTGCACT CTAGATACCT 4140 CCTGAGACCT CCGTCCTCTG CTTTCCGGGC AGCTCTCACC ACCCCAGGCC CCGGCATGAG 4200 GCCTTTCCTC AGTCCTGTGG CCTCTCAGAG GACACCTGAT GCTCACCTGC CCCTCTTTCT 4260 10 CCTGCACTTG GCTTGCAGTG AGATGCTCCC AGATGCATTT GTCCAGTGCC CCATCATGGG 4320 CCTGAAAGGC AGAGAAACTT TTTCCTACAC AGATTCTTTT CCCCATCTCC TCCTGTGGTT 4380 TGCATCCATG GCTCTTTGGC CATGAGGTTC CTGGCAGTGC TGGGAGTTTG GATGGGATCG 4440 TGCCCAGCTT TGCTTAGCTT TCTTTATTTC TGCAAATCTG TTAGCATAAT TCCAAGGTGG 4500 CCAAGCAGAT GTCACATGGA GTTAGTCAAA GCACAAAGTC ACGATTCCAC AATGGAGGGG 4560 15 AGACCTGGCC AAGGGAGCCA GCCAGCGTGC AACTGCCCAA GCTCCAGGTC TCCAGGACAA 4620 GAGCAGTTGT CTGCCATGAG CACCCATCCA GGATGGAGAA TAAGGGCTTC TCTGCCTCTC 4680 AGAATTCTTT TTAATTGAAG ATGTCTTGAG CTCTGCAAAG ATCAGAGCAG GTGAGCATCC 4740 ACTTTGACAT GAAGGACAAG AAGACGCATG GCTCATGGCG GGCACATGCG GCTGCCAGTG 4800 AGACAGCGTC TCCTCTGGGA GCTGGGCGGG CACAGCATCC TCAGTTCTGT GCCCAGCCAA 4860 0 GGGTGAGCAT CTCTGCTGAG ACAGTCCTTT TGCTCTCGGA GGCCAGGGAA GATGGTACTT 4920 . AGAGGCTTTT CCCCTATCGC TCTGGGTGTC TAGGAATCCC ACCAGCTTGT CTTAACAGTA 4980 CAACAGCTTC TTTGAGGACC CAGTGGGTAT GGAGTATAGA CAGAACCCAG GGTTGAGAAC 5040 AGAAGGTGGG CGGCAGGATC AGAGTGAAAG CAGAGGCGTG AGGAGAGGAA AGCAGGGAGG 5100 TCTCCTGGGCTGCCAGGTCA GCCTCTCTGG CAAGGCTTTCTTGAGCCCCG CCCCTTTCTT 5160 5 TCCCCGGAGTCCCTCCACCC CATAACAATA CCTCGAATTT CCAAAAGAGG TCACCAGATG 5220 CACATGGGCC GCAAAACACA CAGTCAGGCT TCCAGCACAT TCTCCCCCAT TTGGAGGATA 5280 CTCGAATGTC AGGTTTTTGG TTTTATTATT ATTTCAGAAC TAGCTCAGCC CATCTCTAAT 5340 TATAAAACAT GGTTTTGTTT TTTTTrTTTC CTTTπTTCT TGATTAGGTC TGGAACAGCT 5400 CTAGAATGAA CACATAAAAT TTAGCAATTT AAAATCTTTC TTTACTGCAA GTTTAAATAG 5460 0 TTGTACAGAT AGTTTATAAG CACAATATTT TAAGAAAAAA AAGTGGCTGG TCTACTAGGC 5520 AGCCTTTGTG CCACTTCAGT GCTAGAAAGT TAAAGAAAAA AAAACTTTTG TGATTTAATA 5580 ATACTATTTC TGTGGAATAA TTATAAAAGT ATGACCTTTT TAAATCAACC TTATTTGGAT 5640 GCATCTGAAC CAGCAGAGCT GTGTTATATT TTCTATCTTT GCTAGAACTT CGTCATTGAA 5700 GGACAATTTC TTCAAAGTGG TTACAATTCA TAATGCAGCA GTTTCTCCAA AAACAAAAAC 5760 5 AAAACACACA CCACACACAC GCGCTTTTCC AGTCACACAC CCCTGATGTT GGAACCAAGT 5820 TTTTGGACCT TCTGTTCCAA AACCTTTTGC AGGTCAATCT TTGTATTTGA AATGATCCAA 5880 TCCAACTTGA AGTCAATTGA ATATTAAGGC GCTTTACTTC CGTGTGCTTT CAGTTTTTCC 5940 ATCATGAGAT GAATGAGCAT TACTCTAGAT AAATTTCAAG ACAGGATACT ACAGGTGGCC 6000 TGCTGAGGCT GCCCCATATT TTAGAAAATG TAAAAATGGT GGTTTGGCCA TTAATTTGTC 6060 0 TTCCATTTGA TGATACCGCA AAATTCCGTG AGTCCATTCC TTTGGCATGG CACTTTCCCT 6120 GGGCCTACAG TTGGTATTAC CTCTGTGCTC AGTGCCAGGC AAAACACTAG CTCAAAGGAG 6180 AGTCAAGGAA ACCGCTGGCA GACGATAACC AGTCGAAACT CGTGACTTCG GTTTGTTGAA 6240 CTTTGGCAGC CAGTTGGTGA GGGCCAGATG TTATTCCCTT TCTTAAAGAT ACTCCAAGCC 6300 ACATGCCACT AACCACAAGC AAGCTGGCTG CAAGACTAAA GAGCTGATAA CATAGTTTAT 6360 5 TTTTACACTG TCTTATTATA GAGAAGTAAT AGACCTATCA GAACCTGCAC TGACCAACAA 6420 ATAAACACAT GTTGCCAAGA TGAATCGGTC TCTATCTCTA TCTGCTTATT TTGGTACTGA 6480 AAGCAATAGT TCCTCATTCA AATCACCACC CACTGTTCTC CCCCTTTGGG ACATGTTAGG 6540 ACGAGGCCCT ATTCCATGCC CCTCTTTAAT GGTGGAACAA ATGTTAAACT GCTCATCTAA 6600 _ AGATCATGTT GATATTATTC CAGGTTTTAA GATCAACTTT TGTTACATAC TGTAATTTAA 6660 0 ATAAACTGCA TTTACATGCC TAGTTTCTGT AATATTGTGT ATACAAAACC CAAATCTCTC 6720 AAAATGTAAA TTATGTATAC CTGCCAAGAT ACCπTTCCA GGGTGTCTGC GCACATTTTA 6780 AGTTAATTCA CATAATATAA AAATTACTCA ATGTGACTGT TGATTTGCTG AACTTTACAT 6840 ATCACAAAGT GAATTATTTG TGATACTTTA GTTAATAAAA TGGTAAATTT TTTTCTCAGT 6900 TATTGAACAA GCAAGCATTA TCCAGTTGATCTGGCAATGA CTTTTTGTGTGTGGGCCACA 6960 5 ATATTGATTT TCCCATTAAC AATITI ITIT' TG 111TT1 AA ATACTAATAT GTTTCACACT 7020 ATAGTTTGTG TAACAACACG TGTTCGCATT ATCTATGTTG CTGTTACTTT TGTGCTTTTA 7080 TTCTTTTTAG ACTTTATAAA AAAAAAAAAA AGCTCCTGTA ATTTGCACTT TCTCCCAATC 7140 CTTAAATCTC TTGTATGGCA ACCAAAATTA CTGTAAAAAA ATAAATATAC TATTGCACTA 7200 AGGTTGTGGTTCTGATTGCA AACAAACAGT GAACACTGTCTGAATTAAAC AAAAAGCTGC 7260 0 CCGACTTGCA ATCTAATGTA GATTATCTCA GGCATTGTGG CCAGCTCTGC CTCTCTAAAA 7320 CTGACCAGAA AAATCTCTCT CATCGAGTAA ACAGGCTCCT GTCACTGAGC TAATCTGCCT 7380 TGGTTCCATT TCCTTATTCT CAATTTATCA ATGGATACGT GCATGTTATT TCAGAATTAT 7440 GCAAAACGTC AAAATCTGCT TCTGTGACCG CTGCTATAGG CGTGGAGCTG AGGCTCGGCT 7500 TTTCCTTTTG TTCTGGGTGG AAGCAGCGGT GCCGCGGAGG GCCAGCCAGA TCCGGACCCT 7560 5 TCCCTTAGGG TCCAGTCTCC CCACACCCCA GCAGGGTGTC TTCTAGCCAT AAGGCCAAGG 7620 GAGTGGCAGA ACTGGGCCGC CTCTCTGGTT GACAAGCAAA CCACATGCTA AGGCTTGGAG 7680 CAAGAGAGAA TTTGTGTCTA TTGGCAAAGA ACTAAGCCAG GAAGACATGG GCCATCCCTC 7740 CGCTTTAGGG AAGCATATTT TAAACCTAAA CGTTGAACTT CTTCTTTGGC CTCACCAGTG 7800 AAAACTTGTT GTCTTTAGTT CCTAAAGTTT CTTCTACTTT GGCACATTCC CCAGTTGAGC 7860 0 AGCAGCCTCT ATGCTTCCAC GTTCAGGAAA AATTCCAGTC CTCATATCTT TTGTAGTTCA 7920 CCCTCAAGCT CTCCCGCTTC ACCATCCAAT AGTTTCTCCC AAACCTTGGC ACCCCCCTAG 7980 ACTTTGCTTC CAATGGTTTC TTCCAGACCA CTTTTCCTAG ATGAATATAT TCGTTTACCT 8040 TACTAGGAAA ATTATTGGAA GATTTTTTCT TTTACTTGAA ATTGGAGGCA TTTTAATAAC 8100 _ TGGCGAACTG GAATGTGTTT CTGTATTTGT AGACAACCATGTACCCATGC AAGTAGGTGA 8160 5 ACATTCCACA GTGGCTGGGT GACCACAGCA GCTGCATGCA GACAGGACTG CCCGTGCTTT 8220 GTGGGGAATC AGAGAATTTC CAAACTTGTT TCTCAGACTT CCGCAGATCT CATCACTTTG 8280 ATTTCTAATC CATGCTGTAT TGGTGATTTT GTTTATCGTT CCTGTAACTT GTTCTACATT 8340 CCACAGTCTT TACCGTTTTA TGTTCAAAAT TACAACAATC CCTGTCCATT GATTCCACTC 8400 TGGAACTCTT TGTTCATGCC AATTTTGAAA TTTTAATACG AGCCTTCAAA TAAACACAGA 8460 AAAGAAAAAAAAAAAAAAAA AAAAAAAA - SEQ ID NO:165 PEZ6 Protein sequence: 5 Protein Accession*: BAA82974.1 I 11 21 31 41 51 n I I I I I I U MMMNVPGGGA AAVMMTGYNN GRCPRNSLYS DCIIEEKTVV LQKKDNEGFG FVLRGAKADT 60 PIEEFTPTPA FPALQYLESV DEGGVAWQAG LRTGDFLIEV NNENVVKVGH RQVVNMIRQG 120 GNHLVLKVVT VTRNLDPDDT ARKKAPPPPK RAPTTALTLR SKSMTSELEE LVDKDKPEEI 180 VPASKPSRAA ENMAVEPRVA TIKQRPSSRC FPAGSDMNSV YERQGIAVMT PTVPGSPKAP 240 FLGIPRGTMR RQKSIDSRIFLSGITEEERQ FLAPPMLKFT RSLSMPDTSE DIPPPPQSVP 300 PSPPPPSPTT YNCPKSPTPR VYGTIKPAFN QNS AAKVSPA TRSDTVATMM REKGMYFRRE 360 LDRYSLDSED LYSRNAGPQA NFRNKRGQMP ENPYSEVGKI ASKAVYVPAK PARRKGMLVK 420 QSNVEDSPEK TCSIPIPTU VKEPSTSSSG KSSQGSSMEI DPQAPEPPSQ LRPDESLTVS 480 SPFAAAIAGA VRDREKRLEA RRNSPAFLST DLGDEDVGLG PPAPRTRPSM FPEEGDFADE 540 DSAEQLSSPM PSATPREPEN HFVGGAEASA PGEAGRPLNS TSKAQGPESS PAVPSASSGT 600 0 AGPGNYVHPLTGRLLDPSSP LALALSARDR AMKESQQGPKGEAPKADLNKPLYIDTKMRP 660 SLDAGFPTVT RQNTRGPLRR QETENKYETD LGRDRKGDDK KNMLIDIMDT SQQKSAGLLM 720 VHTVDATKLD NALQEEDEKA EVEMKPDSSP SEVPEGVSET EGALQISAAP EPTTVPGRTI 780 VAVGSMEEAV ILPFRIPPPP LASVDLDEDF IFTEPLPPPL EFANSFDIPD DRAASVPALS 840 DLVKQKKSDTPQSPSLNSSQ PTNSADSKKP ASLSNCLPAS FLPPPESEDA VADSGIEEVD 900 5 SRSSSDHHLE TTSTISTVSS ISTLSSEGGE NVDTCTVYAD GQAFMVDKPP VPPKPKMKPI 960 IHKSNALYQD ALVEEDVDSF VIPPPAPPPP PGS AQPGMAK VLQPRTSKLW GDVTEIKSPI 1020 LSGPKANVIS ELNSILQQMN REKLAKPGEG LDSPMGAKSA SLAPRSPE-M STISGTRSTT 1080 VTFTVRPGTS QPITLQSRPP DYESRTSGTR RAPSPV VSPT EMNKETLPAP LS AATASPSP 1140 ALSDVFSLPS QPPSGDLFG NPAGRSRSPS PSILQQPISN KPFTTKPVHLWTKPDVADWL 1200 0 ESLNLGEHKE AFMDNEIDGS HLPNLQKEDL IDLGVTRVGH RMNIERALKQ LLDR SEQ ID NO.-166 PEZ4 DNA SEQUENCE _ Nucleic Acid Accession*: NM_000024 5 Coding sequence: 220-1461 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I ACTGCGAAGC GGCTTCTTCA GAGCACGGGC TGGAACTGGC AGGCACCGCG AGCCCCTAGC 60 0 ACCCGACAAG CTGAGTGTGC AGGACGAGTC CCCACCACAC CCACACCACA GCCGCTGAAT 120 GAGGCTTCCA GGCGTCCGCT CGCGGCCCGC AGAGCCCCGC CGTGGGTCCG CCCGCTGAGG 180 CGCCCCCAGC CAGTGCGCTT ACCTGCCAGA CTGCGCGCCA TSGGGCAACC CGGGAACGGC 240 AGCGCCTTCT TGCTGGCACC CAATAGAAGC CATGCGCCGG ACCACGACGT CACGCAGCAA 300 AGGGACGAGG TGTGGGTGGT GGGCATGGGC ATCGTCATGTCTCTCATCGT CCTGGCCATC 360 5 GTGTTTGGCA ATGTGCTGGTCATCACAGCC ATTGCCAAGT TCGAGCGTCT GCAGACGGTC 420 ACCAACTACT TCATCACTTC ACTGGCCTGT GCTGATCTGG TCATGGGCCT GGCAGTGGTG 480 CCCTTTGGGG CCGCCCATAT TCTTATGAAA ATGTGGACTT TTGGCAACTT CTGGTGCGAG 540 TTTTGGACTT CCATTGATGT GCTGTGCGTC ACGGCCAGCA TTGAGACCCT GTGCGTGATC 600 GCAGTGGATC GCTACTTTGC CATTACTTCA CCTTTCAAGTACCAGAGCCTGCTGACCAAG 660 0 AATAAGGCCC GGGTGATCATTCTGATGGTG TGGATTGTGTCAGGCCTTAC CTCCTTCTTG 720 CCCATTCAGA TGCACTGGTA CCGGGCCACC CACCAGGAAG CCATCAACTG CTATGCCAAT 780 GAGACCTGCT GTGACTTCTT CACGAACCAA GCCTATGCCA TTGCCTCTTC CATCGTGTCC 840 TTCTACGTTC CCCTGGTGAT CATGGTCTTC GTCTACTCCA GGGTCTTTCA GGAGGCCAAA 900 AGGCAGCTCC AG AAGATTGA CAAATCTG AG GGCCGCTTCC ATGTCCAGAA CCTTAGCCAG 960 5 GTGGAGCAGG ATGGGCGGAC GGGGCATGGA CTCCGCAGAT CTTCCAAGTT CTGCTTGAAG 1020 GAGCACAAAG CCCTCAAGAC GTTAGGCATC ATCATGGGCA CTTTCACCCT CTGCTGGCTG 1080 CCCTTCTTCA TCGTTAACAT TGTGCATGTG ATCCAGGATA ACCTCATCCG TAAGGAAGTT 1140 TACATCCTCC TAAATTGGAT AGGCTATGTC AATTCTGGTT TCAATCCCCT TATCTACTGC 1200 CGGAGCCCAG ATTTCAGGAT TGCCTTCCAG GAGCTTCTGT GCCTGCGCAG GTCTTCTTTG 1260 0 AAGGCCTATG GGAATGGCTA CTCCAGCAAC GGCAACACAG GGGAGCAGAG TGGATATCAC 1320 GTGGAACAGG AGAAAGAAAA TAAACTGCTG TGTGAAGACC TCCCAGGCAC GGAAGACTTT 1380 GTGGGCCATC AAGGTACTGT GCCTAGCGAT AACATTGATT CACAAGGGAG GAATTGTAGT 1440 ACAAATGACT CACTGCTGIA AAGCAGTTTT TCTACTTTTA AAGACCCCCC CCCCCCCAAC 1500 AGAACACTAA ACAGACTATT TAACTTGAGG GTAATAAACTTAGAATAAAA TTGTAAAAAT 1560 5 TGTATAGAGA TATGCAGAAG GAAGGGCATC CTTCTGCCTTTTTTATTTT TTAAGCTGTA 1620 AAAAGAGAGA AAACTTATTT GAGTGATTAT TTGTTATTTG TACAGTTCAG TTCCTCTTTG 1680 CATGGAATTT GTAAGTTTAT GTCTAAAGAG CTTTAGTCCT AGAGGACCTG AGTCTGCTAT 1740 ATTTTCATGA CTTTTCCATG TATCTACCTC ACTATTCAAG TATTAGGGGT AATATATTGC 1800 TGCTGGTAAT TTGTATCTGA AGGAGATTTT CCTTCCTACA CCCTTGGACT TGAGGATTTT 1860 0 GAGTATCTCG GACCTTTCAG CTGTGAACAT GGACTCTTCC CCCACTCCTC TTATTTGCTC 1920 ACACGGGGTA TTTTAGGCAG GGATTTGAGG AGCAGCTTCA GTTGTTTTCC CGAGCAAAGG 1980 TCTAAAGTTT ACAGTAAATA AAATGTTTGA CCATG 5 SEQ ID NO:167 PEZ4 Protein sequence: Protein Accession * NP_000015.1 1 11 21 31 41 51 I I I I I I MGQPGNGSAF LLAPNRSHAP DHDVTQQRDE VWVVGMGIVM SLIVLAIVFG NVLVITAIAK 60 FERLQTVTNY FITSLACADL VMGLAVVPFG AAHILMKMWT FGNFWCEFWT SIDVLCVTAS 120 IETLCVIAVD RYFAITSPFK YQSLLTKNKA RVIILMVWIV SGLTSFLPIQ MHWYRATHQE 180 AINCYANETC CDFFTNQAYA IASSIVSFYV PLVIMVFVYS RVFQEAKRQL QKIDKSEGRF 240 HVQNLSQVEQ DGRTGHGLRR SSKFCLKEHK ALKTLGIIMG TFTLCWLPFF IVNIVHVIQD 300 NLIRKEVYIL LNWIGYVNSG FNPLIYCRSP DFRIAFQELL CLRRSSLKAY GNGYSSNGNT 360 GEQSGYHVEQ EKENKLLCED LPGTEDFVGH QGTVPSDNID SQGRNCSTND SLL 0 SEQ ID NO:168 PEZ1 DNA SEQUENCE Nucleic Acid Accession* NM_004457 5 Coding sequence: 143-2305 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 n I I I I I I U GAATTCGTTG TTGGGAAGGA CTGGGGAAAC AGCTGTAACA TTTGCCACCC TCAGAAGCTG 60 CTGGTCCTGT GTCACACCAC CTTAGCCTCT TGATCGAGGA AGATTCTCGC TGAAGTCTGT 120 TAATTCTACT TTTTGAGTAC TTATGAATAA CCACGTGTCT TCAAAACCAT CTACCATGAA 180 GCTAAAACAT ACCATCAACC CTATTCTTTT ATATTTTATA CATTTTCTAA TATCACTTTA 240 TACTATTTTA ACATAC^TTC CGTTTTATTTTTTCTCCGAG TCAAGACAAG AAAAATCAAA 300 5 CCGAATTAAA GCAAAGCCTG TAAATTCAAA ACCTGATTCT GCATACAGATCTGTTAATAG 360 TTTGGATGGT TTGGCTTCAG TATTATACCC TGGATGTGAT ACTTTAGATA AAGTTTTTAC 420 ATATGCAAAA AACAAATTTA AGAACAAAAG ACTCTTGGGA ACACGTGAAG TTTTAAATGA 480 GGAAGATGAA GTACAACCAA ATGGAAAAAT TTTTAAAAAG GTTATTCTTG GACAGTATAA 540 TTGGCTTTCC TATGAAGATG TCTTTGTTCG AGCCTTTAATTTTGGAAATG GATTACAGAT 600 0 GTTGGGTCAG AAACCAAAGA CCAACATCGC CATCTTCTGTGAGACCAGGG CCGAGTGGAT 660 GATAGCTGCA CAGGCGTGTT TTATGTATAA TTTTCAGCTT GTTACATTAT ATGCCACTCT 720 AGGAGGTCCA GCCATTGTTC ATGCATTAAA TGAAACAGAG GTGACCAACA TCATTACTAG 780 TAAAGAACTC TTACAAACAA AGTTGAAGGA TATAGTTTCT TTGGTCCCAC GCCTGCGGCA 840 CATCATCACTGTTGATGGAA AGCCACCGAC CTGGTCCGAC TTCCCCAAGG GCATCATTGT 900 5 GCATACCATG GCTGCAGTGG AGGCCCTGGG AGCCAAGGCC AGCATGGAAA ACCAACCTCA 960 TAGCAAACCA TTGCCCTCAG ATATTGCAGT AATCATGTAC ACAAGTGGAT CCACAGGACT 1020 TCCAAAGGGA GTCATGATCT CACATAGTAA CATTATTGCT GGTATAACTG GGATGGCAGA 1080 AAGG ATTCC A G AACTAGG AG AGG AAG ATGT CTAC ATTGG A TATTTGCCTC TGGCCCATGT 1140 TCTAGAATTA AGTGCTGAGC TTGTCTGTCTTTCTCACGGA TGCCGCATTG GTTACTCTTC 1200 0 ACCACAGACT TTAGCAGATC AGTCTTCAAA AATTAAAAAA GGAAGCAAAG GGGATACATC 1260 CATGTTGAAA CCAACACTGA TGGCAGCAGT TCCGGAAATC ATGGATCGGA TCTACAAAAA 1320 TGTCATGAAT AAAGTCAGTG AAATGAGTAG TTTTCAACGT AATCTGTTTA TTCTGGCCTA 1380 TAATTACAAA ATGGAACAGA TTTCAAAAGG ACGTAATACT CCACTGTGCG ACAGCTTTGT 1440 TTTCCGGAAA GTTCGAAGCT TGCTAGGGGG AAATATTCGT CTCCTGTTGTGTGGTGGCGC 1500 5 TCCACTTTCT GCAACCACGC AGCGATTCATGAACATCTGT TTCTGCTGTC CTGTTGGTCA 1560 GGGATACGGG CTCACTGAAT CTGCTGGGGC TGGAACAATT TCCGAAGTGT GGGACTACAA 1620 TACTGGCAGA GTGGGAGCAC CATTAGTTTG CTGTGAAATC AAATTAAAAA ACTGGGAGGA 1680 AGGTGGATAC TTTAATACTG ATAAGCCACA CCCCAGGGGT GAAATTCTTA TTGGGGGCCA 1740 AAGTGTGACA ATGGGGTACT ACAAAAATGA AGCAAAAACA AAAGCTGATT TCTCTGAAGA 1800 0 TGAAAATGGA CAAAGGTGGC TCTGTACTGG GGATATTGGA GAGTTTGAAC CCGATGGATG 1860 CTTAAAGATT ATTGATCGTA AAAAGGACCT TGTAAAACTA CAGGCAGGGG AATATGTTTC 1920 TCTTGGGAAA GTAGAGGCAG CTTTGAAGAA TCTTCCACTA GTAGATAACA TTTGTGCATA 1980 TGCAAACAGT TATCATTCTT ATGTCATTGG ATTTGTTGTG CCAAATCAAA AGGAACTAAC 2040 TGAACTAGCT CGAAAGAAAG GACTTAAAGG GACTTGGGAG GAGCTGTGTA ACAGTTGTGA 2100 5 AATGGAAAAT GAGGTACTTA AAGTGCTTTC CGAAGCTGCT ATTTCAGCAA GTCTGGAAAA 2160 GTTTGAAATT CCAGTAAAAA TTCGTTTGAG TCCTGAACCG TGGACCCCTG AAACTGGTCT 2220 GGTGACAGAT GCCTTCAAGC TGAAACGCAA AGAGCTTAAA ACACATTACC AGGCGGACAT 2280 TGAGCGAATG TATGGAAGAA AATAATTATT CTCTTCTGGC ATCAGTTTGC TACAGTGAGC 2340 TCACATCAAA TAGGAAAATA CTTGAAATGC ATGTCTCAAG CTGCAAGGCA AACTCCATTC 2400 0 CTCATATTAA ACrATrACTr CTCATGACGTCACCATTTTT AACTGACAGG ATTAGTAAAA 2460 CATTAAGACA GCAAACTTGT GTCTGTCTCT TCTTTCATTT TCCCCGCCAC CAACTTACTT 2520 TACCACCTAT GACTGTACTT GTCAGTATGA GAATTTTTCT GAATCATATT GGGGAAGCAG 2580 TGATTTTAAA ACCTCAAGTT TTTAAACATG ATTTATATGT TCTGTATAAT GTTCAGTTTG 2640 TAACTTTTTA AAAGTTTGGA TGTATAGAGG GATAA ATAGG AAATATAAGA ATTGGTTATT 2700 5 TGGGGGCTTT TTTACTTACT GTATTTAAAA ATACAAGGGT ATTGATATGA AATTATGTAA 2760 ATTTCAAATG CTTATGAATC AAATCATTGT TGAACAAAAG ATTTGTTGCT GTGTAATTAT 2820 TGTCTTGTAT GCATTTGAGA GAAATAAATA TACCCATACT TATGTTTTAA GAAGTTGAGA 2880 TCTTGTGAAT ATATGCCTGT CAGTGTCTTC TTTATATATT TATTTTTTAT TAGAAAAAAT 2940 GAAGTTTGGT TGGTGATGCA TGAAACAAAA TAGCAAGAGA GGGTTATAGT TTAATAGTAA 3000 0 GGGAGATAAC ACAGCATGTG TAGCACCAGT TGATAATTGG TCTCTAGTAG CTTACTGTCA 3060 AAATGTTCAA TGAAGTCTTC TGTTCATCTG TTGAAACTAG GAAAATACCC AAACTTAAAT 3120 GGAAGAATTC TGAAAGAGAG GATAGAATTT AAAGAACAAG AGTATATAAA GTTATTCTTT 3180 GAATATTTCG TTGACTATAT GTACATTGAG TTATCTATAT TTGTAAACAA ATTAGTCATG 3240 GAAAATTATT CTATTCCAAA GTCTCCTTTT AGTCTAG ATA ATCATTATTT CATTTTAAAA 3300 5 TTAGTGTTTT TCATAGTTTG CACTGATGCG TGTATGGATG TGTGTGAGTC AGTGGTAGCT 3360 TATTTAAAAA GCACCTTATC CTTTCTCCCA TAACCTTTGT ACACTAAAAA ATGAAAGAAT 3420 TTAGAATGTA TTTGATGATA GCATTCTCAC TAAGACACAT GAGAATTTAA CTTTATAACC 3480 GCGTGAGTTA AGATTTAATT CATAGGTTTT GATGTCATTG TTGAAGTTAT TTGTAATTCA 3540 GAAACCTTGC TTGTGTGATA CATAGTAAGT CTCTTCATTT ATTACTGCTT GCCTGTTGTT 3600 ATATCTGGAT TATCAAAAGC AATAGTGCAC CAATTAAGAT GTGCTCAAAT CAGGACTTAA 3660 ATCATAGGCA CCACATTTTT CATGTCAGAC TAGTTACTTT GTTGATTCTC AGTTACTGTA 3720 GGCATCAAAA GGCAAAAATC A SEQIDNO:169 PEZ1 Protein sequence: Protein Accession*: NP 004448.1 1 I I 21 31 41 51 I I I I I I MNNHVSSKPS TMKLKHTINP ILLYFIHFLI SLYTILTYIP FYFFSESRQE KSNRKAKPV 60 NSKPDSAYRS VNSLDGLAS V LYPGCDTLDK VFTYAKNKFK NKRLLGTREV LNEEDEVQPN 120 GKIFKKVILG QYNWLS YEDV FVR AFNFGNG LQMLGQKPKT NIAIFCETR A EWMIAAQACF 180 MYNFQLVTLY ATLGGPAIVH ALNETEVTNI ITSKELLQTK LKDIVSLVPR LRHIITVDGK 240 PPTWSDFPKG IIVHTMAAVE ALGAKASMEN QPHSKPLPSD IAVIMYTSGS TGLPKGVMIS 300 HSNIIAGITG MAERIPELGE EDVYIGYLPL AHVLELSAEL VCLSHGCRIG YSSPQTLADQ 360 SSKIKKGSKG DTSMLKPTLM AAVPEIMDRI YKNVMNKVSE MSSFQRNLFI LAYNYKMEQI 420 SKGRNTPLCD SFVFRKVRSL LGGNIRLLLC GGAPLSATTQ RFMNICFCCP VGQGYGLTES 480 AGAGTISEVW DYNTGRVGAP LVCCEIKLKN WEEGGYFNTD KPHPRGEHJ GGQSVTMGYY 540 KNEAKTKADF SEDENGQRWL CTGDIGEFEP DGCLKIIDRK KDLVKLQAGE YVSLGKVEAA 600 LKNLPLVDNI CAYANSYHSY VIGFWPNQK ELTELARKKG LKGTWEELCN SCEMENEVLK 660 VLSEAAISAS LEKFEIPVKI RLSPEPWTPE TGLVTDAFKL KRKELKTHYQ ADIERMYGRK SEQ ID N0:170 PCQ7 DNA SEQUENCE Nucleic Acid Accession * none found Coding sequence: 38-1075(undertined sequence corresponds to start and stop codon) 11 21 31 41 51 I I I I I AGCAACGACG CCGGGCAGCG GGAGCGGCGG CCGCGCCATG TGGCTGCTGG GGCCGCTGTG 60 CCTGCTGCTG AGCAGCGCCG CGGAGAGCCA GCTCCTCCCC GGGAACAACT TCACCAATGA 120 GTGCAACATA CCAGGCAACT TCATGTGCAG CAATGGACGG TGCATCCCGG GCGCCTGGCA 180 GTGTCACGGG CTGCCTGACT GCTTCGACAA GAGTGATGAG AAGGAGTGCC CCAAGGCTAA 240 GTCGAAATGT GGCCCAACCT TCTTCCCCTG TGCCAGCGGC ATCCATTCCA TCATTGGTCG 300 CTTCCGGTCC AATGGGTTTG AGGACTGTCC CGATGGCAGC GATGAAGAGA ACTGCACAGC 360 AAACCCTCTC CTTTGCTCCA CCGCCCGCTA CCACTGCAAG AACGGCCTCT GTATTCACAA 420 GAGCTTCATC TGCGATGGAC AGAATAACTG TCAAGACAAC AGTCATGAGG AAAGCTGTGA 480 AAGTTCTCAA GAACCCGGCA GTGGGCAGGT GTTTCTCACT TCAGAGAACC AACTTGTCTA 540 TTACCCCAGC ATCACCTATG CCATCATCGG CAGCTCCGTC ATTTTTGTGC TGGTGGTCGC 600 CCTGCTGGCA CTGGTCTTGC ACCACCAGCG GAAGCGGAAC AACCTCATGA CGCTGCCCGT 660 GCACCGGCTG CAGCACCCTG TGCTGCTGTC CCGCCTGGTG GTCCTGGACC ACCCCCACCA 720 CTGCAACGTC ACCTACAACG TCAATAATGG CATCCAGTAT GTCGCCAGCC AGGCGGAGCA 780 GAATCCGTCG GAAGTAGGCT CCCCACCCTC CTACTCCGAG GCCTTGCTGG ACCAGAGGCC 840 TGCGTGGTAT GACCTTCCTC CACCGCCCTA CTCTTCTGAC ACGGAATCTC TCAACCAAGC 900 CGACCTGCCC CCCTACCGCT CCCGGTCCGG GAGTGCCAAC AGTGCCAGCT CCCAGGCAGC 960 CAGCAGCCTC CTCAGCGTGG AAGACACCAG CCACAGCCCG GGGCAGCCTG GCCCCCAGGA 1020 GGGCACTGCT GAGCCCAGGG ACTCTCAGCC CAGCCAGGGC ACTGAAGAAG TATAAGTCCC 1080 AGTTATTCCA AAGTCCATAT GGGTTAATCT GCTCTCACTT GTTGCCATTC TAACAATTTG 1140 TGCTCATGGG AAGCTCTTTA AGCACCTGTA AGGATGTCTC AAGTTACAGT TTGGGATATT 1200 AACTATCTCT GCATTCCCCT CCTCCCCCAG ACTTCAGAGA TGTTTTTCTG GCGTCTCAGT 1260 TGACATCATC TCTTGTGCGT CTTTTCTGTC AGGTCACTCT TCCCTTCGGA CCCGAGATCA 1320 CACCCTCATT TTTCACATTA TTCTGTTTCT GTTCGAGAGA CAGCATATAA AACAGTATTG 1380 AAATAGGCTG GGAGAGAGCA ATCTTTCTGT GCTATATTGG ATGCTCAGAA GTGCAGGAGA 1440 CGCTGGACCC AATTCTCTCT GCTCGGTAGT TACCTTATAG CATTTGGGGA TTTGGGTTAG 1500 ATCATCTAAC CAGGAGGCCA TCACTCGATC GTCACCCCCC CAAAAAAATT CCATTTCAGC 1560 ATCAAAACCT GCTTTGCACA ATCCTATTTG ATCCCCCCAG TTCAGCAGAG TCAGTCGCCA 1620 AAGAAAACTT TGGACGTGAG TAACACCCTT CAGCAGTCGC AACGTTATTT TGGTTTTGTG 1680 AAGGACTCTC AAACCATCTA CCCTCTATAA ATTCTGGCTT TAGAAATTTC CCCAAGAATG 1740 CTCATTCTGA GAGCTTTCCT CAGCAGCATA TATCATCAGC CTCATCCTAA AATAGGCAGG 1800 GAGCCCCTCC CATGAGTTTA TCCAAGTTCT CAGCTCCTAA AATGCAGGCT GCCAAGACCC 1860 TACACCTGCC CTGGCTCTAC AGCCACTTAC CTGGTTTCTG GACTGTCACC CTCCCAGCTG 1920 ACCTGCCCGT AGCCAAGGAA TGAGGACCTA ACTTGAGTTG GCCCAAAGTC TGACCTGGCT 1980 GTATGTCCCT GTGGCCCACA CCCAGCCTGT CTTGCTCATT CATGCAGCCT CAACACTGGC 2040 CTCCAAAGTT CCCTTAACAC TTGCAAAGTC CTTTTTACCT GTGCATTTGG ACTTGAGGAC 2100 ACTGGTTTCT ATCACAGGTG AGAGCCATGT TCAATACCTC CAGCAAGCTC TCCTGGCTCC 2160 CTGCACTGTG CACGCTCCTC TTCCCAAGGT CCCAATACCA GCACCTCTAG TTAGAGTTAG 2220 GGTCAGGGTC AGGCCTCTCC CAACATCCCA GTAGTTTCTC CTCTGAGACA CATGGGCAAG 2280 AGACAATTTG GAGTCAAGAT TTTCCATTTG GATCTATTTT AAATCTTTTA GAAATGCATT 2340 TGAAACAGTG TGTTTGTTTT TTCCCTTCTA GTTAAGGGAC TATTTATATC TGTATAGGAA 2400 AGCTGTCTCT TTTTTTGTTT TTCCTTTAAC AAGGTCCAAA GAAAGATGCA AAAGGAGATC 2460 ACACCCTTGC CCCGCTGAGC CCCGTGATAA CAAGTCACTC CAGACTAACC TGTGTGCCAG 2520 ACATTTGTCC ATTGTTGCAC TTTGAGGTTA TTATTTATCA AGTTCTTCAA GGAAGCAGAA 2580 AGAGGGACTC CTCTCTCCCT CCGTGTATAG TCTCTATCTT TGTGCTAGTT TTTCTTTTTT 2640 TTCTCTCTGT CCAGTCAGCC ACAGGGCCCG CCTCCCTGCA GGAATAAGGG GTAAAACGTT 2700 AGGTCTTCTT TGGCAAGAAA CCACACTGAC TGATCAGGGG TAAAATGGAA CCAGGTAGAG 2760 CCACTCCGGG CAGCTGTCAC CCATTCAGAA CTTCTTTCCG CAGCTGAAGA AATGTTCAGT 2820 AACCTGTTTG ACGCTAATTA AAACAGAGCC TGCAGGAAGT GGGGCTAAAG TGGCATTCAG 2880 TGATCCTCTT CTGTAGACTT TTCTTTCTTT TTTTAACCAA ATCCAAAGGA TGTTACAGAA 2940 AAGCTAGCCA CTGGTATTTT GTTTTGTTTA AAAAAAAAAA GAAAGAAAGA AAGAAAGAAA 3000 AACGGAAAGG AACCTAGCTC CCTCTATCTT TCATTTTTAA AATAGCACTT GAGTTATTTT 3060 CTGAGTAATC CAATAAAGAA CTTTTCATCA CAGCCAGAAT GTGTTAGAAC TCTGGCTGAA 3120 CATTTCATCT CCTGTGAGTC AGAAGGGCTT TATTTCTCCC TTTGATGGGG CCCCTTCTTC 3180 TTTCTGGTGC TCTGGAAGTT GTTTAGAGGA AAGAATTCTA ATTTTAATTA ATTGCGCAGT 3240 GAGTTAATCT CACTCGCTTT TCTCCTTCCA GGCATCTTAG GAAAAACAAA TGGTTTTAGT 3300 AGATAAGGGA TGCCTACTAA TGCTTTTTTA AAACAAACAG GGACATTTTT ATTATAGATT 3360 TGATTTTTTT AATGAATGTT TTTAAAAATA TATAAATAGG ACACCAAAGC GGCAGGGTTT 3420 TTTTTGGGGG GAGGGGGTTT GTTTTCCAAC TCAAGATGGC ACATTAGTGG CCAGCAATAT 3480 TTTTTAACTC ATTCCAACCA GGAAGCTTTT TTATACATTG CCTAAATCTA CGCCAACCAG 3540 AAAATAGTCT CATCTCTTTT TTTCTCAAAT GAGATCCGTG TTTTATTTTA GCATTAAATT 3600 AGTTACACTG TGATGACTGG CCTATTACCT GACTCAGCTC CCTCTACCTT GAAATTGACA 3660 TTTTTAAAAA ATGCAACTAA GTCGTTAATA GTGTGTGACG CTCAAAGTTA ATGTAAACTG 3720 GAAAGGTTGT GTGTCGTTGC TTTTTGTGTT TTCGTTAGGC TTGGTTTTGT TTTTTAATTT 3780 TTATACTTTC TAATAAATTT GCAGTTTCAT TCTTTCTGTT TGTGCAAAWG GWMCTAMARM 3840 AAMMAAAAAC AWYWTTCGGG GGGCTTGGGC CTCGGAAAAA GTTTTTAACA CCACTTCGGG 3900 TGGGGCGGCG GGGCCCACGT AGGTACGGCG ACCACGCGGG CCCAAACGGG ACCCCAGAAG 3960 GAAACCCTCG CCAAGAAAAA GGTGGCGAGA ATTCTCCACA CCAGAAAAAA ACGCGCCGGG 4020 GGAAACCGCA GAGTGTTGCG TAAACCACAC CCGAAGAGAG AACTCAGAAG CACACAAGCG 4080 GGACTCAACC AGGAGGACCC AAGGGAACCC GATAGAGTAC G SEQ ID NO:171 PCQ7 Protein sequence: Protein Accession * none found 11 21 31 41 51 I l l l l MWLLGPLCLL LSSAAESQLL PGNNFTNECN IPGNFMCSNG RCIPGAWQCD GLPDCFDKSD 60 EKECPKAKSK CGPTFFPCAS GIHCIIGRFR CNGFEDCPDG SDEENCTANP LLCSTARYHC 120 KNGLCIDKSF ICDGQNNCQD NSDEESCESS QEPGSGQVFV TSENQLVYYP SITYAIIGSS 180 VIFVLWALL ALVLHHQRKR NNLMTLPVHR LQHPVLLSRL WLDHPHHCN VTYNVNNGIQ 240 YVASQAEQNA SEVGSPPSYS EALLDQRPAW YDLPPPPYSS DTESLNQADL PPYRSRSGSA 300 NSASSQAASΞ LLSVEDTSHS PGQPGPQEGT AEPRDSEPSQ GTEEV SEQ ID NO:172 PEL3 DNA SEQUENCE Nucleic Acid Accession * NM_005856.1 Coding sequence: 57-1535 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 GTCATATTGA ACATTCCAGA TACCTATCAT TACTCGATGC TGTTGATAAC AGCAAGATGG 60 CTTTGAACTC AGGGTCACCA CCAGCTATTG GACCTTACTA TGAAAACCAT GGATACCAAC 120 CGGAAAACCC CTATCCCGCA CAGCCCACTG TGGTCCCCAC TGTCTACGAG GTGCATCCGG 180 CTCAGTACTA CCCGTCCCCC GTGCCCCAGT ACGCCCCGAG GGTCCTGACG CAGGCTTCCA 240 ACCCCGTCGT CTGCACGCAG CCCAAATCCC CATCCGGGAC AGTGTCCACC TCAAAGACTA 300 AGAAAGCACT GTGCATCACC TTGACCCTGG GGACCTTCCT CGTGGGAGCT GCGCTGGCCG 360 CTGGCCTACT CTGGAAGTTC ATGGGCAGCA AGTGCTCCAA CTCTGGGATA GAGTGCGACT 420 CCTCAGGTAC CTGCATCAAC CCCTCTAACT GGTGTGATGG CGTGTCACAC TGCCCCGGCG 480 GGGAGGACGA GAATCGGTCT GTTCGCCTCT ACGGACCAAA CTTCATCCTT CAGATGTACT 540 CATCTCAGAG GAAGTCCTGβ CACCCTGTCT GCCAAGACGA CTGGAACGAG AACTACGGGC 600 GGGCGGCCTG CAGGGACATC GGCTATAAGA ATAATTTTTA CTCTAGCCAA GGAATAGTGG 660 ATGACAGCGG ATCCACCAGC TTTATGAAAC TGAACACAAG TGCCGGCAAT GTCGATATCT 720 ATAAAAAACT GTACCACAGT GATGCCTGTT CTTCAAAAGC AGTGGTTTCT TTACGCTGTT 780 TAGCCTGCGG GGTCAACTTG AACTCAAGCC GCCAGAGCAG GATCGTGGGC GGTGAGAGCG 840 CGCTCCCGGG GGCCTGGCCC TGGCAGGTCA GCCTGCACGT CCAGAACGTC CACGTCTGCG 900 GAGGCTCCAT CATCACCCCC GAGTGGATCG TGACAGCCGC CCACTCCGTG GAAAAACCTC 960 TTAACAATCC ATGGCATTGG ACGGCATTTG CGGGGATTTT GAGACAATCT TTCATGTTCT 1020 ATGGAGCCGG ATACCAAGTA CAAAAAGTCA TTTCTCATCC AAATTATGAC TCCAAGACCS. 1080 AGAACAATGA CATTGCGCTG ATGAAGCTGC AGAAGCCTCT GACTTTCAAC GACCTAGTCA 1140 AACCAGTGTG TCTGCCCAAC CCAGGCATCA TGCTCCAGCC AGAACAGCTC TGCTGGATTT 1200 CCGGGTGGGG GGCCACCGAG GAGAAAGGGA AGACCTCAGA AGTGCTGAAC GCTCCCAAGG 1260 TGCTTCTCAT TCAGACACAG AGATGCAACA GCAGATATGT CTATGACAAC CTGATCACAC 1320 CAGCCATGAT CTCTGCCGGC TTCCTGCAGG GGAACGTCGA TTCTTGCCAG GGTGACAGTG 1380 GAGGGCCTCT GGTCACTTCG AACAACAATA TCTGGTGGCT GATAGGGGAT ACAAGCTCGG 1440 GTTCTGGCTG TGCCAAAGCT TACAGACCAG GAGTGTACGG GAATGTGATG GTATTCACGG 1500 ACTGGATTTA TCGACAAATG AAGGCAAACG GCTAATCCAC ATGGTCTTCG TCCTTGACGT 1560 CGTTTTACAA GAAAACAATG GGGCTGGTTT TGCTTCCCCG TGCATGATTT ACTCTTAGAG 1620 ATGATTCAGA GGTCACTTCA TTTTTATTAA ACAGTGAACT TGTCTCGCTT TGGCACTCTC 1680 TGCCATACTG TGCAGGCTGC AGTGGCTCCC CTGCCCAGCC TGCTCTCCCT AACCCCTTGT 1740 CCGCAAGGGG TGATGGCCGG CTGGTTGTCG GCACTGGCGG TCAATTGTCG AAGGAAGAGG 1800 GTTGGAGGCT GCCCCCATTG AGATCTTCCT GCTGAGTCCT TTCCAGGGGC CAATTTTCGA 1860 TGAGCATGGA GCTGTCACTT CTCAGCTGCT GGATCACTTG AGATGAAAAA GGAGAGACAT 1920 GGAAAGGGAG ACAGCCAGGT GGCACCTGCA GCGGCTGCCC TCTGGGGCCA CTTGGTAGTC 1980 TCCCCAGCCT ACTTCACAAG GGGATTTTGC TGATGGGTTC TTAGAGCCTT AGCAGCCCTC 2040 GATGGTGGCC AGAAATAAAG GGACCAGCCC TTCATGGGTG GTGACGTGGT AGTCACTTGT 2100 AAGGGGAACA GAAACATTTT TCTTCTTATG GGGTGAGAAT ATAGACAGTG CCCTTGGTGC 2160 GAGGGAAGCA ATTCAAAAGG AACTTGCCCT GAGCACTCCT GGTGCAGGTC TCCACCTGCA 2220 CATTGGGTGG GGCTCCTGGG AGGGAGACTC AGCCTTCCTC CTCATCCTCC CTCACCCTGC 2280 TCCTAGCACC CTGGAGAGTG AATGCCCCTT GGTCCCTGGC AGGGCGCCAA GTTTGGCACC 2340 ATGTCGGCCT CTTCAGGCCT GATAGTCATT GGAAATTCAG GTCCATGGGG GAAATCAAGG 2400 ATGCTCAGTT TAAGGTACAC TGTTTCCATG TTATGTTTCT ACACATTGAT GGTCGTCACC 2460 CTCAGTTCAA AGCCATCTT SEQ ID NO:173 PEL3 Protein sequence: Protein Accession *: NPJJ05647.1 11 21 31 41 51 I I I I I MALNSGSPPA IGPYYENHGY QPENPYPAQP TWPTVYEVH PAQYYPSFVP QYAPRVLTQA 60 SNPWCTQPK SPSGTVCTSK TKKALCITLT LGTFLVGAAL AAGLLWKFMG SKCSNSGIEC 120 DSSGTCINPS NWCDGVSHCP GGEDENRCVR LYGPNFILQM YSSQRKSWHP VCQDDWNENY 180 GRAACRDMGY KNNFYSSQGI VDDSGSTSFM KLNTSAGNVD IYKKLYHSDA CSSKAWSLR 240 CLACGVNLNS SRQSRIVGGE SALPGAWPWQ VSLHVQNVHV CGGSIITPEW ΓVTAAHCVEK 300 PLNNPWHWTA FAGILRQSFM FYGAGYQVQK VISHPNYDSK TKNNDIALMK LQKPLTFNDL 360 VKPVCLPNPG MMLQPEQLCW ISGWGATEEK GKTSEVLNAA KVLLIETQRC NSRYVYDNLI 420 TPAMICAGFL QGNVDSCQGD SGGPLVTSNN NIWWLIGDTS WGSGCAKAYR PGVYGNVMVF 480 TDWIYRQMKA NG SEQ ID NO:174 PBJ4 DNA SEQUENCE Nucleic Acid Accession * AI694767 Coding sequence: 130-1086 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I CAGAGAGGCT GTATTTCAGT GCAGCCTGCC AGACCTCTTC TGGAGGAAGA CTGGACAAAG 60 GGGGTCACAC ATTCCTTCCA TACGGTTGAG CCTCTACCTG CCTCGTGCTG GTCACAGTTC 120 AGCTTCTTCA TGATGGTGGA TCCCAATGGC AATGAATCCA GTGCTACATA CTTCATCCTA 180 ATAGGCCTCC CTGGTTTAGA AGAGGCTCAG TTCTGGTTGG CCTTCCCATT GTGCTCCCTC 240 TACCTTATTG CTCTGCTAGG TAACTTGACA ATCATCTACA TTGTGCGGAC TGAGCACAGC 300 CTGCATGAGC CCATGTATAT ATTTCTTTGC ATGCTTTCAG GCATTGACAT CCTCATCTCC 360 ACCTCATCCA TGCCCAAAAT GCTGGCCATC TTCTGGTTCA ATTCCACTAC CATCCAGTTT 420 GATGCTTCTC TGCTACAGAT GTTTCCCATC CACTCCTTAT CTCGCATGGA ATCCACAGTG 480 CTGCTGGCCA TCGCTTTTGA CCGCTATGTG GCCATCTGTC ACCCACTGCG CCATGCCACA 540 GTACTTACGT TGCCTCGTGT CACCAAAATT GGTGTGGCTC CTGTGGTGCG GGGGGCTGCA 600 CTGATGGCAC CCCTTCCTGT CTTCATCAAG CAGCTGCCCT TCTGCCGCTC CAATATCCTT 660 TCCCATTCCT ACTGCCTACA CCAAGATCTC ATCAAGCTGG CCTCTGATGA TATCCGGGTC 720 AATCTCGTCT ATGGCCTTAT CGTCATCATC TCCGCCATTG GCCTGGACTC ACTTCTCATC 780 TCCTTCTCAT ATCTGCTTAT TCTTAAGACT GTCTTGGGCT TGACACGTCA AGCCCAGGCC 840 AAGGCATTTG GCACTTGCGT CTCTCATGTG TGTCCTCTGT TCATATTCTA TGTACCTTTC 900 ATTGGATTGT CCATCGTGCA TCGCTTTAGC AAGCGGCGTC ACTCTCCACT GCCCGTCATC 960 TTGGCCAATA TCTATCTGCT GGTTCCTCCT GTGCTCAACC CAATTCTCTA TGGAGTGAAG 1020 ACAAAGGAGA TTCGACAGCG CATCCTTCGA CTTTTCCATC TGGCCACACA CGCTTCAGAG 1080 CCCTAGGTGT CAGTCATCAA ACTTCTTTTC CATTCAGAGT CCTCTGATTC AGATTTTAAT 1140 GTTAACATTT TGGAAGACAG TATTCAGAAA AAAAATTTCC TTAATAAAAA TACAACTCAG 1200 ATCCTTCAAA TATGAAACTC GTTGGGGAAT CTCCATTTTT TCAATATTAT TTTCTTCTTT 1260 GTTTTCTTGC TACATATAAT TATTAATACC CTCACTAGGT TCTGGTTGGA GGGTTATTAC 1320 TTTTCATTTT ACCATGCAGT CCAAATCTAA ACTCCTTCTA CTCATGGTTT ACAGCATTCT 1380 GAGATAAGAA TGGTACATCT AGAGAACATT TGCCAAAGGC CTAAGCACAG CAAAGGAAAA 1440 TAAACACAGA ATATAATAAA ATGAGATAAT CTAGCTTAAA ACTATAACTT CCTCTTCAGA 1500 ACTCCCAACC ACATTCGATC TCAGAAAAAT ACTGTCTTCA AAATGACTTC TACAGAGAAG 1560 AAATAATTTT TCCTCTCGAC ACTAGCACTT AAGGGGAAGA TTGGAAGTAA AGCCTTCAAA 1620 AGAGTACATT TACCTACGTT AATGAAAGTT GACACACTGT TCTGAGAGTT TTCACAGCAT 1680 ATGGACCCTC TTTTTCCTAT TTAATTTTCT TATCAACCCT TTAATTAGGC AAAGATATTA 1740 TTAGTACCCT CATTCTAGCC ATGGGAAAAT TGATCTTCAG TGGGGATCAG TGAATTAAAT -1800 GGGGTCATAC AAGTATAAAA ATTAAAAAAA AAAGACTTCA TGCCCAATCT CATATCATGT 1860 GGAAGAACTG TTAAAGAGAC CAACAGGGTA GTGGGTTAGA GATTTCCAGA GTCTTACATT 1920 TTCTARAGGA GGTATTTAAT TTCTTCTCAC TCATCCAGTG TTGTATTTAG GAATTTCCTG 1980 GCAACAGAAC TCATGGCTTT AATCCCACTA GCTATTGCTT ATTGTCCTGG TCCAATTGCC 2040 AATTACCTGT GTCTTGGAAG AAGTCATTTC TAGGTTCACC ATTATGGAAG ATTCTTATTC 2100 AGAAAGTCTG CATAGGGCTT ATAGCAAGTT ATTTATTTTT AAAAGTTCCA TAGGTCTTTC 2160 TGATAGGCAG TCAGGTTAGG GAGCCACCAG TTATGATGGG AAGTATCGAA TGGCAGGTGT 2220 TGAAGATAAC ATTCGCCTTT TGAGTGTGAC TCGTAGCTGG AAAGTGAGGG AATCTTCAGG 2280 ACCATGCTTT ATTTGGGGCT TTGTGCAGTA TGGAACAGGG ACTTTGAGAC CGGGAAAGCA 2340 ATCTGACTTA GGCATGGGAA TCAGGCATTT TTGCTTCTGA GGGGCTATTA CCAAGGGTTA 2400 ATAGGTTTCA TCTTCAACAG GATATGACAA CAGTCTTAAC CAAGAAACTC AAATTACATA 2460 TACTAAAACA TGTGATCATA TATCTGGTAA GTTTCATTTT CTTTTTCAAT CCTCAGGTTC 2520 CCTGATATGG ATTCCTATNA CATGCTTTCA TCCCCTTTTG TAATGGATAT CATATTTGGA 2580 AATGCCTATT TAATACTTGT ATTTGCTGCT GGACTCTAAG CCCATGAGGG CACTGTTTAT 2640 TATTGAATGT CATCTCTGTT CATCATTGAC TGCTCTTTGC TCATCATTGA ATCCCCCAGC 2700 AAAGTGCCTA GAACATAATA GTGCTTATGC TTCACACCGG TTATTTTTCA TCAAACCTGA 2760 TTCCTTCTGT GCTGAACACA TAGCCAGGCA ATTTTCCAGC CTTCTTTGAG TTGGGTATTA 2820 TTAAATTTTA GCCATTACTT CCAATGTGAG TCGAAGTCAC ATGTGCAATT TTTATACCTG 2880 GCTCATAAAA CCCTCCCATG TGCAGCCTTT CATCTTGACA TTAAATGTGA CTTGGGAAGC 2940 TATGTGTTAC ACAGAGTTAA TTAACCNGAA AGGCCTGGNA ATTTTTTGNN AANNAAACTG 3000 TGGCCNNGAG GCCCNCAACC CTTTTTNNNA ATTTGGCAAN NTCCCACTTT GTANTTTGGT 3060 AAGGAGGCCA GTTGGATAAG TGAAAAATAA AGTACTATTG TGTC SEQ ID NO:175 PBJ4 PROTEIN SEQUENCE Protein Accession #: not available, cloned at Eos 11 21 31 41 51 MVDPNGNESS ATYFILIGLP GLEEAQFWLA FPLCSLYLIA VLGNLTIIYI VRTEHSLHEP 60 MYIFLCMLSG IDILISTSSM PKMLAIFWFN STTIQFDACL LQMFAIHSLS GMESTVLLAM 120 AFDRYVAICH PLRHATVLTL PRVTKIGVAA WRGAALMAP LPVFIKQLPF CRSNILSHSY 180 CLHQDVMKLA CDDIRVNWY GLIVIISAIG LDSLLISFSY LLILKTVLGL TREAQAKAFG 240 TCVSHVCAVF IFYVPFIGLS MVHRFSKRRD SPLPVILANI YLLVPPVLNP IVYGVKTKEI 300 RQRILRLFHV ATHASEP SEQ ID NO:176 P 72 DNA SEQUENCE Nucleic Acid Accession* N _004624.1 Coding sequence: 57-1544 (underlined sequences correspond to start and stop codons) TCGGAGCCTG CGGAGGGTGG TGGTGGTGGT GGTGGTGGCC CTCGCCCGCC TCACTCATGC 60 CTCCTCCTCC TCTGCTCTCG CTCAGGCGCC TCGGTGGCGG TTGGTCGGCG GTTACGCGGC 120 TGGTGGTCGC GGCGGCCGGG GCTCGCTCTC GGGGAGGCCG GGGCGGATCT CGCGGCGCAG 180 GCGGCGGCGG CCGAGGTGGG GTCGCGCGGC GGAGGCGGCT CGAGCTTCGT GCTGCGCGCT 240 CGCTCTTGGG CTCCTCGCTG CAGGAGGAGT GTGACTATGT GCAGATGATC GAGGTGCAGC 3 00 ACAAGCAGTG CCTGGAGGAG GCCCAGCTGG AGAATGAGAC AATAGGCTGC AGCAAGATGT 360 GGGACAACCT CACCTGCTGG CCAGCCACCC CTCGGGGCCA GGTAGTTGTC TTGGCCTGTC 420 CCCTCATCTT CAAGCTCTTC TCCTCCATTC AAGGCCGCAA TGTAAGCCGC AGCTGCACCG 480 ACGAAGGCTG GACGCACCTG GAGCCTGGCC CGTACCCCAT TGCCTGTGGT TTGGATGACA 540 AGGCAGCGAG TTTGGATGAG CAGCAGACCA TGTTCTACGG TTCTGTGAAG ACCGGCTACA 600 CCATTGGCTA CGGCCTGTCC CTCGCCACCC TTCTGGTCGC CACAGCTATC CTGAGCCTGT 660 TCAGGAAGCT CCACTGCACG CGGAACTACA TCCACATGCA CCTCTTCATA TCCTTCATCC 720 TGAGGGCTGC CGCTGTCTTC ATCAAAGACT TGGCCCTCTT CGACAGCGGG GAGTCGGACC 780 AGTGCTCCGA GGGCTCGGTG GGCTGTAAGG CAGCCATGGT CTTTTTCCAA TATTGTGTCA 840 TGGCTAACTT CTTCTGGCTG CTGGTGGAGG GCCTCTACCT GTACACCCTG CTTGCCGTCT 900 CCTTCTTCTC TGAGCGGAAG TACTTCTGGG GGTACATACT CATCGGCTGG GGGGTACCCA 960 GCACATTCAC CATGGTGTGG ACCATCGCCA GGATCCATTT TGAGGATTAT GGTCTGCTCA 1020 GGTGCTGGGA CACCATCAAC TCCTCACTGT GGTGGATCAT AAAGGGCCCC ATCCTCACCT 1080 CCATCTTGGT AAACTTCATC CTGTTTATTT GCATCATCCG AATCCTGCTT CAGAAACTGC 1140 GGCCCCCAGA TATCAGGAAG AGTGACAGCA GTCCATACTC AAGGCTAGCC AGGTCCACAC 1200 TCCTGCTGAT CCCCCTGTTT GGAGTACACT ACATCATGTT CGCCTTCTTT CCGGACAATT 1260 TTAAGCCTGA AGTGAAGATG GTCTTTGAGC TCGTCGTGGG GTCTTTCCAG GGTTTTGTGG 1 3 20 TGGCTATCCT CTACTGCTTC CTCAATGGTG AGGTGCAGGC GGAGCTGAGG CGGAAGTGGC 1380 GGCGCTGGCA CCTGCAGGGC GTCCTGGGCT GGAACCCCAA ATACCGGCAC CCGTCGGGAG 1440 GCAGCAACGG CGCCACGTGC AGCACGCAGG TTTCCATGCT GACCCGCGTC AGCCCAGGTG 1500 CCCGCCGCTC CTCCAGCTTC CAAGCCGAAG TCTCCCTGGT CTGACCACCA GGATCCCAGC 1560 CCAAGCGGCC CCTCCCGCCC CTTCCCACTC GCAGCAGACG CCGGGGACAG AGGCCTGCCC 1620 GGGCGCGCCA GCCCCGGCCC TGGGCTCGGA GGCTGCCCCC GGCCCCCTGG TCTCTGGTCC 1680 GGACACTCCT AGAGAACGCA GCCCTAGAGC CTGCCTGGAG CGTTTCTAGC AAGTGAGAGA 1740 GATGGGAGCT CCTCTCCTGG AGGATGCAGG TGGAACTCAG TCATTAGACT CCTCCTCCAA 1800 AGGCCCCCTA CGCCAATCAA GGGCAAAAAG TCTACATACT TTCATCCTGA CTCTGCCCCC 1860 TGCTGGCTCT TCTGCCCAAT TGGAGGAAAG CAACCGGTGG ATCCTCAAAC AACACTGGTG 1920 TGACCTGAGG GCAGAAAGGT TCTGCCCGGG AAGGTCACCA GCACCAACAC CACGGTAGTG 1980 CCTGAAATTT CACCATTGCT GTCAAGTTCC TTTGGGTTAA GCATTACCAC TCAGGCATTT 2040 GACTGAAGAT GCAGCTCACT ACCCTATTCT CTCTTTACGC TTAGTTATCA GCTTTTTAAA 2100 GTGGGTTATT CTGGAGTTTT TGTTTGGAGA GCACACCTAT CTTAGTGGTT CCCCACCGAA 2160 GTGGACTGGC CCCTGGGTCA GTCTGGTGGG AGGACGGTGC AACCCAAGGA CTGAGGGACT 2220 CTGAAGCCTC TGGGAAATGA GAAGGCAGCC ACCAGCGAAT GCTAGGTCTC GGACTAAGCC 2280 TACCTGCTCT CCAAGTCTCA GTGGCTTCAT CTGTCAAGTG GGACTCTGTC ACACCAGCCA 2340 TTCTTATCTC TCTGTGCTGT GGAAGCAACA GGAATCAAGA GACTGCCCTC CTTGTCCACC 2400 CACCTATGTG CCAACTGTTG TAACTAGGCT CAGAGATGTG CACCCATGGG CTCTGACAGA 2460 AAGCAGATCC TCACCCTGCT ACACATACAG GATTTGAACT CAGATCTGTC TGATAGGAAT 2520 GTGAAAGCAC GGACTCTTAC TGCTAACTTT TGTGTATCGT AACCAGCCAG ATCCTCTTGG 2580 TTATTTGTTT ACCACTTGTA TTATTAATGC CATTATCCCT GAATTCCCCT TGCCACCCCA 2640 CCCTCCCTGG AGTGTGGCTG AGGAGGCCTC CATCTCATGT ATCATCTGGA TAGGAGCCTG 2700 CTGGTCACAG CCTCCTCTGT CTGCCCTTCA CCCCAGTGGC CACTCAGCTT CCTACCCACA 2760 CCTCTGCCAG AAGATCCCCT CAGGACTGCA ACAGGCTTGT GCAACAATAA ATGTTGGCTT 2820 GGAAAAAAAA AAAA SEQ ID NO:177 P 72 Protein sequence: Protein Accession *: JC2195 1 11 21 31 41 51 I I I I I I MPPPPLLSLR RLGGGWSAVT RLWAAAGAR SRGGRGGSRG AGGGGRGGVA RRRRLELRAA 60 RSLLGSSLQE ECDYVQMIEV QHKQCLEEAQ LENETIGCSK MWDNLTCWPA TPRGQWVLA 120 CPLIFKLFSS IQGRNVSRSC TDEGWTHLEP GPYPIACGLD DKAASLDEQQ TMFYGSVKTG 180 YTIGYGLSLA TLLVATAILS LFRKLHCTRN YIHMHLFISF ILRAAAVFIK DLALFDSGES 240 DQCSEGSVGC KAAMVFFQYC VMANFFWLLV EGLYLYTLLA VSFFSERKYF WGYILIGWGV 300 PSTFTMVWTI ARIHFEDYGL LRCWDTINSS LWWIIKGPIL TSILVNFILF ICIIRILLQK 360 LRPPDIRKSD SSPYSRLARS TLLLIPLFGV HYIMFAFFPD NFKPEVKMVF ELWGSFQGF 420 WAILYCFLN GEVQAELRRK WRRWHLQGVL GWNPKYRHPS GGSNGATCST QVSMLTRVSP 480 GARRSSSFQA EVSLV SEQ ID NO:178 BFF8 DNA SEQUENCE Nucleic Acid Accession * AL133619 Coding sequence: 1-2070 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 l l l l ATCAGCGGTC CGGGGGTGGC GGCTGGGACG CGGCCCCCCA GCTCGCCGAC CCCGGGCTCT 60 CGGCGCCGGC GCCAGCGCCC CTCTGTGGGC GTCCAGTCCT TGAGGCCGCA GAGCCCGCAG 120 CTCAGGCAGA GCGACCCGCA GAAACGGAAC CTGGACCTGG AGAAAAGCCT GCAGTTCCTC 180 CAGCAGCAGC ACTCGGAGAT GCTGGCCAAG CTCCATGAGG AGATCGAGCA TCTGAAGCGG 240 GAAAACAAGG GTGAGCCGGC GCGGGGCCCT AGGCCGGCCC TGCCTCCCCA GGCACACTCA 300 ACACTGCCGC TCCCGCAGCA CAGAAACACA GCCATCAACT CCAGCACACG CCTGGGCTCA 360 GGGGGAACAC AGGACGGGGA GCCCCTCCAG ACTCTCCTTG CCCACCTGGC TCCACTCGCC 420 CCTCTATGCC AACCCAGTGG GTACAGGTTC TGGGGGACCT GGACAGATGC CGCTACCTCT 480 AGCCGTGGCT GGACGATCTT ATGCAGCCAA GCACAGCACG TGCTGCTCTC GGGAAGCCCA 540 GGGCCTGAGG TCATTCCAGG GCGGCAGGTG GCCACAGGGT GCTCCCCAGA CCTCCCTCCT 600 CCAAGTAGAG CTCAAATGGG AAGGAACCCC TCGGACAGCC CCTGCCCTGC TAGATCTTTG 660 CCTCAGATTG CTCCTCTCGC CAGGCCCAGG ATTTCCAGCC CTATGGCTCT GAGTCCTCAC 720 ATGCTGGGGG CCCAGGGGAT ATGGACACAC TCCATCCAGG GATCCCTTCC TGCCATCTGG 780 GCAGCAACCA TGGGGACAAA GGGAGGAAGC AGAGTCCTGT TTCCTTGCCA CTTGTCCAAG 840 GCACTTCCCC ATCCTGACAG CGGCCCCCAC CCAGCCCAGG ATCCTGGGCT GTGGTCTCAA 900 GCTCACTTCC CATTATCTTT GGGGCTGGGG CTGACATCAG GAGGACATCT GACTGGTGGA 960 TGGAGCCAGC CTGGGAACAT CGCAGCTGGG GCAGTCCCTA GGGCTCTCCC TTCCCAGGGA 1020 GACATGGAGA AGGGGGTTGA GGGAGGGCCC TTCCCTAGCC GCTGTGGCAA CTCCAGTGAG 1080 CTCTTCTGGG CAAAGTGTGG CCCAAGTCGG CAGCCCCAGC CCTGCAGTCC TGGGGACGCT 1140 GACAGGACAC GGGAAGAGGC CATGCTTTCC CTCGGGACCT GCTGTTCCAT GTGTCCCAAG 1200 CCCTCCTGCT TTCCAGATGG CCCCTCAGGA AACCACCTTT CCAGGGCCTC TGCTCCCTTG 1260 GGCGCTCGCT GGGTCTGCAT CAACGGAGTG TGGGTAGAGC CGGGAGGACC CAGCCCTGCC 1320 AGGCTGAAGG AGGGCTCCTC ACGGACACAC AGGCCAGGAG GCAAGCGTCG GCGTCTTGCG 1380 GGCGGTAGCG CCGACACTCT GCGCTCTCCT GCAGACAGCC TCTCCATGTC AAGCTTCCAG 1440 TCTGTCAAGT CCATCTCTAA TTCAGCCAAC TCTCAAGGCA AGGCCAGGCC CCAGCCCGGC 1500 TCCTTCAACA AGCAAGATTC AAAAGCTCAC GTCTCCCAGA AGGCGGACCT GGAAGAGGAG 1560 CCCCTACTTC ACAACAGCAA GCTGGACAAA GTTCCTGGGG TACAAGGGCA GGCCAGAAAG 1620 GAGAAAGCAG AGGCCTCTAA TGCAGGAGCT GCCTCTATGG GGAACAGCCA GCACCAGGGC 1680 AGGCAGATGG GGGCGGGGGC ACACCCCCCA ATGATCCTGC CCCTTCCCCT GCGAAAGCCC 1740 ACCACACTTA GGCAGTGCGA AGTGCTCATC CGCGAGCTGT GGAATACCAA CCTCCTGCAG 1800 ACCCAAGAGC TGCGGCACCT CAAGTCCCTC CTCGAAGGGA GCCAGAGGCC CCAGGCAGCC 1860 CCGGAGGAAG CTAGCTTTCC CAGGGACCAA GAAGCCACGC ATTTCCCCAA GGTCTCCACC 1920 AAGAGCCTCT CCAAGAAATC CCTGAGCCCA CCTCTGGCGG AGCGTGCCAT CCTGCCCGCA 1980 CTGAAGCAGA CCCCGAAGAA CAACTTTGCC GAGAGGCAGA AGAGGCTGCA GGCAATGCAG 2040 AAACGGCGCCTGCATCGCTCAGTGCTTJ___ SEQ ID NO:179 BFF8 Protein sequence: Protein Accession* T43457 11 21 31 41 51 I I I I I MSGAGVAAGT RPPSSPTPGS RRRRQRPSVG VQSLRPQSPQ LRQSDPQKRN LDLEKSLQFL 60 QQQHSEMLAK LHEEIEHLKR ENKGEPARGP RPALPPQAHS TLPLPQHRNT AINSSTRLGS 120 GGTQDGEPLQ TVLAHLAALA PVCQPSGYRF WGTWTDAATS SRGWTMLCSQ AQHVLLSGSP 180 GPEVIAGRQV ATGCSPDLPP PSRAEMGRNP WDSPCPARSL PQIAAVARPR ISΞPMALSPH 240 MLGAQGIWTH SIQGSLPAIW AATMGTKGGS RVLFPCHLSK ALPHPDSGPH PAQDPGLWSQ 300 AHFPLSLGLG LTSGGHLTGG WSQPGNIAAG AVPRALPSQG DMEKGVEGGP FPSRCGNSSE 360 LFWAKCGPSR QPQPCSAGDA DRTREEAMLS LGTCCSMCPK PSCFPDGPSG NHLSRASAPL 420 GARWVCINGV WVEPGGPSPA RLKEGSSRTH RPGGKRGRLA GGSADTVRSP ADSLSMSSFQ 480 SVKSISNSAN SQGKARPQPG SFNKQDSKAD VSQKADLEEE PLLHNSKLDK VPGVQGQARK 540 EKAEASNAGA ACMGNSQHQG RQMGAGAHPP MILPLPLRKP TTLRQCEVLI RELWNTNLLQ 600 TQELRHLKSL LEGSQRPQAA PEEASFPRDQ EATHFPKVST KSLSKKCLSP PVAERAILPA 660 LKQTPKNNFA ERQKRLQAMQ KRRLHRSVL SEQ ID NO:180 BCR4 DNA SEQUENCE Nucleic Acid Accession *: N 012319.2 Coding sequence: 138-2405 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I I CTCGTGCCGA ATTCGGCACG AGACCGCGTG TTCGCGCCTG GTAGAGATTT CTCGAAGACA 60 CCAGTGGGCC CGTCTGGAAC CAAACCTGCG CGCGTGGCCG GGCCGTGGGA CAACGAGGCC 120 GCGGAGACGA AGGCGCAATG GCGAGGAAGT TATCTGTAAT CTTGATCCTG ACCTTTGCCC 180 TCTCTCTCAC AAATCCCCTT CATGAACTAA AAGCAGCTCC TTTCCCCCAG ACCACTCAGA 240 AAATTAGTCC GAATTGGGAA TCTGGCATTA ATCTTGACTT GGCAATTTCC ACACGGCAAT 300 ATCATCTACA ACAGCTTTTC TACCGCTATG GAGAAAATAA ΪTCTTTGTCA GTTGAAGGGT 360 TCAGAAAATT ACTTCAAAAT ATAGGCATAG ATAAGATTAA AAGAATCCAT ATACACCATG 420 ACCACGACCA TCACTCAGAC CACGAGCATC ACTCAGACCA TGAGCGTCAC TCAGACCATG 480 AGCATCACTC AGACCACGAG CATCACTCTβ ACCATGATCA TCACTCTCAC CATAATCATG 540 CTGCTTCTGG TAAAAATAAG CGAAAAGCTC TTTGCCCAGA CCATGACTCA GATAGTTCAG 600 GTAAAGATCC TAGAAACAGC CAGGGGAAAG GAGCTCACCG ACCAGAACAT GCCAGTCGTA 660 GAAGGAATGT CAAGGACAGT GTTAGTGCTA GTGAAGTCAC CTCAACTCTG TACAACACTG 720 TCTCTCAAGG AACTCACTTT CTAGAGACAA TAGAGACTCC AAGACCTGGA AAACTCTTCC 780 CCAAAGATGT AAGCAGCTCC ACTCCACCCA GTGTCACATC AAAGAGCCGG GTGAGCCGGC 840 TGGCTGGTAG GAAAACAAAT GAATCTGTGA GTGAGCCCCG AAAAGGCTTT ATGTATTCCA 900 GAAACACAAA TGAAAATCCT CAGGAGTGTT TCAATGCATC AAAGCTACTG ACATCTCATG 960 GCATGGGCAT CCAGGTTCCG CTGAATGCAA CAGAGTTCAA CTATCTCTGT CCAGCCATCA 1020 TCAACCAAAT TGATGCTAGA TCTTGTCTGA TTCATACAAG TGAAAAGAAG GCTGAAATCC 1080 CTCCAAAGAC CTATTCATTA CAAATAGCCT GGGTTCGTGG TTTTATAGCC ATTTCCATCA 1140 TCAGTTTCCT GTCTCTGCTG GGGGTTATCT TAGTGCCTCT CATGAATCGG GTGTTTTTCA 1200 AATTTCTCCT GAGTTTCCTT GTGGCACTGG CCGTTCGGAC TTTGAGTGGT GATCCTTTTT 1260 TACACCTTCT TCCACATTCT CATGCAAGTC ACCACCATAG TCATAGCCAT GAAGAACCAG 1320 CAATGGAAAT GAAAAGAGGA CCACTTTTCA GTCATCTCTC TTCTCAAAAC ATAGAAGAAA 1 3 80 GTGCCTATTT TGATTCCACG TGGAAGGGTC TAACAGCTCT AGGAGGCCTC TATTTCATGT 1440 TTCTTGTTGA ACATGTCCTC ACATTGATCA AACAATTTAA AGATAAGAAG AAAAAGAATC 1500 AGAAGAAACC TCAAAATGAT GATGATGTGG AGATTAAGAA GCAGTTCTCC AAGTATGAAT 1560 CTCAACTTTC AACAAATGAG GAGAAAGTAG ATACAGATCA TCGAACTCAA GGCTATTTAC 1620 GAGCAGACTC ACAAGAGCCC TCCCACTTTG ATTCTCAGCA GCCTGCAGTC TTGGAAGAAG 1680 AAGAGGTCAT GATAGCTCAT GCTCATCCAC AGGAAGTCTA CAATGAATAT GTACCCAGAG 1740 GGTCCAAGAA TAAATGCCAT TCACATTTCC ACGATACACT CGGCCAGTCA GACGATCTCA 1800 TTCACCACCA TCATGACTAC CATCATATTC TCCATCATCA CCACCACCAA AACCACCATC 1860 CTCACAGTCA CAGCCAGCGC TACTCTCGGG AGGAGCTGAA AGATCCCGGC GTCGCCACTT 1920 TGGCCTGGAT GGTGATAATG GGTGATGGCC TCCACAATTT CAGCGATGGC CTAGCAATTG 1980 GTGCTGCTTT TACTGAAGGC TTATCAAGTG GTTTAAGTAC TTCTGTTGCT GTCTTCTGTC 2040 ATGAGTTGCC TCATGAATTA GGTGACTTTG CTGTTCTACT AAAGGCTGGC ATGACCGTTA 2100 AGCAGGCTGT CCTTTATAAT GCATTGTCAG CCATGCTCGC GTATCTTGGA ATGGCAACAG 2160 GAATTTTCAT TGGTCATTAT GCTGAAAATG TTTCTATGTC GATATTTGCA CTTACTGCTG 2220 GCTTATTCAT GTATGTTGCT CTGGTTGATA TGGTACCTCA AATGCTGCAC AATCATCCTA 2280 GTGACCATGG ATGTAGCCGC TGGGGGTATT TCTTTTTACA GAATGCTGGG ATGCTTTTGG 2340 GTTTTGGAAT TATGTTACTT ATTTCCATAT TTGAACATAA AATCGTGTTT CGTATAAATT 2400 TCTAGTTAAG GTTTAAATGC TAGAGTAGCT TAAAAAGTTG TCATAGTTTC AGTAGGTCAT 2460 AGGGAGATGA GTTTGTATGC TGTACTATGC AGCGTTTAAA GTTAGTGGGT TTTGTGATTT 2520 TTGTATTGAA TATTGCTGTC TGTTACAAAG TCAGTTAAAG GTACGTTTTA ATATTTAAGT 2580 TATTCTATCT TGGAGATAAA ATCTGTATGT GCAATTCACC GGTATTACCA GTTTATTATG 2640 TAAACAAGAG ATTTGGCATG ACATGTTCTG TATGTTTCAG GGAAAAATGT CTTTAATGCT 2700 TTTTCAAGAA CTAACACAGT TATTCCTATA CTGGATTTTA GGTCTCTGAA GAACTGCTGG 2760 TGTTTAGGAA TAAGAATGTG CATCAAGCCT AAAATACCAA GAAAGCTTAT ACTCAATTTA 2820 AGCAAAGAAA TAAAGGAGAA AAGAGAAGAA TCTCAGAATT GGGGAGGCAT AGATTCTTAT 2880 AAAAATCACA AAATTTGTTG TAAATTAGAG GGGAGAAATT TAGAATTAAG TATAAAAAGG 2940 CAGAATTAGT ATAGAGTACA TTCATTAAAC ATTTTTGTCA GGATTATTTC CCGTAAAAAC 3 000 GTAGTGAGCA CTCTCATATA CTAATTAGTG TACATTTAAC TTTGTATAAT ACAGAAATCT 3060 AAATATATTT AATCAATTCA AGCAATATAC ACTTCACCAA GAAATTCGAA TTTCAAAATG 3120 TTCGTGCGGG TTATATACCA GATGAGTACA GTGAGTAGTT TATCTATCAC CAGACTGGGT 3180 TATTCCCAAG TTATATATCA CCAAAAGCTG TATGACTGGA TGTTCTCGTT ACCTGGTTTA 3240 CAAAATTATC AGAGTAGTAA AACTTTGATA TATATGAGGA TATTAAAACT ACACTAAGTA 3300 TCATTTGATT CGATTCAGAA AGTACTTTGA TATCTCTCAG TGCTTCAGTG CTATCATTGT 3360 GAGCAATTGT CTTTATATAC GGTACTGTAG CCATACTAGG CCTGTCTGTG GCATTCTCTA 3420 GATGTTTCTT TTTTACACAA TAAATTCCTT ATATCAGCTT G SEQ ID N0:181 BCR4 PROTEIN SEQUENCE Protein Accession * NP 036451 11 21 31 41 51 I I I MARKLSVILI LTFALSVTNP LHELKAAAFP QTTEKISPNW E ISGINVDI-AI S ITRQYHLQQL 60 FYRYGENNSL SVEGFRKLLQ NIGIDKIKRI HIHHDHDHHS DHEHHSDHER HSDHEHHSDH 120 EHHSDHDHHS HHNHAASGKN KRKALCPDHD SDSSGKDPRN SQGKGAHRPE HASGRRNVKD 180 SVSASEVTST VYNTVSEGTH FLETIETPRP GKLFPKDVSS STPPSVTSKS RVSRLAGRKT 240 NESVSEPRKG FMYSRNTNEN PQECFNASKL LTSHGMGIQV PLNATEFNYL CPAIINQIDA 300 RSCLIHTSEK KAEIPPKTYS LQIAWVGGFI AISIISFLSL LGVILVPLMN RVFFKFLLSF 360 LVALAVGTLS GDAFLHLLPH SHASHHHΞHS HEEPAMEMKR GPLFSHLSSQ NIEESAYFDS 420 TWKGLTALGG LYFMFLVEHV LTLIKQFKDK KKKNQKKPEN DDDVEIKKQL SKYESQLSTN 480 EEKVDTDDRT EGYLRADSQE PSHFDSQQPA VLEEEEVMIA HAHPQEVYNE YVPRGCKNKC 540 HSHFHDTLGQ SDDLIHHHHD YHHILHHHHH QNHHPHSHSQ RYSREELKDA GVATLAWMVI 600 MGDGLHNFSD GLAIGAAFTE GLSSGLSTSV AVFCHELPHE LGDFAVLLKA GMTVKQAVLY 660 NALSAMLAYL GMATGIFIGH YAENVSMWIF ALTAGLFMYV ALVDMVPEML HNDASDHGCS 720 RWGYFFLQNA GMLLGFGIML LISIFEHKΓV FRINF SEQ ID NO:182BCY2 DNA sequence Nucleic Acid Accession *: NM_001203 Coding sequence: 274-1782 (underiined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I CGCGGGGCGC GGAGTCGGCG GGGCCTCGCG GGACGCGGGC AGTGCGGAGA CCGCGGCGCT 60 GAGGACGCGG GAGCCGGGAG CGCACGCGCG GGGTGGAGTT CAGCCTACTC TTTCTTAGAT 120 GTGAAAGGAA AGGAAGATCA TTTCATCCCT TGTTGATAAA GGTTCAGACT TCTGCTGATT 180 CATAACC ATT TGGCTCTG AG CTATGACAAG AGAGGAAACA AAA AGTTAAA CTTACAAGCC 240 TGCCATAAGT GAGAAGCAAA CTTCCTTGAT AACATGCTTT TGCGAAGTGC AGGAAAATTA 300 AATGTGGGCA CCAAGAAAGA GGATGGTGAG AGTACAGCCC CCACCCCCCG TCCAAAGGTC 360 TTGCGTTGTA AATGCCACCA CCATTGTCCA GAAGACTCAG TCAACAATAT TTGCAGCACA 420 GACGGATATT GTTTCACGATGATAGAAGAG GATGACTCTG GGTTGCCTGT GGTCACTTCT 480 GGTTGCCTAG GACTAGAAGG CTCAGATTTT CAGTGTCGGG ACACTCCCATTCCTCATCAA 540 AGAAGATCAA TTGAATGCTG CACAGAAAGG AACGAATGTA ATAAAGACCT ACACCCTACA 600 CTGCCTCCAT TGAAAAACAG AGATTTTGTT GATGGACCTA TACACCACAG GGCTTTACTT 660 ATATCTGTGA CTGTCTGTAG TTTGCTCTTG GTCCTTATCA TATTATTTTG TTACTTCCGG 720 TATAAAAGAC AAGAAACCAG ACCTCGATAC AGCATTGGGTTAGAACAGGA TGAAACTTAC 780 ATTCCTCCTG GAGAATCCCT GAGAGACTTA ATTGAGCAGTCTCAGAGCTC AGGAAGTGGA 840 TCAGGCCTCC CTCTGCTGGT CCAAAGGACT ATAGCTAAGC AGATTCAGAT GGTGAAACAG 900 ATTGGAAAAG GTCGCTATGG GGAAGTTTGG ATGGGAAAGT GGCGTCGCGA AAAGGTAGCT 960 GTGAAAGTGT TCTTCACCAC AGAGGAAGCC AGCTGGTTCA GAGAGACAGA AATATATCAG 1020 ACAGTGTTGA TGAGGCATG A AAACATTTTG GGTTTCATTG CTGCAGATAT CAAAGGGACA 1080 GGGTCCTGGA CCCAGTTGTA CCTAATC ACA GACTATCATG AAAATGGTTC CCTTTATGAT 1140 TATCTGAAGT CCACCACCCT AGACGCTAAA TCAATGCTGA AGTTAGCCTA CTCTTCTGTC 1200 AGTGGCTTAT GTCATTTACA CACAGAAATC TTTAGTACTC AAGGCAAACC AGCAATTGCC 1260 CATCGAGATC TGAAAAGTAA AAACATTCTG GTGAAGAAAA ATGGAACTTG CTGTATTGCT 1320 GACCTGGGCC TGGCTGTTAA ATTTATTAGT GATACAAATG AAGTTGACAT ACCACCTAAC 1380 ACTCGAGTTG GCACCAAACG CTATATGCCT CCAGAAGTGT TGGACGAGAG CTTGAACAGA 1440 AATCACTTCC AGTCTTACAT CATGGCTGAC ATGTATAGTT TTGGCCTCAT CCTTTGGGAG 1500 GTTGCTAGGA GATGTGTATC AGGAGGTATA GTGGAAGAAT ACCAGCTTCC TTATCATGAC 1560 CTAGTGCCCA GTGACCCCTC TTATGAGGAC ATGAGGGAGA TTGTGTGCAT CAAGAAGTTA 1620 CGCCCCTCAT TCCCAAACCG GTGGAGCAGT GATGAGTGTC TAAGGCAGAT GGGAAAACTC 1680 ATGACAGAAT GCTGGGCTCA CAATCCTGCA TCAAGGCTGA CAGCCCTGCG GGTTAAGAAA 1740 ACACTTGCCA AAATGTCAGA GTCCCAGGAC ATTAAACTCT GATAGGAGAG GAAAAGTAAG 1800 CATCTCTGCA GAAAGCCAAC AGGTACTCTT CTGTTTGTGG GCAGAGCAAA AGACATCAAA 1860 TAAGCATCCA CAGTACAAGC CTTGAACATC GTCCTGCTTC CCAGTGGGTT CAGACCTCAC 1920 CTTTCAGGGA GCGACCTGGG CAAAGACAGA GAAGCTCCCA GAAGGAGAGA TTGATCCGTG 1980 TCTGTTTGTA GGCGGAGAAA CCGTTGGGTA ACTTGTTCAA GATATGATGC AT SEQ ID NO:183 BCY2 Protein sequence Protein Accession*: NP_001194 1 11 21 31 41 51 I I I I I I MIXRSAGKLN VGTKKEDGES TAPTPRPKVL RCKCHHHCPE DS VNNICSTD GYCFTMIEED 60 DSGIJVVTSG CLGLEGSDFQ CRDTPIPHQR RSIECCTERN ECNKDLHPTLPPLKNRDFVD 120 GPIHHRALU SVTVCSLI-LV LIILFCYFRY KRQETRPRYS IGLEQDETYIPPGESLRDLI 180 EQSQSSGSGS GLPLLVQRTI AKQIQMVKQI GKGRYGEVWM GKWRGEKVAV KVFFTTEEAS 240 WFRETEIYQT VLMRHENILG HAADKGTG SWTQLYLITD YHENGSLYDY LKSTTLDAKS 300 M KLAYSSVS GLCHLHTEIF STQGKPAIAH RDLKSKNILV KKNGTCCIAD LGLAVKFISD 360 TNEVDIPPNTRVGTKRYMPP EVLDESLNRN HFQSYIMADM YSFGLILWEV A-RRCVSGGrV 420 EEYQLPYHDLVPSDPSYEDM REIVCIKKLR PSFPNRWSSD ECLRQMGKLM TECWAHNPAS 480 RLTALRVKKT LAKMSESQDI KL SEQ ID NO:184CBF9 DNA sequence Nucleic Acid Accession*: AC005383 Coding Sequence: 328-2751 (undedined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I GACAGTGTTC GCGGCTGCAC CGCTCGGAGG CTGGGTGACC CGCGTAGAAG TGAAGTACTT 60 TTTTATTTCC AGACCTGGGC CGATGCCGCT TTAAAAAACG CGAGGGGCTC TATGCACCTC 120 CCTGGCGGTA GTTCCTCCGA CCTCAGCCGG GTCGGGTCGT GCCGCCCTCT CCCAGGAGAG 180 ACAAACAGGT GTCCCACGTG GCAGCCGCGC CCCGGGCGCC CCTCCTCTCA TCCCGTAGCG 240 CCCCCTGGCC CGAGCCGCGC CCGGGTCTGT GAGTAGAGCC GCCCGGGCAC CGAGCGCTGG 300 TCGCCGCTCT CCTTCCGTTA TATCAACATG CCCCCTTTCC TGTTGCTGGA GGCCGTCTGT 3 60 GTTTTCCTGT TTTCCAGAGT GCCCCCATCT CTCCCTCTCC AGGAAGTCCA TGTAAGCAAA 420 GAAACCATCG GGAAGATTTC AGCTGCCAGC AAAATGATGT GGTGCTCGGC TCCAGTGGAC 480 ATCATCTTTC TGTTAGATGG GTCTAACAGC GTCGGGAAAG GGAGCTTTGA AAGGTCCAAG 540 CACTTTGCCA TCACAGTCTG TGACGGTCTG GACATCAGCC CCGAGAGGGT CAGAGTGGGA 600 GCATTCCAGT TCAGTTCCAC TCCTCATCTG GAATTCCCCT TGGATTCATT TTCAACCCAA 660 CAGGAAGTCA AGGCAAGAAT CAAGAGGATC GTTTTCAAAG GAGGGCGCAC GGAGACGGAA 720 CTTGCTCTGA AATACCTTCT GCACAGAGGG TTCCCTGGAG GCAGAAATGC TTCTCTGCCC 780 CAGATCCTCA TCATCGTCAC TCATGGGAAG TCCCAGGGGG ATCTGGCACT GCCATCCAAG 840 CAGCTGAAGG AAAGGGGTCT CACTGTCTTT GCTGTGGGGG TCAGGTTTCC CAGGTGGGAG 900 GAGCTGCATG CACTGGCCAG CGAGCCTAGA GGGCAGCACG TGCTGTTCGC TGAGCAGGTG 960 GAGGATCCCA CCAACGGCCT CTTCAGCACC CTCAGCAGCT CGGCCATCTβ CTCCAGCGCC 1020 ACGCCAGACT GCAGGGTCGA GGCTCACCCC TCTGAGCACA GGACGCTCGA GATGGTCCGG 1080 GAGTTCGCTG GCAATGCCCC ATGCTGGAGA GGATCGCGGC GGACCCTTGC GGTCCTGGCT 1140 GCACACTCTC CCTTCTACAG CTGGAAGAGA GTGTTCCTAA CCCACCCTGC CACCTGCTAC 1200 .0 AGGACCACCT GCCCAGGCCC CTGTGACTCG CAGCCCTGCC AGAATGGAGG CACATCTCTT 1260 CCAGAAGGAC TGGACGGCTA CCAGTCCCTC TGCCCGCTCG CCTTTGGAGG GGAGGCTAAC 1320 TGTGCCCTGA AGCTGAGCCT GGAATCCAGG GTCGACCTCC TCTTCCTGCT GGACAGCTCT 1380 GCGGGCACCA CTCTGGACGG CTTCCTGCGG GCCAAAGTCT TCGTGAAGCG GTTTGTGCGG 1440 GCCGTGCTGA GCGAGGACTC TCGGGCCCGA GTGGGTCTGG CCACATACAG CAGGGAGCTG 1500 .5 CTGGTGGCGG TGCCTGTCGG GGAGTACCAG GATGTCCCTG ACCTGGTCTG GAGCCTCGAT 1560 GGCATTCCCT TCCGTGGTGG CCCCACCCTC ACGGGCAGTG CCTTGCGGCA GGCGGCAGAG 1620 CGTGGCTTCG GGAGCGCCAC CAGGACAGGC CAGGACCGGC CACGTAGAGT GGTGGTTTTG 1680 CTCACTGAGT CACACTCCGA GGATGAGGTT GCGGGCCCAG CGCGTCACGC AAGGGCGCGA 1740 GAGCTGCTCC TCCTGGGTCT AGGCAGTGAG GCCGTGCGGG CAGAGCTGGA GGAGATCACA 1800 »0 GGCAGCCCAA AGCATGTCAT GGTCTACTCG GATCCTCAGG ATCTGTTCAA CCAAATCCCT 1860 GAGCTGCAGG GGAAGCTGTG CAGCCGGCAG CGGCCAGGGT GCCGGACACA AGCCCTCGAC 1920 CTCGTCTTCA TGTTGGACAC CTCTGCCTCA GTAGGGCCCG AGAATTTTCC TCAGATGCAG 1980 AGCTTTCTCA GAAGCTGTGC CCTCCAGTTT GAGGTGAACC CTGACGTGAC ACAGGTCGGC 2040 CTCGTGGTGT ATGGCAGCCA GGTGCAGACT GCCTTCGGGC TCGACACCAA ACCCACCCGG 2100 55 GCTGCGATGC TGCGGGCCAT TAGCCAGGCC CCCTACCTAG GTGGGGTGGβ CTCAGCCGGC 2160 ACCGCCCTCC TGCACATCTA TGACAAAGTG ATGACCGTCC AGAGGGGTGC CCGGCCTGGT 2220 GTCCCCAAAG CTGTGGTGGT GCTCACAGGC GGGAGAGGCG CAGAGGATGC AGCCGTTCCT 2280 GCCCAGAAGC TGAGGAACAA TGGCATCTCT GTCTTGGTCG TGGGCGTGGG GCCTGTCCTA 2340 AGTGAGGGTC TGCGGAGGCT TGCAGGTCCC CGGGATTCCC TCATCCACGT GGCAGCTTAC 2400 JO GCCGACCTGC GGTACCACCA GGACGTCCTC ATTGAGTGGC TGTGTGGAGA AGCCAAGCAG 2460 CCAGTCAACC TCTGCAAACC CAGCCCGTGC ATGAATCAGG GCAGCTGCGT CCTGCAGAAT 2520 GGGAGCTACC GCTGCAAGTG TCGGGATCGC TGGGAGGGCC CCCACTGCGA GAACCGTGAG 2580 TGGAGCTCTT GCTCTGTATG TCTGAGCCAG GGATGGATTC TTCAGACGCC CCTGAGGCAC 2640 ATGGCTCCCG TCCAGGAGGG CAGCAGCCGT ACCCCTCCCA GCAACTACAG AGAAGGCCTG 2700 )5 GGCACTGAAA TGGTGCCTAC CTTCTGGAAT GTCTCTCCCC CAGGTCCTTA GAATCTCTGC 2760 TTCCCGCCGT GGCCAGGACC ACTATTCTCA CTGAGGGAGG AGGATGTCCC AACTCCAGCC 2820 ATGCTGCTTA GAGACAAGAA AGCAGCTCAT GTCACCCACA AACGATGTTG TTGAAAAGTT 2880 TTGATGTGTA AGTAAATACC CACTTTCTGT ACCTGCTGTG CCTTGTTGAG GCTATGTCAT 2940 CTGCCACCTT TCCCTTGAGG ATAAACAAGG GGTCCTCAAG ACTTAAATTT AGCGGCCTGA 3000 10 CGTTCCTTTG CACACAATCA ATGCTCGCCA GAATGTTGTT GACACAGTAA TGCCCAGCAG 3060 AGGCCTTTAC TAGAGCATCC TTTGGACGGC GAAGGCCACG GCCTTTCAAG ATGGAAAGCA 3120 GCAGCTTTTC CACTTCCCCA GAGACATTCT GGATGCATTT GCATTGAGTC TGAAAGGGGG 3180 CTTGAGGGAC GTTTGTGACT TCTTGGCGAC TGCCTTTTGT GTGTGGAAGA GACTTGGAAA 3240 GGTCTCAGAC TGAATGTGAC CAATTAACCA GCTTGGTTGA TGATGGGGGA GGGGCTGAGT 3300 15 TGTCCATGGG CCCAGGTCTG GAGGGCCACG TAAAATCGTT CTGAGTCGTG AGCAGTGTCC 3360 ACCTTGAAGG TCTTC SEQ ID NO:185 CBF9 Protein sequence Protein Accession* none found 50 11 21 31 41 51 I I I I I I MPPFLLLEAV CVFLFSRVPP SLPLQEVHVS KETIGKISAA SKMMWCSAAV DIMFLLDGSN 60 55 SVGKGSFERS KHFAITVCDG LDISPERVRV GAFQFSSTPH LEFPLDSFST QQEVKARIKR 120 MVFKGGRTET ELALKYLLHR GLPGGRNASV PQILIIVTDG KSQGDVALPS KQLKERGVTV 180 FAVGVRFPRW EELHALASEP RGQHVLLAEQ VEDATNGLFS TLSSSAICSS ATPDCRVEAH 240 PCEHRTLEMV REFAGNAPCW RGSRRTLAVL AAHCPFYSWK RVFLTHPATC YRTTCPGPCD 300 SQPCQNGGTC VPEGLDGYQC LCPLAFGGEA NCALKLSLEC RVDLLFLLDS SAGTTLDGFL 360 0 RAKVFVKRFV RAVLSEDSRA RVGVATYSRE LLVAVPVGEY QDVPDLVWSL DGIPFRGGPT 420 LTGSALRQAA ERGFGSATRT GQDRPRRVW LLTESHSEDE VAGPARHARA RELLLLGVGS 480 EAVRAELEEI TGSPKHVMVY SDPQDLFNQI PELQGKLCSR QRPGCRTQAL DLVFMLDTSA 540 SVGPENFAQM QSFVRSCALQ FEVNPDVTQV GLWYGSQVQ TAFGLDTKPT RAAMLRAISQ 600 APYLGGVGSA GTALLHIYDK VMTVQRGARP GVPKAVWLT GGRGAEDAAV PAQKLRNNGI 660 5 SVLWGVGPV LSEGLRRLAG PRDSLIHVAA YADLRYHQDV LIEWLCGEAK QPVNLCKPSP 720 CMNEGSCVLQ NGSYRCKCRD GWEGPHCENR EWSSCSVCVS QGWILETPLR HMAFVQEGSS 780 RTPPSNYREG LGTEMVPTFW NVCAPGP 0 SEQ ID NO:186 PAV1 DNA sequence Nucleic Acid Accession*: AF272890 ' Coding Sequence: 87-1520 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 5 I TGCTACCCGC GCCCGGGCTT CTCGGGTCTT CCCCAACCAC GGCCCAGCCC TGCCACACCC 60 CCCGCCCCCG GCCTCCGCAG CTCGGCATGG GCGCGGGGGT GCTCGTCCTC GGCGCCTCCG 120 AGCCCGGTAA CCTGTCGTCG GCCGCACCGC TCCCCGACGG CGCGGCCACC GCGGCGCGGC 180 TGCTGGTGCC CGCGTCGCCG CCCGCCTCGT TGCTGCCTCC CGCCAGCGAA AGCCCCGAGC 240 CGCTGTCTCA GCAGTGGACA GCGGGCATGG GTCTGCTGAT GGCGCTCATC GTGCTGCTCA 300 TCGTGGCGGG CAATGTGCTG GTGATCGTGG CCATCGCCAA GACGCCGCGG CTGCAGACGC 360 TCACCAACCT CTTCATCATG TCCCTGGCCA GCGCCGACCT GGTCATGGGG CTGCTGGTGG 420 TGCCGTTCGG GGCCACCATC GTGGTGTGGG GCCGCTGGGA GTACGGCTCC TTCTTCTGCG 480 AGCTGTGGAC CTCAGTGGAC GTGCTGTGCG TGACGGCCAG CATCGAGACC CTGTGTGTCA 540 TTGCCCTGGA CCGCTACCTC GCCATCACCT CGCCCTTCCG CTACCAGAGC CTGCTGACGC 600 GCGCGCGGGC GCGGGGCCTC GTGTGCACCG TGTGGGCCAT CTCGGCCCTG GTGTCCTTCC 660 TGCCCATCCT CATGCACTGG TGGCGGGCGG AGAGCGACGA GGCGCGCCGC TGCTACAACG 720 ACCCCAAGTG CTGCGACTTC GTCACCAACC GGGCCTACGC CATCGCCTCG TCCGTAGTCT 780 CCTTCTACGT GCCCCTGTGC ATCATGGCCT TCGTGTACCT GCGGGTGTTC CGCGAGGCCC 840 AGAAGCAGGT GAAGAAGATC GACAGCTGCG AGCGCCGTTT CCTCGGCGGC CCAGCGCGGC 900 CGCCCTCGCC CTCGCCCTCG CCCGTCCCCG CGCCCGCGCC GCCGCCCGGA CCCCCGCGCC 960 CCGCCGCCGC CGCCGCCACC GCCCCGCTGG CCAACGGGCG TGCGGGTAAG CGGCGGCCCT 1020 CGCGCCTCGT GGCCCTACGC GAGCAGAAGG CGCTCAAGAC GCTGGGCATC ATCATGGGCG 1080 TCTTCACGCT CTGCTGGCTG CCCTTCTTCC TGGCCAACGT GGTGAAGGCC TTCCACCGCG 1140 AGCTGGTGCC CGACCGCCTC TTCGTCTTCT TCAACTGGCT GGGCTACGCC AACTCGGCCT 1200 TCAACCCCAT CATCTACTGC CGCAGCCCCG ACTTCCGCAA GGCCTTCCAG GGACTGCTCT 1260 GCTGCGCGCG CAGGGCTGCC CGCCGGCGCC ACGCGACCCA CGGAGACCGG CCGCGCGCCT 1320 CGGGCTGTCT GGCCCGGCCC GGACCCCCGC CATCGCCCGG GGCCGCCTCG GACGACGACG 1380 ACGACGATGT CGTCGGGGCC ACGCCGCCCG CGCGCCTGCT GGAGCCCTGG GCCGGCTGCA 1440 ACGGCGGGGC GGCGGCGGAC AGCGACTCGA GCCTGGACGA GCCGTGCCGC CCCGGCTTCG 1500 CCTCGGAATC CAAGGTGTAG GGCCCGGCGC GGGGCGCGGA CTCCGGGCAC GGCTTCCCAG 1560 GGGAACGAGG AGATCTGTGT TTACTTAAGA CCGATAGCAG GTGAACTCGA AGCCCACAAT 1620 CCTCGTCTGA ATCATCCGAG GCAAAGAGAA AAGCCACGGA CCGTTGCACA AAAAGGAAAG 1680 TTTGGGAAGG GATGGGAGAG TGGCTTGCTG ATGTTCCTTG TTG SEQ ID NO:187 PAV1 Protein sequence Protein Accession #: AA011176 11 21 31 41 51 I I I I I MGAGVLVLGA SEPGNLSSAA PLPDGAATAA RLLVPASPPA SLLPPASESP EPLSQQWTAG 60 MGLLMALIVL LIVAGNVLVI VAIAKTPRLQ TLTNLFIMSL ASADLVMGLL WPFGATIW 120 WGRWEYGSFF CELWTSVDVL CVTASIETLC VIALDRYLAI TSPFRYQSLL TRARARGLVC 180 TVWAISALVS FLPILMHWWR AESDEARRCY NDPKCCDFVT NHAYAIASSV VSFYVPLCIM 240 AFVYLRVFRE AQKQVKKIDS CERRFLGGPA RPPSPSPSPV PAPAPPPGPP RPAAAAATAP 300 LANGRAGKRR PSRLVALREQ KALKTLGIIM GVFTLCWLPF FLANWKAFH RELVPDRLFV 360 FFNWLGYANS AFNPIIYCRS PDFRKAFQGL LCCARRAARR RHATHGDRPR ASGCLARPGP 420 PPSPGAASDD DDDDWGATP PARLLEPWAG CNGGAAADSD SSLDEPCRPG FASESKV SEQ ID NO:188 BC02 DNA sequence Nucleic Acid Accession *: AJ400877 Ceding sequence: 81-3080 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I GGCGTCCGCG CACACCTCCC CGCGCCGCCG CCGCCACCGC CCGCACTCCG CCGCCTCTGC 60 CCGCAACCGC TGAGCCATCC ATGGGGGTCG CGGGCCGCAA CCGTCCCGGG GCGGCCTGGG 120 CGGTGCTGCT GCTGCTGCTG CTGCTGCCGC CACTGCTGCT GCTGGCGGGG GCCGTCCCGC 180 CGGGTCGGGG CCGTGCCGCG GGGCCGCAGG AGGATGTAGA TGAGTGTGCC CAAGGGCTAG 240 ATGACTGCCA TGCCGACGCC CTGTGTCAGA ACACACCCAC CTCCTACAAG TGCTCCTGCA 300 AGCCTGGCTA CCAAGGGGAA GGCAGGCAGT GTGAGGACAT CGATGAATGT GGAAATGAGC 360 TCAATGGAGG CTGTGTCCAT GACTGTTTGA ATATTCCAGG CAATTATCGT TGCACTTGTT 420 TTGATGGCTT CATGTTGGCT CATGACGGTC ATAATTGTCT TGATGTGGAC GAGTGCCTGG 480 AGAACAATGG CGGCTGCCAG CATACCTGTG TCAACGTCAT GGGGAGCTAT GAGTGCTGCT 540 GCAAGGAGGG GTTTTTCCTG AGTGACAATC AGCACACCTG CATTCACCGC TCGGAAGAGG 600 GCCTGAGCTG CATGAATAAG GATCACGGCT GTAGTCACAT CTGCAAGGAG GCCCCAAGGG 660 GCAGCGTCGC CTGTGAGTGC AGGCCTGGTT TTGAGCTGGC CAAGAACCAG AGAGACTGCA 720 TCTTGACCTG TAACCATGGG AACGGTGGGT GCCAGCACTC CTGTGACGAT ACAGCCGATG 780 GCCCAGAGTG CAGCTGCCAT CCACAGTACA AGATGCACAC AGATGGGAGG AGCTGCCTTG 840 AGCGAGAGGA CACTGTCCTG GAGGTGACAG AGAGCAACAC CACATCAGTG GTGGATGGGG 900 ATAAACGGGT GAAACGGCGG CTGCTCATGG AAACGTGTGC TGTCAACAAT GGAGGCTGTG 960 ACCGCACCTG TAAGGATACT TCGACAGGTG TCCACTGCAG TTGTCCTGTT GGATTCACTC 1020 TCCAGTTGGA TGGGAAGACA TGTAAAGATA TTGATGAGTG CCAGACCCGC AATGGAGGTT 1080 GTGATCATTT CTGCAAAAAC ATCGTGGGCA GTTTTGACTG CGGCTGCAAG AAAGGATTTA 1140 AATTATTAAC AGATGAGAAG TCTTGCCAAG ATGTGGATGA GTGCTCTTTG GATAGGACCT 1200 GTGACCACAG CTGCATCAAC CACCCTGGCA CATTTGCTTG TGCTTGCAAC CGAGGGTACA 1260 CCCTGTATGG CTTCACCCAC TGTGGAGACA CCAATGAGTG CAGCATCAAC AACGGAGGCT 1320 GTCAGCAGGT CTGTGTGAAC ACAGTGGGCA GCTATGAATG CCAGTGCCAC CCTGGGTACA 1380 AGCTCCACTG GAATAAAAAA GACTGTGTGG AAGTGAAGGG GCTCCTGCCC ACAAGTGTGT 1440 CACCCCGTGT GTCCCTGCAC TGCGGTAAGA GTGGTGGAGG AGACGGGTGC TTCCTCAGAT 1500 GTCACTCTGG CATTCACCTC TCTTCAGATG TCACCACCAT CAGGACAAGT GTAACCTTTA 1560 AGCTAAATGA AGGCAAGTGT AGTTTGAAAA ATGCTGAGCT GTTTCCCGAG GGTCTGCGAC 1620 CAGCACTACC AGAGAAGCAC AGCTCAGTAA AAGAGAGCTT CCGCTACGTA AACCTTACAT 1680 GCAGCTCTGG CAAGCAAGTC CCAGGAGCCC CTGGCCGACC AAGCAGCCCT AAGGAAATGT 1740 TTATCACTGT TGAGTTTGAG CTTGAAACTA ACCAAAAGGA GGTGACAGCT TCTTGTGACC 1800 TGAGCTGCAT CGTAAAGCGA ACCGAGAAGC GGCTCCGTAA AGCCATCCGC ACGCTCAGAA 1860 AGGCCGTCCA CAGGGAGCAG TTTCACCTCC AGCTCTCAGG CATGAACCTC GACGTGGCTA 1920 AAAAGCCTCC CAGAACATCT GAACGCCAGG CAGAGTCCTG TGGAGTGGGC CAGGGTCATG 1980 CAGAAAACCAATGTGTCAGTTGCAGGGCTG GGACCTATTATGATGGAGCA CGAGAACGCT 2040 5 GCATTTTATG TCCAAATGGA ACCTTCCAAA ATGAGGAAGG ACAAATGACT TGTGAACCAT 2100 GCCCAAGACC AGGAAATTCT GGGGCCCTGA AGACCCCAGA AGCTTGGAAT ATGTCTGAAT 2160 GTGGAGGTCT GTGTCAACCT GGTGAATATT CTGCAGATGG CTTTGCACCT TGCCAGCTCT 2220 GTGCCCTGGG CACGTTCCAG CCTGAAGCTG GTCGAACTTC CTGCTTCCCC TGTGGAGGAG 2280 GCCTTGCCAC CAAACATCAG GGAGCTACTT CCTTTCAGGA CTGTGAAACC AGAGTTCAAT 2340 10 GTTCACCTGG ACATTTCTAC AAC ACCACC A CTCACCGATG TATTCGTTGC CCAGTGGGAA 2400 CATACCAGCC TGAATTTGGA AAAAATAATT GTGTTTCTTG CCCAGGAAAT ACTACGACTG 2460 ACTTTGATGG CTCCACAAAC ATAACCCAGT GTAAAAACAG AAGATGTGGA GGGGAGCTCβ 2520 GAGATTTCAC TGGGTACATT GAATCCCCAA ACTACCCAGG CAATTACCCA GCCAACACCG 2580 AGTGTACGTG GACCATCAAC CCACCCCCCA AGCGCCGCAT CCTGATCGTG GTCCCTGAGA 2640 15 TCTTCCTGCCCATAGAGGAC GACTGTGGGG ACTATCTGGTGATGCGGAAA ACCTCTTCAT 2700 CCAATTCTGT GACAACATAT GAAACCTGCC AGACCTACGA ACGCCCCATC GCCTTCACCT 2760 CCAGGTCAAA GAAGCTGTGG ATTCAGTTCA AGTCCAATGA AGGGAACAGC GCTAGAGGGT 2820 TCCAGGTCCC ATACGTGACA TATG ATGAGG ACTACCAGGA ACTCATTGAA G ACATAGTTC 2880 GAGATGGCAG GCTCTATGCA TCTGAGAACC ATCAGGAAAT ACTTAAGGAT AAGAAACTTA 2940 20 TCAAGGCTCTGTTTGATGTCCTGGCCCATCCCCAGAACTATTTCAAGTACACAGCCCAGG 3000 AGTCCCGAGA GATGTTTCCA AGATCGTTCA TCCGATTGCT ACGTTCCAAA GTGTCCAGGT 3060 TTTTGAGACC TTACAAATGA CTCAGCCCAC GTGCCACTCA ATACAAATGT TCTGCTATAG 3120 GGTTGGTGGG ACAGAGCTGT CTTCCTTCTG CATGTCAGCA CAGTCGGGTA TTGCTGCCTC 3180 CCGTATCAGT GACTCATTAG AGTTCAATTT TTATAG ATAA TACAGATATT TTGGTAAATT 3240 25 GAACTTGGTT TTTCTTTCCC AGCATCGTGG ATGTAGACTG AGAATGGCTT TGAGTGGCAT 3300 CAGCTTCTCA CTGCTGTGGG CGGATGTCTT GGATAGATCA CGGGCTGGCT GAGCTGGACT 3360 TTGGTCAGCC TAGGTGAGAC TCACCTGTCC TTCTGGGGTC TTACTCCTCC TCAAGGAGTC 3420 TGTAGTGGAA AGGAGGCCAC AGAATAAGCT GCTTATTCTG AAACTTCAGC TTCCTCTAGC 3480 CCGGCCCTCT CTAAGGGAGC CCTCTGCACT CGTGTGCAGG CTCTGACCAG GCAGAACAGG 3540 30 CAAGAGGGGA GGGAAGGAGA CCCCTGCAGG CTCCCTCCAC CCACCTTGAG ACCTGGGAGG 3600 ACTCAGTTTC TCCACAGCCT TCTCCAGCCT GTGTGATACA AGTTTGATCC CAGGAACTTG 3660 AGTTCTAAGC AGTGCTCGTG AAAAAAAAAA GCAGAAAGAA TTAGAAATAA ATAAAAACTA 3720 AGCACTTCTG GAGACAT 35 SEQ ID NO:189 BC02 Protein sequence Protein Accession * CAB92285 1 11 21 31 41 51 40 I I I I I I MGVAGRNRPG AAWAVLLLLL LLPPLLLLAG AVPPGRGRAA GPQEDVDECA QGLDDCHADA 60 LCQNTPTSYK CSCKPGYQGE GRQCEDIDEC GNELNGGCVH DCLNIPGNYR CTCFDGFMLA 120 HDGHNCLDVD ECLENNGGCQ HTCVNVMGSY ECCCKEGFFL SDNQHTCIHR SEEGLSCMNK 180 DHGCSHICKEAPRGSVACECRPGFELAKNQRDCILTCNHG NGGCQHSCDDTADGPECSCH 240 45 I JYKMHTrX3RSCI REDTVLEVTESNTTSV VDGDKRVKRR I-LMETCAVNNGGCDRTCKDT 300 STGVHCSCPV GFTLQLDGKT CKDIDECQTR NGGCDHFCKN IVGSFDCGCK KGFKLLTDEK 360 SCQDVDECSL DRTCDHSCIN HPGTFACACN RGYTLYGFTH CGDTNECSIN NGGCQQVCVN 420 TVGSYECQCH PGYKLHWNKK DCVEVKGLLP TSVSPRVSLH CGKSGGGDGC FLRCHSGIHL 480 SSDVTTIRTS VTFKI-NEGKCSLKNAELFPEGLRPALPEKHSSVKESFRYVNLTCSSGKQV 540 50 PGAPGRPSTP KEMITI 'EFELETNQKEVTA SCDLSCIVKRTEKRLRKAIRTLRKAVHREQ 600 FHLQLSGMNL DVAKKPPRTS ERQAESCGVG QGHAENQCVS CRAGTYYDGA RERCILCPNG 660 TFQNEEGQMT CEPCPRPGNS GALKTPEAWN MSECGGLCQP GEYSADGFAP CQLCALGTFQ 720 PEAGRTSCFP CGGGLATKHQ GATSFQDCET RVQCSPGHFY NTTTHRCIRC PVGTYQPEFG 780 KNNCVSCIKSN TTTDFIXSSTN Π'QCKNRRCG GELGDFTGYI ESPNYPGNYP ANTECTWTIN 840 55 PPPKRRILIV VPEIFLPIEDDCGDYLVMRKTSSSNSVTTY ETCQTYERPIAFTSRSKKLW 900 IQFKSNEGNS ARGFQVPYVT YDEDYQELIE DIVRDGRLYA SENHQEILKD KKLDCALFDV 960 LAHPQNYFKY TAQESREMFP RSFIRLLRSK VSRFLRPYK , Λ SEQ ID N0:190 BFG1 DNA sequence 60 Nucleic Acid Accession*: AF007170 Coding sequence: 1-1725 (underlined sequences correspond to stop codon) 1 11 21 31 41 51 Λ< I I I I I I 55 AAGGAGGCGG CCTCCGGGAA AAGCGACCGCAGGACTCCTG AGAGCAGCCTCCATGAGGCC 60 CTGGACCAGT GCATGACCGC CCTGGACCTC TTCCTCACCA ACCAGTTCTC AGAAGCACTC 120 AGCTACCTCA AGCCCAGAAC CAAGGAAAGC ATGTACCACT CACTGACATA TGCCACCATC 180 CTGGAGATGC AGGCCATGAT GACCTTTGAC CCTCAGGACA TCCTGCTTGC CGGCAACATG 240 ATGAAGGAGG CACAGATGCT GTGTCAGAGG CACCGGAGGA AGTCTTCTGT AACAGATTCC 300 70 TTCAGCAGCCTGGTGAACCG CCCCACGCTG GGCCAATTCA CTGAAGAAGA AATCCACGCT 360 GAGGTCTGCT ATGCAGAGTG CCTGCTGCAG CGAGCAGCCC TGACCTTCCT GCAGGACGAG 420 AACATGGTGA GCTTCATCAA AGGCGGCATC AAAGTTCGAA ACAGCTACCA GACCTACAAG 480 GAGCTGGACA GCCTTGTTCA GTCCTCACAA TACTGCAAGG GTGAGAACCA CCCGCACTTT 540 GAAGGAGGAG TGAAGCTTGG TGTAGGGGCC TTCAACCTG A CACTGTCCAT GCTTCCTACT 600 75 AGGATCCTGAGGCTGTTGGA GTTTGTGGGG TTTTCAGGAA ACAAGGACTA TGGGCTGCTG 660 CAGCTGGAGG AGGGAGCGTC AGGGCACAGC TTCCGCTCTG TGCTCTGTGT CATGCTCCTG 720 CTGTGCTACC ACACCTTCCT CACCTTCGTG CTCGGTACTG GGAACGTCAA CATCGAGGAG 780 GCCGAGAAGC TCTTGAAGCC CTACCTGAAC CGGTACCCTA AGGGTGCCAT CTTCCTGTTC 840 TTTGCAGGGA GGATTGAAGT CATTAAAGGC AACATTGATG CAGCCATCCG GCGTTTCGAG 900 GAGTGCTGTG AGGCCCAGCA GCACTGGAAG CAGTTTCACC ACATGTGCTA CTGGGAGCTG 960 ATGTGGTGCT TCACCTACAA GGGCCAGTGG AAGATGTCCT ACTTCTACGC CGACCTGCTC 1020 AGCAAGGAGA ACTGCTGGTC CAAGGCCACC TACATTTACA TGAAGGCCGC CTACCTCAGC 1080 ATGTTTGGGA AGGAGGACCA CAAGCCGTTC GGGGACGACG AAGTGGAATT ATTTCGAGCT 1140 GTGCCAGGCC TGAAGCTCAA GATTGCTGGG AAATCTCTAC CCACAGAGAA GTTTGCCATC 1200 CGGAAGTCCC GGCGCTACTT CTCCTCCAAC CCTATCTCGC TGCCAGTGCC TGCTCTGGAA 1260 ATGATGTACA TCTGGAACGG CTACGCCGTG ATTGGGAAGC AGCCGAAACT CACGGATGGG 1320 ATACTTGAGA TTATCACTAA GGCTGAAGAG ATGCTGGAGA AAGGCCCAGA GAACGAGTAC 1380 TCAGTGGATG ACGAGTGCTT GGTGAAATTG TTGAAAGGCC TGTGTCTGAA ATACCTGGGC 1440 CGTGTCCAGG AGGCCGAGGA GAATTTTAGG AGCATCTCTG CCAATGAAAA GAAGATTAAA 1500 TATGACCACT ACTTGATCCC AAACGCCCTG CTGGAGCTGG CCCTGCTGCT TATGGAGCAA 1560 GACAGAAACG AAGAGGCCAT CAAACTTTTG GAATCTGCCA AGCAAAACTA CAAGAATTAC 1620 TCCATGGAGT CAAGGACACA CTTTCGAATC CAGGCAGCCA CACTCCAAGC CAAGTCTTCC 1680 CTAGAGAACA GCAGCAGATC CATGGTCTCA TCAGTGTCCT TGTASCTTTG TGCAGCAGTT 1740 CCGGGCTGGA AGACAGAGAC AGCTGGACAG AGCTCCTGAA AACATTTCAA AATACCCCCT 1800 CCCCCTGCCC TGCCCTGCCT TTGGGGTCCA CCGGCACTCC AGTTGGATGG CACAACATAG 1860 TGTATCCGTG CAGAAGCCGA GCTGGCATTT TCACCAGTGT AGCCAAGGGC CTTTGCCAAG 1920 GGCAGAGCAG GTGGAGCCCT CTGCCTGCCC TATCACACAT ACGGGTACTT GCTTTTCACT 1980 GTGATGTTTA AGAGAATGTA TGAACAGTTT ACATTTTCCT TAGAAATACA TTGATGGGAT 2040 CACAGTTGGC TTTAAAAACC AACAACAATC AACCACCTGT AAGTCTTTGT CTTCACCTAT 2100 TATCATCTGG AGGTAAATCT CTTTATATGA TGATGCCAAA GGGCAAATTG CTTTTCAAAT 2160 TCAGCAAGTT CTCAGCTTGT GTGACGGAAG GTCCTTCAGA GGACCTGAGG AATGCCTGGG 2220 AGAGGCTAAG CCTCAGGCTT CAATGCTTCT GGGGTTGGGC ATGAGGATGT ACACAGACAC 2280 CCACTACCTT ACTACTCACA CTTCATTTCA CTCCTTTTGT AAATTTCCAA TTTAAAAATC 2340 AAGCACGTCT TTTTAGTGAG ATAAAATCTG AGCTCTTCTG TAGAAAAATC AATCTCTACC 2400 AGTAGAAAAT GCCAGGGCTT GATGGAAGAG CTGTGTAGCC CTTTCTATGC CAAAGCCAGG 2460 AAATTTGGGG GGCAGGAGGA GGTTCTCAGA ATCCAGTCTG TATCTTTGCT GTATGCCAAA 2520 CTGAAACCAC TGGGAATAAT TTATGAAACA TAAAAATCTT CTGTACTTCA CTCCAAGGTA 2580 CATITGCTTA CTGACAGCATTTTTGTTAAA ACTGTTATTC TTGAAAAAAA AAAAAAAAAA 2640 AA SEQ ID N0:191 BFG1 Protein sequence Protein Accession *: AAC39582 1 11 21 31 41 51 I I I I I I MTALDLFLTN QFSEALSYLK PRTKESMYHS LTYATILEMQ AMMTFDPQDI LAGNMMKEA 60 QMI QRHRRK SSVTDSraSL VNRPTLGQFT EEEIHAEVC AECLLQRAALTFLQDENMVS 120 πKGGIKVRN SYQTYKELDS LVQSSQYCKG ENHPHFEGGV KLGVGAFNLT LSMLPTRILR 180 LLEFVGFSGN KDYGLLQLEE GASGHSFRSV LCVMLLLCYH TFLTFVLGTG NVNIEEAEKL 240 LKPYLNRYPK GAIFLFFAGR IEVIKGNIDA A-RRFEECCE AQQHWKQFHH MCYWELMWCF 300 TYKGQWKMSY FYADLLSKEN CWSKATYIYM KAAYLSMFGK EDHKPFGDDE VELFRAVPGL 360 KLKIAGKSLP TEKFAIRKSR RYFSSNPISL PVPALEMMYI WNGYAVIGKQ PKLTDGILEI 420 ITKAEEMLEK GPENEYSVDD ECLVKLLKGL CLKYLGRVQE AEENFRSISA NEKKIKYDHY 480 LIPNALLELA LLLMEQDRNE EAIKLLESAK QNYKNYSMES RTHFRIQAAT LQAKSSLENS 540 SRSMVSSVSL SEQ ID NO:192 BF06 DNA sequence Nucleic Acid Accession* NM_032583 Coding sequence: 1-4044 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I ATGACTAGGA AGAGGACATA CTGGGTGCCC AACTCTTCTG GTGGCCTCGT GAATCGTGGC 60 ATCGACATAG GCGATGACAT GGTTTCAGGA CTTATTTATA AAACCTATAC TCTCCAAGAT 120 GGCCCCTGGA GTCAGCAAGA GAGAAATCCT GAGGCTCCAG GGAGGGCAGC TGTCCCACCG 180 TGGGGGAAGT ATGATGCTGC CTTGAGAACC ATGATTCCCTTCCGTCCCAA GCCGAGGTTT 240 CCTGCCCCCC AGCCCCTGGA CAATGCTGGC CTGTTCTCCT ACCTCACCGT GTCATGGCTC 300 ACCCCGCTCA TGATCCAAAG CTTACGGAGT CGCTTAGATG AGAACACCAT CCCTCCACTG 360 TCAGTCCATG ATGCCTCAGA CAAAAATGTC CAAAGGCTTC ACCGCCTTTG GGAAGAAGAA 420 GTCTCAAGGC GAGGGATTGA AAAAGCTTCA GTGCTTCTGG TGATGCTGAG GTTCCAGAGA 480 ACAAGGTTGA TTTTCGATGC ACTTCTGGGC ATCTCCTTCT GCATTGCCAG TGTACTCGGG 540 CCAATATTGA TTATACCAAA GATCCTGGAA TATTCAGAAG AGCAGTTGGG GAATGTTGTC 600 CATGGAGTGG GACTCTGCTT TGCCCTTTTT CTCTCCGAAT GTGTGAAGTC TCTGAGTTTC 660 TCCTCCAGTT GGATCATCAA CCAACGCACA GCCATCAGGT TCCGAGCAGC TGTTTCCTCC 720 TTTGCCTTTG AGAAGCTCAT CCAATTTAAG TCTGTAATAC ACATCACCTC AGGAGAGGCC 780 ATCAGCTTCTTCACCGGTGA TGTAAACTAC CTGTTTGAAG GGGTGTGCTA TGGACCCCTA 840 GTACTGATCA CCTGCGCATC GCTGGTCATC TGCAGCATTT CTTCCTACTT CATTATTGGA 900 TACACTGCAT TTATTGCCAT CTTATGCTAT CTCCTGGTTT TCCCACTGGC GGTATTCATG 960 ACAAGAATGG CTGTGAAGGC TCAGCATCAC ACATCTGAGG TCAGCGACCA GCGCATCCGT 1020 GTGACCAGTG AAGTTCTCAC TTGCATTAAG CTGATTAAAA TGTACACATG GGAGAAACCA 1080 TTTGCAAAAA TCATTGAAGG TATGGAAAGT CTGACTTTCT GCTCCAAACC TGGTGATGGC 1140 ATGGCCTTCA GCATGCTGGC CTCCTTGAAT CTCCTTCGGC TGTCAGTGTT CTTTGTGCCT 1200 ATTGCAGTCA AAGGTCTCAC GAATTCCAAG TCTGCAGTGA TGAGGTTCAA GAAGTTTTTC 1260 CTCCAGGAGA GCCCTGTTTT CTATGTCCAG ACATTACAAG ACCCCAGCAA AGCTCTGGTC 1320 TTTGAGGAGG CCACCTTGTC ATGGCAACAG ACCTGTCCCG GGATCGTCAA TGGGGCACTG 1380 GAGCTGGAGA GGAACGGGCA TGCTTCTGAG GGGATGACCA GGCCTAGAGA TGCCCTCGGG 1440 CCAGAGGAAG AAGGGAACAG CCTGGGCCCA GAGTTGCACA AGATCAACCT GGTGGTGTCC 1500 AAGGGGATGA TGTTAGGGGT CTGCGGCAAC ACGGGGAGTG GTAAGAGCAG CCTGTTGTCA 1560 GCCATCCTGG AGGAGATGCA CTTGCTCGAG GGCTCGGTGG GGGTGCAGGG AAGCCTGGCC 1620 TATGTCCCCC AGCAGGCCTG GATCGTCAGC GGGAACATCA GGGAGAACAT CCTCATGGGA 1680 GGCGCATATG ACAAGGCCCG ATACCTCCAG GTGCTCCACT GCTGCTCCCT GAATCGGGAC 1740 CTGGAACTTC TGCCCTTTGG AGACATGACA GAGATTGGAG AGCGGGGCCT CAACCTCTCT 1800 GGGGGGCAGA AACAGAGGAT CAGCCTGGCC CGCGCCGTCT ATTCCGACCG TCAGATCTAC 1860 CTGCTGGACG ACCCCCTGTC TGCTGTGGAC GCCCACGTGG GGAAGCACAT TTTTGAGGAG 1920 TGCATTAAGA AGACACTCAG GGGGAAGACG GTCGTCCTGG TGACCCACCA GCTGCAGTAC 1980 TTAGAATTTT GTGGCCAGAT CATTTTGTTG GAAAATGGGA AAATCTGTGA AAATGGAACT 2040 CACAGTGAGT TAATGCAGAA AAAGGGGAAA TATGCCCAAC TTATCCAGAA GATGCACAAG 2100 GAAGCCACTT CGGACATGTT GCAGGACACA GCAAAGATAG CAGAGAAGCC AAAGGTAGAA 2160 AGTCAGGCTC TGGCCACCTC CCTGGAAGAG TCTCTCAACG GAAATGCTGT GCCGGAGCAT 2220 CAGCTCACAC AGGAGGAGGA GATGGAAGAA GGCTCCTTGA GTTGGAGGGT CTACCACCAC 2280 TACATCCAGG CAGCTGGAGG TTACATGGTC TCTTGCATAA TTTTCTTCTT CGTGGTGCTG 2340 ATCGTCTTCT TAACGATCTT CAGCTTCTGG TGGCTGAGCT ACTGGTTGGA GCAGGGCTCG 2400 GGGACCAATA GCAGCCGAGA GAGCAATGGA ACCATGGCAG ACCTGGGCAA CATTGCAGAC 2460 AATCCTCAAC TGTCCTTCTA CCAGCTGGTG TACGGGCTCA ACGCCCTGCT CCTCATCTGT 2520 GTGGGGGTCTGCTCCTCAGG GATTTTCACC AAAGTCACGA GGAAGGCATC CACGGCCCTG 2580 CACAACAAGC TCTTCAACAA GGTTTTCCGC TGCCCCATGA GTTTCTTTGA CACCATCCCA 2640 ATAGGCCGGC TTTTGAACTG CTTCGCAGGG GACTTGGAAC AGCTGGACCA GCTCTTGCCC 2700 ATCTTTTCAG AGCAGTTCCT GGTCCTGTCC TTAATGGTGA TCGCCGTCCT GTTGATTGTC 2760 AGTGTGCTGT CTCCATATAT CCTGTTAATG GGAGCCATAA TCATGGTTAT TTGCTTCATT 2820 TATTATATGA TGTTCAAGAA GGCCATCGGT GTGTTCAAGA GACTGGAGAA CTATAGCCGG 2880 TCTCCTTTAT TCTCCCACAT CCTCAATTCT CTGCAAGGCC TGAGCTCCAT CCATGTCTAT 2940 GGAAAAACTG AAGACTTCAT CAGCCAGTTT AAGAGGCTGA CTGATGCGCA GAATAACTAC 3000 CTGCTGTTGT TTCTATCTTC CACACGATGG ATGGCATTGA GGCTGGAGAT CATGACCAAC 3060 CTTGTGACCT TGGCTGTTGC CCTGTTCGTG GCTTTTGGCA TTTCCTCCAC CCCCTACTCC 3120 TTTAAAGTCA TGGCTGTCAA CATCGTGCTG CAGCTGGCGT CCAGCTTCCA GGCCACTGCC 3180 CGGATTGGCTTGGAGACAGA GGCACAGTTC ACGGCTGTAG AGAGGATACT GCAGTACATG 3240 AAGATGTGTG TCTCGGAAGC TCCTTTACAC ATGGAAGGCA CAAGTTGTCC CCAGGGGTGG 3300 CCACAGCATG GGGAAATCAT ATTTCAGGAT TATCACATGA AATACAGAGA CAACACACCC 33 60 ACCGTGCTTC ACGGCATCAA CCTGACCATC CGCGGCCACG AAGTGGTGGG CATCGTGGGA 3 420 AGGACGGGCTCTGGGAAGTC CTCCTTGGGC ATGGCTCTCT TCCGCCTGGT GGAGCCCATG 3480 GCAGGCCGGA TTCTCATTGA CGGCGTGGAC ATTTGCAGCA TCGGCCTGGA GGACTTGCGG 3540 TCCAAGCTCT CAGTGATCCC TCAAGATCCA GTGCTGCTCT CAGGAACCAT CAGATTCAAC 3600 CTAGATCCCT TTGACCGTCA CACTGACCAG CAGATCTGGG ATGCCTTGGA GAGGACATTC 3660 CTGACCAAGG CCATCTCAAA GTTCCCCAAA AAGCTGCATA CAGATGTGGT GGAAAACGGT 3720 GGAAACTTCT CTGTGGGGGA GAGGCAGCTG CTCTGCATTG CCAGGGCTGT GCTTCGCAAC 3780 TCCAAGATCA TCCTTATCGA TGAAGCCACA GCCTCCATTG ACATGGAGAC AGACACCCTG 3840 ATCCAGCGCA CAATCCGTGA AGCCTTCCAG GGCTGCACCG TGCTCGTCAT TGCCCACCGT 3900 GTCACCACTG TGCTGAACTG TGACCACATC CTGGTTATGG GCAATGGGAA GGTGGTAGAA 3960 TTTGATCGGC CGGAGGTACT GCGGAAGAAG CCTGGGTCAT TGTTCGCAGC CCTCATGGCC 4020 ACAGCCACTT CTTCACTGAG ATAAGGAGAT GTGGAGACTT CATGGAGGCT GGCAGCTGAG 4080 CTCAGAGGTT CACACAGGTG CAGCTTCGAG GCCCACAGTC TGCGACCTTC TTGTTTGGAG 4140 ATGAGAACTT CTCCTGGAAG CAGGGGTAAA TGTAGGGGGG GTGGGGATTG CTGGATGGAA 4200 ACCCTGGAAT AGGCTACTTG ATGGCTCTCA AGACCTTAGA ACCCCAGAAC CATCTAAGAC 4260 ATGGGATTCA GTGATCATGT GGTTCTCCTT TTAACTTACA TGCTGAATAA TTTTATAATA 4320 AGGTAAAAGC TTATAGTTTT CTGATCTGTG TTAGAAGTGY TGCAAATGCT GTACTGACTT 4380 TGTAAAATAT AAAACTAAGG AAAACTCAAA AAAAAAAAAA AAAAAAA SEQ ID NO:193 BF06 Protein sequence Protein Accession* NP_11597 1 1 11 21 31 41 51 I I I I I I MTRKRTYWVP NSSGGLVNRG IDIGDDMVSG LIYKTYTLQD GPWSQQERNP EAPGRAAVPP 60 WGKYDAALRTMIPFRPKPRFPAPQPLDNAG LFSYLTVSWLTPLMIQSLRS RLDENTIPPL 120 SVHDASDKNV QRLHRLWEEE VSRRGffiKAS VLLVMLRFQR TRLIFDALLG ICFCIASVLG 180 P-LHP--ILE YSEEQLGNW HGVGLCFALF LSECVKSLSF SSSWIINQRT AIRFRAAVSS .240 FAFEKLIQFK SVIHUSGEA ISFFTGDVNY LFEGVCYGPL VLITCASLVI CSISSYFIIG 300 YTAFIAILCY LLVFPLAVFM TRMAVKAQHH TSEVSDQRIR VTSEVLTCIK UKMYTWEKP 360 FAKIIEGMES LTFCSKPGDG MAFSMLASLN LLRLSVFFVP IAVKGLTNSK SAVMRFKKFF 420 LQESPVFYVQ TLQDPSKALV FEEATLSWQQ TCPGIVNGALELERNGHASEGMTRPRDALG 480 PEEEGNSLGP ELHKINLVVS KGMMLGVCGN TGSGKSSLLS AILEEMHLLE GSVGVQGSLA 540 YVPQQAWIVS GN-RENILMG GAYDKARYLQ VLHCCSLNRD LELLPFGDMT EIGERGLNLS 600 GGQKQRISLA RAVYSDRQIY LLDDPLSAVD AHVGKHIFEE CIKKTLRGKT LVTHQLQY 660 LEFCGQIILL ENGKICENGT HSELMQKKGK YAQLIQKMHK EATSDMLQDT AKIAEKPKVE 720 SQALATSLEE SLNGNAVPEH QLTQEEEMEE GSLSWRVYHH YIQAAGGYMV SCIIFFFVVL 780 IVFLTIFSFW WLSYWLEQGS GTNSSRESNG TMADLGNIAD NPQLSFYQLV YGLNALLUC 840 VGVCSSGDFT KVTRKASTAL HNKLFNKVFR CPMSFFDT P IGRLLNCFAG DLEQLDQLLP 900 IFSEQFLVLS LMVIAVLLIV SVLSPY1LLM GAHMVICH YYMMFKKAIG VFKRLENYSR 960 SPLFSHILNS LQGLSSIHVY GKTEDFISQF KRLTDAQNNY LLLFLSSTRW MALRLEIMTN 1020 LVTLAVALFV AFGISSTPYS FKVMAVNIVLQLASSFQATA RIGLETEAQFTAVERILQYM 1080 KMCVSEAPLH MEGTSCPQGW PQHGEIIFQD YHMKYRDNTPTVLHGINLTI RGHEVVGrVG 1140 RTGSGKSSLG MALFRLVEPM AGRILIDGVD ICSIGLEDLR SKLSVIPQDP VLLSGTIRFN 1200 LDPFDRHTDQ QIWDALERTF LTKAISKFPK KLHTDVVENG GNFSVGERQL LCIARAVLRN 1260 SKULIDEAT ASIDMETDT IQRTTREAFQ GCTVLVIAHR VTTVLNCDHI VMGNGKVVE 1320 FDRPEVLRKK PGSLFAALMA TATSSLR SEQ ID N0:194 BHB6 DNA sequence Nucleic Acid Accession*: AA983251 Coding sequence: 1-1749 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 ATGCTGTCTG GCTTCTTCAT GAGTCCCAGT ACCCAGCACA GAGCACAGTA CACTCCCGGA 60 GGAAAGAAAC TTCCGTGGGA GGCTTCCATC GGTGCGCACA CCTCCCGAGG GCGAGGCAGC 120 GACCGGGAGA GGGAGAGCCG GCCGGAGGCT GCCGGGCTCC TGTGGGACCG CGCTCCAGCC 180 GGGGAGGCGG AGAAGGGGAA CCGGGGCGAG CCGCCCGCCT GGATCCGCGC CCAGCAGCAG 240 CCGCGGCCGC CGCCAGCTGG GCAGGCTCCC GGGACTCCGG CTGGGGGCGC GCAGGACCCT 300 CGCCTGCGTC CTCGACGTTC CCGGGGGAGG GTCCGGTTGC CAGTGAAACC TCCAGAGGCT 360 TCCGGACGAC AGCCCCGGGG GCCTTCTCAC TGCATCCCGA GATTTCCATC AGCGAGTGCA 420 ACTCATAAGG CAGTCCCTAA GGGGACCGGG CCACCGGCTG AGGACGGGGA TGGCTTAGGA 480 GCTCCTGGAC CTAGGGCCCG GCGTCGTCGC CTCCTGGGCG TCGCGGCAGA GGGGAGTGGC 540 CCGCGCGGAA AGCGCCGCGG GACAGTCAGT GACGAGGCCC GGGGGTCGCC GGGGCCACGA 600 CTTCTCGGAG ACCGTCCTGC GCTCTCTGGA GACGCGCTCT CCGCGCCCAG GGTGGTGCCA 660 TGTGGGGCGC TCGCCGCTCG TCCGTCTCCT CATCCTGGAA CGCCGCTTCG CTCCTGCAGC 720 TCCTCCTGGC TGCGCTGCTC GCGGCGGGGG CGAGGGCCCA GCGGCGAGTA CTGCCACGGC 780 TCGCTGGACG CGCAGGGCGT CTCGCGCATC GGCTTCCAGT GTCCCGAGCG CTTCGACGGC 840 GGCGACGCCA CCATCTGCTC CGGCAGCTGC GCGTTGCGCT ACTGCTGCTC CAGCGCCGAG 900 GCGCGCCTGG ACCAGGGCGG CTGCGACAAT GACCGCCAGC AGGGCGCTGG CGAGCCTGGC 960 CGGGCGGACA AAGACGGGCC CCGACGGCTC GGCAGGGCTT CATGTCTTAG GGGTACCCAA 1020 GGAGACGGCG AGGGTGCGCC CCCACCCGTG AGGGCCTGGC AGCGGTGCTC CCCTGAAGGC 1080 TCCCCGAAAG GAAGGCAGCT CCTCAGGGCT TTCCCGGGGC TGCTGCCCCG TGCCAGACGC 1140 CGCGGATTCC CATCTTCTCC ACGCGGCGGC CCCTCTCCCC TGCAGCGGCC CGCCTTGCCC 1200 ATCTACGTGC CGTTCCTCAT TGTTCGCTCC GTGTTTGTCG CCTTTATCAT CTTGGGGTCC 1260 CTGGTGGCAG CCTGTTGCTG CAGATGTCTC CGGCCTAAGC AGGATCCCCA GCAGAGCCGA 1320 GCCCCAGGGG GTAACCGCTT GATGGAGACC ATCCCCATGA TCCCCAGTCC CAGCACCTCC 1380 CGGGGGTCGT CCTCACGCCA GTCCAGCACA GCTGCCAGTT CCAGCTCCAG CGCCAACTCC 1440 GGGGCCCGGG CGCCCCCAAC AAGGTCACAG ACCAACTGTT GCTTGCCGGA AGGGACCATG 1500 AACAACGTCT ATGTCAACAT GCCCACGAAT TTCTCTGTGC TGAACTGTCA GCAGGCCACC 1560 CAGATTGTCC CACATCAAGG GCAGTATCTG CATCCCCCAT ACGTGGGGTA CACGGTCCAG 1620 CACGACTCTG TGCCCATCAC AGCTGTGCCA CCTTTCATGG ACGGCCTGCA GCCTGGCTAC 1680 AGGCAGATTC AGTCCCCCTT CCCTCACACC AACAGTGAAC AGAAGATGTA CCCAGCGGTG 1740 ACTGTATAAC CGAGAGTCAC TGGTCGGTTC CTTTACTGAA GGGAGACGAA GGCAGGGGTG 1800 GATTCTCGAG GTCGAAGTCC GCACATGTCG GTGGTATTTA TGGCACGATT CCTTTGGATG 1860 GCTTCATTTC CCCCCAGACT GTATGAAAAC ATCTCCGAAT TAGCATTTCT GGATATGTTT 1920 CATCCAGGGT ATCATTGATT TATGATGGAA AACCGGCCTC AGCTGGAGAT GACTGTCATG 1980 TTGCTGATGG GTCTATAACA AATCCTTGAG TCCGAAGTGC CCTTGAGATA TGGTTCACGA 2040 AAGAATTTTA TAAACTGATA AATTAAGGAT TTTTATTATC TTGTTATTAT TATTTCTTTT 2100 TTCTTCTTCA CTGCACAGGA TCAAAATCCC TCTTATCTCC CTTTTACTCG GACTTTTTTT 2160 TTTTTTTTTT TTTTTTTTAA TCAGACAGGG TCTTGCTCTG TTGCCCAGGC TGGAGTGCAG 2220 TGGTGCGATC TCGGCTCACT GCAACTTCAG CCTCCTGGAT TCAGGCAACA CTCCTGCCTC 2280 AGCCTCCCAC GTGGCTGGGA TTACAGGTGC CTGCCCCCAT GGCTAATTTT TTGTATTTTT 2340 TGTAGAGATG GGGTTTCACC ATGTTCGCTG GGCTGGTCTC ACTCTCCTGA CCTCAAGCAA 2400 TCTGCCTGTC TCAGCCTCCC AAAGTGCTGG GATTACAGGC GTCAGCCACC GCCCCCAGCC 2460 TGAGCCTTTT TTTTTTTCTA ATGCATCCAA GGTTAAGGGβ AAGACGCAAA TAACAGGACT 2520 ATTCTAAAAG GAAACCTCTT TCAACTCTGT GAGATCAGTC ATCAGTCTCA GTATTCCACA 2580 GGCACACCTT AATTTCATTG TAAAAAGATA TATATATTTT GTCTATTTTT GTGCTTTTCG 2640 GGGCCTATTT TCTCCTTTTT TACCTTATGT AGAGATCTTA TTACAAAGTG ATTTTCTACA 2700 TTAAAAAGAG ACTCAAATAA ATTGTATAGT TACTTAACTA ATGAAGACAT TTCAGAACTC 2760 TGGGATGATT TTAATCTTGA AGTAGTAGGT GGTATAGTCA TAAAACCATT CATCCCCTTC 2820 TTGATTGTAT CTTAATTTTC TGGCTTTAAG GTGACATCTG AGAGGTAATG CATTCTTTTT 2880 TATATTGAAA TCATAAACTA TCACCCGCTC CTTCTCTGAG TTACTTTTAA TTTTGCCTTG 2940 TGGTTATGGT TTGGCGTTTC CTTCTCTTTC GTTTTCAGAG CCCCATGTCT ATATAGTCCT 3000 GAGTCCAAGT AATTACTATA CTTGTAAATβ AAGATCAGTA TTTCTGCCTA GATCTGATAA 3060 AAAAATTTTC TTGTCTTAGT TATAAAAATT CAAAGAAATG TGTTACAAAG ATACTTAGTA 3120 TAGCTCCTCA GCCATAACCT GAGACTTGGG ATCAAATTTA AACCAGATAC GATTTACTTT 3180 GCAGATCATA AGGCTTTTTA TACTCTTGTT ATCAAAATGG CTTATTTTTC AGGCACTAAG 3240 GATTGTTAAG AGAAAAGCTT TTCAACGAAG GATTGCCTTT CTTCTCCCAC ACTGTTCTTG 3300 ATTTCCTCTC TCTTTCAGGC CTCAACAGGC ACTGTATTCA TTGCCAATCT TCCAAATTAT 3360 CAAATTCAAG TGAATTTATT TGTGTCTTCT TTACTTATAT AAAAAAAGAT AACTTTAAGG 3420 ATGTGCAAGT ACATTTCCAA CTGCTAGCAC AACCAGTATT TTGTAATTAA ACAAATCGCT 3480 GTATGGTATG GTCTTCTACA CATTTATCTC TATAGATATC TATCGATCAT CTTTCTATTC 3540 TCTTTCATGA CTGAATAATG TAAAACCAGT GTTCGCAATT GGTATCATCA ATGATACTCA 3600 TTTTTTAATA ACCAAAGGCA GGGGAAAATC ATTTTACTTA TTAATAAATA TTTTATGATG 3660 TGAAAAAAAA AAAAAAAAAA AAAAAAAAAA SEQ ID N0:195 BHB8 Protein sequence Protein Accession*: none found 11 21 31 41 51 MLSGFLMSPS TQHRAQYTPG GKKLPWEASI GAHTSRGRGS DRERESRPEA AGLLWDRAAA 60 GEAEKGNRGE PPAWIRAQQQ PRPPPAGQAP GTAAGGAQDP RLRPGRSRGR VRLPVKPPEA 120 SGRQPRGPSD CIPRFPSASA THKAVPKGTG PPAEDGDGLG APGPRARRRR LLGVAAEGSG 180 PRGKRRGTVS DEARGSPGPR LLGDRPALSG DALSAPRWP CGALAARPSP HPGTPLRSCS 240 CCWLRCWRRG RGPSGEYCHG WLDAQGVWRI GFQCPERFDG GDATICCGSC ALRYCCSSAE 300 ARLDQGGCDN DRQQGAGEPG RADKDGPRRL GRASCLRGTQ GDGEGAPPPV RAWQRCSPEG 360 SPKGRQLLRA FPGLLPRARR RGFPSSPRGG PSPLQRPALP IYVPFLIVGS VFVAFIILGS 420 LVAACCCRCL RPKQDPQQSR APGGNRLMET IPMIPSASTS RGSSSRQSST AASSSSSANS 480 GARAPPTRSQ TNCCLPEGTM NNVYVNMPTN FSVLNCQQAT QIVPHQGQYL HPPYVGYTVQ 540 HDSVPMTAVP PFMDGLQPGY RQIQSPFPHT NSEQKMYPAV TV SEQ ID N0:196 CQA5 DNA SEQUENCE Nucleic Acid Accession *: AA088458 Coding sequence: 862-1995 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I GCCCTTGGAC ACTGACATCG ACTGAAGGAG TAGAATGGAG CACGAGGACA CTGACATGGA 60 CTGAAGAAAA AGGAGCTGGA GCAGGAGAAG GAGGTGCTGC TGCAGGGTTT GGAGATCATG 120 GCGCGGGGCC GCGACTGGTA CCAGCAGCAG CTGCAACGAG TGCAGGAGCG CCAGCGCCGC 180 CTGGGCCAGA GCAGAGCCAG CGCCGACTTT GGGGCTCCAG GGAGCCCCCG CCCACTGGGG 240 CGGCTACTGC CCAAGGTACA AGAGGTGGCC CGGTGCCTCG GGGAGCTCCT GGCTGCAGCC 300 TGTGCCAGCC GGGCCCTGCC CCCGTCCTCC TCCGGGCCCC CCTCCCCTGC CCTGACGTCC 360 ACCTCACCCC CGGTCTGGCA GCAGCAGACC ATCCTCATGC TGAAGGAGCA GAACCGACTC 420 CTCACCCAGG AGGTGACCGA GAAGAGTGAG CGCATCACGC AGCTGGAGCA GGAGAAGTCG 480 GCGCTCATTA AGCAGCTGTT TCAGGCCCGC GCCCTGAGCC AGCAGGACGG GGGACCTCTG 540 GATTCCACCT TCATCTAGTC CTTGTGGGCC GCGTCGGCCC CCAGGGCCAG CCTGGCACTC 600 AGCCCTTCGA GGGTGGGCGC CCCATCGCAC CCACCCTCTC TGGCTGGAGA CCCCCGGCAG 660 GCCCAGGCAC AGTCCCGGAG TGGGCGCCTT CCTCCCGCCC TTGCCAGATG GGCTCCCCAG 720 GCCTGCCCCC GGCTGGTCCC CGCACCGAGC GCTTCACTCC GTTTKGGCTC CTGGTTGYTG 780 ACATGGGCTG GGGGCTCTCT TGAGTCCGCA TAGTCCGCAG CTACTACTGG CCGCTGTCAG 840 TGGACAGTCG GGTACCCCTC CATGAGTTAG CGTCCCCCCG TTTCCAGCGG TGCCGCCCTG 900 GGTCCCATCT TCAGGGAAAG GCACTGCCCA CGCCAGGCTG CACTTCCAAC AACGGGCAGC 960 AGAGGGCGCG GGGCGGCTCC GACGCGGGTC CAAGGGCAGC TTCCCGCTCA ACCAGGGCAC 1020 CAGGACGAGG TGGCTGTAGC TCGGACGGAC GGAAGTAGAT GGAGGGGGTG GGGACGGCCT 1080 GTAAGCGGGG GGTCCCTGCC TGGCTCGGGA GCCCCAGGGA TAGCGGTCGG ACTTCAGGTT 1140 CTGGCCAAGG CTCAGGGACC CTGGCTGCAG CGGATCGGCA CGCCGGGTGG GCGAGAGCTT 1200 GGCCTGCATG TGCCTCCCAC AGACCCTGGG GTGATGGCCT TCCCCCTCTT GGCCGGGACG 1260 TTGCCCCACG TTGAGTCCCA CACAACATCC TGTCAGCCTG GCTCCCCAGG AGGGCCCCCA 1320 GACAGCTCCC AGGCACGTCA TAGGCAAAGC CTGTTTCCCC CGACTCAGGA TTTCCAAGGC 1380 CTCGGGTCCT GCTCACCCCC CTTTGCTCTC ACGCCCAGCC TCTCCCCAGG TTTCAGCTGG 1440 GAGAGGCCAC CTCCCTCAGC CAAGGAAAAC GAGAACCCCC AGGGTACAGG AGGAGGCTGG 1500 GGCAGGTCCC CTTGGGTGTC ACTCCCTCAG CCCCTCCCCA GGCCCACTCC CGCTGGTGCT 1560 GGAGTACGCA CTGGTGGGGG GGCCCTGCTC AGCCCAACCT GGAGGGTCCC AGTGTCACCA 1620 GAACCAGGGG CACGGCAACA GCATCGATGG GTTCTGCAGC CCAGGGCCCC CGATCCGGGG 1680 TCAGTCTCTG TGGGGCGCAG GGCCTCCGAT GCGGGGTCAG TGCGTCGGGG GCGCAGGGCC 1740 CCCGATGCGG GGTCAGTGCG TGGGGGGCGC AGGGCCCCCT CGTGTCCAGG GCACTTTGGT 1800 ACACTGTCCC ACAAGGCACC TGTCTCAGAG GAGGGGCCCT GGCAGGCAGC GTGGCAACTC 1860 CCTTCCGGAG CCCAGCTCCA TGCTAACCTC CCCACAGCAA CCCCACAGAG CCACATTCCC 1920 TGCTGCACCT GGTCTGCAGG GGTGTCCCAG GACAGGCCCA AGTCAGCCCA GCATGCAGCT 1980 GCCCTCCTAC CCTCAAGATG GGAGTGGGCT TTCCAGGGGA CATAAGGATG TCAGGCCTGG 2040 ACCTCCTGGG CAGGAAAGGG TGCAGGTCCT GAGGGCCTGT GCCCCACAGC CCCAGCACCC 2100 AGGTCGACTG CAGCGCAGTG GGTGGGCCAG TCGCAGCCAG GGAGAAGCCC CCCGTCAGCA 2160 GGCTGGGGTC TGCCCACCAG GGCCTCCCCA CGTCTCCCTT TGAGGGTGCC TGCCATCCCC 2220 TGGGGGATCC TGGCATCTTT ACTCGACTGG AAGCAGGAGA CAGAACAGTG TCTGTCCCGG 2280 GGTCACTTCA TCAGGAGACC GCCCACATAG AGCTCGACCC CGCAGCTGAA GCGGAAATGT 2340 GAGACAGGCT GGCACCTCCG GAAAAACTGC CTTTCAGCCT TCGTCTTCCG TGCAAGGTGA 2400 AAAGAAATAG GTCCTCCCAG TTTACAGCTT GAAATCAGGC TAGTCAGTGG CCCTGGAGAC 2460 CACGAGGGGA GAATTTAAAG GCCCCGGCTG GCAGGGTCTA GGTCGCTGGC AGAGGCACAT 2520 GCAGACCCTG CCTGGAGCCT GCCCTAGGAC GCTGGGCGGG TCAGTCTCCG TGCAGGATGT 2580 GAGCAGCGTC CCTGGGCTCT ATCCGCGAGG TGCCAGTAGC GTGTGCAGGT ACATACACGT 2640 GCGTGCACAC TGTGATGACA CCCGGAAATG TCTCAGGATC TTGAAATGTG TCCTTGGGGG 2700 CAGAAGTGTC CCCAGTTGAG AATCTGCCCC AGAGGAACAC ACCCACACCA GGCCTCAGGA 2760 TTTTGTGTTG ATCAAGTTCC AAGGAAAAGG AACATCTCAG CCGGGCGTGG TGGTTCACGC 2820 CTGGAATCCC AGCACTTGAG GCCAGGAGTT CCAGAGCAGC CTGGGCAACG CAGTGAGAGA 2880 CCCCATCTCT ACAARAAAAA AAAAAGAAAG AAAGAAAATC AGAGATCCAG GTTTAAAAAT 2940 TCATAAACAC CACAAGGAAA CAATACACTA TCAGACCCAG CAGAAGCAAC AGATTGACTC 3000 TAGACCCAGA TACTAGAATT ATCAGAGAGA ATATAAAGTA ACAGTGTTTT ATATATCTAA 3060 AGAAATAAAA GAGATTTCTG GAAACATCAA AAAAAA SEQ ID NO:197 LBG2 DNA SEQUENCE Nucleic Acid Accession* X63629 Coding sequence: 54-2543 (start and stop codons are underlined) 1 11 21 31 41 51 I I I I I I GCGGAACACC GGCCCGCCGT CGCGGCAGCT GCTTCACCCC TCTCTCTGCA GCCATfiGGGC 60 TCCCTCGTGG ACCTCTCGCG TCTCTCCTCC TTCTCCAGGT TTGCTGGCTG CAGTGCGCGG 120 CCTCCGAGCC GTGCCGGGCG GTCTTCAGGG AGGCTGAAGT GACCTTGGAG GCGGGAGGCG 180 CGGAGCAGGA GCCCGGCCAG GCGCTGGGGA AAGTATTCA GGGCTGCCCTGGGCAAGAGC 240 CAGCTCTGTT TAGCACTGAT AATGATGACT TCACTGTGCG GAATGGCGAG ACAGTCCAGG 300 AAAGAAGGTC ACTGAAGGAA AGGAATCCAT TGAAGATCTT CCCATCCAAA CGTATCTTAC 360 GAAGACACAA G AGAGATTGG GTGGTTGCTC CAATATCTGT CCCTGAAAAT GGCAAGGGTC 420 CCTTCCCCCAGAGACTGAATCAGCTCAAGTCTAATAAAGA TAGAGACACCAAGATTTTCT 480 ACAGCATCAC GGGGCCGGGG GCAGACAGCC CCCCTGAGGG TGTCTTCGCT GTAGAGAAGG 540 AGACAGGCTG GTTGTTGTTG AATAAGCCAC TGGACCGGGA GGAGATTGCC AAGTATGAGC 600 TCTTTGGCCA CGCTGTGTCA GAGAATGGTG CCTCAGTGGA GGACCCCATG AACATCTCCA 660 TCATCGTGAC CGACCAGAAT GACCACAAGC CCAAGTTTAC CCAGGACACC TTCCGAGGGA 720 GTGTCTTAGA GGGAGTCCTA CCAGGTACTT CTGTGATGCA GGTGACAGCC ACAGATGAGG 780 ATGATGCCATCTACACCTAC AATGGGGTGGTTGCTTACTCCATCCATAGC CAAGAACCAA 840 AGGACCCACA CGACCTCATG TTCACAATTC ACCGGAGCAC AGGCACCATC AGCGTCATCT 900 CCAGTGGCCT GGACCGGGAA AAAGTCCCTG AGTACACACT GACCATCCAG GCCACAGACA 960 TGGATGGGGA CGGCTCCACC ACCACGGCAG TGGCAGTAGT GGAGATCCTT GATGCCAATG 1020 ACAATGCTCCCATGTTTGAC CCCCAGAAGTACGAGGCCCATGTGCCTGAG AATGCAGTGG 1080 GCCATGAGGT GCAGAGGCTG ACGGTCACTG ATCTGGACGC CCCCAACTCA CCAGCGTGGC 1140 GTGCCACCTA CCTTATCATG GGCGGTGACG ACGGGGACCA TTTTACCATC ACCACCCACC 1200 CTGAGAGCAA CCAGGGCATC CTGACAACCA GGAAGGGTTT GGATTTTGAG GCCAAAAACC 1260 AGCACACCCT GTACGTTGAA GTGACCAACG AGGCCCCTTT TGTGCTGAAG CTCCCAACCT 1320 CCACAGCCAC CATAGTGGTC CACGTGGAGG ATGTGAATGA GGCACCTGTG TTTGTCCCAC 1380 CCTCCAAAGTCGTTGAGGTCCAGGAGGGCATCCCCACTGG GGAGCCTGTG TGTGTCTACA 1440 CTGCAGAAGA CCCTGACAAG GAGAATCAAA AGATCAGCTA CCGCATCCTG AGAGACCCAG 1500 CAGGGTGGCT AGCCATGGAC CCAGACAGTG GGCAGGTCAC AGCTGTGGGC ACCCTCGACC 1560 GTGAGGATGA GCAGTTTGTG AGGAACAACA TCTATGAAGT CATGGTCTTG GCCATGGACA 1620 ATGGAAGCCCTCCCACCACTGGCACGGGAACCCTTCTGCTAACACTGATTGATGTCAACG 1680 ACCATGGCCCAGTCCCTGAG CCCCGTCAGA TCACCATCTGCAACCAAAGCCCTGTGCGCC 1740 ACGTGCTGAA CATCACGGAC AAGGACCTGT CTCCCCACAC CTCCCCTTTC CAGGCCCAGC 1800 TCACAGATGA CTCAGACATC TACTGGACGG CAGAGGTCAA CGAGGAAGGT GACACAGTGG 1860 TCTTGTCCCT GAAGAAGTTC CTGAAGCAGG ATACATATGA CGTGCACCTT TCTCTGTCTG 1920 ACCATGGCAACAAAGAGCAG CTGACGGTGATCAGGGCCACTGTGTGCGACTGCCATGGCC 1980 ATGTCGAAAC CTGCCCTGGA CCCTGGAAAG GAGGTTTCAT CCTCCCTGTG CTGGGGGCTG 2040 TCCTGGCTCT GCTGTTCCTC CTGCTGGTGC TGCTTTTGTT GGTGAGAAAG AAGCGGAAGA 2100 TCAAGGAGCC CCTCCTACTC CCAGAAGATG ACACCCGTGA CAACGTCTTC TACTATGGCG 2160 AAGAGGGGGG TGGCGAAGAG GACCAGGACT ATGACATCAC CCAGCTCCAC CGAGGTCTGG 2220 AGGCCAGGCC GGAGGTGGTT CTCCGCAATG ACGTGGCACC AACCATCATC CCGACACCCA 2280 TGTACCGTCCTAGGCCAGCCAACCCAGATGAAATCGGCAACTTTATAATTGAGAACCTGA 2340 AGGCGGCTAA CACAGACCCC ACAGCCCCGC CCTACGACAC CCTCTTGGTG TTCGACTATG 2400 AGGGCAGCGG CTCCGACGCC GCGTCCCTGA GCTCCCTCAC CTCCTCCGCC TCCGACCAAG 2460 ACCAAGATTA CGATT ATCTG AACGAGTGGG GCAGCCGCTT CAAGAAGCTG GCAGACATGT 2520 ACGGTGGCGG GGAGGACGAC JAQGCGGCCT GCCTGCAGGG CTGGGGACCA AACGTCAGGC 2580 CACAGAGCAT CTCCAAGGGG TCTCAGTTCC CCCTTCAGCT GAGGACTTCG GAGCTTGTCA 2640 GGAAGTGGCC GTAGCAACTT GGCGGAG ACA GGCTATGAGT CTG ACGTTAG AGTGGTTGCT 2700 TCCTTAGCCT TTCAGGATGG AGGAATGTGG GCAGTTTGAC TTCAGCACTG AAAACCTCTC 2760 CACCTGGGCC AGGGTTGCCT CAGAGGCCAA GTTTCCAGAA GCCTCTTACC TGCCGTAAAA 2820 TGCTCAACCC TGTGTCCTGG GCCTGGGCCT GCTGTGACTG ACCTACAGTG GACTTTCTCT 2880 CTGGAATGGA ACCTTCTTAG GCCTCCTGGT GCAACTTAAT TTTTTTTTTT AATGCTATCT 2940 TCAAAACGTT AGAGAAAGTT CTTCAAAAGT GCAGCCCAGA GCTGCTGGGC CCACTGGCCG 3000 TCCTGCATTT CTGGTTTCCA GACCCCAATG CCTCCCATTC GGATGGATCT CTGCGTTTTT 3060 ATACTGAGTG TGCCTAGGTT GCCCCTTATT TTTTATTTTC CCTGTTGCGT TGCTATAGAT 3120 GAAGGGTGAG GACAATCGTG TATATGTACT AGAACTTTTT TATTAAAGAA A SEQ ID NO:198 LBG2 Protein sequence: Protein Accession * CAA45177 1 11 21 31 41 51 I I I MGLPRGPLAS LLLLQVCWLQ CAASEPCRAV FREAEVTLEA GGAEQEPGQA LGKVFMGCPG 60 QEPALFSTD DDFTVRNGETVQERRSLKERNPLKIFPSKRILRRHKRDWVVAPISVPENG 120 KGPFPQRLNQ LKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLN KPLDREEIAK 180 YELFGHAVSE NGASVEDPMN ISIIVTDQND HKPKFTQDTF RGSVLEGVLP GTSVMQVTAT 240 DEDDAIYTYN G WAYSIHSQ EPKDPHDLMF TIHRSTGTIS VISSGLDREK VPEYTLΗQA 300 TDMDGDGSTT TAVAWEILD ANDNAPMFDP QKYEAHVPEN AVGHEVQRLT VTDLDAPNSP 360 AWllATYLIMG GDDGDHFTnT--P--SNQGILTTRKGLDFEA KNQHTLYVEVTNEAPFVLKL 420 PTSTAT-VVHVEDVNEAPVFVPPSKVVEVQEGIPTGEPVC VYTAEDPDKENQKISYRILR 480 DPAGWLAMDP DSGQVTAVGT LDREDEQFVR NNIYEVMVLA MDNGSPPTTG TGTLLLTUD 540 VNDHGPVPEP RQ-TICNQSP VRHVLNITDK DLSPHTSPFQ AQLTDDSDIY WTAEVNEEGD 600 TWLSLKKFL KQDTYDVHLS LSDHGNKEQL TVIRATVCDC HGHVETCPGP WKGGFHJPVL 660 GAVLALU VLLIiVRKKRKIKEPIXI PEDDTRDNVFY YGEEGGGEED QDYDπ'QLHR 720 GLEARPEVVL RNDVAPTϋP TPMYRPRPAN PDEIGNFIIE NLKAANTDPT APPYDTLLVF 780 DYEGSGSDAA SLSSLTSSAS DQDQDYDYLN EWGSRFKKLA DMYGGGEDD SEQ ID NO:199 OBI5 DNA SEQUENCE Nucleic Acid Accession *: NM_012152 Coding sequence: 43-1104 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I CTTCTTTAAA TTTCTTTCTA GGATGTTCAC TTCTTCTCCA CAATGAATGA GTGTCACTAT 60 GACAAGCACA TGGACTTTTT TTATAATAGG AGCAACACTG ATACTGTCGA TGACTGGACA 120 GGAACAAAGC TTGTGATTGT TTTGTGTGTT GGGACGTTTT TCTGCCTGTT TATTTTTTTT 180 TCTAATTCTC TGGTCATCGC GGCAGTGATC AAAAACAGAA AATTTCATTT CCCCTTCTAC 240 TACCTGTTGG CTAATTTAGC TGCTGCCGAT TTCTTCGCTG GAATTGCCTA TGTATTCCTG 300 ATGTTTAACA CAGGCCCAGT TTCAAAAACT TTGACTGTCA ACCGCTGGTT TCTCCGTCAG 360 GGGCTTCTGG ACAGTAGCTT GACTCCTTCC CTCACCAACT TGCTGGTTAT CGCCGTGGAG 420 AGGCACATGT CAATCATGAG GATGCGGGTC CATAGCAACC TGACCAAAAA GAGGGTGACA 480 CTGCTCATTT TGCTTGTCTC GGCCATCGCC ATTTTTATCG GGGCGGTCCC CACACTGGGC 540 TGGAATTGCC TCTGCAACAT CTCTGCCTGC TCTTCCCTGG CCCCCATTTA CAGCAGGAGT 600 TACCTTCTTT TCTGGACAGT GTCCAACCTC ATGGCCTTCC TCATCATGGT TGTGGTGTAC 660 CTGCGGATCT ACGTCTACGT CAAGAGGAAA ACCAACGTCT TGTCTCCGCA TACAAGTGGG 720 TCCATCAGCC GCCGGAGGAC ACCCATGAAG CTAATGAAGA CGGTGATCAC TGTCTTAGGG 780 GCGTTTGTGG TATCCTGGAC CCCGGGCCTG GTGGTTCTGC TCCTCGACGG CCTGAACTCC 840 AGGCAGTGTG GCGTCCAGCA TGTGAAAAGG TGGTTCCTCC TGCTGGCGCT GCTCAACTCC 900 GTCGTGAACC CCATCATCTA CTCCTACAAG GACGAGGACA TGTATGGCAC CATGAAGAAG 960 ATGATCTGCT GCTTCTCTCA GGAGAACCCA GAGAGGCGTC CCTCTCGCAT CCCCTCCACA 1020 GTCCTCAGCA GGAGTGACAC AGGCAGCCAG TACATAGAGG ATAGTATTAG CCAAGGTGCA 1080 GTCTGCAATA AAAGCACTTC CTAAACTCTG GATGCCTCTC GGCCCACCCA GGTGATCACT 1140 GTCTTAGG SEQ ID NO:2000BI5 Protein sequence: Protein Accession #: NP 036284 11 21 31 41 51 I I I MNECHYDKHM DFFYNRSNTD TVDDWTGTKL VIVLCVGTFF CLFIFFSNSL VIAAVIKNRK 60 FHFPFYYLLA NLAAADFFAG IAYVFLMFNT GPVSKTLTVN RWFLRQGLLD SSLTASLTNL 120 LVIAVERHMS IMRMRVHSNL TKKRVTLLIL LVWAIAIFMG AVPTLGWNCL CNISACSSLA 180 PIYSRSYLVF WTVSNLMAFL IMWYLRIY VYVKRKTNVL SPHTSGSISR RRTPMKLMKT 240 VMTVLGAFW CWTPGLWLL LDGLNCRQCG VQHVKRWFLL LALLNSWNP IIYSYKDEDM 300 YGTMKKMICC FSQENPERRPSRIPSTVLSR SDTGSQYIED SISQGAVCNKSTS SEQ ID NO:201 PAA6 DNA SEQUENCE Nucleic Acid Accession #: AA569531 Coding sequence: 1-504 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I ATGACCTACA GTTACTCATT TTTCAGGCCT GAGTTCATCG TTAATCATCT TAATTATGTT 60 CATTCTGAAG CCAACAGGAG AACCAAGACC AAAACTTTAT TGTCTCTCCT TTCATTTCTT 120 GATGAAACCT CTGGACTAAG CACACATCTT CCTTGTTTAT CTCTCTCAAA GGAGTGTGGA 180 GTGCTTCATC TGGACATCCA CGGGAAGAAG GAAGACATCA GAATCACCCA ACAGTCTTCC 240 CAGCTATACC TCTGGGACAT GGGTCGTTTT ACAATATTTA AGAACCTGTC GATCAGCCTC 300 ATACCCAGAG GGAACAAACG CTCCCCAAAA AGAGTTACAG AAACCATCCT GAGAGATTTT 360 AAGCAGAAGC AAAGTTCAAA GATCCAAGAG GAGAGACGAA GAGAGTCTGC AGGACCAAAC 420 CTCTCTTCAT TCTGGTTTGT GGGGAATGCT GGAAGAGGAG ACAGGCCCCA GATTTGGGCA 480 GGAAGTAAAC AGTTTTCAGG CTGAGGCCAA TCTCAGCAGG AACATTCCAA TATTTCTTCA 540 GCTACGTTCT CCCAGCACTT CACTGGTTAA CCTTTTATGT CCACCATTTG TGGATTTCAC 600 AGCTACTTGT CAATGGTGAA TATTGATCAT CATCATTATC TACTCAGCTG CTACCATAT€ 660 CCAGCTACTC CTTGCATGTT GTTCATTATT TTCTCAACAC TCAGCATATT TGCAATATGT 720 TATGTAATAT CACAGACAAG GAAACTGAAC GCAGAAATGT TTTATTTCTT GCCAAACATC 780 ACATGAGGAT GAACAATGAA ACCGATTTGA AACCAGGATT GTCTGATTCC AACATCTCTG 840 GGTCCTTTTT CACTCTGATA TGCTGCAATT AAAAAGCCAT TTCTAAGACT GT SEQ ID NO:202 PAA6 Protein sequence: Protein Accession * none found 1 11 21 31 41 51 I I I I I I MTYSYSFFRP ELIVNHLNYV HSEANRRTKT KTLLSLLSFL DETSGLSTHL PCLSLSKECG 60 VLHLDIHGKK EDMRITQQSS QLYLWDMGGF TIFKNLWMSL IPRGNKRSPK RVTETILRDF 120 KQKQSSKIQE ERRRESAGPN LSSFWFVGNA GRGDRPQIWA GSKQFSG SEQ ID NO.203 PAB2 DNA SEQUENCE Nucleic Acid Accession* XM.050197 Coding sequence: 310-1971 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I TCACACGTGC CAAGGGGCTG GCTCAGCGGA ACCAGCCTGC ACGCGCTCGC TCCGGGTGAC 60 AGCCGCGCGC CTCGGCCAGG ATCTGAGTGA TGAGACGTGT CCCCACTCAG GTGCCCCACA 120 GCAGCAGGTC TTGAGCATGG GCTCAGAAGC TGGACCGGCA CCAAAGGGCT GGCAGAAATG 180 GGCGCCTGGC TCATTCCTAG GCAGTTGGCG GCAGCAAGGA GGAGAGGCCG CAGCTTCTGG 240 AGCAGAGCCG AGACGAAGCA GTTCTGGAGT GCCTGAACGG CCCCCTGAGC CCTACCCGCC 300 TGGCCCACTA TGGTCCAGAG GCTGTGGGTG AGCCGCCTGC TCCGGCACCG GAAAGCCCAG 360 CTCTTCCTGG TCAACCTGCT AACCTTTGGC CTCGAGGTGT GTTTGGCCGC AGGCATCACC 420 TATGTCCCGC CTCTGCTGCT GGAAGTGGGG GTAGAGGAGA AGTTCATCAC CATGGTGCTG 480 GGCATTCGTC CAGTCCTGGG CCTGGTCTGT GTCCCGCTCC TAGGCTCAGC CAGTGACCAC 540 TGGCGTGGAC GCTATGGCCG CCGCCGGCCC TTCATCTCGG CACTGTCCTT GGGCATCCTG 600 CTCAGCCTCT TTCTCATCCC AAGGGCCGGC TGGCTAGCAG GGCTGCTGTG CCCGGATCCC 660 AGGCCCCTGG AGCTGGCACT GCTCATCCTG GGCGTCGGGC TCCTGGACTT CTGTGGCCAG 720 GTCTGCTTCA CTCCACTGGA GGCCCTGCTC TCTGACCTCT TCCGGGACCC GGACCACTCT 780 CGCCAGGCCT ACTCTGTCTA TGCCTTCATG ATCAGTCTTG GGGGCTCCCT GGGCTACCTC 840 CTCCCTGCCA TTGACTGGGA CACCAGTCCC CTCGCCCCCT ACCTGGGCAC CCAGGAGGAG 900 TGCCTCTTTG GCCTCCTCAC CCTCATCTTC CTCACCTGCG TAGCAGCCAC ACTGCTGGTG 960 GCTGAGGAGG CAGCGCTGGG CCCCACCGAG CCAGCAGAAG GGCTGTCGGC CCCCTCCTTG 1020 TCGCCCCACT GCTGTCCATG CCGGGCCCGC TTGGCTTTCC GGAACCTGGG CGCCCTGCTT 1080 CCCCGGCTGC ACCAGCTGTG CTGCCGCATG CCCCGCACCC TGCGCCGGCT CTTCGTGGCT 1140 GAGCTGTCCA GCTGGATGGC ACTCATGACC TTCACGCTGT TTTACACGGA TTTCGTCGGC 1200 GAGGGGCTGT ACCAGGGCGT GCCCAGAGCT GAGCCGGGCA CCGAGGCCCG GAGACACTAT 1260 GATCAAGGCG TTCGGATGGG CAGCCTCGGG CTCTTCCTGC AGTGCGCCAT CTCCCTGGTC 1320 TTCTCTCTGG TCATGGACCG GCTCGTCCAG CGATTCGGCA CTCGAGCAGT CTATTTGGCC 1380 AGTGTGGCAG CTTTCCCTGT GGCTGCCGGT GCCACATGCC TGTCCCACAG TGTGGCCGTC 1440 GTCACAGCTT CAGCCGCCCT CACCGGGTTC ACCTTCTCAG CCCTGCAGAT CCTGCCCTAC 1500 ACACTGGCCT CCCTCTACCA CCGGGAGAAG CAGGTGTTCC TGCCCAAATA CCGAGGGGAC 1560 ACTCGAGGTG CTAGCAGTCA GGACAGCCTG ATGACCAGCT TCCTGCCAGG CCCTAAGCCT 1620 GGAGCTCCCT TCCCTAATGG ACACGTGGGT GCTCGAGGCA GTGGCCTGCT CCCACCTCCA 1680 CCCGCGCTCT GCGGGGCCTC TGCCTGTGAT GTCTCCGTAC GTGTGGTGGT GGGTGAGCCC 1740 ACCGAGGCCA GGGTGGTTCC GGGCCGGGGC ATCTGCCTGG ACCTCGCCAT CCTGGATAGT 1800 GCCTTCCTGC TGTCCCAGGT GGCCCCATCC CTGTTTATGG GCTCCATTGT CCAGCTCAGC 1860 CA6TCTCTCA CTGCCTATAT GGTGTCTGCC GCAGGCCTGG GTCTGGTCGC CATTTACTTT 1920 GCTACACAGG TAGTATTTCA CAAGAGCGAC TTGGCCAAAT ACTCAGCGTA GAAAACTTCC 1980 AGCACATTGG GGTGGAGGGC CTGCCTCACT GGGTCCCAGC TCCCCGCTCC TGTTAGCCCC 2040 ATGGGGCTGC CGGGCTGGCC GCCAGTTTCT GTTGCTGCCA AAGTAATGTG GCTCTCTCCT 2100 GCCACCCTGT GCTGCTGAGG TGCGTAGCTG CACAGCTCGG GGCTGGGGCG TCCCTCTCCT 2160 CTCTCCCCAG TCTCTAGGGC TGCCTGACTG GAGGCCTTCC AAGGGGGTTT CAGTCTGGAC 2220 TTATACAGGG AGGCCAGAAG GGCTCCATGC ACTGGAATGC GGGGACTCTC CAGGTCGATT 2280 ACCCAGGCTC AGGGTTAACA GCTAGCCTCC TAGTTGAGAC ACACCTAGAG AAGGGTTTTT 2340 GGGAGCTGAA TAAACTCAGT CACCTGGTTT CCCATCTCTA AGCCCCTTAA CCTGCAGCTT 2400 CGTTTAATGT AGCTCTTGCA TGGGAGTTTC TAGGATGAAA CACTCCTCCA TGGGATTTGA 2460 ACATATGAAA GTTATTTCTA GGGGAAGAGT CCTCAGGGGC AACACACAAG AACCAGGTCC 2520 CCTCAGCCCC ACAGGCACTC GTCTTTTTTG CTNGANTCCA CCCCCCCCCT CTTTACCCTT 2580 TT SEQ ID NO:204 PAB2 Protein sequence: Protein Accession*: XP.050197 11 21 31 41 51 MVQRLWVSRL LRHRKAQLLL VNLLTFGLEV CLAAGITYVP PLLLEVGVEE KFMTMVLGIG 60 PVLGLVCVPL LGSASDHWRG RYGRRRPFIW ALSLGILLSL FLIPRAGWLA GLLCPDPRPL 120 ELALLILGVG LLDFCGQVCF TPLEALLSDL FRDPDHCRQA YSVYAFMISL GGCLGYLLPA 180 IDWDTSALAP YLGTQEECLF GLLTLIFLTC VAATLLVAEE AALGPTEPAE GLSAPSLStΗ 240 CCPCRARLAF RNLGALLPRL HQLCCRMPRT LRRLFVAELC SWMALMTFTL FYTDFVGEGL 300 YQGVPRAEPG TEARRHYDEG VRMGSLGLFL QCAISLVFSL VMDRLVQRFG TRAVYLASVA 360 AFFVAAGATC LSHSVAWTA SAALTGFTFS ALQILPYTLA SLYHREKQVF LPKYRGDTGG 420 ASSEDSLMTS FLPGPKPGAP FPNGHVGAGG SGLLPPPPAL CGASACDVSV RWVGEPTEA 480 RWPGRGICL DLAILDSAFL LSQVAPSLFM GSTVQLSQSV TAYMVSAAGL GLVAIYFATQ 540 WFDKSDLAK YSA SEQ ID N0:205 PAJ3 DNA SEQUENCE Nucleic Acid Accession* AK002126 Coding sequence: 1-1593 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I ATGGTTCGCC GGGGGCTGCT TGCGTGGATT TCCCGGGTGG TGGTTTTCCT GGTGCTCCTC 60 TGCTGTGCTA TCTCTGTCCT GTACATGTTG GCCTGCACCC CAAAAGGTCA CGAGGAGCAG 120 CTGGCACTGC CCAGGGCCAA CAGCCCCACG GGGAAGGAGG GGTACCAGGC CGTCCTTCAG 180 GAGTGGGAGG AGCAGCACCG CAACTACGTG AGCAGCCTCA AGCGGCAGAT CGCACAGCTC 240 AAGGAGGAGC TGCAGGAGAG GAGTCAGCAG CTCAGGAATC GGCAGTACCA AGCCAGCGAT 300 GCTGCTGGCC TGGGTCTCGA CAGGAGCCCC CCAGAGAAAA CCCAGGCCGA CCTCCTGGCC 360 TTCCTCCACT CGCAGGTCGA CAAGGCAGAG GTGAATGCTG GCGTCAAGCT GGCCACAGAG 420 TATGCAGCAG TGCCTTTCGA TAGCTTTACT CTACAGAAGG TGTACCAGCT GGAGACTGGC 480 CTTACCCGCC ACCCCGAGGA GAAGCCTGTC AGGAAGGACA AGCGGGATCA GTTGGTGGAA 540 GCCATTGAAT CAGCCTTCGA GACCCTGAAC AATCCTCCAG AGAACAGCCC CAATCACCGT 600 CCTTACACGG CCTCTGATTT CATAGAAGGG ATCTACCGAA CAGAAAGGGA CAAAGGGACA 660 TTGTATGAGC TCACCTTCAA AGGGGACCAC AAACACGAAT TCAAACGGCT CATCTTATTT 720 CGACCATTCG GCCCCATCAT GAAAGTGAAA AATCAAAAGC TCAACATCGC CAACACGCTT 780 ATCAATGTTA TCGTGCCTCT AGCAAAAAGG GTCGACAAGT TCCGGCAGTT CATGCAGAAT 840 TTCAGGGAGA TGTGCATTCA GCAGGATGGG AGAGTCCATC TCACTGTTGT TTACTTTGGG 900 AAAGAAGAAA TAAATGAAGT CAAAGGAATA CTTGAAAACA CTTCCAAAGC TGCCAACTTC 960 AGGAACTTTA CCTTCATCCA GCTGAATGGA GAATTTTCTC GGGGAAAGGG ACTTGATGTT 1020 GGAGCCCGCT TCTGGAAGGG AAGCAACGTC CTTCTCTTTT TCTGTGATGT GGACATCTAC 1080 TTCACATCTG AATTCCTCAA TACGTCTAGG CTGAATACAC AGCCAGGGAA GAAGGTATTT 1140 TATCCAGTTC TTTTCAGTCA GTACAATCCT GGCATAATAT ACGGCCACCA TGATGCAGTC 1200 CCTCCCTTGG AACAGCAGCT GGTCATAAAG AAGGAAACTG GATTTTGGAG AGACTTTGGA 1260 TTTGGGATGA CGTGTCAGTA TCGGTCAGAC TTCATCAATA TAGGTCGGTT TGATCTGGAC 1320 ATCAAAGGCT GGGGCGGAGA GGATCTGCAC CTTTATCGCA AGTATCTCCA CAGCAACCTC 1380 ATAGTGGTAC GGACGCCTCT GCGAGGACTC TTCCACCTCT GGCATGAGAA GCGCTGCATG 1440 GACGAGCTGA CCCCCGAGCA GTACAAGATC TGCATGCAGT CCAAGGCCAT GAACGAGGCA 1500 TCCCACGGCC AGCTGGGCAT βCTGGTGTTC AGGCACGAGA TAGAGGCTCA CCTTCGCAAA 1560 CAGAAACAGA AGACAAGTAG CAAAAAAACA TGA SEQ ID N0:206 PAJ3 Protein sequence: Protein Accession* NP_060841 1 11 21 31 41 51 I I I I I I MVRRGLLAWI SRVWLLVLL CCAISVLYML ACTPKGDEEQ LALPRANSPT GKEGYQAVLQ 60 EWEEQHRNYV SSLKRQIAQL KEELQERSEQ LRNGQYQASD AAGLGLDRSP PEKTQADLLA 120 FLHSQVDKAE VNAGVKLATE YAAVPFDSFT LQKVYQLETG LTRHPEEKPV RKDKRDELVE 180 AIESALETLN NPAENSPNHR PYTASDFIEG IYRTERDKGT LYELTFKGDH KHEFKRLILF 240 RPFGPIMKVK NEKLNMANTL INVIVPLAKR VDKFRQFMQN FREMCIEQDG RVHLTWYFG 300 KEEINEVKGI LENTSKAANF RNFTFIQLNG EFSRGKGLDV GARFWKGSNV LLFFCDVDIY 360 FTSEFLNTCR LNTQPGKKVF YPVLFSQYNP GIIYGHHDAV PPLEQQLVIK KETGFWRDFG 420 FGMTCQYRSD FINIGGFDLD IKGWGGEDVH LYRKYLHSNL IWRTFVRGL FHLWHEKRCM 480 DELTPEQYKM CMQSKAMNEA SHGQLGMLVFRHEIEAH1--RK QKQKTSSKKT SEQ ID NO:207 PAJ5 DNA SEQUENCE Nucleic Acid Accession * AF189723 Coding sequence: 1-2712 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I ATGATTCCTC TATTGACATC AAAAAAAGCA AGTGAATTAC CAGTCAGTGA AGTTCCAAGC 60 ATTCTCCAAG CTGATCTTCA GAATCGTCTA AACAAATCTC AAGTTAGTCA TAGGCGAGCC 120 TTTCATGGCT GGAATGAGTT TGATATTAGT GAAGATGAGC CACTGTGGAA GAAGTATATT 180 TCTCAGTTTA AAAATCCCCT TATTATGCTC CTTCTCGCTT CTGCAGTCAT CAGTCTTTTA 240 ATGCATCAGT TTCATGATGC CGTCAGTATC ACTGTGGCAA TACTTATCGT TGTTACAGTT 300 GCCTTTGTTC AGGAATATCG TTCAGAAAAA TCTCTTGAAG AATTGAGTAA ACTTGTCCCA 360 CCAGAATCCC ATTGTGTGCG TCAAGGAAAA TTCGAGCATA CACTTGCCCG AGACTTGGTT 420 CCAGGTCATA CAGTTTGCCT TTCTGTTGGG GATAGAGTTC CTGCTCACTT ACGCTTGTTT 480 GAGGCTGTCG ATCTTTCCAT TGATGAGTCC AGCTTGACAG GTGAGACAAC GCCTTCTTCT 540 AAGGTGACAG CTCCTCAGCC AGCTGCAACT AATGGAGATC TTCCATCGAG AAGTAACATT 600 GCCTTTATGG GAACACTGGT CAGATCTGGC AAAGCAAAGG GTGTTGTCAT TGGAACAGGA 660 GAAAATTCTG AATTTGGGGA GGTTTTTAAA ATGATGCAAG CAGAAGAGGC ACCAAAAACC 720 CCTCTGCAGA AGAGCATGGA CCTCTTAGGA AAACAACTTT CCTTTTACTC CTTTGGTATA 780 ATAGGAATCA TCATGTTCGT TGGCTCGTTA CTGGGAAAAG ATATCCTGGA AATGTTTACT 840 ATTAGTGTAA GTTTGGCTCT AGCAGCAATT CCTGAAGGTC TCCCCATTGT GGTCACAGTG 900 ACGCTAGCTC TTGGTGTTAT GAGAATGGTG AAGAAAAGGG CCATTGTGAA AAAGCTGCCT 960 ATTGTTGAAA CTCTGGGCTG CTCTAATGTG ATTTGTTCAG ATAAAACTGG AACACTCACG 1020 AAGAATGAAA TGACTGTTAC TCACATATTT ACTTCAGATG GTCTGCATGC TGAGGTTACT 1080 GGAGTTGGCT ATAATCAATT TGGGGAAGTG ATTGTTGATG GTGATCTTGT TCATGGATTC 1140 TATAACCCAG CTGTTAGCAG AATTGTTGAG GCGGGCTGTG TGTGCAATCA TGCTGTAATT 1200 AGAAACAATA CTCTAATGGG GAAGCCAACA GAAGGGGCCT TAATTGCTCT TGCAATGAAG 1260 ATGGGTCTTG ATGGACTTCA ACAAGACTAC ATCAGAAAAG CTGAATACCC TTTTAGCTCT 1320 GAGCAAAAGT GGATGGCTGT TAAGTCTCTA CACCGAACAC AGCAGGACAG ACCAGAGATT 1380 TGTTTTATGA AAGGTGCTTA CGAACAAGTA ATTAAGTACT GTACTACATA CCAGAGCAAA 1440 GGGCAGACCT TGACACTTAC TCAGCAGCAG AGAGATGTCT ACCAACAAGA GAAGGCACGC 1500 ATGGGCTCAG CGGGACTCAG AGTTCTTGCT TTGGCTTCTC GTCCTCAACT GGGACAGCTG 1560 ACATTTCTTC GCTTGGTGGG AATCATTGAT CCACCTAGAA CTGGTCTGAA AGAAGCTCTT 1620 ACAACACTCA TTGCCTCAGG AGTATCAATA AAAATGATTA CTGGAGATTC ACAGGAGACT 1680 GCAGTTGCAA TCGCCAGTCG TCTGGGATTG TATTCCAAAA CTTCCCAGTC AGTCTCAGGA 1740 GAAGAAATAG ATGCAATGGA TGTTCAGCAG CTTTCACAAA TAGTACCAAA GGTTGCAGTA 1800 TTTTACAGAG CTAGCCCAAG GCACAAGATG AAAATTATTA AGTCGCTACA GAAGAACGGT 1860 TCAGTTCTAG CCATGACAGG AGATGGAGTA AATGATGCAG TTGCTCTGAA GGCTGCAGAC 1920 ATTGGAGTTG CGATGGGCCA GACTGGTACA GATGTTTCCA AAGAGGCAGC AGACATGATC 1980 CTAGTGGATG ATCATTTTCA AACCATAATC TCTCCAATCG AAGAGGGTAA AGGGATTTAT 2040 AATAACATTA AAAATTTCGT TAGATTCCAG CTGAGCACGA GTATAGCAGC ATTAACTTTA 2100 ATCTCATTGG CTACATTAAT GAACTTTCCT AATCCTCTCA ATGCCATGCA GATTTTGTGG 2160 ATCAATATTA TTATCGATCG ACCCCCAGCT CAGAGCCTTG GAGTAGAACC AGTGGATAAA 2220 GATGTCATTC GTAAACCTCC TCGCAACTGG AAAGACAGCA TTTTGACTAA AAACTTGATA 2280 CTTAAAATAC TTGTTTCATC AATAATCATT GTTTGTGGGA CTTTGTTTGT CTTCTGGCGT 2340 GAGCTACGAG ACAATGTGAT TACACCTCGA GACACAACAA TGACCTTCAC ATGCTTTGTG 2400 TTTTTTCACA TGTTCAATGC ACTAAGTTCC AGATCCCAGA CCAAGTCTGT GTTTGAGATT 2460 10 GGACTCTGCA GTAATAGAAT GTTTTCCTAT GCAGTTCTTG GATCCATCAT GGGACAATTA 2520 CTAGTTATTT ACTTTCCTCC GCTTCAGAAG GTTTTTCAGA CTGAGAGCCT AAGCATACTG 2580 GATCTGTTGT TTCTTTTGGG TCTCACCTCA TCAGTGTGCA TAGTGGCAGA AATTATAAAG 2640 AAGGTTCAAA GGAGCAGGGA AAAGATCCAG AAGCATGTTA GTTCGACATC ATCATCTTTT 2700 CTTGAAGTAT GA 15 SEQ ID NO:208 PAJ5 Protein sequence: Protein Accession *: AAF27813 11 21 31 41 51 20 I I I I I I MIPVLTSKKA SELPVSEVAS ILQADLQNGL NKCEVSHRRA FHGWNEFDIS EDEPLWKKYI 60 SQFKNPLIML LLASAVISVL MHQFDDAVSI TVAILIWTV AFVQEYRSEK SLEELSKLVP 120 PECHCVREGK LEHTLARDLV PGDTVCLSVG DRVPADLRLF EAVDLSIDES SLTGETTPCS 180 KVTAPQPAAT NGDLASRSNI AFMGTLVRCG KAKGWIGTC ENSEFGEVFK MMQAEEAPKT 240 25 PLQKSMDLLG KQLSFYSFGI IGIIMLVGWL LGKDILEMFT ISVSLAVAAI PEGLPIWTV 300 TLALGVMRMV KKRAIVKKLP IVETLGCCNV ICSDKTGTLT KNEMTVTHIF TSDGLHAEVT 360 GVGYNQFGEV IVDGDWHGF YNPAVSRIVE AGCVCNDAVI RNNTLMGKPT EGALIALAMK 420 MGLDGLQQDY IRKAEYPFSS EQKWMAVKCV HRTQQDRPEI CFMKGAYEQV IKYCTTYQSK 480 GQTLTLTQQQ RDVYQQEKAR MGSAGLRVLA LASGPELGQL TFLGLVGIID PPRTGVKEAV 540 30 TTLIASGVSI KMITCDSQET AVAIASRLGL YSKTSQSVSG EEIDAMDVQQ LSQΓVPKVAV 600 FYRASPRHKM KIIKSLQKNG SWAMTGDGV NDAVALKAAD IGVAMGQTGT DVCKEAADMI 660 LVDDDFQTIM SAIEEGKGIY NNIKNFVRFQ LSTSIAALTL ISLATLMNFP NPLNAMQILW 720 INIIMDGPPA QSLGVEPVDK DVIRKPPRNW KDSILTKNLI LKILVSSIII VCGTLFVFWR 780 ELRDNVITPR DTTMTFTCFV FFDMFNALSS RSQTKSVFEI GLCSNRMFCY AVLGSIMGQL 840 35 LVIYFPPLQK VFQTESLSIL DLLFLLGLTS SVCIVAEIIK KVERSREKIQ KHVSSTSSSF 900 LEV SEQ ID NO:209 PAV4 VARIANT 1 DNA SEQUENCE Nucleic Acid Accession *: N62096 40 Coding sequence: 1-1284 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 4 , I I I I I I 4j ATGGGCTACC AGAGGCAGGA GCCTGTCATC CCGCCGCAGA GAGGATTGCC TTATTCAATG . 60 AAGCAAGCTC GGTTTCCTTT GGGAATATTG CTTTTATTCT GGGTTTCATA TCTTACAGAC 120 TTTTCCCTTC TTTTATTGAT AAAAGGAGGG GCCCTCTCTC GAACAGATAC CTACCAGTCT 180 TTGGTCAATA AAACTTTCGG CTTTCCAGGG TATCTGCTCC TCTCTCTTCT TCAGTTTTTG 240 _ TATCCTTTTA TAGCAATCAT AAGTTACAAT ATAATAGCTG GAGATACTTT GAGCAAAGTT 300 50 TTTCAAAGAA TCCCAGGAGT TGATCCTGAA AACGTCTTTA TTGGTCGCCA CTTCATTATT 360 GGACTTTCCA CAGTTACCTT TACTCTGCCT TTATCCTTCT ACCGAAATAT AGCAAAGCTT 420 GGAAAGGTCT CCCTCATCTC TACAGGTTTA ACAACTCTCA TTCTTGGAAT TGTAATGGCA 480 AGGGCAATTT CACTGGGTCC ACACATACCA AAAACAGAAG ACGCTTGGGT ATTTGCAAAG 540 _ _ CCCAATGCCA TTCAAGCGGT CGGGGTTATG TCTTTTGCAT TTATTTGCCA CCATAACTCC 600 55 TTCTTAGTTT ACAGTTCTCT AGAAGAACCC ACAGTAGCTA AGTGGTCCCG CCTTATCCAT 660 ATGTCCATCG TGATTTCTGT ATTTATCTGT ATATTCTTTG CTACATGTCG ATACTTCACA 720 TTTACTCGCT TCACCCAAGG GGACTTATTT GAAAATTACT GCAGAAATGA TGACCTGGTA 780 ACATTTGGAA GATTTTCTTA TGGTCTCACT GTCATTTTGA CATACCCTAT GGAATCCTTT 840 _._ GTCACAAGAG AGGTAATTGC CAATGTGTTT TTTGGTCGGA ATCTTTCATC GGTTTTCCAC 900 60 ATTGTTGTAA CAGTCATGGT CATCACTGTA GCCACGCTTG TGTCATTGCT GATTCATTGC 960 CTCGGGATAG TTCTAGAACT CAATGGTGTG CTCTCTGCAA CTCCCCTCAT TTTTATCATT 1020 CCATCAGCCT GTTATCTGAA ACTGTCTGAA GAACCAAGGA CACACTCCGA TAAGATTA'fG 1080 TCTTCTGTCA TGCTTCCCAT TGGTGCTGTG GTCATGGTTT TTGGATTCGT CATGGCTATT 1140 - ACAAATACTC AAGACTCCAC CCATGGGCAG GAAATGTTCT ACTGCTTTCC TGACAATTTC 1200 65 TCTCTCACAA ATACCTCAGA GTCTCATCTT CAGCAGACAA CACAACTTTC TACTTTAAAT 1260 ATTAGTATCT TTCAACTCGA GTAA SEQ ID N0.210 P AV4 Variant 1 Protein sequence: 70 Protein Accession* none found 11 21 31 41 51 l l l l MGYQRQEPVI P IPQRGLPYSM KQAGFPLGIL LLFWVSYVTD FSLVLLIKGG ALSGTDTYQS 60 75 LVNKTFGFPG YLLLSVLQFL YPFIAMISYN IIAGDTLSKV FQRIPGVDPE NVFIGRHFII 120 GLSTVTFTLP LSLYRNIAKL GKVSLISTGL TTLILGIVMA RAISLGPHIP KTEDAWVFAK 180 PNAIQAVGVM SFAFICHHNS FLVYSSLEEP TVAKWSRLIH MSIVISVFIC IFFATCGYLT 240 FTGFTQGDLF ENYCRNDDLV TFGRFCYGVT VILTYPMECF VTREVIANVF FGGNLSSVFH 300 IWTVMVITV ATLVSLLIDC LGIVLELNGV LCATPLIFII PSACYLKLSE EPRTHSDKIM 360 80 SCVMLPIGAV VMVFGFVMAI TNTQDCTHGQ EMFYCFPDNF SLTNTSESHV QQTTQLSTLN 420 ISIFQLE SEQ ID NO:211 PAV4 VARIANT2 DNA SEQUENCE Nucleic Acid Accession*: N62096 Coding sequence: 1-1203 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I ATGGGCTACC AGAGGCAGGA GCCTGTCATC CCGCCGCAGT T ITTCCCTTGT I TTTATTGATA 60 AAAGGAGGGG CCCTCTCTGG AACAGATACC TACCAGTCTT TGGTCAATAA AACTTTCGGC 120 TTTCCAGGGT ATCTCCTCCT CTCTGTTCTT CAGTTTTTGT ATCCTTTTAT AGCAATGATA 180 AGTTACAATA TAATAGCTGG AGATACTTTG AGCAAAGTTT TTCAAAGAAT CCCAGGAGTT 240 GATCCTCAAA ACGTCTTTAT TGGTCGCCAC TTCATTATTC GACTTTCCAC AGTTACCTTT 300 ACTCTGCCTT TATCCTTGTA CCGAAATATA GCAAAGCTTG GAAAGGTCTC CCTCATCTCT 360 ACAGGTTTAA CAACTCTGAT TCTTGGAATT GTAATGGCAA GGGCAATTTC ACTGGGTCCA 420 CACATACCAA AAACAGAAGA CGCTTGGGTA TTTGCAAAGC CCAATGCCAT TCAAGCGGTC 480 GGGGTTATGT CTTTTGCATT TATTTCCCAC CATAACTCCT TCTTAGTTTA CAGTTCTCTA 540 GAAGAACCCA CAGTAGCTAA GTGGTCCCGC CTTATCCATA TGTCCATCGT GATTTCTCTA 600 TTTATCTGTA TATTCTTTGC TACATCTGGA TACTTGACAT TTACTGGCTT CACCCAAGGG 660 GACTTATTTβ AAAATTACTG CAGAAATGAT GACCTGGTAA CATTTCGAAG ATTTTCTTAT 720 GGTGTCACTβ TCATTTTGAC ATACCCTATG GAATGCTTTG TGACAAGAGA GGTAATTGCC 780 AATGTCTTTT TTGGTGGGAA TCTTTCATCG GTTTTCCACA TTCTTGTAAC AGTCATGGTC 840 ATCACTGTAG CCACGCTTGT GTCATTGCTC ATTGATTGCC TCGGGATAGT TCTAGAACTC 900 AATGGTGTGC TCTGTGCAAC TCCCCTCATT TTTATCATTC CATCAGCCTG TTATCTGAAA 960 CTGTCTGAAG AACCAAGGAC ACACTCCGAT AAGATTATGT CTTCTCTCAT GCTTCCCATT 1020 GGTCCTCTCG TGATGGTTTT TCGATTCGTC ATGGCTATTA CAAATACTCA AGACTGCACC 1080 CATGGGCAGG AAATCTTCTA CTGCTTTCCT GACAATTTCT CTCTCACAAA TACCTCAGAG 1140 TCTCATGTTC AGCAGACAAC ACAACTTTCT ACTTTAAATA TTAGTATCTT TCAACTCGAG 1200 TAA SEQ ID NO:212 PAV4 Variant 2 Protein sequence: Protein Accession ft none found 1 11 21 31 41 51 l l l l MGYQRQEPVI PPQFSLVLLI KGGALSGTDT YQSLVNKTFG FPGYLLLSVL QFLYPFIAMI 60 SYNIIAGDTL SKVFQRIPGV DPENVFIGRH FIIGLSTVTF TLPLSLYRNI AKLGKVSLIS 120 TGLTTLILGI VMARAISLGP HIPKTEDAWV FAKPNAIQAV GVMSFAFICH HNSFLVYSSL 180 EEPTVAKWSR LIHMSIVISV FICIFFATCG YLTFTGFTQG DLFENYCRND DLVTFGRFCY 240 GVTVILTYPM ECFVTREVIA NVFFGGNLSS VFHIWTVMV ITVATLVSLL IDCLGIVLEL 300 NGVLCATPLI FIIPSACYLK LSEEPRTHSD KIMSCVMLPI GAWMVFGFV MAITNTQDCT 360 HGQEMFYCFP DNFSLTNTSE SHVQQTTQLS TLNISIFQLE SEQ ID NO:213 PAV4 VARIANT 3 DNA SEQUENCE Nucleic Acid Accession* N6209E Coding sequence: 1-1140 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 1 1 11 11 1 1 1 1 ATGGGCTACC AGAGGCAGGA GCCTGTCATC CCGCCGCAGG TCAATAAAAC TTTCGGCTTT 60 CCAGGGTATC TGCTCCTCTC TCTTCTTCAG TTTTTGTATC CTTTTATAGC AATCATAAGT 120 TACAATATAA TAGCTGGAGA TACTTTGAGC AAAGTTTTTC AAAGAATCCC AGGAGTTGAT 180 CCTGAAAACG TGTTTATTGG TCGCCACTTC ATTATTGGAC TTTCCACAGT TACCTTTACT 240 CTGCCTTTAT CCTTGTACCG AAATATAGCA AAGCTTGGAA AGGTCTCCCT CATCTCTACA 300 GGTTTAACAA CTCTGATTCT TGGAATTGTA ATGGCAAGGG CAATTTCACT GGGTCCACAC 360 ATACCAAAAA CAGAAGACGC TTGGGTATTT GCAAAGCCCA ATGCCATTCA AGCGGTCGGG 420 GTTATGTCTT TTGCATTTAT TTGCCACCAT AACTCCTTCT TAGTTTACAG TTCTCTAGAA 480 GAACCCACAG TAGCTAAGTG GTCCCGCCTT ATCCATATGT CCATCGTGAT TTCTGTATTT 540 ATCTGTATAT TCTTTGCTAC ATGTGGATAC TTGACATTTA CTGGCTTCAC CCAAGGGGAC 600 TTATTTGAAA ATTACTGCAG AAATGATGAC CTGGTAACAT TTGGAAGATT TTGTTATCGT 660 GTCACTGTCA TTTTCACATA CCCTATGGAA TCCTTTGTGA CAAGAGAGGT AATTGCCAAT 720 βTGTTTTTTG GTGGGAATCT TTCATCGGTT TTCCACATTG TTGTAACAGT GATCGTCATC 780 ACTGTAGCCA CGCTTGTGTC ATTGCTGATT GATTGCCTCG GGATAGTTCT AGAACTCAAT 840 GGTGTGCTCT GTGCAACTCC CCTCATTTTT ATCATTCCAT CAGCCTGTTA TCTGAAACTG 900 TCTGAAGAAC CAAGGACACA CTCCGATAAG ATTATGTCTT GTGTCATGCT TCCCATTGGT 960 GCTGTGGTGA TGGTTTTTGG ATTCGTCATG GCTATTACAA ATACTCAAGA CTGCACCCAT 1020 GGGCAGGAAA TGTTCTACTC CTTTCCTGAC AATTTCTCTC TCACAAATAC CTCAGAGTCT 1080 CATGTTCAGC AGACAACACA ACTTTCTACT TTAAATATTA GTATCTTTCA ACTCGAGTAA SEQ ID NO:214 PAV4 Variant 3 Protein seαuence: Proton Accession *: none found 1 11 21 31 41 51 1 1 1 1 1 1 MGYQRQEPVI PPQVNKTFGF PGYLLLSVLQ FLYPFIAMIS YNIIAGDTLS KVFQRIPGVD 60 PENVFIGRHF IIGLSTVTFT LPLSLYRNIA KLGKVSLIST GLTTLILGIV MARAISLGPH 120 IPKTEDAWVF AKPNAIQAVG VMSFAFICHH NSFLVYSSLE EPTVAKWSRL IHMSIVISVF 180 ICIFFATCGY LTFTGFTQGD LFENYCRNDD LVTFGRFCYG VTVILTYPME CFVTREVIAN 240 VFFGGNLSSV FHIWTVMVI TVATLVSLLI DCLGIVLELN GVLCATPLIF IIPSACYLKL 300 SEEPRTHSDK IMSCVMLPIG AWMVFGFVM AITNTQDCTH GQEMFYCFPD NFSLTNTSES 360 HVQQTTQLST LNISIFQLE SEQ ID NO:215 PAV4 VARIANT 4 DNA SEQUENCE: Nucleic Acid Accession * N62096 Coding sequence: 1-1389 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I ATGGGCTACC AGAGGCAGGA GCCTGTCATC CCGCCGCAGA GAGATTTAGA TGACAGAGAA 60 ACCCTTGTTT CTGAACATCA GTATAAAGAG AAAACCTGTC AGTCTCCTGC TCTTTTTAAT 120 GTTGTCAACT CGATTATAGG ATCTGGTATA ATAGGATTGC CTTATTCAAT GAAGCAAGCT 180 GGGTTTCCTT TGGGAATATT GCTTTTATTC TGGGTTTCAT ATGTTACAGA CTTTTCCCTT 240 GTTTTATTGA TAAAAGGAGG GGCCCTCTCT GGAACAGATA CCTACCAGTC TTTGGTCAAT 300 AAAACTTTCG GCTTTCCAGG GTATCTGCTC CTCTCTCTTC TTCAGTTTTT GTATCCTTTT 36C ATAGCAATGA TAAGTTACAA TATAATAGCT GGAGATACTT TGAGCAAAGT TTTTCAAAGA 420 ATCCCAGGAG TTGATCCTGA AAACGTGTTT ATTGGTCGCC ACTTCATTAT TGGACTTTCC 480 ACAGTTACCT TTACTCTGCC TTTATCCTTG TACCGAAATA TAGCAAAGCT TCGAAAGGTC 540 TCCCTCATCT CTACAGGTTT AACAACTCTG ATTCTTGGAA TTGTAATGGC AAGGGCAATT 600 TCACTGGGTC CACACATACC AAAAACAGAA GACGCTTGGG TATTTGCAAA GCCCAATGCC 660 ATTCAAGCGG TCGGGGTTAT GTCTTTTCCA TTTATTTGCC ACCATAACTC CTTCTTAGTT 720 TACAGTTCTC TAGAAGAACC CACAGTAGCT AAGTGGTCCC GCCTTATCCA TATCTCCATC 780 GTCATTTCTG TATTTATCTG TATATTCTTT GCTACATGTG GATACTTGAC ATTTACTGGC 840 TTCACCCAAG GGGACTTATT TGAAAATTAC TGCAGAAATC ATGACCTGGT AACATTTGGA 900 AGATTTTGTT ATGGTGTCAC TGTCATTTTG ACATACCCTA TGGAATGCTT TGTGACAAGA 960 GAGGTAATTG CCAATGTCTT TTTTGGTGGG AATCTTTCAT CGGTTTTCCA CATTGTTGTA 1020 ACAGTCATGG TCATCACTGT AGCCACGCTT GTCTCATTGC TGATTCATTG CCTCGGGATA 1080 GTTCTAGAAC TCAATGGTGT GCTCTGTGCA ACTCCCCTCA TTTTTATCAT TCCATCAGCC 1140 TGTTATCTGA AACTGTCTGA AGAACCAAGG ACACACTCCG ATAAGATTAT GTCTTGTCTC 1200 ATGCTTCCCA TTGGTGCTGT GGTGATGGTT TTTGGATTCG TCATGGCTAT TACAAATACT 1260 CAAGACTGCA CCCATGGGCA GGAAATGTTC TACTCCTTTC CTGACAATTT CTCTCTCACA 1320 AATACCTCAG AGTCTCATGT TCAGCAGACA ACACAACTTT CTACTTTAAA TATTAGTATC 1380 TTTCAATGA SEQ ID NO:216 PAV4 Variant 4 Protein sequence: Protein Accession* none found 11 21 31 41 51 I I I I I I MGYQRQEPVI PPQRDLDDRE TLVSEHEYKE KTCQSAALFN WNSIIGSGI IGLPYSMKQA 60 GFPLGILLLF WVSYVTDFSL VLLIKGGALS GTDTYQSLVN KTFGFPGYLL LSVLQFLYPF 120 IAMISYNIIA GDTLSKVFQR IPGVDPENVF IGRHFIIGLS TVTFTLPLSL YRNIAKLGKV 180 SLISTGLΪTL ILGIVMARAI SLGPHIPKTE DAWVFAKPNA IQAVGVMSFA FICHHNSFLV 240 YSSLEEPTVA KWSRLIHMSI VISVFICIFF ATCGYLTFTC FTQGDLFENY CRNDDLVTFG 300 RFCYGVTVIL TYPMECFVTR EVIANVFFGG NLSSVFHIW TVMVITVATL VSLLIDCLGI 360 VLELNGVLCA TPLIFIIPSA CYLKLSEEPR THSDKIMSCV MLPIGAWMV FGFVMAITNT 420 QDCTHGQEMF YCFPDNFSLT NTSESHVQQT TQLSTLNISI FQ SEQ ID NO:217 PAV9 DNA SEQUENCE Nucleic Acid Accession *: N _017636 Coding sequence: 1-3501 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I ATGGAGGATG CCTTCGGGGC AGCCGTGGTG ACCGTGTGGG ACAGCGATGC ACACACCACG 60 GAGAAGCCCA CCGATGCCTA CGGAGAGCTC GACTTCACGG GGGCCGGCCG CAAGCACAGC 120 AATTTCCTCC GGCTCTCTGA CCGAACGGAT CCAGCTCCAG TTTATAGTCT GGTCACACGC 180 ACATGGGGCT TCCGTGCCCC GAACCTCGTG GTGTCAGTGC TGGGGGGATC GGGGGGCCCC 240 GTCCTCCAGA CCTCGCTGCA GGACCTGCTG CGTCGTCGGC TGGTGCGGGC TCCCCAGAGC 300 ACAGGAGCCT GGATTGTCAC TGGGGGTCTG CACACGGGCA TCGGCCGGCA TGTTCGTCTG 360 GCTGTACGGG ACCATCAGAT GGCCAGCACT GGGGGCACCA AGGTGGTGGC CATGGGTGTG 420 GCCCCCTGGG GTGTGGTCCG GAATAGAGAC ACCCTCATCA ACCCCAAGGG CTCGTTCCCT 480 GCGAGGTACC GGTGGCGCGG TCACCCGGAG GACGGGGTCC AGTTTCCCCT GGACTACAAC 540 TACTCGGCCT TCTTCCTGGT GGACGACGGC ACACACGGCT GCCTGGGGGG CGAGAACCGC 600 TTCCGCTTGC GCCTGGAGTC CTACATCTCA CAGCAGAAGA CGGGCGTGGG AGGGACTGGA 660 ATTGACATCC CTGTCCTGCT CCTCCTGATT GATGGTGATG AGAAGATGTT GACGCGAATA 720 GAGAACGCCA CCCAGGCTCA GCTCCCATGT CTCCTCGTGG CTGGCTCAGG GGGAGCTGCG 780 GACTGCCTGG CGGAGACCCT GGAAGACACT CTGGCCCCAG GGAGTGGGGG AGCCAGGCAA 840 GGCGAAGCCC GAGATCGAAT CAGGCGTTTC TTTCCCAAAG GGGACCTTGA GGTCCTGCAG 900 GCCCAGGTGG AGAGGATTAT GACCCGGAAG GAGCTCCTGA CAGTCTATTC TTCTGAGGAT 960 GGGTCTCAGG AATTCGAGAC CATAGTTTTG AAGGCCCTTG TGAAGGCCTG TGGGAGCTCG 1020 GAGGCCTCAG CCTACCTGGA TGAGCTGCGT TTGGCTGTGG CTTCGAACCG CGTGGACATT 1080 GCCCAGAGTG AACTCTTTCG GGGGGACATC CAATGGCGGT CCTTCCATCT CGAAGCTTCC 1140 CTCATGGACG CCCTGCTCAA TGACCGGCCT GAGTTCGTCC GCTTGCTCAT TTCCCACGGC 1200 CTCAGCCTCG GCCACTTCCT GACCCCGATC CGCCTGGCCC AACTCTACAG CGCGGCGCCC 1260 TCCAACTCGC TCATCCGCAA CCTTTTGGAC CAGGCGTCCC ACAGCGCAGG CACCAAAGCC 1320 CCAGCCCTAA AAGGGGGAGC TGCGGAGCTC CGGCCCCCTC ACGTGGGGCA TGTGCTGAGG 1380 ATGCTCCTGG GGAAGATGTG CGCGCCGAGG TACCCCTCCG GGGGCGCCTG GGACCCTCAC 1440 CCAGGCCAGG GCTTCGGGGA GAGCATGTAT CTGCTCTCGG ACAAGGCCAC CTCGCCGCTC 1500 TCGCTCGATC CTGGCCTCGG GCAGGCCCCC TGGAGCGACC TGCTTCTTTG GGCACTGTTC 1560 CTGAACAGGG CACAGATGGC CATGTACTTC TGGGAGATGG GTTCCAATGC AGTTTCCTCA 1620 GCTCTTCGGG CCTCTTTGCT GCTCCGGGTG ATGGCACGCC TGGAGCCTGA CGCTGAGGAG 1680 GCAGCACGGA GGAAAGACCT GGCGTTCAAG TTTGAGGGGA TGGGCGTTGA CCTCTTTGGC 1740 GAGTGCTATC GCAGCAGTGA GGTGAGGGCT GCCCGCCTCC TCCTCCGTCG CTGCCCGCTC 1800 TGGGGGGATG CCACTTGCCT CCAGCTGGCC ATGCAAGCTG ACGCCCGTGC CTTCTTTCCC 1860 CAGGATGGGG TACAGTCTCT GCTGACACAG AAGTGGTGGG GAGATATGGC CAGCACTACA 1920 CCCATCTGGG CCCTGGTTCT CGCCTTCTTT TGCCCTCCAC TCATCTACAC CCGCCTCATC 1980 ACCTTCAGGA AATCAGAAGA GGAGCCCACA CGGGAGGAGC TAGAGTTTGA CATGGATAGT 2040 GTCATTAATG GGGAAGGGCC TCTCGGGACG GCGGACCCAG CCGAGAAGAC GCCGCTGGGG 2100 GTCCCGCGCC AGTCGGGCCG TCCGGGTTGC TGCGGGGGCC GCTGCGGGGG GCGCCGGTGC 2160 CTACGCCGCT GGTTCCACTT CTGGGGCGCG CCGGTGACCA TCTTCATCGG CAACGTGGTC 2220 AGCTACCTGC TCTTCCTGCT GCTTTTCTCG CGGGTGCTGC TCGTCGATTT CCAGCCGGCG 2280 CCGCCCGGCT CCCTGGAGCT GCTGCTCTAT TTCTCGGCTT TCACGCTGCT GTGCGAGGAA 2340 CTGCGCCAGG GCCTGAGCGG AGGCGGGGGC AGCCTCGCCA GCGGGGGCCC CGGGCCTCGC 2400 CATCCCTCAC TCAGCCAGCG CCTGCGCCTC TACCTCGCCG ACAGCTCGAA CCAGTGCGAC 2460 CTAGTCGCTC TCACCTGCTT CCTCCTCGGC GTGGGCTCCC GGCTGACCCC GGGTTTCTAC 2520 CACCTCGGCC GCACTGTCCT CTGCATCGAC TTCATGGTTT TCACGGTGCG GCTGCTTCAC 2580 ATCTTCACGG TCAACAAACA GCTGGGGCCC AAGATCGTCA TCGTCAGCAA GATGATGAAG 2640 GACGTCTTCT TCTTCCTCTT CTTCCTCGGC GTGTGGCTCG TAGCCTATCG CGTGGCCACG 2700 GAGGGGCTCC TGAGGCCACG GGACAGTGAC TTCCCAAGTA TCCTGCGCCG CGTCTTCTAC 2760 CGTCCCTACC TGCAGATCTT CGGGCAGATT CCCCAGGAGG ACATGGACGT GGCCCTCATG 2820 GAGCACAGCA ACTGCTCGTC GGAGCCCGGC TTCTGGGCAC ACCCTCCTGG GGCCCAGGCG 2880 GGCACCTCCG TCTCCCAGTA TGCCAACTCG CTGGTGGTGC TGCTCCTCGT CATCTTCCTG 2940 CTCGTGGCCA ACATCCTGCT GGTCAACTTC CTCATTCCCA TCTTCAGTTA CACATTCGGC 3000 AAAGTACAGG GCAACAGCGA TCTCTACTGG AAGGCGCAGC GTTACCGCCT CATCCGGGAA 3060 TTCCACTCTC GGCCCGCGCT GGCCCCGCCC TTTATCGTCA TCTCCCACTT GCGCCTCCTG 3120 CTCAGGCAAT TGTCCAGGCG ACCCCGGAGC CCCCAGCCGT CCTCCCCGGC CCTCGAGCAT 3180 TTCCGGGTTT ACCTTTCTAA GGAAGCCGAG CGGAAGCTCC TAACGTGGGA ATCGGTGCAT 3 240 AAGGAGAACT TTCTGCTGGC ACGCGCTAGG GACAAGCGGG AGAGCGACTC CGAGCGTCTG 3300 AAGCGCACGT CCCAGAAGGT GGACTTGGCA CTCAAACAGC TGGGACACAT CCGCGAGTAC 3360 GAACAGCGCC TGAAAGTGCT GGAGCGGGAG GTCCAGCAGT GTAGCCGCGT CCTGGGGTCG 3420 GTGGCCGAGG CCCTCAGCCG CTCTGCCTTG CTGCCCCCAG GTGGGCCGCC ACCCCCTCAC 3480 CTCCCTGGGT CCAAAGACTG A SEQ ID NO:218 PAV9 Protein sequence: Protein Accession* none found 11 21 31 41 51 I I I I I MEDAFGAAW TVWDSDAHTT EKPTDAYGEL DFTGAGRKHS NFLRLSDRTD PAAVYSLVTR 60 TWGFRAPNLV VSVLGGSGGP VLQTWLQDLL RRGLVRAAQS TCAWIVTCGL HTGIGRHVGV 120 AVRDHQMAST GGTKWAMGV APWGWRNRD TLINPKGSFP ARYRWRGDPE DGVQFPLDYN 180 YSAFFLVDDG THGCLGGENR FRLRLESYIS QQKTGVGGTG IDIFVLLLLI DGDEKMLTRI 240 ENATQAQLPC LLVAGSGGAA DCLAETLEDT LAPGSGGARQ GEARDRIRRF FPKGDLEVLQ 300 AQVERIMTRK ELLTVYSSED GSEEFETΓVL KALVKACGSS EASAYLDELR LAVAWNRVDI 360 AQSELFRGDI QWRSFHLEAS LMDALLNDRP EFVRLLISHG LSLGHFLTPM RLAQLYSAAP 420 SNSLIRNLLD QASHSAGTKA PALKGGAAEL RPPDVGHVLR MLLGKMCAPR YPSGGAWDPH 480 PGQGFGESMY LLSDKATSPL SLDAGLGQAP WSDLLLWALL LNRAQMAMYF WEMGSNAVSS 540 ALGACLLLRV MARLEPDAEE AARRKDLAFK FEGMGVDLFG ECYRSSEVRA ARLLLRRCPL 600 WGDATCLQLA MQADARAFFA QDGVQSLLTQ KWWGDMASTT PIWALVLAFF CPPLIYTRLI 660 TFRKSEEEPT REELEFDMDS VINGEGFVGT ADPAEKTPLG VPRQSGRPGC CGGRCGGRRC 720 LRRWFHFWGA PVTIFMGNW SYLLFLLLFS RVLLVDFQPA PPGSLELLLY FWAFTLLCEE 780 LRQGLSGGGG SLASGGPGPG HASLSQRLRL YLADSWNQCD LVALTCFLLG VGCRLTPGLY 840 HLGRTVLCID FMVFTVRLLH IFTVNKQLGP KIVIVSKMMK DVFFFLFFLG VWLVAYGVAT 900 EGLLRPRDSD FPSILRRVFY RPYLQIFGQI PQEDMDVALM EHSNCSSEPG FWAHPPGAQA 960 GTCVSQYANW LWLLLVIFL LVANILLVNL LIAMFSYTFG KVQGNSDLYW KAQRYRLIRE 1020 FHSRPALAPP FΓVISHLRLL LRQLCRRPRS PQPSSPALEH FRVYLSKEAE RKLLTWESVH 1080 KENFLLARAR DKRESDSERL KRTSQKVDLA LKQLGHIREY EQRLKVLERE VQQCSRVLGW 1140 VAEALSRSAL LPPGGPPPPD LPGSKD SEQ ID NO:219 PBF1 DNA SEQUENCE Nucleic Acid Accession * AA054237 Coding sequence: 1-894 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51 ATGGAGCCGC GGGCGCTCGT CACGGCGCTC AGCCTCGGCC TCAGCCTGTG CTCCCTGGGG 60 CTGCTCGTCA CGGCCATCTT CACCGACCAC TGGTACGAGA CCGACCCCCG GCGCCACAAG 120 GAGAGCTGCG AGCGCAGCCG CGCGGGCGCC GACCCCCCGG ACCAGAAGAA CCGCCTCATC 180 CCGCTCTCGC ACCTCCCGCT GCGGGACTCG CCCCCGCTGG GGCGCCGGCT GCTCCCGGGC 240 GGCCCGGGGC GCGCCGACCC CGAGTCCTGG CGCTCGCTCC TGGGGCTCGG CGGGCTCGAC 300 GCCGAGTGCG GCCGGCCCCT CTTCGCCACC TACTCGGGCC TCTGGAGGAA GTCCTACTTC 360 CTCGGCATCG ACCGGGACAT CGACACCCTC ATCCTGAAAG GTATTCCGCA GCGATCCACG 420 GCCATCAAGT ACCACTTTTC TCAGCCCATC CGCTTGCGAA ACATTCCTTT TAATTTAACC 480 AAGACCATAC AGCAAGATGA GTCGCACCTC CTTCATTTAA GAAGAATCAC TGCTGGCTTC 540 CTCGGCATCG CCGTAGCCGT CCTTCTCTGC GGCTGCATTG TGGCCACAGT CAGTTTCTTC 600 TGGGAGGAGA GCTTGACCCA GCACGTGGCT GGACTCCTGT TCCTCATGAC AGGGATATTT 660 TCCACCATTT CCCTCTGTAC TTATGCCGCC AGTATCTCGT ATGATTTGAA CCGGCTCCCA 720 AAGCTAATTT ATAGCCTGCC TGCTCATCTG GAACATGGTT ACAGCTCGTC CATCTTTTGC 780 GCCTGGTGCA GTTTAGGCTT TATTGTGGCA GCTCGAGGTC TCTGCATCGC TTATCCGTTT 840 ATTAGCCGGA CCAAGATTGC ACAGCTAAAG TCTCGCAGAG ACTCCACGGT ATGA SEQ ID NO:22Q PBF1 Protein sequence: Protein Accession *: none found 11 21 31 41 51 I MEPRALVTAL SLGLSLCSLG LLVTAIFTDH WYETDPRRHK ESCERSRAGA DPPDQKNRLM 60 PLSHLPLRDS PPLGRRLLPG GPGRADPESW RSLLGLGGLD AECGRPLFAT YSGLWRKCYF 120 LGIDRDIDTL ILKGIAQRCT AIKYHFSQPI RLRNIPFNLT KTIQQDEWHL LHLRRITAGF 180 LGMAVAVLLC GCIVATVSFF WEESLTQHVA GLLFLMTGIF CTISLCTYAA SISYDLNRLP 240 KLIYSLPADV EHGYSWSIFC AWCSLGFIVA AGGLCIAYPF ISRTKIAQLK SGRDSTV SEQ ID NO:221 PCI4 DNA SEQUENCE Nucleic Acid Accession * NM_016570 Coding sequence: 1- 1134 (undedined sequences correspond to start and stop codons) 11 21 31 41 51 ATCAGGCGAC TGAATCGGAA AAAAACTTTA AGTTTCGTAA AAGAGTTGGA TCCCTTTCCG 60 AAGGTTCCTC AGAGCTATGT AGAGACTTCA GCCAGTGGAG GTACAGTTTC TCTAATAGCA 120 TTTACAACTA TGGCTTTATT AACCATAATC GAATTCTCAG TATATCAAGA TACATCGATG 180 AAGTATGAAT ACGAAGTAGA CAAGGATTTT TCTAGCAAAT TAAGAATTAA TATAGATATT 240 ACTGTTGCCA TGAAGTGTCA ATATGTTCGA GCGGATGTAT TGGATTTAGC AGAAACAATG 300 GTTGCATCTG CAGATGGTTT AGTTTATGAA CCAACAGTAT TTGATCTTTC ACCACAGCAG 360 AAAGAGTGGC AGAGGATGCT GCAGCTGATT CAGAGTAGGC TACAAGAAGA GCATTCACTT 420 CAAGATGTGA TATTTAAAAG TGCTTTTAAA AGTACATCAA CAGCTCTTCC ACCAAGAGAA 480 GATGATTCAT CACAGTCTCC AAATGCATGC AGAATTCATC GCCATCTATA TCTCAATAAA 540 GTAGCAGGGA ATTTTCACAT AACAGTGGGC AAGGCAATTC CACATCCTCG TGGTCATGCA 600 CATTTGGCAG CACTTGTCAA CCATGAATCT TACAATTTTT CTCATAGAAT AGATCATTTG 660 TCTTTTGGAG AGCTTGTTCC AGCAATTATT AATCCTTTAG ATGGAACTCA AAAAATTGCT 720 ATAGATCACA ACCAGATCTT CCAATATTTT ATTACAGTTG TGCCAACAAA ACTACATACA 780 TATAAAATAT CAGCAGACAC CCATCAGTTT TCTGTCACAG AAAGGGAACG TATCATTAAC 840 CATGCTCCAG GCAGCCATGG AGTCTCTCGG ATATTTATCA AATATCATCT CAGTTCTCTT 900 ATGGTGACAG TTACTGAGGA GCACATGCCA TTCTGGCAGT TTTTTCTAAG ACTCTGTGGT 960 ATTGTTGGAG GAATCTTTTC AACAACAGGC ATGTTACATG GAATTGGAAA ATTTATAGTT 1020 GAAATAATTT GCTGTCGTTT CAGACTTGGA TCCTATAAAC CTGTCAATTC TCTTCCTTTT 1080 GAGGATGGCC ACACAGACAA CCACTTACCT CTTTTAGAAA ATAATACACA TTGA SEQ ID NO:222 PCI4 Protein sequence: Protein Accessien* NP.057654 1 11 21 31 41 51 I I I I I I MRRLNRKKTL SLVKELDAFP KVPESYVETS ASGGTVSLIA FTTMALLTIM EFSVYQDTWM 60 KYEYEVDKDF SSKLRINIDI TVAMKCQYVG ADVLDLAETM VASADGLVYE PTVFDLSPQQ 120 KEWQRMLQLI QSRLQEEHSL QDVIFKSAFK ΞTSTALPPRE DDSSQSPNAC RIHGHLYVNK 180 VAGNFHITVG KAIPHPRGHA HLAALVNHES YNFSHRIDHL SFGELVPAII NPLDGTEKIA 240 IDHNQMFQYF ITWPTKLHT YKISADTHQF SVTERERIIN HAAGSHGVSG IFMKYDLSSL 300 MVTVTEEHMP FWQFFVRLCG IVGGIFSTTG MLHGIGKFIV EIICCRFRLG SYKPVNSVPF 360 EDGHTDNHLP LLENNTH SEQ ID N0.223 PEZ3 DNA SEQUENCE Nucleic Acid Accession *: NM_001935.1 Coding sequence: 76-2301 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I CGCGCGTCTC CGCCGCCCGG GTCACTTCTG CCTGCGCTCC TTCTCTGAAC GCTCACTTCC 60 GAGGAGACGC CGACGATCAA GACACCGTGG AAGATTCTTC TGGGACTGCT GGGTGCTGCT 120 GCGCTTGTCA CCATCATCAC CGTGCCCGTG GTTCTGCTGA ACAAAGGCAC AGATGATGCT 180 ACAGCTGACA GTCGCAAAAC TTACACTCTA ACTGATTACT TAAAAAATAC TTATAGACTG 240 AAGTTATACT CCTTAAGATC GATTTCAGAT CATGAATATC TCTACAAACA AGAAAATAAT 300 ATCTTGGTAT TCAATGCTGA ATATGGAAAC AGCTCAGTTT TCTTCGAGAA CAGTACATTT 360 GATGAGTTTC GACATTCTAT CAATGATTAT TCAATATCTC CTGATGGGCA GTTTATTCTC 420 TTAGAATACA ACTACGTGAA GCAATGGAGG CATTCCTACA CAGCTTCATA TGACATTTAT 480 GATTTAAATA AAAGGCAGCT GATTACAGAA GAGAGGATTC CAAACAACAC ACAGTGGGTC 540 ACATGGTCAC CAGTGGGTCA TAAATTCGCA TATGTTTGGA ACAATGACAT TTATGTTAAA 600 ATTGAACCAA ATTTACCAAG TTACAGAATC ACATCGACGG GGAAAGAAGA TATAATATAT 660 AATGGAATAA CTGACTGGGT TTATGAAGAG GAAGTCTTCA GTGCCTACTC TGCTCTGTGG 720 TGGTCTCCAA ACGGCACTTT TTTAGCATAT GCCCAATTTA ACGACACAGA AGTCCCACTT 780 ATTGAATACT CCTTCTACTC TCATCAGTCA CTCCAGTACC CAAAGACTGT ACGGGTTCCA 840 TATCCAAAGG CAGGAGCTGT GAATCCAACT GTAAAGTTCT TTGTTGTAAA TACAGACTCT 900 CTCAGCTCAG TCACCAATGC AACTTCCATA CAAATCACTC CTCCTCCTTC TATGTTGATA 960 GGGGATCACT ACTTGTGTGA TGTCACATGG GCAACACAAG AAAGAATTTC TTTGCAGTGG 1020 CTCAGGAGGA TTCAGAACTA TTCGGTCATG GATATTTGTG ACTATGATGA ATCCAGTGGA 1080 AGATCGAACT GCTTAGTGGC ACGGCAACAC ATTGAAATCA GTACTACTGG CTGGGTTGGA 1140 AGATTTAGGC CTTCAGAACC TCATTTTACC CTTGATGGTA ATAGCTTCTA CAAGATCATC 1200 AGCAATGAAG AAGGTTACAG ACACATTTGC TATTTCCAAA TAGATAAAAA AGACTGCACA 1260 TTTATTACAA AAGGCACCTG GGAAGTCATC GGGATAGAAG CTCTAACCAG TGATTATCTA 1320 TACTACATTA GTAATGAATA TAAAGGAATG CCAGGAGGAA GGAATCTTTA TAAAATCCAA 1380 CTTATTGACT ATACAAAAGT GACATGCCTC AGTTGTGAGC TGAATCCGGA AAGGTGTCAG 1440 TACTATTCTC TGTCATTCAG TAAAGAGGCG AAGTATTATC AGCTGAGATG TTCCGGTCCT 1500 GGTCTGCCCC TCTATACTCT ACACAGCAGC GTGAATGATA AAGGGCTGAG AGTCCTGGAA 1560 GACAATTCAG CTTTGGATAA AATGCTGCAG AATGTCCAGA TGCCCTCCAA AAAACTGGAC 1620 TTCATTATTT TGAATGAAAC AAAATTTTGG TATCAGATCA TCTTCCCTCC TCATTTTGAT 1680 AAATCCAAGA AATATCCTCT ACTATTAGAT GTGTATGCAG GCCCATGTAG TCAAAAAGCA 1740 GACACTGTCT TCAGACTGAA CTGGGCCACT TACCTTGCAA GCACAGAAAA CATTATAGTA 1800 GCTAGCTTTC ATGGCAGAGβ AAGTGGTTAC CAAGGAGATA AGATCATGCA TGCAATCAAC 1860 AGAAGACTGG GAACATTTGA AGTTCAAGAT CAAATTGAAG CAGCCAGACA ATTTTCAAAA 1920 ATCGGATTTG TGGACAACAA ACGAATTGCA ATTTCGGGCT GGTCATATGG AGGGTACGTA 1980 ACCTCAATGG TCCTCGGATC GGGAAGTGGC GTGTTCAAGT GTGGAATAGC CGTGGCGCCT 2040 GTATCCCGGT GGGAGTACTA TGACTCAGTG TACACAGAAG GTTACATGGG TCTCCCAACT 2100 CCAGAAGACA ACCTTGACCA TTACAGAAAT TCAACAGTCA TGAGCAGAGC TGAAAATTTT 2160 AAACAAGTTG AGTACCTCCT TATTCATGGA ACAGCAGATG ATAACGTTCA CTTTCAGCAG 2220 TCAGCTCAGA TCTCCAAAGC CCTGGTCGAT GTTGGAGTGG ATTTCCAGGC AATGTGGTAT 2280 ACTCATCAAG ACCATGGAAT_AGCTAGCAGC ACAGCACACC AACATATATA TACCCACATG 2340 AGCCACTTCA TAAAACAATG TTTCTCTTTA CCTTAGCACC TCAAAATACC ATGCCATTTA 2400 AAGCTTATTA AAACTCATTT TTGTTTTCAT TATCTCAAAA CTGCACTGTC AAGATGATGA 2460 TGATCTTTAA AATACACACT CAAATCAAGA AACTTAAGGT TACCTTTGTT CCCAAATTTC 2520 ATACCTATCA TCTTAAGTAG GGACTTCTGT CTTCACAACA GATTATTACC TTACAGAAGT 2580 TTGAATTATC CGGTCGGGTT TTATTGTTTA AAATCATTTC TGCATCAGCT GCTGAAACAA 2640 CAAATAGGAA TTCTTTTTAT GGAGGCTTTG CATAGATTCC CTGAGCAGGA TTTTAATCTT 2700 TTTCTAACTC GACTGGTTCA AATCTTGTTC TCTTCTTTAA AGGGATGGCA AGATGTGGGC 2760 AGTCATGTCA CTAGGGCAGG GACAGGATAA GAGGGATTAG GGAGAGAAGA TAGCAGGGCA 2820 TGGCTGGGAA CCCAAGTCCA AGCATACCAA CACGAGCAGG CTACTGTCAG CTCCCCTCGG 2880 AGAAGAGCTC TTCACCACGA GACTGGCACA GTTTTCTCAG AAAGACTATT CAAACAGTCT 2940 CAGGAAATCA AATATCGAAA GCACTGACTT CTAAGTAAAC CACAGCAGTT GAAAGACTCC 3000 AAAGAAATGT AAGGGAAACT GCCAGCAACG CAGCCCCCAG GTGCCAGTTA TGGCTATAGG 3060 TGCTACAAAA ACACAGCAAG GGTGATGGGA AAGCATTGTA AATGTGCTTT TAAAAAAAAA 3120 TACTCATGTT CCTAGTGAAA GAGGCAGCTT GAAACTGAGA TCTCAACACA TCAGCTTGCC 3180 CTGTTAAAAG ATGAAAATAT TTCTATCACA AATCTTAACT TGAAGGAGTC CTTGCATCAA 3240 TTTTTCTTAT TTCATTTCTT TGAGTGTCTT AATTAAAAGA ATATTTTAAC TTCCTTGGAC 3300 TCATTTTAAA AAATGGAACA TAAAATACAA TGTTATGTAT TATTATTCCC ATTCTACATA 3360 CTATGGAATT TCTCCCAGTC ATTTAATAAA TGTGCCTTCA TTTTTTC SEQ ID NO:224 PEZ3 Protein sequence: Protein Accession* NPJM1926.1 1 11 21 31 41 51 1 I 1I 1 l 1l 1l 1l MKTPWKILLG LLGAAALVTI ITVPWLLNK GTDDATADSR KTYTLTDYLK NTYRLKLYSL 60 RWISDHEYLY KQENNILVFN AEYGNSSVFL ENSTFDEFGH SINDYSISPD GQFILLEYNY 120 VKQWRHSYTA SYDIYDLNKR QLITEERIPN NTQWVTWSPV GHKLAYVWNN DIYVKIEPNL 180 PSYRITWTGK EDIIYNGITD WVYEEEVFSA YSALWWSPNG TFLAYAQFND TEVPLIEYSF 240 YSDESLQYPK TVRVPYPKAG AVNPTVKFFV VNTDSLSSVT NATSIQITAP ASMLIGDHYL 300 CDVTWATQER ISLQWLRRIQ NYSVMDICDY DESSGRWNCL VARQHIEMST TGWVGRFRPS 360 EPHFTLDGNS FYKIISNEEG YRHICYFQID KKDCTFITKG TWEVIGIEAL TSDYLYYISN 420 EYKGMPGGRN LYKIQLIDYT KVTCLSCELN PERCQYYSVS FSKEAKYYQL RCΞGPGLPLY 480 TLHSSVNDKG LRVLEDNSAL DKMLQNVQMP SKKLDFIILN ETKFWYQMIL PPHFDKSKKY 540 PLLLDVYAGP CSQKADTVFR LNWATYLAST ENIIVASFDG RGSGYQGDKI MHAINRRLGT 600 FEVEDQIEAA RQFSKMGFVD NKRIAIWGWS YGGYVTSMVL GSGSGVFKCG IAVAPVSRWE 660 YYDSVYTERY MGLPTPEDNL DHYRNSTVMS RAENFKQVEY LLIHGTADDN VHFQQSAQIS 720 KALVDVGVDF QAMWYTDEDH GIASSTAHQH IYTHMSHFIK QCFSLP SEQ ID N0.225 PBJ2 DNA SEQUENCE Nucleic Acid Accession*: none found Coding sequence: 1-261 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 ATGGCTCTGG CGAAGGTGAG GGAGCCAAAC GCAAATCACA ATGCCATCAG AGTTGACAAC 60 AGAAGTGTGA TTAAAGTGCG TGCTAACCAG TGTTCCCTCC ATGAGGCAGA AAGTGAATCC 120 AGAAACCCTC AGGAGCTCTG GATGGGCCTG CTCCTCTTGA TGGGGGTCCT AGAAGCATCT 180 GTGGAAATGA GGCCTCTGTC AGTCTGGTCC CTGAGAGATG ACAAGGAGCA GAGCCCCCAC 240 CAGCCCACAC TGGATCTCTA A SEQ ID NO'226 PBJ2 Protein sequence. Protein Accession * none found 1 11 21 3311 41 51 I I I I I I MALAKVREPN ANDNAIRVDN RSVIKVRANQ CSLHEAESES RNPQELWMGL LLLMGVLEAC 60 VEMRPLSVWS LRDDKEQSPH QPTLDV SEQ ID NO:227 PB 2 DNA SEQUENCE Nucleic Acid Accession* none found Coding sequence 1-462 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 ATGCCAAATG CTGAGTTAGA AGCAAAGAGC CTTGGAAGCA GTAAATGTTT AAAAACTGCT 60 CTCATACTTG CTCTATGTTG TGGATCAGCA AATATAGTCA GCCCTCTACT TGAGCAAAAT 120 ATTCATGTAT CTTCTCAAGA TCTCGACAGA CGGCCAGAGA GTATGCTGTT TCTAGTCATC 180 ATCATCTGGA CCAGTTTTGT GGAAGACAAT CTTTCCATGG GCTGGGGGAA GCTAGAAGAT 240 TTTATGGCTA TTGAAGAAGA AATGAAGAAG CACGGAAGTA CTCATGTGGG ATTCCCAGAA 300 AACCTGACTA ATGGTGCCGC TGCTGGCAAT GGTGATGATG GATTAATTCC TCCAAGGAAG 360 AGCAGAACAC CTCAAAGCCA GCAATTTCCT GACACTGAGA ATCAAGAGTA TCACAGGTTT 420 GTCAAAGATC AGATAGTTCT AGATATGCGG CGTTATTTCT GA SEQ ID NO-228 PBM2 Protein sequence Protein Accession* none found 1 11 21 31 41 51 I I I I I I MPNAELEAKS LGSSKCLKTA LILAVCCGSA NIVSPLLEQN IDVSSQDLDR RPESMLFLVI 60 IMWTSFVEDN LSMGWGKLED FMAIEEEMKK HGSTHVGFPE NLTNGAAAGN GDDGLIPPRK 120 SRTPESQQEP DTENEEYHRF VKDQIVVDMR RYF SEQ ID N0.229 PEZ2 DNA SEQUENCE Nucleic Acid Accession* NM.014253 Coding sequence 65-8242 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I GACTGCTTGC ATTAAAGGAC TTCCTCATCC TTTTTTTCAT GAAACTGAGC TTGCTTAATC 60 AGAGATCGAG CAAACTGACT GCAAACCCTA CCAGCCTCTA CCAAAAGTCA AGCATGAAAT 120 GGATCTAGCT TACACCAGTT CTTCTCATCA GAGTCAAGAT GGAAGAAAAC CAAGACAGTC 180 ATACAACTCC AGGGAGACCC TGCACGAGTA TAACCAGGAG CTCAGGATCA ATTACAATAG 240 CCAGAGTAGA AAGAGGAAAG AAGTAGAAAA ATCTACTCAA GAGATCGAAT TCTGTGAAAC 300 CTCTCACACT CTGTGCTCTG GCTACCAAAC AGACATGCAC AGCGTTTCTC GGCATGGCTA 360 CCAGCTAGAG ATGGGATCTC ATGTGGACAC AGAGACAGAA GGTCCTGCCT CACCTGACCA 420 TGCACTAAGA ATGTGGATAA GGGGAATGAA ATCAGAGCAT AGTTCCTGTT TGTCCAGCCG 480 GGCCAACTCT GCATTATCCT TGACTCACAC TGACCATCAA AGGAAGTCTC ATGGGGAAAA 540 TGGTTTCAAA TTCTCTCCTG TTTGTTGTGA CATGGAGGCT CAAGCTGGGT CTACTCAAGA 600 TGTGCAGAGC AGCCCACACA ACCAGTTCAC CTTCAGACCC CTCCCACCGC CACCTCCGCC 660 TCCTCATGCC TCCACCTCTG CCAGGAAGCC ACCCCCTGCA GCGGACTCTC TTCAGAGGAG 720 ATCAATGACT ACCCGCAGCC AGCCCAGCCC AGCTGCTCCA GCTCCCCCAA CCAGCACGCft 780 GGATTCAGTC CATCTGCATA ACAGCTCGGT CCTGAACAGC AACATACCAT TGGAGACCAG 840 GCATTCCCTG TTCAAACATG GATCTGGTTC CTCTGCGATC TTCAGTGCAG CCAGTCAGAA 900 CTACCCTCTG ACATCCAATA CCGTGTACTC GCCCCCTCCC AGGCCTCTTC CTCGAAGCAC 960 CTTTTCCCGA CCTGCCTTTA CCTTTAACAA ACCTTACAGG TGCTCCAACT GGAAGTGCAC 1020 AGCATTGAGC GCCACTCCAA TCACAGTGAC TTTGGCCTTG TTACTAGCCT ATGTGATTGC 1080 AGTGCATTTG TTCGGCCTGA CTTGGCAGTT GCAACCAGTT GAAGGAGAGC TGTATCCAAA 1140 TGGAGTTAGC AAAGGGAACA GGGGGACCGA GTCCATGGAC ACTACTTACT CTCCAATTGG 1200 AGGAAAAGTT TCTGATAAAT CAGAGAAAAA AGTGTTTCAG AAGGGACGGG CGATAGACAC 1260 TGGAGAAGTT GACATTGGTG CACAGGTCAT GCAGACCATT CCACCTGGTT TATTCTGGCG 1320 TTTCCAGATT ACTATCCACC ATCCAATATA TCTGAAGTTC AATATTTCTT TAGCCAAGGA 1380 CTCTCTCCTG GGAATTTATG GCAGAAGAAA CATTCCACCT ACACATACTC AGTTTGATTT 1440 TGTAAAACTA ATGGATGGCA AACAGCTGGT CAAGCAGGAC TCCAAGGGCT CTGATCATAC 1500 ACAGCACTCC CCTCGGAACC TCATCTTAAC TTCGCTTCAG GAGACAGGTT TCATAGAGTA 1560 TATGGATCAA GGACCTTCGT ATCTGGCGTT TTACAATGAT GGAAAAAAGA TGGAGCAAGT 1620 ATTCGTCTTA ACTACAGCAA TTCAAATAAT GGATGACTCT TCAACCAATT GCAATGGAAA 1680 TGGAGAGTGT ATCTCTGGCC ATTGTCATTG TTTCCCAGGA TTCCTTGGAC CTGACTGTGC 1740 TAGAGATTCC TGCCCTGTCC TGTGTGGTGG GAATGGAGAA TACGAGAAAG GACACTCTGT 1800 CTGCCGGCAT GGCTCGAAGG GGCCAGAGTG TGACGTTCCG GAAGAACAAT GCATTGATCC 1860 AACATGCTTT GGCCACGGCA CCTGCATCAT GGGAGTCTGC ATCTCTCTGC CAGGATACAA 1920 AGGAGAAATA TGCGAGGAAG AGGACTGCCT AGACCCAATG TGTTCCAACC ATGGCATCTG 1980 TGTAAAAGGA GAATGTCACT GTTCTACTGG CTGGGGAGGA GTTAACTGTG AAACACCACT 2040 TCCTGTATGT CAAGAGCAGT GCTCAGGACA CGGAACTTTT CTTCTGGACG CTGGAGTATC 2100 CAGCTGTGAT CCCAAGTCGA CAGGATCTCA CTCCTCAACA GAGCTGTGTA CCATGGAGTG 2160 TGGTAGCCAT GGAGTCTCCT CAAGAGGAAT TTGCCAGTGT GAAGAAGGCT GGGTAGGACC 2220 AACATGTGAG GAACGCTCCT GTCATTCTCA TTGTACTGAG CATGGCCAAT GCAAAGATGG 2280 AAAATGTCAG TCTAGCCCTG GATGGGAGGβ CGACCACTCC ACAATTGCTC ACTACTTAGA 2340 TGCTGTCCGA GATCGCTGCC CAGGGCTCTG CTTTGGAAAT GGACGATGTA CCCTGGATCA 2400 AAATGGTTGG CACTCTGTGT GTCAGGTCGG TTGGAGTGGG ACAGGCTGCA ATGTTGTCAT 2460 GGAAATGCTT TGTCGAGATA ACTTGGACAA TCATGGAGAT GGTTTAACCG ACTGTGTGGA 2520 TCCTGACTGT TCTCAACAAA GCAACTGTTA TATAAGTCCT CTCTGCCAGG GCTCACCAGA 2580 TCCTCTTGAC CTCATTCAGC AAAGCCAAAC TCTCTTCTCT CAGCACACTT CAAGACTTTT 2640 TTATCATCGA ATCAAATTCC TCATTGGCAA GGACAGTACT CATGTCATTC CTCCTGAGGT 2700 GTCATTTGAC AGCAGGCGTG CCTCTGTGAT TCGAGGCCAA GTGGTGGCCA TAGATGGAAC 2760 TCCTCTAGTG GGAGTGAATG TCAGTTTCTT GCACCACAGT GATTATGGGT TTACCATCAG 2820 CCGGCAAGAT GGAAGCTTTG ACCTCGTCGC CATCGGTGGC ATCTCTGTCA TCTTAATCTT 2880 CGACCGATCC CCTTTCCTGC CTGAGAAGAG AACACTCTGG TTGCCTTGGA ATCAGTTTAT 2940 TGTGGTAGAG AAAGTCACCA TGCAGAGAGT TGTATCAGAC CCGCCATCCT GCGATATCTC 3000 CAACTTTATC AGCCCAAACC CTATTGTGCT TCCTTCACCG CTCACATCAT TTGGAGGGTC 3060 CTGTCCAGAG AGGGGAACTA TTCTTCCTCA GCTGCAGGTT GTACAGGAGG AAATTCCCAT 3120 TCCCTCCAGC TTTCTCAGGC TGAGTTACCT GAGCAGCCGC ACCCCTGGGT ATAAAACCCT 3180 GCTACGGATC CTTCTCACAC ATTCAACGAT TCCCGTAGGC ATCATAAAAG TACACCTCAC 3240 AGTAGCTGTG GAAGGGCGAC TCACACAGAA GTGGTTTCCC GCCGCAATTA ATCTTGTCTA 3300 CACATTTGCT TGGAACAAGA CCGATATCTA TGGACAGAAG GTTTGGGGCC TCGCAGAGGC 3360 TTTGGTATCT GTGGGATATG AATATGAAAC GTCCCCTGAC TTTATTCTCT GGGAGCAAAG 3420 GACAGTCGTT TTACAAGGTT TTGAGATGGA TGCTTCTAAC CTAGGAGACT GGTCTTTCAA 3480 TAAGCATCAC ATTTTGAATC CTCAAAGTCG AATCATACAT AAAGGGAATG GAGAAAATAT 3540 GTTCATTTCC CAGCAGCCCC CAGTCATATC AACCATAATG GGTAATGGAC ACCAAAGGAG 3600 TCTAGCCTGC ACCAACTGCA ATGGCCCAGC CCACAACAAC AAACTCTTTG CTCCTCTCGC 3660 CTTAGCTTCT GGCCCTGATC GCAGTCTGTA TGTTGGCGAC TTCAATTTTG TAAGGAGAAT 3720 ATTTCCCTCG GGAAACTCCG TTAGTATTTT GGAATTAAGC ACAAGTCCTG CTCACAAATA 3780 CTATCTGGCT ATGGACCCTG TGTCTGAATC ACTCTATCTA TCAGACACCA ATACTCGCAA 3840 AGTCTACAAG TTGAAATCTC TTGTGGAGAC GAAAGATCTG TCCAAGAATT TTGAAGTGGT 3900 GGCAGGAACT GGTGATCAGT GCCTTCCCTT TGACCAGAGT CATTGTGGAG ATGGTGGGAG 3960 AGCATCGGAA GCTTCACTGA ATAGCCCTCG AGGCATCACA GTTGATAGGC ATGGATTTAT 4020 TTACTTTGTG GATGGGACTA TGATTCGCAA AATTGATGAG AATGCTGTGA TCACAACTGT 4080 AATCGGCTCA AATGGTCTGA CTTCCACACA ACCACTGAGC TGTGACTCAG GAATGGACAT 4140 CACTCAGGTG CGATTAGAGT GGCCAACAGA CCTTGCAGTA AATCCTATGG ACAATTCATT 4200 GTATGTCTTG GATAACAACA TTGTGCTGCA AATTTCTGAG AACAGGCGTG TTCGGATCAT 4260 CGCAGGACGC CCCATTCACT GCCAGGTGCC AGGCATCGAT CATTTCCTGG TCAGCAAGGT 4320 AGCAATTCAC TCCACTCTAG AGTCAGCGAG GGCCATCAGT GTCTCCCACA GCGGGCTGCT 4380 CTTCATAGCT GAAACAGACG AGAGGAAAGT AAACCGCATT CAGCAAGTAA CCACCAATGG 4440 GGAGATCTAC ATCATCGCTG GTGCCCCCAC TGACTGTGAC TGCAAAATTG ATCCAAACTG 4500 TGACTGTTTT TCAGGTGATG GTGGCTATCC CAAAGATGCA AAGATGAAAG CCCCTTCCTC 4560 CTTAGCAGTG TCGCCTGATG GAACCCTCTA TGTGGCAGAC CTCGGAAATC TTCGAATTCG 4620 TACCATCAGC AGGAACCAAG CCCACCTGAA TCACATGAAC ATTTATGAGA TTCCTTCACC 4680 CGCTGATCAG GAACTGTACC AGTTCACTGT AAATGGAACC CACCTACACA CCCTGAACTT 4740 GATAACAAGG GACTATGTTT ATAACTTCAC CTACAATTCT GAAGGTGACT TGGGCGCGAT 4800 TACCAGCAGC AATGGCAATT CAGTGCACAT TCGCCGTGAT GCAGGCGGAA TCCCGCTATC 4860 GCTTGTGGTG CCTGGCGGAC AAGTATACTG GCTGACTATA AGCAGCAATG GAGTCCTCAA 4920 AAGAGTGTCA GCCCAAGGCT ATAATCCGGC CTTAATGACC TATCCAGGAA ACACAGGGCT 4980 TCTGGCTACC AAAAGTAACG AAAATCGATC GACAACCGTT TATGAGTATG ACCCCGAGGG 5040 ACACCTGACC AATGCAACGT TTCCCACTCG AGAGGTCAGC AGCTTCCACA GTGACCTGGA 5100 GAAGCTGACA AAAGTGGAGC TAGATACTTC CAACCGTGAA AATGTCCTCA TCTCAACCAA 5160 CTTCACGGCA ACTAGTACCA TATATATTTT AAAACAAGAA AATACTCAAA GTACCTATCG 5220 GGTCAATCCA GATGGTTCCC TGCGTGTCAC TTTTGCCAGC GGGATGGAGA TCGGCCTCAG 5280 CTCAGAGCCC CACATCCTGG CAGGGGCAGT CAACCCTACC CTGGGCAAAT GCAACATCTC' 5340 ATTGCCCGGA GAGCACAATG CAAACCTCAT CGAGTGGCGG CAGAGGAAGG AGCAAAACAA 5400 AGGCAATGTT TCGGCTTTTG AAAGGAGGCT GAGGGCCCAC AACAGAAACC TACTCTCCAT 5460 AGATTTTCAT CATATAACCC GCACAGGAAA GATCTATGAT GACCATCGAA AATTCACCCT 5520 TCGAATTCTT TATGACCAGA CTGGGCGACC CATTCTGTGG TCTCCTGTAA GCAGATATAA 5580 TGAAGTGAAC ATCACATATT CACCTTCGGG ATTGGTGACG TTTATTCAAA GAGGAACGTG 5640 GAATGAAAAA ATGGAATATG ACCAGAGTGG GAAAATTATT TCAAGAACTT GGGCTGATGG 5700 GAAAATTTGG AGCTATACCT ACTTAGAAAA ATCTGTGATG CTTCTCCTAC ACAGCCAGCG 5760 GCGTTACATC TTTGAGTATG ACCAATCAGA TTGCCTGCTG TCAGTTACCA TGCCTAGCAT 5820 GGTGCGCCAC AGCTTACAAA CCATGCTTTC AGTCGGCTAC TACCGTAATA TCTACACCCC 5880 ACCGGACAGT AGCACTTCTT TTATCCAAGA CTATAGTCGA GATGGCCGAT TGCTACAGAC 5940 CCTGCATCTG GGGACAGGGC GCAGAGTCTT ATACAAGTAC ACCAAGCAAG CAAGGCTTTC 6000 TGAGGTTCTC TATGATACCA CTCAGGTCAC ATTAACATAT GAAGAGTCTT CTCGAGTGAT 6060 TAAGACAATA CACCTCATGC ATCACGGATT CATCTGCACA ATCAGATACA GGCAAACAGG 6120 ACCTCTTATT GGACGCCAGA TTTTCAGATT CAGTGAAGAA GGCCTTGTGA ATGCACGGTT 6180 CGACTACAGC TACAACAATT TCCGAGTCAC AAGCATGCAA GCTGTAATCA ATCAAACCCC 6240 TTTGCCTATA GATCTTTACC GATATCTTCA TGTCTCTGGC AGAACAGAGC AGTTTGGAAA 6300 ATTCAGTGTA ATTAATTACG ATTTAAATCA GGTCATAACT ACTACAGTGA TGAAACACAC 6360 CAAAATCTTC AGTGCCAATG GACAAGTCAT TGAAGTCCAA TATGAAATCC TAAAGGCAAT 6420 TGCCTACTGG ATGACCATTC AATATGATAA TGTGGGCCGA CATGGTAATA TCTGCATAAG 6480 GGTAGGAGTA GATGCCAATA TAACAAGGTA CTTCTATGAA TACGATGCTC ATCGGCAACT 6540 TCAGACTGTT TCTGTAAATG ACAAAACCCA GTGGCGTTAT AGTTACGATC TGAATGGAGA 6600 CATCAACCTC TTAAGCCATG GGAAGAGTGC TCGTCTTACT CCTCTCCGAT ATGACCTCCG 6660 AGACCGCATC ACCAGATTAG GAGAAATTCA GTATAAAATG GATCAAGATG GCTTTCTGAG 6720 GCAGAGGGGA AATCATATTT TTGAATATAA TTCTAATGGC CTGCTCCAGA AAGCCTACAA 6780 TAAGGCTTCT GGCTCGACTG TGCAGTATTA CTATGATCGG CTTGGGCGAC GTGTCGCGAG 6840 TAAGTCCAGC CTAGGGCAGC ACCTTCAGTT CTTTGTCGAC GCGACCGCGA ACCCCATAAG 6900 AGTTACTCAT TTGTACAACC ACACAAGCTC GGAGATTACA TCTCTGTATT ATGATCTCCA 6960 AGGTCACCTT ATTCCCATCG AGTTAAGCAG TGGTGAAGAA TATTATCTAG CCTCTCATAA 7020 TACAGGTACC CCACTAGCTG TGTTCAGCAG CCGAGGTCAG GTCATAAAGG AGATACTATA 7080 CACACCTTAT GGCGATATCT ATCATGACAC TTACCCTGAC TTTCAGGTCA TAATTGGTTT 7140 TCATCGAGGA CTCTATCATT TCCTTACTAA ATTAGTGCAC CTGGGGCAAA GGGATTATGA 7200 TGTTGTTGCT GGCAGATGGA CAACGGCCTA TCATCACATA TGGAAACAGT TGAACCTCCT 7260 TCCTAAACCA TTCAACCTCT ACTCCTTTCA AAATAACTAC CCAGTTGGCA AAATTCAAGA 7320 TGTTGCAAAG TATACCACAG ACATCAGAAG TTGGTTGGAG CTATTTCGTT TCCAATTACA 7380 CAATGTACTA CCTCGATTTC CCAAACCTGA ATTAGAAAAT TTAGAATTAA CTTACGAGCT 7440 TCTACGGCTT CAGACAAAAA CTCAAGAGTG GGATCCTGGA AAGACTATCC TGGGCATTCA 7500 GTGTGAACTC CAGAAACAGC TCAGGAATTT CATTTCCTTG GACCAACTAC CTATCACTCC 7560 CCGATACAAT GATGGACGGT GCCTTGAAGG AGGGAAGCAA CCAAGGTTTG CTGCTCTCCC 7620 TTCTCTTTTT GGGAAAGGTA TAAAATTTGC CATCAAGGAT GGCATAGTAA CAGCTGATAT 7680 TATAGGAGTA GCCAATGAAG ATAGCAGGCG GCTTGCTGCC ATTCTCAATA ATGCCCATTA 7740 CCTGGAAAAC CTACATTTTA CCATAGAGGG GAGGGACACT CACTACTTCA TTAAGCTTGG 7800 GTCTCTCGAG GAAGACCTCG TGCTCATCGG TAACACTCGG GGGAGGCGGA TTCTGGAGAA 7860 TCGTCTCAAT GTCACTGTGT CCCAGATGAC TTCTCTGTTC AATGGGAGGA CTAGACGGTT 7920 TCCAGATATT CAGCTCCAGC ATGGAGCCCT GTGCTTCAAC ATCCGGTATC GGACAACTGT 7980 CGAAGAGGAA AAGAATCACG TGTTGGAGAT TCCCAGACAG CGCGCAGTGG CCCAGGCCTC 8040 GACTAAGGAA CAAAGAAGGC TGCAAGAGGG GGAAGAGGGG ATTAGGGCAT GGACAGAAGG 8100 GGAAAAGCAG CAGCTTTTCA GCACTGGGCG GGTACAAGGT TACGATCGGT ATTTTGTTTT 8160 GTCTGTTGAG CAGTATTTAG AACTTTCTGA CAGTGCCAAT AATATTCACT TTATCAGACA 8220 GAGCGAAATA GGCAGGAGGT_ AACAAAAATA TCTCTGCCTT TGCGTCACCA AAGACTGCCT 8280 GTTTTTAAAA CATAAAATGG TTTATTGTAT TGGTTTTCTA GATCAGAACT CTGTATATGT 8340 AAATATGGAG GAAAAACATA TCCAACTGCC TTTCAATGTG ACGGAAGATC GTATTTTAAT 8400 ATTGTTTCTT TAAACTCTTT AAGAAATGAC AGAGATTTTT AGTTCTTGTC TGGCAGTATT 8460 CAAAATAACA CAAGTAGAAC TCAAACAGCT AAAAACAGTT TTCAGAAAGC ACCACTTTCA 8520 ATTTGCCGAG CCATGCATAT GTTCCAATAT GCAGAAAGAA CCCAAGGTTC TCTATCTCTA 8580 TTGTGAGAAG CAGTTTCATC CTTAACTGTT GGCAGAACTT ACGGGCTATT TGAATAGGTG 8640 GTGCAATAGT ATCTGAAACT TGCCTTTCGA AAGACTGCCA GCCCTTTGAC GTTTTCCAGA 8700 TCTGTTATAG GAAACTTAAA AACAGGTGTA AAATCTCTTC AGCCACCATC TCCTAGAGTC 8760 AGGACCCAAT TGCCCTTCCT TCTTGATTAT TCCTCCTTGC TTCTTAAAGT AAATGCCATA 8820 TTGTTGTGCT GTCTTTTCGC GTGTGGTGGC TGGGTTCTGT CTACCATGCT TCCCTGTGGG 8880 TCTGGTAACC AGACTGTATA GCCGCTATTT GCTCGTGTGT ACATGATACC AAAGCAGCTG 8940 GCCAGCGTGA CCTCTCTCAC ACGACCTGTT TTGACTCAAT TTTTTACTAA AAGTTCTTCA 9000 GCTGTATTGG TATCATGTAA ACATAGCTTT TATTAACCTG GGTAGGAATT TCTCATTTAT 9060 ATATAGGATG TGTTTTGGTC ATAGTTTCAC ATTAGTGATT CAGTATCTAT ACACTCACCC 9120 AATGGTTTTG TGCACATGAA CGGTAATTTA CTTAAAAGTA TGATTCTGGT ACAAAAACAA 9180 ACAAAGGCTT TAGCAGGCAT ACGTGTCTGG GATGCCGATA CATACATTAA CTACTACTGC 9240 AGAAATTCAT AAGAGCCAAA ACCTTAAAAA AATAGACCTG GTACTTAAGT GAAAGTACTA 9300 AAGGGAAGAC CAGACCAAAC ATCACAGCAG TTCCTGCCAC ATTGTTTCAG CCCACTTAGA 9360 TTTATCTTTC AAATGTACAA TTCTGTATTC AACATCTCCC AGCCATCTTC AGGAAATCGA 9420 ATCAAGTAAA TCCTTTCCAA CCGAAAACAT TTCAACTAAC TATAGAGAGG CAGACTCATT 9480 TTTACTAAAA TAATTTATAC AGTTAGTTAT TTTCGTTCTC CGTACTTACC CATTTATCTT 9540 TATTTAATCG TCTCTACTGC CTAGGAAAAT AACTATTTTC CAGGACGGGT TATTTCTTCT 9600 GCGATCATTT AAAATTTGGA GAAAGGTCAG GATTAGTCTT AATATCAGCT GCAGTTTCTC 9660 AATCTCTAGG AATCCTGCAG TAAAACAAGC CCCTTCGTCA GCTGGAAGAT TTGTGCCCAG 9720 TGACAAAGAG ATAGTTTGTA AAATGCTCTC TAATTGTAAG TTACCACAAA TGAAAATACA 9780 TCACAGCACA ATGTCGCCCG TAGAAAATTC CCCTGAGCCA GCTTCTGCAC TTTCATCACC 9840 GAATCTCAAC ATTTGCTATG TCTCAAGGCA AATTTATGAT GGAATGTTAG TTTGGATTCT 9900 TTCCAGATGC TACCTAAATG CAGTGTGGGG TCATTGCCTT GCTTTGCGAT GACAGTTTCT 9960 TTCAAAATAT GCAAAGTCAT AAGCTCATGT TAAGGTTTTT CAAGAGTCTG CCTCCTACTA 10020 CACAAAGGAA AGCAAGGGAA AGGAAATGAC CCTGGCAAAC AGTAGGGAAG GGTGTATTCA 10080 AACATTTCAT TTTCAAAACC TTCGGGTTAG AATACCACTT ACACATCTAT TCTGAGAGAC 10140 AGAATTCATG AGGAACTCAT CTCTCTTTAT AACTGGAAAC ACACCAGCTT GATATATTGC 10200 TAATCCATAC TAAAATCATA TTATTGGGTT TTTTCTGAAT CAGGCCTGTA TTAATCGTAC 10260 AGTATTTATT CAGAATGGAA TTCTAAAATT ACTAACAAAC TTCTTCAAAA TTTGAATACC 10320 TCCACACCAA CCTAAAAATG GACCTTAAGT TCCTAGAACC TCTGATCTTC TTTTAAATTA 10380 ATGGAAAAAT AATTTGTGAA CTGTATATAG AGAGTGCATT CATAAATGTG ATTATCTATT 10440 TTATCACAAA TCCAAAATGT CAATATTAGA GTCTATTTTG CTTATATTTT AAGCAATTAT 10500 ACGTTTTTGC AATTCATTGA TGATGTATCA TTTTCAAACT GCTTTAAATA TCCATTAGAA 10560 ACAAATATTT GAAGCTTTTA CTTAATAGTC ATTACCTTCA ACTGTGCATT TCTAGTTTGT 10620 AATACGTATT TCGTTGGTTC GTGCCTTTAG TTTGTTAAAG TTACATTTGT ATTATATTCA 10680 GGAAATGCAC TTTTTATTAC TTACAGCTGT GGTTTTAATA CTGCCTTCAA CTATTATTAT 10740 TCTTTTTACA ACTCCTAAAG CTTGAGGGAG GAAAGAAAAA AAAAACAAAA CTACTAATCA 10800 GTAGTAAATC GAAGAGAAAC ATTTTGGCAT TTCTTAAGAA GAAGATGGAG ATATTGAGTA 10860 TATCACTTCC TATTCAGCTG AATAGAAAGA ATGCCTTCAT TGACTTGCAG TTCTGCAGTT 10920 TAAATTATTG AAAGAACAAT TCGTTTGCAT TTCCTCATGA AAGTAAAAGC ATTTTTCAGA 10980 GAAACATATG AATTTCTCAT ACCCAGCAGA CAGATGGCTG ACACTCCACA GCCACACACC 11040 ATTCGAGTAA GTTAAAGTGA GAGCATAGTA GTTGGACTCT CCTATGAAGA ACATTCTGGG 11100 CTCGAGGCAG GGAATACTCC ATGGTTCTTT CTTTTTCCTA CTTAAGCCCA TTTTGTTTGT 11160 GCTTTTCTGT TTTCTTTTGT TTTCACTCTT GCACTACAGT CTAGAGATCC AAATGAACTG 11220 AAAAGTTCAA AGTTTAACAC ATTTAAATAT GTTTACTTTT AGTTGTCATT CTAATCGTTA 11280 TTGATTAGAA GCATGACTCC TGAAGGAAAG GGAAATAAAT CTCAATTCAT ACTAACTTGC 11340 AACAAAACAC TTTTACCATA TAAATAAGTA TATGATTTAT TTTTAACCCA AAAAATGTAT 11400 AAAATAAGTG TCTCCTTTAC TGTCAATTTA TCGAGAAGAT CTATAATATA TAGACTACAT 11460 ATATATAATA TATACAACAT AGCCAAATGT ATGAAAACTT GACAATGTAT AATTTGGAAT 11520 TCACATGCTA CCTATGTAGA CAGGTATGAA ATTAAGTTAT AATTTTCATC AGACATTTTC 11580 ATCACTCTTC ACACAGTTTC AAGGCATTCC ATCATCTTAT TTTGACTCTT TTTCTTTTTT 11640 TTTTCTTTAA AAATATATTT TTAACTAGAC CAGGCCCCAC TATAATATCA CTTAAGAGAG 11700 TCAGGGCAAA GTTTTTCCAT TTATGAAGAT GTGTTCATGT AAGGGTGATT GTAATCGAGT 11760 TCATTCGTAA TAGAAGCAAA AGTACAGTAA CGAAGTATTC AAAAGAAAAT TTTCGAGACA 11820 TTGGAGCATA TTATATATAG CTTGTGGAAA GACATAAGGC TACAGATGGA ATGGAACATT 11880 CCTGTTTTCT TGAAGAAATT CACATACACA TAGCTGACCT GACTAGTACT TCAGCTCTTC 11940 CACAGCCTTC TATAAAGGTT CTTTCTTCTC CAAAGAAAAC AAAACAAAAC AAAACAAAAC 12000 AAAAAAAAAC AAAAAAAGCG CAAAAAACAA AAAAACAAAA AAAAGCAAAG TAAAATTTAA 12060 AAATACAGAA AACAAACAAC AAAAAAGAAT TCAACCATAA ATAGTGACTA TTATTTTCAG 12120 TCTGTCCTTC ATGTCAAAGC TATTAAGGAC CAAATATACT ACTGTTCATA AGAAGAAATT 12180 ACTTTCTAAA CAGTAACTCA AAATACTTAG AGTTAAACTT GCTGTGGATT TTGTCTTGGC 12240 AGTTGTCATC TTACATTATT TGTCAAAGGA AATGTGTTTG GCAGTTAAAA ATCTTTCCTT 12300 AGATTTAGTG GTCGACTTTA ACCTCTTAAA TAAATGTTAG TATATCAGAT TGTGTCCTTG 12360 AAAAATATTT TACTTGTATG AATCATGACA ACGTCTAAAT CTTTACTATT CTTCTGGCAA 12420 AAGCATCAGT AAGAAAGAAG GCGAAAAAGA GAAGTATAGC CTTTATGTCA GAAAAACATT 12480 CTTTTTAGCT GCTTACTTTC TCATGAAAAG TAAAGATGTT TACAGTGTAT GCCAAGTTTT 12540 CAGTTTCTGT ATAACAACAG GTAGAGGTTC TAATCATATT GAAAATTGTG TTATAATGGT 12600 CTGAGCCATG TTGCTAGGAA ACAATAGGTT CCAATTTTGT ATTCCTGCTC TCCTCTCCTG 12660 AAAAGTCACT GGATACTGTA CAGGTTCATG TTCTCTCGCT GCAGTTAAAT GGTCTTTTGC 12720 ATTTTGCTCT GGCTTTCAGG CCAGAAGCAT GCATTTTTCT ACAAGAGCAT CACAACAACA 12780 TGCTGTAAAT ATTTAAAGTT AAACATTATG TGTTGATATT TCAAAGAAAA GTACTTTGAA 12840 TATTTCATTT TTAAAAAATA AAATTGCCAA TCAAAAAAAA SEQ ID NO:230 PEZ2 Protein sequence: Protein Accession* NP_055068 11 21 31 41 51 MEQTDCKPYQ PLPKVKHEMD LAYTSSSDES EDGRKPRQSY NSRETLHEYN QELRMNYNSQ 60 SRKRKEVEKS TQEMEFCETS HTLCSGYQTD MHSVSRHGYQ LEMGSDVDTE TEGAASPDHA 120 LRMWIRGMKS EHSSCLSSRA NSALSLTDTD HERKSDGENG FKFSPVCCDM EAQAGSTQDV 180 QSSPHNQFTF RPLPPPPPPP HACTCARKPP PAADSLQRRS MTTRSQPSPA APAPPTSTQD 240 SVHLHNSWVL NSNIPLETRH SLFKHGSGSS AIFSAASQNY PLTSNTVYSP PPRPLPRSTF 300 SRPAFTFNKP YRCCNWKCTA LSATAITVTL ALLLAYVIAV HLFGLTWQLQ PVEGELYANG 360 VSKGNRGTES MDTTYSPIGG KVSDKSEKKV FQKGRAIDTG EVDIGAQVMQ TIPPGLFWRF 420 QITIHHPIYL KFNISLAKDS LLGIYGRRNI PPTHTQFDFV KLMDGKQLVK QDSKGSDDTQ 480 HSPRNLILTS LQETCFIEYM DQGPWYLAFY NDGKKMEQVF VLTTAIEIMD DCSTNCNGNG 540 ECISGHCHCF PGFLGPDCAR DSCPVLCGGN GEYEKGHCVC RHGWKGPECD VPEEQCIDPT 600 CFGHGTCIMG VCICVPGYKG EICEEEDCLD PMCSNHGICV KGECHCSTCW GGVNCETPLP 660 VCQEQCSGHG TFLLDAGVCS CDPKWTGSDC STELCTMECG SHGVCSRGIC QCEEGWVGPT 720 CEERSCHSHC TEHGQCKDGK CECSPGWEGD HCTIAHYLDA VRDGCPGLCF GNGRCTLDQN 780 GWHCVCQVGW SGTGCNWME MLCGDNLDND GDGLTDCVDP DCCQQSNCYI SPLCQGSPDP 840 LDLIQQSQTL FSQHTSRLFY DRIKFLIGKD STHVIPPEVS FDSRRACVIR GQWAIDGTP 900 LVGVNVSFLH HSDYGFTISR QDGSFDLVAI GGISVILIFD RSPFLPEKRT LWLPWNQFIV 960 VEKVTMQRW SDPPSCDISN FISPNPΓVLP SPLTSFGGSC PERGTIVPEL QWQEEIPIP 1020 SSFVRLSYLS SRTPGYKTLL RILLTHSTIP VGMIKVHLTV AVEGRLTQKW FPAAINLVYT 1080 FAWNKTDIYG QKVWGLAEAL VSVGYEYETC PDFILWEQRT WLQGFEMDA SNLGDWSLNK 1140 HHILNPQSGI IHKGNGEMF ISQQPPVIST IMGNGHQRSV ACTNCNGPAH NNKLFAPVAL 1200 ASGPDGSVYV GDFNFVRRIF PSGNSVSILE LSTSPAHKYY LAMDPVSESL YLSDTNTRKV 1260 YKLKSLVETK DLSKNFEWA GTCDQCLPFD QSHCGDGGRA SEASLNSPRG ITVDRHGFIY 1320 FVDGTMIRKI DENAVITTVI GSNGLTSTQP LSCDSGMDIT QVRLEWPTDL AVNPMDNSLY 1380 VLDNNIVLQI SENRRVRIIA GRPIHCQVPG IDHFLVSKVA IHSTLESARA ISVSHSGLLF 1440 IAETDERKVN RIQQVTTNGE IYIIAGAPTD CDCKIDPNCD CFSGDGGYAK DAKMKAPSSL 1500 AVSPDGTLYV ADLGNVRIRT ISRNQAHLND MNIYEIASPA DQELYQFTVN GTHLHTLNLI 1560 TRDYVYNFTY NSEGDLGAIT SSNGNSVHIR RDAGGMPLWL WPGGQVYWL TISSNGVLKR 1620 VSAQGYNPAL MTYPGNTCLL ATKSNENGWT TVYEYDPEGH LTNATFPTGE VSSFHSDLEK 1680 LTKVELDTSN RENVLMSTNL TATSTIYILK QENTQSTYRV NPDGSLRVTF ASGMEIGLSS 1740 EPHILAGAVN PTLGKCNISL PGEHNANLIE WRQRKEQNKG NVSAFERRLR AHNRNLLSID 1800 FDHITRTGKI YDDHRKFTLR ILYDQTGRPI LWSPVSRYNE VNITYSPSGL VTFIQRGTWN 1860 EKMEYDQSGK IISRTWADGK IWSYTYLEKS VMLLLHSQRR YIFEYDQSDC LLSVTMPSMV 1920 RHSLQTMLSV GYYRNIYTPP DSSTSFIQDY SRDGRLLQTL HLGTGRRVLY KYTKQARLSE 1980 VLYDTTQVTL TYEESSGVIK TIHLMHDGFI CTIRYRQTGP LIGRQIFRFS EEGLVNARFD 2040 YSYNNFRVTS MQAVINETPL PIDLYRYVDV SGRTEQFGKF SVINYDLNQV ITTTVMKHTK 2100 IFSANGQVIE VQYEILKAIA YWMTIQYDNV GRHGNMCIRV GVDANITRYF YEYDADGQLQ 2160 TVSVNDKTQW RYSYDLNGDI NLLSHGKSAR LTPLRYDLRD RITRLGEIQY KMDEDGFLRQ 2220 RGNDIFEYNS NGLLQKAYNK ASGWTVQYYY DGLGRRVASK SSLGQHLQFF VDATANPIRV 2230 THLYNHTSSE ITSLYYDLQG HLIAMELSSG EEYYVACDNT GTPLAVFSSR GQVIKEILYT 2340 PYGDIYHDTY PDFQVIIGFH GGLYDFLTKL VHLGQRDYDV VAGRWTTAYH HIWKQLNLLP 2400 KPFNLYSFEN NYFVGKIQDV AKYTTDIRSW LELFGFQLHN VLPGFPKPEL ENLELTYELL 2460 RLQTKTQEWD PGKTILGIQC ELQKQLRNFI SLDQLPMTPR YNDGRCLEGG KQPRFAAVPS 2520 VFGKGIKFAI KDGIVTADII GVANEDSRRL AAILNNAHYL ENLHFTIEGR DTHYFIKLGS 2580 LEEDLVLIGN TGGRRILENG VNVTVSQMTS LLNGRTRRFA DIQLQHGALC FNIRYGTTVE 2640 EEKNHVLEIA RQRAVAQAWT KEQRRLQEGE EGIRAWTEGE KQQLLSTGRV QGYDGYFVLS 2700 VEQYLELSDS ANNIHFMRQS EIGRR SEQ ID NO:231 PFD4 DNA SEQUENCE: Nucleic Acid Accession * NM XM441 Coding sequence: 225-2567 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I CTCAGCCTTC CCGGTTCGGG AAAGGGGAAG AATCCAGGAG GGGTAGGATT TCTTTCCTCA 60 TAGGATCGGT TGGGAAAGAC CGCAGCCTGT GTGTGTCTTT CCCTTCGACC AAGGTGTCTG 120 TTGCTCCGTA AATAAAACGT CCCACTGCCT TCTCAGAGCG CTATAAAGGC AGCGGAAGGG 180 TAGTCCGCGG GGCATTCCGG GCGGGGCGCG AGCAGAGACA GGTCATGGCA GCGCCAGGCG 240 GCAGGTCGGA GCCGCCGCAG CTCCCCGAGT ACAGCTGCAG CTACATGGTG TCGCGGCCGG 300 TCTACAGCGA GCTCGCTTTC CAGCAACAGC ACGAGCGGCG CCTGCAGGAG CGCAAGACGC 360 TGCGGGAGAG CCTGGCCAAG TGCTGCAGTT GTTCAAGAAA GAGAGCCTTT GGTGTGCTAA 420 AGACTCTTGT GCCCATCTTG GAGTCGCTCC CCAAATACCG AGTCAAGGAA TGGCTGCTTA 480 GTGACGTCAT TTCGGGAGTT AGTACTGGGC TAGTCGCCAC GCTGCAAGGG ATCGCATATC 540 CCCTACTAGC TGCAGTTCCT GTCGGATATG GTCTCTACTC TGCTTTTTTC CCTATCCTGA 600 CATACTTTAT CTTTCGAACA TCAAGACATA TCTCAGTTCG ACCTTTTCCA GTGGTGAGTT 660 TAATGGTCGG ATCTGTTGTT CTGAGCATCG CCCCCGACGA ACACTTTCTC GTATCCAGCA 720 GCAATGGAAC TGTATTAAAT ACTACTATGA TAGACACTGC AGCTAGAGAT ACAGCTAGAG 780 TCCTGATTGC CAGTGCCCTC ACTCTGCTGG TTGGAATTAT ACAGTTGATA TTTGGTCGCT 840 TGCAGATTGG ATTCATAGTG AGGTACTTCG CAGATCCTTT GGTTCGTGGC TTCACAACAG 900 CTGCTGCCTT CCAAGTGCTG GTCTCACAGC TAAAGATTCT CCTCAATGTT TCAACCAAAA 960 ACTACAATGG AGTTCTCTCT ATTATCTATA CGCTGGTTGA GATTTTTCAA AATATTGGTG 1020 ATACCAATCT TGCTCATTTC ACTGCTGGAT TCCTCACCAT TGTCGTCTGT ATGGCAGTTA 1080 AGGAATTAAA TGATCGGTTT AGACACAAAA TCCCAGTCCC TATTCCTATA GAAGTAATTG 1140 TGACGATAAT TGCTACTCCC ATTTCATATG GAGCCAACCT GGAAAAAAAT TACAATCCTG 1200 GCATTGTTAA ATCCATCCCA AGGGGGTTTT TGCCTCCTGA ACTTCCACCT GTGAGCTTCT 1260 TCTCGGAGAT GCTGGCTCCA TCATTTTCCA TCGCTGTGGT GGCTTATGCT ATTGCAGTCT 1320 CAGTAGGAAA AGTATATGCC ACCAAGTATG ATTACACCAT CGATGGGAAC CAGGAATTCA 1380 TTGCCTTTGG GATCAGCAAC ATCTTCTCAG GATTCTTCTC TTCTTTTGTC GCCACCACTC 1440 CTCTTTCCCG CACGGCCGTC CAGGAGAGCA CTCGAGGAAA GACACAGGTT GCTGGCATCA 1500 TCTCTCCTCC GATTCTGATG ATCGCCATTC TTGCCCTCGG GAAGCTTCTG GAACCCTTGC 1560 AGAAGTCGGT CTTGGCAGCT GTTGTAATTC CCAACCTCAA AGGGATGTTT ATCCAGCTGT 1620 GTGACATTCC TCGTCTGTCG AGACAGAATA AGATTGATGC TGTTATCTGG GTCTTTACGT 1680 GTATAGTGTC CATCATTCTC GGGCTGGATC TCGGTTTACT AGCTGGCCTT ATATTTGGAC 1740 TGTTCACTGT GGTCCTGAGA GTTCAGTTTC CTTCTTCGAA TCGCCTTGGA AGCATCCCTA 1800 GCACAGATAT CTACAAAAGT ACCAAGAATT ACAAAAACAT TGAAGAACCT CAAGGAGTCA 1860 AGATTCTTAG ATTTTCCAGT CCTATTTTCT ATGGCAATGT CGATGGTTTT AAAAAATGTA 1920 TCAAGTCCAC AGTTGGATTT GATGCCATTA GAGTATATAA TAAGAGGCTG AAAGCGCTGA 1980 GGAAAATACA GAAACTAATA AAAAGTGGAC AATTAAGAGC AACAAAGAAT GGCATCATAA 2040 GTGATGCTGT TTCAACAAAT AATGCTTTTG AGCCTCATGA GGATATTGAA GATCTGGAGG 2100 AACTTGATAT CCCAACCAAG GAAATAGAGA TTCAAGTGGA TTGGAACTCT GAGCTTCCAG 2160 TCAAAGTGAA CGTTCCCAAA GTGCCAATCC ATAGCCTTGT GCTTGACTGT GGAGCTATAT 2220 CTTTCCTCGA CGTTGTTGGA GTGAGATCAC TGCGGGTGAT TGTCAAAGAA TTCCAAAGAA 2280 TTGATGTGAA TGTCTATTTT GCATCACTTC AAGATTATGT GATAGAAAAG CTGGAGCAAT 2340 GCGGGTTCTT TGACGACAAC ATTAGAAAGG ACACATTCTT TTTGACGGTC CATGATGCTA 2400 TACTCTATCT ACAGAACCAA GTGAAATCTC AAGAGGGTCA AGGTTCCATT TTAGAAACGA 2460 TCACTCTCAT TCAGGATTGT AAAGATACCC TTGAATTAAT AGAAACAGAG CTGACGGAAG 2520 AAGAACTTGA TGTCCAGGAT GAGGCTATCC GTACACTTGC ATCCTGAAAG TGGGTTCGGG 2580 AGGTCTCTAT GAGCAAGGAA TACAAGACAA AACTTCCTCA ATCCATTGAC TATTTCTTCA 2640 GACTCAAAAC ACTCATTCTT TTTTCTATTA AGCCATTGAA AGAGAAGCAC TAAGACTGCT 2700 TCTAGGCTTT ATTTATAAAA TAAACACCTT ATCCCTAACA TCGGCAAAAT GGCTAGAATT 2760 ATTCAGACGA TTTCGCAGCG TCCAGGGTAA GCTGGTGTTA TAATACGCTG CTGATCTACA 2820 TCACAGATTT GCTAATAATG TTCACGTGGG CCCTCGCATA TCTCTCTTCA GTTAGAGTCA 2880 GTGCTGACCC AACAGCCTCT GTGGTCAAGC GAGTCACGAA TGATTAATCA TAAAGAAAAA 2940 TCAGTTTTTG ACTGACCTCG ATATCCATGA GCTGCACTGA TCACCATGTA AGGTCACATT 3000 TAGTAAATGC TGAAATAAAA TGATTAATGC ATTTATCAAT AAAAGCCTTT GAAAATACTT 3060 TGGATAATAA ATTGGAGTTT TAAAAATGCA AATTTGCTTA GTATCTAATA ATGAAGTGTT 3120 ATTACATATA GCCGGAATTC AGGATCTCTT TGATCCTGGA AATGGTTTAC CTAAAAGCTA 3180 CAGAACCAGG CCAATATATT TTCAAATATT GATGCAGACA AATCAAATAA TAAAGAGATT 3240 TTCATGGTTT ATAAAAATCT TTTTTCATAT GATAATAATC ATGATCACAA CTGAGATCAA 3300 AAAAATATAT GACAGATTAT TTTGTTTAAA AATCCAGTTT TAATTATCTT AGTCTATAGA 3360 AATGATCATT GCATGGAGGC ATGTATAGGT ATGATCTCTG TAAAATCTGA CATAAAAACA 3420 GTGCTATTCT GAGTGAAAAT TTTTTTCATG TGCTTACATA ACCATGGTGA TTAAAATCAG 3480 TTTATATTTT TTCTCAAAAA TTTTAGCAGT GTGTAAAGTA AGTAATCTTT AACTGAACTC 3540 TGACCACTTA AAAAAAAATC TAAAAATTGA ACTACCTATA GTAGTCTGTC TTTAAAGTGA 3 600 ATTTTTAAAG ACAAAGCATT CTAAATGAAC TCAATATAAA AACATTCATT TCGAATCTAC 3660 ATACTGAAAA ATACAGGTTT TTTTGACCAA AAGTTTTTAT ATCTTTTCTT TTTATTTATT 3720 TTTTTCCTAA GTGCCAACAA TTTTCTAGAT ATTATATACA ACACAGGCTT TGATCTTCGG 3780 GACTTTTCCC ATATATTTCA CACTGGAGTG AATGAAGTTG TACTTCATTT CTAGAGAAAA 3840 GTTATACCCA GGTCCCCAAT TGAGAATGTC TTGCTTGATT GAAAACGACA TCATCCCTTC 3900 GTATACTCCA GGGATTGGTT TCAGGACCCC TGCATTTACC AAAATTTGTG CACACTCAAG 3960 TCCTGCAGTC ACCCCTGCCT AAAGATAGAA TGGCTTCTCT GTTTTTCTTC TGAAATACAA 4020 CCAGAAACAA TGTGTCTATT TCTCAAAGAA TAGGATTAAT GATCATACAA ATGGGTTAAT 4080 CCTGAATTCT GGTTGTAAAT CTGGTTACAG CATAACTAGG ATTATAATGC TGCCTCATTT 4140 TCACAGCACT ACTTGCTTAT ATTGACAACA AATCATCTCG CTAAAGAGTG AATCTAGGCC 4200 AGGCGCGGTG GCTCATGCCT GTAATCCCAG CACTTTGGGA GGCCGAGGCG GGTGGATCAC 4260 GAGGTCAGGA GATCGAGACC ATCCTCGCTA ACATCGTAAA ACCCCGTCTC TACTAAAAAT 4320 AGAAAAAAAG AAATTAGCCT AGCGTGGTGG CTCGCGGGCG CCTCTAGTCC CAGCTATTTC 4380 GGAGGCTAAG GCAGGAGAAT GGCGTCAACC CGGGAGGCGG AGCTTGCAGT GAGCCGAGGT 4440 CGTGCCACTC CACTCCAGCC TGGGCGACAG AGCAAGACTC CGTCTCAAAA AAAAAAAAAA 4500 AAAAAAAAAA AGAGTGAATG TAATAGTCTT GCAGAAAATC AATGAATACC TTTCTTCAAT 4560 AAAGGAAATA TCCACTGCTC ACTTTTTTCA AGGAAATGCC AAAGTTACGT TTTACAACAA 4620 GGCTAGAGTT TGTAAATTCT GGGTTCATTT GTGATGACAT AAGTCAGCAA ACTCCGGGAA 4680 TACTCTCTCT TCTATGTATT TTGTGAATAG TAAGCATAAT TTTAGTTTTG TATTATCAAT 4740 GAAAATTTCA CTTGAAATTA AAGCTCCCTT TTCTTATATT TTTAACCTAT AGGATAAGAT 4800 TCCAGTATTG TATATGAGTT TTAACAAATT AAAAAATCAA ATCATGTACA TTTGAAAATA 4860 TTTCCACACA TTTAAAAATA AATGTAAAGT TGTCTTTTAA ACTACTCGGA TGTGTCCTTT 4920 CTGAACAAAA SEQ ID NO-232 PFD4 Protein sequence Protein Accession*. 043511 11 21 31 41 51 I I I MAAPGGRSEP I PQLPEYSCSY MVSRPVYSEL I AFQQQHERRL QERKTLRESL AKCCSCSRKR 60 AFGVLKTLVP ILEWLPKYRV KEWLLSDVIS GVSTGLVATL QGMAYALLAA VPVGYGLYSA 120 FFPILTYFIF GTSRHISVGP FPWSLMVGS WLSMAPDEH FLVSSSNGTV LNTTMIDTAA 180 RDTARVLIAS ALTLLVGIIQ LIFGGLQIGF IVRYLADPLV GGFTTAAAFQ VLVSQLKIVL 240 NVSTKNYNGV LSIIYTLVEI FQNIGDTNLA DFTAGLLTIV VCMAVKELND RFRHKIPVPI 300 PIEVIVTIIA TAISYGANLE KNYNAGΓVKS IPRGFLPPEL PFVSLFSEML AASFSIAWA 360 YAIAVSVGKV YATKYDYTID GNQEFIAFGI SNIFSGFFSC FVATTALSRT AVQESTCGKT 420 QVAGIISAAI VMIAILALGK LLEPLQKSVL AAWIANLKG MFMQLCDIPR LWRQNKIDAV 480 IWVFTCΓVSI ILGLDLGLLA GLIFGLLTW LRVQFPSWNG LGSIPSTDIY KSTKNYKNIE 540 EPQGVKILRF SSPIFYGNVD GFKKCIKSTV GFDAIRVYNK RLKALRKIQK LIKSGQLRAT 600 KNGIISDAVS TNNAFEPDED IEDLEELDIP TKEIEIQVDW NSELPVKVNV PKVPIHSLVL 660 DCGAISFLDV VGVRSLRVIV KEFQRIDVNV YFASLQDYVI EKLEQCGFFD DNIRKDTFFL 720 TVHDAILYLQ NQVKSQEGQG SILETITLIQ DCKDTLELIE TELTEEELDV QDEAMRTLAS 780 QDEAMRTLAS SEQ ID NO:233 PFH2 DNA SEQUENCE. Nucleic Acid Accession* NM_016029 Coding sequence. 228-1097 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I CTGCGATCCC GCAGGGCAGC GACGCGACTC I TGGTCCGGGC CGTCTTCTTC CCCCCGAGCT 60 GGGCGTGCGC GGCCGCAATC AACTGGGAGC TGCTGCTGTG GCTCCTGGTG CTGTCCGCGC 120 TGCTCCTGCT CTTGGTGCAG CTGCTGCGCT TCCTGAGGGC TGACGGCGAC CTGACGCTAC 180 TATGGGCCGA GTGGCAGGGA CGACGCCCAG AATGGGAGCT GACTGATATG GTGGTGTGGG 240 TGACTGGAGC CTCGAGTGGA ATTCGTCAGG AGCTGGCTTA CCAGTTCTCT AAACTAGGAG 300 TTTCTCTTGT GCTGTCAGCC AGAAGAGTGC ATGAGCTGGA AAGGGTGAAA AGAAGATGCC 360 TAGAGAATCG CAATTTAAAA GAAAAAGATA TACTTGTTTT GCCCCTTGAC CTGACCGACA 420 CTGGTTCCCA TGAAGCGGCT ACCAAAGCTG TTCTCCAGGA GTTTGGTAGA ATCGACATTC 480 TGGTCAACAA TGGTGGAATG TCCCAGCGTT CTCTGTGCAT GGATACCAGC TTGGATGTCT 540 ACAGAAAGCT AATAGAGCTT AACTACTTAG GGACGGTGTC CTTCACAAAA TGTGTTCTGC 600 CTCACATCAT CGAGAGGAAG CAAGGAAAGA TTGTTACTCT GAATAGCATC CTGGGTATCA 660 TATCTGTACC TCTTTCCATT GGATACTCTG CTAGCAAGCA TGCTCTCCGG GGTTTTTTTA 720 ATGGCCTTCG AACAGAACTT GCCACATACC CAGGTATAAT AGTTTCTAAC ATTTGCCCAG 780 GACCTGTCCA ATCAAATATT GTGGAGAATT CCCTAGCTCG AGAAGTCACA AAGACTATAG 840 GCAATAATCG AGACCAGTCC CACAAGATGA CAACCAGTCG TTGTGTGCGG CTGATCTTAA 900 TCAGCATGGC CAATGATTTG AAAGAAGTTT GGATCTCAGA ACAACCTTTC TTGTTAGTAA 960 CATATTTCTC GCAATACATG CCAACCTGGG CCTGGTCGAT AACCAACAAG ATCGGGAAGA 1020 AAAGGATTGA GAACTTTAAG AGTGGTGTGG ATCCAGACTC TTCTTATTTT AAAATCTTTA 1080 AGACAAAACA TGACTCAAAA GAGCACCTGT ACTTTTCAAG CCACTGGAGG GAGAAATGGA 1140 AAACATGAAA ACAGCAATCT TCTTATGCTT CTGAATAATC AAAGACTAAT TTGTGATTTT 1200 ACTTTTTAAT AGATATGACT TTGCTTCCAA CATGGAATGA AATAAAAAAT AAATAATAAA 1260 AGATTGCCAT GAATCTTGCA AA SEQ ID N0.234 PFH2 Protein sequence. Protein Accession* NP_057113 11 21 31 41 51 I I I M.MWELLLWLL VLCALLLLLV QLLRFLRADG DLTLLWAEWQ I I GRRPEWELTD MWWVTGASS 60 GIGEELAYQL SKLGVSLVLS ARRVHELERV KRRCLENGNL KEKDILVLPL DLTDTGSHEA 120 ATKAVLQEFG RIDILVNNGG MSQRSLCMDT SLDVYRKLIE LNYLGTVSLT KCVLPHMIER 180 KQGKIVTVNS ILGIISVPLS IGYCASKHAL RGFFNGLRTE LATYPGIIVS NICPGPVQSN 240 IVENSLAGEV TKTIGNNGDQ SHKMTTSRCV RLMLISMAND LKEVWISEQP FLLVTYLWQY 300 MPTWAWWITN KMGKKRIENF KSGVDADSSY FKIFKTKHD SEQ ID N0:235 ACC5 DNA SEQUENCE Nucleic Add Accession* NM.000450 Coding sequence: 1-1833 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 ATGATTGCTT CACAGTTTCT CTCAGCTCTC ACTTTGGTGC TTCTCATTAA AGAGAGTCGA 60 GCCTGGTCTT ACAACACCTC CACGGAAGCT ATGACTTATG ATGAGGCCAG TCCTTATTGT 120 CAGCAAAGGT ACACACACCT GGTTGCAATT CAAAACAAAG AAGAGATTGA GTACCTAAAC 180 TCCATATTGA GCTATTCACC AAGTTATTAC TGGATTGGAA TCAGAAAAGT CAACAATGTG 240 TCGGTCTGGG TAGGAACCCA GAAACCTCTC ACAGAAGAAG CCAAGAACTG GGCTCCAGGT 300 GAACCCAACA ATAGGCAAAA AGATGAGGAC TGCGTGGAGA TCTACATCAA GAGAGAAAAA 360 GATGTGGGCA TCTCGAATCA TGAGAGGTCC AGCAAGAAGA AGCTTGCCCT ATGCTACACA 420 GCTGCCTGTA CCAATACATC CTGCAGTCGC CACGGTGAAT GTGTAGAGAC CATCAATAAT 480 TACACTTGCA AGTGTGACCC TGGCTTCAGT GGACTCAAGT GTGAGCAAAT TCTGAACTGT 540 ACAGCCCTGG AATCCCCTCA GCATGGAAGC CTGGTTTGCA GTCACCCACT GGGAAACTTC 600 AGCTACAATT CTTCCTGCTC TATCAGCTGT GATAGGGGTT ACCTGCCAAG CAGCATCGAG 660 ACCATGCAGT GTATGTCCTC TGGAGAATGG AGTGCTCCTA TTCCAGCCTG CAATGTGGTT 720 GAGTGTGATG CTCTGACAAA TCCAGCCAAT GGGTTCGTGG AATGTTTCCA AAACCCTCGA 780 AGCTTCCCAT GGAACACAAC CTGTACATTT GACTGTGAAG AAGGATTTGA ACTAATGGGA 840 GCCCAGAGCC TTCAGTGTAC CTCATCTCGG AATTGGGACA ACGAGAAGCC AACGTGTAAA 900 GCTCTGACAT GCAGGGCCGT CCGCCAGCCT CAGAATGGCT CTGTGAGGTG CAGCCATTCC 960 CCTGCTGGAG AGTTCACCTT CAAATCATCC TGCAACTTCA CCTGTGAGGA AGGCTTCATC 1020 TTGCAGGGAC CAGCCCAGGT TGAATGCACC ACTCAAGGGC AGTGGACACA GCAAATCCCA 1080 GTTTGTGAAG CTTTCCAGTC CACAGCCTTG TCCAACCCCG AGCGAGGCTA CATGAATTGT 1140 CTTCCTAGTG CTTCTGGCAG TTTCCGTTAT GGGTCCAGCT GTCAGTTCTC CTGTGAGCAG 1200 GGTTTTGTGT TGAAGGGATC CAAAAGGCTC CAATGTGGCC CCACAGGGGA GTGGGACAAC 1260 GAGAAGCCCA CATCTGAAGC TCTCAGATGC GATGCTGTCC ACCAGCCCCC GAAGGGTTTC 1320 GTGAGGTGTC CTCATTCCCC TATTCGAGAA TTCACCTACA AGTCCTCTTG TGCCTTCAGC 1380 TGTGAGGAGG GATTTGAATT ATATGGATCA ACTCAACTTC AGTGCACATC TCAGGGACAA 1440 TGGACAGAAG AGGTTCCTTC CTCCCAAGTC GTAAAATGTT CAAGCCTGGC AGTTCCGGGA 1500 AAGATCAACA TGAGCTGCAG TCGGGAGCCC GTGTTTGGCA CTGTGTGCAA GTTCGCCTCT 1560 CCTGAAGGAT GGACGCTCAA TGGCTCTGCA GCTCGGACAT GTGGAGCCAC AGGACACTGG 1620 TCTGGCCTGC TACCTACCTG TGAAGCTCCC ACTGAGTCCA ACATTCCCTT GGTAGCTGGA 1680 CTTTCTGCTG CTCGACTCTC CCTCCTCACA TTAGCACCAT TTCTCCTCTG GCTTCGGAAA 1740 TGCTTACGGA AAGCAAAGAA ATTTCTTCCT GCCAGCAGCT GCCAAAGCCT TGAATCAGAC 1800 GGAAGCTACC AAAAGCCTTC TTACATCCTT TAA SEQ ID NO:236 ACC5 Protein sequence: Protein Accession* NP.000441 11 21 31 41 51 I I I I I MIASQFLSAL TLVLLIKESG AWSYNTSTEA MTYDEASAYC QQRYTHLVAI QNKEEIEYLN 60 SILSYSPSYY WIGIRKVNNV WVWVGTQKPL TEEAKNWAPG EPNNRQKDED CVEIYIKREK 120 DVGMWNDERC SKKKLALCYT AACTNTSCSG HGECVETINN YTCKCDPGFS GLKCEQTVNC 180 TALESPEHGS LVCSHPLGNF SYNSSCSISC DRGYLPSSME TMQCMSSGEW SAPIPACNW 240 ECDAVTNPAN GFVECFQNPG SFPWNTTCTF DCEEGFELMG AQSLQCTSSG NWDNEKPTCK 300 AVTCRAVRQP QNGSVRCSHS PAGEFTFKSS CNFTCEEGFM LQGPAQVECT TQGQWTQQIP 360 VCEAFQCTAL SNPERGYMNC LPSASGSFRY GSSCEFSCEQ GFVLKGSKRL QCGPTGEWDN 420 EKPTCEAVRC DAVHQPPKGL VRCAHSPIGE FTYKSSCAFS CEEGFELYGS TQLECTSQGQ 480 WTEEVPSCQV VKCSSLAVPG KINMSCSGEP VFGTVCKFAC PEGWTLNGSA ARTCGATGHW 540 SGLLPTCEAP TESNIPLVAG LSAAGLSLLT LAPFLLWLRK CLRKAKKFVP ASSCQSLESD 600 GSYQKPSYIL SEQ ID N0:237 PM28 DNA SEQUENCE Nucleic Acid Accession* N51002 Coding sequence: 1-3793 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 I I I I I ATGATGTGTC AAGTGATGCC CACGATTAAT GAGGACACCC CAATGAGCCA AAGGGGGTCC 60 CAAAGCAGTG GCTCGGACTC AGACTCCCAT TTTGAGCAGC TGATGGTCAA TATGCTAGAT 120 GAAAGGGATC GTCTTCTAGA CACCCTTCGG GAGACCCAGG AAAGCCTCTC ACTTCCCCAG 180 CAAAGACTTC AGGATGTCAT CTATGACCGA GACTCACTCC AGAGACAGCT CAATTCAGCC 240 CTGCCACAGG ATATCGAATC CCTAACAGGA GGGCTGGCTG GTTCTAAGGG GGCTGATCCA 300 CCGGAATTTC CTGCACTGAC AAAAGAATTA AATGCCTCCA GGGAACAACT TCTAGAAAAG 360 GAAGAAGAAA TCTCTGAACT TAAAGCTGAA AGAAACAACA CAAGACTATT ACTGGAGCAT 420 TTGGAGTGCC TTGTGTCACG ACATGAAAGA TCACTAAGAA TGACGGTGGT AAAACGGCAA 480 GCCCAGTCTC CCTCAGGAGT ATCCAGTCAA GTTGAAGTTC TCAAGGCACT GAAATCTTTG 540 TTTGAGCACC ACAAGGCCTT GGATGAAAAG GTAAGGGAGC GACTGAGGGT TTCTTTAGAA 600 AGAGTCTCTG CACTGGAAGA AGAACTAGCT GCTGCTAATC AGGAGATTGT TGCCTTGCGT 660 GAACAAAATG TTCATATACA AAGAAAAATG GCATCAAGCG AGGGATCCAC AGAGTCAGAA 720 CATCTTGAAG GGATGGAACC TGGACAGAAA GTCCATCAGA AGCGTTTGTC CAATGGTTCT 780 ATAGACTCAA CCGATGAAAC TAGTCAAATA GTTGAACTAC AAGAATTGCT TGAAAAGCAA 840 AACTATGAAA TGGCCCAGAT GAAAGAACGT TTAGCAGCCC TTTCTTCCCG AGTGGGAGAG 900 GTGGAACAGG AAGCAGAGAC AGCAAGAAAG GATCTCATTA AAACAGAAGA AATCAACACC 960 AAGTATCAAA GGGACATTAG GGAGGCCATC GCACAAAAGG AAGATATGGA AGAAAGAATT 1020 ACAACCCTTC AAAAGCGTTA CCTCAGTGCT CAGAGAGAAT CTACCTCCAT ACATCACATG 1080 AATGATAAAC TAGAAAATGA GTTAGCAAAT AAAGAAGCTA TCCTACGGCA GATGGAAGAG 1140 AAAAACAGAC AGTTACAAGA ACGTCTTGAG CTAGCTCAAC AAAAGTTGCA GCAGACCATC 1200 AGAAAGGCTG AAACCTTGCC TGAAGTAGAG GCTGAACTGG CTCAGAGAAT TGCAGCCCTA 1260 ACCAAGGCTG AAGAGAGACA TGGAAATATT GAAGAACGTA TGAGACATTT AGAGGGTCAA 1320 CTTCAAGAGA AGAATCAAGA ACTTCAAAGA GCTAGGCAAA GAGAGAAAAT GAATCAGGAG 1380 CATAACAAGA GATTATCGGA TACGGTTGAT AGACTTCTCA CTGAATCCAA TGAACGCCTA 1440 CAACTACACT TAAAGGAAAG AATGGCTGCT CTAGAAGAAA AGAATGTTTT AATTCAAGAA 1500 TCAGAAACTT TCAGAAAGAA TCTTGAAGAA TCTTTACATG ATAAGGAAAG ATTAGCAGAA 1560 GAAATTGAAA AGCTGAGATC TGAACTTGAC CAATTGAAAA TGAGAACTGG CTCTTTAATT 1620 GAACCCACAA TACCAAGAAC TCATCTAGAC ACCTCAGCTG AGTTCCGGTA CTCAGTGGGA 1680 TCCCTAGTGG ACAGCCAGTC TGATTACAGA ACAACTAAAG TAATAAGAAG ACCAAGGAGA 1740 GGCCGCATGG GTGTGCGAAG AGATGAGCCA AAGGTCAAAT CTCTTCGGGA TCACGAGTGG 1800 AATAGAACTC AACAGATTGG AGTACTAAGC AGCCACCCTT TTGAAAGTGA CACTGAAATG 1860 TCTGATATTC ATGATGATGA CAGAGAAACA ATTTTTAGCT CAATGGATCT TCTCTCTCCA 1920 AGTGGTCATT CCGATGCCCA GACGCTAGCC ATGATGCTTC AGGAACAATT GGATGCCATC 1980 AACAAAGAAA TCAGGCTAAT TCAGGAAGAA AAAGAATCTA CAGAGTTGCG TGCTGAAGAA 2040 ATTCAAAATA GAGTGGCTAG TGTGAGCCTC GAAGGCCTCA ATTTGGCAAG GGTCCACCCA 2100 GGTACCTCCA TTACTGCCTC TGTTACAGCT TCATCGCTGG CCAGTTCATC TCCCCCCAGT 2160 GGACACTCAA CTCCAAAGCT CACCCCTCGA AGCCCTGCCA GGGAAATGGA TCGGATGGGA 2220 GTCATGACAC TGCCAAGTGA TCTGAGGAAA CATCGGAGAA AGATTGCAGT TCTCGAAGAA 2280 GATGGTCGAG AGGACAAAGC AACAATTAAA TGTCAAACTT CTCCTCCTCC TACCCCTAGA 2340 GCCCTCAGAA TCACTCACAC TCTCCCTTCT TCCTACCACA ATGATCCTCG AAGTAGTTTA 2400 TCTGTCTCTC TTCAGCCAGA AAGCCTCGGG CTTGGTAGTG CCAACAGCAG CCAAGACTCT 2460 CTTCACAAAG CCCCCAAGAA GAAAGGAATC AAGTCTTCAA TAGGACGTTT GTTTGGTAAA 2520 AAAGAAAAAG CTCGACTTGG GCAGCTCCGA GGCTTTATGG AGACTCAAGC TGCAGCTCAG 2580 GAGTCCCTGG GGTTAGGCAA ACTCGGAACT CAAGCTCAGA AGGATCGAAG ACTAAAGAAA 2640 AAGCATGAAC TTCTTGAAGA AGCTCGGAGA AAGGGATTAC CTTTTCCCCA GTGGGATGGG 2700 CCAACTCTGG TCGCATGGCT AGAGCTTTGG TTGGGAATGC CTGCGTCGTA CGTGGCAGCC 2760 TGCCGAGCCA ACGTCAAGAG TGGTGCCATC ATGTCTGCTT TATCTGACAC TGAGATCCAG 2820 AGAGAAATTG GAATCAGCAA TCCACTCCAT CGCTTAAAAC TTCGATTAGC AATCCAGGAG 2880 ATGGTTTCCC TAACAAGTCC TTCAGCTCCT CCAACATCTC GAACTCCTTC AGGCAACGTT 2940 TGGGTGACTC ATCAAGAAAT GGAAAATCTT GCAGCTCCAG CAAAAACGAA AGAATCTGAG 3000 GAAGGAAGCT GGGCCCAGTG TCCGGTTTTT CTACAGACCC TGGCTTATGG AGATATGAAT 3060 CATCAGTGGA TTGGAAATGA ATGGCTTCCC AGCTTGGGGT TACCTCAGTA CAGAAGTTAC 3120 TTTATGGAAT GCTTGGTAGA TGCAAGAATC TTAGATCACC TAACAAAAAA AGATCTCCGT 3180 GTCCATTTAA AAATGGTGGA TAGTTTCCAT CGAACAAGTT TACAATATGG AATTATGTGC 3240 TTAAAGAGGT TGAATTATCA CAGAAAAGAA CTAGAAAGAA GACGGGAAGC AAGCCAACAT 3300 GAAATAAAAG ACGTGTTGGT GTGGAGCAAT GACCGAATTA TTCGCTGGAT ACAAGCAATT 3360 GGACTTCGAG AATATGCAAA TAATATACTT GAGAGCGGTC TGCATCGCTC ACTTATAGCC 3420 CTGGATGAAA ACTTTGACTA CAGCAGCTTA ACTTTATTAT TACAGATTCC AACACAGAAC 3480 ACCCAGGCAA GGCAGATTCT TGAAAGAGAA TACAATAACC TCTTCGCCCT GGGAACTGAA 3540 AGGCGACTGG ATCAAAGTGA TGACAAGAAC TTCAGACGTG GATCAACCTG GAGAAGGCAG 3600 TTTCCTCCTC GTGAAGTACA TGGAATCAGC ATGATGCCTG GGTCCTCAGA AACATTACCA 3660 GCTGGATTTA GGTTAACCAC AACCTCTGGG CAATCAAGAA AAATGACAAC AGATCTTCCT 3720 TCATCAAGAC TGCAGAGGTT AGACAACTCC ACTCTTCGCA CATACTCATG TCTCGAGTAA 3780 GCGGCCGCTT TAA SEQ ID NO:238 P 28 Protein sequence: Protein Accession* none found 11 21 31 41 51 I I I I MMCEVMPTIN EDTPMSQRGS QSSGSDSDSH FEQLMVNMLD E IRDRLLDTLR ETQESLSLAQ 60 QRLQDVIYDR DSLQRQLNSA LPQDIESLTC GLAGSKGADP PEFAALTKEL NACREQLLEK 120 EEEISELKAE RNNTRLLLEH LECLVSRHER SLRMTWKRQ AQSPSGVSSE VEVLKALKSL 180 FEHHKALDEK VRERLRVSLE RVSALEEELA AANQEΓVALR EQNVHIQRKM ASSEGSTESE 240 HLEGMEPGQK VHEKRLSNGS IDSTDETSQI VELQELLEKQ NYEMAQMKER LAALSSRVGE 300 VEQEAETARK DLIKTEEMNT KYQRDIREAM AQKEDMEERI TTLEKRYLSA QRESTSIHDM 360 NDKLENELAN KEAILRQMEE KNRQLQERLE LAEQKLQQTM RKAETLPEVE AELAQRIAAL 420 TKAEERHGNI EERMRHLEGQ LEEKNQELQR ARQREKMNEE HNKRLSDTVD RLLTESNERL 480 QLHLKERMAA LEEKNVLIQE SETFRKNLEE SLHDKERLAE EIEKLRSELD QLKMRTGSLI 540 EPTIPRTHLD TSAELRYSVG SLVDSQSDYR TTKVIRRPRR GRMGVRRDEP KVKSLGDHEW 600 NRTQQIGVLS SHPFESDTEM SDIDDDDRET IFSSMDLLSP SGHSDAQTLA MMLQEQLDAI 660 NKEIRLIQEE KESTELRAEE IENRVASVSL EGLNLARVHP GTSITASVTA SSLASSSPPS 720 GHSTPKLTPR SPAREMDRMG VMTLPSDLRK HRRKIAWEE DGREDKATIK CETSPPPTPR 780 ALRMTHTLPS SYHNDARSSL SVSLEPESLG LGSANSSQDS LHKAPKKKGI KSSIGRLFGK 840 KEKARLGQLR GFMETEAAAQ ESLGLGKLGT QAEKDRRLKK KHELLEEARR KGLPFAQWDG 900 PTWAWLELW LGMPAWYVAA CRANVKSGAI MSALSDTEIQ REIGISNPLH RLKLRLAIQE 960 MVSLTSPSAP PTSRTPSGNV WVTHEEMENL AAPAKTKESE EGSWAQCPVF LQTLAYGDMN 1020 HEWIGNEWLP SLGLPQYRSY FMECLVDARM LDHLTKKDLR VHLKMVDSFH RTSLQYGIMC 1080 LKRLNYDRKE LERRREASQH EIKDVLVWSN DRIIRWIQAI GLREYANNIL ESGVHGSLIA 1140 LDENFDYSSL TLLLQIPTQN TQARQILERE YNNLLALGTE RRLDESDDKN FRRGSTWRRQ 1200 FPPREVHGIS MMPGSSETLP AGFRLTTTSG QSRKMTTDVA SSRLQRLDNS TVRTYSCLE SEQ ID NO:239 PCI4 DNA SEQUENCE Nucleic Acid Accession*: N JH6570 Coding sequence: 1- 1134 (underiined sequences correspond to start and stop codons) 1 11 21 31 41 51 I I I I I I ATCAGGCGAC TCAATCGGAA AAAAACTTTA AGTTTCGTAA AAGAGTTCGA TCCCTTTCCG 60 5 AAGGTTCCTG AGAGCTATGT AGAGACTTCA GCCAGTGGAG GTACAGTTTC TCTAATAGCA 120 TTTACAACTA TGGCTTTATT AACCATAATG GAATTCTCAG TATATCAAGA TACATGGATG 180 AAGTATGAAT ACGAAGTAGA CAAGGATTTT TCTAGCAAAT TAAGAATTAA TATAGATATT 240 ACTGTTGCCA TCAAGTCTCA ATATGTTGGA GCGGATCTAT TGGATTTAGC AGAAACAATG 300 GTTGCATCTG CAGATGGTTT AGTTTATGAA CCAACAGTAT TTGATCTTTC ACCACAGCAG 360 10 AAAGAGTGGC AGAGGATCCT GCAGCTGATT CAGAGTAGGC TACAAGAAGA GCATTCACTT 420 CAAGATGTGA TATTTAAAAG TGCTTTTAAA AGTACATCAA CAGCTCTTCC ACCAAGAGAA 480 GATGATTCAT CACAGTCTCC AAATCCATGC AGAATTCATG GCCATCTATA TGTCAATAAA 540 GTAGCAGGGA ATTTTCACAT AACAGTGGGC AAGGCAATTC CACATCCTCG TGGTCATGCA 600 CATTTGGCAG CACTTGTCAA CCATGAATCT TACAATTTTT CTCATAGAAT AGATCATTTG 660 15 TCTTTTGGAG AGCTTGTTCC AGCAATTATT AATCCTTTAG ATGGAACTGA AAAAATTGCT 720 ATAGATCACA ACCAGATGTT CCAATATTTT ATTACAGTTC TGCCAACAAA ACTACATACA 780 TATAAAATAT CAGCAGACAC CCATCAGTTT TCTGTGACAG AAAGGGAACG TATCATTAAC 840 CATGCTGCAG GCAGCCATGG AGTCTCTCGG ATATTTATGA AATATGATCT CAGTTCTCTT 900 ATGGTCACAG TTACTGAGGA GCACATGCCA TTCTGGCAGT TTTTTGTAAG ACTCTGTGGT 960 20 ATTGTTGGAG GAATCTTTTC AACAACAGGC ATGTTACATG GAATTGGAAA ATTTATAGTT 1020 GAAATAATTT GCTGTCGTTT CAGACTTGGA TCCTATAAAC CTGTCAATTC TCTTCCTTTT 1080 GAGGATGGCC ACACAGACAA CCACTTACCT CTTTTAGAAA ATAATACACA TTGA 25 SEQ ID NO:240 PCI4 Protein sequence: Protein Accession* NP_057654 1 11 21 31 41 51 ~ π I I I I I I OU MRRLNRKKTL SLVKELDAFP KVPESYVETS ASGGTVSLIA FTTMALLTIM EFSVYQDTWM 60 KYEYEVDKDF SSKLRINIDI TVAMKCQYVG ADVLDLAETM VASADGLVYE PTVFDLSPQQ 120 KEWQRMLQLI QSRLQEEHSL QDVIFKSAFK STSTALPPRE DDSSQSPNAC RIHGHLYVNK 180 VAGNFHITVG KAIPHPRGHA HLAALVNHES YNFSHRIDHL SFGELVPAII NPLDGTEKIA 240 IDHNQMFQYF ITWPTKLHT YKISADTHQF SVTERERIIN HAAGSHGVSG IFMKYDLSSL 300 35 MVTVTEEHMP FWQFFVRLCG IVGGIFSTTG MLHGIGKFIV EIICCRFRLG SYKFVNSVPF 360 EDGHTDNHLP LLENNTH SEQ ID N0.241 PBA7 DNA SEQUENCE Nucleic Acid Accession* AA219134 40 Coding sequence: 24-1815 (underlined sequences correspond to start and stop codons) AATTCGCCCT TGCTTAATTA AGCATQTTTA CCTTCCTGTC ATCTGTCACT GCTGCTGTCA 60 GTGGCCTCCTGGTGGGTTATGAACTTGGGA TCATCTCTGG GGCTCTTCTTCAGATCAAAA 120 45 CCTTATTAGCCCTGAGCTGCCATGAGCAGGAAATGGTTGTGAGCTCCCTCGTCATTGGAG 180 CCCTCCTTGC CTCACTCACC GGAGGGGTCC TGATAGACAG ATATGGAAGA AGGACAGCAA 240 TCATCTTGTC ATCCTGCCTG CTTGGACTCG GAAGCTTAGT CTTGATCCTC AGTTTATCCT 300 ACACGGTTCT TATAGTGGGA CGCATTGCCA TAGGGGTTTC CATCTCCCTC TCTTCCATTG 360 CCACTTGTGTTTACATCGCAGAGATTGCTCCTCAACACAG AAGAGGCCTTCTTGTGTCAC 420 50 TGAATGAGCTGATGATTGTCATCGGCATTCTTTCTGCCTATATTTCAAATTACGCATTTG 480 CCAATGTTTT CCATGGCTGG AAGTACATGT TTGGTCTTGT GATTCCCTTG GGAGTTTTGC 540 AAGCAATTGC AATGTATTTT CTTCCTCCAA GCCCTCGGTT TCTGGTGATG AAAGGACAAG 600 AGGGAGCTGC TAGCAAGGTT CTTGGAAGGT TAAGAGCACT CTCAGATACA ACTGAGGAAC 660 TCACTGTGAT CAAATCCTCC CTGAAAGATG AATATCAGTA CAGTTTTTGG GATCTGTTTC 720 55 GTΓCAAAAGA CAACATGCGG ACCCGAATAA TGATAGGACTAACACTAGTA TTTTTTGTAC 780 AAATCACTGG CCAACCAAAC ATATTGTTCT ATGCATCAAC TGTTTTGAAG TCAGTTGGAT 840 TTCAAAGCAA TGAGGCAGCT AGCCTCGCCT CCACTGGGGT TGGAGTCGTC AAGGTCATTA 900 GCACCATCCC TGCCACTCTT CTTGTAGACC ATGTCGGCAG CAAAACATTC CTCTGCATTG 960 GCTCCTCTGTGATGGCAGCTTCGTTGGTGACCATGGGCATCGTAAATCTCAACATCCACA 1020 60 TGAACTTCAC CCATATCTGC AGAAGCCACA ATTCTATCAACCAGTCCTTGGATGAGTCTG 1080 TGATTTATGG ACCAGGAAAC CTGTCAACCA ACAACAATAC TCTCAGAGAC CACTTCAAAG 1140 GGATTTCTTC CCATAGCAGA AGCTCACTCA TGCCCCTGAG AAATGATGTG GATAAGAGAG 1200 GGGAGACGAC CTCAGCATCC TTGCTAAATG CTGGATTAAG CCACACTGAA TACCAGATAG 1260 TCACAGACCC TGGGGACGTCCCAGCTTTTTTGAAATGGCTGTCCTTAGCCAGCTTGCTTG 1320 65 TTTATGTTGC TGCTTTTTCAATTGGTCTAG GACCAATGCC CTGGCTGGTG CTCAGCGAGA 1380 TCTTTCCTGG TGGGATCAGA GGACGAGCCA TGGCTTTAAC TTCTAGCATG AACTGGGGCA 1440 TCAATCTCCT CATCTCGCTG ACATTTTTGA CTGTAACTGA TCTTATTGGC CTGCCATGGG 1500 TGTGCTTTAT ATATACAATC ATGAGTCTAG ATCTTATTGG CCTGCCATGG GTGTGCTTTA 1560 TATATACAATCATGAGTCTAGCATCCCTGCTTTTTGTTGTTATGTTTATA CCTGAGACAA 1620 70 AGGGATGCTC TTTGGAACAA ATATCAATGG AGCTAGCAAA AGTGAACTAT GTGAAAAACA 1680 ACATTTGTTT TATGAGTCAT CACCAAGAAG AATTAGTGCC AAAACAGCCT CAAAAAAGAA 1740 AACCCCAGGA GCAGCTCTTG GAGTGTAACA AGCTGTGTGG TAGGGGCCAA TCCAGGCAGC 1800 TTTCTCCAGA GACCJAATGG CCTCAACACC TTCTGAACGT GGATAGTGCC AGAACACTTA 1860 GGAGGGTGTCTTTGGACCAATGCATAGTTG CGACTCCTGTGCTCTCTTTTCAGTGTCATG 1920 75 GAACTGGTTTTGAAGAGACA CTCTGAAATG ATAAAGACAG CCTTTAATCCCCCTCCTCMC 1980 CAGAAGGAAC CTCAAAAGGT AGATGAGGTA CAAGGTCCTA AGTGATCTCT TTTTCTGAGC 2040 AGGATATCAG GTTAAAAAAA AAAAGTTACT GGCTGGTTTA ATACTTTCTA CCTTCTTCAC 2100 AGAGCAGCCT TTGAATAGAC TATGTCCTAG TGAAGACATC AACCTCCGCC TTAAGCTATG 2160 TATGTATGGAGGCCAGTCGC AGCTTTATTATGCAGACACA CAAGTGGTCTGGACATGAGG 2220 80 GTACAGTTTC TGCCTACCAA GACACTACTT GCACTGGATC TTACGCAAAA AAGAACCAGA 2280 ACACACAGTG TGGACAACTG CCCATATATT CTATCTAGAT TAGGAGAGGG TCCTGGCTAG 2340 GATTTTAGTG GTAATTCCTA GTTACATTCA ACAAGTATAA AGATTATAGA GCTTATTTTA 2400 TGAACTATAA ACTATAATTT AATGCAAAAT ATCCTTTTAT GAATTTCATG TTAATATTGT 2460 GAAATATTAA AATAATTCCR CAATAGTTGA GAAAAATGAG CATTTTTTTC CATTTTTAAA 2520 AAATGCATAG AAAAGACAAT TTTAAAATCC TGGGACCATA TTTATTTAGA AGTAGCTGTT 2580 AGTAAAACAT TAGAAAAGGA GTCAGGCCAT TAGGTTATTT ATCCAAATCT CTAAGCAATT 2640 AGGTTGAAGT TATTAAGTCA AGCCTAGAAA AGCTGCCTCC TTGTAAGGCT TTCATGACAA 2700 TGTATAGTAA TCCACAGTGT CCAATTCTTC ACACTCCTCA GGAATATCAC TACCTCAGGT 2760 TACGGTACAC AGGCTATAAT TGATGATGAT GTTCAGATAA CTGAAGACAC AATAAATGAC 2820 10 ATTCAGACAT CAGGAMAAWW CCCTCATGTT CTTTTCTATG ATGGCCACCT GTACCAGCAA 2880 CGTGGGTTTC ACCCACACAA CGATGAACTG TTCTCTTACT TCTCCAGTTG ATTTTAAAGA 2940 CTTGTTAAGA GGTCTTACTA ATAAAATTTG GGTATGATAG AAAAWCCACA ATCAAAWCTT 3000 GAACCAAATA ACATATTAAA TTACTAATAT TTAAGTGATG GAAGACACAC AAAAAACTTA 3060 AAAGCACGAA CAACCTAACT TGAAAAAGAA TTTTAAAATA TGATTAACCT GAAGAAAAGA 3120 15 GAATCCTAAG AGCCAAAGCT CCTTTTTATT TAGCTTGGAA TTTTCCTATT GGTTCCTAAC 3180 AAACTGTCCC AATGTCATAT AAGGAAACAT GATCTATTAC ATTCCTTTAT AACAATGTGG 3240 AGAGACTATA AACCTATGTA AGTAGTAAAA CTATATYAGA GACTCAGGAG ACTGACTAAA 3300 AGGCCTGGAT CTGCAGTGTA TTATCTGTAT AAAAATTGGC AGGGGGAAGC TAAAAGGAAA 3360 GGAGATTGGA GATCTCAATT CTATCATGGT GTATTTCATA CGCAAATCAG AGCATGCATT 3420 20 GTTTTTTGTT TTTGGAAAGA GAAGGGAAGT GTGTTCTGCC CCATGTTTCC TTCCGTGTTT 3480 ATAGTTCAAA CTCTATATAT ACTTCAGGTA TTTTTTGTTT AGCCCTTCAT TATAAATGGG 3540 CAGGAAATTG TTTATCAACC TAGCCAGTTT ATTACTAGTG ACCTTGACTT CAGTATCTTG 3600 AGCATTCTTT TATATTTTTC TTTTATTATC CTGAGTCTGT AACTAAACAA TTTTGTCTTC 3660 AAATTTTTAT CCAATATCCA TTGCACCACA CCAAATCAAG CTTCTTGATT TTCAAAAATA 3720 25 AAAAGGGGGA AATACTTACA ACTTGTACAT ATATATTCAC AGTTTTTATT TATAAAAAAA 3780 ATTTACAGTA CTTATGGAGA GCCAGCAGAA GACATCAGAG CACTCACTTC TTCCCATCTT 3840 TGTTAAGGTT AGCGAATTAC CCATGGACAC TGTTAGGTGA GGCTCATTCG GCAGCCCTGA 3900 AAACAAACCT GGTCACACTG TCTTTACCCT CTCCCTTCAG ATAAAGCACT TCGATTATCT 3960 ATTGATCTGC CCAGTTTTCA AGTCATGCGA ATACTAAAAA GGTTACATCA TCTGGATCTG 4020 30 TACCTTGGCT ATATAAGCAT GTTTTCCCCC TATTCTATGT TTCTTTTTTT GGTGAACATT 4080 GAAAAACAGG AGGTGACTTA TTACTGTTAA TTAAAACTAA ATGAAAAATG TCAAGTCTTT 4140 AAAACAGTGA GCTTGTAACT CTTTCATGTA ATTTTATTCT CTATGAATTT GGCTATCCTA 4200 CTGAATCTTA AAATAAAGGA AATAAACACT TTTTTTTWAA AAAAAAGGAA AAATAMAARW 4260 MWAAAAATCT CAATGAAATA TTTCACAAGA AGGAAAAA 35 SEQ ID NO:242 PBA7 Protein sequence: Protein Accession * AAF91431 40 MFTFLSSVTA AVSGLLVGYE LGIISGALLQ IKTLLALSCH EQEMWSSLV IGALLASLTG 60 GVLIDRYGRR TAIILSSCLL GLGSLVLILS LSYTVLIVGR IAIGVSISLS SIATCVYIAE 120 IAPQHRRGLL VSLNELMIVI GILSAYISNY AFANVFHGWK YMFGLVIPLG VLQAIAMYFL 180 PPSPRFLVMK GQEGAASKVL GRLRALSDTT EELTVIKSSL KDEYQYSFWD LFRSKDNMRT 240 RIMIGLTLVF FVQITGQPNI LFYASTVLKS VGFQSNEAAS LASTGVGWK VTSTIPATLL 300 45 VDHVGSKTFL CIGSSVMAAS LVTMGIVNLN IHMNFTHICR SHNSINQSLD ESVIYGPGNL 360 STNNNTLRDH FKGISSHSRS SLMPLRNDVD KRGETTSASL LNAGLSHTEY QIVTDPGDVP 420 AFLKWLSLAS LLVYVAAFSI GLGPMPWLVL SEIFPGGIRG RAMALTSSMN WGINIXISLT 480 FLTVTDUGLPWVCFIYTIM SU3LIGLPWV CIT riMSIA SLLFVVMFIPETKGCSLEQI 540 SMELAKVNYV KNNICFMSHH QEELVPKQPQ KRKPQEQLLE CNKLCGRGQS RQLSPET 50 SEQ ID NO:243 PAB4 DNA sequence: Nucleic Acid Accession*: AA172056 Coding sequence: 121-339 (underlined sequences correspond to start and stop codons) 55 TTTAGCCACC AGAGGANTTC TCTTGAAATA CCCAAAATCC ATCAGTATCT TGAATCATGC 60 TGGATTTTG A AGAATTCTTA AGAAGCCATG TAAAGGGGGC TCTCTGGCCT TGAAATAGTG 120 sr, fi'ITTTTTA TACAGAAAGG AGAATGCAGA ATGGTCAGAC TATCATGCAC TGTTAAATTT 180 60 GATTTCAAGA AATTACAGGA AAACTTTCCA AAGTTCCATC TCACAGAA m TTATTTTNCC 240 AAGAATTCCA AGATAAGTTT AGTTTTATGG AAGACTTTTA TGTGGTTTTT ACTCACTCTT 300 CATCTCAGAC ATCGACAGAT GATTACATCA CTTATAGTTC TAGTAAATTT ATTAATATAA 360 AACTCAGAGA CATTCCAATA TCCACATTGC TTACACCATT AGGCATAGAT TCAGTGTCAG 420 CTATGACAAT TGAAAATGAG CTGTTrTGTG ATTTAAAGGTTTAAATTTCTCTAACCAAAC 480 65 TGCTTGATCC AGATGCAGGA CTGCAAATGTTAATATTTGT TCTGGAAGAA CAATCAAATA 540 AGACTTAAGA GGAAAGGGAA TGGCCACAAT CCACCTGAAA TTTTTTCTTA AAAAGTGTGC 600 AGCCTACTAA ATCAGAATGA AAATAGAAGT ACAAGATTAT AAACAAAATG CAATCAAACT 660 TTTCTTAAGC TTACCTAAAG TTATTTCATC TGAAAATTTC AAGCAACTTT GTTCAACATT 720 AAATTGACAA TCTAAACTAA CAAGTCTTTT GAATTTATGC ATGGTAGTAA ACATTCTCTC 780 70 TATΓAACTTΓ ATTACCTAAG GCTAAACCTA AAATTTTTAA GCAAAATTAG AAAAATAGTC 840 TTCACTCATC AAAAAATAAA GTTTGTTACA TTTAGTATTT TCCCAATAAA ATTGGTCGTT 900 CrrGGTTTTτ TATTTGGAGA GTCTGTGCAA AATGTCACTA AAAATAAATΓ AGCACΓAGAA 960 ATTATTTCTA AATACCAAA 75 SEQ ID N0.2 PBQ8 DNA SEQUENCE Nucleic Acid Accession*: X51405 Coding sequence: 3-1721 (underlined sequence corresponds to start and stop codon) 11 21 31 41 51 AAATGGCGTC CCCGTCTCTC CGCCGGCCCC CTGCCTCGCA GTCGTTTCTC CTGCAGCTCC 60 CCTGGGCTCC GCGGCCAGTA GTGCAGCCCG TGGAGCCGCG GCTTTGCCCG TCTCCTCTGG 120 GTGGCCCCAG TGCGCGGGCT GACACTCATT CAGCCGGGGA AGGTCAGGCG AGTAGAGGCT 180 GGTCCGGAAC TTGCCGCCCC CAGCAGCGGC GGCGGGCTAA GCCCAGGGCC GGGCAGACAA 240 AAGAGGCCGC CCGCGTAGGA AGGCACGGCC GGCGGCGGCG GAGCGCAGCG ATCGCCGGGC 300 GAGGGGGCAG CGCGCTCCTG GCTCTGTGCG GGGCACTCGC TGCCTGCGGG TCGCTCCTCG 360 GCGCCGAAGC CCAGGAGCCC GGGGCGCCCG CGGCGGGCAT GAGGCGGCGC CGGCGGCTGC 420 AGCAAGAGGA CGGCATCTCC TTCGAGTACC ACCGCTACCC CGAGCTGCGC GAGGCGCTCG 480 TGTCCGTGTC GCTCCAGTGC ACCGCCATCA GCAGGATTTA CACGGTCGGG CGCAGCTTCG 540 AGGGCCGGGA GCTCCTCGTC ATCGAGCTGT CCGACAACCC TCGCGTCCAT GAGCCTGGTG 600 AGCCTCAATT TAAATACATT GGGAATATGC ATGGGAATGA GGCTGTTGGA CGAGAACTCC 660 TCATTTTCTT GGCCCAGTAC CTATGCAACG AATACCAGAA GGGGAACGAG ACAATTGTCA 720 ACCTGATCCA CAGTACCCGC ATTCACATCA TGCCTTCCCT GAACCCAGAT GGCTTTGAGA 780 AGGCAGCGTC TCAGCCTGGT GAACTCAAGG ACTGGTTTGT GGGTCGAAGC AATGCCCAGG 840 GAATAGATCT GAACCGGAAC TTTCCAGACC TCGATAGGAT AGTGTACGTG AATGAGAAAG 900 AAGGTCGTCC AAATAATCAT CTCTTGAAAA ATATGAAGAA AATTGTCGAT CAAAACACAA 960 AGCTTGCTCC TCAGACCAAG GCTGTCATTC ATTCGATTAT GGATATTCCT TTTGTGCTTT 1020 CTGCCAATCT CCATGGAGGA GACCTTCTGG CCAATTATCC ATATGATCAG ACGCGGAGTG 1080 GTAGTCCTCA CGAATACAGC TCCTCCCCAG ATCACGCCAT TTTCCAAAGC TTGGCCCGGG 1140 CATACTCTTC TTTCAACCCG GCCATGTCTG ACCCCAATCG GCCACCATGT CGCAAGAATG 1200 ATGATGACAG CAGCTTTGTA GATCGAACCA CCAACGGTCG TGCTTGGTAC AGCGTACCTC 1260 GAGGGATGCA AGACTTCAAT TACCTTAGCA GCAACTGTTT TGAGATCACC GTGGAGCTTA 1320 GCTGTCAGAA GTTCCCACCT GAAGAGACTC TGAAGACCTA CTGGGAGGAT AACAAAAACT 1380 CCCTCATTAG CTACCTTGAG CAGATACACC GAGGAGTTAA AGGATTTGTC CGAGACCTTC 1440 AAGGTAACCC AATTGCGAAT GCCACCATCT CCGTGGAAGG AATAGACCAC GATGTTACAT 1500 CCGCAAAGGA TGGTGATTAC TGGAGATTGC TTATACCTGG AAACTATAAA CTTACAGCCT 1560 CAGCTCCAGG CTATCTGGCA ATAACAAAGA AAGTGGCAGT TCCTTACAGC CCTGCTCCTG 1620 GGGTTGATTT TCAACTGGAG TCATTTTCTG AAAGGAAAGA AGAGGAGAAG GAAGAATTGA 1680 TGGAATGGTG GAAAATGATC TCAGAAACTT TAAATTTTTA AAAAGGCTTC TAGTTAGCTG 1740 CTTTAAATCT ATCTATATAA TCTAGTATCA TCTAATGTGG TCTTTTTTTT AGATTTTGTC 1800 CAGTTAATAC TTAACATTGA TTTATTTTTT AATCATTTAA ATATTAATCA ACTTTCCTTA 1860 AAATAAATAG CCTCTTAGGT AAAAATATAA GAACTTGATA TATTTCATTC TCTTATATAG 1920 TATTCATTTT CCTACCTATA TTACACAAAA AAGTATAGAA AAGATTTAAG TAATTTTGCC 1980 ATCCTAGGCT TAAATGCAAT ATTCCTCGTA TTATTTACAA TGCAGAATTT TTTGAGTAAT 2040 TCTAGCTTTC AAAAATTAGT GAAGTTCTTT TACTGTAATT GGTGACAATG TCACATAATC 2100 AATGCTATTG AAAAGGTTAA CAGATACAGC TCGGAGTTGT GAGCACTCTA CTGCAAGACT 2160 TAAATAGTTC AGTATAAATT GTCGTTTTTT TCTTGTGCTG ACTAACTATA AGCATGATCT 2220 TGTTAATCCA TTTTTCATGG GAAGAAAAGG TACATGTTTA CAAAGAGGTT TTATGAAAAG 2280 AATAAAAATT GACTTCTTGC TTGTACATAT AGGAGCAATA CTATTATATT ATGTAGTCCG 2340 TTAACACTAC TTAAAAGTTT AGGGTTTTCT CTTGGTTGTA GAGTGGCCCA GAATTGCATT 2400 CTGAATGAAT AAAGGTTAAA AAAAAATCCC CAGTGAAAAA AAA SEQ ID NO:245 PBQ8 Protein sequence Protein Accession*: P16870 MAGRGGSALL ALCGALAACG WLLGAEAQEP GAPAAGMRRR RRLQQEDGIS FEYHRYPELR 60 EALVSVWLQC TAISRIYTVG RSFEGRELLV IELSDNPGVH EPGEPEFKYI GNMHGNEAVG 120 RELLIFLAQY LCNEYQKGNE TIVNLIHSTR IHIMPSLNPD GFEKAASQPG ELKDWFVGRS 180 NAQGIDLNRN FPDLDRIVYV NEKEGGPNNH LLKNMKKIVD QNTKLAPETK AVIHWIMDIP 240 FVLSANLHGG DLVANYPYDE TRSGS AHEYS SSPDDAIFQS LARAYSSFNP AMSDPNRPPC 300 RKNDDDSSFV DGTTNGGAWY SVPGGMQDFN YLSSNCFEIT VELSCEKFPP EETLKTYWED 360 NKNSD5YLE QIHRGVKGFV RDLQGNPIAN ATISVEGIDH DVTSAKDGDY WRLLIPGNYK 420 LTASAPGYLA ITKKVAVPYS PAAGVDFELE SFSERKEEEK EELMEWWKMM SETLNF SEQ ID NO:246 PBY4 DNA sequence Nucleic Acid Accession*: AF038966 Coding sequence: 91-1107 (underlined sequence corresponds to start and stop codon) 11 21 31 41 51 GGGGCGACGT GAGCGCGCAG GGGGGCGGCG GCCTCGCCTC GTCTCTCTCT CTCCGCCTGG 60 GTCGGGTGGG TGACGCCGAG AGCCAGAGAG ATGTCGGATT TCGACAGTAA CCCGTTTGCC 120 GACCCGGATC TCAACAATCC CTTCAAGGAT CCATCAGTTA CACAAGTCAC AAGAAATGTT 180 CCACCAGGAC TTGATGAATA TAATCCATTC TCGGATTCTA GAACACCTCC ACCAGGCGGT 240 GTCAAGATGC CTAATGTACC CAATACACAA CCAGCAATAA TCAAACCAAC AGAGGAACAT 300 CCAGCTTATA CACAGATTGC AAAGGAACAT GCATTGGCCC AAGCTGAACT TCTTAAGCGC 360 CAAGAAGAAC TAGAAAGAAA AGCCGCAGAA TTAGATCGTC GGGAACGAGA AATGCAAAAC 420 CTCAGTCAAC ATCGTAGAAA AAATATTTGG CCACCTCTTC CTAGCAATTT TCCTGTCGGA 480 CCTTCTTTCT ATCAGGAATT TTCTGTAGAC ATTCCTGTAG AATTCCAAAA GACAGTAAAG 540 CTTATGTACT ACTTGTGGAT GTTCCATGCA GTAACACTGT TTCTAAATAT CTTCGGATGC 600 TTGGCTTGGT TTTGTGTTGA TTCTGCAAGA GCGGTTGATT TTGGATTGAG TATCCTCTGG 660 TTCTTGCTTT TTACTCCTTG TTCATTTGTC TGTTGGTACA GACCACTTTA TGGAGCTTTC 720 AGGAGTGACA GTTCATTTAG ATTCTTTGTA TTCTTCTTCG TCTATATTTC TCAGTTTGCT 780 GTACATGTAC TCCAAGCTGC AGGATTTCAT AACTGGGGCA ATTCTGGTTG GATTTCATCC 840 CTTACTGGTC TCAACCAAAA TATTCCTGTT GGAATCATGA TGATAATCAT AGCAGCACTT 900 TTCACAGCAT CAGCAGTCAT CTCACTAGTT ATGTTCAAAA AAGTACATGβ ACTATATCGC 960 ACAACAGGTC CTAGTTTTCA GAAGGCCCAA CAGGAGTTTG CAACAGGTGT GATGTCCAAC 1020 AAAACTGTCC AGACCGCAGC TGCAAATGCA GCTTCAACTG CAGCATCTAG TGCAGCTCAG 1080 AATGCTTTCA AGGGTAACCA GATTTAAGAA TCTTCAAACA ATACACTGTT ACCTTTTGAC 1140 TGTACCTTTT TCTCCAGTTA CTGTATTCTA CAAATATTTT TATGTTCAAA ACACACAGTA 1200 CAGACAGCAT GGATATTTCC TGTTCACTTG TGCATGGGCT AAAACCAGGA AAACTTCCTT 1260 GTCTTATTAC TTTACCTAAT AGTTTCTTAA TATTTCAGTG CCCCTTGCAG AAAAAATATT 13 0 ACATGCTAAA TAAATATTCT CCATATΪTTT GGGGGATGAC ATTCAGTGAA TTATTTCAGT 1380 GGTGACCCAC TGAAAATTAA TAATGGTACT TATGATTAAA AACGCATTTA ATACTAACTG 1440 CAGTAGTTCT TTCAAGAATC TTTAGAGATA AGGATTGCAC ATTGGAAAAG TAAACCATGT 1500 TTCATTCCTT TTTCCCTATT TATATTGAAA GAAATAGGCC AGCAGAGACT TAGGGATTTT 1560 AAATTGGCTT GCTTTTTAGC TGTTTCAGTC ACCAGTGAAG AGCCTATGTG CATTTTGTAG 1620 10 TAGATAATGT AAAATTTGTC ATCTTTTTCT TTTCTTTTTT TTAGAATAGC TGATATTTTG 1680 ATAACAATCT CTAATTTGCA TGGGCACCAC ATTTCTTATA TTAAAAGAAT TAGTGTTTTG 1740 GCTTCTGTAC TGCTTATGGT TGTAGGATTC AGGGGTTAAT GGAATCACAG AAATGATATT 1800 CTGCAAGAAT TTCTTTTAAA TAAAAAGTTT GGGGGTGCAA TATAAGAAGT TTATATAATA 1860 TGCAGTACAT TATCCAAAAG AGAAGGTAGT TAATGCAGTA GAAAGTAGTG GTAATAATTC 1920 15 CTTTTT SEQ ID NO: 247 PBY4 Protein sequence: _ „ Protein Accession #: 20 MSDFDSNPFA DPDLNNPFKD PS VTQVTRNV PPGLDEYNPF SDSRTPPPGG VKMPNVPNTQ 60 PAIMKPTEEH PAYTQIAKEH ALAQAELLKR QEELERKAAE LDRREREMQN LSQHGRKNIW 120 PPLPSNFPVG PCFYQEFS VD IPVEFQKT VK LMYYLWMFHA VTLFLNIFGC LAWFCVDS AR 180 AVDFGLSILW FLLFTPCSFV CWYRPLYGAF RSDSSFRFFV FFFVYICQFA VHVLQAAGFH 240 25 NWGNCGWISS LTGLNQNIPV GIMMIIIAAL FTASAVISLV MFKKVHGLYR TTGASFEKAQ 300 QEFATGVMSN KTVQTAAANA ASTAASSAAQ NAFKGNQI SEQ ID NO:248 PBH2 DNA sequence 30 Nucleic Acid Accession*: none found Coding sequence: 1-613 (underlined sequence corresponds to start and stop codon) ATGAGAGACA ATAAATCGTG TGCTTTTTTC ATGGGAAAGT TAAATGTTTG TTTTGAAGGC 60 35 ACAGTAATAG CAGGCTATTC AGTGTTTGCC ACTACCTGCA TCATTCATCT GGCTGTAGCT 120 AGTGCACTAC AATTTCCTAA AAAGTCTTCT CACCCTCACA GGACTGCTCT ACATCTGGCC 180 TCTGCCAATG GAAATTCAGA AGTAGTAAAA CTCCTGCTGG ACAGACGATG TCAACTTAAT 240 ATCCTTGACA ACAAAAAGAG GACAGCTCTG ACAAAGGCCG TACAATGCCA GGAAGATGAA 300 TGTGCGTTAA TGTTGCTGGA ACATGGCACT GATCCGAATA TTCCAGATGA GTATGGAAAT 360 0 ACCGCTCTAC ACTATGCTAT CTACAATGAA GATAAATTAA TGGCCAAAGC ACTGCTCTTA 420 TACGGTGCTG ATATCGAATC AAAAAACAAG CATGGCCTCA CACCACTGTT ACTTGGTGTA 480 CATGAGCAAA AACAGCAAGT GGTGAAATTT TTAATCAAGA AAAAAGCAAA TTTAAATGCA 540 CTGGATAGAT ATGGAAGGTG TGTGACCTTG GGAACGTTAT TTACCACCAA ATATGTTGTC 600 ATATATGAAA AGTAG 5 SEQ ID NO:249 PBH2 Protein sequence: Protein Accession #: none found 50 MRDNKSCAFF MGKLNVCFEG TVIAGYSVFA TTCIIHLAVA SALQFPKKSS HPHRTALHLA 60 SANGNSEVVK LLLDRRCQLN ELDNKKRTAL TKAVQCQEDE CALMLLEHGT DPNIPDEYGN 120 TALHYAIYNE DKLMAKALLL YGADIESKNK HGLTPLLLGV HEQKQQVVKF LIKKKANLNA 180 LDRYGRCVTL GTLFTTKYVV IYEK 55 SEQ ID NO:250 PBJ1 DNA sequence Nucleic Add Accession* X _005829 Coding sequence: 1 -3043 (underlined sequence corresponds to start and stop codon) 60 ATGGTGATCA TCTATCTTTC TTTCTGCAAT TATTACATGG AGTTCTACAG AGAAGAGCTT 60 CCCCACATTG ACTATTTGAT TGACATTCAG TTTGCAACAG GAAAGGTTAC TCAGCCGGGA 120 GAGGACACTT CCTACCATCA ATGCGCTCAG CTTGAAGCCA GAGACGAAGG CACCGACAGT 180 TTATTATTAA ACAATGGCAG CAGCGCCACG CTGAAGACAC GAACGCGCTG TTATGGAACC 240 CCCAGAGGTC TCCCCCATCG TAGCCTGCTC CAGCCGACTC CGCCCACATG TAAAACGAAG 300 65 ATCAGGAGCA GATTTGAAGA ATTACAAAGT GAATTGGTGC CAGTCAGCAT GTCAGAGACA 360 GACCACATAG CCTCTACTTC CTCTGATAAA AATGTTGGGA AAACACCTGA ATTAAAGGAA 420 GACTCATGCA ACTTGTTTTC TGGCAATGAA AGCAGCAAAT TAGAAAATGA GTCCAAACTA 480 TTGTCATTAA ACACTGATAA AACTTTATGT CAACCTAATG AGCATAATAA TCGAATTGAA 540 GCCCAGGAAA ATTATATTCC AGATCATGGT GGAGGTGAGG ATTCTTGTGC CAAAACAGAC 600 0 ACAGGCTCAG AAAATTCTGA ACAAATAGCT AATTTTCCTA GTGGAAATTT TGCTAAACAT 660 ATTTCAAAAA CAAATGAAAC AGAACAGAAA GTAACACAAA TATTGGTGGA ATTAAGGTCA 720 TCTACATTTC CAGAATCAGC TAATGAAAAG ACTTATTCAG AAAGCCCCTA TGATACAGAG 780 TGCACCAAGA AATTTATTTC AAAAATAAAG AGCGTTTCAG CATCAGAGGA TTTGTTGGAA 840 GAAATAGA AT CTGAGCTCTT ATCTACGGAG TTTGCAGAAC ATCGAGTACC AAATGGAATG 900 75 AATAAGGGAG AACATGCATT AGTTCTGTTT GAAAAGTGTG TGCAAGATAA ATATTTGCAG 960 CAGGAACATA TCATAAAAAA GTTAATTAAA GAAAATAAGA AGCATCAGGA GCTCTTCGTA 1020 GACATTTGTT CAGAAAAAGA CAATTTAAGA GAAGAACTAA AGAAAAGAAC AGAAACTGAG 1080 AAGCAGCATA TGAACACAAT TAAACAGTTA GAATCAAGAA TAGAAGAACT TAATAAAGAA 1140 GTTAAAGCTT CCAGAGATCA ACTAATAGCT CAAGACGTTA CAGCTAAAAA TGCAGTTCAG 1200 CAGTTACACA AAGAGATGGC CCAACGGATG GAACAGGCCA ACAAGAAATG TGAAGAGGCA 1260 CGCCAAGAAA AAGAAGCAAT GGTAATGAAA TATGTAAGAG GTGAGAAGGA ATCTTTAGAT 1320 CTTCGAAAGG AAAAAGAGAC ACTTGAGAAA AAACTTAGAG ATGCAAATAA GGAACTTGAG 1380 AAAAACACTA ACAAAATTAA GCAGCTTTCTCAGGAGAAAGGACGGTTGCA CCAGCTGTAT 1440 GAAACTAAGG AAGGCGAAAC GACTAGACTC ATCAGAGAAA TAGACAAATT AAAGGAAGAC 1500 ATTAACTCTC ACGTCATCAA AGTAAAGTGG GCACAAAACA AATTAAAAGC TGAAATGGAT 1560 TCACACAAGG AAACCAAAGA TAAACTCAAA GAAACAACAA CAAAATTAAC ACAAGCAAAG 1620 GAAGAAGCAG ATCAGATACG AAAAAACTGT CAGGATATGA TAAAAACATA TCAGGAGTCA 1680 GAAGAAATTA AATCAAATGAGCTTGATGCA AAGCTTAGAGTCACAAAAGG AGAACTTGAA 1740 AAACAAATGC AAGAAAAATCTGACCAGCTA GAGATGCATC ATGCCAAAATAAAGGAACTA 1800 GAAGATCTGA AGAGAACATT TAAGGAGGGT ATGGATGAGT TAAGAACACT GAGAACAAAG 1860 GTGAAATGTC TAGAAGATGA ACGATTAAGA ACAGAAGATG AATTATCAAA ATATAAGGAA 1920 ATTATTAATC GCCAAAAAGC TGAAATTCAG AATTTATTGG ACAAGGTGAA AACTGCAGAT 1980 CAGCTACAGG AGCAGCTTCA AAGAGGTAAG CAAGAAATTG AAAATTTGAA AGAAGAAGTG 2040 GAAAGTCTTA ATTCTTTGAT TAATGACCTA CAAAAAGACA TCGAAGGCAG TAGGAAAAGA 2100 GAATCTGAGC TGCTGCTGTT TACAGAAAGG CTCACTAGTA AGAATGCACA GCTTCAGTCT 2160 GAATCCAATT CTTTGCAGTC ACAATTTGAT AAAGTTTCCT GTAGTGAAAG TCAGTTACAA 2220 AGCCAGTGTG AACAAATGAA ACAGACAAAT ATTAATTTGG AAAGTAGGTT GTTGAAAGAG 2280 GAAGAACTGC GAAAAGAGGA AGTCCAAACT CTGCAAGCTG AACTCGCTTG TAGACAAACA 2340 GAAGTTAAAG CATTGAGTAC CCAGGTAGAA GAATTAAAAG ATGAGTTAGT AACTCAGAGA 2400 CGTAAACATG CCTCTAGTAT CAAGGATCTC ACCAAACAAC TTCAGCAAGC ACGAAGAAAA 2460 TTAGATCAGG TTGAGAGTGG AAGCTATGAC AAAGAAGTCA GCAGCATGGG AAGTCGTTCT 2520 AGTTCATCAG GGTCCCTGAA TGCTCGAAGC AGTGCAGAAG ATCGATCTCC AGAAAATACT 2580 GGGTCCTCAGTAGCTGTGGATAACTTTCCACAAGTAGATAAGGCCATGTTGATTGAGAGA 2640 ATAGTTAGGC TGCAAAAAGC ACATGCCCGG AAAAATGAAA AGATAGAATT TATGGAGGAC 2700 CACATCAAAC AACTGGTGGA AGAAATTAGG AAAAAAACAA AAATAATTCA AAGTTATATT 2760 TTACGAGAAG AATCAGGCAC ACTTTCTTCA GAGGCATCTG ATTTTAACAA AGTTCATTTA 2820 AGTAGACGGG GTGGCATCAT GGCATCTTTA TATACATCCC ATCCAGCTGA CAATGGATTA 2880 ACATTGGAGCTCTCTTTGGAAATCAACCGA AAATTACAGGCTGTTTTGGA GGATACGTTA 2940 CTAAAAAATA TTACTTTGAA GGAAAATCTA CAAACACTTG GAACAGAAAT AGAACGTCTT 3000 ATTAAACACC AGCATGAACT AGAACAGAGG AGAAAGAAAA CCTAAAACAA GCCTCTTGCT 3060 CAGTAAAGAG ACAAAAGCCA CACAGGAGTA GGTGCCACTG ACCTCTATTG TTGGAGACTT 3120 TGTTCCACTT TTTGTTTCAG CCAGTAAAAA TATTGTTTTG CTTCATCTGT ACACAAAAAA 3180 ATACCCTTTT ACAATATGAATGCATTGCTG TATATACTGTAAGACTGAAAGCTTTGATGA 3240 AATTTGTTTTTGTATGGTGCAATATGACAG CCTGTCATTGAATCTAAACA ACTTAATTTG 3300 CTTGTATTCA TAAGAAGTGT TGAACATTAC AAGGGCTTTT AT SEQ ID N0:251 PBJ1 Protein sequence: Protein Accession*: NP_060487 MVΠYLSFCN YYMEFYREEL PHIDYLIDIQ FATGKVTQPG EDTSYHQCAQ LEARDEGTDS 60 LLLNNGSSAT LKTRTRCYGT PRGLPHRSLL QPTPPTCKT IRSRFEELQS ELVPVSMSET 120 DHIASTSSDK^WGKTPEU EDSCN FSGNESSKl£NESKLI^L rroKTLCQPNEHNNRIE 180 AQENYIPDHG GGEDSCAKTDTGSENSEQIANFPSGNFAKHISKTNETEQKVTQILVELRS 240 STFPES ANEK TYSESPYDTD CTKKFISKIK S VS ASEDLLE EIESELLSTE FAEHRVPNGM 300 NKGEHALVLF EKCVQDKYLQ QEHIIKKLIK ENKKHQELFV DICSEKDNLR EELKKRTETE 360 KQHMNTIKQL ESRIEELNKE VKASRDQLIA QDVTAKNAVQ QLHKEMAQRM EQANKKCEEA 420 RQEKEAMVMKYVRGEKESLD U---E--ET--EK--LRDANKELEKNTNKIKQLS QEKGRLHQLY 480 ETKEGETTRLIRE©K-LKED INSHVIKVKW AQNKLKAEMDSHKETKDKI ETTTKLTQAK 540 EEADQKKNC QDMIKTYQES EEIKSNELDA KLRVTKGELE KQMQEKSDQL EMHHAKIKEL 600 EDLKRTFKEGMDELRTLRTKVKCLEDERLRTEDELSKYKEIINRQKAHQNLLDKVKTAD 660 QLQEQLQRGK QEIENLKEEV ESLNSLINDL QKDIEGSRKR ESELLLFTER LTSKNAQLQS 720 ESNSLQSQFDKVSCSESQLQSQCEQMKQTNINLESRLLKEEELRKEEVQTLQAELACRQT 780 EVKALSTQVEELKDELVTQRRKHASSIKDLTKQLQQARRKLDQVESGSYD EVSSMGSRS 840 SSSGSLNARS SAEDRSPENT GSSVAVDNFP QVDKAMI-IER IVRLQKAHAR KNEKIEFMED 900 HIKQLVEEK KKTKIIQSYI LREESGTLSS EASDFNKVHL SRRGGMASL YTSHPADNGL 960 TLELSLEINR KLQAVLEDTL LKNITLKENL QTLGTEIERL IKHQHELEQR TKKT SEQ ID NO:252 PBJ6 DNA sequence Nucleic Acid Accession*: D83760 Coding sequence: 56-1459 (underlined sequence corresponds to start and slop codon) 1 11 21 31 41 51 I I I I I I TTGCCGTCAA GGGCTGTCCG GTTCCCGTGC GCGCCGGAGC CTGCTCTGGC CTCTTATGCA 60 CTCCACCACC CCCATCAGCT CCCTCTTCTC CTTCACCAGC CCCGCAGTGA AGAGACTCCT 120 AGGCTGGAAG CAAGGAGATC AAGAGGAAAA GTGGGCAGAG AAGGCAGTGG ACTCTCTAGT 180 GAAGAAGTTA AAGAAGAAGA AGGGAGCCAT GGACGAGCTG GAGAGGGCTC TCAGCTGCCC 240 GGGGCAGCCC AGCAAATGCG TCACGATTCC CCGCTCCCTG GACGGGCGGC TGCAGGTGTC 300 CCACCGCAAG GGCCTCCCCC ATGTGATTTA CTGTCGCGTC TCGCGCTGGC CGGATCTGCA 3 60 GTCCCACCAC GAGCTGAAGC CGCTGGAGTG CTGTGAGTTC CCATTTGGCT CCAAGCAGAA 420 AGAAGTGTGC ATTAACCCTT ACCACTACCG CCGGGTGGAG ACTCCAGTAC TGCCTCCTGT 480 GCTCGTGCCA AGACACAGTG AATATAACCC CCAGCTCAGC CTCCTGGCCA AGTTCCGCAG 540 CGCCTCCCTG CACAGTCAGC CACTCATGCC ACACAACGCC ACCTATCCTG ACTCTTTCCA 600 GCAGCCTCCG TGCTCTGCAC TCCCTCCCTC ACCCAGCCAC GCGTTCTCCC AGTCCCCGTG 660 CACGGCCAGC TACCCTCACT CCCCAGGAAG TCCTTCTGAG CCAGAGAGTC CCTATCAACA 720 CTCAGTTGAC ACACCACCCC TGCCTTATCA TGCCACAGAA GCCTCTCAGA CCCAGAGTGG 780 CCAACCTGTA GATCCCACAG CTCATAGACA TGTAGTGCTA TCGATACCAA ATGGAGACTT 840 TCGACCAGTT TCTTACGAGG AGCCCCAGCA CTGGTGCTCG GTCGCCTACT ATGAACTCAA 900 CAACCGAGTT GGGGAGACAT TCCAGGCTTC CTCCCGAAGT GTGCTCATAG ATCGGTTCAC 960 CGACCCTTCA AATAACAGGA ACAGATTCTC TCTTGGACTT CTTTCTAATC TAAACAGAAA 1020 CTCAACGATA GAAAATACCA GGAGACATAT AGGAAAGGGT GTGCACTTCT ACTACGTCGG 1080 GGGAGAGGTC TATGCCGAGT GCGTCAGTCA CAGCAGCATC TTTGTCCAGA GCCGGAACTG 1140 CAACTATCAA CACGGCTTCC ACCCAGCTAC CGTCTGCAAG ATCCCCAGCG GCTGCAGCCT 1200 CAAGGTCTTC AACAACCAGC TCTTCGCTCA GCTCCTCGCC CAGTCAGTTC ACCACGGCTT 1260 TGAAGTCGTG TATGAACTGA CCAAGATGTβ TACTATCCGG ATGAGTTTTG TTAAGGGTTG 1320 GGGTGCTCAG TATCATCGCC AGGATGTCAC CAGCACCCCC TGCTGGATTG AGATTCATCT 1380 TCATGGGCCA CTGCAGTCGC TGGACAAAGT TCTGACTCAG ATGGGCTCTC CACATAACCC 1440 CATTTCTTCA GTCTCTTAAC AGTCATGTCT TAAGCTGCAT TTCCATAGGA T SEQ ID NO:253 PBJ6 Protein sequence: Protein Accession* NPJJ05896 MHSTTPISSL FSFTSPAVKR LLGWKQGDEE EKWAEKAVDS LVKKLKKKKG AMDELERALS 60 CPGQPSKCVT IPRSLDGRLQ VSHRKGLPHV IYCRVWRWPD LQSHHELKPL ECCEFPFGSK 120 QKEVCINPYH YRRVETPVLP PVLVPRHSEY NPQLSLLAKF RSASLHSEPL MPHNATYPDS 180 FQQPPCSALP PSPSHAFSQS PCTAS YPHSP GSPSEPESPY QHSVDTPPLP YHATEASETQ 240 SGQPVDATAD RHVVLSIPNG DFRPVCYEEP QHWCSVAYYE LNNRVGETFQ ASSRSVLIDG 300 FTDPSNNRNR FCLGLLSNVN RNSTIENTRR HIGKGVHLYY VGGEVYAECV SDSSBFVQSR 360 NCNYQHGFHP ATVCKIPSGC SLKVFNNQLF AQLLAQS VHH GFEWYELTK MCTIRMSFVK 420 GWGAEYHRQD VTSTPCWIEI HLHGPLQWLD KVLTQMGSPH NPISSVS SEQ ID NO:254 PBJ8 DNA sequence Nucleic Acid Accession*: AB04684 Coding sequence: 472-4377 (underlined sequence corresponds to start and stop codon) 11 21 31 41 51 TGCAGGTTTG CAGGGTCTCA GATTACTTGG GCTTTTCCTG CCTTTTTCTT TTGCTTAAGG 60 GATGGACAAG GAGCTGAGAT TTATGACCCT TATTAGAGAA AAAAATGTCC CTTGCTAGGG 120 TGGGGACACT TCGTTGATGC AGTCTCTCTC TCTCTTTCTC GGTGTTTATA ACAAAACAAA 180 ACCAAAATGA ACTGAGGGGT TTGTAATCGT AGTTTCTTTG TTGCTGGAGA ATGCTACTTT 240 GCATGCTTTT TTTCTCTTGC AGGGTATCTT CTGTCTTGTG CTTTTTCTTT TAGAAGCTAC 300 TAAAGGGTGT TGGGGATCCT TCTCACTATT ATCAAGGCCA AAAGGCCTGT TGACTGGGGC 360 TGCTTTTAAC CCTTTCCTAT TTGCTCAGAA TGCAGCCGTG TGACAGTAAC TGAACATTGG 420 TCTAAAGTCT TTCCAAAAGG TCAAGGTTCA CAAGAACATC TGCTCAAATT AATGACCATC 480 GGGGATATGA AGACCCCAGA CTTTGATGAC CTCCTGGCAG CATTTGACAT CCCAGATATG 540 GTCGATCCTA AAGCAGCTAT TGAGTCTGGA CACGATGACC ATGAAAGCCA CATCAAGCAG 600 AATGCTCACG GAGAGGATGA CTCCCACGCA CCATCATCTT CTGATGTGGG TGTCAGCGTT 660 ATCGTCAAGA ATGTTCGGAA CATTCACTCT TCCGAGGGCG GGGAGAAAGA CGGCCACAAC 720 CCCACTGGCA ATGGCTTACA TAATGGGTTT CTCACAGCAT CCTCCCTTCA CAGTTACAGT 780 AAAGATGGAG CAAAGTCCTT GAAAGGAGAT GTGCCTGCCT CTGAGGTGAC ACTCAAAGAC 840 TCGACATTCA GCCAGTTTAG CCCGATCTCC AGTGCTGAAG AGTTTGATCA CGACGAGAAG 900 ATTGAGGTGG ATGACCCCCC TCACAAGGAG GACATGCGAT CAAGCTTCAG GTCGAATGTG 960 TTGACGGGGT CGGCTCCCCA GCAGGACTAC GATAAGCTGA AGGCACTCGG AGGGGAAAAC 1020 TCCAGCAAAA CTGGACTCTC TACGTCAGGC AATCTGGAGA AAAACAAAGC TCTTAAGAGA 1080 GAAACAGAAG CCAGTTCTAT AAACCTGAGT GTTTATGAAC CTTTTAAAGT CAGAAAAGCA 1140 GAGGATAAAT TCAAGGAAAG CTCTCACAAG GTGCTGGAAA ACAGAGTCCT AGATGGGAAG 1200 CTGAGCTCCG AGAAGAATCA CACCAGCCTC CCCAGCGTTG CGCCATCAAA GACAAAGTCG 1260 TCCTCCAAGC TCTCGTCCTC CATCGCTGCC ATCGCGGCTC TCAGCGCTAA AAAGGCGGCT 1320 TCAGACTCCT GCAAAGAACC AGTGGCCAAT TCGAGGGAAT CCTCCCCGTT ACCAAAAGAA 1380 GTAAATGACA GTCCGAGAGC CGCTCACAAG TCTCCTCAAT CCCAGAATCT CATCGACGGG 1440 ACCAAAAAAC CATCCCTCAA GCAACCGGAT AGTCCCAGAA GCATCTCAAG TCAGAACAGC 1500 AGCAAAGGAT CCCCGTCCTC TCCCGCAGGG TCCACACCAG CAATCCCCAA AGTCCGCATA 1560 AAAACCATTA AGACATCTTC TGGGGAAATC AAGAGAACAG TGACCAGGGT ATTGCCAGAA 1620 GTGGATCTTO ACTCTGGAAA GAAACCTTCC GAGCAGACAG CGTCCGTGAT GGCCTCTCTC 1680 ACATCCCTTC TGTCGTCTCC AGCATCAGCC GCCGTCCTTT CCTCTCCCCC CAGGGCGCCT 1740 CTCCAGTCTG CGGTCGTGAC CAATGCAGTT TCCCCTGCAG AGCTCACCCC CAAACAGGTC 1800 ACAATCAAGC CTGTGGCTAC TGCTTTCCTC CCAGTGTCTG CTGTGAAGAC GGCAGGATCC 1860 CAAGTCATTA ATTTCAAGCT CGCTAACAAC ACCACGGTGA AAGCCACGGT CATATCTCCT 1920 GCCTCTGTCC AGAGTGCCAG CAGCGCCATC ATTAAAGCTG CCAACGCCAT CCAGCAGCAA 1980 ACTGTCGTGG TGCCGGCATC CAGCCTGGCC AATGCCAAAC TCGTGCCAAA GACTGTGCAC 2040 CTTGCCAACC TTAACCTTTT GCCTCAGGGT GCCCAGGCCA CCTCTGAACT CCGCCAAGTC 2100 CTAACCAAAC CTCAGCAACA AATAAAGCAG GCAATAATCA ATGCAGCAGC CTCGCAACCC 2160 CCCAAAAAGG TGTCTCGAGT CCAGGTGGTG TCGTCCTTCC AGAGTTCTGT GGTGGAAGCT 2220 TTCAACAAGG TGCTGAGCAG TGTCAATCCA GTCCCTGTTT ACATCCCAAA CCTCAGTCCT 2280 CCCGCCAATG CAGGGATCAC GTTACCGACG CGTGGGTACA AGTGCTTGGA GTCTGGGGAC 2340 TCCTTTGCAC TTCAAAAGAG TCTGACCCAG CACTACGACA GACGGAGCGT GCGCATCGAA 2400 GTAACGTGCA ACCATTGTAC AAAGAACCTC GTTTTTTACA ACAAATCCAG CCTCCTTTCC 2460 CATGCCCGTG GGCATAAGGA GAAAGGGGTG GTAATGCAAT GCTCCCACTT AATTTTAAAG 2520 CCAGTCCCAG CAGATCAAAT GATAGTTTCT CCGTCAAGCA ATACTTCCAC TTCAACTTCC 2580 ACTCTTCAGA GCCCTGTGGG AGCTGGCACA CACACTGTCA CAAAAATTCA GTCTGGCATA 2640 ACTGGGACAG TCATATCGGC TCCTTCAAGC ACTCCCATCA CCCCAGCCAT GCCCCTAGAT 2700 GAAGACCCCT CCAAACTGTG TAGACATAGT CTAAAATGTT TGGAGTGTAA TGAAGTCTTC 2760 CAGGACGAGA CATCACTGGC TACACATTTC CAGCAGGCTG CAGATACGAG TGGACAAAAG 2820 ACTTGCACTA TCTGCCAGAT GCTCCTTCCT AACCAGTGCA GTTATGCATC ACACCAGAGA 2880 ATCCATCAGC ACAAATCTCC CTACACCTGC CCTGAGTGTG GGGCCATCTC CAGGTCGGTG 2940 CACTTCCAGA CCCACGTCAC CAAGAACTGT CTGCACTACA CGAGGAGAGT TGGTTTTCGA 3000 TGTCTGCATT GCAATGTTGT GTACTCTGAT GTGGCTGCTC TCAAGTCTCA CATTCAAGGT 3060 TCTCACTGTG AAGTCTTCTA CAAGTCTCCT ATTTGTCCAA TCGCGTTTAA GTCTGCCCCA 3120 AGCACACATT CCCACGCCTA CACACAGCAT CCTGGCATCA AGATAGGAGA ACCAAAAATA 3180 ATATATAAGT GTTCCATGTG CGACACTGTG TTCACCCTCC AAACCTTCCT GTATCGCCAC 3240 TTTCACCAAC ACATTGAAAA CCAGAAGGTG TCTGTTTTCA AGTGTCCAGA CTGTTCTCTT 3300 TTATATGCAC AGAAGCAACT TATGATGGAC CATATCAAGT CTATGCATGG AACATTGAAA 3360 AGTATTGAAG GGCCTCCAAA CTTGGGTATA AACTTGCCTT TGAGCATTAA GCCTCCAACT 3420 CAAAATTCAG CAAATCAGAA CAAAGAGGAC ACCAAATCCA TGAATGGGAA AGAGAAATTG 3480 GAAAAGAAAT CTCCATCTCC TGTCAAAAAA TCAATGGAAA CCAAGAAAGT GGCCAGTCCT 3540 GGGTCGACGT GTTGGGAGTG TCACTGCCTG TTCATGCAGA GAGATGTGTA CATATCCCAC 3600 GTCAGGAAGG AGCACGGGAA GCAAATGAAG AAACACCCCT GCCGCCAGTG TGACAAGTCT 3660 TTCAGCTCGT CCCACAGCCT GTCCCGGCAC AACCGGATCA AGCACAAAGG CATCAGGAAA 3720 GTCTACGCCT GCTCGCACTG CCCAGACTCC AGACGTACCT TTACCAAACG TTTGATCCTG 3780 GAGAAGCACG TCCAGCTGAT GCATGGCATC AAGGACCCTG ACCTGAAAGA AATGACAGAT 3840 GCCACCAATG AGGAGGAAAC AGAAATAAAA GAAGACACTA AGGTCCCCAG TCCCAAGCGG 3900 AAGTTGGAAG AACCAGTTCT GGAGTTCAGG CCTCCCCGAG GAGCAATCAC TCAACCACTG 3960 AAAAAGCTGA AAATCAATGT TTTTAAGGTT CACAAGTGTC CCGTCTCTGG CTTCACCACC 4020 GAAAACCTGC TGCAATTCCA CGAACACATC CCTCAGCACA AATCGGATGG TTCTTCCTAC 4080 CAGTGCCGGβ AGTGTGGCCT CTGCTACACG TCTCACGTCT CTCTGTCCAG GCACCTCTTC 4140 ATCGTACACA AGTTAAAGGA ACCTCAGCCA GTGTCCAAGC AAAATGGGGC TCGGGAAGAT 4200 AACCAACAGG AGAACAAACC CAGCCACGAG GATCAATCCC CTGATGGCGC CGTGTCAGAC 4260 AGAAAGTCCA AAGTGTGCGC AAAAACTTTT GAAACTGAAG CTGCCTTAAA TACTCACATG 4320 CGGACACACG GCATGGCCTT CATCAAATCC AAAAGGATGA GCTCAGCCGA GAAATAGCCA 4380 CAGATGCTCC ATGAGGAAAA TCCCTGTCCA CATTGGAATA AAAAAGACAT TTTTCTTACA 4440 AAGTTTGCAG TATAATAGAG TTAACAGTAC TGTCTAGGCT GTTGCAATAT ATTCTCTTTC 4500 AATGTACCTT CCTTCACCTC GTCGTATATA TCCTCGATAA GTATTAAAAC AGTATTTGAG 4560 TTTAAAAGAG TTTGTATATA TTTAAATGAA TAACTTTTTA TACTCTTTCT TACATGTTTG 4620 TATCAGTATT TAGTGGAAAA CCATTTGAGT TGTTTTCGGT TAGAATTTTT CTTTTTGTAC 4680 TGTTTCTTTA AAACAGAGTT CTTAGTAACA GGGGCAGTTC CTGAATTCAA ATAAACCATT 4740 TTGTATGTTT GGATTTTGAA TGGGTTAACT AATTACAGGC TAAAATAATG CCTTTTTTAG 4800 TGTTTTTAAT TTTTAGAATT CACTACATAA ATTGTAAGTA ATTGTGGGTC TCAAAAACAC 4860 TAGGAACTTT TAAGTGTCTT AGCACTTCCT CGATCTGCCT GCCCTGAGGG AGTGAGTTCA 4920 CATTTGAGAC AACTGCACTC CAGTGTGGAC GTGCCTTTGT CTTCAGGCCA TGCCGAAGGG 4980 TGTTTAAAGC AGTCTTGCAG GTCGCTCCTT TCCCAGCCGT GGATAAAAAC TGAAGCTAGG 5040 AATCTAATAA GGAATGCTGA TTTCCTCAGT TCCATTTTCA GGAATGGGGA AGGCTATTCT 5100 AAAGAAAAAA ATGGGATTTG TTTTCTCGGC AGATCTGCAA GGCTGGCTTT AAGAGCACAA 5160 GGAGGGAAAG TAACGAAAGG GCTGGACTAC TATAAAAGTT ACAAATACGT AGTTAGACCA 5220 ATAGATTTAT ATAGTCAGGT TTTTGTCATG TAATTTATTA ACTAACTATT ACAGAAACAC 5280 AGCTAAGAAT ATCAAGTATT TCTCTGGCTC TTGACAGAAA AAAATCAGTT GACTTAACCC 5340 TTTGCTGTCA AAAGAGTTGG CGTTTCCTGT TCTCGGTGCT ACTCCCAAAC GTTATGGTAC 5400 TTAGAGTCGG GATGCACAAC TTCAACCACC GACTTATCAA TGCAGCCGCC TGTGTATTGC 5460 AATTGGCCGT TACCTTAAGC ACTGAGCCAC CCGGGTTTAG TTCAGCCATT TCAAGAAGTA 5520 TATTTAACGT CGGTAGTTCT GCTTTATTAA AATCCAGCAG AGGTACTCTT CTCTCCCTTC 5580 CGTTTATAGT TCTCTGAGAG AGTTCTATTT TTTCGTTTTC TTTTGTGTTT TCTTTTCCAT 5640 TTTCTATCTT GTATTTATCC CTGAACATCT TTTCTACCTT TTTTTTTTTT TTTTTTTTAA 5700 GAAAAGGAAT TCTTTTGTGT ATATATAGAT ACTTGCATGA TATACTGTAG TCAATCTTCG 5760 GTTCCTCAAA AGGTCTTGCT GCTCTCAGGT GTTATGCACT CCATCCATCA TAACTGTATG 5820 AAACACATTT CATATGTAAA TAAACGTCGG ACATTTG SEQ ID NO:255 PBJ8 Protein sequence: Protein Accession * BAB13455 MKTPDFDDLL AAFDIPDMVD PKAAEESGHD DHESHMKQNA HGEDDSHAPS SSDVGVSVIV 60 KNVRNIDSSE GGEKDGHNPT GNGLHNGFLT ASSLDSYSKD GAKSLKGDVP ASEVTLKDST 120 FSQFSPISS A EEFDDDEKIE VDDPPDKEDM RSSFRSNVLT GSAPQQDYDK LKALGGENSS 180 KTGLSTSGNV EKNKAVKRET EASSINLS V Y EPFKVRKAED KLKESSDKVL ENRVLDGKLS 240 SEKNDTSLPS VAPSKTKSSS KLSSCIAAIA ALSAKKAASD SCKEPVANSR ESSPLPKEVN 300 DSPRAADKSP ESQNL1DGTK KPSLKQPDSP RSISSENSSK GSPSSPAGST PAIPKVRIKT 360 IKTSSGEIKR TVTRVLPEVD LDSGKKPSEQ TASVMASVTS LLSSPASAAV LSSPPRAPLQ 420 SAWTNAVSP AELTPKQVTI KPVATAFLPV SAVKTAGSQV INLKLANNTT VKATVISAAS 480 VQSASSAHK AANAIQQQTV WPASSLANA KLVPKTVHLA NLNLLPQGAQ ATSELRQVLT 540 KPQQQIKQAI INAAASQPPK KVSRVQVVSS LQSSWEAFN KVLSSVNPVP VYIPNLSPPA 600 NAG-TLPTRG YKCLECGDSF ALEKSLTQHY DRRSVRIEVT CNHCTKNLVF YNKCSLLSHA 660 RGHKEKGVVM QCSHLILKPV PADQMIVSPS SNTSTSTSTL QSPVGAGTHT VTKIQSGITG 720 TVISAPSSTP ITPAMPLDED PSKLCRHSLK CLECNEVFQD ETSLATHFQQ AADTSGQKTC 780 ΗCQMLLPNQ CSYASHQRIH QHKSPYTCPE CGAICRSVHF QTHVTKNCLH YTRRVGFRCV 840 HCNWYSDVA ALKSHIQGSH CEVFYKCPIC PMAFKSAPST HSHAYTQHPG KIGEPKIIY 900 KCSMCDTVFT LQTLLYRHFD QHIENQKVSV FKCPDCSIXY AQKQLMMDHI KSMHGTLKSI 960 EGPPNLGINL PLSIKPATQN SANQNKEDTK SMNGKEKLEK KSPSPVKKSM ETKKVASPGW 1020 TCWECDCLFM QRDVYISHVR KEHGKQMKKH PCRQCDKSFS SSHSLCRHNR IKHKGIRKVY 1080 ACSHCPDSRR TFTKRLMLEK HVQLMHGIKD PDLKEMTDAT NEEETEIKED TKVPSPKRKL 1140 EEPVLEFRPP RGA1TQPLKK LKINVFKVHK CAVCGFTTEN LLQFHEHIPQ HKSDGSSYQC 1200 RECGLCYTSH VSLSRHLFIV HKLKEPQPVS KQNGAGEDNQ QENKPSHEDE SPDGAVSDRK 1260 CKVCAKTFET EAALNTHMRT HGMAFIKSKR MSSAEK SEQ ID NO:256 PB 1 DNA sequence Nucleic Acid Accession*: AF111847 Coding sequence: 58-1608 (underlined sequence corresponds to start and stop codon) 11 21 31 41 51 TTTTCGTCGA CTCTTACCGG TTGGCTGGGC CAGCTGCGCC GCGGCTCACA GCTCACGATG 60 GGGGACCCCA GCAAGCAGGA CATCTTGACC ATCTTCAAGC GCCTCCGCTC GGTCCCCACT 120 AACAAGGTCT GTTTTGATTG TGGTCCCAAA AATCCCAGCT GGGCAAGCAT AACCTATGGA 180 GTGTTCCTTT GCATTGATTG CTCAGGGTCC CACCGGTCAC TTGGTGTTCA CTTGAGTTTT 240 ATTCGATCTA CAGAGTTGGA TTCCAACTGG TCATGGTTTC AGTTGCGATG CATGCAAGTC 300 GGAGGAAACG CTAGTCCATC TTCCTTTTTT CATCAACATG GGTGTTCCAC CAATGACACC 360 AATGCCAAGT ACAACAGTCG TGCTCCTCAG CTCTATAGGG AGAAAATCAA ATCGCTCGCC 420 TCTCAAGCAA CACGGAAGCA TGGCACTGAT CTGTGGCTTC ATAGTTCTCT GGTTCCACCT 480 TTGTCCCCTC CACCAAAGGA GGAAGATTTT TTTGCCTCTC ACGTTTCTCC TGAGGTGAGT 540 GACACAGCGT GGGCATCAGC AATAGCAGAA CCATCTTCTT TAACATCAAG GCCTCTCGAA 600 ACCACTTTGG AAAATAATGA AGGTCGACAA GAGCAAGGAC CAAGTCTGGA AGGTCTTAAT 660 GTACCAACAA AGGCTACTTT AGAGGTATCC TCTATCATAA AAAAGAAACC AAATCAAGCT 720 AAAAAAGGCC TTGGGGCCAA AAAAGGAAGT TTGGGAGCTC AGAAACTGGC AAACACATGC 780 TTTAATCAAA TTGAAAAACA AGCTCAAGCT GCGGATAAAA TGAAGGAGCA GGAAGACCTG 840 GCCAAGGTCG TATCTAAAGA AGAATCAATT GTTTCATCAT TACGATTAGC CTATAAGGAT 900 CTTGAAATTC AAATGAAGAA AGACGAAAAG ATGAACATTA GTGGCAAAAA AAATGTTCAC 960 TCAGACAGAC TCGGCATGGG ATTTGGAAAT TGCAGAAGTG TTATTTCACA TTCAGTCACT 1020 TCAGATATGC AGACCATAGA GCAGGAATCA CCCATTATGG CAAAACCAAG AAAAAAGTAT 1080 AATGATCACA GTGACGATTC ATATTTTACT TCCAGCTCAA GTTACTTTCA CGAGCCAGTC 1140 GAGTTAAGGA GCAGTTCTTT CTCTAGCTGG GATGACAGTT CAGATTCCTA TTGGAAAAAA 1200 GAGACCAGCA AAGATACTGA AACAGTTCTG AAAACCACAG GCTATTCAGA CAGACCTACT 1260 GCTCGCCGCA AGCCAGATTA TGAGCCAGTT GAAAATACAG ATGAGGCCCA GAAGAAGTTT 1320 GGCAATGTCA AGGCCATTTC ATCAGATATG TATTTTGGAA GACAATCCCA GGCTCATTAT 1380 GAGACCAGGG CCCGCCTAGA GAGGCTGTCG GCAAGTTCCT CCATAAGCTC GGCTCATCTG 1440 TTCGAGGAGC CGAGGAAGCA GCCAGCAGGG AACTACAGCC TGTCCAGTCT GCTCCCCAAC 1500 GCCCCCGACA TGGCGCAGTT CAAGCAGGGA GTGAGATCGG TTGCTGGAAA ACTCTCCGTC 1560 TTTCCTAATG GAGTCGTCAC TTCAATTCAG GATCGCTACG GTTCTTAATA CTCAAGTCAT 1620 GATGTGTATT TCCTGGAGAA ATTCCTCTTT AAATGAACAA GTAACCACAT CTCAGGCGGC 1680 AGTGAAGTCC AGATAGTTTT GCAGATTCTT TTGCTACTTT TTCATATGGT ATATGTTTCT 1740 GATTTTTAAT ATTTCTTTTG AGAAATTCTG AGTTCTGATG TAGGAGCTTT CCTGTCATTT 1800 CTGTTTCACG TTCCTTCCTG TCACACCCTC CTTTGGCGTC TCTGTGTATA TCCTTCCTTT 1860 ATTTTCTTGG AACCTTTGAT TTCAACACTG AGGGCCTGGA GACCTCGGCT CCTCCTGCTC 1920 CTGAACCAGG AGGCTTCATC TGGGGGAGGA GGAGAGGTCT CCATGTGACA CATGGGCTCA 1980 GGGCTCCCAG AATCAGCGGA TGCTGGATGG GCCTGCAGAA ACAACACTCA CCACACACAC 2040 TTCCTTCAAA AGACCAAAAG TGACTGGTGT CTCGTGTCAC AGATTGCTTC ATTTATGTTT 2100 CTACATAGTA AGGTGACTGC CAAATAATAT TTGAAGTCAT CTCTCTCTTT GTAAATTATT 2160 TTATATGACC TATAAATTTA AAAATGTTTT TCAGTGAGTG CTTTTAACAA ACTTAAGCTT 2220 CTGCCCTGCC AAGGGAATTA ATGTTATCTT GTGAAAGGTG TTGCTGTTTG AATTGATGAG 2280 AAATGGAAGA TGAGAACTCC CTAAGAGTTC TCATAATAAA TCATCTCATC ACAAATCAAT 2340 ACGGTATACA GAGTTAAAGT GGAATGAGGT AAGAAGATAC AGCTACAGAA AATAGTTGCG 2400 TGTATGGGAG AACAGTCATT GTAATTGGGT AGTTTTGTTA ATAAATATTT TTAAATCTTG 2460 CTTTTCAGAA ATTACCGAAT GTGTATAAAC AAATAAAGAA AAATAATTTA GCTGTCTTTT 2520 AGACAGCATT AGAATATATT GTTCAGCACA GTAAAATATA TTTGAAATTT GATAAGCCAA 2580 AAATGTGGTT TTGAATGAAT ATTTTCTCAA TCTTTCTTAA AAGCTCAAAT TTGTAGACTT 2640 CTAAATAGAA TAAACACTTG CAGCAGAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 2700 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 2760 AAAAAAAAAA AAAAAAAAAA AAAAAAAA SEQ ID NO:257 PBM1 Protein sequence: PBM1 Protein sequence: CAB76901 MGDPSKQDIL TIFKRLRSVP TNKVCFDCGA KNPSWASITY GVFLCIDCSG SHRSLGVHLS 60 FIRSTELDSN WSWFQLRCMQ VGGNASASSF FHQHGCSTND TNAKYNSRAA QLYREKIKSL 120 ASQATRKHGT DLWLDSCWP PLSPPPKEED FFASHVSPEV SDTAWASAIA EPSSLTSRPV 180 ETTLENNEGG QEQGPSVEGL NVPTKATLEV SSIIKKKPNQ AKKGLGAKKG SLGAQKLANT 240 CFNEIEKQAQ AADKMKEQED LAKWSKEES IVSSLRLAYK DLEIQMKKDE KMNISGKKNV 3 00 DSDRLGMGFG NCRSVISHSV TSDMQTIEQE SPIMAKPRKK YNDDSDDSYF TSSSSYFDEP 3 60 VELRSSSFSS WDDSSDS YWK KETSKDTETV LKTTGYSDRP TARRKPDYEP VENTDEAQKK 420 FGNVKAISSD MYFGRQSQAD YETRARLERL SASSSISSAD LFEEPRKQPA GNYSLSSVLP 480 NAPDMAQFKQ GVRSVAGKLS VFANGWTSI QDRYGS SEQ ID NO:258 PBM4 DNA sequence Nucleic Acid Accession*: D30891 Coding sequence: 1 -4032 (underlined sequence corresponds to start and stop codon) ATQGATACTG TCATG AAGCA G ACAC ATGCT GACACACCTG TTGATCATTG TCTATCTGGC 60 ATAAGAAAGT GTAGCAGCAC CTTTAAGCTT AAAAGTGAAG TCAACAAGCA TGAAACAGCC 120 CTTGAAATGC AGAATCCAAA TTTGAACAAT AAAGAATGTT GTTTCACCTT TACGTTGAAT 180 GGAAACTCCA GAAAATTAGA CCGTAGTGTG TTTACAGCAT ATGGTAAACC CAGCGAGAGT 240 ATCTACTCAG CCCTGAGTGC TAATGACTAT TTCAGTGAAA GGATAAAGAA TCAGTTTAAT 300 AAGAACATTA TTGTTTATGA AGAAAAGACA ATAGATGGAC ATATAAATTT AGGAATGCCT 360 CTCAAGTGCCTGCCTAGTGA TTCTCATTT AAAATTACATTTGGTCAAAG AAAGAGTAGC 420 AAAGAAGATG GACACATATT ACGCCAATGT GAAAATCCAA ACATGGAATG CATTCTTTTT 480 CATGTTGTTG CTATAGGAAG GACAAGAAAG AAGATTGTTA AGATCAACGA ACTTCATGAA 540 AAAGGAAGTA AACTTTGTAT TTATGCCTTG AAGGGTGAGA CTATTGAAGG AGCCTTATGC 600 AAGGATGGCC GTTTTCGGTC TGACATAGGT GAATTTGAAT GGAAACTAAA GGAAGGTCAT 660 AAGAAAATTT ATGGAAAACA GTCCATGGTG GATGAAGTAT CTGGAAAAGT CTTAGAAATG 720 GACATTTCAA AAAAAAAAGC ATTACAACAG AAAGATATCC ATAAAAAAAT TAAACAGAAT 780 GAAAGTGCCA CTGATGAAAT TAATCACCAG AGTCTGATAC AGTCTAAGAA AAAAGTCCAC 840 AAACCAAAGA AAGATGGAGA GACCAAAGAT GTAGAACACA GCAGAGAGCA AATTCTCCCA 900 CCTCAGGATC TAAGCCATTA TATTAAAGAT AAAACTCGCC AGACAATTCC CAGGATTAGA 960 AATTATTACTTTTGTAGTTT GCCCCGAAAA TATAGGCAAA TAAACTCACA AGTTAGACGG 1020 AGGCCGCATC TGGGTAGGCG GTATGCTATT AATCTGGATG TCCAAAAGGA GGCAATTAAT 1080 CTCTTAAAGA ATTATCAAAC GTTGAATGAA GCCATAATGC ATCAGTATCC GAATTTTAAA 1140 GAGGAGGCAC AGTGGGTAAG AAAATATTTT CGGGAAGAAC AAAAGAGAAT GAATCTTTCA 1200 CCAGCTAAGC AATTCAACAT ATATAAAAAG GACTTCGGAA AAATGACTGC AAATTCTGTT 1260 TCAGTTGCAA CCTGCGAACA GCTTACATAT TATAGCAAGT CAGTTGGGTT CATGCAATGG 1320 GACAATAATG GAAACACAGG TAATGCTACT TGCTTTGTCT TCAATGGTGG TTATATTTTC 1380 ACCTGTCGAC ATGTTGTACA TCTTATGGTG GGTAAAAACA CACATCCAAG TTTGTGGCCA 1440 GATATAATTA GCAAATGTGC GAAGGTAACC TTCACTTATA CAGAGTTCTG CCCTACTCCT 1500 GACAATTGGT TTCCATTGA GCCATGGCTT AAAGTGTCCA ATGAAAATCT AGATTATGCC 1560 ATTTTAAAAC TAAAAGAAAA TGGAAATGCG TTTCCTCCAG GACTATGGCG ACAGATTTCT 1620 CCTCAACCAT CTACTGGTTT GATTTATTTA ATTGGTCATC CTGAAGGCCA GATCAAGAAA 1680 ATAGATGGTT GTACTGTGAT TCCTCTAAAC GAACGATTGA AAAAATATCC AAACGATTGT 1740 CAAGATGGGT TGGTAGATCT CTATGATACC ACCAGTAATG TATACTGTAT GTTTACCCAA 1800 AGAAGTTTCC TATCAGAGGT TTGGAACACA CACACGCTTA GTTATGATAC TTGTTTCTCT 1860 GATGGGTCCT CAGGCTCCCC AGTGTTTAATGCATCTGGCA AATTGGTTGC TTTGCATACC 1920 TTTGGGCTTT TTTATCAACG AGGATTTAAT GTGCATGCCC TTATTGAATT TGGTTATTCT 1980 ATGGATTCTA TTCTTTGTGA TATTAAAAAG ACAAATGAGA GCTTGTATAA ATCATTAAAT 2040 GATGAGAAAC TTGAGACCTA CGATGAAGAG AAAGCCCGGC CCAGGCCAGC CTACCGGCGA 2100 CTAGGATGCT TTCGCTTTCG CTCTCGCTTT CCAATACTCG GGACTGGGGA AACCGGGAGA 2160 ATAGAAGCAG GCAAGGACCG CCGTGGGCAC GGGGTCAGTG AGACAGGGTC CTGCTCGCGG 2220 CGTCAAGGAG GAGCGCTGTG GGTGTCCCCA GCGCAGCCAA TCGGCTTCCG AAGTAGCTGG 2280 AGCTCTGGAG CCTTTGCTTC CTCAAATACG AGCGGGAACT GCGTTGAGCG CTGGATTCCA 2340 GGCCGAGTGC TGGCGAGGCG CGCAGTCTCT AAAGAGCAAC AGAATAATTG CAGTACTTCT 2400 CTAATGAGGA TGGAGTCTAG AGGAGACCCA AGAGCCACAA CTAATACCCA GGCTCAAAGA 2460 TTCCATTCAC CTAAGAAAAA TCCAGAAGAC CAGACCATGC CCCAAAATAG GACAATATAT 2520 GTTACCTTGA AGGCTGTCAG AAAAGAGATA GAAACTCACC AAGGCCAAGA AATGCTTGTG 2580 CGTGGCACAG AAGGAATCAA AGAGTACATA AACCTTGGAA TGCCCCTCAG TTGTTTCCCT 2640 GAAGGTGGCC AGGTGGTCAT TACATTTTCC CAAAGTAAAA GTAAGCAGAA GGAAGATAAC 2700 CACATATTTG GCAGGCAGGA CAAAGCATCG ACTGAATGTG TCAAATTTTA CATTCATGCA 2760 ATTGGAATTG GGAAGTGTAA AAGAAGGATT GTTAAATGTG GGAAGCTTCA CAAAAAGGGG 2820 CGCAAACTCT GTGTTTATGC TTTCAAAGGA GAAACCATCA AGGATGCACT GTGCAAGGAT 2880 GGCAGATTTC TTTCCTTTCT GGAGAATGAT GATTGGAAAC TCATTGAAAA CAATGACACC 2940 ATTTTAGAAA GCACCCAGCC AGTTGATGAA TTAGAAGGCA GATACTTTCA GGTTGAGGTT 3000 GAGAAAAGAA TGGTCCCCAG TGCAGCAGCT TCTCAGAATC CTGAGTCAGA GAAAAGAAAC 3060 ACCTGTGTGT TGAGAGAACA AATCGTGGCTCAGTACCCCA GTTTGAAAAG AGAAAGTGAA 3120 AAAATCATTG AAAACTTCAA GAAAAAAATG AAAGTAAAAA ATGGGGAAAC ATTATTTGAA 3180 TTGCATAGAA CAACGTTTGG GAAAGTAACA AAAAATTCTT CTTCGATTAA AGTAGTGAAA 3240 CTTCTTGTAC GTCTCAGTGA CTCAGTTGGG TACTTATTCT GGGACAGTGC AACTACGGGT 3300 TACGCCACCTGCTTTGTTrrTAAAGGATTG TTCATTTTAA CTTGTCGGCATGTAATAGAT 3360 AGCATTGTGG GAGACGGAATAGAGCCAAGTAAGTGGGCAA CCATAATTGG TCAATGTGTA 3420 AGGGTGACAT TTGGTTATGA AGAGCTAAAA GACAAGGAAA CAAACTACTT TTTTGTTGAA 3480 CCTTGGTTTG AGATACATAA TGAAGAGCTT GACTATGCTG TCCTGAAACT GAAGGAAAAT 3540 GGACAACAAG TACCTATGGA ACTATATAAT GGAATTACTC CTGTGCCACT TAGTGGGTTG 3600 ATACATATTA TTGGCCATCC ATATGGAGAA AAAAAGCAGA TTGATGCTTG TGCTGTGATC 3660 CCTCAGGGTC AGCGAGCAAA GAAATGTCAG GAACGTGTTC AGTCTAAAAA AGCAGAAAGT 3720 CCAGAGTATG TCCATATGTA TACTCAAAGA AGTTTCCAGA AAATAGTTCA CAACCCTGAT 3780 GTGATTACCT ATGACACTGA AT1 1TTCTTT GGGGCTTCCG GCTCCCCTGT GTTTGATTCA 3840 AAAGGTTCAT TGGTGGCCAT GCATGCTGCT GGCTTTGCTT ATACTTACCA AAATGAGACT 3900 CGTAGTATCA TTGAGTTTGG CTCTACCATG GAATCCATCCTCCTTGATATTAAGCAAAGA 3960 CATAAACCAT GGTATGAAGA AGTATTTGTA AATCAGCAGG ATGTAGAAAT GATGAGTGAT 4020 GAGGACTTGT jAGAATTCAG TCTACTGGAT TTAAGGGAAT GGCTTATGGA GTTGTTATTT 4080 CGTAGGCATT GAAAATGGTT TTCTAAACTC CAAAATGGTC ATCTTATCAA TAATAATAAT 4140 ATTGACCATT TCCTATCTGC CAGGCATTTT TCTAAGCACA TGAAGAAATT AGTCCTAACA 4200 ACACTATGAG ATGGACTATA ACTTGCCCAA ATTTTTTTTT TTTTTGAGAC TGAGTCTCAC 4260 TCTGTCGCCT GGGCTGGAGT ACAGTGGTGC GATCTCAGCT CACTGCAACT TCCACCTCCC 4320 AGGTTCAAGC GATTCTTATG CCTCAGTCTC CTGAGCAGCT GGGATTACAG GCAAACGCCA 4380 CCACACCCAG CTAAATTTTT TTTTTTTTTT TGTATTTTTA GTAGAGACAG GGTTTCACCA 4440 TGTTGGTCAG GCGGGTCTCG AACTCCTGAC CTCGTGATCC ACCTGCCTCG GCCTTCCAAA 4500 GTGCTGGGAT TACAAGTTTG AGCCACTGCA CCTGGCTAAC TTGCCCTATT TTAAAGTCAA 4560 GCAATGGGAA GAATAACAAG ATTATATAGT AATCAGTTTC ATGACACTAA AAGTCATATA 4620 GTCATAGGGT TTTTTCATCT TTCATATCTT TGCCTAAATT CATTTGCTAC AGTGCAGGAA 4680 CCAAAACTTG TTCATCTCAT GATTCCCTAC ATCTGACATA AGGAAAGTAA GTGCTCAGAA 4740 AAATGTGCAG GTCAATAAGT TGCAAAAGTT GGGGCTGCAA TTAATGCTAA CATAAGAGCT 4800 AAATGCTTGA TTAGAAATGA TCTCAAAACC TTTTAGAATT TCCAAAATCT TCATATTACT 4860 GAAACTGTCG GAATATATGG GTCCTGAAAT TCAGAAGATG ATAGTCACTC TTCCCATATT 4920 TATAGGCTAT TAAGGCAAGG GATATCTTAA ACATCATATT ACTTTATTTA GATTTCTACT 4980 ACTCCAATTA TTAATGTTAT GTATTTCTCA TTGTTTTACT TCTTCATGGT ATTATGAAGA 5040 CTATATAGAT GATTCAACCA AGCCTGCAAA TCTCCCTCTT GTGGAATTCC ACTGGACCCA 5100 ATCTGTTTTC CATTTCCATT GCAATACTAC TAAAGCCATA CAATATCAAG CACCCTCCCT 5160 CTAGGTCCAG GGACTATCAC AGAAGAAGCA GGCATGTAAG ATTTTAAGGA CTGGTTTCGA 5220 GGGGTCGAGT GTAGGAAAAC AGCCTGTTGC ATTGTAAGAG TGATGTCACC TTGAAGAGCA 5280 GCTGGCATGA TGACTGCTGT TTGACTCCTG CATACCAAGA TATTCTGCAG CAATGTCTTT 5340 AAACAGTGCC GGTAGTACAG ATAACCCCTC ATAAAGATGC TTATCTAACC TCCCCAGTGT 5400 TCAGGTGTTT CACAAGAAAG TCTGAGATAT GACTAGCTAC ACGTTTTGCC AAAAATGCTT 5460 GTTATATAAA GGGTACTTTT GGGAGGGTGA GTGCCGCCAT TTAGTGGCTG CTAGAAACAT 5520 TGCTTCTGTT TGTAAGTTCC TATTAAATGT TCTTTCTGAG AAAAAAAAAA A SEQ ID NO:259 PB 4 Protein sequence: PB 4 Protein sequence: BAB67788 MDTVMKQTHA DTPVDHCLSG IRKCSSTFKL KSEVNKHETA LEMQNPNLNN KECCFTFTLN 60 GNSRKLDRSV FTAYGKPSES IYSALSANDY FSERIKNQFN KNIIVYEEKT-DGH-NLGMP 120 LKCLPSDSHFKπTGQRKSS KE-XiHILRQC E^IPNMECILFHVVAIGRTRKK^ H^IE HE 180 KGSKLCIYAL KGEΗEGALC KDGRFRSDIG EEEWKLKEGH KKIYGKQSMV DEVSGKVLEM 240 DISKKKALQQ KD-HKKIKQN ESATDEINHQ SLIQSKKKVH KPKKDGETKD VEHSREQILP 300 PQDLSHYIKD KTRQTIPRIR NYYFCSLPRK YRQINSQVRR RPHLGRRYAI NLDVQKEAIN 360 LLKNYQTLNEAIMHQYPNFK EEAQWVRKYFREEQKRMNLS PAKQFNIYKKDFGKMTANSV 420 SVATCEQLTYYSKSVGFMQW DNNGNTGNATCFVFNGGYIFTCRHWHLMVGKNTHPSLWP 480 DϋSKCAKVT FTYTEFCPTP DNWFSIEPWL KVSNENLDYA ILKLKENGNA EPPGLWRQIS 540 PQPSTGLIYL IGHPEGQIKK IDGCTVIPLN ERLKKYPNDC QDGLVDLYDT TSNVYCMFTQ 600 RSFLSEVWNT HTLSYDTCFS DGSSGSPVFN ASGKLVALHT FGLFYQRGFN VHALIEFGYS 660 MDSILCDIKKTNESLYKSLN DEKLETYDEEKARPRPAYRR LGCERFRSRFPILGTGETGR 720 IEAGKDRRGHGVSETGSCSR RQGGALWVSPAQPIGFRSSW SSGAFASSNTSGNCVERWIP 780 GRVLARRAVS KEQQNNCSTS LMRMESRGDP RATTNTQAQR FHSPKKNPED QTMPQNRTTY 840 VTLKAVRKEI ETHQGQEMLV RGTEGIKEYI NLGMPLSCFP EGGQWTTFS QSKSKQKEDN 900 HIFGRQDKAS TECVKFYIHA IGIGKCKRRI VKCGKLHKKG RKLCVYAFKG EΗKDALCKD 960 GRFLSFLEND DWKLIENNDT ILESTQPVDE LEGRYFQVEV EKRMVPSAAA SQNPESEKRN 1020 TCVI-R-^IVAQYPSL--RESE KIIENFKKKM KVKNGETIi-5 I-HRTTFGKVT --NSSSIKVVK 1080 LLVRLSDSVG YLFWDSATTG YATCFVFKGL FILTCRHV-D SIVGDGIEPS KWATT-GQCV 1140 RVTFGYEELK DKETNYFFVE PWFEIHNEEL DYAVLKLKEN GQQVPMELYN GITPVPLSGL 1200 IffllGHPYGE KKQEDACAVI PQGQRAKKCQ ERVQSKKAES PEYVHMYTQR SFQKIVHNPD 1260 VITYDTEFFF GASGSPVFDS KGSLVAMHAA GFAYTYQNET RSπEFGSTM ESILLDIKQR 1320 HKPWYEEVFV NQQDVEMMSD EDL SEQ ID NO:260 PBQ1 DNA sequence Nucleic Acid Accessien* NM_015642 Coding sequence: 489-2489 (underlined sequence corresponds to start and stop codon) 11 21 31 41 51 ACATTTCAAA A IAAAATACAT A IGACTGATGT I TTCAGACTTG T IGCAGCATAA G ICCTACAGGG 60 TACGAAGAAT GAACTCTGAG AATCTTTGGA GAATGTTTCA TCATTACTAA CAGGATATTC 120 CTCATCACAT TGCTGTCTGA TCTTTGACCA TCAGTCTCTG ACCTGCCCCT TCTCTTTACA 180 TCCAGCCGCT CTCTCCTCCC TCCCCCAATG AACATCTCCA CTAGGCCCAA GCCTTGGAGT 240 AATTTACCTG AAGAGTCACA CCATTGATTT TCAAACTACT GAAGAAACCC AAGACAGCTG 300 AAAACCAGAA GGCATCTGAG GAGAATGAGA TTACTCAGCC GGGTGGATCC AGCGCCAAGC 360 CGGGCCTTCC CTGCCTGAAC TTTCAAGCTG TTTTCTCTCC AGACCCAGCC CTCATCCACT 420 CAACACATTC ACTGACAAAC TCTCACGCTC ACACCGGGTC ATCTGATTGT GACATCAGTT 480 GCAAGGGGAT GACCGAGCGC ATTCACAGCA TCAACCTTCA CAACTTCAGC AATTCCGTGC 540 TCGAGACCCT CAACGAGCAG CGCAACCGTG GCCACTTCTC TGACGTAACG GTGCGCATCC 600 ACGGGAGCAT GCTCCGCGCA CACCGCTGCG TCCTGGCAGC CGGCAGCCCC TTCTTCCAGG 660 ACAAACTCCT GCTTCGCTAC AGCGACATCG AGATCCCGTC GGTGGTCTCA GTGCAGTCAG 720 TGCAAAAGCT CATTGACTTC ATCTACAGCG GCGTCCTACG GGTCTCGCAG TCGGAAGCTC 780 TGCAGATCCT CACGGCCGCC AGCATCCTGC AGATCAAAAC AGTCATCGAC GAGTGCACGC 840 GCATCGTGTC ACAGAACGTG GGCGATGTGT TCCCGGGGAT CCAGGACTCG GGCCAGGACA 900 CGCCGCGGGG CACTCCCGAG TCAGGCACGT CAGGCCAGAG CAGCGACACG GAGTCGGGCT 960 ACCTCCAGAG CCACCCACAG CACAGCGTGG ACAGGATCTA CTCGGCACTC TACGCGTGCT 1020 CCATGCAGAA TGGCAGCGGC GAGCGCTCTT TTTACAGCGG CGCAGTGGTC AGCCACCACG 1080 AGACTGCGCT CGGCCTGCCC CGCGACCACC ACATCGAAGA CCCCAGCTGG ATCACACGCA 1140 TCCATGAGCG CTCGCAGCAG ATGGAGCGCT ACCTGTCCAC CACCCCCGAG ACCACGCACT 1200 GCCGCAAGCA GCCCCGGCCT GTGCGCATCC AGACCCTAGT GGGCAACATC CACATCAAGC 1260 AGGAGATGGA GGACGATTAC GACTACTACG GGCAGCAAAG GGTGCAGATC CTCGAACGCA 1320 ACGAATCCGA GGAGTGCACG GAAGACACAG ACCAGGCCGA GGGCACCGAG AGTCAGCCCA 1380 AAGGTCAAAG CTTCGACTCG GGCGTCAGCT CCTCCATAGG CACCGAGCCT GACTCGGTGG 1440 AGCAGCAGTT TGGGCCTGGG GCGGCGCGGG ACAGCCAGGC TGAACCCACC CAACCCGAGC 1500 AGGCTGCAGA AGCCCCCGCT GAGGGTGGTC CGCAGACAAA CCAGCTAGAA ACAGGTGCTT 1560 CCTCTCCGGA GAGAAGCAAT GAAGTGGAGA TGGACAGCAC TGTTATCACT GTCAGCAACA 1620 GCTCCGACAA GAGCGTCCTA CAACAGCCTT CGGTCAACAC GTCCATCGGG CAGCCATTCC 1680 CAAGTACCCA GCTCTACTTA CGCCAGACAG AAACCCTCAC CAGCAACCTG AGGATGCCTC 1740 TGACCTTGAC CAGCAACACG CAGGTCATTG GCACAGCTGG CAACACCTAC CTGCCAGCCC 1800 TCTTCACTAC CCAGCCCGCG GGCAGTGGCC CCAAGCCTTT CCTCTTCAGC CTGCCACAGC 1860 CCCTCGCAGG CCAGCAGACC CAGTTTGTGA CAGTCTCCCA GCCCGGTCTG TCGACCTTTA 1920 CTGCACAGCT GCCAGCGCCA CAGCCCCTGG CCTCATCCGC AGGCCACAGC ACAGCCAGTG 1980 GGCAAGGCGA AAAAAAGCCT TATGAGTGCA CTCTCTCCAA CAAGACTTTC ACCGCCAAAC 2040 AGAACTACGT CAAGCACATG TTCGTACACA CAGGTGAGAA GCCCCACCAA TGCAGCATCT 2100 GTTGGCGCTC CTTCTCCTTA AAGGATTACC TTATCAAGCA CATGGTGACA CACACAGGAG 2160 TCAGGGCATA CCAGTGTAGT ATCTGCAACA AGCGCTTCAC CCAGAAGAGC TCCCTCAACG 2220 TGCACATGCG CCTCCACCGG GGAGAGAAGT CCTACGAGTG CTACATCTGC AAAAAGAAGT 2280 TCTCTCACAA GACCCTCCTC GAGCGACACG TGGCCCTGCA CAGTGCCAGC AATCGGACCC 2340 CCCCTGCAGG CACACCCCCA GGTCCCCGCG CTGGCCCCCC AGGCGTGGTG GCCTGCACGG 2400 AGGGGACCAC TTACGTCTGC TCCGTCTGCC CAGCAAAGTT TGACCAAATC GAGCAGTTCA 2460 ACGACCACAT GAGGATGCAT GTGTCTGACG GATAAGTAGT ATCTTTCTCT CTTTCTTATG 2520 AACAAAACAA AACAACAACA AAAAACAAAC AAACAAAAAA GCTATGGCAC TAGAATTTAA 2580 GAAATGTTTT GGTTTCATTT TTACTTTCTG TTTTTGTTTT TGTTTCGTTT CATTTTGTAC 2640 TACATGAAGA ACTGTTTTTT GCCTGCTCGT ACATTACATT TCCGGAGGCT TGGGTCAATA 2700 ATAGTTTTCC CAGTCTCCCT CGGATGGTGG CCTTAAGGCC TGGTAGTGCT TCAAGAGGTC 2760 CACTGGTTGG ATCTCTAGCT ACTGGCCTCT AAATACAACC CTTCTTTACA AAAAAAAAAA 2820 AAAAAAAAA SEQ ID NO:261 PBQ1 Protein sequence: PBQ1 Protein sequence: NP_056457 MTERIHSINL HNFSNSVLET LNEQRNRGHF CDVTVRIHGS MLRAHRCVLA AGSPFFQDKL 60 LLGYSDIE-P SVVSVQSVQK LIDFMYSGVL RVSQSEALQI LTAASBLQIK TVIDECTRIV 120 SQNVGDVFPG IQDSGQDTPR GTPESGTSGQ SSDTESGYLQ SHPQHSVDRI YSALYACSMQ 180 NGSGERSFYS GAWSHHETA LGLPRDHHME DPSWITRIHE RSQQMERYLS TTPETTHCRK 240 QPRPVRIQTL VGNIHIKQEM EDDYDYYGQQ RVQILERNES EECTEDTDQA EGTESEPKGE 300 SFDSGVSSSI GTEPDSVEQQ FGPGAARDSQ AEPTQPEQAA EAPAEGGPQT NQLETGASSP 360 ERSNEVEMDS TVITVSNSSD KSVLQQPSVN TSIGQPLPST QLYLRQTETL TSNLRMPLTL 420 TSNTQVIGTA GNTYLPALFT TQPAGSGPKP FLFSLPQPLA GQQTQFVTVS QPGLSTFTAQ 480 LPAPQPLASS AGHSTASGQG EKKPYECTLC NKTFTAKQNY VKHMFVHTGE KPHQCSICWR 540 SFSLKDYLIK HMVTHTGVRA YQCSICNKRF TQKSSLNVHM RLHRGEKSYE CYICKKKFSH 600 KTLLERHVAL HSASNGTPPA GTPPGARAGP PGVVACTEGT TYVCSVCPAK FDQIEQFNDH 660 MRMHVSDG SEQ ID NO: 262 PBQ6 DNA sequence Nucleic Acid Accession*: AI654187 Coding sequence: 1-912 (underlined sequence conesponds to start and stop codon) 11 21 31 41 51 ATGGTGGAAG AGGAAACAGG CATATCTTAC ATGGTCGCAG ACAAGGGACA CCCTTCTACA 60 AACTCTACCA CTTCTGCGCC GTCGTTTCGA CCATATAAAA ACGACCTATG CGAACTCCGT 120 CGGAAAACTC CCTCACGATG TAAAACGAAG ATCAGGAGCA GATTTCAAGA ATTACAAAGT 180 GAATTGGTGC CAGTCAGCAT GTCAGAGACA GACCACATAG CCTCTACTTC CTCTGATAAA 240 AATGTTCGGA AAACACCTGA ATTAAAGGAA GACTCATGCA ACTTCTTTTC TGGCAATGAA 300 AGCAGCAAAT TAGAAAATGA GTCCAAACTA TTGTCATTAA ACACTGATAA AACTTTATCT 360 CAACCTAATC AGCATAATAA TCGAATTGAA GCCCAGGAAA ATTATATTCC AGATCATCGT 420 GGAGGTCAGG ATTCTTGTGC CAAAACAGAC ACAGGCTCAG AAAATTCTGA ACAAATAGCT 480 AATTTTCCTA GTGGAAATTT TGCTAAACAT ATTTCAAAAA CAAATGAAAC AGAACAGAAA 540 GTAACACAAA TATTGGTGGA ATTAAGGTCA TCTACATTTC CAGAATCAGC TAATGAAAAG 600 ACTTATTCAG AAAGCCCCTA TCATACAGAC TCCACCAAGA AATTTATTTC AAAAATAAAG 660 AGCGTTTCAG CATCAGAGGA TTTCTTGGAA GAAATAGAAT CTCAGCTCTT ATCTACGGAG 720 TTTGCAGAAC ATCGAGTACC AAATGGAATG AATAAGGGAG AACATCCATT AGTTCTCTTT 780 GAAAAGTGTG TGCAAGATAA ATATTTGCAG CAGGAACATA TCATAAAAAA GGCCAGACTT 840 GGTCTCTCTT ATTTGCCATC AAGAACCTCA ATTGACACGT TAATTCCGTT TATCCCAAAT 900 TTATATAGAT AA SEQ ID NO:263 PBQ6 Protein sequence: Protein Accession*: NP_060170 MEPKEATGKE NMVTKKKNLA FLRSRLYMLE RRKTDTWES SVSGDHSGTL RRSQSDRTEY 60 NQKLQEKMTP QGECSVAETL TPEEEHHMKR MMAKREKIIK ELIQTEKDYL NDLELCVREV 120 VQPLRNKKTD RLDVDSLFSN IESVHQISAK LLSLLEEATT DVEPAMQVIG EVFLQIKGPL 180 EDIYKIYCYH HDEAHSILES YEKEEELKEH LSHCIQSLK SEQ ID NO.-264 PBY7 DNA sequence Nucleic Acid Accession*: N _014323 Coding sequence: 662-2725 (underlined sequence corresponds to start and stop codon) 11 21 31 41 51 I I I I I GGGCCTACTC TCCCGCCGCC GCCGCCCGCC CGCTCCAGCC GCCGCCGCCG CCGCCACCGC 60 CCTCCAGGCT CCGGGACCCG GCCCGCGCCA CCGCCCCCGT GCGCGCCCCG CCGCCGCCGC 120 CTTCGCCTTC GCCTTTTGTT TCCTCCGCTC CGGCGCCCCC GCCCCGGCTC GCGCTTTGCA 180 GGGGACGCAG CGCGCGCCCC CAGCGGGCCC GGGAAAAGCC GCGGCGCGCG CGCGCGCCTG 240 CGCGGCGGAC CCCTCCTTCT CCTCCCCGCG TGCGCGTGCC CTTCTTGGCT GCGCGCCGGC 300 GCCGCCTGGC GGGCGGGAGG GGAGGTGGCA GGCGCGTTTG CAGGAGGGGC GCACCTCTTC 360 GCTCGCGCAC CCCCCCGGAA GGTAGACCGG GAAGGGGAGG CGGGCGGGCG GAGAGGAGAG 420 AGTGGCGCGC AGTCCAGCGA GGGCGGGGGT TGGCTATGTC GGGGGTCGTC CACCCCGCAG 480 TCTAGACAGT CTGATCCGGG CTGGGGGCGT GTACACTCGG CGCACCTGCG AGACTACAGA 540 GCCTCGGGCC GGCACGTCTC GGGAGTGTGG ACACGTCTGC TGCGCCCCGC TTCTCGCTGC 600 TGAGGGGAAG GGAGGGGGCG GGCAGGTGCA GCGGCCGGGC TAGTGGGAGG GGGCGGCGGC 660 CATCGAGCGG GTCAACGACG CTTCGTGCGG CCCGTCTCGC TCCTACACAT ACCAGGTCAG 720 CAGACACAGC ACGGAGATGC TGCACAACCT GAACCAGCAG CGCAAAAACG GCGGGCGCTT 780 CTGCGACGTG CTCTTGCGGG TAGGCGACGA GAGCTTCCCA GCGCACCGCG CCGTGCTCGC 840 CGCCTCCAGC GAGTACTTTG AGTCGGTGTT CAGCGCCCAG TTGGGCGACG GCGGAGCTGC 900 GGACGGGGGT CCGGCTCATG TAGGGGGCGC GACGGCAGCA CCAGGCGGCG GGGCCGGGGG 960 CAGCCGGGAG CTCGAGATGC ACACTATCAG CTCCAAGGTA TTTCGGGACA TTCTGGACTT 1020 CGCCTACACT TCCCGCATCG TCGTGCGCTT GGAGAGCTTT CCCGAACTCA TGACGGCCGC 1080 CAAGTTCCTC CTCATGAGGT CGGTTATCGA GATCTGCCAG GAAGTCATCA AACAGTCCAA 1140 CGTACAGATC CTCGTACCCC CTGCCCGCGC CGATATAATG CTCTTTCGCC CCCCTGGGAC 1200 CTCGGACTTG GGCTTCCCTT TGGACATCAC CAACGGGGCA GCCTTGGCAG CCAACAGCAA 1260 TGGCATCGCC GGCAGCATGC AGCCAGAGGA GGAGGCAGCT CGGGCGGCTG GTGCAGCCAT 1320 TGCAGGCCAA GCCTCTTTGC CTCTGTTACC TGGGGTGGAC CGCTTGCCCA TCGTGGCTGG 1380 ACCCCTATCC CCCCAACTGC TGACTTCCCC ATTCCCCAGT GTGGCATCCA GTGCCCCTCC 1440 CCTGACTGGC AAGCGAGGCC GGGGCCGCCC AAGGAAGGCC AACCTGCTGG ACTCAATGTT 1500 TGGGTCCCCA GGGGGCCTGA GGGAGGCAGG CATCCTTCCA TGCGGTCTAT GTGGTAAGGT 1560 GTTCACTGAT GCCAACCGGC TCCGGCAGCA CGAGGCCCAG CACGGTGTCA CCAGCCTCCA 1620 GCTCGGCTAC ATCGACCTTC CTCCTCCGAG GCTGGGTCAG AATGGGCTAC CCATCTCTCA 1680 AGACCCCGAC GGCCCCCGAA AGAGGAGCCG GACCAGGAAG CAGGTGGCTT GTGAGATCTG 1740 CGGCAAGATC TTCCGTGATG TGTATCATCT TAACCGGCAC AAGCTGTCCC ACTCTCGGGA 1800 GAAGCCCTAC TCCTGCCCTG TGTGTGGGTT GCGGTTCAAG AGAAAAGACC GCATCTCCTA 1860 CCATGTGCGG TCCCATGATG GGTCCGTGGG CAAGCCTTAC ATCTGCCAGA GCTGTGGGAA 1920 AGGCTTCTCC AGGCCTGATC ACTTGAACGG ACATATCAAG CAGGTGCACA CTTCTGAGCG 1980 GCCTCACAAG TGTCAGACCT GCAATGCTTC TTTTGCCACC CGAGACCGTC TGCGCTCCCA 2040 CCTGGCCTGT CATCAAGACA AGGTGCCCTG CCAGGTGTGT GGGAAGTACT TCCGGGCAGC 2100 ATACATGGCA GACCACCTGA AGAAGCACAG CGAGGGGCCC AGCAACTTCT GCAGTATCTG 2160 TAACCGAGGT TTCTCCTCTG CCTCCTACTT AAAGGTCCAT GTTAAAACCC ACCACGGTGT 2220 TCCCCTTCCC CAGGTCTCCA GGCACCAGGA GCCCATCCTC AATCGGGGAG CAGCGTTCCA 2280 CTGCGCCAGG ACCTATGGCA ACAAAGAAGG CCAGAAATGC TCACATCAGG ATCCGATTGA 2340 GAGCTCTGAC TCCTATGGTG ACCTCTCAGA TCCCAGCGAC CTGAAGACGC CAGAGAAGCA 2400 GAGTGCCAAT GGCTCTTTCT CCTGCGACAT GGCAGTCCCC AAAAACAAAA TGGAGTCTGA 2460 TGGGGAGAAG AAGTACCCAT GCCCTCAATC TGGGAGCTTC TTCCGCTCTA AGTCCTACTT 2520 GAACAAACAC ATCCAGAAGG TCCATCTCCG GGCTCTCGGG GGCCCCCTGG GGGACCTGGG 2580 CCCTGCCCTT GGCTCACCTT TCTCTCCTCA GCAGAACATG TCTCTCCTCG AGTCCTTTGG 2640 GTTTCAGATT GTTCAGTCGG CATTTGCGTC ATCTTTAGTA GATCCTGAGG TTGACCAGCA 2700 GCCCATGGGG CCTGAAGGGA AATGAGGCAG CTGCTGTCTC CCCACGGAAA CAACCATCTG 2760 GGGACTGCTG GGAAATGCTC TGAATGCGGA GGGAAGTGAT GTTTGGGTTC TGTAGCTCAG 2820 AGATTTTTAT TCATTTTTAA CTCCCCCCCA ACCCCACTCC AACTCCTTCT CCACCACCCA 2880 TTCTCCCAAT GGTCTTTAGA AATAGATTTT CATCTGATAT TCTGCAGAAA TATCAATCAG 2940 ACTTCGTATG GGACAGGGGC AGAAAACACT ACATAGGCCT CCAAGGCAAA ACCAGTCCCA 3000 GTTTCTTTAA TGGGAAGAAG CTCGAATTCC TGGTGCTCAA TTCTTAGTGA CCCCAATCCT 3060 ATACCCAAAT CTATGATATT CTGGGACCTC AGTGATTTTG GTCCCCTCCC ACTTCTCTAG 3120 TTCGTCATCC TCCCTTCCCA TATCCTTCAA AAGAACCACA CTAGGGTCTC CACCTACTTA 3180 TACAATGCGG ATGCCCAACT GTTTTTAAGG AAGCCAGAAG CATCCCATGG ACCATGGGGT 3240 GAGTGTCCTC CAAGAGCCCC CTGAGCTCAG CCCTCTGCCT GGAGGGCTCC AGACCTTTCT 3300 GAGCCCTGCT TGGAGGCGAG CATTTTCACT GCTAGGACAA GCTCAGCTGT TGAGGACACC 3360 CCCACCCCAA ATTTCAGTTC TTACGTCATT TTAACCATTC AACATGCTGT TGGGTTTTAA 3420 TTCTCTAATT ATTATTATTA TTGTTATTAT TTTTTAGGAC CAGTTGTAGT GAATTGCTAC 3480 TGAAAGCTAT CCCAGGTGAT ACAGAGCTCT TTCTAAACCG CAGTCACACA TTAGGGTTAG 3540 TATTAAACTT TGTTTAGATG TACCATAATT AACTTGGCTA GTTGATTGTT TCAAGTCTAT 3600 GGAAGAAATA GTTTTATGCA AAATTTTAAA AAATGCCAGT CTGGTCAGGG AAGTAGGGGG 3660 TTTCAATGCT GTTCGGAACC AGGAAGGTCG GACAGCCGGC AGGTAGGGAC ATTGTGTACC 3720 TCAGTTGTCT CACATCTGAG CAAGCCCAGG TTGACCTTGT GATGTGAATT GATCTGATCA 3780 GACTGTATTA AAAATCTTAG TACATTACTC TA SEQ ID NO:265 PBY7 Protein sequence: Protein Accession*: NP_114439 MERVNDASCG PSGCYTYQVS RHSTEMLHNL NQQRKNGGRF CDVLLRVGDE SFPAHRAVLA 60 ACSEYFESVF SAQLGDGGAA DGGPADVGGA TAAPGGGAGG SRELEMHTIS SKVFGDILDF 120 AYTSRIVVRL ESFPELMTAA KFLLMRSVIE ICQEVIKQSN VQILVPPARA DIMLFRPPGΪ 180 SDLGFPLDMT NGAALAANSN GIAGSMQPEE EAARAAGAAI AGQASLPVLP GVDRLPMVAG 240 PLSPQLLTSPFPSVASSAPP LTGKRGRGRPRKANLLDSMFGSPGGLREAG ILPCGLCGKV 300 FTDANRLRQH EAQHGVTSLQ LGYIDLPPPR LGENGLPISE DPDGPRKRSR TRKQVACEIC 360 GKIFRDVYHL NRHKLSHSGE KPYSCPVCGL RFKRKDRMS Y HVRSHDGSVG KPYICQSCGK 420 GFSRPDHLNG HIKQVHTSER PHKCQTCNAS FATRDRLRSH LACHEDKVPC QVCGKYLRAA 480 YMADHLKKHS EGPSNFCSIC NREGQKCSHQ DPIESSDSYG DLSDASDLKT PEKQSANGSF 540 SCDMAVPKNK MESDGEKKYP CPECGSFFRS KSYLNKHIQK VHVRALGGPL GDLGPALGSP 600 FSPQQNMSLL ESFGFQIVQS AFASSLVDPE VDQQPMGPEG K SEQ ID NO:266 PBY9 DNA sequence Nucleic Acid Accession*: N _012429 Coding sequence: 174-1385 (underlined sequence corresponds to start and stop codon) 1 11 21 31 41 51 I I I I I I CCCTACTCCG CCTCTCGGGA TCCTTTAAGA GGCGGGGCTT GGCTGCCAGC TCCGCGGCCC 60 GGGCAAAAGG CTGGGACTTT ACTCCGGGTC GCGGCGAGGA CGAGTCTGTC CTCCATCAGC 120 TGCCGCACCC GCCGCCTCCC GCCCCCAAAC CCCATCCCCG CGGTTGAGCC ACGATGAGCG 180 GCAGAGTCGG CGATCTCAGC CCCAGGCAGA AGGAGGCATT GGCCAAGTTT CGGGAGAATC 240 TCCAGGATGT GCTCCCGGCC CTGCCGAATC CAGATGACTA TTTTCTCCTG CGTTCGCTCC 300 GAGCCAGAAG CTTCGACCTG CAGAAGTCGG AGGCCATGCT CCGGAAGCAT GTGGAGTTCC 360 GAAAGCAAAA GGACATTGAC AACATCATTA GCTGGCAGCC TCCAGAGGTC ATCCAACAGT 420 ATCTGTCAGG GGGTATCTGT GGCTATGACC TGGATCGCTG CCCAGTCTGG TACGACATAA 480 TTGGACCTCT GGATGCCAAG GGTCTGCTGT TCTCAGCCTC CAAACAGGAC CTGCTGAGGA 540 CCAAGATGCG GGAGTGTGAG CTGCTTCTGC AAGAGTGTCC CCACCAGACC ACAAAGTTGG 600 GGAGGAAGGT GGAGACCATC ACCATAATTT ATGACTCCGA GGGGCTTGGC CTCAAGCATC 660 TCTGGAAGCC TGCTGTGGAG GCCTATGGAG AGTTTCTCTG CATGTTTGAG GAAAATTATC 720 CCGAAACACT GAAGCGTCTT TTTGTTGTTA AAGCCCCCAA ACTGTTTCCT GTCGCCTATA 780 ACCTCATCAA ACCCTTCCTG AGTGAGGACA CTCGTAAGAA GATCATGGTC CTCGGAGCAA 840 ATTGGAAGGA GGTTTTACTG AAACATATCA GCCCTCACCA GGTGCCTGTG GAGTATGGGG 900 GCACCATGAC TGACCCTGAT GGAAACCCCA AGTGCAAATC CAAGATCAAC TACGGGGGTG 960 ACATCCCCAG GAAGTATTAT GTGCGAGACC AGGTGAAACA GCAGTATGAA CACAGCGTGC 1020 AGATTTCCCG TGGCTCCTCC CACCAAGTGG AGTATGAGAT CCTCTTCCCT GGCTGTGTCC 1080 TCAGGTCGCA GTTTATCTCA GATGGAGCGG ATGTTCGTTT TCGGATTTTC CTGAAGACCA 1140 AGATGGGAGA GAGGCAGCGG GCAGGGGAGA TGACAGAGGT GCTCCCCAAC CAGAGGTACA 1200 ACTCCCACCT GGTCCCTGAA GATGGGACCC TCACCTGCAG TGATCCTCGC ATCTATGTCC 1260 TGCGGTTTGA CAACACCTAC AGCTTCATTC ATGCCAAGAA GGTCAATTTC ACTGTGGAGG 1320 TCCTGCTTCC AGACAAAGCC TCAGAAGAGA AGATCAAACA GCTCGGGGCA GGCACCCCGA 1380 AATAACACCT TCTCCTATAG CAGGCCTGGC CCCCTCAGTG TCTCCCTGTC AATTTCTACC 1440 CCTTCTAGCA GTCATTTTCG CACAACCCTG AAGCCCAAAG AAACTGGGCT GGAGGACAGA 1500 CCTCAGGAGC TTTCATTTCA GTTAGGCAGA GGAAGAGCGA CTGCAGTGGG TCTCCGTGTC 1560 TATCAAATAC CTAAGGAGTC CCCAGGAGCT GGCTGGCCAT CGTGATAGGA TCTGTCTGTC 1620 CTCTAAACTG TCCCAACTTC ACCTGTCCAG GGACAGCGAA GCTCGGGGTC GCGGGGGGCA 1680 TGTACCACAG GGTGGCAGCA GGGAAAAAAA TTAGAAAAGG GTCAAAGATT GGGACTTAAC 1740 ACTTCAGGGA AGTCAGCTCC CGGGGAGAAA CTTGCTCCTA AATCAACACA TAAGTTTAGA 1800 TCGCAATGAG GAGTAGCAGG GTAGCTCGTT GCTAGAGTTA CGGTGGGGAT CAGAAACTCT 1860 TCCAAACATT TTAGCACTGA GGCTGGGGTA GCTTTTGGCT TTTCCCAGGT CTCAGGAGGT 1920 GGCCTGAGTC AGCACACATC TTCCCACTCG GTAGACAGGC TGGCCTCTCC CTCACTTTGA 1980 GACTTTGGCA ACTCCTGGGC CACACGGCCT GCCTCTTTGA TTACTAATGA TTGTCAGTGA 2040 CTCAGAGCTT CCTGGGACTT CGGGTACCCA CCCβCTCTTC TCCATGCAAA CAAAGCGCCA 2100 GGGAAATGAC CCACAGGGAT CGCAGCTGCA GGGAGGGCCA GGGAGGTTGG GGGTGGGAGT 2160 GAATGCTAAA AGCAGATCGT CCAGTCCCCT TTTCAGTGCT ACCGGCCTCT CACCAAGCAG 2220 TCCTCCATGT GAGCAACCCC GAGACAAAAA TGCTAAGTGG GATCAAGAGA GCAGCACTCG 2280 GAGAGGGTGT TTGCCAGTCT GAGTGTCCCG CGGTGCCCGC CAACCCGCTT CCTGACTGAC 2340 CTCAGCAAGG TCTTACTAAG CAGTCCCATC TCTGTGGGAG GCATGCAACG CGTGCAGGGA 2400 GTTCAGGTGC CGGTCGGCGT AGCCAGGCCT GGAGGCCCCC CAGGCAGGAG GCCGCCCAAA 2460 GGCGGGGCCG GCGTCTCGCA GACTAGGGGC TGGGGGCGGC CACAGACGGC CTCGAAACCA 2520 CAGCCCTTAC CCCAATCCCA CGAGCCCCGC CAACGAACCA CAGGTGCTGG GCTTTAGAGA 2580 ACATCGGAAβ GCGGCCCCAG ACCTGGCGGG AACGCCTTTC CCTCAGAGCC AGGCCCCGGC 2640 CCCGTCTGGG AAGCTCATCT TGCGAAGCTG AGGGAGCTCA GGGCAAAGGC CAGGCTAGCG 2700 CGGACCGGAA GGGGCCGAGG CTGCACGGGC CTCTCCCAGA ACGCTCAGGA CATCCCGGCC 2760 TCGGTTTACA ACGCTCTTAG GAAAATTAAC CAATCAATAA AGCAACGTTC AGTCCGCA SEQ ID NO:267 PBY9 Protein sequence: Protein Accession*: NP_036561 MSGRVGDLSP RQKEALAKFR ENVQDVLPAL PNPDDYFLLR WLRARSFDLQ KSEAMLRKHV 60 EFRKQKDIDN IISWQPPEVI QQYLSGGMCG YDLDGCPVWY DIIGPLDAKG LLFSASKQDL 120 LRTKMRECELLIXJECAHQTT KLGRKVEΉT IIYDCEGLGL KHLWKPAVEA YGEFLCMFEE 180 NYPETLKRLF VVKAPKLFPV AYNLIKPFLS EDTRKKIMVL GANWKEVLLK HISPDQVPVE 240 YGGTMTDPDG NPKCKSKINY GGDIPRKYYV RDQVKQQYEH SVQISRGSSH QVEYEILFPG 300 CVLRWQFMSD GADVGFGIFL KTKMGERQRA GEMTEVLPNQ RYNSHLVPED GTLTCSDPGI 360 YVLRFDNTYS FIHAKKVNFT VEVLLPDKAS EEKMKQLGAG TPK SEQ ID NO:268 PBH8 DNA sequence Nucleic Acid Accession*: XM_009756 Coding sequence: 301 -1440 (undedined sequence corresponds to start and stop codon) 11 21 31 41 51 GTGGGGACAG C ICGAGCCGCG C ICGGGCCCCT G IGACGGCGTC G ICCAAGGAGC TC IGGATCGCA 60 CTTCCTGCAG ACTTTGGATG GATTTGTTTT TGTGGTAGCA TCTGATGGCA AAATCATGTA 120 TATATCCGAG ACCGCTTCTC TCCATTTAGG CTTATCCCAG GTCGAGCTCA CGGGCAACAG 180 TATTTATCAA TACATCCATC CTTCTCACCA CGATGAGATG ACCGCTGTCC TCACGGCCCA 240 CCAGCCGCTβ CACCACCACC TGCTCCAAGG TATGAGATAG AGAGGTCGTT CTTTCTTCGA 300 ATGAAATGTG TCTTGGCGAA AAGGAACGCG GGCCTGACCT GCAGCGGATA CAAGGTCATC 360 CACTGCAGTβ GCTACTTGAA GATCAGGCAG TATATCCTCG ACATGTCCCT GTACGACTCC 420 TGCTACCAGA TTGTGGGGCT GGTGGCCGTG GGCCAGTCGC TGCCACCCAG TGCCATCACC 480 GAGATCAAGC TGTACAGTAA CATGTTCATG TTCAGGGCCA GCCTTGACCT GAAGCTGATA 540 TTCCTGGATT CCAGGGTGAC CGAGGTGACG GGGTACGAGC CGCAGGACCT GATCGAGAAG 600 ACCCTATACC ATCACGTCCA CGGCTGCGAC GTGTTCCACC TCCGCTACGC ACACCACCTC 660 CTGTTGGTGA AGGGCCAGGT CACCACCAAG TACTACCGGC TGCTGTCCAA GCGGGGCGGC 720 TCGGTGTGGβ TGCAGAGCTA CGCCACCGTC GTCCACAACA GCCGCTCGTC CCGGCCCCAC 780 TCCATCGTGA GTCTCAATTA TGTACTCACG GAGATTGAAT ACAAGGAACT TCAGCTCTCC 840 CTGGAGCAGG TGTCCACTGC CAAGTCCCAG GACTCCTGGA GGACCGCCTT GTCTACCTCA 900 CAAGAAACTA GGAAATTAGT GAAACCCAAA AATACCAAGA TCAAGACAAA GCTCAGAACA 960 AACCCTTACC CCCCACAGCA ATACAGCTCG TTCCAAATGG ACAAACTGGA ATGCGGCCAG 1020 CTCGGAAACT GGAGAGCCAG TCCCCCTGCA AGCGCTGCTG CTCCTCCAGA ACTGCAGCCC 1080 CACTCAGAAA GCAGTGACCT TCTGTACACG CCATCCTACA GCCTCCCCTT CTCCTACCAT 1140 TACGGACACT TCCCTCTGGA CTCTCACGTC TTCAGCAGCA AAAAGCCAAT GTTGCCGGCC 1200 AAGTTCGGGC AGCCCCAAGG ATCCCCTTGT GAGGTGGCAC GCTTTTTCCT GAGCACACTC 1260 CCAGCCAGCG GTCAATGCCA GTGGCATTAT GCCAACCCCC TAGTGCCTAG CAGCTCGTCT 1320 CCAGCTAAAA ATCCTCCAGA GCCACCGGCG AACACTCCTA GGCACAGCCT GGTCCCAAGC 1380 TACGAAGGCA AGCAGATGTC CTCTGCGGAG ATACCGCCAG CTCCCCAGGA CGCAGACTGA 1440 CTCCTGTTTG CTCGCTGGAC CAAC SEQ ID NO:269 PBHB Protein sequence: Protein Accession ft NP_005060 MKEKSKNAAK TRREKENGEF YELAKLLPLP SAITSQLDKA SDRLTTSYL KMRAVFPEGL 60 GDAWGQPSRA GPLDGVAKEL GSHLLQTLDG FVFVVASDGK IMYISETASV HLGLSQVELT 120 GNSIYEYIHP SDHDEMTAVL TAHQPLHHHL LQEYEIERSF FLRMKCVLAK RNAGLTCSGY 180 KVIHCSGYLK IRQYMLDMSL YDSCYQIVGL VAVGQSLPPS AITEIKLYSN MFMFRASLDL 240 KLIFLDSRVT EVTGYEPQDL IEKTLYHHVH GCDVFHLRYA HHLLLVKGQV TTKYYRLLSK 300 RGGWVWVQSY ATWHNSRSS RPHCIVSVNY VLTEIEYKEL QLSLEQVSTA KSQDSWRTAL 360 STSQETRKLV KP--NTKMKTK LRTNPYPPQQ YSSFQMDKLE CGQLGNWRAS PPASAAAPPE 420 LQPHSESSDL LYTPSYSLPF SYHYGHEPLD SHVFSSKKPM LPAKFGQPQG SPCEVARFFL 480 STLPASGECQ WHYANPLVPS SSSPAKNPPE PPANTARHSL VPSYEAPAAA VRRFGEDTAP 540 PSFPSCGHYR EEPALGPAKA ARQAARDGAR LALARAAPEC CAPPTPEAPG APAQLPFVLL 600 NYHRVLARRG PLGGAAPAAS GLACAPGGPE AATGALRLRH PSPAATSPPG APLPHYLGAS 660 VΠTNGR SEQ ID NO:270 PBJ9 DNA sequence: Nucleic Acid Accession*: AA760894 GGCACGAGGA GAAGATGTGG CTTGCTCATG CTTGACTTCT GCCATGGTTG TGAGGCCTCC 60 CCAGCCATGTGGAACTGTTTTCAGGTGCTG GTTCCATGGCTCTTCCTGAG CCGAAAATAA 120 GGAAACTCCA TAGACCTTGT CCACTGGAAC TCGTTCCCAT CTACCCTCCA CTCTATCCAG 180 GGTGATGGAT CTCTGCAGTA AGTGGAAGAG TTCTTCATGG CCCCCAAGGT TATATCCATC 240 TAGAACTTCA GCACGTAATT TCATCTGGAA ATAGTGCCTT TGTGGATATA AGTTAGGTAA 300 AACTGAAGAT GAGATCATAC TGGATTAGGA TGGGATCTAA ATCCAATGAA AATGTCTTCA 360 TAAAAAACAG GAAAGAACCC ATAGAAACAC AAGGAAGAAG GTCATGTGAA GATGGAGGCA 420 GAGATTGGAG GGATGCAGCC ACCGGCCCAG GAATGCCAGC AGCCACCCAG AAGCTGGAAG 480 GAAATGAGGG ATTCTCTCCT AGAACCTTTA GAGAGRACAT GGTCCTGTGA ACAGCTTGAT 540 TTTGGACTTG CCCATAGCTT GTATACTCTT ACTTTGGATA CAATTTTATC CAAACTTGGC 600 TAAACAGTTT CTCAGCCTAT GGAAAATTTA AAATGGAGAA GATTCAACTC GATTCTTACA 660 GATTCAAAGC AAGAAAATGA TGGGAACATA GGAGGAGACC AAGAAAGCCT ATAAAAAGCA 720 AAAATATGAAGTGAACATTG TGGTAGCTTTAAGATGTTTA GTGTAGCTGCAGGCACCCTA 780 TACACATGAA AACCCCCAAG GGGAATCCCC ATATCACAGT GTAGTGTGAT ATTTGACATT 840 YGTGATCATY TAGAGATGTA CAGAAAAGGT GAATCTGTGT TCTGTATATT CTGCCTAAGG 900 CAAAGAAATG TTTAGCTYTC TTTAAAATAG TTCCATAATT TTTTYTAAAA AGCTTTGCTT 960 GAAAACTGTA AGCTTCCCATATCTGGAGCATTTCACTTTAAATATTTGGATAAATATGTT 1020 ATCTTCTTACTTGGACATTTCATGTGTTTAGGGATTGTYTTYTAAATTCTTCCTAATTCA 1080 TATAGCTGCT AACACTTCCC GCAGAGCTAA ACCATTACAG ANTATGAAAT AAAGACCCTA 1140 TTGATTTGAA CTTAAAAAAA AAAAMAMAAA AAAAAAAAAA AAAAAAAAAT GA SEQ ID NO:271 PBQ4 DNA sequence Nucleic Acid Accession*: AA149579 Coding sequence: 1-1363 (undeitined sequence corresponds to start and stop codon) 11 21 31 41 51 I I I I I ATGGAATCAA TCTCTATGAT GGGAAGCCCT AAGAGCCTTA GTCAAACTTG TTTACCTAAT 60 GGCATAAATG GTATCAAAGA TGCAAGGAAG GTCACTGTAG GTGTCATTGG AAGTGGAGAT 120 TTTGCCAAAT CCTTGACCAT TCGACTTATT AGATGCGGCT ATCATGTGGT CATAGGAAGT 180 AGAAATCCTA AGTTTGCTTC TGAATTTTTT CCTCATGTGG TAGATGTCAC TCATCATGAA 240 GATGCTCTCA CAAAAACAAA TATAATATTT GTTGCTATAC ACAGAGAACA TTATACCTCC 300 CTGTGGGACC TCAGACATCT GCTTGTGGGT AAAATCCTGA TTGATGTGAG CAATAACATG 360 AGGATAAACC AGTACCCAGA ATCCAATGCT GAATATTTGG CTTCATTATT CCCAGATTCT 420 TTGATTGTCA AAGGATTTAA TGTTGTCTCA GCTTGGGCAC TTCAGTTAGG ACCTAAGGAT 480 GCCAGCCGGC AGGTTTATAT ATCCAGCAAC AATATTCAAG CGCGACAACA GGTTATTCAA 540 CTTGCCCGCC AGTTGAATTT CATTCCCATT GACTTGGGAT CCTTATCATC AGCCAGAGAG 600 ATTGAAAATT TACCCCTACG ACTCTTTACT CTCTGGAGAG GGCCAGTGGT GGTAGCTATA 660 AGCTTGGCCA (^TTTTTTTT CCTTTATTCC TTTGTCAGAG ATGTGATTCA TCCATATGCT 720 AGAAACCAAC AGAGTGACTT TTACAAAATT CCTATAGAGA TTGTGAATAA AACCTTACCT 780 ATAGTTGCCA TTACTTTGCT CTCCCTAGTA TACCTCGCAG GTCTTCTGGC AGCTGCTTAT 840 CAACTTTATT ACGGCACCAA GTATAGGAGA TTTCCACCTT GGTTGGAAAC CTGGTTACAG 900 TGTAGAAAAC AGCTTGGATT ACTAAGTTTT TTCTTCGCTA TGGTCCATGT TGCCTACAGC 960 CTCTGCTTAC CGATGAGAAG GTCAGAGAGA TATTTGTTTC TCAACATGGC TTATCAGCAG 1020 GTTCATCCAA ATATTCAAAA CTCTTGGAAT GAGGAAGAAG TTTGGAGAAT TGAAATGTAT 1080 ATCTCCTTTG GCATAATGAG CCTTGGCTTA CTTTCCCTCC TGGCAGTCAC TTCTATCCCT 1140 TCAGTGAGCA ATGCTTTAAA CTGGAGAGAA TTCAGTTTTA TTCAGTCTAC ACTTGGATAT 1200 GTCGCTCTGC TCATAAGTAC TTTCCATGTT TTAATTTATG GATGGAAACG AGCTTTTGAG 1260 GAAGAGTACT ACAGATTTTA TACACCACCA AACTTTCTTC TTGCTCTTGT TTTGCCCTCA 1320 ATTGTAATTC TGGATCTTTT GCAGCTTTGC AGATACCCAβ ACTGA SEQ ID NO:272 PBQ4 Protein sequence: Protein Accession *: none 11 21 31 41 51 I I I I I I MESISMMGSP KSLSETCLPN GINGIKDARK VTVGVIGSGD FAKSLTIRLI RCGYHWIGS 60 RNPKFASEFF PHWDVTHHE DALTKTNIIF VAIHREHYTS LWDLRHLLVG KILIDVSNNM 120 RINQYPESNA EYLASLFPDS LIVKGFNWS AWALQLGPKD ASRQVYICSN NIQARQQVIE 180 LARQLNFIPI DLGSLSSARE IENLPLRLFT LWRGPVWAI SLATFFFLYS FVRDVIHPYA 240 RNQQSDFYKI PIEΓVNKTLP IVAITLLSLV YLAGLLAAAY QLYYGTKYRR FPPWLETWLQ 300 CRKQLGLLSF FFAMVHVAYS LCLPMRRSER YLFLNMAYQQ VHANIENSWN EEEVWRIEMY 360 ISFGIMSLGL LSLLAVTSIP SVSNALNWRE FSFIQSTLGY VALLISTFHV LIYGWKRAFE 420 EEYYRFYTPP NFVLALVLPS IVILDLLQLC RYPD SEQ ID N0.273 PBQ5 DNA SEQUENCE Nucleic Acid Accession*: NM_001973 Coding sequence: 150-1445 (underlined sequence corresponds to start and stop codon) 11 21 31 41 51 I I I I I CCGCCGCCTT CTACTCCGCC GCGGGGGTCG CAGCGGCTGC CGCGCCGTCC TCGAGTTTCC 60 AGCGTGAGGA GGAGGCTGAG GGCGGAGAGG CGCATCGTGT TCGAGGCGGA GACCGAGGGG 120 GAGCCCCGCG CGCGGCGTCG CTCATTCCTA TCGACAGTGC TATCACCCTG TGGCAGTTCC 180 TTCTTCAGCT CCTGCAGAAG CCTCAGAACA AGCACATGAT CTCTTGGACC TCTAATGATC 240 GGCAGTTTAA GCTTTTGCAG GCAGAAGAGG TGGCTCGTCT CTGGGGGATT CGCAAGAACA 300 AGCCTAACAT GAATTATGAC AAACTCAGCC GAGCCCTCAG ATACTATTAT GTAAAGAATA 360 TCATCAAAAA AGTGAATGGT CAGAAGTTTC TGTACAAGTT TGTCTCTTAT CCAGAGATTT 420 TGAACATCGA TCCAATCACA GTCGGCAGGA TTGAGGGTGA CTCTGAAAGT TTAAACTTCA 480 GTGAAGTCAG CAGCAGTTCC AAAGATGTGG AGAATGGAGG GAAAGATAAA CCACCTCAGC 540 CTGGTGCCAA GACCTCTAGC CGCAATGACT ACATACACTC TGGCTTATAT TCTTCATTTA 600 CTCTCAACTC TTTGAACTCC TCCAATCTAA AGCTTTTCAA ATTGATAAAG ACTCAGAATC 660 CAGCCGAGAA ACTGGCAGAG AAAAAATCTC CTCAGGAGCC CACACCATCT GTCATCAAAT 720 TTGTCACGAC ACCTTCCAAA AAGCCACCAG TTGAACCTGT TGCTGCCACC ATTTCAATTG 780 GCCCAAGTAT TTCTCCATCT TCAGAAGAAA CTATCCAAGC TTTGGAGACA TTGGTTTCCC 840 CAAAACTGCC TTCCCTCGAA GCCCCAACCT CTGCCTCTAA CGTAATCACT GCTTTTGCCA 900 CCACACCACC CATTTCGTCC ATACCCCCTT TGCAGGAACC TCCCAGAACA CCTTCACCAC 960 CACTGAGTTC TCACCCAGAC ATCGACACAG ACATTGATTC AGTGGCTTCT CAGCCAATGG 1020 AACTTCCAGA GAATTTGTCT CTGGAGCCTA AAGACCAGGA TTCAGTCTTG CTAGAAAAGG 1080 ACAAAGTAAA TAATTCATCA AGATCCAAGA AACCCAAAGG GTTAGGACTG GCACCCACCC 1140 TTGTGATCAC GAGCAGTGAT CCAAGCCCAC TGGGAATACT GAGCCCATCT CTCCCTACAG 1200 CTTCTCTTAC ACCAGCATTT TTTTCACAGA CACCCATCAT ACTGACTCCA AGCCCCTTGC 1260 TCTCCAGTAT CCACTTCTGG AGTACTCTCA GTCCTGTTGC TCCCCTAAGT CCAGCCAGAC 1320 TGCAAGGTGC TAACACACTT TTCCAGTTTC CTTCTGTACT GAACAGTCAT GGGCCATTCA 1380 CTCTGTCTGG GCTGGATGGA CCTTCCACCC CTGGCCCATT TTCCCCAGAC CTACAGAAGA 1440 CATAACCTAT GCACTTCTGG AATGAGAGAA CCGAGGAACG AAGAAACAGA CATTCAACAT 1500 GATTGCATTT GAAGTGAGCA ATTCATAGTT CTACAATGCT GATAATAGAC TATTCTGATT 1560 TTTGCCATTC CCCATTCAAA ACATCTTTTT AGGATTCTCT TTGAATAGGA CTCAAGTTGG 1620 ACTATATCTA TAAAAATCCC TTAATTGGAG TCTAAACTCC ACCTCCCTCT GTCTTTTCCT 1680 TTTCTTTTTC TTTCCTTCCT TCCTTTTCTT TTCTCCTTTA AAAATATTTT GAGCTTTGTG 1740 CTCAAGAAGT TTTTGGTGGG CTTTAGTCAC TGTGCTTTGC AAAAGCAATT AAGAACAAAG 1800 TTACTCCTTC TGGCTATTGG GACCCTTTCG CCAGGAAAAA TTATGCTTAG AATCTATTAT 1860 TTAAAGAAGT ATTTGTCAAA TCAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1920 AAAAAAAAAA AAA SEQ ID N0:274 PBQ5 Protein sequence: Protein Accession* NP_001964 MDSA-TLWQF LLQLLQKPQN KHMICWTSND GQFKLLQAEE VARLWGIRKN KPNMNYDKLS 60 RALRYYYVKN IIKKVNGQKF VYKFVSYPEI LNMDPMTVGR IEGDCESLNF SEVSSSSKDV 120 ENGGKDKPPQ PGAKTSSRND YIHSGLYSSF TLNSLNSSNV KLFKLIKTEN PAEKLAEKKS 180 PQEPTPSVIK FVTTPSKKPP VEPVAAΗSI GPSISPSSEE TIQALETLVS PKLPSLEAPT 240 SASNVMTAFA TTPPISSIPP LQEPPRTPSP PLSSHPDIDT DIDSVASQPM ELPENLSLEP 300 KDQDSVLLEK DKVNNSSRSK KPKGLGLAPT LVITSSDPSP LGILSPSLPT ASLTPAFFSQ 360 TPIILTPSPL LSSIHFWSTL SPVAPLSPAR LQGANTLFQF PSVLNSHGPF TLSGLDGPST 420 PGPFSPDLQ T SEQ ID NO:275 PBY3 DNA SEQUENCE Nucleic Acid Accession* AB040921 Coding sequence: 131-2560 (underlined sequence corresponds to start and stop codon) 11 21 31 41 51 I AATCAGGAAC AGATCATATA TTGACCGAGA TTCTGAGTAT CTCTTCCAAG AAAATCAACC 60 AGATGGAACT TTAGACCAAA AATTATTGGA AGATTTACAA AAGAAAAAAA ATCACCTTCG 120 GTATATTGAA ATCCAGCATT TCAGAGAAAA GCTGCCTTCG TATGGAATGC AAAAGGAATT 180 GGTAAATTTA ATTGATAACC ATCAGGTAAC AGTAATAAGT GGTGAAACTG GTTCTGGCAA 240 AACCACTCAA GTTACTCAGT TCATTTTGGA TAACTACATT GAAAGAGGAA AAGGATCTCC 300 TTGCAGAATA GTTTCTACTC AGCCAAGAAG AATTAGTGCC ATTTCAGTTG CGGAAAGAGT 360 AGCTGCAGAA AGGGCAGAAT CTTCTGGCAG TGGTAATAGT ACTCGATATC AAATTCGTCT 420 CCAGAGTCGG TTGCCAAGGA AACAGGGTTC TATCTTATAC TGTACAACAG GAATCATCCT 480 TCAGTGGCTC CAGTCAGACC CGTATTTGTC CAGTGTTAGT CATATCGTAC TTGATGAAAT 540 CCATGAAAGA AATCTGCAGT CAGATGTTTT AATGACTGTT GTTAAAGACC TTCTCAATTT 600 TCGATCTGAC TTGAAAGTAA TATTGATGAG TGCAACATTG AATGCAGAAA AGTTTTCAGA 660 ATATTTTGGT AACTGTCCAA TGATACATAT ACCTGGTTTT ACCTTTCCGG TTGTGGAATA 720 TCTTTTGGAA GATGTAATTG AAAAAATAAG GTATGTTCCA GAACAAAAAG AACACAGATC 780 CCAGTTTAAG AGGGGTTTCA TGCAAGGGCA TGTAAATAGA CAAGAAAAAG AAGAAAAAGA 840 AGCAATATAT AAAGAACGTT GGCCAGATTA TGTAAGGGAA CTGCGAAGAA GGTATTCTGC 900 AAGTACTGTA GATGTTATAG AAATGATGGA GGATGATAAA GTTGATCTCA ATTTGATTGT 960 TGCCCTCATC CGATACATTC TTTTCGAAGA AGAGGATGGT GCGATACTCG TCTTTCTCCC 1020 AGGCTGGGAC AATATCAGCA CTTTACATGA TCTCTTGATG TCACAAGTAA TGTTTAAATC 1080 AGATAAATTT TTAATTATAC CTTTACATTC ACTGATGCCT ACAGTTAACC AGACACAGGT 1140 GTTTAAAAGA ACCCCTCCTG GTGTTCGGAA AATAGTAATT GCTACCAACA TTGCGGAGAC 1200 TAGCATTACC ATAGATGATG TCGTTTATCT GATAGATCGA GGAAAAATAA AAGAGACGCA 1260 TTTTCATACT CAGAACAATA TCAGTACAAT GTCCGCTCAG TGGGTTAGTA AAGCTAATCC 1320 CAAACAGAGA AAAGGTCGAG CTGGAAGAGT TCAACCTCGT CATTCCTATC ATCTGTATAA 1380 TGGTCTTAGA GCAAGTCTTC TAGATGACTA TCAACTCCCA GAAATTTTCA GAACTCCTTT 1440 GGAAGAACTT TCTTTACAAA TAAAGATTTT AAGGCTAGGT GGAATTGCTT ATTTTCTCAG 1500 TAGATTAATG GACCCACCAT CAAATGAGGC AGTGTTACTC TCCATAAGAC ACCTGATGGA 1560 GCTGAACGCT TTGGATAAAC AAGAAGAATT GACACCTCTT GGAGTCCACT TGGCACGATT 1620 ACCCGTTCAG CCACATATTG GAAAAATGAT TCTTTTTGGA GCACTCTTCT GCTGCTTAGA 1680 CCCAGTACTC ACTATTGCTG CTAGTCTCAG TTTCAAAGAT CCATTTGTCA TTCCACTGGG 1740 AAAAGAAAAG ATTGCAGATG CAAGAAGAAA GGAATTGGCA AAGGATACTA GAAGTGATCA 1800 CTTAACAGTT GTGAATCCGT TTGAGGGCTG GGAAGAGGCT AGGCGACGTG GTTTCAGATA 1860 CGAAAAGGAC TATTGCTGGG AATATTTTCT GTCTTCAAAC ACACTGCAGA TGCTGCATAA 1920 CATGAAAGGA CAGTTTGCTC AGCATCTTCT TGGAGCTGGA TTTGTAAGCA GTAGAAATCC 1980 TAAAGATCCA GAATCTAATA TAAATTCAGA TAATGAGAAG ATAATTAAAG CTGTCATCTC 2040 TGCTCGTTTA TATCCCAAAG TTGCTAAAAT TCGACTAAAT TTCGGTAAAA AAAGAAAAAT 2100 GGTAAAAGTT TACACAAAAA CCGATGGCCT GGTTGCTCTT CATCCTAAAT CTGTTAATGT 2160 GGAGCAAACA GACTTTCACT ACAACTGGCT TATCTATCAC CTAAAGATGA GAACAAGCAG 2220 TATATACTTC TATGACTGCA CAGAGGTTTC CCCATACTCT CTCTTCTTTT TTGGAGGTGA 2280 CATTTCCATC CAGAAGGATA ACGATCAGGA AACTATTGCT GTAGATCAGT GGATTGTATT 2340 TCAGTCTCCA GCAAGAATTG CCCATCTTGT TAAGGAATTA AGAAAGGAAC TAGATATTCT 2400 TCTCCAAGAG AAGATTCAAA GTCCTCATCC TGTAGACTGG AATGACACTA AATCCAGAGA 2460 CTGTGCAGTA CTCTCAGCTA TTATAGACTT GATCAAAACA CAGGAAAAGG CAACTCCCAG 2520 GAACTTTCCG CCACGATTCC AGGATGGATA TTACAGCTGA CAGCTTTTCA GGGGTGGTCT 2580 GAAAAGCCAG TTTGACAGCC ATTCTTCATC ATTGTTTAAA TTTTGGCTGG ATGCCAAACC 2640 CTCGGACATG AACAATTTTC ATGTGTAAGG TAGAAGCCTT CAGTAGGTAG TAAAGACTTA 2700 ATCTGCATGA CTTGATGTTA TATGTAGAGA TATATATATA TATATATATA CCATAAAAGC 2760 AATATCTTCT CTGATCATAT ACTCTGCTCT GGTCATGCCC ACTCTTTGGG AGTATATTCC 2820 CTTTATATAT ATTCAGTATT GTACCACTTG AGAAATTCCT TTGTTCTGTT ATACAAAATT 2880 AATCTTTCTC CTCATAATGA TTGATGATAC CACCAGTAAA AATAGGATCT TTACCCCAAA 2940 ACAAGTGTCA ATTAAGAATT TCAACACAAC CACATTTTTT AAAATCAAAC TTCTATCGGA 3000 AGTAAATTAA TTTGTTCTAA TAAAGTCCAG TATTTAATAA AATGTACAAT GTTAAATCTC SEQ ID N0:276 PBY3 Protein sequence: Protein Accession * BAA96012 SEQ ID NO:277 PBY6 DNA SEQUENCE Nucleic Acid Accession*: AA464018 Coding sequence: 64-1669(underiined sequence corresponds to start and stop codon) GATTTTATCC TGGAACATTA CAGTGAAGAT GGCTATTTAT ATGAAGATGA AATTGCAGAT 60 CTTATGGATC TGAGACAAGC TTGTCGGACG CCTAGCCGGG ATGAGGCCGG GGTGGAACTG 120 CTGATGACAT ACTTCATCCA GCTGGGCTTT GTCGAGAGTC GATTCTTCCC GCCCACACGG 180 CAGATGGGAC TCCTGTTCAC CTGGTATGAC TCTCTCACCG GGGTTCCGGT CAGCCAGCAG 240 AACCTGCTGC TGGAGAAGGC CAGTGTCCTG TTCAACACTG GGGCCCTCTA CACCCAGATT 300 GGGACCCGGTGTGATCGGCA GACGCAGGCTGGGCTGGAGA GTGCCATAGA TGCCTTTCAG 360 AGAGCCGCAG GGGTTTTAAA TTACCTGAAA GACACATTTA CCCATACTCC AAGTTACGAC 420 ATGAGCCCTG CCATGCTCAG CGTGCTCGTC AAAATGATGC TTGCACAAGC CCAAGAAAGC 480 GTGTTTGAGA AAATCAGCCT TCCTGGGATC CGGAATGAAT TCTTCATGCT GGTGAAGGTG 540 GCTCAGGAGG CTGCTAAGGT GGGAGAGGTC TACCAACAGC TACACGCAGC CATGAGCCAG 600 GCGCCGGTGA AAGAGAACAT CCCCTACTCC TGGGCCAGCT TAGCCTGCGT GAAGGCCCAC 660 CACTACGCGG CCCTGGCCCA CTACTTCACT GCCATCCTCC TCATCGACCA CCAGGTGAAG 720 CCAGGCACGG ATCTGGACCA CCAGGAGAAG TGCCTGTCCC AGCTCTACGA CCACATGCCA 780 GAGGGGCTGA CACCCTTGGC CACACTGAAG AATGATCAGC AGCGCCGACA GCTGGGGAAG 840 TCCCACTTGC GCAGAGCCAT GGCTCATCAC GAGGAGTCGG TGCGGGAGGC CAGCCTCTGC 900 AAGAAGCTGC GGAGCATTGA GGTGCTACAG AAGGTGCTGT GTGCCGCACA GGAACGCTCC 960 CGGCTCACGT ACGCCCAGCA CCAGGAGGAG GATGACCTGC TGAACCTGAT CGACGCCCCC 1020 AGTGTTGTTG CTAAAACTGA GCAAGAGGTT GACATTATAT TGCCCCAGTT CTCCAAGCTG 1080 ACAGTCACGG ACTTCTTCCA GAAGCTGGGC CCCTTATCTG TGTTTTCGGC TAACAAGCGG 1140 TGGACGCCTC CTCGAAGCAT CCGCTTCACT GCAGAAGAAG GGGACTTGGG GTTCACCTTG 1200 AGAGGGAACGCCCCCGTTCA GGTTCACTTC CTGGATCCTTACTGCTCTGC CTCGGTGGCA 1260 GGAGCCCGGGAAGGAGATTA TATTGTCTCC ATTCAGCTTGTGGATTGTAAGTGGCTGACG 1320 CTGAGTGAGG TTATGAAGCT GCTGAAGAGC TTTGGCGAGG ACGAGATCGA GATGAAAGTC 1380 GTGAGCCTCC TGGACTCCAC ATCATCCATG CATAATAAGA GTGCCACATA CTCCGTGGGA 1440 ATGCAGAAAA CGTACTCCAT GATCTGCTTA GCCATTGATG ATGACGACAA AACTGATAAA 1500 ACCAAGAAAA TCTCCAAGAA GCTTTCCTTC CTGAGTTGGG GCACCAACAA GAACAGACAG. 1560 AAGTCAGCCA GCACCTTGTG CCTCCCATCG GTCGGGGCTG CACGGCCTCA GGTCAAGAAG 1620 AAGCTGCCCT CCCCTTTCAG CCTTCTCAAC TCAGACAGTT CTTGGTACIA A SEQ ID NO:278 PBY6 Protein sequence: Protein Accession*: NPJ49094 DFILEHYSED GYLYEDEIAD LMDLRQACRT PSRDEAGVEL LMTYFIQLGF VESRFFPPTR 60 QMGLLFTWYD SLTGVPVSQQ NLLLEKASVL FNTGALYTQI GTRCDRQTQA GLESAIDAFQ 120 I-AAGVLNYLKDTFTHTPSYD MSPAMLSVLV KMMLAQAQES VEEKISLPGIRNEFFMLVKV 180 AQEAAKVGEV YQQLHAAMSQ APVKENIPYS WASLACVKAH HYAALAHYFT AILLIDHQVK 240 PGTDLDHQEK CLSQLYDHMP EGLTPLATLK NDQQRRQLGK SHLRRAMAHH EES VREASLC 300 KKLRSIEVLQ KVLCAAQERS RLTYAQHQEE DDLLNLIDAP SVVAKTEQEV DIILPQFSKL 360 TVTDFFQKLG PLS VFS ANKR WTPPRSIRFT AEEGDLGFTL RGNAPVQVHF LDPYCS ASVA 420 GAREGDYIVS IQLVDCKWLTLSEVMKLLKS FGEDEIEMKV VSLLDSTSSMHNKSATYSVG 480 MQKTYSMICLAIDDDDKTDKTKKISKKLSFLSWGTNKNRQ KSASTLCLPS VGAARPQVKK 540 KLPSPFSLLN SDSSWY SEQ ID N0:279 PBY8 DNA SEQUENCE Nucleic Acid Accession*: AF107493 Coding sequence: 125-556 (underlined sequence corresponds to start and stop codon) 11 21 31 41 51 I I I I I GAATTCGGCA CGAGCCTTGT TGGAGGTTCT GGGGCGCAGA ACCGCTACTG CTGCTTCGGT 60 CTCTCCTTGG GAAAAAATAA AATTTGAACC TTTTGGAGCT GTCTGCTAAA TCTTCAGTGG 120 GACAATGGGT TCAGACAAAA GAGTGAGTAG AACAGAGCGT AGTCGAAGAT ACGGTTCCAT 180 CATAGACAGG GATCACCGTG ATGAGCGTGA AtCCCGAAGC AGGCGGAGGG ACTCAGATTA 240 CAAAAGATCT AGTCATGATC GGAGGGGTGA TAGATATGAT GACTACCGAG ACTATGACAG 300 TCCAGAGAGA GAGCGTGAAA GAAGGAACAG TGACCGATCC GAAGATGGCT ACCATTCAGA 360 TGGTGACTAT GGTCAGCACG ACTATAGGCA TCACATCAGT GACGAGAGGG AGAGCAAGAC 420 CATCATGCTG CGCGGCCTTC CCATCACCAT CACAGAGAGC GATATTCGAG AAATCATGGA 480 GTCCTTCGAA GGCCCTCAGC CTCCGGATGT GAGGCTGATG AAGAGGAAAA CAGGTGAGAG 540 CTTGCTTAGT TCCTGATATT ATTGTTCTCT TCCCCATTCC CACCTCAGTC CCTAAAGAAC 600 ATCCTGATTC CCCCAGTCTT CAAGCACATG AATTCAGAAT GAAAGGTTTG CCATGGCTAA 660 GGAATCTGAC TCTTTCAAAA CCATGTTAGC ATCTGAGGAA CTTTTTTAAA cτττGτττ , ιfA 720 GGGACTTTTT TTTCCTTAGG TAAGTAATGA TTTATAAACT CCTTTTTTTT TTTGACTATA 780 GTCGGTTGCA TGGTTACTTT AAGCGTCGAA TCAAATGGAG TGGCATTTAG TTCAGGCGGC 840 TTCTTCCTTG CCATGGCAAA GTATCAAGAA GATCCCCAAG TCAAGTCACA TTTCTAAAGC 900 TGCTTCCCAA TTGGCTTTGT CACGCAGTGT TGAAGCAGTβ GGAGAGAGAT TCACCTGTTA 960 TAAAGGAACT GACTAACACA AGTATCCCGT CTATATCTGA ATCCTGTCTC TAGGTGTAAG 1020 CCGTCGTTTC GCCTTCGTGG AGTTTTATCA CTTCCAAGAT GCTACCAGCT GGATCGAAGC 1080 CAATCAGGTT GCTTCACTCA CCAAGTCTAG ATATTCATGA AAATGGAACA AGTCTGTACA 1140 ATTTTAAAAA AAGGTTGAAG GAGTGGTTTG TTCCAAAGGA GTGACTTTTT TTTAAAAAAA 1200 AAGCTTTGTA TATATTAAAA TTGATGTTAC TAGAATAAGT ACAGTACCAA GGACTTCATT 1260 ATAGAATTTG TTCTGCCTTT AAACATGGCT ACCTACCTGG CAGGGCTTTG TTAACTACTG 1320 AATACCTGTC TGGTAATCAC TAAAACATCT TTATGTTTCC CTTTTTTCTA GTTTGTTATA 1380 TTCCTATTAT GTCCATTGAG AGTAAGCTTA GTATATCAAA CTCTCCATTT GACAGTGAAG 1440 AGAACATAGT GAAAGTCTCT GGCGGCATTT TTATAAGTAA TTCCTTATTT CTCCCTGAAG 1500 ACCACAAAGC CTCCTGGAGG CGTAACTGCT CAGACCGGTC TTCAGGGAAT ATTTAAGGAC 1560 TTAGTCGAAT TTATGAACAA TAAGTCTGAT GAGATTAGCC TCGSAGTGGT GTCCTGCAGC 1620 TGTCTAATCT AGAGTGGCAT TAACATTCTA ATCTCCTTGA GAATGCCTTT TATAGTCTGT 1680 TCAAAGCAAG TCATTCATGG TTCTTCGAGG TAGTGTTAAC TCAAGTGTTC TTCAGTTTGT 1740 CAAGATAATG TTCAGTGCTT GGCACTTAAA TAACATTTTT TGCAAGAACT CCAAGGCACA 1800 TTATTCAATG CCTTTAACCA AGTCCATTCT GGGAAGTTTG CTTGACTCAT TATCTTGCTT 1860 TTCTCCAGCA TTCTGTGATT TGAGTCATCC ATGAATCCAT GAATAAAAGT TACATTCTTT 1920 GATTGGTAAT ATTGCCATTT ATAACAAGAC TCACTAATCA GGGTATCACT TTGACTGACT 1980 GATTTGTTAA AGTTTTTAAG CCTCTCATTT TCCTAACCCA GAAATCACAG CCTGATTTTA 2040 TTAAAAGTAG AGCTTCATTC ATTTCATACC ATAGATACCA TCCTAGTAAA TCCAGAACAT 2100 ATACAAGGTT CATGTGAGTC TGCTTTCTTC ACATGATAGC ATTGTTTGAT GCAGTCGATA 2160 TGTCAGAATG ACTAACCTAG GAGTTTCAAA CTCCTAAGAA ACTAAAACCT GTAAGACATT 2220 TAAAAGTCTC CACAATTTTA ATGTATACAA AGCTATGTTA CTGTGTAACA CATTACAGTT 2280 CAAATTCACT CCAGAAATAA AAGGCCAGTA GGATTAGGGA CTCACTGGTA GTTTGGAGTC 2340 TCCCAGCACA CATCCCTCCT AGTCGGATGA TCTATTCACA TATCTCCCAG CTTTTTTATT 2400 TTTGCTTCTG TATATCACAG TGAGTCGATC GCCCTTCAGC TTTTTCTCTC CTGGCCAGAC 2460 ATGCAGTCTT GCCTTTAGAT ATCGCAGAGA CAAAATTCAC AGCATGTCTT AAATCTTCCA 2520 GGATTTGCAA GAACCAAATT GCTCAACAGT ATGTATGTTT AGAGGGGTTA GACTCCTTTT 2580 TAAAATCTGG ATATCTAACC ACCTACTTAA ATCTCTTTGA TAGTGTCAAA CCACCCCCAC 2640 CCTTGATCCT CCCACCCCCA AAAAAAAAAA AAAA SEQ ID NO:280 PBY8 Protein sequence Protein Accession*. XPJM3261 MGSDKRVSRT ERSGRYGSII DRDDRDERES RSRRRDSDYK RSSDDRRGDR YDDYRDYDSP 60 ERERERRNSD RSEDGYHSDG DYGEHDYRHD ISDERESKTI MLRGLP-TIT ESDIREMMES 120 FEGPQPADVR LMKRKTGESL LSS SEQ ID NO:281 PCI2 DNA SEQUENCE Nucleic Acid Accession* AF208291 Coding sequence: 109-3705 (underlined sequence corresponds to start and stop codon) 11 21 31 41 51 I I I I I CGGCCGCTTT TTTCTCAAGA TGGCAGATTC CCACTGAGGC TGAGGGGGCC GAGCTCGCGC 60 GCCGCGTTCC CTTCTCCGTT GCCATCAACC GCGGACACCC CGGCCCCGAT GGCCCCCGTG 120 TACGAAGGTA TGGCCTCACA TGTGCAAGTT TTCTCCCCTC ACACCCTTCA ATCAAGTGCC 180 TTCTGTAGTG TGAAGAAACT AAAAGTAGAG CCAAGTTCCA ACTGGGACAT GACTCGGTAC 240 GGCTCCCACA GCAAAGTGTA CAGCCAGAGC AAGAACATAC CACCTTCTCA GCCAGCCTCC 300 ACAACCGTCA GCACCTCCTT GCCGGTCCCA AACCCAAGCC TACCTTACGA GCAGACCATC 360 GTCTTCCCAG GAAGCACCGG GCACATCGTG GTCACCTCAG CAAGCAGCAC TTCTGTCACC 420 GGGCAAGTCC TCGGCGGACC ACACAACCTA ATGCGTCGAA GCACTGTGAG CCTCCTTGAT 480 ACCTACCAAA AATGTGGACT CAAGCGTAAG AGCGAGGAGA TCGAGAACAC AAGCAGCGTG 540 CAGATCATCG AGGAGCATCC ACCCATGATT CAGAATAATG CAAGCGGGGC CACTGTCGCC 600 ACTGCCACCA CGTCTACTGC CACCTCCAAA AACAGCGGCT CCAACAGCGA GGGCGACTAT 660 CAGCTGGTGC AGCATGAGGT GCTGTCCTCC ATGACCAACA CCTACGAGGT CTTAGAGTTC 720 TTGGGCCGAG GGACGTTTGG ACAAGTGGTC AAGTGCTGGA AACGGGGCAC CAATGAGATC 780 GTAGCCATCA AGATCCTGAA GAACCGCCCA TCCTATGCCC GACAAGGTCA GATTGAAGTG 840 AGCATCCTGG CCCGGTTCAG CACGGAGAGT GCCGATGACT ATAACTTCGT CCGGGCCTAC 900 GAATCCTTCC AGCACAAGAA CCACACGTGC TTGGTCTTCG AGATCTTGGA GCAGAACCTC 960 TATGACTTTC TGAAGCAAAA CAAGTTTAGC CCCTTGCCCC TCAAATACAT TCGCCCAGTT 1020 CTCCAGCAGG TAGCCACAGC CCTGATCAAA CTCAAAAGCC TAGGTCTTAT CCACGCTGAC 1080 CTCAAACCAG AAAACATCAT GCTGGTGGAT CCATCTAGAC AACCATACAG AGTCAAGGTC 1140 ATCGACTTTG GTTCAGCCAG CCACGTCTCC AAGGCTGTGT GCTCCACCTA CTTGCAGTCC 1200 AGATATTACA GGGCCCCTGA GATCATCCTT GGTTTACCAT TTTCTGAGGC AATTGACATG 1260 TGGTCCCTGG GCTGTGTTAT TGCAGAATTC TTCCTGGGTT GGCCGTTATA TCCAGGAGCT 1320 TCGGAGTATG ATCAGATTCG GTATATTTCA CAAACACAGG GTTTGCCTGC TGAATATTTA 1380 TTAAGCGCCG GGACAAAGAC AACTAGGTTT TTCAACCGTC ACACGGACTC ACCATATCCT 1440 TTCTGGAGAC TGAAGACACC AGATGACCAT GAAGGAGAGA CAGGGATTAA GTCAAAAGAA 1500 GCAAGAAAGT ACATTTTCAA CTGTTTAGAT GATATGGCCC AGGTGAACAT GACGACAGAT 1560 TTGGAAGGGA GCGACATGTT GGTAGAAAAG GCTCACCGGC GGGAGTTCAT TGACCTGTTG 1620 AAGAAGATGC TGACCATTCA TGCTGACAAG AGAATCACTC CAATCGAAAC CCTGAACCAT 1680 CCCTTTGTCA CCATGACACA CTTACTCGAT TTTCCCCACA GCACACACGT CAAATCATCT 1740 TTCCAGAACA TGGAGATCTG CAAGCGTCGG GTGAATATGT ATGACACGGT GAACCAGAGC 1800 AAAACCCCTT TCATCACGCA CGTGGCCCCC AGCACGTCCA CCAACCTGAC CATGACCTTT 1860 AACAACCAGC TGACCACTGT CCACAACCAG GCTCCCTCCT CTACCAGTGC CACTATTTCC 1920 TTAGCCAATC CCGAAGTCTC CATACTAAAC TACCCATCTA CACTCTACCA GCCCTCAGCG 1980 GCATCCATGG CTGCAGTGGC CCAGCGGAGC ATGCCCCTGC AGACAGGAAC AGCCCAGATT 2040 TCTGCCCGGC CTGACCCGTT CCAGCAAGCT CTCATCGTGT GTCCCCCCGG CTTCCAAGGC 2100 TTGCAGGCCT CTCCCTCTAA GCACGCTGGC TACTCGGTGC GAATGGAAAA TGCAGTTCCC 2160 ATCGTCACTC AAGCCCCAGG AGCTCAGCCT CTTCAGATCC AACCAGGTCT GCTTGCCCAG 2220 CAGGCTTGGC CAAGTGGGAC CCAGCAGATC CTGCTTCCCC CAGCATGGCA GCAACTGACT 2280 GGAGTGGCCA CCCACACATC AGTGGAGCAT GCCACCGTGA TTCCCGAGAC CATGGCAGGC 2340 ACCCAGCAGC TGGCGGACTC GAGAAATACG CATGCTCACG GAAGCCATTA TAATCCCATC 2400 ATGCAGCAGC CTGCACTATT GACCGGTCAT GTGACCCTTC CAGCAGCACA GCCCTTAAAT 2460 GTGGGTGTGG CCCACGTGAT GCGGCAGCAG CCAACCAGCA CCACCTCCTC CCGGAAGAGT 2520 AAGCAGCACC AGTCATCTGT GAGAAATGTC TCCACCTGTG AGGTGTCCTC CTCTCAGGCC 2580 ATCAGCTCCC CACAGCGATC CAAGCGTGTC AAGGAGAACA CACCTCCCCG CTGTCCCATG 2640 GTGCACAGTA GCCCGGCCTC CAGCACCTCG GTCACCTGTG GGTGGGGCGA CGTGGCCTCC 2700 AGCACCACCC GGGAACGGCA GCGGCAGACA ATTGTCATTC CCGACACTCC CAGCCCCACG 2760 GTCAGCGTCA TCACCATCAG CAGTGACACG GACGAGGAGG AGGAACAGAA ACACGCCCCC 2820 ACCAGCACTG TCTCCAAGCA AAGAAAAAAC GTCATCAGCT GTCTCACAGT CCACGACTCC 2880 CCCTACTCCG ACTCCTCCAG CAACACCAGC CCCTACTCCG TCCAGCAGCG TGCTGGGCAC 2940 AACAATCCCA ATGCCTTTGA CACCAAGGGG AGCCTCGAGA ATCACTGCAC GGGGAACCCC 3000 CGAACCATCA TCGTGCCACC CCTGAAAACC CAGGCCAGCG AAGTATTGGT GGAGTCTGAT 3060 AGCCTCGTGC CAGTCAACAC CAGTCACCAC TCGTCCTCCT ACAAGTCCAA GTCCTCCAGC 3120 AACGTGACCT CCACCAGCGG TCACTCTTCA GGGAGCTCAT CTCGAGCCAT CACCTACCGG 3180 CAGCAGCGGC CGGGCCCCCA CTTCCAGCAG CAGCAGCCAC TCAATCTCAG CCAGGCTCAG 3240 CAGCACATCA CCACGGACCG CACTGGGAGC CACCGAAGGC AGCAGGCCTA CATCACTCCC 3300 ACCATGGCCC AGGCTCCGTA CTCCTTCCCG CACAACAGCC CCAGCCACGG CACTGTGCAC 3360 CCGCATCTGG CTGCAGCCGC TGCCGCTGCC CACCTCCCCA CCCAGCCCCA CCTCTACACC 3420 TACACTGCGC CGGCGGCCCT GGGCTCCACC GGCACCGTGG CCCACCTGGT GGCCTCGCAA 3480 GGCTCTGCGC GCCACACCGT GCAGCACACT GCCTACCCAG CCAGCATCGT CCACCAGGTC 3540 CCCGTGAGCA TGGGCCCCCG GGTCCTGCCC TCGCCCACCA TCCACCCGAG TCAGTATCCA 3600 GCCCAATTTG CCCACCAGAC CTACATCAGC GCCTCGCCAG CCTCCACCGT CTACACTGGA 3660 TACCCACTGA GCCCCGCCAA GGTCAACCAG TACCCTTACA TATAAACACT GGAGGGGAGG 3720 GAGGGAGGGA GGGAGGGAGA GAATGGCCCG AGGGAGGAGG GAGAGAAGGA GGGAGGCGCT 3780 CCTGGGACCG TGGGCGCTGG CCTTTTATAC TGAAGATGCC GCACACAAAC AATGCAAACG 3840 GGGCAGGGGC GGGGGGGGGG GGGGCAGAGG GCAGGGGGAC GGGTCGGGAC ACCAGTGAAA 3900 CTTGAACCGG GAAGTGGGAG GACGTAGAGC AGAGAAGAGA ACATTTTTAA AAGGAAGGGA 3960 TTAAAGAGGβ TGGGAAATCT ATGGTTTTTA TTTTAAAAAA SEQ ID NO:282 PCI2 Protein sequence: Protein Accession #: NP_073577 MAPVYEGMAS HVQVFSPHTL QSSAFCSVKK LKVEPSSNWD MTGYGSHSKV YSQSKNIPPS 60 QPASTTVSTS LPVPNPSLPY EQTTVFPGST GHIVVTSASS TSVTGQVLGG PHNLMRRSTV 120 SLLDTYQKCG LKRKSEEIEN TSSVQIIEEH PPMIQNNASG ATVATATTST ATSKNSGSNS 180 EGDYQLVQHE VLCSMTNTYE VLEFLGRGTF GQVVKCWKRG TNEIVAIKIL KNRPSYARQG 240 QIEVSILARL STESADDYNF VRAYECFQHK NHTCLVFEML EQNLYDFLKQ NKFSPLPLKY 300 IRPVLQQVAT ALMKLKSLGL IHADLKPENI MLVDPSRQPY RVKVIDFGSA SHVSKAVCST 360 YLQSRYYRAP EIILGLPFCE AIDMWSLGCV IAELFLGWPL YPGASEYDQI YISQTQGLP 420 AEYLLSAGTK TTRFFNRDTD SPYPLWRLKT PDDHEAETGI KSKEARKYIF NCLDDMAQVN 480 MTTDLEGSDM LVEKADRREF IDLLKKMLTI DADKRITPffi TLNHPFVTMT HLLDFPHSTH 540 VKSCFQNMEI CKRRVNMYDT VNQSKTPFIT HVAPSTSTNL TMTFNNQLTT VHNQAPSSTS 600 ATTSLANPEV SILNYPSTLY QPSAASMAAV AQRSMPLQTG TAQICARPDP FQQALIVCPP 660 GFQGLQASPS KHAGYSVRME NAVPIVTQAP GAQPLQIQPG LLAQQAWPSG TQQILLPPAW 720 QQLTGVATHT SVQHATVIPE TMAGTQQLAD WRNTHAHGSH YNPIMQQPAL LTGHVTLPAA 780 QPLNVGVAHV MRQQPTSTTS SRKSKQHQSS VRNVSTCEVS SSQAISSPQR SKRVKENTPP 840 RCAMVHSSPA CSTSVTCGWG DVASSTTRER QRQTIVIPDT PSPTVSVITI SSDTDEEEEQ 900 KHAPTSTVSK QRKNVISCVT VHDSPYSDSS SNTSPYSVQQ RAGHNNANAF DTKGSLENHC 960 TGNPRTIIVP PLKTQASEVL VECDSLVPVN TSHHSSSYKS KSSSNVTSTS GHSSGSSSGA 1020 ITYRQQRPGP HFQQQQPLNL SQAQQHITTD RTGSHRRQQA Y-TPTMAQAP YSFPHNSPSH 1080 GTVHPHLAAA AAAAHLPTQP HLYTYTAPAA LGSTGTVAHL VASQGSARHT VQHTAYPASI 1140 VHQVPVSMGP RVLPSPTIHP SQYPAQFAHQ TYIS ASPAST VYTGYPLSPA KVNQYPYI SEQ ID N0:283 PBY1 DNA SEQUENCE Nucleic Acid Accession*: N _017700 Coding sequence: 147-806 (underlined sequence corresponds to start and stop codon) 11 21 31 41 51 I I I I I AGTCACAGCC AGGTAACCCT GGAGTCAAGC GGTTTAGTTA GAAGGGAGCA GATAAACTCG 60 TCACTCTAGT AGCTTTAACC CTCACCCTGA GGCACCTTAG CAATCAGCCA TTGCCTGCAA 120 GCCTCCAAAG CTTGTCTTTC CCTAATATCG AGCCCAAAGA AGCCACTGGG AAAGAAAACA 180 TGGTCACCAA GAAAAAGAAT CTGGCCTTCT TGAGGTCTAG ACTCTATATC CTGGAGAGAA 240 GGAAGACTGA CACTGTGGTT GAGAGCAGTG TTTCTCGGGA CCACTCTGGC ACCTTCAGGA 3 00 GGAGCCAATC TGACAGGACC GAATACAACC AGAAATTACA AGAAAAGATC ACTCCACAGG 360 GTGAGTGTTC TGTAGCTGAG ACCTTAACCC CAGAGGAAGA GCATCATATG AAGAGGATGA 420 TGGCAAAGCG GGAAAAGATC ATTAAGGAGC TGATACAGAC AGAAAAGGAT TATCTCAATG 480 ATCTAGAGCT GTGTGTTAGG GAAGTGGTTC AGCCCCTCAG AAATAAAAAG ACTGATAGGC 540 TGGATCTCGA TAGCTTGTTT AGCAACATTG AGTCCGTCCA TCAGATATCA GCCAAGCTCC 600 TCTCATTCTT GGAAGAGGCC ACAACAGACG TGGAACCGGC CATGCAAGTA ATTGGAGAAG 660 TATTCTTGCA GATTAAAGGG CCACTGGAAG ATATTTATAA AATCTACTCC TATCACCATC 720 ATCAAGCACA TAGTATACTC GAGTCCTATC AAAAGGAAGA AGAGCTCAAG GAACATTTGA 780 GCCACTGTAT CCAGTCCTTA AAGTAAGGCC TTTTCAAATC ATGATTCCCA TCTCCTCTCA 840 GTTGCCTAGC AGGGAACATT TTAAATGGAT GTAGATGAAA GGTCTCACAT AAATCCTATG 900 TTTTATCAGA CTTCCTGGGA GCTCTGCTTT GCATTCCCTT TATAAAAAGC TGACATCCCA 960 GAAGCCCTGA TTGACTTTTT TTCCCCCTCC GAGAATGACT AAAAATAACA TCGAAGAAGA 1020 TTTAGAGCTC TGCAGCGATT GAAAAATGCA ATATCAAAAT ATAAAATGTC GAAGAAAAGC 1080 CTCTTCTTAA AGCTATTGTA ACTTGCCTGG CCCCACGTAG TTCAAGGATT ATGTGAGATA 1140 ACACGTGGCC CCATGACCAC TGGAGCACAT GGGTTAATGG AGTTAGGGGA ATGGCCTACA 1200 ACTCTGCATG GCCGTCTTCT TTCCCCAAAC TCACTGTGGG GAGATGGGTG AAGACAAGTC 1260 AGGCCTTGTT AAAGTTAGTT TCAGAACAAT TACTCATGCC TTCCTTTCTC ATCCCTAAAA 1320 CATTCGTCGG GGAGCTACAC AATGTACTTT TTCTTTTCTA GAGGAAGTAT CTATTCACTC 1380 TGAAAATCTG AAAAATATAA CAAAGTATCT GTAAGATAAA AACCCCTTGC TATTTCAAAA 1440 AAAAAAAAAA AAAAAAAAAA AAAA SEQ ID N0.284 PBY1 Protein sequence: Protein Accession* NPJJ60170 11 21 31 41 51 I I I I I I MEPKEATGKE NMVTKKKNLA FLRSRLYMLE RRKTDTWES SVSGDHSGTL RRSQSDRTEY 60 NQKLQEKMTP QGECSVAETL TPEEEHHMKR MMAKREKIIK ELIQTEKDYL NDLELCVREV 120 VQPLRNKKTD RLDVDSLFSN IESVHQISAK LLSLLEEATT DVEPAMQVIG EVFLQIKGPL 180 EDIYKIYCYH HDEAHSILES YEKEEELKEH LSHCIQSLK SEQ ID NO:285 PBQ9 DNA SEQUENCE Nucleic Acid Accession*: X66534 Coding sequence: 523-2676 (underlined sequence corresponds to start and stop codon) 11 21 31 41 51 I I I I I CCCTTATGGC GATTGGGCGG CTGCAGAGAC CAGGACTCAG TTCCCCTGCC CTAGTCTGAG 60 CCTAGTCGGT GGGACTCAGC TCAGAGTCAG TTTTCAGAAG CAGGTTTCAG TTGCAGAGTT 120 TTCCTACACT TTTCCTCCGC TAGAGCAGCG AGCAGCCTCG AACAGACCCA GGCGGAGGAC 180 ACCTCTGGGG GAGGGAGCGC CTGGAGGAGC TTAGAGACCC CAGCCGGGCG TGATCTCACC 240 ATGTGCGGAT TTGCGAGGCG CGCCCTCGAG CTGCTAGAGA TCCGGAAGCA CAGCCCCGAG 300 GTGTGCGAAG CCACCAAGAC TGCGGCTCTT GGAGAAAGCG TCAGCAGGGG GCCACCGCGG 360 TCTCCGGCCT GTCTGCACCC TCTCGCCTGA GCTGCCTGAC AGTGACAATG ACATCCCAGT 420 TACCAGTGTC CTTCAATTCA TAGTGGCTTC TCTTTCTCAG TCTCATATAA GAACTACAGC 430 TCATCAGGAG GAGATCGCAG CAGGGTAAGA GACACCAACA CCATGTTCTG CACGAAGCTC 540 AAGGATCTCA AGATCACAGG AGAGTGTCCT TTCTCCTTAC TGGCACCAGG TCAAGTTCCT 600 AACGAGTCTT CAGAGGAGGC AGCAGGAAGC TCAGAGAGCT GCAAAGCAAC CGTGCCCATC 660 TCTCAAGACA TTCCTCAGAA GAACATACAA GAAAGTCTTC CTCAAAGAAA AACCAGTCGG 720 AGCCGAGTCT ATCTTCACAC TTTGGCAGAG AGTATTTGCA AACTCATTTT CCCAGAGTTT 780 GAACGGCTGA ATGTTGCACT TCAGAGAACA TTCGCAAAGC ACAAAATAAA AGAAAGCAGG 840 AAATCTTTGG AAAGAGAAGA CTTTGAAAAA ACAATTGCAG AGCAAGCAGT GCAGCAGAGT 900 CCAGTCGAGT TATCAAAGAA TCTCTTGGTG AAGAGGTTTT TAAAATATGT TACGAGGAAG 960 ATCAAAACAT CCTTGGGGTC GTTGGAGGCA CCCTTAAAGA TTTTTAAACA GCTTCAGTAC 1020 CCTTCTGAAA CAGAGCAGCC ATTGCCAAGA AGCAGGAAAA AGGGGCAGCT TGAGGACGCC 1080 TCCATTCTAT GCCTGGATAA GGAGGATGAT TTTCTACATG TTTACTACTT CTTCCCTAAG 1140 AGAACCACCT CCCTGATTCT TCCCGGCATC ATAAAGGCAG CTGCTCACGT ATTATATCAA 1200 ACGGAAGTGG AAGTGTCGTT AATGCCTCCC TGCTTCCATA ATGATTGCAG CGAGTTTGTG 1260 AATCAGCCCT ACTTGTTGTA CTCCGTTCAC ATGAAAAGCA CCAAGCCATC CCTGTCCCCC 1320 AGCAAACCCC AGTCCTCGCT GGTGATTCCC ACATCGCTAT TCTGCAAGAC ATTTCCATTC 1380 CATTTCATGT TTGACAAAGA TATGACAATT CTGCAATTTG GCAATCGCAT CAGAAGGCTG 1440 ATGAACAGGA GAGACTTTCA AGGAAAGCCT AATTTTGAAT ACTTTCAAAT TCTCACTCCA 1500 AAAATCAACC AGACCTTTAG CGGGATCATG ACTATGTTGA ATATGCAGTT TGTTGTACGA 1560 GTGAGGAGAT GGGACAACTC TGTCAAGAAA TCTTCAAGGG TTATGGACCT CAAAGGCCAA 1620 ATCATCTACA TTCTTGAATC CAGTGCAATC TTGTTTTTGG GGTCACCCTG TGTGGACAGA 1680 TTAGAAGATT TTACAGGACG AGGGCTCTAC CTCTCAGACA TCCCAATTCA CAATGCACTG 1740 AGGGATGTGG TCTTAATAGG GGAACAAGCC CGAGCTCAAG ATGGCCTGAA GAAGAGGCTC 1800 GGGAAGCTGA AGGCTACCCT TGAGCAAGCC CACCAAGCCC TGGAGGAGGA GAAGAAAAAG 1860 ACAGTAGACC TTCTGTGCTC CATATTTCCC TGTGAGGTTG CTCAGCAGCT GTGGCAAGGG 1920 CAAGTTGTGC AAGCCAAGAA GTTCAGTAAT GTCACCATGC TCTTCTCAGA CATCGTTGGG 1980 TTCACTGCCA TCTGCTCCCA GTGCTCACCG CTCCAGGTCA TCACCATGCT CAATGCACTG 2040 TACACTCGCT TCGACCAGCA GTGTGGAGAG CTGGATGTCT ACAAGGTGGA GACCATTGCG 2100 ATGCCTATTG TGTGGCTTCG GGGATTACAC AAAGAGAGTG ATACTCATGC TGTTCAGATA 2160 GCGCTGATGG CCCTGAAGAT GATGGAGCTC TCTGATGAAG TTATGTCTCC CCATGGAGAA 2220 CCTATCAAGA TGCGAATTGG ACTGCACTCT GGATCAGTTT TTCCTGGCGT CGTTGGAGTT 2280 AAAATCCCCC GTTACTCTCT TTTTGGAAAC AATCTCACTC TGGCTAACAA ATTTGAGTCC 2340 TGCAGTGTAC CACGAAAAAT CAATGTCAGC CCAACAACTT ACAGATTACT CAAAGACTGT 2400 CCTGGTTTCG TGTTTACCCC TCGATCAAGG GAGGAACTTC CACCAAACTT CCCTAGTCAA 2460 ATCCCCGGAA TCTGCCATTT TCTGGATGCT TACCAACAAG GAACAAACTC AAAACCATGC 2520 TTCCAAAAGA AAGATGTGGA AGATGCAAGC CAATTTTTTA GGCAAAGCAT CAGGAATAGA 2580 TTAGCAACCT ATATACCTAT TTATAAGTCT TTCGGGTTTC ACTCATTGAA GATCTGTAGA 2640 GCCTCTGAAA GCACTTTAGG GATTGTAGAT GGCTAACAAG CAGTATTAAA ATTTCAGGAG 2700 CCAAGTCACA ATCTTTCTCC TG TTAACAT GACAAAATGT ACTCACTTCA GTACTTCAGC 2760 TCTTCAAGAA AAAAAAAAAA ACCTTAAAAA GCTACTTTTG TCGGAGTATT TCTATTATAT 2820 AACCAGCACT TACTACCTCT ACTCAAAATT CAGCACCTTG TACATATATC AGATAATTGT 2880 AGTCAATTGT ACAAACTGAT GGAGTCACCT GCAATCTCAT ATCCTGGTCG AATGCCATCG 2940 TTATTAAAGT GTCTTTGTCA TAGTTGTCGT CAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 3000 AAAA SEQ ID NO:286 PBQ9 Protein sequence: Protein Accession *: Q02108 11 21 31 41 51 I I I I I MFCTKLKDLK ITGECPFSLL APGQVPNESS EEAAGSSESC KATVPICQDI PEKNIQESLP 60 QRKTSRSRVY LHTLAESICK LIFPEFERLN VALQRTLAKH KIKESRKSLE REDFEKTIAE 120 QAVAAGVPVE VIKESLGEEV FKICYEEDEN ILGWGGTLK DFLNSFSTLL KQSSHCQEAG 180 KRGRLEDASI LCLDKEDDFL HVYYFFPKRT TSLILPGIIK AAAHVLYETE VEVSLMPPCF 240 HNDCSEFVNQ PYLLYSVHMK STKPSLSPSK PQSSLVIPTS LFCKTFPFHF MFDKDMTILQ 300 FGNGIRRLMN RRDFQGKPNF EEYFEILTPK INQTFSGIMT MLNMQFWRV RRWDNSVKKS 360 SRVMDLKGQM IYIVESSAIL FLGSPCVDRL EDFTCRGLYL SDIPIHNALR DWLIGEQAR 420 AQDGLKKRLG KLKATLEQAH QALEEEKKKT VDLLCSIFPC EVAQQLWQGQ WQAKKFSNV 480 TMLFSDΓVGF TAICSQCSPL QVITMLNALY TRFDQQCGEL DVYKVETIGD AYCVAGGLHK 540 ESDTHAVQIA LMALKMMELS DEVMSPHGEP IKMRIGLHSG SVFAGWGVK MPRYCLFGNN 600 VTLANKFESC SVPRKINVSP TTYRLLKDCP GFVFTPRSRE ELPPNFPSEI PGICHFLDAY. 660 QQGTNSKPCF QKKDVEDGNA NFLGKASGID SEQ ID NO:287 PFD2 DNA SEQUENCE Nucteic Acid Accession*: N _000720 Coding sequence: 119-6664 (underlined sequence corresponds to start and stop codon) 11 21 31 41 51 AGAATAAGGG CAGGGACCGC GGCTCCTATC TCTTGGTGAT CCCCTTCCCC ATTCCGCCCC 60 CGCCTCAACG CCCAGCACAG TGCCCTGCAC ACAGTAGTCG CTCAATAAAT GTTCGTCGAT 120 GATGATGATG ATGATGATGA AAAAAATGCA GCATCAACGG CAGCAGCAAG CGGACCACGC 180 GAACGAGGCA AACTATGCAA GAGGCACCAG ACTTCCTCTT TCTGGTGAAG GACCAACTTC 240 TCAGCCGAAT AGCTCCAAGC AAACTGTCCT GTCTTGGCAA GCTGCAATCG ATGCTGCTAG 300 ACAGGCCAAG GCTGCCCAAA CTATGAGCAC CTCTGCACCC CCACCTGTAG GATCTCTCTC 360 CCAAAGAAAA CGTCAGCAAT ACGCCAAGAG CAAAAAACAG GGTAACTCGT CCAACAGCCG 420 ACCTGCCCGC GCCCTTTTCT GTTTATCACT CAATAACCCC ATCCGAAGAG CCTGCATTAG 480 TATAGTGGAA TGGAAACCAT TTGACATATT TATATTATTG GCTATTTTTG CCAATTGTGT 540 GGCCTTAGCT ATTTACATCC CATTCCCTGA AGATGATTCT AATTCAACAA ATCATAACTT 600 GGAAAAAGTA GAATATGCCT TCCTCATTAT TTTTACAGTC GAGACATTTT TGAAGATTAT 660 AGCGTATGGA TTATTGCTAC ATCCTAATGC TTATGTTAGG AATGGATCGA ATTTACTGGA 720 TTTTGTTATA GTAATAGTAG GATTCTTTAG TCTAATTTTG GAACAATTAA CCAAAGAAAC 780 AGAAGGCGGG AACCACTCAA GCGGCAAATC TGGAGGCTTT GATGTCAAAG CCCTCCGTGC 840 CTTTCGAGTG TTGCGACCAC TTCGACTAGT GTCAGGGGTG CCCAGTTTAC AAGTTGTCCT 900 GAACTCCATT ATAAAAGCCA TGGTTCCCCT CCTTCACATA GCCCTTTTGG TATTATTTCT 960 AATCATAATC TATGCTATTA TAGGATTGGA ACTTTTTATT GGAAAAATGC ACAAAACATC 1020 TTTTTTTGCT GACTCAGATA TCGTAGCTCA AGAGGACCCA GCTCCATGTG CGTTCTCAGG 1080 GAATGGACGC CAGTGTACTG CCAATCGCAC GGAATGTAGG AGTGGCTGGG TTGGCCCGAA 1140 CGGAGGCATC ACCAACTTTG ATAACTTTGC CTTTCCCATG CTTACTGTGT TTCAGTCCAT 1200 CACCATGGAG GGCTGGACAG ACGTCCTCTA CTGGGTAAAT GATGCGATAG GATGGGAATG 1260 GCCATGGGTG TATTTTGTTA GTCTCATCAT CCTTGGCTCA TTTTTCGTCC TTAACCTCGT 1320 TCTTGGTGTC CTTAGTGGAG AATTCTCAAA GGAAAGAGAG AAGGCAAAAG CACGGGGAGA 1380 TTTCCAGAAG CTCCGGGAGA AGCAGCAGCT GGAGGAGGAT CTAAAGGGCT ACTTGGATTG 1440 GATCACCCAA GCTGAGGACA TCGATCCGGA GAATCAGGAA GAAGGAGGAG AGGAAGGCAA 1500 ACGAAATACT AGCATGCCCA CCAGCGAGAC TGAGTCTGTC AACACAGAGA ACGTCAGCGG 1560 TGAAGGCGAG AACCGAGGCT GCTGTGGAAG TCTCTGGTGC TGGTGGAGAC GGAGAGGCGC 1620 GGCCAAGGCG GGGCCCTCTG GGTCTCGGCG GTGGGGTCAA GCCATCTCAA AATCCAAACT 1680 CAGCCGACGC TGGCGTCGCT GGAACCGATT CAATCGCAGA AGATGTAGGG CCGCCGTGAA 1740 GTCTGTCACG TTTTACTGGC TGGTTATCGT CCTGGTGTTT CTGAACACCT TAACCATTTC 1800 CTCTGAGCAC TACAATCAGC CAGATTCGTT GACACAGATT CAAGATATTG CCAACAAAGT 1860 CCTCTTCGCT CTGTTCACCT GCGAGATGCT GGTAAAAATG TACAGCTTGG GCCTCCAAGC 1920 ATATTTCGTC TCTCTTTTCA ACCGGTTTGA TTGCTTCGTC GTCTGTGGTG GAATCACTCA 1980 GACGATCCTG GTGGAACTCG AAATCATGTC TCCCCTGGGG ATCTCTGTGT TTCGGTCTGT 2040 GCGCCTCTTA AGAATCTTCA AAGTCACCAG GCACTGGACT TCCCTCAGCA ACTTAGTCGC 2100 ATCCTTATTA AACTCCATGA AGTCCATCGC TTCGCTGTTG CTTCTCCTTT TTCTCTTCAT 2160 TATCATCTTT TCCTTGCTTC GGATGCAGCT GTTTGGCGGC AAGTTTAATT TTCATCAAAC 2220 GCAAACCAAG CGGAGCACCT TTGACAATTT CCCTCAAGCA CTTCTCACAG TCTTCCAGAT 2280 CCTGACAGGC GAAGACTGGA ATGCTCTGAT GTACGATGGC ATCATCGCTT ACGGGGGCCC 2340 ATCCTCTTCA GGAATGATCG TCTGCATCTA CTTCATCATC CTCTTCATTT GTCGTAACTA 2400 TATTCTACTG AATGTCTTCT TGGCCATCGC TCTAGACAAT TTGGCTGATG CTCAAAGTCT 2460 GAACACTGCT CAGAAAGAAG AAGCGGAAGA AAAGGAGAGG AAAAAGATTG CCAGAAAAGA 2520 GAGCCTAGAA AATAAAAAGA ACAACAAACC AGAAGTCAAC CAGATAGCCA ACAGTCACAA 2580 CAAGGTTACA ATTGATGACT ATAGAGAAGA GGATGAAGAC AAGGACCCCT ATCCGCCTTG 2640 CGATGTGCCA GTAGGGGAAG AGGAAGAGGA AGAGGAGGAG GATGAACCTG AGGTTCCTGC 2700 CGGACCCCGT CCTCGAAGGA TCTCGGAGTT GAACATGAAG GAAAAAATTG CCCCCATCCC 2760 TGAAGGGAGC GCTTTCTTCA TTCTTAGCAA GACCAACCCG ATCCGCGTAG GCTGCCACAA 2820 GCTCATCAAC CACCACATCT TCACCAACCT CATCCTTGTC TTCATCATGC TGAGCAGCGC 2880 TGCCCTGGCC GCAGAGGACC CCATCCGCAG CCACTCCTTC CGGAACACGA TACTGGGTTA 2940 CTTTCACTAT GCCTTCACAG CCATCTTTAC TGTTCAGATC CTGTTGAAGA TGACAACTTT 3000 TGGAGCTTTC CTCCACAAAG GGGCCTTCTG CAGGAACTAC TTCAATTTGC TGGATATGCT 3060 GGTGGTTCGG GTGTCTCTGG TGTCATTTGG GATTCAATCC AGTGCCATCT CCGTTGTGAA 3120 GATTCTGAGG GTCTTAAGGG TCCTGCGTCC CCTCAGGGCC ATCAACAGAG CAAAAGGACT 3180 TAAGCACGTG GTCCAGTGCG TCTTCGTCGC CATCCGGACC ATCGGCAACA TCATGATCGT 3240 CACTACCCTC CTGCAGTTCA TGTTTGCCTG TATCGGGGTC CAGTTGTTCA AGGGGAAGTT 3300 CTATCGCTGT ACGGATCAAG CCAAAAGTAA CCCTGAAGAA TGCAGGGGAC TTTTCATCCT 3360 CTACAAGGAT GGGGATGTTG ACAGTCCTGT GGTCCGTGAA CGGATCTGGC AAAACAGTCA 3420 TTTCAACTTC GACAACGTCC TCTCTGCTAT GATCGCGCTC TTCACAGTCT CCACGTTTGA 3480 GGGCTGGCCT GCGTTGCTGT ATAAAGCCAT CGACTCGAAT GGAGAGAACA TCGGCCCAAT 3540 CTACAACCAC CGCGTGGAGA TCTCCATCTT CTTCATCATC TACATCATCA TTGTAGCTTT 3600 CTTCATCATG AACATCTTTG TGGGCTTTGT CATCGTTACA TTTCAGGAAC AAGGAGAAAA 3660 AGAGTATAAG AACTGTGAGC TGGACAAAAA TCAGCGTCAG TGTGTTGAAT ACGCCTTCAA 3720 AGCACGTCCC TTCCGGAGAT ACATCCCCAA AAACCCCTAC CAGTACAAGT TCTGGTACGT 3780 GGTCAACTCT TCGCCTTTCG AATACATGAT GTTTGTCCTC ATCATGCTCA ACACACTCTG 3840 CTTGGCCATG CAGCACTACG AGCAGTCCAA GATGTTCAAT GATGCCATGG ACATTCTGAA 3900 CATGGTCTTC ACCGGGGTGT TCACCGTCGA GATGGTTTTG AAAGTCATCG CATTTAAGCC 3960 TAAGGGGTAT TTTAGTCACG CCTGGAACAC GTTTGACTCC CTCATCGTAA TCGGCAGCAT 4020 TATAGACGTC GCCCTCAGCG AAGCGGACCC AACTGAAAGT GAAAATGTCC CTGTCCCAAC 4080 TCCTACACCT GGGAACTCTG AAGAGAGCAA TAGAATCTCC ATCACCTTTT TCCGTCTTTT 4140 CCGAGTCATG CGATTGGTGA AGCTTCTCAG CAGGGGGGAA GGCATCCGGA CATTGCTCTC 4200 GACTTTTATT AAGTCCTTTC AGGCGCTCCC GTATGTGGCC CTCCTCATAG CCATGCTGTT 4260 CTTCATCTAT GCGGTCATTG GCATGCAGAT GTTTCGGAAA GTTGCCATCA GAGATAACAA 4320 CCAGATCAAT AGGAACAATA ACTTCCAGAC GTTTCCCCAG GCGGTGCTGC TGCTCTTCAG 4380 GTGTCCAACA GGTCAGGCCT GGCAGGAGAT CATGCTGGCC TGTCTCCCAG GGAAGCTCTG 4440 TGACCCTGAG TCAGATTACA ACCCCGGGGA GGAGTATACA TGTCGGAGCA ACTTTGCCAT 4500 TCTCTATTTC ATCAGTTTTT ACATGCTCTG TGCATTTCTG ATCATCAATC TGTTTGTGGC 4560 TGTCATCATG GATAATTTCG ACTATCTGAC CCGGGACTGG TCTATTTTGG GGCCTCACCA 4620 TTTAGATCAA TTCAAAAGAA TATGGTCAGA ATATGACCCT GAGGCAAAGG GAAGGATAAA 4680 ACACCTTGAT GTCGTCACTC TGCTTCGACG CATCCAGCCT CCCCTGGGGT TTGGGAAGTT 4740 ATGTCCACAC AGGGTAGCGT GCAAGAGATT AGTTGCCATG AACATCCCTC TCAACAGTGA 4800 CGGGACAGTC ATGTTTAATG CAACCCTGTT TGCTTTGGTT CGAACGGCTC TTAAGATCAA 4860 GACCGAAGGG AACCTGGAGC AAGCTAATGA AGAACTTCGG GCTGTGATAA AGAAAATTTG 4920 GAAGAAAACC AGCATGAAAT TACTTGACCA AGTTGTCCCT CCAGCTGGTG ATGATGAGGT 4980 AACCGTGGGG AAGTTCTATG CCACTTTCCT GATACAGGAC TACTTTAGGA AATTCAAGAA 5040 ACGGAAAGAA CAAGGACTGG TGGGAAAGTA CCCTCCGAAG AACACCACAA TTGCCCTACA 5100 GGCGGGATTA AGGACACTGC ATGACATTGG GCCAGAAATC CGGCGTGCTA TATCGTGTGA 5160 TTTGCAAGAT GACGAGCCTG AGGAAACAAA ACGAGAAGAA GAAGATGATG TGTTCAAAAG 5220 AAATCGTGCC CTGCTTGGAA ACCATCTCAA TCATGTTAAT AGTGATAGGA GAGATTCCCT 5280 TCAGCAGACC AATACCACCC ACCGTCCCCT GCATCTCCAA AGGCCTTCAA TTCCACCTGC 5340 AAGTCATACT GAGAAACCGC TGTTTCCTCC AGCAGGAAAT TCGGTGTCTC ATAACCATCA 5400 TAACCATAAT TCCATAGGAA AGCAAGTTCC CACCTCAACA AATGCCAATC TCAATAATGC 5460 CAATATGTCC AAAGCTGCCC ATGGAAAGCG GCCCAGCATT GGGAACCTTG AGCATCTGTC 5520 TGAAAATGGG CATCATTCTT CCCACAAGCA TGACCGGGAG CCTCAGAGAA GGTCCAGTGT 5580 GAAAAGAACC CGCTATTATG AAACTTACAT TAGGTCCGAC TCAGGAGATG AACAGCTCCC 5640 AACTATTTGC CGGGAAGACC CAGAGATACA TGGCTATTTC AGGGACCCCC ACTGCTTGGG 5700 GGAGCAGGAG TATTTCAGTA GTGAGGAATG CTACGAGGAT GACAGCTCGC CCACCTGGAG 5760 CAGGCAAAAC TATGGCTACT ACAGCAGATA CCCAGGCAGA AACATCGACT CTGAGAGGCC 5820 CCGAGGCTAC CATCATCCCC AAGGATTCTT GGAGGACGAT GACTCGCCCG TTTGCTATGA 5880 TTCACGGAGA TCTCCAAGGA GACGCCTACT ACCTCCCACC CCAGCATCCC ACCGGAGATC 5940 CTCCTTCAAC TTTCAGTCCC TGCGCCGGCA GAGCAGCCAG GAAGAGGTCC CGTCGTCTCC 6000 CATCTTCCCC CATCGCACGG CCCTGCCTCT GCATCTAATG CAGCAACAGA TCATGGCAGT 6060 TCCCGGCCTA GATTCAAGTA AAGCCCAGAA GTACTCACCG AGTCACTCGA CCCGGTCGTG 6120 GGCCACCCCT CCAGCAACCC CTCCCTACCG GGACTCGACA CCGTGCTACA CCCCCCTGAT 6180 CCAAGTGGAG CAGTCAGAGG CCCTGGACCA GGTGAACGGC AGCCTGCCGT CCCTCCACCG 6240 CAGCTCCTGG TACACAGACG AGCCCGACAT CTCCTACCGG ACTTTCACAC CAGCCAGCCT 6300 GACTCTCCCC AGCAGCTTCC GGAACAAAAA CAGCGACAAG CAGAGGAGTG CGGACAGCTT 6360 GGTGGAGGCA GTCCTGATAT CCGAAGGCTT GGGACGCTAT GCAAGGGACC CAAAATTTGT 6420 GTCAGCAACA AAACACGAAA TCGCTGATGC CTCTGACCTC ACCATCGACG AGATGGAGAG 6480 TGCAGCCAGC ACCCTGCTTA ATGGGAACGT GCGTCCCCGA GCCAACGGGG ATGTGGGCCC 6540 CCTCTCACAC CGGCAGGACT ATGAGCTACA GGACTTTGGT CCTGGCTACA GCGACGAAGA 6600 GCCAGACCCT GGGAGGGATG AGGAGGACCT GGCGGATGAA ATCATATGCA TCACCACCTT 6660 GTAGCCCCCA GCGAGGGGCA GACTGGCTCT GGCCTCAGGT GGGGCGCAGG AGAGCCAGGG 6720 GGAAAAftAAGTGCC TCATAGTTAG GAAAGTTTAG GCACTAGTTG GGAGTAATAT TCAATTAATT 6780 AGACTTTTGT ATAAGAGATG TCATCCCTCA AGAAAGCCAT AAACCTGGTA GGAACAGGTC 6840 CCAAGCGGTT GAGCCTGGCA GAGTACCATC CGCTCGGCCC CAGCTGCAGG AAACAGCAGG 6900 CCCCGCCCTC TCACAGAGGA TGGGTGAGGA GGCCAGACCT GCCCTGCCCC ATTCTCCAGA 6960 TGGGCACTGC TGTCGAGTCT GCTTCTCCCA TGTACCAGGG CACCAGGCCC ACCCAACTGA 7020 AGGCATGGCG GCGGGGTGCA GGGGAAAGTT AAAGGTGATG ACGATCATCA CACCTCGTGT 7080 CGTTACCTCA GCCATCGGTC TAGCATATCA GTCACTGGGC CCAACATATC CATTTTTAAA 7140 CCCTTTCCCC CAAATACACT GCGTCCTGGT TCCTCTTTAG CTGTTCTGAA ATA SEQ ID NO-288 PFD2 Protein sequence: Protein Accession* A38198 11 21 31 41 51 I I I MMMMMMMKKM QHQRQQQADH ANEANYARGT RLPLSGEGPT SQPNSSKQTV LSWQAAIDAA 60 RQAKAAQTMS TSAPPPVGSL SQRKRQQYAK SKKQGNSSNS RPARALFCLS LNNPIRRACI 120 SIVEWKPFDI FILLAIFANC VALAIYIPFP EDDSNSTNHN LEKVEYAFLI IFTVETFLKI 180 IAYGLLLHPN AYVRNGWNLL DFVIVIVGLF SVILEQLTKE TEGGNHSSGK SGGFDVKALR 240 AFRVLRPLRL VSGVPSLQW LNSIIKAMVP LLHIALLVLF VIIIYAIIGL ELFIGKMHKT 300 CFFADSDIVA EEDPAPCAFS GNGRQCTANG TECRSGWVGP NGGITNFDNF AFAMLTVFQC 360 ITMEGWTDVL YWVNDAIGWE WPWVYFVSLI ILGSFFVLNL VLGVLSGEFS KEREKAKARG 420 DFQKLREKQQ LEEDLKGYLD WITQAEDIDP ENEEEGGEEG KRNTSMPTSE TESVNTENVS 480 GEGENRGCCG SLWCWWRRRG AAKAGPSGCR RWGQAISKSK LSRRWRRWNR FNRRRCRAAV 540 KSVTFYWI-VI VLVFLNTLTI SSEHYNQPDW LTQIQDIANK VLLALFTCEM LVKMYSLGLQ 600 AYFVSLFNRF DCFWCGGIT ETILVELEIM SPLGISVFRC VRLLRIFKVT RHWTSLSNLV 660 ASLLNSMKSI ASLLLLLFLF IIIFSLLGMQ LFGGKFNFDE TQTKRSTFDN FPQALLTVFQ 720 ILTGEDWNAV MYDGIMAYGG PSSSGMIVCI YFIILFICGN YILLNVFLAI AVDNLADAES 780 LNTAQKEEAE EKERKKIARK ESLENKKNNK PEVNQIANSD NKVTIDDYRE EDEDKDPYPP 840 CDVPVGEEEE EEEEDEPEVP AGPRPRRISE LNMKEKIAPI PEGSAFFILS KTNPIRVGCH 900 KLINHHIFTN LILVFIMLSS AALAAEDPIR SHSFRNTILG YFDYAFTAIF TVEILLKMTT 960 FGAFLHKGAF CRNYFNLLDM LWGVSLVSF GIQSSAISW KILRVLRVLR PLRAINRAKG 1020 LKHWQCVFV AIRTIGNIMI VTTLLQFMFA CIGVQLFKGK FYRCTDEAKS NPEECRGLFI 1080 LYKDGDVDSP WRERIWQNS DFNFDNVLSA MMALFTVSTF EGWPALLYKA IDSNGENIGP 1140 IYNHRVEISI FFIIYIIIVA FFMMNIFVGF VIVTFQEQGE KEYKNCELDK NQRQCVEYAL 1200 KARPLRRYIP KNPYQYKFWY WNSSPFEYM MFVLIMLNTL CLAMQHYEQS KMFNDAMDIL 1260 NMVFTGVFTV EMVLKVIAFK PKGYFSDAWN TFDSLIVIGS IIDVALSEAD PTESENVPVP 1320 TATPGNSEES NRISITFFRL FRVMRLVKLL SRGEGIRTLL WTFIKSFQAL PYVALLIAML 1380 FFIYAVIGMQ MFGKVAMRDN NQINRNNNFQ TFPQAVLLLF RCATGEAWQE IMLACLPGKL 1440 CDPESDYNPG EEYTCGSNFA IVYFISFYML CAFLIINLFV AVIMDNFDYL TRDWSILGPH 1500 HLDEFKRIWS EYDPEAKGRI KHLDWTLLR RIQPPLGFGK LCPHRVACKR LVAMNMPLNS 1560 DGTVMFNATL FALVRTALKI KTEGNLEQAN EELRAVIKKI WKKTSMKLLD QWPPAGDDE 1620 VTVGKFYATF LIQDYFRKFK KRKEQGLVGK YPAKNTTIAL QAGLRTLHDI GPEIRRAISC 1680 DLQDDEPEET KREEEDDVFK RNGALLGNHV NHVNSDRRDS LQQTNTTHRP LHVQRPSIPP 1740 ASDTEKPLFP PAGNSVCHNH HNHNSIGKQV PTSTNANLNN ANMΞKAAHGK RPSIGNLEHV 1800 SENGHHSSHK HDREPQRRSS VKRTRYYETY IRSDSGDEQL PTICREDPEI HGYFRDPHCL 1860 GEQEYFSSEE CYEDDSSPTW SRQNYGYYSR YPGRNIDSER PRGYHHPQGF LEDDDSPVCY 1920 DSRRSPRRRL LPPTPASHRR SSFNFECLRR QSSQEEVPSS PIFPHRTALP LHLMQQQIMA 1980 VAGLDSSKAQ KYSPSHSTRS WATPPATPPY RDWTPCYTPL IQVEQSEALD QVNGSLPSLH 2040 RSSWYTDEPD ISYRTFTPAS LTVPSSFRNK NSDKQRSADS LVEAVLISEG LGRYARDPKF 2100 VSATKHEIAD ACDLTIDEME SAASTLLNGN VRPRANGDVG PLSHRQDYEL QDFGPGYSDE 2160 EPDPGRDEED LADEMICITT L SEQ ID NO:2890BI6 DNA SEQUENCE Nucleic Acid Accession*: N _002812 Coding sequence: 150-3362 (underlined sequence corresponds to start and stop codon) 11 21 31 41 51 AACTCCCGCC TCGGGACGCC TCGGGGTCGG GCTCCGGCTG CGGCTGCTCC TGCGGCGCCC 60 GCGCTCCGGT GCGTCCGCCT CCTGTGCCCG CCGCGGAGCA GTCTCCGGCC CGCCGTCCGC 120 CCTCAGCTCC TTTTCCTCAG CCCGCCGCGA_ TGGGAGCTGC GCGGGGATCC CCGGCCAGAC 180 CCCGCCGGTT GCCTC GCTC AGCGTCCTCC TGCTGCCGCT GCTGGGCGGT ACCCAGACAG 240 CCATTCTCTT CATCAAGCAG CCGTCCTCCC AGGATGCACT GCAGGGGCGC CGGGCGCTGC 300 TTCGCTGTGA GGTTGAGGCT CCGGGCCCGG TACATGTCTA CTCGCTGCTC GATCGGGCCC 360 CTGTCCAGGA CACGGAGCGG CGTTTCGCCC AGGGCAGCAG CCTGAGCTTT GCAGCTGTGG 420 ACCGGCTCCA GGACTCTGGC ACCTTCCAGT GTGTGGCTCG GGATGATGTC ACTGGAGAAG 480 AAGCCCGCAG TGCCAACGCC TCCTTCAACA TCAAATGGAT TGAGGCAGGT CCTGTGGTCC 540 TGAAGCATCC AGCCTCGGAA GCTGAGATCC AGCCACAGAC CCAGGTCACA CTTCGTTCCC 600 ACATTGATGG GCACCCTCGG CCCACCTACC AATGGTTCCG AGATGGGACC CCCCTTTCTG 660 ATGGTCAGAG CAACCACACA GTCAGCAGCA AGGAGCGGAA CCTGACGCTC CGGCCAGCTG 720 GTCCTCAGCA TAGTGGGCTG TATTCCTGCT GCGCCCACAG TGCTTTTGGC CAGGCTTGCA 780 GCAGCCAGAA CTTCACCTTG AGCATTGCTG ATGAAAGCTT TGCCAGGGTC GTGCTCGCAC 840 CCCAGGACGT GGTAGTAGCG AGGTATGAGG AGGCCATGTT CCATTGCCAG TTCTCAGCCC 900 AGCCACCCCC GAGCCTGCAG TGGCTCTTTG AGGATGAGAC TCCCATCACT AACCGCAGTC 960 GCCCCCCACA CCTCCGCAGA GCCACAGTGT TTGCCAACGG GTCTCTGCTG CTGACCCAGG 1020 TCCGGCCACG CAATGCAGGG ATCTACCGCT GCATTCGCCA GGGGCAGAGG GGCCCACCCA 1080 TCATCCTGGA AGCCACACTT CACCTAGCAG AGATTGAAGA CATGCCGCTA TTTGAGCCAC 1140 GGGTGTTTAC AGCTGGCAGC GAGGAGCGTG TGACCTGCCT TCCCCCCAAG GGTCTGCCAG 1200 AGCCCAGCGT GTGGTGGGAG CACGCGGGAG TCCGGCTGCC CACCCATCGC AGGGTCTACC 1260 AGAAGGGCCA CGAGCTGGTC TTGGCCAATA TTGCTCAAAG TGATGCTGGT GTCTACACCT 1320 GCCACGCGGC CAACCTGGCT GGTCAGCGGA GACAGGATGT CAACATCACT GTCGCCACTβ 1380 TGCCCTCCTC GCTCAAGAAG CCCCAAGACA GCCAGCTGGA GGAGGGCAAA CCCGGCTACT 1440 TGGATTGCCT GACCCAGGCC ACACCAAAAC CTACAGTTGT CTGGTACAGA AACCAGATCC 1500 TCATCTCAGA GGACTCACGG TTCGAGGTCT TCAAGAATGG GACCTTGCGC ATCAACAGCβ 1560 TGGAGGTCTA TCATGGGACA TGGTACCGTT GTATGAGCAG CACCCCAGCC GGCAGCATCG 1620 AGGCGCAAGC CCGTGTCCAA GTGCTGGAAA AGCTCAAGTT CACACCACCA CCCCAGCCAC 1680 AGCAGTGCAT GGAGTTTGAC AAGGAGGCCA CGGTGCCCTG TTCAGCCACA GGCCGAGAGA 1740 AGCCCACTAT TAAGTGGGAA CGGGCAGATG GGAGCAGCCT CCCAGAGTGG GTGACAGACA 1800 ACGCTGGGAC CCTCCATTTT GCCCGGGTGA CTCGAGATGA CGCTCGCAAC TACACTTCCA 1860 TTGCCTCCAA CGGGCCGCAG GGCCAGATTC GTGCCCATGT CCAGCTCACT GTCGCAGTTT 1920 TTATCACCTT CAAAGTGGAA CCAGAGCGTA CGACTGTGTA CCAGGGCCAC ACAGCCCTAC 1980 TGCAGTCCGA GGCCCAGGGG GACCCCAAGC CGCTGATTCA GTGGAAAGGC AAGGACCGCA 2040 TCCTCGACCC CACCAAGCTG GGACCCAGGA TGCACATCTT CCAGAATGGC TCCCTGGTCA 2100 TCCATGACGT GGCCCCTCAG GACTCAGGCC GCTACACCTG CATTGCAGGC AACAGCTGCA 2160 ACATCAAGCA CACGGAGGCC CCCCTCTATG TCGTGGACAA GCCTGTGCCG GAGGAGTCGG 2220 AGGGCCCTGG CAGCCCTCCC CCCTACAAGA TGATCCAGAC CATTCGGTTG TCGGTGGGTG 2280 CCGCTGTGGC CTACATCATT GCCGTGCTGG GCCTCATGTT CTACTCCAAG AAGCGCTGCA 2340 AAGCCAAGCG GCTGCAGAAG CAGCCCGAGG GCGAGGAGCC AGAGATGGAA TCCCTCAACG 2400 GAGGGCCTTT GCAGAACGGG CAGCCCTCAG CAGAGATCCA AGAAGAAGTG GCCTTGACCA 2460 GCTTGGGCTC CGGCCCCGCG GCCACCAACA AACGCCACAG CACAAGTGAT AAGATGCACT 2520 TCCCACGGTC TAGCCTGCAG CCCATCACCA CGCTGGGGAA GAGTGAGTTT GGGGAGGTGT 2580 TCCTGGCAAA GGCTCAGGGC TTGGAGGAGG GAGTGGCAGA GACCCTGGTA CTTGTGAAGA 2640 GCCTGCAGAC GAAGGATCAG CAGCAGCAGC TGGACTTCCG GAGGGAGTTG GAGATGTTTG 2700 GGAAGCTGAA CCACGCCAAC GTGGTGCGGC TCCTGGGGCT GTGCCGGGAG GCTGAGCCCC 2760 ACTACATGGT GCTGGAATAT GTCGATCTCG GAGACCTCAA GCAGTTCCTC AGGATTTCCA 2820 AGAGCAAGGA TGAAAAATTG AAGTCACAGC CCCTCAGCAC CAAGCAGAAG GTGGCCCTAT 2880 GCACCCAGGT AGCCCTGGGC ATCGAGCACC TGTCCAACAA CCGCTTTGTG CATAAGGACT 2940 TGGCTCCGCG TAACTGCCTG GTCAGTGCCC AGAGACAAGT GAAGGTGTCT GCCCTGGGCC 3000 TCAGCAAGGA TCTGTACAAC AGTCAGTACT ACCACTTCCG CCAGGCCTGG GTGCCGCTGC 3060 GCTGGATCTC CCCCGAGGCC ATCCTCGAGG GTGACTTCTC TACCAAGTCT GATGTCTGGG 3120 CCTTCGGTCT GCTGATGTGG GAAGTGTTTA CACATGGAGA GATGCCCCAT GGTGGGCAGG 3180 CAGATCATGA AGTACTGGCA GATTTGCAGG CTGGGAAGGC TAGACTTCCT CAGCCCGAGG 3240 GCTGCCCTTC CAAACTCTAT CGGCTGATGC AGCGCTCCTC GGCCCTCAGC CCCAAGGACC 3300 GGCCCTCCTT CAGTGAGATT GCCAGCGCCC TGGGAGACAG CACCGTGGAC AGCAAGCCGT 3360 GAGGAGGGAG CCCGCTCAGG ATGGCCTGGG CAGGGGAGGA CATCTCTAGA GGGAAGCTCA 3420 CAGCATGATG GGCAAGATCC CTCTCCTCCT GGGCCCTGAG GTGCCCTAGT GCAACAGGCA 3480 TTGCTGAGGT CTGAGCAGGG CCTGGCCTTT CCTCCTCTTC CTCACCCTCA TCCTTTGGGA 3540 GGCTGACTTG GACCCAAACT GGGCGACTAG GGCTTTGAGC TGGGCAGTTT CCCCTGCCAC 3600 CTCTTCCTCT ATCAGGGACA GTGTGGGTCC CACAGGTAAC CCCAATTTCT GGCCTTCAAC 3660 TTCTCCCCTT GACCGGGTCC AACTCTCCCA CTCATCTGCC AACTTTCCCT GGGGAGGGCT 3720 AGGCTTGGGA TGAGCTGGGT TTGTGGGGAG TTCCTTAATA TTCTCAAGTT CTGGGCACAC 3780 AGGGTTAATG AGTCTCTTGC CCACTGGTCC ACTTGGGGGT CTAGACCAGG ATTATAGAGG 3840 ACACAGCAAG TGAGTCCTCC CCACTCTCGG CTTCTCCACA CTGACCCAGA CCCACGTCTT 3900 CCCCACCCTT CTCTCCTTTC CTCATCCTAA GTCCCTGGCA GATCAAGGAG TTTTCAGGAG 3960 CTTTTGACAC TATATAAACC GCCCTTTTTG TATGCACCAC GGGCGGCTTT TATATGTAAT 4020 TGCAGCGTGG GGTGGGTGGG CATGGGAGGT AGGGGTGGGC CCTGGAGATG AGGAGGGTGG 4080 GCCATCCTTA CCCCACACTT TTATTGTTGT CGTTTTTTGT TTGTTTTGTT TTTTTGTTTT 4140 TGTTTTTCTT TTTACACTCG CTGCTCTCAA TAAATAAGCC TTTTTTA SEQ ID NO.-290 OBI6 Protein sequence: Protein Accession*: NP_002812 11 21 31 41 51 I I I I I MGAARGSPAR PRRLPLLSVL LLPLLGGTQT AIVFIKQPSS QDALQGRRAL LRCEVEAPGP 60 VHVYWLLDGA PVQDTERRFA QGSSLSFAAV DRLQDSGTFQ CVARDDVTGE EARSANASFN 120 IKWIEAGPW LKHPASEAEI QPQTQVTLRC HIDGHPRPTY QWFRDGTPLS DGQSNHTVSS 180 KERNLTLRPA GPEHSGLYSC CAHSAFGQAC SSQNFTLSIA DESFARWLA PQDVWARYE 240 EAMFHCQFSA QPPPSLQWLF EDETPITNRS RPPHLRRATV FANGSLLLTQ VRPRNAGIYR 300 CIGQGQRGPP IILEATLHLA EIEDMPLFEP RVFTAGSEER VTCLPPKGLP EPSVWWEHAG 360 VRLPTHGRVY QKGHELVLAN IAESDAGVYT CHAANLAGQR RQDVNITVAT VPSWLKKPQD 420 SQLEEGKPGY LDCLTQATPK PTWWYRNQM LISEDSRFEV FKNGTLRINS VEVYDGTWYR 480 CMSSTPAGSI EAQARVQVLE KLKFTPPPQP QQCMEFDKEA TVPCSATGRE KPTIKWERAD 540 GSSLPEWVTD NAGTLHFARV TRDDAGNYTC IASNGPQGQI RAHVQLTVAV FITFKVEPER 600 TTVYQGHTAL LQCEAQGDPK PLIQWKGKDR ILDPTKLGPR MHIFQNGSLV IHDVAPEDSG 660 RYTCIAGNSC NIKHTEAPLY WDKPVPEES EGPGSPPPYK MIQTIGLSVG AAVAYIIAVL 720 GLMFYCKKRC KAKRLQKQPE GEEPEMECLN GGPLQNGQPS AEIQEEVALT SLGSGPAATN 780 KRHSTSDKMH FPRSSLQPIT TLGKSEFGEV FLAKAQGLEE GVAETLVLVK SLQTKDEQQQ 840 LDFRRELEMF GKLNHANWR LLGLCREAEP HYMVLEYVDL GDLKQFLRIS KSKDEKLKSQ 900 PLSTKQKVAL CTQVALGMEH LSNNRFVHKD LAARNCLVSA QRQVKVSALG LSKDVYNSEY 960 YHFRQAWVPL RWMSPEAILE GDFSTKSDVW AFGVLMWEVF THGEMPHGGQ ADDEVLADLQ 1020 AGKARLPQPE GCPSKLYRLM QRCWALSPKD RPSFSEIASA LGDSTVDSKP SEQ ID NO:291 AAB1 DNA SEQUENCE Nucleic Acid Accession *: N _002205 Coding sequence: 1-3150 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 ATGGGGAGCC GGACGCCAGA GTCCCCTCTC CACGCCGTGC AGCTGCGCTG GGGCCCCCGG 60 CGCCGACCCC CGCTSSTGCC GCTCCTGTTC CTGCTSSTGC CGCCGCCACC CAGGGTCGGG 120 GGCTTCAACT TAGACGCGGA GGCCCCAGCA GTACTCTCGG GGCCCCCGGG CTCCTTCTTC 180 GGATTCTCAG TGGAGTTTTA CCGGCCGGGA ACAGACGGGG TCAGTCTCCT GGTGGGAGCA 240 CCCAAGGCTA ATACCAGCCA GCCAGGAGTG CTGCAGGGTC GTGCTCTCTA CCTCTGTCCT 300 TGGGGTCCCA GCCCCACACA GTGCACCCCC ATTGAATTTC ACAGCAAAGG CTCTCGGCTC 360 CTGGAGTCCT CACTGTCCAG CTCAGAGGGA GAGGAGCCTC TGGAGTACAA GTCCTTGCAG 420 TGGTTCGGGG CAACAGTTCG AGCCCATGGC TCCTCCATCT TGGCATGCGC TCCACTGTAC 480 AGCTGGCGCA CAGAGAAGGA GCCACTGAGC GACCCCGTGG GCACCTCCTA CCTCTCCACA 540 GATAACTTCA CCCGAATTCT GGAGTATGCA CCCTGCCGCT CAGATTTCAG CTGGGCAGCA 600 GGACAGGGTT ACTGCCAAGG AGGCTTCAGT GCCGAGTTCA CCAAGACTCG CCGTGTGGTT 660 TTAGGTCGAC CAGGAAGCTA TTTCTGGCAA GGCCAGATCC TGTCTCCCAC TCAGGAGCAG 720 ATTGCAGAAT CTTATTACCC CGAGTACCTG ATCAACCTGG TTCAGGGGCA GCTGCAGACT 780 CGCCAGGCCA GTTCCATCTA TCATGACAGC TACCTAGGAT ACTCTGTGGC TGTTGGTGAA 840 TTCAGTGGTG ATGACACAGA AGACTTTGTT GCTGGTGTGC CCAAAGGGAA CCTCACTTAC 900 GGCTATGTCA CCATCCTTAA TGGCTCAGAC ATTCGATCCC TCTACAACTT CTCAGGGGAA 960 CAGATGGCCT CCTACTTTCG CTATCCAGTC GCCGCCACAG ACGTCAATGG GGACGGGCTG 1020 GATGACTTGC TGGTGGGGGC ACCCCTCCTC ATGGATCGGA CCCCTCACGG GCGGCCTCAG 1080 GAGGTGGGCA GGGTCTACGT CTACCTCCAG CACCCAGCCG GCATAGAGCC CACGCCCACC 1140 CTTACCCTCA CTCGCCATGA TGAGTTTCGC CGATTTGGCA GCTCCTTGAC CCCCCTGGGG 1200 GACCTGGACC AGGATGGCTA CAATGATCTG GCCATCGGGG CTCCCTTTGG TGGGGAGACC 1260 CAGCAGGGAG TAGTGTTTGT ATTTCCTCGG GGCCCAGGAG GGCTGGGCTC TAAGCCTTCC 1320 CAGGTTCTGC AGCCCCTGTG GGCAGCCAGC CACACCCCAG ACTTCTTTCβ CTCTCCCCTT 1380 CGAGGAGGCC GAGACCTCGA TGGCAATGGA TATCCTGATC TGATTGTGGG GTCCTTTGGT 1440 GTGGACAAGG CTGTGGTATA CAGGGGCCGC CCCATCGTGT CCGCTAGTGC CTCCCTCACC 1500 ATCTTCCCCG CCATGTTCAA CCCAGAGGAG CGGAGCTGCA GCTTAGAGGG GAACCCTGTG 1560 GCCTGCATCA ACCTTAGCTT CTGCCTCAAT GCTTCTGGAA AACACGTTCC TGACTCCATT 1620 GGTTTCACAG TGGAACTTCA GCTGGACTGG CAGAAGCAGA AGGGAGGGGT ACGGCGGGCA 1680 CTGTTCCTGG CCTCCAGGCA GGCAACCCTG ACCCAGACCC TGCTCATCCA GAATGGGGCT 1740 CGAGAGGATT GCAGAGAGAT GAAGATCTAC CTCAGGAACG AGTCAGAATT TCGAGACAAA 1800 CTCTCGCCGA TTCACATCGC TCTCAACTTC TCCTTGGACC CCCAAGCCCC AGTGGACAGC 1860 CACGGCCTCA GGCCAGCCCT ACATTATCAG AGCAAGAGCC GGATAGAGGA CAAGGCTCAG 1920 ATCTTGCTGG ACTGTGGAGA AGACAACATC TGTCTGCCTG ACCTGCAGCT GGAAGTCTTT 1980 GGGGAGCAGA ACCATGTCTA CCTGGGTGAC AAGAATGCCC TGAACCTCAC TTTCCATCCC 2040 CAGAATGTGG GTGAGGGTCG CGCCTATGAG GCTGAGCTTC GGGTCACCGC CCCTCCAGAG 2100 GCTGAGTACT CAGGACTCGT CAGACACCCA GGGAACTTCT CCAGCCTGAG CTGTGACTAC 2160 TTTGCCGTCA ACCAGAGCCG CCTCCTCGTC TGTGACCTCG GCAACCCCAT GAAGGCAGGA 2220 GCCAGTCTGT GGGGTGGCCT TCGGTTTACA GTCCCTCATC TCCGGGACAC TAAGAAAACC 2280 ATCCAGTTTG ACTTCCAGAT CCTCAGCAAG AATCTCAACA ACTCGCAAAG CGACGTGGTT 2340 TCCTTTCGGC TCTCCGTGGA GGCTCAGGCC CAGGTCACCC TGAACGGTGT CTCCAAGCCT 2400 GAGGCAGTCC TATTCCCAGT AAGCGACTGG CATCCCCGAG ACCAGCCTCA GAAGGAGGAG 2460 GACCTGGGAC CTGCTGTCCA CCATGTCTAT GAGCTCATCA ACCAAGGCCC CAGCTCCATT 2520 AGCCAGGGTG TGCTGGAACT CAGCTGTCCC CAGGCTCTGG AAGGTCAGCA GCTCCTATAT 2580 GTCACCAGAG TTACGGGACT CAACTCCACC ACCAATCACC CCATTAACCC AAAGGGCCTG 2640 GAGTTGGATC CCGAGGGTTC CCTCCACCAC CAGCAAAAAC GGGAAGCTCC AAGCCGCAGC 2700 TCTGCTTCCT CGGGACCTCA GATCCTGAAA TGCCCGGAGG CTGAGTGTTT CAGGCTCCGC 2760 TCTGAGCTCG GGCCCCTGCA CCAACAAGAG AGCCAAAGTC TGCAGTTGCA TTTCCGAGTC 2820 TGGGCCAAGA CTTTCTTGCA GCGGGAGCAC CAGCCATTTA GCCTGCAGTC TGAGGCTGTG 2880 TACAAAGCCC TGAAGATGCC CTACCGAATC CTGCCTCGGC AGCTCCCCCA AAAAGAGCGT 2940 CAGGTGGCCA CAGCTGTGCA ATGGACCAAG GCAGAAGGCA GCTATGGCGT CCCACTGTGG 3000 ATCATCATCC TAGCCATCCT GTTTGGCCTC CTGCTCCTAG GTCTACTCAT CTACATCCTC 3060 TACAAGCTTG GATTCTTCAA ACGCTCCCTC CCATATGGCA CCGCCATGGA AAAAGCTCAG 3120 CTCAAGCCTC CAGCCACCTC TCATCCCTCA SEQ ID NO:292 AAB1 Protein sequence: Protein Accession * NPJM2196 11 21 31 41 51 I I MGSRTPESPL HAVQLRWGPR R IRPPLLPLLL I LLLPPPPRVG GFNLDAEAPA V ILSGPPGSFF 60 GFSVEFYRPG TDGVSVLVGA PKANTSQPGV LQGGAVYLCP WGASPTQCTP IEFDSKGSRL 120 LESSLSSSEG EEPVEYKSLQ WFGATVRAHG SSILACAPLY SWRTEKEPLS DFVGTCYLST 180 DNFTRILEYA PCRSDFSWAA GQGYCQGGFS AEFTKTGRW LGGPGSYFWQ GQILSATQEQ 240 IAESYYPEYL INLVQGQLQT RQASSIYDDS YLGYSVAVGE FSGDDTEDFV AGVPKGNLTY 300 GYVTILNGSD IRSLYNFSGE QMASYFGYAV AATDVNGDGL DDLLVGAPLL MDRTPDGRPQ 360 EVGRVYVYLQ HPAGIEPTPT LTLTGHDEFG RFGSSLTPLG DLDQDGYNDV AIGAPFGGET 420 QQGWFVFPG GPGGLGSKPS QVLQPLWAAS HTPDFFGSAL RGGRDLDGNG YPDLIVGSFG 480 VDKAWYRGR PIVSASASLT IFPAMFNPEE RSCSLEGNPV ACINLSFCLN ASGKHVADSI 540 GFTVELQLDW QKQKGGVRRA LFLASRQATL TQTLLIQNGA REDCREMKIY LRNESEFRDK 600 LSPIHIALNF SLDPQAPVDS HGLRPALHYQ SKSRIEDKAQ ILLDCGEDNI CVPDLQLEVF 660 GEQNHVYLGD KNA NLTFHA QNVGEGGAYE AELRVTAPPE AEYSGLVRHP GNFSSLSCDY 720 FAVNQSRLLV CDLGNPMKAG ASLWGGLRFT VPHLRDTKKT IQFDFQILSK NLNNSQSDW 780 SFRLSVEAQA QVTLNGVSKP EAVLFPVSDW HPRDQPQKEE DLGPAVHHVY ELINQGPSSI 840 SQGVLELSCP QALEGQQLLY VTRVTGLNCT TNHPINPKGL ELDPEGSLHH QQKREAPSRS 900 SASSGPQILK CPEAECFRLR CELGPLHQQE SQSLQLHFRV WAKTFLQREH QPFSLQCEAV 960 YKALKMPYRI LPRQLPQKER QVATAVQWTK AEGSYGVPLW IIILAILFGL LLLGLLIYIL 1020 YKLGFFKRSL PYGTAMEKAQ LKPPATSDA SEQ ID NO:293 LBH4 DNA SEQUENCE Nucleic Acid Accession* BC001291 Coding sequence: 44-541 (start and stop codons are underlined) 1 11 21 31 41 51 I GGGG IGCGC ICG CG I CGCT IGACC I CTCCCTGGGC ACCGCTGGGG ACGATeGCGC TGCTCGCCTT 60 GCTGCTGGTC GTGGCCCTAC CGCGGGTGTG GACAGACGCC AACCTGACTG CGAGACAACG 120 AGATCCAGAG GACTCCCAGC GAACGGACGA GGGTGACAAT AGAGTGTGGT GTCATGTTTG 180 TGAGAGAGAA AACACTTTCG AGTGCCAGAA CCCAAGGAGG TGCAAATGGA CAGAGCCATA 240 CTGCGTTATA GCGGCCGTGA AAATATITCC ACGTTTTTTC ATGGTTGCGA AGCAGTGCTC 300 CGCTGGTTGT GCAGCGATGG AGAGACCCAA GCCAGAGGAG AAGCGGTTTC TCCTGGAAGA 360 GCCCATGCCC TTCTTTTACC TCAAGTGTTG TAAAATTCGC TACTGCAATT TAGAGGGGCC 420 ACCTATCAAC TCATCAGTGT TCAAAGAATA TGCTGGGAGC ATGGGTGAGA GCTGTGGTGG 480 GCTGTGGCTG GCCATCCTCC TGCTGCTGGC CTCCATTGCA GCCGGCCTCA GCCTGTCTTβ 540 ΔGCCACGGGA CTGCCACAGA CTGAGCCTTC CGGAGCATGG ACTCGCTCCA GACCGTTGTC 600 ACCTGTTGCA TTAAACTTGT TTTCTGTTGA TTACCTCTTG GTTTGACTTC CCAGGGTCTT 660 GGGATGGGAG AGTGGGGATC AGGTGCAGTT GGCTCTTAAC CCTCAAGGGT TCTTTAACTC 720 ACATTCAGAG GAAGTCCAGA TCTCCTGAGT AGTGATTTTG GTGACAAGTT TTTCTCTTTG 780 AAATCAAACC TTGTAACTCA TTTATTGCTG ATGGCCACTC TTTTCCTTGA CTCCCCTCTG 840 CCTCTGAGGG CTTCAGTATT GATGGGGAGG GAGGCCTAAG TACCACTCAT GGAGAGTATG 900 TGCTGAGATG CTTCCGACCTTTCAGGTGAC GCAGGAACAC TGGGGGAGTC TGAATGATTG 960 GGGTGAAGAC ATCCCTGGAG TGAAGGACTC CTCAGCATGG GGGGCAGTGG GGCACACGTT 1020 AGGGCTGCCC CCATTCCAGT GGTGGAGGCG CTGTGGATGG CTGCTTTTCC TCAACCTTTC 1080 CTACCAGATT CCAGGAGGCA GAAGATAACT AATTGTGTTG AAGAAACTTA GACTTCACCC 1140 ACCAGCTGGC ACAGGTGCAC AGATTCATAA ATTCCCACAC GTGTGTGTTC AACATCTGAA 1200 ACTTAGGCCA AGTAGAGAGC ATCAGGGTAA ATGGCGTTCA TTTCTCTGTT AAGATGCAGC 1260 CATCCATGGG GAGCTGAGAA ATCAGACTCA AAGTTCCACC AAAAACAAAT ACAAGGGGAC 1320 TTCAAAAGTT CACGAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAA SEQ ID NO:294 LBH4 Protein sequence: Protein Accession * AAH01291 1 11 21 31 41 51 1 I I I I I MALLALLLW ALPRVWTDAN LTARQRDPED SQRTDEGDNR VWCHVCEREN TFECQNPRRC 60 KWTEPYCVIA AVKIFPRFFM VAKQCSAGCA AMERPKPEEK RFLLEEPMPF FYLKCCK1RY 120 CNLEGPPINS SVFKEYAGSM GESCGGLWLA ILLLLASIAA GLSLS It is understood that the examples described above in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All publications, sequences of accession numbers, and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Claims: WHAT IS CLAIMED IS: 1. A method of detecting a prostate cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-16. 2. The method of claim 1, wherein the polynucleotide selectively hybridizes to a sequence at least 95% identical to a sequence as shown in Tables 1-16. 3. The method of claim 1, wherein the biological sample is a tissue sample. 4. The method of claim 1, wherein the biological sample comprises isolated nucleic acids. 5. The method of claim 4, wherein the nucleic acids are mRNA. 6. The method of claim 4, further comprising the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide. 7. The method of claim 1, wherein the polynucleotide comprises a sequence as shown in Tables 1-16. 8. The method of claim 1 , wherein the polynucleotide is labeled. 9. The method of claim 8, wherein the label is a fluorescent label. 10. The method of claim 1 , wherein the polynucleotide is immobilized on a solid surface. 11. The method of claim 1 , wherein the patient is undergoing a therapeutic regimen to treat prostate cancer. 12. The method of claim 1 , wherein the patient is suspected of having prostate cancer. 13. A method of monitoring the efficacy of a therapeutic treatment of prostate cancer, the method comprising the steps of: (i) providing a biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of a prostate cancer-associated transcript in the biological sample by contacting the biological sample with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-16, thereby monitoring the efficacy of the therapy. 14. The method of claim 13, further comprising the step of: (iii) comparing the level of the prostate cancer-associated transcript to a level of the prostate cancer- associated transcript in a biological sample from the patient prior to, or earlier in, the therapeutic treatment. 15. The method of claim 13, wherein the patient is a human. 16. A method of monitoring the efficacy of a therapeutic treatment of prostate cancer, the method comprising the steps of: (i) providing a biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of a prostate cancer-associated antibody in the biological sample by contacting the biological sample with a polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-16, wherein the polypeptide specifically binds to the prostate cancer- associated antibody, thereby monitoring the efficacy of the therapy. 17. The method of claim 16, further comprising the step of: (iii) comparing the level of the prostate cancer-associated antibody to a level of the prostate cancer- associated antibody in a biological sample from the patient prior to, or earlier in, the therapeutic treatment. 18. The method of claim 16, wherein the patient is a human. 19. A method of monitoring the efficacy of a therapeutic treatment of prostate cancer, the method comprising the steps of: (i) providing a biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of a prostate cancer-associated polypeptide in the biological sample by contacting the biological sample with an antibody, wherein the antibody specifically binds to a polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-16, thereby monitoring the efficacy of the therapy. 20. The method of claim 19, further comprising the step of: (iii) comparing the level of the prostate cancer-associated polypeptide to a level of the prostate cancer- associated polypeptide in a biological sample from the patient prior to, or earlier in, the therapeutic treatment. 21. The method of claim 19, wherein the patient is a human. 22. An isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1-16. 23. The nucleic acid molecule of claim 22, which is labeled. 24. The nucleic acid of claim 23, wherein the label is a fluorescent label 25. An expression vector comprising the nucleic acid of claim 22. 26. A host cell comprising the expression vector of claim 25. 27. An isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-16. 28. An antibody that specifically binds a polypeptide of claim 27. 29. The antibody of claim 28, further conjugated to an effector component. 30. The antibody of claim 29, wherein the effector component is a fluorescent label. 31. The antibody of claim 29, wherein the effector component is a radioisotope or a cytotoxic chemical. 32. The antibody of claim 29, which is an antibody fragment. 33. The antibody of claim 29, which is a humanized antibody 34. A method of detecting a prostate cancer cell in a biological sample from a patient, the method comprising contacting the biological sample with an antibody of claim 28. 35. The method of claim 34, wherein the antibody is further conjugated to an effector component. 36. The method of claim 35, wherein the effector component is a fluorescent label. 37. A method of detecting antibodies specific to prostate cancer in a patient, the method comprising contacting a biological sample from the patient with a polypeptide encoded by a nucleic acid comprises a sequence from Tables 1-16. 38. A method for identifying a compound that modulates a prostate cancer- associated polypeptide, the method comprising the steps of: (i) contacting the compound with a prostate cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-16; and (ii) determining the functional effect of the compound upon the polypeptide. 39. The method of claim 38, wherein the functional effect is a physical effect. 40. The method of claim 38, wherein the functional effect is a chemical effect. 41. The method of claim 38, wherein the polypeptide is expressed in a eukaryotic host cell or cell membrane. 42. The method of claim 38, wherein the functional effect is determined by measuring ligand binding to the polypeptide. 43. The method of claim 38, wherein the polypeptide is recombinant. 44. A method of inhibiting proliferation of a prostate cancer-associated cell to treat prostate cancer in a patient, the method comprising the step of administering to the subject a therapeutically effective amount of a compound identified using the method of claim 38. 45. The method of claim 44, wherein the compound is an antibody. 46. The method of claim 45, wherein the patient is a human. 47. A drug screening assay comprising the steps of (i) administering a test compound to a mammal having prostate cancer or a cell isolated therefrom; (ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-16 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of prostate cancer. 48. The assay of claim 47, wherein the control is a mammal with prostate cancer or a cell therefrom that has not been treated with the test compound. 49. The assay of claim 47, wherein the control is a normal cell or mammal. 50. A method for treating a mammal having prostate cancer comprising administering a compound identified by the assay of claim 47. 51. A pharmaceutical composition for treating a mammal having prostate cancer, the composition comprising a compound identified by the assay of claim 47 and a physiologically acceptable excipient. 52. The method according to claim 1, wherein said biological sample is contacted with a plurality of polynucleotides comprising a first polynucleotide that selectively hybridizes to a sequence at least 80% identical to a first sequence as shown in Tables 1-16; and a second polynucleotide that selectively hybridizes to a second sequence at least 80% identical to a second sequence as shown in Tables 1-16. 53. A method according to claim 52, wherein the plurality of polynucleotides comprises a third polynucleotide that selectively hybridizes to a sequence at least 80% identical to a third sequence as shown in Tables 1-16.. 54. A method of detecting a prostate cancer associated transcript, the method comprising contacting a biological sample from the patient with a plurality of polynucleotides wherein at least two of said polynucleotides selectively hybridize to a difference sequence at least 80% identical to a sequence as shown in Tables 1-16. 55. A method of detecting a prostate cancer, the method comprising the steps of: (i) providing a biological sample from a patient; (ii) contacting the biological sample with a first polynucleotide that selectively hybridizes to a sequence at least 80% identical to a first sequence as shown in Tables 1-16 to determine the level of a prostate cancer-associated transcript in the biological sample; and with a second polynucleotide that selectively hybridizes to a second sequence at least 80% identical to a sequence not shown in Tables 1-16; wherein the expression of said second sequence is not substantially changed in prostate cancer, to detemine the level of expression of a control transcript in the biological sample; (iii) comparing the level of the prostate cancer-associated transcript to a level of the normal tissue associated transcript in the biological sample. 56. A method of quantitating a prostate cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-16. 57. The method of claim 56, wherein the polynucleotide selectively hybridizes to a sequence at least 95% identical to a sequence as shown in Tables 1-16. 58. The method of claim 56, wherein the biological sample is a tissue sample. 59. The method of claim 56, wherein the biological sample comprises isolated nucleic acids. 60. The method of claim 56, wherein the nucleic acids are mRNA. 61. The method of claim 59, further comprising the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide. 62. The method of claim 56, wherein the polynucleotide comprises a sequence as shown in Tables 1-16. 63. The method of claim 56, wherein the polynucleotide is labeled. 64. The method of claim 63, wherein the label is a fluorescent label. 65. The method of claim 56, wherein the polynucleotide is immobilized on a solid surface. . 66. The method of claim 56, wherein the patient is undergoing a therapeutic regimen to treat metastatic prostate cancer. 67. The method of claim 56, wherein the patient is suspected of having metastatic prostate cancer. 68. A biochip comprising a plurality of polynucleotides that selectively hybridize to a sequence at least 80% identical to a sequence as shown in Tables 1-16. 69. A method of screening drug candidates comprising: i) providing a cell that expresses an expression profile gene selected from the group consisting of an expression profile gene set forth in Tables 1-16 or fragment thereof; ii) adding a drug candidate to said cell; and iii) determining the effect of said drug candidate on the expression of said expression profile gene. 70. A method according to claim 59 wherein said determining comprises comparing the level of expression in the absence of said drug candidate to the level of expression in the presence of said drug candidate. SF 1277890 vl

Inventors: AFAR DANIEL, GISH KURT C, HEVEZI PETER, MACK DAVID H, WILSON KEITH E, AFAR, DANIEL, GISH, KURT, C., HEVEZI, PETER, MACK, DAVID, H., WILSON, KEITH, E.
Applicants: EOS BIOTECHNOLOGY INC, EOS BIOTECHNOLOGY, INC.
Application year: 2001
Main classification: A61B
IPC codes: A61K45, A61P13, A61P35, C07K14, C07K16, C07K19, C12M1, C12N1, C12N5, C12N15, C12Q1, G01N33